-DOCSTART- -X- -X- O
   
Torsade NN NN B-Disease
de NN NN I-Disease
pointes NN NN I-Disease
ventricular NN NN B-Disease
tachycardia NN NN I-Disease
during NN NN O
low NN NN O
dose NN NN O
intermittent NN NN O
dobutamine NN NN O
treatment NN NN O
in NN NN O
a NN NN O
patient NN NN O
with NN NN O
dilated NN NN B-Disease
cardiomyopathy NN NN I-Disease
and NN NN O
congestive NN NN B-Disease
heart NN NN I-Disease
failure NN NN I-Disease
. NN NN O
   
The NN NN O
authors NN NN O
describe NN NN O
the NN NN O
case NN NN O
of NN NN O
a NN NN O
56 NN NN O
- NN NN O
year NN NN O
- NN NN O
old NN NN O
woman NN NN O
with NN NN O
chronic NN NN O
, NN NN O
severe NN NN O
heart NN NN B-Disease
failure NN NN I-Disease
secondary NN NN O
to NN NN O
dilated NN NN B-Disease
cardiomyopathy NN NN I-Disease
and NN NN O
absence NN NN O
of NN NN O
significant NN NN O
ventricular NN NN B-Disease
arrhythmias NN NN I-Disease
who NN NN O
developed NN NN O
QT NN NN B-Disease
prolongation NN NN I-Disease
and NN NN O
torsade NN NN B-Disease
de NN NN I-Disease
pointes NN NN I-Disease
ventricular NN NN B-Disease
tachycardia NN NN I-Disease
during NN NN O
one NN NN O
cycle NN NN O
of NN NN O
intermittent NN NN O
low NN NN O
dose NN NN O
( NN NN O
2 NN NN O
. NN NN O
5 NN NN O
mcg NN NN O
/ NN NN O
kg NN NN O
per NN NN O
min NN NN O
) NN NN O
dobutamine NN NN O
. NN NN O
   
This NN NN O
report NN NN O
of NN NN O
torsade NN NN B-Disease
de NN NN I-Disease
pointes NN NN I-Disease
ventricular NN NN B-Disease
tachycardia NN NN I-Disease
during NN NN O
intermittent NN NN O
dobutamine NN NN O
supports NN NN O
the NN NN O
hypothesis NN NN O
that NN NN O
unpredictable NN NN O
fatal NN NN O
arrhythmias NN NN B-Disease
may NN NN O
occur NN NN O
even NN NN O
with NN NN O
low NN NN O
doses NN NN O
and NN NN O
in NN NN O
patients NN NN O
with NN NN O
no NN NN O
history NN NN O
of NN NN O
significant NN NN O
rhythm NN NN O
disturbances NN NN O
. NN NN O
   
The NN NN O
mechanisms NN NN O
of NN NN O
proarrhythmic NN NN O
effects NN NN O
of NN NN O
Dubutamine NN NN O
are NN NN O
discussed NN NN O
. NN NN O
   
Positive NN NN O
skin NN NN O
tests NN NN O
in NN NN O
late NN NN O
reactions NN NN O
to NN NN O
radiographic NN NN O
contrast NN NN O
media NN NN O
. NN NN O
   
In NN NN O
the NN NN O
last NN NN O
few NN NN O
years NN NN O
delayed NN NN O
reactions NN NN O
several NN NN O
hours NN NN O
after NN NN O
the NN NN O
injection NN NN O
of NN NN O
radiographic NN NN O
and NN NN O
contrast NN NN O
materials NN NN O
( NN NN O
PRC NN NN O
) NN NN O
have NN NN O
been NN NN O
described NN NN O
with NN NN O
increasing NN NN O
frequency NN NN O
. NN NN O
   
The NN NN O
authors NN NN O
report NN NN O
two NN NN O
observations NN NN O
on NN NN O
patients NN NN O
with NN NN O
delayed NN NN O
reactions NN NN O
in NN NN O
whom NN NN O
intradermoreactions NN NN O
( NN NN O
IDR NN NN O
) NN NN O
and NN NN O
patch NN NN O
tests NN NN O
to NN NN O
a NN NN O
series NN NN O
of NN NN O
ionic NN NN O
and NN NN O
non NN NN O
ionic NN NN O
PRC NN NN O
were NN NN O
studied NN NN O
. NN NN O
   
After NN NN O
angiography NN NN O
by NN NN O
the NN NN O
venous NN NN O
route NN NN O
in NN NN O
patient NN NN O
n NN NN O
degree NN NN O
1 NN NN O
a NN NN O
biphasic NN NN O
reaction NN NN O
with NN NN O
an NN NN O
immediate NN NN O
reaction NN NN O
( NN NN O
dyspnea NN NN B-Disease
, NN NN O
loss NN NN B-Disease
of NN NN I-Disease
consciousness NN NN I-Disease
) NN NN O
and NN NN O
delayed NN NN O
macro NN NN B-Disease
- NN NN I-Disease
papular NN NN I-Disease
rash NN NN I-Disease
appeared NN NN O
, NN NN O
whilst NN NN O
patient NN NN O
n NN NN O
degree NN NN O
2 NN NN O
developed NN NN O
a NN NN O
generalised NN NN O
sensation NN NN O
of NN NN O
heat NN NN O
, NN NN O
persistent NN NN O
pain NN NN B-Disease
at NN NN O
the NN NN O
site NN NN O
of NN NN O
injection NN NN O
immediately NN NN O
and NN NN O
a NN NN O
generalised NN NN O
macro NN NN O
- NN NN O
papular NN NN O
reaction NN NN O
after NN NN O
24 NN NN O
hours NN NN O
. NN NN O
   
The NN NN O
skin NN NN O
tests NN NN O
revealed NN NN O
positive NN NN O
delayed NN NN O
reactions NN NN O
of NN NN O
24 NN NN O
hours NN NN O
and NN NN O
48 NN NN O
hours NN NN O
by NN NN O
IDR NN NN O
and NN NN O
patch NN NN O
tests NN NN O
to NN NN O
only NN NN O
some NN NN O
PRC NN NN O
with NN NN O
common NN NN O
chains NN NN O
in NN NN O
their NN NN O
structures NN NN O
. NN NN O
   
The NN NN O
positive NN NN O
skin NN NN O
tests NN NN O
are NN NN O
in NN NN O
favour NN NN O
of NN NN O
immunological NN NN O
reactions NN NN O
and NN NN O
may NN NN O
help NN NN O
in NN NN O
diagnosis NN NN O
of NN NN O
allergy NN NN B-Disease
in NN NN O
the NN NN O
patients NN NN O
. NN NN O
   
Risk NN NN O
of NN NN O
transient NN NN O
hyperammonemic NN NN B-Disease
encephalopathy NN NN I-Disease
in NN NN O
cancer NN NN B-Disease
patients NN NN O
who NN NN O
received NN NN O
continuous NN NN O
infusion NN NN O
of NN NN O
5 NN NN O
- NN NN O
fluorouracil NN NN O
with NN NN O
the NN NN O
complication NN NN O
of NN NN O
dehydration NN NN B-Disease
and NN NN O
infection NN NN B-Disease
. NN NN O
   
From NN NN O
1986 NN NN O
to NN NN O
1998 NN NN O
, NN NN O
29 NN NN O
cancer NN NN B-Disease
patients NN NN O
who NN NN O
had NN NN O
32 NN NN O
episodes NN NN O
of NN NN O
transient NN NN O
hyperammonemic NN NN B-Disease
encephalopathy NN NN I-Disease
related NN NN O
to NN NN O
continuous NN NN O
infusion NN NN O
of NN NN O
5 NN NN O
- NN NN O
fluorouracil NN NN O
( NN NN O
5 NN NN O
- NN NN O
FU NN NN O
) NN NN O
were NN NN O
identified NN NN O
. NN NN O
   
   O
of NN NN O
the NN NN O
patients NN NN O
had NN NN O
decompensated NN NN O
liver NN NN B-Disease
disease NN NN I-Disease
. NN NN O
   
Onset NN NN O
of NN NN O
hyperammonemic NN NN B-Disease
encephalopathy NN NN I-Disease
varied NN NN O
from NN NN O
0 NN NN O
. NN NN O
5 NN NN O
to NN NN O
5 NN NN O
days NN NN O
( NN NN O
mean NN NN O
: NN NN O
2 NN NN O
. NN NN O
6 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
1 NN NN O
. NN NN O
3 NN NN O
days NN NN O
) NN NN O
after NN NN O
the NN NN O
initiation NN NN O
of NN NN O
chemotherapy NN NN O
. NN NN O
   
Plasma NN NN O
ammonium NN NN O
level NN NN O
ranged NN NN O
from NN NN O
248 NN NN O
to NN NN O
2387 NN NN O
microg NN NN O
% NN NN O
( NN NN O
mean NN NN O
: NN NN O
626 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
431 NN NN O
microg NN NN O
% NN NN O
) NN NN O
. NN NN O
   
Among NN NN O
the NN NN O
32 NN NN O
episodes NN NN O
, NN NN O
26 NN NN O
( NN NN O
81 NN NN O
% NN NN O
) NN NN O
had NN NN O
various NN NN O
degrees NN NN O
of NN NN O
azotemia NN NN B-Disease
, NN NN O
18 NN NN O
( NN NN O
56 NN NN O
% NN NN O
) NN NN O
occurred NN NN O
during NN NN O
bacterial NN NN B-Disease
infections NN NN I-Disease
and NN NN O
14 NN NN O
( NN NN O
44 NN NN O
% NN NN O
) NN NN O
without NN NN O
infection NN NN B-Disease
occurred NN NN O
during NN NN O
periods NN NN O
of NN NN O
dehydration NN NN B-Disease
. NN NN O
   
Higher NN NN O
plasma NN NN O
ammonium NN NN O
levels NN NN O
and NN NN O
more NN NN O
rapid NN NN O
onset NN NN O
of NN NN O
hyperammonemia NN NN B-Disease
were NN NN O
seen NN NN O
in NN NN O
18 NN NN O
patients NN NN O
with NN NN O
bacterial NN NN B-Disease
infections NN NN I-Disease
( NN NN O
p NN NN O
= NN NN O
0 NN NN O
. NN NN O
003 NN NN O
and NN NN O
0 NN NN O
. NN NN O
0006 NN NN O
, NN NN O
respectively NN NN O
) NN NN O
and NN NN O
in NN NN O
nine NN NN O
patients NN NN O
receiving NN NN O
high NN NN O
daily NN NN O
doses NN NN O
( NN NN O
2600 NN NN O
or NN NN O
1800 NN NN O
mg NN NN O
/ NN NN O
m2 NN NN O
) NN NN O
of NN NN O
5 NN NN O
- NN NN O
FU NN NN O
( NN NN O
p NN NN O
= NN NN O
0 NN NN O
. NN NN O
0001 NN NN O
and NN NN O
< NN NN O
0 NN NN O
. NN NN O
0001 NN NN O
, NN NN O
respectively NN NN O
) NN NN O
. NN NN O
   
In NN NN O
25 NN NN O
out NN NN O
of NN NN O
32 NN NN O
episodes NN NN O
( NN NN O
78 NN NN O
% NN NN O
) NN NN O
, NN NN O
plasma NN NN O
ammonium NN NN O
levels NN NN O
and NN NN O
mental NN NN O
status NN NN O
returned NN NN O
to NN NN O
normal NN NN O
within NN NN O
2 NN NN O
days NN NN O
after NN NN O
adequate NN NN O
management NN NN O
. NN NN O
   
In NN NN O
conclusion NN NN O
, NN NN O
hyperammonemic NN NN B-Disease
encephalopathy NN NN I-Disease
can NN NN O
occur NN NN O
in NN NN O
patients NN NN O
receiving NN NN O
continuous NN NN O
infusion NN NN O
of NN NN O
5 NN NN O
- NN NN O
FU NN NN O
. NN NN O
   
Azotemia NN NN B-Disease
, NN NN O
body NN NN O
fluid NN NN O
insufficiency NN NN O
and NN NN O
bacterial NN NN B-Disease
infections NN NN I-Disease
were NN NN O
frequently NN NN O
found NN NN O
in NN NN O
these NN NN O
patients NN NN O
. NN NN O
   
It NN NN O
is NN NN O
therefore NN NN O
important NN NN O
to NN NN O
recognize NN NN O
this NN NN O
condition NN NN O
in NN NN O
patients NN NN O
receiving NN NN O
continuous NN NN O
infusion NN NN O
of NN NN O
5 NN NN O
- NN NN O
FU NN NN O
. NN NN O
   
The NN NN O
effects NN NN O
of NN NN O
quinine NN NN O
and NN NN O
4 NN NN O
- NN NN O
aminopyridine NN NN O
on NN NN O
conditioned NN NN O
place NN NN O
preference NN NN O
and NN NN O
changes NN NN O
in NN NN O
motor NN NN O
activity NN NN O
induced NN NN O
by NN NN O
morphine NN NN O
in NN NN O
rats NN NN O
. NN NN O
   
1 NN NN O
. NN NN O
   
The NN NN O
effects NN NN O
of NN NN O
two NN NN O
unselective NN NN O
potassium NN NN O
( NN NN O
K NN NN O
( NN NN O
+ NN NN O
) NN NN O
- NN NN O
) NN NN O
channel NN NN O
blockers NN NN O
, NN NN O
quinine NN NN O
( NN NN O
12 NN NN O
. NN NN O
5 NN NN O
, NN NN O
25 NN NN O
and NN NN O
50 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
) NN NN O
and NN NN O
4 NN NN O
- NN NN O
aminopyridine NN NN O
( NN NN O
1 NN NN O
and NN NN O
2 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
) NN NN O
, NN NN O
on NN NN O
conditioned NN NN O
place NN NN O
preference NN NN O
and NN NN O
biphasic NN NN O
changes NN NN O
in NN NN O
motor NN NN O
activity NN NN O
induced NN NN O
by NN NN O
morphine NN NN O
( NN NN O
10 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
) NN NN O
were NN NN O
tested NN NN O
in NN NN O
Wistar NN NN O
rats NN NN O
. NN NN O
   
Quinine NN NN O
is NN NN O
known NN NN O
to NN NN O
block NN NN O
voltage NN NN O
- NN NN O
, NN NN O
calcium NN NN O
- NN NN O
and NN NN O
ATP NN NN O
- NN NN O
sensitive NN NN O
K NN NN O
( NN NN O
+ NN NN O
) NN NN O
- NN NN O
channels NN NN O
while NN NN O
4 NN NN O
- NN NN O
aminopyridine NN NN O
is NN NN O
known NN NN O
to NN NN O
block NN NN O
voltage NN NN O
- NN NN O
sensitive NN NN O
K NN NN O
( NN NN O
+ NN NN O
) NN NN O
- NN NN O
channels NN NN O
. NN NN O
   
2 NN NN O
. NN NN O
   
In NN NN O
the NN NN O
counterbalanced NN NN O
method NN NN O
, NN NN O
quinine NN NN O
attenuated NN NN O
morphine NN NN O
- NN NN O
induced NN NN O
place NN NN O
preference NN NN O
, NN NN O
whereas NN NN O
4 NN NN O
- NN NN O
aminopyridine NN NN O
was NN NN O
ineffective NN NN O
. NN NN O
   
In NN NN O
the NN NN O
motor NN NN O
activity NN NN O
test NN NN O
measured NN NN O
with NN NN O
an NN NN O
Animex NN NN O
- NN NN O
activity NN NN O
meter NN NN O
neither NN NN O
of NN NN O
the NN NN O
K NN NN O
( NN NN O
+ NN NN O
) NN NN O
- NN NN O
channel NN NN O
blockers NN NN O
affected NN NN O
morphine NN NN O
- NN NN O
induced NN NN O
hypoactivity NN NN B-Disease
, NN NN O
but NN NN O
both NN NN O
K NN NN O
( NN NN O
+ NN NN O
) NN NN O
- NN NN O
channel NN NN O
blockers NN NN O
prevented NN NN O
morphine NN NN O
- NN NN O
induced NN NN O
secondary NN NN O
hyperactivity NN NN B-Disease
. NN NN O
   
3 NN NN O
. NN NN O
   
These NN NN O
results NN NN O
suggest NN NN O
the NN NN O
involvement NN NN O
of NN NN O
quinine NN NN O
- NN NN O
sensitive NN NN O
but NN NN O
not NN NN O
4 NN NN O
- NN NN O
aminopyridine NN NN O
- NN NN O
sensitive NN NN O
K NN NN O
( NN NN O
+ NN NN O
) NN NN O
- NN NN O
channels NN NN O
in NN NN O
morphine NN NN O
reward NN NN O
. NN NN O
   
It NN NN O
is NN NN O
also NN NN O
suggested NN NN O
that NN NN O
the NN NN O
blockade NN NN O
of NN NN O
K NN NN O
( NN NN O
+ NN NN O
) NN NN O
- NN NN O
channels NN NN O
sensitive NN NN O
to NN NN O
these NN NN O
blockers NN NN O
is NN NN O
not NN NN O
sufficient NN NN O
to NN NN O
prevent NN NN O
morphine NN NN O
- NN NN O
induced NN NN O
hypoactivity NN NN B-Disease
whereas NN NN O
morphine NN NN O
- NN NN O
induced NN NN O
hyperactivity NN NN B-Disease
seems NN NN O
to NN NN O
be NN NN O
connected NN NN O
to NN NN O
both NN NN O
quinine NN NN O
- NN NN O
and NN NN O
4 NN NN O
- NN NN O
aminopyridine NN NN O
- NN NN O
sensitive NN NN O
K NN NN O
( NN NN O
+ NN NN O
) NN NN O
- NN NN O
channels NN NN O
. NN NN O
   
Nociceptin NN NN O
/ NN NN O
orphanin NN NN O
FQ NN NN O
and NN NN O
nocistatin NN NN O
on NN NN O
learning NN NN B-Disease
and NN NN I-Disease
memory NN NN I-Disease
impairment NN NN I-Disease
induced NN NN O
by NN NN O
scopolamine NN NN O
in NN NN O
mice NN NN O
. NN NN O
   
1 NN NN O
. NN NN O
   
Nociceptin NN NN O
, NN NN O
also NN NN O
known NN NN O
as NN NN O
orphanin NN NN O
FQ NN NN O
, NN NN O
is NN NN O
an NN NN O
endogenous NN NN O
ligand NN NN O
for NN NN O
the NN NN O
orphan NN NN O
opioid NN NN O
receptor NN NN O
- NN NN O
like NN NN O
receptor NN NN O
1 NN NN O
( NN NN O
ORL1 NN NN O
) NN NN O
and NN NN O
involves NN NN O
in NN NN O
various NN NN O
functions NN NN O
in NN NN O
the NN NN O
central NN NN O
nervous NN NN O
system NN NN O
( NN NN O
CNS NN NN O
) NN NN O
. NN NN O
   
On NN NN O
the NN NN O
other NN NN O
hand NN NN O
, NN NN O
nocistatin NN NN O
is NN NN O
recently NN NN O
isolated NN NN O
from NN NN O
the NN NN O
same NN NN O
precursor NN NN O
as NN NN O
nociceptin NN NN O
and NN NN O
blocks NN NN O
nociceptin NN NN O
- NN NN O
induced NN NN O
allodynia NN NN B-Disease
and NN NN O
hyperalgesia NN NN B-Disease
. NN NN O
   
2 NN NN O
. NN NN O
   
Although NN NN O
ORL1 NN NN O
receptors NN NN O
which NN NN O
display NN NN O
a NN NN O
high NN NN O
degree NN NN O
of NN NN O
sequence NN NN O
homology NN NN O
with NN NN O
classical NN NN O
opioid NN NN O
receptors NN NN O
are NN NN O
abundant NN NN O
in NN NN O
the NN NN O
hippocampus NN NN O
, NN NN O
little NN NN O
is NN NN O
known NN NN O
regarding NN NN O
their NN NN O
role NN NN O
in NN NN O
learning NN NN O
and NN NN O
memory NN NN O
. NN NN O
   
3 NN NN O
. NN NN O
   
The NN NN O
present NN NN O
study NN NN O
was NN NN O
designed NN NN O
to NN NN O
investigate NN NN O
whether NN NN O
nociceptin NN NN O
/ NN NN O
orphanin NN NN O
FQ NN NN O
and NN NN O
nocistatin NN NN O
could NN NN O
modulate NN NN O
impairment NN NN B-Disease
of NN NN I-Disease
learning NN NN I-Disease
and NN NN I-Disease
memory NN NN I-Disease
induced NN NN O
by NN NN O
scopolamine NN NN O
, NN NN O
a NN NN O
muscarinic NN NN O
cholinergic NN NN O
receptor NN NN O
antagonist NN NN O
, NN NN O
using NN NN O
spontaneous NN NN O
alternation NN NN O
of NN NN O
Y NN NN O
- NN NN O
maze NN NN O
and NN NN O
step NN NN O
- NN NN O
down NN NN O
type NN NN O
passive NN NN O
avoidance NN NN O
tasks NN NN O
in NN NN O
mice NN NN O
. NN NN O
   
4 NN NN O
. NN NN O
   
While NN NN O
nocistatin NN NN O
( NN NN O
0 NN NN O
. NN NN O
5 NN NN O
- NN NN O
5 NN NN O
. NN NN O
0 NN NN O
nmol NN NN O
mouse NN NN O
- NN NN O
1 NN NN O
, NN NN O
i NN NN O
. NN NN O
c NN NN O
. NN NN O
v NN NN O
. NN NN O
) NN NN O
administered NN NN O
30 NN NN O
min NN NN O
before NN NN O
spontaneous NN NN O
alternation NN NN O
performance NN NN O
or NN NN O
the NN NN O
training NN NN O
session NN NN O
of NN NN O
the NN NN O
passive NN NN O
avoidance NN NN O
task NN NN O
, NN NN O
had NN NN O
no NN NN O
effect NN NN O
on NN NN O
spontaneous NN NN O
alternation NN NN O
or NN NN O
passive NN NN O
avoidance NN NN O
behaviours NN NN O
, NN NN O
a NN NN O
lower NN NN O
per NN NN O
cent NN NN O
alternation NN NN O
and NN NN O
shorter NN NN O
median NN NN O
step NN NN O
- NN NN O
down NN NN O
latency NN NN O
in NN NN O
the NN NN O
retention NN NN O
test NN NN O
were NN NN O
obtained NN NN O
in NN NN O
nociceptin NN NN O
( NN NN O
1 NN NN O
. NN NN O
5 NN NN O
and NN NN O
/ NN NN O
or NN NN O
5 NN NN O
. NN NN O
0 NN NN O
nmol NN NN O
mouse NN NN O
- NN NN O
1 NN NN O
, NN NN O
i NN NN O
. NN NN O
c NN NN O
. NN NN O
v NN NN O
. NN NN O
) NN NN O
- NN NN O
treated NN NN O
normal NN NN O
mice NN NN O
. NN NN O
   
5 NN NN O
. NN NN O
   
Administration NN NN O
of NN NN O
nocistatin NN NN O
( NN NN O
1 NN NN O
. NN NN O
5 NN NN O
and NN NN O
/ NN NN O
or NN NN O
5 NN NN O
. NN NN O
0 NN NN O
nmol NN NN O
mouse NN NN O
- NN NN O
1 NN NN O
, NN NN O
i NN NN O
. NN NN O
c NN NN O
. NN NN O
v NN NN O
. NN NN O
) NN NN O
30 NN NN O
min NN NN O
before NN NN O
spontaneous NN NN O
alternation NN NN O
performance NN NN O
or NN NN O
the NN NN O
training NN NN O
session NN NN O
of NN NN O
the NN NN O
passive NN NN O
avoidance NN NN O
task NN NN O
, NN NN O
attenuated NN NN O
the NN NN O
scopolamine NN NN O
- NN NN O
induced NN NN O
impairment NN NN O
of NN NN O
spontaneous NN NN O
alternation NN NN O
and NN NN O
passive NN NN O
avoidance NN NN O
behaviours NN NN O
. NN NN O
   
6 NN NN O
. NN NN O
   
These NN NN O
results NN NN O
indicated NN NN O
that NN NN O
nocistatin NN NN O
, NN NN O
a NN NN O
new NN NN O
biologically NN NN O
active NN NN O
peptide NN NN O
, NN NN O
ameliorates NN NN O
impairments NN NN O
of NN NN O
spontaneous NN NN O
alternation NN NN O
and NN NN O
passive NN NN O
avoidance NN NN O
induced NN NN O
by NN NN O
scopolamine NN NN O
, NN NN O
and NN NN O
suggested NN NN O
that NN NN O
these NN NN O
peptides NN NN O
play NN NN O
opposite NN NN O
roles NN NN O
in NN NN O
learning NN NN O
and NN NN O
memory NN NN O
. NN NN O
   
Meloxicam NN NN O
- NN NN O
induced NN NN O
liver NN NN B-Disease
toxicity NN NN I-Disease
. NN NN O
   
We NN NN O
report NN NN O
the NN NN O
case NN NN O
of NN NN O
a NN NN O
female NN NN O
patient NN NN O
with NN NN O
rheumatoid NN NN B-Disease
arthritis NN NN I-Disease
who NN NN O
developed NN NN O
acute NN NN O
cytolytic NN NN O
hepatitis NN NN B-Disease
due NN NN O
to NN NN O
meloxicam NN NN O
. NN NN O
   
Recently NN NN O
introduced NN NN O
in NN NN O
Belgium NN NN O
, NN NN O
meloxicam NN NN O
is NN NN O
the NN NN O
first NN NN O
nonsteroidal NN NN O
antiinflammatory NN NN O
drug NN NN O
with NN NN O
selective NN NN O
action NN NN O
on NN NN O
the NN NN O
inducible NN NN O
form NN NN O
of NN NN O
cyclooxygenase NN NN O
2 NN NN O
. NN NN O
   
The NN NN O
acute NN NN O
cytolytic NN NN O
hepatitis NN NN B-Disease
occurred NN NN O
rapidly NN NN O
after NN NN O
meloxicam NN NN O
administration NN NN O
and NN NN O
was NN NN O
associated NN NN O
with NN NN O
the NN NN O
development NN NN O
of NN NN O
antinuclear NN NN O
antibodies NN NN O
suggesting NN NN O
a NN NN O
hypersensitivity NN NN B-Disease
mechanism NN NN O
. NN NN O
   
This NN NN O
first NN NN O
case NN NN O
of NN NN O
meloxicam NN NN O
related NN NN O
liver NN NN B-Disease
toxicity NN NN I-Disease
demonstrates NN NN O
the NN NN O
potential NN NN O
of NN NN O
this NN NN O
drug NN NN O
to NN NN O
induce NN NN O
hepatic NN NN B-Disease
damage NN NN I-Disease
. NN NN O
   
Induction NN NN O
of NN NN O
apoptosis NN NN O
by NN NN O
remoxipride NN NN O
metabolites NN NN O
in NN NN O
HL60 NN NN O
and NN NN O
CD34 NN NN O
+ NN NN O
/ NN NN O
CD19 NN NN O
- NN NN O
human NN NN O
bone NN NN O
marrow NN NN O
progenitor NN NN O
cells NN NN O
: NN NN O
potential NN NN O
relevance NN NN O
to NN NN O
remoxipride NN NN O
- NN NN O
induced NN NN O
aplastic NN NN B-Disease
anemia NN NN I-Disease
. NN NN O
   
The NN NN O
antipsychotic NN NN O
agent NN NN O
, NN NN O
remoxipride NN NN O
[ NN NN O
( NN NN O
S NN NN O
) NN NN O
- NN NN O
( NN NN O
- NN NN O
) NN NN O
- NN NN O
3 NN NN O
- NN NN O
bromo NN NN O
- NN NN O
N NN NN O
- NN NN O
[ NN NN O
( NN NN O
1 NN NN O
- NN NN O
ethyl NN NN O
- NN NN O
2 NN NN O
- NN NN O
pyrrolidinyl NN NN O
) NN NN O
methyl NN NN O
] NN NN O
- NN NN O
2 NN NN O
, NN NN O
6 NN NN O
- NN NN O
dimethoxybenz NN NN O
amide NN NN O
] NN NN O
has NN NN O
been NN NN O
associated NN NN O
with NN NN O
acquired NN NN O
aplastic NN NN B-Disease
anemia NN NN I-Disease
. NN NN O
   
We NN NN O
have NN NN O
examined NN NN O
the NN NN O
ability NN NN O
of NN NN O
remoxipride NN NN O
, NN NN O
three NN NN O
pyrrolidine NN NN O
ring NN NN O
metabolites NN NN O
and NN NN O
five NN NN O
aromatic NN NN O
ring NN NN O
metabolites NN NN O
of NN NN O
the NN NN O
parent NN NN O
compound NN NN O
to NN NN O
induce NN NN O
apoptosis NN NN O
in NN NN O
HL60 NN NN O
cells NN NN O
and NN NN O
human NN NN O
bone NN NN O
marrow NN NN O
progenitor NN NN O
( NN NN O
HBMP NN NN O
) NN NN O
cells NN NN O
. NN NN O
   
Cells NN NN O
were NN NN O
treated NN NN O
for NN NN O
0 NN NN O
- NN NN O
24 NN NN O
h NN NN O
with NN NN O
each NN NN O
compound NN NN O
( NN NN O
0 NN NN O
- NN NN O
200 NN NN O
microM NN NN O
) NN NN O
. NN NN O
   
Apoptosis NN NN O
was NN NN O
assessed NN NN O
by NN NN O
fluorescence NN NN O
microscopy NN NN O
in NN NN O
Hoechst NN NN O
33342 NN NN O
- NN NN O
and NN NN O
propidium NN NN O
iodide NN NN O
stained NN NN O
cell NN NN O
samples NN NN O
. NN NN O
   
Results NN NN O
were NN NN O
confirmed NN NN O
by NN NN O
determination NN NN O
of NN NN O
internucleosomal NN NN O
DNA NN NN O
fragmentation NN NN O
using NN NN O
gel NN NN O
electrophoresis NN NN O
for NN NN O
HL60 NN NN O
cell NN NN O
samples NN NN O
and NN NN O
terminal NN NN O
deoxynucleotidyl NN NN O
transferase NN NN O
assay NN NN O
in NN NN O
HBMP NN NN O
cells NN NN O
. NN NN O
   
The NN NN O
catechol NN NN O
and NN NN O
hydroquinone NN NN O
metabolites NN NN O
, NN NN O
NCQ436 NN NN O
and NN NN O
NCQ344 NN NN O
, NN NN O
induced NN NN O
apoptosis NN NN O
in NN NN O
HL60 NN NN O
and NN NN O
HBMP NN NN O
cells NN NN O
in NN NN O
a NN NN O
time NN NN O
- NN NN O
and NN NN O
concentration NN NN O
dependent NN NN O
manner NN NN O
, NN NN O
while NN NN O
the NN NN O
phenols NN NN O
, NN NN O
NCR181 NN NN O
, NN NN O
FLA873 NN NN O
, NN NN O
and NN NN O
FLA797 NN NN O
, NN NN O
and NN NN O
the NN NN O
derivatives NN NN O
formed NN NN O
by NN NN O
oxidation NN NN O
of NN NN O
the NN NN O
pyrrolidine NN NN O
ring NN NN O
, NN NN O
FLA838 NN NN O
, NN NN O
NCM001 NN NN O
, NN NN O
and NN NN O
NCL118 NN NN O
, NN NN O
had NN NN O
no NN NN O
effect NN NN O
. NN NN O
   
No NN NN O
necrosis NN NN B-Disease
was NN NN O
observed NN NN O
in NN NN O
cells NN NN O
treated NN NN O
with NN NN O
NCQ436 NN NN O
but NN NN O
NCQ344 NN NN O
had NN NN O
a NN NN O
biphasic NN NN O
effect NN NN O
in NN NN O
both NN NN O
cell NN NN O
types NN NN O
, NN NN O
inducing NN NN O
apoptosis NN NN O
at NN NN O
lower NN NN O
concentrations NN NN O
and NN NN O
necrosis NN NN B-Disease
at NN NN O
higher NN NN O
concentrations NN NN O
. NN NN O
   
These NN NN O
data NN NN O
show NN NN O
that NN NN O
the NN NN O
catechol NN NN O
and NN NN O
hydroquinone NN NN O
metabolites NN NN O
of NN NN O
remoxipride NN NN O
have NN NN O
direct NN NN O
toxic NN NN O
effects NN NN O
in NN NN O
HL60 NN NN O
and NN NN O
HBMP NN NN O
cells NN NN O
, NN NN O
leading NN NN O
to NN NN O
apoptosis NN NN O
, NN NN O
while NN NN O
the NN NN O
phenol NN NN O
metabolites NN NN O
were NN NN O
inactive NN NN O
. NN NN O
   
Similarly NN NN O
, NN NN O
benzene NN NN O
- NN NN O
derived NN NN O
catechol NN NN O
and NN NN O
hydroquinone NN NN O
, NN NN O
but NN NN O
not NN NN O
phenol NN NN O
, NN NN O
induce NN NN O
apoptosis NN NN O
in NN NN O
HBMP NN NN O
cells NN NN O
[ NN NN O
Moran NN NN O
et NN NN O
al NN NN O
. NN NN O
, NN NN O
Mol NN NN O
. NN NN O
Pharmacol NN NN O
. NN NN O
, NN NN O
50 NN NN O
( NN NN O
1996 NN NN O
) NN NN O
610 NN NN O
- NN NN O
615 NN NN O
] NN NN O
. NN NN O
   
We NN NN O
propose NN NN O
that NN NN O
remoxipride NN NN O
and NN NN O
benzene NN NN O
may NN NN O
induce NN NN O
aplastic NN NN B-Disease
anemia NN NN I-Disease
via NN NN O
production NN NN O
of NN NN O
similar NN NN O
reactive NN NN O
metabolites NN NN O
and NN NN O
that NN NN O
the NN NN O
ability NN NN O
of NN NN O
NCQ436 NN NN O
and NN NN O
NCQ344 NN NN O
to NN NN O
induce NN NN O
apoptosis NN NN O
in NN NN O
HBMP NN NN O
cells NN NN O
may NN NN O
contribute NN NN O
to NN NN O
the NN NN O
mechanism NN NN O
underlying NN NN O
acquired NN NN O
aplastic NN NN B-Disease
anemia NN NN I-Disease
that NN NN O
has NN NN O
been NN NN O
associated NN NN O
with NN NN O
remoxipride NN NN O
. NN NN O
   
Synthesis NN NN O
and NN NN O
preliminary NN NN O
pharmacological NN NN O
investigations NN NN O
of NN NN O
1 NN NN O
- NN NN O
( NN NN O
1 NN NN O
, NN NN O
2 NN NN O
- NN NN O
dihydro NN NN O
- NN NN O
2 NN NN O
- NN NN O
acenaphthylenyl NN NN O
) NN NN O
piperazine NN NN O
derivatives NN NN O
as NN NN O
potential NN NN O
atypical NN NN O
antipsychotic NN NN O
agents NN NN O
in NN NN O
mice NN NN O
. NN NN O
   
In NN NN O
research NN NN O
towards NN NN O
the NN NN O
development NN NN O
of NN NN O
new NN NN O
atypical NN NN O
antipsychotic NN NN O
agents NN NN O
, NN NN O
one NN NN O
strategy NN NN O
is NN NN O
that NN NN O
the NN NN O
dopaminergic NN NN O
system NN NN O
can NN NN O
be NN NN O
modulated NN NN O
through NN NN O
manipulation NN NN O
of NN NN O
the NN NN O
serotonergic NN NN O
system NN NN O
. NN NN O
   
The NN NN O
synthesis NN NN O
and NN NN O
preliminary NN NN O
pharmacological NN NN O
evaluation NN NN O
of NN NN O
a NN NN O
series NN NN O
of NN NN O
potential NN NN O
atypical NN NN O
antipsychotic NN NN O
agents NN NN O
based NN NN O
on NN NN O
the NN NN O
structure NN NN O
of NN NN O
1 NN NN O
- NN NN O
( NN NN O
1 NN NN O
, NN NN O
2 NN NN O
- NN NN O
dihydro NN NN O
- NN NN O
2 NN NN O
- NN NN O
acenaphthylenyl NN NN O
) NN NN O
piperazine NN NN O
( NN NN O
7 NN NN O
) NN NN O
is NN NN O
described NN NN O
. NN NN O
   
Compound NN NN O
7e NN NN O
, NN NN O
5 NN NN O
- NN NN O
{ NN NN O
2 NN NN O
- NN NN O
[ NN NN O
4 NN NN O
- NN NN O
( NN NN O
1 NN NN O
, NN NN O
2 NN NN O
- NN NN O
dihydro NN NN O
- NN NN O
2 NN NN O
- NN NN O
acenaphthylenyl NN NN O
) NN NN O
piperazinyl NN NN O
] NN NN O
ethyl NN NN O
} NN NN O
- NN NN O
2 NN NN O
, NN NN O
3 NN NN O
- NN NN O
dihy NN NN O
dro NN NN O
- NN NN O
1H NN NN O
- NN NN O
indol NN NN O
- NN NN O
2 NN NN O
- NN NN O
one NN NN O
, NN NN O
from NN NN O
this NN NN O
series NN NN O
showed NN NN O
significant NN NN O
affinities NN NN O
at NN NN O
the NN NN O
5 NN NN O
- NN NN O
HT1A NN NN O
and NN NN O
5 NN NN O
- NN NN O
HT2A NN NN O
receptors NN NN O
and NN NN O
moderate NN NN O
affinity NN NN O
at NN NN O
the NN NN O
D2 NN NN O
receptor NN NN O
. NN NN O
   
7e NN NN O
exhibits NN NN O
a NN NN O
high NN NN O
reversal NN NN O
of NN NN O
catalepsy NN NN B-Disease
induced NN NN O
by NN NN O
haloperidol NN NN O
indicating NN NN O
its NN NN O
atypical NN NN O
antipsychotic NN NN O
nature NN NN O
. NN NN O
   
Sub NN NN O
- NN NN O
chronic NN NN O
inhibition NN NN O
of NN NN O
nitric NN NN O
- NN NN O
oxide NN NN O
synthesis NN NN O
modifies NN NN O
haloperidol NN NN O
- NN NN O
induced NN NN O
catalepsy NN NN B-Disease
and NN NN O
the NN NN O
number NN NN O
of NN NN O
NADPH NN NN O
- NN NN O
diaphorase NN NN O
neurons NN NN O
in NN NN O
mice NN NN O
. NN NN O
   
RATIONALE NN NN O
: NN NN O
NG NN NN O
- NN NN O
nitro NN NN O
- NN NN O
L NN NN O
- NN NN O
arginine NN NN O
( NN NN O
L NN NN O
- NN NN O
NOARG NN NN O
) NN NN O
, NN NN O
an NN NN O
inhibitor NN NN O
of NN NN O
nitric NN NN O
- NN NN O
oxide NN NN O
synthase NN NN O
( NN NN O
NOS NN NN O
) NN NN O
, NN NN O
induces NN NN O
catalepsy NN NN B-Disease
in NN NN O
mice NN NN O
. NN NN O
   
This NN NN O
effect NN NN O
undergoes NN NN O
rapid NN NN O
tolerance NN NN O
, NN NN O
showing NN NN O
a NN NN O
significant NN NN O
decrease NN NN O
after NN NN O
2 NN NN O
days NN NN O
of NN NN O
sub NN NN O
- NN NN O
chronic NN NN O
L NN NN O
- NN NN O
NOARG NN NN O
treatment NN NN O
. NN NN O
   
Nitric NN NN O
oxide NN NN O
( NN NN O
NO NN NN O
) NN NN O
has NN NN O
been NN NN O
shown NN NN O
to NN NN O
influence NN NN O
dopaminergic NN NN O
neurotransmission NN NN O
in NN NN O
the NN NN O
striatum NN NN O
. NN NN O
   
Neuroleptic NN NN O
drugs NN NN O
such NN NN O
as NN NN O
haloperidol NN NN O
, NN NN O
which NN NN O
block NN NN O
dopamine NN NN O
receptors NN NN O
, NN NN O
also NN NN O
cause NN NN O
catalepsy NN NN B-Disease
in NN NN O
rodents NN NN O
. NN NN O
   
OBJECTIVES NN NN O
: NN NN O
To NN NN O
investigate NN NN O
the NN NN O
effects NN NN O
of NN NN O
subchronic NN NN O
L NN NN O
- NN NN O
NOARG NN NN O
treatment NN NN O
in NN NN O
haloperidol NN NN O
- NN NN O
induced NN NN O
catalepsy NN NN B-Disease
and NN NN O
the NN NN O
number NN NN O
of NN NN O
NOS NN NN O
neurons NN NN O
in NN NN O
areas NN NN O
related NN NN O
to NN NN O
motor NN NN O
control NN NN O
. NN NN O
   
METHODS NN NN O
: NN NN O
Male NN NN O
albino NN NN O
Swiss NN NN O
mice NN NN O
were NN NN O
treated NN NN O
sub NN NN O
- NN NN O
chronically NN NN O
( NN NN O
twice NN NN O
a NN NN O
day NN NN O
for NN NN O
4 NN NN O
days NN NN O
) NN NN O
with NN NN O
L NN NN O
- NN NN O
NOARG NN NN O
( NN NN O
40 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
i NN NN O
. NN NN O
p NN NN O
. NN NN O
) NN NN O
or NN NN O
haloperidol NN NN O
( NN NN O
1 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
i NN NN O
. NN NN O
p NN NN O
. NN NN O
) NN NN O
. NN NN O
   
Catalepsy NN NN B-Disease
was NN NN O
evaluated NN NN O
at NN NN O
the NN NN O
beginning NN NN O
and NN NN O
the NN NN O
end NN NN O
of NN NN O
the NN NN O
treatments NN NN O
. NN NN O
   
Reduced NN NN O
nicotinamide NN NN O
adenine NN NN O
dinucleotide NN NN O
phosphate NN NN O
- NN NN O
diaphorase NN NN O
( NN NN O
NADPH NN NN O
- NN NN O
d NN NN O
) NN NN O
histochemistry NN NN O
was NN NN O
also NN NN O
employed NN NN O
to NN NN O
visualize NN NN O
NOS NN NN O
as NN NN O
an NN NN O
index NN NN O
of NN NN O
enzyme NN NN O
expression NN NN O
in NN NN O
mice NN NN O
brain NN NN O
regions NN NN O
related NN NN O
to NN NN O
motor NN NN O
control NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
L NN NN O
- NN NN O
NOARG NN NN O
sub NN NN O
- NN NN O
chronic NN NN O
administration NN NN O
produced NN NN O
tolerance NN NN O
of NN NN O
L NN NN O
- NN NN O
NOARG NN NN O
and NN NN O
of NN NN O
haloperidol NN NN O
- NN NN O
induced NN NN O
catalepsy NN NN B-Disease
. NN NN O
   
It NN NN O
also NN NN O
induced NN NN O
an NN NN O
increase NN NN O
in NN NN O
the NN NN O
number NN NN O
of NN NN O
NADPH NN NN O
- NN NN O
d NN NN O
- NN NN O
positive NN NN O
cells NN NN O
in NN NN O
the NN NN O
dorsal NN NN O
part NN NN O
of NN NN O
the NN NN O
caudate NN NN O
and NN NN O
accumbens NN NN O
nuclei NN NN O
compared NN NN O
with NN NN O
haloperidol NN NN O
and NN NN O
in NN NN O
the NN NN O
pedunculopontine NN NN O
tegmental NN NN O
nucleus NN NN O
compared NN NN O
with NN NN O
saline NN NN O
. NN NN O
   
In NN NN O
contrast NN NN O
, NN NN O
there NN NN O
was NN NN O
a NN NN O
decrease NN NN O
in NN NN O
NADPH NN NN O
- NN NN O
d NN NN O
neuron NN NN O
number NN NN O
in NN NN O
the NN NN O
substantia NN NN O
nigra NN NN O
, NN NN O
pars NN NN O
compacta NN NN O
in NN NN O
both NN NN O
haloperidol NN NN O
- NN NN O
treated NN NN O
and NN NN O
L NN NN O
- NN NN O
NOARG NN NN O
- NN NN O
treated NN NN O
animals NN NN O
. NN NN O
   
CONCLUSIONS NN NN O
: NN NN O
The NN NN O
results NN NN O
give NN NN O
further NN NN O
support NN NN O
to NN NN O
the NN NN O
hypothesis NN NN O
that NN NN O
NO NN NN O
plays NN NN O
a NN NN O
role NN NN O
in NN NN O
motor NN NN O
behavior NN NN O
control NN NN O
and NN NN O
suggest NN NN O
that NN NN O
it NN NN O
may NN NN O
take NN NN O
part NN NN O
in NN NN O
the NN NN O
synaptic NN NN O
changes NN NN O
produced NN NN O
by NN NN O
antipsychotic NN NN O
treatment NN NN O
. NN NN O
   
Prolonged NN NN O
left NN NN B-Disease
ventricular NN NN I-Disease
dysfunction NN NN I-Disease
occurs NN NN O
in NN NN O
patients NN NN O
with NN NN O
coronary NN NN B-Disease
artery NN NN I-Disease
disease NN NN I-Disease
after NN NN O
both NN NN O
dobutamine NN NN O
and NN NN O
exercise NN NN O
induced NN NN O
myocardial NN NN B-Disease
ischaemia NN NN I-Disease
. NN NN O
   
OBJECTIVE NN NN O
: NN NN O
To NN NN O
determine NN NN O
whether NN NN O
pharmacological NN NN O
stress NN NN O
leads NN NN O
to NN NN O
prolonged NN NN O
but NN NN O
reversible NN NN O
left NN NN B-Disease
ventricular NN NN I-Disease
dysfunction NN NN I-Disease
in NN NN O
patients NN NN O
with NN NN O
coronary NN NN B-Disease
artery NN NN I-Disease
disease NN NN I-Disease
, NN NN O
similar NN NN O
to NN NN O
that NN NN O
seen NN NN O
after NN NN O
exercise NN NN O
. NN NN O
   
DESIGN NN NN O
: NN NN O
A NN NN O
randomised NN NN O
crossover NN NN O
study NN NN O
of NN NN O
recovery NN NN O
time NN NN O
of NN NN O
systolic NN NN O
and NN NN O
diastolic NN NN O
left NN NN O
ventricular NN NN O
function NN NN O
after NN NN O
exercise NN NN O
and NN NN O
dobutamine NN NN O
induced NN NN O
ischaemia NN NN B-Disease
. NN NN O
   
SUBJECTS NN NN O
: NN NN O
10 NN NN O
patients NN NN O
with NN NN O
stable NN NN B-Disease
angina NN NN I-Disease
, NN NN O
angiographically NN NN O
proven NN NN O
coronary NN NN B-Disease
artery NN NN I-Disease
disease NN NN I-Disease
, NN NN O
and NN NN O
normal NN NN O
left NN NN O
ventricular NN NN O
function NN NN O
. NN NN O
   
INTERVENTIONS NN NN O
: NN NN O
Treadmill NN NN O
exercise NN NN O
and NN NN O
dobutamine NN NN O
stress NN NN O
were NN NN O
performed NN NN O
on NN NN O
different NN NN O
days NN NN O
. NN NN O
   
Quantitative NN NN O
assessment NN NN O
of NN NN O
systolic NN NN O
and NN NN O
diastolic NN NN O
left NN NN O
ventricular NN NN O
function NN NN O
was NN NN O
performed NN NN O
using NN NN O
transthoracic NN NN O
echocardiography NN NN O
at NN NN O
baseline NN NN O
and NN NN O
at NN NN O
regular NN NN O
intervals NN NN O
after NN NN O
each NN NN O
test NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
Both NN NN O
forms NN NN O
of NN NN O
stress NN NN O
led NN NN O
to NN NN O
prolonged NN NN O
but NN NN O
reversible NN NN O
systolic NN NN O
and NN NN O
diastolic NN NN O
dysfunction NN NN O
. NN NN O
   
There NN NN O
was NN NN O
no NN NN O
difference NN NN O
in NN NN O
the NN NN O
maximum NN NN O
double NN NN O
product NN NN O
( NN NN O
p NN NN O
= NN NN O
0 NN NN O
. NN NN O
53 NN NN O
) NN NN O
or NN NN O
ST NN NN O
depression NN NN B-Disease
( NN NN O
p NN NN O
= NN NN O
0 NN NN O
. NN NN O
63 NN NN O
) NN NN O
with NN NN O
either NN NN O
form NN NN O
of NN NN O
stress NN NN O
. NN NN O
   
After NN NN O
exercise NN NN O
, NN NN O
ejection NN NN O
fraction NN NN O
was NN NN O
reduced NN NN O
at NN NN O
15 NN NN O
and NN NN O
30 NN NN O
minutes NN NN O
compared NN NN O
with NN NN O
baseline NN NN O
( NN NN O
mean NN NN O
( NN NN O
SEM NN NN O
) NN NN O
, NN NN O
- NN NN O
5 NN NN O
. NN NN O
6 NN NN O
( NN NN O
1 NN NN O
. NN NN O
5 NN NN O
) NN NN O
% NN NN O
, NN NN O
p NN NN O
< NN NN O
0 NN NN O
. NN NN O
05 NN NN O
; NN NN O
and NN NN O
- NN NN O
6 NN NN O
. NN NN O
1 NN NN O
( NN NN O
2 NN NN O
. NN NN O
2 NN NN O
) NN NN O
% NN NN O
, NN NN O
p NN NN O
< NN NN O
0 NN NN O
. NN NN O
01 NN NN O
) NN NN O
, NN NN O
and NN NN O
at NN NN O
30 NN NN O
and NN NN O
45 NN NN O
minutes NN NN O
after NN NN O
dobutamine NN NN O
( NN NN O
- NN NN O
10 NN NN O
. NN NN O
8 NN NN O
( NN NN O
1 NN NN O
. NN NN O
8 NN NN O
) NN NN O
% NN NN O
and NN NN O
- NN NN O
5 NN NN O
. NN NN O
5 NN NN O
( NN NN O
1 NN NN O
. NN NN O
8 NN NN O
) NN NN O
% NN NN O
, NN NN O
both NN NN O
p NN NN O
< NN NN O
0 NN NN O
. NN NN O
01 NN NN O
) NN NN O
. NN NN O
   
Regional NN NN O
analysis NN NN O
showed NN NN O
a NN NN O
reduction NN NN O
in NN NN O
the NN NN O
worst NN NN O
affected NN NN O
segment NN NN O
15 NN NN O
and NN NN O
30 NN NN O
minutes NN NN O
after NN NN O
exercise NN NN O
( NN NN O
- NN NN O
27 NN NN O
. NN NN O
9 NN NN O
( NN NN O
7 NN NN O
. NN NN O
2 NN NN O
) NN NN O
% NN NN O
and NN NN O
- NN NN O
28 NN NN O
. NN NN O
6 NN NN O
( NN NN O
5 NN NN O
. NN NN O
7 NN NN O
) NN NN O
% NN NN O
, NN NN O
both NN NN O
p NN NN O
< NN NN O
0 NN NN O
. NN NN O
01 NN NN O
) NN NN O
, NN NN O
and NN NN O
at NN NN O
30 NN NN O
minutes NN NN O
after NN NN O
dobutamine NN NN O
( NN NN O
- NN NN O
32 NN NN O
( NN NN O
5 NN NN O
. NN NN O
3 NN NN O
) NN NN O
% NN NN O
, NN NN O
p NN NN O
< NN NN O
0 NN NN O
. NN NN O
01 NN NN O
) NN NN O
. NN NN O
   
The NN NN O
isovolumic NN NN O
relaxation NN NN O
period NN NN O
was NN NN O
prolonged NN NN O
45 NN NN O
minutes NN NN O
after NN NN O
each NN NN O
form NN NN O
of NN NN O
stress NN NN O
( NN NN O
p NN NN O
< NN NN O
0 NN NN O
. NN NN O
05 NN NN O
) NN NN O
. NN NN O
   
CONCLUSIONS NN NN O
: NN NN O
In NN NN O
patients NN NN O
with NN NN O
coronary NN NN B-Disease
artery NN NN I-Disease
disease NN NN I-Disease
, NN NN O
dobutamine NN NN O
induced NN NN O
ischaemia NN NN B-Disease
results NN NN O
in NN NN O
prolonged NN NN O
reversible NN NN O
left NN NN B-Disease
ventricular NN NN I-Disease
dysfunction NN NN I-Disease
, NN NN O
presumed NN NN O
to NN NN O
be NN NN O
myocardial NN NN B-Disease
stunning NN NN I-Disease
, NN NN O
similar NN NN O
to NN NN O
that NN NN O
seen NN NN O
after NN NN O
exercise NN NN O
. NN NN O
   
Dobutamine NN NN O
induced NN NN O
ischaemia NN NN B-Disease
could NN NN O
therefore NN NN O
be NN NN O
used NN NN O
to NN NN O
study NN NN O
the NN NN O
pathophysiology NN NN O
of NN NN O
this NN NN O
phenomenon NN NN O
further NN NN O
in NN NN O
patients NN NN O
with NN NN O
coronary NN NN B-Disease
artery NN NN I-Disease
disease NN NN I-Disease
. NN NN O
   
Anorexigens NN NN O
and NN NN O
pulmonary NN NN B-Disease
hypertension NN NN I-Disease
in NN NN O
the NN NN O
United NN NN O
States NN NN O
: NN NN O
results NN NN O
from NN NN O
the NN NN O
surveillance NN NN O
of NN NN O
North NN NN O
American NN NN O
pulmonary NN NN B-Disease
hypertension NN NN I-Disease
. NN NN O
   
BACKGROUND NN NN O
: NN NN O
The NN NN O
use NN NN O
of NN NN O
appetite NN NN O
suppressants NN NN O
in NN NN O
Europe NN NN O
has NN NN O
been NN NN O
associated NN NN O
with NN NN O
the NN NN O
development NN NN O
of NN NN O
primary NN NN B-Disease
pulmonary NN NN I-Disease
hypertension NN NN I-Disease
( NN NN O
PPH NN NN B-Disease
) NN NN O
. NN NN O
   
Recently NN NN O
, NN NN O
fenfluramine NN NN O
appetite NN NN O
suppressants NN NN O
became NN NN O
widely NN NN O
used NN NN O
in NN NN O
the NN NN O
United NN NN O
States NN NN O
but NN NN O
were NN NN O
withdrawn NN NN O
in NN NN O
September NN NN O
1997 NN NN O
because NN NN O
of NN NN O
concerns NN NN O
over NN NN O
adverse NN NN O
effects NN NN O
. NN NN O
   
MATERIALS NN NN O
AND NN NN O
METHODS NN NN O
: NN NN O
We NN NN O
conducted NN NN O
a NN NN O
prospective NN NN O
surveillance NN NN O
study NN NN O
on NN NN O
patients NN NN O
diagnosed NN NN O
with NN NN O
pulmonary NN NN B-Disease
hypertension NN NN I-Disease
at NN NN O
12 NN NN O
large NN NN O
referral NN NN O
centers NN NN O
in NN NN O
North NN NN O
America NN NN O
. NN NN O
   
Data NN NN O
collected NN NN O
on NN NN O
patients NN NN O
seen NN NN O
from NN NN O
September NN NN O
1 NN NN O
, NN NN O
1996 NN NN O
, NN NN O
to NN NN O
December NN NN O
31 NN NN O
, NN NN O
1997 NN NN O
, NN NN O
included NN NN O
the NN NN O
cause NN NN O
of NN NN O
the NN NN O
pulmonary NN NN B-Disease
hypertension NN NN I-Disease
and NN NN O
its NN NN O
severity NN NN O
. NN NN O
   
Patients NN NN O
with NN NN O
no NN NN O
identifiable NN NN O
cause NN NN O
of NN NN O
pulmonary NN NN B-Disease
hypertension NN NN I-Disease
were NN NN O
classed NN NN O
as NN NN O
PPH NN NN B-Disease
. NN NN O
   
A NN NN O
history NN NN O
of NN NN O
drug NN NN O
exposure NN NN O
also NN NN O
was NN NN O
taken NN NN O
with NN NN O
special NN NN O
attention NN NN O
on NN NN O
the NN NN O
use NN NN O
of NN NN O
antidepressants NN NN O
, NN NN O
anorexigens NN NN O
, NN NN O
and NN NN O
amphetamines NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
Five NN NN O
hundred NN NN O
seventy NN NN O
- NN NN O
nine NN NN O
patients NN NN O
were NN NN O
studied NN NN O
, NN NN O
205 NN NN O
with NN NN O
PPH NN NN B-Disease
and NN NN O
374 NN NN O
with NN NN O
pulmonary NN NN B-Disease
hypertension NN NN I-Disease
from NN NN O
other NN NN O
causes NN NN O
( NN NN O
secondary NN NN O
pulmonary NN NN B-Disease
hypertension NN NN I-Disease
[ NN NN O
SPH NN NN O
] NN NN O
) NN NN O
. NN NN O
   
The NN NN O
use NN NN O
of NN NN O
anorexigens NN NN O
was NN NN O
common NN NN O
in NN NN O
both NN NN O
groups NN NN O
. NN NN O
   
However NN NN O
, NN NN O
of NN NN O
the NN NN O
medications NN NN O
surveyed NN NN O
, NN NN O
only NN NN O
the NN NN O
fenfluramines NN NN O
had NN NN O
a NN NN O
significant NN NN O
preferential NN NN O
association NN NN O
with NN NN O
PPH NN NN B-Disease
as NN NN O
compared NN NN O
with NN NN O
SPH NN NN O
( NN NN O
adjusted NN NN O
odds NN NN O
ratio NN NN O
for NN NN O
use NN NN O
> NN NN O
6 NN NN O
months NN NN O
, NN NN O
7 NN NN O
. NN NN O
5 NN NN O
; NN NN O
95 NN NN O
% NN NN O
confidence NN NN O
interval NN NN O
, NN NN O
1 NN NN O
. NN NN O
7 NN NN O
to NN NN O
32 NN NN O
. NN NN O
4 NN NN O
) NN NN O
. NN NN O
   
The NN NN O
association NN NN O
was NN NN O
stronger NN NN O
with NN NN O
longer NN NN O
duration NN NN O
of NN NN O
use NN NN O
when NN NN O
compared NN NN O
to NN NN O
shorter NN NN O
duration NN NN O
of NN NN O
use NN NN O
and NN NN O
was NN NN O
more NN NN O
pronounced NN NN O
in NN NN O
recent NN NN O
users NN NN O
than NN NN O
in NN NN O
remote NN NN O
users NN NN O
. NN NN O
   
An NN NN O
unexpectedly NN NN O
high NN NN O
( NN NN O
11 NN NN O
. NN NN O
4 NN NN O
% NN NN O
) NN NN O
number NN NN O
of NN NN O
patients NN NN O
with NN NN O
SPH NN NN O
had NN NN O
used NN NN O
anorexigens NN NN O
. NN NN O
   
CONCLUSION NN NN O
: NN NN O
The NN NN O
magnitude NN NN O
of NN NN O
the NN NN O
association NN NN O
with NN NN O
PPH NN NN B-Disease
, NN NN O
the NN NN O
increase NN NN O
of NN NN O
association NN NN O
with NN NN O
increasing NN NN O
duration NN NN O
of NN NN O
use NN NN O
, NN NN O
and NN NN O
the NN NN O
specificity NN NN O
for NN NN O
fenfluramines NN NN O
are NN NN O
consistent NN NN O
with NN NN O
previous NN NN O
studies NN NN O
indicating NN NN O
that NN NN O
fenfluramines NN NN O
are NN NN O
causally NN NN O
related NN NN O
to NN NN O
PPH NN NN B-Disease
. NN NN O
   
The NN NN O
high NN NN O
prevalence NN NN O
of NN NN O
anorexigen NN NN O
use NN NN O
in NN NN O
patients NN NN O
with NN NN O
SPH NN NN O
also NN NN O
raises NN NN O
the NN NN O
possibility NN NN O
that NN NN O
these NN NN O
drugs NN NN O
precipitate NN NN O
pulmonary NN NN B-Disease
hypertension NN NN I-Disease
in NN NN O
patients NN NN O
with NN NN O
underlying NN NN O
conditions NN NN O
associated NN NN O
with NN NN O
SPH NN NN O
. NN NN O
   
Clinical NN NN O
aspects NN NN O
of NN NN O
heparin NN NN O
- NN NN O
induced NN NN O
thrombocytopenia NN NN B-Disease
and NN NN O
thrombosis NN NN B-Disease
and NN NN O
other NN NN O
side NN NN O
effects NN NN O
of NN NN O
heparin NN NN O
therapy NN NN O
. NN NN O
   
Heparin NN NN O
, NN NN O
first NN NN O
used NN NN O
to NN NN O
prevent NN NN O
the NN NN O
clotting NN NN O
of NN NN O
blood NN NN O
in NN NN O
vitro NN NN O
, NN NN O
has NN NN O
been NN NN O
clinically NN NN O
used NN NN O
to NN NN O
treat NN NN O
thrombosis NN NN B-Disease
for NN NN O
more NN NN O
than NN NN O
50 NN NN O
years NN NN O
. NN NN O
   
Although NN NN O
several NN NN O
new NN NN O
anticoagulant NN NN O
drugs NN NN O
are NN NN O
in NN NN O
development NN NN O
, NN NN O
heparin NN NN O
remains NN NN O
the NN NN O
anticoagulant NN NN O
of NN NN O
choice NN NN O
to NN NN O
treat NN NN O
acute NN NN O
thrombotic NN NN B-Disease
episodes NN NN O
. NN NN O
   
The NN NN O
clinical NN NN O
effects NN NN O
of NN NN O
heparin NN NN O
are NN NN O
meritorious NN NN O
, NN NN O
but NN NN O
side NN NN O
effects NN NN O
do NN NN O
exist NN NN O
. NN NN O
   
Bleeding NN NN B-Disease
is NN NN O
the NN NN O
primary NN NN O
untoward NN NN O
effect NN NN O
of NN NN O
heparin NN NN O
. NN NN O
   
Major NN NN O
bleeding NN NN B-Disease
is NN NN O
of NN NN O
primary NN NN O
concern NN NN O
in NN NN O
patients NN NN O
receiving NN NN O
heparin NN NN O
therapy NN NN O
. NN NN O
   
However NN NN O
, NN NN O
additional NN NN O
important NN NN O
untoward NN NN O
effects NN NN O
of NN NN O
heparin NN NN O
therapy NN NN O
include NN NN O
heparin NN NN O
- NN NN O
induced NN NN O
thrombocytopenia NN NN B-Disease
, NN NN O
heparin NN NN O
- NN NN O
associated NN NN O
osteoporosis NN NN B-Disease
, NN NN O
eosinophilia NN NN B-Disease
, NN NN O
skin NN NN B-Disease
reactions NN NN I-Disease
, NN NN O
allergic NN NN B-Disease
reactions NN NN I-Disease
other NN NN O
than NN NN O
thrombocytopenia NN NN B-Disease
, NN NN O
alopecia NN NN B-Disease
, NN NN O
transaminasemia NN NN O
, NN NN O
hyperkalemia NN NN B-Disease
, NN NN O
hypoaldosteronism NN NN B-Disease
, NN NN O
and NN NN O
priapism NN NN B-Disease
. NN NN O
   
These NN NN O
side NN NN O
effects NN NN O
are NN NN O
relatively NN NN O
rare NN NN O
in NN NN O
a NN NN O
given NN NN O
individual NN NN O
, NN NN O
but NN NN O
given NN NN O
the NN NN O
extremely NN NN O
widespread NN NN O
use NN NN O
of NN NN O
heparin NN NN O
, NN NN O
some NN NN O
are NN NN O
quite NN NN O
common NN NN O
, NN NN O
particularly NN NN O
HITT NN NN B-Disease
and NN NN O
osteoporosis NN NN B-Disease
. NN NN O
   
Although NN NN O
reasonable NN NN O
incidences NN NN O
of NN NN O
many NN NN O
of NN NN O
these NN NN O
side NN NN O
effects NN NN O
can NN NN O
be NN NN O
"""""""" NN NN O
softly NN NN O
"""""""" NN NN O
deduced NN NN O
from NN NN O
current NN NN O
reports NN NN O
dealing NN NN O
with NN NN O
unfractionated NN NN O
heparin NN NN O
, NN NN O
at NN NN O
present NN NN O
the NN NN O
incidences NN NN O
of NN NN O
these NN NN O
side NN NN O
effects NN NN O
with NN NN O
newer NN NN O
low NN NN O
molecular NN NN O
weight NN NN O
heparins NN NN O
appear NN NN O
to NN NN O
be NN NN O
much NN NN O
less NN NN O
common NN NN O
. NN NN O
   
However NN NN O
, NN NN O
only NN NN O
longer NN NN O
experience NN NN O
will NN NN O
more NN NN O
clearly NN NN O
define NN NN O
the NN NN O
incidence NN NN O
of NN NN O
each NN NN O
side NN NN O
effect NN NN O
with NN NN O
low NN NN O
molecular NN NN O
weight NN NN O
preparations NN NN O
. NN NN O
   
A NN NN O
case NN NN O
of NN NN O
bilateral NN NN O
optic NN NN B-Disease
neuropathy NN NN I-Disease
in NN NN O
a NN NN O
patient NN NN O
on NN NN O
tacrolimus NN NN O
( NN NN O
FK506 NN NN O
) NN NN O
therapy NN NN O
after NN NN O
liver NN NN O
transplantation NN NN O
. NN NN O
   
PURPOSE NN NN O
: NN NN O
To NN NN O
report NN NN O
a NN NN O
case NN NN O
of NN NN O
bilateral NN NN O
optic NN NN B-Disease
neuropathy NN NN I-Disease
in NN NN O
a NN NN O
patient NN NN O
receiving NN NN O
tacrolimus NN NN O
( NN NN O
FK NN NN O
506 NN NN O
, NN NN O
Prograf NN NN O
; NN NN O
Fujisawa NN NN O
USA NN NN O
, NN NN O
Inc NN NN O
, NN NN O
Deerfield NN NN O
, NN NN O
Illinois NN NN O
) NN NN O
for NN NN O
immunosuppression NN NN O
after NN NN O
orthotropic NN NN O
liver NN NN O
transplantation NN NN O
. NN NN O
   
METHOD NN NN O
: NN NN O
Case NN NN O
report NN NN O
. NN NN O
   
In NN NN O
a NN NN O
58 NN NN O
- NN NN O
year NN NN O
- NN NN O
old NN NN O
man NN NN O
receiving NN NN O
tacrolimus NN NN O
after NN NN O
orthotropic NN NN O
liver NN NN O
transplantation NN NN O
, NN NN O
serial NN NN O
neuro NN NN O
- NN NN O
ophthalmologic NN NN O
examinations NN NN O
and NN NN O
laboratory NN NN O
studies NN NN O
were NN NN O
performed NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
The NN NN O
patient NN NN O
had NN NN O
episodic NN NN O
deterioration NN NN O
of NN NN O
vision NN NN O
in NN NN O
both NN NN O
eyes NN NN O
, NN NN O
with NN NN O
clinical NN NN O
features NN NN O
resembling NN NN O
ischemic NN NN B-Disease
optic NN NN I-Disease
neuropathies NN NN I-Disease
. NN NN O
   
Deterioration NN NN B-Disease
of NN NN I-Disease
vision NN NN I-Disease
occurred NN NN O
despite NN NN O
discontinuation NN NN O
of NN NN O
the NN NN O
tacrolimus NN NN O
. NN NN O
   
CONCLUSION NN NN O
: NN NN O
Tacrolimus NN NN O
and NN NN O
other NN NN O
immunosuppressive NN NN O
agents NN NN O
may NN NN O
be NN NN O
associated NN NN O
with NN NN O
optic NN NN B-Disease
nerve NN NN I-Disease
toxicity NN NN I-Disease
. NN NN O
   
Hypercalcemia NN NN B-Disease
, NN NN O
arrhythmia NN NN B-Disease
, NN NN O
and NN NN O
mood NN NN O
stabilizers NN NN O
. NN NN O
   
Recent NN NN O
findings NN NN O
in NN NN O
a NN NN O
bipolar NN NN B-Disease
patient NN NN O
receiving NN NN O
maintenance NN NN O
lithium NN NN O
therapy NN NN O
who NN NN O
developed NN NN O
hypercalcemia NN NN B-Disease
and NN NN O
severe NN NN O
bradyarrhythmia NN NN B-Disease
prompted NN NN O
the NN NN O
authors NN NN O
to NN NN O
conduct NN NN O
a NN NN O
retrospective NN NN O
study NN NN O
of NN NN O
bipolar NN NN B-Disease
patients NN NN O
with NN NN O
lithium NN NN O
- NN NN O
associated NN NN O
hypercalcemia NN NN B-Disease
. NN NN O
   
A NN NN O
printout NN NN O
of NN NN O
all NN NN O
cases NN NN O
of NN NN O
hypercalcemia NN NN B-Disease
that NN NN O
presented NN NN O
during NN NN O
a NN NN O
1 NN NN O
- NN NN O
year NN NN O
period NN NN O
was NN NN O
generated NN NN O
. NN NN O
   
After NN NN O
eliminating NN NN O
spurious NN NN O
hypercalcemias NN NN B-Disease
or NN NN O
those NN NN O
associated NN NN O
with NN NN O
intravenous NN NN O
fluids NN NN O
, NN NN O
the NN NN O
authors NN NN O
identified NN NN O
18 NN NN O
non NN NN O
- NN NN O
lithium NN NN O
- NN NN O
treated NN NN O
patients NN NN O
with NN NN O
hypercalcemias NN NN B-Disease
related NN NN O
to NN NN O
malignancies NN NN B-Disease
and NN NN O
other NN NN O
medical NN NN O
conditions NN NN O
( NN NN O
group NN NN O
A NN NN O
) NN NN O
and NN NN O
12 NN NN O
patients NN NN O
with NN NN O
lithium NN NN O
- NN NN O
associated NN NN O
hypercalcemia NN NN B-Disease
( NN NN O
group NN NN O
B NN NN O
) NN NN O
. NN NN O
   
Patients NN NN O
in NN NN O
group NN NN O
B NN NN O
were NN NN O
not NN NN O
comparable NN NN O
to NN NN O
those NN NN O
in NN NN O
group NN NN O
A NN NN O
, NN NN O
as NN NN O
the NN NN O
latter NN NN O
were NN NN O
medically NN NN O
compromised NN NN O
and NN NN O
were NN NN O
receiving NN NN O
multiple NN NN O
pharmacotherapies NN NN O
. NN NN O
   
Thus NN NN O
, NN NN O
two NN NN O
control NN NN O
groups NN NN O
were NN NN O
generated NN NN O
: NN NN O
group NN NN O
C1 NN NN O
, NN NN O
which NN NN O
included NN NN O
age NN NN O
- NN NN O
and NN NN O
sex NN NN O
- NN NN O
comparable NN NN O
lithium NN NN O
- NN NN O
treated NN NN O
bipolar NN NN B-Disease
normocalcemic NN NN O
patients NN NN O
, NN NN O
and NN NN O
group NN NN O
C2 NN NN O
, NN NN O
which NN NN O
included NN NN O
bipolar NN NN B-Disease
normocalcemic NN NN O
patients NN NN O
treated NN NN O
with NN NN O
anticonvulsant NN NN O
mood NN NN O
stabilizers NN NN O
. NN NN O
   
The NN NN O
electrocardiographic NN NN O
( NN NN O
ECG NN NN O
) NN NN O
findings NN NN O
for NN NN O
patients NN NN O
in NN NN O
group NN NN O
B NN NN O
were NN NN O
compared NN NN O
with NN NN O
those NN NN O
of NN NN O
patients NN NN O
in NN NN O
groups NN NN O
C1 NN NN O
and NN NN O
C2 NN NN O
. NN NN O
   
It NN NN O
was NN NN O
found NN NN O
that NN NN O
these NN NN O
groups NN NN O
did NN NN O
not NN NN O
differ NN NN O
in NN NN O
their NN NN O
overall NN NN O
frequency NN NN O
of NN NN O
ECG NN NN O
abnormalities NN NN O
; NN NN O
however NN NN O
, NN NN O
there NN NN O
were NN NN O
significant NN NN O
differences NN NN O
in NN NN O
the NN NN O
frequency NN NN O
of NN NN O
conduction NN NN O
defects NN NN O
. NN NN O
   
Patients NN NN O
with NN NN O
hypercalcemia NN NN B-Disease
resulting NN NN O
from NN NN O
medical NN NN O
diseases NN NN O
and NN NN O
bipolar NN NN B-Disease
patients NN NN O
with NN NN O
lithium NN NN O
- NN NN O
associated NN NN O
hypercalcemia NN NN B-Disease
had NN NN O
significantly NN NN O
higher NN NN O
frequencies NN NN O
of NN NN O
conduction NN NN O
defects NN NN O
. NN NN O
   
Patients NN NN O
in NN NN O
group NN NN O
A NN NN O
had NN NN O
significant NN NN O
mortality NN NN O
at NN NN O
2 NN NN O
- NN NN O
year NN NN O
follow NN NN O
- NN NN O
up NN NN O
( NN NN O
28 NN NN O
% NN NN O
) NN NN O
, NN NN O
in NN NN O
contrast NN NN O
to NN NN O
zero NN NN O
mortality NN NN O
in NN NN O
the NN NN O
other NN NN O
three NN NN O
groups NN NN O
. NN NN O
   
The NN NN O
clinical NN NN O
implications NN NN O
of NN NN O
these NN NN O
findings NN NN O
are NN NN O
discussed NN NN O
. NN NN O
   
Attenuation NN NN O
of NN NN O
nephrotoxicity NN NN B-Disease
by NN NN O
a NN NN O
novel NN NN O
lipid NN NN O
nanosphere NN NN O
( NN NN O
NS NN NN O
- NN NN O
718 NN NN O
) NN NN O
incorporating NN NN O
amphotericin NN NN O
B NN NN O
. NN NN O
   
NS NN NN O
- NN NN O
718 NN NN O
, NN NN O
a NN NN O
lipid NN NN O
nanosphere NN NN O
incorporating NN NN O
amphotericin NN NN O
B NN NN O
, NN NN O
is NN NN O
effective NN NN O
against NN NN O
pathogenic NN NN O
fungi NN NN O
and NN NN O
has NN NN O
low NN NN O
toxicity NN NN B-Disease
. NN NN O
   
We NN NN O
compared NN NN O
the NN NN O
toxicity NN NN B-Disease
of NN NN O
NS NN NN O
- NN NN O
718 NN NN O
with NN NN O
that NN NN O
of NN NN O
Fungizone NN NN O
( NN NN O
amphotericin NN NN O
B NN NN O
- NN NN O
sodium NN NN O
deoxycholate NN NN O
; NN NN O
D NN NN O
- NN NN O
AmB NN NN O
) NN NN O
in NN NN O
vitro NN NN O
using NN NN O
renal NN NN O
cell NN NN O
cultures NN NN O
and NN NN O
in NN NN O
vivo NN NN O
by NN NN O
biochemical NN NN O
analysis NN NN O
, NN NN O
histopathological NN NN O
study NN NN O
of NN NN O
the NN NN O
kidney NN NN O
and NN NN O
pharmacokinetic NN NN O
study NN NN O
of NN NN O
amphotericin NN NN O
B NN NN O
following NN NN O
intravenous NN NN O
infusion NN NN O
of NN NN O
the NN NN O
formulation NN NN O
in NN NN O
rats NN NN O
. NN NN O
   
Incubation NN NN O
with NN NN O
NS NN NN O
- NN NN O
718 NN NN O
resulted NN NN O
in NN NN O
significantly NN NN O
less NN NN O
damage NN NN O
of NN NN O
cultured NN NN O
human NN NN O
renal NN NN O
proximal NN NN O
tubular NN NN O
epithelial NN NN O
cells NN NN O
compared NN NN O
with NN NN O
D NN NN O
- NN NN O
AmB NN NN O
. NN NN O
   
Serum NN NN O
blood NN NN O
urea NN NN O
and NN NN O
creatinine NN NN O
concentrations NN NN O
increased NN NN O
significantly NN NN O
in NN NN O
rats NN NN O
given NN NN O
an NN NN O
iv NN NN O
infusion NN NN O
of NN NN O
D NN NN O
- NN NN O
AmB NN NN O
3 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
but NN NN O
not NN NN O
in NN NN O
those NN NN O
given NN NN O
the NN NN O
same NN NN O
dose NN NN O
of NN NN O
NS NN NN O
- NN NN O
718 NN NN O
. NN NN O
   
Histopathological NN NN O
examination NN NN O
of NN NN O
the NN NN O
kidney NN NN O
showed NN NN O
tubular NN NN B-Disease
necrosis NN NN I-Disease
in NN NN O
D NN NN O
- NN NN O
AmB NN NN O
- NN NN O
treated NN NN O
rats NN NN O
but NN NN O
no NN NN O
change NN NN O
in NN NN O
NS NN NN O
- NN NN O
718 NN NN O
- NN NN O
treated NN NN O
rats NN NN O
. NN NN O
   
Amphotericin NN NN O
B NN NN O
concentrations NN NN O
in NN NN O
the NN NN O
kidney NN NN O
in NN NN O
NS NN NN O
- NN NN O
718 NN NN O
- NN NN O
treated NN NN O
rats NN NN O
were NN NN O
higher NN NN O
than NN NN O
those NN NN O
in NN NN O
D NN NN O
- NN NN O
AmB NN NN O
- NN NN O
treated NN NN O
rats NN NN O
. NN NN O
   
Our NN NN O
in NN NN O
vitro NN NN O
and NN NN O
in NN NN O
vivo NN NN O
results NN NN O
suggest NN NN O
that NN NN O
incorporation NN NN O
of NN NN O
amphotericin NN NN O
B NN NN O
into NN NN O
lipid NN NN O
nanospheres NN NN O
of NN NN O
NS NN NN O
- NN NN O
718 NN NN O
attenuates NN NN O
the NN NN O
nephrotoxicity NN NN B-Disease
of NN NN O
amphotericin NN NN O
B NN NN O
. NN NN O
   
Patterns NN NN O
of NN NN O
sulfadiazine NN NN O
acute NN NN B-Disease
nephrotoxicity NN NN I-Disease
. NN NN O
   
Sulfadiazine NN NN O
acute NN NN B-Disease
nephrotoxicity NN NN I-Disease
is NN NN O
reviving NN NN O
specially NN NN O
because NN NN O
of NN NN O
its NN NN O
use NN NN O
in NN NN O
toxoplasmosis NN NN B-Disease
in NN NN O
HIV NN NN O
- NN NN O
positive NN NN O
patients NN NN O
. NN NN O
   
We NN NN O
report NN NN O
4 NN NN O
cases NN NN O
, NN NN O
one NN NN O
of NN NN O
them NN NN O
in NN NN O
a NN NN O
previously NN NN O
healthy NN NN O
person NN NN O
. NN NN O
   
Under NN NN O
treatment NN NN O
with NN NN O
sulfadiazine NN NN O
they NN NN O
developed NN NN O
oliguria NN NN B-Disease
, NN NN O
abdominal NN NN B-Disease
pain NN NN I-Disease
, NN NN O
renal NN NN B-Disease
failure NN NN I-Disease
and NN NN O
showed NN NN O
multiple NN NN O
radiolucent NN NN O
renal NN NN B-Disease
calculi NN NN I-Disease
in NN NN O
echography NN NN O
. NN NN O
   
All NN NN O
patients NN NN O
recovered NN NN O
their NN NN O
previous NN NN O
normal NN NN O
renal NN NN O
function NN NN O
after NN NN O
adequate NN NN O
hydration NN NN O
and NN NN O
alcalinization NN NN O
. NN NN O
   
A NN NN O
nephrostomy NN NN O
tube NN NN O
had NN NN O
to NN NN O
be NN NN O
placed NN NN O
in NN NN O
one NN NN O
of NN NN O
the NN NN O
patients NN NN O
for NN NN O
ureteral NN NN B-Disease
lithiasis NN NN I-Disease
in NN NN O
a NN NN O
single NN NN O
functional NN NN O
kidney NN NN O
. NN NN O
   
   O
of NN NN O
them NN NN O
needed NN NN O
dialysis NN NN O
or NN NN O
a NN NN O
renal NN NN O
biopsy NN NN O
because NN NN O
of NN NN O
a NN NN O
typical NN NN O
benign NN NN O
course NN NN O
. NN NN O
   
Treatment NN NN O
with NN NN O
sulfadiazine NN NN O
requires NN NN O
exquisite NN NN O
control NN NN O
of NN NN O
renal NN NN O
function NN NN O
, NN NN O
an NN NN O
increase NN NN O
in NN NN O
water NN NN O
ingestion NN NN O
and NN NN O
possibly NN NN O
the NN NN O
alcalinization NN NN O
of NN NN O
the NN NN O
urine NN NN O
. NN NN O
   
We NN NN O
communicate NN NN O
a NN NN O
case NN NN O
in NN NN O
a NN NN O
previously NN NN O
healthy NN NN O
person NN NN O
, NN NN O
a NN NN O
fact NN NN O
not NN NN O
found NN NN O
in NN NN O
the NN NN O
recent NN NN O
literature NN NN O
. NN NN O
   
Probably NN NN O
many NN NN O
more NN NN O
cases NN NN O
are NN NN O
not NN NN O
detected NN NN O
. NN NN O
   
We NN NN O
think NN NN O
that NN NN O
a NN NN O
prospective NN NN O
study NN NN O
would NN NN O
be NN NN O
useful NN NN O
. NN NN O
   
Downbeat NN NN B-Disease
nystagmus NN NN I-Disease
associated NN NN O
with NN NN O
intravenous NN NN O
patient NN NN O
- NN NN O
controlled NN NN O
administration NN NN O
of NN NN O
morphine NN NN O
. NN NN O
   
IMPLICATIONS NN NN O
: NN NN O
This NN NN O
case NN NN O
documents NN NN O
a NN NN O
patient NN NN O
who NN NN O
developed NN NN O
dizziness NN NN B-Disease
with NN NN O
downbeating NN NN B-Disease
nystagmus NN NN I-Disease
while NN NN O
receiving NN NN O
a NN NN O
relatively NN NN O
large NN NN O
dose NN NN O
of NN NN O
IV NN NN O
patient NN NN O
- NN NN O
controlled NN NN O
analgesia NN NN O
morphine NN NN O
. NN NN O
   
Although NN NN O
there NN NN O
have NN NN O
been NN NN O
case NN NN O
reports NN NN O
of NN NN O
epidural NN NN O
morphine NN NN O
with NN NN O
these NN NN O
symptoms NN NN O
and NN NN O
signs NN NN O
, NN NN O
this NN NN O
has NN NN O
not NN NN O
been NN NN O
previously NN NN O
documented NN NN O
with NN NN O
IV NN NN O
or NN NN O
patient NN NN O
- NN NN O
controlled NN NN O
analgesia NN NN O
morphine NN NN O
. NN NN O
   
Hemodynamic NN NN O
and NN NN O
antiadrenergic NN NN O
effects NN NN O
of NN NN O
dronedarone NN NN O
and NN NN O
amiodarone NN NN O
in NN NN O
animals NN NN O
with NN NN O
a NN NN O
healed NN NN O
myocardial NN NN B-Disease
infarction NN NN I-Disease
. NN NN O
   
The NN NN O
hemodynamic NN NN O
and NN NN O
antiadrenergic NN NN O
effects NN NN O
of NN NN O
dronedarone NN NN O
, NN NN O
a NN NN O
noniodinated NN NN O
compound NN NN O
structurally NN NN O
related NN NN O
to NN NN O
amiodarone NN NN O
, NN NN O
were NN NN O
compared NN NN O
with NN NN O
those NN NN O
of NN NN O
amiodarone NN NN O
after NN NN O
prolonged NN NN O
oral NN NN O
administration NN NN O
, NN NN O
both NN NN O
at NN NN O
rest NN NN O
and NN NN O
during NN NN O
sympathetic NN NN O
stimulation NN NN O
in NN NN O
conscious NN NN O
dogs NN NN O
with NN NN O
a NN NN O
healed NN NN O
myocardial NN NN B-Disease
infarction NN NN I-Disease
. NN NN O
   
All NN NN O
dogs NN NN O
( NN NN O
n NN NN O
= NN NN O
6 NN NN O
) NN NN O
randomly NN NN O
received NN NN O
orally NN NN O
dronedarone NN NN O
( NN NN O
10 NN NN O
and NN NN O
30 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
) NN NN O
, NN NN O
amiodarone NN NN O
( NN NN O
10 NN NN O
and NN NN O
30 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
) NN NN O
, NN NN O
and NN NN O
placebo NN NN O
twice NN NN O
daily NN NN O
for NN NN O
7 NN NN O
days NN NN O
, NN NN O
with NN NN O
a NN NN O
3 NN NN O
- NN NN O
week NN NN O
washout NN NN O
between NN NN O
consecutive NN NN O
treatments NN NN O
. NN NN O
   
Heart NN NN O
rate NN NN O
( NN NN O
HR NN NN O
) NN NN O
, NN NN O
mean NN NN O
arterial NN NN O
pressure NN NN O
( NN NN O
MBP NN NN O
) NN NN O
, NN NN O
positive NN NN O
rate NN NN O
of NN NN O
increase NN NN O
of NN NN O
left NN NN O
ventricular NN NN O
pressure NN NN O
( NN NN O
+ NN NN O
LVdP NN NN O
/ NN NN O
dt NN NN O
) NN NN O
, NN NN O
echocardiographically NN NN O
assessed NN NN O
left NN NN O
ventricular NN NN O
ejection NN NN O
fraction NN NN O
( NN NN O
LVEF NN NN O
) NN NN O
, NN NN O
and NN NN O
fractional NN NN O
shortening NN NN O
( NN NN O
FS NN NN O
) NN NN O
, NN NN O
as NN NN O
well NN NN O
as NN NN O
chronotropic NN NN O
response NN NN O
to NN NN O
isoproterenol NN NN O
and NN NN O
exercise NN NN O
- NN NN O
induced NN NN O
sympathetic NN NN O
stimulation NN NN O
were NN NN O
evaluated NN NN O
under NN NN O
baseline NN NN O
and NN NN O
posttreatment NN NN O
conditions NN NN O
. NN NN O
   
Resting NN NN O
values NN NN O
of NN NN O
LVEF NN NN O
, NN NN O
FS NN NN O
, NN NN O
+ NN NN O
LVdP NN NN O
/ NN NN O
dt NN NN O
, NN NN O
and NN NN O
MBP NN NN O
remained NN NN O
unchanged NN NN O
whatever NN NN O
the NN NN O
drug NN NN O
and NN NN O
the NN NN O
dosing NN NN O
regimen NN NN O
, NN NN O
whereas NN NN O
resting NN NN O
HR NN NN O
was NN NN O
significantly NN NN O
and NN NN O
dose NN NN O
- NN NN O
dependently NN NN O
lowered NN NN O
after NN NN O
dronedarone NN NN O
and NN NN O
to NN NN O
a NN NN O
lesser NN NN O
extent NN NN O
after NN NN O
amiodarone NN NN O
. NN NN O
   
Both NN NN O
dronedarone NN NN O
and NN NN O
amiodarone NN NN O
significantly NN NN O
reduced NN NN O
the NN NN O
exercise NN NN O
- NN NN O
induced NN NN O
tachycardia NN NN B-Disease
and NN NN O
, NN NN O
at NN NN O
the NN NN O
highest NN NN O
dose NN NN O
, NN NN O
decreased NN NN O
the NN NN O
isoproterenol NN NN O
- NN NN O
induced NN NN O
tachycardia NN NN B-Disease
. NN NN O
   
Thus NN NN O
, NN NN O
dronedarone NN NN O
and NN NN O
amiodarone NN NN O
displayed NN NN O
a NN NN O
similar NN NN O
level NN NN O
of NN NN O
antiadrenergic NN NN O
effect NN NN O
and NN NN O
did NN NN O
not NN NN O
impair NN NN O
the NN NN O
resting NN NN O
left NN NN O
ventricular NN NN O
function NN NN O
. NN NN O
   
Consequently NN NN O
, NN NN O
dronedarone NN NN O
might NN NN O
be NN NN O
particularly NN NN O
suitable NN NN O
for NN NN O
the NN NN O
treatment NN NN O
and NN NN O
prevention NN NN O
of NN NN O
various NN NN O
clinical NN NN O
arrhythmias NN NN B-Disease
, NN NN O
without NN NN O
compromising NN NN O
the NN NN O
left NN NN O
ventricular NN NN O
function NN NN O
. NN NN O
   
Phase NN NN O
2 NN NN O
trial NN NN O
of NN NN O
liposomal NN NN O
doxorubicin NN NN O
( NN NN O
40 NN NN O
mg NN NN O
/ NN NN O
m NN NN O
( NN NN O
2 NN NN O
) NN NN O
) NN NN O
in NN NN O
platinum NN NN O
/ NN NN O
paclitaxel NN NN O
- NN NN O
refractory NN NN O
ovarian NN NN B-Disease
and NN NN I-Disease
fallopian NN NN I-Disease
tube NN NN I-Disease
cancers NN NN I-Disease
and NN NN O
primary NN NN O
carcinoma NN NN B-Disease
of NN NN I-Disease
the NN NN I-Disease
peritoneum NN NN I-Disease
. NN NN O
   
BACKGROUND NN NN O
: NN NN O
Several NN NN O
studies NN NN O
have NN NN O
demonstrated NN NN O
liposomal NN NN O
doxorubicin NN NN O
( NN NN O
Doxil NN NN O
) NN NN O
to NN NN O
be NN NN O
an NN NN O
active NN NN O
antineoplastic NN NN O
agent NN NN O
in NN NN O
platinum NN NN O
- NN NN O
resistant NN NN O
ovarian NN NN B-Disease
cancer NN NN I-Disease
, NN NN O
with NN NN O
dose NN NN O
limiting NN NN O
toxicity NN NN B-Disease
of NN NN O
the NN NN O
standard NN NN O
dosing NN NN O
regimen NN NN O
( NN NN O
50 NN NN O
mg NN NN O
/ NN NN O
m NN NN O
( NN NN O
2 NN NN O
) NN NN O
q NN NN O
4 NN NN O
weeks NN NN O
) NN NN O
being NN NN O
severe NN NN O
erythrodysesthesia NN NN B-Disease
( NN NN O
"""""""" NN NN O
hand NN NN B-Disease
- NN NN I-Disease
foot NN NN I-Disease
syndrome NN NN I-Disease
"""""""" NN NN O
) NN NN O
and NN NN O
stomatitis NN NN B-Disease
. NN NN O
   
We NN NN O
wished NN NN O
to NN NN O
develop NN NN O
a NN NN O
more NN NN O
tolerable NN NN O
liposomal NN NN O
doxorubicin NN NN O
treatment NN NN O
regimen NN NN O
and NN NN O
document NN NN O
its NN NN O
level NN NN O
of NN NN O
activity NN NN O
in NN NN O
a NN NN O
well NN NN O
- NN NN O
defined NN NN O
patient NN NN O
population NN NN O
with NN NN O
platinum NN NN O
/ NN NN O
paclitaxel NN NN O
- NN NN O
refractory NN NN O
disease NN NN O
. NN NN O
   
METHODS NN NN O
AND NN NN O
MATERIALS NN NN O
: NN NN O
Patients NN NN O
with NN NN O
ovarian NN NN B-Disease
or NN NN I-Disease
fallopian NN NN I-Disease
tube NN NN I-Disease
cancers NN NN I-Disease
or NN NN O
primary NN NN O
peritoneal NN NN B-Disease
carcinoma NN NN I-Disease
with NN NN O
platinum NN NN O
/ NN NN O
paclitaxel NN NN O
- NN NN O
refractory NN NN O
disease NN NN O
( NN NN O
stable NN NN O
or NN NN O
progressive NN NN O
disease NN NN O
following NN NN O
treatment NN NN O
with NN NN O
these NN NN O
agents NN NN O
or NN NN O
previous NN NN O
objective NN NN O
response NN NN O
< NN NN O
3 NN NN O
months NN NN O
in NN NN O
duration NN NN O
) NN NN O
were NN NN O
treated NN NN O
with NN NN O
liposomal NN NN O
doxorubicin NN NN O
at NN NN O
a NN NN O
dose NN NN O
of NN NN O
40 NN NN O
mg NN NN O
/ NN NN O
m NN NN O
( NN NN O
2 NN NN O
) NN NN O
q NN NN O
4 NN NN O
weeks NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
A NN NN O
total NN NN O
of NN NN O
49 NN NN O
patients NN NN O
( NN NN O
median NN NN O
age NN NN O
: NN NN O
60 NN NN O
; NN NN O
range NN NN O
41 NN NN O
- NN NN O
81 NN NN O
) NN NN O
entered NN NN O
this NN NN O
phase NN NN O
2 NN NN O
trial NN NN O
. NN NN O
   
The NN NN O
median NN NN O
number NN NN O
of NN NN O
prior NN NN O
regimens NN NN O
was NN NN O
2 NN NN O
( NN NN O
range NN NN O
: NN NN O
1 NN NN O
- NN NN O
6 NN NN O
) NN NN O
. NN NN O
   
Six NN NN O
( NN NN O
12 NN NN O
% NN NN O
) NN NN O
and NN NN O
4 NN NN O
( NN NN O
8 NN NN O
% NN NN O
) NN NN O
patients NN NN O
experienced NN NN O
grade NN NN O
2 NN NN O
hand NN NN B-Disease
- NN NN I-Disease
foot NN NN I-Disease
syndrome NN NN I-Disease
and NN NN O
stomatitis NN NN B-Disease
, NN NN O
respectively NN NN O
( NN NN O
no NN NN O
episodes NN NN O
of NN NN O
grade NN NN O
3 NN NN O
) NN NN O
. NN NN O
   
One NN NN O
patient NN NN O
developed NN NN O
grade NN NN O
3 NN NN O
diarrhea NN NN B-Disease
requiring NN NN O
hospitalization NN NN O
for NN NN O
hydration NN NN O
. NN NN O
   
Six NN NN O
( NN NN O
12 NN NN O
% NN NN O
) NN NN O
individuals NN NN O
required NN NN O
dose NN NN O
reductions NN NN O
. NN NN O
   
The NN NN O
median NN NN O
number NN NN O
of NN NN O
courses NN NN O
of NN NN O
liposomal NN NN O
doxorubicin NN NN O
administered NN NN O
on NN NN O
this NN NN O
protocol NN NN O
was NN NN O
2 NN NN O
( NN NN O
range NN NN O
: NN NN O
1 NN NN O
- NN NN O
12 NN NN O
) NN NN O
. NN NN O
   
Four NN NN O
of NN NN O
44 NN NN O
patients NN NN O
( NN NN O
9 NN NN O
% NN NN O
) NN NN O
evaluable NN NN O
for NN NN O
response NN NN O
exhibited NN NN O
objective NN NN O
and NN NN O
subjective NN NN O
evidence NN NN O
of NN NN O
an NN NN O
antineoplastic NN NN O
effect NN NN O
of NN NN O
therapy NN NN O
. NN NN O
   
CONCLUSION NN NN O
: NN NN O
This NN NN O
modified NN NN O
liposomal NN NN O
doxorubicin NN NN O
regimen NN NN O
results NN NN O
in NN NN O
less NN NN O
toxicity NN NN B-Disease
( NN NN O
stomatitis NN NN B-Disease
, NN NN O
hand NN NN B-Disease
- NN NN I-Disease
foot NN NN I-Disease
syndrome NN NN I-Disease
) NN NN O
than NN NN O
the NN NN O
standard NN NN O
FDA NN NN O
- NN NN O
approved NN NN O
dose NN NN O
schedule NN NN O
. NN NN O
   
Definite NN NN O
, NN NN O
although NN NN O
limited NN NN O
, NN NN O
antineoplastic NN NN O
activity NN NN O
is NN NN O
observed NN NN O
in NN NN O
patients NN NN O
with NN NN O
well NN NN O
- NN NN O
defined NN NN O
platinum NN NN O
- NN NN O
and NN NN O
paclitaxel NN NN O
- NN NN O
refractory NN NN O
ovarian NN NN B-Disease
cancer NN NN I-Disease
. NN NN O
   
Efficacy NN NN O
of NN NN O
olanzapine NN NN O
in NN NN O
acute NN NN O
bipolar NN NN B-Disease
mania NN NN I-Disease
: NN NN O
a NN NN O
double NN NN O
- NN NN O
blind NN NN O
, NN NN O
placebo NN NN O
- NN NN O
controlled NN NN O
study NN NN O
. NN NN O
   
The NN NN O
Olanzipine NN NN O
HGGW NN NN O
Study NN NN O
Group NN NN O
. NN NN O
   
BACKGROUND NN NN O
: NN NN O
We NN NN O
compared NN NN O
the NN NN O
efficacy NN NN O
and NN NN O
safety NN NN O
of NN NN O
olanzapine NN NN O
vs NN NN O
placebo NN NN O
for NN NN O
the NN NN O
treatment NN NN O
of NN NN O
acute NN NN O
bipolar NN NN B-Disease
mania NN NN I-Disease
. NN NN O
   
METHODS NN NN O
: NN NN O
Four NN NN O
- NN NN O
week NN NN O
, NN NN O
randomized NN NN O
, NN NN O
double NN NN O
- NN NN O
blind NN NN O
, NN NN O
parallel NN NN O
study NN NN O
. NN NN O
   
A NN NN O
total NN NN O
of NN NN O
115 NN NN O
patients NN NN O
with NN NN O
a NN NN O
DSM NN NN O
- NN NN O
IV NN NN O
diagnosis NN NN O
of NN NN O
bipolar NN NN B-Disease
disorder NN NN I-Disease
, NN NN O
manic NN NN B-Disease
or NN NN O
mixed NN NN O
, NN NN O
were NN NN O
randomized NN NN O
to NN NN O
olanzapine NN NN O
, NN NN O
5 NN NN O
to NN NN O
20 NN NN O
mg NN NN O
/ NN NN O
d NN NN O
( NN NN O
n NN NN O
= NN NN O
55 NN NN O
) NN NN O
, NN NN O
or NN NN O
placebo NN NN O
( NN NN O
n NN NN O
= NN NN O
60 NN NN O
) NN NN O
. NN NN O
   
The NN NN O
primary NN NN O
efficacy NN NN O
measure NN NN O
was NN NN O
the NN NN O
Young NN NN O
- NN NN O
Mania NN NN B-Disease
Rating NN NN O
Scale NN NN O
( NN NN O
Y NN NN O
- NN NN O
MRS NN NN O
) NN NN O
total NN NN O
score NN NN O
. NN NN O
   
Response NN NN O
and NN NN O
euthymia NN NN O
were NN NN O
defined NN NN O
, NN NN O
a NN NN O
priori NN NN O
, NN NN O
as NN NN O
at NN NN O
least NN NN O
a NN NN O
50 NN NN O
% NN NN O
improvement NN NN O
from NN NN O
baseline NN NN O
to NN NN O
end NN NN O
point NN NN O
and NN NN O
as NN NN O
a NN NN O
score NN NN O
of NN NN O
no NN NN O
less NN NN O
than NN NN O
12 NN NN O
at NN NN O
end NN NN O
point NN NN O
in NN NN O
the NN NN O
Y NN NN O
- NN NN O
MRS NN NN O
total NN NN O
score NN NN O
, NN NN O
respectively NN NN O
. NN NN O
   
Safety NN NN O
was NN NN O
assessed NN NN O
using NN NN O
adverse NN NN O
events NN NN O
, NN NN O
Extrapyramidal NN NN B-Disease
Symptom NN NN I-Disease
( NN NN O
EPS NN NN B-Disease
) NN NN O
rating NN NN O
scales NN NN O
, NN NN O
laboratory NN NN O
values NN NN O
, NN NN O
electrocardiograms NN NN O
, NN NN O
vital NN NN O
signs NN NN O
, NN NN O
and NN NN O
weight NN NN O
change NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
Olanzapine NN NN O
- NN NN O
treated NN NN O
patients NN NN O
demonstrated NN NN O
a NN NN O
statistically NN NN O
significant NN NN O
greater NN NN O
mean NN NN O
( NN NN O
+ NN NN O
/ NN NN O
- NN NN O
SD NN NN O
) NN NN O
improvement NN NN O
in NN NN O
Y NN NN O
- NN NN O
MRS NN NN O
total NN NN O
score NN NN O
than NN NN O
placebo NN NN O
- NN NN O
treated NN NN O
patients NN NN O
( NN NN O
- NN NN O
14 NN NN O
. NN NN O
8 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
12 NN NN O
. NN NN O
5 NN NN O
and NN NN O
- NN NN O
8 NN NN O
. NN NN O
1 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
12 NN NN O
. NN NN O
7 NN NN O
, NN NN O
respectively NN NN O
; NN NN O
P NN NN O
< NN NN O
. NN NN O
001 NN NN O
) NN NN O
, NN NN O
which NN NN O
was NN NN O
evident NN NN O
at NN NN O
the NN NN O
first NN NN O
postbaseline NN NN O
observation NN NN O
1 NN NN O
week NN NN O
after NN NN O
randomization NN NN O
and NN NN O
was NN NN O
maintained NN NN O
throughout NN NN O
the NN NN O
study NN NN O
( NN NN O
last NN NN O
observation NN NN O
carried NN NN O
forward NN NN O
) NN NN O
. NN NN O
   
Olanzapine NN NN O
- NN NN O
treated NN NN O
patients NN NN O
demonstrated NN NN O
a NN NN O
higher NN NN O
rate NN NN O
of NN NN O
response NN NN O
( NN NN O
65 NN NN O
% NN NN O
vs NN NN O
43 NN NN O
% NN NN O
, NN NN O
respectively NN NN O
; NN NN O
P NN NN O
= NN NN O
. NN NN O
02 NN NN O
) NN NN O
and NN NN O
euthymia NN NN O
( NN NN O
61 NN NN O
% NN NN O
vs NN NN O
36 NN NN O
% NN NN O
, NN NN O
respectively NN NN O
; NN NN O
P NN NN O
= NN NN O
. NN NN O
01 NN NN O
) NN NN O
than NN NN O
placebo NN NN O
- NN NN O
treated NN NN O
patients NN NN O
. NN NN O
   
There NN NN O
were NN NN O
no NN NN O
statistically NN NN O
significant NN NN O
differences NN NN O
in NN NN O
EPSs NN NN B-Disease
between NN NN O
groups NN NN O
. NN NN O
   
However NN NN O
, NN NN O
olanzapine NN NN O
- NN NN O
treated NN NN O
patients NN NN O
had NN NN O
a NN NN O
statistically NN NN O
significant NN NN O
greater NN NN O
mean NN NN O
( NN NN O
+ NN NN O
/ NN NN O
- NN NN O
SD NN NN O
) NN NN O
weight NN NN B-Disease
gain NN NN I-Disease
than NN NN O
placebo NN NN O
- NN NN O
treated NN NN O
patients NN NN O
( NN NN O
2 NN NN O
. NN NN O
1 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
2 NN NN O
. NN NN O
8 NN NN O
vs NN NN O
0 NN NN O
. NN NN O
45 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
2 NN NN O
. NN NN O
3 NN NN O
kg NN NN O
, NN NN O
respectively NN NN O
) NN NN O
and NN NN O
also NN NN O
experienced NN NN O
more NN NN O
treatment NN NN O
- NN NN O
emergent NN NN O
somnolence NN NN B-Disease
( NN NN O
21 NN NN O
patients NN NN O
[ NN NN O
38 NN NN O
. NN NN O
2 NN NN O
% NN NN O
] NN NN O
vs NN NN O
5 NN NN O
[ NN NN O
8 NN NN O
. NN NN O
3 NN NN O
% NN NN O
] NN NN O
, NN NN O
respectively NN NN O
) NN NN O
. NN NN O
   
CONCLUSION NN NN O
: NN NN O
Olanzapine NN NN O
demonstrated NN NN O
greater NN NN O
efficacy NN NN O
than NN NN O
placebo NN NN O
in NN NN O
the NN NN O
treatment NN NN O
of NN NN O
acute NN NN O
bipolar NN NN B-Disease
mania NN NN I-Disease
and NN NN O
was NN NN O
generally NN NN O
well NN NN O
tolerated NN NN O
. NN NN O
   
The NN NN O
effect NN NN O
of NN NN O
pupil NN NN B-Disease
dilation NN NN I-Disease
with NN NN O
tropicamide NN NN O
on NN NN O
vision NN NN O
and NN NN O
driving NN NN O
simulator NN NN O
performance NN NN O
. NN NN O
   
PURPOSE NN NN O
: NN NN O
To NN NN O
assess NN NN O
the NN NN O
effect NN NN O
of NN NN O
pupil NN NN B-Disease
dilation NN NN I-Disease
on NN NN O
vision NN NN O
and NN NN O
driving NN NN O
ability NN NN O
. NN NN O
   
METHODS NN NN O
: NN NN O
A NN NN O
series NN NN O
of NN NN O
tests NN NN O
on NN NN O
various NN NN O
parameters NN NN O
of NN NN O
visual NN NN O
function NN NN O
and NN NN O
driving NN NN O
simulator NN NN O
performance NN NN O
were NN NN O
performed NN NN O
on NN NN O
12 NN NN O
healthy NN NN O
drivers NN NN O
, NN NN O
before NN NN O
and NN NN O
after NN NN O
pupil NN NN B-Disease
dilation NN NN I-Disease
using NN NN O
guttae NN NN O
tropicamide NN NN O
1 NN NN O
% NN NN O
. NN NN O
   
A NN NN O
driving NN NN O
simulator NN NN O
( NN NN O
Transport NN NN O
Research NN NN O
Laboratory NN NN O
) NN NN O
was NN NN O
used NN NN O
to NN NN O
measure NN NN O
reaction NN NN O
time NN NN O
( NN NN O
RT NN NN O
) NN NN O
, NN NN O
speed NN NN O
maintenance NN NN O
and NN NN O
steering NN NN O
accuracy NN NN O
. NN NN O
   
Tests NN NN O
of NN NN O
basic NN NN O
visual NN NN O
function NN NN O
included NN NN O
high NN NN O
- NN NN O
and NN NN O
low NN NN O
- NN NN O
contrast NN NN O
visual NN NN O
acuity NN NN O
( NN NN O
HCVA NN NN O
and NN NN O
LCVA NN NN O
) NN NN O
, NN NN O
Pelli NN NN O
- NN NN O
Robson NN NN O
contrast NN NN O
threshold NN NN O
( NN NN O
CT NN NN O
) NN NN O
and NN NN O
Goldmann NN NN O
perimetry NN NN O
( NN NN O
FIELDS NN NN O
) NN NN O
. NN NN O
   
Useful NN NN O
Field NN NN O
of NN NN O
View NN NN O
( NN NN O
UFOV NN NN O
- NN NN O
- NN NN O
a NN NN O
test NN NN O
of NN NN O
visual NN NN O
attention NN NN O
) NN NN O
was NN NN O
also NN NN O
undertaken NN NN O
. NN NN O
   
The NN NN O
mean NN NN O
differences NN NN O
in NN NN O
the NN NN O
pre NN NN O
- NN NN O
and NN NN O
post NN NN O
- NN NN O
dilatation NN NN O
measurements NN NN O
were NN NN O
tested NN NN O
for NN NN O
statistical NN NN O
significance NN NN O
at NN NN O
the NN NN O
95 NN NN O
% NN NN O
level NN NN O
using NN NN O
one NN NN O
- NN NN O
tail NN NN O
paired NN NN O
t NN NN O
- NN NN O
tests NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
Pupillary NN NN B-Disease
dilation NN NN I-Disease
resulted NN NN O
in NN NN O
a NN NN O
statistically NN NN O
significant NN NN O
deterioration NN NN O
in NN NN O
CT NN NN O
and NN NN O
HCVA NN NN O
only NN NN O
. NN NN O
   
Five NN NN O
of NN NN O
12 NN NN O
drivers NN NN O
also NN NN O
exhibited NN NN O
deterioration NN NN O
in NN NN O
LCVA NN NN O
, NN NN O
CT NN NN O
and NN NN O
RT NN NN O
. NN NN O
   
Little NN NN O
evidence NN NN O
emerged NN NN O
for NN NN O
deterioration NN NN O
in NN NN O
FIELDS NN NN O
and NN NN O
UFOV NN NN O
. NN NN O
   
Also NN NN O
, NN NN O
7 NN NN O
of NN NN O
12 NN NN O
drivers NN NN O
appeared NN NN O
to NN NN O
adjust NN NN O
their NN NN O
driving NN NN O
behaviour NN NN O
by NN NN O
reducing NN NN O
their NN NN O
speed NN NN O
on NN NN O
the NN NN O
driving NN NN O
simulator NN NN O
, NN NN O
leading NN NN O
to NN NN O
improved NN NN O
steering NN NN O
accuracy NN NN O
. NN NN O
   
CONCLUSIONS NN NN O
: NN NN O
Pupillary NN NN B-Disease
dilation NN NN I-Disease
may NN NN O
lead NN NN O
to NN NN O
a NN NN O
decrease NN NN O
in NN NN O
vision NN NN O
and NN NN O
daylight NN NN O
driving NN NN O
performance NN NN O
in NN NN O
young NN NN O
people NN NN O
. NN NN O
   
A NN NN O
larger NN NN O
study NN NN O
, NN NN O
including NN NN O
a NN NN O
broader NN NN O
spectrum NN NN O
of NN NN O
subjects NN NN O
, NN NN O
is NN NN O
warranted NN NN O
before NN NN O
guidelines NN NN O
can NN NN O
be NN NN O
recommended NN NN O
. NN NN O
   
A NN NN O
case NN NN O
of NN NN O
isotretinoin NN NN B-Disease
embryopathy NN NN I-Disease
with NN NN O
bilateral NN NN O
anotia NN NN B-Disease
and NN NN O
Taussig NN NN B-Disease
- NN NN I-Disease
Bing NN NN I-Disease
malformation NN NN I-Disease
. NN NN O
   
We NN NN O
report NN NN O
a NN NN O
newborn NN NN O
infant NN NN O
with NN NN O
multiple NN NN O
congenital NN NN O
anomalies NN NN O
( NN NN O
anotia NN NN B-Disease
and NN NN O
Taussig NN NN B-Disease
- NN NN I-Disease
Bing NN NN I-Disease
malformation NN NN I-Disease
) NN NN O
due NN NN O
to NN NN O
exposure NN NN O
to NN NN O
isotretinoin NN NN O
within NN NN O
the NN NN O
first NN NN O
trimester NN NN O
. NN NN O
   
In NN NN O
this NN NN O
paper NN NN O
we NN NN O
aim NN NN O
to NN NN O
draw NN NN O
to NN NN O
the NN NN O
fact NN NN O
that NN NN O
caution NN NN O
is NN NN O
needed NN NN O
when NN NN O
prescribing NN NN O
vitamin NN NN O
A NN NN O
- NN NN O
containing NN NN O
drugs NN NN O
to NN NN O
women NN NN O
of NN NN O
childbearing NN NN O
years NN NN O
. NN NN O
   
Effect NN NN O
of NN NN O
methoxamine NN NN O
on NN NN O
maximum NN NN O
urethral NN NN O
pressure NN NN O
in NN NN O
women NN NN O
with NN NN O
genuine NN NN O
stress NN NN B-Disease
incontinence NN NN I-Disease
: NN NN O
a NN NN O
placebo NN NN O
- NN NN O
controlled NN NN O
, NN NN O
double NN NN O
- NN NN O
blind NN NN O
crossover NN NN O
study NN NN O
. NN NN O
   
The NN NN O
aim NN NN O
of NN NN O
the NN NN O
study NN NN O
was NN NN O
to NN NN O
evaluate NN NN O
the NN NN O
potential NN NN O
role NN NN O
for NN NN O
a NN NN O
selective NN NN O
alpha1 NN NN O
- NN NN O
adrenoceptor NN NN O
agonist NN NN O
in NN NN O
the NN NN O
treatment NN NN O
of NN NN O
urinary NN NN B-Disease
stress NN NN I-Disease
incontinence NN NN I-Disease
. NN NN O
   
A NN NN O
randomised NN NN O
, NN NN O
double NN NN O
- NN NN O
blind NN NN O
, NN NN O
placebo NN NN O
- NN NN O
controlled NN NN O
, NN NN O
crossover NN NN O
study NN NN O
design NN NN O
was NN NN O
employed NN NN O
. NN NN O
   
Half NN NN O
log NN NN O
incremental NN NN O
doses NN NN O
of NN NN O
intravenous NN NN O
methoxamine NN NN O
or NN NN O
placebo NN NN O
( NN NN O
saline NN NN O
) NN NN O
were NN NN O
administered NN NN O
to NN NN O
a NN NN O
group NN NN O
of NN NN O
women NN NN O
with NN NN O
genuine NN NN O
stress NN NN B-Disease
incontinence NN NN I-Disease
while NN NN O
measuring NN NN O
maximum NN NN O
urethral NN NN O
pressure NN NN O
( NN NN O
MUP NN NN O
) NN NN O
, NN NN O
blood NN NN O
pressure NN NN O
, NN NN O
heart NN NN O
rate NN NN O
, NN NN O
and NN NN O
symptomatic NN NN O
side NN NN O
effects NN NN O
. NN NN O
   
Methoxamine NN NN O
evoked NN NN O
non NN NN O
- NN NN O
significant NN NN O
increases NN NN O
in NN NN O
MUP NN NN O
and NN NN O
diastolic NN NN O
blood NN NN O
pressure NN NN O
but NN NN O
caused NN NN O
a NN NN B-Disease
significant NN NN I-Disease
rise NN NN I-Disease
in NN NN I-Disease
systolic NN NN I-Disease
blood NN NN I-Disease
pressure NN NN I-Disease
and NN NN O
significant NN NN O
fall NN NN O
in NN NN O
heart NN NN O
rate NN NN O
at NN NN O
maximum NN NN O
dosage NN NN O
. NN NN O
   
Systemic NN NN O
side NN NN O
effects NN NN O
including NN NN O
piloerection NN NN O
, NN NN O
headache NN NN B-Disease
, NN NN O
and NN NN O
cold NN NN O
extremities NN NN O
were NN NN O
experienced NN NN O
in NN NN O
all NN NN O
subjects NN NN O
. NN NN O
   
The NN NN O
results NN NN O
indicate NN NN O
that NN NN O
the NN NN O
clinical NN NN O
usefulness NN NN O
of NN NN O
direct NN NN O
, NN NN O
peripherally NN NN O
acting NN NN O
sub NN NN O
- NN NN O
type NN NN O
- NN NN O
selective NN NN O
alpha1 NN NN O
- NN NN O
adrenoceptor NN NN O
agonists NN NN O
in NN NN O
the NN NN O
medical NN NN O
treatment NN NN O
of NN NN O
stress NN NN B-Disease
incontinence NN NN I-Disease
may NN NN O
be NN NN O
limited NN NN O
by NN NN O
associated NN NN O
piloerection NN NN O
and NN NN O
cardiovascular NN NN O
side NN NN O
effects NN NN O
. NN NN O
   
Hyperglycemic NN NN B-Disease
effect NN NN O
of NN NN O
amino NN NN O
compounds NN NN O
structurally NN NN O
related NN NN O
to NN NN O
caproate NN NN O
in NN NN O
rats NN NN O
. NN NN O
   
The NN NN O
chronic NN NN O
feeding NN NN O
of NN NN O
small NN NN O
amounts NN NN O
( NN NN O
0 NN NN O
. NN NN O
3 NN NN O
- NN NN O
3 NN NN O
% NN NN O
of NN NN O
diet NN NN O
weight NN NN O
) NN NN O
of NN NN O
certain NN NN O
amino NN NN O
derivatives NN NN O
of NN NN O
caproate NN NN O
resulted NN NN O
in NN NN O
hyperglycemia NN NN B-Disease
, NN NN O
an NN NN O
elevated NN NN O
glucose NN NN O
tolerance NN NN O
curve NN NN O
and NN NN O
, NN NN O
occasionally NN NN O
, NN NN O
glucosuria NN NN B-Disease
. NN NN O
   
Effective NN NN O
compounds NN NN O
included NN NN O
norleucine NN NN O
, NN NN O
norvaline NN NN O
, NN NN O
glutamate NN NN O
, NN NN O
epsilon NN NN O
- NN NN O
aminocaproate NN NN O
, NN NN O
methionine NN NN O
, NN NN O
and NN NN O
leucine NN NN O
. NN NN O
   
Toleration NN NN O
of NN NN O
high NN NN O
doses NN NN O
of NN NN O
angiotensin NN NN O
- NN NN O
converting NN NN O
enzyme NN NN O
inhibitors NN NN O
in NN NN O
patients NN NN O
with NN NN O
chronic NN NN O
heart NN NN B-Disease
failure NN NN I-Disease
: NN NN O
results NN NN O
from NN NN O
the NN NN O
ATLAS NN NN O
trial NN NN O
. NN NN O
   
The NN NN O
Assessment NN NN O
of NN NN O
Treatment NN NN O
with NN NN O
Lisinopril NN NN O
and NN NN O
Survival NN NN O
. NN NN O
   
BACKGROUND NN NN O
: NN NN O
Treatment NN NN O
with NN NN O
angiotensin NN NN O
- NN NN O
converting NN NN O
enzyme NN NN O
( NN NN O
ACE NN NN O
) NN NN O
inhibitors NN NN O
reduces NN NN O
mortality NN NN O
and NN NN O
morbidity NN NN O
in NN NN O
patients NN NN O
with NN NN O
chronic NN NN O
heart NN NN B-Disease
failure NN NN I-Disease
( NN NN O
CHF NN NN B-Disease
) NN NN O
, NN NN O
but NN NN O
most NN NN O
affected NN NN O
patients NN NN O
are NN NN O
not NN NN O
receiving NN NN O
these NN NN O
agents NN NN O
or NN NN O
are NN NN O
being NN NN O
treated NN NN O
with NN NN O
doses NN NN O
lower NN NN O
than NN NN O
those NN NN O
found NN NN O
to NN NN O
be NN NN O
efficacious NN NN O
in NN NN O
trials NN NN O
, NN NN O
primarily NN NN O
because NN NN O
of NN NN O
concerns NN NN O
about NN NN O
the NN NN O
safety NN NN O
and NN NN O
tolerability NN NN O
of NN NN O
these NN NN O
agents NN NN O
, NN NN O
especially NN NN O
at NN NN O
the NN NN O
recommended NN NN O
doses NN NN O
. NN NN O
   
The NN NN O
present NN NN O
study NN NN O
examines NN NN O
the NN NN O
safety NN NN O
and NN NN O
tolerability NN NN O
of NN NN O
high NN NN O
- NN NN O
compared NN NN O
with NN NN O
low NN NN O
- NN NN O
dose NN NN O
lisinopril NN NN O
in NN NN O
CHF NN NN B-Disease
. NN NN O
   
METHODS NN NN O
: NN NN O
The NN NN O
Assessment NN NN O
of NN NN O
Lisinopril NN NN O
and NN NN O
Survival NN NN O
study NN NN O
was NN NN O
a NN NN O
multicenter NN NN O
, NN NN O
randomized NN NN O
, NN NN O
double NN NN O
- NN NN O
blind NN NN O
trial NN NN O
in NN NN O
which NN NN O
patients NN NN O
with NN NN O
or NN NN O
without NN NN O
previous NN NN O
ACE NN NN O
inhibitor NN NN O
treatment NN NN O
were NN NN O
stabilized NN NN O
receiving NN NN O
medium NN NN O
- NN NN O
dose NN NN O
lisinopril NN NN O
( NN NN O
12 NN NN O
. NN NN O
5 NN NN O
or NN NN O
15 NN NN O
. NN NN O
0 NN NN O
mg NN NN O
once NN NN O
daily NN NN O
[ NN NN O
OD NN NN O
] NN NN O
) NN NN O
for NN NN O
2 NN NN O
to NN NN O
4 NN NN O
weeks NN NN O
and NN NN O
then NN NN O
randomized NN NN O
to NN NN O
high NN NN O
- NN NN O
( NN NN O
35 NN NN O
. NN NN O
0 NN NN O
or NN NN O
32 NN NN O
. NN NN O
5 NN NN O
mg NN NN O
OD NN NN O
) NN NN O
or NN NN O
low NN NN O
- NN NN O
dose NN NN O
( NN NN O
5 NN NN O
. NN NN O
0 NN NN O
or NN NN O
2 NN NN O
. NN NN O
5 NN NN O
mg NN NN O
OD NN NN O
) NN NN O
groups NN NN O
. NN NN O
   
Patients NN NN O
with NN NN O
New NN NN O
York NN NN O
Heart NN NN O
Association NN NN O
classes NN NN O
II NN NN O
to NN NN O
IV NN NN O
CHF NN NN B-Disease
and NN NN O
left NN NN O
ventricular NN NN O
ejection NN NN O
fractions NN NN O
of NN NN O
no NN NN O
greater NN NN O
than NN NN O
0 NN NN O
. NN NN O
30 NN NN O
( NN NN O
n NN NN O
= NN NN O
3164 NN NN O
) NN NN O
were NN NN O
randomized NN NN O
and NN NN O
followed NN NN O
up NN NN O
for NN NN O
a NN NN O
median NN NN O
of NN NN O
46 NN NN O
months NN NN O
. NN NN O
   
We NN NN O
examined NN NN O
the NN NN O
occurrence NN NN O
of NN NN O
adverse NN NN O
events NN NN O
and NN NN O
the NN NN O
need NN NN O
for NN NN O
discontinuation NN NN O
and NN NN O
dose NN NN O
reduction NN NN O
during NN NN O
treatment NN NN O
, NN NN O
with NN NN O
a NN NN O
focus NN NN O
on NN NN O
hypotension NN NN B-Disease
and NN NN O
renal NN NN B-Disease
dysfunction NN NN I-Disease
. NN NN O
   
RESULTS NN NN O
: NN NN O
Of NN NN O
405 NN NN O
patients NN NN O
not NN NN O
previously NN NN O
receiving NN NN O
an NN NN O
ACE NN NN O
inhibitor NN NN O
, NN NN O
doses NN NN O
in NN NN O
only NN NN O
4 NN NN O
. NN NN O
2 NN NN O
% NN NN O
could NN NN O
not NN NN O
be NN NN O
titrated NN NN O
to NN NN O
the NN NN O
medium NN NN O
doses NN NN O
required NN NN O
for NN NN O
randomization NN NN O
because NN NN O
of NN NN O
symptoms NN NN O
possibly NN NN O
related NN NN O
to NN NN O
hypotension NN NN B-Disease
( NN NN O
2 NN NN O
. NN NN O
0 NN NN O
% NN NN O
) NN NN O
or NN NN O
because NN NN O
of NN NN O
renal NN NN B-Disease
dysfunction NN NN I-Disease
or NN NN O
hyperkalemia NN NN B-Disease
( NN NN O
2 NN NN O
. NN NN O
3 NN NN O
% NN NN O
) NN NN O
. NN NN O
   
Doses NN NN O
in NN NN O
more NN NN O
than NN NN O
90 NN NN O
% NN NN O
of NN NN O
randomized NN NN O
patients NN NN O
in NN NN O
the NN NN O
high NN NN O
- NN NN O
and NN NN O
low NN NN O
- NN NN O
dose NN NN O
groups NN NN O
were NN NN O
titrated NN NN O
to NN NN O
their NN NN O
assigned NN NN O
target NN NN O
, NN NN O
and NN NN O
the NN NN O
mean NN NN O
doses NN NN O
of NN NN O
blinded NN NN O
medication NN NN O
in NN NN O
both NN NN O
groups NN NN O
remained NN NN O
similar NN NN O
throughout NN NN O
the NN NN O
study NN NN O
. NN NN O
   
Withdrawals NN NN O
occurred NN NN O
in NN NN O
27 NN NN O
. NN NN O
1 NN NN O
% NN NN O
of NN NN O
the NN NN O
high NN NN O
- NN NN O
and NN NN O
30 NN NN O
. NN NN O
7 NN NN O
% NN NN O
of NN NN O
the NN NN O
low NN NN O
- NN NN O
dose NN NN O
groups NN NN O
. NN NN O
   
Subgroups NN NN O
presumed NN NN O
to NN NN O
be NN NN O
at NN NN O
higher NN NN O
risk NN NN O
for NN NN O
ACE NN NN O
inhibitor NN NN O
intolerance NN NN O
( NN NN O
blood NN NN O
pressure NN NN O
, NN NN O
< NN NN O
120 NN NN O
mm NN NN O
Hg NN NN O
; NN NN O
creatinine NN NN O
, NN NN O
> NN NN O
or NN NN O
= NN NN O
132 NN NN O
. NN NN O
6 NN NN O
micromol NN NN O
/ NN NN O
L NN NN O
[ NN NN O
> NN NN O
or NN NN O
= NN NN O
1 NN NN O
. NN NN O
5 NN NN O
mg NN NN O
/ NN NN O
dL NN NN O
] NN NN O
; NN NN O
age NN NN O
, NN NN O
> NN NN O
or NN NN O
= NN NN O
70 NN NN O
years NN NN O
; NN NN O
and NN NN O
patients NN NN O
with NN NN O
diabetes NN NN B-Disease
) NN NN O
generally NN NN O
tolerated NN NN O
the NN NN O
high NN NN O
- NN NN O
dose NN NN O
strategy NN NN O
. NN NN O
   
CONCLUSIONS NN NN O
: NN NN O
These NN NN O
findings NN NN O
demonstrate NN NN O
that NN NN O
ACE NN NN O
inhibitor NN NN O
therapy NN NN O
in NN NN O
most NN NN O
patients NN NN O
with NN NN O
CHF NN NN B-Disease
can NN NN O
be NN NN O
successfully NN NN O
titrated NN NN O
to NN NN O
and NN NN O
maintained NN NN O
at NN NN O
high NN NN O
doses NN NN O
, NN NN O
and NN NN O
that NN NN O
more NN NN O
aggressive NN NN O
use NN NN O
of NN NN O
these NN NN O
agents NN NN O
is NN NN O
warranted NN NN O
. NN NN O
   
Cocaine NN NN O
, NN NN O
ethanol NN NN O
, NN NN O
and NN NN O
cocaethylene NN NN O
cardiotoxity NN NN B-Disease
in NN NN O
an NN NN O
animal NN NN O
model NN NN O
of NN NN O
cocaine NN NN B-Disease
and NN NN I-Disease
ethanol NN NN I-Disease
abuse NN NN I-Disease
. NN NN O
   
OBJECTIVES NN NN O
: NN NN O
Simultaneous NN NN O
abuse NN NN B-Disease
of NN NN I-Disease
cocaine NN NN I-Disease
and NN NN I-Disease
ethanol NN NN I-Disease
affects NN NN O
12 NN NN O
million NN NN O
Americans NN NN O
annually NN NN O
. NN NN O
   
In NN NN O
combination NN NN O
, NN NN O
these NN NN O
substances NN NN O
are NN NN O
substantially NN NN O
more NN NN O
toxic NN NN O
than NN NN O
either NN NN O
drug NN NN O
alone NN NN O
. NN NN O
   
Their NN NN O
combined NN NN O
cardiac NN NN B-Disease
toxicity NN NN I-Disease
may NN NN O
be NN NN O
due NN NN O
to NN NN O
independent NN NN O
effects NN NN O
of NN NN O
each NN NN O
drug NN NN O
; NN NN O
however NN NN O
, NN NN O
they NN NN O
may NN NN O
also NN NN O
be NN NN O
due NN NN O
to NN NN O
cocaethylene NN NN O
( NN NN O
CE NN NN O
) NN NN O
, NN NN O
a NN NN O
cocaine NN NN O
metabolite NN NN O
formed NN NN O
only NN NN O
in NN NN O
the NN NN O
presence NN NN O
of NN NN O
ethanol NN NN O
. NN NN O
   
The NN NN O
purpose NN NN O
of NN NN O
this NN NN O
study NN NN O
was NN NN O
to NN NN O
delineate NN NN O
the NN NN O
role NN NN O
of NN NN O
CE NN NN O
in NN NN O
the NN NN O
combined NN NN O
cardiotoxicity NN NN B-Disease
of NN NN O
cocaine NN NN O
and NN NN O
ethanol NN NN O
in NN NN O
a NN NN O
model NN NN O
simulating NN NN O
their NN NN O
abuse NN NN O
. NN NN O
   
METHODS NN NN O
: NN NN O
Twenty NN NN O
- NN NN O
three NN NN O
dogs NN NN O
were NN NN O
randomized NN NN O
to NN NN O
receive NN NN O
either NN NN O
1 NN NN O
) NN NN O
three NN NN O
intravenous NN NN O
( NN NN O
IV NN NN O
) NN NN O
boluses NN NN O
of NN NN O
cocaine NN NN O
7 NN NN O
. NN NN O
5 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
with NN NN O
ethanol NN NN O
( NN NN O
1 NN NN O
g NN NN O
/ NN NN O
kg NN NN O
) NN NN O
as NN NN O
an NN NN O
IV NN NN O
infusion NN NN O
( NN NN O
C NN NN O
+ NN NN O
E NN NN O
, NN NN O
n NN NN O
= NN NN O
8 NN NN O
) NN NN O
, NN NN O
2 NN NN O
) NN NN O
three NN NN O
cocaine NN NN O
boluses NN NN O
only NN NN O
( NN NN O
C NN NN O
, NN NN O
n NN NN O
= NN NN O
6 NN NN O
) NN NN O
, NN NN O
3 NN NN O
) NN NN O
ethanol NN NN O
infusion NN NN O
only NN NN O
( NN NN O
E NN NN O
, NN NN O
n NN NN O
= NN NN O
5 NN NN O
) NN NN O
, NN NN O
or NN NN O
4 NN NN O
) NN NN O
placebo NN NN O
boluses NN NN O
and NN NN O
infusion NN NN O
( NN NN O
n NN NN O
= NN NN O
4 NN NN O
) NN NN O
. NN NN O
   
Hemodynamic NN NN O
measurements NN NN O
, NN NN O
electrocardiograms NN NN O
, NN NN O
and NN NN O
serum NN NN O
drug NN NN O
concentrations NN NN O
were NN NN O
obtained NN NN O
at NN NN O
baseline NN NN O
, NN NN O
and NN NN O
then NN NN O
at NN NN O
fixed NN NN O
time NN NN O
intervals NN NN O
after NN NN O
each NN NN O
drug NN NN O
was NN NN O
administered NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
Two NN NN O
of NN NN O
eight NN NN O
dogs NN NN O
in NN NN O
the NN NN O
C NN NN O
+ NN NN O
E NN NN O
group NN NN O
experienced NN NN O
cardiovascular NN NN B-Disease
collapse NN NN I-Disease
. NN NN O
   
The NN NN O
most NN NN O
dramatic NN NN O
hemodynamic NN NN O
changes NN NN O
occurred NN NN O
after NN NN O
each NN NN O
cocaine NN NN O
bolus NN NN O
in NN NN O
the NN NN O
C NN NN O
+ NN NN O
E NN NN O
and NN NN O
C NN NN O
only NN NN O
groups NN NN O
; NN NN O
however NN NN O
, NN NN O
persistent NN NN O
hemodynamic NN NN O
changes NN NN O
occurred NN NN O
in NN NN O
the NN NN O
C NN NN O
+ NN NN O
E NN NN O
group NN NN O
. NN NN O
   
Peak NN NN O
CE NN NN O
levels NN NN O
were NN NN O
associated NN NN O
with NN NN O
a NN NN O
45 NN NN O
% NN NN O
( NN NN O
SD NN NN O
+ NN NN O
/ NN NN O
- NN NN O
22 NN NN O
% NN NN O
, NN NN O
95 NN NN O
% NN NN O
CI NN NN O
= NN NN O
22 NN NN O
% NN NN O
to NN NN O
69 NN NN O
% NN NN O
) NN NN O
decrease NN NN B-Disease
in NN NN I-Disease
cardiac NN NN I-Disease
output NN NN I-Disease
( NN NN O
p NN NN O
< NN NN O
0 NN NN O
. NN NN O
05 NN NN O
) NN NN O
, NN NN O
a NN NN O
56 NN NN O
% NN NN O
( NN NN O
SD NN NN O
+ NN NN O
/ NN NN O
- NN NN O
23 NN NN O
% NN NN O
, NN NN O
95 NN NN O
% NN NN O
CI NN NN O
= NN NN O
32 NN NN O
% NN NN O
to NN NN O
80 NN NN O
% NN NN O
) NN NN O
decrease NN NN O
in NN NN O
dP NN NN O
/ NN NN O
dt NN NN O
( NN NN O
max NN NN O
) NN NN O
( NN NN O
p NN NN O
< NN NN O
. NN NN O
006 NN NN O
) NN NN O
, NN NN O
and NN NN O
a NN NN O
23 NN NN O
% NN NN O
( NN NN O
SD NN NN O
+ NN NN O
/ NN NN O
- NN NN O
15 NN NN O
% NN NN O
, NN NN O
95 NN NN O
% NN NN O
CI NN NN O
= NN NN O
7 NN NN O
% NN NN O
to NN NN O
49 NN NN O
% NN NN O
) NN NN O
decrease NN NN O
in NN NN O
SVO NN NN O
( NN NN O
2 NN NN O
) NN NN O
( NN NN O
p NN NN O
< NN NN O
0 NN NN O
. NN NN O
025 NN NN O
) NN NN O
. NN NN O
   
Ventricular NN NN B-Disease
arrhythmias NN NN I-Disease
were NN NN O
primarily NN NN O
observed NN NN O
in NN NN O
the NN NN O
C NN NN O
+ NN NN O
E NN NN O
group NN NN O
, NN NN O
in NN NN O
which NN NN O
four NN NN O
of NN NN O
eight NN NN O
dogs NN NN O
experienced NN NN O
ventricular NN NN B-Disease
tachycardia NN NN I-Disease
. NN NN O
   
CONCLUSIONS NN NN O
: NN NN O
Cocaine NN NN O
and NN NN O
ethanol NN NN O
in NN NN O
combination NN NN O
were NN NN O
more NN NN O
toxic NN NN O
than NN NN O
either NN NN O
substance NN NN O
alone NN NN O
. NN NN O
   
Co NN NN O
- NN NN O
administration NN NN O
resulted NN NN O
in NN NN O
prolonged NN NN O
cardiac NN NN B-Disease
toxicity NN NN I-Disease
and NN NN O
was NN NN O
dysrhythmogenic NN NN O
. NN NN O
   
Peak NN NN O
serum NN NN O
cocaethylene NN NN O
concentrations NN NN O
were NN NN O
associated NN NN O
with NN NN O
prolonged NN NN O
myocardial NN NN B-Disease
depression NN NN I-Disease
. NN NN O
   
Worsening NN NN O
of NN NN O
Parkinsonism NN NN B-Disease
after NN NN O
the NN NN O
use NN NN O
of NN NN O
veralipride NN NN O
for NN NN O
treatment NN NN O
of NN NN O
menopause NN NN O
: NN NN O
case NN NN O
report NN NN O
. NN NN O
   
We NN NN O
describe NN NN O
a NN NN O
female NN NN O
patient NN NN O
with NN NN O
stable NN NN O
Parkinson NN NN B-Disease
' NN NN I-Disease
s NN NN I-Disease
disease NN NN I-Disease
who NN NN O
has NN NN O
shown NN NN O
a NN NN O
marked NN NN O
worsening NN NN O
of NN NN O
her NN NN O
motor NN NN O
functions NN NN O
following NN NN O
therapy NN NN O
of NN NN O
menopause NN NN O
related NN NN O
symptoms NN NN O
with NN NN O
veralipride NN NN O
, NN NN O
as NN NN O
well NN NN O
as NN NN O
the NN NN O
improvement NN NN O
of NN NN O
her NN NN O
symptoms NN NN O
back NN NN O
to NN NN O
baseline NN NN O
after NN NN O
discontinuation NN NN O
of NN NN O
the NN NN O
drug NN NN O
. NN NN O
   
We NN NN O
emphasize NN NN O
the NN NN O
anti NN NN O
- NN NN O
dopaminergic NN NN O
effect NN NN O
of NN NN O
veralipride NN NN O
. NN NN O
   
Viracept NN NN O
and NN NN O
irregular NN NN B-Disease
heartbeat NN NN I-Disease
warning NN NN O
. NN NN O
   
A NN NN O
group NN NN O
of NN NN O
doctors NN NN O
in NN NN O
Boston NN NN O
warn NN NN O
that NN NN O
the NN NN O
protease NN NN O
inhibitor NN NN O
Viracept NN NN O
may NN NN O
cause NN NN O
an NN NN O
irregular NN NN B-Disease
heart NN NN I-Disease
beat NN NN I-Disease
, NN NN O
known NN NN O
as NN NN O
bradycardia NN NN B-Disease
, NN NN O
in NN NN O
people NN NN O
with NN NN O
HIV NN NN O
. NN NN O
   
Bradycardia NN NN B-Disease
occurred NN NN O
in NN NN O
a NN NN O
45 NN NN O
- NN NN O
year NN NN O
- NN NN O
old NN NN O
male NN NN O
patient NN NN O
who NN NN O
was NN NN O
Viracept NN NN O
in NN NN O
combination NN NN O
with NN NN O
other NN NN O
anti NN NN O
- NN NN O
HIV NN NN O
drugs NN NN O
. NN NN O
   
The NN NN O
symptoms NN NN O
ceased NN NN O
after NN NN O
switching NN NN O
to NN NN O
another NN NN O
drug NN NN O
combination NN NN O
. NN NN O
   
Frequency NN NN O
of NN NN O
appearance NN NN O
of NN NN O
myeloperoxidase NN NN O
- NN NN O
antineutrophil NN NN O
cytoplasmic NN NN O
antibody NN NN O
( NN NN O
MPO NN NN O
- NN NN O
ANCA NN NN O
) NN NN O
in NN NN O
Graves NN NN B-Disease
' NN NN I-Disease
disease NN NN I-Disease
patients NN NN O
treated NN NN O
with NN NN O
propylthiouracil NN NN O
and NN NN O
the NN NN O
relationship NN NN O
between NN NN O
MPO NN NN O
- NN NN O
ANCA NN NN O
and NN NN O
clinical NN NN O
manifestations NN NN O
. NN NN O
   
OBJECTIVE NN NN O
: NN NN O
Myeloperoxidase NN NN O
antineutrophil NN NN O
cytoplasmic NN NN O
antibody NN NN O
( NN NN O
MPO NN NN O
- NN NN O
ANCA NN NN O
) NN NN O
- NN NN O
positive NN NN O
vasculitis NN NN B-Disease
has NN NN O
been NN NN O
reported NN NN O
in NN NN O
patients NN NN O
with NN NN O
Graves NN NN B-Disease
' NN NN I-Disease
disease NN NN I-Disease
who NN NN O
were NN NN O
treated NN NN O
with NN NN O
propylthiouracil NN NN O
( NN NN O
PTU NN NN O
) NN NN O
. NN NN O
   
The NN NN O
appearance NN NN O
of NN NN O
MPO NN NN O
- NN NN O
ANCA NN NN O
in NN NN O
these NN NN O
cases NN NN O
was NN NN O
suspected NN NN O
of NN NN O
being NN NN O
related NN NN O
to NN NN O
PTU NN NN O
because NN NN O
the NN NN O
titres NN NN O
of NN NN O
MPO NN NN O
- NN NN O
ANCA NN NN O
decreased NN NN O
when NN NN O
PTU NN NN O
was NN NN O
stopped NN NN O
. NN NN O
   
Nevertheless NN NN O
, NN NN O
there NN NN O
have NN NN O
been NN NN O
no NN NN O
studies NN NN O
on NN NN O
the NN NN O
temporal NN NN O
relationship NN NN O
between NN NN O
the NN NN O
appearance NN NN O
of NN NN O
MPO NN NN O
- NN NN O
ANCA NN NN O
and NN NN O
vasculitis NN NN B-Disease
during NN NN O
PTU NN NN O
therapy NN NN O
, NN NN O
or NN NN O
on NN NN O
the NN NN O
incidence NN NN O
of NN NN O
MPO NN NN O
- NN NN O
ANCA NN NN O
in NN NN O
untreated NN NN O
Graves NN NN B-Disease
' NN NN I-Disease
disease NN NN I-Disease
patients NN NN O
. NN NN O
   
Therefore NN NN O
, NN NN O
we NN NN O
sought NN NN O
to NN NN O
address NN NN O
these NN NN O
parameters NN NN O
in NN NN O
patients NN NN O
with NN NN O
Graves NN NN B-Disease
' NN NN I-Disease
disease NN NN I-Disease
. NN NN O
   
PATIENTS NN NN O
: NN NN O
We NN NN O
investigated NN NN O
102 NN NN O
untreated NN NN O
patients NN NN O
with NN NN O
hyperthyroidism NN NN B-Disease
due NN NN O
to NN NN O
Graves NN NN B-Disease
' NN NN I-Disease
disease NN NN I-Disease
for NN NN O
the NN NN O
presence NN NN O
of NN NN O
MPO NN NN O
- NN NN O
ANCA NN NN O
, NN NN O
and NN NN O
for NN NN O
the NN NN O
development NN NN O
vasculitis NN NN B-Disease
after NN NN O
starting NN NN O
PTU NN NN O
therapy NN NN O
. NN NN O
   
Twenty NN NN O
- NN NN O
nine NN NN O
of NN NN O
them NN NN O
were NN NN O
later NN NN O
excluded NN NN O
because NN NN O
of NN NN O
adverse NN NN O
effects NN NN O
of NN NN O
PTU NN NN O
or NN NN O
because NN NN O
the NN NN O
observation NN NN O
period NN NN O
was NN NN O
less NN NN O
than NN NN O
3 NN NN O
months NN NN O
. NN NN O
   
The NN NN O
remaining NN NN O
73 NN NN O
patients NN NN O
( NN NN O
55 NN NN O
women NN NN O
and NN NN O
18 NN NN O
men NN NN O
) NN NN O
, NN NN O
all NN NN O
of NN NN O
whom NN NN O
were NN NN O
examined NN NN O
for NN NN O
more NN NN O
than NN NN O
3 NN NN O
months NN NN O
, NN NN O
were NN NN O
adopted NN NN O
as NN NN O
the NN NN O
subjects NN NN O
of NN NN O
the NN NN O
investigation NN NN O
. NN NN O
   
The NN NN O
median NN NN O
observation NN NN O
period NN NN O
was NN NN O
23 NN NN O
. NN NN O
6 NN NN O
months NN NN O
( NN NN O
range NN NN O
: NN NN O
3 NN NN O
- NN NN O
37 NN NN O
months NN NN O
) NN NN O
. NN NN O
   
MEASUREMENTS NN NN O
: NN NN O
MPO NN NN O
- NN NN O
ANCA NN NN O
was NN NN O
measured NN NN O
at NN NN O
intervals NN NN O
of NN NN O
2 NN NN O
- NN NN O
6 NN NN O
months NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
Before NN NN O
treatment NN NN O
, NN NN O
the NN NN O
MPO NN NN O
- NN NN O
ANCA NN NN O
titres NN NN O
of NN NN O
all NN NN O
102 NN NN O
untreated NN NN O
Graves NN NN B-Disease
' NN NN I-Disease
disease NN NN I-Disease
patients NN NN O
were NN NN O
within NN NN O
the NN NN O
reference NN NN O
range NN NN O
( NN NN O
below NN NN O
10 NN NN O
U NN NN O
/ NN NN O
ml NN NN O
) NN NN O
. NN NN O
   
Three NN NN O
( NN NN O
4 NN NN O
. NN NN O
1 NN NN O
% NN NN O
) NN NN O
of NN NN O
the NN NN O
73 NN NN O
patients NN NN O
were NN NN O
positive NN NN O
for NN NN O
MPO NN NN O
- NN NN O
ANCA NN NN O
at NN NN O
13 NN NN O
, NN NN O
16 NN NN O
and NN NN O
17 NN NN O
months NN NN O
, NN NN O
respectively NN NN O
, NN NN O
after NN NN O
the NN NN O
start NN NN O
of NN NN O
PTU NN NN O
therapy NN NN O
. NN NN O
   
In NN NN O
two NN NN O
of NN NN O
them NN NN O
, NN NN O
the NN NN O
MPO NN NN O
- NN NN O
ANCA NN NN O
titres NN NN O
transiently NN NN O
increased NN NN O
to NN NN O
12 NN NN O
. NN NN O
8 NN NN O
and NN NN O
15 NN NN O
. NN NN O
0 NN NN O
U NN NN O
/ NN NN O
ml NN NN O
, NN NN O
respectively NN NN O
, NN NN O
despite NN NN O
continued NN NN O
PTU NN NN O
therapy NN NN O
, NN NN O
but NN NN O
no NN NN O
vasculitic NN NN B-Disease
disorders NN NN I-Disease
developed NN NN O
. NN NN O
   
In NN NN O
the NN NN O
third NN NN O
patient NN NN O
, NN NN O
the NN NN O
MPO NN NN O
- NN NN O
ANCA NN NN O
titre NN NN O
increased NN NN O
to NN NN O
204 NN NN O
U NN NN O
/ NN NN O
ml NN NN O
and NN NN O
she NN NN O
developed NN NN O
a NN NN O
higher NN NN O
fever NN NN B-Disease
, NN NN O
oral NN NN B-Disease
ulcers NN NN I-Disease
and NN NN O
polyarthralgia NN NN B-Disease
, NN NN O
but NN NN O
the NN NN O
symptoms NN NN O
resolved NN NN O
2 NN NN O
weeks NN NN O
after NN NN O
stopping NN NN O
PTU NN NN O
therapy NN NN O
, NN NN O
and NN NN O
the NN NN O
MPO NN NN O
- NN NN O
ANCA NN NN O
titre NN NN O
decreased NN NN O
to NN NN O
20 NN NN O
. NN NN O
7 NN NN O
U NN NN O
/ NN NN O
ml NN NN O
by NN NN O
4 NN NN O
months NN NN O
after NN NN O
discontinuing NN NN O
PTU NN NN O
. NN NN O
   
CONCLUSIONS NN NN O
: NN NN O
PTU NN NN O
therapy NN NN O
may NN NN O
be NN NN O
related NN NN O
to NN NN O
the NN NN O
appearance NN NN O
of NN NN O
MPO NN NN O
- NN NN O
ANCA NN NN O
, NN NN O
but NN NN O
MPO NN NN O
- NN NN O
ANCA NN NN O
does NN NN O
not NN NN O
appear NN NN O
to NN NN O
be NN NN O
closely NN NN O
related NN NN O
to NN NN O
vasculitis NN NN B-Disease
. NN NN O
   
Prevalence NN NN O
of NN NN O
heart NN NN B-Disease
disease NN NN I-Disease
in NN NN O
asymptomatic NN NN O
chronic NN NN O
cocaine NN NN O
users NN NN O
. NN NN O
   
To NN NN O
determine NN NN O
the NN NN O
prevalence NN NN O
of NN NN O
heart NN NN B-Disease
disease NN NN I-Disease
in NN NN O
outpatient NN NN O
young NN NN O
asymptomatic NN NN O
chronic NN NN O
cocaine NN NN O
users NN NN O
, NN NN O
35 NN NN O
cocaine NN NN O
users NN NN O
and NN NN O
32 NN NN O
age NN NN O
- NN NN O
matched NN NN O
controls NN NN O
underwent NN NN O
resting NN NN O
and NN NN O
exercise NN NN O
electrocardiography NN NN O
( NN NN O
ECG NN NN O
) NN NN O
and NN NN O
Doppler NN NN O
echocardiography NN NN O
. NN NN O
   
Findings NN NN O
consistent NN NN O
with NN NN O
coronary NN NN B-Disease
artery NN NN I-Disease
disease NN NN I-Disease
were NN NN O
detected NN NN O
in NN NN O
12 NN NN O
( NN NN O
34 NN NN O
% NN NN O
) NN NN O
patients NN NN O
and NN NN O
3 NN NN O
( NN NN O
9 NN NN O
% NN NN O
) NN NN O
controls NN NN O
( NN NN O
p NN NN O
= NN NN O
0 NN NN O
. NN NN O
01 NN NN O
) NN NN O
. NN NN O
   
Decreased NN NN O
left NN NN O
ventricular NN NN O
systolic NN NN O
function NN NN O
was NN NN O
demonstrated NN NN O
in NN NN O
5 NN NN O
( NN NN O
14 NN NN O
% NN NN O
) NN NN O
patients NN NN O
, NN NN O
but NN NN O
in NN NN O
none NN NN O
of NN NN O
the NN NN O
controls NN NN O
( NN NN O
p NN NN O
= NN NN O
0 NN NN O
. NN NN O
055 NN NN O
) NN NN O
. NN NN O
   
Finally NN NN O
, NN NN O
resting NN NN O
and NN NN O
peak NN NN O
exercise NN NN O
abnormal NN NN B-Disease
left NN NN I-Disease
ventricular NN NN I-Disease
filling NN NN I-Disease
was NN NN O
detected NN NN O
in NN NN O
38 NN NN O
and NN NN O
35 NN NN O
% NN NN O
of NN NN O
patients NN NN O
as NN NN O
compared NN NN O
to NN NN O
19 NN NN O
and NN NN O
9 NN NN O
% NN NN O
of NN NN O
controls NN NN O
, NN NN O
respectively NN NN O
( NN NN O
p NN NN O
= NN NN O
0 NN NN O
. NN NN O
11 NN NN O
and NN NN O
0 NN NN O
. NN NN O
02 NN NN O
, NN NN O
respectively NN NN O
) NN NN O
. NN NN O
   
We NN NN O
conclude NN NN O
that NN NN O
coronary NN NN B-Disease
artery NN NN I-Disease
or NN NN I-Disease
myocardial NN NN I-Disease
disease NN NN I-Disease
is NN NN O
common NN NN O
( NN NN O
38 NN NN O
% NN NN O
) NN NN O
in NN NN O
young NN NN O
asymptomatic NN NN O
chronic NN NN O
cocaine NN NN O
users NN NN O
. NN NN O
   
Therefore NN NN O
, NN NN O
screening NN NN O
ECG NN NN O
and NN NN O
echocardiography NN NN O
may NN NN O
be NN NN O
warranted NN NN O
in NN NN O
these NN NN O
patients NN NN O
. NN NN O
   
Cardioprotective NN NN O
effects NN NN O
of NN NN O
Picrorrhiza NN NN O
kurroa NN NN O
against NN NN O
isoproterenol NN NN O
- NN NN O
induced NN NN O
myocardial NN NN O
stress NN NN O
in NN NN O
rats NN NN O
. NN NN O
   
The NN NN O
cardioprotective NN NN O
effect NN NN O
of NN NN O
the NN NN O
ethanol NN NN O
extract NN NN O
of NN NN O
Picrorrhiza NN NN O
kurroa NN NN O
rhizomes NN NN O
and NN NN O
roots NN NN O
( NN NN O
PK NN NN O
) NN NN O
on NN NN O
isoproterenol NN NN O
- NN NN O
induced NN NN O
myocardial NN NN B-Disease
infarction NN NN I-Disease
in NN NN O
rats NN NN O
with NN NN O
respect NN NN O
to NN NN O
lipid NN NN O
metabolism NN NN O
in NN NN O
serum NN NN O
and NN NN O
heart NN NN O
tissue NN NN O
has NN NN O
been NN NN O
investigated NN NN O
. NN NN O
   
Oral NN NN O
pre NN NN O
- NN NN O
treatment NN NN O
with NN NN O
PK NN NN O
( NN NN O
80 NN NN O
mg NN NN O
kg NN NN O
( NN NN O
- NN NN O
1 NN NN O
) NN NN O
day NN NN O
( NN NN O
- NN NN O
1 NN NN O
) NN NN O
for NN NN O
15 NN NN O
days NN NN O
) NN NN O
significantly NN NN O
prevented NN NN O
the NN NN O
isoproterenol NN NN O
- NN NN O
induced NN NN O
myocardial NN NN B-Disease
infarction NN NN I-Disease
and NN NN O
maintained NN NN O
the NN NN O
rats NN NN O
at NN NN O
near NN NN O
normal NN NN O
status NN NN O
. NN NN O
   
Phase NN NN O
2 NN NN O
early NN NN O
afterdepolarization NN NN O
as NN NN O
a NN NN O
trigger NN NN O
of NN NN O
polymorphic NN NN O
ventricular NN NN B-Disease
tachycardia NN NN I-Disease
in NN NN O
acquired NN NN O
long NN NN B-Disease
- NN NN I-Disease
QT NN NN I-Disease
syndrome NN NN I-Disease
: NN NN O
direct NN NN O
evidence NN NN O
from NN NN O
intracellular NN NN O
recordings NN NN O
in NN NN O
the NN NN O
intact NN NN O
left NN NN O
ventricular NN NN O
wall NN NN O
. NN NN O
   
BACKGROUND NN NN O
: NN NN O
This NN NN O
study NN NN O
examined NN NN O
the NN NN O
role NN NN O
of NN NN O
phase NN NN O
2 NN NN O
early NN NN O
afterdepolarization NN NN O
( NN NN O
EAD NN NN O
) NN NN O
in NN NN O
producing NN NN O
a NN NN O
trigger NN NN O
to NN NN O
initiate NN NN O
torsade NN NN B-Disease
de NN NN I-Disease
pointes NN NN I-Disease
( NN NN O
TdP NN NN B-Disease
) NN NN O
with NN NN O
QT NN NN B-Disease
prolongation NN NN I-Disease
induced NN NN O
by NN NN O
dl NN NN O
- NN NN O
sotalol NN NN O
and NN NN O
azimilide NN NN O
. NN NN O
   
The NN NN O
contribution NN NN O
of NN NN O
transmural NN NN O
dispersion NN NN O
of NN NN O
repolarization NN NN O
( NN NN O
TDR NN NN O
) NN NN O
to NN NN O
transmural NN NN O
propagation NN NN O
of NN NN O
EAD NN NN O
and NN NN O
the NN NN O
maintenance NN NN O
of NN NN O
TdP NN NN B-Disease
was NN NN O
also NN NN O
evaluated NN NN O
. NN NN O
   
METHODS NN NN O
AND NN NN O
RESULTS NN NN O
: NN NN O
Transmembrane NN NN O
action NN NN O
potentials NN NN O
from NN NN O
epicardium NN NN O
, NN NN O
midmyocardium NN NN O
, NN NN O
and NN NN O
endocardium NN NN O
were NN NN O
recorded NN NN O
simultaneously NN NN O
, NN NN O
together NN NN O
with NN NN O
a NN NN O
transmural NN NN O
ECG NN NN O
, NN NN O
in NN NN O
arterially NN NN O
perfused NN NN O
canine NN NN O
and NN NN O
rabbit NN NN O
left NN NN O
ventricular NN NN O
preparations NN NN O
. NN NN O
   
dl NN NN O
- NN NN O
Sotalol NN NN O
preferentially NN NN O
prolonged NN NN O
action NN NN O
potential NN NN O
duration NN NN O
( NN NN O
APD NN NN O
) NN NN O
in NN NN O
M NN NN O
cells NN NN O
dose NN NN O
- NN NN O
dependently NN NN O
( NN NN O
1 NN NN O
to NN NN O
100 NN NN O
micromol NN NN O
/ NN NN O
L NN NN O
) NN NN O
, NN NN O
leading NN NN O
to NN NN O
QT NN NN B-Disease
prolongation NN NN I-Disease
and NN NN O
an NN NN O
increase NN NN O
in NN NN O
TDR NN NN O
. NN NN O
   
Azimilide NN NN O
, NN NN O
however NN NN O
, NN NN O
significantly NN NN O
prolonged NN NN O
APD NN NN O
and NN NN O
QT NN NN O
interval NN NN O
at NN NN O
concentrations NN NN O
from NN NN O
0 NN NN O
. NN NN O
1 NN NN O
to NN NN O
10 NN NN O
micromol NN NN O
/ NN NN O
L NN NN O
but NN NN O
shortened NN NN O
them NN NN O
at NN NN O
30 NN NN O
micromol NN NN O
/ NN NN O
L NN NN O
. NN NN O
   
Unlike NN NN O
dl NN NN O
- NN NN O
sotalol NN NN O
, NN NN O
azimilide NN NN O
( NN NN O
> NN NN O
3 NN NN O
micromol NN NN O
/ NN NN O
L NN NN O
) NN NN O
increased NN NN O
epicardial NN NN O
APD NN NN O
markedly NN NN O
, NN NN O
causing NN NN O
a NN NN O
diminished NN NN O
TDR NN NN O
. NN NN O
   
Although NN NN O
both NN NN O
dl NN NN O
- NN NN O
sotalol NN NN O
and NN NN O
azimilide NN NN O
rarely NN NN O
induced NN NN O
EADs NN NN O
in NN NN O
canine NN NN O
left NN NN O
ventricles NN NN O
, NN NN O
they NN NN O
produced NN NN O
frequent NN NN O
EADs NN NN O
in NN NN O
rabbits NN NN O
, NN NN O
in NN NN O
which NN NN O
more NN NN O
pronounced NN NN O
QT NN NN B-Disease
prolongation NN NN I-Disease
was NN NN O
seen NN NN O
. NN NN O
   
An NN NN O
increase NN NN O
in NN NN O
TDR NN NN O
by NN NN O
dl NN NN O
- NN NN O
sotalol NN NN O
facilitated NN NN O
transmural NN NN O
propagation NN NN O
of NN NN O
EADs NN NN O
that NN NN O
initiated NN NN O
multiple NN NN O
episodes NN NN O
of NN NN O
spontaneous NN NN O
TdP NN NN B-Disease
in NN NN O
3 NN NN O
of NN NN O
6 NN NN O
rabbit NN NN O
left NN NN O
ventricles NN NN O
. NN NN O
   
Of NN NN O
note NN NN O
, NN NN O
although NN NN O
azimilide NN NN O
( NN NN O
3 NN NN O
to NN NN O
10 NN NN O
micromol NN NN O
/ NN NN O
L NN NN O
) NN NN O
increased NN NN O
APD NN NN O
more NN NN O
than NN NN O
dl NN NN O
- NN NN O
sotalol NN NN O
, NN NN O
its NN NN O
EADs NN NN O
often NN NN O
failed NN NN O
to NN NN O
propagate NN NN O
transmurally NN NN O
, NN NN O
probably NN NN O
because NN NN O
of NN NN O
a NN NN O
diminished NN NN O
TDR NN NN O
. NN NN O
   
CONCLUSIONS NN NN O
: NN NN O
This NN NN O
study NN NN O
provides NN NN O
the NN NN O
first NN NN O
direct NN NN O
evidence NN NN O
from NN NN O
intracellular NN NN O
action NN NN O
potential NN NN O
recordings NN NN O
that NN NN O
phase NN NN O
2 NN NN O
EAD NN NN O
can NN NN O
be NN NN O
generated NN NN O
from NN NN O
intact NN NN O
ventricular NN NN O
wall NN NN O
and NN NN O
produce NN NN O
a NN NN O
trigger NN NN O
to NN NN O
initiate NN NN O
the NN NN O
onset NN NN O
of NN NN O
TdP NN NN B-Disease
under NN NN O
QT NN NN B-Disease
prolongation NN NN I-Disease
. NN NN O
   
A NN NN O
pilot NN NN O
study NN NN O
to NN NN O
assess NN NN O
the NN NN O
safety NN NN O
of NN NN O
dobutamine NN NN O
stress NN NN O
echocardiography NN NN O
in NN NN O
the NN NN O
emergency NN NN O
department NN NN O
evaluation NN NN O
of NN NN O
cocaine NN NN O
- NN NN O
associated NN NN O
chest NN NN B-Disease
pain NN NN I-Disease
. NN NN O
   
STUDY NN NN O
OBJECTIVE NN NN O
: NN NN O
Chest NN NN B-Disease
pain NN NN I-Disease
in NN NN O
the NN NN O
setting NN NN O
of NN NN O
cocaine NN NN O
use NN NN O
poses NN NN O
a NN NN O
diagnostic NN NN O
dilemma NN NN O
. NN NN O
   
Dobutamine NN NN O
stress NN NN O
echocardiography NN NN O
( NN NN O
DSE NN NN O
) NN NN O
is NN NN O
a NN NN O
widely NN NN O
available NN NN O
and NN NN O
sensitive NN NN O
test NN NN O
for NN NN O
evaluating NN NN O
cardiac NN NN O
ischemia NN NN B-Disease
. NN NN O
   
Because NN NN O
of NN NN O
the NN NN O
theoretical NN NN O
concern NN NN O
regarding NN NN O
administration NN NN O
of NN NN O
dobutamine NN NN O
in NN NN O
the NN NN O
setting NN NN O
of NN NN O
cocaine NN NN O
use NN NN O
, NN NN O
we NN NN O
conducted NN NN O
a NN NN O
pilot NN NN O
study NN NN O
to NN NN O
assess NN NN O
the NN NN O
safety NN NN O
of NN NN O
DSE NN NN O
in NN NN O
emergency NN NN O
department NN NN O
patients NN NN O
with NN NN O
cocaine NN NN O
- NN NN O
associated NN NN O
chest NN NN B-Disease
pain NN NN I-Disease
. NN NN O
   
METHODS NN NN O
: NN NN O
A NN NN O
prospective NN NN O
case NN NN O
series NN NN O
was NN NN O
conducted NN NN O
in NN NN O
the NN NN O
intensive NN NN O
diagnostic NN NN O
and NN NN O
treatment NN NN O
unit NN NN O
in NN NN O
the NN NN O
ED NN NN O
of NN NN O
an NN NN O
urban NN NN O
tertiary NN NN O
- NN NN O
care NN NN O
teaching NN NN O
hospital NN NN O
. NN NN O
   
Patients NN NN O
were NN NN O
eligible NN NN O
for NN NN O
DSE NN NN O
if NN NN O
they NN NN O
had NN NN O
used NN NN O
cocaine NN NN O
within NN NN O
24 NN NN O
hours NN NN O
preceding NN NN O
the NN NN O
onset NN NN O
of NN NN O
chest NN NN B-Disease
pain NN NN I-Disease
and NN NN O
had NN NN O
a NN NN O
normal NN NN O
ECG NN NN O
and NN NN O
tropinin NN NN O
I NN NN O
level NN NN O
. NN NN O
   
Patients NN NN O
exhibiting NN NN O
signs NN NN O
of NN NN O
continuing NN NN O
cocaine NN NN O
toxicity NN NN B-Disease
were NN NN O
excluded NN NN O
from NN NN O
the NN NN O
study NN NN O
. NN NN O
   
All NN NN O
patients NN NN O
were NN NN O
admitted NN NN O
to NN NN O
the NN NN O
hospital NN NN O
for NN NN O
serial NN NN O
testing NN NN O
after NN NN O
the NN NN O
DSE NN NN O
testing NN NN O
in NN NN O
the NN NN O
intensive NN NN O
diagnostic NN NN O
and NN NN O
treatment NN NN O
unit NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
Twenty NN NN O
- NN NN O
four NN NN O
patients NN NN O
were NN NN O
enrolled NN NN O
. NN NN O
   
Two NN NN O
patients NN NN O
had NN NN O
inadequate NN NN O
resting NN NN O
images NN NN O
, NN NN O
one NN NN O
DSE NN NN O
was NN NN O
terminated NN NN O
because NN NN O
of NN NN O
inferior NN NN O
hypokinesis NN NN B-Disease
, NN NN O
another NN NN O
DSE NN NN O
was NN NN O
terminated NN NN O
because NN NN O
of NN NN O
a NN NN O
rate NN NN O
- NN NN O
related NN NN O
atrial NN NN O
conduction NN NN O
deficit NN NN O
, NN NN O
and NN NN O
1 NN NN O
patient NN NN O
did NN NN O
not NN NN O
reach NN NN O
the NN NN O
target NN NN O
heart NN NN O
rate NN NN O
. NN NN O
   
Thus NN NN O
, NN NN O
19 NN NN O
patients NN NN O
completed NN NN O
a NN NN O
DSE NN NN O
and NN NN O
reached NN NN O
their NN NN O
target NN NN O
heart NN NN O
rates NN NN O
. NN NN O
   
   O
of NN NN O
the NN NN O
patients NN NN O
experienced NN NN O
signs NN NN O
of NN NN O
exaggerated NN NN O
adrenergic NN NN O
response NN NN O
, NN NN O
which NN NN O
was NN NN O
defined NN NN O
as NN NN O
a NN NN O
systolic NN NN O
blood NN NN O
pressure NN NN O
of NN NN O
greater NN NN O
than NN NN O
200 NN NN O
mm NN NN O
Hg NN NN O
or NN NN O
the NN NN O
occurrence NN NN O
of NN NN O
tachydysrhythmias NN NN B-Disease
( NN NN O
excluding NN NN O
sinus NN NN B-Disease
tachycardia NN NN I-Disease
) NN NN O
. NN NN O
   
Further NN NN O
suggesting NN NN O
lack NN NN O
of NN NN O
exaggerated NN NN O
adrenergic NN NN O
response NN NN O
, NN NN O
13 NN NN O
( NN NN O
65 NN NN O
% NN NN O
) NN NN O
of NN NN O
20 NN NN O
patients NN NN O
required NN NN O
supplemental NN NN O
atropine NN NN O
to NN NN O
reach NN NN O
their NN NN O
target NN NN O
heart NN NN O
rates NN NN O
. NN NN O
   
CONCLUSION NN NN O
: NN NN O
No NN NN O
exaggerated NN NN O
adrenergic NN NN O
response NN NN O
was NN NN O
detected NN NN O
when NN NN O
dobutamine NN NN O
was NN NN O
administered NN NN O
to NN NN O
patients NN NN O
with NN NN O
cocaine NN NN O
- NN NN O
related NN NN O
chest NN NN B-Disease
pain NN NN I-Disease
. NN NN O
   
Prenatal NN NN O
cocaine NN NN O
exposure NN NN O
and NN NN O
cranial NN NN O
sonographic NN NN O
findings NN NN O
in NN NN O
preterm NN NN B-Disease
infants NN NN I-Disease
. NN NN O
   
PURPOSE NN NN O
: NN NN O
Prenatal NN NN O
cocaine NN NN O
exposure NN NN O
has NN NN O
been NN NN O
linked NN NN O
with NN NN O
subependymal NN NN O
hemorrhage NN NN B-Disease
and NN NN O
the NN NN O
formation NN NN O
of NN NN O
cysts NN NN B-Disease
that NN NN O
are NN NN O
detectable NN NN O
on NN NN O
cranial NN NN O
sonography NN NN O
in NN NN O
neonates NN NN O
born NN NN O
at NN NN O
term NN NN O
. NN NN O
   
We NN NN O
sought NN NN O
to NN NN O
determine NN NN O
if NN NN O
prenatal NN NN O
cocaine NN NN O
exposure NN NN O
increases NN NN O
the NN NN O
incidence NN NN O
of NN NN O
subependymal NN NN B-Disease
cysts NN NN I-Disease
in NN NN O
preterm NN NN B-Disease
infants NN NN I-Disease
. NN NN O
   
METHODS NN NN O
: NN NN O
We NN NN O
retrospectively NN NN O
reviewed NN NN O
the NN NN O
medical NN NN O
records NN NN O
and NN NN O
cranial NN NN O
sonograms NN NN O
obtained NN NN O
during NN NN O
a NN NN O
1 NN NN O
- NN NN O
year NN NN O
period NN NN O
on NN NN O
122 NN NN O
premature NN NN B-Disease
( NN NN I-Disease
< NN NN I-Disease
36 NN NN I-Disease
weeks NN NN I-Disease
of NN NN I-Disease
gestation NN NN I-Disease
) NN NN I-Disease
infants NN NN I-Disease
. NN NN O
   
Infants NN NN O
were NN NN O
categorized NN NN O
into NN NN O
1 NN NN O
of NN NN O
2 NN NN O
groups NN NN O
: NN NN O
those NN NN O
exposed NN NN O
to NN NN O
cocaine NN NN O
and NN NN O
those NN NN O
not NN NN O
exposed NN NN O
to NN NN O
cocaine NN NN O
. NN NN O
   
Infants NN NN O
were NN NN O
assigned NN NN O
to NN NN O
the NN NN O
cocaine NN NN O
- NN NN O
exposed NN NN O
group NN NN O
if NN NN O
there NN NN O
was NN NN O
a NN NN O
maternal NN NN O
history NN NN O
of NN NN O
cocaine NN NN B-Disease
abuse NN NN I-Disease
during NN NN O
pregnancy NN NN O
or NN NN O
if NN NN O
maternal NN NN O
or NN NN O
neonatal NN NN O
urine NN NN O
toxicology NN NN O
results NN NN O
were NN NN O
positive NN NN O
at NN NN O
the NN NN O
time NN NN O
of NN NN O
delivery NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
Five NN NN O
of NN NN O
the NN NN O
122 NN NN O
infants NN NN O
were NN NN O
excluded NN NN O
from NN NN O
the NN NN O
study NN NN O
because NN NN O
of NN NN O
insufficient NN NN O
medical NN NN O
and NN NN O
drug NN NN O
histories NN NN O
. NN NN O
   
The NN NN O
incidence NN NN O
of NN NN O
subependymal NN NN B-Disease
cysts NN NN I-Disease
in NN NN O
the NN NN O
117 NN NN O
remaining NN NN O
infants NN NN O
was NN NN O
14 NN NN O
% NN NN O
( NN NN O
16 NN NN O
of NN NN O
117 NN NN O
) NN NN O
. NN NN O
   
The NN NN O
incidence NN NN O
of NN NN O
subependymal NN NN B-Disease
cysts NN NN I-Disease
in NN NN O
infants NN NN O
exposed NN NN O
to NN NN O
cocaine NN NN O
prenatally NN NN O
was NN NN O
44 NN NN O
% NN NN O
( NN NN O
8 NN NN O
of NN NN O
18 NN NN O
) NN NN O
compared NN NN O
with NN NN O
8 NN NN O
% NN NN O
( NN NN O
8 NN NN O
of NN NN O
99 NN NN O
) NN NN O
in NN NN O
the NN NN O
unexposed NN NN O
group NN NN O
( NN NN O
p NN NN O
< NN NN O
0 NN NN O
. NN NN O
01 NN NN O
) NN NN O
. NN NN O
   
CONCLUSIONS NN NN O
: NN NN O
We NN NN O
found NN NN O
an NN NN O
increased NN NN O
incidence NN NN O
of NN NN O
subependymal NN NN B-Disease
cyst NN NN I-Disease
formation NN NN O
in NN NN O
preterm NN NN B-Disease
infants NN NN I-Disease
who NN NN O
were NN NN O
exposed NN NN O
to NN NN O
cocaine NN NN O
prenatally NN NN O
. NN NN O
   
This NN NN O
result NN NN O
is NN NN O
consistent NN NN O
with NN NN O
results NN NN O
of NN NN O
similar NN NN O
studies NN NN O
in NN NN O
term NN NN O
infants NN NN O
. NN NN O
   
Thalidomide NN NN O
neuropathy NN NN B-Disease
in NN NN O
patients NN NN O
treated NN NN O
for NN NN O
metastatic NN NN O
prostate NN NN B-Disease
cancer NN NN I-Disease
. NN NN O
   
We NN NN O
prospectively NN NN O
evaluated NN NN O
thalidomide NN NN O
- NN NN O
induced NN NN O
neuropathy NN NN B-Disease
using NN NN O
electrodiagnostic NN NN O
studies NN NN O
. NN NN O
   
Sixty NN NN O
- NN NN O
seven NN NN O
men NN NN O
with NN NN O
metastatic NN NN O
androgen NN NN O
- NN NN O
independent NN NN O
prostate NN NN B-Disease
cancer NN NN I-Disease
in NN NN O
an NN NN O
open NN NN O
- NN NN O
label NN NN O
trial NN NN O
of NN NN O
oral NN NN O
thalidomide NN NN O
underwent NN NN O
neurologic NN NN O
examinations NN NN O
and NN NN O
nerve NN NN O
conduction NN NN O
studies NN NN O
( NN NN O
NCS NN NN O
) NN NN O
prior NN NN O
to NN NN O
and NN NN O
at NN NN O
3 NN NN O
- NN NN O
month NN NN O
intervals NN NN O
during NN NN O
treatment NN NN O
. NN NN O
   
NCS NN NN O
included NN NN O
recording NN NN O
of NN NN O
sensory NN NN O
nerve NN NN O
action NN NN O
potentials NN NN O
( NN NN O
SNAPs NN NN O
) NN NN O
from NN NN O
median NN NN O
, NN NN O
radial NN NN O
, NN NN O
ulnar NN NN O
, NN NN O
and NN NN O
sural NN NN O
nerves NN NN O
. NN NN O
   
SNAP NN NN O
amplitudes NN NN O
for NN NN O
each NN NN O
nerve NN NN O
were NN NN O
expressed NN NN O
as NN NN O
the NN NN O
percentage NN NN O
of NN NN O
its NN NN O
baseline NN NN O
, NN NN O
and NN NN O
the NN NN O
mean NN NN O
of NN NN O
the NN NN O
four NN NN O
was NN NN O
termed NN NN O
the NN NN O
SNAP NN NN O
index NN NN O
. NN NN O
   
A NN NN O
40 NN NN O
% NN NN O
decline NN NN O
in NN NN O
the NN NN O
SNAP NN NN O
index NN NN O
was NN NN O
considered NN NN O
clinically NN NN O
significant NN NN O
. NN NN O
   
Thalidomide NN NN O
was NN NN O
discontinued NN NN O
in NN NN O
55 NN NN O
patients NN NN O
for NN NN O
lack NN NN O
of NN NN O
therapeutic NN NN O
response NN NN O
. NN NN O
   
Of NN NN O
67 NN NN O
patients NN NN O
initially NN NN O
enrolled NN NN O
, NN NN O
24 NN NN O
remained NN NN O
on NN NN O
thalidomide NN NN O
for NN NN O
3 NN NN O
months NN NN O
, NN NN O
8 NN NN O
remained NN NN O
at NN NN O
6 NN NN O
months NN NN O
, NN NN O
and NN NN O
3 NN NN O
remained NN NN O
at NN NN O
9 NN NN O
months NN NN O
. NN NN O
   
Six NN NN O
patients NN NN O
developed NN NN O
neuropathy NN NN B-Disease
. NN NN O
   
Clinical NN NN O
symptoms NN NN O
and NN NN O
a NN NN O
decline NN NN O
in NN NN O
the NN NN O
SNAP NN NN O
index NN NN O
occurred NN NN O
concurrently NN NN O
. NN NN O
   
Older NN NN O
age NN NN O
and NN NN O
cumulative NN NN O
dose NN NN O
were NN NN O
possible NN NN O
contributing NN NN O
factors NN NN O
. NN NN O
   
Neuropathy NN NN B-Disease
may NN NN O
thus NN NN O
be NN NN O
a NN NN O
common NN NN O
complication NN NN O
of NN NN O
thalidomide NN NN O
in NN NN O
older NN NN O
patients NN NN O
. NN NN O
   
The NN NN O
SNAP NN NN O
index NN NN O
can NN NN O
be NN NN O
used NN NN O
to NN NN O
monitor NN NN O
peripheral NN NN B-Disease
neuropathy NN NN I-Disease
, NN NN O
but NN NN O
not NN NN O
for NN NN O
early NN NN O
detection NN NN O
. NN NN O
   
Overexpression NN NN O
of NN NN O
copper NN NN O
/ NN NN O
zinc NN NN O
- NN NN O
superoxide NN NN O
dismutase NN NN O
protects NN NN O
from NN NN O
kanamycin NN NN O
- NN NN O
induced NN NN O
hearing NN NN B-Disease
loss NN NN I-Disease
. NN NN O
   
The NN NN O
participation NN NN O
of NN NN O
reactive NN NN O
oxygen NN NN O
species NN NN O
in NN NN O
aminoglycoside NN NN O
- NN NN O
induced NN NN O
ototoxicity NN NN B-Disease
has NN NN O
been NN NN O
deduced NN NN O
from NN NN O
observations NN NN O
that NN NN O
aminoglycoside NN NN O
- NN NN O
iron NN NN O
complexes NN NN O
catalyze NN NN O
the NN NN O
formation NN NN O
of NN NN O
superoxide NN NN O
radicals NN NN O
in NN NN O
vitro NN NN O
and NN NN O
that NN NN O
antioxidants NN NN O
attenuate NN NN O
ototoxicity NN NN B-Disease
in NN NN O
vivo NN NN O
. NN NN O
   
We NN NN O
therefore NN NN O
hypothesized NN NN O
that NN NN O
overexpression NN NN O
of NN NN O
Cu NN NN O
/ NN NN O
Zn NN NN O
- NN NN O
superoxide NN NN O
dismutase NN NN O
( NN NN O
h NN NN O
- NN NN O
SOD1 NN NN O
) NN NN O
should NN NN O
protect NN NN O
transgenic NN NN O
mice NN NN O
from NN NN O
ototoxicity NN NN B-Disease
. NN NN O
   
Immunocytochemistry NN NN O
confirmed NN NN O
expression NN NN O
of NN NN O
h NN NN O
- NN NN O
SOD1 NN NN O
in NN NN O
inner NN NN O
ear NN NN O
tissues NN NN O
of NN NN O
transgenic NN NN O
C57BL NN NN O
/ NN NN O
6 NN NN O
- NN NN O
TgN NN NN O
[ NN NN O
SOD1 NN NN O
] NN NN O
3Cje NN NN O
mice NN NN O
. NN NN O
   
Transgenic NN NN O
and NN NN O
nontransgenic NN NN O
littermates NN NN O
received NN NN O
kanamycin NN NN O
( NN NN O
400 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
body NN NN O
weight NN NN O
/ NN NN O
day NN NN O
) NN NN O
for NN NN O
10 NN NN O
days NN NN O
beginning NN NN O
on NN NN O
day NN NN O
10 NN NN O
after NN NN O
birth NN NN O
. NN NN O
   
Auditory NN NN O
thresholds NN NN O
were NN NN O
tested NN NN O
by NN NN O
evoked NN NN O
auditory NN NN O
brain NN NN O
stem NN NN O
responses NN NN O
at NN NN O
1 NN NN O
month NN NN O
after NN NN O
birth NN NN O
. NN NN O
   
In NN NN O
nontransgenic NN NN O
animals NN NN O
, NN NN O
the NN NN O
threshold NN NN O
in NN NN O
the NN NN O
kanamycin NN NN O
- NN NN O
treated NN NN O
group NN NN O
was NN NN O
45 NN NN O
- NN NN O
50 NN NN O
dB NN NN O
higher NN NN O
than NN NN O
in NN NN O
saline NN NN O
- NN NN O
injected NN NN O
controls NN NN O
. NN NN O
   
In NN NN O
the NN NN O
transgenic NN NN O
group NN NN O
, NN NN O
kanamycin NN NN O
increased NN NN O
the NN NN O
threshold NN NN O
by NN NN O
only NN NN O
15 NN NN O
dB NN NN O
over NN NN O
the NN NN O
respective NN NN O
controls NN NN O
. NN NN O
   
The NN NN O
effects NN NN O
were NN NN O
similar NN NN O
at NN NN O
12 NN NN O
and NN NN O
24 NN NN O
kHz NN NN O
. NN NN O
   
The NN NN O
protection NN NN O
by NN NN O
overexpression NN NN O
of NN NN O
superoxide NN NN O
dismutase NN NN O
supports NN NN O
the NN NN O
hypothesis NN NN O
that NN NN O
oxidant NN NN O
stress NN NN O
plays NN NN O
a NN NN O
significant NN NN O
role NN NN O
in NN NN O
aminoglycoside NN NN O
- NN NN O
induced NN NN O
ototoxicity NN NN B-Disease
. NN NN O
   
The NN NN O
results NN NN O
also NN NN O
suggest NN NN O
transgenic NN NN O
animals NN NN O
as NN NN O
suitable NN NN O
models NN NN O
to NN NN O
investigate NN NN O
the NN NN O
underlying NN NN O
mechanisms NN NN O
and NN NN O
possible NN NN O
strategies NN NN O
for NN NN O
prevention NN NN O
. NN NN O
   
Fatty NN NN B-Disease
liver NN NN I-Disease
induced NN NN O
by NN NN O
tetracycline NN NN O
in NN NN O
the NN NN O
rat NN NN O
. NN NN O
   
Dose NN NN O
- NN NN O
response NN NN O
relationships NN NN O
and NN NN O
effect NN NN O
of NN NN O
sex NN NN O
. NN NN O
   
Dose NN NN O
- NN NN O
response NN NN O
relationships NN NN O
, NN NN O
biochemical NN NN O
mechanisms NN NN O
, NN NN O
and NN NN O
sex NN NN O
differences NN NN O
in NN NN O
the NN NN O
experimental NN NN O
fatty NN NN B-Disease
liver NN NN I-Disease
induced NN NN O
by NN NN O
tetracycline NN NN O
were NN NN O
studied NN NN O
in NN NN O
the NN NN O
intact NN NN O
rat NN NN O
and NN NN O
with NN NN O
the NN NN O
isolated NN NN O
perfused NN NN O
rat NN NN O
liver NN NN O
in NN NN O
vitro NN NN O
. NN NN O
   
In NN NN O
the NN NN O
intact NN NN O
male NN NN O
and NN NN O
female NN NN O
rat NN NN O
, NN NN O
no NN NN O
direct NN NN O
relationship NN NN O
was NN NN O
observed NN NN O
between NN NN O
dose NN NN O
of NN NN O
tetracycline NN NN O
and NN NN O
hepatic NN NN O
accumulation NN NN O
of NN NN O
triglyceride NN NN O
. NN NN O
   
With NN NN O
provision NN NN O
of NN NN O
adequate NN NN O
oleic NN NN O
acid NN NN O
as NN NN O
a NN NN O
substrate NN NN O
for NN NN O
the NN NN O
isolated NN NN O
perfused NN NN O
liver NN NN O
, NN NN O
a NN NN O
direct NN NN O
relationship NN NN O
was NN NN O
observed NN NN O
between NN NN O
dose NN NN O
of NN NN O
tetracycline NN NN O
and NN NN O
both NN NN O
accumulation NN NN O
of NN NN O
triglyceride NN NN O
in NN NN O
the NN NN O
liver NN NN O
and NN NN O
depression NN NN B-Disease
of NN NN O
output NN NN O
of NN NN O
triglyceride NN NN O
by NN NN O
livers NN NN O
from NN NN O
male NN NN O
and NN NN O
female NN NN O
rats NN NN O
. NN NN O
   
Marked NN NN O
differences NN NN O
were NN NN O
observed NN NN O
between NN NN O
female NN NN O
and NN NN O
male NN NN O
rats NN NN O
with NN NN O
regard NN NN O
to NN NN O
base NN NN O
line NN NN O
( NN NN O
control NN NN O
) NN NN O
hepatic NN NN O
concentration NN NN O
of NN NN O
triglyceride NN NN O
and NN NN O
output NN NN O
of NN NN O
triglyceride NN NN O
. NN NN O
   
Accumulation NN NN O
of NN NN O
hepatic NN NN O
triglyceride NN NN O
, NN NN O
as NN NN O
a NN NN O
per NN NN O
cent NN NN O
of NN NN O
control NN NN O
values NN NN O
, NN NN O
in NN NN O
response NN NN O
to NN NN O
graded NN NN O
doses NN NN O
of NN NN O
tetracycline NN NN O
, NN NN O
did NN NN O
not NN NN O
differ NN NN O
significantly NN NN O
between NN NN O
male NN NN O
, NN NN O
female NN NN O
and NN NN O
pregnant NN NN O
rat NN NN O
livers NN NN O
. NN NN O
   
However NN NN O
, NN NN O
livers NN NN O
from NN NN O
female NN NN O
, NN NN O
and NN NN O
especially NN NN O
pregnant NN NN O
female NN NN O
rats NN NN O
, NN NN O
were NN NN O
strikingly NN NN O
resistant NN NN O
to NN NN O
the NN NN O
effects NN NN O
of NN NN O
tetracycline NN NN O
on NN NN O
depression NN NN B-Disease
of NN NN O
output NN NN O
of NN NN O
triglyceride NN NN O
under NN NN O
these NN NN O
experimental NN NN O
conditions NN NN O
. NN NN O
   
These NN NN O
differences NN NN O
between NN NN O
the NN NN O
sexes NN NN O
could NN NN O
not NN NN O
be NN NN O
related NN NN O
to NN NN O
altered NN NN O
disposition NN NN O
of NN NN O
tetracycline NN NN O
or NN NN O
altered NN NN O
uptake NN NN O
of NN NN O
oleic NN NN O
acid NN NN O
. NN NN O
   
Depressed NN NN O
hepatic NN NN O
secretion NN NN O
of NN NN O
triglyceride NN NN O
accounted NN NN O
only NN NN O
for NN NN O
30 NN NN O
to NN NN O
50 NN NN O
% NN NN O
of NN NN O
accumulated NN NN O
hepatic NN NN O
triglyceride NN NN O
, NN NN O
indicating NN NN O
that NN NN O
additional NN NN O
mechanisms NN NN O
must NN NN O
be NN NN O
involved NN NN O
in NN NN O
the NN NN O
production NN NN O
of NN NN O
the NN NN O
triglyceride NN NN O
- NN NN O
rich NN NN O
fatty NN NN B-Disease
liver NN NN I-Disease
in NN NN O
response NN NN O
to NN NN O
tetracycline NN NN O
. NN NN O
   
Prednisone NN NN O
induces NN NN O
anxiety NN NN B-Disease
and NN NN O
glial NN NN O
cerebral NN NN O
changes NN NN O
in NN NN O
rats NN NN O
. NN NN O
   
OBJECTIVE NN NN O
: NN NN O
To NN NN O
assess NN NN O
whether NN NN O
prednisone NN NN O
( NN NN O
PDN NN NN O
) NN NN O
produces NN NN O
anxiety NN NN B-Disease
and NN NN O
/ NN NN O
or NN NN O
cerebral NN NN O
glial NN NN O
changes NN NN O
in NN NN O
rats NN NN O
. NN NN O
   
METHODS NN NN O
: NN NN O
Male NN NN O
Wistar NN NN O
rats NN NN O
were NN NN O
studied NN NN O
and NN NN O
3 NN NN O
groups NN NN O
were NN NN O
formed NN NN O
( NN NN O
8 NN NN O
rats NN NN O
per NN NN O
group NN NN O
) NN NN O
. NN NN O
   
The NN NN O
moderate NN NN O
- NN NN O
dose NN NN O
group NN NN O
received NN NN O
5 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
/ NN NN O
day NN NN O
PDN NN NN O
released NN NN O
from NN NN O
a NN NN O
subcutaneous NN NN O
implant NN NN O
. NN NN O
   
In NN NN O
the NN NN O
high NN NN O
- NN NN O
dose NN NN O
group NN NN O
, NN NN O
implants NN NN O
containing NN NN O
PDN NN NN O
equivalent NN NN O
to NN NN O
60 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
/ NN NN O
day NN NN O
were NN NN O
applied NN NN O
. NN NN O
   
In NN NN O
the NN NN O
control NN NN O
group NN NN O
implants NN NN O
contained NN NN O
no NN NN O
PDN NN NN O
. NN NN O
   
Anxiety NN NN B-Disease
was NN NN O
assessed NN NN O
using NN NN O
an NN NN O
open NN NN O
field NN NN O
and NN NN O
elevated NN NN O
plus NN NN O
- NN NN O
maze NN NN O
devices NN NN O
. NN NN O
   
The NN NN O
number NN NN O
of NN NN O
cells NN NN O
and NN NN O
cytoplasmic NN NN O
transformation NN NN O
of NN NN O
astrocytes NN NN O
and NN NN O
microglia NN NN O
cells NN NN O
were NN NN O
assessed NN NN O
by NN NN O
immunohistochemical NN NN O
analyses NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
Anxiety NN NN B-Disease
was NN NN O
documented NN NN O
in NN NN O
both NN NN O
groups NN NN O
of NN NN O
PDN NN NN O
treated NN NN O
rats NN NN O
compared NN NN O
with NN NN O
controls NN NN O
. NN NN O
   
The NN NN O
magnitude NN NN O
of NN NN O
transformation NN NN O
of NN NN O
the NN NN O
microglia NN NN O
assessed NN NN O
by NN NN O
the NN NN O
number NN NN O
of NN NN O
intersections NN NN O
was NN NN O
significantly NN NN O
higher NN NN O
in NN NN O
the NN NN O
PDN NN NN O
groups NN NN O
than NN NN O
in NN NN O
controls NN NN O
in NN NN O
the NN NN O
prefrontal NN NN O
cortex NN NN O
( NN NN O
moderate NN NN O
- NN NN O
dose NN NN O
, NN NN O
24 NN NN O
. NN NN O
1 NN NN O
; NN NN O
high NN NN O
- NN NN O
dose NN NN O
, NN NN O
23 NN NN O
. NN NN O
6 NN NN O
; NN NN O
controls NN NN O
18 NN NN O
. NN NN O
7 NN NN O
; NN NN O
p NN NN O
< NN NN O
0 NN NN O
. NN NN O
01 NN NN O
) NN NN O
and NN NN O
striatum NN NN O
( NN NN O
moderate NN NN O
- NN NN O
dose NN NN O
25 NN NN O
. NN NN O
6 NN NN O
; NN NN O
high NN NN O
- NN NN O
dose NN NN O
26 NN NN O
. NN NN O
3 NN NN O
; NN NN O
controls NN NN O
18 NN NN O
. NN NN O
9 NN NN O
; NN NN O
p NN NN O
< NN NN O
0 NN NN O
. NN NN O
01 NN NN O
) NN NN O
, NN NN O
but NN NN O
not NN NN O
in NN NN O
hippocampus NN NN O
. NN NN O
   
The NN NN O
number NN NN O
of NN NN O
stained NN NN O
microglia NN NN O
cells NN NN O
was NN NN O
significantly NN NN O
higher NN NN O
in NN NN O
the NN NN O
PDN NN NN O
treated NN NN O
groups NN NN O
in NN NN O
the NN NN O
prefrontal NN NN O
cortex NN NN O
than NN NN O
in NN NN O
controls NN NN O
( NN NN O
moderate NN NN O
- NN NN O
dose NN NN O
, NN NN O
29 NN NN O
. NN NN O
1 NN NN O
; NN NN O
high NN NN O
- NN NN O
dose NN NN O
, NN NN O
28 NN NN O
. NN NN O
4 NN NN O
; NN NN O
control NN NN O
, NN NN O
17 NN NN O
. NN NN O
7 NN NN O
cells NN NN O
per NN NN O
field NN NN O
; NN NN O
p NN NN O
< NN NN O
0 NN NN O
. NN NN O
01 NN NN O
) NN NN O
. NN NN O
   
Stained NN NN O
microglia NN NN O
cells NN NN O
were NN NN O
significantly NN NN O
more NN NN O
numerous NN NN O
striatum NN NN O
and NN NN O
hippocampus NN NN O
in NN NN O
the NN NN O
high NN NN O
- NN NN O
dose NN NN O
group NN NN O
compared NN NN O
to NN NN O
controls NN NN O
. NN NN O
   
CONCLUSION NN NN O
: NN NN O
Subacute NN NN O
exposure NN NN O
to NN NN O
PDN NN NN O
induced NN NN O
anxiety NN NN B-Disease
and NN NN O
reactivity NN NN O
of NN NN O
microglia NN NN O
. NN NN O
   
The NN NN O
relevance NN NN O
of NN NN O
these NN NN O
features NN NN O
for NN NN O
patients NN NN O
using NN NN O
PDN NN NN O
remains NN NN O
to NN NN O
be NN NN O
elucidated NN NN O
. NN NN O
   
Phase NN NN O
II NN NN O
study NN NN O
of NN NN O
carboplatin NN NN O
and NN NN O
liposomal NN NN O
doxorubicin NN NN O
in NN NN O
patients NN NN O
with NN NN O
recurrent NN NN O
squamous NN NN B-Disease
cell NN NN I-Disease
carcinoma NN NN I-Disease
of NN NN I-Disease
the NN NN I-Disease
cervix NN NN I-Disease
. NN NN O
   
BACKGROUND NN NN O
: NN NN O
The NN NN O
activity NN NN O
of NN NN O
the NN NN O
combination NN NN O
of NN NN O
carboplatin NN NN O
and NN NN O
liposomal NN NN O
doxorubicin NN NN O
was NN NN O
tested NN NN O
in NN NN O
a NN NN O
Phase NN NN O
II NN NN O
study NN NN O
of NN NN O
patients NN NN O
with NN NN O
recurrent NN NN O
cervical NN NN B-Disease
carcinoma NN NN I-Disease
. NN NN O
   
METHODS NN NN O
: NN NN O
The NN NN O
combination NN NN O
of NN NN O
carboplatin NN NN O
( NN NN O
area NN NN O
under NN NN O
the NN NN O
concentration NN NN O
curve NN NN O
[ NN NN O
AUC NN NN O
] NN NN O
, NN NN O
5 NN NN O
) NN NN O
and NN NN O
liposomal NN NN O
doxorubicin NN NN O
( NN NN O
Doxil NN NN O
; NN NN O
starting NN NN O
dose NN NN O
, NN NN O
40 NN NN O
mg NN NN O
/ NN NN O
m NN NN O
( NN NN O
2 NN NN O
) NN NN O
) NN NN O
was NN NN O
administered NN NN O
intravenously NN NN O
every NN NN O
28 NN NN O
days NN NN O
to NN NN O
37 NN NN O
patients NN NN O
with NN NN O
recurrent NN NN O
squamous NN NN B-Disease
cell NN NN I-Disease
cervical NN NN I-Disease
carcinoma NN NN I-Disease
to NN NN O
determine NN NN O
antitumor NN NN O
activity NN NN O
and NN NN O
toxicity NN NN B-Disease
profile NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
Twenty NN NN O
- NN NN O
nine NN NN O
patients NN NN O
were NN NN O
assessable NN NN O
for NN NN O
response NN NN O
, NN NN O
and NN NN O
35 NN NN O
patients NN NN O
were NN NN O
assessable NN NN O
for NN NN O
toxicity NN NN B-Disease
. NN NN O
   
The NN NN O
overall NN NN O
response NN NN O
rate NN NN O
was NN NN O
38 NN NN O
% NN NN O
, NN NN O
the NN NN O
median NN NN O
time NN NN O
to NN NN O
response NN NN O
was NN NN O
10 NN NN O
weeks NN NN O
, NN NN O
the NN NN O
median NN NN O
duration NN NN O
of NN NN O
response NN NN O
was NN NN O
26 NN NN O
weeks NN NN O
, NN NN O
and NN NN O
the NN NN O
median NN NN O
survival NN NN O
was NN NN O
37 NN NN O
weeks NN NN O
. NN NN O
   
The NN NN O
main NN NN O
toxic NN NN O
effect NN NN O
was NN NN O
myelosuppression NN NN B-Disease
, NN NN O
with NN NN O
Grade NN NN O
3 NN NN O
and NN NN O
4 NN NN O
neutropenia NN NN B-Disease
in NN NN O
16 NN NN O
patients NN NN O
, NN NN O
anemia NN NN B-Disease
in NN NN O
12 NN NN O
patients NN NN O
, NN NN O
thrombocytopenia NN NN B-Disease
in NN NN O
11 NN NN O
patients NN NN O
, NN NN O
and NN NN O
neutropenic NN NN B-Disease
fever NN NN I-Disease
in NN NN O
3 NN NN O
patients NN NN O
. NN NN O
   
Four NN NN O
patients NN NN O
had NN NN O
five NN NN O
infusion NN NN O
- NN NN O
related NN NN O
reactions NN NN O
during NN NN O
the NN NN O
infusion NN NN O
of NN NN O
liposomal NN NN O
doxorubicin NN NN O
, NN NN O
leading NN NN O
to NN NN O
treatment NN NN O
discontinuation NN NN O
in NN NN O
three NN NN O
patients NN NN O
. NN NN O
   
Grade NN NN O
> NN NN O
or NN NN O
= NN NN O
2 NN NN O
nonhematologic NN NN O
toxicity NN NN B-Disease
included NN NN O
nausea NN NN B-Disease
in NN NN O
17 NN NN O
patients NN NN O
, NN NN O
emesis NN NN B-Disease
in NN NN O
14 NN NN O
patients NN NN O
, NN NN O
fatigue NN NN B-Disease
in NN NN O
9 NN NN O
patients NN NN O
, NN NN O
mucositis NN NN B-Disease
and NN NN O
/ NN NN O
or NN NN O
stomatitis NN NN B-Disease
in NN NN O
8 NN NN O
patients NN NN O
, NN NN O
constipation NN NN B-Disease
in NN NN O
6 NN NN O
patients NN NN O
, NN NN O
weight NN NN B-Disease
loss NN NN I-Disease
in NN NN O
5 NN NN O
patients NN NN O
, NN NN O
hand NN NN B-Disease
- NN NN I-Disease
foot NN NN I-Disease
syndrome NN NN I-Disease
in NN NN O
2 NN NN O
patients NN NN O
, NN NN O
and NN NN O
skin NN NN B-Disease
reactions NN NN I-Disease
in NN NN O
3 NN NN O
patients NN NN O
. NN NN O
   
CONCLUSIONS NN NN O
: NN NN O
The NN NN O
combination NN NN O
of NN NN O
carboplatin NN NN O
and NN NN O
liposomal NN NN O
doxorubicin NN NN O
has NN NN O
modest NN NN O
activity NN NN O
in NN NN O
patients NN NN O
with NN NN O
recurrent NN NN O
cervical NN NN B-Disease
carcinoma NN NN I-Disease
. NN NN O
   
Antimicrobial NN NN O
- NN NN O
induced NN NN O
mania NN NN B-Disease
( NN NN O
antibiomania NN NN B-Disease
) NN NN O
: NN NN O
a NN NN O
review NN NN O
of NN NN O
spontaneous NN NN O
reports NN NN O
. NN NN O
   
The NN NN O
authors NN NN O
reviewed NN NN O
reported NN NN O
cases NN NN O
of NN NN O
antibiotic NN NN O
- NN NN O
induced NN NN O
manic NN NN B-Disease
episodes NN NN O
by NN NN O
means NN NN O
of NN NN O
a NN NN O
MEDLINE NN NN O
and NN NN O
PsychLit NN NN O
search NN NN O
for NN NN O
reports NN NN O
of NN NN O
antibiotic NN NN O
- NN NN O
induced NN NN O
mania NN NN B-Disease
. NN NN O
   
Unpublished NN NN O
reports NN NN O
were NN NN O
requested NN NN O
from NN NN O
the NN NN O
World NN NN O
Health NN NN O
Organization NN NN O
( NN NN O
WHO NN NN O
) NN NN O
and NN NN O
the NN NN O
Food NN NN O
and NN NN O
Drug NN NN O
Administration NN NN O
( NN NN O
FDA NN NN O
) NN NN O
. NN NN O
   
Twenty NN NN O
- NN NN O
one NN NN O
reports NN NN O
of NN NN O
antimicrobial NN NN O
- NN NN O
induced NN NN O
mania NN NN B-Disease
were NN NN O
found NN NN O
in NN NN O
the NN NN O
literature NN NN O
. NN NN O
   
There NN NN O
were NN NN O
6 NN NN O
cases NN NN O
implicating NN NN O
clarithromycin NN NN O
, NN NN O
13 NN NN O
implicating NN NN O
isoniazid NN NN O
, NN NN O
and NN NN O
1 NN NN O
case NN NN O
each NN NN O
implicating NN NN O
erythromycin NN NN O
and NN NN O
amoxicillin NN NN O
. NN NN O
   
The NN NN O
WHO NN NN O
reported NN NN O
82 NN NN O
cases NN NN O
. NN NN O
   
Of NN NN O
these NN NN O
, NN NN O
clarithromycin NN NN O
was NN NN O
implicated NN NN O
in NN NN O
23 NN NN O
( NN NN O
27 NN NN O
. NN NN O
6 NN NN O
% NN NN O
) NN NN O
cases NN NN O
, NN NN O
ciprofloxacin NN NN O
in NN NN O
12 NN NN O
( NN NN O
14 NN NN O
. NN NN O
4 NN NN O
% NN NN O
) NN NN O
cases NN NN O
, NN NN O
and NN NN O
ofloxacin NN NN O
in NN NN O
10 NN NN O
( NN NN O
12 NN NN O
% NN NN O
) NN NN O
cases NN NN O
. NN NN O
   
Cotrimoxazole NN NN O
, NN NN O
metronidazole NN NN O
, NN NN O
and NN NN O
erythromycin NN NN O
were NN NN O
involved NN NN O
in NN NN O
15 NN NN O
reported NN NN O
manic NN NN B-Disease
episodes NN NN O
. NN NN O
   
Cases NN NN O
reported NN NN O
by NN NN O
the NN NN O
FDA NN NN O
showed NN NN O
clarithromycin NN NN O
and NN NN O
ciprofloxacin NN NN O
to NN NN O
be NN NN O
the NN NN O
most NN NN O
frequently NN NN O
associated NN NN O
with NN NN O
the NN NN O
development NN NN O
of NN NN O
mania NN NN B-Disease
. NN NN O
   
Statistical NN NN O
analysis NN NN O
of NN NN O
the NN NN O
data NN NN O
would NN NN O
not NN NN O
have NN NN O
demonstrated NN NN O
a NN NN O
significant NN NN O
statistical NN NN O
correlative NN NN O
risk NN NN O
and NN NN O
was NN NN O
therefore NN NN O
not NN NN O
undertaken NN NN O
. NN NN O
   
Patients NN NN O
have NN NN O
an NN NN O
increased NN NN O
risk NN NN O
of NN NN O
developing NN NN O
mania NN NN B-Disease
while NN NN O
being NN NN O
treated NN NN O
with NN NN O
antimicrobials NN NN O
. NN NN O
   
Although NN NN O
this NN NN O
is NN NN O
not NN NN O
a NN NN O
statistically NN NN O
significant NN NN O
risk NN NN O
, NN NN O
physicians NN NN O
must NN NN O
be NN NN O
aware NN NN O
of NN NN O
the NN NN O
effect NN NN O
and NN NN O
reversibility NN NN O
. NN NN O
   
Further NN NN O
research NN NN O
clearly NN NN O
is NN NN O
required NN NN O
to NN NN O
determine NN NN O
the NN NN O
incidence NN NN O
of NN NN O
antimicrobial NN NN O
- NN NN O
induced NN NN O
mania NN NN B-Disease
, NN NN O
the NN NN O
relative NN NN O
risk NN NN O
factors NN NN O
of NN NN O
developing NN NN O
an NN NN O
antimicrobial NN NN O
- NN NN O
induced NN NN O
manic NN NN B-Disease
episode NN NN O
among NN NN O
various NN NN O
demographic NN NN O
populations NN NN O
, NN NN O
and NN NN O
the NN NN O
incidence NN NN O
of NN NN O
patients NN NN O
who NN NN O
continue NN NN O
to NN NN O
have NN NN O
persistent NN NN O
affective NN NN O
disorders NN NN O
once NN NN O
the NN NN O
initial NN NN O
episode NN NN O
, NN NN O
which NN NN O
occurs NN NN O
while NN NN O
the NN NN O
patient NN NN O
is NN NN O
taking NN NN O
antibiotics NN NN O
, NN NN O
subsides NN NN O
. NN NN O
   
The NN NN O
authors NN NN O
elected NN NN O
to NN NN O
name NN NN O
this NN NN O
syndrome NN NN O
"""""""" NN NN O
antibiomania NN NN B-Disease
. NN NN O
"""""""" NN NN O
   
Levodopa NN NN O
- NN NN O
induced NN NN O
ocular NN NN B-Disease
dyskinesias NN NN I-Disease
in NN NN O
Parkinson NN NN B-Disease
' NN NN I-Disease
s NN NN I-Disease
disease NN NN I-Disease
. NN NN O
   
Levodopa NN NN O
- NN NN O
induced NN NN O
ocular NN NN B-Disease
dyskinesias NN NN I-Disease
are NN NN O
very NN NN O
uncommon NN NN O
. NN NN O
   
Usually NN NN O
they NN NN O
occur NN NN O
simultaneously NN NN O
with NN NN O
limb NN NN O
peak NN NN O
- NN NN O
dose NN NN O
choreatic NN NN B-Disease
dyskinesias NN NN I-Disease
. NN NN O
   
We NN NN O
report NN NN O
on NN NN O
a NN NN O
patient NN NN O
with NN NN O
leftward NN NN O
and NN NN O
upward NN NN O
deviations NN NN O
of NN NN O
gaze NN NN O
during NN NN O
the NN NN O
peak NN NN O
effect NN NN O
of NN NN O
levodopa NN NN O
, NN NN O
and NN NN O
hypothesize NN NN O
that NN NN O
a NN NN O
severe NN NN O
dopaminergic NN NN O
denervation NN NN O
in NN NN O
the NN NN O
caudate NN NN O
nucleus NN NN O
is NN NN O
needed NN NN O
for NN NN O
the NN NN O
appearance NN NN O
of NN NN O
these NN NN O
levodopa NN NN O
- NN NN O
induce NN NN O
ocular NN NN B-Disease
dyskinesias NN NN I-Disease
. NN NN O
   
A NN NN O
comparison NN NN O
of NN NN O
glyceryl NN NN O
trinitrate NN NN O
with NN NN O
diclofenac NN NN O
for NN NN O
the NN NN O
treatment NN NN O
of NN NN O
primary NN NN O
dysmenorrhea NN NN B-Disease
: NN NN O
an NN NN O
open NN NN O
, NN NN O
randomized NN NN O
, NN NN O
cross NN NN O
- NN NN O
over NN NN O
trial NN NN O
. NN NN O
   
Primary NN NN O
dysmenorrhea NN NN B-Disease
is NN NN O
a NN NN O
syndrome NN NN O
characterized NN NN O
by NN NN O
painful NN NN O
uterine NN NN O
contractility NN NN O
caused NN NN O
by NN NN O
a NN NN O
hypersecretion NN NN O
of NN NN O
endometrial NN NN O
prostaglandins NN NN O
; NN NN O
non NN NN O
- NN NN O
steroidal NN NN O
anti NN NN O
- NN NN O
inflammatory NN NN O
drugs NN NN O
are NN NN O
the NN NN O
first NN NN O
choice NN NN O
for NN NN O
its NN NN O
treatment NN NN O
. NN NN O
   
However NN NN O
, NN NN O
in NN NN O
vivo NN NN O
and NN NN O
in NN NN O
vitro NN NN O
studies NN NN O
have NN NN O
demonstrated NN NN O
that NN NN O
myometrial NN NN O
cells NN NN O
are NN NN O
also NN NN O
targets NN NN O
of NN NN O
the NN NN O
relaxant NN NN O
effects NN NN O
of NN NN O
nitric NN NN O
oxide NN NN O
( NN NN O
NO NN NN O
) NN NN O
. NN NN O
   
The NN NN O
aim NN NN O
of NN NN O
the NN NN O
present NN NN O
study NN NN O
was NN NN O
to NN NN O
determine NN NN O
the NN NN O
efficacy NN NN O
of NN NN O
glyceryl NN NN O
trinitrate NN NN O
( NN NN O
GTN NN NN O
) NN NN O
, NN NN O
an NN NN O
NO NN NN O
donor NN NN O
, NN NN O
in NN NN O
the NN NN O
resolution NN NN O
of NN NN O
primary NN NN O
dysmenorrhea NN NN B-Disease
in NN NN O
comparison NN NN O
with NN NN O
diclofenac NN NN O
( NN NN O
DCF NN NN O
) NN NN O
. NN NN O
   
A NN NN O
total NN NN O
of NN NN O
24 NN NN O
patients NN NN O
with NN NN O
the NN NN O
diagnosis NN NN O
of NN NN O
severe NN NN O
primary NN NN O
dysmenorrhea NN NN B-Disease
were NN NN O
studied NN NN O
during NN NN O
two NN NN O
consecutive NN NN O
menstrual NN NN O
cycles NN NN O
. NN NN O
   
In NN NN O
an NN NN O
open NN NN O
, NN NN O
cross NN NN O
- NN NN O
over NN NN O
, NN NN O
controlled NN NN O
design NN NN O
, NN NN O
patients NN NN O
were NN NN O
randomized NN NN O
to NN NN O
receive NN NN O
either NN NN O
DCF NN NN O
per NN NN O
os NN NN O
or NN NN O
GTN NN NN O
patches NN NN O
the NN NN O
first NN NN O
days NN NN O
of NN NN O
menses NN NN O
, NN NN O
when NN NN O
menstrual NN NN O
cramps NN NN O
became NN NN O
unendurable NN NN O
. NN NN O
   
In NN NN O
the NN NN O
subsequent NN NN O
cycle NN NN O
the NN NN O
other NN NN O
treatment NN NN O
was NN NN O
used NN NN O
. NN NN O
   
Patients NN NN O
received NN NN O
up NN NN O
to NN NN O
3 NN NN O
doses NN NN O
/ NN NN O
day NN NN O
of NN NN O
50 NN NN O
mg NN NN O
DCF NN NN O
or NN NN O
2 NN NN O
. NN NN O
5 NN NN O
mg NN NN O
/ NN NN O
24 NN NN O
h NN NN O
transdermal NN NN O
GTN NN NN O
for NN NN O
the NN NN O
first NN NN O
3 NN NN O
days NN NN O
of NN NN O
the NN NN O
cycle NN NN O
, NN NN O
according NN NN O
to NN NN O
their NN NN O
needs NN NN O
. NN NN O
   
The NN NN O
participants NN NN O
recorded NN NN O
menstrual NN NN O
symptoms NN NN O
and NN NN O
possible NN NN O
side NN NN O
- NN NN O
effects NN NN O
at NN NN O
different NN NN O
times NN NN O
( NN NN O
0 NN NN O
, NN NN O
30 NN NN O
, NN NN O
60 NN NN O
, NN NN O
120 NN NN O
minutes NN NN O
) NN NN O
after NN NN O
the NN NN O
first NN NN O
dose NN NN O
of NN NN O
medication NN NN O
on NN NN O
the NN NN O
first NN NN O
day NN NN O
of NN NN O
the NN NN O
cycle NN NN O
, NN NN O
with NN NN O
both NN NN O
drugs NN NN O
. NN NN O
   
The NN NN O
difference NN NN O
in NN NN O
pain NN NN B-Disease
intensity NN NN O
score NN NN O
( NN NN O
DPI NN NN O
) NN NN O
was NN NN O
the NN NN O
main NN NN O
outcome NN NN O
variable NN NN O
. NN NN O
   
Both NN NN O
treatments NN NN O
significantly NN NN O
reduced NN NN O
DPI NN NN O
by NN NN O
the NN NN O
30th NN NN O
minute NN NN O
( NN NN O
GTN NN NN O
, NN NN O
- NN NN O
12 NN NN O
. NN NN O
8 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
17 NN NN O
. NN NN O
9 NN NN O
; NN NN O
DCF NN NN O
, NN NN O
- NN NN O
18 NN NN O
. NN NN O
9 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
16 NN NN O
. NN NN O
6 NN NN O
) NN NN O
. NN NN O
   
However NN NN O
, NN NN O
DCF NN NN O
continued NN NN O
to NN NN O
be NN NN O
effective NN NN O
in NN NN O
reducing NN NN O
pelvic NN NN B-Disease
pain NN NN I-Disease
for NN NN O
two NN NN O
hours NN NN O
, NN NN O
whereas NN NN O
GTN NN NN O
scores NN NN O
remained NN NN O
more NN NN O
or NN NN O
less NN NN O
stable NN NN O
after NN NN O
30 NN NN O
min NN NN O
and NN NN O
significantly NN NN O
higher NN NN O
than NN NN O
those NN NN O
for NN NN O
DFC NN NN O
( NN NN O
after NN NN O
one NN NN O
hour NN NN O
: NN NN O
GTN NN NN O
, NN NN O
- NN NN O
12 NN NN O
. NN NN O
8 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
17 NN NN O
. NN NN O
9 NN NN O
; NN NN O
DFC NN NN O
, NN NN O
- NN NN O
18 NN NN O
. NN NN O
9 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
16 NN NN O
. NN NN O
6 NN NN O
and NN NN O
after NN NN O
two NN NN O
hours NN NN O
: NN NN O
GTN NN NN O
, NN NN O
- NN NN O
23 NN NN O
. NN NN O
7 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
20 NN NN O
. NN NN O
5 NN NN O
; NN NN O
DFC NN NN O
, NN NN O
- NN NN O
59 NN NN O
. NN NN O
7 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
17 NN NN O
. NN NN O
9 NN NN O
, NN NN O
p NN NN O
= NN NN O
0 NN NN O
. NN NN O
0001 NN NN O
) NN NN O
. NN NN O
   
Low NN NN B-Disease
back NN NN I-Disease
pain NN NN I-Disease
was NN NN O
also NN NN O
relieved NN NN O
by NN NN O
both NN NN O
drugs NN NN O
. NN NN O
   
Headache NN NN B-Disease
was NN NN O
significantly NN NN O
increased NN NN O
by NN NN O
GTN NN NN O
but NN NN O
not NN NN O
by NN NN O
DCF NN NN O
. NN NN O
   
Eight NN NN O
patients NN NN O
stopped NN NN O
using NN NN O
GTN NN NN O
because NN NN O
headache NN NN B-Disease
- NN NN O
- NN NN O
attributed NN NN O
to NN NN O
its NN NN O
use NN NN O
- NN NN O
- NN NN O
became NN NN O
intolerable NN NN O
. NN NN O
   
These NN NN O
findings NN NN O
indicate NN NN O
that NN NN O
GTN NN NN O
has NN NN O
a NN NN O
reduced NN NN O
efficacy NN NN O
and NN NN O
tolerability NN NN O
by NN NN O
comparison NN NN O
with NN NN O
DCF NN NN O
in NN NN O
the NN NN O
treatment NN NN O
of NN NN O
primary NN NN O
dysmenorrhea NN NN B-Disease
. NN NN O
   
Temocapril NN NN O
, NN NN O
a NN NN O
long NN NN O
- NN NN O
acting NN NN O
non NN NN O
- NN NN O
SH NN NN O
group NN NN O
angiotensin NN NN O
converting NN NN O
enzyme NN NN O
inhibitor NN NN O
, NN NN O
modulates NN NN O
glomerular NN NN B-Disease
injury NN NN I-Disease
in NN NN O
chronic NN NN O
puromycin NN NN O
aminonucleoside NN NN O
nephrosis NN NN B-Disease
. NN NN O
   
The NN NN O
purpose NN NN O
of NN NN O
the NN NN O
present NN NN O
study NN NN O
was NN NN O
to NN NN O
determine NN NN O
whether NN NN O
chronic NN NN O
administration NN NN O
of NN NN O
temocapril NN NN O
, NN NN O
a NN NN O
long NN NN O
- NN NN O
acting NN NN O
non NN NN O
- NN NN O
SH NN NN O
group NN NN O
angiotensin NN NN O
converting NN NN O
enzyme NN NN O
( NN NN O
ACE NN NN O
) NN NN O
inhibitor NN NN O
, NN NN O
reduced NN NN O
proteinuria NN NN B-Disease
, NN NN O
inhibited NN NN O
glomerular NN NN O
hypertrophy NN NN B-Disease
and NN NN O
prevented NN NN O
glomerulosclerosis NN NN B-Disease
in NN NN O
chronic NN NN O
puromycin NN NN O
aminonucleoside NN NN O
( NN NN O
PAN NN NN O
) NN NN O
- NN NN O
induced NN NN O
nephrotic NN NN B-Disease
rats NN NN O
. NN NN O
   
Nephrosis NN NN B-Disease
was NN NN O
induced NN NN O
by NN NN O
injection NN NN O
of NN NN O
PAN NN NN O
( NN NN O
15mg NN NN O
/ NN NN O
100g NN NN O
body NN NN O
weight NN NN O
) NN NN O
in NN NN O
male NN NN O
Sprague NN NN O
- NN NN O
Dawley NN NN O
( NN NN O
SD NN NN O
) NN NN O
rats NN NN O
. NN NN O
   
Four NN NN O
groups NN NN O
were NN NN O
used NN NN O
, NN NN O
i NN NN O
) NN NN O
the NN NN O
PAN NN NN O
group NN NN O
( NN NN O
14 NN NN O
) NN NN O
, NN NN O
ii NN NN O
) NN NN O
PAN NN NN O
/ NN NN O
temocapril NN NN O
( NN NN O
13 NN NN O
) NN NN O
, NN NN O
iii NN NN O
) NN NN O
temocapril NN NN O
( NN NN O
14 NN NN O
) NN NN O
and NN NN O
iv NN NN O
) NN NN O
untreated NN NN O
controls NN NN O
( NN NN O
15 NN NN O
) NN NN O
. NN NN O
   
Temocapril NN NN O
( NN NN O
8 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
/ NN NN O
day NN NN O
) NN NN O
was NN NN O
administered NN NN O
to NN NN O
the NN NN O
rats NN NN O
which NN NN O
were NN NN O
killed NN NN O
at NN NN O
weeks NN NN O
4 NN NN O
, NN NN O
14 NN NN O
or NN NN O
20 NN NN O
. NN NN O
   
At NN NN O
each NN NN O
time NN NN O
point NN NN O
, NN NN O
systolic NN NN O
blood NN NN O
pressure NN NN O
( NN NN O
BP NN NN O
) NN NN O
, NN NN O
urinary NN NN O
protein NN NN O
excretion NN NN O
and NN NN O
renal NN NN O
histopathological NN NN O
findings NN NN O
were NN NN O
evaluated NN NN O
, NN NN O
and NN NN O
morphometric NN NN O
image NN NN O
analysis NN NN O
was NN NN O
done NN NN O
. NN NN O
   
Systolic NN NN O
BP NN NN O
in NN NN O
the NN NN O
PAN NN NN O
group NN NN O
was NN NN O
significantly NN NN O
high NN NN O
at NN NN O
4 NN NN O
, NN NN O
14 NN NN O
and NN NN O
20 NN NN O
weeks NN NN O
, NN NN O
but NN NN O
was NN NN O
normal NN NN O
in NN NN O
the NN NN O
PAN NN NN O
/ NN NN O
temocapril NN NN O
group NN NN O
. NN NN O
   
Urinary NN NN O
protein NN NN O
excretion NN NN O
in NN NN O
the NN NN O
PAN NN NN O
group NN NN O
increased NN NN O
significantly NN NN O
, NN NN O
peaking NN NN O
at NN NN O
8 NN NN O
days NN NN O
, NN NN O
then NN NN O
decreased NN NN O
at NN NN O
4 NN NN O
weeks NN NN O
, NN NN O
but NN NN O
rose NN NN O
again NN NN O
significantly NN NN O
at NN NN O
14 NN NN O
and NN NN O
20 NN NN O
weeks NN NN O
. NN NN O
   
Temocapril NN NN O
did NN NN O
not NN NN O
attenuate NN NN O
proteinuria NN NN B-Disease
at NN NN O
8 NN NN O
days NN NN O
, NN NN O
but NN NN O
it NN NN O
did NN NN O
markedly NN NN O
lower NN NN O
it NN NN O
from NN NN O
weeks NN NN O
4 NN NN O
to NN NN O
20 NN NN O
. NN NN O
   
The NN NN O
glomerulosclerosis NN NN B-Disease
index NN NN O
( NN NN O
GSI NN NN O
) NN NN O
was NN NN O
6 NN NN O
. NN NN O
21 NN NN O
% NN NN O
at NN NN O
4 NN NN O
weeks NN NN O
and NN NN O
respectively NN NN O
25 NN NN O
. NN NN O
35 NN NN O
% NN NN O
and NN NN O
30 NN NN O
. NN NN O
49 NN NN O
% NN NN O
at NN NN O
14 NN NN O
and NN NN O
20 NN NN O
weeks NN NN O
in NN NN O
the NN NN O
PAN NN NN O
group NN NN O
. NN NN O
   
There NN NN O
was NN NN O
a NN NN O
significant NN NN O
correlation NN NN O
between NN NN O
urinary NN NN O
protein NN NN O
excretion NN NN O
and NN NN O
GSI NN NN O
( NN NN O
r NN NN O
= NN NN O
0 NN NN O
. NN NN O
808 NN NN O
, NN NN O
p NN NN O
< NN NN O
0 NN NN O
. NN NN O
0001 NN NN O
) NN NN O
. NN NN O
   
The NN NN O
ratio NN NN O
of NN NN O
glomerular NN NN O
tuft NN NN O
area NN NN O
to NN NN O
the NN NN O
area NN NN O
of NN NN O
Bowman NN NN O
' NN NN O
s NN NN O
capsules NN NN O
( NN NN O
GT NN NN O
/ NN NN O
BC NN NN O
) NN NN O
in NN NN O
the NN NN O
PAN NN NN O
group NN NN O
was NN NN O
significantly NN NN O
increased NN NN O
, NN NN O
but NN NN O
it NN NN O
was NN NN O
significantly NN NN O
lower NN NN O
in NN NN O
the NN NN O
PAN NN NN O
/ NN NN O
temocapril NN NN O
group NN NN O
. NN NN O
   
It NN NN O
appears NN NN O
that NN NN O
temocapril NN NN O
was NN NN O
effective NN NN O
in NN NN O
retarding NN NN O
renal NN NN O
progression NN NN O
and NN NN O
protected NN NN O
renal NN NN O
function NN NN O
in NN NN O
PAN NN NN O
neprotic NN NN B-Disease
rats NN NN O
. NN NN O
   
Pulmonary NN NN B-Disease
hypertension NN NN I-Disease
after NN NN O
ibuprofen NN NN O
prophylaxis NN NN O
in NN NN O
very NN NN O
preterm NN NN O
infants NN NN O
. NN NN O
   
We NN NN O
report NN NN O
three NN NN O
cases NN NN O
of NN NN O
severe NN NN O
hypoxaemia NN NN B-Disease
after NN NN O
ibuprofen NN NN O
administration NN NN O
during NN NN O
a NN NN O
randomised NN NN O
controlled NN NN O
trial NN NN O
of NN NN O
prophylactic NN NN O
treatment NN NN O
of NN NN O
patent NN NN B-Disease
ductus NN NN I-Disease
arteriosus NN NN I-Disease
with NN NN O
ibuprofen NN NN O
in NN NN O
premature NN NN O
infants NN NN O
born NN NN O
at NN NN O
less NN NN O
than NN NN O
28 NN NN O
weeks NN NN O
of NN NN O
gestation NN NN O
. NN NN O
   
Echocardiography NN NN O
showed NN NN O
severely NN NN O
decreased NN NN O
pulmonary NN NN O
blood NN NN O
flow NN NN O
. NN NN O
   
Hypoxaemia NN NN B-Disease
resolved NN NN O
quickly NN NN O
on NN NN O
inhaled NN NN O
nitric NN NN O
oxide NN NN O
therapy NN NN O
. NN NN O
   
We NN NN O
suggest NN NN O
that NN NN O
investigators NN NN O
involved NN NN O
in NN NN O
similar NN NN O
trials NN NN O
pay NN NN O
close NN NN O
attention NN NN O
to NN NN O
pulmonary NN NN O
pressure NN NN O
if NN NN O
hypoxaemia NN NN B-Disease
occurs NN NN O
after NN NN O
prophylactic NN NN O
administration NN NN O
of NN NN O
ibuprofen NN NN O
. NN NN O
   
Hyponatremia NN NN B-Disease
and NN NN O
syndrome NN NN B-Disease
of NN NN I-Disease
inappropriate NN NN I-Disease
anti NN NN I-Disease
- NN NN I-Disease
diuretic NN NN I-Disease
hormone NN NN I-Disease
reported NN NN O
with NN NN O
the NN NN O
use NN NN O
of NN NN O
Vincristine NN NN O
: NN NN O
an NN NN O
over NN NN O
- NN NN O
representation NN NN O
of NN NN O
Asians NN NN O
? NN NN O
   
PURPOSE NN NN O
: NN NN O
This NN NN O
retrospective NN NN O
study NN NN O
used NN NN O
a NN NN O
pharmaceutical NN NN O
company NN NN O
' NN NN O
s NN NN O
global NN NN O
safety NN NN O
database NN NN O
to NN NN O
determine NN NN O
the NN NN O
reporting NN NN O
rate NN NN O
of NN NN O
hyponatremia NN NN B-Disease
and NN NN O
/ NN NN O
or NN NN O
syndrome NN NN B-Disease
of NN NN I-Disease
inappropriate NN NN I-Disease
secretion NN NN I-Disease
of NN NN I-Disease
anti NN NN I-Disease
- NN NN I-Disease
diuretic NN NN I-Disease
hormone NN NN I-Disease
( NN NN O
SIADH NN NN B-Disease
) NN NN O
among NN NN O
vincristine NN NN O
- NN NN O
treated NN NN O
patients NN NN O
and NN NN O
to NN NN O
explore NN NN O
the NN NN O
possibility NN NN O
of NN NN O
at NN NN O
- NN NN O
risk NN NN O
population NN NN O
subgroups NN NN O
. NN NN O
   
METHOD NN NN O
: NN NN O
We NN NN O
searched NN NN O
the NN NN O
Eli NN NN O
Lilly NN NN O
and NN NN O
Company NN NN O
' NN NN O
s NN NN O
computerized NN NN O
adverse NN NN O
event NN NN O
database NN NN O
for NN NN O
all NN NN O
reported NN NN O
cases NN NN O
of NN NN O
hyponatremia NN NN B-Disease
and NN NN O
/ NN NN O
or NN NN O
SIADH NN NN B-Disease
as NN NN O
of NN NN O
1 NN NN O
November NN NN O
1999 NN NN O
that NN NN O
had NN NN O
been NN NN O
reported NN NN O
during NN NN O
the NN NN O
use NN NN O
of NN NN O
vincristine NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
A NN NN O
total NN NN O
of NN NN O
76 NN NN O
cases NN NN O
of NN NN O
hyponatremia NN NN B-Disease
and NN NN O
/ NN NN O
or NN NN O
SIADH NN NN B-Disease
associated NN NN O
with NN NN O
vincristine NN NN O
use NN NN O
were NN NN O
identified NN NN O
. NN NN O
   
The NN NN O
overall NN NN O
reporting NN NN O
rate NN NN O
was NN NN O
estimated NN NN O
to NN NN O
be NN NN O
1 NN NN O
. NN NN O
3 NN NN O
/ NN NN O
100 NN NN O
, NN NN O
000 NN NN O
treated NN NN O
patients NN NN O
. NN NN O
   
The NN NN O
average NN NN O
age NN NN O
of NN NN O
patients NN NN O
was NN NN O
35 NN NN O
. NN NN O
6 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
28 NN NN O
. NN NN O
3 NN NN O
years NN NN O
, NN NN O
and NN NN O
62 NN NN O
% NN NN O
were NN NN O
males NN NN O
. NN NN O
   
Approximately NN NN O
75 NN NN O
% NN NN O
of NN NN O
the NN NN O
patients NN NN O
were NN NN O
receiving NN NN O
treatment NN NN O
for NN NN O
leukemia NN NN B-Disease
or NN NN O
lymphoma NN NN B-Disease
. NN NN O
   
Among NN NN O
the NN NN O
39 NN NN O
reports NN NN O
that NN NN O
included NN NN O
information NN NN O
on NN NN O
race NN NN O
, NN NN O
the NN NN O
racial NN NN O
distribution NN NN O
was NN NN O
: NN NN O
1 NN NN O
Black NN NN O
, NN NN O
3 NN NN O
Caucasian NN NN O
, NN NN O
and NN NN O
35 NN NN O
Asian NN NN O
. NN NN O
   
CONCLUSION NN NN O
: NN NN O
Our NN NN O
data NN NN O
suggest NN NN O
that NN NN O
Asian NN NN O
patients NN NN O
may NN NN O
be NN NN O
at NN NN O
increased NN NN O
risk NN NN O
of NN NN O
hyponatremia NN NN B-Disease
and NN NN O
/ NN NN O
or NN NN O
SIADH NN NN B-Disease
associated NN NN O
with NN NN O
vincristine NN NN O
use NN NN O
. NN NN O
   
Although NN NN O
the NN NN O
overall NN NN O
reported NN NN O
rate NN NN O
of NN NN O
SIADH NN NN B-Disease
associated NN NN O
with NN NN O
vincristine NN NN O
is NN NN O
very NN NN O
low NN NN O
, NN NN O
physicians NN NN O
caring NN NN O
for NN NN O
Asian NN NN O
oncology NN NN O
patients NN NN O
should NN NN O
be NN NN O
aware NN NN O
of NN NN O
this NN NN O
potential NN NN O
serious NN NN O
but NN NN O
reversible NN NN O
adverse NN NN O
event NN NN O
. NN NN O
   
Delayed NN NN O
toxicity NN NN B-Disease
of NN NN O
cyclophosphamide NN NN O
on NN NN O
the NN NN O
bladder NN NN O
of NN NN O
DBA NN NN O
/ NN NN O
2 NN NN O
and NN NN O
C57BL NN NN O
/ NN NN O
6 NN NN O
female NN NN O
mouse NN NN O
. NN NN O
   
The NN NN O
present NN NN O
study NN NN O
describes NN NN O
the NN NN O
delayed NN NN O
development NN NN O
of NN NN O
a NN NN O
severe NN NN O
bladder NN NN O
pathology NN NN O
in NN NN O
a NN NN O
susceptible NN NN O
strain NN NN O
of NN NN O
mice NN NN O
( NN NN O
DBA NN NN O
/ NN NN O
2 NN NN O
) NN NN O
but NN NN O
not NN NN O
in NN NN O
a NN NN O
resistant NN NN O
strain NN NN O
( NN NN O
C57BL NN NN O
/ NN NN O
6 NN NN O
) NN NN O
when NN NN O
both NN NN O
were NN NN O
treated NN NN O
with NN NN O
a NN NN O
single NN NN O
300 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
dose NN NN O
of NN NN O
cyclophosphamide NN NN O
( NN NN O
CY NN NN O
) NN NN O
. NN NN O
   
Inbred NN NN O
DBA NN NN O
/ NN NN O
2 NN NN O
and NN NN O
C57BL NN NN O
/ NN NN O
6 NN NN O
female NN NN O
mice NN NN O
were NN NN O
injected NN NN O
with NN NN O
CY NN NN O
, NN NN O
and NN NN O
the NN NN O
effect NN NN O
of NN NN O
the NN NN O
drug NN NN O
on NN NN O
the NN NN O
bladder NN NN O
was NN NN O
assessed NN NN O
during NN NN O
100 NN NN O
days NN NN O
by NN NN O
light NN NN O
microscopy NN NN O
using NN NN O
different NN NN O
staining NN NN O
procedures NN NN O
, NN NN O
and NN NN O
after NN NN O
30 NN NN O
days NN NN O
by NN NN O
conventional NN NN O
electron NN NN O
microscopy NN NN O
. NN NN O
   
Early NN NN O
CY NN NN O
toxicity NN NN B-Disease
caused NN NN O
a NN NN O
typical NN NN O
haemorrhagic NN NN B-Disease
cystitis NN NN B-Disease
in NN NN O
both NN NN O
strains NN NN O
that NN NN O
was NN NN O
completely NN NN O
repaired NN NN O
in NN NN O
about NN NN O
7 NN NN O
- NN NN O
10 NN NN O
days NN NN O
. NN NN O
   
After NN NN O
30 NN NN O
days NN NN O
of NN NN O
CY NN NN O
injection NN NN O
ulcerous NN NN O
and NN NN O
non NN NN O
- NN NN O
ulcerous NN NN O
forms NN NN O
of NN NN O
chronic NN NN O
cystitis NN NN B-Disease
appeared NN NN O
in NN NN O
86 NN NN O
% NN NN O
of NN NN O
DBA NN NN O
/ NN NN O
2 NN NN O
mice NN NN O
but NN NN O
only NN NN O
in NN NN O
4 NN NN O
% NN NN O
of NN NN O
C57BL NN NN O
/ NN NN O
6 NN NN O
mice NN NN O
. NN NN O
   
Delayed NN NN O
cystitis NN NN B-Disease
was NN NN O
characterized NN NN O
by NN NN O
infiltration NN NN O
and NN NN O
transepithelial NN NN O
passage NN NN O
into NN NN O
the NN NN O
lumen NN NN O
of NN NN O
inflammatory NN NN O
cells NN NN O
and NN NN O
by NN NN O
frequent NN NN O
exfoliation NN NN O
of NN NN O
the NN NN O
urothelium NN NN O
. NN NN O
   
Mast NN NN O
cells NN NN O
appeared NN NN O
in NN NN O
the NN NN O
connective NN NN O
and NN NN O
muscular NN NN O
layers NN NN O
of NN NN O
the NN NN O
bladder NN NN O
at NN NN O
a NN NN O
much NN NN O
higher NN NN O
number NN NN O
in NN NN O
DBA NN NN O
/ NN NN O
2 NN NN O
mice NN NN O
than NN NN O
in NN NN O
C57BL NN NN O
/ NN NN O
6 NN NN O
mice NN NN O
or NN NN O
untreated NN NN O
controls NN NN O
. NN NN O
   
Electron NN NN O
microscopy NN NN O
disclosed NN NN O
the NN NN O
absence NN NN O
of NN NN O
the NN NN O
typical NN NN O
discoidal NN NN O
vesicles NN NN O
normally NN NN O
present NN NN O
in NN NN O
the NN NN O
cytoplasm NN NN O
of NN NN O
surface NN NN O
cells NN NN O
. NN NN O
   
Instead NN NN O
, NN NN O
numerous NN NN O
abnormal NN NN O
vesicles NN NN O
containing NN NN O
one NN NN O
or NN NN O
several NN NN O
dark NN NN O
granules NN NN O
were NN NN O
observed NN NN O
in NN NN O
the NN NN O
cytoplasm NN NN O
of NN NN O
cells NN NN O
from NN NN O
all NN NN O
the NN NN O
epithelial NN NN O
layers NN NN O
. NN NN O
   
Delayed NN NN O
cystitis NN NN B-Disease
still NN NN O
persisted NN NN O
in NN NN O
DBA NN NN O
/ NN NN O
2 NN NN O
mice NN NN O
100 NN NN O
days NN NN O
after NN NN O
treatment NN NN O
. NN NN O
   
These NN NN O
results NN NN O
indicate NN NN O
that NN NN O
delayed NN NN O
toxicity NN NN B-Disease
of NN NN O
CY NN NN O
in NN NN O
female NN NN O
DBA NN NN O
/ NN NN O
2 NN NN O
mice NN NN O
causes NN NN O
a NN NN O
bladder NN NN O
pathology NN NN O
that NN NN O
is NN NN O
not NN NN O
observed NN NN O
in NN NN O
C57BL NN NN O
/ NN NN O
6 NN NN O
mice NN NN O
. NN NN O
   
This NN NN O
pathology NN NN O
resembles NN NN O
interstitial NN NN B-Disease
cystitis NN NN I-Disease
in NN NN O
humans NN NN O
and NN NN O
could NN NN O
perhaps NN NN O
be NN NN O
used NN NN O
as NN NN O
an NN NN O
animal NN NN O
model NN NN O
for NN NN O
studies NN NN O
on NN NN O
the NN NN O
disease NN NN O
. NN NN O
   
High NN NN O
- NN NN O
dose NN NN O
5 NN NN O
- NN NN O
fluorouracil NN NN O
/ NN NN O
folinic NN NN O
acid NN NN O
in NN NN O
combination NN NN O
with NN NN O
three NN NN O
- NN NN O
weekly NN NN O
mitomycin NN NN O
C NN NN O
in NN NN O
the NN NN O
treatment NN NN O
of NN NN O
advanced NN NN O
gastric NN NN B-Disease
cancer NN NN I-Disease
. NN NN O
   
A NN NN O
phase NN NN O
II NN NN O
study NN NN O
. NN NN O
   
BACKGROUND NN NN O
: NN NN O
The NN NN O
24 NN NN O
- NN NN O
hour NN NN O
continuous NN NN O
infusion NN NN O
of NN NN O
5 NN NN O
- NN NN O
fluorouracil NN NN O
( NN NN O
5 NN NN O
- NN NN O
FU NN NN O
) NN NN O
and NN NN O
folinic NN NN O
acid NN NN O
( NN NN O
FA NN NN O
) NN NN O
as NN NN O
part NN NN O
of NN NN O
several NN NN O
new NN NN O
multidrug NN NN O
chemotherapy NN NN O
regimens NN NN O
in NN NN O
advanced NN NN O
gastric NN NN B-Disease
cancer NN NN I-Disease
( NN NN O
AGC NN NN B-Disease
) NN NN O
has NN NN O
shown NN NN O
to NN NN O
be NN NN O
effective NN NN O
, NN NN O
with NN NN O
low NN NN O
toxicity NN NN B-Disease
. NN NN O
   
In NN NN O
a NN NN O
previous NN NN O
phase NN NN O
II NN NN O
study NN NN O
with NN NN O
3 NN NN O
- NN NN O
weekly NN NN O
bolus NN NN O
5 NN NN O
- NN NN O
FU NN NN O
, NN NN O
FA NN NN O
and NN NN O
mitomycin NN NN O
C NN NN O
( NN NN O
MMC NN NN O
) NN NN O
we NN NN O
found NN NN O
a NN NN O
low NN NN O
toxicity NN NN B-Disease
rate NN NN O
and NN NN O
response NN NN O
rates NN NN O
comparable NN NN O
to NN NN O
those NN NN O
of NN NN O
regimens NN NN O
such NN NN O
as NN NN O
ELF NN NN O
, NN NN O
FAM NN NN O
or NN NN O
FAMTX NN NN O
, NN NN O
and NN NN O
a NN NN O
promising NN NN O
median NN NN O
overall NN NN O
survival NN NN O
. NN NN O
   
In NN NN O
order NN NN O
to NN NN O
improve NN NN O
this NN NN O
MMC NN NN O
- NN NN O
dependent NN NN O
schedule NN NN O
we NN NN O
initiated NN NN O
a NN NN O
phase NN NN O
II NN NN O
study NN NN O
with NN NN O
high NN NN O
- NN NN O
dose NN NN O
5 NN NN O
- NN NN O
FU NN NN O
/ NN NN O
FA NN NN O
and NN NN O
3 NN NN O
- NN NN O
weekly NN NN O
bolus NN NN O
MMC NN NN O
. NN NN O
   
PATIENTS NN NN O
AND NN NN O
METHODS NN NN O
: NN NN O
From NN NN O
February NN NN O
, NN NN O
1998 NN NN O
to NN NN O
September NN NN O
, NN NN O
2000 NN NN O
we NN NN O
recruited NN NN O
33 NN NN O
patients NN NN O
with NN NN O
AGC NN NN B-Disease
to NN NN O
receive NN NN O
weekly NN NN O
24 NN NN O
- NN NN O
hour NN NN O
5 NN NN O
- NN NN O
FU NN NN O
2 NN NN O
, NN NN O
600 NN NN O
mg NN NN O
/ NN NN O
m NN NN O
( NN NN O
2 NN NN O
) NN NN O
preceded NN NN O
by NN NN O
2 NN NN O
- NN NN O
hour NN NN O
FA NN NN O
500 NN NN O
mg NN NN O
/ NN NN O
m NN NN O
( NN NN O
2 NN NN O
) NN NN O
for NN NN O
6 NN NN O
weeks NN NN O
, NN NN O
followed NN NN O
by NN NN O
a NN NN O
2 NN NN O
- NN NN O
week NN NN O
rest NN NN O
period NN NN O
. NN NN O
   
Bolus NN NN O
MMC NN NN O
10 NN NN O
mg NN NN O
/ NN NN O
m NN NN O
( NN NN O
2 NN NN O
) NN NN O
was NN NN O
added NN NN O
in NN NN O
3 NN NN O
- NN NN O
weekly NN NN O
intervals NN NN O
. NN NN O
   
Treatment NN NN O
given NN NN O
on NN NN O
an NN NN O
outpatient NN NN O
basis NN NN O
, NN NN O
using NN NN O
portable NN NN O
pump NN NN O
systems NN NN O
, NN NN O
was NN NN O
repeated NN NN O
on NN NN O
day NN NN O
57 NN NN O
. NN NN O
   
Patients NN NN O
' NN NN O
characteristics NN NN O
were NN NN O
: NN NN O
male NN NN O
/ NN NN O
female NN NN O
ratio NN NN O
20 NN NN O
/ NN NN O
13 NN NN O
; NN NN O
median NN NN O
age NN NN O
57 NN NN O
( NN NN O
27 NN NN O
- NN NN O
75 NN NN O
) NN NN O
years NN NN O
; NN NN O
median NN NN O
WHO NN NN O
status NN NN O
1 NN NN O
( NN NN O
0 NN NN O
- NN NN O
2 NN NN O
) NN NN O
. NN NN O
   
18 NN NN O
patients NN NN O
had NN NN O
a NN NN O
primary NN NN O
AGC NN NN B-Disease
, NN NN O
and NN NN O
15 NN NN O
showed NN NN O
a NN NN O
relapsed NN NN O
AGC NN NN B-Disease
. NN NN O
   
Median NN NN O
follow NN NN O
- NN NN O
up NN NN O
was NN NN O
11 NN NN O
. NN NN O
8 NN NN O
months NN NN O
( NN NN O
range NN NN O
of NN NN O
those NN NN O
surviving NN NN O
: NN NN O
2 NN NN O
. NN NN O
7 NN NN O
- NN NN O
11 NN NN O
. NN NN O
8 NN NN O
months NN NN O
) NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
32 NN NN O
patients NN NN O
were NN NN O
evaluable NN NN O
for NN NN O
response NN NN O
- NN NN O
complete NN NN O
remission NN NN O
9 NN NN O
. NN NN O
1 NN NN O
% NN NN O
( NN NN O
n NN NN O
= NN NN O
3 NN NN O
) NN NN O
, NN NN O
partial NN NN O
remission NN NN O
45 NN NN O
. NN NN O
5 NN NN O
% NN NN O
( NN NN O
n NN NN O
= NN NN O
15 NN NN O
) NN NN O
, NN NN O
no NN NN O
change NN NN O
27 NN NN O
. NN NN O
3 NN NN O
% NN NN O
( NN NN O
n NN NN O
= NN NN O
9 NN NN O
) NN NN O
, NN NN O
progressive NN NN O
disease NN NN O
15 NN NN O
. NN NN O
1 NN NN O
% NN NN O
( NN NN O
n NN NN O
= NN NN O
5 NN NN O
) NN NN O
. NN NN O
   
Median NN NN O
overall NN NN O
survival NN NN O
time NN NN O
was NN NN O
10 NN NN O
. NN NN O
2 NN NN O
months NN NN O
[ NN NN O
95 NN NN O
% NN NN O
confidence NN NN O
interval NN NN O
( NN NN O
CI NN NN O
) NN NN O
: NN NN O
8 NN NN O
. NN NN O
7 NN NN O
- NN NN O
11 NN NN O
. NN NN O
6 NN NN O
] NN NN O
, NN NN O
and NN NN O
median NN NN O
progression NN NN O
- NN NN O
free NN NN O
survival NN NN O
time NN NN O
was NN NN O
7 NN NN O
. NN NN O
6 NN NN O
months NN NN O
( NN NN O
95 NN NN O
% NN NN O
CI NN NN O
: NN NN O
4 NN NN O
. NN NN O
4 NN NN O
- NN NN O
10 NN NN O
. NN NN O
9 NN NN O
) NN NN O
. NN NN O
   
The NN NN O
worst NN NN O
toxicities NN NN B-Disease
( NN NN O
% NN NN O
) NN NN O
observed NN NN O
were NN NN O
( NN NN O
CTC NN NN O
- NN NN O
NCI NN NN O
1 NN NN O
/ NN NN O
2 NN NN O
/ NN NN O
3 NN NN O
) NN NN O
: NN NN O
leukopenia NN NN B-Disease
45 NN NN O
. NN NN O
5 NN NN O
/ NN NN O
18 NN NN O
. NN NN O
2 NN NN O
/ NN NN O
6 NN NN O
. NN NN O
1 NN NN O
, NN NN O
thrombocytopenia NN NN B-Disease
33 NN NN O
. NN NN O
3 NN NN O
/ NN NN O
9 NN NN O
. NN NN O
1 NN NN O
/ NN NN O
6 NN NN O
. NN NN O
1 NN NN O
, NN NN O
vomitus NN NN B-Disease
24 NN NN O
. NN NN O
2 NN NN O
/ NN NN O
9 NN NN O
. NN NN O
1 NN NN O
/ NN NN O
0 NN NN O
, NN NN O
diarrhea NN NN B-Disease
36 NN NN O
. NN NN O
4 NN NN O
/ NN NN O
6 NN NN O
. NN NN O
1 NN NN O
/ NN NN O
3 NN NN O
. NN NN O
0 NN NN O
, NN NN O
stomatitis NN NN B-Disease
18 NN NN O
. NN NN O
2 NN NN O
/ NN NN O
9 NN NN O
. NN NN O
1 NN NN O
/ NN NN O
0 NN NN O
, NN NN O
hand NN NN B-Disease
- NN NN I-Disease
foot NN NN I-Disease
syndrome NN NN I-Disease
12 NN NN O
. NN NN O
1 NN NN O
/ NN NN O
0 NN NN O
/ NN NN O
0 NN NN O
. NN NN O
   
Two NN NN O
patients NN NN O
developed NN NN O
hemolytic NN NN B-Disease
- NN NN I-Disease
uremic NN NN I-Disease
syndrome NN NN I-Disease
( NN NN O
HUS NN NN B-Disease
) NN NN O
. NN NN O
   
CONCLUSIONS NN NN O
: NN NN O
High NN NN O
- NN NN O
dose NN NN O
5 NN NN O
- NN NN O
FU NN NN O
/ NN NN O
FA NN NN O
/ NN NN O
MMC NN NN O
is NN NN O
an NN NN O
effective NN NN O
and NN NN O
well NN NN O
- NN NN O
tolerated NN NN O
outpatient NN NN O
regimen NN NN O
for NN NN O
AGC NN NN B-Disease
( NN NN O
objective NN NN O
response NN NN O
rate NN NN O
54 NN NN O
. NN NN O
6 NN NN O
% NN NN O
) NN NN O
. NN NN O
   
It NN NN O
may NN NN O
serve NN NN O
as NN NN O
an NN NN O
alternative NN NN O
to NN NN O
cisplatin NN NN O
- NN NN O
containing NN NN O
regimens NN NN O
; NN NN O
however NN NN O
, NN NN O
it NN NN O
has NN NN O
to NN NN O
be NN NN O
considered NN NN O
that NN NN O
possibly NN NN O
HUS NN NN B-Disease
may NN NN O
occur NN NN O
. NN NN O
   
Persistent NN NN O
sterile NN NN O
leukocyturia NN NN B-Disease
is NN NN O
associated NN NN O
with NN NN O
impaired NN NN B-Disease
renal NN NN I-Disease
function NN NN I-Disease
in NN NN O
human NN NN B-Disease
immunodeficiency NN NN I-Disease
virus NN NN I-Disease
type NN NN I-Disease
1 NN NN I-Disease
- NN NN I-Disease
infected NN NN I-Disease
children NN NN O
treated NN NN O
with NN NN O
indinavir NN NN O
. NN NN O
   
BACKGROUND NN NN O
: NN NN O
Prolonged NN NN O
administration NN NN O
of NN NN O
indinavir NN NN O
is NN NN O
associated NN NN O
with NN NN O
the NN NN O
occurrence NN NN O
of NN NN O
a NN NN O
variety NN NN O
of NN NN O
renal NN NN O
complications NN NN O
in NN NN O
adults NN NN O
. NN NN O
   
These NN NN O
well NN NN O
- NN NN O
documented NN NN O
side NN NN O
effects NN NN O
have NN NN O
restricted NN NN O
the NN NN O
use NN NN O
of NN NN O
this NN NN O
potent NN NN O
protease NN NN O
inhibitor NN NN O
in NN NN O
children NN NN O
. NN NN O
   
DESIGN NN NN O
: NN NN O
A NN NN O
prospective NN NN O
study NN NN O
to NN NN O
monitor NN NN O
indinavir NN NN O
- NN NN O
related NN NN O
nephrotoxicity NN NN B-Disease
in NN NN O
a NN NN O
cohort NN NN O
of NN NN O
30 NN NN O
human NN NN B-Disease
immunodeficiency NN NN I-Disease
virus NN NN I-Disease
type NN NN I-Disease
1 NN NN I-Disease
- NN NN I-Disease
infected NN NN I-Disease
children NN NN O
treated NN NN O
with NN NN O
indinavir NN NN O
. NN NN O
   
METHODS NN NN O
: NN NN O
Urinary NN NN O
pH NN NN O
, NN NN O
albumin NN NN O
, NN NN O
creatinine NN NN O
, NN NN O
the NN NN O
presence NN NN O
of NN NN O
erythrocytes NN NN O
, NN NN O
leukocytes NN NN O
, NN NN O
bacteria NN NN O
and NN NN O
crystals NN NN O
, NN NN O
and NN NN O
culture NN NN O
were NN NN O
analyzed NN NN O
every NN NN O
3 NN NN O
months NN NN O
for NN NN O
96 NN NN O
weeks NN NN O
. NN NN O
   
Serum NN NN O
creatinine NN NN O
levels NN NN O
were NN NN O
routinely NN NN O
determined NN NN O
at NN NN O
the NN NN O
same NN NN O
time NN NN O
points NN NN O
. NN NN O
   
Steady NN NN O
- NN NN O
state NN NN O
pharmacokinetics NN NN O
of NN NN O
indinavir NN NN O
were NN NN O
done NN NN O
at NN NN O
week NN NN O
4 NN NN O
after NN NN O
the NN NN O
initiation NN NN O
of NN NN O
indinavir NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
The NN NN O
cumulative NN NN O
incidence NN NN O
of NN NN O
persistent NN NN O
sterile NN NN O
leukocyturia NN NN B-Disease
( NN NN O
> NN NN O
or NN NN O
= NN NN O
75 NN NN O
cells NN NN O
/ NN NN O
micro NN NN O
L NN NN O
in NN NN O
at NN NN O
least NN NN O
2 NN NN O
consecutive NN NN O
visits NN NN O
) NN NN O
after NN NN O
96 NN NN O
weeks NN NN O
was NN NN O
53 NN NN O
% NN NN O
. NN NN O
   
Persistent NN NN O
sterile NN NN O
leukocyturia NN NN B-Disease
was NN NN O
frequently NN NN O
associated NN NN O
with NN NN O
a NN NN O
mild NN NN O
increase NN NN O
in NN NN O
the NN NN O
urine NN NN O
albumin NN NN O
/ NN NN O
creatinine NN NN O
ratio NN NN O
and NN NN O
by NN NN O
microscopic NN NN O
hematuria NN NN B-Disease
. NN NN O
   
The NN NN O
cumulative NN NN O
incidence NN NN O
of NN NN O
serum NN NN O
creatinine NN NN O
levels NN NN O
> NN NN O
50 NN NN O
% NN NN O
above NN NN O
normal NN NN O
was NN NN O
33 NN NN O
% NN NN O
after NN NN O
96 NN NN O
weeks NN NN O
. NN NN O
   
Children NN NN O
with NN NN O
persistent NN NN O
sterile NN NN O
leukocyturia NN NN B-Disease
more NN NN O
frequently NN NN O
had NN NN O
serum NN NN O
creatinine NN NN O
levels NN NN O
of NN NN O
50 NN NN O
% NN NN O
above NN NN O
normal NN NN O
than NN NN O
those NN NN O
children NN NN O
without NN NN O
persistent NN NN O
sterile NN NN O
leukocyturia NN NN B-Disease
. NN NN O
   
In NN NN O
children NN NN O
younger NN NN O
than NN NN O
5 NN NN O
. NN NN O
6 NN NN O
years NN NN O
, NN NN O
persistent NN NN O
sterile NN NN O
leukocyturia NN NN B-Disease
was NN NN O
significantly NN NN O
more NN NN O
frequent NN NN O
than NN NN O
in NN NN O
older NN NN O
children NN NN O
. NN NN O
   
A NN NN O
higher NN NN O
cumulative NN NN O
incidence NN NN O
of NN NN O
persistent NN NN O
leukocyturia NN NN B-Disease
was NN NN O
found NN NN O
in NN NN O
children NN NN O
with NN NN O
an NN NN O
area NN NN O
under NN NN O
the NN NN O
curve NN NN O
> NN NN O
19 NN NN O
mg NN NN O
/ NN NN O
L NN NN O
x NN NN O
h NN NN O
or NN NN O
a NN NN O
peak NN NN O
serum NN NN O
level NN NN O
of NN NN O
indinavir NN NN O
> NN NN O
12 NN NN O
mg NN NN O
/ NN NN O
L NN NN O
. NN NN O
   
In NN NN O
4 NN NN O
children NN NN O
, NN NN O
indinavir NN NN O
was NN NN O
discontinued NN NN O
because NN NN O
of NN NN O
nephrotoxicity NN NN B-Disease
. NN NN O
   
Subsequently NN NN O
, NN NN O
the NN NN O
serum NN NN O
creatinine NN NN O
levels NN NN O
decreased NN NN O
, NN NN O
the NN NN O
urine NN NN O
albumin NN NN O
/ NN NN O
creatinine NN NN O
ratios NN NN O
returned NN NN O
to NN NN O
zero NN NN O
, NN NN O
and NN NN O
the NN NN O
leukocyturia NN NN B-Disease
disappeared NN NN O
within NN NN O
3 NN NN O
months NN NN O
. NN NN O
   
CONCLUSIONS NN NN O
: NN NN O
Children NN NN O
treated NN NN O
with NN NN O
indinavir NN NN O
have NN NN O
a NN NN O
high NN NN O
cumulative NN NN O
incidence NN NN O
of NN NN O
persistent NN NN O
sterile NN NN O
leukocyturia NN NN B-Disease
. NN NN O
   
Children NN NN O
with NN NN O
persistent NN NN O
sterile NN NN O
leukocyturia NN NN B-Disease
more NN NN O
frequently NN NN O
had NN NN O
an NN NN O
increase NN NN O
in NN NN O
serum NN NN O
creatinine NN NN O
levels NN NN O
of NN NN O
> NN NN O
50 NN NN O
% NN NN O
above NN NN O
normal NN NN O
. NN NN O
   
Younger NN NN O
children NN NN O
have NN NN O
an NN NN O
additional NN NN O
risk NN NN O
for NN NN O
renal NN NN O
complications NN NN O
. NN NN O
   
The NN NN O
impairment NN NN B-Disease
of NN NN I-Disease
the NN NN I-Disease
renal NN NN I-Disease
function NN NN I-Disease
in NN NN O
these NN NN O
children NN NN O
occurred NN NN O
in NN NN O
the NN NN O
absence NN NN O
of NN NN O
clinical NN NN O
symptoms NN NN O
of NN NN O
nephrolithiasis NN NN B-Disease
. NN NN O
   
Indinavir NN NN O
- NN NN O
associated NN NN O
nephrotoxicity NN NN B-Disease
must NN NN O
be NN NN O
monitored NN NN O
closely NN NN O
, NN NN O
especially NN NN O
in NN NN O
children NN NN O
with NN NN O
risk NN NN O
factors NN NN O
such NN NN O
as NN NN O
persistent NN NN O
sterile NN NN O
leukocyturia NN NN B-Disease
, NN NN O
age NN NN O
< NN NN O
5 NN NN O
. NN NN O
6 NN NN O
years NN NN O
, NN NN O
an NN NN O
area NN NN O
under NN NN O
the NN NN O
curve NN NN O
of NN NN O
indinavir NN NN O
> NN NN O
19 NN NN O
mg NN NN O
/ NN NN O
L NN NN O
x NN NN O
h NN NN O
, NN NN O
and NN NN O
a NN NN O
C NN NN O
( NN NN O
max NN NN O
) NN NN O
> NN NN O
12 NN NN O
mg NN NN O
/ NN NN O
L NN NN O
. NN NN O
   
Utility NN NN O
of NN NN O
troponin NN NN O
I NN NN O
in NN NN O
patients NN NN O
with NN NN O
cocaine NN NN O
- NN NN O
associated NN NN O
chest NN NN B-Disease
pain NN NN I-Disease
. NN NN O
   
Baseline NN NN O
electrocardiogram NN NN O
abnormalities NN NN O
and NN NN O
market NN NN O
elevations NN NN O
not NN NN O
associated NN NN O
with NN NN O
myocardial NN NN B-Disease
necrosis NN NN I-Disease
make NN NN O
accurate NN NN O
diagnosis NN NN O
of NN NN O
myocardial NN NN B-Disease
infarction NN NN I-Disease
( NN NN O
MI NN NN B-Disease
) NN NN O
difficult NN NN O
in NN NN O
patients NN NN O
with NN NN O
cocaine NN NN O
- NN NN O
associated NN NN O
chest NN NN B-Disease
pain NN NN I-Disease
. NN NN O
   
Troponin NN NN O
sampling NN NN O
may NN NN O
offer NN NN O
greater NN NN O
diagnostic NN NN O
utility NN NN O
in NN NN O
these NN NN O
patients NN NN O
. NN NN O
   
OBJECTIVE NN NN O
: NN NN O
To NN NN O
assess NN NN O
outcomes NN NN O
based NN NN O
on NN NN O
troponin NN NN O
positivity NN NN O
in NN NN O
patients NN NN O
with NN NN O
cocaine NN NN O
chest NN NN B-Disease
pain NN NN I-Disease
admitted NN NN O
for NN NN O
exclusion NN NN O
of NN NN O
MI NN NN B-Disease
. NN NN O
   
METHODS NN NN O
: NN NN O
Outcomes NN NN O
were NN NN O
examined NN NN O
in NN NN O
patients NN NN O
admitted NN NN O
for NN NN O
possible NN NN O
MI NN NN B-Disease
after NN NN O
cocaine NN NN O
use NN NN O
. NN NN O
   
All NN NN O
patients NN NN O
underwent NN NN O
a NN NN O
rapid NN NN O
rule NN NN O
- NN NN O
in NN NN O
protocol NN NN O
that NN NN O
included NN NN O
serial NN NN O
sampling NN NN O
of NN NN O
creatine NN NN O
kinase NN NN O
( NN NN O
CK NN NN O
) NN NN O
, NN NN O
CK NN NN O
- NN NN O
MB NN NN O
, NN NN O
and NN NN O
cardiac NN NN O
troponin NN NN O
I NN NN O
( NN NN O
cTnI NN NN O
) NN NN O
over NN NN O
eight NN NN O
hours NN NN O
. NN NN O
   
Outcomes NN NN O
included NN NN O
CK NN NN O
- NN NN O
MB NN NN O
MI NN NN B-Disease
( NN NN O
CK NN NN O
- NN NN O
MB NN NN O
> NN NN O
or NN NN O
= NN NN O
8 NN NN O
ng NN NN O
/ NN NN O
mL NN NN O
with NN NN O
a NN NN O
relative NN NN O
index NN NN O
[ NN NN O
( NN NN O
CK NN NN O
- NN NN O
MB NN NN O
x NN NN O
100 NN NN O
) NN NN O
/ NN NN O
total NN NN O
CK NN NN O
] NN NN O
> NN NN O
or NN NN O
= NN NN O
4 NN NN O
, NN NN O
cardiac NN NN B-Disease
death NN NN I-Disease
, NN NN O
and NN NN O
significant NN NN O
coronary NN NN B-Disease
disease NN NN I-Disease
( NN NN O
> NN NN O
or NN NN O
= NN NN O
50 NN NN O
% NN NN O
) NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
Of NN NN O
the NN NN O
246 NN NN O
admitted NN NN O
patients NN NN O
, NN NN O
34 NN NN O
( NN NN O
14 NN NN O
% NN NN O
) NN NN O
met NN NN O
CK NN NN O
- NN NN O
MB NN NN O
criteria NN NN O
for NN NN O
MI NN NN B-Disease
and NN NN O
38 NN NN O
( NN NN O
16 NN NN O
% NN NN O
) NN NN O
had NN NN O
cTnI NN NN O
elevations NN NN O
. NN NN O
   
Angiography NN NN O
was NN NN O
performed NN NN O
in NN NN O
29 NN NN O
of NN NN O
38 NN NN O
patients NN NN O
who NN NN O
were NN NN O
cTnI NN NN O
- NN NN O
positive NN NN O
, NN NN O
with NN NN O
significant NN NN O
disease NN NN O
present NN NN O
in NN NN O
25 NN NN O
( NN NN O
86 NN NN O
% NN NN O
) NN NN O
. NN NN O
   
Three NN NN O
of NN NN O
the NN NN O
four NN NN O
patients NN NN O
without NN NN O
significant NN NN O
disease NN NN O
who NN NN O
had NN NN O
cTnI NN NN O
elevations NN NN O
met NN NN O
CK NN NN O
- NN NN O
MB NN NN O
criteria NN NN O
for NN NN O
MI NN NN B-Disease
, NN NN O
and NN NN O
the NN NN O
other NN NN O
had NN NN O
a NN NN O
peak NN NN O
CK NN NN O
- NN NN O
MB NN NN O
level NN NN O
of NN NN O
13 NN NN O
ng NN NN O
/ NN NN O
mL NN NN O
. NN NN O
   
Sensitivities NN NN O
, NN NN O
specificities NN NN O
, NN NN O
and NN NN O
positive NN NN O
and NN NN O
negative NN NN O
likelihood NN NN O
ratios NN NN O
for NN NN O
predicting NN NN O
cardiac NN NN B-Disease
death NN NN I-Disease
or NN NN O
significant NN NN O
disease NN NN O
were NN NN O
high NN NN O
for NN NN O
both NN NN O
CK NN NN O
- NN NN O
MB NN NN O
MI NN NN B-Disease
and NN NN O
cTnI NN NN O
and NN NN O
were NN NN O
not NN NN O
significantly NN NN O
different NN NN O
. NN NN O
   
CONCLUSIONS NN NN O
: NN NN O
Most NN NN O
patients NN NN O
with NN NN O
cTnI NN NN O
elevations NN NN O
meet NN NN O
CK NN NN O
- NN NN O
MB NN NN O
criteria NN NN O
for NN NN O
MI NN NN B-Disease
, NN NN O
as NN NN O
well NN NN O
as NN NN O
have NN NN O
a NN NN O
high NN NN O
incidence NN NN O
of NN NN O
underlying NN NN O
significant NN NN O
disease NN NN O
. NN NN O
   
Troponin NN NN O
appears NN NN O
to NN NN O
have NN NN O
an NN NN O
equivalent NN NN O
diagnostic NN NN O
accuracy NN NN O
compared NN NN O
with NN NN O
CK NN NN O
- NN NN O
MB NN NN O
for NN NN O
diagnosing NN NN O
necrosis NN NN B-Disease
in NN NN O
patients NN NN O
with NN NN O
cocaine NN NN O
- NN NN O
associated NN NN O
chest NN NN B-Disease
pain NN NN I-Disease
and NN NN O
suspected NN NN O
MI NN NN B-Disease
. NN NN O
   
Acute NN NN O
interstitial NN NN B-Disease
nephritis NN NN I-Disease
due NN NN O
to NN NN O
nicergoline NN NN O
( NN NN O
Sermion NN NN O
) NN NN O
. NN NN O
   
We NN NN O
report NN NN O
a NN NN O
case NN NN O
of NN NN O
acute NN NN O
interstitial NN NN B-Disease
nephritis NN NN I-Disease
( NN NN O
AIN NN NN B-Disease
) NN NN O
due NN NN O
to NN NN O
nicergoline NN NN O
( NN NN O
Sermion NN NN O
) NN NN O
. NN NN O
   
A NN NN O
50 NN NN O
- NN NN O
year NN NN O
- NN NN O
old NN NN O
patient NN NN O
admitted NN NN O
to NN NN O
our NN NN O
hospital NN NN O
for NN NN O
fever NN NN B-Disease
and NN NN O
acute NN NN B-Disease
renal NN NN I-Disease
failure NN NN I-Disease
. NN NN O
   
Before NN NN O
admission NN NN O
, NN NN O
he NN NN O
had NN NN O
been NN NN O
taking NN NN O
nicergoline NN NN O
and NN NN O
bendazac NN NN O
lysine NN NN O
due NN NN O
to NN NN O
retinal NN NN B-Disease
vein NN NN I-Disease
occlusion NN NN I-Disease
at NN NN O
ophthalmologic NN NN O
department NN NN O
. NN NN O
   
Thereafter NN NN O
, NN NN O
he NN NN O
experienced NN NN O
intermittent NN NN O
fever NN NN B-Disease
and NN NN O
skin NN NN B-Disease
rash NN NN I-Disease
. NN NN O
   
On NN NN O
admission NN NN O
, NN NN O
clinical NN NN O
symptoms NN NN O
( NN NN O
i NN NN O
. NN NN O
e NN NN O
. NN NN O
arthralgia NN NN B-Disease
and NN NN O
fever NN NN B-Disease
) NN NN O
and NN NN O
laboratory NN NN O
findings NN NN O
( NN NN O
i NN NN O
. NN NN O
e NN NN O
. NN NN O
eosinophilia NN NN B-Disease
and NN NN O
renal NN NN B-Disease
failure NN NN I-Disease
) NN NN O
suggested NN NN O
AIN NN NN B-Disease
, NN NN O
and NN NN O
which NN NN O
was NN NN O
confirmed NN NN O
by NN NN O
pathologic NN NN O
findings NN NN O
on NN NN O
renal NN NN O
biopsy NN NN O
. NN NN O
   
A NN NN O
lymphocyte NN NN O
transformation NN NN O
test NN NN O
demonstrated NN NN O
a NN NN O
positive NN NN O
result NN NN O
against NN NN O
nicergoline NN NN O
. NN NN O
   
Treatment NN NN O
was NN NN O
consisted NN NN O
of NN NN O
withdrawal NN NN O
of NN NN O
nicergoline NN NN O
and NN NN O
intravenous NN NN O
methylprednisolone NN NN O
, NN NN O
and NN NN O
his NN NN O
renal NN NN O
function NN NN O
was NN NN O
completely NN NN O
recovered NN NN O
. NN NN O
   
To NN NN O
our NN NN O
knowledge NN NN O
, NN NN O
this NN NN O
is NN NN O
the NN NN O
first NN NN O
report NN NN O
of NN NN O
nicergoline NN NN O
- NN NN O
associated NN NN O
AIN NN NN B-Disease
. NN NN O
   
Neuroleptic NN NN B-Disease
malignant NN NN I-Disease
syndrome NN NN I-Disease
complicated NN NN O
by NN NN O
massive NN NN O
intestinal NN NN O
bleeding NN NN B-Disease
in NN NN O
a NN NN O
patient NN NN O
with NN NN O
chronic NN NN B-Disease
renal NN NN I-Disease
failure NN NN I-Disease
. NN NN O
   
A NN NN O
patient NN NN O
with NN NN O
chronic NN NN B-Disease
renal NN NN I-Disease
failure NN NN I-Disease
( NN NN O
CRF NN NN B-Disease
) NN NN O
developed NN NN O
neuroleptic NN NN B-Disease
malignant NN NN I-Disease
syndrome NN NN I-Disease
( NN NN O
NMS NN NN B-Disease
) NN NN O
after NN NN O
administration NN NN O
of NN NN O
risperidone NN NN O
and NN NN O
levomepromazine NN NN O
. NN NN O
   
In NN NN O
addition NN NN O
to NN NN O
the NN NN O
typical NN NN O
symptoms NN NN O
of NN NN O
NMS NN NN B-Disease
, NN NN O
massive NN NN O
intestinal NN NN O
bleeding NN NN B-Disease
was NN NN O
observed NN NN O
during NN NN O
the NN NN O
episode NN NN O
. NN NN O
   
This NN NN O
report NN NN O
suggests NN NN O
that NN NN O
NMS NN NN B-Disease
in NN NN O
a NN NN O
patient NN NN O
with NN NN O
CRF NN NN B-Disease
may NN NN O
be NN NN O
complicated NN NN O
by NN NN O
intestinal NN NN O
bleeding NN NN B-Disease
and NN NN O
needs NN NN O
special NN NN O
caution NN NN O
for NN NN O
this NN NN O
complication NN NN O
. NN NN O
   
Blood NN NN O
brain NN NN O
barrier NN NN O
in NN NN O
right NN NN O
- NN NN O
and NN NN O
left NN NN O
- NN NN O
pawed NN NN O
female NN NN O
rats NN NN O
assessed NN NN O
by NN NN O
a NN NN O
new NN NN O
staining NN NN O
method NN NN O
. NN NN O
   
The NN NN O
asymmetrical NN NN O
breakdown NN NN O
of NN NN O
the NN NN O
blood NN NN O
- NN NN O
brain NN NN O
barrier NN NN O
( NN NN O
BBB NN NN O
) NN NN O
was NN NN O
studied NN NN O
in NN NN O
female NN NN O
rats NN NN O
. NN NN O
   
Paw NN NN O
preference NN NN O
was NN NN O
assessed NN NN O
by NN NN O
a NN NN O
food NN NN O
reaching NN NN O
test NN NN O
. NN NN O
   
Adrenaline NN NN O
- NN NN O
induced NN NN O
hypertension NN NN B-Disease
was NN NN O
used NN NN O
to NN NN O
destroy NN NN O
the NN NN O
BBB NN NN O
, NN NN O
which NN NN O
was NN NN O
evaluated NN NN O
using NN NN O
triphenyltetrazolium NN NN O
( NN NN O
TTC NN NN O
) NN NN O
staining NN NN O
of NN NN O
the NN NN O
brain NN NN O
slices NN NN O
just NN NN O
after NN NN O
giving NN NN O
adrenaline NN NN O
for NN NN O
30 NN NN O
s NN NN O
. NN NN O
   
In NN NN O
normal NN NN O
rats NN NN O
, NN NN O
the NN NN O
whole NN NN O
brain NN NN O
sections NN NN O
exhibited NN NN O
complete NN NN O
staining NN NN O
with NN NN O
TTC NN NN O
. NN NN O
   
After NN NN O
adrenaline NN NN O
infusion NN NN O
for NN NN O
30 NN NN O
s NN NN O
, NN NN O
there NN NN O
were NN NN O
large NN NN O
unstained NN NN O
areas NN NN O
in NN NN O
the NN NN O
left NN NN O
brain NN NN O
in NN NN O
right NN NN O
- NN NN O
pawed NN NN O
animals NN NN O
, NN NN O
and NN NN O
vice NN NN O
versa NN NN O
in NN NN O
left NN NN O
- NN NN O
pawed NN NN O
animals NN NN O
. NN NN O
   
Similar NN NN O
results NN NN O
were NN NN O
obtained NN NN O
in NN NN O
seizure NN NN B-Disease
- NN NN O
induced NN NN O
breakdown NN NN O
of NN NN O
BBB NN NN O
. NN NN O
   
These NN NN O
results NN NN O
were NN NN O
explained NN NN O
by NN NN O
an NN NN O
asymmetric NN NN O
cerebral NN NN O
blood NN NN O
flow NN NN O
depending NN NN O
upon NN NN O
the NN NN O
paw NN NN O
preference NN NN O
in NN NN O
rats NN NN O
. NN NN O
   
It NN NN O
was NN NN O
suggested NN NN O
that NN NN O
this NN NN O
new NN NN O
method NN NN O
and NN NN O
the NN NN O
results NN NN O
are NN NN O
consistent NN NN O
with NN NN O
contralateral NN NN O
motor NN NN O
control NN NN O
that NN NN O
may NN NN O
be NN NN O
important NN NN O
in NN NN O
determining NN NN O
the NN NN O
dominant NN NN O
cerebral NN NN O
hemisphere NN NN O
in NN NN O
animals NN NN O
. NN NN O
   
Carvedilol NN NN O
protects NN NN O
against NN NN O
doxorubicin NN NN O
- NN NN O
induced NN NN O
mitochondrial NN NN O
cardiomyopathy NN NN B-Disease
. NN NN O
   
Several NN NN O
cytopathic NN NN O
mechanisms NN NN O
have NN NN O
been NN NN O
suggested NN NN O
to NN NN O
mediate NN NN O
the NN NN O
dose NN NN O
- NN NN O
limiting NN NN O
cumulative NN NN O
and NN NN O
irreversible NN NN O
cardiomyopathy NN NN B-Disease
caused NN NN O
by NN NN O
doxorubicin NN NN O
. NN NN O
   
Recent NN NN O
evidence NN NN O
indicates NN NN O
that NN NN O
oxidative NN NN O
stress NN NN O
and NN NN O
mitochondrial NN NN B-Disease
dysfunction NN NN I-Disease
are NN NN O
key NN NN O
factors NN NN O
in NN NN O
the NN NN O
pathogenic NN NN O
process NN NN O
. NN NN O
   
The NN NN O
objective NN NN O
of NN NN O
this NN NN O
investigation NN NN O
was NN NN O
to NN NN O
test NN NN O
the NN NN O
hypothesis NN NN O
that NN NN O
carvedilol NN NN O
, NN NN O
a NN NN O
nonselective NN NN O
beta NN NN O
- NN NN O
adrenergic NN NN O
receptor NN NN O
antagonist NN NN O
with NN NN O
potent NN NN O
antioxidant NN NN O
properties NN NN O
, NN NN O
protects NN NN O
against NN NN O
the NN NN O
cardiac NN NN O
and NN NN O
hepatic NN NN O
mitochondrial NN NN O
bioenergetic NN NN O
dysfunction NN NN O
associated NN NN O
with NN NN O
subchronic NN NN O
doxorubicin NN NN O
toxicity NN NN B-Disease
. NN NN O
   
Heart NN NN O
and NN NN O
liver NN NN O
mitochondria NN NN O
were NN NN O
isolated NN NN O
from NN NN O
rats NN NN O
treated NN NN O
for NN NN O
7 NN NN O
weeks NN NN O
with NN NN O
doxorubicin NN NN O
( NN NN O
2 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
sc NN NN O
/ NN NN O
week NN NN O
) NN NN O
, NN NN O
carvedilol NN NN O
( NN NN O
1 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
ip NN NN O
/ NN NN O
week NN NN O
) NN NN O
, NN NN O
or NN NN O
the NN NN O
combination NN NN O
of NN NN O
the NN NN O
two NN NN O
drugs NN NN O
. NN NN O
   
Heart NN NN O
mitochondria NN NN O
isolated NN NN O
from NN NN O
doxorubicin NN NN O
- NN NN O
treated NN NN O
rats NN NN O
exhibited NN NN O
depressed NN NN O
rates NN NN O
for NN NN O
state NN NN O
3 NN NN O
respiration NN NN O
( NN NN O
336 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
26 NN NN O
versus NN NN O
425 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
53 NN NN O
natom NN NN O
O NN NN O
/ NN NN O
min NN NN O
/ NN NN O
mg NN NN O
protein NN NN O
) NN NN O
and NN NN O
a NN NN O
lower NN NN O
respiratory NN NN O
control NN NN O
ratio NN NN O
( NN NN O
RCR NN NN O
) NN NN O
( NN NN O
4 NN NN O
. NN NN O
3 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
0 NN NN O
. NN NN O
6 NN NN O
versus NN NN O
5 NN NN O
. NN NN O
8 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
0 NN NN O
. NN NN O
4 NN NN O
) NN NN O
compared NN NN O
with NN NN O
cardiac NN NN O
mitochondria NN NN O
isolated NN NN O
from NN NN O
saline NN NN O
- NN NN O
treated NN NN O
rats NN NN O
. NN NN O
   
Mitochondrial NN NN O
calcium NN NN O
- NN NN O
loading NN NN O
capacity NN NN O
and NN NN O
the NN NN O
activity NN NN O
of NN NN O
NADH NN NN O
- NN NN O
dehydrogenase NN NN O
were NN NN O
also NN NN O
suppressed NN NN O
in NN NN O
cardiac NN NN O
mitochondria NN NN O
from NN NN O
doxorubicin NN NN O
- NN NN O
treated NN NN O
rats NN NN O
. NN NN O
   
Doxorubicin NN NN O
treatment NN NN O
also NN NN O
caused NN NN O
a NN NN O
decrease NN NN O
in NN NN O
RCR NN NN O
for NN NN O
liver NN NN O
mitochondria NN NN O
( NN NN O
3 NN NN O
. NN NN O
9 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
0 NN NN O
. NN NN O
9 NN NN O
versus NN NN O
5 NN NN O
. NN NN O
6 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
0 NN NN O
. NN NN O
7 NN NN O
for NN NN O
control NN NN O
rats NN NN O
) NN NN O
and NN NN O
inhibition NN NN O
of NN NN O
hepatic NN NN O
cytochrome NN NN O
oxidase NN NN O
activity NN NN O
. NN NN O
   
Coadministration NN NN O
of NN NN O
carvedilol NN NN O
decreased NN NN O
the NN NN O
extent NN NN O
of NN NN O
cellular NN NN O
vacuolization NN NN O
in NN NN O
cardiac NN NN O
myocytes NN NN O
and NN NN O
prevented NN NN O
the NN NN O
inhibitory NN NN O
effect NN NN O
of NN NN O
doxorubicin NN NN O
on NN NN O
mitochondrial NN NN O
respiration NN NN O
in NN NN O
both NN NN O
heart NN NN O
and NN NN O
liver NN NN O
. NN NN O
   
Carvedilol NN NN O
also NN NN O
prevented NN NN O
the NN NN O
decrease NN NN O
in NN NN O
mitochondrial NN NN O
Ca NN NN O
( NN NN O
2 NN NN O
+ NN NN O
) NN NN O
loading NN NN O
capacity NN NN O
and NN NN O
the NN NN O
inhibition NN NN O
of NN NN O
the NN NN O
respiratory NN NN O
complexes NN NN O
of NN NN O
heart NN NN O
mitochondria NN NN O
caused NN NN O
by NN NN O
doxorubicin NN NN O
. NN NN O
   
Carvedilol NN NN O
by NN NN O
itself NN NN O
did NN NN O
not NN NN O
affect NN NN O
any NN NN O
of NN NN O
the NN NN O
parameters NN NN O
measured NN NN O
for NN NN O
heart NN NN O
or NN NN O
liver NN NN O
mitochondria NN NN O
. NN NN O
   
It NN NN O
is NN NN O
concluded NN NN O
that NN NN O
this NN NN O
protection NN NN O
by NN NN O
carvedilol NN NN O
against NN NN O
both NN NN O
the NN NN O
structural NN NN O
and NN NN O
functional NN NN O
cardiac NN NN O
tissue NN NN O
damage NN NN O
may NN NN O
afford NN NN O
significant NN NN O
clinical NN NN O
advantage NN NN O
in NN NN O
minimizing NN NN O
the NN NN O
dose NN NN O
- NN NN O
limiting NN NN O
mitochondrial NN NN B-Disease
dysfunction NN NN I-Disease
and NN NN O
cardiomyopathy NN NN B-Disease
that NN NN O
accompanies NN NN O
long NN NN O
- NN NN O
term NN NN O
doxorubicin NN NN O
therapy NN NN O
in NN NN O
cancer NN NN B-Disease
patients NN NN O
. NN NN O
   
Cocaine NN NN O
- NN NN O
induced NN NN O
hyperactivity NN NN B-Disease
is NN NN O
more NN NN O
influenced NN NN O
by NN NN O
adenosine NN NN O
receptor NN NN O
agonists NN NN O
than NN NN O
amphetamine NN NN O
- NN NN O
induced NN NN O
hyperactivity NN NN B-Disease
. NN NN O
   
The NN NN O
influence NN NN O
of NN NN O
adenosine NN NN O
receptor NN NN O
agonists NN NN O
and NN NN O
antagonists NN NN O
on NN NN O
cocaine NN NN O
- NN NN O
and NN NN O
amphetamine NN NN O
- NN NN O
induced NN NN O
hyperactivity NN NN B-Disease
was NN NN O
examined NN NN O
in NN NN O
mice NN NN O
. NN NN O
   
All NN NN O
adenosine NN NN O
receptor NN NN O
agonists NN NN O
significantly NN NN O
decreased NN NN B-Disease
the NN NN I-Disease
locomotor NN NN I-Disease
activity NN NN I-Disease
in NN NN O
mice NN NN O
, NN NN O
and NN NN O
the NN NN O
effects NN NN O
were NN NN O
dose NN NN O
- NN NN O
dependent NN NN O
. NN NN O
   
It NN NN O
seems NN NN O
that NN NN O
adenosine NN NN O
A1 NN NN O
and NN NN O
A2 NN NN O
receptors NN NN O
might NN NN O
be NN NN O
involved NN NN O
in NN NN O
this NN NN O
reaction NN NN O
. NN NN O
   
Moreover NN NN O
, NN NN O
all NN NN O
adenosine NN NN O
receptor NN NN O
agonists NN NN O
: NN NN O
2 NN NN O
- NN NN O
p NN NN O
- NN NN O
( NN NN O
2 NN NN O
- NN NN O
carboxyethyl NN NN O
) NN NN O
phenethylamino NN NN O
- NN NN O
5 NN NN O
' NN NN O
- NN NN O
N NN NN O
- NN NN O
ethylcarboxamidoadenosine NN NN O
( NN NN O
CGS NN NN O
21680 NN NN O
) NN NN O
, NN NN O
A2A NN NN O
receptor NN NN O
agonist NN NN O
, NN NN O
N6 NN NN O
- NN NN O
cyclopentyladenosine NN NN O
( NN NN O
CPA NN NN O
) NN NN O
, NN NN O
A1 NN NN O
receptor NN NN O
agonist NN NN O
, NN NN O
and NN NN O
5 NN NN O
' NN NN O
- NN NN O
N NN NN O
- NN NN O
ethylcarboxamidoadenosine NN NN O
( NN NN O
NECA NN NN O
) NN NN O
, NN NN O
A2 NN NN O
/ NN NN O
A1 NN NN O
receptor NN NN O
agonist NN NN O
significantly NN NN O
and NN NN O
dose NN NN O
- NN NN O
dependently NN NN O
decreased NN NN O
cocaine NN NN O
- NN NN O
induced NN NN O
locomotor NN NN O
activity NN NN O
. NN NN O
   
CPA NN NN O
reduced NN NN O
cocaine NN NN O
action NN NN O
at NN NN O
the NN NN O
doses NN NN O
which NN NN O
, NN NN O
given NN NN O
alone NN NN O
, NN NN O
did NN NN O
not NN NN O
influence NN NN O
motility NN NN O
, NN NN O
while NN NN O
CGS NN NN O
21680 NN NN O
and NN NN O
NECA NN NN O
decreased NN NN O
the NN NN O
action NN NN O
of NN NN O
cocaine NN NN O
at NN NN O
the NN NN O
doses NN NN O
which NN NN O
, NN NN O
given NN NN O
alone NN NN O
, NN NN O
decreased NN NN O
locomotor NN NN O
activity NN NN O
in NN NN O
animals NN NN O
. NN NN O
   
These NN NN O
results NN NN O
suggest NN NN O
the NN NN O
involvement NN NN O
of NN NN O
both NN NN O
adenosine NN NN O
receptors NN NN O
in NN NN O
the NN NN O
action NN NN O
of NN NN O
cocaine NN NN O
although NN NN O
agonists NN NN O
of NN NN O
A1 NN NN O
receptors NN NN O
seem NN NN O
to NN NN O
have NN NN O
stronger NN NN O
influence NN NN O
on NN NN O
it NN NN O
. NN NN O
   
The NN NN O
selective NN NN O
blockade NN NN O
of NN NN O
A2 NN NN O
adenosine NN NN O
receptor NN NN O
by NN NN O
DMPX NN NN O
( NN NN O
3 NN NN O
, NN NN O
7 NN NN O
- NN NN O
dimethyl NN NN O
- NN NN O
1 NN NN O
- NN NN O
propargylxanthine NN NN O
) NN NN O
significantly NN NN O
enhanced NN NN O
cocaine NN NN O
- NN NN O
induced NN NN O
locomotor NN NN O
activity NN NN O
of NN NN O
animals NN NN O
. NN NN O
   
Caffeine NN NN O
had NN NN O
similar NN NN O
action NN NN O
but NN NN O
the NN NN O
effect NN NN O
was NN NN O
not NN NN O
significant NN NN O
. NN NN O
   
CPT NN NN O
( NN NN O
8 NN NN O
- NN NN O
cyclopentyltheophylline NN NN O
) NN NN O
- NN NN O
- NN NN O
A1 NN NN O
receptor NN NN O
antagonist NN NN O
, NN NN O
did NN NN O
not NN NN O
show NN NN O
any NN NN O
influence NN NN O
in NN NN O
this NN NN O
test NN NN O
. NN NN O
   
Similarly NN NN O
, NN NN O
all NN NN O
adenosine NN NN O
receptor NN NN O
agonists NN NN O
decreased NN NN O
amphetamine NN NN O
- NN NN O
induced NN NN O
hyperactivity NN NN B-Disease
, NN NN O
but NN NN O
at NN NN O
the NN NN O
higher NN NN O
doses NN NN O
than NN NN O
those NN NN O
which NN NN O
were NN NN O
active NN NN O
in NN NN O
cocaine NN NN O
- NN NN O
induced NN NN O
hyperactivity NN NN B-Disease
. NN NN O
   
The NN NN O
selective NN NN O
blockade NN NN O
of NN NN O
A2 NN NN O
adenosine NN NN O
receptors NN NN O
( NN NN O
DMPX NN NN O
) NN NN O
and NN NN O
non NN NN O
- NN NN O
selective NN NN O
blockade NN NN O
of NN NN O
adenosine NN NN O
receptors NN NN O
( NN NN O
caffeine NN NN O
) NN NN O
significantly NN NN O
increased NN NN O
the NN NN O
action NN NN O
of NN NN O
amphetamine NN NN O
in NN NN O
the NN NN O
locomotor NN NN O
activity NN NN O
test NN NN O
. NN NN O
   
Our NN NN O
results NN NN O
have NN NN O
shown NN NN O
that NN NN O
all NN NN O
adenosine NN NN O
receptor NN NN O
agonists NN NN O
( NN NN O
A1 NN NN O
and NN NN O
A2 NN NN O
) NN NN O
reduce NN NN O
cocaine NN NN O
- NN NN O
and NN NN O
amphetamine NN NN O
- NN NN O
induced NN NN O
locomotor NN NN O
activity NN NN O
and NN NN O
indicate NN NN O
that NN NN O
cocaine NN NN O
- NN NN O
induced NN NN O
hyperactivity NN NN B-Disease
is NN NN O
more NN NN O
influenced NN NN O
by NN NN O
adenosine NN NN O
receptor NN NN O
agonists NN NN O
( NN NN O
particularly NN NN O
A1 NN NN O
receptors NN NN O
) NN NN O
than NN NN O
amphetamine NN NN O
- NN NN O
induced NN NN O
hyperactivity NN NN B-Disease
. NN NN O
   
Amiodarone NN NN O
and NN NN O
the NN NN O
risk NN NN O
of NN NN O
bradyarrhythmia NN NN B-Disease
requiring NN NN O
permanent NN NN O
pacemaker NN NN O
in NN NN O
elderly NN NN O
patients NN NN O
with NN NN O
atrial NN NN B-Disease
fibrillation NN NN I-Disease
and NN NN O
prior NN NN O
myocardial NN NN B-Disease
infarction NN NN I-Disease
. NN NN O
   
OBJECTIVES NN NN O
: NN NN O
The NN NN O
aim NN NN O
of NN NN O
this NN NN O
study NN NN O
was NN NN O
to NN NN O
determine NN NN O
whether NN NN O
the NN NN O
use NN NN O
of NN NN O
amiodarone NN NN O
in NN NN O
patients NN NN O
with NN NN O
atrial NN NN B-Disease
fibrillation NN NN I-Disease
( NN NN O
AF NN NN B-Disease
) NN NN O
increases NN NN O
the NN NN O
risk NN NN O
of NN NN O
bradyarrhythmia NN NN B-Disease
requiring NN NN O
a NN NN O
permanent NN NN O
pacemaker NN NN O
. NN NN O
   
BACKGROUND NN NN O
: NN NN O
Reports NN NN O
of NN NN O
severe NN NN O
bradyarrhythmia NN NN B-Disease
during NN NN O
amiodarone NN NN O
therapy NN NN O
are NN NN O
infrequent NN NN O
and NN NN O
limited NN NN O
to NN NN O
studies NN NN O
assessing NN NN O
the NN NN O
therapy NN NN O
' NN NN O
s NN NN O
use NN NN O
in NN NN O
the NN NN O
management NN NN O
of NN NN O
patients NN NN O
with NN NN O
ventricular NN NN B-Disease
arrhythmias NN NN I-Disease
. NN NN O
   
METHODS NN NN O
: NN NN O
A NN NN O
study NN NN O
cohort NN NN O
of NN NN O
8 NN NN O
, NN NN O
770 NN NN O
patients NN NN O
age NN NN O
> NN NN O
or NN NN O
= NN NN O
65 NN NN O
years NN NN O
with NN NN O
a NN NN O
new NN NN O
diagnosis NN NN O
of NN NN O
AF NN NN B-Disease
was NN NN O
identified NN NN O
from NN NN O
a NN NN O
provincewide NN NN O
database NN NN O
of NN NN O
Quebec NN NN O
residents NN NN O
with NN NN O
a NN NN O
myocardial NN NN B-Disease
infarction NN NN I-Disease
( NN NN O
MI NN NN B-Disease
) NN NN O
between NN NN O
1991 NN NN O
and NN NN O
1999 NN NN O
. NN NN O
   
Using NN NN O
a NN NN O
nested NN NN O
case NN NN O
- NN NN O
control NN NN O
design NN NN O
, NN NN O
477 NN NN O
cases NN NN O
of NN NN O
bradyarrhythmia NN NN B-Disease
requiring NN NN O
a NN NN O
permanent NN NN O
pacemaker NN NN O
were NN NN O
matched NN NN O
( NN NN O
1 NN NN O
: NN NN O
4 NN NN O
) NN NN O
to NN NN O
1 NN NN O
, NN NN O
908 NN NN O
controls NN NN O
. NN NN O
   
Multivariable NN NN O
logistic NN NN O
regression NN NN O
was NN NN O
used NN NN O
to NN NN O
estimate NN NN O
the NN NN O
odds NN NN O
ratio NN NN O
( NN NN O
OR NN NN O
) NN NN O
of NN NN O
pacemaker NN NN O
insertion NN NN O
associated NN NN O
with NN NN O
amiodarone NN NN O
use NN NN O
, NN NN O
controlling NN NN O
for NN NN O
baseline NN NN O
risk NN NN O
factors NN NN O
and NN NN O
exposure NN NN O
to NN NN O
sotalol NN NN O
, NN NN O
Class NN NN O
I NN NN O
antiarrhythmic NN NN O
agents NN NN O
, NN NN O
beta NN NN O
- NN NN O
blockers NN NN O
, NN NN O
calcium NN NN O
channel NN NN O
blockers NN NN O
, NN NN O
and NN NN O
digoxin NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
amiodarone NN NN O
use NN NN O
was NN NN O
associated NN NN O
with NN NN O
an NN NN O
increased NN NN O
risk NN NN O
of NN NN O
pacemaker NN NN O
insertion NN NN O
( NN NN O
OR NN NN O
: NN NN O
2 NN NN O
. NN NN O
14 NN NN O
, NN NN O
95 NN NN O
% NN NN O
confidence NN NN O
interval NN NN O
[ NN NN O
CI NN NN O
] NN NN O
: NN NN O
1 NN NN O
. NN NN O
30 NN NN O
to NN NN O
3 NN NN O
. NN NN O
54 NN NN O
) NN NN O
. NN NN O
   
This NN NN O
effect NN NN O
was NN NN O
modified NN NN O
by NN NN O
gender NN NN O
, NN NN O
with NN NN O
a NN NN O
greater NN NN O
risk NN NN O
in NN NN O
women NN NN O
versus NN NN O
men NN NN O
( NN NN O
OR NN NN O
: NN NN O
3 NN NN O
. NN NN O
86 NN NN O
, NN NN O
95 NN NN O
% NN NN O
CI NN NN O
: NN NN O
1 NN NN O
. NN NN O
70 NN NN O
to NN NN O
8 NN NN O
. NN NN O
75 NN NN O
vs NN NN O
. NN NN O
OR NN NN O
: NN NN O
1 NN NN O
. NN NN O
52 NN NN O
, NN NN O
95 NN NN O
% NN NN O
CI NN NN O
: NN NN O
0 NN NN O
. NN NN O
80 NN NN O
to NN NN O
2 NN NN O
. NN NN O
89 NN NN O
) NN NN O
. NN NN O
   
Digoxin NN NN O
was NN NN O
the NN NN O
only NN NN O
other NN NN O
medication NN NN O
associated NN NN O
with NN NN O
an NN NN O
increased NN NN O
risk NN NN O
of NN NN O
pacemaker NN NN O
insertion NN NN O
( NN NN O
OR NN NN O
: NN NN O
1 NN NN O
. NN NN O
78 NN NN O
, NN NN O
95 NN NN O
% NN NN O
CI NN NN O
: NN NN O
1 NN NN O
. NN NN O
37 NN NN O
to NN NN O
2 NN NN O
. NN NN O
31 NN NN O
) NN NN O
. NN NN O
   
CONCLUSIONS NN NN O
: NN NN O
This NN NN O
study NN NN O
suggests NN NN O
that NN NN O
the NN NN O
use NN NN O
of NN NN O
amiodarone NN NN O
in NN NN O
elderly NN NN O
patients NN NN O
with NN NN O
AF NN NN B-Disease
and NN NN O
a NN NN O
previous NN NN O
MI NN NN B-Disease
increases NN NN O
the NN NN O
risk NN NN O
of NN NN O
bradyarrhythmia NN NN B-Disease
requiring NN NN O
a NN NN O
permanent NN NN O
pacemaker NN NN O
. NN NN O
   
The NN NN O
finding NN NN O
of NN NN O
an NN NN O
augmented NN NN O
risk NN NN O
of NN NN O
pacemaker NN NN O
insertion NN NN O
in NN NN O
elderly NN NN O
women NN NN O
receiving NN NN O
amiodarone NN NN O
requires NN NN O
further NN NN O
investigation NN NN O
. NN NN O
   
Indomethacin NN NN O
- NN NN O
induced NN NN O
morphologic NN NN O
changes NN NN O
in NN NN O
the NN NN O
rat NN NN O
urinary NN NN O
bladder NN NN O
epithelium NN NN O
. NN NN O
   
OBJECTIVES NN NN O
: NN NN O
To NN NN O
evaluate NN NN O
the NN NN O
morphologic NN NN O
changes NN NN O
in NN NN O
rat NN NN O
urothelium NN NN O
induced NN NN O
by NN NN O
indomethacin NN NN O
. NN NN O
   
Nonsteroidal NN NN O
anti NN NN O
- NN NN O
inflammatory NN NN O
drug NN NN O
- NN NN O
induced NN NN O
cystitis NN NN B-Disease
is NN NN O
a NN NN O
poorly NN NN O
recognized NN NN O
and NN NN O
under NN NN O
- NN NN O
reported NN NN O
condition NN NN O
. NN NN O
   
In NN NN O
addition NN NN O
to NN NN O
tiaprofenic NN NN O
acid NN NN O
, NN NN O
indomethacin NN NN O
has NN NN O
been NN NN O
reported NN NN O
to NN NN O
be NN NN O
associated NN NN O
with NN NN O
this NN NN O
condition NN NN O
. NN NN O
   
METHODS NN NN O
: NN NN O
Three NN NN O
groups NN NN O
were NN NN O
established NN NN O
: NN NN O
a NN NN O
control NN NN O
group NN NN O
( NN NN O
n NN NN O
= NN NN O
10 NN NN O
) NN NN O
, NN NN O
a NN NN O
high NN NN O
- NN NN O
dose NN NN O
group NN NN O
( NN NN O
n NN NN O
= NN NN O
10 NN NN O
) NN NN O
, NN NN O
treated NN NN O
with NN NN O
one NN NN O
intraperitoneal NN NN O
injection NN NN O
of NN NN O
indomethacin NN NN O
20 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
, NN NN O
and NN NN O
a NN NN O
therapeutic NN NN O
dose NN NN O
group NN NN O
( NN NN O
n NN NN O
= NN NN O
10 NN NN O
) NN NN O
in NN NN O
which NN NN O
oral NN NN O
indomethacin NN NN O
was NN NN O
administered NN NN O
3 NN NN O
. NN NN O
25 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
body NN NN O
weight NN NN O
daily NN NN O
for NN NN O
3 NN NN O
weeks NN NN O
. NN NN O
   
The NN NN O
animals NN NN O
were NN NN O
then NN NN O
killed NN NN O
and NN NN O
the NN NN O
bladders NN NN O
removed NN NN O
for NN NN O
light NN NN O
and NN NN O
electron NN NN O
microscopic NN NN O
studies NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
The NN NN O
light NN NN O
microscopic NN NN O
findings NN NN O
showed NN NN O
some NN NN O
focal NN NN O
epithelial NN NN O
degeneration NN NN O
that NN NN O
was NN NN O
more NN NN O
prominent NN NN O
in NN NN O
the NN NN O
high NN NN O
- NN NN O
dose NN NN O
group NN NN O
. NN NN O
   
When NN NN O
compared NN NN O
with NN NN O
the NN NN O
control NN NN O
group NN NN O
, NN NN O
both NN NN O
indomethacin NN NN O
groups NN NN O
revealed NN NN O
statistically NN NN O
increased NN NN O
numbers NN NN O
of NN NN O
mast NN NN O
cells NN NN O
in NN NN O
the NN NN O
mucosa NN NN O
( NN NN O
P NN NN O
< NN NN O
0 NN NN O
. NN NN O
0001 NN NN O
) NN NN O
and NN NN O
penetration NN NN O
of NN NN O
lanthanum NN NN O
nitrate NN NN O
through NN NN O
intercellular NN NN O
areas NN NN O
of NN NN O
the NN NN O
epithelium NN NN O
. NN NN O
   
Furthermore NN NN O
, NN NN O
the NN NN O
difference NN NN O
in NN NN O
mast NN NN O
cell NN NN O
counts NN NN O
between NN NN O
the NN NN O
high NN NN O
and NN NN O
therapeutic NN NN O
dose NN NN O
groups NN NN O
was NN NN O
also NN NN O
statistically NN NN O
significant NN NN O
( NN NN O
P NN NN O
< NN NN O
0 NN NN O
. NN NN O
0001 NN NN O
) NN NN O
. NN NN O
   
CONCLUSIONS NN NN O
: NN NN O
Indomethacin NN NN O
resulted NN NN O
in NN NN O
histopathologic NN NN O
findings NN NN O
typical NN NN O
of NN NN O
interstitial NN NN B-Disease
cystitis NN NN I-Disease
, NN NN O
such NN NN O
as NN NN O
leaky NN NN O
bladder NN NN O
epithelium NN NN O
and NN NN O
mucosal NN NN O
mastocytosis NN NN B-Disease
. NN NN O
   
The NN NN O
true NN NN O
incidence NN NN O
of NN NN O
nonsteroidal NN NN O
anti NN NN O
- NN NN O
inflammatory NN NN O
drug NN NN O
- NN NN O
induced NN NN O
cystitis NN NN B-Disease
in NN NN O
humans NN NN O
must NN NN O
be NN NN O
clarified NN NN O
by NN NN O
prospective NN NN O
clinical NN NN O
trials NN NN O
. NN NN O
   
An NN NN O
open NN NN O
- NN NN O
label NN NN O
phase NN NN O
II NN NN O
study NN NN O
of NN NN O
low NN NN O
- NN NN O
dose NN NN O
thalidomide NN NN O
in NN NN O
androgen NN NN O
- NN NN O
independent NN NN O
prostate NN NN B-Disease
cancer NN NN I-Disease
. NN NN O
   
The NN NN O
antiangiogenic NN NN O
effects NN NN O
of NN NN O
thalidomide NN NN O
have NN NN O
been NN NN O
assessed NN NN O
in NN NN O
clinical NN NN O
trials NN NN O
in NN NN O
patients NN NN O
with NN NN O
various NN NN O
solid NN NN O
and NN NN O
haematological NN NN B-Disease
malignancies NN NN I-Disease
. NN NN O
   
Thalidomide NN NN O
blocks NN NN O
the NN NN O
activity NN NN O
of NN NN O
angiogenic NN NN O
agents NN NN O
including NN NN O
bFGF NN NN O
, NN NN O
VEGF NN NN O
and NN NN O
IL NN NN O
- NN NN O
6 NN NN O
. NN NN O
   
We NN NN O
undertook NN NN O
an NN NN O
open NN NN O
- NN NN O
label NN NN O
study NN NN O
using NN NN O
thalidomide NN NN O
100 NN NN O
mg NN NN O
once NN NN O
daily NN NN O
for NN NN O
up NN NN O
to NN NN O
6 NN NN O
months NN NN O
in NN NN O
20 NN NN O
men NN NN O
with NN NN O
androgen NN NN O
- NN NN O
independent NN NN O
prostate NN NN B-Disease
cancer NN NN I-Disease
. NN NN O
   
The NN NN O
mean NN NN O
time NN NN O
of NN NN O
study NN NN O
was NN NN O
109 NN NN O
days NN NN O
( NN NN O
median NN NN O
107 NN NN O
, NN NN O
range NN NN O
4 NN NN O
- NN NN O
184 NN NN O
days NN NN O
) NN NN O
. NN NN O
   
Patients NN NN O
underwent NN NN O
regular NN NN O
measurement NN NN O
of NN NN O
prostate NN NN O
- NN NN O
specific NN NN O
antigen NN NN O
( NN NN O
PSA NN NN O
) NN NN O
, NN NN O
urea NN NN O
and NN NN O
electrolytes NN NN O
, NN NN O
serum NN NN O
bFGF NN NN O
and NN NN O
VEGF NN NN O
. NN NN O
   
Three NN NN O
men NN NN O
( NN NN O
15 NN NN O
% NN NN O
) NN NN O
showed NN NN O
a NN NN O
decline NN NN O
in NN NN O
serum NN NN O
PSA NN NN O
of NN NN O
at NN NN O
least NN NN O
50 NN NN O
% NN NN O
, NN NN O
sustained NN NN O
throughout NN NN O
treatment NN NN O
. NN NN O
   
Of NN NN O
16 NN NN O
men NN NN O
treated NN NN O
for NN NN O
at NN NN O
least NN NN O
2 NN NN O
months NN NN O
, NN NN O
six NN NN O
( NN NN O
37 NN NN O
. NN NN O
5 NN NN O
% NN NN O
) NN NN O
showed NN NN O
a NN NN O
fall NN NN O
in NN NN O
absolute NN NN O
PSA NN NN O
by NN NN O
a NN NN O
median NN NN O
of NN NN O
48 NN NN O
% NN NN O
. NN NN O
   
Increasing NN NN O
levels NN NN O
of NN NN O
serum NN NN O
bFGF NN NN O
and NN NN O
VEGF NN NN O
were NN NN O
associated NN NN O
with NN NN O
progressive NN NN O
disease NN NN O
; NN NN O
five NN NN O
of NN NN O
six NN NN O
men NN NN O
who NN NN O
demonstrated NN NN O
a NN NN O
fall NN NN O
in NN NN O
PSA NN NN O
also NN NN O
showed NN NN O
a NN NN O
decline NN NN O
in NN NN O
bFGF NN NN O
and NN NN O
VEGF NN NN O
levels NN NN O
, NN NN O
and NN NN O
three NN NN O
of NN NN O
four NN NN O
men NN NN O
with NN NN O
a NN NN O
rising NN NN O
PSA NN NN O
showed NN NN O
an NN NN O
increase NN NN O
in NN NN O
both NN NN O
growth NN NN O
factors NN NN O
. NN NN O
   
Adverse NN NN O
effects NN NN O
included NN NN O
constipation NN NN B-Disease
, NN NN O
morning NN NN O
drowsiness NN NN B-Disease
, NN NN O
dizziness NN NN B-Disease
and NN NN O
rash NN NN B-Disease
, NN NN O
and NN NN O
resulted NN NN O
in NN NN O
withdrawal NN NN O
from NN NN O
the NN NN O
study NN NN O
by NN NN O
three NN NN O
men NN NN O
. NN NN O
   
Evidence NN NN O
of NN NN O
peripheral NN NN B-Disease
sensory NN NN I-Disease
neuropathy NN NN I-Disease
was NN NN O
found NN NN O
in NN NN O
nine NN NN O
of NN NN O
13 NN NN O
men NN NN O
before NN NN O
treatment NN NN O
. NN NN O
   
In NN NN O
the NN NN O
seven NN NN O
men NN NN O
who NN NN O
completed NN NN O
six NN NN O
months NN NN O
on NN NN O
thalidomide NN NN O
, NN NN O
subclinical NN NN O
evidence NN NN O
of NN NN O
peripheral NN NN B-Disease
neuropathy NN NN I-Disease
was NN NN O
found NN NN O
in NN NN O
four NN NN O
before NN NN O
treatment NN NN O
, NN NN O
but NN NN O
in NN NN O
all NN NN O
seven NN NN O
at NN NN O
repeat NN NN O
testing NN NN O
. NN NN O
   
The NN NN O
findings NN NN O
indicate NN NN O
that NN NN O
thalidomide NN NN O
may NN NN O
be NN NN O
an NN NN O
option NN NN O
for NN NN O
patients NN NN O
who NN NN O
have NN NN O
failed NN NN O
other NN NN O
forms NN NN O
of NN NN O
therapy NN NN O
, NN NN O
provided NN NN O
close NN NN O
follow NN NN O
- NN NN O
up NN NN O
is NN NN O
maintained NN NN O
for NN NN O
development NN NN O
of NN NN O
peripheral NN NN B-Disease
neuropathy NN NN I-Disease
. NN NN O
   
Central NN NN B-Disease
nervous NN NN I-Disease
system NN NN I-Disease
toxicity NN NN I-Disease
following NN NN O
the NN NN O
administration NN NN O
of NN NN O
levobupivacaine NN NN O
for NN NN O
lumbar NN NN O
plexus NN NN O
block NN NN O
: NN NN O
A NN NN O
report NN NN O
of NN NN O
two NN NN O
cases NN NN O
. NN NN O
   
BACKGROUND NN NN O
AND NN NN O
OBJECTIVES NN NN O
: NN NN O
Central NN NN B-Disease
nervous NN NN I-Disease
system NN NN I-Disease
and NN NN I-Disease
cardiac NN NN I-Disease
toxicity NN NN I-Disease
following NN NN O
the NN NN O
administration NN NN O
of NN NN O
local NN NN O
anesthetics NN NN O
is NN NN O
a NN NN O
recognized NN NN O
complication NN NN O
of NN NN O
regional NN NN O
anesthesia NN NN O
. NN NN O
   
Levobupivacaine NN NN O
, NN NN O
the NN NN O
pure NN NN O
S NN NN O
( NN NN O
- NN NN O
) NN NN O
enantiomer NN NN O
of NN NN O
bupivacaine NN NN O
, NN NN O
was NN NN O
developed NN NN O
to NN NN O
improve NN NN O
the NN NN O
cardiac NN NN O
safety NN NN O
profile NN NN O
of NN NN O
bupivacaine NN NN O
. NN NN O
   
We NN NN O
describe NN NN O
2 NN NN O
cases NN NN O
of NN NN O
grand NN NN B-Disease
mal NN NN I-Disease
seizures NN NN I-Disease
following NN NN O
accidental NN NN O
intravascular NN NN O
injection NN NN O
of NN NN O
levobupivacaine NN NN O
. NN NN O
   
CASE NN NN O
REPORT NN NN O
: NN NN O
Two NN NN O
patients NN NN O
presenting NN NN O
for NN NN O
elective NN NN O
orthopedic NN NN O
surgery NN NN O
of NN NN O
the NN NN O
lower NN NN O
limb NN NN O
underwent NN NN O
blockade NN NN O
of NN NN O
the NN NN O
lumbar NN NN O
plexus NN NN O
via NN NN O
the NN NN O
posterior NN NN O
approach NN NN O
. NN NN O
   
Immediately NN NN O
after NN NN O
the NN NN O
administration NN NN O
of NN NN O
levobupivacaine NN NN O
0 NN NN O
. NN NN O
5 NN NN O
% NN NN O
with NN NN O
epinephrine NN NN O
2 NN NN O
. NN NN O
5 NN NN O
microgram NN NN O
/ NN NN O
mL NN NN O
, NN NN O
the NN NN O
patients NN NN O
developed NN NN O
grand NN NN B-Disease
mal NN NN I-Disease
seizures NN NN I-Disease
, NN NN O
despite NN NN O
negative NN NN O
aspiration NN NN O
for NN NN O
blood NN NN O
and NN NN O
no NN NN O
clinical NN NN O
signs NN NN O
of NN NN O
intravenous NN NN O
epinephrine NN NN O
administration NN NN O
. NN NN O
   
The NN NN O
seizures NN NN B-Disease
were NN NN O
successfully NN NN O
treated NN NN O
with NN NN O
sodium NN NN O
thiopental NN NN O
in NN NN O
addition NN NN O
to NN NN O
succinylcholine NN NN O
in NN NN O
1 NN NN O
patient NN NN O
. NN NN O
   
Neither NN NN O
patient NN NN O
developed NN NN O
signs NN NN O
of NN NN O
cardiovascular NN NN B-Disease
toxicity NN NN I-Disease
. NN NN O
   
Both NN NN O
patients NN NN O
were NN NN O
treated NN NN O
preoperatively NN NN O
with NN NN O
beta NN NN O
- NN NN O
adrenergic NN NN O
antagonist NN NN O
medications NN NN O
, NN NN O
which NN NN O
may NN NN O
have NN NN O
masked NN NN O
the NN NN O
cardiovascular NN NN O
signs NN NN O
of NN NN O
the NN NN O
unintentional NN NN O
intravascular NN NN O
administration NN NN O
of NN NN O
levobupivacaine NN NN O
with NN NN O
epinephrine NN NN O
. NN NN O
   
CONCLUSIONS NN NN O
: NN NN O
Although NN NN O
levobupivacaine NN NN O
may NN NN O
have NN NN O
a NN NN O
safer NN NN O
cardiac NN NN B-Disease
toxicity NN NN I-Disease
profile NN NN O
than NN NN O
racemic NN NN O
bupivacaine NN NN O
, NN NN O
if NN NN O
adequate NN NN O
amounts NN NN O
of NN NN O
levobupivacaine NN NN O
reach NN NN O
the NN NN O
circulation NN NN O
, NN NN O
it NN NN O
will NN NN O
result NN NN O
in NN NN O
convulsions NN NN B-Disease
. NN NN O
   
Plasma NN NN O
concentrations NN NN O
sufficient NN NN O
to NN NN O
result NN NN O
in NN NN O
central NN NN B-Disease
nervous NN NN I-Disease
system NN NN I-Disease
toxicity NN NN I-Disease
did NN NN O
not NN NN O
produce NN NN O
manifestations NN NN O
of NN NN O
cardiac NN NN B-Disease
toxicity NN NN I-Disease
in NN NN O
these NN NN O
2 NN NN O
patients NN NN O
. NN NN O
   
Amiodarone NN NN O
- NN NN O
induced NN NN O
torsade NN NN B-Disease
de NN NN I-Disease
pointes NN NN I-Disease
during NN NN O
bladder NN NN O
irrigation NN NN O
: NN NN O
an NN NN O
unusual NN NN O
presentation NN NN O
- NN NN O
- NN NN O
a NN NN O
case NN NN O
report NN NN O
. NN NN O
   
The NN NN O
authors NN NN O
present NN NN O
a NN NN O
case NN NN O
of NN NN O
early NN NN O
( NN NN O
within NN NN O
4 NN NN O
days NN NN O
) NN NN O
development NN NN O
of NN NN O
torsade NN NN B-Disease
de NN NN I-Disease
pointes NN NN I-Disease
( NN NN O
TdP NN NN B-Disease
) NN NN O
associated NN NN O
with NN NN O
oral NN NN O
amiodarone NN NN O
therapy NN NN O
. NN NN O
   
Consistent NN NN O
with NN NN O
other NN NN O
reports NN NN O
this NN NN O
case NN NN O
of NN NN O
TdP NN NN B-Disease
occurred NN NN O
in NN NN O
the NN NN O
context NN NN O
of NN NN O
multiple NN NN O
exacerbating NN NN O
factors NN NN O
including NN NN O
hypokalemia NN NN B-Disease
and NN NN O
digoxin NN NN O
excess NN NN O
. NN NN O
   
Transient NN NN O
prolongation NN NN O
of NN NN O
the NN NN O
QT NN NN O
during NN NN O
bladder NN NN O
irrigation NN NN O
prompted NN NN O
the NN NN O
episode NN NN O
of NN NN O
TdP NN NN B-Disease
. NN NN O
   
It NN NN O
is NN NN O
well NN NN O
known NN NN O
that NN NN O
bradycardia NN NN B-Disease
exacerbates NN NN O
acquired NN NN O
TdP NN NN B-Disease
. NN NN O
   
The NN NN O
authors NN NN O
speculate NN NN O
that NN NN O
the NN NN O
increased NN NN O
vagal NN NN O
tone NN NN O
during NN NN O
bladder NN NN O
irrigation NN NN O
, NN NN O
a NN NN O
vagal NN NN O
maneuver NN NN O
, NN NN O
in NN NN O
the NN NN O
context NN NN O
of NN NN O
amiodarone NN NN O
therapy NN NN O
resulted NN NN O
in NN NN O
amiodarone NN NN O
- NN NN O
induced NN NN O
proarrhythmia NN NN B-Disease
. NN NN O
   
In NN NN O
the NN NN O
absence NN NN O
of NN NN O
amiodarone NN NN O
therapy NN NN O
, NN NN O
a NN NN O
second NN NN O
bladder NN NN O
irrigation NN NN O
did NN NN O
not NN NN O
induce NN NN O
TdP NN NN B-Disease
despite NN NN O
hypokalemia NN NN B-Disease
and NN NN O
hypomagnesemia NN NN B-Disease
. NN NN O
   
Anaesthetic NN NN O
complications NN NN O
associated NN NN O
with NN NN O
myotonia NN NN B-Disease
congenita NN NN I-Disease
: NN NN O
case NN NN O
study NN NN O
and NN NN O
comparison NN NN O
with NN NN O
other NN NN O
myotonic NN NN B-Disease
disorders NN NN I-Disease
. NN NN O
   
Myotonia NN NN B-Disease
congenita NN NN I-Disease
( NN NN O
MC NN NN B-Disease
) NN NN O
is NN NN O
caused NN NN O
by NN NN O
a NN NN O
defect NN NN O
in NN NN O
the NN NN O
skeletal NN NN O
muscle NN NN O
chloride NN NN O
channel NN NN O
function NN NN O
, NN NN O
which NN NN O
may NN NN O
cause NN NN O
sustained NN NN B-Disease
membrane NN NN I-Disease
depolarisation NN NN I-Disease
. NN NN O
   
We NN NN O
describe NN NN O
a NN NN O
previously NN NN O
healthy NN NN O
32 NN NN O
- NN NN O
year NN NN O
- NN NN O
old NN NN O
woman NN NN O
who NN NN O
developed NN NN O
a NN NN O
life NN NN O
- NN NN O
threatening NN NN O
muscle NN NN B-Disease
spasm NN NN I-Disease
and NN NN O
secondary NN NN O
ventilation NN NN O
difficulties NN NN O
following NN NN O
a NN NN O
preoperative NN NN O
injection NN NN O
of NN NN O
suxamethonium NN NN O
. NN NN O
   
The NN NN O
muscle NN NN B-Disease
spasms NN NN I-Disease
disappeared NN NN O
spontaneously NN NN O
and NN NN O
the NN NN O
surgery NN NN O
proceeded NN NN O
without NN NN O
further NN NN O
problems NN NN O
. NN NN O
   
When NN NN O
subsequently NN NN O
questioned NN NN O
, NN NN O
she NN NN O
reported NN NN O
minor NN NN O
symptoms NN NN O
suggesting NN NN O
a NN NN O
myotonic NN NN B-Disease
condition NN NN I-Disease
. NN NN O
   
Myotonia NN NN B-Disease
was NN NN O
found NN NN O
on NN NN O
clinical NN NN O
examination NN NN O
and NN NN O
EMG NN NN O
. NN NN O
   
The NN NN O
diagnosis NN NN O
MC NN NN B-Disease
was NN NN O
confirmed NN NN O
genetically NN NN O
. NN NN O
   
Neither NN NN O
the NN NN O
patient NN NN O
nor NN NN O
the NN NN O
anaesthetist NN NN O
were NN NN O
aware NN NN O
of NN NN O
the NN NN O
diagnosis NN NN O
before NN NN O
this NN NN O
potentially NN NN O
lethal NN NN O
complication NN NN O
occurred NN NN O
. NN NN O
   
We NN NN O
give NN NN O
a NN NN O
brief NN NN O
overview NN NN O
of NN NN O
ion NN NN B-Disease
channel NN NN I-Disease
disorders NN NN I-Disease
including NN NN O
malignant NN NN B-Disease
hyperthermia NN NN I-Disease
and NN NN O
their NN NN O
anaesthetic NN NN O
considerations NN NN O
. NN NN O
   
Respiratory NN NN O
pattern NN NN O
in NN NN O
a NN NN O
rat NN NN O
model NN NN O
of NN NN O
epilepsy NN NN B-Disease
. NN NN O
   
PURPOSE NN NN O
: NN NN O
Apnea NN NN B-Disease
is NN NN O
known NN NN O
to NN NN O
occur NN NN O
during NN NN O
seizures NN NN B-Disease
, NN NN O
but NN NN O
systematic NN NN O
studies NN NN O
of NN NN O
ictal NN NN O
respiratory NN NN O
changes NN NN O
in NN NN O
adults NN NN O
are NN NN O
few NN NN O
. NN NN O
   
Data NN NN O
regarding NN NN O
respiratory NN NN O
pattern NN NN O
defects NN NN O
during NN NN O
interictal NN NN O
periods NN NN O
also NN NN O
are NN NN O
scarce NN NN O
. NN NN O
   
Here NN NN O
we NN NN O
sought NN NN O
to NN NN O
generate NN NN O
information NN NN O
with NN NN O
regard NN NN O
to NN NN O
the NN NN O
interictal NN NN O
period NN NN O
in NN NN O
animals NN NN O
with NN NN O
pilocarpine NN NN O
- NN NN O
induced NN NN O
epilepsy NN NN B-Disease
. NN NN O
   
METHODS NN NN O
: NN NN O
Twelve NN NN O
rats NN NN O
( NN NN O
six NN NN O
chronically NN NN O
epileptic NN NN B-Disease
animals NN NN O
and NN NN O
six NN NN O
controls NN NN O
) NN NN O
were NN NN O
anesthetized NN NN O
, NN NN O
given NN NN O
tracheotomies NN NN O
, NN NN O
and NN NN O
subjected NN NN O
to NN NN O
hyperventilation NN NN B-Disease
or NN NN O
hypoventilation NN NN O
conditions NN NN O
. NN NN O
   
Breathing NN NN O
movements NN NN O
caused NN NN O
changes NN NN O
in NN NN O
thoracic NN NN O
volume NN NN O
and NN NN O
forced NN NN O
air NN NN O
to NN NN O
flow NN NN O
tidally NN NN O
through NN NN O
a NN NN O
pneumotachograph NN NN O
. NN NN O
   
This NN NN O
flow NN NN O
was NN NN O
measured NN NN O
by NN NN O
using NN NN O
a NN NN O
differential NN NN O
pressure NN NN O
transducer NN NN O
, NN NN O
passed NN NN O
through NN NN O
a NN NN O
polygraph NN NN O
, NN NN O
and NN NN O
from NN NN O
this NN NN O
to NN NN O
a NN NN O
computer NN NN O
with NN NN O
custom NN NN O
software NN NN O
that NN NN O
derived NN NN O
ventilation NN NN O
( NN NN O
VE NN NN O
) NN NN O
, NN NN O
tidal NN NN O
volume NN NN O
( NN NN O
VT NN NN O
) NN NN O
, NN NN O
inspiratory NN NN O
time NN NN O
( NN NN O
TI NN NN O
) NN NN O
, NN NN O
expiratory NN NN O
time NN NN O
( NN NN O
TE NN NN O
) NN NN O
, NN NN O
breathing NN NN O
frequency NN NN O
( NN NN O
f NN NN O
) NN NN O
, NN NN O
and NN NN O
mean NN NN O
inspiratory NN NN O
flow NN NN O
( NN NN O
VT NN NN O
/ NN NN O
TI NN NN O
) NN NN O
on NN NN O
a NN NN O
breath NN NN O
- NN NN O
by NN NN O
- NN NN O
breath NN NN O
basis NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
The NN NN O
hyperventilation NN NN B-Disease
maneuver NN NN O
caused NN NN O
a NN NN O
decrease NN NN O
in NN NN O
spontaneous NN NN O
ventilation NN NN O
in NN NN O
pilocarpine NN NN O
- NN NN O
treated NN NN O
and NN NN O
control NN NN O
rats NN NN O
. NN NN O
   
Although NN NN O
VE NN NN O
had NN NN O
a NN NN O
similar NN NN O
decrease NN NN O
in NN NN O
both NN NN O
groups NN NN O
, NN NN O
in NN NN O
the NN NN O
epileptic NN NN B-Disease
group NN NN O
, NN NN O
the NN NN O
decrease NN NN O
in NN NN O
VE NN NN O
was NN NN O
due NN NN O
to NN NN O
a NN NN O
significant NN NN O
( NN NN O
p NN NN O
< NN NN O
0 NN NN O
. NN NN O
05 NN NN O
) NN NN O
increase NN NN O
in NN NN O
TE NN NN O
peak NN NN O
in NN NN O
relation NN NN O
to NN NN O
that NN NN O
of NN NN O
the NN NN O
control NN NN O
animals NN NN O
. NN NN O
   
The NN NN O
hypoventilation NN NN O
maneuver NN NN O
led NN NN O
to NN NN O
an NN NN O
increase NN NN O
in NN NN O
the NN NN O
arterial NN NN O
Paco2 NN NN O
, NN NN O
followed NN NN O
by NN NN O
an NN NN O
increase NN NN O
in NN NN O
VE NN NN O
. NN NN O
   
In NN NN O
the NN NN O
epileptic NN NN B-Disease
group NN NN O
, NN NN O
the NN NN O
increase NN NN O
in NN NN O
VE NN NN O
was NN NN O
mediated NN NN O
by NN NN O
a NN NN O
significant NN NN O
( NN NN O
p NN NN O
< NN NN O
0 NN NN O
. NN NN O
05 NN NN O
) NN NN O
decrease NN NN O
in NN NN O
TE NN NN O
peak NN NN O
compared NN NN O
with NN NN O
the NN NN O
control NN NN O
group NN NN O
. NN NN O
   
Systemic NN NN O
application NN NN O
of NN NN O
KCN NN NN O
, NN NN O
to NN NN O
evaluate NN NN O
the NN NN O
effects NN NN O
of NN NN O
peripheral NN NN O
chemoreception NN NN O
activation NN NN O
on NN NN O
ventilation NN NN O
, NN NN O
led NN NN O
to NN NN O
a NN NN O
similar NN NN O
increase NN NN O
in NN NN O
VE NN NN O
for NN NN O
both NN NN O
groups NN NN O
. NN NN O
   
CONCLUSIONS NN NN O
: NN NN O
The NN NN O
data NN NN O
indicate NN NN O
that NN NN O
pilocarpine NN NN O
- NN NN O
treated NN NN O
animals NN NN O
have NN NN O
an NN NN O
altered NN NN O
ability NN NN O
to NN NN O
react NN NN O
to NN NN O
( NN NN O
or NN NN O
compensate NN NN O
for NN NN O
) NN NN O
blood NN NN O
gas NN NN O
changes NN NN O
with NN NN O
changes NN NN O
in NN NN O
ventilation NN NN O
and NN NN O
suggest NN NN O
that NN NN O
it NN NN O
is NN NN O
centrally NN NN O
determined NN NN O
. NN NN O
   
We NN NN O
speculate NN NN O
on NN NN O
the NN NN O
possible NN NN O
relation NN NN O
of NN NN O
the NN NN O
current NN NN O
findings NN NN O
on NN NN O
treating NN NN O
different NN NN O
epilepsy NN NN B-Disease
- NN NN O
associated NN NN O
conditions NN NN O
. NN NN O
   
Fatal NN NN O
myeloencephalopathy NN NN B-Disease
due NN NN O
to NN NN O
intrathecal NN NN O
vincristine NN NN O
administration NN NN O
. NN NN O
   
Vincristine NN NN O
was NN NN O
accidentally NN NN O
given NN NN O
intrathecally NN NN O
to NN NN O
a NN NN O
child NN NN O
with NN NN O
leukaemia NN NN B-Disease
, NN NN O
producing NN NN O
sensory NN NN B-Disease
and NN NN I-Disease
motor NN NN I-Disease
dysfunction NN NN I-Disease
followed NN NN O
by NN NN O
encephalopathy NN NN B-Disease
and NN NN O
death NN NN O
. NN NN O
   
Separate NN NN O
times NN NN O
for NN NN O
administering NN NN O
vincristine NN NN O
and NN NN O
intrathecal NN NN O
therapy NN NN O
is NN NN O
recommended NN NN O
. NN NN O
   
Progesterone NN NN O
potentiation NN NN O
of NN NN O
bupivacaine NN NN O
arrhythmogenicity NN NN O
in NN NN O
pentobarbital NN NN O
- NN NN O
anesthetized NN NN O
rats NN NN O
and NN NN O
beating NN NN O
rat NN NN O
heart NN NN O
cell NN NN O
cultures NN NN O
. NN NN O
   
The NN NN O
effects NN NN O
of NN NN O
progesterone NN NN O
treatment NN NN O
on NN NN O
bupivacaine NN NN O
arrhythmogenicity NN NN O
in NN NN O
beating NN NN O
rat NN NN O
heart NN NN O
myocyte NN NN O
cultures NN NN O
and NN NN O
on NN NN O
anesthetized NN NN O
rats NN NN O
were NN NN O
determined NN NN O
. NN NN O
   
After NN NN O
determining NN NN O
the NN NN O
bupivacaine NN NN O
AD50 NN NN O
( NN NN O
the NN NN O
concentration NN NN O
of NN NN O
bupivacaine NN NN O
that NN NN O
caused NN NN O
50 NN NN O
% NN NN O
of NN NN O
all NN NN O
beating NN NN O
rat NN NN O
heart NN NN O
myocyte NN NN O
cultures NN NN O
to NN NN O
become NN NN O
arrhythmic NN NN B-Disease
) NN NN O
, NN NN O
we NN NN O
determined NN NN O
the NN NN O
effect NN NN O
of NN NN O
1 NN NN O
- NN NN O
hour NN NN O
progesterone NN NN O
HCl NN NN O
exposure NN NN O
on NN NN O
myocyte NN NN O
contractile NN NN O
rhythm NN NN O
. NN NN O
   
Each NN NN O
concentration NN NN O
of NN NN O
progesterone NN NN O
( NN NN O
6 NN NN O
. NN NN O
25 NN NN O
, NN NN O
12 NN NN O
. NN NN O
5 NN NN O
, NN NN O
25 NN NN O
, NN NN O
and NN NN O
50 NN NN O
micrograms NN NN O
/ NN NN O
ml NN NN O
) NN NN O
caused NN NN O
a NN NN O
significant NN NN O
and NN NN O
concentration NN NN O
- NN NN O
dependent NN NN O
reduction NN NN O
in NN NN O
the NN NN O
AD50 NN NN O
for NN NN O
bupivacaine NN NN O
. NN NN O
   
Estradiol NN NN O
treatment NN NN O
also NN NN O
increased NN NN O
the NN NN O
arrhythmogenicity NN NN O
of NN NN O
bupivacaine NN NN O
in NN NN O
myocyte NN NN O
cultures NN NN O
, NN NN O
but NN NN O
was NN NN O
only NN NN O
one NN NN O
fourth NN NN O
as NN NN O
potent NN NN O
as NN NN O
progesterone NN NN O
. NN NN O
   
Neither NN NN O
progesterone NN NN O
nor NN NN O
estradiol NN NN O
effects NN NN O
on NN NN O
bupivacaine NN NN O
arrhythmogenicity NN NN O
were NN NN O
potentiated NN NN O
by NN NN O
epinephrine NN NN O
. NN NN O
   
Chronic NN NN O
progesterone NN NN O
pretreatment NN NN O
( NN NN O
5 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
/ NN NN O
day NN NN O
for NN NN O
21 NN NN O
days NN NN O
) NN NN O
caused NN NN O
a NN NN O
significant NN NN O
increase NN NN O
in NN NN O
bupivacaine NN NN O
arrhythmogenicity NN NN O
in NN NN O
intact NN NN O
pentobarbital NN NN O
- NN NN O
anesthetized NN NN O
rats NN NN O
. NN NN O
   
There NN NN O
was NN NN O
a NN NN O
significant NN NN O
decrease NN NN O
in NN NN O
the NN NN O
time NN NN O
to NN NN O
onset NN NN O
of NN NN O
arrhythmia NN NN B-Disease
as NN NN O
compared NN NN O
with NN NN O
control NN NN O
nonprogesterone NN NN O
- NN NN O
treated NN NN O
rats NN NN O
( NN NN O
6 NN NN O
. NN NN O
2 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
1 NN NN O
. NN NN O
3 NN NN O
vs NN NN O
. NN NN O
30 NN NN O
. NN NN O
8 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
2 NN NN O
. NN NN O
5 NN NN O
min NN NN O
, NN NN O
mean NN NN O
+ NN NN O
/ NN NN O
- NN NN O
SE NN NN O
) NN NN O
. NN NN O
   
The NN NN O
results NN NN O
of NN NN O
this NN NN O
study NN NN O
indicate NN NN O
that NN NN O
progesterone NN NN O
can NN NN O
potentiate NN NN O
bupivacaine NN NN O
arrhythmogenicity NN NN O
both NN NN O
in NN NN O
vivo NN NN O
and NN NN O
in NN NN O
vitro NN NN O
. NN NN O
   
Potentiation NN NN O
of NN NN O
bupivacaine NN NN O
arrhythmia NN NN B-Disease
in NN NN O
myocyte NN NN O
cultures NN NN O
suggests NN NN O
that NN NN O
this NN NN O
effect NN NN O
is NN NN O
at NN NN O
least NN NN O
partly NN NN O
mediated NN NN O
at NN NN O
the NN NN O
myocyte NN NN O
level NN NN O
. NN NN O
   
Increased NN NN O
serum NN NN O
soluble NN NN O
Fas NN NN O
in NN NN O
patients NN NN O
with NN NN O
acute NN NN B-Disease
liver NN NN I-Disease
failure NN NN I-Disease
due NN NN O
to NN NN O
paracetamol NN NN O
overdose NN NN B-Disease
. NN NN O
   
BACKGROUND NN NN O
/ NN NN O
AIMS NN NN O
: NN NN O
Experimental NN NN O
studies NN NN O
have NN NN O
suggested NN NN O
that NN NN O
apoptosis NN NN O
via NN NN O
the NN NN O
Fas NN NN O
/ NN NN O
Fas NN NN O
Ligand NN NN O
signaling NN NN O
system NN NN O
may NN NN O
play NN NN O
an NN NN O
important NN NN O
role NN NN O
in NN NN O
the NN NN O
development NN NN O
of NN NN O
acute NN NN B-Disease
liver NN NN I-Disease
failure NN NN I-Disease
. NN NN O
   
The NN NN O
aim NN NN O
of NN NN O
the NN NN O
study NN NN O
was NN NN O
to NN NN O
investigate NN NN O
the NN NN O
soluble NN NN O
form NN NN O
of NN NN O
Fas NN NN O
in NN NN O
patients NN NN O
with NN NN O
acute NN NN B-Disease
liver NN NN I-Disease
failure NN NN I-Disease
. NN NN O
   
METHODOLOGY NN NN O
: NN NN O
Serum NN NN O
levels NN NN O
of NN NN O
sFas NN NN O
( NN NN O
soluble NN NN O
Fas NN NN O
) NN NN O
were NN NN O
measured NN NN O
by NN NN O
ELISA NN NN O
in NN NN O
24 NN NN O
patients NN NN O
with NN NN O
acute NN NN B-Disease
liver NN NN I-Disease
failure NN NN I-Disease
and NN NN O
10 NN NN O
normal NN NN O
control NN NN O
subjects NN NN O
. NN NN O
   
Serum NN NN O
levels NN NN O
of NN NN O
tumor NN NN B-Disease
necrosis NN NN B-Disease
factor NN NN O
- NN NN O
alpha NN NN O
and NN NN O
interferon NN NN O
- NN NN O
gamma NN NN O
were NN NN O
also NN NN O
determined NN NN O
by NN NN O
ELISA NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
Serum NN NN O
sFas NN NN O
was NN NN O
significantly NN NN O
increased NN NN O
in NN NN O
patients NN NN O
with NN NN O
acute NN NN B-Disease
liver NN NN I-Disease
failure NN NN I-Disease
( NN NN O
median NN NN O
, NN NN O
26 NN NN O
. NN NN O
8 NN NN O
U NN NN O
/ NN NN O
mL NN NN O
; NN NN O
range NN NN O
, NN NN O
6 NN NN O
. NN NN O
9 NN NN O
- NN NN O
52 NN NN O
. NN NN O
7 NN NN O
U NN NN O
/ NN NN O
mL NN NN O
) NN NN O
compared NN NN O
to NN NN O
the NN NN O
normal NN NN O
controls NN NN O
( NN NN O
median NN NN O
, NN NN O
8 NN NN O
. NN NN O
6 NN NN O
U NN NN O
/ NN NN O
mL NN NN O
; NN NN O
range NN NN O
, NN NN O
6 NN NN O
. NN NN O
5 NN NN O
- NN NN O
12 NN NN O
. NN NN O
0 NN NN O
U NN NN O
/ NN NN O
mL NN NN O
, NN NN O
P NN NN O
< NN NN O
0 NN NN O
. NN NN O
0001 NN NN O
) NN NN O
. NN NN O
   
Levels NN NN O
were NN NN O
significantly NN NN O
greater NN NN O
in NN NN O
patients NN NN O
with NN NN O
acute NN NN B-Disease
liver NN NN I-Disease
failure NN NN I-Disease
due NN NN O
to NN NN O
paracetamol NN NN O
overdose NN NN B-Disease
( NN NN O
median NN NN O
, NN NN O
28 NN NN O
. NN NN O
7 NN NN O
U NN NN O
/ NN NN O
mL NN NN O
; NN NN O
range NN NN O
, NN NN O
12 NN NN O
. NN NN O
8 NN NN O
- NN NN O
52 NN NN O
. NN NN O
7 NN NN O
U NN NN O
/ NN NN O
mL NN NN O
, NN NN O
n NN NN O
= NN NN O
17 NN NN O
) NN NN O
than NN NN O
those NN NN O
due NN NN O
to NN NN O
non NN NN O
- NN NN O
A NN NN O
to NN NN O
E NN NN O
hepatitis NN NN B-Disease
( NN NN O
median NN NN O
, NN NN O
12 NN NN O
. NN NN O
5 NN NN O
U NN NN O
/ NN NN O
mL NN NN O
; NN NN O
range NN NN O
, NN NN O
6 NN NN O
. NN NN O
9 NN NN O
- NN NN O
46 NN NN O
. NN NN O
0 NN NN O
U NN NN O
/ NN NN O
mL NN NN O
, NN NN O
n NN NN O
= NN NN O
7 NN NN O
, NN NN O
P NN NN O
< NN NN O
0 NN NN O
. NN NN O
01 NN NN O
) NN NN O
. NN NN O
   
There NN NN O
was NN NN O
no NN NN O
relationship NN NN O
of NN NN O
sFas NN NN O
to NN NN O
eventual NN NN O
outcome NN NN O
in NN NN O
the NN NN O
patients NN NN O
. NN NN O
   
A NN NN O
significant NN NN O
correlation NN NN O
was NN NN O
observed NN NN O
between NN NN O
serum NN NN O
sFas NN NN O
levels NN NN O
and NN NN O
aspartate NN NN O
aminotransferase NN NN O
( NN NN O
r NN NN O
= NN NN O
0 NN NN O
. NN NN O
613 NN NN O
, NN NN O
P NN NN O
< NN NN O
0 NN NN O
. NN NN O
01 NN NN O
) NN NN O
. NN NN O
   
CONCLUSIONS NN NN O
: NN NN O
The NN NN O
increased NN NN O
concentration NN NN O
of NN NN O
sFas NN NN O
in NN NN O
serum NN NN O
of NN NN O
patients NN NN O
with NN NN O
acute NN NN B-Disease
liver NN NN I-Disease
failure NN NN I-Disease
may NN NN O
reflect NN NN O
activation NN NN O
of NN NN O
Fas NN NN O
- NN NN O
mediated NN NN O
apoptosis NN NN O
in NN NN O
the NN NN O
liver NN NN O
and NN NN O
this NN NN O
together NN NN O
with NN NN O
increased NN NN O
tumor NN NN B-Disease
necrosis NN NN B-Disease
factor NN NN O
- NN NN O
alpha NN NN O
may NN NN O
be NN NN O
an NN NN O
important NN NN O
factor NN NN O
in NN NN O
liver NN NN O
cell NN NN O
loss NN NN O
. NN NN O
   
Bilateral NN NN O
subthalamic NN NN O
nucleus NN NN O
stimulation NN NN O
for NN NN O
Parkinson NN NN B-Disease
' NN NN I-Disease
s NN NN I-Disease
disease NN NN I-Disease
. NN NN O
   
High NN NN O
frequency NN NN O
stimulation NN NN O
of NN NN O
the NN NN O
subthalamic NN NN O
nucleus NN NN O
( NN NN O
STN NN NN O
) NN NN O
is NN NN O
known NN NN O
to NN NN O
ameliorate NN NN O
the NN NN O
signs NN NN O
and NN NN O
symptoms NN NN O
of NN NN O
advanced NN NN O
Parkinson NN NN B-Disease
' NN NN I-Disease
s NN NN I-Disease
disease NN NN I-Disease
. NN NN O
   
AIM NN NN O
: NN NN O
We NN NN O
studied NN NN O
the NN NN O
effect NN NN O
of NN NN O
high NN NN O
frequency NN NN O
STN NN NN O
stimulation NN NN O
in NN NN O
23 NN NN O
patients NN NN O
. NN NN O
   
METHOD NN NN O
: NN NN O
Twenty NN NN O
- NN NN O
three NN NN O
patients NN NN O
suffering NN NN O
from NN NN O
severe NN NN O
Parkinson NN NN B-Disease
' NN NN I-Disease
s NN NN I-Disease
disease NN NN I-Disease
( NN NN O
Stages NN NN O
III NN NN O
- NN NN O
V NN NN O
on NN NN O
Hoehn NN NN O
and NN NN O
Yahr NN NN O
scale NN NN O
) NN NN O
and NN NN O
, NN NN O
particularly NN NN O
bradykinesia NN NN B-Disease
, NN NN O
rigidity NN NN B-Disease
, NN NN O
and NN NN O
levodopa NN NN O
- NN NN O
induced NN NN O
dyskinesias NN NN B-Disease
underwent NN NN O
bilateral NN NN O
implantation NN NN O
of NN NN O
electrodes NN NN O
in NN NN O
the NN NN O
STN NN NN O
. NN NN O
   
Preoperative NN NN O
and NN NN O
postoperative NN NN O
assessments NN NN O
of NN NN O
these NN NN O
patients NN NN O
at NN NN O
1 NN NN O
, NN NN O
3 NN NN O
, NN NN O
6 NN NN O
and NN NN O
12 NN NN O
months NN NN O
follow NN NN O
- NN NN O
up NN NN O
, NN NN O
in NN NN O
"""""""" NN NN O
on NN NN O
"""""""" NN NN O
and NN NN O
"""""""" NN NN O
off NN NN O
"""""""" NN NN O
drug NN NN O
conditions NN NN O
, NN NN O
was NN NN O
carried NN NN O
out NN NN O
using NN NN O
Unified NN NN O
Parkinson NN NN B-Disease
' NN NN I-Disease
s NN NN I-Disease
Disease NN NN I-Disease
Rating NN NN O
Scale NN NN O
, NN NN O
Hoehn NN NN O
and NN NN O
Yahr NN NN O
staging NN NN O
, NN NN O
England NN NN O
activities NN NN O
of NN NN O
daily NN NN O
living NN NN O
score NN NN O
and NN NN O
video NN NN O
recordings NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
After NN NN O
one NN NN O
year NN NN O
of NN NN O
electrical NN NN O
stimulation NN NN O
of NN NN O
the NN NN O
STN NN NN O
, NN NN O
the NN NN O
patients NN NN O
' NN NN O
scores NN NN O
for NN NN O
activities NN NN O
of NN NN O
daily NN NN O
living NN NN O
and NN NN O
motor NN NN O
examination NN NN O
scores NN NN O
( NN NN O
Unified NN NN O
Parkinson NN NN B-Disease
' NN NN I-Disease
s NN NN I-Disease
Disease NN NN I-Disease
Rating NN NN O
Scale NN NN O
parts NN NN O
II NN NN O
and NN NN O
III NN NN O
) NN NN O
off NN NN O
medication NN NN O
improved NN NN O
by NN NN O
62 NN NN O
% NN NN O
and NN NN O
61 NN NN O
% NN NN O
respectively NN NN O
( NN NN O
p NN NN O
< NN NN O
0 NN NN O
. NN NN O
0005 NN NN O
) NN NN O
. NN NN O
   
The NN NN O
subscores NN NN O
for NN NN O
the NN NN O
akinesia NN NN B-Disease
, NN NN O
rigidity NN NN B-Disease
, NN NN O
tremor NN NN B-Disease
and NN NN O
gait NN NN O
also NN NN O
improved NN NN O
. NN NN O
   
( NN NN O
p NN NN O
< NN NN O
0 NN NN O
. NN NN O
0005 NN NN O
) NN NN O
. NN NN O
   
The NN NN O
average NN NN O
levodopa NN NN O
dose NN NN O
decreased NN NN O
from NN NN O
813 NN NN O
mg NN NN O
to NN NN O
359 NN NN O
mg NN NN O
. NN NN O
   
The NN NN O
cognitive NN NN O
functions NN NN O
remained NN NN O
unchanged NN NN O
. NN NN O
   
Two NN NN O
patients NN NN O
developed NN NN O
device NN NN O
- NN NN O
related NN NN O
complications NN NN O
and NN NN O
two NN NN O
patients NN NN O
experienced NN NN O
abnormal NN NN O
weight NN NN O
gain NN NN O
. NN NN O
   
CONCLUSION NN NN O
: NN NN O
Bilateral NN NN O
subthalamic NN NN O
nucleus NN NN O
stimulation NN NN O
is NN NN O
an NN NN O
effective NN NN O
treatment NN NN O
for NN NN O
advanced NN NN O
Parkinson NN NN B-Disease
' NN NN I-Disease
s NN NN I-Disease
disease NN NN I-Disease
. NN NN O
   
It NN NN O
reduces NN NN O
the NN NN O
severity NN NN O
of NN NN O
"""""""" NN NN O
off NN NN O
"""""""" NN NN O
phase NN NN O
symptoms NN NN O
, NN NN O
improves NN NN O
the NN NN O
axial NN NN O
symptoms NN NN O
and NN NN O
reduces NN NN O
levodopa NN NN O
requirements NN NN O
. NN NN O
   
The NN NN O
reduction NN NN O
in NN NN O
the NN NN O
levodopa NN NN O
dose NN NN O
is NN NN O
useful NN NN O
in NN NN O
controlling NN NN O
drug NN NN B-Disease
- NN NN I-Disease
induced NN NN I-Disease
dyskinesias NN NN I-Disease
. NN NN O
   
Acute NN NN B-Disease
renal NN NN I-Disease
failure NN NN I-Disease
occurring NN NN O
during NN NN O
intravenous NN NN O
desferrioxamine NN NN O
therapy NN NN O
: NN NN O
recovery NN NN O
after NN NN O
haemodialysis NN NN O
. NN NN O
   
A NN NN O
patient NN NN O
with NN NN O
transfusion NN NN O
- NN NN O
dependent NN NN O
thalassemia NN NN B-Disease
was NN NN O
undergoing NN NN O
home NN NN O
intravenous NN NN O
desferrioxamine NN NN O
( NN NN O
DFX NN NN O
) NN NN O
treatment NN NN O
by NN NN O
means NN NN O
of NN NN O
a NN NN O
totally NN NN O
implanted NN NN O
system NN NN O
because NN NN O
of NN NN O
his NN NN O
poor NN NN O
compliance NN NN O
with NN NN O
the NN NN O
nightly NN NN O
subcutaneous NN NN O
therapy NN NN O
. NN NN O
   
Due NN NN O
to NN NN O
an NN NN O
accidental NN NN O
malfunctioning NN NN O
of NN NN O
the NN NN O
infusion NN NN O
pump NN NN O
, NN NN O
the NN NN O
patient NN NN O
was NN NN O
inadvertently NN NN O
administered NN NN O
a NN NN O
toxic NN NN O
dosage NN NN O
of NN NN O
the NN NN O
drug NN NN O
which NN NN O
caused NN NN O
renal NN NN B-Disease
insufficiency NN NN I-Disease
. NN NN O
   
Given NN NN O
the NN NN O
progressive NN NN O
deterioration NN NN O
of NN NN O
the NN NN O
symptoms NN NN O
and NN NN O
of NN NN O
the NN NN O
laboratory NN NN O
values NN NN O
, NN NN O
despite NN NN O
adequate NN NN O
medical NN NN O
treatment NN NN O
, NN NN O
a NN NN O
decision NN NN O
was NN NN O
made NN NN O
to NN NN O
introduce NN NN O
haemodialytical NN NN O
therapy NN NN O
in NN NN O
order NN NN O
to NN NN O
remove NN NN O
the NN NN O
drug NN NN O
and NN NN O
therapy NN NN O
reduce NN NN O
the NN NN O
nephrotoxicity NN NN B-Disease
. NN NN O
   
From NN NN O
the NN NN O
results NN NN O
obtained NN NN O
, NN NN O
haemodialysis NN NN O
can NN NN O
therefore NN NN O
be NN NN O
suggested NN NN O
as NN NN O
a NN NN O
useful NN NN O
therapy NN NN O
in NN NN O
rare NN NN O
cases NN NN O
of NN NN O
progressive NN NN O
acute NN NN B-Disease
renal NN NN I-Disease
failure NN NN I-Disease
caused NN NN O
by NN NN O
desferrioxamine NN NN O
. NN NN O
   
Ocular NN NN O
motility NN NN O
changes NN NN O
after NN NN O
subtenon NN NN O
carboplatin NN NN O
chemotherapy NN NN O
for NN NN O
retinoblastoma NN NN B-Disease
. NN NN O
   
BACKGROUND NN NN O
: NN NN O
Focal NN NN O
subtenon NN NN O
carboplatin NN NN O
injections NN NN O
have NN NN O
recently NN NN O
been NN NN O
used NN NN O
as NN NN O
a NN NN O
presumably NN NN O
toxicity NN NN B-Disease
- NN NN O
free NN NN O
adjunct NN NN O
to NN NN O
systemic NN NN O
chemotherapy NN NN O
for NN NN O
intraocular NN NN O
retinoblastoma NN NN B-Disease
. NN NN O
   
OBJECTIVE NN NN O
: NN NN O
To NN NN O
report NN NN O
our NN NN O
clinical NN NN O
experience NN NN O
with NN NN O
abnormal NN NN B-Disease
ocular NN NN I-Disease
motility NN NN I-Disease
in NN NN O
patients NN NN O
treated NN NN O
with NN NN O
subtenon NN NN O
carboplatin NN NN O
chemotherapy NN NN O
. NN NN O
   
METHODS NN NN O
: NN NN O
We NN NN O
noted NN NN O
abnormal NN NN B-Disease
ocular NN NN I-Disease
motility NN NN I-Disease
in NN NN O
10 NN NN O
consecutive NN NN O
patients NN NN O
with NN NN O
retinoblastoma NN NN B-Disease
who NN NN O
had NN NN O
received NN NN O
subtenon NN NN O
carboplatin NN NN O
. NN NN O
   
During NN NN O
ocular NN NN O
manipulation NN NN O
under NN NN O
general NN NN O
anesthesia NN NN O
, NN NN O
we NN NN O
assessed NN NN O
their NN NN O
eyes NN NN O
by NN NN O
forced NN NN O
duction NN NN O
testing NN NN O
, NN NN O
comparing NN NN O
ocular NN NN O
motility NN NN O
after NN NN O
tumor NN NN B-Disease
control NN NN O
with NN NN O
ocular NN NN O
motility NN NN O
at NN NN O
diagnosis NN NN O
. NN NN O
   
Eyes NN NN O
subsequently NN NN O
enucleated NN NN O
because NN NN O
of NN NN O
treatment NN NN O
failure NN NN O
( NN NN O
n NN NN O
= NN NN O
4 NN NN O
) NN NN O
were NN NN O
examined NN NN O
histologically NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
Limitation NN NN O
of NN NN O
ocular NN NN O
motility NN NN O
was NN NN O
detected NN NN O
in NN NN O
all NN NN O
12 NN NN O
eyes NN NN O
of NN NN O
10 NN NN O
patients NN NN O
treated NN NN O
for NN NN O
intraocular NN NN O
retinoblastoma NN NN B-Disease
with NN NN O
1 NN NN O
to NN NN O
6 NN NN O
injections NN NN O
of NN NN O
subtenon NN NN O
carboplatin NN NN O
as NN NN O
part NN NN O
of NN NN O
multimodality NN NN O
therapy NN NN O
. NN NN O
   
Histopathological NN NN O
examination NN NN O
revealed NN NN O
many NN NN O
lipophages NN NN O
in NN NN O
the NN NN O
periorbital NN NN O
fat NN NN O
surrounding NN NN O
the NN NN O
optic NN NN O
nerve NN NN O
in NN NN O
1 NN NN O
eye NN NN O
, NN NN O
indicative NN NN O
of NN NN O
phagocytosis NN NN O
of NN NN O
previously NN NN O
existing NN NN O
fat NN NN O
cells NN NN O
and NN NN O
suggesting NN NN O
prior NN NN O
fat NN NN O
necrosis NN NN B-Disease
. NN NN O
   
The NN NN O
enucleations NN NN O
were NN NN O
technically NN NN O
difficult NN NN O
and NN NN O
hazardous NN NN O
for NN NN O
globe NN NN O
rupture NN NN B-Disease
because NN NN O
of NN NN O
extensive NN NN O
orbital NN NN O
soft NN NN O
tissue NN NN O
adhesions NN NN O
. NN NN O
   
CONCLUSIONS NN NN O
: NN NN O
Subtenon NN NN O
carboplatin NN NN O
chemotherapy NN NN O
is NN NN O
associated NN NN O
with NN NN O
significant NN NN O
fibrosis NN NN B-Disease
of NN NN O
orbital NN NN O
soft NN NN O
tissues NN NN O
, NN NN O
leading NN NN O
to NN NN O
mechanical NN NN O
restriction NN NN O
of NN NN O
eye NN NN O
movements NN NN O
and NN NN O
making NN NN O
subsequent NN NN O
enucleation NN NN O
difficult NN NN O
. NN NN O
   
Subtenon NN NN O
carboplatin NN NN O
is NN NN O
not NN NN O
free NN NN O
of NN NN O
toxicity NN NN B-Disease
, NN NN O
and NN NN O
its NN NN O
use NN NN O
is NN NN O
best NN NN O
restricted NN NN O
to NN NN O
specific NN NN O
indications NN NN O
. NN NN O
   
Ethambutol NN NN O
and NN NN O
optic NN NN B-Disease
neuropathy NN NN I-Disease
. NN NN O
   
PURPOSE NN NN O
: NN NN O
To NN NN O
demonstrate NN NN O
the NN NN O
association NN NN O
between NN NN O
ethambutol NN NN O
and NN NN O
optic NN NN B-Disease
neuropathy NN NN I-Disease
. NN NN O
   
METHOD NN NN O
: NN NN O
Thirteen NN NN O
patients NN NN O
who NN NN O
developed NN NN O
optic NN NN B-Disease
neuropathy NN NN I-Disease
after NN NN O
being NN NN O
treated NN NN O
with NN NN O
ethambutol NN NN O
for NN NN O
tuberculosis NN NN B-Disease
of NN NN I-Disease
the NN NN I-Disease
lung NN NN I-Disease
or NN NN I-Disease
lymph NN NN I-Disease
node NN NN I-Disease
at NN NN O
Siriraj NN NN O
Hospital NN NN O
between NN NN O
1997 NN NN O
and NN NN O
2001 NN NN O
were NN NN O
retrospectively NN NN O
reviewed NN NN O
. NN NN O
   
The NN NN O
clinical NN NN O
characteristics NN NN O
and NN NN O
initial NN NN O
and NN NN O
final NN NN O
visual NN NN O
acuity NN NN O
were NN NN O
analyzed NN NN O
to NN NN O
determine NN NN O
visual NN NN O
outcome NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
All NN NN O
patients NN NN O
had NN NN O
optic NN NN B-Disease
neuropathy NN NN I-Disease
between NN NN O
1 NN NN O
to NN NN O
6 NN NN O
months NN NN O
( NN NN O
mean NN NN O
= NN NN O
2 NN NN O
. NN NN O
9 NN NN O
months NN NN O
) NN NN O
after NN NN O
starting NN NN O
ethambutol NN NN O
therapy NN NN O
at NN NN O
a NN NN O
dosage NN NN O
ranging NN NN O
from NN NN O
13 NN NN O
to NN NN O
20 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
/ NN NN O
day NN NN O
( NN NN O
mean NN NN O
= NN NN O
17 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
/ NN NN O
day NN NN O
) NN NN O
. NN NN O
   
Seven NN NN O
( NN NN O
54 NN NN O
% NN NN O
) NN NN O
of NN NN O
the NN NN O
13 NN NN O
patients NN NN O
experienced NN NN O
visual NN NN O
recovery NN NN O
after NN NN O
stopping NN NN O
the NN NN O
drug NN NN O
. NN NN O
   
Of NN NN O
6 NN NN O
patients NN NN O
with NN NN O
irreversible NN NN O
visual NN NN B-Disease
impairment NN NN I-Disease
, NN NN O
4 NN NN O
patients NN NN O
had NN NN O
diabetes NN NN B-Disease
mellitus NN NN I-Disease
, NN NN O
glaucoma NN NN B-Disease
and NN NN O
a NN NN O
history NN NN O
of NN NN O
heavy NN NN O
smoking NN NN O
. NN NN O
   
CONCLUSION NN NN O
: NN NN O
Early NN NN O
recognition NN NN O
of NN NN O
optic NN NN B-Disease
neuropathy NN NN I-Disease
should NN NN O
be NN NN O
considered NN NN O
in NN NN O
patients NN NN O
with NN NN O
ethambutol NN NN O
therapy NN NN O
. NN NN O
   
A NN NN O
low NN NN O
dose NN NN O
and NN NN O
prompt NN NN O
discontinuation NN NN O
of NN NN O
the NN NN O
drug NN NN O
is NN NN O
recommended NN NN O
particularly NN NN O
in NN NN O
individuals NN NN O
with NN NN O
diabetes NN NN B-Disease
mellitus NN NN I-Disease
, NN NN O
glaucoma NN NN B-Disease
or NN NN O
who NN NN O
are NN NN O
heavy NN NN O
smokers NN NN O
. NN NN O
   
Treatment NN NN O
of NN NN O
compensatory NN NN O
gustatory NN NN B-Disease
hyperhidrosis NN NN I-Disease
with NN NN O
topical NN NN O
glycopyrrolate NN NN O
. NN NN O
   
Gustatory NN NN B-Disease
hyperhidrosis NN NN I-Disease
is NN NN O
facial NN NN O
sweating NN NN B-Disease
usually NN NN O
associated NN NN O
with NN NN O
the NN NN O
eating NN NN O
of NN NN O
hot NN NN O
spicy NN NN O
food NN NN O
or NN NN O
even NN NN O
smelling NN NN O
this NN NN O
food NN NN O
. NN NN O
   
Current NN NN O
options NN NN O
of NN NN O
treatment NN NN O
include NN NN O
oral NN NN O
anticholinergic NN NN O
drugs NN NN O
, NN NN O
the NN NN O
topical NN NN O
application NN NN O
of NN NN O
anticholinergics NN NN O
or NN NN O
aluminum NN NN O
chloride NN NN O
, NN NN O
and NN NN O
the NN NN O
injection NN NN O
of NN NN O
botulinum NN NN O
toxin NN NN O
. NN NN O
   
Thirteen NN NN O
patients NN NN O
have NN NN O
been NN NN O
treated NN NN O
to NN NN O
date NN NN O
with NN NN O
1 NN NN O
. NN NN O
5 NN NN O
% NN NN O
or NN NN O
2 NN NN O
% NN NN O
topical NN NN O
glycopyrrolate NN NN O
. NN NN O
   
All NN NN O
patients NN NN O
had NN NN O
gustatory NN NN B-Disease
hyperhidrosis NN NN I-Disease
, NN NN O
which NN NN O
interfered NN NN O
with NN NN O
their NN NN O
social NN NN O
activities NN NN O
, NN NN O
after NN NN O
transthroacic NN NN O
endoscopic NN NN O
sympathectomy NN NN O
, NN NN O
and NN NN O
which NN NN O
was NN NN O
associated NN NN O
with NN NN O
compensatory NN NN O
focal NN NN O
hyperhidrosis NN NN B-Disease
. NN NN O
   
After NN NN O
applying NN NN O
topical NN NN O
glycopyrrolate NN NN O
, NN NN O
the NN NN O
subjective NN NN O
effect NN NN O
was NN NN O
excellent NN NN O
( NN NN O
no NN NN O
sweating NN NN B-Disease
after NN NN O
eating NN NN O
hot NN NN O
spicy NN NN O
food NN NN O
) NN NN O
in NN NN O
10 NN NN O
patients NN NN O
( NN NN O
77 NN NN O
% NN NN O
) NN NN O
, NN NN O
and NN NN O
fair NN NN O
( NN NN O
clearly NN NN O
reduced NN NN O
sweating NN NN B-Disease
) NN NN O
in NN NN O
3 NN NN O
patients NN NN O
( NN NN O
23 NN NN O
% NN NN O
) NN NN O
. NN NN O
   
All NN NN O
had NN NN O
reported NN NN O
incidents NN NN O
of NN NN O
being NN NN O
very NN NN O
embarrassed NN NN O
whilst NN NN O
eating NN NN O
hot NN NN O
spicy NN NN O
foods NN NN O
. NN NN O
   
Adverse NN NN O
effects NN NN O
included NN NN O
a NN NN O
mildly NN NN O
dry NN NN B-Disease
mouth NN NN I-Disease
and NN NN O
a NN NN O
sore NN NN B-Disease
throat NN NN I-Disease
in NN NN O
2 NN NN O
patients NN NN O
( NN NN O
2 NN NN O
% NN NN O
glycopyrrolate NN NN O
) NN NN O
, NN NN O
a NN NN O
light NN NN O
headache NN NN B-Disease
in NN NN O
1 NN NN O
patient NN NN O
( NN NN O
1 NN NN O
. NN NN O
5 NN NN O
% NN NN O
glycopyrrolate NN NN O
) NN NN O
. NN NN O
   
The NN NN O
topical NN NN O
application NN NN O
of NN NN O
a NN NN O
glycopyrrolate NN NN O
pad NN NN O
appeared NN NN O
to NN NN O
be NN NN O
safe NN NN O
, NN NN O
efficacious NN NN O
, NN NN O
well NN NN O
tolerated NN NN O
, NN NN O
and NN NN O
a NN NN O
convenient NN NN O
method NN NN O
of NN NN O
treatment NN NN O
for NN NN O
moderate NN NN O
to NN NN O
severe NN NN O
symptoms NN NN O
of NN NN O
gustatory NN NN B-Disease
hyperhidrosis NN NN I-Disease
in NN NN O
post NN NN O
transthoracic NN NN O
endoscopic NN NN O
sympathectomy NN NN O
or NN NN O
sympathicotomy NN NN O
patients NN NN O
, NN NN O
with NN NN O
few NN NN O
side NN NN O
effects NN NN O
. NN NN O
   
Neuroleptic NN NN O
- NN NN O
associated NN NN O
hyperprolactinemia NN NN B-Disease
. NN NN O
   
Can NN NN O
it NN NN O
be NN NN O
treated NN NN O
with NN NN O
bromocriptine NN NN O
? NN NN O
   
Six NN NN O
stable NN NN O
psychiatric NN NN O
outpatients NN NN O
with NN NN O
hyperprolactinemia NN NN B-Disease
and NN NN O
amenorrhea NN NN B-Disease
/ NN NN O
oligomenorrhea NN NN B-Disease
associated NN NN O
with NN NN O
their NN NN O
neuroleptic NN NN O
medications NN NN O
were NN NN O
treated NN NN O
with NN NN O
bromocriptine NN NN O
. NN NN O
   
Daily NN NN O
dosages NN NN O
of NN NN O
5 NN NN O
- NN NN O
10 NN NN O
mg NN NN O
corrected NN NN O
the NN NN O
hyperprolactinemia NN NN B-Disease
and NN NN O
restored NN NN O
menstruation NN NN O
in NN NN O
four NN NN O
of NN NN O
the NN NN O
six NN NN O
patients NN NN O
. NN NN O
   
One NN NN O
woman NN NN O
, NN NN O
however NN NN O
, NN NN O
developed NN NN O
worsened NN NN O
psychiatric NN NN B-Disease
symptoms NN NN I-Disease
while NN NN O
taking NN NN O
bromocriptine NN NN O
, NN NN O
and NN NN O
it NN NN O
was NN NN O
discontinued NN NN O
. NN NN O
   
Thus NN NN O
, NN NN O
three NN NN O
of NN NN O
six NN NN O
patients NN NN O
had NN NN O
their NN NN O
menstrual NN NN O
irregularity NN NN O
successfully NN NN O
corrected NN NN O
with NN NN O
bromocriptine NN NN O
. NN NN O
   
This NN NN O
suggests NN NN O
that NN NN O
bromocriptine NN NN O
should NN NN O
be NN NN O
further NN NN O
evaluated NN NN O
as NN NN O
potential NN NN O
therapy NN NN O
for NN NN O
neuroleptic NN NN O
- NN NN O
associated NN NN O
hyperprolactinemia NN NN B-Disease
and NN NN O
amenorrhea NN NN B-Disease
/ NN NN O
galactorrhea NN NN B-Disease
. NN NN O
   
Ethacrynic NN NN O
acid NN NN O
- NN NN O
induced NN NN O
convulsions NN NN B-Disease
and NN NN O
brain NN NN O
neurotransmitters NN NN O
in NN NN O
mice NN NN O
. NN NN O
   
Intracerebroventricular NN NN O
injection NN NN O
of NN NN O
ethacrynic NN NN O
acid NN NN O
( NN NN O
50 NN NN O
% NN NN O
convulsive NN NN B-Disease
dose NN NN O
; NN NN O
50 NN NN O
micrograms NN NN O
/ NN NN O
mouse NN NN O
) NN NN O
accelerated NN NN O
the NN NN O
synthesis NN NN O
/ NN NN O
turnover NN NN O
of NN NN O
5 NN NN O
- NN NN O
hydroxytryptamine NN NN O
( NN NN O
5 NN NN O
- NN NN O
HT NN NN O
) NN NN O
but NN NN O
suppressed NN NN O
the NN NN O
synthesis NN NN O
of NN NN O
gamma NN NN O
- NN NN O
aminobutyric NN NN O
acid NN NN O
and NN NN O
acetylcholine NN NN O
in NN NN O
mouse NN NN O
brain NN NN O
. NN NN O
   
These NN NN O
effects NN NN O
were NN NN O
completely NN NN O
antagonized NN NN O
by NN NN O
pretreatment NN NN O
with NN NN O
a NN NN O
glutamate NN NN O
/ NN NN O
N NN NN O
- NN NN O
methyl NN NN O
- NN NN O
D NN NN O
- NN NN O
aspartate NN NN O
antagonist NN NN O
, NN NN O
aminophosphonovaleric NN NN O
acid NN NN O
. NN NN O
   
In NN NN O
ethacrynic NN NN O
acid NN NN O
- NN NN O
induced NN NN O
convulsions NN NN B-Disease
, NN NN O
these NN NN O
neurotransmitter NN NN O
systems NN NN O
may NN NN O
be NN NN O
differentially NN NN O
modulated NN NN O
, NN NN O
probably NN NN O
through NN NN O
activation NN NN O
of NN NN O
glutaminergic NN NN O
neurons NN NN O
in NN NN O
the NN NN O
brain NN NN O
. NN NN O
   
Pharmacology NN NN O
of NN NN O
gamma NN NN O
- NN NN O
aminobutyric NN NN O
acidA NN NN O
receptor NN NN O
complex NN NN O
after NN NN O
the NN NN O
in NN NN O
vivo NN NN O
administration NN NN O
of NN NN O
the NN NN O
anxioselective NN NN O
and NN NN O
anticonvulsant NN NN O
beta NN NN O
- NN NN O
carboline NN NN O
derivative NN NN O
abecarnil NN NN O
. NN NN O
   
In NN NN O
rodents NN NN O
, NN NN O
the NN NN O
effect NN NN O
of NN NN O
the NN NN O
beta NN NN O
- NN NN O
carboline NN NN O
derivative NN NN O
isopropyl NN NN O
- NN NN O
6 NN NN O
- NN NN O
benzyloxy NN NN O
- NN NN O
4 NN NN O
- NN NN O
methoxymethyl NN NN O
- NN NN O
beta NN NN O
- NN NN O
carboline NN NN O
- NN NN O
3 NN NN O
- NN NN O
carboxylate NN NN O
( NN NN O
abecarrnil NN NN O
) NN NN O
, NN NN O
a NN NN O
new NN NN O
ligand NN NN O
for NN NN O
benzodiazepine NN NN O
receptors NN NN O
possessing NN NN O
anxiolytic NN NN O
and NN NN O
anticonvulsant NN NN O
properties NN NN O
, NN NN O
was NN NN O
evaluated NN NN O
on NN NN O
the NN NN O
function NN NN O
of NN NN O
central NN NN O
gamma NN NN O
- NN NN O
aminobutyric NN NN O
acid NN NN O
( NN NN O
GABA NN NN O
) NN NN O
A NN NN O
receptor NN NN O
complex NN NN O
, NN NN O
both NN NN O
in NN NN O
vitro NN NN O
and NN NN O
in NN NN O
vivo NN NN O
. NN NN O
   
Added NN NN O
in NN NN O
vitro NN NN O
to NN NN O
rat NN NN O
cortical NN NN O
membrane NN NN O
preparation NN NN O
, NN NN O
abecarnil NN NN O
increased NN NN O
[ NN NN O
3H NN NN O
] NN NN O
GABA NN NN O
binding NN NN O
, NN NN O
enhanced NN NN O
muscimol NN NN O
- NN NN O
stimulated NN NN O
36Cl NN NN O
- NN NN O
uptake NN NN O
and NN NN O
reduced NN NN O
the NN NN O
binding NN NN O
of NN NN O
t NN NN O
- NN NN O
[ NN NN O
35S NN NN O
] NN NN O
butylbicyclophosphorothionate NN NN O
( NN NN O
[ NN NN O
35S NN NN O
] NN NN O
TBPS NN NN O
) NN NN O
. NN NN O
   
These NN NN O
effects NN NN O
were NN NN O
similar NN NN O
to NN NN O
those NN NN O
induced NN NN O
by NN NN O
diazepam NN NN O
, NN NN O
whereas NN NN O
the NN NN O
partial NN NN O
agonist NN NN O
Ro NN NN O
16 NN NN O
- NN NN O
6028 NN NN O
( NN NN O
tert NN NN O
- NN NN O
butyl NN NN O
- NN NN O
( NN NN O
S NN NN O
) NN NN O
- NN NN O
8 NN NN O
- NN NN O
bromo NN NN O
- NN NN O
11 NN NN O
, NN NN O
12 NN NN O
, NN NN O
13 NN NN O
, NN NN O
13a NN NN O
- NN NN O
tetrahydro NN NN O
- NN NN O
9 NN NN O
- NN NN O
oxo NN NN O
- NN NN O
9H NN NN O
- NN NN O
imidazo NN NN O
[ NN NN O
1 NN NN O
, NN NN O
5 NN NN O
- NN NN O
a NN NN O
] NN NN O
- NN NN O
pyrrolo NN NN O
- NN NN O
[ NN NN O
2 NN NN O
, NN NN O
1 NN NN O
- NN NN O
c NN NN O
] NN NN O
[ NN NN O
1 NN NN O
, NN NN O
4 NN NN O
] NN NN O
benzodiazepine NN NN O
- NN NN O
1 NN NN O
- NN NN O
carboxylate NN NN O
) NN NN O
showed NN NN O
very NN NN O
weak NN NN O
efficacy NN NN O
in NN NN O
these NN NN O
biochemical NN NN O
tests NN NN O
. NN NN O
   
After NN NN O
i NN NN O
. NN NN O
p NN NN O
. NN NN O
injection NN NN O
to NN NN O
rats NN NN O
, NN NN O
abecarnil NN NN O
and NN NN O
diazepam NN NN O
decreased NN NN O
in NN NN O
a NN NN O
time NN NN O
- NN NN O
dependent NN NN O
and NN NN O
dose NN NN O
- NN NN O
related NN NN O
( NN NN O
0 NN NN O
. NN NN O
25 NN NN O
- NN NN O
20 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
i NN NN O
. NN NN O
p NN NN O
. NN NN O
) NN NN O
manner NN NN O
[ NN NN O
35S NN NN O
] NN NN O
TBPS NN NN O
binding NN NN O
measured NN NN O
ex NN NN O
vivo NN NN O
in NN NN O
the NN NN O
cerebral NN NN O
cortex NN NN O
. NN NN O
   
Moreover NN NN O
, NN NN O
both NN NN O
drugs NN NN O
at NN NN O
the NN NN O
dose NN NN O
of NN NN O
0 NN NN O
. NN NN O
5 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
antagonized NN NN O
completely NN NN O
the NN NN O
convulsant NN NN O
activity NN NN O
and NN NN O
the NN NN O
increase NN NN O
of NN NN O
[ NN NN O
35S NN NN O
] NN NN O
TBPS NN NN O
binding NN NN O
induced NN NN O
by NN NN O
isoniazide NN NN O
( NN NN O
350 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
s NN NN O
. NN NN O
c NN NN O
. NN NN O
) NN NN O
as NN NN O
well NN NN O
as NN NN O
the NN NN O
increase NN NN O
of NN NN O
[ NN NN O
35S NN NN O
] NN NN O
TBPS NN NN O
binding NN NN O
induced NN NN O
by NN NN O
foot NN NN O
- NN NN O
shock NN NN O
stress NN NN O
. NN NN O
   
To NN NN O
better NN NN O
correlate NN NN O
the NN NN O
biochemical NN NN O
and NN NN O
the NN NN O
pharmacological NN NN O
effects NN NN O
, NN NN O
we NN NN O
studied NN NN O
the NN NN O
action NN NN O
of NN NN O
abecarnil NN NN O
on NN NN O
[ NN NN O
35S NN NN O
] NN NN O
TBPS NN NN O
binding NN NN O
, NN NN O
exploratory NN NN O
motility NN NN O
and NN NN O
on NN NN O
isoniazid NN NN O
- NN NN O
induced NN NN O
biochemical NN NN O
and NN NN O
pharmacological NN NN O
effects NN NN O
in NN NN O
mice NN NN O
. NN NN O
   
In NN NN O
these NN NN O
animals NN NN O
, NN NN O
abecarnil NN NN O
produced NN NN O
a NN NN O
paralleled NN NN O
dose NN NN O
- NN NN O
dependent NN NN O
( NN NN O
0 NN NN O
. NN NN O
05 NN NN O
- NN NN O
1 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
i NN NN O
. NN NN O
p NN NN O
. NN NN O
) NN NN O
reduction NN NN O
of NN NN O
both NN NN O
motor NN NN O
behavior NN NN O
and NN NN O
cortical NN NN O
[ NN NN O
35S NN NN O
] NN NN O
TBPS NN NN O
binding NN NN O
. NN NN O
   
Moreover NN NN O
, NN NN O
0 NN NN O
. NN NN O
05 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
of NN NN O
this NN NN O
beta NN NN O
- NN NN O
carboline NN NN O
reduced NN NN O
markedly NN NN O
the NN NN O
increase NN NN O
of NN NN O
[ NN NN O
35S NN NN O
] NN NN O
TBPS NN NN O
binding NN NN O
and NN NN O
the NN NN O
convulsions NN NN B-Disease
induced NN NN O
by NN NN O
isoniazid NN NN O
( NN NN O
200 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
s NN NN O
. NN NN O
c NN NN O
. NN NN O
) NN NN O
. NN NN O
( NN NN O
ABSTRACT NN NN O
TRUNCATED NN NN O
AT NN NN O
250 NN NN O
WORDS NN NN O
) NN NN O
   
Recurrent NN NN O
myocardial NN NN B-Disease
infarction NN NN I-Disease
in NN NN O
a NN NN O
postpartum NN NN O
patient NN NN O
receiving NN NN O
bromocriptine NN NN O
. NN NN O
   
Myocardial NN NN B-Disease
infarction NN NN I-Disease
in NN NN O
puerperium NN NN O
is NN NN O
infrequently NN NN O
reported NN NN O
. NN NN O
   
Spasm NN NN B-Disease
, NN NN O
coronary NN NN O
dissection NN NN O
, NN NN O
or NN NN O
atheromatous NN NN O
etiology NN NN O
has NN NN O
been NN NN O
described NN NN O
. NN NN O
   
Bromocriptine NN NN O
has NN NN O
been NN NN O
implicated NN NN O
in NN NN O
several NN NN O
previous NN NN O
case NN NN O
reports NN NN O
of NN NN O
myocardial NN NN B-Disease
infarction NN NN I-Disease
in NN NN O
the NN NN O
puerperium NN NN O
. NN NN O
   
Our NN NN O
case NN NN O
( NN NN O
including NN NN O
an NN NN O
inadvertent NN NN O
rechallenge NN NN O
) NN NN O
suggests NN NN O
such NN NN O
a NN NN O
relationship NN NN O
. NN NN O
   
Although NN NN O
generally NN NN O
regarded NN NN O
as NN NN O
"""""""" NN NN O
safe NN NN O
, NN NN O
"""""""" NN NN O
possible NN NN O
serious NN NN O
cardiac NN NN O
effects NN NN O
of NN NN O
bromocriptine NN NN O
should NN NN O
be NN NN O
acknowledged NN NN O
. NN NN O
   
Asterixis NN NN B-Disease
induced NN NN O
by NN NN O
carbamazepine NN NN O
therapy NN NN O
. NN NN O
   
There NN NN O
are NN NN O
very NN NN O
few NN NN O
reports NN NN O
about NN NN O
asterixis NN NN B-Disease
as NN NN O
a NN NN O
side NN NN O
effect NN NN O
of NN NN O
treatment NN NN O
with NN NN O
psychopharmacologic NN NN O
agents NN NN O
. NN NN O
   
In NN NN O
this NN NN O
report NN NN O
we NN NN O
present NN NN O
four NN NN O
patients NN NN O
treated NN NN O
with NN NN O
a NN NN O
combination NN NN O
of NN NN O
different NN NN O
psychotropic NN NN O
drugs NN NN O
, NN NN O
in NN NN O
whom NN NN O
asterixis NN NN B-Disease
was NN NN O
triggered NN NN O
either NN NN O
by NN NN O
adding NN NN O
carbamazepine NN NN O
( NN NN O
CBZ NN NN O
) NN NN O
to NN NN O
a NN NN O
treatment NN NN O
regimen NN NN O
, NN NN O
or NN NN O
by NN NN O
increasing NN NN O
its NN NN O
dosage NN NN O
. NN NN O
   
Neither NN NN O
dosage NN NN O
nor NN NN O
serum NN NN O
levels NN NN O
of NN NN O
CBZ NN NN O
were NN NN O
in NN NN O
a NN NN O
higher NN NN O
range NN NN O
. NN NN O
   
We NN NN O
consider NN NN O
asterixis NN NN B-Disease
to NN NN O
be NN NN O
an NN NN O
easily NN NN O
overlooked NN NN O
sign NN NN O
of NN NN O
neurotoxicity NN NN B-Disease
, NN NN O
which NN NN O
may NN NN O
occur NN NN O
even NN NN O
at NN NN O
low NN NN O
or NN NN O
moderate NN NN O
dosage NN NN O
levels NN NN O
, NN NN O
if NN NN O
certain NN NN O
drugs NN NN O
as NN NN O
lithium NN NN O
or NN NN O
clozapine NN NN O
are NN NN O
used NN NN O
in NN NN O
combination NN NN O
with NN NN O
CBZ NN NN O
. NN NN O
   
Pharmacodynamics NN NN O
of NN NN O
the NN NN O
hypotensive NN NN B-Disease
effect NN NN O
of NN NN O
levodopa NN NN O
in NN NN O
parkinsonian NN NN B-Disease
patients NN NN O
. NN NN O
   
Blood NN NN O
pressure NN NN O
effects NN NN O
of NN NN O
i NN NN O
. NN NN O
v NN NN O
. NN NN O
levodopa NN NN O
were NN NN O
examined NN NN O
in NN NN O
parkinsonian NN NN B-Disease
patients NN NN O
with NN NN O
stable NN NN O
and NN NN O
fluctuating NN NN O
responses NN NN O
to NN NN O
levodopa NN NN O
. NN NN O
   
The NN NN O
magnitude NN NN O
of NN NN O
the NN NN O
hypotensive NN NN B-Disease
effect NN NN O
of NN NN O
levodopa NN NN O
was NN NN O
concentration NN NN O
dependent NN NN O
and NN NN O
was NN NN O
fit NN NN O
to NN NN O
an NN NN O
Emax NN NN O
model NN NN O
in NN NN O
fluctuating NN NN O
responders NN NN O
. NN NN O
   
Stable NN NN O
responders NN NN O
demonstrated NN NN O
a NN NN O
small NN NN O
hypotensive NN NN B-Disease
response NN NN O
. NN NN O
   
Baseline NN NN O
blood NN NN O
pressures NN NN O
were NN NN O
higher NN NN O
in NN NN O
fluctuating NN NN O
patients NN NN O
; NN NN O
a NN NN O
higher NN NN O
baseline NN NN O
blood NN NN O
pressure NN NN O
correlated NN NN O
with NN NN O
greater NN NN O
hypotensive NN NN B-Disease
effects NN NN O
. NN NN O
   
Antiparkinsonian NN NN O
effects NN NN O
of NN NN O
levodopa NN NN O
temporally NN NN O
correlated NN NN O
with NN NN O
blood NN NN O
pressure NN NN O
changes NN NN O
. NN NN O
   
Phenylalanine NN NN O
, NN NN O
a NN NN O
large NN NN O
neutral NN NN O
amino NN NN O
acid NN NN O
( NN NN O
LNAA NN NN O
) NN NN O
competing NN NN O
with NN NN O
levodopa NN NN O
for NN NN O
transport NN NN O
across NN NN O
the NN NN O
blood NN NN O
- NN NN O
brain NN NN O
barrier NN NN O
, NN NN O
reduced NN NN O
the NN NN O
hypotensive NN NN B-Disease
and NN NN O
antiparkinsonian NN NN O
effects NN NN O
of NN NN O
levodopa NN NN O
. NN NN O
   
We NN NN O
conclude NN NN O
that NN NN O
levodopa NN NN O
has NN NN O
a NN NN O
central NN NN O
hypotensive NN NN B-Disease
action NN NN O
that NN NN O
parallels NN NN O
the NN NN O
motor NN NN O
effects NN NN O
in NN NN O
fluctuating NN NN O
patients NN NN O
. NN NN O
   
The NN NN O
hypotensive NN NN B-Disease
effect NN NN O
appears NN NN O
to NN NN O
be NN NN O
related NN NN O
to NN NN O
the NN NN O
higher NN NN O
baseline NN NN O
blood NN NN O
pressure NN NN O
we NN NN O
observed NN NN O
in NN NN O
fluctuating NN NN O
patients NN NN O
relative NN NN O
to NN NN O
stable NN NN O
patients NN NN O
. NN NN O
   
Syndrome NN NN B-Disease
of NN NN I-Disease
inappropriate NN NN I-Disease
secretion NN NN I-Disease
of NN NN I-Disease
antidiuretic NN NN I-Disease
hormone NN NN I-Disease
after NN NN O
infusional NN NN O
vincristine NN NN O
. NN NN O
   
A NN NN O
77 NN NN O
- NN NN O
year NN NN O
- NN NN O
old NN NN O
woman NN NN O
with NN NN O
refractory NN NN O
multiple NN NN B-Disease
myeloma NN NN I-Disease
was NN NN O
treated NN NN O
with NN NN O
a NN NN O
4 NN NN O
- NN NN O
day NN NN O
continuous NN NN O
intravenous NN NN O
infusion NN NN O
of NN NN O
vincristine NN NN O
and NN NN O
doxorubicin NN NN O
and NN NN O
4 NN NN O
days NN NN O
of NN NN O
oral NN NN O
dexamethasone NN NN O
. NN NN O
   
Nine NN NN O
days NN NN O
after NN NN O
her NN NN O
second NN NN O
cycle NN NN O
she NN NN O
presented NN NN O
with NN NN O
lethargy NN NN B-Disease
and NN NN O
weakness NN NN B-Disease
associated NN NN O
with NN NN O
hyponatremia NN NN B-Disease
. NN NN O
   
Evaluation NN NN O
revealed NN NN O
the NN NN O
syndrome NN NN B-Disease
of NN NN I-Disease
inappropriate NN NN I-Disease
secretion NN NN I-Disease
of NN NN I-Disease
antidiuretic NN NN I-Disease
hormone NN NN I-Disease
, NN NN O
which NN NN O
was NN NN O
attributed NN NN O
to NN NN O
the NN NN O
vincristine NN NN O
infusion NN NN O
. NN NN O
   
After NN NN O
normal NN NN O
serum NN NN O
sodium NN NN O
levels NN NN O
returned NN NN O
, NN NN O
further NN NN O
doxorubicin NN NN O
and NN NN O
dexamethasone NN NN O
chemotherapy NN NN O
without NN NN O
vincristine NN NN O
did NN NN O
not NN NN O
produce NN NN O
this NN NN O
complication NN NN O
. NN NN O
   
Heart NN NN B-Disease
failure NN NN I-Disease
: NN NN O
to NN NN O
digitalise NN NN O
or NN NN O
not NN NN O
? NN NN O
   
The NN NN O
view NN NN O
against NN NN O
. NN NN O
   
Despite NN NN O
extensive NN NN O
clinical NN NN O
experience NN NN O
the NN NN O
role NN NN O
of NN NN O
digoxin NN NN O
is NN NN O
still NN NN O
not NN NN O
well NN NN O
defined NN NN O
. NN NN O
   
In NN NN O
patients NN NN O
with NN NN O
atrial NN NN B-Disease
fibrillation NN NN I-Disease
digoxin NN NN O
is NN NN O
beneficial NN NN O
for NN NN O
ventricular NN NN O
rate NN NN O
control NN NN O
. NN NN O
   
For NN NN O
patients NN NN O
in NN NN O
sinus NN NN O
rhythm NN NN O
and NN NN O
heart NN NN B-Disease
failure NN NN I-Disease
the NN NN O
situation NN NN O
is NN NN O
less NN NN O
clear NN NN O
. NN NN O
   
Digoxin NN NN O
has NN NN O
a NN NN O
narrow NN NN O
therapeutic NN NN O
: NN NN O
toxic NN NN O
ratio NN NN O
and NN NN O
concentrations NN NN O
are NN NN O
affected NN NN O
by NN NN O
a NN NN O
number NN NN O
of NN NN O
drugs NN NN O
. NN NN O
   
Also NN NN O
, NN NN O
digoxin NN NN O
has NN NN O
undesirable NN NN O
effects NN NN O
such NN NN O
as NN NN O
increasing NN NN O
peripheral NN NN O
resistance NN NN O
and NN NN O
myocardial NN NN O
demands NN NN O
, NN NN O
and NN NN O
causing NN NN O
arrhythmias NN NN B-Disease
. NN NN O
   
There NN NN O
is NN NN O
a NN NN O
paucity NN NN O
of NN NN O
data NN NN O
from NN NN O
well NN NN O
- NN NN O
designed NN NN O
trials NN NN O
. NN NN O
   
The NN NN O
trials NN NN O
that NN NN O
are NN NN O
available NN NN O
are NN NN O
generally NN NN O
small NN NN O
with NN NN O
limitations NN NN O
in NN NN O
design NN NN O
and NN NN O
these NN NN O
show NN NN O
variation NN NN O
in NN NN O
patient NN NN O
benefit NN NN O
. NN NN O
   
More NN NN O
convincing NN NN O
evidence NN NN O
is NN NN O
required NN NN O
showing NN NN O
that NN NN O
digoxin NN NN O
improves NN NN O
symptoms NN NN O
or NN NN O
exercise NN NN O
capacity NN NN O
. NN NN O
   
Furthermore NN NN O
, NN NN O
no NN NN O
trial NN NN O
has NN NN O
had NN NN O
sufficient NN NN O
power NN NN O
to NN NN O
evaluate NN NN O
mortality NN NN O
. NN NN O
   
Pooled NN NN O
analysis NN NN O
of NN NN O
the NN NN O
effects NN NN O
of NN NN O
other NN NN O
inotropic NN NN O
drugs NN NN O
shows NN NN O
an NN NN O
excess NN NN O
mortality NN NN O
and NN NN O
there NN NN O
is NN NN O
a NN NN O
possibility NN NN O
that NN NN O
digoxin NN NN O
may NN NN O
increase NN NN O
mortality NN NN O
after NN NN O
myocardial NN NN B-Disease
infarction NN NN I-Disease
( NN NN O
MI NN NN B-Disease
) NN NN O
. NN NN O
   
Angiotensin NN NN O
- NN NN O
converting NN NN O
enzyme NN NN O
( NN NN O
ACE NN NN O
) NN NN O
inhibitors NN NN O
should NN NN O
be NN NN O
used NN NN O
first NN NN O
as NN NN O
they NN NN O
are NN NN O
safer NN NN O
, NN NN O
do NN NN O
not NN NN O
require NN NN O
blood NN NN O
level NN NN O
monitoring NN NN O
, NN NN O
modify NN NN O
progression NN NN O
of NN NN O
disease NN NN O
, NN NN O
relieve NN NN O
symptoms NN NN O
, NN NN O
improve NN NN O
exercise NN NN O
tolerance NN NN O
and NN NN O
reduce NN NN O
mortality NN NN O
. NN NN O
   
Caution NN NN O
should NN NN O
be NN NN O
exercised NN NN O
in NN NN O
using NN NN O
digoxin NN NN O
until NN NN O
large NN NN O
mortality NN NN O
trials NN NN O
are NN NN O
completed NN NN O
showing NN NN O
either NN NN O
benefit NN NN O
or NN NN O
harm NN NN O
. NN NN O
   
Until NN NN O
then NN NN O
digoxin NN NN O
should NN NN O
be NN NN O
considered NN NN O
a NN NN O
third NN NN O
- NN NN O
line NN NN O
therapy NN NN O
. NN NN O
   
Isradipine NN NN O
treatment NN NN O
for NN NN O
hypertension NN NN B-Disease
in NN NN O
general NN NN O
practice NN NN O
in NN NN O
Hong NN NN O
Kong NN NN O
. NN NN O
   
A NN NN O
6 NN NN O
- NN NN O
week NN NN O
open NN NN O
study NN NN O
of NN NN O
the NN NN O
introduction NN NN O
of NN NN O
isradipine NN NN O
treatment NN NN O
was NN NN O
conducted NN NN O
in NN NN O
general NN NN O
practice NN NN O
in NN NN O
Hong NN NN O
Kong NN NN O
. NN NN O
   
303 NN NN O
Chinese NN NN O
patients NN NN O
with NN NN O
mild NN NN O
to NN NN O
moderate NN NN O
hypertension NN NN B-Disease
entered NN NN O
the NN NN O
study NN NN O
. NN NN O
   
Side NN NN O
effects NN NN O
were NN NN O
reported NN NN O
in NN NN O
21 NN NN O
% NN NN O
of NN NN O
patients NN NN O
and NN NN O
caused NN NN O
withdrawal NN NN O
from NN NN O
the NN NN O
study NN NN O
in NN NN O
3 NN NN O
patients NN NN O
. NN NN O
   
The NN NN O
main NN NN O
side NN NN O
- NN NN O
effects NN NN O
were NN NN O
headache NN NN B-Disease
, NN NN O
dizziness NN NN B-Disease
, NN NN O
palpitation NN NN B-Disease
and NN NN O
flushing NN NN B-Disease
and NN NN O
these NN NN O
were NN NN O
not NN NN O
more NN NN O
frequent NN NN O
than NN NN O
reported NN NN O
in NN NN O
other NN NN O
studies NN NN O
with NN NN O
isradipine NN NN O
or NN NN O
with NN NN O
placebo NN NN O
. NN NN O
   
Supine NN NN O
blood NN NN O
pressure NN NN O
was NN NN O
reduced NN NN O
( NN NN O
P NN NN O
less NN NN O
than NN NN O
0 NN NN O
. NN NN O
01 NN NN O
) NN NN O
from NN NN O
170 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
20 NN NN O
/ NN NN O
102 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
6 NN NN O
mmHg NN NN O
to NN NN O
153 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
19 NN NN O
/ NN NN O
92 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
8 NN NN O
, NN NN O
147 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
18 NN NN O
/ NN NN O
88 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
7 NN NN O
and NN NN O
144 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
14 NN NN O
/ NN NN O
87 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
6 NN NN O
mmHg NN NN O
at NN NN O
2 NN NN O
, NN NN O
4 NN NN O
and NN NN O
6 NN NN O
weeks NN NN O
respectively NN NN O
in NN NN O
evaluable NN NN O
patients NN NN O
. NN NN O
   
Similar NN NN O
reductions NN NN O
occurred NN NN O
in NN NN O
standing NN NN O
blood NN NN O
pressure NN NN O
and NN NN O
there NN NN O
was NN NN O
no NN NN O
evidence NN NN O
of NN NN O
postural NN NN B-Disease
hypotension NN NN I-Disease
. NN NN O
   
Normalization NN NN O
and NN NN O
responder NN NN O
rates NN NN O
at NN NN O
6 NN NN O
weeks NN NN O
were NN NN O
86 NN NN O
% NN NN O
and NN NN O
69 NN NN O
% NN NN O
respectively NN NN O
. NN NN O
   
Dosage NN NN O
was NN NN O
increased NN NN O
from NN NN O
2 NN NN O
. NN NN O
5 NN NN O
mg NN NN O
b NN NN O
. NN NN O
d NN NN O
. NN NN O
to NN NN O
5 NN NN O
mg NN NN O
b NN NN O
. NN NN O
d NN NN O
. NN NN O
at NN NN O
4 NN NN O
weeks NN NN O
in NN NN O
patients NN NN O
with NN NN O
diastolic NN NN O
blood NN NN O
pressure NN NN O
greater NN NN O
than NN NN O
90 NN NN O
mmHg NN NN O
and NN NN O
their NN NN O
further NN NN O
response NN NN O
was NN NN O
greater NN NN O
than NN NN O
those NN NN O
remaining NN NN O
on NN NN O
2 NN NN O
. NN NN O
5 NN NN O
mg NN NN O
b NN NN O
. NN NN O
d NN NN O
. NN NN O
   
Pharmacological NN NN O
characteristics NN NN O
and NN NN O
side NN NN O
effects NN NN O
of NN NN O
a NN NN O
new NN NN O
galenic NN NN O
formulation NN NN O
of NN NN O
propofol NN NN O
without NN NN O
soyabean NN NN O
oil NN NN O
. NN NN O
   
We NN NN O
compared NN NN O
the NN NN O
pharmacokinetics NN NN O
, NN NN O
pharmacodynamics NN NN O
and NN NN O
safety NN NN O
profile NN NN O
of NN NN O
a NN NN O
new NN NN O
galenic NN NN O
formulation NN NN O
of NN NN O
propofol NN NN O
( NN NN O
AM149 NN NN O
1 NN NN O
% NN NN O
) NN NN O
, NN NN O
which NN NN O
does NN NN O
not NN NN O
contain NN NN O
soyabean NN NN O
oil NN NN O
, NN NN O
with NN NN O
a NN NN O
standard NN NN O
formulation NN NN O
of NN NN O
propofol NN NN O
( NN NN O
Disoprivan NN NN O
1 NN NN O
% NN NN O
) NN NN O
. NN NN O
   
In NN NN O
a NN NN O
randomised NN NN O
, NN NN O
double NN NN O
- NN NN O
blind NN NN O
, NN NN O
cross NN NN O
- NN NN O
over NN NN O
study NN NN O
, NN NN O
30 NN NN O
healthy NN NN O
volunteers NN NN O
received NN NN O
a NN NN O
single NN NN O
intravenous NN NN O
bolus NN NN O
injection NN NN O
of NN NN O
2 NN NN O
. NN NN O
5 NN NN O
mg NN NN O
. NN NN O
kg NN NN O
- NN NN O
1 NN NN O
propofol NN NN O
. NN NN O
   
Plasma NN NN O
propofol NN NN O
levels NN NN O
were NN NN O
measured NN NN O
for NN NN O
48 NN NN O
h NN NN O
following NN NN O
drug NN NN O
administration NN NN O
and NN NN O
evaluated NN NN O
according NN NN O
to NN NN O
a NN NN O
three NN NN O
- NN NN O
compartment NN NN O
model NN NN O
. NN NN O
   
The NN NN O
pharmacodynamic NN NN O
parameters NN NN O
assessed NN NN O
included NN NN O
induction NN NN O
and NN NN O
emergence NN NN O
times NN NN O
, NN NN O
respiratory NN NN O
and NN NN O
cardiovascular NN NN O
effects NN NN O
, NN NN O
and NN NN O
pain NN NN B-Disease
on NN NN O
injection NN NN O
. NN NN O
   
Patients NN NN O
were NN NN O
monitored NN NN O
for NN NN O
side NN NN O
effects NN NN O
over NN NN O
48 NN NN O
h NN NN O
. NN NN O
   
Owing NN NN O
to NN NN O
a NN NN O
high NN NN O
incidence NN NN O
of NN NN O
thrombophlebitis NN NN B-Disease
, NN NN O
the NN NN O
study NN NN O
was NN NN O
terminated NN NN O
prematurely NN NN O
and NN NN O
only NN NN O
the NN NN O
data NN NN O
of NN NN O
the NN NN O
two NN NN O
parallel NN NN O
treatment NN NN O
groups NN NN O
( NN NN O
15 NN NN O
patients NN NN O
in NN NN O
each NN NN O
group NN NN O
) NN NN O
were NN NN O
analysed NN NN O
. NN NN O
   
Plasma NN NN O
concentrations NN NN O
did NN NN O
not NN NN O
differ NN NN O
significantly NN NN O
between NN NN O
the NN NN O
two NN NN O
formulations NN NN O
. NN NN O
   
Anaesthesia NN NN O
induction NN NN O
and NN NN O
emergence NN NN O
times NN NN O
, NN NN O
respiratory NN NN O
and NN NN O
cardiovascular NN NN O
variables NN NN O
showed NN NN O
no NN NN O
significant NN NN O
differences NN NN O
between NN NN O
the NN NN O
two NN NN O
treatment NN NN O
groups NN NN O
. NN NN O
   
Pain NN NN B-Disease
on NN NN O
injection NN NN O
( NN NN O
80 NN NN O
vs NN NN O
. NN NN O
20 NN NN O
% NN NN O
, NN NN O
p NN NN O
< NN NN O
0 NN NN O
. NN NN O
01 NN NN O
) NN NN O
and NN NN O
thrombophlebitis NN NN B-Disease
( NN NN O
93 NN NN O
. NN NN O
3 NN NN O
vs NN NN O
. NN NN O
6 NN NN O
. NN NN O
6 NN NN O
% NN NN O
, NN NN O
p NN NN O
< NN NN O
0 NN NN O
. NN NN O
001 NN NN O
) NN NN O
occurred NN NN O
more NN NN O
frequently NN NN O
with NN NN O
AM149 NN NN O
than NN NN O
with NN NN O
Disoprivan NN NN O
. NN NN O
   
Although NN NN O
both NN NN O
formulations NN NN O
had NN NN O
similar NN NN O
pharmacokinetic NN NN O
and NN NN O
pharmacodynamic NN NN O
profiles NN NN O
the NN NN O
new NN NN O
formulation NN NN O
is NN NN O
not NN NN O
suitable NN NN O
for NN NN O
clinical NN NN O
use NN NN O
due NN NN O
to NN NN O
the NN NN O
high NN NN O
incidence NN NN O
of NN NN O
thrombophlebitis NN NN B-Disease
produced NN NN O
. NN NN O
   
Pure NN NN B-Disease
red NN NN I-Disease
cell NN NN I-Disease
aplasia NN NN I-Disease
, NN NN O
toxic NN NN B-Disease
dermatitis NN NN I-Disease
and NN NN O
lymphadenopathy NN NN B-Disease
in NN NN O
a NN NN O
patient NN NN O
taking NN NN O
diphenylhydantoin NN NN O
. NN NN O
   
A NN NN O
patient NN NN O
taking NN NN O
diphenylhydantoin NN NN O
for NN NN O
3 NN NN O
weeks NN NN O
developed NN NN O
a NN NN O
generalized NN NN O
skin NN NN B-Disease
rash NN NN I-Disease
, NN NN O
lymphadenopathy NN NN B-Disease
and NN NN O
pure NN NN B-Disease
red NN NN I-Disease
cell NN NN I-Disease
aplasia NN NN I-Disease
. NN NN O
   
After NN NN O
withdrawal NN NN O
of NN NN O
the NN NN O
pharmacon NN NN O
all NN NN O
symptoms NN NN O
disappeared NN NN O
spontaneously NN NN O
. NN NN O
   
Skin NN NN B-Disease
rash NN NN I-Disease
is NN NN O
a NN NN O
well NN NN O
- NN NN O
known NN NN O
complication NN NN O
of NN NN O
diphenylhydantoin NN NN O
treatment NN NN O
as NN NN O
is NN NN O
benign NN NN O
and NN NN O
malignant NN NN O
lymphadenopathy NN NN B-Disease
. NN NN O
   
Pure NN NN B-Disease
red NN NN I-Disease
cell NN NN I-Disease
aplasia NN NN I-Disease
associated NN NN O
with NN NN O
diphenylhydantoin NN NN O
medication NN NN O
has NN NN O
been NN NN O
reported NN NN O
in NN NN O
3 NN NN O
patients NN NN O
. NN NN O
   
The NN NN O
exact NN NN O
mechanism NN NN O
by NN NN O
which NN NN O
diphenylhydantoin NN NN O
exerts NN NN O
its NN NN O
toxic NN NN O
effects NN NN O
is NN NN O
not NN NN O
known NN NN O
. NN NN O
   
In NN NN O
this NN NN O
patient NN NN O
the NN NN O
time NN NN O
relation NN NN O
between NN NN O
the NN NN O
ingestion NN NN O
of NN NN O
diphenylhydantoin NN NN O
and NN NN O
the NN NN O
occurrence NN NN O
of NN NN O
the NN NN O
skin NN NN B-Disease
rash NN NN I-Disease
, NN NN O
lymphadenopathy NN NN B-Disease
and NN NN O
pure NN NN B-Disease
red NN NN I-Disease
cell NN NN I-Disease
aplasia NN NN I-Disease
is NN NN O
very NN NN O
suggestive NN NN O
of NN NN O
a NN NN O
direct NN NN O
connection NN NN O
. NN NN O
   
Vinorelbine NN NN O
- NN NN O
related NN NN O
cardiac NN NN O
events NN NN O
: NN NN O
a NN NN O
meta NN NN O
- NN NN O
analysis NN NN O
of NN NN O
randomized NN NN O
clinical NN NN O
trials NN NN O
. NN NN O
   
Several NN NN O
cases NN NN O
of NN NN O
cardiac NN NN O
adverse NN NN O
reactions NN NN O
related NN NN O
to NN NN O
vinorelbine NN NN O
( NN NN O
VNR NN NN O
) NN NN O
have NN NN O
been NN NN O
reported NN NN O
in NN NN O
the NN NN O
literature NN NN O
. NN NN O
   
In NN NN O
order NN NN O
to NN NN O
quantify NN NN O
the NN NN O
incidence NN NN O
of NN NN O
these NN NN O
cardiac NN NN O
events NN NN O
, NN NN O
we NN NN O
performed NN NN O
a NN NN O
meta NN NN O
- NN NN O
analysis NN NN O
of NN NN O
clinical NN NN O
trials NN NN O
comparing NN NN O
VNR NN NN O
with NN NN O
other NN NN O
chemotherapeutic NN NN O
agents NN NN O
in NN NN O
the NN NN O
treatment NN NN O
of NN NN O
various NN NN O
malignancies NN NN B-Disease
. NN NN O
   
Randomized NN NN O
clinical NN NN O
trials NN NN O
comparing NN NN O
VNR NN NN O
with NN NN O
other NN NN O
drugs NN NN O
in NN NN O
the NN NN O
treatment NN NN O
of NN NN O
cancer NN NN B-Disease
were NN NN O
searched NN NN O
in NN NN O
Medline NN NN O
, NN NN O
Embase NN NN O
, NN NN O
Evidence NN NN O
- NN NN O
based NN NN O
Medicine NN NN O
Reviews NN NN O
databases NN NN O
and NN NN O
the NN NN O
Cochrane NN NN O
library NN NN O
from NN NN O
1987 NN NN O
to NN NN O
2002 NN NN O
. NN NN O
   
Outcomes NN NN O
of NN NN O
interest NN NN O
were NN NN O
severe NN NN O
cardiac NN NN O
events NN NN O
, NN NN O
toxic NN NN O
deaths NN NN O
and NN NN O
cardiac NN NN O
event NN NN O
- NN NN O
related NN NN O
deaths NN NN O
reported NN NN O
in NN NN O
each NN NN O
publication NN NN O
. NN NN O
   
We NN NN O
found NN NN O
19 NN NN O
trials NN NN O
, NN NN O
involving NN NN O
2441 NN NN O
patients NN NN O
treated NN NN O
by NN NN O
VNR NN NN O
and NN NN O
2050 NN NN O
control NN NN O
patients NN NN O
. NN NN O
   
The NN NN O
incidence NN NN O
of NN NN O
cardiac NN NN O
events NN NN O
with NN NN O
VNR NN NN O
was NN NN O
1 NN NN O
. NN NN O
19 NN NN O
% NN NN O
[ NN NN O
95 NN NN O
% NN NN O
confidence NN NN O
interval NN NN O
( NN NN O
CI NN NN O
) NN NN O
( NN NN O
0 NN NN O
. NN NN O
75 NN NN O
; NN NN O
1 NN NN O
. NN NN O
67 NN NN O
) NN NN O
] NN NN O
. NN NN O
   
There NN NN O
was NN NN O
no NN NN O
difference NN NN O
in NN NN O
the NN NN O
risk NN NN O
of NN NN O
cardiac NN NN O
events NN NN O
between NN NN O
VNR NN NN O
and NN NN O
other NN NN O
drugs NN NN O
[ NN NN O
odds NN NN O
ratio NN NN O
: NN NN O
0 NN NN O
. NN NN O
92 NN NN O
, NN NN O
95 NN NN O
% NN NN O
CI NN NN O
( NN NN O
0 NN NN O
. NN NN O
54 NN NN O
; NN NN O
1 NN NN O
. NN NN O
55 NN NN O
) NN NN O
] NN NN O
. NN NN O
   
The NN NN O
risk NN NN O
of NN NN O
VNR NN NN O
cardiac NN NN O
events NN NN O
was NN NN O
similar NN NN O
to NN NN O
vindesine NN NN O
( NN NN O
VDS NN NN O
) NN NN O
and NN NN O
other NN NN O
cardiotoxic NN NN B-Disease
drugs NN NN O
[ NN NN O
fluorouracil NN NN O
, NN NN O
anthracyclines NN NN O
, NN NN O
gemcitabine NN NN O
( NN NN O
GEM NN NN O
) NN NN O
em NN NN O
leader NN NN O
] NN NN O
. NN NN O
   
Even NN NN O
if NN NN O
it NN NN O
did NN NN O
not NN NN O
reach NN NN O
statistical NN NN O
significance NN NN O
because NN NN O
of NN NN O
a NN NN O
few NN NN O
number NN NN O
of NN NN O
cases NN NN O
, NN NN O
the NN NN O
risk NN NN O
was NN NN O
lower NN NN O
in NN NN O
trials NN NN O
excluding NN NN O
patients NN NN O
with NN NN O
cardiac NN NN O
history NN NN O
, NN NN O
and NN NN O
seemed NN NN O
to NN NN O
be NN NN O
higher NN NN O
in NN NN O
trials NN NN O
including NN NN O
patients NN NN O
with NN NN O
pre NN NN O
- NN NN O
existing NN NN O
cardiac NN NN B-Disease
diseases NN NN I-Disease
. NN NN O
   
Vinorelbine NN NN O
- NN NN O
related NN NN O
cardiac NN NN O
events NN NN O
concern NN NN O
about NN NN O
1 NN NN O
% NN NN O
of NN NN O
treated NN NN O
patients NN NN O
in NN NN O
clinical NN NN O
trials NN NN O
. NN NN O
   
However NN NN O
, NN NN O
the NN NN O
risk NN NN O
associated NN NN O
with NN NN O
VNR NN NN O
seems NN NN O
to NN NN O
be NN NN O
similar NN NN O
to NN NN O
that NN NN O
of NN NN O
other NN NN O
chemotherapeutic NN NN O
agents NN NN O
in NN NN O
the NN NN O
same NN NN O
indications NN NN O
. NN NN O
   
MRI NN NN O
findings NN NN O
of NN NN O
hypoxic NN NN O
cortical NN NN O
laminar NN NN O
necrosis NN NN B-Disease
in NN NN O
a NN NN O
child NN NN O
with NN NN O
hemolytic NN NN B-Disease
anemia NN NN I-Disease
crisis NN NN O
. NN NN O
   
We NN NN O
present NN NN O
magnetic NN NN O
resonance NN NN O
imaging NN NN O
findings NN NN O
of NN NN O
a NN NN O
5 NN NN O
- NN NN O
year NN NN O
- NN NN O
old NN NN O
girl NN NN O
who NN NN O
had NN NN O
a NN NN O
rapidly NN NN O
installing NN NN O
hemolytic NN NN B-Disease
anemia NN NN I-Disease
crisis NN NN O
induced NN NN O
by NN NN O
trimethoprim NN NN O
- NN NN O
sulfomethoxazole NN NN O
, NN NN O
resulting NN NN O
in NN NN O
cerebral NN NN B-Disease
anoxia NN NN I-Disease
leading NN NN O
to NN NN O
permanent NN NN O
damage NN NN O
. NN NN O
   
Magnetic NN NN O
Resonance NN NN O
imaging NN NN O
revealed NN NN O
cortical NN NN O
laminar NN NN O
necrosis NN NN B-Disease
in NN NN O
arterial NN NN O
border NN NN O
zones NN NN O
in NN NN O
both NN NN O
cerebral NN NN O
hemispheres NN NN O
, NN NN O
ischemic NN NN O
changes NN NN O
in NN NN O
subcortical NN NN O
white NN NN O
matter NN NN O
of NN NN O
left NN NN O
cerebral NN NN O
hemisphere NN NN O
, NN NN O
and NN NN O
in NN NN O
the NN NN O
left NN NN O
putamen NN NN O
. NN NN O
   
Although NN NN O
cortical NN NN O
laminar NN NN O
necrosis NN NN B-Disease
is NN NN O
a NN NN O
classic NN NN O
entity NN NN O
in NN NN O
adulthood NN NN O
related NN NN O
to NN NN O
conditions NN NN O
of NN NN O
energy NN NN O
depletions NN NN O
, NN NN O
there NN NN O
are NN NN O
few NN NN O
reports NN NN O
available NN NN O
in NN NN O
children NN NN O
. NN NN O
   
A NN NN O
wide NN NN O
review NN NN O
of NN NN O
the NN NN O
literature NN NN O
is NN NN O
also NN NN O
presented NN NN O
. NN NN O
   
The NN NN O
natural NN NN O
history NN NN O
of NN NN O
Vigabatrin NN NN O
associated NN NN O
visual NN NN B-Disease
field NN NN I-Disease
defects NN NN I-Disease
in NN NN O
patients NN NN O
electing NN NN O
to NN NN O
continue NN NN O
their NN NN O
medication NN NN O
. NN NN O
   
PURPOSE NN NN O
: NN NN O
To NN NN O
determine NN NN O
the NN NN O
natural NN NN O
history NN NN O
of NN NN O
visual NN NN B-Disease
field NN NN I-Disease
defects NN NN I-Disease
in NN NN O
a NN NN O
group NN NN O
of NN NN O
patients NN NN O
known NN NN O
to NN NN O
have NN NN O
Vigabatrin NN NN O
- NN NN O
associated NN NN O
changes NN NN O
who NN NN O
elected NN NN O
to NN NN O
continue NN NN O
the NN NN O
medication NN NN O
because NN NN O
of NN NN O
good NN NN O
seizure NN NN B-Disease
control NN NN O
. NN NN O
   
METHODS NN NN O
: NN NN O
All NN NN O
patients NN NN O
taking NN NN O
Vigabatrin NN NN O
alone NN NN O
or NN NN O
in NN NN O
combination NN NN O
with NN NN O
other NN NN O
antiepileptic NN NN O
drugs NN NN O
for NN NN O
at NN NN O
least NN NN O
5 NN NN O
years NN NN O
( NN NN O
range NN NN O
5 NN NN O
- NN NN O
12 NN NN O
years NN NN O
) NN NN O
were NN NN O
entered NN NN O
into NN NN O
a NN NN O
visual NN NN O
surveillance NN NN O
programme NN NN O
. NN NN O
   
Patients NN NN O
were NN NN O
followed NN NN O
up NN NN O
at NN NN O
6 NN NN O
- NN NN O
monthly NN NN O
intervals NN NN O
for NN NN O
not NN NN O
less NN NN O
than NN NN O
18 NN NN O
months NN NN O
( NN NN O
range NN NN O
18 NN NN O
- NN NN O
43 NN NN O
months NN NN O
) NN NN O
. NN NN O
   
In NN NN O
all NN NN O
, NN NN O
16 NN NN O
patients NN NN O
with NN NN O
unequivocal NN NN O
defects NN NN O
continued NN NN O
the NN NN O
medication NN NN O
. NN NN O
   
Following NN NN O
already NN NN O
published NN NN O
methodology NN NN O
( NN NN O
Eye NN NN O
2002 NN NN O
; NN NN O
16 NN NN O
; NN NN O
567 NN NN O
- NN NN O
571 NN NN O
) NN NN O
monocular NN NN O
mean NN NN O
radial NN NN O
degrees NN NN O
( NN NN O
MRDs NN NN O
) NN NN O
to NN NN O
the NN NN O
I NN NN O
/ NN NN O
4e NN NN O
isopter NN NN O
on NN NN O
Goldmann NN NN O
perimetry NN NN O
was NN NN O
calculated NN NN O
for NN NN O
the NN NN O
right NN NN O
eye NN NN O
at NN NN O
the NN NN O
time NN NN O
of NN NN O
discovery NN NN O
of NN NN O
a NN NN O
visual NN NN B-Disease
field NN NN I-Disease
defect NN NN I-Disease
and NN NN O
again NN NN O
after NN NN O
not NN NN O
less NN NN O
than NN NN O
18 NN NN O
months NN NN O
follow NN NN O
- NN NN O
up NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
Mean NN NN O
right NN NN O
eye NN NN O
MRD NN NN O
at NN NN O
presentation NN NN O
was NN NN O
36 NN NN O
. NN NN O
98 NN NN O
degrees NN NN O
( NN NN O
range NN NN O
22 NN NN O
. NN NN O
25 NN NN O
- NN NN O
51 NN NN O
. NN NN O
0 NN NN O
) NN NN O
, NN NN O
compared NN NN O
to NN NN O
38 NN NN O
. NN NN O
40 NN NN O
degrees NN NN O
( NN NN O
range NN NN O
22 NN NN O
. NN NN O
5 NN NN O
- NN NN O
49 NN NN O
. NN NN O
75 NN NN O
) NN NN O
after NN NN O
follow NN NN O
- NN NN O
up NN NN O
; NN NN O
P NN NN O
= NN NN O
0 NN NN O
. NN NN O
338 NN NN O
unpaired NN NN O
t NN NN O
- NN NN O
test NN NN O
. NN NN O
   
Only NN NN O
one NN NN O
patient NN NN O
demonstrated NN NN O
a NN NN O
deterioration NN NN B-Disease
in NN NN I-Disease
visual NN NN I-Disease
field NN NN I-Disease
during NN NN O
the NN NN O
study NN NN O
period NN NN O
and NN NN O
discontinued NN NN O
treatment NN NN O
. NN NN O
   
CONCLUSION NN NN O
: NN NN O
Established NN NN O
visual NN NN B-Disease
field NN NN I-Disease
defects NN NN I-Disease
presumed NN NN O
to NN NN O
be NN NN O
due NN NN O
to NN NN O
Vigabatrin NN NN O
therapy NN NN O
did NN NN O
not NN NN O
usually NN NN O
progress NN NN O
in NN NN O
spite NN NN O
of NN NN O
continuing NN NN O
use NN NN O
of NN NN O
the NN NN O
medication NN NN O
. NN NN O
   
These NN NN O
data NN NN O
give NN NN O
support NN NN O
to NN NN O
the NN NN O
hypothesis NN NN O
that NN NN O
the NN NN O
pathogenesis NN NN O
of NN NN O
Vigabatrin NN NN O
- NN NN O
associated NN NN O
visual NN NN B-Disease
field NN NN I-Disease
defects NN NN I-Disease
may NN NN O
be NN NN O
an NN NN O
idiosyncratic NN NN O
adverse NN NN O
drug NN NN O
reaction NN NN O
rather NN NN O
than NN NN O
dose NN NN O
- NN NN O
dependent NN NN O
toxicity NN NN B-Disease
. NN NN O
   
Induction NN NN O
of NN NN O
rosaceiform NN NN O
dermatitis NN NN B-Disease
during NN NN O
treatment NN NN O
of NN NN O
facial NN NN B-Disease
inflammatory NN NN I-Disease
dermatoses NN NN I-Disease
with NN NN O
tacrolimus NN NN O
ointment NN NN O
. NN NN O
   
BACKGROUND NN NN O
: NN NN O
Tacrolimus NN NN O
ointment NN NN O
is NN NN O
increasingly NN NN O
used NN NN O
for NN NN O
anti NN NN O
- NN NN O
inflammatory NN NN O
treatment NN NN O
of NN NN O
sensitive NN NN O
areas NN NN O
such NN NN O
as NN NN O
the NN NN O
face NN NN O
, NN NN O
and NN NN O
recent NN NN O
observations NN NN O
indicate NN NN O
that NN NN O
the NN NN O
treatment NN NN O
is NN NN O
effective NN NN O
in NN NN O
steroid NN NN O
- NN NN O
aggravated NN NN O
rosacea NN NN B-Disease
and NN NN O
perioral NN NN B-Disease
dermatitis NN NN I-Disease
. NN NN O
   
We NN NN O
report NN NN O
on NN NN O
rosaceiform NN NN O
dermatitis NN NN B-Disease
as NN NN O
a NN NN O
complication NN NN O
of NN NN O
treatment NN NN O
with NN NN O
tacrolimus NN NN O
ointment NN NN O
. NN NN O
   
OBSERVATIONS NN NN O
: NN NN O
Six NN NN O
adult NN NN O
patients NN NN O
with NN NN O
inflammatory NN NN B-Disease
facial NN NN I-Disease
dermatoses NN NN I-Disease
were NN NN O
treated NN NN O
with NN NN O
tacrolimus NN NN O
ointment NN NN O
because NN NN O
of NN NN O
the NN NN O
ineffectiveness NN NN O
of NN NN O
standard NN NN O
treatments NN NN O
. NN NN O
   
Within NN NN O
2 NN NN O
to NN NN O
3 NN NN O
weeks NN NN O
of NN NN O
initially NN NN O
effective NN NN O
and NN NN O
well NN NN O
- NN NN O
tolerated NN NN O
treatment NN NN O
, NN NN O
3 NN NN O
patients NN NN O
with NN NN O
a NN NN O
history NN NN O
of NN NN O
rosacea NN NN B-Disease
and NN NN O
1 NN NN O
with NN NN O
a NN NN O
history NN NN O
of NN NN O
acne NN NN B-Disease
experienced NN NN O
sudden NN NN O
worsening NN NN O
with NN NN O
pustular NN NN O
rosaceiform NN NN O
lesions NN NN O
. NN NN O
   
Biopsy NN NN O
revealed NN NN O
an NN NN O
abundance NN NN O
of NN NN O
Demodex NN NN O
mites NN NN O
in NN NN O
2 NN NN O
of NN NN O
these NN NN O
patients NN NN O
. NN NN O
   
In NN NN O
1 NN NN O
patient NN NN O
with NN NN O
eyelid NN NN O
eczema NN NN B-Disease
, NN NN O
rosaceiform NN NN O
periocular NN NN B-Disease
dermatitis NN NN I-Disease
gradually NN NN O
appeared NN NN O
after NN NN O
3 NN NN O
weeks NN NN O
of NN NN O
treatment NN NN O
. NN NN O
   
In NN NN O
1 NN NN O
patient NN NN O
with NN NN O
atopic NN NN B-Disease
dermatitis NN NN I-Disease
, NN NN O
telangiectatic NN NN O
and NN NN O
papular NN NN B-Disease
rosacea NN NN I-Disease
insidiously NN NN O
appeared NN NN O
after NN NN O
5 NN NN O
months NN NN O
of NN NN O
treatment NN NN O
. NN NN O
   
CONCLUSIONS NN NN O
: NN NN O
Our NN NN O
observations NN NN O
suggest NN NN O
that NN NN O
the NN NN O
spectrum NN NN O
of NN NN O
rosaceiform NN NN O
dermatitis NN NN B-Disease
as NN NN O
a NN NN O
complication NN NN O
of NN NN O
treatment NN NN O
with NN NN O
tacrolimus NN NN O
ointment NN NN O
is NN NN O
heterogeneous NN NN O
. NN NN O
   
A NN NN O
variety NN NN O
of NN NN O
factors NN NN O
, NN NN O
such NN NN O
as NN NN O
vasoactive NN NN O
properties NN NN O
of NN NN O
tacrolimus NN NN O
, NN NN O
proliferation NN NN O
of NN NN O
Demodex NN NN O
due NN NN O
to NN NN O
local NN NN O
immunosuppression NN NN O
, NN NN O
and NN NN O
the NN NN O
occlusive NN NN O
properties NN NN O
of NN NN O
the NN NN O
ointment NN NN O
, NN NN O
may NN NN O
be NN NN O
involved NN NN O
in NN NN O
the NN NN O
observed NN NN O
phenomena NN NN O
. NN NN O
   
Future NN NN O
studies NN NN O
are NN NN O
needed NN NN O
to NN NN O
identify NN NN O
individual NN NN O
risk NN NN O
factors NN NN O
. NN NN O
   
Intravascular NN NN O
hemolysis NN NN B-Disease
and NN NN O
acute NN NN B-Disease
renal NN NN I-Disease
failure NN NN I-Disease
following NN NN O
intermittent NN NN O
rifampin NN NN O
therapy NN NN O
. NN NN O
   
Renal NN NN B-Disease
failure NN NN I-Disease
is NN NN O
a NN NN O
rare NN NN O
complication NN NN O
associated NN NN O
with NN NN O
the NN NN O
use NN NN O
of NN NN O
rifampin NN NN O
. NN NN O
   
Intravascular NN NN O
hemolysis NN NN B-Disease
leading NN NN O
to NN NN O
acute NN NN B-Disease
renal NN NN I-Disease
failure NN NN I-Disease
following NN NN O
rifampin NN NN O
therapy NN NN O
is NN NN O
extremely NN NN O
rare NN NN O
. NN NN O
   
Two NN NN O
patients NN NN O
with NN NN O
leprosy NN NN B-Disease
who NN NN O
developed NN NN O
hemolysis NN NN B-Disease
and NN NN O
acute NN NN B-Disease
renal NN NN I-Disease
failure NN NN I-Disease
following NN NN O
rifampin NN NN O
are NN NN O
reported NN NN O
. NN NN O
   
Structural NN NN O
abnormalities NN NN O
in NN NN O
the NN NN O
brains NN NN O
of NN NN O
human NN NN O
subjects NN NN O
who NN NN O
use NN NN O
methamphetamine NN NN O
. NN NN O
   
We NN NN O
visualize NN NN O
, NN NN O
for NN NN O
the NN NN O
first NN NN O
time NN NN O
, NN NN O
the NN NN O
profile NN NN O
of NN NN O
structural NN NN B-Disease
deficits NN NN I-Disease
in NN NN I-Disease
the NN NN I-Disease
human NN NN I-Disease
brain NN NN I-Disease
associated NN NN O
with NN NN O
chronic NN NN O
methamphetamine NN NN O
( NN NN O
MA NN NN O
) NN NN O
abuse NN NN O
. NN NN O
   
Studies NN NN O
of NN NN O
human NN NN O
subjects NN NN O
who NN NN O
have NN NN O
used NN NN O
MA NN NN O
chronically NN NN O
have NN NN O
revealed NN NN O
deficits NN NN O
in NN NN O
dopaminergic NN NN O
and NN NN O
serotonergic NN NN O
systems NN NN O
and NN NN O
cerebral NN NN O
metabolic NN NN B-Disease
abnormalities NN NN I-Disease
. NN NN O
   
Using NN NN O
magnetic NN NN O
resonance NN NN O
imaging NN NN O
( NN NN O
MRI NN NN O
) NN NN O
and NN NN O
new NN NN O
computational NN NN O
brain NN NN O
- NN NN O
mapping NN NN O
techniques NN NN O
, NN NN O
we NN NN O
determined NN NN O
the NN NN O
pattern NN NN O
of NN NN O
structural NN NN O
brain NN NN O
alterations NN NN O
associated NN NN O
with NN NN O
chronic NN NN O
MA NN NN O
abuse NN NN O
in NN NN O
human NN NN O
subjects NN NN O
and NN NN O
related NN NN O
these NN NN O
deficits NN NN O
to NN NN O
cognitive NN NN B-Disease
impairment NN NN I-Disease
. NN NN O
   
We NN NN O
used NN NN O
high NN NN O
- NN NN O
resolution NN NN O
MRI NN NN O
and NN NN O
surface NN NN O
- NN NN O
based NN NN O
computational NN NN O
image NN NN O
analyses NN NN O
to NN NN O
map NN NN O
regional NN NN O
abnormalities NN NN B-Disease
in NN NN I-Disease
the NN NN I-Disease
cortex NN NN I-Disease
, NN NN I-Disease
hippocampus NN NN I-Disease
, NN NN I-Disease
white NN NN I-Disease
matter NN NN I-Disease
, NN NN I-Disease
and NN NN I-Disease
ventricles NN NN I-Disease
in NN NN O
22 NN NN O
human NN NN O
subjects NN NN O
who NN NN O
used NN NN O
MA NN NN O
and NN NN O
21 NN NN O
age NN NN O
- NN NN O
matched NN NN O
, NN NN O
healthy NN NN O
controls NN NN O
. NN NN O
   
Cortical NN NN O
maps NN NN O
revealed NN NN O
severe NN NN O
gray NN NN O
- NN NN O
matter NN NN O
deficits NN NN O
in NN NN O
the NN NN O
cingulate NN NN O
, NN NN O
limbic NN NN O
, NN NN O
and NN NN O
paralimbic NN NN O
cortices NN NN O
of NN NN O
MA NN NN O
abusers NN NN O
( NN NN O
averaging NN NN O
11 NN NN O
. NN NN O
3 NN NN O
% NN NN O
below NN NN O
control NN NN O
; NN NN O
p NN NN O
< NN NN O
0 NN NN O
. NN NN O
05 NN NN O
) NN NN O
. NN NN O
   
On NN NN O
average NN NN O
, NN NN O
MA NN NN O
abusers NN NN O
had NN NN O
7 NN NN O
. NN NN O
8 NN NN O
% NN NN O
smaller NN NN O
hippocampal NN NN O
volumes NN NN O
than NN NN O
control NN NN O
subjects NN NN O
( NN NN O
p NN NN O
< NN NN O
0 NN NN O
. NN NN O
01 NN NN O
; NN NN O
left NN NN O
, NN NN O
p NN NN O
= NN NN O
0 NN NN O
. NN NN O
01 NN NN O
; NN NN O
right NN NN O
, NN NN O
p NN NN O
< NN NN O
0 NN NN O
. NN NN O
05 NN NN O
) NN NN O
and NN NN O
significant NN NN O
white NN NN O
- NN NN O
matter NN NN O
hypertrophy NN NN B-Disease
( NN NN O
7 NN NN O
. NN NN O
0 NN NN O
% NN NN O
; NN NN O
p NN NN O
< NN NN O
0 NN NN O
. NN NN O
01 NN NN O
) NN NN O
. NN NN O
   
Hippocampal NN NN O
deficits NN NN O
were NN NN O
mapped NN NN O
and NN NN O
correlated NN NN O
with NN NN O
memory NN NN O
performance NN NN O
on NN NN O
a NN NN O
word NN NN O
- NN NN O
recall NN NN O
test NN NN O
( NN NN O
p NN NN O
< NN NN O
0 NN NN O
. NN NN O
05 NN NN O
) NN NN O
. NN NN O
   
MRI NN NN O
- NN NN O
based NN NN O
maps NN NN O
suggest NN NN O
that NN NN O
chronic NN NN O
methamphetamine NN NN O
abuse NN NN O
causes NN NN O
a NN NN O
selective NN NN O
pattern NN NN O
of NN NN O
cerebral NN NN O
deterioration NN NN O
that NN NN O
contributes NN NN O
to NN NN O
impaired NN NN B-Disease
memory NN NN I-Disease
performance NN NN I-Disease
. NN NN O
   
MA NN NN O
may NN NN O
selectively NN NN O
damage NN NN O
the NN NN O
medial NN NN O
temporal NN NN O
lobe NN NN O
and NN NN O
, NN NN O
consistent NN NN O
with NN NN O
metabolic NN NN O
studies NN NN O
, NN NN O
the NN NN O
cingulate NN NN O
- NN NN O
limbic NN NN O
cortex NN NN O
, NN NN O
inducing NN NN O
neuroadaptation NN NN O
, NN NN O
neuropil NN NN O
reduction NN NN O
, NN NN O
or NN NN O
cell NN NN O
death NN NN O
. NN NN O
   
Prominent NN NN O
white NN NN O
- NN NN O
matter NN NN O
hypertrophy NN NN B-Disease
may NN NN O
result NN NN O
from NN NN O
altered NN NN O
myelination NN NN O
and NN NN O
adaptive NN NN O
glial NN NN O
changes NN NN O
, NN NN O
including NN NN O
gliosis NN NN B-Disease
secondary NN NN O
to NN NN O
neuronal NN NN B-Disease
damage NN NN I-Disease
. NN NN O
   
These NN NN O
brain NN NN O
substrates NN NN O
may NN NN O
help NN NN O
account NN NN O
for NN NN O
the NN NN O
symptoms NN NN O
of NN NN O
MA NN NN O
abuse NN NN O
, NN NN O
providing NN NN O
therapeutic NN NN O
targets NN NN O
for NN NN O
drug NN NN O
- NN NN O
induced NN NN O
brain NN NN B-Disease
injury NN NN I-Disease
. NN NN O
   
Disruption NN NN O
of NN NN O
hepatic NN NN O
lipid NN NN O
homeostasis NN NN O
in NN NN O
mice NN NN O
after NN NN O
amiodarone NN NN O
treatment NN NN O
is NN NN O
associated NN NN O
with NN NN O
peroxisome NN NN O
proliferator NN NN O
- NN NN O
activated NN NN O
receptor NN NN O
- NN NN O
alpha NN NN O
target NN NN O
gene NN NN O
activation NN NN O
. NN NN O
   
Amiodarone NN NN O
, NN NN O
an NN NN O
efficacious NN NN O
and NN NN O
widely NN NN O
used NN NN O
antiarrhythmic NN NN O
agent NN NN O
, NN NN O
has NN NN O
been NN NN O
reported NN NN O
to NN NN O
cause NN NN O
hepatotoxicity NN NN B-Disease
in NN NN O
some NN NN O
patients NN NN O
. NN NN O
   
To NN NN O
gain NN NN O
insight NN NN O
into NN NN O
the NN NN O
mechanism NN NN O
of NN NN O
this NN NN O
unwanted NN NN O
effect NN NN O
, NN NN O
mice NN NN O
were NN NN O
administered NN NN O
various NN NN O
doses NN NN O
of NN NN O
amiodarone NN NN O
and NN NN O
examined NN NN O
for NN NN O
changes NN NN O
in NN NN O
hepatic NN NN O
histology NN NN O
and NN NN O
gene NN NN O
regulation NN NN O
. NN NN O
   
Amiodarone NN NN O
induced NN NN O
hepatomegaly NN NN B-Disease
, NN NN O
hepatocyte NN NN O
microvesicular NN NN O
lipid NN NN O
accumulation NN NN O
, NN NN O
and NN NN O
a NN NN O
significant NN NN O
decrease NN NN O
in NN NN O
serum NN NN O
triglycerides NN NN O
and NN NN O
glucose NN NN O
. NN NN O
   
Northern NN NN O
blot NN NN O
analysis NN NN O
of NN NN O
hepatic NN NN O
RNA NN NN O
revealed NN NN O
a NN NN O
dose NN NN O
- NN NN O
dependent NN NN O
increase NN NN O
in NN NN O
the NN NN O
expression NN NN O
of NN NN O
a NN NN O
number NN NN O
of NN NN O
genes NN NN O
critical NN NN O
for NN NN O
fatty NN NN O
acid NN NN O
oxidation NN NN O
, NN NN O
lipoprotein NN NN O
assembly NN NN O
, NN NN O
and NN NN O
lipid NN NN O
transport NN NN O
. NN NN O
   
Many NN NN O
of NN NN O
these NN NN O
genes NN NN O
are NN NN O
regulated NN NN O
by NN NN O
the NN NN O
peroxisome NN NN O
proliferator NN NN O
- NN NN O
activated NN NN O
receptor NN NN O
- NN NN O
alpha NN NN O
( NN NN O
PPARalpha NN NN O
) NN NN O
, NN NN O
a NN NN O
ligand NN NN O
- NN NN O
activated NN NN O
nuclear NN NN O
hormone NN NN O
receptor NN NN O
transcription NN NN O
factor NN NN O
. NN NN O
   
The NN NN O
absence NN NN O
of NN NN O
induction NN NN O
of NN NN O
these NN NN O
genes NN NN O
as NN NN O
well NN NN O
as NN NN O
hepatomegaly NN NN B-Disease
in NN NN O
PPARalpha NN NN O
knockout NN NN O
[ NN NN O
PPARalpha NN NN O
- NN NN O
/ NN NN O
- NN NN O
] NN NN O
mice NN NN O
indicated NN NN O
that NN NN O
the NN NN O
effects NN NN O
of NN NN O
amiodarone NN NN O
were NN NN O
dependent NN NN O
upon NN NN O
the NN NN O
presence NN NN O
of NN NN O
a NN NN O
functional NN NN O
PPARalpha NN NN O
gene NN NN O
. NN NN O
   
Compared NN NN O
to NN NN O
wild NN NN O
- NN NN O
type NN NN O
mice NN NN O
, NN NN O
treatment NN NN O
of NN NN O
PPARalpha NN NN O
- NN NN O
/ NN NN O
- NN NN O
mice NN NN O
with NN NN O
amiodarone NN NN O
resulted NN NN O
in NN NN O
an NN NN O
increased NN NN O
rate NN NN O
and NN NN O
extent NN NN O
of NN NN O
total NN NN O
body NN NN O
weight NN NN B-Disease
loss NN NN I-Disease
. NN NN O
   
The NN NN O
inability NN NN O
of NN NN O
amiodarone NN NN O
to NN NN O
directly NN NN O
activate NN NN O
either NN NN O
human NN NN O
or NN NN O
mouse NN NN O
PPARalpha NN NN O
transiently NN NN O
expressed NN NN O
in NN NN O
human NN NN O
HepG2 NN NN O
hepatoma NN NN B-Disease
cells NN NN O
indicates NN NN O
that NN NN O
the NN NN O
effects NN NN O
of NN NN O
amiodarone NN NN O
on NN NN O
the NN NN O
function NN NN O
of NN NN O
this NN NN O
receptor NN NN O
were NN NN O
indirect NN NN O
. NN NN O
   
Based NN NN O
upon NN NN O
these NN NN O
results NN NN O
, NN NN O
we NN NN O
conclude NN NN O
that NN NN O
amiodarone NN NN O
disrupts NN NN O
hepatic NN NN O
lipid NN NN O
homeostasis NN NN O
and NN NN O
that NN NN O
the NN NN O
increased NN NN O
expression NN NN O
of NN NN O
PPARalpha NN NN O
target NN NN O
genes NN NN O
is NN NN O
secondary NN NN O
to NN NN O
this NN NN O
toxic NN NN O
effect NN NN O
. NN NN O
   
These NN NN O
results NN NN O
provide NN NN O
important NN NN O
new NN NN O
mechanistic NN NN O
information NN NN O
regarding NN NN O
the NN NN O
hepatotoxic NN NN B-Disease
effects NN NN O
of NN NN O
amiodarone NN NN O
and NN NN O
indicate NN NN O
that NN NN O
PPARalpha NN NN O
protects NN NN O
against NN NN O
amiodarone NN NN O
- NN NN O
induced NN NN O
hepatotoxicity NN NN B-Disease
. NN NN O
   
Safety NN NN O
and NN NN O
compliance NN NN O
with NN NN O
once NN NN O
- NN NN O
daily NN NN O
niacin NN NN O
extended NN NN O
- NN NN O
release NN NN O
/ NN NN O
lovastatin NN NN O
as NN NN O
initial NN NN O
therapy NN NN O
in NN NN O
the NN NN O
Impact NN NN O
of NN NN O
Medical NN NN O
Subspecialty NN NN O
on NN NN O
Patient NN NN O
Compliance NN NN O
to NN NN O
Treatment NN NN O
( NN NN O
IMPACT NN NN O
) NN NN O
study NN NN O
. NN NN O
   
Niacin NN NN O
extended NN NN O
- NN NN O
release NN NN O
/ NN NN O
lovastatin NN NN O
is NN NN O
a NN NN O
new NN NN O
combination NN NN O
product NN NN O
approved NN NN O
for NN NN O
treatment NN NN O
of NN NN O
primary NN NN O
hypercholesterolemia NN NN B-Disease
and NN NN O
mixed NN NN O
dyslipidemia NN NN B-Disease
. NN NN O
   
This NN NN O
open NN NN O
- NN NN O
labeled NN NN O
, NN NN O
multicenter NN NN O
study NN NN O
evaluated NN NN O
the NN NN O
safety NN NN O
of NN NN O
bedtime NN NN O
niacin NN NN O
extended NN NN O
- NN NN O
release NN NN O
/ NN NN O
lovastatin NN NN O
when NN NN O
dosed NN NN O
as NN NN O
initial NN NN O
therapy NN NN O
and NN NN O
patient NN NN O
compliance NN NN O
to NN NN O
treatment NN NN O
in NN NN O
various NN NN O
clinical NN NN O
practice NN NN O
settings NN NN O
. NN NN O
   
A NN NN O
total NN NN O
of NN NN O
4 NN NN O
, NN NN O
499 NN NN O
patients NN NN O
with NN NN O
dyslipidemia NN NN B-Disease
requiring NN NN O
drug NN NN O
intervention NN NN O
was NN NN O
enrolled NN NN O
at NN NN O
1 NN NN O
, NN NN O
081 NN NN O
sites NN NN O
. NN NN O
   
Patients NN NN O
were NN NN O
treated NN NN O
with NN NN O
1 NN NN O
tablet NN NN O
( NN NN O
500 NN NN O
mg NN NN O
of NN NN O
niacin NN NN O
extended NN NN O
- NN NN O
release NN NN O
/ NN NN O
20 NN NN O
mg NN NN O
of NN NN O
lovastatin NN NN O
) NN NN O
once NN NN O
nightly NN NN O
for NN NN O
4 NN NN O
weeks NN NN O
and NN NN O
then NN NN O
2 NN NN O
tablets NN NN O
for NN NN O
8 NN NN O
weeks NN NN O
. NN NN O
   
Patients NN NN O
also NN NN O
received NN NN O
dietary NN NN O
counseling NN NN O
, NN NN O
educational NN NN O
materials NN NN O
, NN NN O
and NN NN O
reminders NN NN O
to NN NN O
call NN NN O
a NN NN O
toll NN NN O
- NN NN O
free NN NN O
number NN NN O
that NN NN O
provided NN NN O
further NN NN O
education NN NN O
about NN NN O
dyslipidemia NN NN B-Disease
and NN NN O
niacin NN NN O
extended NN NN O
- NN NN O
release NN NN O
/ NN NN O
lovastatin NN NN O
. NN NN O
   
Primary NN NN O
end NN NN O
points NN NN O
were NN NN O
study NN NN O
compliance NN NN O
, NN NN O
increases NN NN O
in NN NN O
liver NN NN O
transaminases NN NN O
to NN NN O
> NN NN O
3 NN NN O
times NN NN O
the NN NN O
upper NN NN O
limit NN NN O
of NN NN O
normal NN NN O
, NN NN O
and NN NN O
clinical NN NN O
myopathy NN NN B-Disease
. NN NN O
   
Final NN NN O
study NN NN O
status NN NN O
was NN NN O
available NN NN O
for NN NN O
4 NN NN O
, NN NN O
217 NN NN O
patients NN NN O
( NN NN O
94 NN NN O
% NN NN O
) NN NN O
. NN NN O
   
Compliance NN NN O
to NN NN O
niacin NN NN O
extended NN NN O
- NN NN O
release NN NN O
/ NN NN O
lovastatin NN NN O
was NN NN O
77 NN NN O
% NN NN O
, NN NN O
with NN NN O
3 NN NN O
, NN NN O
245 NN NN O
patients NN NN O
completing NN NN O
the NN NN O
study NN NN O
. NN NN O
   
Patients NN NN O
in NN NN O
the NN NN O
southeast NN NN O
and NN NN O
those NN NN O
enrolled NN NN O
by NN NN O
endocrinologists NN NN O
had NN NN O
the NN NN O
lowest NN NN O
compliance NN NN O
and NN NN O
highest NN NN O
adverse NN NN O
event NN NN O
rates NN NN O
. NN NN O
   
Flushing NN NN B-Disease
was NN NN O
the NN NN O
most NN NN O
common NN NN O
adverse NN NN O
event NN NN O
, NN NN O
reported NN NN O
by NN NN O
18 NN NN O
% NN NN O
of NN NN O
patients NN NN O
and NN NN O
leading NN NN O
to NN NN O
discontinuation NN NN O
by NN NN O
6 NN NN O
% NN NN O
. NN NN O
   
Incidence NN NN O
of NN NN O
increased NN NN O
aspartate NN NN O
aminotransferase NN NN O
and NN NN O
/ NN NN O
or NN NN O
alanine NN NN O
aminotransferase NN NN O
> NN NN O
3 NN NN O
times NN NN O
the NN NN O
upper NN NN O
limit NN NN O
of NN NN O
normal NN NN O
was NN NN O
< NN NN O
0 NN NN O
. NN NN O
3 NN NN O
% NN NN O
. NN NN O
   
An NN NN O
increase NN NN O
of NN NN O
creatine NN NN O
phosphokinase NN NN O
to NN NN O
> NN NN O
5 NN NN O
times NN NN O
the NN NN O
upper NN NN O
limit NN NN O
of NN NN O
normal NN NN O
occurred NN NN O
in NN NN O
0 NN NN O
. NN NN O
24 NN NN O
% NN NN O
of NN NN O
patients NN NN O
, NN NN O
and NN NN O
no NN NN O
cases NN NN O
of NN NN O
drug NN NN O
- NN NN O
induced NN NN O
myopathy NN NN B-Disease
were NN NN O
observed NN NN O
. NN NN O
   
Niacin NN NN O
extended NN NN O
- NN NN O
release NN NN O
/ NN NN O
lovastatin NN NN O
1 NN NN O
, NN NN O
000 NN NN O
/ NN NN O
40 NN NN O
mg NN NN O
, NN NN O
dosed NN NN O
as NN NN O
initial NN NN O
therapy NN NN O
, NN NN O
was NN NN O
associated NN NN O
with NN NN O
good NN NN O
compliance NN NN O
and NN NN O
safety NN NN O
and NN NN O
had NN NN O
very NN NN O
low NN NN O
incidences NN NN O
of NN NN O
increased NN NN O
liver NN NN O
and NN NN O
muscle NN NN O
enzymes NN NN O
. NN NN O
   
Protective NN NN O
effect NN NN O
of NN NN O
Terminalia NN NN O
chebula NN NN O
against NN NN O
experimental NN NN O
myocardial NN NN B-Disease
injury NN NN I-Disease
induced NN NN O
by NN NN O
isoproterenol NN NN O
. NN NN O
   
Cardioprotective NN NN O
effect NN NN O
of NN NN O
ethanolic NN NN O
extract NN NN O
of NN NN O
Terminalia NN NN O
chebula NN NN O
fruits NN NN O
( NN NN O
500 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
body NN NN O
wt NN NN O
) NN NN O
was NN NN O
examined NN NN O
in NN NN O
isoproterenol NN NN O
( NN NN O
200 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
body NN NN O
wt NN NN O
) NN NN O
induced NN NN O
myocardial NN NN B-Disease
damage NN NN I-Disease
in NN NN O
rats NN NN O
. NN NN O
   
In NN NN O
isoproterenol NN NN O
administered NN NN O
rats NN NN O
, NN NN O
the NN NN O
level NN NN O
of NN NN O
lipid NN NN O
peroxides NN NN O
increased NN NN O
significantly NN NN O
in NN NN O
the NN NN O
serum NN NN O
and NN NN O
heart NN NN O
. NN NN O
   
A NN NN O
significant NN NN O
decrease NN NN O
was NN NN O
observed NN NN O
in NN NN O
the NN NN O
activity NN NN O
of NN NN O
the NN NN O
myocardial NN NN O
marker NN NN O
enzymes NN NN O
with NN NN O
a NN NN O
concomitant NN NN O
increase NN NN O
in NN NN O
their NN NN O
activity NN NN O
in NN NN O
serum NN NN O
. NN NN O
   
Histopathological NN NN O
examination NN NN O
was NN NN O
carried NN NN O
out NN NN O
to NN NN O
confirm NN NN O
the NN NN O
myocardial NN NN O
necrosis NN NN B-Disease
. NN NN O
   
T NN NN O
. NN NN O
chebula NN NN O
extract NN NN O
pretreatment NN NN O
was NN NN O
found NN NN O
to NN NN O
ameliorate NN NN O
the NN NN O
effect NN NN O
of NN NN O
isoproterenol NN NN O
on NN NN O
lipid NN NN O
peroxide NN NN O
formation NN NN O
and NN NN O
retained NN NN O
the NN NN O
activities NN NN O
of NN NN O
the NN NN O
diagnostic NN NN O
marker NN NN O
enzymes NN NN O
. NN NN O
   
A NN NN O
case NN NN O
of NN NN O
postoperative NN NN O
anxiety NN NN B-Disease
due NN NN O
to NN NN O
low NN NN O
dose NN NN O
droperidol NN NN O
used NN NN O
with NN NN O
patient NN NN O
- NN NN O
controlled NN NN O
analgesia NN NN O
. NN NN O
   
A NN NN O
multiparous NN NN O
woman NN NN O
in NN NN O
good NN NN O
psychological NN NN O
health NN NN O
underwent NN NN O
urgent NN NN O
caesarean NN NN O
section NN NN O
in NN NN O
labour NN NN O
. NN NN O
   
Postoperatively NN NN O
, NN NN O
she NN NN O
was NN NN O
given NN NN O
a NN NN O
patient NN NN O
- NN NN O
controlled NN NN O
analgesia NN NN O
device NN NN O
delivering NN NN O
boluses NN NN O
of NN NN O
diamorphine NN NN O
0 NN NN O
. NN NN O
5 NN NN O
mg NN NN O
and NN NN O
droperidol NN NN O
0 NN NN O
. NN NN O
025 NN NN O
mg NN NN O
. NN NN O
   
Whilst NN NN O
using NN NN O
the NN NN O
device NN NN O
she NN NN O
gradually NN NN O
became NN NN O
anxious NN NN O
, NN NN O
the NN NN O
feeling NN NN O
worsening NN NN O
after NN NN O
each NN NN O
bolus NN NN O
. NN NN O
   
The NN NN O
diagnosis NN NN O
of NN NN O
droperidol NN NN O
- NN NN O
induced NN NN O
psychological NN NN B-Disease
disturbance NN NN I-Disease
was NN NN O
not NN NN O
made NN NN O
straight NN NN O
away NN NN O
although NN NN O
on NN NN O
subsequent NN NN O
close NN NN O
questioning NN NN O
the NN NN O
patient NN NN O
gave NN NN O
a NN NN O
very NN NN O
clear NN NN O
history NN NN O
. NN NN O
   
After NN NN O
she NN NN O
had NN NN O
received NN NN O
a NN NN O
total NN NN O
of NN NN O
only NN NN O
0 NN NN O
. NN NN O
9 NN NN O
mg NN NN O
droperidol NN NN O
, NN NN O
a NN NN O
syringe NN NN O
containing NN NN O
diamorphine NN NN O
only NN NN O
was NN NN O
substituted NN NN O
and NN NN O
her NN NN O
unease NN NN O
resolved NN NN O
completely NN NN O
. NN NN O
   
We NN NN O
feel NN NN O
that NN NN O
, NN NN O
although NN NN O
the NN NN O
dramatic NN NN O
extrapyramidal NN NN O
side NN NN O
effects NN NN O
of NN NN O
dopaminergic NN NN O
antiemetics NN NN O
are NN NN O
well NN NN O
known NN NN O
, NN NN O
more NN NN O
subtle NN NN O
manifestations NN NN O
may NN NN O
easily NN NN O
be NN NN O
overlooked NN NN O
. NN NN O
   
Accurate NN NN O
patient NN NN O
history NN NN O
contributes NN NN O
to NN NN O
differentiating NN NN O
diabetes NN NN B-Disease
insipidus NN NN I-Disease
: NN NN O
a NN NN O
case NN NN O
study NN NN O
. NN NN O
   
This NN NN O
case NN NN O
study NN NN O
highlights NN NN O
the NN NN O
important NN NN O
contribution NN NN O
of NN NN O
nursing NN NN O
in NN NN O
obtaining NN NN O
an NN NN O
accurate NN NN O
health NN NN O
history NN NN O
. NN NN O
   
The NN NN O
case NN NN O
discussed NN NN O
herein NN NN O
initially NN NN O
appeared NN NN O
to NN NN O
be NN NN O
neurogenic NN NN B-Disease
diabetes NN NN I-Disease
insipidus NN NN I-Disease
( NN NN O
DI NN NN B-Disease
) NN NN O
secondary NN NN O
to NN NN O
a NN NN O
traumatic NN NN B-Disease
brain NN NN I-Disease
injury NN NN I-Disease
. NN NN O
   
The NN NN O
nursing NN NN O
staff NN NN O
, NN NN O
by NN NN O
reviewing NN NN O
the NN NN O
patient NN NN O
' NN NN O
s NN NN O
health NN NN O
history NN NN O
with NN NN O
his NN NN O
family NN NN O
, NN NN O
discovered NN NN O
a NN NN O
history NN NN O
of NN NN O
polydipsia NN NN B-Disease
and NN NN O
long NN NN O
- NN NN O
standing NN NN O
lithium NN NN O
use NN NN O
. NN NN O
   
Lithium NN NN O
is NN NN O
implicated NN NN O
in NN NN O
drug NN NN O
- NN NN O
induced NN NN O
nephrogenic NN NN B-Disease
DI NN NN I-Disease
, NN NN O
and NN NN O
because NN NN O
the NN NN O
patient NN NN O
had NN NN O
not NN NN O
received NN NN O
lithium NN NN O
since NN NN O
being NN NN O
admitted NN NN O
to NN NN O
the NN NN O
hospital NN NN O
, NN NN O
his NN NN O
treatment NN NN O
changed NN NN O
to NN NN O
focus NN NN O
on NN NN O
nephrogenic NN NN B-Disease
DI NN NN I-Disease
. NN NN O
   
By NN NN O
combining NN NN O
information NN NN O
from NN NN O
the NN NN O
patient NN NN O
history NN NN O
, NN NN O
the NN NN O
physical NN NN O
examination NN NN O
, NN NN O
and NN NN O
radiologic NN NN O
and NN NN O
laboratory NN NN O
studies NN NN O
, NN NN O
the NN NN O
critical NN NN O
care NN NN O
team NN NN O
demonstrated NN NN O
that NN NN O
the NN NN O
patient NN NN O
had NN NN O
been NN NN O
self NN NN O
- NN NN O
treating NN NN O
his NN NN O
lithium NN NN O
- NN NN O
induced NN NN O
nephrogenic NN NN B-Disease
DI NN NN I-Disease
and NN NN O
developed NN NN O
neurogenic NN NN B-Disease
DI NN NN I-Disease
secondary NN NN O
to NN NN O
brain NN NN B-Disease
trauma NN NN I-Disease
. NN NN O
   
Thus NN NN O
successful NN NN O
treatment NN NN O
required NN NN O
that NN NN O
nephrogenic NN NN O
and NN NN O
neurogenic NN NN B-Disease
DI NN NN I-Disease
be NN NN O
treated NN NN O
concomitantly NN NN O
. NN NN O
   
Factors NN NN O
contributing NN NN O
to NN NN O
ribavirin NN NN O
- NN NN O
induced NN NN O
anemia NN NN B-Disease
. NN NN O
   
BACKGROUND NN NN O
AND NN NN O
AIM NN NN O
: NN NN O
Interferon NN NN O
and NN NN O
ribavirin NN NN O
combination NN NN O
therapy NN NN O
for NN NN O
chronic NN NN B-Disease
hepatitis NN NN I-Disease
C NN NN I-Disease
produces NN NN O
hemolytic NN NN B-Disease
anemia NN NN I-Disease
. NN NN O
   
This NN NN O
study NN NN O
was NN NN O
conducted NN NN O
to NN NN O
identify NN NN O
the NN NN O
factors NN NN O
contributing NN NN O
to NN NN O
ribavirin NN NN O
- NN NN O
induced NN NN O
anemia NN NN B-Disease
. NN NN O
   
METHODS NN NN O
: NN NN O
Eighty NN NN O
- NN NN O
eight NN NN O
patients NN NN O
with NN NN O
chronic NN NN B-Disease
hepatitis NN NN I-Disease
C NN NN I-Disease
who NN NN O
received NN NN O
interferon NN NN O
- NN NN O
alpha NN NN O
- NN NN O
2b NN NN O
at NN NN O
a NN NN O
dose NN NN O
of NN NN O
6 NN NN O
MU NN NN O
administered NN NN O
intramuscularly NN NN O
for NN NN O
24 NN NN O
weeks NN NN O
in NN NN O
combination NN NN O
with NN NN O
ribavirin NN NN O
administered NN NN O
orally NN NN O
at NN NN O
a NN NN O
dose NN NN O
of NN NN O
600 NN NN O
mg NN NN O
or NN NN O
800 NN NN O
mg NN NN O
participated NN NN O
in NN NN O
the NN NN O
study NN NN O
. NN NN O
   
A NN NN O
hemoglobin NN NN O
concentration NN NN O
of NN NN O
< NN NN O
10 NN NN O
g NN NN O
/ NN NN O
dL NN NN O
was NN NN O
defined NN NN O
as NN NN O
ribavirin NN NN O
- NN NN O
induced NN NN O
anemia NN NN B-Disease
. NN NN O
   
RESULTS NN NN O
: NN NN O
Ribavirin NN NN O
- NN NN O
induced NN NN O
anemia NN NN B-Disease
occurred NN NN O
in NN NN O
18 NN NN O
( NN NN O
20 NN NN O
. NN NN O
5 NN NN O
% NN NN O
) NN NN O
patients NN NN O
during NN NN O
treatment NN NN O
. NN NN O
   
A NN NN O
2 NN NN O
g NN NN O
/ NN NN O
dL NN NN O
decrease NN NN O
in NN NN O
hemoglobin NN NN O
concentrations NN NN O
in NN NN O
patients NN NN O
with NN NN O
anemia NN NN B-Disease
was NN NN O
observed NN NN O
at NN NN O
week NN NN O
2 NN NN O
after NN NN O
the NN NN O
start NN NN O
of NN NN O
treatment NN NN O
. NN NN O
   
The NN NN O
hemoglobin NN NN O
concentration NN NN O
in NN NN O
patients NN NN O
with NN NN O
> NN NN O
or NN NN O
= NN NN O
2 NN NN O
g NN NN O
/ NN NN O
dL NN NN O
decrease NN NN O
at NN NN O
week NN NN O
2 NN NN O
was NN NN O
observed NN NN O
to NN NN O
be NN NN O
significantly NN NN O
lower NN NN O
even NN NN O
after NN NN O
week NN NN O
2 NN NN O
than NN NN O
in NN NN O
patients NN NN O
with NN NN O
< NN NN O
2 NN NN O
g NN NN O
/ NN NN O
dL NN NN O
decrease NN NN O
( NN NN O
P NN NN O
< NN NN O
0 NN NN O
. NN NN O
01 NN NN O
) NN NN O
. NN NN O
   
A NN NN O
significant NN NN O
relationship NN NN O
was NN NN O
observed NN NN O
between NN NN O
the NN NN O
rate NN NN O
of NN NN O
reduction NN NN O
of NN NN O
hemoglobin NN NN O
concentrations NN NN O
at NN NN O
week NN NN O
2 NN NN O
and NN NN O
the NN NN O
severity NN NN O
of NN NN O
anemia NN NN B-Disease
( NN NN O
P NN NN O
< NN NN O
0 NN NN O
. NN NN O
01 NN NN O
) NN NN O
. NN NN O
   
Such NN NN O
factors NN NN O
as NN NN O
sex NN NN O
( NN NN O
female NN NN O
) NN NN O
, NN NN O
age NN NN O
( NN NN O
> NN NN O
or NN NN O
= NN NN O
60 NN NN O
years NN NN O
old NN NN O
) NN NN O
, NN NN O
and NN NN O
the NN NN O
ribavirin NN NN O
dose NN NN O
by NN NN O
body NN NN O
weight NN NN O
( NN NN O
12 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
or NN NN O
more NN NN O
) NN NN O
were NN NN O
significant NN NN O
by NN NN O
univariate NN NN O
analysis NN NN O
. NN NN O
   
CONCLUSIONS NN NN O
: NN NN O
Careful NN NN O
administration NN NN O
is NN NN O
necessary NN NN O
in NN NN O
patients NN NN O
> NN NN O
or NN NN O
= NN NN O
60 NN NN O
years NN NN O
old NN NN O
, NN NN O
in NN NN O
female NN NN O
patients NN NN O
, NN NN O
and NN NN O
in NN NN O
patients NN NN O
receiving NN NN O
a NN NN O
ribavirin NN NN O
dose NN NN O
of NN NN O
12 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
or NN NN O
more NN NN O
. NN NN O
   
Patients NN NN O
who NN NN O
experience NN NN O
a NN NN O
fall NN NN O
in NN NN O
hemoglobin NN NN O
concentrations NN NN O
of NN NN O
2 NN NN O
g NN NN O
/ NN NN O
dL NN NN O
or NN NN O
more NN NN O
at NN NN O
week NN NN O
2 NN NN O
after NN NN O
the NN NN O
start NN NN O
of NN NN O
treatment NN NN O
should NN NN O
be NN NN O
monitored NN NN O
with NN NN O
particular NN NN O
care NN NN O
. NN NN O
   
Zidovudine NN NN O
- NN NN O
induced NN NN O
hepatitis NN NN B-Disease
. NN NN O
   
A NN NN O
case NN NN O
of NN NN O
acute NN NN O
hepatitis NN NN B-Disease
induced NN NN O
by NN NN O
zidovudine NN NN O
in NN NN O
a NN NN O
38 NN NN O
- NN NN O
year NN NN O
- NN NN O
old NN NN O
patient NN NN O
with NN NN O
AIDS NN NN B-Disease
is NN NN O
presented NN NN O
. NN NN O
   
The NN NN O
mechanism NN NN O
whereby NN NN O
the NN NN O
hepatitis NN NN B-Disease
was NN NN O
induced NN NN O
is NN NN O
not NN NN O
known NN NN O
. NN NN O
   
However NN NN O
, NN NN O
the NN NN O
patient NN NN O
tolerated NN NN O
well NN NN O
an NN NN O
alternative NN NN O
reverse NN NN O
transcriptase NN NN O
inhibitor NN NN O
, NN NN O
2 NN NN O
' NN NN O
3 NN NN O
' NN NN O
dideoxyinosine NN NN O
. NN NN O
   
Physicians NN NN O
caring NN NN O
for NN NN O
patients NN NN O
with NN NN O
AIDS NN NN B-Disease
should NN NN O
be NN NN O
aware NN NN O
of NN NN O
this NN NN O
hitherto NN NN O
rarely NN NN O
reported NN NN O
complication NN NN O
. NN NN O
   
Oxidative NN NN O
damage NN NN O
precedes NN NN O
nitrative NN NN O
damage NN NN O
in NN NN O
adriamycin NN NN O
- NN NN O
induced NN NN O
cardiac NN NN O
mitochondrial NN NN B-Disease
injury NN NN I-Disease
. NN NN O
   
The NN NN O
purpose NN NN O
of NN NN O
the NN NN O
present NN NN O
study NN NN O
was NN NN O
to NN NN O
determine NN NN O
if NN NN O
elevated NN NN O
reactive NN NN O
oxygen NN NN O
( NN NN O
ROS NN NN O
) NN NN O
/ NN NN O
nitrogen NN NN O
species NN NN O
( NN NN O
RNS NN NN O
) NN NN O
reported NN NN O
to NN NN O
be NN NN O
present NN NN O
in NN NN O
adriamycin NN NN O
( NN NN O
ADR NN NN O
) NN NN O
- NN NN O
induced NN NN O
cardiotoxicity NN NN B-Disease
actually NN NN O
resulted NN NN O
in NN NN O
cardiomyocyte NN NN O
oxidative NN NN O
/ NN NN O
nitrative NN NN O
damage NN NN O
, NN NN O
and NN NN O
to NN NN O
quantitatively NN NN O
determine NN NN O
the NN NN O
time NN NN O
course NN NN O
and NN NN O
subcellular NN NN O
localization NN NN O
of NN NN O
these NN NN O
postulated NN NN O
damage NN NN O
products NN NN O
using NN NN O
an NN NN O
in NN NN O
vivo NN NN O
approach NN NN O
. NN NN O
   
B6C3 NN NN O
mice NN NN O
were NN NN O
treated NN NN O
with NN NN O
a NN NN O
single NN NN O
dose NN NN O
of NN NN O
20 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
ADR NN NN O
. NN NN O
   
Ultrastructural NN NN O
damage NN NN O
and NN NN O
levels NN NN O
of NN NN O
4 NN NN O
- NN NN O
hydroxy NN NN O
- NN NN O
2 NN NN O
- NN NN O
nonenal NN NN O
( NN NN O
4HNE NN NN O
) NN NN O
- NN NN O
protein NN NN O
adducts NN NN O
and NN NN O
3 NN NN O
- NN NN O
nitrotyrosine NN NN O
( NN NN O
3NT NN NN O
) NN NN O
were NN NN O
analyzed NN NN O
. NN NN O
   
Quantitative NN NN O
ultrastructural NN NN O
damage NN NN O
using NN NN O
computerized NN NN O
image NN NN O
techniques NN NN O
showed NN NN O
cardiomyocyte NN NN O
injury NN NN O
as NN NN O
early NN NN O
as NN NN O
3 NN NN O
hours NN NN O
, NN NN O
with NN NN O
mitochondria NN NN O
being NN NN O
the NN NN O
most NN NN O
extensively NN NN O
and NN NN O
progressively NN NN O
injured NN NN O
subcellular NN NN O
organelle NN NN O
. NN NN O
   
Analysis NN NN O
of NN NN O
4HNE NN NN O
protein NN NN O
adducts NN NN O
by NN NN O
immunogold NN NN O
electron NN NN O
microscopy NN NN O
showed NN NN O
appearance NN NN O
of NN NN O
4HNE NN NN O
protein NN NN O
adducts NN NN O
in NN NN O
mitochondria NN NN O
as NN NN O
early NN NN O
as NN NN O
3 NN NN O
hours NN NN O
, NN NN O
with NN NN O
a NN NN O
peak NN NN O
at NN NN O
6 NN NN O
hours NN NN O
and NN NN O
subsequent NN NN O
decline NN NN O
at NN NN O
24 NN NN O
hours NN NN O
. NN NN O
   
3NT NN NN O
levels NN NN O
were NN NN O
significantly NN NN O
increased NN NN O
in NN NN O
all NN NN O
subcellular NN NN O
compartments NN NN O
at NN NN O
6 NN NN O
hours NN NN O
and NN NN O
subsequently NN NN O
declined NN NN O
at NN NN O
24 NN NN O
hours NN NN O
. NN NN O
   
Our NN NN O
data NN NN O
showed NN NN O
ADR NN NN O
induced NN NN O
4HNE NN NN O
- NN NN O
protein NN NN O
adducts NN NN O
in NN NN O
mitochondria NN NN O
at NN NN O
the NN NN O
same NN NN O
time NN NN O
point NN NN O
as NN NN O
when NN NN O
mitochondrial NN NN B-Disease
injury NN NN I-Disease
initially NN NN O
appeared NN NN O
. NN NN O
   
These NN NN O
results NN NN O
document NN NN O
for NN NN O
the NN NN O
first NN NN O
time NN NN O
in NN NN O
vivo NN NN O
that NN NN O
mitochondrial NN NN B-Disease
oxidative NN NN I-Disease
damage NN NN I-Disease
precedes NN NN O
nitrative NN NN O
damage NN NN O
. NN NN O
   
The NN NN O
progressive NN NN O
nature NN NN O
of NN NN O
mitochondrial NN NN B-Disease
injury NN NN I-Disease
suggests NN NN O
that NN NN O
mitochondria NN NN O
, NN NN O
not NN NN O
other NN NN O
subcellular NN NN O
organelles NN NN O
, NN NN O
are NN NN O
the NN NN O
major NN NN O
site NN NN O
of NN NN O
intracellular NN NN O
injury NN NN O
. NN NN O
   
Sotalol NN NN O
- NN NN O
induced NN NN O
coronary NN NN B-Disease
spasm NN NN I-Disease
in NN NN O
a NN NN O
patient NN NN O
with NN NN O
dilated NN NN B-Disease
cardiomyopathy NN NN I-Disease
associated NN NN O
with NN NN O
sustained NN NN O
ventricular NN NN B-Disease
tachycardia NN NN I-Disease
. NN NN O
   
A NN NN O
54 NN NN O
- NN NN O
year NN NN O
- NN NN O
old NN NN O
man NN NN O
with NN NN O
severe NN NN O
left NN NN O
ventricular NN NN B-Disease
dysfunction NN NN I-Disease
due NN NN O
to NN NN O
dilated NN NN B-Disease
cardiomyopathy NN NN I-Disease
was NN NN O
referred NN NN O
to NN NN O
our NN NN O
hospital NN NN O
for NN NN O
symptomatic NN NN O
incessant NN NN O
sustained NN NN O
ventricular NN NN B-Disease
tachycardia NN NN I-Disease
( NN NN O
VT NN NN B-Disease
) NN NN O
. NN NN O
   
After NN NN O
the NN NN O
administration NN NN O
of NN NN O
nifekalant NN NN O
hydrochloride NN NN O
, NN NN O
sustained NN NN O
VT NN NN B-Disease
was NN NN O
terminated NN NN O
. NN NN O
   
An NN NN O
alternate NN NN O
class NN NN O
III NN NN O
agent NN NN O
, NN NN O
sotalol NN NN O
, NN NN O
was NN NN O
also NN NN O
effective NN NN O
for NN NN O
the NN NN O
prevention NN NN O
of NN NN O
VT NN NN B-Disease
. NN NN O
   
However NN NN O
, NN NN O
one NN NN O
month NN NN O
after NN NN O
switching NN NN O
over NN NN O
nifekalant NN NN O
to NN NN O
sotalol NN NN O
, NN NN O
a NN NN O
short NN NN O
duration NN NN O
of NN NN O
ST NN NN O
elevation NN NN O
was NN NN O
documented NN NN O
in NN NN O
ECG NN NN O
monitoring NN NN O
at NN NN O
almost NN NN O
the NN NN O
same NN NN O
time NN NN O
for NN NN O
three NN NN O
consecutive NN NN O
days NN NN O
. NN NN O
   
ST NN NN O
elevation NN NN O
with NN NN O
chest NN NN O
discomfort NN NN O
disappeared NN NN O
since NN NN O
he NN NN O
began NN NN O
taking NN NN O
long NN NN O
- NN NN O
acting NN NN O
diltiazem NN NN O
. NN NN O
   
Coronary NN NN B-Disease
vasospasm NN NN I-Disease
may NN NN O
be NN NN O
induced NN NN O
by NN NN O
the NN NN O
non NN NN O
- NN NN O
selective NN NN O
beta NN NN O
- NN NN O
blocking NN NN O
properties NN NN O
of NN NN O
sotalol NN NN O
. NN NN O
   
Effects NN NN O
of NN NN O
the NN NN O
antidepressant NN NN O
trazodone NN NN O
, NN NN O
a NN NN O
5 NN NN O
- NN NN O
HT NN NN O
2A NN NN O
/ NN NN O
2C NN NN O
receptor NN NN O
antagonist NN NN O
, NN NN O
on NN NN O
dopamine NN NN O
- NN NN O
dependent NN NN O
behaviors NN NN O
in NN NN O
rats NN NN O
. NN NN O
   
RATIONALE NN NN O
: NN NN O
5 NN NN O
- NN NN O
Hydroxytryptamine NN NN O
, NN NN O
via NN NN O
stimulation NN NN O
of NN NN O
5 NN NN O
- NN NN O
HT NN NN O
2C NN NN O
receptors NN NN O
, NN NN O
exerts NN NN O
a NN NN O
tonic NN NN O
inhibitory NN NN O
influence NN NN O
on NN NN O
dopaminergic NN NN O
neurotransmission NN NN O
, NN NN O
whereas NN NN O
activation NN NN O
of NN NN O
5 NN NN O
- NN NN O
HT NN NN O
2A NN NN O
receptors NN NN O
enhances NN NN O
stimulated NN NN O
DAergic NN NN O
neurotransmission NN NN O
. NN NN O
   
The NN NN O
antidepressant NN NN O
trazodone NN NN O
is NN NN O
a NN NN O
5 NN NN O
- NN NN O
HT NN NN O
2A NN NN O
/ NN NN O
2C NN NN O
receptor NN NN O
antagonist NN NN O
. NN NN O
   
OBJECTIVES NN NN O
: NN NN O
To NN NN O
evaluate NN NN O
the NN NN O
effect NN NN O
of NN NN O
trazodone NN NN O
treatment NN NN O
on NN NN O
behaviors NN NN O
dependent NN NN O
on NN NN O
the NN NN O
functional NN NN O
status NN NN O
of NN NN O
the NN NN O
nigrostriatal NN NN O
DAergic NN NN O
system NN NN O
. NN NN O
   
METHODS NN NN O
: NN NN O
The NN NN O
effect NN NN O
of NN NN O
pretreatment NN NN O
with NN NN O
trazodone NN NN O
on NN NN O
dexamphetamine NN NN O
- NN NN O
and NN NN O
apomorphine NN NN O
- NN NN O
induced NN NN O
oral NN NN B-Disease
stereotypies NN NN I-Disease
, NN NN O
on NN NN O
catalepsy NN NN B-Disease
induced NN NN O
by NN NN O
haloperidol NN NN O
and NN NN O
apomorphine NN NN O
( NN NN O
0 NN NN O
. NN NN O
05 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
, NN NN O
i NN NN O
. NN NN O
p NN NN O
. NN NN O
) NN NN O
, NN NN O
on NN NN O
ergometrine NN NN O
- NN NN O
induced NN NN O
wet NN NN O
dog NN NN O
shake NN NN O
( NN NN O
WDS NN NN O
) NN NN O
behavior NN NN O
and NN NN O
fluoxetine NN NN O
- NN NN O
induced NN NN O
penile NN NN O
erections NN NN O
was NN NN O
studied NN NN O
in NN NN O
rats NN NN O
. NN NN O
   
We NN NN O
also NN NN O
investigated NN NN O
whether NN NN O
trazodone NN NN O
induces NN NN O
catalepsy NN NN B-Disease
in NN NN O
rats NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
Trazodone NN NN O
at NN NN O
2 NN NN O
. NN NN O
5 NN NN O
- NN NN O
20 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
i NN NN O
. NN NN O
p NN NN O
. NN NN O
did NN NN O
not NN NN O
induce NN NN O
catalepsy NN NN B-Disease
, NN NN O
and NN NN O
did NN NN O
not NN NN O
antagonize NN NN O
apomorphine NN NN O
( NN NN O
1 NN NN O
. NN NN O
5 NN NN O
and NN NN O
3 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
) NN NN O
stereotypy NN NN O
and NN NN O
apomorphine NN NN O
( NN NN O
0 NN NN O
. NN NN O
05 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
) NN NN O
- NN NN O
induced NN NN O
catalepsy NN NN B-Disease
. NN NN O
   
However NN NN O
, NN NN O
pretreatment NN NN O
with NN NN O
5 NN NN O
, NN NN O
10 NN NN O
and NN NN O
20 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
i NN NN O
. NN NN O
p NN NN O
. NN NN O
trazodone NN NN O
enhanced NN NN O
dexamphetamine NN NN O
stereotypy NN NN O
, NN NN O
and NN NN O
antagonized NN NN O
haloperidol NN NN O
catalepsy NN NN B-Disease
, NN NN O
ergometrine NN NN O
- NN NN O
induced NN NN O
WDS NN NN O
behavior NN NN O
and NN NN O
fluoxetine NN NN O
- NN NN O
induced NN NN O
penile NN NN O
erections NN NN O
. NN NN O
   
Trazodone NN NN O
at NN NN O
30 NN NN O
, NN NN O
40 NN NN O
and NN NN O
50 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
i NN NN O
. NN NN O
p NN NN O
. NN NN O
induced NN NN O
catalepsy NN NN B-Disease
and NN NN O
antagonized NN NN O
apomorphine NN NN O
and NN NN O
dexamphetamine NN NN O
stereotypies NN NN O
. NN NN O
   
CONCLUSIONS NN NN O
: NN NN O
Our NN NN O
results NN NN O
indicate NN NN O
that NN NN O
trazodone NN NN O
at NN NN O
2 NN NN O
. NN NN O
5 NN NN O
- NN NN O
20 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
does NN NN O
not NN NN O
block NN NN O
pre NN NN O
- NN NN O
and NN NN O
postsynaptic NN NN O
striatal NN NN O
D2 NN NN O
DA NN NN O
receptors NN NN O
, NN NN O
while NN NN O
at NN NN O
30 NN NN O
, NN NN O
40 NN NN O
and NN NN O
50 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
it NN NN O
blocks NN NN O
postsynaptic NN NN O
striatal NN NN O
D2 NN NN O
DA NN NN O
receptors NN NN O
. NN NN O
   
Furthermore NN NN O
, NN NN O
at NN NN O
5 NN NN O
, NN NN O
10 NN NN O
and NN NN O
20 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
, NN NN O
trazodone NN NN O
blocks NN NN O
5 NN NN O
- NN NN O
HT NN NN O
2A NN NN O
and NN NN O
5 NN NN O
- NN NN O
HT NN NN O
2C NN NN O
receptors NN NN O
. NN NN O
   
We NN NN O
suggest NN NN O
that NN NN O
trazodone NN NN O
( NN NN O
5 NN NN O
, NN NN O
10 NN NN O
and NN NN O
20 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
) NN NN O
, NN NN O
by NN NN O
blocking NN NN O
the NN NN O
5 NN NN O
- NN NN O
HT NN NN O
2C NN NN O
receptors NN NN O
, NN NN O
releases NN NN O
the NN NN O
nigrostriatal NN NN O
DAergic NN NN O
neurons NN NN O
from NN NN O
tonic NN NN O
inhibition NN NN O
caused NN NN O
by NN NN O
5 NN NN O
- NN NN O
HT NN NN O
, NN NN O
and NN NN O
thereby NN NN O
potentiates NN NN O
dexamphetamine NN NN O
stereotypy NN NN O
and NN NN O
antagonizes NN NN O
haloperidol NN NN O
catalepsy NN NN B-Disease
. NN NN O
   
Swallowing NN NN B-Disease
abnormalities NN NN I-Disease
and NN NN O
dyskinesia NN NN B-Disease
in NN NN O
Parkinson NN NN B-Disease
' NN NN I-Disease
s NN NN I-Disease
disease NN NN I-Disease
. NN NN O
   
Gastrointestinal NN NN B-Disease
abnormalities NN NN I-Disease
in NN NN O
Parkinson NN NN B-Disease
' NN NN I-Disease
s NN NN I-Disease
disease NN NN I-Disease
( NN NN O
PD NN NN B-Disease
) NN NN O
have NN NN O
been NN NN O
known NN NN O
for NN NN O
almost NN NN O
two NN NN O
centuries NN NN O
, NN NN O
but NN NN O
many NN NN O
aspects NN NN O
concerning NN NN O
their NN NN O
pathophysiology NN NN O
have NN NN O
not NN NN O
been NN NN O
completely NN NN O
clarified NN NN O
. NN NN O
   
The NN NN O
aim NN NN O
of NN NN O
this NN NN O
study NN NN O
was NN NN O
to NN NN O
characterize NN NN O
the NN NN O
oropharyngeal NN NN O
dynamics NN NN O
in NN NN O
PD NN NN B-Disease
patients NN NN O
with NN NN O
and NN NN O
without NN NN O
levodopa NN NN O
- NN NN O
induced NN NN O
dyskinesia NN NN B-Disease
. NN NN O
   
Fifteen NN NN O
dyskinetic NN NN B-Disease
, NN NN O
12 NN NN O
nondyskinetic NN NN O
patients NN NN O
, NN NN O
and NN NN O
a NN NN O
control NN NN O
group NN NN O
were NN NN O
included NN NN O
. NN NN O
   
Patients NN NN O
were NN NN O
asked NN NN O
about NN NN O
dysphagia NN NN B-Disease
and NN NN O
evaluated NN NN O
with NN NN O
the NN NN O
Unified NN NN O
Parkinson NN NN B-Disease
' NN NN I-Disease
s NN NN I-Disease
Disease NN NN I-Disease
Rating NN NN O
Scale NN NN O
Parts NN NN O
II NN NN O
and NN NN O
III NN NN O
and NN NN O
the NN NN O
Hoehn NN NN O
and NN NN O
Yahr NN NN O
scale NN NN O
. NN NN O
   
Deglutition NN NN O
was NN NN O
assessed NN NN O
using NN NN O
modified NN NN O
barium NN NN O
swallow NN NN O
with NN NN O
videofluoroscopy NN NN O
. NN NN O
   
Nondyskinetic NN NN O
patients NN NN O
, NN NN O
but NN NN O
not NN NN O
the NN NN O
dyskinetic NN NN B-Disease
ones NN NN O
, NN NN O
showed NN NN O
less NN NN O
oropharyngeal NN NN O
swallowing NN NN O
efficiency NN NN O
( NN NN O
OPSE NN NN O
) NN NN O
for NN NN O
liquid NN NN O
food NN NN O
than NN NN O
controls NN NN O
( NN NN O
Dunnett NN NN O
, NN NN O
P NN NN O
= NN NN O
0 NN NN O
. NN NN O
02 NN NN O
) NN NN O
. NN NN O
   
Dyskinetic NN NN B-Disease
patients NN NN O
tended NN NN O
to NN NN O
have NN NN O
a NN NN O
greater NN NN O
OPSE NN NN O
than NN NN O
nondyskinetic NN NN O
( NN NN O
Dunnett NN NN O
, NN NN O
P NN NN O
= NN NN O
0 NN NN O
. NN NN O
06 NN NN O
) NN NN O
. NN NN O
   
Patients NN NN O
who NN NN O
were NN NN O
using NN NN O
a NN NN O
higher NN NN O
dose NN NN O
of NN NN O
levodopa NN NN O
had NN NN O
a NN NN O
greater NN NN O
OPSE NN NN O
and NN NN O
a NN NN O
trend NN NN O
toward NN NN O
a NN NN O
smaller NN NN O
oral NN NN O
transit NN NN O
time NN NN O
( NN NN O
Pearson NN NN O
' NN NN O
s NN NN O
correlation NN NN O
, NN NN O
P NN NN O
= NN NN O
0 NN NN O
. NN NN O
01 NN NN O
and NN NN O
0 NN NN O
. NN NN O
08 NN NN O
, NN NN O
respectively NN NN O
) NN NN O
. NN NN O
   
Neither NN NN O
the NN NN O
report NN NN O
of NN NN O
dysphagia NN NN B-Disease
nor NN NN O
any NN NN O
of NN NN O
the NN NN O
PD NN NN B-Disease
severity NN NN O
parameters NN NN O
correlated NN NN O
to NN NN O
the NN NN O
videofluoroscopic NN NN O
variables NN NN O
. NN NN O
   
In NN NN O
the NN NN O
current NN NN O
study NN NN O
, NN NN O
dyskinetic NN NN B-Disease
patients NN NN O
performed NN NN O
better NN NN O
in NN NN O
swallowing NN NN O
function NN NN O
, NN NN O
which NN NN O
could NN NN O
be NN NN O
explained NN NN O
on NN NN O
the NN NN O
basis NN NN O
of NN NN O
a NN NN O
greater NN NN O
levodopa NN NN O
dose NN NN O
. NN NN O
   
Our NN NN O
results NN NN O
suggest NN NN O
a NN NN O
role NN NN O
for NN NN O
levodopa NN NN O
in NN NN O
the NN NN O
oral NN NN O
phase NN NN O
of NN NN O
deglutition NN NN O
and NN NN O
confirm NN NN O
that NN NN O
dysphagia NN NN B-Disease
is NN NN O
not NN NN O
a NN NN O
good NN NN O
predictor NN NN O
of NN NN O
deglutition NN NN O
alterations NN NN O
in NN NN O
PD NN NN B-Disease
. NN NN O
   
Inhibition NN NN O
of NN NN O
nuclear NN NN O
factor NN NN O
- NN NN O
kappaB NN NN O
activation NN NN O
attenuates NN NN O
tubulointerstitial NN NN B-Disease
nephritis NN NN I-Disease
induced NN NN O
by NN NN O
gentamicin NN NN O
. NN NN O
   
BACKGROUND NN NN O
: NN NN O
Animals NN NN O
treated NN NN O
with NN NN O
gentamicin NN NN O
can NN NN O
show NN NN O
residual NN NN O
areas NN NN O
of NN NN O
interstitial NN NN O
fibrosis NN NN B-Disease
in NN NN O
the NN NN O
renal NN NN O
cortex NN NN O
. NN NN O
   
This NN NN O
study NN NN O
investigated NN NN O
the NN NN O
expression NN NN O
of NN NN O
nuclear NN NN O
factor NN NN O
- NN NN O
kappaB NN NN O
( NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
) NN NN O
, NN NN O
mitogen NN NN O
- NN NN O
activated NN NN O
protein NN NN O
( NN NN O
MAP NN NN O
) NN NN O
kinases NN NN O
and NN NN O
macrophages NN NN O
in NN NN O
the NN NN O
renal NN NN O
cortex NN NN O
and NN NN O
structural NN NN O
and NN NN O
functional NN NN O
renal NN NN O
changes NN NN O
of NN NN O
rats NN NN O
treated NN NN O
with NN NN O
gentamicin NN NN O
or NN NN O
gentamicin NN NN O
+ NN NN O
pyrrolidine NN NN O
dithiocarbamate NN NN O
( NN NN O
PDTC NN NN O
) NN NN O
, NN NN O
an NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
inhibitor NN NN O
. NN NN O
   
METHODS NN NN O
: NN NN O
38 NN NN O
female NN NN O
Wistar NN NN O
rats NN NN O
were NN NN O
injected NN NN O
with NN NN O
gentamicin NN NN O
, NN NN O
40 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
, NN NN O
twice NN NN O
a NN NN O
day NN NN O
for NN NN O
9 NN NN O
days NN NN O
, NN NN O
38 NN NN O
with NN NN O
gentamicin NN NN O
+ NN NN O
PDTC NN NN O
, NN NN O
and NN NN O
28 NN NN O
with NN NN O
0 NN NN O
. NN NN O
15 NN NN O
M NN NN O
NaCl NN NN O
solution NN NN O
. NN NN O
   
The NN NN O
animals NN NN O
were NN NN O
killed NN NN O
5 NN NN O
and NN NN O
30 NN NN O
days NN NN O
after NN NN O
these NN NN O
injections NN NN O
and NN NN O
the NN NN O
kidneys NN NN O
were NN NN O
removed NN NN O
for NN NN O
histological NN NN O
and NN NN O
immunohistochemical NN NN O
studies NN NN O
. NN NN O
   
The NN NN O
results NN NN O
of NN NN O
the NN NN O
immunohistochemical NN NN O
studies NN NN O
were NN NN O
scored NN NN O
according NN NN O
to NN NN O
the NN NN O
extent NN NN O
of NN NN O
staining NN NN O
. NN NN O
   
The NN NN O
fractional NN NN O
interstitial NN NN O
area NN NN O
was NN NN O
determined NN NN O
by NN NN O
morphometry NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
Gentamicin NN NN O
- NN NN O
treated NN NN O
rats NN NN O
presented NN NN O
a NN NN O
transitory NN NN O
increase NN NN O
in NN NN O
plasma NN NN O
creatinine NN NN O
levels NN NN O
. NN NN O
   
Increased NN NN O
ED NN NN O
- NN NN O
1 NN NN O
, NN NN O
MAP NN NN O
kinases NN NN O
and NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
staining NN NN O
were NN NN O
also NN NN O
observed NN NN O
in NN NN O
the NN NN O
renal NN NN O
cortex NN NN O
from NN NN O
all NN NN O
gentamicin NN NN O
- NN NN O
treated NN NN O
rats NN NN O
compared NN NN O
to NN NN O
control NN NN O
( NN NN O
p NN NN O
< NN NN O
0 NN NN O
. NN NN O
05 NN NN O
) NN NN O
. NN NN O
   
The NN NN O
animals NN NN O
killed NN NN O
on NN NN O
day NN NN O
30 NN NN O
also NN NN O
presented NN NN O
fibrosis NN NN B-Disease
in NN NN O
the NN NN O
renal NN NN O
cortex NN NN O
despite NN NN O
the NN NN O
recovery NN NN O
of NN NN O
renal NN NN O
function NN NN O
. NN NN O
   
Treatment NN NN O
with NN NN O
PDTC NN NN O
reduced NN NN O
the NN NN O
functional NN NN O
and NN NN O
structural NN NN O
changes NN NN O
induced NN NN O
by NN NN O
gentamicin NN NN O
. NN NN O
   
CONCLUSIONS NN NN O
: NN NN O
These NN NN O
data NN NN O
show NN NN O
that NN NN O
inhibition NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
activation NN NN O
attenuates NN NN O
tubulointerstitial NN NN B-Disease
nephritis NN NN I-Disease
induced NN NN O
by NN NN O
gentamicin NN NN O
. NN NN O
   
Glucose NN NN O
metabolism NN NN O
in NN NN O
patients NN NN O
with NN NN O
schizophrenia NN NN B-Disease
treated NN NN O
with NN NN O
atypical NN NN O
antipsychotic NN NN O
agents NN NN O
: NN NN O
a NN NN O
frequently NN NN O
sampled NN NN O
intravenous NN NN O
glucose NN NN O
tolerance NN NN O
test NN NN O
and NN NN O
minimal NN NN O
model NN NN O
analysis NN NN O
. NN NN O
   
BACKGROUND NN NN O
: NN NN O
While NN NN O
the NN NN O
incidence NN NN O
of NN NN O
new NN NN O
- NN NN O
onset NN NN O
diabetes NN NN B-Disease
mellitus NN NN I-Disease
may NN NN O
be NN NN O
increasing NN NN O
in NN NN O
patients NN NN O
with NN NN O
schizophrenia NN NN B-Disease
treated NN NN O
with NN NN O
certain NN NN O
atypical NN NN O
antipsychotic NN NN O
agents NN NN O
, NN NN O
it NN NN O
remains NN NN O
unclear NN NN O
whether NN NN O
atypical NN NN O
agents NN NN O
are NN NN O
directly NN NN O
affecting NN NN O
glucose NN NN O
metabolism NN NN O
or NN NN O
simply NN NN O
increasing NN NN O
known NN NN O
risk NN NN O
factors NN NN O
for NN NN O
diabetes NN NN B-Disease
. NN NN O
   
OBJECTIVE NN NN O
: NN NN O
To NN NN O
study NN NN O
the NN NN O
2 NN NN O
drugs NN NN O
most NN NN O
clearly NN NN O
implicated NN NN O
( NN NN O
clozapine NN NN O
and NN NN O
olanzapine NN NN O
) NN NN O
and NN NN O
risperidone NN NN O
using NN NN O
a NN NN O
frequently NN NN O
sampled NN NN O
intravenous NN NN O
glucose NN NN O
tolerance NN NN O
test NN NN O
. NN NN O
   
DESIGN NN NN O
: NN NN O
A NN NN O
cross NN NN O
- NN NN O
sectional NN NN O
design NN NN O
in NN NN O
stable NN NN O
, NN NN O
treated NN NN O
patients NN NN O
with NN NN O
schizophrenia NN NN B-Disease
evaluated NN NN O
using NN NN O
a NN NN O
frequently NN NN O
sampled NN NN O
intravenous NN NN O
glucose NN NN O
tolerance NN NN O
test NN NN O
and NN NN O
the NN NN O
Bergman NN NN O
minimal NN NN O
model NN NN O
analysis NN NN O
. NN NN O
   
SETTING NN NN O
: NN NN O
Subjects NN NN O
were NN NN O
recruited NN NN O
from NN NN O
an NN NN O
urban NN NN O
community NN NN O
mental NN NN O
health NN NN O
clinic NN NN O
and NN NN O
were NN NN O
studied NN NN O
at NN NN O
a NN NN O
general NN NN O
clinical NN NN O
research NN NN O
center NN NN O
. NN NN O
   
Patients NN NN O
Fifty NN NN O
subjects NN NN O
signed NN NN O
informed NN NN O
consent NN NN O
and NN NN O
41 NN NN O
underwent NN NN O
the NN NN O
frequently NN NN O
sampled NN NN O
intravenous NN NN O
glucose NN NN O
tolerance NN NN O
test NN NN O
. NN NN O
   
Thirty NN NN O
- NN NN O
six NN NN O
nonobese NN NN O
subjects NN NN O
with NN NN O
schizophrenia NN NN B-Disease
or NN NN O
schizoaffective NN NN B-Disease
disorder NN NN I-Disease
, NN NN O
matched NN NN O
by NN NN O
body NN NN O
mass NN NN O
index NN NN O
and NN NN O
treated NN NN O
with NN NN O
either NN NN O
clozapine NN NN O
, NN NN O
olanzapine NN NN O
, NN NN O
or NN NN O
risperidone NN NN O
, NN NN O
were NN NN O
included NN NN O
in NN NN O
the NN NN O
analysis NN NN O
. NN NN O
   
MAIN NN NN O
OUTCOME NN NN O
MEASURES NN NN O
: NN NN O
Fasting NN NN O
plasma NN NN O
glucose NN NN O
and NN NN O
fasting NN NN O
serum NN NN O
insulin NN NN O
levels NN NN O
, NN NN O
insulin NN NN B-Disease
sensitivity NN NN I-Disease
index NN NN O
, NN NN O
homeostasis NN NN O
model NN NN O
assessment NN NN O
of NN NN O
insulin NN NN B-Disease
resistance NN NN I-Disease
, NN NN O
and NN NN O
glucose NN NN O
effectiveness NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
The NN NN O
mean NN NN O
+ NN NN O
/ NN NN O
- NN NN O
SD NN NN O
duration NN NN O
of NN NN O
treatment NN NN O
with NN NN O
the NN NN O
identified NN NN O
atypical NN NN O
antipsychotic NN NN O
agent NN NN O
was NN NN O
68 NN NN O
. NN NN O
3 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
28 NN NN O
. NN NN O
9 NN NN O
months NN NN O
( NN NN O
clozapine NN NN O
) NN NN O
, NN NN O
29 NN NN O
. NN NN O
5 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
17 NN NN O
. NN NN O
5 NN NN O
months NN NN O
( NN NN O
olanzapine NN NN O
) NN NN O
, NN NN O
and NN NN O
40 NN NN O
. NN NN O
9 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
33 NN NN O
. NN NN O
7 NN NN O
( NN NN O
risperidone NN NN O
) NN NN O
. NN NN O
   
Fasting NN NN O
serum NN NN O
insulin NN NN O
concentrations NN NN O
differed NN NN O
among NN NN O
groups NN NN O
( NN NN O
F NN NN O
( NN NN O
33 NN NN O
) NN NN O
= NN NN O
3 NN NN O
. NN NN O
35 NN NN O
; NN NN O
P NN NN O
= NN NN O
. NN NN O
047 NN NN O
) NN NN O
( NN NN O
clozapine NN NN O
> NN NN O
olanzapine NN NN O
> NN NN O
risperidone NN NN O
) NN NN O
with NN NN O
significant NN NN O
differences NN NN O
between NN NN O
clozapine NN NN O
and NN NN O
risperidone NN NN O
( NN NN O
t NN NN O
( NN NN O
33 NN NN O
) NN NN O
= NN NN O
2 NN NN O
. NN NN O
32 NN NN O
; NN NN O
P NN NN O
= NN NN O
. NN NN O
03 NN NN O
) NN NN O
and NN NN O
olanzapine NN NN O
and NN NN O
risperidone NN NN O
( NN NN O
t NN NN O
( NN NN O
33 NN NN O
) NN NN O
= NN NN O
2 NN NN O
. NN NN O
15 NN NN O
; NN NN O
P NN NN O
= NN NN O
. NN NN O
04 NN NN O
) NN NN O
. NN NN O
   
There NN NN O
was NN NN O
a NN NN O
significant NN NN O
difference NN NN O
in NN NN O
insulin NN NN B-Disease
sensitivity NN NN I-Disease
index NN NN O
among NN NN O
groups NN NN O
( NN NN O
F NN NN O
( NN NN O
33 NN NN O
) NN NN O
= NN NN O
10 NN NN O
. NN NN O
66 NN NN O
; NN NN O
P NN NN O
< NN NN O
. NN NN O
001 NN NN O
) NN NN O
( NN NN O
clozapine NN NN O
< NN NN O
olanzapine NN NN O
< NN NN O
risperidone NN NN O
) NN NN O
, NN NN O
with NN NN O
subjects NN NN O
who NN NN O
received NN NN O
clozapine NN NN O
and NN NN O
olanzapine NN NN O
exhibiting NN NN O
significant NN NN O
insulin NN NN B-Disease
resistance NN NN I-Disease
compared NN NN O
with NN NN O
subjects NN NN O
who NN NN O
were NN NN O
treated NN NN O
with NN NN O
risperidone NN NN O
( NN NN O
clozapine NN NN O
vs NN NN O
risperidone NN NN O
, NN NN O
t NN NN O
( NN NN O
33 NN NN O
) NN NN O
= NN NN O
- NN NN O
4 NN NN O
. NN NN O
29 NN NN O
; NN NN O
P NN NN O
< NN NN O
. NN NN O
001 NN NN O
; NN NN O
olanzapine NN NN O
vs NN NN O
risperidone NN NN O
, NN NN O
t NN NN O
( NN NN O
33 NN NN O
) NN NN O
= NN NN O
- NN NN O
3 NN NN O
. NN NN O
62 NN NN O
; NN NN O
P NN NN O
= NN NN O
. NN NN O
001 NN NN O
[ NN NN O
P NN NN O
< NN NN O
. NN NN O
001 NN NN O
] NN NN O
) NN NN O
. NN NN O
   
The NN NN O
homeostasis NN NN O
model NN NN O
assessment NN NN O
of NN NN O
insulin NN NN B-Disease
resistance NN NN I-Disease
also NN NN O
differed NN NN O
significantly NN NN O
among NN NN O
groups NN NN O
( NN NN O
F NN NN O
( NN NN O
33 NN NN O
) NN NN O
= NN NN O
4 NN NN O
. NN NN O
92 NN NN O
; NN NN O
P NN NN O
= NN NN O
. NN NN O
01 NN NN O
) NN NN O
( NN NN O
clozapine NN NN O
> NN NN O
olanzapine NN NN O
> NN NN O
risperidone NN NN O
) NN NN O
( NN NN O
clozapine NN NN O
vs NN NN O
risperidone NN NN O
, NN NN O
t NN NN O
( NN NN O
33 NN NN O
) NN NN O
= NN NN O
2 NN NN O
. NN NN O
94 NN NN O
; NN NN O
P NN NN O
= NN NN O
. NN NN O
006 NN NN O
; NN NN O
olanzapine NN NN O
vs NN NN O
risperidone NN NN O
, NN NN O
t NN NN O
( NN NN O
33 NN NN O
) NN NN O
= NN NN O
2 NN NN O
. NN NN O
42 NN NN O
; NN NN O
P NN NN O
= NN NN O
. NN NN O
02 NN NN O
) NN NN O
. NN NN O
   
There NN NN O
was NN NN O
a NN NN O
significant NN NN O
difference NN NN O
among NN NN O
groups NN NN O
in NN NN O
glucose NN NN O
effectiveness NN NN O
( NN NN O
F NN NN O
( NN NN O
30 NN NN O
) NN NN O
= NN NN O
4 NN NN O
. NN NN O
18 NN NN O
; NN NN O
P NN NN O
= NN NN O
. NN NN O
02 NN NN O
) NN NN O
( NN NN O
clozapine NN NN O
< NN NN O
olanzapine NN NN O
< NN NN O
risperidone NN NN O
) NN NN O
with NN NN O
significant NN NN O
differences NN NN O
between NN NN O
clozapine NN NN O
and NN NN O
risperidone NN NN O
( NN NN O
t NN NN O
( NN NN O
30 NN NN O
) NN NN O
= NN NN O
- NN NN O
2 NN NN O
. NN NN O
59 NN NN O
; NN NN O
P NN NN O
= NN NN O
. NN NN O
02 NN NN O
) NN NN O
and NN NN O
olanzapine NN NN O
and NN NN O
risperidone NN NN O
( NN NN O
t NN NN O
( NN NN O
30 NN NN O
) NN NN O
= NN NN O
- NN NN O
2 NN NN O
. NN NN O
34 NN NN O
, NN NN O
P NN NN O
= NN NN O
. NN NN O
03 NN NN O
) NN NN O
. NN NN O
   
CONCLUSIONS NN NN O
: NN NN O
Both NN NN O
nonobese NN NN O
clozapine NN NN O
- NN NN O
and NN NN O
olanzapine NN NN O
- NN NN O
treated NN NN O
groups NN NN O
displayed NN NN O
significant NN NN O
insulin NN NN B-Disease
resistance NN NN I-Disease
and NN NN O
impairment NN NN O
of NN NN O
glucose NN NN O
effectiveness NN NN O
compared NN NN O
with NN NN O
risperidone NN NN O
- NN NN O
treated NN NN O
subjects NN NN O
. NN NN O
   
Patients NN NN O
taking NN NN O
clozapine NN NN O
and NN NN O
olanzapine NN NN O
must NN NN O
be NN NN O
examined NN NN O
for NN NN O
insulin NN NN B-Disease
resistance NN NN I-Disease
and NN NN O
its NN NN O
consequences NN NN O
. NN NN O
   
Thoracic NN NN B-Disease
hematomyelia NN NN I-Disease
secondary NN NN O
to NN NN O
coumadin NN NN O
anticoagulant NN NN O
therapy NN NN O
: NN NN O
a NN NN O
case NN NN O
report NN NN O
. NN NN O
   
A NN NN O
case NN NN O
of NN NN O
thoracic NN NN B-Disease
hematomyelia NN NN I-Disease
secondary NN NN O
to NN NN O
anticoagulant NN NN O
therapy NN NN O
is NN NN O
presented NN NN O
. NN NN O
   
Clinical NN NN O
features NN NN O
, NN NN O
similar NN NN O
to NN NN O
2 NN NN O
other NN NN O
previously NN NN O
reported NN NN O
cases NN NN O
, NN NN O
are NN NN O
discussed NN NN O
. NN NN O
   
A NN NN O
high NN NN O
index NN NN O
of NN NN O
suspicion NN NN O
may NN NN O
lead NN NN O
to NN NN O
a NN NN O
quick NN NN O
diagnostic NN NN O
procedure NN NN O
and NN NN O
successful NN NN O
decompressive NN NN O
surgery NN NN O
. NN NN O
   
Mania NN NN B-Disease
associated NN NN O
with NN NN O
fluoxetine NN NN O
treatment NN NN O
in NN NN O
adolescents NN NN O
. NN NN O
   
Fluoxetine NN NN O
, NN NN O
a NN NN O
selective NN NN O
serotonin NN NN O
reuptake NN NN O
inhibitor NN NN O
, NN NN O
is NN NN O
gaining NN NN O
increased NN NN O
acceptance NN NN O
in NN NN O
the NN NN O
treatment NN NN O
of NN NN O
adolescent NN NN O
depression NN NN B-Disease
. NN NN O
   
Generally NN NN O
safe NN NN O
and NN NN O
well NN NN O
tolerated NN NN O
by NN NN O
adults NN NN O
, NN NN O
fluoxetine NN NN O
has NN NN O
been NN NN O
reported NN NN O
to NN NN O
induce NN NN O
mania NN NN B-Disease
. NN NN O
   
The NN NN O
cases NN NN O
of NN NN O
five NN NN O
depressed NN NN B-Disease
adolescents NN NN O
, NN NN O
14 NN NN O
- NN NN O
16 NN NN O
years NN NN O
of NN NN O
age NN NN O
, NN NN O
who NN NN O
developed NN NN O
mania NN NN B-Disease
during NN NN O
pharmacotherapy NN NN O
with NN NN O
fluoxetine NN NN O
, NN NN O
are NN NN O
reported NN NN O
here NN NN O
. NN NN O
   
Apparent NN NN O
risk NN NN O
factors NN NN O
for NN NN O
the NN NN O
development NN NN O
of NN NN O
mania NN NN B-Disease
or NN NN O
hypomania NN NN B-Disease
during NN NN O
fluoxetine NN NN O
pharmacotherapy NN NN O
in NN NN O
this NN NN O
population NN NN O
were NN NN O
the NN NN O
combination NN NN O
of NN NN O
attention NN NN B-Disease
- NN NN I-Disease
deficit NN NN I-Disease
hyperactivity NN NN I-Disease
disorder NN NN I-Disease
and NN NN O
affective NN NN O
instability NN NN O
; NN NN O
major NN NN O
depression NN NN B-Disease
with NN NN O
psychotic NN NN B-Disease
features NN NN O
; NN NN O
a NN NN O
family NN NN O
history NN NN O
of NN NN O
affective NN NN B-Disease
disorder NN NN I-Disease
, NN NN O
especially NN NN O
bipolar NN NN B-Disease
disorder NN NN I-Disease
; NN NN O
and NN NN O
a NN NN O
diagnosis NN NN O
of NN NN O
bipolar NN NN B-Disease
disorder NN NN I-Disease
. NN NN O
   
Further NN NN O
study NN NN O
is NN NN O
needed NN NN O
to NN NN O
determine NN NN O
the NN NN O
optimal NN NN O
dosage NN NN O
and NN NN O
to NN NN O
identify NN NN O
risk NN NN O
factors NN NN O
that NN NN O
increase NN NN O
individual NN NN O
vulnerability NN NN O
to NN NN O
fluoxetine NN NN O
induced NN NN O
mania NN NN B-Disease
in NN NN O
adolescents NN NN O
. NN NN O
   
Acute NN NN B-Disease
renal NN NN I-Disease
insufficiency NN NN I-Disease
after NN NN O
high NN NN O
- NN NN O
dose NN NN O
melphalan NN NN O
in NN NN O
patients NN NN O
with NN NN O
primary NN NN B-Disease
systemic NN NN I-Disease
amyloidosis NN NN I-Disease
during NN NN O
stem NN NN O
cell NN NN O
transplantation NN NN O
. NN NN O
   
BACKGROUND NN NN O
: NN NN O
Patients NN NN O
with NN NN O
primary NN NN B-Disease
systemic NN NN I-Disease
amyloidosis NN NN I-Disease
( NN NN O
AL NN NN B-Disease
) NN NN O
have NN NN O
a NN NN O
poor NN NN O
prognosis NN NN O
. NN NN O
   
Median NN NN O
survival NN NN O
time NN NN O
from NN NN O
standard NN NN O
treatments NN NN O
is NN NN O
only NN NN O
17 NN NN O
months NN NN O
. NN NN O
   
High NN NN O
- NN NN O
dose NN NN O
intravenous NN NN O
melphalan NN NN O
followed NN NN O
by NN NN O
peripheral NN NN O
blood NN NN O
stem NN NN O
cell NN NN O
transplant NN NN O
( NN NN O
PBSCT NN NN O
) NN NN O
appears NN NN O
to NN NN O
be NN NN O
the NN NN O
most NN NN O
promising NN NN O
therapy NN NN O
, NN NN O
but NN NN O
treatment NN NN O
mortality NN NN O
can NN NN O
be NN NN O
high NN NN O
. NN NN O
   
The NN NN O
authors NN NN O
have NN NN O
noted NN NN O
the NN NN O
development NN NN O
of NN NN O
acute NN NN B-Disease
renal NN NN I-Disease
insufficiency NN NN I-Disease
immediately NN NN O
after NN NN O
melphalan NN NN O
conditioning NN NN O
. NN NN O
   
This NN NN O
study NN NN O
was NN NN O
undertaken NN NN O
to NN NN O
further NN NN O
examine NN NN O
its NN NN O
risk NN NN O
factors NN NN O
and NN NN O
impact NN NN O
on NN NN O
posttransplant NN NN O
mortality NN NN O
. NN NN O
   
METHODS NN NN O
: NN NN O
Consecutive NN NN O
AL NN NN B-Disease
patients NN NN O
who NN NN O
underwent NN NN O
PBSCT NN NN O
were NN NN O
studied NN NN O
retrospectively NN NN O
. NN NN O
   
Acute NN NN B-Disease
renal NN NN I-Disease
insufficiency NN NN I-Disease
( NN NN O
ARI NN NN B-Disease
) NN NN O
after NN NN O
high NN NN O
- NN NN O
dose NN NN O
melphalan NN NN O
was NN NN O
defined NN NN O
by NN NN O
a NN NN O
minimum NN NN O
increase NN NN O
of NN NN O
0 NN NN O
. NN NN O
5 NN NN O
mg NN NN O
/ NN NN O
dL NN NN O
( NN NN O
44 NN NN O
micromol NN NN O
/ NN NN O
L NN NN O
) NN NN O
in NN NN O
the NN NN O
serum NN NN O
creatinine NN NN O
level NN NN O
that NN NN O
is NN NN O
greater NN NN O
than NN NN O
50 NN NN O
% NN NN O
of NN NN O
baseline NN NN O
immediately NN NN O
after NN NN O
conditioning NN NN O
. NN NN O
   
Urine NN NN O
sediment NN NN O
score NN NN O
was NN NN O
the NN NN O
sum NN NN O
of NN NN O
the NN NN O
individual NN NN O
types NN NN O
of NN NN O
sediment NN NN O
identified NN NN O
on NN NN O
urine NN NN O
microscopy NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
Of NN NN O
the NN NN O
80 NN NN O
patients NN NN O
studied NN NN O
, NN NN O
ARI NN NN B-Disease
developed NN NN O
in NN NN O
18 NN NN O
. NN NN O
8 NN NN O
% NN NN O
of NN NN O
the NN NN O
patients NN NN O
after NN NN O
high NN NN O
- NN NN O
dose NN NN O
melphalan NN NN O
. NN NN O
   
Univariate NN NN O
analysis NN NN O
identified NN NN O
age NN NN O
, NN NN O
hypoalbuminemia NN NN B-Disease
, NN NN O
heavy NN NN O
proteinuria NN NN B-Disease
, NN NN O
diuretic NN NN O
use NN NN O
, NN NN O
and NN NN O
urine NN NN O
sediment NN NN O
score NN NN O
( NN NN O
> NN NN O
3 NN NN O
) NN NN O
as NN NN O
risk NN NN O
factors NN NN O
. NN NN O
   
Age NN NN O
and NN NN O
urine NN NN O
sediment NN NN O
score NN NN O
remained NN NN O
independently NN NN O
significant NN NN O
risk NN NN O
factors NN NN O
in NN NN O
the NN NN O
multivariate NN NN O
analysis NN NN O
. NN NN O
   
Patients NN NN O
who NN NN O
had NN NN O
ARI NN NN B-Disease
after NN NN O
high NN NN O
- NN NN O
dose NN NN O
melphalan NN NN O
underwent NN NN O
dialysis NN NN O
more NN NN O
often NN NN O
( NN NN O
P NN NN O
= NN NN O
0 NN NN O
. NN NN O
007 NN NN O
) NN NN O
, NN NN O
and NN NN O
had NN NN O
a NN NN O
worse NN NN O
1 NN NN O
- NN NN O
year NN NN O
survival NN NN O
( NN NN O
P NN NN O
= NN NN O
0 NN NN O
. NN NN O
03 NN NN O
) NN NN O
. NN NN O
   
CONCLUSION NN NN O
: NN NN O
The NN NN O
timing NN NN O
of NN NN O
renal NN NN B-Disease
injury NN NN I-Disease
strongly NN NN O
suggests NN NN O
melphalan NN NN O
as NN NN O
the NN NN O
causative NN NN O
agent NN NN O
. NN NN O
   
Ongoing NN NN O
tubular NN NN B-Disease
injury NN NN I-Disease
may NN NN O
be NN NN O
a NN NN O
prerequisite NN NN O
for NN NN O
renal NN NN B-Disease
injury NN NN I-Disease
by NN NN O
melphalan NN NN O
as NN NN O
evidenced NN NN O
by NN NN O
the NN NN O
active NN NN O
urinary NN NN O
sediment NN NN O
. NN NN O
   
Development NN NN O
of NN NN O
ARI NN NN B-Disease
adversely NN NN O
affected NN NN O
the NN NN O
outcome NN NN O
after NN NN O
PBSCT NN NN O
. NN NN O
   
Effective NN NN O
preventive NN NN O
measures NN NN O
may NN NN O
help NN NN O
decrease NN NN O
the NN NN O
treatment NN NN O
mortality NN NN O
of NN NN O
PBSCT NN NN O
in NN NN O
AL NN NN B-Disease
patients NN NN O
. NN NN O
   
Focal NN NN O
cerebral NN NN B-Disease
ischemia NN NN I-Disease
in NN NN O
rats NN NN O
: NN NN O
effect NN NN O
of NN NN O
phenylephrine NN NN O
- NN NN O
induced NN NN O
hypertension NN NN B-Disease
during NN NN O
reperfusion NN NN O
. NN NN O
   
After NN NN O
180 NN NN O
min NN NN O
of NN NN O
temporary NN NN O
middle NN NN B-Disease
cerebral NN NN I-Disease
artery NN NN I-Disease
occlusion NN NN I-Disease
in NN NN O
spontaneously NN NN O
hypertensive NN NN B-Disease
rats NN NN O
, NN NN O
the NN NN O
effect NN NN O
of NN NN O
phenylephrine NN NN O
- NN NN O
induced NN NN O
hypertension NN NN B-Disease
on NN NN O
ischemic NN NN B-Disease
brain NN NN I-Disease
injury NN NN I-Disease
and NN NN O
blood NN NN O
- NN NN O
brain NN NN O
barrier NN NN O
permeability NN NN O
was NN NN O
determined NN NN O
. NN NN O
   
Blood NN NN O
pressure NN NN O
was NN NN O
manipulated NN NN O
by NN NN O
one NN NN O
of NN NN O
the NN NN O
following NN NN O
schedules NN NN O
during NN NN O
120 NN NN O
min NN NN O
of NN NN O
reperfusion NN NN O
: NN NN O
Control NN NN O
, NN NN O
normotensive NN NN O
reperfusion NN NN O
; NN NN O
90 NN NN O
/ NN NN O
hypertension NN NN B-Disease
( NN NN O
90 NN NN O
/ NN NN O
HTN NN NN B-Disease
) NN NN O
, NN NN O
blood NN NN O
pressure NN NN O
was NN NN O
increased NN NN O
by NN NN O
35 NN NN O
mm NN NN O
Hg NN NN O
during NN NN O
the NN NN O
initial NN NN O
90 NN NN O
min NN NN O
of NN NN O
reperfusion NN NN O
only NN NN O
; NN NN O
15 NN NN O
/ NN NN O
hypertension NN NN B-Disease
( NN NN O
15 NN NN O
/ NN NN O
HTN NN NN B-Disease
) NN NN O
, NN NN O
normotensive NN NN O
reperfusion NN NN O
for NN NN O
30 NN NN O
min NN NN O
followed NN NN O
by NN NN O
15 NN NN O
min NN NN O
of NN NN O
hypertension NN NN B-Disease
and NN NN O
75 NN NN O
min NN NN O
of NN NN O
normotension NN NN O
. NN NN O
   
Part NN NN O
A NN NN O
, NN NN O
for NN NN O
eight NN NN O
rats NN NN O
in NN NN O
each NN NN O
group NN NN O
brain NN NN B-Disease
injury NN NN I-Disease
was NN NN O
evaluated NN NN O
by NN NN O
staining NN NN O
tissue NN NN O
using NN NN O
2 NN NN O
, NN NN O
3 NN NN O
, NN NN O
5 NN NN O
- NN NN O
triphenyltetrazolium NN NN O
chloride NN NN O
and NN NN O
edema NN NN B-Disease
was NN NN O
evaluated NN NN O
by NN NN O
microgravimetry NN NN O
. NN NN O
   
Part NN NN O
B NN NN O
, NN NN O
for NN NN O
eight NN NN O
different NN NN O
rats NN NN O
in NN NN O
each NN NN O
group NN NN O
blood NN NN O
- NN NN O
brain NN NN O
barrier NN NN O
permeability NN NN O
was NN NN O
evaluated NN NN O
by NN NN O
measuring NN NN O
the NN NN O
amount NN NN O
and NN NN O
extent NN NN O
of NN NN O
extravasation NN NN O
of NN NN O
Evans NN NN O
Blue NN NN O
dye NN NN O
. NN NN O
   
Brain NN NN B-Disease
injury NN NN I-Disease
( NN NN O
percentage NN NN O
of NN NN O
the NN NN O
ischemic NN NN B-Disease
hemisphere NN NN I-Disease
) NN NN O
was NN NN O
less NN NN O
in NN NN O
the NN NN O
15 NN NN O
/ NN NN O
HTN NN NN B-Disease
group NN NN O
( NN NN O
16 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
6 NN NN O
, NN NN O
mean NN NN O
+ NN NN O
/ NN NN O
- NN NN O
SD NN NN O
) NN NN O
versus NN NN O
the NN NN O
90 NN NN O
/ NN NN O
HTN NN NN B-Disease
group NN NN O
( NN NN O
30 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
6 NN NN O
) NN NN O
, NN NN O
which NN NN O
was NN NN O
in NN NN O
turn NN NN O
less NN NN O
than NN NN O
the NN NN O
control NN NN O
group NN NN O
( NN NN O
42 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
5 NN NN O
) NN NN O
. NN NN O
   
Specific NN NN O
gravity NN NN O
was NN NN O
greater NN NN O
in NN NN O
the NN NN O
15 NN NN O
/ NN NN O
HTN NN NN B-Disease
group NN NN O
( NN NN O
1 NN NN O
. NN NN O
043 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
0 NN NN O
. NN NN O
002 NN NN O
) NN NN O
versus NN NN O
the NN NN O
90 NN NN O
/ NN NN O
HTN NN NN B-Disease
( NN NN O
1 NN NN O
. NN NN O
036 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
0 NN NN O
. NN NN O
003 NN NN O
) NN NN O
and NN NN O
control NN NN O
( NN NN O
1 NN NN O
. NN NN O
037 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
0 NN NN O
. NN NN O
003 NN NN O
) NN NN O
groups NN NN O
. NN NN O
   
Evans NN NN O
Blue NN NN O
( NN NN O
mug NN NN O
g NN NN O
- NN NN O
1 NN NN O
of NN NN O
brain NN NN O
tissue NN NN O
) NN NN O
was NN NN O
greater NN NN O
in NN NN O
the NN NN O
90 NN NN O
/ NN NN O
HTN NN NN B-Disease
group NN NN O
( NN NN O
24 NN NN O
. NN NN O
4 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
6 NN NN O
. NN NN O
0 NN NN O
) NN NN O
versus NN NN O
the NN NN O
control NN NN O
group NN NN O
( NN NN O
12 NN NN O
. NN NN O
3 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
4 NN NN O
. NN NN O
1 NN NN O
) NN NN O
, NN NN O
which NN NN O
was NN NN O
in NN NN O
turn NN NN O
greater NN NN O
than NN NN O
the NN NN O
15 NN NN O
/ NN NN O
HTN NN NN B-Disease
group NN NN O
( NN NN O
7 NN NN O
. NN NN O
3 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
3 NN NN O
. NN NN O
2 NN NN O
) NN NN O
. NN NN O
   
This NN NN O
study NN NN O
supports NN NN O
a NN NN O
hypothesis NN NN O
that NN NN O
during NN NN O
reperfusion NN NN O
, NN NN O
a NN NN O
short NN NN O
interval NN NN O
of NN NN O
hypertension NN NN B-Disease
decreases NN NN O
brain NN NN B-Disease
injury NN NN I-Disease
and NN NN O
edema NN NN B-Disease
; NN NN O
and NN NN O
that NN NN O
sustained NN NN O
hypertension NN NN B-Disease
increases NN NN O
the NN NN O
risk NN NN O
of NN NN O
vasogenic NN NN B-Disease
edema NN NN I-Disease
. NN NN O
   
People NN NN O
aged NN NN O
over NN NN O
75 NN NN O
in NN NN O
atrial NN NN B-Disease
fibrillation NN NN I-Disease
on NN NN O
warfarin NN NN O
: NN NN O
the NN NN O
rate NN NN O
of NN NN O
major NN NN O
hemorrhage NN NN B-Disease
and NN NN O
stroke NN NN B-Disease
in NN NN O
more NN NN O
than NN NN O
500 NN NN O
patient NN NN O
- NN NN O
years NN NN O
of NN NN O
follow NN NN O
- NN NN O
up NN NN O
. NN NN O
   
OBJECTIVES NN NN O
: NN NN O
To NN NN O
determine NN NN O
the NN NN O
incidence NN NN O
of NN NN O
major NN NN O
hemorrhage NN NN B-Disease
and NN NN O
stroke NN NN B-Disease
in NN NN O
people NN NN O
aged NN NN O
76 NN NN O
and NN NN O
older NN NN O
with NN NN O
atrial NN NN B-Disease
fibrillation NN NN I-Disease
on NN NN O
adjusted NN NN O
- NN NN O
dose NN NN O
warfarin NN NN O
who NN NN O
had NN NN O
been NN NN O
recently NN NN O
been NN NN O
admitted NN NN O
to NN NN O
hospital NN NN O
. NN NN O
   
DESIGN NN NN O
: NN NN O
A NN NN O
retrospective NN NN O
observational NN NN O
cohort NN NN O
study NN NN O
. NN NN O
   
SETTING NN NN O
: NN NN O
A NN NN O
major NN NN O
healthcare NN NN O
network NN NN O
involving NN NN O
four NN NN O
tertiary NN NN O
hospitals NN NN O
. NN NN O
   
PARTICIPANTS NN NN O
: NN NN O
Two NN NN O
hundred NN NN O
thirty NN NN O
- NN NN O
five NN NN O
patients NN NN O
aged NN NN O
76 NN NN O
and NN NN O
older NN NN O
admitted NN NN O
to NN NN O
a NN NN O
major NN NN O
healthcare NN NN O
network NN NN O
between NN NN O
July NN NN O
1 NN NN O
, NN NN O
2001 NN NN O
, NN NN O
and NN NN O
June NN NN O
30 NN NN O
, NN NN O
2002 NN NN O
, NN NN O
with NN NN O
atrial NN NN B-Disease
fibrillation NN NN I-Disease
on NN NN O
warfarin NN NN O
were NN NN O
enrolled NN NN O
. NN NN O
   
MEASUREMENTS NN NN O
: NN NN O
Information NN NN O
regarding NN NN O
major NN NN O
bleeding NN NN B-Disease
episodes NN NN O
, NN NN O
strokes NN NN B-Disease
, NN NN O
and NN NN O
warfarin NN NN O
use NN NN O
was NN NN O
obtained NN NN O
from NN NN O
patients NN NN O
, NN NN O
relatives NN NN O
, NN NN O
primary NN NN O
physicians NN NN O
, NN NN O
and NN NN O
medical NN NN O
records NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
Two NN NN O
hundred NN NN O
twenty NN NN O
- NN NN O
eight NN NN O
patients NN NN O
( NN NN O
42 NN NN O
% NN NN O
men NN NN O
) NN NN O
with NN NN O
a NN NN O
mean NN NN O
age NN NN O
of NN NN O
81 NN NN O
. NN NN O
1 NN NN O
( NN NN O
range NN NN O
76 NN NN O
- NN NN O
94 NN NN O
) NN NN O
were NN NN O
included NN NN O
in NN NN O
the NN NN O
analysis NN NN O
. NN NN O
   
Total NN NN O
follow NN NN O
- NN NN O
up NN NN O
on NN NN O
warfarin NN NN O
was NN NN O
530 NN NN O
years NN NN O
( NN NN O
mean NN NN O
28 NN NN O
months NN NN O
) NN NN O
. NN NN O
   
There NN NN O
were NN NN O
53 NN NN O
major NN NN O
hemorrhages NN NN B-Disease
, NN NN O
for NN NN O
an NN NN O
annual NN NN O
rate NN NN O
of NN NN O
10 NN NN O
. NN NN O
0 NN NN O
% NN NN O
, NN NN O
including NN NN O
24 NN NN O
( NN NN O
45 NN NN O
. NN NN O
3 NN NN O
% NN NN O
) NN NN O
life NN NN O
- NN NN O
threatening NN NN O
and NN NN O
five NN NN O
( NN NN O
9 NN NN O
. NN NN O
4 NN NN O
% NN NN O
) NN NN O
fatal NN NN O
bleeds NN NN O
. NN NN O
   
The NN NN O
annual NN NN O
stroke NN NN B-Disease
rate NN NN O
after NN NN O
initiation NN NN O
of NN NN O
warfarin NN NN O
was NN NN O
2 NN NN O
. NN NN O
6 NN NN O
% NN NN O
. NN NN O
   
CONCLUSION NN NN O
: NN NN O
The NN NN O
rate NN NN O
of NN NN O
major NN NN O
hemorrhage NN NN B-Disease
was NN NN O
high NN NN O
in NN NN O
this NN NN O
old NN NN O
, NN NN O
frail NN NN O
group NN NN O
, NN NN O
but NN NN O
excluding NN NN O
fatalities NN NN O
, NN NN O
resulted NN NN O
in NN NN O
no NN NN O
long NN NN O
- NN NN O
term NN NN O
sequelae NN NN O
, NN NN O
and NN NN O
the NN NN O
stroke NN NN B-Disease
rate NN NN O
on NN NN O
warfarin NN NN O
was NN NN O
low NN NN O
, NN NN O
demonstrating NN NN O
how NN NN O
effective NN NN O
warfarin NN NN O
treatment NN NN O
is NN NN O
. NN NN O
   
Safety NN NN O
of NN NN O
celecoxib NN NN O
in NN NN O
patients NN NN O
with NN NN O
adverse NN NN O
skin NN NN B-Disease
reactions NN NN I-Disease
to NN NN O
acetaminophen NN NN O
( NN NN O
paracetamol NN NN O
) NN NN O
and NN NN O
nimesulide NN NN O
associated NN NN O
or NN NN O
not NN NN O
with NN NN O
common NN NN O
non NN NN O
- NN NN O
steroidal NN NN O
anti NN NN O
- NN NN O
inflammatory NN NN O
drugs NN NN O
. NN NN O
   
BACKGROUND NN NN O
: NN NN O
Acetaminophen NN NN O
( NN NN O
paracetamol NN NN O
- NN NN O
- NN NN O
P NN NN O
) NN NN O
and NN NN O
Nimesulide NN NN O
( NN NN O
N NN NN O
) NN NN O
are NN NN O
widely NN NN O
used NN NN O
analgesic NN NN O
- NN NN O
antipyretic NN NN O
/ NN NN O
anti NN NN O
- NN NN O
inflammatory NN NN O
drugs NN NN O
. NN NN O
   
The NN NN O
rate NN NN O
of NN NN O
adverse NN NN O
hypersensitivity NN NN B-Disease
reactions NN NN O
to NN NN O
these NN NN O
agents NN NN O
is NN NN O
generally NN NN O
low NN NN O
. NN NN O
   
On NN NN O
the NN NN O
contrary NN NN O
non NN NN O
- NN NN O
steroidal NN NN O
anti NN NN O
- NN NN O
inflammatory NN NN O
drugs NN NN O
( NN NN O
NSAIDs NN NN O
) NN NN O
are NN NN O
commonly NN NN O
involved NN NN O
in NN NN O
such NN NN O
reactions NN NN O
. NN NN O
   
Celecoxib NN NN O
( NN NN O
CE NN NN O
) NN NN O
is NN NN O
a NN NN O
novel NN NN O
drug NN NN O
, NN NN O
with NN NN O
high NN NN O
selectivity NN NN O
and NN NN O
affinity NN NN O
for NN NN O
COX NN NN O
- NN NN O
2 NN NN O
enzyme NN NN O
. NN NN O
   
OBJECTIVE NN NN O
: NN NN O
We NN NN O
evaluated NN NN O
the NN NN O
tolerability NN NN O
of NN NN O
CE NN NN O
in NN NN O
a NN NN O
group NN NN O
of NN NN O
patients NN NN O
with NN NN O
documented NN NN O
history NN NN O
of NN NN O
adverse NN NN O
cutaneous NN NN B-Disease
reactions NN NN I-Disease
to NN NN O
P NN NN O
and NN NN O
N NN NN O
associated NN NN O
or NN NN O
not NN NN O
to NN NN O
classic NN NN O
NSAIDs NN NN O
. NN NN O
   
METHODS NN NN O
: NN NN O
We NN NN O
studied NN NN O
9 NN NN O
patients NN NN O
with NN NN O
hypersensitivity NN NN B-Disease
to NN NN O
P NN NN O
and NN NN O
N NN NN O
with NN NN O
or NN NN O
without NN NN O
associated NN NN O
reactions NN NN O
to NN NN O
classic NN NN O
NSAIDs NN NN O
. NN NN O
   
The NN NN O
diagnosis NN NN O
of NN NN O
P NN NN O
and NN NN O
N NN NN O
- NN NN O
induced NN NN O
skin NN NN B-Disease
reactions NN NN I-Disease
was NN NN O
based NN NN O
in NN NN O
vivo NN NN O
challenge NN NN O
. NN NN O
   
The NN NN O
placebo NN NN O
was NN NN O
blindly NN NN O
administered NN NN O
at NN NN O
the NN NN O
beginning NN NN O
of NN NN O
each NN NN O
challenge NN NN O
. NN NN O
   
After NN NN O
three NN NN O
days NN NN O
, NN NN O
a NN NN O
cumulative NN NN O
dosage NN NN O
of NN NN O
200 NN NN O
mg NN NN O
of NN NN O
CE NN NN O
in NN NN O
refracted NN NN O
doses NN NN O
were NN NN O
given NN NN O
. NN NN O
   
After NN NN O
2 NN NN O
- NN NN O
3 NN NN O
days NN NN O
, NN NN O
a NN NN O
single NN NN O
dose NN NN O
of NN NN O
200 NN NN O
mg NN NN O
was NN NN O
administered NN NN O
. NN NN O
   
All NN NN O
patients NN NN O
were NN NN O
observed NN NN O
for NN NN O
6 NN NN O
hours NN NN O
after NN NN O
each NN NN O
challenge NN NN O
, NN NN O
and NN NN O
controlled NN NN O
again NN NN O
after NN NN O
24 NN NN O
hours NN NN O
to NN NN O
exclude NN NN O
delayed NN NN O
reactions NN NN O
. NN NN O
   
The NN NN O
challenge NN NN O
was NN NN O
considered NN NN O
positive NN NN O
if NN NN O
one NN NN O
or NN NN O
more NN NN O
of NN NN O
the NN NN O
following NN NN O
appeared NN NN O
: NN NN O
erythema NN NN B-Disease
, NN NN O
rush NN NN O
or NN NN O
urticaria NN NN B-Disease
- NN NN O
angioedema NN NN B-Disease
. NN NN O
   
RESULTS NN NN O
: NN NN O
No NN NN O
reaction NN NN O
was NN NN O
observed NN NN O
with NN NN O
placebo NN NN O
and NN NN O
eight NN NN O
patients NN NN O
( NN NN O
88 NN NN O
. NN NN O
8 NN NN O
% NN NN O
) NN NN O
tolerated NN NN O
CE NN NN O
. NN NN O
   
Only NN NN O
one NN NN O
patient NN NN O
developed NN NN O
a NN NN O
moderate NN NN O
angioedema NN NN B-Disease
of NN NN O
the NN NN O
lips NN NN O
. NN NN O
   
CONCLUSION NN NN O
: NN NN O
Only NN NN O
one NN NN O
hypersensitivity NN NN B-Disease
reaction NN NN O
to NN NN O
CE NN NN O
was NN NN O
documented NN NN O
among NN NN O
9 NN NN O
P NN NN O
and NN NN O
N NN NN O
- NN NN O
highly NN NN O
NSAIDs NN NN O
intolerant NN NN O
patients NN NN O
. NN NN O
   
Thus NN NN O
, NN NN O
we NN NN O
conclude NN NN O
that NN NN O
CE NN NN O
is NN NN O
a NN NN O
reasonably NN NN O
safe NN NN O
alternative NN NN O
to NN NN O
be NN NN O
used NN NN O
in NN NN O
subjects NN NN O
who NN NN O
do NN NN O
not NN NN O
tolerate NN NN O
P NN NN O
and NN NN O
N NN NN O
. NN NN O
   
Case NN NN O
- NN NN O
control NN NN O
study NN NN O
of NN NN O
regular NN NN O
analgesic NN NN O
and NN NN O
nonsteroidal NN NN O
anti NN NN O
- NN NN O
inflammatory NN NN O
use NN NN O
and NN NN O
end NN NN B-Disease
- NN NN I-Disease
stage NN NN I-Disease
renal NN NN I-Disease
disease NN NN I-Disease
. NN NN O
   
BACKGROUND NN NN O
: NN NN O
Studies NN NN O
on NN NN O
the NN NN O
association NN NN O
between NN NN O
the NN NN O
long NN NN O
- NN NN O
term NN NN O
use NN NN O
of NN NN O
aspirin NN NN O
and NN NN O
other NN NN O
analgesic NN NN O
and NN NN O
nonsteroidal NN NN O
anti NN NN O
- NN NN O
inflammatory NN NN O
drugs NN NN O
( NN NN O
NSAIDs NN NN O
) NN NN O
and NN NN O
end NN NN B-Disease
- NN NN I-Disease
stage NN NN I-Disease
renal NN NN I-Disease
disease NN NN I-Disease
( NN NN O
ESRD NN NN B-Disease
) NN NN O
have NN NN O
given NN NN O
conflicting NN NN O
results NN NN O
. NN NN O
   
In NN NN O
order NN NN O
to NN NN O
examine NN NN O
this NN NN O
association NN NN O
, NN NN O
a NN NN O
case NN NN O
- NN NN O
control NN NN O
study NN NN O
with NN NN O
incident NN NN O
cases NN NN O
of NN NN O
ESRD NN NN B-Disease
was NN NN O
carried NN NN O
out NN NN O
. NN NN O
   
METHODS NN NN O
: NN NN O
The NN NN O
cases NN NN O
were NN NN O
all NN NN O
patients NN NN O
entering NN NN O
the NN NN O
local NN NN O
dialysis NN NN O
program NN NN O
because NN NN O
of NN NN O
ESRD NN NN B-Disease
in NN NN O
the NN NN O
study NN NN O
area NN NN O
between NN NN O
June NN NN O
1 NN NN O
, NN NN O
1995 NN NN O
and NN NN O
November NN NN O
30 NN NN O
, NN NN O
1997 NN NN O
. NN NN O
   
They NN NN O
were NN NN O
classified NN NN O
according NN NN O
to NN NN O
the NN NN O
underlying NN NN O
disease NN NN O
, NN NN O
which NN NN O
had NN NN O
presumably NN NN O
led NN NN O
them NN NN O
to NN NN O
ESRD NN NN B-Disease
. NN NN O
   
Controls NN NN O
were NN NN O
patients NN NN O
admitted NN NN O
to NN NN O
the NN NN O
same NN NN O
hospitals NN NN O
from NN NN O
where NN NN O
the NN NN O
cases NN NN O
arose NN NN O
, NN NN O
also NN NN O
matched NN NN O
by NN NN O
age NN NN O
and NN NN O
sex NN NN O
. NN NN O
   
Odds NN NN O
ratios NN NN O
were NN NN O
calculated NN NN O
using NN NN O
a NN NN O
conditional NN NN O
logistic NN NN O
model NN NN O
, NN NN O
including NN NN O
potential NN NN O
confounding NN NN O
factors NN NN O
, NN NN O
both NN NN O
for NN NN O
the NN NN O
whole NN NN O
study NN NN O
population NN NN O
and NN NN O
for NN NN O
the NN NN O
various NN NN O
underlying NN NN O
diseases NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
Five NN NN O
hundred NN NN O
and NN NN O
eighty NN NN O
- NN NN O
three NN NN O
cases NN NN O
and NN NN O
1190 NN NN O
controls NN NN O
were NN NN O
included NN NN O
in NN NN O
the NN NN O
analysis NN NN O
. NN NN O
   
Long NN NN O
- NN NN O
term NN NN O
use NN NN O
of NN NN O
any NN NN O
analgesic NN NN O
was NN NN O
associated NN NN O
with NN NN O
an NN NN O
overall NN NN O
odds NN NN O
ratio NN NN O
of NN NN O
1 NN NN O
. NN NN O
22 NN NN O
( NN NN O
95 NN NN O
% NN NN O
CI NN NN O
, NN NN O
0 NN NN O
. NN NN O
89 NN NN O
- NN NN O
1 NN NN O
. NN NN O
66 NN NN O
) NN NN O
. NN NN O
   
For NN NN O
specific NN NN O
groups NN NN O
of NN NN O
drugs NN NN O
, NN NN O
the NN NN O
risks NN NN O
were NN NN O
1 NN NN O
. NN NN O
56 NN NN O
( NN NN O
1 NN NN O
. NN NN O
05 NN NN O
- NN NN O
2 NN NN O
. NN NN O
30 NN NN O
) NN NN O
for NN NN O
aspirin NN NN O
, NN NN O
1 NN NN O
. NN NN O
03 NN NN O
( NN NN O
0 NN NN O
. NN NN O
60 NN NN O
- NN NN O
1 NN NN O
. NN NN O
76 NN NN O
) NN NN O
for NN NN O
pyrazolones NN NN O
, NN NN O
0 NN NN O
. NN NN O
80 NN NN O
( NN NN O
0 NN NN O
. NN NN O
39 NN NN O
- NN NN O
1 NN NN O
. NN NN O
63 NN NN O
) NN NN O
for NN NN O
paracetamol NN NN O
, NN NN O
and NN NN O
0 NN NN O
. NN NN O
94 NN NN O
( NN NN O
0 NN NN O
. NN NN O
57 NN NN O
- NN NN O
1 NN NN O
. NN NN O
56 NN NN O
) NN NN O
for NN NN O
nonaspirin NN NN O
NSAIDs NN NN O
. NN NN O
   
The NN NN O
risk NN NN O
of NN NN O
ESRD NN NN B-Disease
associated NN NN O
with NN NN O
aspirin NN NN O
was NN NN O
related NN NN O
to NN NN O
the NN NN O
cumulated NN NN O
dose NN NN O
and NN NN O
duration NN NN O
of NN NN O
use NN NN O
, NN NN O
and NN NN O
it NN NN O
was NN NN O
particularly NN NN O
high NN NN O
among NN NN O
the NN NN O
subset NN NN O
of NN NN O
patients NN NN O
with NN NN O
vascular NN NN O
nephropathy NN NN B-Disease
as NN NN O
underlying NN NN O
disease NN NN O
[ NN NN O
2 NN NN O
. NN NN O
35 NN NN O
( NN NN O
1 NN NN O
. NN NN O
17 NN NN O
- NN NN O
4 NN NN O
. NN NN O
72 NN NN O
) NN NN O
] NN NN O
. NN NN O
   
CONCLUSION NN NN O
: NN NN O
Our NN NN O
data NN NN O
indicate NN NN O
that NN NN O
long NN NN O
- NN NN O
term NN NN O
use NN NN O
of NN NN O
nonaspirin NN NN O
analgesic NN NN O
drugs NN NN O
and NN NN O
NSAIDs NN NN O
is NN NN O
not NN NN O
associated NN NN O
with NN NN O
an NN NN O
increased NN NN O
risk NN NN O
of NN NN O
ESRD NN NN B-Disease
. NN NN O
   
However NN NN O
, NN NN O
the NN NN O
chronic NN NN O
use NN NN O
of NN NN O
aspirin NN NN O
may NN NN O
increase NN NN O
the NN NN O
risk NN NN O
of NN NN O
ESRD NN NN B-Disease
. NN NN O
   
Two NN NN O
cases NN NN O
of NN NN O
amisulpride NN NN O
overdose NN NN B-Disease
: NN NN O
a NN NN O
cause NN NN O
for NN NN O
prolonged NN NN B-Disease
QT NN NN I-Disease
syndrome NN NN I-Disease
. NN NN O
   
Two NN NN O
cases NN NN O
of NN NN O
deliberate NN NN O
self NN NN O
- NN NN O
poisoning NN NN B-Disease
with NN NN O
5 NN NN O
g NN NN O
and NN NN O
3 NN NN O
. NN NN O
6 NN NN O
g NN NN O
of NN NN O
amisulpride NN NN O
, NN NN O
respectively NN NN O
, NN NN O
are NN NN O
reported NN NN O
. NN NN O
   
In NN NN O
both NN NN O
cases NN NN O
, NN NN O
QT NN NN B-Disease
prolongation NN NN I-Disease
and NN NN O
hypocalcaemia NN NN B-Disease
were NN NN O
noted NN NN O
. NN NN O
   
The NN NN O
QT NN NN B-Disease
prolongation NN NN I-Disease
appeared NN NN O
to NN NN O
respond NN NN O
to NN NN O
administration NN NN O
of NN NN O
i NN NN O
. NN NN O
v NN NN O
. NN NN O
calcium NN NN O
gluconate NN NN O
. NN NN O
   
Growth NN NN O
- NN NN O
associated NN NN O
protein NN NN O
43 NN NN O
expression NN NN O
in NN NN O
hippocampal NN NN O
molecular NN NN O
layer NN NN O
of NN NN O
chronic NN NN O
epileptic NN NN B-Disease
rats NN NN O
treated NN NN O
with NN NN O
cycloheximide NN NN O
. NN NN O
   
PURPOSE NN NN O
: NN NN O
GAP43 NN NN O
has NN NN O
been NN NN O
thought NN NN O
to NN NN O
be NN NN O
linked NN NN O
with NN NN O
mossy NN NN O
fiber NN NN O
sprouting NN NN O
( NN NN O
MFS NN NN O
) NN NN O
in NN NN O
various NN NN O
experimental NN NN O
models NN NN O
of NN NN O
epilepsy NN NN B-Disease
. NN NN O
   
To NN NN O
investigate NN NN O
how NN NN O
GAP43 NN NN O
expression NN NN O
( NN NN O
GAP43 NN NN O
- NN NN O
ir NN NN O
) NN NN O
correlates NN NN O
with NN NN O
MFS NN NN O
, NN NN O
we NN NN O
assessed NN NN O
the NN NN O
intensity NN NN O
( NN NN O
densitometry NN NN O
) NN NN O
and NN NN O
extension NN NN O
( NN NN O
width NN NN O
) NN NN O
of NN NN O
GAP43 NN NN O
- NN NN O
ir NN NN O
in NN NN O
the NN NN O
inner NN NN O
molecular NN NN O
layer NN NN O
of NN NN O
the NN NN O
dentate NN NN O
gyrus NN NN O
( NN NN O
IML NN NN O
) NN NN O
of NN NN O
rats NN NN O
subject NN NN O
to NN NN O
status NN NN B-Disease
epilepticus NN NN I-Disease
induced NN NN O
by NN NN O
pilocarpine NN NN O
( NN NN O
Pilo NN NN O
) NN NN O
, NN NN O
previously NN NN O
injected NN NN O
or NN NN O
not NN NN O
with NN NN O
cycloheximide NN NN O
( NN NN O
CHX NN NN O
) NN NN O
, NN NN O
which NN NN O
has NN NN O
been NN NN O
shown NN NN O
to NN NN O
inhibit NN NN O
MFS NN NN O
. NN NN O
   
METHODS NN NN O
: NN NN O
CHX NN NN O
was NN NN O
injected NN NN O
before NN NN O
the NN NN O
Pilo NN NN O
injection NN NN O
in NN NN O
adult NN NN O
Wistar NN NN O
rats NN NN O
. NN NN O
   
The NN NN O
Pilo NN NN O
group NN NN O
was NN NN O
injected NN NN O
with NN NN O
the NN NN O
same NN NN O
drugs NN NN O
, NN NN O
except NN NN O
for NN NN O
CHX NN NN O
. NN NN O
   
Animals NN NN O
were NN NN O
killed NN NN O
between NN NN O
30 NN NN O
and NN NN O
60 NN NN O
days NN NN O
later NN NN O
, NN NN O
and NN NN O
brain NN NN O
sections NN NN O
were NN NN O
processed NN NN O
for NN NN O
GAP43 NN NN O
immunohistochemistry NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
Densitometry NN NN O
showed NN NN O
no NN NN O
significant NN NN O
difference NN NN O
regarding NN NN O
GAP43 NN NN O
- NN NN O
ir NN NN O
in NN NN O
the NN NN O
IML NN NN O
between NN NN O
Pilo NN NN O
, NN NN O
CHX NN NN O
+ NN NN O
Pilo NN NN O
, NN NN O
and NN NN O
control NN NN O
groups NN NN O
. NN NN O
   
However NN NN O
, NN NN O
the NN NN O
results NN NN O
of NN NN O
the NN NN O
width NN NN O
of NN NN O
the NN NN O
GAP43 NN NN O
- NN NN O
ir NN NN O
band NN NN O
in NN NN O
the NN NN O
IML NN NN O
showed NN NN O
that NN NN O
CHX NN NN O
+ NN NN O
Pilo NN NN O
and NN NN O
control NN NN O
animals NN NN O
had NN NN O
a NN NN O
significantly NN NN O
larger NN NN O
band NN NN O
( NN NN O
p NN NN O
= NN NN O
0 NN NN O
. NN NN O
03 NN NN O
) NN NN O
as NN NN O
compared NN NN O
with NN NN O
that NN NN O
in NN NN O
the NN NN O
Pilo NN NN O
group NN NN O
. NN NN O
   
CONCLUSIONS NN NN O
: NN NN O
Our NN NN O
current NN NN O
finding NN NN O
that NN NN O
animals NN NN O
in NN NN O
the NN NN O
CHX NN NN O
+ NN NN O
Pilo NN NN O
group NN NN O
have NN NN O
a NN NN O
GAP43 NN NN O
- NN NN O
ir NN NN O
band NN NN O
in NN NN O
the NN NN O
IML NN NN O
, NN NN O
similar NN NN O
to NN NN O
that NN NN O
of NN NN O
controls NN NN O
, NN NN O
reinforces NN NN O
prior NN NN O
data NN NN O
on NN NN O
the NN NN O
blockade NN NN O
of NN NN O
MFS NN NN O
in NN NN O
these NN NN O
animals NN NN O
. NN NN O
   
The NN NN O
change NN NN O
in NN NN O
GAP43 NN NN O
- NN NN O
ir NN NN O
present NN NN O
in NN NN O
Pilo NN NN O
- NN NN O
treated NN NN O
animals NN NN O
was NN NN O
a NN NN O
thinning NN NN O
of NN NN O
the NN NN O
band NN NN O
to NN NN O
a NN NN O
very NN NN O
narrow NN NN O
layer NN NN O
just NN NN O
above NN NN O
the NN NN O
granule NN NN O
cell NN NN O
layer NN NN O
that NN NN O
is NN NN O
likely NN NN O
to NN NN O
be NN NN O
associated NN NN O
with NN NN O
the NN NN O
loss NN NN O
of NN NN O
hilar NN NN O
cell NN NN O
projections NN NN O
that NN NN O
express NN NN O
GAP NN NN O
- NN NN O
43 NN NN O
. NN NN O
   
Nicotine NN NN O
antagonizes NN NN O
caffeine NN NN O
- NN NN O
but NN NN O
not NN NN O
pentylenetetrazole NN NN O
- NN NN O
induced NN NN O
anxiogenic NN NN O
effect NN NN O
in NN NN O
mice NN NN O
. NN NN O
   
RATIONALE NN NN O
: NN NN O
Nicotine NN NN O
and NN NN O
caffeine NN NN O
are NN NN O
widely NN NN O
consumed NN NN O
licit NN NN O
psychoactive NN NN O
drugs NN NN O
worldwide NN NN O
. NN NN O
   
Epidemiological NN NN O
studies NN NN O
showed NN NN O
that NN NN O
they NN NN O
were NN NN O
generally NN NN O
used NN NN O
concurrently NN NN O
. NN NN O
   
Although NN NN O
some NN NN O
studies NN NN O
in NN NN O
experimental NN NN O
animals NN NN O
indicate NN NN O
clear NN NN O
pharmacological NN NN O
interactions NN NN O
between NN NN O
them NN NN O
, NN NN O
no NN NN O
studies NN NN O
have NN NN O
shown NN NN O
a NN NN O
specific NN NN O
interaction NN NN O
on NN NN O
anxiety NN NN B-Disease
responses NN NN O
. NN NN O
   
OBJECTIVES NN NN O
: NN NN O
The NN NN O
present NN NN O
study NN NN O
investigates NN NN O
the NN NN O
effects NN NN O
of NN NN O
nicotine NN NN O
on NN NN O
anxiety NN NN B-Disease
induced NN NN O
by NN NN O
caffeine NN NN O
and NN NN O
another NN NN O
anxiogenic NN NN O
drug NN NN O
, NN NN O
pentylenetetrazole NN NN O
, NN NN O
in NN NN O
mice NN NN O
. NN NN O
   
The NN NN O
elevated NN NN O
plus NN NN O
- NN NN O
maze NN NN O
( NN NN O
EPM NN NN O
) NN NN O
test NN NN O
was NN NN O
used NN NN O
to NN NN O
evaluate NN NN O
the NN NN O
effects NN NN O
of NN NN O
drugs NN NN O
on NN NN O
anxiety NN NN B-Disease
. NN NN O
   
METHODS NN NN O
: NN NN O
Adult NN NN O
male NN NN O
Swiss NN NN O
Webster NN NN O
mice NN NN O
( NN NN O
25 NN NN O
- NN NN O
32 NN NN O
g NN NN O
) NN NN O
were NN NN O
given NN NN O
nicotine NN NN O
( NN NN O
0 NN NN O
. NN NN O
05 NN NN O
- NN NN O
0 NN NN O
. NN NN O
25 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
s NN NN O
. NN NN O
c NN NN O
. NN NN O
) NN NN O
or NN NN O
saline NN NN O
10 NN NN O
min NN NN O
before NN NN O
caffeine NN NN O
( NN NN O
70 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
i NN NN O
. NN NN O
p NN NN O
. NN NN O
) NN NN O
or NN NN O
pentylenetetrazole NN NN O
( NN NN O
15 NN NN O
and NN NN O
30 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
i NN NN O
. NN NN O
p NN NN O
. NN NN O
) NN NN O
injections NN NN O
. NN NN O
   
After NN NN O
15 NN NN O
min NN NN O
, NN NN O
mice NN NN O
were NN NN O
evaluated NN NN O
for NN NN O
their NN NN O
open NN NN O
- NN NN O
and NN NN O
closed NN NN O
- NN NN O
arm NN NN O
time NN NN O
and NN NN O
entries NN NN O
on NN NN O
the NN NN O
EPM NN NN O
for NN NN O
a NN NN O
10 NN NN O
- NN NN O
min NN NN O
session NN NN O
. NN NN O
   
Locomotor NN NN O
activity NN NN O
was NN NN O
recorded NN NN O
for NN NN O
individual NN NN O
groups NN NN O
by NN NN O
using NN NN O
the NN NN O
same NN NN O
treatment NN NN O
protocol NN NN O
with NN NN O
the NN NN O
EPM NN NN O
test NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
Nicotine NN NN O
( NN NN O
0 NN NN O
. NN NN O
05 NN NN O
- NN NN O
0 NN NN O
. NN NN O
25 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
) NN NN O
itself NN NN O
did NN NN O
not NN NN O
produce NN NN O
any NN NN O
significant NN NN O
effect NN NN O
in NN NN O
the NN NN O
EPM NN NN O
test NN NN O
, NN NN O
whereas NN NN O
caffeine NN NN O
( NN NN O
70 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
) NN NN O
and NN NN O
pentylenetetrazole NN NN O
( NN NN O
30 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
) NN NN O
produced NN NN O
an NN NN O
anxiogenic NN NN O
effect NN NN O
, NN NN O
apparent NN NN O
with NN NN O
decreases NN NN O
in NN NN O
open NN NN O
- NN NN O
arm NN NN O
time NN NN O
and NN NN O
entry NN NN O
. NN NN O
   
Nicotine NN NN O
( NN NN O
0 NN NN O
. NN NN O
25 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
) NN NN O
pretreatment NN NN O
blocked NN NN O
the NN NN O
caffeine NN NN O
- NN NN O
but NN NN O
not NN NN O
pentylenetetrazole NN NN O
- NN NN O
induced NN NN O
anxiety NN NN B-Disease
. NN NN O
   
Administration NN NN O
of NN NN O
each NN NN O
drug NN NN O
and NN NN O
their NN NN O
combinations NN NN O
did NN NN O
not NN NN O
produce NN NN O
any NN NN O
effect NN NN O
on NN NN O
locomotor NN NN O
activity NN NN O
. NN NN O
   
CONCLUSIONS NN NN O
: NN NN O
Our NN NN O
results NN NN O
suggest NN NN O
that NN NN O
the NN NN O
antagonistic NN NN O
effect NN NN O
of NN NN O
nicotine NN NN O
on NN NN O
caffeine NN NN O
- NN NN O
induced NN NN O
anxiety NN NN B-Disease
is NN NN O
specific NN NN O
to NN NN O
caffeine NN NN O
, NN NN O
instead NN NN O
of NN NN O
a NN NN O
non NN NN O
- NN NN O
specific NN NN O
anxiolytic NN NN O
effect NN NN O
. NN NN O
   
Thus NN NN O
, NN NN O
it NN NN O
may NN NN O
extend NN NN O
the NN NN O
current NN NN O
findings NN NN O
on NN NN O
the NN NN O
interaction NN NN O
between NN NN O
nicotine NN NN O
and NN NN O
caffeine NN NN O
. NN NN O
   
Long NN NN O
term NN NN O
hormone NN NN O
therapy NN NN O
for NN NN O
perimenopausal NN NN O
and NN NN O
postmenopausal NN NN O
women NN NN O
. NN NN O
   
BACKGROUND NN NN O
: NN NN O
Hormone NN NN O
therapy NN NN O
( NN NN O
HT NN NN O
) NN NN O
is NN NN O
widely NN NN O
used NN NN O
for NN NN O
controlling NN NN O
menopausal NN NN B-Disease
symptoms NN NN I-Disease
. NN NN O
   
It NN NN O
has NN NN O
also NN NN O
been NN NN O
used NN NN O
for NN NN O
the NN NN O
management NN NN O
and NN NN O
prevention NN NN O
of NN NN O
cardiovascular NN NN B-Disease
disease NN NN I-Disease
, NN NN O
osteoporosis NN NN B-Disease
and NN NN O
dementia NN NN B-Disease
in NN NN O
older NN NN O
women NN NN O
but NN NN O
the NN NN O
evidence NN NN O
supporting NN NN O
its NN NN O
use NN NN O
for NN NN O
these NN NN O
indications NN NN O
is NN NN O
largely NN NN O
observational NN NN O
. NN NN O
   
OBJECTIVES NN NN O
: NN NN O
To NN NN O
assess NN NN O
the NN NN O
effect NN NN O
of NN NN O
long NN NN O
- NN NN O
term NN NN O
HT NN NN O
on NN NN O
mortality NN NN O
, NN NN O
heart NN NN B-Disease
disease NN NN I-Disease
, NN NN O
venous NN NN B-Disease
thromboembolism NN NN I-Disease
, NN NN O
stroke NN NN B-Disease
, NN NN O
transient NN NN B-Disease
ischaemic NN NN I-Disease
attacks NN NN I-Disease
, NN NN O
breast NN NN B-Disease
cancer NN NN I-Disease
, NN NN O
colorectal NN NN B-Disease
cancer NN NN I-Disease
, NN NN O
ovarian NN NN B-Disease
cancer NN NN I-Disease
, NN NN O
endometrial NN NN B-Disease
cancer NN NN I-Disease
, NN NN O
gallbladder NN NN B-Disease
disease NN NN I-Disease
, NN NN O
cognitive NN NN O
function NN NN O
, NN NN O
dementia NN NN B-Disease
, NN NN O
fractures NN NN B-Disease
and NN NN O
quality NN NN O
of NN NN O
life NN NN O
. NN NN O
   
SEARCH NN NN O
STRATEGY NN NN O
: NN NN O
We NN NN O
searched NN NN O
the NN NN O
following NN NN O
databases NN NN O
up NN NN O
to NN NN O
November NN NN O
2004 NN NN O
: NN NN O
the NN NN O
Cochrane NN NN O
Menstrual NN NN O
Disorders NN NN O
and NN NN O
Subfertility NN NN O
Group NN NN O
Trials NN NN O
Register NN NN O
, NN NN O
Cochrane NN NN O
Central NN NN O
Register NN NN O
of NN NN O
Controlled NN NN O
Trials NN NN O
( NN NN O
CENTRAL NN NN O
) NN NN O
, NN NN O
MEDLINE NN NN O
, NN NN O
EMBASE NN NN O
, NN NN O
Biological NN NN O
Abstracts NN NN O
. NN NN O
   
Relevant NN NN O
non NN NN O
- NN NN O
indexed NN NN O
journals NN NN O
and NN NN O
conference NN NN O
abstracts NN NN O
were NN NN O
also NN NN O
searched NN NN O
. NN NN O
   
SELECTION NN NN O
CRITERIA NN NN O
: NN NN O
Randomised NN NN O
double NN NN O
- NN NN O
blind NN NN O
trials NN NN O
of NN NN O
HT NN NN O
( NN NN O
oestrogens NN NN O
with NN NN O
or NN NN O
without NN NN O
progestogens NN NN O
) NN NN O
versus NN NN O
placebo NN NN O
, NN NN O
taken NN NN O
for NN NN O
at NN NN O
least NN NN O
one NN NN O
year NN NN O
by NN NN O
perimenopausal NN NN O
or NN NN O
postmenopausal NN NN O
women NN NN O
. NN NN O
   
DATA NN NN O
COLLECTION NN NN O
AND NN NN O
ANALYSIS NN NN O
: NN NN O
Fifteen NN NN O
RCTs NN NN O
were NN NN O
included NN NN O
. NN NN O
   
Trials NN NN O
were NN NN O
assessed NN NN O
for NN NN O
quality NN NN O
and NN NN O
two NN NN O
review NN NN O
authors NN NN O
extracted NN NN O
data NN NN O
independently NN NN O
. NN NN O
   
They NN NN O
calculated NN NN O
risk NN NN O
ratios NN NN O
for NN NN O
dichotomous NN NN O
outcomes NN NN O
and NN NN O
weighted NN NN O
mean NN NN O
differences NN NN O
for NN NN O
continuous NN NN O
outcomes NN NN O
. NN NN O
   
Clinical NN NN O
heterogeneity NN NN O
precluded NN NN O
meta NN NN O
- NN NN O
analysis NN NN O
for NN NN O
most NN NN O
outcomes NN NN O
. NN NN O
   
MAIN NN NN O
RESULTS NN NN O
: NN NN O
All NN NN O
the NN NN O
statistically NN NN O
significant NN NN O
results NN NN O
were NN NN O
derived NN NN O
from NN NN O
the NN NN O
two NN NN O
biggest NN NN O
trials NN NN O
. NN NN O
   
In NN NN O
relatively NN NN O
healthy NN NN O
women NN NN O
, NN NN O
combined NN NN O
continuous NN NN O
HT NN NN O
significantly NN NN O
increased NN NN O
the NN NN O
risk NN NN O
of NN NN O
venous NN NN B-Disease
thromboembolism NN NN I-Disease
or NN NN O
coronary NN NN O
event NN NN O
( NN NN O
after NN NN O
one NN NN O
year NN NN O
' NN NN O
s NN NN O
use NN NN O
) NN NN O
, NN NN O
stroke NN NN B-Disease
( NN NN O
after NN NN O
3 NN NN O
years NN NN O
) NN NN O
, NN NN O
breast NN NN B-Disease
cancer NN NN I-Disease
( NN NN O
after NN NN O
5 NN NN O
years NN NN O
) NN NN O
and NN NN O
gallbladder NN NN B-Disease
disease NN NN I-Disease
. NN NN O
   
Long NN NN O
- NN NN O
term NN NN O
oestrogen NN NN O
- NN NN O
only NN NN O
HT NN NN O
also NN NN O
significantly NN NN O
increased NN NN O
the NN NN O
risk NN NN O
of NN NN O
stroke NN NN B-Disease
and NN NN O
gallbladder NN NN B-Disease
disease NN NN I-Disease
. NN NN O
   
Overall NN NN O
, NN NN O
the NN NN O
only NN NN O
statistically NN NN O
significant NN NN O
benefits NN NN O
of NN NN O
HT NN NN O
were NN NN O
a NN NN O
decreased NN NN O
incidence NN NN O
of NN NN O
fractures NN NN B-Disease
and NN NN O
colon NN NN B-Disease
cancer NN NN I-Disease
with NN NN O
long NN NN O
- NN NN O
term NN NN O
use NN NN O
. NN NN O
   
Among NN NN O
relatively NN NN O
healthy NN NN O
women NN NN O
over NN NN O
65 NN NN O
years NN NN O
taking NN NN O
continuous NN NN O
combined NN NN O
HT NN NN O
, NN NN O
there NN NN O
was NN NN O
a NN NN O
statistically NN NN O
significant NN NN O
increase NN NN O
in NN NN O
the NN NN O
incidence NN NN O
of NN NN O
dementia NN NN B-Disease
. NN NN O
   
Among NN NN O
women NN NN O
with NN NN O
cardiovascular NN NN B-Disease
disease NN NN I-Disease
, NN NN O
long NN NN O
- NN NN O
term NN NN O
use NN NN O
of NN NN O
combined NN NN O
continuous NN NN O
HT NN NN O
significantly NN NN O
increased NN NN O
the NN NN O
risk NN NN O
of NN NN O
venous NN NN B-Disease
thromboembolism NN NN I-Disease
. NN NN O
   
No NN NN O
trials NN NN O
focussed NN NN O
specifically NN NN O
on NN NN O
younger NN NN O
women NN NN O
. NN NN O
   
However NN NN O
, NN NN O
one NN NN O
trial NN NN O
analysed NN NN O
subgroups NN NN O
of NN NN O
2839 NN NN O
relatively NN NN O
healthy NN NN O
50 NN NN O
to NN NN O
59 NN NN O
year NN NN O
- NN NN O
old NN NN O
women NN NN O
taking NN NN O
combined NN NN O
continuous NN NN O
HT NN NN O
and NN NN O
1637 NN NN O
taking NN NN O
oestrogen NN NN O
- NN NN O
only NN NN O
HT NN NN O
, NN NN O
versus NN NN O
similar NN NN O
- NN NN O
sized NN NN O
placebo NN NN O
groups NN NN O
. NN NN O
   
The NN NN O
only NN NN O
significantly NN NN O
increased NN NN O
risk NN NN O
reported NN NN O
was NN NN O
for NN NN O
venous NN NN B-Disease
thromboembolism NN NN I-Disease
in NN NN O
women NN NN O
taking NN NN O
combined NN NN O
continuous NN NN O
HT NN NN O
; NN NN O
their NN NN O
absolute NN NN O
risk NN NN O
remained NN NN O
very NN NN O
low NN NN O
. NN NN O
   
AUTHORS NN NN O
' NN NN O
CONCLUSIONS NN NN O
: NN NN O
HT NN NN O
is NN NN O
not NN NN O
indicated NN NN O
for NN NN O
the NN NN O
routine NN NN O
management NN NN O
of NN NN O
chronic NN NN B-Disease
disease NN NN I-Disease
. NN NN O
   
We NN NN O
need NN NN O
more NN NN O
evidence NN NN O
on NN NN O
the NN NN O
safety NN NN O
of NN NN O
HT NN NN O
for NN NN O
menopausal NN NN O
symptom NN NN O
control NN NN O
, NN NN O
though NN NN O
short NN NN O
- NN NN O
term NN NN O
use NN NN O
appears NN NN O
to NN NN O
be NN NN O
relatively NN NN O
safe NN NN O
for NN NN O
healthy NN NN O
younger NN NN O
women NN NN O
. NN NN O
   
Drug NN NN B-Disease
- NN NN I-Disease
induced NN NN I-Disease
liver NN NN I-Disease
injury NN NN I-Disease
: NN NN O
an NN NN O
analysis NN NN O
of NN NN O
461 NN NN O
incidences NN NN O
submitted NN NN O
to NN NN O
the NN NN O
Spanish NN NN O
registry NN NN O
over NN NN O
a NN NN O
10 NN NN O
- NN NN O
year NN NN O
period NN NN O
. NN NN O
   
BACKGROUND NN NN O
& NN NN O
AIMS NN NN O
: NN NN O
Progress NN NN O
in NN NN O
the NN NN O
understanding NN NN O
of NN NN O
susceptibility NN NN O
factors NN NN O
to NN NN O
drug NN NN B-Disease
- NN NN I-Disease
induced NN NN I-Disease
liver NN NN I-Disease
injury NN NN I-Disease
( NN NN O
DILI NN NN B-Disease
) NN NN O
and NN NN O
outcome NN NN O
predictability NN NN O
are NN NN O
hampered NN NN O
by NN NN O
the NN NN O
lack NN NN O
of NN NN O
systematic NN NN O
programs NN NN O
to NN NN O
detect NN NN O
bona NN NN O
fide NN NN O
cases NN NN O
. NN NN O
   
METHODS NN NN O
: NN NN O
A NN NN O
cooperative NN NN O
network NN NN O
was NN NN O
created NN NN O
in NN NN O
1994 NN NN O
in NN NN O
Spain NN NN O
to NN NN O
identify NN NN O
all NN NN O
suspicions NN NN O
of NN NN O
DILI NN NN B-Disease
following NN NN O
a NN NN O
prospective NN NN O
structured NN NN O
report NN NN O
form NN NN O
. NN NN O
   
The NN NN O
liver NN NN B-Disease
damage NN NN I-Disease
was NN NN O
characterized NN NN O
according NN NN O
to NN NN O
hepatocellular NN NN O
, NN NN O
cholestatic NN NN B-Disease
, NN NN O
and NN NN O
mixed NN NN O
laboratory NN NN O
criteria NN NN O
and NN NN O
to NN NN O
histologic NN NN O
criteria NN NN O
when NN NN O
available NN NN O
. NN NN O
   
Further NN NN O
evaluation NN NN O
of NN NN O
causality NN NN O
assessment NN NN O
was NN NN O
centrally NN NN O
performed NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
Since NN NN O
April NN NN O
1994 NN NN O
to NN NN O
August NN NN O
2004 NN NN O
, NN NN O
461 NN NN O
out NN NN O
of NN NN O
570 NN NN O
submitted NN NN O
cases NN NN O
, NN NN O
involving NN NN O
505 NN NN O
drugs NN NN O
, NN NN O
were NN NN O
deemed NN NN O
to NN NN O
be NN NN O
related NN NN O
to NN NN O
DILI NN NN B-Disease
. NN NN O
   
The NN NN O
antiinfective NN NN O
group NN NN O
of NN NN O
drugs NN NN O
was NN NN O
the NN NN O
more NN NN O
frequently NN NN O
incriminated NN NN O
, NN NN O
amoxicillin NN NN O
- NN NN O
clavulanate NN NN O
accounting NN NN O
for NN NN O
the NN NN O
12 NN NN O
. NN NN O
8 NN NN O
% NN NN O
of NN NN O
the NN NN O
whole NN NN O
series NN NN O
. NN NN O
   
The NN NN O
hepatocellular NN NN O
pattern NN NN O
of NN NN O
damage NN NN O
was NN NN O
the NN NN O
most NN NN O
common NN NN O
( NN NN O
58 NN NN O
% NN NN O
) NN NN O
, NN NN O
was NN NN O
inversely NN NN O
correlated NN NN O
with NN NN O
age NN NN O
( NN NN O
P NN NN O
< NN NN O
. NN NN O
0001 NN NN O
) NN NN O
, NN NN O
and NN NN O
had NN NN O
the NN NN O
worst NN NN O
outcome NN NN O
( NN NN O
Cox NN NN O
regression NN NN O
, NN NN O
P NN NN O
< NN NN O
. NN NN O
034 NN NN O
) NN NN O
. NN NN O
   
Indeed NN NN O
, NN NN O
the NN NN O
incidence NN NN O
of NN NN O
liver NN NN O
transplantation NN NN O
and NN NN O
death NN NN O
in NN NN O
this NN NN O
group NN NN O
was NN NN O
11 NN NN O
. NN NN O
7 NN NN O
% NN NN O
if NN NN O
patients NN NN O
had NN NN O
jaundice NN NN B-Disease
at NN NN O
presentation NN NN O
, NN NN O
whereas NN NN O
the NN NN O
corresponding NN NN O
figure NN NN O
was NN NN O
3 NN NN O
. NN NN O
8 NN NN O
% NN NN O
in NN NN O
nonjaundiced NN NN O
patients NN NN O
( NN NN O
P NN NN O
< NN NN O
. NN NN O
04 NN NN O
) NN NN O
. NN NN O
   
Factors NN NN O
associated NN NN O
with NN NN O
the NN NN O
development NN NN O
of NN NN O
fulminant NN NN B-Disease
hepatic NN NN I-Disease
failure NN NN I-Disease
were NN NN O
female NN NN O
sex NN NN O
( NN NN O
OR NN NN O
= NN NN O
25 NN NN O
; NN NN O
95 NN NN O
% NN NN O
CI NN NN O
: NN NN O
4 NN NN O
. NN NN O
1 NN NN O
- NN NN O
151 NN NN O
; NN NN O
P NN NN O
< NN NN O
. NN NN O
0001 NN NN O
) NN NN O
, NN NN O
hepatocellular NN NN O
damage NN NN O
( NN NN O
OR NN NN O
= NN NN O
7 NN NN O
. NN NN O
9 NN NN O
; NN NN O
95 NN NN O
% NN NN O
CI NN NN O
: NN NN O
1 NN NN O
. NN NN O
6 NN NN O
- NN NN O
37 NN NN O
; NN NN O
P NN NN O
< NN NN O
. NN NN O
009 NN NN O
) NN NN O
, NN NN O
and NN NN O
higher NN NN O
baseline NN NN O
plasma NN NN O
bilirubin NN NN O
value NN NN O
( NN NN O
OR NN NN O
= NN NN O
1 NN NN O
. NN NN O
15 NN NN O
; NN NN O
95 NN NN O
% NN NN O
CI NN NN O
: NN NN O
1 NN NN O
. NN NN O
09 NN NN O
- NN NN O
1 NN NN O
. NN NN O
22 NN NN O
; NN NN O
P NN NN O
< NN NN O
. NN NN O
0001 NN NN O
) NN NN O
. NN NN O
   
CONCLUSIONS NN NN O
: NN NN O
Patients NN NN O
with NN NN O
drug NN NN O
- NN NN O
induced NN NN O
hepatocellular NN NN O
jaundice NN NN B-Disease
have NN NN O
11 NN NN O
. NN NN O
7 NN NN O
% NN NN O
chance NN NN O
of NN NN O
progressing NN NN O
to NN NN O
death NN NN O
or NN NN O
transplantation NN NN O
. NN NN O
   
Amoxicillin NN NN O
- NN NN O
clavulanate NN NN O
stands NN NN O
out NN NN O
as NN NN O
the NN NN O
most NN NN O
common NN NN O
drug NN NN O
related NN NN O
to NN NN O
DILI NN NN B-Disease
. NN NN O
   
Morphological NN NN O
evaluation NN NN O
of NN NN O
the NN NN O
effect NN NN O
of NN NN O
d NN NN O
- NN NN O
ribose NN NN O
on NN NN O
adriamycin NN NN O
- NN NN O
evoked NN NN O
cardiotoxicity NN NN B-Disease
in NN NN O
rats NN NN O
. NN NN O
   
The NN NN O
influence NN NN O
of NN NN O
d NN NN O
- NN NN O
ribose NN NN O
on NN NN O
adriamycin NN NN O
- NN NN O
induced NN NN O
myocardiopathy NN NN B-Disease
in NN NN O
rats NN NN O
was NN NN O
studied NN NN O
. NN NN O
   
Adriamycin NN NN O
in NN NN O
the NN NN O
cumulative NN NN O
dose NN NN O
of NN NN O
25 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
evoked NN NN O
fully NN NN O
developed NN NN O
cardiac NN NN B-Disease
toxicity NN NN I-Disease
. NN NN O
   
D NN NN O
- NN NN O
ribose NN NN O
in NN NN O
the NN NN O
multiple NN NN O
doses NN NN O
of NN NN O
200 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
did NN NN O
not NN NN O
influence NN NN O
ADR NN NN O
cardiotoxicity NN NN B-Disease
. NN NN O
   
In NN NN O
vivo NN NN O
evidences NN NN O
suggesting NN NN O
the NN NN O
role NN NN O
of NN NN O
oxidative NN NN O
stress NN NN O
in NN NN O
pathogenesis NN NN O
of NN NN O
vancomycin NN NN O
- NN NN O
induced NN NN O
nephrotoxicity NN NN B-Disease
: NN NN O
protection NN NN O
by NN NN O
erdosteine NN NN O
. NN NN O
   
The NN NN O
aims NN NN O
of NN NN O
this NN NN O
study NN NN O
were NN NN O
to NN NN O
examine NN NN O
vancomycin NN NN O
( NN NN O
VCM NN NN O
) NN NN O
- NN NN O
induced NN NN O
oxidative NN NN O
stress NN NN O
that NN NN O
promotes NN NN O
production NN NN O
of NN NN O
reactive NN NN O
oxygen NN NN O
species NN NN O
( NN NN O
ROS NN NN O
) NN NN O
and NN NN O
to NN NN O
investigate NN NN O
the NN NN O
role NN NN O
of NN NN O
erdosteine NN NN O
, NN NN O
an NN NN O
expectorant NN NN O
agent NN NN O
, NN NN O
which NN NN O
has NN NN O
also NN NN O
antioxidant NN NN O
properties NN NN O
, NN NN O
on NN NN O
kidney NN NN O
tissue NN NN O
against NN NN O
the NN NN O
possible NN NN O
VCM NN NN O
- NN NN O
induced NN NN O
renal NN NN B-Disease
impairment NN NN I-Disease
in NN NN O
rats NN NN O
. NN NN O
   
Rats NN NN O
were NN NN O
divided NN NN O
into NN NN O
three NN NN O
groups NN NN O
: NN NN O
sham NN NN O
, NN NN O
VCM NN NN O
and NN NN O
VCM NN NN O
plus NN NN O
erdosteine NN NN O
. NN NN O
   
VCM NN NN O
was NN NN O
administrated NN NN O
intraperitoneally NN NN O
( NN NN O
i NN NN O
. NN NN O
p NN NN O
. NN NN O
) NN NN O
with NN NN O
200mgkg NN NN O
( NN NN O
- NN NN O
1 NN NN O
) NN NN O
twice NN NN O
daily NN NN O
for NN NN O
7 NN NN O
days NN NN O
. NN NN O
   
Erdosteine NN NN O
was NN NN O
administered NN NN O
orally NN NN O
. NN NN O
   
VCM NN NN O
administration NN NN O
to NN NN O
control NN NN O
rats NN NN O
significantly NN NN O
increased NN NN O
renal NN NN O
malondialdehyde NN NN O
( NN NN O
MDA NN NN O
) NN NN O
and NN NN O
urinary NN NN O
N NN NN O
- NN NN O
acetyl NN NN O
- NN NN O
beta NN NN O
- NN NN O
d NN NN O
- NN NN O
glucosaminidase NN NN O
( NN NN O
NAG NN NN O
, NN NN O
a NN NN O
marker NN NN O
of NN NN O
renal NN NN B-Disease
tubular NN NN I-Disease
injury NN NN I-Disease
) NN NN O
excretion NN NN O
but NN NN O
decreased NN NN O
superoxide NN NN O
dismutase NN NN O
( NN NN O
SOD NN NN O
) NN NN O
and NN NN O
catalase NN NN O
( NN NN O
CAT NN NN O
) NN NN O
activities NN NN O
. NN NN O
   
Erdosteine NN NN O
administration NN NN O
with NN NN O
VCM NN NN O
injections NN NN O
caused NN NN O
significantly NN NN O
decreased NN NN O
renal NN NN O
MDA NN NN O
and NN NN O
urinary NN NN O
NAG NN NN O
excretion NN NN O
, NN NN O
and NN NN O
increased NN NN O
SOD NN NN O
activity NN NN O
, NN NN O
but NN NN O
not NN NN O
CAT NN NN O
activity NN NN O
in NN NN O
renal NN NN O
tissue NN NN O
when NN NN O
compared NN NN O
with NN NN O
VCM NN NN O
alone NN NN O
. NN NN O
   
Erdosteine NN NN O
showed NN NN O
histopathological NN NN O
protection NN NN O
against NN NN O
VCM NN NN O
- NN NN O
induced NN NN O
nephrotoxicity NN NN B-Disease
. NN NN O
   
There NN NN O
were NN NN O
a NN NN O
significant NN NN O
dilatation NN NN O
of NN NN O
tubular NN NN O
lumens NN NN O
, NN NN O
extensive NN NN O
epithelial NN NN O
cell NN NN O
vacuolization NN NN O
, NN NN O
atrophy NN NN B-Disease
, NN NN O
desquamation NN NN B-Disease
, NN NN O
and NN NN O
necrosis NN NN B-Disease
in NN NN O
VCM NN NN O
- NN NN O
treated NN NN O
rats NN NN O
more NN NN O
than NN NN O
those NN NN O
of NN NN O
the NN NN O
control NN NN O
and NN NN O
the NN NN O
erdosteine NN NN O
groups NN NN O
. NN NN O
   
Erdosteine NN NN O
caused NN NN O
a NN NN O
marked NN NN O
reduction NN NN O
in NN NN O
the NN NN O
extent NN NN O
of NN NN O
tubular NN NN O
damage NN NN O
. NN NN O
   
It NN NN O
is NN NN O
concluded NN NN O
that NN NN O
oxidative NN NN O
tubular NN NN O
damage NN NN O
plays NN NN O
an NN NN O
important NN NN O
role NN NN O
in NN NN O
the NN NN O
VCM NN NN O
- NN NN O
induced NN NN O
nephrotoxicity NN NN B-Disease
and NN NN O
the NN NN O
modulation NN NN O
of NN NN O
oxidative NN NN O
stress NN NN O
with NN NN O
erdosteine NN NN O
reduces NN NN O
the NN NN O
VCM NN NN O
- NN NN O
induced NN NN O
kidney NN NN B-Disease
damage NN NN I-Disease
both NN NN O
at NN NN O
the NN NN O
biochemical NN NN O
and NN NN O
histological NN NN O
levels NN NN O
. NN NN O
   
Gemfibrozil NN NN O
- NN NN O
lovastatin NN NN O
therapy NN NN O
for NN NN O
primary NN NN O
hyperlipoproteinemias NN NN B-Disease
. NN NN O
   
The NN NN O
specific NN NN O
aim NN NN O
of NN NN O
this NN NN O
retrospective NN NN O
, NN NN O
observational NN NN O
study NN NN O
was NN NN O
to NN NN O
assess NN NN O
safety NN NN O
and NN NN O
efficacy NN NN O
of NN NN O
long NN NN O
- NN NN O
term NN NN O
( NN NN O
21 NN NN O
months NN NN O
/ NN NN O
patient NN NN O
) NN NN O
, NN NN O
open NN NN O
- NN NN O
label NN NN O
, NN NN O
gemfibrozil NN NN O
- NN NN O
lovastatin NN NN O
treatment NN NN O
in NN NN O
80 NN NN O
patients NN NN O
with NN NN O
primary NN NN O
mixed NN NN O
hyperlipidemia NN NN B-Disease
( NN NN O
68 NN NN O
% NN NN O
of NN NN O
whom NN NN O
had NN NN O
atherosclerotic NN NN B-Disease
vascular NN NN I-Disease
disease NN NN I-Disease
) NN NN O
. NN NN O
   
Because NN NN O
ideal NN NN O
lipid NN NN O
targets NN NN O
were NN NN O
not NN NN O
reached NN NN O
( NN NN O
low NN NN O
- NN NN O
density NN NN O
lipoprotein NN NN O
( NN NN O
LDL NN NN O
) NN NN O
cholesterol NN NN O
less NN NN O
than NN NN O
130 NN NN O
mg NN NN O
/ NN NN O
dl NN NN O
, NN NN O
high NN NN O
- NN NN O
density NN NN O
lipoprotein NN NN O
( NN NN O
HDL NN NN O
) NN NN O
cholesterol NN NN O
greater NN NN O
than NN NN O
35 NN NN O
mg NN NN O
/ NN NN O
dl NN NN O
, NN NN O
or NN NN O
total NN NN O
cholesterol NN NN O
/ NN NN O
HDL NN NN O
cholesterol NN NN O
less NN NN O
than NN NN O
4 NN NN O
. NN NN O
5 NN NN O
mg NN NN O
/ NN NN O
dl NN NN O
) NN NN O
with NN NN O
diet NN NN O
plus NN NN O
a NN NN O
single NN NN O
drug NN NN O
, NN NN O
gemfibrozil NN NN O
( NN NN O
1 NN NN O
. NN NN O
2 NN NN O
g NN NN O
/ NN NN O
day NN NN O
) NN NN O
- NN NN O
lovastatin NN NN O
( NN NN O
primarily NN NN O
20 NN NN O
or NN NN O
40 NN NN O
mg NN NN O
) NN NN O
treatment NN NN O
was NN NN O
given NN NN O
. NN NN O
   
Follow NN NN O
- NN NN O
up NN NN O
visits NN NN O
were NN NN O
scheduled NN NN O
with NN NN O
2 NN NN O
- NN NN O
drug NN NN O
therapy NN NN O
every NN NN O
6 NN NN O
to NN NN O
8 NN NN O
weeks NN NN O
, NN NN O
an NN NN O
average NN NN O
of NN NN O
10 NN NN O
. NN NN O
3 NN NN O
visits NN NN O
per NN NN O
patient NN NN O
, NN NN O
with NN NN O
741 NN NN O
batteries NN NN O
of NN NN O
6 NN NN O
liver NN NN O
function NN NN O
tests NN NN O
and NN NN O
714 NN NN O
creatine NN NN O
phosphokinase NN NN O
levels NN NN O
measured NN NN O
. NN NN O
   
Only NN NN O
1 NN NN O
of NN NN O
the NN NN O
4 NN NN O
, NN NN O
446 NN NN O
liver NN NN O
function NN NN O
tests NN NN O
( NN NN O
0 NN NN O
. NN NN O
02 NN NN O
% NN NN O
) NN NN O
, NN NN O
a NN NN O
gamma NN NN O
glutamyl NN NN O
transferase NN NN O
, NN NN O
was NN NN O
greater NN NN O
than NN NN O
or NN NN O
equal NN NN O
to NN NN O
3 NN NN O
times NN NN O
the NN NN O
upper NN NN O
normal NN NN O
limit NN NN O
. NN NN O
   
Of NN NN O
the NN NN O
714 NN NN O
creatine NN NN O
phosphokinase NN NN O
levels NN NN O
, NN NN O
9 NN NN O
% NN NN O
were NN NN O
high NN NN O
; NN NN O
only NN NN O
1 NN NN O
( NN NN O
0 NN NN O
. NN NN O
1 NN NN O
% NN NN O
) NN NN O
was NN NN O
greater NN NN O
than NN NN O
or NN NN O
equal NN NN O
to NN NN O
3 NN NN O
times NN NN O
the NN NN O
upper NN NN O
normal NN NN O
limit NN NN O
. NN NN O
   
With NN NN O
2 NN NN O
- NN NN O
drug NN NN O
therapy NN NN O
, NN NN O
mean NN NN O
total NN NN O
cholesterol NN NN O
decreased NN NN O
22 NN NN O
% NN NN O
from NN NN O
255 NN NN O
to NN NN O
200 NN NN O
mg NN NN O
/ NN NN O
dl NN NN O
, NN NN O
triglyceride NN NN O
levels NN NN O
decreased NN NN O
35 NN NN O
% NN NN O
from NN NN O
236 NN NN O
to NN NN O
154 NN NN O
mg NN NN O
/ NN NN O
dl NN NN O
, NN NN O
LDL NN NN O
cholesterol NN NN O
decreased NN NN O
26 NN NN O
% NN NN O
from NN NN O
176 NN NN O
to NN NN O
131 NN NN O
mg NN NN O
/ NN NN O
dl NN NN O
, NN NN O
and NN NN O
the NN NN O
total NN NN O
cholesterol NN NN O
/ NN NN O
HDL NN NN O
cholesterol NN NN O
ratio NN NN O
decreased NN NN O
24 NN NN O
% NN NN O
from NN NN O
7 NN NN O
. NN NN O
1 NN NN O
to NN NN O
5 NN NN O
. NN NN O
4 NN NN O
, NN NN O
all NN NN O
p NN NN O
less NN NN O
than NN NN O
or NN NN O
equal NN NN O
to NN NN O
0 NN NN O
. NN NN O
0001 NN NN O
. NN NN O
   
Myositis NN NN B-Disease
, NN NN O
attributable NN NN O
to NN NN O
the NN NN O
drug NN NN O
combination NN NN O
and NN NN O
symptomatic NN NN O
enough NN NN O
to NN NN O
discontinue NN NN O
it NN NN O
, NN NN O
occurred NN NN O
in NN NN O
3 NN NN O
% NN NN O
of NN NN O
patients NN NN O
, NN NN O
and NN NN O
in NN NN O
1 NN NN O
% NN NN O
with NN NN O
concurrent NN NN O
high NN NN O
creatine NN NN O
phosphokinase NN NN O
( NN NN O
769 NN NN O
U NN NN O
/ NN NN O
liter NN NN O
) NN NN O
; NN NN O
no NN NN O
patients NN NN O
had NN NN O
rhabdomyolysis NN NN B-Disease
or NN NN O
myoglobinuria NN NN B-Disease
. NN NN O
( NN NN O
ABSTRACT NN NN O
TRUNCATED NN NN O
AT NN NN O
250 NN NN O
WORDS NN NN O
) NN NN O
   
Does NN NN O
domperidone NN NN O
potentiate NN NN O
mirtazapine NN NN O
- NN NN O
associated NN NN O
restless NN NN B-Disease
legs NN NN I-Disease
syndrome NN NN I-Disease
? NN NN O
   
There NN NN O
is NN NN O
now NN NN O
evidence NN NN O
to NN NN O
suggest NN NN O
a NN NN O
central NN NN O
role NN NN O
for NN NN O
the NN NN O
dopaminergic NN NN O
system NN NN O
in NN NN O
restless NN NN B-Disease
legs NN NN I-Disease
syndrome NN NN I-Disease
( NN NN O
RLS NN NN B-Disease
) NN NN O
. NN NN O
   
For NN NN O
example NN NN O
, NN NN O
the NN NN O
symptoms NN NN O
of NN NN O
RLS NN NN B-Disease
can NN NN O
be NN NN O
dramatically NN NN O
improved NN NN O
by NN NN O
levodopa NN NN O
and NN NN O
dopamine NN NN O
agonists NN NN O
, NN NN O
whereas NN NN O
central NN NN O
dopamine NN NN O
D2 NN NN O
receptor NN NN O
antagonists NN NN O
can NN NN O
induce NN NN O
or NN NN O
aggravate NN NN O
RLS NN NN B-Disease
symptoms NN NN O
. NN NN O
   
To NN NN O
our NN NN O
knowledge NN NN O
, NN NN O
there NN NN O
is NN NN O
no NN NN O
previous NN NN O
report NN NN O
regarding NN NN O
whether NN NN O
domperidone NN NN O
, NN NN O
a NN NN O
peripheral NN NN O
dopamine NN NN O
D2 NN NN O
receptor NN NN O
antagonist NN NN O
, NN NN O
can NN NN O
also NN NN O
induce NN NN O
or NN NN O
aggravate NN NN O
symptoms NN NN O
of NN NN O
RLS NN NN B-Disease
. NN NN O
   
Mirtazapine NN NN O
, NN NN O
the NN NN O
first NN NN O
noradrenergic NN NN O
and NN NN O
specific NN NN O
serotonergic NN NN O
antidepressant NN NN O
( NN NN O
NaSSA NN NN O
) NN NN O
, NN NN O
has NN NN O
been NN NN O
associated NN NN O
with NN NN O
RLS NN NN B-Disease
in NN NN O
several NN NN O
recent NN NN O
publications NN NN O
. NN NN O
   
The NN NN O
authors NN NN O
report NN NN O
here NN NN O
a NN NN O
depressed NN NN O
patient NN NN O
comorbid NN NN O
with NN NN O
postprandial NN NN B-Disease
dyspepsia NN NN I-Disease
who NN NN O
developed NN NN O
RLS NN NN B-Disease
after NN NN O
mirtazapine NN NN O
had NN NN O
been NN NN O
added NN NN O
to NN NN O
his NN NN O
domperidone NN NN O
therapy NN NN O
. NN NN O
   
Our NN NN O
patient NN NN O
started NN NN O
to NN NN O
have NN NN O
symptoms NN NN O
of NN NN O
RLS NN NN B-Disease
only NN NN O
after NN NN O
he NN NN O
had NN NN O
been NN NN O
treated NN NN O
with NN NN O
mirtazapine NN NN O
, NN NN O
and NN NN O
his NN NN O
RLS NN NN B-Disease
symptoms NN NN O
resolved NN NN O
completely NN NN O
upon NN NN O
discontinuation NN NN O
of NN NN O
his NN NN O
mirtazapine NN NN O
. NN NN O
   
Such NN NN O
a NN NN O
temporal NN NN O
relationship NN NN O
between NN NN O
the NN NN O
use NN NN O
of NN NN O
mirtazapine NN NN O
and NN NN O
the NN NN O
symptoms NN NN O
of NN NN O
RLS NN NN B-Disease
in NN NN O
our NN NN O
patient NN NN O
did NN NN O
not NN NN O
support NN NN O
a NN NN O
potentiating NN NN O
effect NN NN O
of NN NN O
domperione NN NN O
on NN NN O
mirtazapine NN NN O
- NN NN O
associated NN NN O
RLS NN NN B-Disease
. NN NN O
   
However NN NN O
, NN NN O
physicians NN NN O
should NN NN O
be NN NN O
aware NN NN O
of NN NN O
the NN NN O
possibility NN NN O
that NN NN O
mirtazapine NN NN O
can NN NN O
be NN NN O
associated NN NN O
with NN NN O
RLS NN NN B-Disease
in NN NN O
some NN NN O
individuals NN NN O
, NN NN O
especially NN NN O
those NN NN O
receiving NN NN O
concomitant NN NN O
dopamine NN NN O
D2 NN NN O
receptor NN NN O
antagonists NN NN O
. NN NN O
   
Antiandrogenic NN NN O
therapy NN NN O
can NN NN O
cause NN NN O
coronary NN NN B-Disease
arterial NN NN I-Disease
disease NN NN I-Disease
. NN NN O
   
AIM NN NN O
: NN NN O
To NN NN O
study NN NN O
the NN NN O
change NN NN O
of NN NN O
lipid NN NN O
metabolism NN NN O
by NN NN O
antiandrogen NN NN O
therapy NN NN O
in NN NN O
patients NN NN O
with NN NN O
prostate NN NN B-Disease
cancer NN NN I-Disease
. NN NN O
   
MATERIALS NN NN O
AND NN NN O
METHODS NN NN O
: NN NN O
We NN NN O
studied NN NN O
with NN NN O
a NN NN O
2 NN NN O
. NN NN O
5 NN NN O
years NN NN O
follow NN NN O
- NN NN O
up NN NN O
the NN NN O
changes NN NN O
in NN NN O
plasma NN NN O
cholesterols NN NN O
( NN NN O
C NN NN O
) NN NN O
, NN NN O
triglycerides NN NN O
( NN NN O
TG NN NN O
) NN NN O
, NN NN O
lipoproteins NN NN O
( NN NN O
LP NN NN O
) NN NN O
, NN NN O
and NN NN O
apolipoproteins NN NN O
( NN NN O
Apo NN NN O
) NN NN O
B NN NN O
- NN NN O
100 NN NN O
, NN NN O
A NN NN O
- NN NN O
I NN NN O
, NN NN O
and NN NN O
A NN NN O
- NN NN O
II NN NN O
pro NN NN O
fi NN NN O
les NN NN O
in NN NN O
24 NN NN O
patients NN NN O
of NN NN O
mean NN NN O
age NN NN O
60 NN NN O
years NN NN O
with NN NN O
low NN NN O
risk NN NN O
prostate NN NN B-Disease
cancer NN NN I-Disease
( NN NN O
stage NN NN O
: NN NN O
T1cN0M0 NN NN O
, NN NN O
Gleason NN NN O
score NN NN O
: NN NN O
2 NN NN O
- NN NN O
5 NN NN O
) NN NN O
during NN NN O
treatment NN NN O
with NN NN O
cyproterone NN NN O
acetate NN NN O
( NN NN O
CPA NN NN O
) NN NN O
without NN NN O
surgical NN NN O
management NN NN O
or NN NN O
radiation NN NN O
therapy NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
Significant NN NN O
decreases NN NN O
of NN NN O
HDL NN NN O
- NN NN O
C NN NN O
, NN NN O
Apo NN NN O
A NN NN O
- NN NN O
I NN NN O
and NN NN O
Apo NN NN O
A NN NN O
- NN NN O
II NN NN O
and NN NN O
an NN NN O
increase NN NN O
of NN NN O
triglyceride NN NN O
levels NN NN O
in NN NN O
VLDL NN NN O
were NN NN O
induced NN NN O
by NN NN O
CPA NN NN O
. NN NN O
   
After NN NN O
a NN NN O
period NN NN O
of NN NN O
2 NN NN O
. NN NN O
5 NN NN O
years NN NN O
on NN NN O
CPA NN NN O
treatment NN NN O
, NN NN O
four NN NN O
patients NN NN O
out NN NN O
of NN NN O
twenty NN NN O
- NN NN O
four NN NN O
were NN NN O
found NN NN O
to NN NN O
be NN NN O
affected NN NN O
by NN NN O
coronary NN NN B-Disease
heart NN NN I-Disease
disease NN NN I-Disease
. NN NN O
   
CONCLUSIONS NN NN O
: NN NN O
Ischaemic NN NN O
coronary NN NN B-Disease
arteriosclerosis NN NN I-Disease
with NN NN O
an NN NN O
incidence NN NN O
rate NN NN O
of NN NN O
16 NN NN O
. NN NN O
6 NN NN O
% NN NN O
as NN NN O
caused NN NN O
by NN NN O
prolonged NN NN O
CPA NN NN O
therapy NN NN O
is NN NN O
mediated NN NN O
through NN NN O
changes NN NN O
in NN NN O
HDL NN NN O
cholesterol NN NN O
, NN NN O
Apo NN NN O
A NN NN O
- NN NN O
I NN NN O
and NN NN O
Apo NN NN O
A NN NN O
- NN NN O
II NN NN O
pro NN NN O
fi NN NN O
les NN NN O
, NN NN O
other NN NN O
than NN NN O
the NN NN O
well NN NN O
- NN NN O
known NN NN O
hyperglyceridemic NN NN B-Disease
effect NN NN I-Disease
caused NN NN O
by NN NN O
estrogen NN NN O
. NN NN O
   
5 NN NN O
- NN NN O
Fluorouracil NN NN O
cardiotoxicity NN NN B-Disease
induced NN NN O
by NN NN O
alpha NN NN O
- NN NN O
fluoro NN NN O
- NN NN O
beta NN NN O
- NN NN O
alanine NN NN O
. NN NN O
   
Cardiotoxicity NN NN B-Disease
is NN NN O
a NN NN O
rare NN NN O
complication NN NN O
occurring NN NN O
during NN NN O
5 NN NN O
- NN NN O
fluorouracil NN NN O
( NN NN O
5 NN NN O
- NN NN O
FU NN NN O
) NN NN O
treatment NN NN O
for NN NN O
malignancies NN NN B-Disease
. NN NN O
   
We NN NN O
herein NN NN O
report NN NN O
the NN NN O
case NN NN O
of NN NN O
a NN NN O
70 NN NN O
- NN NN O
year NN NN O
- NN NN O
old NN NN O
man NN NN O
with NN NN O
5 NN NN O
- NN NN O
FU NN NN O
- NN NN O
induced NN NN O
cardiotoxicity NN NN B-Disease
, NN NN O
in NN NN O
whom NN NN O
a NN NN O
high NN NN O
serum NN NN O
level NN NN O
of NN NN O
alpha NN NN O
- NN NN O
fluoro NN NN O
- NN NN O
beta NN NN O
- NN NN O
alanine NN NN O
( NN NN O
FBAL NN NN O
) NN NN O
was NN NN O
observed NN NN O
. NN NN O
   
The NN NN O
patient NN NN O
, NN NN O
who NN NN O
had NN NN O
unresectable NN NN O
colon NN NN B-Disease
cancer NN NN I-Disease
metastases NN NN O
to NN NN O
the NN NN O
liver NN NN O
and NN NN O
lung NN NN O
, NN NN O
was NN NN O
referred NN NN O
to NN NN O
us NN NN O
for NN NN O
chemotherapy NN NN O
from NN NN O
an NN NN O
affiliated NN NN O
hospital NN NN O
; NN NN O
he NN NN O
had NN NN O
no NN NN O
cardiac NN NN O
history NN NN O
. NN NN O
   
After NN NN O
admission NN NN O
, NN NN O
the NN NN O
patient NN NN O
received NN NN O
a NN NN O
continuous NN NN O
intravenous NN NN O
infusion NN NN O
of NN NN O
5 NN NN O
- NN NN O
FU NN NN O
( NN NN O
1000 NN NN O
mg NN NN O
/ NN NN O
day NN NN O
) NN NN O
, NN NN O
during NN NN O
which NN NN O
precordial NN NN B-Disease
pain NN NN I-Disease
with NN NN O
right NN NN B-Disease
bundle NN NN I-Disease
branch NN NN I-Disease
block NN NN I-Disease
occurred NN NN O
concomitantly NN NN O
with NN NN O
a NN NN O
high NN NN O
serum NN NN O
FBAL NN NN O
concentration NN NN O
of NN NN O
1955 NN NN O
ng NN NN O
/ NN NN O
ml NN NN O
. NN NN O
   
Both NN NN O
the NN NN O
precordial NN NN B-Disease
pain NN NN I-Disease
and NN NN O
the NN NN O
electrocardiographic NN NN O
changes NN NN O
disappeared NN NN O
spontaneously NN NN O
after NN NN O
the NN NN O
discontinuation NN NN O
of NN NN O
5 NN NN O
- NN NN O
FU NN NN O
. NN NN O
   
As NN NN O
the NN NN O
precordial NN NN B-Disease
pain NN NN I-Disease
in NN NN O
this NN NN O
patient NN NN O
was NN NN O
considered NN NN O
to NN NN O
have NN NN O
been NN NN O
due NN NN O
to NN NN O
5 NN NN O
- NN NN O
FU NN NN O
- NN NN O
induced NN NN O
cardiotoxicity NN NN B-Disease
, NN NN O
the NN NN O
administration NN NN O
of NN NN O
5 NN NN O
- NN NN O
FU NN NN O
was NN NN O
abandoned NN NN O
. NN NN O
   
Instead NN NN O
, NN NN O
oral NN NN O
administration NN NN O
of NN NN O
S NN NN O
- NN NN O
1 NN NN O
( NN NN O
a NN NN O
derivative NN NN O
of NN NN O
5 NN NN O
- NN NN O
FU NN NN O
) NN NN O
, NN NN O
at NN NN O
200 NN NN O
mg NN NN O
/ NN NN O
day NN NN O
twice NN NN O
a NN NN O
week NN NN O
, NN NN O
was NN NN O
instituted NN NN O
, NN NN O
because NN NN O
S NN NN O
- NN NN O
1 NN NN O
has NN NN O
a NN NN O
strong NN NN O
inhibitory NN NN O
effect NN NN O
on NN NN O
dihydropyrimidine NN NN O
dehydrogenase NN NN O
, NN NN O
which NN NN O
catalyzes NN NN O
the NN NN O
degradative NN NN O
of NN NN O
5 NN NN O
- NN NN O
FU NN NN O
into NN NN O
FBAL NN NN O
. NN NN O
   
The NN NN O
serum NN NN O
FBAL NN NN O
concentration NN NN O
subsequently NN NN O
decreased NN NN O
to NN NN O
352 NN NN O
ng NN NN O
/ NN NN O
ml NN NN O
, NN NN O
the NN NN O
same NN NN O
as NN NN O
the NN NN O
value NN NN O
measured NN NN O
on NN NN O
the NN NN O
first NN NN O
day NN NN O
of NN NN O
S NN NN O
- NN NN O
1 NN NN O
administration NN NN O
. NN NN O
   
Thereafter NN NN O
, NN NN O
no NN NN O
cardiac NN NN B-Disease
symptoms NN NN I-Disease
were NN NN O
observed NN NN O
. NN NN O
   
The NN NN O
patient NN NN O
achieved NN NN O
a NN NN O
partial NN NN O
response NN NN O
6 NN NN O
months NN NN O
after NN NN O
the NN NN O
initiation NN NN O
of NN NN O
the NN NN O
S NN NN O
- NN NN O
1 NN NN O
treatment NN NN O
. NN NN O
   
The NN NN O
experience NN NN O
of NN NN O
this NN NN O
case NN NN O
, NN NN O
together NN NN O
with NN NN O
a NN NN O
review NN NN O
of NN NN O
the NN NN O
literature NN NN O
, NN NN O
suggests NN NN O
that NN NN O
FBAL NN NN O
is NN NN O
related NN NN O
to NN NN O
5 NN NN O
- NN NN O
FU NN NN O
- NN NN O
induced NN NN O
cardiotoxicity NN NN B-Disease
. NN NN O
   
S NN NN O
- NN NN O
1 NN NN O
may NN NN O
be NN NN O
administered NN NN O
safely NN NN O
to NN NN O
patients NN NN O
with NN NN O
5 NN NN O
- NN NN O
FU NN NN O
- NN NN O
induced NN NN O
cardiotoxicity NN NN B-Disease
. NN NN O
   
Hepatocellular NN NN B-Disease
carcinoma NN NN I-Disease
in NN NN O
Fanconi NN NN B-Disease
' NN NN I-Disease
s NN NN I-Disease
anemia NN NN I-Disease
treated NN NN O
with NN NN O
androgen NN NN O
and NN NN O
corticosteroid NN NN O
. NN NN O
   
The NN NN O
case NN NN O
of NN NN O
an NN NN O
11 NN NN O
- NN NN O
year NN NN O
- NN NN O
old NN NN O
boy NN NN O
is NN NN O
reported NN NN O
who NN NN O
was NN NN O
known NN NN O
to NN NN O
have NN NN O
Fanconi NN NN B-Disease
' NN NN I-Disease
s NN NN I-Disease
anemia NN NN I-Disease
for NN NN O
3 NN NN O
years NN NN O
and NN NN O
was NN NN O
treated NN NN O
with NN NN O
androgens NN NN O
, NN NN O
corticosteroids NN NN O
and NN NN O
transfusions NN NN O
. NN NN O
   
Two NN NN O
weeks NN NN O
before NN NN O
his NN NN O
death NN NN O
he NN NN O
was NN NN O
readmitted NN NN O
because NN NN O
of NN NN O
aplastic NN NN O
crisis NN NN O
with NN NN O
septicemia NN NN B-Disease
and NN NN O
marked NN NN O
abnormalities NN NN O
in NN NN O
liver NN NN O
function NN NN O
and NN NN O
died NN NN O
of NN NN O
hemorrhagic NN NN B-Disease
bronchopneumonia NN NN I-Disease
. NN NN O
   
At NN NN O
autopsy NN NN O
peliosis NN NN B-Disease
and NN NN O
multiple NN NN O
hepatic NN NN B-Disease
tumors NN NN I-Disease
were NN NN O
found NN NN O
which NN NN O
histologically NN NN O
proved NN NN O
to NN NN O
be NN NN O
well NN NN O
- NN NN O
differentiated NN NN O
hepatocellular NN NN B-Disease
carcinoma NN NN I-Disease
. NN NN O
   
This NN NN O
case NN NN O
contributes NN NN O
to NN NN O
the NN NN O
previous NN NN O
observations NN NN O
that NN NN O
non NN NN O
- NN NN O
metastasizing NN NN O
hepatic NN NN B-Disease
neoplasms NN NN I-Disease
and NN NN O
peliosis NN NN B-Disease
can NN NN O
develop NN NN O
in NN NN O
patients NN NN O
with NN NN O
androgen NN NN O
- NN NN O
and NN NN O
corticosteroid NN NN O
- NN NN O
treated NN NN O
Fanconi NN NN B-Disease
' NN NN I-Disease
s NN NN I-Disease
anemia NN NN I-Disease
. NN NN O
   
The NN NN O
influence NN NN O
of NN NN O
the NN NN O
time NN NN O
interval NN NN O
between NN NN O
monoHER NN NN O
and NN NN O
doxorubicin NN NN O
administration NN NN O
on NN NN O
the NN NN O
protection NN NN O
against NN NN O
doxorubicin NN NN O
- NN NN O
induced NN NN O
cardiotoxicity NN NN B-Disease
in NN NN O
mice NN NN O
. NN NN O
   
PURPOSE NN NN O
: NN NN O
Despite NN NN O
its NN NN O
well NN NN O
- NN NN O
known NN NN O
cardiotoxicity NN NN B-Disease
, NN NN O
the NN NN O
anthracyclin NN NN O
doxorubicin NN NN O
( NN NN O
DOX NN NN O
) NN NN O
continues NN NN O
to NN NN O
be NN NN O
an NN NN O
effective NN NN O
and NN NN O
widely NN NN O
used NN NN O
chemotherapeutic NN NN O
agent NN NN O
. NN NN O
   
DOX NN NN O
- NN NN O
induced NN NN O
cardiac NN NN B-Disease
damage NN NN I-Disease
presumably NN NN O
results NN NN O
from NN NN O
the NN NN O
formation NN NN O
of NN NN O
free NN NN O
radicals NN NN O
by NN NN O
DOX NN NN O
. NN NN O
   
Reactive NN NN O
oxygen NN NN O
species NN NN O
particularly NN NN O
affect NN NN O
the NN NN O
cardiac NN NN O
myocytes NN NN O
because NN NN O
these NN NN O
cells NN NN O
seem NN NN O
to NN NN O
have NN NN O
a NN NN O
relatively NN NN O
poor NN NN O
antioxidant NN NN O
defense NN NN O
system NN NN O
. NN NN O
   
The NN NN O
semisynthetic NN NN O
flavonoid NN NN O
monohydroxyethylrutoside NN NN O
( NN NN O
monoHER NN NN O
) NN NN O
showed NN NN O
cardioprotection NN NN O
against NN NN O
DOX NN NN O
- NN NN O
induced NN NN O
cardiotoxicity NN NN B-Disease
through NN NN O
its NN NN O
radical NN NN O
scavenging NN NN O
and NN NN O
iron NN NN O
chelating NN NN O
properties NN NN O
. NN NN O
   
Because NN NN O
of NN NN O
the NN NN O
relatively NN NN O
short NN NN O
final NN NN O
half NN NN O
- NN NN O
life NN NN O
of NN NN O
monoHER NN NN O
( NN NN O
about NN NN O
30 NN NN O
min NN NN O
) NN NN O
, NN NN O
it NN NN O
is NN NN O
expected NN NN O
that NN NN O
the NN NN O
time NN NN O
interval NN NN O
between NN NN O
monoHER NN NN O
and NN NN O
DOX NN NN O
might NN NN O
be NN NN O
of NN NN O
influence NN NN O
on NN NN O
the NN NN O
cardioprotective NN NN O
effect NN NN O
of NN NN O
monoHER NN NN O
. NN NN O
   
Therefore NN NN O
, NN NN O
the NN NN O
aim NN NN O
of NN NN O
the NN NN O
present NN NN O
study NN NN O
was NN NN O
to NN NN O
investigate NN NN O
this NN NN O
possible NN NN O
effect NN NN O
. NN NN O
   
METHODS NN NN O
: NN NN O
Six NN NN O
groups NN NN O
of NN NN O
6 NN NN O
BALB NN NN O
/ NN NN O
c NN NN O
mice NN NN O
were NN NN O
treated NN NN O
with NN NN O
saline NN NN O
, NN NN O
DOX NN NN O
alone NN NN O
or NN NN O
DOX NN NN O
( NN NN O
4 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
i NN NN O
. NN NN O
v NN NN O
. NN NN O
) NN NN O
preceded NN NN O
by NN NN O
monoHER NN NN O
( NN NN O
500 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
i NN NN O
. NN NN O
p NN NN O
. NN NN O
) NN NN O
with NN NN O
an NN NN O
interval NN NN O
of NN NN O
10 NN NN O
, NN NN O
30 NN NN O
, NN NN O
60 NN NN O
or NN NN O
120 NN NN O
min NN NN O
. NN NN O
   
After NN NN O
a NN NN O
6 NN NN O
- NN NN O
week NN NN O
treatment NN NN O
period NN NN O
and NN NN O
additional NN NN O
observation NN NN O
for NN NN O
2 NN NN O
weeks NN NN O
, NN NN O
the NN NN O
mice NN NN O
were NN NN O
sacrificed NN NN O
. NN NN O
   
Their NN NN O
cardiac NN NN O
tissues NN NN O
were NN NN O
processed NN NN O
for NN NN O
light NN NN O
microscopy NN NN O
, NN NN O
after NN NN O
which NN NN O
cardiomyocyte NN NN B-Disease
damage NN NN I-Disease
was NN NN O
evaluated NN NN O
according NN NN O
to NN NN O
Billingham NN NN O
( NN NN O
in NN NN O
Cancer NN NN B-Disease
Treat NN NN O
Rep NN NN O
62 NN NN O
( NN NN O
6 NN NN O
) NN NN O
: NN NN O
865 NN NN O
- NN NN O
872 NN NN O
, NN NN O
1978 NN NN O
) NN NN O
. NN NN O
   
Microscopic NN NN O
evaluation NN NN O
revealed NN NN O
that NN NN O
treatment NN NN O
with NN NN O
DOX NN NN O
alone NN NN O
induced NN NN O
significant NN NN O
cardiac NN NN B-Disease
damage NN NN I-Disease
in NN NN O
comparison NN NN O
to NN NN O
the NN NN O
saline NN NN O
control NN NN O
group NN NN O
( NN NN O
P NN NN O
< NN NN O
0 NN NN O
. NN NN O
001 NN NN O
) NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
The NN NN O
number NN NN O
of NN NN O
damaged NN NN O
cardiomyocytes NN NN O
was NN NN O
9 NN NN O
. NN NN O
6 NN NN O
- NN NN O
fold NN NN O
( NN NN O
95 NN NN O
% NN NN O
CI NN NN O
4 NN NN O
. NN NN O
4 NN NN O
- NN NN O
21 NN NN O
. NN NN O
0 NN NN O
) NN NN O
higher NN NN O
in NN NN O
mice NN NN O
treated NN NN O
with NN NN O
DOX NN NN O
alone NN NN O
than NN NN O
that NN NN O
in NN NN O
animals NN NN O
of NN NN O
the NN NN O
control NN NN O
group NN NN O
. NN NN O
   
The NN NN O
ratio NN NN O
of NN NN O
aberrant NN NN O
cardiomyocytes NN NN O
in NN NN O
mice NN NN O
treated NN NN O
with NN NN O
DOX NN NN O
preceded NN NN O
by NN NN O
monoHER NN NN O
and NN NN O
those NN NN O
in NN NN O
mice NN NN O
treated NN NN O
with NN NN O
saline NN NN O
ranged NN NN O
from NN NN O
1 NN NN O
. NN NN O
6 NN NN O
to NN NN O
2 NN NN O
. NN NN O
8 NN NN O
( NN NN O
mean NN NN O
2 NN NN O
. NN NN O
2 NN NN O
, NN NN O
95 NN NN O
% NN NN O
CI NN NN O
1 NN NN O
. NN NN O
2 NN NN O
- NN NN O
4 NN NN O
. NN NN O
1 NN NN O
, NN NN O
P NN NN O
= NN NN O
0 NN NN O
. NN NN O
019 NN NN O
) NN NN O
. NN NN O
   
The NN NN O
mean NN NN O
protective NN NN O
effect NN NN O
by NN NN O
adding NN NN O
monoHER NN NN O
before NN NN O
DOX NN NN O
led NN NN O
to NN NN O
a NN NN O
significant NN NN O
4 NN NN O
. NN NN O
4 NN NN O
- NN NN O
fold NN NN O
reduction NN NN O
( NN NN O
P NN NN O
< NN NN O
0 NN NN O
. NN NN O
001 NN NN O
, NN NN O
95 NN NN O
% NN NN O
CI NN NN O
2 NN NN O
. NN NN O
3 NN NN O
- NN NN O
8 NN NN O
. NN NN O
2 NN NN O
) NN NN O
of NN NN O
abnormal NN NN O
cardiomyocytes NN NN O
. NN NN O
   
This NN NN O
protective NN NN O
effect NN NN O
did NN NN O
not NN NN O
depend NN NN O
on NN NN O
the NN NN O
time NN NN O
interval NN NN O
between NN NN O
monoHER NN NN O
and NN NN O
DOX NN NN O
administration NN NN O
( NN NN O
P NN NN O
= NN NN O
0 NN NN O
. NN NN O
345 NN NN O
) NN NN O
. NN NN O
   
CONCLUSION NN NN O
: NN NN O
The NN NN O
results NN NN O
indicate NN NN O
that NN NN O
in NN NN O
an NN NN O
outpatient NN NN O
clinical NN NN O
setting NN NN O
monoHER NN NN O
may NN NN O
be NN NN O
administered NN NN O
shortly NN NN O
before NN NN O
DOX NN NN O
. NN NN O
   
Clinical NN NN O
evaluation NN NN O
of NN NN O
adverse NN NN O
effects NN NN O
during NN NN O
bepridil NN NN O
administration NN NN O
for NN NN O
atrial NN NN B-Disease
fibrillation NN NN I-Disease
and NN NN I-Disease
flutter NN NN I-Disease
. NN NN O
   
BACKGROUND NN NN O
: NN NN O
Bepridil NN NN O
hydrochloride NN NN O
( NN NN O
Bpd NN NN O
) NN NN O
has NN NN O
attracted NN NN O
attention NN NN O
as NN NN O
an NN NN O
effective NN NN O
drug NN NN O
for NN NN O
atrial NN NN B-Disease
fibrillation NN NN I-Disease
( NN NN O
AF NN NN B-Disease
) NN NN O
and NN NN O
atrial NN NN B-Disease
flutter NN NN I-Disease
( NN NN O
AFL NN NN B-Disease
) NN NN O
. NN NN O
   
However NN NN O
, NN NN O
serious NN NN O
adverse NN NN O
effects NN NN O
, NN NN O
including NN NN O
torsade NN NN B-Disease
de NN NN I-Disease
pointes NN NN I-Disease
( NN NN O
Tdp NN NN B-Disease
) NN NN O
, NN NN O
have NN NN O
been NN NN O
reported NN NN O
. NN NN O
   
METHODS NN NN O
AND NN NN O
RESULTS NN NN O
: NN NN O
Adverse NN NN O
effects NN NN O
of NN NN O
Bpd NN NN O
requiring NN NN O
discontinuation NN NN O
of NN NN O
treatment NN NN O
were NN NN O
evaluated NN NN O
. NN NN O
   
Bpd NN NN O
was NN NN O
administered NN NN O
to NN NN O
459 NN NN O
patients NN NN O
( NN NN O
361 NN NN O
males NN NN O
, NN NN O
63 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
12 NN NN O
years NN NN O
old NN NN O
) NN NN O
comprising NN NN O
378 NN NN O
AF NN NN B-Disease
and NN NN O
81 NN NN O
AFL NN NN B-Disease
cases NN NN O
. NN NN O
   
Mean NN NN O
left NN NN O
ventricular NN NN O
ejection NN NN O
fraction NN NN O
and NN NN O
atrial NN NN O
dimension NN NN O
( NN NN O
LAD NN NN O
) NN NN O
were NN NN O
66 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
11 NN NN O
% NN NN O
and NN NN O
40 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
6 NN NN O
mm NN NN O
, NN NN O
respectively NN NN O
. NN NN O
   
Adverse NN NN O
effects NN NN O
were NN NN O
observed NN NN O
in NN NN O
19 NN NN O
patients NN NN O
( NN NN O
4 NN NN O
% NN NN O
) NN NN O
during NN NN O
an NN NN O
average NN NN O
follow NN NN O
- NN NN O
up NN NN O
of NN NN O
20 NN NN O
months NN NN O
. NN NN O
   
There NN NN O
was NN NN O
marked NN NN O
QT NN NN B-Disease
prolongation NN NN I-Disease
greater NN NN O
than NN NN O
0 NN NN O
. NN NN O
55 NN NN O
s NN NN O
in NN NN O
13 NN NN O
patients NN NN O
, NN NN O
bradycardia NN NN B-Disease
less NN NN O
than NN NN O
40 NN NN O
beats NN NN O
/ NN NN O
min NN NN O
in NN NN O
6 NN NN O
patients NN NN O
, NN NN O
dizziness NN NN B-Disease
and NN NN O
general NN NN O
fatigue NN NN B-Disease
in NN NN O
1 NN NN O
patient NN NN O
each NN NN O
. NN NN O
   
In NN NN O
4 NN NN O
of NN NN O
13 NN NN O
patients NN NN O
with NN NN O
QT NN NN B-Disease
prolongation NN NN I-Disease
, NN NN O
Tdp NN NN B-Disease
occurred NN NN O
. NN NN O
   
The NN NN O
major NN NN O
triggering NN NN O
factors NN NN O
of NN NN O
Tdp NN NN B-Disease
were NN NN O
hypokalemia NN NN B-Disease
and NN NN O
sudden NN NN O
decrease NN NN O
in NN NN O
heart NN NN O
rate NN NN O
. NN NN O
   
There NN NN O
were NN NN O
no NN NN O
differences NN NN O
in NN NN O
the NN NN O
clinical NN NN O
backgrounds NN NN O
of NN NN O
the NN NN O
patients NN NN O
with NN NN O
and NN NN O
without NN NN O
Tdp NN NN B-Disease
other NN NN O
than NN NN O
LAD NN NN O
and NN NN O
age NN NN O
, NN NN O
which NN NN O
were NN NN O
larger NN NN O
and NN NN O
older NN NN O
in NN NN O
the NN NN O
patients NN NN O
with NN NN O
Tdp NN NN B-Disease
. NN NN O
   
CONCLUSION NN NN O
: NN NN O
Careful NN NN O
observation NN NN O
of NN NN O
serum NN NN O
potassium NN NN O
concentration NN NN O
and NN NN O
the NN NN O
ECG NN NN O
should NN NN O
always NN NN O
be NN NN O
done NN NN O
during NN NN O
Bpd NN NN O
administration NN NN O
, NN NN O
particularly NN NN O
in NN NN O
elderly NN NN O
patients NN NN O
. NN NN O
   
Enhanced NN NN O
isoproterenol NN NN O
- NN NN O
induced NN NN O
cardiac NN NN B-Disease
hypertrophy NN NN I-Disease
in NN NN O
transgenic NN NN O
rats NN NN O
with NN NN O
low NN NN O
brain NN NN O
angiotensinogen NN NN O
. NN NN O
   
We NN NN O
have NN NN O
previously NN NN O
shown NN NN O
that NN NN O
a NN NN O
permanent NN NN O
deficiency NN NN O
in NN NN O
the NN NN O
brain NN NN O
renin NN NN O
- NN NN O
angiotensin NN NN O
system NN NN O
( NN NN O
RAS NN NN O
) NN NN O
may NN NN O
increase NN NN O
the NN NN O
sensitivity NN NN O
of NN NN O
the NN NN O
baroreflex NN NN O
control NN NN O
of NN NN O
heart NN NN O
rate NN NN O
. NN NN O
   
In NN NN O
this NN NN O
study NN NN O
we NN NN O
aimed NN NN O
at NN NN O
studying NN NN O
the NN NN O
involvement NN NN O
of NN NN O
the NN NN O
brain NN NN O
RAS NN NN O
in NN NN O
the NN NN O
cardiac NN NN O
reactivity NN NN O
to NN NN O
the NN NN O
beta NN NN O
- NN NN O
adrenoceptor NN NN O
( NN NN O
beta NN NN O
- NN NN O
AR NN NN O
) NN NN O
agonist NN NN O
isoproterenol NN NN O
( NN NN O
Iso NN NN O
) NN NN O
. NN NN O
   
Transgenic NN NN O
rats NN NN O
with NN NN O
low NN NN O
brain NN NN O
angiotensinogen NN NN O
( NN NN O
TGR NN NN O
) NN NN O
were NN NN O
used NN NN O
. NN NN O
   
In NN NN O
isolated NN NN O
hearts NN NN O
, NN NN O
Iso NN NN O
induced NN NN O
a NN NN O
significantly NN NN O
greater NN NN O
increase NN NN O
in NN NN O
left NN NN O
ventricular NN NN O
( NN NN O
LV NN NN O
) NN NN O
pressure NN NN O
and NN NN O
maximal NN NN O
contraction NN NN O
( NN NN O
+ NN NN O
dP NN NN O
/ NN NN O
dt NN NN O
( NN NN O
max NN NN O
) NN NN O
) NN NN O
in NN NN O
the NN NN O
TGR NN NN O
than NN NN O
in NN NN O
the NN NN O
Sprague NN NN O
- NN NN O
Dawley NN NN O
( NN NN O
SD NN NN O
) NN NN O
rats NN NN O
. NN NN O
   
LV NN NN B-Disease
hypertrophy NN NN I-Disease
induced NN NN O
by NN NN O
Iso NN NN O
treatment NN NN O
was NN NN O
significantly NN NN O
higher NN NN O
in NN NN O
TGR NN NN O
than NN NN O
in NN NN O
SD NN NN O
rats NN NN O
( NN NN O
in NN NN O
g NN NN O
LV NN NN O
wt NN NN O
/ NN NN O
100 NN NN O
g NN NN O
body NN NN O
wt NN NN O
, NN NN O
0 NN NN O
. NN NN O
28 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
0 NN NN O
. NN NN O
004 NN NN O
vs NN NN O
. NN NN O
0 NN NN O
. NN NN O
24 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
0 NN NN O
. NN NN O
004 NN NN O
, NN NN O
respectively NN NN O
) NN NN O
. NN NN O
   
The NN NN O
greater NN NN O
LV NN NN B-Disease
hypertrophy NN NN I-Disease
in NN NN O
TGR NN NN O
rats NN NN O
was NN NN O
associated NN NN O
with NN NN O
more NN NN O
pronounced NN NN O
downregulation NN NN O
of NN NN O
beta NN NN O
- NN NN O
AR NN NN O
and NN NN O
upregulation NN NN O
of NN NN O
LV NN NN O
beta NN NN O
- NN NN O
AR NN NN O
kinase NN NN O
- NN NN O
1 NN NN O
mRNA NN NN O
levels NN NN O
compared NN NN O
with NN NN O
those NN NN O
in NN NN O
SD NN NN O
rats NN NN O
. NN NN O
   
The NN NN O
decrease NN NN O
in NN NN O
the NN NN O
heart NN NN O
rate NN NN O
( NN NN O
HR NN NN O
) NN NN O
induced NN NN O
by NN NN O
the NN NN O
beta NN NN O
- NN NN O
AR NN NN O
antagonist NN NN O
metoprolol NN NN O
in NN NN O
conscious NN NN O
rats NN NN O
was NN NN O
significantly NN NN O
attenuated NN NN O
in NN NN O
TGR NN NN O
compared NN NN O
with NN NN O
SD NN NN O
rats NN NN O
( NN NN O
- NN NN O
9 NN NN O
. NN NN O
9 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
1 NN NN O
. NN NN O
7 NN NN O
% NN NN O
vs NN NN O
. NN NN O
- NN NN O
18 NN NN O
. NN NN O
1 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
1 NN NN O
. NN NN O
5 NN NN O
% NN NN O
) NN NN O
, NN NN O
whereas NN NN O
the NN NN O
effect NN NN O
of NN NN O
parasympathetic NN NN O
blockade NN NN O
by NN NN O
atropine NN NN O
on NN NN O
HR NN NN O
was NN NN O
similar NN NN O
in NN NN O
both NN NN O
strains NN NN O
. NN NN O
   
These NN NN O
results NN NN O
indicate NN NN O
that NN NN O
TGR NN NN O
are NN NN O
more NN NN O
sensitive NN NN O
to NN NN O
beta NN NN O
- NN NN O
AR NN NN O
agonist NN NN O
- NN NN O
induced NN NN O
cardiac NN NN B-Disease
inotropic NN NN I-Disease
response NN NN O
and NN NN O
hypertrophy NN NN B-Disease
, NN NN O
possibly NN NN O
due NN NN O
to NN NN O
chronically NN NN O
low NN NN O
sympathetic NN NN O
outflow NN NN O
directed NN NN O
to NN NN O
the NN NN O
heart NN NN O
. NN NN O
   
Drug NN NN O
- NN NN O
induced NN NN O
long NN NN B-Disease
QT NN NN I-Disease
syndrome NN NN I-Disease
in NN NN O
injection NN NN O
drug NN NN O
users NN NN O
receiving NN NN O
methadone NN NN O
: NN NN O
high NN NN O
frequency NN NN O
in NN NN O
hospitalized NN NN O
patients NN NN O
and NN NN O
risk NN NN O
factors NN NN O
. NN NN O
   
BACKGROUND NN NN O
: NN NN O
Drug NN NN O
- NN NN O
induced NN NN O
long NN NN B-Disease
QT NN NN I-Disease
syndrome NN NN I-Disease
is NN NN O
a NN NN O
serious NN NN O
adverse NN NN O
drug NN NN O
reaction NN NN O
. NN NN O
   
Methadone NN NN O
prolongs NN NN O
the NN NN O
QT NN NN O
interval NN NN O
in NN NN O
vitro NN NN O
in NN NN O
a NN NN O
dose NN NN O
- NN NN O
dependent NN NN O
manner NN NN O
. NN NN O
   
In NN NN O
the NN NN O
inpatient NN NN O
setting NN NN O
, NN NN O
the NN NN O
frequency NN NN O
of NN NN O
QT NN NN B-Disease
interval NN NN I-Disease
prolongation NN NN I-Disease
with NN NN O
methadone NN NN O
treatment NN NN O
, NN NN O
its NN NN O
dose NN NN O
dependence NN NN O
, NN NN O
and NN NN O
the NN NN O
importance NN NN O
of NN NN O
cofactors NN NN O
such NN NN O
as NN NN O
drug NN NN O
- NN NN O
drug NN NN O
interactions NN NN O
remain NN NN O
unknown NN NN O
. NN NN O
   
METHODS NN NN O
: NN NN O
We NN NN O
performed NN NN O
a NN NN O
systematic NN NN O
, NN NN O
retrospective NN NN O
study NN NN O
comparing NN NN O
active NN NN O
or NN NN O
former NN NN O
intravenous NN NN O
drug NN NN O
users NN NN O
receiving NN NN O
methadone NN NN O
and NN NN O
those NN NN O
not NN NN O
receiving NN NN O
methadone NN NN O
among NN NN O
all NN NN O
patients NN NN O
hospitalized NN NN O
over NN NN O
a NN NN O
5 NN NN O
- NN NN O
year NN NN O
period NN NN O
in NN NN O
a NN NN O
tertiary NN NN O
care NN NN O
hospital NN NN O
. NN NN O
   
A NN NN O
total NN NN O
of NN NN O
167 NN NN O
patients NN NN O
receiving NN NN O
methadone NN NN O
fulfilled NN NN O
the NN NN O
inclusion NN NN O
criteria NN NN O
and NN NN O
were NN NN O
compared NN NN O
with NN NN O
a NN NN O
control NN NN O
group NN NN O
of NN NN O
80 NN NN O
injection NN NN O
drug NN NN O
users NN NN O
not NN NN O
receiving NN NN O
methadone NN NN O
. NN NN O
   
In NN NN O
addition NN NN O
to NN NN O
methadone NN NN O
dose NN NN O
, NN NN O
15 NN NN O
demographic NN NN O
, NN NN O
biological NN NN O
, NN NN O
and NN NN O
pharmacological NN NN O
variables NN NN O
were NN NN O
considered NN NN O
as NN NN O
potential NN NN O
risk NN NN O
factors NN NN O
for NN NN O
QT NN NN B-Disease
prolongation NN NN I-Disease
. NN NN O
   
RESULTS NN NN O
: NN NN O
Among NN NN O
167 NN NN O
methadone NN NN O
maintenance NN NN O
patients NN NN O
, NN NN O
the NN NN O
prevalence NN NN O
of NN NN O
QTc NN NN O
prolongation NN NN O
to NN NN O
0 NN NN O
. NN NN O
50 NN NN O
second NN NN O
( NN NN O
( NN NN O
1 NN NN O
/ NN NN O
2 NN NN O
) NN NN O
) NN NN O
or NN NN O
longer NN NN O
was NN NN O
16 NN NN O
. NN NN O
2 NN NN O
% NN NN O
compared NN NN O
with NN NN O
0 NN NN O
% NN NN O
in NN NN O
80 NN NN O
control NN NN O
subjects NN NN O
. NN NN O
   
Six NN NN O
patients NN NN O
( NN NN O
3 NN NN O
. NN NN O
6 NN NN O
% NN NN O
) NN NN O
in NN NN O
the NN NN O
methadone NN NN O
group NN NN O
presented NN NN O
torsades NN NN B-Disease
de NN NN I-Disease
pointes NN NN I-Disease
. NN NN O
   
QTc NN NN O
length NN NN O
was NN NN O
weakly NN NN O
but NN NN O
significantly NN NN O
associated NN NN O
with NN NN O
methadone NN NN O
daily NN NN O
dose NN NN O
( NN NN O
Spearman NN NN O
rank NN NN O
correlation NN NN O
coefficient NN NN O
, NN NN O
0 NN NN O
. NN NN O
20 NN NN O
; NN NN O
P NN NN O
< NN NN O
. NN NN O
01 NN NN O
) NN NN O
. NN NN O
   
Multivariate NN NN O
regression NN NN O
analysis NN NN O
allowed NN NN O
attribution NN NN O
of NN NN O
31 NN NN O
. NN NN O
8 NN NN O
% NN NN O
of NN NN O
QTc NN NN O
variability NN NN O
to NN NN O
methadone NN NN O
dose NN NN O
, NN NN O
cytochrome NN NN O
P NN NN O
- NN NN O
450 NN NN O
3A4 NN NN O
drug NN NN O
- NN NN O
drug NN NN O
interactions NN NN O
, NN NN O
hypokalemia NN NN B-Disease
, NN NN O
and NN NN O
altered NN NN O
liver NN NN O
function NN NN O
. NN NN O
   
CONCLUSIONS NN NN O
: NN NN O
QT NN NN B-Disease
interval NN NN I-Disease
prolongation NN NN I-Disease
in NN NN O
methadone NN NN O
maintenance NN NN O
patients NN NN O
hospitalized NN NN O
in NN NN O
a NN NN O
tertiary NN NN O
care NN NN O
center NN NN O
is NN NN O
a NN NN O
frequent NN NN O
finding NN NN O
. NN NN O
   
Methadone NN NN O
dose NN NN O
, NN NN O
presence NN NN O
of NN NN O
cytochrome NN NN O
P NN NN O
- NN NN O
450 NN NN O
3A4 NN NN O
inhibitors NN NN O
, NN NN O
potassium NN NN O
level NN NN O
, NN NN O
and NN NN O
liver NN NN O
function NN NN O
contribute NN NN O
to NN NN O
QT NN NN B-Disease
prolongation NN NN I-Disease
. NN NN O
   
Long NN NN B-Disease
QT NN NN I-Disease
syndrome NN NN I-Disease
can NN NN O
occur NN NN O
with NN NN O
low NN NN O
doses NN NN O
of NN NN O
methadone NN NN O
. NN NN O
   
Mechanisms NN NN O
of NN NN O
hypertension NN NN B-Disease
induced NN NN O
by NN NN O
nitric NN NN O
oxide NN NN O
( NN NN O
NO NN NN O
) NN NN O
deficiency NN NN O
: NN NN O
focus NN NN O
on NN NN O
venous NN NN O
function NN NN O
. NN NN O
   
Loss NN NN O
of NN NN O
endothelial NN NN O
cell NN NN O
- NN NN O
derived NN NN O
nitric NN NN O
oxide NN NN O
( NN NN O
NO NN NN O
) NN NN O
in NN NN O
hypertension NN NN B-Disease
is NN NN O
a NN NN O
hallmark NN NN O
of NN NN O
arterial NN NN B-Disease
dysfunction NN NN I-Disease
. NN NN O
   
Experimental NN NN O
hypertension NN NN B-Disease
created NN NN O
by NN NN O
the NN NN O
removal NN NN O
of NN NN O
NO NN NN O
, NN NN O
however NN NN O
, NN NN O
involves NN NN O
mechanisms NN NN O
in NN NN O
addition NN NN O
to NN NN O
decreased NN NN O
arterial NN NN O
vasodilator NN NN O
activity NN NN O
. NN NN O
   
These NN NN O
include NN NN O
augmented NN NN O
endothelin NN NN O
- NN NN O
1 NN NN O
( NN NN O
ET NN NN O
- NN NN O
1 NN NN O
) NN NN O
release NN NN O
, NN NN O
increased NN NN O
sympathetic NN NN O
nervous NN NN O
system NN NN O
activity NN NN O
, NN NN O
and NN NN O
elevated NN NN O
tissue NN NN O
oxidative NN NN O
stress NN NN O
. NN NN O
   
We NN NN O
hypothesized NN NN O
that NN NN O
increased NN NN O
venous NN NN O
smooth NN NN O
muscle NN NN O
( NN NN O
venomotor NN NN O
) NN NN O
tone NN NN O
plays NN NN O
a NN NN O
role NN NN O
in NN NN O
Nomega NN NN O
- NN NN O
nitro NN NN O
- NN NN O
L NN NN O
- NN NN O
arginine NN NN O
( NN NN O
LNNA NN NN O
) NN NN O
hypertension NN NN B-Disease
through NN NN O
these NN NN O
mechanisms NN NN O
. NN NN O
   
Rats NN NN O
were NN NN O
treated NN NN O
with NN NN O
the NN NN O
NO NN NN O
synthase NN NN O
inhibitor NN NN O
LNNA NN NN O
( NN NN O
0 NN NN O
. NN NN O
5 NN NN O
g NN NN O
/ NN NN O
L NN NN O
in NN NN O
drinking NN NN O
water NN NN O
) NN NN O
for NN NN O
2 NN NN O
weeks NN NN O
. NN NN O
   
Mean NN NN O
arterial NN NN O
pressure NN NN O
of NN NN O
conscious NN NN O
rats NN NN O
was NN NN O
119 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
2 NN NN O
mm NN NN O
Hg NN NN O
in NN NN O
control NN NN O
and NN NN O
194 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
5 NN NN O
mm NN NN O
Hg NN NN O
in NN NN O
LNNA NN NN O
rats NN NN O
( NN NN O
P NN NN O
< NN NN O
0 NN NN O
. NN NN O
05 NN NN O
) NN NN O
. NN NN O
   
Carotid NN NN O
arteries NN NN O
and NN NN O
vena NN NN O
cava NN NN O
were NN NN O
removed NN NN O
for NN NN O
measurement NN NN O
of NN NN O
isometric NN NN O
contraction NN NN O
. NN NN O
   
Maximal NN NN O
contraction NN NN O
to NN NN O
norepinephrine NN NN O
was NN NN O
modestly NN NN O
reduced NN NN O
in NN NN O
arteries NN NN O
from NN NN O
LNNA NN NN O
compared NN NN O
with NN NN O
control NN NN O
rats NN NN O
whereas NN NN O
the NN NN O
maximum NN NN O
contraction NN NN O
to NN NN O
ET NN NN O
- NN NN O
1 NN NN O
was NN NN O
significantly NN NN O
reduced NN NN O
( NN NN O
54 NN NN O
% NN NN O
control NN NN O
) NN NN O
. NN NN O
   
Maximum NN NN O
contraction NN NN O
of NN NN O
vena NN NN O
cava NN NN O
to NN NN O
norepinephrine NN NN O
( NN NN O
37 NN NN O
% NN NN O
control NN NN O
) NN NN O
also NN NN O
was NN NN O
reduced NN NN O
but NN NN O
no NN NN O
change NN NN O
in NN NN O
response NN NN O
to NN NN O
ET NN NN O
- NN NN O
1 NN NN O
was NN NN O
observed NN NN O
. NN NN O
   
Mean NN NN O
circulatory NN NN O
filling NN NN O
pressure NN NN O
, NN NN O
an NN NN O
in NN NN O
vivo NN NN O
measure NN NN O
of NN NN O
venomotor NN NN O
tone NN NN O
, NN NN O
was NN NN O
not NN NN O
elevated NN NN O
in NN NN O
LNNA NN NN O
hypertension NN NN B-Disease
at NN NN O
1 NN NN O
or NN NN O
2 NN NN O
weeks NN NN O
after NN NN O
LNNA NN NN O
. NN NN O
   
The NN NN O
superoxide NN NN O
scavenger NN NN O
tempol NN NN O
( NN NN O
30 NN NN O
, NN NN O
100 NN NN O
, NN NN O
and NN NN O
300 NN NN O
micromol NN NN O
kg NN NN O
( NN NN O
- NN NN O
1 NN NN O
) NN NN O
, NN NN O
IV NN NN O
) NN NN O
did NN NN O
not NN NN O
change NN NN O
arterial NN NN O
pressure NN NN O
in NN NN O
control NN NN O
rats NN NN O
but NN NN O
caused NN NN O
a NN NN O
dose NN NN O
- NN NN O
dependent NN NN O
decrease NN NN O
in NN NN O
LNNA NN NN O
rats NN NN O
( NN NN O
- NN NN O
18 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
8 NN NN O
, NN NN O
- NN NN O
26 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
15 NN NN O
, NN NN O
and NN NN O
- NN NN O
54 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
11 NN NN O
mm NN NN O
Hg NN NN O
) NN NN O
. NN NN O
   
Similarly NN NN O
, NN NN O
ganglionic NN NN O
blockade NN NN O
with NN NN O
hexamethonium NN NN O
caused NN NN O
a NN NN O
significantly NN NN O
greater NN NN O
fall NN NN O
in NN NN O
LNNA NN NN O
hypertensive NN NN B-Disease
rats NN NN O
( NN NN O
76 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
9 NN NN O
mm NN NN O
Hg NN NN O
) NN NN O
compared NN NN O
with NN NN O
control NN NN O
rats NN NN O
( NN NN O
35 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
10 NN NN O
mm NN NN O
Hg NN NN O
) NN NN O
. NN NN O
   
Carotid NN NN O
arteries NN NN O
, NN NN O
vena NN NN O
cava NN NN O
, NN NN O
and NN NN O
sympathetic NN NN O
ganglia NN NN O
from NN NN O
LNNA NN NN O
rats NN NN O
had NN NN O
higher NN NN O
basal NN NN O
levels NN NN O
of NN NN O
superoxide NN NN O
compared NN NN O
with NN NN O
those NN NN O
from NN NN O
control NN NN O
rats NN NN O
. NN NN O
   
These NN NN O
data NN NN O
suggest NN NN O
that NN NN O
while NN NN O
NO NN NN O
deficiency NN NN O
increases NN NN O
oxidative NN NN O
stress NN NN O
and NN NN O
sympathetic NN NN O
activity NN NN O
in NN NN O
both NN NN O
arterial NN NN O
and NN NN O
venous NN NN O
vessels NN NN O
, NN NN O
the NN NN O
impact NN NN O
on NN NN O
veins NN NN O
does NN NN O
not NN NN O
make NN NN O
a NN NN O
major NN NN O
contribution NN NN O
to NN NN O
this NN NN O
form NN NN O
of NN NN O
hypertension NN NN B-Disease
. NN NN O
   
Association NN NN O
of NN NN O
DRD2 NN NN O
polymorphisms NN NN O
and NN NN O
chlorpromazine NN NN O
- NN NN O
induced NN NN O
extrapyramidal NN NN B-Disease
syndrome NN NN I-Disease
in NN NN O
Chinese NN NN O
schizophrenic NN NN B-Disease
patients NN NN O
. NN NN O
   
AIM NN NN O
: NN NN O
Extrapyramidal NN NN B-Disease
syndrome NN NN I-Disease
( NN NN O
EPS NN NN B-Disease
) NN NN O
is NN NN O
most NN NN O
commonly NN NN O
affected NN NN O
by NN NN O
typical NN NN O
antipsychotic NN NN O
drugs NN NN O
that NN NN O
have NN NN O
a NN NN O
high NN NN O
affinity NN NN O
with NN NN O
the NN NN O
D2 NN NN O
receptor NN NN O
. NN NN O
   
Recently NN NN O
, NN NN O
many NN NN O
research NN NN O
groups NN NN O
have NN NN O
reported NN NN O
on NN NN O
the NN NN O
positive NN NN O
relationship NN NN O
between NN NN O
the NN NN O
genetic NN NN O
variations NN NN O
in NN NN O
the NN NN O
DRD2 NN NN O
gene NN NN O
and NN NN O
the NN NN O
therapeutic NN NN O
response NN NN O
in NN NN O
schizophrenia NN NN B-Disease
patients NN NN O
as NN NN O
a NN NN O
result NN NN O
of NN NN O
the NN NN O
role NN NN O
of NN NN O
variations NN NN O
in NN NN O
the NN NN O
receptor NN NN O
in NN NN O
modulating NN NN O
receptor NN NN O
expression NN NN O
. NN NN O
   
In NN NN O
this NN NN O
study NN NN O
, NN NN O
we NN NN O
evaluate NN NN O
the NN NN O
role NN NN O
DRD2 NN NN O
plays NN NN O
in NN NN O
chlorpromazine NN NN O
- NN NN O
induced NN NN O
EPS NN NN B-Disease
in NN NN O
schizophrenic NN NN B-Disease
patients NN NN O
. NN NN O
   
METHODS NN NN O
: NN NN O
We NN NN O
identified NN NN O
seven NN NN O
SNP NN NN O
( NN NN O
single NN NN O
nucleotide NN NN O
polymorphism NN NN O
) NN NN O
( NN NN O
- NN NN O
141Cins NN NN O
> NN NN O
del NN NN O
, NN NN O
TaqIB NN NN O
, NN NN O
TaqID NN NN O
, NN NN O
Ser311Cys NN NN O
, NN NN O
rs6275 NN NN O
, NN NN O
rs6277 NN NN O
and NN NN O
TaqIA NN NN O
) NN NN O
in NN NN O
the NN NN O
DRD2 NN NN O
gene NN NN O
in NN NN O
146 NN NN O
schizophrenic NN NN B-Disease
inpatients NN NN O
( NN NN O
59 NN NN O
with NN NN O
EPS NN NN B-Disease
and NN NN O
87 NN NN O
without NN NN O
EPS NN NN B-Disease
according NN NN O
to NN NN O
the NN NN O
Simpson NN NN O
- NN NN O
Angus NN NN O
Scale NN NN O
) NN NN O
treated NN NN O
with NN NN O
chlorpromazine NN NN O
after NN NN O
8 NN NN O
weeks NN NN O
. NN NN O
   
The NN NN O
alleles NN NN O
of NN NN O
all NN NN O
loci NN NN O
were NN NN O
determined NN NN O
by NN NN O
PCR NN NN O
( NN NN O
polymerase NN NN O
chain NN NN O
reaction NN NN O
) NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
Polymorphisms NN NN O
TaqID NN NN O
, NN NN O
Ser311Cys NN NN O
and NN NN O
rs6277 NN NN O
were NN NN O
not NN NN O
polymorphic NN NN O
in NN NN O
the NN NN O
population NN NN O
recruited NN NN O
in NN NN O
the NN NN O
present NN NN O
study NN NN O
. NN NN O
   
No NN NN O
statistical NN NN O
significance NN NN O
was NN NN O
found NN NN O
in NN NN O
the NN NN O
allele NN NN O
distribution NN NN O
of NN NN O
- NN NN O
141Cins NN NN O
> NN NN O
del NN NN O
, NN NN O
TaqIB NN NN O
, NN NN O
rs6275 NN NN O
and NN NN O
TaqIA NN NN O
or NN NN O
in NN NN O
the NN NN O
estimated NN NN O
haplotypes NN NN O
( NN NN O
constituted NN NN O
by NN NN O
TaqIB NN NN O
, NN NN O
rs6275 NN NN O
and NN NN O
TaqIA NN NN O
) NN NN O
in NN NN O
linkage NN NN O
disequilibrium NN NN O
between NN NN O
the NN NN O
two NN NN O
groups NN NN O
. NN NN O
   
CONCLUSION NN NN O
: NN NN O
Our NN NN O
results NN NN O
did NN NN O
not NN NN O
lend NN NN O
strong NN NN O
support NN NN O
to NN NN O
the NN NN O
view NN NN O
that NN NN O
the NN NN O
genetic NN NN O
variation NN NN O
of NN NN O
the NN NN O
DRD2 NN NN O
gene NN NN O
plays NN NN O
a NN NN O
major NN NN O
role NN NN O
in NN NN O
the NN NN O
individually NN NN O
variable NN NN O
adverse NN NN O
effect NN NN O
induced NN NN O
by NN NN O
chlorpromazine NN NN O
, NN NN O
at NN NN O
least NN NN O
in NN NN O
Chinese NN NN O
patients NN NN O
with NN NN O
schizophrenia NN NN B-Disease
. NN NN O
   
Our NN NN O
results NN NN O
confirmed NN NN O
a NN NN O
previous NN NN O
study NN NN O
on NN NN O
the NN NN O
relationship NN NN O
between NN NN O
DRD2 NN NN O
and NN NN O
EPS NN NN B-Disease
in NN NN O
Caucasians NN NN O
. NN NN O
   
Physical NN NN O
training NN NN O
decreases NN NN O
susceptibility NN NN O
to NN NN O
subsequent NN NN O
pilocarpine NN NN O
- NN NN O
induced NN NN O
seizures NN NN B-Disease
in NN NN O
the NN NN O
rat NN NN O
. NN NN O
   
Regular NN NN O
motor NN NN O
activity NN NN O
has NN NN O
many NN NN O
benefits NN NN O
for NN NN O
mental NN NN O
and NN NN O
physical NN NN O
condition NN NN O
but NN NN O
its NN NN O
implications NN NN O
for NN NN O
epilepsy NN NN B-Disease
are NN NN O
still NN NN O
controversial NN NN O
. NN NN O
   
In NN NN O
order NN NN O
to NN NN O
elucidate NN NN O
this NN NN O
problem NN NN O
, NN NN O
we NN NN O
have NN NN O
studied NN NN O
the NN NN O
effect NN NN O
of NN NN O
long NN NN O
- NN NN O
term NN NN O
physical NN NN O
activity NN NN O
on NN NN O
susceptibility NN NN O
to NN NN O
subsequent NN NN O
seizures NN NN B-Disease
. NN NN O
   
Male NN NN O
Wistar NN NN O
rats NN NN O
were NN NN O
subjected NN NN O
to NN NN O
repeated NN NN O
training NN NN O
sessions NN NN O
in NN NN O
a NN NN O
treadmill NN NN O
and NN NN O
swimming NN NN O
pool NN NN O
. NN NN O
   
Thereafter NN NN O
, NN NN O
seizures NN NN B-Disease
were NN NN O
induced NN NN O
by NN NN O
pilocarpine NN NN O
injections NN NN O
in NN NN O
trained NN NN O
and NN NN O
non NN NN O
- NN NN O
trained NN NN O
control NN NN O
groups NN NN O
. NN NN O
   
During NN NN O
the NN NN O
acute NN NN O
period NN NN O
of NN NN O
status NN NN B-Disease
epilepticus NN NN I-Disease
, NN NN O
we NN NN O
measured NN NN O
: NN NN O
( NN NN O
1 NN NN O
) NN NN O
the NN NN O
latency NN NN O
of NN NN O
the NN NN O
first NN NN O
motor NN NN O
sign NN NN O
, NN NN O
( NN NN O
2 NN NN O
) NN NN O
the NN NN O
intensity NN NN O
of NN NN O
seizures NN NN B-Disease
, NN NN O
( NN NN O
3 NN NN O
) NN NN O
the NN NN O
time NN NN O
when NN NN O
it NN NN O
occurred NN NN O
within NN NN O
the NN NN O
6 NN NN O
- NN NN O
h NN NN O
observation NN NN O
period NN NN O
, NN NN O
and NN NN O
( NN NN O
4 NN NN O
) NN NN O
the NN NN O
time NN NN O
when NN NN O
the NN NN O
acute NN NN O
period NN NN O
ended NN NN O
. NN NN O
   
All NN NN O
these NN NN O
behavioral NN NN O
parameters NN NN O
showed NN NN O
statistically NN NN O
significant NN NN O
changes NN NN O
suggesting NN NN O
that NN NN O
regular NN NN O
physical NN NN O
exercises NN NN O
decrease NN NN O
susceptibility NN NN O
to NN NN O
subsequently NN NN O
induced NN NN O
seizures NN NN B-Disease
and NN NN O
ameliorate NN NN O
the NN NN O
course NN NN O
of NN NN O
experimentally NN NN O
induced NN NN O
status NN NN B-Disease
epilepticus NN NN I-Disease
. NN NN O
   
Tonic NN NN O
dopaminergic NN NN O
stimulation NN NN O
impairs NN NN B-Disease
associative NN NN I-Disease
learning NN NN I-Disease
in NN NN O
healthy NN NN O
subjects NN NN O
. NN NN O
   
Endogenous NN NN O
dopamine NN NN O
plays NN NN O
a NN NN O
central NN NN O
role NN NN O
in NN NN O
salience NN NN O
coding NN NN O
during NN NN O
associative NN NN O
learning NN NN O
. NN NN O
   
Administration NN NN O
of NN NN O
the NN NN O
dopamine NN NN O
precursor NN NN O
levodopa NN NN O
enhances NN NN O
learning NN NN O
in NN NN O
healthy NN NN O
subjects NN NN O
and NN NN O
stroke NN NN B-Disease
patients NN NN O
. NN NN O
   
Because NN NN O
levodopa NN NN O
increases NN NN O
both NN NN O
phasic NN NN O
and NN NN O
tonic NN NN O
dopaminergic NN NN O
neurotransmission NN NN O
, NN NN O
the NN NN O
critical NN NN O
mechanism NN NN O
mediating NN NN O
the NN NN O
enhancement NN NN O
of NN NN O
learning NN NN O
is NN NN O
unresolved NN NN O
. NN NN O
   
We NN NN O
here NN NN O
probed NN NN O
how NN NN O
selective NN NN O
tonic NN NN O
dopaminergic NN NN O
stimulation NN NN O
affects NN NN O
associative NN NN O
learning NN NN O
. NN NN O
   
Forty NN NN O
healthy NN NN O
subjects NN NN O
were NN NN O
trained NN NN O
in NN NN O
a NN NN O
novel NN NN O
vocabulary NN NN O
of NN NN O
45 NN NN O
concrete NN NN O
nouns NN NN O
over NN NN O
the NN NN O
course NN NN O
of NN NN O
5 NN NN O
consecutive NN NN O
training NN NN O
days NN NN O
in NN NN O
a NN NN O
prospective NN NN O
, NN NN O
randomized NN NN O
, NN NN O
double NN NN O
- NN NN O
blind NN NN O
, NN NN O
placebo NN NN O
- NN NN O
controlled NN NN O
design NN NN O
. NN NN O
   
Subjects NN NN O
received NN NN O
the NN NN O
tonically NN NN O
stimulating NN NN O
dopamine NN NN O
- NN NN O
receptor NN NN O
agonist NN NN O
pergolide NN NN O
( NN NN O
0 NN NN O
. NN NN O
1 NN NN O
mg NN NN O
) NN NN O
vs NN NN O
placebo NN NN O
120 NN NN O
min NN NN O
before NN NN O
training NN NN O
on NN NN O
each NN NN O
training NN NN O
day NN NN O
. NN NN O
   
The NN NN O
dopamine NN NN O
agonist NN NN O
significantly NN NN O
impaired NN NN B-Disease
novel NN NN I-Disease
word NN NN I-Disease
learning NN NN I-Disease
compared NN NN O
to NN NN O
placebo NN NN O
. NN NN O
   
This NN NN O
learning NN NN O
decrement NN NN O
persisted NN NN O
up NN NN O
to NN NN O
the NN NN O
last NN NN O
follow NN NN O
- NN NN O
up NN NN O
4 NN NN O
weeks NN NN O
post NN NN O
- NN NN O
training NN NN O
. NN NN O
   
Subjects NN NN O
treated NN NN O
with NN NN O
pergolide NN NN O
also NN NN O
showed NN NN O
restricted NN NN O
emotional NN NN O
responses NN NN O
compared NN NN O
to NN NN O
the NN NN O
PLACEBO NN NN O
group NN NN O
. NN NN O
   
The NN NN O
extent NN NN O
of NN NN O
' NN NN O
flattened NN NN O
' NN NN O
affect NN NN O
with NN NN O
pergolide NN NN O
was NN NN O
related NN NN O
to NN NN O
the NN NN O
degree NN NN O
of NN NN O
learning NN NN O
inhibition NN NN O
. NN NN O
   
These NN NN O
findings NN NN O
suggest NN NN O
that NN NN O
tonic NN NN O
occupation NN NN O
of NN NN O
dopamine NN NN O
receptors NN NN O
impairs NN NN O
learning NN NN O
by NN NN O
competition NN NN O
with NN NN O
phasic NN NN O
dopamine NN NN O
signals NN NN O
. NN NN O
   
Thus NN NN O
, NN NN O
phasic NN NN O
signaling NN NN O
seems NN NN O
to NN NN O
be NN NN O
the NN NN O
critical NN NN O
mechanism NN NN O
by NN NN O
which NN NN O
dopamine NN NN O
enhances NN NN O
associative NN NN O
learning NN NN O
in NN NN O
healthy NN NN O
subjects NN NN O
and NN NN O
stroke NN NN B-Disease
patients NN NN O
. NN NN O
   
Minocycline NN NN O
- NN NN O
induced NN NN O
vasculitis NN NN B-Disease
fulfilling NN NN O
the NN NN O
criteria NN NN O
of NN NN O
polyarteritis NN NN B-Disease
nodosa NN NN I-Disease
. NN NN O
   
A NN NN O
47 NN NN O
- NN NN O
year NN NN O
- NN NN O
old NN NN O
man NN NN O
who NN NN O
had NN NN O
been NN NN O
taking NN NN O
minocycline NN NN O
for NN NN O
palmoplantar NN NN B-Disease
pustulosis NN NN I-Disease
developed NN NN O
fever NN NN B-Disease
, NN NN O
myalgias NN NN B-Disease
, NN NN O
polyneuropathy NN NN B-Disease
, NN NN O
and NN NN O
testicular NN NN B-Disease
pain NN NN I-Disease
, NN NN O
with NN NN O
elevated NN NN O
C NN NN O
- NN NN O
reactive NN NN O
protein NN NN O
( NN NN O
CRP NN NN O
) NN NN O
. NN NN O
   
Neither NN NN O
myeloperoxidase NN NN O
- NN NN O
nor NN NN O
proteinase NN NN O
- NN NN O
3 NN NN O
- NN NN O
antineutrophil NN NN O
cytoplasmic NN NN O
antibody NN NN O
was NN NN O
positive NN NN O
. NN NN O
   
These NN NN O
manifestations NN NN O
met NN NN O
the NN NN O
American NN NN O
College NN NN O
of NN NN O
Rheumatology NN NN O
1990 NN NN O
criteria NN NN O
for NN NN O
the NN NN O
classification NN NN O
of NN NN O
polyarteritis NN NN B-Disease
nodosa NN NN I-Disease
. NN NN O
   
Stopping NN NN O
minocycline NN NN O
led NN NN O
to NN NN O
amelioration NN NN O
of NN NN O
symptoms NN NN O
and NN NN O
normalization NN NN O
of NN NN O
CRP NN NN O
level NN NN O
. NN NN O
   
To NN NN O
our NN NN O
knowledge NN NN O
, NN NN O
this NN NN O
is NN NN O
the NN NN O
second NN NN O
case NN NN O
of NN NN O
minocycline NN NN O
- NN NN O
induced NN NN O
vasculitis NN NN B-Disease
satisfying NN NN O
the NN NN O
criteria NN NN O
. NN NN O
   
Differential NN NN O
diagnosis NN NN O
for NN NN O
drug NN NN O
- NN NN O
induced NN NN O
disease NN NN O
is NN NN O
invaluable NN NN O
even NN NN O
for NN NN O
patients NN NN O
with NN NN O
classical NN NN O
polyarteritis NN NN B-Disease
nodosa NN NN I-Disease
. NN NN O
   
Intramuscular NN NN O
hepatitis NN NN B-Disease
B NN NN I-Disease
immune NN NN O
globulin NN NN O
combined NN NN O
with NN NN O
lamivudine NN NN O
in NN NN O
prevention NN NN O
of NN NN O
hepatitis NN NN B-Disease
B NN NN I-Disease
recurrence NN NN O
after NN NN O
liver NN NN O
transplantation NN NN O
. NN NN O
   
BACKGROUND NN NN O
: NN NN O
Combined NN NN O
hepatitis NN NN B-Disease
B NN NN I-Disease
immune NN NN O
globulin NN NN O
( NN NN O
HBIg NN NN O
) NN NN O
and NN NN O
lamivudine NN NN O
in NN NN O
prophylaxis NN NN O
of NN NN O
the NN NN O
recurrence NN NN O
of NN NN O
hepatitis NN NN B-Disease
B NN NN I-Disease
after NN NN O
liver NN NN O
transplantation NN NN O
has NN NN O
significantly NN NN O
improved NN NN O
the NN NN O
survival NN NN O
of NN NN O
HBsAg NN NN O
positive NN NN O
patients NN NN O
. NN NN O
   
This NN NN O
study NN NN O
was NN NN O
undertaken NN NN O
to NN NN O
evaluate NN NN O
the NN NN O
outcomes NN NN O
of NN NN O
liver NN NN O
transplantation NN NN O
for NN NN O
patients NN NN O
with NN NN O
hepatitis NN NN B-Disease
B NN NN I-Disease
virus NN NN O
( NN NN O
HBV NN NN O
) NN NN O
. NN NN O
   
METHODS NN NN O
: NN NN O
A NN NN O
retrospective NN NN O
chart NN NN O
analysis NN NN O
and NN NN O
a NN NN O
review NN NN O
of NN NN O
the NN NN O
organ NN NN O
transplant NN NN O
database NN NN O
identified NN NN O
51 NN NN O
patients NN NN O
( NN NN O
43 NN NN O
men NN NN O
and NN NN O
8 NN NN O
women NN NN O
) NN NN O
transplanted NN NN O
for NN NN O
benign NN NN O
HBV NN NN O
- NN NN O
related NN NN O
cirrhotic NN NN B-Disease
diseases NN NN I-Disease
between NN NN O
June NN NN O
2002 NN NN O
and NN NN O
December NN NN O
2004 NN NN O
who NN NN O
had NN NN O
survived NN NN O
more NN NN O
than NN NN O
3 NN NN O
months NN NN O
. NN NN O
   
HBIg NN NN O
was NN NN O
administered NN NN O
intravenously NN NN O
during NN NN O
the NN NN O
first NN NN O
week NN NN O
and NN NN O
intramuscularly NN NN O
thereafter NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
At NN NN O
a NN NN O
median NN NN O
follow NN NN O
- NN NN O
up NN NN O
of NN NN O
14 NN NN O
. NN NN O
1 NN NN O
months NN NN O
, NN NN O
the NN NN O
overall NN NN O
recurrence NN NN O
rate NN NN O
in NN NN O
the NN NN O
51 NN NN O
patients NN NN O
was NN NN O
3 NN NN O
. NN NN O
9 NN NN O
% NN NN O
( NN NN O
2 NN NN O
/ NN NN O
51 NN NN O
) NN NN O
. NN NN O
   
The NN NN O
overall NN NN O
patient NN NN O
survival NN NN O
was NN NN O
88 NN NN O
. NN NN O
3 NN NN O
% NN NN O
, NN NN O
and NN NN O
82 NN NN O
. NN NN O
4 NN NN O
% NN NN O
after NN NN O
1 NN NN O
and NN NN O
2 NN NN O
years NN NN O
, NN NN O
respectively NN NN O
. NN NN O
   
A NN NN O
daily NN NN O
oral NN NN O
dose NN NN O
of NN NN O
100 NN NN O
mg NN NN O
lamivudine NN NN O
for NN NN O
2 NN NN O
weeks NN NN O
before NN NN O
transplantation NN NN O
for NN NN O
10 NN NN O
patients NN NN O
enabled NN NN O
57 NN NN O
. NN NN O
1 NN NN O
% NN NN O
( NN NN O
4 NN NN O
/ NN NN O
7 NN NN O
) NN NN O
and NN NN O
62 NN NN O
. NN NN O
5 NN NN O
% NN NN O
( NN NN O
5 NN NN O
/ NN NN O
8 NN NN O
) NN NN O
of NN NN O
HBV NN NN O
- NN NN O
DNA NN NN O
and NN NN O
HBeAg NN NN O
positive NN NN O
patients NN NN O
respectively NN NN O
to NN NN O
convert NN NN O
to NN NN O
be NN NN O
negative NN NN O
. NN NN O
   
Intramuscular NN NN O
HBIg NN NN O
was NN NN O
well NN NN O
tolerated NN NN O
in NN NN O
all NN NN O
patients NN NN O
. NN NN O
   
CONCLUSION NN NN O
: NN NN O
Lamivudine NN NN O
combined NN NN O
with NN NN O
intramuscular NN NN O
HBIg NN NN O
can NN NN O
effectively NN NN O
prevent NN NN O
allograft NN NN O
from NN NN O
the NN NN O
recurrence NN NN O
of NN NN O
HBV NN NN O
after NN NN O
liver NN NN O
transplantation NN NN O
. NN NN O
   
Anticonvulsant NN NN O
effect NN NN O
of NN NN O
eslicarbazepine NN NN O
acetate NN NN O
( NN NN O
BIA NN NN O
2 NN NN O
- NN NN O
093 NN NN O
) NN NN O
on NN NN O
seizures NN NN B-Disease
induced NN NN O
by NN NN O
microperfusion NN NN O
of NN NN O
picrotoxin NN NN O
in NN NN O
the NN NN O
hippocampus NN NN O
of NN NN O
freely NN NN O
moving NN NN O
rats NN NN O
. NN NN O
   
Eslicarbazepine NN NN O
acetate NN NN O
( NN NN O
BIA NN NN O
2 NN NN O
- NN NN O
093 NN NN O
, NN NN O
S NN NN O
- NN NN O
( NN NN O
- NN NN O
) NN NN O
- NN NN O
10 NN NN O
- NN NN O
acetoxy NN NN O
- NN NN O
10 NN NN O
, NN NN O
11 NN NN O
- NN NN O
dihydro NN NN O
- NN NN O
5H NN NN O
- NN NN O
dibenzo NN NN O
/ NN NN O
b NN NN O
, NN NN O
f NN NN O
/ NN NN O
azepine NN NN O
- NN NN O
5 NN NN O
- NN NN O
carboxamide NN NN O
) NN NN O
is NN NN O
a NN NN O
novel NN NN O
antiepileptic NN NN O
drug NN NN O
, NN NN O
now NN NN O
in NN NN O
Phase NN NN O
III NN NN O
clinical NN NN O
trials NN NN O
, NN NN O
designed NN NN O
with NN NN O
the NN NN O
aim NN NN O
of NN NN O
improving NN NN O
efficacy NN NN O
and NN NN O
safety NN NN O
in NN NN O
comparison NN NN O
with NN NN O
the NN NN O
structurally NN NN O
related NN NN O
drugs NN NN O
carbamazepine NN NN O
( NN NN O
CBZ NN NN O
) NN NN O
and NN NN O
oxcarbazepine NN NN O
( NN NN O
OXC NN NN O
) NN NN O
. NN NN O
   
We NN NN O
have NN NN O
studied NN NN O
the NN NN O
effects NN NN O
of NN NN O
oral NN NN O
treatment NN NN O
with NN NN O
eslicarbazepine NN NN O
acetate NN NN O
on NN NN O
a NN NN O
whole NN NN O
- NN NN O
animal NN NN O
model NN NN O
in NN NN O
which NN NN O
partial NN NN O
seizures NN NN B-Disease
can NN NN O
be NN NN O
elicited NN NN O
repeatedly NN NN O
on NN NN O
different NN NN O
days NN NN O
without NN NN O
changes NN NN O
in NN NN O
threshold NN NN O
or NN NN O
seizure NN NN B-Disease
patterns NN NN O
. NN NN O
   
In NN NN O
the NN NN O
animals NN NN O
treated NN NN O
with NN NN O
threshold NN NN O
doses NN NN O
of NN NN O
picrotoxin NN NN O
, NN NN O
the NN NN O
average NN NN O
number NN NN O
of NN NN O
seizures NN NN B-Disease
was NN NN O
2 NN NN O
. NN NN O
3 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
1 NN NN O
. NN NN O
2 NN NN O
, NN NN O
and NN NN O
average NN NN O
seizure NN NN B-Disease
duration NN NN O
was NN NN O
39 NN NN O
. NN NN O
5 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
8 NN NN O
. NN NN O
4s NN NN O
. NN NN O
   
Pre NN NN O
- NN NN O
treatment NN NN O
with NN NN O
a NN NN O
dose NN NN O
of NN NN O
30 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
2h NN NN O
before NN NN O
picrotoxin NN NN O
microperfusion NN NN O
prevented NN NN O
seizures NN NN B-Disease
in NN NN O
the NN NN O
75 NN NN O
% NN NN O
of NN NN O
the NN NN O
rats NN NN O
. NN NN O
   
Lower NN NN O
doses NN NN O
( NN NN O
3 NN NN O
and NN NN O
10mg NN NN O
/ NN NN O
kg NN NN O
) NN NN O
did NN NN O
not NN NN O
suppress NN NN O
seizures NN NN B-Disease
, NN NN O
however NN NN O
, NN NN O
after NN NN O
administration NN NN O
of NN NN O
10mg NN NN O
/ NN NN O
kg NN NN O
, NN NN O
significant NN NN O
reductions NN NN O
in NN NN O
seizures NN NN B-Disease
duration NN NN O
( NN NN O
24 NN NN O
. NN NN O
3 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
6 NN NN O
. NN NN O
8s NN NN O
) NN NN O
and NN NN O
seizure NN NN B-Disease
number NN NN O
( NN NN O
1 NN NN O
. NN NN O
6 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
0 NN NN O
. NN NN O
34 NN NN O
) NN NN O
were NN NN O
found NN NN O
. NN NN O
   
No NN NN O
adverse NN NN O
effects NN NN O
of NN NN O
eslicarbazepine NN NN O
acetate NN NN O
were NN NN O
observed NN NN O
in NN NN O
the NN NN O
behavioral NN NN O
/ NN NN O
EEG NN NN O
patterns NN NN O
studied NN NN O
, NN NN O
including NN NN O
sleep NN NN O
/ NN NN O
wakefulness NN NN O
cycle NN NN O
, NN NN O
at NN NN O
the NN NN O
doses NN NN O
studied NN NN O
. NN NN O
   
Acute NN NN B-Disease
renal NN NN I-Disease
failure NN NN I-Disease
associated NN NN O
with NN NN O
prolonged NN NN O
intake NN NN O
of NN NN O
slimming NN NN O
pills NN NN O
containing NN NN O
anthraquinones NN NN O
. NN NN O
   
Chinese NN NN O
herbal NN NN O
medicine NN NN O
preparations NN NN O
are NN NN O
widely NN NN O
available NN NN O
and NN NN O
often NN NN O
regarded NN NN O
by NN NN O
the NN NN O
public NN NN O
as NN NN O
natural NN NN O
and NN NN O
safe NN NN O
remedies NN NN O
for NN NN O
a NN NN O
variety NN NN O
of NN NN O
medical NN NN O
conditions NN NN O
. NN NN O
   
Nephropathy NN NN B-Disease
caused NN NN O
by NN NN O
Chinese NN NN O
herbs NN NN O
has NN NN O
previously NN NN O
been NN NN O
reported NN NN O
, NN NN O
usually NN NN O
involving NN NN O
the NN NN O
use NN NN O
of NN NN O
aristolochic NN NN O
acids NN NN O
. NN NN O
   
We NN NN O
report NN NN O
a NN NN O
23 NN NN O
- NN NN O
year NN NN O
- NN NN O
old NN NN O
woman NN NN O
who NN NN O
developed NN NN O
acute NN NN B-Disease
renal NN NN I-Disease
failure NN NN I-Disease
following NN NN O
prolonged NN NN O
use NN NN O
of NN NN O
a NN NN O
proprietary NN NN O
Chinese NN NN O
herbal NN NN O
slimming NN NN O
pill NN NN O
that NN NN O
contained NN NN O
anthraquinone NN NN O
derivatives NN NN O
, NN NN O
extracted NN NN O
from NN NN O
Rhizoma NN NN O
Rhei NN NN O
( NN NN O
rhubarb NN NN O
) NN NN O
. NN NN O
   
The NN NN O
renal NN NN B-Disease
injury NN NN I-Disease
was NN NN O
probably NN NN O
aggravated NN NN O
by NN NN O
the NN NN O
concomitant NN NN O
intake NN NN O
of NN NN O
a NN NN O
non NN NN O
- NN NN O
steroidal NN NN O
anti NN NN O
- NN NN O
inflammatory NN NN O
drug NN NN O
, NN NN O
diclofenac NN NN O
. NN NN O
   
Renal NN NN O
pathology NN NN O
was NN NN O
that NN NN O
of NN NN O
hypocellular NN NN O
interstitial NN NN O
fibrosis NN NN B-Disease
. NN NN O
   
Spontaneous NN NN O
renal NN NN O
recovery NN NN O
occurred NN NN O
upon NN NN O
cessation NN NN O
of NN NN O
the NN NN O
slimming NN NN O
pills NN NN O
, NN NN O
but NN NN O
mild NN NN O
interstitial NN NN O
fibrosis NN NN B-Disease
and NN NN O
tubular NN NN O
atrophy NN NN B-Disease
was NN NN O
still NN NN O
evident NN NN O
histologically NN NN O
4 NN NN O
months NN NN O
later NN NN O
. NN NN O
   
Although NN NN O
a NN NN O
causal NN NN O
relationship NN NN O
between NN NN O
the NN NN O
use NN NN O
of NN NN O
an NN NN O
anthraquinone NN NN O
- NN NN O
containing NN NN O
herbal NN NN O
agent NN NN O
and NN NN O
renal NN NN B-Disease
injury NN NN I-Disease
remains NN NN O
to NN NN O
be NN NN O
proven NN NN O
, NN NN O
phytotherapy NN NN O
- NN NN O
associated NN NN O
interstitial NN NN O
nephropathy NN NN B-Disease
should NN NN O
be NN NN O
considered NN NN O
in NN NN O
patients NN NN O
who NN NN O
present NN NN O
with NN NN O
unexplained NN NN O
renal NN NN B-Disease
failure NN NN I-Disease
. NN NN O
   
Chloroacetaldehyde NN NN O
as NN NN O
a NN NN O
sulfhydryl NN NN O
reagent NN NN O
: NN NN O
the NN NN O
role NN NN O
of NN NN O
critical NN NN O
thiol NN NN O
groups NN NN O
in NN NN O
ifosfamide NN NN O
nephropathy NN NN B-Disease
. NN NN O
   
Chloroacetaldehyde NN NN O
( NN NN O
CAA NN NN O
) NN NN O
is NN NN O
a NN NN O
metabolite NN NN O
of NN NN O
the NN NN O
alkylating NN NN O
agent NN NN O
ifosfamide NN NN O
( NN NN O
IFO NN NN O
) NN NN O
and NN NN O
putatively NN NN O
responsible NN NN O
for NN NN O
renal NN NN B-Disease
damage NN NN I-Disease
following NN NN O
anti NN NN O
- NN NN O
tumor NN NN B-Disease
therapy NN NN O
with NN NN O
IFO NN NN O
. NN NN O
   
Depletion NN NN O
of NN NN O
sulfhydryl NN NN O
( NN NN O
SH NN NN O
) NN NN O
groups NN NN O
has NN NN O
been NN NN O
reported NN NN O
from NN NN O
cell NN NN O
culture NN NN O
, NN NN O
animal NN NN O
and NN NN O
clinical NN NN O
studies NN NN O
. NN NN O
   
In NN NN O
this NN NN O
work NN NN O
the NN NN O
effect NN NN O
of NN NN O
CAA NN NN O
on NN NN O
human NN NN O
proximal NN NN O
tubule NN NN O
cells NN NN O
in NN NN O
primary NN NN O
culture NN NN O
( NN NN O
hRPTEC NN NN O
) NN NN O
was NN NN O
investigated NN NN O
. NN NN O
   
Toxicity NN NN B-Disease
of NN NN O
CAA NN NN O
was NN NN O
determined NN NN O
by NN NN O
protein NN NN O
content NN NN O
, NN NN O
cell NN NN O
number NN NN O
, NN NN O
LDH NN NN O
release NN NN O
, NN NN O
trypan NN NN O
blue NN NN O
exclusion NN NN O
assay NN NN O
and NN NN O
caspase NN NN O
- NN NN O
3 NN NN O
activity NN NN O
. NN NN O
   
Free NN NN O
thiols NN NN O
were NN NN O
measured NN NN O
by NN NN O
the NN NN O
method NN NN O
of NN NN O
Ellman NN NN O
. NN NN O
   
CAA NN NN O
reduced NN NN O
hRPTEC NN NN O
cell NN NN O
number NN NN O
and NN NN O
protein NN NN O
, NN NN O
induced NN NN O
a NN NN O
loss NN NN O
in NN NN O
free NN NN O
intracellular NN NN O
thiols NN NN O
and NN NN O
an NN NN O
increase NN NN O
in NN NN O
necrosis NN NN B-Disease
markers NN NN O
. NN NN O
   
CAA NN NN O
but NN NN O
not NN NN O
acrolein NN NN O
inhibited NN NN O
the NN NN O
cysteine NN NN O
proteases NN NN O
caspase NN NN O
- NN NN O
3 NN NN O
, NN NN O
caspase NN NN O
- NN NN O
8 NN NN O
and NN NN O
cathepsin NN NN O
B NN NN O
. NN NN O
   
Caspase NN NN O
activation NN NN O
by NN NN O
cisplatin NN NN O
was NN NN O
inhibited NN NN O
by NN NN O
CAA NN NN O
. NN NN O
   
In NN NN O
cells NN NN O
stained NN NN O
with NN NN O
fluorescent NN NN O
dyes NN NN O
targeting NN NN O
lysosomes NN NN O
, NN NN O
CAA NN NN O
induced NN NN O
an NN NN O
increase NN NN O
in NN NN O
lysosomal NN NN O
size NN NN O
and NN NN O
lysosomal NN NN O
leakage NN NN O
. NN NN O
   
The NN NN O
effects NN NN O
of NN NN O
CAA NN NN O
on NN NN O
cysteine NN NN O
protease NN NN O
activities NN NN O
and NN NN O
thiols NN NN O
could NN NN O
be NN NN O
reproduced NN NN O
in NN NN O
cell NN NN O
lysate NN NN O
. NN NN O
   
Acidification NN NN O
, NN NN O
which NN NN O
slowed NN NN O
the NN NN O
reaction NN NN O
of NN NN O
CAA NN NN O
with NN NN O
thiol NN NN O
donors NN NN O
, NN NN O
could NN NN O
also NN NN O
attenuate NN NN O
effects NN NN O
of NN NN O
CAA NN NN O
on NN NN O
necrosis NN NN B-Disease
markers NN NN O
, NN NN O
thiol NN NN O
depletion NN NN O
and NN NN O
cysteine NN NN O
protease NN NN O
inhibition NN NN O
in NN NN O
living NN NN O
cells NN NN O
. NN NN O
   
Thus NN NN O
, NN NN O
CAA NN NN O
directly NN NN O
reacts NN NN O
with NN NN O
cellular NN NN O
protein NN NN O
and NN NN O
non NN NN O
- NN NN O
protein NN NN O
thiols NN NN O
, NN NN O
mediating NN NN O
its NN NN O
toxicity NN NN B-Disease
on NN NN O
hRPTEC NN NN O
. NN NN O
   
This NN NN O
effect NN NN O
can NN NN O
be NN NN O
reduced NN NN O
by NN NN O
acidification NN NN O
. NN NN O
   
Therefore NN NN O
, NN NN O
urinary NN NN O
acidification NN NN O
could NN NN O
be NN NN O
an NN NN O
option NN NN O
to NN NN O
prevent NN NN O
IFO NN NN O
nephropathy NN NN B-Disease
in NN NN O
patients NN NN O
. NN NN O
   
Stereological NN NN O
methods NN NN O
reveal NN NN O
the NN NN O
robust NN NN O
size NN NN O
and NN NN O
stability NN NN O
of NN NN O
ectopic NN NN O
hilar NN NN O
granule NN NN O
cells NN NN O
after NN NN O
pilocarpine NN NN O
- NN NN O
induced NN NN O
status NN NN B-Disease
epilepticus NN NN I-Disease
in NN NN O
the NN NN O
adult NN NN O
rat NN NN O
. NN NN O
   
Following NN NN O
status NN NN B-Disease
epilepticus NN NN I-Disease
in NN NN O
the NN NN O
rat NN NN O
, NN NN O
dentate NN NN O
granule NN NN O
cell NN NN O
neurogenesis NN NN O
increases NN NN O
greatly NN NN O
, NN NN O
and NN NN O
many NN NN O
of NN NN O
the NN NN O
new NN NN O
neurons NN NN O
appear NN NN O
to NN NN O
develop NN NN O
ectopically NN NN O
, NN NN O
in NN NN O
the NN NN O
hilar NN NN O
region NN NN O
of NN NN O
the NN NN O
hippocampal NN NN O
formation NN NN O
. NN NN O
   
It NN NN O
has NN NN O
been NN NN O
suggested NN NN O
that NN NN O
the NN NN O
ectopic NN NN O
hilar NN NN O
granule NN NN O
cells NN NN O
could NN NN O
contribute NN NN O
to NN NN O
the NN NN O
spontaneous NN NN O
seizures NN NN B-Disease
that NN NN O
ultimately NN NN O
develop NN NN O
after NN NN O
status NN NN B-Disease
epilepticus NN NN I-Disease
. NN NN O
   
However NN NN O
, NN NN O
the NN NN O
population NN NN O
has NN NN O
never NN NN O
been NN NN O
quantified NN NN O
, NN NN O
so NN NN O
it NN NN O
is NN NN O
unclear NN NN O
whether NN NN O
it NN NN O
is NN NN O
substantial NN NN O
enough NN NN O
to NN NN O
have NN NN O
a NN NN O
strong NN NN O
influence NN NN O
on NN NN O
epileptogenesis NN NN O
. NN NN O
   
To NN NN O
quantify NN NN O
this NN NN O
population NN NN O
, NN NN O
the NN NN O
total NN NN O
number NN NN O
of NN NN O
ectopic NN NN O
hilar NN NN O
granule NN NN O
cells NN NN O
was NN NN O
estimated NN NN O
using NN NN O
unbiased NN NN O
stereology NN NN O
at NN NN O
different NN NN O
times NN NN O
after NN NN O
pilocarpine NN NN O
- NN NN O
induced NN NN O
status NN NN B-Disease
epilepticus NN NN I-Disease
. NN NN O
   
The NN NN O
number NN NN O
of NN NN O
hilar NN NN O
neurons NN NN O
immunoreactive NN NN O
for NN NN O
Prox NN NN O
- NN NN O
1 NN NN O
, NN NN O
a NN NN O
granule NN NN O
- NN NN O
cell NN NN O
- NN NN O
specific NN NN O
marker NN NN O
, NN NN O
was NN NN O
estimated NN NN O
using NN NN O
the NN NN O
optical NN NN O
fractionator NN NN O
method NN NN O
. NN NN O
   
The NN NN O
results NN NN O
indicate NN NN O
that NN NN O
the NN NN O
size NN NN O
of NN NN O
the NN NN O
hilar NN NN O
ectopic NN NN O
granule NN NN O
cell NN NN O
population NN NN O
after NN NN O
status NN NN B-Disease
epilepticus NN NN I-Disease
is NN NN O
substantial NN NN O
, NN NN O
and NN NN O
stable NN NN O
over NN NN O
time NN NN O
. NN NN O
   
Interestingly NN NN O
, NN NN O
the NN NN O
size NN NN O
of NN NN O
the NN NN O
population NN NN O
appears NN NN O
to NN NN O
be NN NN O
correlated NN NN O
with NN NN O
the NN NN O
frequency NN NN O
of NN NN O
behavioral NN NN O
seizures NN NN B-Disease
, NN NN O
because NN NN O
animals NN NN O
with NN NN O
more NN NN O
ectopic NN NN O
granule NN NN O
cells NN NN O
in NN NN O
the NN NN O
hilus NN NN O
have NN NN O
more NN NN O
frequent NN NN O
behavioral NN NN O
seizures NN NN B-Disease
. NN NN O
   
The NN NN O
hilar NN NN O
ectopic NN NN O
granule NN NN O
cell NN NN O
population NN NN O
does NN NN O
not NN NN O
appear NN NN O
to NN NN O
vary NN NN O
systematically NN NN O
across NN NN O
the NN NN O
septotemporal NN NN O
axis NN NN O
, NN NN O
although NN NN O
it NN NN O
is NN NN O
associated NN NN O
with NN NN O
an NN NN O
increase NN NN O
in NN NN O
volume NN NN O
of NN NN O
the NN NN O
hilus NN NN O
. NN NN O
   
The NN NN O
results NN NN O
provide NN NN O
new NN NN O
insight NN NN O
into NN NN O
the NN NN O
potential NN NN O
role NN NN O
of NN NN O
ectopic NN NN O
hilar NN NN O
granule NN NN O
cells NN NN O
in NN NN O
the NN NN O
pilocarpine NN NN O
model NN NN O
of NN NN O
temporal NN NN B-Disease
lobe NN NN I-Disease
epilepsy NN NN I-Disease
. NN NN O
   
A NN NN O
prospective NN NN O
, NN NN O
open NN NN O
- NN NN O
label NN NN O
trial NN NN O
of NN NN O
galantamine NN NN O
in NN NN O
autistic NN NN B-Disease
disorder NN NN I-Disease
. NN NN O
   
OBJECTIVE NN NN O
: NN NN O
Post NN NN O
- NN NN O
mortem NN NN O
studies NN NN O
have NN NN O
reported NN NN O
abnormalities NN NN O
of NN NN O
the NN NN O
cholinergic NN NN O
system NN NN O
in NN NN O
autism NN NN B-Disease
. NN NN O
   
The NN NN O
purpose NN NN O
of NN NN O
this NN NN O
study NN NN O
was NN NN O
to NN NN O
assess NN NN O
the NN NN O
use NN NN O
of NN NN O
galantamine NN NN O
, NN NN O
an NN NN O
acetylcholinesterase NN NN O
inhibitor NN NN O
and NN NN O
nicotinic NN NN O
receptor NN NN O
modulator NN NN O
, NN NN O
in NN NN O
the NN NN O
treatment NN NN O
of NN NN O
interfering NN NN O
behaviors NN NN O
in NN NN O
children NN NN O
with NN NN O
autism NN NN B-Disease
. NN NN O
   
METHODS NN NN O
: NN NN O
Thirteen NN NN O
medication NN NN O
- NN NN O
free NN NN O
children NN NN O
with NN NN O
autism NN NN B-Disease
( NN NN O
mean NN NN O
age NN NN O
, NN NN O
8 NN NN O
. NN NN O
8 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
3 NN NN O
. NN NN O
5 NN NN O
years NN NN O
) NN NN O
participated NN NN O
in NN NN O
a NN NN O
12 NN NN O
- NN NN O
week NN NN O
, NN NN O
open NN NN O
- NN NN O
label NN NN O
trial NN NN O
of NN NN O
galantamine NN NN O
. NN NN O
   
Patients NN NN O
were NN NN O
rated NN NN O
monthly NN NN O
by NN NN O
parents NN NN O
on NN NN O
the NN NN O
Aberrant NN NN O
Behavior NN NN O
Checklist NN NN O
( NN NN O
ABC NN NN O
) NN NN O
and NN NN O
the NN NN O
Conners NN NN O
' NN NN O
Parent NN NN O
Rating NN NN O
Scale NN NN O
- NN NN O
Revised NN NN O
, NN NN O
and NN NN O
by NN NN O
a NN NN O
physician NN NN O
using NN NN O
the NN NN O
Children NN NN O
' NN NN O
s NN NN O
Psychiatric NN NN O
Rating NN NN O
Scale NN NN O
and NN NN O
the NN NN O
Clinical NN NN O
Global NN NN O
Impressions NN NN O
scale NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
Patients NN NN O
showed NN NN O
a NN NN O
significant NN NN O
reduction NN NN O
in NN NN O
parent NN NN O
- NN NN O
rated NN NN O
irritability NN NN B-Disease
and NN NN O
social NN NN O
withdrawal NN NN O
on NN NN O
the NN NN O
ABC NN NN O
as NN NN O
well NN NN O
as NN NN O
significant NN NN O
improvements NN NN O
in NN NN O
emotional NN NN O
lability NN NN O
and NN NN O
inattention NN NN O
on NN NN O
the NN NN O
Conners NN NN O
' NN NN O
Parent NN NN O
Rating NN NN O
Scale NN NN O
- NN NN O
- NN NN O
Revised NN NN O
. NN NN O
   
Similarly NN NN O
, NN NN O
clinician NN NN O
ratings NN NN O
showed NN NN O
reductions NN NN O
in NN NN O
the NN NN O
anger NN NN O
subscale NN NN O
of NN NN O
the NN NN O
Children NN NN O
' NN NN O
s NN NN O
Psychiatric NN NN O
Rating NN NN O
Scale NN NN O
. NN NN O
   
Eight NN NN O
of NN NN O
13 NN NN O
participants NN NN O
were NN NN O
rated NN NN O
as NN NN O
responders NN NN O
on NN NN O
the NN NN O
basis NN NN O
of NN NN O
their NN NN O
improvement NN NN O
scores NN NN O
on NN NN O
the NN NN O
Clinical NN NN O
Global NN NN O
Impressions NN NN O
scale NN NN O
. NN NN O
   
Overall NN NN O
, NN NN O
galantamine NN NN O
was NN NN O
well NN NN O
- NN NN O
tolerated NN NN O
, NN NN O
with NN NN O
no NN NN O
significant NN NN O
adverse NN NN O
effects NN NN O
apart NN NN O
from NN NN O
headaches NN NN B-Disease
in NN NN O
one NN NN O
patient NN NN O
. NN NN O
   
CONCLUSION NN NN O
: NN NN O
In NN NN O
this NN NN O
open NN NN O
trial NN NN O
, NN NN O
galantamine NN NN O
was NN NN O
well NN NN O
- NN NN O
tolerated NN NN O
and NN NN O
appeared NN NN O
to NN NN O
be NN NN O
beneficial NN NN O
for NN NN O
the NN NN O
treatment NN NN O
of NN NN O
interfering NN NN O
behaviors NN NN O
in NN NN O
children NN NN O
with NN NN O
autism NN NN B-Disease
, NN NN O
particularly NN NN O
aggression NN NN B-Disease
, NN NN O
behavioral NN NN B-Disease
dyscontrol NN NN I-Disease
, NN NN O
and NN NN O
inattention NN NN B-Disease
. NN NN O
   
Further NN NN O
controlled NN NN O
trials NN NN O
are NN NN O
warranted NN NN O
. NN NN O
   
Randomized NN NN O
comparison NN NN O
of NN NN O
olanzapine NN NN O
versus NN NN O
risperidone NN NN O
for NN NN O
the NN NN O
treatment NN NN O
of NN NN O
first NN NN O
- NN NN O
episode NN NN O
schizophrenia NN NN B-Disease
: NN NN O
4 NN NN O
- NN NN O
month NN NN O
outcomes NN NN O
. NN NN O
   
OBJECTIVE NN NN O
: NN NN O
The NN NN O
authors NN NN O
compared NN NN O
4 NN NN O
- NN NN O
month NN NN O
treatment NN NN O
outcomes NN NN O
for NN NN O
olanzapine NN NN O
versus NN NN O
risperidone NN NN O
in NN NN O
patients NN NN O
with NN NN O
first NN NN O
- NN NN O
episode NN NN O
schizophrenia NN NN B-Disease
spectrum NN NN O
disorders NN NN O
. NN NN O
   
METHOD NN NN O
: NN NN O
One NN NN O
hundred NN NN O
twelve NN NN O
subjects NN NN O
( NN NN O
70 NN NN O
% NN NN O
male NN NN O
; NN NN O
mean NN NN O
age NN NN O
= NN NN O
23 NN NN O
. NN NN O
3 NN NN O
years NN NN O
[ NN NN O
SD NN NN O
= NN NN O
5 NN NN O
. NN NN O
1 NN NN O
] NN NN O
) NN NN O
with NN NN O
first NN NN O
- NN NN O
episode NN NN O
schizophrenia NN NN B-Disease
( NN NN O
75 NN NN O
% NN NN O
) NN NN O
, NN NN O
schizophreniform NN NN B-Disease
disorder NN NN I-Disease
( NN NN O
17 NN NN O
% NN NN O
) NN NN O
, NN NN O
or NN NN O
schizoaffective NN NN B-Disease
disorder NN NN I-Disease
( NN NN O
8 NN NN O
% NN NN O
) NN NN O
were NN NN O
randomly NN NN O
assigned NN NN O
to NN NN O
treatment NN NN O
with NN NN O
olanzapine NN NN O
( NN NN O
2 NN NN O
. NN NN O
5 NN NN O
- NN NN O
20 NN NN O
mg NN NN O
/ NN NN O
day NN NN O
) NN NN O
or NN NN O
risperidone NN NN O
( NN NN O
1 NN NN O
- NN NN O
6 NN NN O
mg NN NN O
/ NN NN O
day NN NN O
) NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
Response NN NN O
rates NN NN O
did NN NN O
not NN NN O
significantly NN NN O
differ NN NN O
between NN NN O
olanzapine NN NN O
( NN NN O
43 NN NN O
. NN NN O
7 NN NN O
% NN NN O
, NN NN O
95 NN NN O
% NN NN O
CI NN NN O
= NN NN O
28 NN NN O
. NN NN O
8 NN NN O
% NN NN O
- NN NN O
58 NN NN O
. NN NN O
6 NN NN O
% NN NN O
) NN NN O
and NN NN O
risperidone NN NN O
( NN NN O
54 NN NN O
. NN NN O
3 NN NN O
% NN NN O
, NN NN O
95 NN NN O
% NN NN O
CI NN NN O
= NN NN O
39 NN NN O
. NN NN O
9 NN NN O
% NN NN O
- NN NN O
68 NN NN O
. NN NN O
7 NN NN O
% NN NN O
) NN NN O
. NN NN O
   
Among NN NN O
those NN NN O
responding NN NN O
to NN NN O
treatment NN NN O
, NN NN O
more NN NN O
subjects NN NN O
in NN NN O
the NN NN O
olanzapine NN NN O
group NN NN O
( NN NN O
40 NN NN O
. NN NN O
9 NN NN O
% NN NN O
, NN NN O
95 NN NN O
% NN NN O
CI NN NN O
= NN NN O
16 NN NN O
. NN NN O
8 NN NN O
% NN NN O
- NN NN O
65 NN NN O
. NN NN O
0 NN NN O
% NN NN O
) NN NN O
than NN NN O
in NN NN O
the NN NN O
risperidone NN NN O
group NN NN O
( NN NN O
18 NN NN O
. NN NN O
9 NN NN O
% NN NN O
, NN NN O
95 NN NN O
% NN NN O
CI NN NN O
= NN NN O
0 NN NN O
% NN NN O
- NN NN O
39 NN NN O
. NN NN O
2 NN NN O
% NN NN O
) NN NN O
had NN NN O
subsequent NN NN O
ratings NN NN O
not NN NN O
meeting NN NN O
response NN NN O
criteria NN NN O
. NN NN O
   
Negative NN NN O
symptom NN NN O
outcomes NN NN O
and NN NN O
measures NN NN O
of NN NN O
parkinsonism NN NN B-Disease
and NN NN O
akathisia NN NN B-Disease
did NN NN O
not NN NN O
differ NN NN O
between NN NN O
medications NN NN O
. NN NN O
   
Extrapyramidal NN NN B-Disease
symptom NN NN I-Disease
severity NN NN O
scores NN NN O
were NN NN O
1 NN NN O
. NN NN O
4 NN NN O
( NN NN O
95 NN NN O
% NN NN O
CI NN NN O
= NN NN O
1 NN NN O
. NN NN O
2 NN NN O
- NN NN O
1 NN NN O
. NN NN O
6 NN NN O
) NN NN O
with NN NN O
risperidone NN NN O
and NN NN O
1 NN NN O
. NN NN O
2 NN NN O
( NN NN O
95 NN NN O
% NN NN O
CI NN NN O
= NN NN O
1 NN NN O
. NN NN O
0 NN NN O
- NN NN O
1 NN NN O
. NN NN O
4 NN NN O
) NN NN O
with NN NN O
olanzapine NN NN O
. NN NN O
   
Significantly NN NN O
more NN NN O
weight NN NN B-Disease
gain NN NN I-Disease
occurred NN NN O
with NN NN O
olanzapine NN NN O
than NN NN O
with NN NN O
risperidone NN NN O
: NN NN O
the NN NN O
increase NN NN O
in NN NN O
weight NN NN O
at NN NN O
4 NN NN O
months NN NN O
relative NN NN O
to NN NN O
baseline NN NN O
weight NN NN O
was NN NN O
17 NN NN O
. NN NN O
3 NN NN O
% NN NN O
( NN NN O
95 NN NN O
% NN NN O
CI NN NN O
= NN NN O
14 NN NN O
. NN NN O
2 NN NN O
% NN NN O
- NN NN O
20 NN NN O
. NN NN O
5 NN NN O
% NN NN O
) NN NN O
with NN NN O
olanzapine NN NN O
and NN NN O
11 NN NN O
. NN NN O
3 NN NN O
% NN NN O
( NN NN O
95 NN NN O
% NN NN O
CI NN NN O
= NN NN O
8 NN NN O
. NN NN O
4 NN NN O
% NN NN O
- NN NN O
14 NN NN O
. NN NN O
3 NN NN O
% NN NN O
) NN NN O
with NN NN O
risperidone NN NN O
. NN NN O
   
Body NN NN O
mass NN NN O
index NN NN O
at NN NN O
baseline NN NN O
and NN NN O
at NN NN O
4 NN NN O
months NN NN O
was NN NN O
24 NN NN O
. NN NN O
3 NN NN O
( NN NN O
95 NN NN O
% NN NN O
CI NN NN O
= NN NN O
22 NN NN O
. NN NN O
8 NN NN O
- NN NN O
25 NN NN O
. NN NN O
7 NN NN O
) NN NN O
versus NN NN O
28 NN NN O
. NN NN O
2 NN NN O
( NN NN O
95 NN NN O
% NN NN O
CI NN NN O
= NN NN O
26 NN NN O
. NN NN O
7 NN NN O
- NN NN O
29 NN NN O
. NN NN O
7 NN NN O
) NN NN O
with NN NN O
olanzapine NN NN O
and NN NN O
23 NN NN O
. NN NN O
9 NN NN O
( NN NN O
95 NN NN O
% NN NN O
CI NN NN O
= NN NN O
22 NN NN O
. NN NN O
5 NN NN O
- NN NN O
25 NN NN O
. NN NN O
3 NN NN O
) NN NN O
versus NN NN O
26 NN NN O
. NN NN O
7 NN NN O
( NN NN O
95 NN NN O
% NN NN O
CI NN NN O
= NN NN O
25 NN NN O
. NN NN O
2 NN NN O
- NN NN O
28 NN NN O
. NN NN O
2 NN NN O
) NN NN O
with NN NN O
risperidone NN NN O
. NN NN O
   
CONCLUSIONS NN NN O
: NN NN O
Clinical NN NN O
outcomes NN NN O
with NN NN O
risperidone NN NN O
were NN NN O
equal NN NN O
to NN NN O
those NN NN O
with NN NN O
olanzapine NN NN O
, NN NN O
and NN NN O
response NN NN O
may NN NN O
be NN NN O
more NN NN O
stable NN NN O
. NN NN O
   
Olanzapine NN NN O
may NN NN O
have NN NN O
an NN NN O
advantage NN NN O
for NN NN O
motor NN NN O
side NN NN O
effects NN NN O
. NN NN O
   
Both NN NN O
medications NN NN O
caused NN NN O
substantial NN NN O
rapid NN NN O
weight NN NN B-Disease
gain NN NN I-Disease
, NN NN O
but NN NN O
weight NN NN B-Disease
gain NN NN I-Disease
was NN NN O
greater NN NN O
with NN NN O
olanzapine NN NN O
. NN NN O
   
Early NN NN O
paracentral NN NN O
visual NN NN B-Disease
field NN NN I-Disease
loss NN NN I-Disease
in NN NN O
patients NN NN O
taking NN NN O
hydroxychloroquine NN NN O
. NN NN O
   
OBJECTIVE NN NN O
: NN NN O
To NN NN O
review NN NN O
the NN NN O
natural NN NN O
history NN NN O
and NN NN O
ocular NN NN O
and NN NN O
systemic NN NN O
adverse NN NN O
effects NN NN O
of NN NN O
patients NN NN O
taking NN NN O
hydroxychloroquine NN NN O
sulfate NN NN O
who NN NN O
attended NN NN O
an NN NN O
ophthalmic NN NN O
screening NN NN O
program NN NN O
. NN NN O
   
DESIGN NN NN O
: NN NN O
Retrospective NN NN O
study NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
Records NN NN O
of NN NN O
262 NN NN O
patients NN NN O
who NN NN O
were NN NN O
taking NN NN O
hydroxychloroquine NN NN O
and NN NN O
screened NN NN O
in NN NN O
the NN NN O
Department NN NN O
of NN NN O
Ophthalmology NN NN O
were NN NN O
reviewed NN NN O
. NN NN O
   
Of NN NN O
the NN NN O
262 NN NN O
patients NN NN O
, NN NN O
14 NN NN O
( NN NN O
18 NN NN O
% NN NN O
) NN NN O
of NN NN O
76 NN NN O
who NN NN O
had NN NN O
stopped NN NN O
treatment NN NN O
at NN NN O
the NN NN O
time NN NN O
of NN NN O
the NN NN O
study NN NN O
experienced NN NN O
documented NN NN O
adverse NN NN O
effects NN NN O
. NN NN O
   
Systemic NN NN O
adverse NN NN O
effects NN NN O
occurred NN NN O
in NN NN O
8 NN NN O
patients NN NN O
( NN NN O
10 NN NN O
. NN NN O
5 NN NN O
% NN NN O
) NN NN O
and NN NN O
ocular NN NN O
adverse NN NN O
effects NN NN O
, NN NN O
in NN NN O
5 NN NN O
( NN NN O
6 NN NN O
. NN NN O
5 NN NN O
% NN NN O
) NN NN O
. NN NN O
   
Thirty NN NN O
- NN NN O
five NN NN O
patients NN NN O
( NN NN O
13 NN NN O
. NN NN O
4 NN NN O
% NN NN O
) NN NN O
had NN NN O
visual NN NN B-Disease
field NN NN I-Disease
abnormalities NN NN I-Disease
, NN NN O
which NN NN O
were NN NN O
attributed NN NN O
to NN NN O
hydroxychloroquine NN NN O
treatment NN NN O
in NN NN O
4 NN NN O
patients NN NN O
( NN NN O
1 NN NN O
. NN NN O
5 NN NN O
% NN NN O
) NN NN O
. NN NN O
   
Three NN NN O
of NN NN O
the NN NN O
4 NN NN O
patients NN NN O
were NN NN O
taking NN NN O
less NN NN O
than NN NN O
6 NN NN O
. NN NN O
5 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
per NN NN O
day NN NN O
and NN NN O
all NN NN O
patients NN NN O
had NN NN O
normal NN NN O
renal NN NN O
and NN NN O
liver NN NN O
function NN NN O
test NN NN O
results NN NN O
. NN NN O
   
CONCLUSIONS NN NN O
: NN NN O
The NN NN O
current NN NN O
study NN NN O
used NN NN O
a NN NN O
protocol NN NN O
of NN NN O
visual NN NN O
acuity NN NN O
and NN NN O
color NN NN O
vision NN NN O
assessment NN NN O
, NN NN O
funduscopy NN NN O
, NN NN O
and NN NN O
Humphrey NN NN O
10 NN NN O
- NN NN O
2 NN NN O
visual NN NN O
field NN NN O
testing NN NN O
and NN NN O
shows NN NN O
that NN NN O
visual NN NN B-Disease
field NN NN I-Disease
defects NN NN I-Disease
appeared NN NN O
before NN NN O
any NN NN O
corresponding NN NN O
changes NN NN O
in NN NN O
any NN NN O
other NN NN O
tested NN NN O
clinical NN NN O
parameters NN NN O
; NN NN O
the NN NN O
defects NN NN O
were NN NN O
reproducible NN NN O
and NN NN O
the NN NN O
test NN NN O
parameters NN NN O
were NN NN O
reliable NN NN O
. NN NN O
   
Patients NN NN O
taking NN NN O
hydroxychloroquine NN NN O
can NN NN O
demonstrate NN NN O
a NN NN O
toxic NN NN O
reaction NN NN O
in NN NN O
the NN NN O
retina NN NN O
despite NN NN O
the NN NN O
absence NN NN O
of NN NN O
known NN NN O
risk NN NN O
factors NN NN O
. NN NN O
   
Screening NN NN O
, NN NN O
including NN NN O
Humphrey NN NN O
10 NN NN O
- NN NN O
2 NN NN O
visual NN NN O
field NN NN O
assessment NN NN O
, NN NN O
is NN NN O
recommended NN NN O
2 NN NN O
years NN NN O
after NN NN O
the NN NN O
initial NN NN O
baseline NN NN O
and NN NN O
yearly NN NN O
thereafter NN NN O
. NN NN O
   
Peri NN NN O
- NN NN O
operative NN NN O
atrioventricular NN NN B-Disease
block NN NN I-Disease
as NN NN O
a NN NN O
result NN NN O
of NN NN O
chemotherapy NN NN O
with NN NN O
epirubicin NN NN O
and NN NN O
paclitaxel NN NN O
. NN NN O
   
A NN NN O
47 NN NN O
- NN NN O
year NN NN O
- NN NN O
old NN NN O
woman NN NN O
presented NN NN O
for NN NN O
mastectomy NN NN O
and NN NN O
immediate NN NN O
latissimus NN NN O
dorsi NN NN O
flap NN NN O
reconstruction NN NN O
having NN NN O
been NN NN O
diagnosed NN NN O
with NN NN O
carcinoma NN NN B-Disease
of NN NN I-Disease
the NN NN I-Disease
breast NN NN I-Disease
6 NN NN O
months NN NN O
previously NN NN O
. NN NN O
   
In NN NN O
the NN NN O
preceding NN NN O
months NN NN O
she NN NN O
had NN NN O
received NN NN O
neo NN NN O
- NN NN O
adjuvant NN NN O
chemotherapy NN NN O
with NN NN O
epirubicin NN NN O
, NN NN O
paclitaxel NN NN O
( NN NN O
Taxol NN NN O
) NN NN O
and NN NN O
cyclophosphamide NN NN O
. NN NN O
   
This NN NN O
had NN NN O
been NN NN O
apparently NN NN O
uncomplicated NN NN O
and NN NN O
she NN NN O
had NN NN O
maintained NN NN O
a NN NN O
remarkably NN NN O
high NN NN O
level NN NN O
of NN NN O
physical NN NN O
activity NN NN O
. NN NN O
   
She NN NN O
was NN NN O
found NN NN O
to NN NN O
be NN NN O
bradycardic NN NN B-Disease
at NN NN O
pre NN NN O
- NN NN O
operative NN NN O
assessment NN NN O
but NN NN O
had NN NN O
no NN NN O
cardiac NN NN O
symptoms NN NN O
. NN NN O
   
Second NN NN O
degree NN NN O
Mobitz NN NN O
type NN NN O
II NN NN O
atrioventricular NN NN B-Disease
block NN NN I-Disease
was NN NN O
diagnosed NN NN O
on NN NN O
electrocardiogram NN NN O
, NN NN O
and NN NN O
temporary NN NN O
transvenous NN NN O
ventricular NN NN O
pacing NN NN O
instituted NN NN O
in NN NN O
the NN NN O
peri NN NN O
- NN NN O
operative NN NN O
period NN NN O
. NN NN O
   
We NN NN O
discuss NN NN O
how NN NN O
evidence NN NN O
- NN NN O
based NN NN O
guidelines NN NN O
would NN NN O
not NN NN O
have NN NN O
been NN NN O
helpful NN NN O
in NN NN O
this NN NN O
case NN NN O
, NN NN O
and NN NN O
how NN NN O
chemotherapy NN NN O
can NN NN O
exhibit NN NN O
substantial NN NN O
cardiotoxicity NN NN B-Disease
that NN NN O
may NN NN O
develop NN NN O
over NN NN O
many NN NN O
years NN NN O
. NN NN O
   
We NN NN O
suggest NN NN O
that NN NN O
patients NN NN O
who NN NN O
have NN NN O
received NN NN O
chemotherapy NN NN O
at NN NN O
any NN NN O
time NN NN O
should NN NN O
have NN NN O
a NN NN O
pre NN NN O
- NN NN O
operative NN NN O
electrocardiogram NN NN O
even NN NN O
if NN NN O
they NN NN O
are NN NN O
asymptomatic NN NN O
. NN NN O
   
Risks NN NN O
and NN NN O
benefits NN NN O
of NN NN O
COX NN NN O
- NN NN O
2 NN NN O
inhibitors NN NN O
vs NN NN O
non NN NN O
- NN NN O
selective NN NN O
NSAIDs NN NN O
: NN NN O
does NN NN O
their NN NN O
cardiovascular NN NN O
risk NN NN O
exceed NN NN O
their NN NN O
gastrointestinal NN NN O
benefit NN NN O
? NN NN O
   
A NN NN O
retrospective NN NN O
cohort NN NN O
study NN NN O
. NN NN O
   
OBJECTIVES NN NN O
: NN NN O
The NN NN O
risk NN NN O
of NN NN O
acute NN NN B-Disease
myocardial NN NN I-Disease
infarction NN NN I-Disease
( NN NN O
AMI NN NN B-Disease
) NN NN O
with NN NN O
COX NN NN O
- NN NN O
2 NN NN O
inhibitors NN NN O
may NN NN O
offset NN NN O
their NN NN O
gastrointestinal NN NN O
( NN NN O
GI NN NN O
) NN NN O
benefit NN NN O
compared NN NN O
with NN NN O
non NN NN O
- NN NN O
selective NN NN O
( NN NN O
NS NN NN O
) NN NN O
non NN NN O
- NN NN O
steroidal NN NN O
anti NN NN O
- NN NN O
inflammatory NN NN O
drugs NN NN O
( NN NN O
NSAIDs NN NN O
) NN NN O
. NN NN O
   
We NN NN O
aimed NN NN O
to NN NN O
compare NN NN O
the NN NN O
risks NN NN O
of NN NN O
hospitalization NN NN O
for NN NN O
AMI NN NN B-Disease
and NN NN O
GI NN NN B-Disease
bleeding NN NN I-Disease
among NN NN O
elderly NN NN O
patients NN NN O
using NN NN O
COX NN NN O
- NN NN O
2 NN NN O
inhibitors NN NN O
, NN NN O
NS NN NN O
- NN NN O
NSAIDs NN NN O
and NN NN O
acetaminophen NN NN O
. NN NN O
   
METHODS NN NN O
: NN NN O
We NN NN O
conducted NN NN O
a NN NN O
retrospective NN NN O
cohort NN NN O
study NN NN O
using NN NN O
administrative NN NN O
data NN NN O
of NN NN O
patients NN NN O
> NN NN O
or NN NN O
= NN NN O
65 NN NN O
years NN NN O
of NN NN O
age NN NN O
who NN NN O
filled NN NN O
a NN NN O
prescription NN NN O
for NN NN O
NSAID NN NN O
or NN NN O
acetaminophen NN NN O
during NN NN O
1999 NN NN O
- NN NN O
2002 NN NN O
. NN NN O
   
Outcomes NN NN O
were NN NN O
compared NN NN O
using NN NN O
Cox NN NN O
regression NN NN O
models NN NN O
with NN NN O
time NN NN O
- NN NN O
dependent NN NN O
exposures NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
Person NN NN O
- NN NN O
years NN NN O
of NN NN O
exposure NN NN O
among NN NN O
non NN NN O
- NN NN O
users NN NN O
of NN NN O
aspirin NN NN O
were NN NN O
: NN NN O
75 NN NN O
, NN NN O
761 NN NN O
to NN NN O
acetaminophen NN NN O
, NN NN O
42 NN NN O
, NN NN O
671 NN NN O
to NN NN O
rofecoxib NN NN O
65 NN NN O
, NN NN O
860 NN NN O
to NN NN O
celecoxib NN NN O
, NN NN O
and NN NN O
37 NN NN O
, NN NN O
495 NN NN O
to NN NN O
NS NN NN O
- NN NN O
NSAIDs NN NN O
. NN NN O
   
Among NN NN O
users NN NN O
of NN NN O
aspirin NN NN O
, NN NN O
they NN NN O
were NN NN O
: NN NN O
14 NN NN O
, NN NN O
671 NN NN O
to NN NN O
rofecoxib NN NN O
, NN NN O
22 NN NN O
, NN NN O
875 NN NN O
to NN NN O
celecoxib NN NN O
, NN NN O
9 NN NN O
, NN NN O
832 NN NN O
to NN NN O
NS NN NN O
- NN NN O
NSAIDs NN NN O
and NN NN O
38 NN NN O
, NN NN O
048 NN NN O
to NN NN O
acetaminophen NN NN O
. NN NN O
   
Among NN NN O
non NN NN O
- NN NN O
users NN NN O
of NN NN O
aspirin NN NN O
, NN NN O
the NN NN O
adjusted NN NN O
hazard NN NN O
ratios NN NN O
( NN NN O
95 NN NN O
% NN NN O
confidence NN NN O
interval NN NN O
) NN NN O
of NN NN O
hospitalization NN NN O
for NN NN O
AMI NN NN B-Disease
/ NN NN O
GI NN NN O
vs NN NN O
the NN NN O
acetaminophen NN NN O
( NN NN O
with NN NN O
no NN NN O
aspirin NN NN O
) NN NN O
group NN NN O
were NN NN O
: NN NN O
rofecoxib NN NN O
1 NN NN O
. NN NN O
27 NN NN O
( NN NN O
1 NN NN O
. NN NN O
13 NN NN O
, NN NN O
1 NN NN O
. NN NN O
42 NN NN O
) NN NN O
, NN NN O
celecoxib NN NN O
0 NN NN O
. NN NN O
93 NN NN O
( NN NN O
0 NN NN O
. NN NN O
83 NN NN O
, NN NN O
1 NN NN O
. NN NN O
03 NN NN O
) NN NN O
, NN NN O
naproxen NN NN O
1 NN NN O
. NN NN O
59 NN NN O
( NN NN O
1 NN NN O
. NN NN O
31 NN NN O
, NN NN O
1 NN NN O
. NN NN O
93 NN NN O
) NN NN O
, NN NN O
diclofenac NN NN O
1 NN NN O
. NN NN O
17 NN NN O
( NN NN O
0 NN NN O
. NN NN O
99 NN NN O
, NN NN O
1 NN NN O
. NN NN O
38 NN NN O
) NN NN O
and NN NN O
ibuprofen NN NN O
1 NN NN O
. NN NN O
05 NN NN O
( NN NN O
0 NN NN O
. NN NN O
74 NN NN O
, NN NN O
1 NN NN O
. NN NN O
51 NN NN O
) NN NN O
. NN NN O
   
Among NN NN O
users NN NN O
of NN NN O
aspirin NN NN O
, NN NN O
they NN NN O
were NN NN O
: NN NN O
rofecoxib NN NN O
1 NN NN O
. NN NN O
73 NN NN O
( NN NN O
1 NN NN O
. NN NN O
52 NN NN O
, NN NN O
1 NN NN O
. NN NN O
98 NN NN O
) NN NN O
, NN NN O
celecoxib NN NN O
1 NN NN O
. NN NN O
34 NN NN O
( NN NN O
1 NN NN O
. NN NN O
19 NN NN O
, NN NN O
1 NN NN O
. NN NN O
52 NN NN O
) NN NN O
, NN NN O
ibuprofen NN NN O
1 NN NN O
. NN NN O
51 NN NN O
( NN NN O
0 NN NN O
. NN NN O
95 NN NN O
, NN NN O
2 NN NN O
. NN NN O
41 NN NN O
) NN NN O
, NN NN O
diclofenac NN NN O
1 NN NN O
. NN NN O
69 NN NN O
( NN NN O
1 NN NN O
. NN NN O
35 NN NN O
, NN NN O
2 NN NN O
. NN NN O
10 NN NN O
) NN NN O
, NN NN O
naproxen NN NN O
1 NN NN O
. NN NN O
35 NN NN O
( NN NN O
0 NN NN O
. NN NN O
97 NN NN O
, NN NN O
1 NN NN O
. NN NN O
88 NN NN O
) NN NN O
and NN NN O
acetaminophen NN NN O
1 NN NN O
. NN NN O
29 NN NN O
( NN NN O
1 NN NN O
. NN NN O
17 NN NN O
, NN NN O
1 NN NN O
. NN NN O
42 NN NN O
) NN NN O
. NN NN O
   
CONCLUSION NN NN O
: NN NN O
Among NN NN O
non NN NN O
- NN NN O
users NN NN O
of NN NN O
aspirin NN NN O
, NN NN O
naproxen NN NN O
seemed NN NN O
to NN NN O
carry NN NN O
the NN NN O
highest NN NN O
risk NN NN O
for NN NN O
AMI NN NN B-Disease
/ NN NN O
GI NN NN B-Disease
bleeding NN NN I-Disease
. NN NN O
   
The NN NN O
AMI NN NN B-Disease
/ NN NN O
GI NN NN O
toxicity NN NN B-Disease
of NN NN O
celecoxib NN NN O
was NN NN O
similar NN NN O
to NN NN O
that NN NN O
of NN NN O
acetaminophen NN NN O
and NN NN O
seemed NN NN O
to NN NN O
be NN NN O
better NN NN O
than NN NN O
those NN NN O
of NN NN O
rofecoxib NN NN O
and NN NN O
NS NN NN O
- NN NN O
NSAIDs NN NN O
. NN NN O
   
Among NN NN O
users NN NN O
of NN NN O
aspirin NN NN O
, NN NN O
both NN NN O
celecoxib NN NN O
and NN NN O
naproxen NN NN O
seemed NN NN O
to NN NN O
be NN NN O
the NN NN O
least NN NN O
toxic NN NN O
. NN NN O
   
Quinine NN NN O
- NN NN O
induced NN NN O
arrhythmia NN NN B-Disease
in NN NN O
a NN NN O
patient NN NN O
with NN NN O
severe NN NN B-Disease
malaria NN NN I-Disease
. NN NN O
   
It NN NN O
was NN NN O
reported NN NN O
that NN NN O
there NN NN O
was NN NN O
a NN NN O
case NN NN O
of NN NN O
severe NN NN B-Disease
malaria NN NN I-Disease
patient NN NN O
with NN NN O
jaundice NN NN B-Disease
who NN NN O
presented NN NN O
with NN NN O
arrhythmia NN NN B-Disease
( NN NN O
premature NN NN B-Disease
ventricular NN NN I-Disease
contraction NN NN I-Disease
) NN NN O
while NN NN O
getting NN NN O
quinine NN NN O
infusion NN NN O
was NN NN O
reported NN NN O
. NN NN O
   
A NN NN O
man NN NN O
, NN NN O
25 NN NN O
years NN NN O
old NN NN O
, NN NN O
was NN NN O
admitted NN NN O
to NN NN O
hospital NN NN O
with NN NN O
high NN NN O
fever NN NN B-Disease
, NN NN O
chill NN NN B-Disease
, NN NN O
vomiting NN NN B-Disease
, NN NN O
jaundice NN NN B-Disease
. NN NN O
   
The NN NN O
patient NN NN O
was NN NN O
fully NN NN O
conscious NN NN O
, NN NN O
blood NN NN O
pressure NN NN O
120 NN NN O
/ NN NN O
80 NN NN O
mmHg NN NN O
, NN NN O
pulse NN NN O
rate NN NN O
100 NN NN O
x NN NN O
/ NN NN O
minute NN NN O
, NN NN O
regular NN NN O
. NN NN O
   
On NN NN O
admission NN NN O
, NN NN O
laboratory NN NN O
examination NN NN O
showed NN NN O
Plasmodium NN NN O
falciparum NN NN O
( NN NN O
+ NN NN O
+ NN NN O
+ NN NN O
+ NN NN O
) NN NN O
, NN NN O
total NN NN O
bilirubin NN NN O
8 NN NN O
. NN NN O
25 NN NN O
mg NN NN O
/ NN NN O
dL NN NN O
, NN NN O
conjugated NN NN O
bilirubin NN NN O
4 NN NN O
. NN NN O
36 NN NN O
mg NN NN O
/ NN NN O
dL NN NN O
, NN NN O
unconjugated NN NN O
bilirubin NN NN O
3 NN NN O
. NN NN O
89 NN NN O
mg NN NN O
/ NN NN O
dL NN NN O
, NN NN O
potassium NN NN O
3 NN NN O
. NN NN O
52 NN NN O
meq NN NN O
/ NN NN O
L NN NN O
Patient NN NN O
was NN NN O
diagnosed NN NN O
as NN NN O
severe NN NN B-Disease
malaria NN NN I-Disease
with NN NN O
jaundice NN NN B-Disease
and NN NN O
got NN NN O
quinine NN NN O
infusion NN NN O
in NN NN O
dextrose NN NN O
5 NN NN O
% NN NN O
500 NN NN O
mg NN NN O
/ NN NN O
8 NN NN O
hour NN NN O
. NN NN O
   
On NN NN O
the NN NN O
second NN NN O
day NN NN O
the NN NN O
patient NN NN O
had NN NN O
vomitus NN NN B-Disease
, NN NN O
diarrhea NN NN B-Disease
, NN NN O
tinnitus NN NN B-Disease
, NN NN O
loss NN NN B-Disease
of NN NN I-Disease
hearing NN NN I-Disease
. NN NN O
   
After NN NN O
30 NN NN O
hours NN NN O
of NN NN O
quinine NN NN O
infusion NN NN O
the NN NN O
patient NN NN O
felt NN NN O
palpitation NN NN B-Disease
and NN NN O
electrocardiography NN NN O
( NN NN O
ECG NN NN O
) NN NN O
recording NN NN O
showed NN NN O
premature NN NN B-Disease
ventricular NN NN I-Disease
contraction NN NN I-Disease
( NN NN O
PVC NN NN B-Disease
) NN NN O
> NN NN O
5 NN NN O
x NN NN O
/ NN NN O
minute NN NN O
, NN NN O
trigemini NN NN O
, NN NN O
constant NN NN O
type NN NN O
- NN NN O
- NN NN O
sinoatrial NN NN B-Disease
block NN NN I-Disease
, NN NN O
positive NN NN O
U NN NN O
wave NN NN O
. NN NN O
   
He NN NN O
was NN NN O
treated NN NN O
with NN NN O
lidocaine NN NN O
50 NN NN O
mg NN NN O
intravenously NN NN O
followed NN NN O
by NN NN O
infusion NN NN O
1500 NN NN O
mg NN NN O
in NN NN O
dextrose NN NN O
5 NN NN O
% NN NN O
/ NN NN O
24 NN NN O
hour NN NN O
and NN NN O
potassium NN NN O
aspartate NN NN O
tablet NN NN O
. NN NN O
   
Quinine NN NN O
infusion NN NN O
was NN NN O
discontinued NN NN O
and NN NN O
changed NN NN O
with NN NN O
sulfate NN NN O
quinine NN NN O
tablets NN NN O
. NN NN O
   
Three NN NN O
hours NN NN O
later NN NN O
the NN NN O
patient NN NN O
felt NN NN O
better NN NN O
, NN NN O
the NN NN O
frequency NN NN O
of NN NN O
PVC NN NN B-Disease
reduced NN NN O
to NN NN O
4 NN NN O
- NN NN O
5 NN NN O
x NN NN O
/ NN NN O
minute NN NN O
and NN NN O
on NN NN O
the NN NN O
third NN NN O
day NN NN O
ECG NN NN O
was NN NN O
normal NN NN O
, NN NN O
potassium NN NN O
level NN NN O
was NN NN O
3 NN NN O
. NN NN O
34 NN NN O
meq NN NN O
/ NN NN O
L NN NN O
. NN NN O
   
He NN NN O
was NN NN O
discharged NN NN O
on NN NN O
7th NN NN O
day NN NN O
in NN NN O
good NN NN O
condition NN NN O
. NN NN O
   
Quinine NN NN O
, NN NN O
like NN NN O
quinidine NN NN O
, NN NN O
is NN NN O
a NN NN O
chincona NN NN O
alkaloid NN NN O
that NN NN O
has NN NN O
anti NN NN O
- NN NN O
arrhythmic NN NN B-Disease
property NN NN O
, NN NN O
although NN NN O
it NN NN O
also NN NN O
pro NN NN O
- NN NN O
arrhythmic NN NN B-Disease
that NN NN O
can NN NN O
cause NN NN O
various NN NN O
arrhythmias NN NN B-Disease
, NN NN O
including NN NN O
severe NN NN O
arrhythmia NN NN B-Disease
such NN NN O
as NN NN O
multiple NN NN O
PVC NN NN B-Disease
. NN NN O
   
Administration NN NN O
of NN NN O
parenteral NN NN O
quinine NN NN O
must NN NN O
be NN NN O
done NN NN O
carefully NN NN O
and NN NN O
with NN NN O
good NN NN O
observation NN NN O
because NN NN O
of NN NN O
its NN NN O
pro NN NN O
- NN NN O
arrhythmic NN NN B-Disease
effect NN NN O
, NN NN O
especially NN NN O
in NN NN O
older NN NN O
patients NN NN O
who NN NN O
have NN NN O
heart NN NN B-Disease
diseases NN NN I-Disease
or NN NN O
patients NN NN O
with NN NN O
electrolyte NN NN B-Disease
disorder NN NN I-Disease
( NN NN O
hypokalemia NN NN B-Disease
) NN NN O
which NN NN O
frequently NN NN O
occurs NN NN O
due NN NN O
to NN NN O
vomiting NN NN B-Disease
and NN NN O
or NN NN O
diarrhea NN NN B-Disease
in NN NN O
malaria NN NN B-Disease
cases NN NN O
. NN NN O
   
Penicillamine NN NN O
- NN NN O
related NN NN O
lichenoid NN NN B-Disease
dermatitis NN NN I-Disease
and NN NN O
utility NN NN O
of NN NN O
zinc NN NN O
acetate NN NN O
in NN NN O
a NN NN O
Wilson NN NN B-Disease
disease NN NN I-Disease
patient NN NN O
with NN NN O
hepatic NN NN O
presentation NN NN O
, NN NN O
anxiety NN NN B-Disease
and NN NN O
SPECT NN NN O
abnormalities NN NN O
. NN NN O
   
Wilson NN NN B-Disease
' NN NN I-Disease
s NN NN I-Disease
disease NN NN I-Disease
is NN NN O
an NN NN O
autosomal NN NN O
recessive NN NN O
disorder NN NN O
of NN NN O
hepatic NN NN O
copper NN NN O
metabolism NN NN O
with NN NN O
consequent NN NN O
copper NN NN O
accumulation NN NN O
and NN NN O
toxicity NN NN B-Disease
in NN NN O
many NN NN O
tissues NN NN O
and NN NN O
consequent NN NN O
hepatic NN NN B-Disease
, NN NN I-Disease
neurologic NN NN I-Disease
and NN NN I-Disease
psychiatric NN NN I-Disease
disorders NN NN I-Disease
. NN NN O
   
We NN NN O
report NN NN O
a NN NN O
case NN NN O
of NN NN O
Wilson NN NN B-Disease
' NN NN I-Disease
s NN NN I-Disease
disease NN NN I-Disease
with NN NN O
chronic NN NN B-Disease
liver NN NN I-Disease
disease NN NN I-Disease
; NN NN O
moreover NN NN O
, NN NN O
in NN NN O
our NN NN O
patient NN NN O
, NN NN O
presenting NN NN O
also NN NN O
with NN NN O
high NN NN O
levels NN NN O
of NN NN O
state NN NN O
anxiety NN NN B-Disease
without NN NN O
depression NN NN B-Disease
, NN NN O
99mTc NN NN O
- NN NN O
ECD NN NN O
- NN NN O
SPECT NN NN O
showed NN NN O
cortical NN NN O
hypoperfusion NN NN O
in NN NN O
frontal NN NN O
lobes NN NN O
, NN NN O
more NN NN O
marked NN NN O
on NN NN O
the NN NN O
left NN NN O
frontal NN NN O
lobe NN NN O
. NN NN O
   
During NN NN O
the NN NN O
follow NN NN O
- NN NN O
up NN NN O
of NN NN O
our NN NN O
patient NN NN O
, NN NN O
penicillamine NN NN O
was NN NN O
interrupted NN NN O
after NN NN O
the NN NN O
appearance NN NN O
of NN NN O
a NN NN O
lichenoid NN NN B-Disease
dermatitis NN NN I-Disease
, NN NN O
and NN NN O
zinc NN NN O
acetate NN NN O
permitted NN NN O
to NN NN O
continue NN NN O
the NN NN O
successful NN NN O
treatment NN NN O
of NN NN O
the NN NN O
patient NN NN O
without NN NN O
side NN NN O
- NN NN O
effects NN NN O
. NN NN O
   
In NN NN O
our NN NN O
case NN NN O
the NN NN O
therapy NN NN O
with NN NN O
zinc NN NN O
acetate NN NN O
represented NN NN O
an NN NN O
effective NN NN O
treatment NN NN O
for NN NN O
a NN NN O
Wilson NN NN B-Disease
' NN NN I-Disease
s NN NN I-Disease
disease NN NN I-Disease
patient NN NN O
in NN NN O
which NN NN O
penicillamine NN NN O
- NN NN O
related NN NN O
side NN NN O
effects NN NN O
appeared NN NN O
. NN NN O
   
The NN NN O
safety NN NN O
of NN NN O
the NN NN O
zinc NN NN O
acetate NN NN O
allowed NN NN O
us NN NN O
to NN NN O
avoid NN NN O
other NN NN O
potentially NN NN O
toxic NN NN O
chelating NN NN O
drugs NN NN O
; NN NN O
this NN NN O
observation NN NN O
is NN NN O
in NN NN O
line NN NN O
with NN NN O
the NN NN O
growing NN NN O
evidence NN NN O
on NN NN O
the NN NN O
efficacy NN NN O
of NN NN O
the NN NN O
drug NN NN O
in NN NN O
the NN NN O
treatment NN NN O
of NN NN O
Wilson NN NN B-Disease
' NN NN I-Disease
s NN NN I-Disease
disease NN NN I-Disease
. NN NN O
   
Since NN NN O
most NN NN O
of NN NN O
Wilson NN NN B-Disease
' NN NN I-Disease
s NN NN I-Disease
disease NN NN I-Disease
penicillamine NN NN O
- NN NN O
treated NN NN O
patients NN NN O
do NN NN O
not NN NN O
seem NN NN O
to NN NN O
develop NN NN O
this NN NN O
skin NN NN B-Disease
lesion NN NN I-Disease
, NN NN O
it NN NN O
could NN NN O
be NN NN O
conceivable NN NN O
that NN NN O
a NN NN O
specific NN NN O
genetic NN NN O
factor NN NN O
is NN NN O
involved NN NN O
in NN NN O
drug NN NN O
response NN NN O
. NN NN O
   
Further NN NN O
studies NN NN O
are NN NN O
needed NN NN O
for NN NN O
a NN NN O
better NN NN O
clarification NN NN O
of NN NN O
Wilson NN NN B-Disease
' NN NN I-Disease
s NN NN I-Disease
disease NN NN I-Disease
therapy NN NN O
, NN NN O
and NN NN O
in NN NN O
particular NN NN O
to NN NN O
differentiate NN NN O
specific NN NN O
therapies NN NN O
for NN NN O
different NN NN O
Wilson NN NN B-Disease
' NN NN I-Disease
s NN NN I-Disease
disease NN NN I-Disease
phenotypes NN NN O
. NN NN O
   
A NN NN O
dramatic NN NN O
drop NN NN B-Disease
in NN NN I-Disease
blood NN NN I-Disease
pressure NN NN I-Disease
following NN NN O
prehospital NN NN O
GTN NN NN O
administration NN NN O
. NN NN O
   
A NN NN O
male NN NN O
in NN NN O
his NN NN O
sixties NN NN O
with NN NN O
no NN NN O
history NN NN O
of NN NN O
cardiac NN NN O
chest NN NN B-Disease
pain NN NN I-Disease
awoke NN NN O
with NN NN O
chest NN NN B-Disease
pain NN NN I-Disease
following NN NN O
an NN NN O
afternoon NN NN O
sleep NN NN O
. NN NN O
   
The NN NN O
patient NN NN O
did NN NN O
not NN NN O
self NN NN O
medicate NN NN O
. NN NN O
   
The NN NN O
patient NN NN O
' NN NN O
s NN NN O
observations NN NN O
were NN NN O
within NN NN O
normal NN NN O
limits NN NN O
, NN NN O
he NN NN O
was NN NN O
administered NN NN O
oxygen NN NN O
via NN NN O
a NN NN O
face NN NN O
mask NN NN O
and NN NN O
glyceryl NN NN O
trinitrate NN NN O
( NN NN O
GTN NN NN O
) NN NN O
. NN NN O
   
Several NN NN O
minutes NN NN O
after NN NN O
the NN NN O
GTN NN NN O
the NN NN O
patient NN NN O
experienced NN NN O
a NN NN O
sudden NN NN O
drop NN NN B-Disease
in NN NN I-Disease
blood NN NN I-Disease
pressure NN NN I-Disease
and NN NN O
heart NN NN O
rate NN NN O
, NN NN O
this NN NN O
was NN NN O
rectified NN NN O
by NN NN O
atropine NN NN O
sulphate NN NN O
and NN NN O
a NN NN O
fluid NN NN O
challenge NN NN O
. NN NN O
   
There NN NN O
was NN NN O
no NN NN O
further NN NN O
deterioration NN NN O
in NN NN O
the NN NN O
patient NN NN O
' NN NN O
s NN NN O
condition NN NN O
during NN NN O
transport NN NN O
to NN NN O
hospital NN NN O
. NN NN O
   
There NN NN O
are NN NN O
very NN NN O
few NN NN O
documented NN NN O
case NN NN O
like NN NN O
this NN NN O
in NN NN O
the NN NN O
prehospital NN NN O
scientific NN NN O
literature NN NN O
. NN NN O
   
The NN NN O
cause NN NN O
appears NN NN O
to NN NN O
be NN NN O
the NN NN O
Bezold NN NN O
- NN NN O
Jarish NN NN O
reflex NN NN O
, NN NN O
stimulation NN NN O
of NN NN O
the NN NN O
ventricular NN NN O
walls NN NN O
which NN NN O
in NN NN O
turn NN NN O
decreases NN NN O
sympathetic NN NN O
outflow NN NN O
from NN NN O
the NN NN O
vasomotor NN NN O
centre NN NN O
. NN NN O
   
Prehospital NN NN O
care NN NN O
providers NN NN O
who NN NN O
are NN NN O
managing NN NN O
any NN NN O
patient NN NN O
with NN NN O
a NN NN O
syncopal NN NN B-Disease
episode NN NN I-Disease
that NN NN O
fails NN NN O
to NN NN O
recover NN NN O
within NN NN O
a NN NN O
reasonable NN NN O
time NN NN O
frame NN NN O
should NN NN O
consider NN NN O
the NN NN O
Bezold NN NN O
- NN NN O
Jarisch NN NN O
reflex NN NN O
as NN NN O
the NN NN O
cause NN NN O
and NN NN O
manage NN NN O
the NN NN O
patient NN NN O
accordingly NN NN O
. NN NN O
   
Chronic NN NN O
lesion NN NN O
of NN NN O
rostral NN NN O
ventrolateral NN NN O
medulla NN NN O
in NN NN O
spontaneously NN NN O
hypertensive NN NN B-Disease
rats NN NN O
. NN NN O
   
We NN NN O
studied NN NN O
the NN NN O
effects NN NN O
of NN NN O
chronic NN NN O
selective NN NN O
neuronal NN NN O
lesion NN NN O
of NN NN O
rostral NN NN O
ventrolateral NN NN O
medulla NN NN O
on NN NN O
mean NN NN O
arterial NN NN O
pressure NN NN O
, NN NN O
heart NN NN O
rate NN NN O
, NN NN O
and NN NN O
neurogenic NN NN O
tone NN NN O
in NN NN O
conscious NN NN O
, NN NN O
unrestrained NN NN O
spontaneously NN NN O
hypertensive NN NN B-Disease
rats NN NN O
. NN NN O
   
The NN NN O
lesions NN NN O
were NN NN O
placed NN NN O
via NN NN O
bilateral NN NN O
microinjections NN NN O
of NN NN O
30 NN NN O
nmol NN NN O
/ NN NN O
200 NN NN O
nl NN NN O
N NN NN O
- NN NN O
methyl NN NN O
- NN NN O
D NN NN O
- NN NN O
aspartic NN NN O
acid NN NN O
. NN NN O
   
The NN NN O
restimulation NN NN O
of NN NN O
this NN NN O
area NN NN O
with NN NN O
N NN NN O
- NN NN O
methyl NN NN O
- NN NN O
D NN NN O
- NN NN O
aspartic NN NN O
acid NN NN O
15 NN NN O
days NN NN O
postlesion NN NN O
failed NN NN O
to NN NN O
produce NN NN O
a NN NN O
pressor NN NN O
response NN NN O
. NN NN O
   
One NN NN O
day NN NN O
postlesion NN NN O
, NN NN O
the NN NN O
resting NN NN O
mean NN NN O
arterial NN NN O
pressure NN NN O
was NN NN O
significantly NN NN O
decreased NN NN O
in NN NN O
lesioned NN NN O
rats NN NN O
when NN NN O
compared NN NN O
with NN NN O
sham NN NN O
rats NN NN O
( NN NN O
100 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
7 NN NN O
versus NN NN O
173 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
4 NN NN O
mm NN NN O
Hg NN NN O
, NN NN O
p NN NN O
less NN NN O
than NN NN O
0 NN NN O
. NN NN O
05 NN NN O
) NN NN O
. NN NN O
   
Fifteen NN NN O
days NN NN O
later NN NN O
, NN NN O
the NN NN O
lesioned NN NN O
group NN NN O
still NN NN O
showed NN NN O
values NN NN O
significantly NN NN O
lower NN NN O
than NN NN O
the NN NN O
sham NN NN O
group NN NN O
( NN NN O
150 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
6 NN NN O
versus NN NN O
167 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
5 NN NN O
mm NN NN O
Hg NN NN O
, NN NN O
p NN NN O
less NN NN O
than NN NN O
0 NN NN O
. NN NN O
05 NN NN O
) NN NN O
. NN NN O
   
No NN NN O
significant NN NN O
heart NN NN O
rate NN NN O
differences NN NN O
were NN NN O
observed NN NN O
between NN NN O
the NN NN O
sham NN NN O
and NN NN O
lesioned NN NN O
groups NN NN O
. NN NN O
   
The NN NN O
ganglionic NN NN O
blocker NN NN O
trimethaphan NN NN O
( NN NN O
5 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
i NN NN O
. NN NN O
v NN NN O
. NN NN O
) NN NN O
caused NN NN O
similar NN NN O
reductions NN NN O
in NN NN O
mean NN NN O
arterial NN NN O
pressure NN NN O
in NN NN O
both NN NN O
lesioned NN NN O
and NN NN O
sham NN NN O
groups NN NN O
. NN NN O
   
The NN NN O
trimethaphan NN NN O
- NN NN O
induced NN NN O
hypotension NN NN B-Disease
was NN NN O
accompanied NN NN O
by NN NN O
a NN NN O
significant NN NN O
bradycardia NN NN B-Disease
in NN NN O
lesioned NN NN O
rats NN NN O
( NN NN O
- NN NN O
32 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
13 NN NN O
beats NN NN O
per NN NN O
minute NN NN O
) NN NN O
but NN NN O
a NN NN O
tachycardia NN NN B-Disease
in NN NN O
sham NN NN O
rats NN NN O
( NN NN O
+ NN NN O
33 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
12 NN NN O
beats NN NN O
per NN NN O
minute NN NN O
) NN NN O
1 NN NN O
day NN NN O
postlesion NN NN O
. NN NN O
   
Therefore NN NN O
, NN NN O
rostral NN NN O
ventrolateral NN NN O
medulla NN NN O
neurons NN NN O
appear NN NN O
to NN NN O
play NN NN O
a NN NN O
significant NN NN O
role NN NN O
in NN NN O
maintaining NN NN O
hypertension NN NN B-Disease
in NN NN O
conscious NN NN O
spontaneously NN NN O
hypertensive NN NN B-Disease
rats NN NN O
. NN NN O
   
Spinal NN NN O
or NN NN O
suprabulbar NN NN O
structures NN NN O
could NN NN O
be NN NN O
responsible NN NN O
for NN NN O
the NN NN O
gradual NN NN O
recovery NN NN O
of NN NN O
the NN NN O
hypertension NN NN B-Disease
in NN NN O
the NN NN O
lesioned NN NN O
rats NN NN O
. NN NN O
   
Acute NN NN B-Disease
encephalopathy NN NN I-Disease
and NN NN O
cerebral NN NN B-Disease
vasospasm NN NN I-Disease
after NN NN O
multiagent NN NN O
chemotherapy NN NN O
including NN NN O
PEG NN NN O
- NN NN O
asparaginase NN NN O
and NN NN O
intrathecal NN NN O
cytarabine NN NN O
for NN NN O
the NN NN O
treatment NN NN O
of NN NN O
acute NN NN B-Disease
lymphoblastic NN NN I-Disease
leukemia NN NN I-Disease
. NN NN O
   
A NN NN O
7 NN NN O
- NN NN O
year NN NN O
- NN NN O
old NN NN O
girl NN NN O
with NN NN O
an NN NN O
unusual NN NN O
reaction NN NN O
to NN NN O
induction NN NN O
chemotherapy NN NN O
for NN NN O
precursor NN NN O
B NN NN O
- NN NN O
cell NN NN O
acute NN NN B-Disease
lymphoblastic NN NN I-Disease
leukemia NN NN I-Disease
( NN NN O
ALL NN NN B-Disease
) NN NN O
is NN NN O
described NN NN O
. NN NN O
   
The NN NN O
patient NN NN O
developed NN NN O
acute NN NN B-Disease
encephalopathy NN NN I-Disease
evidenced NN NN O
by NN NN O
behavioral NN NN O
changes NN NN O
, NN NN O
aphasia NN NN B-Disease
, NN NN O
incontinence NN NN B-Disease
, NN NN O
visual NN NN B-Disease
hallucinations NN NN I-Disease
, NN NN O
and NN NN O
right NN NN O
- NN NN O
sided NN NN O
weakness NN NN B-Disease
with NN NN O
diffuse NN NN O
cerebral NN NN B-Disease
vasospasm NN NN I-Disease
on NN NN O
magnetic NN NN O
resonance NN NN O
angiography NN NN O
after NN NN O
the NN NN O
administration NN NN O
of NN NN O
intrathecal NN NN O
cytarabine NN NN O
. NN NN O
   
Vincristine NN NN O
, NN NN O
dexamethasone NN NN O
, NN NN O
and NN NN O
polyethylene NN NN O
glycol NN NN O
- NN NN O
asparaginase NN NN O
were NN NN O
also NN NN O
administered NN NN O
before NN NN O
the NN NN O
episode NN NN O
as NN NN O
part NN NN O
of NN NN O
induction NN NN O
therapy NN NN O
. NN NN O
   
Neurologic NN NN O
status NN NN O
returned NN NN O
to NN NN O
baseline NN NN O
within NN NN O
10 NN NN O
days NN NN O
of NN NN O
the NN NN O
acute NN NN O
event NN NN O
, NN NN O
and NN NN O
magnetic NN NN O
resonance NN NN O
angiography NN NN O
findings NN NN O
returned NN NN O
to NN NN O
normal NN NN O
4 NN NN O
months NN NN O
later NN NN O
. NN NN O
   
Comparison NN NN O
of NN NN O
valsartan NN NN O
/ NN NN O
hydrochlorothiazide NN NN O
combination NN NN O
therapy NN NN O
at NN NN O
doses NN NN O
up NN NN O
to NN NN O
320 NN NN O
/ NN NN O
25 NN NN O
mg NN NN O
versus NN NN O
monotherapy NN NN O
: NN NN O
a NN NN O
double NN NN O
- NN NN O
blind NN NN O
, NN NN O
placebo NN NN O
- NN NN O
controlled NN NN O
study NN NN O
followed NN NN O
by NN NN O
long NN NN O
- NN NN O
term NN NN O
combination NN NN O
therapy NN NN O
in NN NN O
hypertensive NN NN B-Disease
adults NN NN O
. NN NN O
   
BACKGROUND NN NN O
: NN NN O
One NN NN O
third NN NN O
of NN NN O
patients NN NN O
treated NN NN O
for NN NN O
hypertension NN NN B-Disease
attain NN NN O
adequate NN NN O
blood NN NN O
pressure NN NN O
( NN NN O
BP NN NN O
) NN NN O
control NN NN O
, NN NN O
and NN NN O
multidrug NN NN O
regimens NN NN O
are NN NN O
often NN NN O
required NN NN O
. NN NN O
   
Given NN NN O
the NN NN O
lifelong NN NN O
nature NN NN O
of NN NN O
hypertension NN NN B-Disease
, NN NN O
there NN NN O
is NN NN O
a NN NN O
need NN NN O
to NN NN O
evaluate NN NN O
the NN NN O
long NN NN O
- NN NN O
term NN NN O
efficacy NN NN O
and NN NN O
tolerability NN NN O
of NN NN O
higher NN NN O
doses NN NN O
of NN NN O
combination NN NN O
anti NN NN O
- NN NN O
hypertensive NN NN B-Disease
therapies NN NN O
. NN NN O
   
OBJECTIVE NN NN O
: NN NN O
This NN NN O
study NN NN O
investigated NN NN O
the NN NN O
efficacy NN NN O
and NN NN O
tolerability NN NN O
of NN NN O
valsartan NN NN O
( NN NN O
VAL NN NN O
) NN NN O
or NN NN O
hydrochlorothiazide NN NN O
( NN NN O
HCTZ NN NN O
) NN NN O
- NN NN O
monotherapy NN NN O
and NN NN O
higher NN NN O
- NN NN O
dose NN NN O
combinations NN NN O
in NN NN O
patients NN NN O
with NN NN O
essential NN NN B-Disease
hypertension NN NN I-Disease
. NN NN O
   
METHODS NN NN O
: NN NN O
The NN NN O
first NN NN O
part NN NN O
of NN NN O
this NN NN O
study NN NN O
was NN NN O
an NN NN O
8 NN NN O
- NN NN O
week NN NN O
, NN NN O
multicenter NN NN O
, NN NN O
randomized NN NN O
, NN NN O
double NN NN O
- NN NN O
blind NN NN O
, NN NN O
placebo NN NN O
controlled NN NN O
, NN NN O
parallel NN NN O
- NN NN O
group NN NN O
trial NN NN O
. NN NN O
   
Patients NN NN O
with NN NN O
essential NN NN B-Disease
hypertension NN NN I-Disease
( NN NN O
mean NN NN O
sitting NN NN O
diastolic NN NN O
BP NN NN O
[ NN NN O
MSDBP NN NN O
] NN NN O
, NN NN O
> NN NN O
or NN NN O
= NN NN O
95 NN NN O
mm NN NN O
Hg NN NN O
and NN NN O
< NN NN O
110 NN NN O
mm NN NN O
Hg NN NN O
) NN NN O
were NN NN O
randomized NN NN O
to NN NN O
1 NN NN O
of NN NN O
8 NN NN O
treatment NN NN O
groups NN NN O
: NN NN O
VAL NN NN O
160 NN NN O
or NN NN O
320 NN NN O
mg NN NN O
; NN NN O
HCTZ NN NN O
12 NN NN O
. NN NN O
5 NN NN O
or NN NN O
25 NN NN O
mg NN NN O
; NN NN O
VAL NN NN O
/ NN NN O
HCTZ NN NN O
160 NN NN O
/ NN NN O
12 NN NN O
. NN NN O
5 NN NN O
, NN NN O
320 NN NN O
/ NN NN O
12 NN NN O
. NN NN O
5 NN NN O
, NN NN O
or NN NN O
320 NN NN O
/ NN NN O
25 NN NN O
mg NN NN O
; NN NN O
or NN NN O
placebo NN NN O
. NN NN O
   
Mean NN NN O
changes NN NN O
in NN NN O
MSDBP NN NN O
and NN NN O
mean NN NN O
sitting NN NN O
systolic NN NN O
BP NN NN O
( NN NN O
MSSBP NN NN O
) NN NN O
were NN NN O
analyzed NN NN O
at NN NN O
the NN NN O
8 NN NN O
- NN NN O
week NN NN O
core NN NN O
study NN NN O
end NN NN O
point NN NN O
. NN NN O
   
VAL NN NN O
/ NN NN O
HCTZ NN NN O
320 NN NN O
/ NN NN O
12 NN NN O
. NN NN O
5 NN NN O
and NN NN O
320 NN NN O
/ NN NN O
25 NN NN O
mg NN NN O
were NN NN O
further NN NN O
investigated NN NN O
in NN NN O
a NN NN O
54 NN NN O
- NN NN O
week NN NN O
, NN NN O
open NN NN O
- NN NN O
label NN NN O
extension NN NN O
. NN NN O
   
Response NN NN O
was NN NN O
defined NN NN O
as NN NN O
MSDBP NN NN O
< NN NN O
90 NN NN O
mm NN NN O
Hg NN NN O
or NN NN O
a NN NN O
> NN NN O
or NN NN O
= NN NN O
10 NN NN O
mm NN NN O
Hg NN NN O
decrease NN NN O
compared NN NN O
to NN NN O
baseline NN NN O
. NN NN O
   
Control NN NN O
was NN NN O
defined NN NN O
as NN NN O
MSDBP NN NN O
< NN NN O
90 NN NN O
mm NN NN O
Hg NN NN O
compared NN NN O
with NN NN O
baseline NN NN O
. NN NN O
   
Tolerability NN NN O
was NN NN O
assessed NN NN O
by NN NN O
monitoring NN NN O
adverse NN NN O
events NN NN O
at NN NN O
randomization NN NN O
and NN NN O
all NN NN O
subsequent NN NN O
study NN NN O
visits NN NN O
and NN NN O
regular NN NN O
evaluation NN NN O
of NN NN O
hematology NN NN O
and NN NN O
blood NN NN O
chemistry NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
A NN NN O
total NN NN O
of NN NN O
1346 NN NN O
patients NN NN O
were NN NN O
randomized NN NN O
into NN NN O
the NN NN O
8 NN NN O
- NN NN O
week NN NN O
core NN NN O
study NN NN O
( NN NN O
734 NN NN O
men NN NN O
, NN NN O
612 NN NN O
women NN NN O
; NN NN O
924 NN NN O
white NN NN O
, NN NN O
291 NN NN O
black NN NN O
, NN NN O
23 NN NN O
Asian NN NN O
, NN NN O
108 NN NN O
other NN NN O
; NN NN O
mean NN NN O
age NN NN O
, NN NN O
52 NN NN O
. NN NN O
7 NN NN O
years NN NN O
; NN NN O
mean NN NN O
weight NN NN O
, NN NN O
92 NN NN O
. NN NN O
6 NN NN O
kg NN NN O
) NN NN O
. NN NN O
   
All NN NN O
active NN NN O
treatments NN NN O
were NN NN O
associated NN NN O
with NN NN O
significantly NN NN O
reduced NN NN O
MSSBP NN NN O
and NN NN O
MSDBP NN NN O
during NN NN O
the NN NN O
core NN NN O
8 NN NN O
- NN NN O
week NN NN O
study NN NN O
, NN NN O
with NN NN O
each NN NN O
monotherapy NN NN O
significantly NN NN O
contributing NN NN O
to NN NN O
the NN NN O
overall NN NN O
effect NN NN O
of NN NN O
combination NN NN O
therapy NN NN O
( NN NN O
VAL NN NN O
and NN NN O
HCTZ NN NN O
, NN NN O
P NN NN O
< NN NN O
0 NN NN O
. NN NN O
001 NN NN O
) NN NN O
. NN NN O
   
Each NN NN O
combination NN NN O
was NN NN O
associated NN NN O
with NN NN O
significantly NN NN O
greater NN NN O
reductions NN NN O
in NN NN O
MSSBP NN NN O
and NN NN O
MSDBP NN NN O
compared NN NN O
with NN NN O
the NN NN O
monotherapies NN NN O
and NN NN O
placebo NN NN O
( NN NN O
all NN NN O
, NN NN O
P NN NN O
< NN NN O
0 NN NN O
. NN NN O
001 NN NN O
) NN NN O
. NN NN O
   
The NN NN O
mean NN NN O
reduction NN NN O
in NN NN O
MSSBP NN NN O
/ NN NN O
MSDBP NN NN O
with NN NN O
VAL NN NN O
/ NN NN O
HCTZ NN NN O
320 NN NN O
/ NN NN O
25 NN NN O
mg NN NN O
was NN NN O
24 NN NN O
. NN NN O
7 NN NN O
/ NN NN O
16 NN NN O
. NN NN O
6 NN NN O
mm NN NN O
Hg NN NN O
, NN NN O
compared NN NN O
with NN NN O
5 NN NN O
. NN NN O
9 NN NN O
/ NN NN O
7 NN NN O
. NN NN O
0 NN NN O
mm NN NN O
Hg NN NN O
with NN NN O
placebo NN NN O
. NN NN O
   
The NN NN O
reduction NN NN O
in NN NN O
MSSBP NN NN O
was NN NN O
significantly NN NN O
greater NN NN O
with NN NN O
VAL NN NN O
/ NN NN O
HCTZ NN NN O
320 NN NN O
/ NN NN O
25 NN NN O
mg NN NN O
compared NN NN O
with NN NN O
VAL NN NN O
/ NN NN O
HCTZ NN NN O
160 NN NN O
/ NN NN O
12 NN NN O
. NN NN O
5 NN NN O
mg NN NN O
( NN NN O
P NN NN O
< NN NN O
0 NN NN O
. NN NN O
002 NN NN O
) NN NN O
. NN NN O
   
Rates NN NN O
of NN NN O
response NN NN O
and NN NN O
BP NN NN O
control NN NN O
were NN NN O
significantly NN NN O
higher NN NN O
in NN NN O
the NN NN O
groups NN NN O
that NN NN O
received NN NN O
combination NN NN O
treatment NN NN O
compared NN NN O
with NN NN O
those NN NN O
that NN NN O
received NN NN O
monotherapy NN NN O
. NN NN O
   
The NN NN O
incidence NN NN O
of NN NN O
hypokalemia NN NN B-Disease
was NN NN O
lower NN NN O
with NN NN O
VAL NN NN O
/ NN NN O
HCTZ NN NN O
combinations NN NN O
( NN NN O
1 NN NN O
. NN NN O
8 NN NN O
% NN NN O
- NN NN O
6 NN NN O
. NN NN O
1 NN NN O
% NN NN O
) NN NN O
than NN NN O
with NN NN O
HCTZ NN NN O
monotherapies NN NN O
( NN NN O
7 NN NN O
. NN NN O
1 NN NN O
% NN NN O
- NN NN O
13 NN NN O
. NN NN O
3 NN NN O
% NN NN O
) NN NN O
. NN NN O
   
The NN NN O
majority NN NN O
of NN NN O
adverse NN NN O
events NN NN O
in NN NN O
the NN NN O
core NN NN O
study NN NN O
were NN NN O
of NN NN O
mild NN NN O
to NN NN O
moderate NN NN O
severity NN NN O
. NN NN O
   
The NN NN O
efficacy NN NN O
and NN NN O
tolerability NN NN O
of NN NN O
VAL NN NN O
/ NN NN O
HCTZ NN NN O
combinations NN NN O
were NN NN O
maintained NN NN O
during NN NN O
the NN NN O
extension NN NN O
( NN NN O
797 NN NN O
patients NN NN O
) NN NN O
. NN NN O
   
CONCLUSIONS NN NN O
: NN NN O
In NN NN O
this NN NN O
study NN NN O
population NN NN O
, NN NN O
combination NN NN O
therapies NN NN O
with NN NN O
VAL NN NN O
/ NN NN O
HCTZ NN NN O
were NN NN O
associated NN NN O
with NN NN O
significantly NN NN O
greater NN NN O
BP NN NN O
reductions NN NN O
compared NN NN O
with NN NN O
either NN NN O
monotherapy NN NN O
, NN NN O
were NN NN O
well NN NN O
tolerated NN NN O
, NN NN O
and NN NN O
were NN NN O
associated NN NN O
with NN NN O
less NN NN O
hypokalemia NN NN B-Disease
than NN NN O
HCTZ NN NN O
alone NN NN O
. NN NN O
   
Succimer NN NN O
chelation NN NN O
improves NN NN O
learning NN NN O
, NN NN O
attention NN NN O
, NN NN O
and NN NN O
arousal NN NN O
regulation NN NN O
in NN NN O
lead NN NN O
- NN NN O
exposed NN NN O
rats NN NN O
but NN NN O
produces NN NN O
lasting NN NN O
cognitive NN NN B-Disease
impairment NN NN I-Disease
in NN NN O
the NN NN O
absence NN NN O
of NN NN O
lead NN NN O
exposure NN NN O
. NN NN O
   
BACKGROUND NN NN O
: NN NN O
There NN NN O
is NN NN O
growing NN NN O
pressure NN NN O
for NN NN O
clinicians NN NN O
to NN NN O
prescribe NN NN O
chelation NN NN O
therapy NN NN O
at NN NN O
only NN NN O
slightly NN NN O
elevated NN NN O
blood NN NN O
lead NN NN O
levels NN NN O
. NN NN O
   
However NN NN O
, NN NN O
very NN NN O
few NN NN O
studies NN NN O
have NN NN O
evaluated NN NN O
whether NN NN O
chelation NN NN O
improves NN NN O
cognitive NN NN O
outcomes NN NN O
in NN NN O
Pb NN NN O
- NN NN O
exposed NN NN O
children NN NN O
, NN NN O
or NN NN O
whether NN NN O
these NN NN O
agents NN NN O
have NN NN O
adverse NN NN O
effects NN NN O
that NN NN O
may NN NN O
affect NN NN O
brain NN NN O
development NN NN O
in NN NN O
the NN NN O
absence NN NN O
of NN NN O
Pb NN NN O
exposure NN NN O
. NN NN O
   
OBJECTIVES NN NN O
: NN NN O
The NN NN O
present NN NN O
study NN NN O
was NN NN O
designed NN NN O
to NN NN O
answer NN NN O
these NN NN O
questions NN NN O
, NN NN O
using NN NN O
a NN NN O
rodent NN NN O
model NN NN O
of NN NN O
early NN NN O
childhood NN NN O
Pb NN NN O
exposure NN NN O
and NN NN O
treatment NN NN O
with NN NN O
succimer NN NN O
, NN NN O
a NN NN O
widely NN NN O
used NN NN O
chelating NN NN O
agent NN NN O
for NN NN O
the NN NN O
treatment NN NN O
of NN NN O
Pb NN NN B-Disease
poisoning NN NN I-Disease
. NN NN O
   
RESULTS NN NN O
: NN NN O
Pb NN NN O
exposure NN NN O
produced NN NN O
lasting NN NN O
impairments NN NN B-Disease
in NN NN I-Disease
learning NN NN I-Disease
, NN NN I-Disease
attention NN NN I-Disease
, NN NN I-Disease
inhibitory NN NN I-Disease
control NN NN I-Disease
, NN NN I-Disease
and NN NN I-Disease
arousal NN NN I-Disease
regulation NN NN I-Disease
, NN NN O
paralleling NN NN O
the NN NN O
areas NN NN O
of NN NN O
dysfunction NN NN O
seen NN NN O
in NN NN O
Pb NN NN O
- NN NN O
exposed NN NN O
children NN NN O
. NN NN O
   
Succimer NN NN O
treatment NN NN O
of NN NN O
the NN NN O
Pb NN NN O
- NN NN O
exposed NN NN O
rats NN NN O
significantly NN NN O
improved NN NN O
learning NN NN O
, NN NN O
attention NN NN O
, NN NN O
and NN NN O
arousal NN NN O
regulation NN NN O
, NN NN O
although NN NN O
the NN NN O
efficacy NN NN O
of NN NN O
the NN NN O
treatment NN NN O
varied NN NN O
as NN NN O
a NN NN O
function NN NN O
of NN NN O
the NN NN O
Pb NN NN O
exposure NN NN O
level NN NN O
and NN NN O
the NN NN O
specific NN NN O
functional NN NN O
deficit NN NN O
. NN NN O
   
In NN NN O
contrast NN NN O
, NN NN O
succimer NN NN O
treatment NN NN O
of NN NN O
rats NN NN O
not NN NN O
previously NN NN O
exposed NN NN O
to NN NN O
Pb NN NN O
produced NN NN O
lasting NN NN O
and NN NN O
pervasive NN NN O
cognitive NN NN B-Disease
and NN NN I-Disease
affective NN NN I-Disease
dysfunction NN NN I-Disease
comparable NN NN O
in NN NN O
magnitude NN NN O
to NN NN O
that NN NN O
produced NN NN O
by NN NN O
the NN NN O
higher NN NN O
Pb NN NN O
exposure NN NN O
regimen NN NN O
. NN NN O
   
CONCLUSIONS NN NN O
: NN NN O
These NN NN O
are NN NN O
the NN NN O
first NN NN O
data NN NN O
, NN NN O
to NN NN O
our NN NN O
knowledge NN NN O
, NN NN O
to NN NN O
show NN NN O
that NN NN O
treatment NN NN O
with NN NN O
any NN NN O
chelating NN NN O
agent NN NN O
can NN NN O
alleviate NN NN O
cognitive NN NN B-Disease
deficits NN NN I-Disease
due NN NN O
to NN NN O
Pb NN NN O
exposure NN NN O
. NN NN O
   
These NN NN O
findings NN NN O
suggest NN NN O
that NN NN O
it NN NN O
may NN NN O
be NN NN O
possible NN NN O
to NN NN O
identify NN NN O
a NN NN O
succimer NN NN O
treatment NN NN O
protocol NN NN O
that NN NN O
improves NN NN O
cognitive NN NN O
outcomes NN NN O
in NN NN O
Pb NN NN O
- NN NN O
exposed NN NN O
children NN NN O
. NN NN O
   
However NN NN O
, NN NN O
they NN NN O
also NN NN O
suggest NN NN O
that NN NN O
succimer NN NN O
treatment NN NN O
should NN NN O
be NN NN O
strongly NN NN O
discouraged NN NN O
for NN NN O
children NN NN O
who NN NN O
do NN NN O
not NN NN O
have NN NN O
elevated NN NN O
tissue NN NN O
levels NN NN O
of NN NN O
Pb NN NN O
or NN NN O
other NN NN O
heavy NN NN O
metals NN NN O
. NN NN O
   
Caffeine NN NN O
challenge NN NN O
test NN NN O
in NN NN O
panic NN NN B-Disease
disorder NN NN I-Disease
and NN NN O
depression NN NN B-Disease
with NN NN O
panic NN NN B-Disease
attacks NN NN I-Disease
. NN NN O
   
Our NN NN O
aim NN NN O
was NN NN O
to NN NN O
observe NN NN O
if NN NN O
patients NN NN O
with NN NN O
panic NN NN B-Disease
disorder NN NN I-Disease
( NN NN O
PD NN NN B-Disease
) NN NN O
and NN NN O
patients NN NN O
with NN NN O
major NN NN B-Disease
depression NN NN I-Disease
with NN NN O
panic NN NN B-Disease
attacks NN NN I-Disease
( NN NN O
MDP NN NN B-Disease
) NN NN O
( NN NN O
Diagnostic NN NN O
and NN NN O
Statistical NN NN O
Manual NN NN O
of NN NN O
Mental NN NN B-Disease
Disorders NN NN I-Disease
, NN NN O
Fourth NN NN O
Edition NN NN O
criteria NN NN O
) NN NN O
respond NN NN O
in NN NN O
a NN NN O
similar NN NN O
way NN NN O
to NN NN O
the NN NN O
induction NN NN O
of NN NN O
panic NN NN B-Disease
attacks NN NN I-Disease
by NN NN O
an NN NN O
oral NN NN O
caffeine NN NN O
challenge NN NN O
test NN NN O
. NN NN O
   
We NN NN O
randomly NN NN O
selected NN NN O
29 NN NN O
patients NN NN O
with NN NN O
PD NN NN B-Disease
, NN NN O
27 NN NN O
with NN NN O
MDP NN NN B-Disease
, NN NN O
25 NN NN O
with NN NN O
major NN NN B-Disease
depression NN NN I-Disease
without NN NN O
panic NN NN B-Disease
attacks NN NN I-Disease
( NN NN O
MD NN NN B-Disease
) NN NN O
, NN NN O
and NN NN O
28 NN NN O
healthy NN NN O
volunteers NN NN O
. NN NN O
   
The NN NN O
patients NN NN O
had NN NN O
no NN NN O
psychotropic NN NN O
drug NN NN O
for NN NN O
at NN NN O
least NN NN O
a NN NN O
4 NN NN O
- NN NN O
week NN NN O
period NN NN O
. NN NN O
   
In NN NN O
a NN NN O
randomized NN NN O
double NN NN O
- NN NN O
blind NN NN O
experiment NN NN O
performed NN NN O
in NN NN O
2 NN NN O
occasions NN NN O
7 NN NN O
days NN NN O
apart NN NN O
, NN NN O
480 NN NN O
mg NN NN O
caffeine NN NN O
and NN NN O
a NN NN O
caffeine NN NN O
- NN NN O
free NN NN O
( NN NN O
placebo NN NN O
) NN NN O
solution NN NN O
were NN NN O
administered NN NN O
in NN NN O
a NN NN O
coffee NN NN O
form NN NN O
and NN NN O
anxiety NN NN B-Disease
scales NN NN O
were NN NN O
applied NN NN O
before NN NN O
and NN NN O
after NN NN O
each NN NN O
test NN NN O
. NN NN O
   
A NN NN O
total NN NN O
of NN NN O
58 NN NN O
. NN NN O
6 NN NN O
% NN NN O
( NN NN O
n NN NN O
= NN NN O
17 NN NN O
) NN NN O
of NN NN O
patients NN NN O
with NN NN O
PD NN NN B-Disease
, NN NN O
44 NN NN O
. NN NN O
4 NN NN O
% NN NN O
( NN NN O
n NN NN O
= NN NN O
12 NN NN O
) NN NN O
of NN NN O
patients NN NN O
with NN NN O
MDP NN NN B-Disease
, NN NN O
12 NN NN O
. NN NN O
0 NN NN O
% NN NN O
( NN NN O
n NN NN O
= NN NN O
3 NN NN O
) NN NN O
of NN NN O
patients NN NN O
with NN NN O
MD NN NN B-Disease
, NN NN O
and NN NN O
7 NN NN O
. NN NN O
1 NN NN O
% NN NN O
( NN NN O
n NN NN O
= NN NN O
2 NN NN O
) NN NN O
of NN NN O
control NN NN O
subjects NN NN O
had NN NN O
a NN NN O
panic NN NN B-Disease
attack NN NN I-Disease
after NN NN O
the NN NN O
480 NN NN O
- NN NN O
mg NN NN O
caffeine NN NN O
challenge NN NN O
test NN NN O
( NN NN O
chi NN NN O
( NN NN O
2 NN NN O
) NN NN O
( NN NN O
3 NN NN O
) NN NN O
= NN NN O
16 NN NN O
. NN NN O
22 NN NN O
, NN NN O
P NN NN O
= NN NN O
. NN NN O
001 NN NN O
) NN NN O
. NN NN O
   
The NN NN O
patients NN NN O
with NN NN O
PD NN NN B-Disease
and NN NN O
MDP NN NN B-Disease
were NN NN O
more NN NN O
sensitive NN NN O
to NN NN O
caffeine NN NN O
than NN NN O
were NN NN O
patients NN NN O
with NN NN O
MD NN NN B-Disease
and NN NN O
healthy NN NN O
volunteers NN NN O
. NN NN O
   
No NN NN O
panic NN NN B-Disease
attack NN NN I-Disease
was NN NN O
observed NN NN O
after NN NN O
the NN NN O
caffeine NN NN O
- NN NN O
free NN NN O
solution NN NN O
intake NN NN O
. NN NN O
   
The NN NN O
patients NN NN O
with NN NN O
MD NN NN B-Disease
had NN NN O
a NN NN O
lower NN NN O
heart NN NN O
rate NN NN O
response NN NN O
to NN NN O
the NN NN O
test NN NN O
than NN NN O
all NN NN O
the NN NN O
other NN NN O
groups NN NN O
( NN NN O
2 NN NN O
- NN NN O
way NN NN O
analysis NN NN O
of NN NN O
variance NN NN O
, NN NN O
group NN NN O
by NN NN O
time NN NN O
interaction NN NN O
with NN NN O
Greenhouse NN NN O
- NN NN O
Geisser NN NN O
correction NN NN O
: NN NN O
F NN NN O
( NN NN O
3 NN NN O
, NN NN O
762 NN NN O
) NN NN O
= NN NN O
2 NN NN O
. NN NN O
85 NN NN O
, NN NN O
P NN NN O
= NN NN O
. NN NN O
026 NN NN O
) NN NN O
. NN NN O
   
Our NN NN O
data NN NN O
suggest NN NN O
that NN NN O
there NN NN O
is NN NN O
an NN NN O
association NN NN O
between NN NN O
panic NN NN B-Disease
attacks NN NN I-Disease
, NN NN O
no NN NN O
matter NN NN O
if NN NN O
associated NN NN O
with NN NN O
PD NN NN B-Disease
or NN NN O
MDP NN NN B-Disease
, NN NN O
and NN NN O
hyperreactivity NN NN O
to NN NN O
an NN NN O
oral NN NN O
caffeine NN NN O
challenge NN NN O
test NN NN O
. NN NN O
   
Mitral NN NN O
annuloplasty NN NN O
as NN NN O
a NN NN O
ventricular NN NN O
restoration NN NN O
method NN NN O
for NN NN O
the NN NN O
failing NN NN B-Disease
left NN NN I-Disease
ventricle NN NN I-Disease
: NN NN O
a NN NN O
pilot NN NN O
study NN NN O
. NN NN O
   
BACKGROUND NN NN O
AND NN NN O
AIM NN NN O
OF NN NN O
THE NN NN O
STUDY NN NN O
: NN NN O
Undersized NN NN O
mitral NN NN O
annuloplasty NN NN O
( NN NN O
MAP NN NN O
) NN NN O
is NN NN O
effective NN NN O
in NN NN O
patients NN NN O
with NN NN O
dilated NN NN B-Disease
cardiomyopathy NN NN I-Disease
and NN NN O
functional NN NN O
mitral NN NN B-Disease
regurgitation NN NN I-Disease
( NN NN O
MR NN NN B-Disease
) NN NN O
since NN NN O
, NN NN O
as NN NN O
well NN NN O
as NN NN O
addressing NN NN O
the NN NN O
MR NN NN B-Disease
, NN NN O
the NN NN O
MAP NN NN O
may NN NN O
also NN NN O
reshape NN NN O
the NN NN O
dilated NN NN O
left NN NN O
ventricular NN NN O
( NN NN O
LV NN NN O
) NN NN O
base NN NN O
. NN NN O
   
However NN NN O
, NN NN O
the NN NN O
direct NN NN O
benefits NN NN O
of NN NN O
this NN NN O
possible NN NN O
reshaping NN NN O
on NN NN O
LV NN NN O
function NN NN O
in NN NN O
the NN NN O
absence NN NN O
of NN NN O
underlying NN NN O
MR NN NN B-Disease
remain NN NN O
incompletely NN NN O
understood NN NN O
. NN NN O
   
The NN NN O
study NN NN O
aim NN NN O
was NN NN O
to NN NN O
identify NN NN O
these NN NN O
benefits NN NN O
in NN NN O
a NN NN O
canine NN NN O
model NN NN O
of NN NN O
acute NN NN O
heart NN NN B-Disease
failure NN NN I-Disease
. NN NN O
   
METHODS NN NN O
: NN NN O
Six NN NN O
dogs NN NN O
underwent NN NN O
MAP NN NN O
with NN NN O
a NN NN O
prosthetic NN NN O
band NN NN O
on NN NN O
the NN NN O
posterior NN NN O
mitral NN NN O
annulus NN NN O
, NN NN O
using NN NN O
four NN NN O
mattress NN NN O
sutures NN NN O
. NN NN O
   
The NN NN O
sutures NN NN O
were NN NN O
passed NN NN O
individually NN NN O
through NN NN O
four NN NN O
tourniquets NN NN O
and NN NN O
exteriorized NN NN O
untied NN NN O
via NN NN O
the NN NN O
left NN NN O
atriotomy NN NN O
. NN NN O
   
Sonomicrometry NN NN O
crystals NN NN O
were NN NN O
implanted NN NN O
around NN NN O
the NN NN O
mitral NN NN O
annulus NN NN O
and NN NN O
left NN NN O
ventricle NN NN O
to NN NN O
measure NN NN O
geometry NN NN O
and NN NN O
regional NN NN O
function NN NN O
. NN NN O
   
Acute NN NN O
heart NN NN B-Disease
failure NN NN I-Disease
was NN NN O
induced NN NN O
by NN NN O
propranolol NN NN O
and NN NN O
volume NN NN O
loading NN NN O
after NN NN O
weaning NN NN O
from NN NN O
cardiopulmonary NN NN O
bypass NN NN O
; NN NN O
an NN NN O
absence NN NN O
of NN NN O
MR NN NN B-Disease
was NN NN O
confirmed NN NN O
by NN NN O
echocardiography NN NN O
. NN NN O
   
MAP NN NN O
was NN NN O
accomplished NN NN O
by NN NN O
cinching NN NN O
the NN NN O
tourniquets NN NN O
. NN NN O
   
Data NN NN O
were NN NN O
acquired NN NN O
at NN NN O
baseline NN NN O
, NN NN O
after NN NN O
induction NN NN O
of NN NN O
acute NN NN O
heart NN NN B-Disease
failure NN NN I-Disease
, NN NN O
and NN NN O
after NN NN O
MAP NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
MAP NN NN O
decreased NN NN O
mitral NN NN O
annular NN NN O
dimensions NN NN O
in NN NN O
both NN NN O
commissure NN NN O
- NN NN O
commissure NN NN O
and NN NN O
septal NN NN O
- NN NN O
lateral NN NN O
directions NN NN O
. NN NN O
   
Concomitantly NN NN O
, NN NN O
the NN NN O
diastolic NN NN O
diameter NN NN O
of NN NN O
the NN NN O
LV NN NN O
base NN NN O
and NN NN O
LV NN NN O
sphericity NN NN O
decreased NN NN O
( NN NN O
i NN NN O
. NN NN O
e NN NN O
. NN NN O
, NN NN O
improved NN NN O
) NN NN O
from NN NN O
37 NN NN O
. NN NN O
4 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
9 NN NN O
. NN NN O
3 NN NN O
to NN NN O
35 NN NN O
. NN NN O
9 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
10 NN NN O
mm NN NN O
( NN NN O
p NN NN O
= NN NN O
0 NN NN O
. NN NN O
063 NN NN O
) NN NN O
, NN NN O
and NN NN O
from NN NN O
67 NN NN O
. NN NN O
9 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
18 NN NN O
. NN NN O
6 NN NN O
% NN NN O
to NN NN O
65 NN NN O
. NN NN O
3 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
18 NN NN O
. NN NN O
9 NN NN O
% NN NN O
( NN NN O
p NN NN O
= NN NN O
0 NN NN O
. NN NN O
016 NN NN O
) NN NN O
, NN NN O
respectively NN NN O
. NN NN O
   
Decreases NN NN O
were NN NN O
evident NN NN O
in NN NN O
both NN NN O
LV NN NN O
end NN NN O
- NN NN O
diastolic NN NN O
pressure NN NN O
( NN NN O
from NN NN O
17 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
7 NN NN O
to NN NN O
15 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
6 NN NN O
mmHg NN NN O
, NN NN O
p NN NN O
= NN NN O
0 NN NN O
. NN NN O
0480 NN NN O
and NN NN O
Tau NN NN O
( NN NN O
from NN NN O
48 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
8 NN NN O
to NN NN O
45 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
8 NN NN O
ms NN NN O
, NN NN O
p NN NN O
< NN NN O
0 NN NN O
. NN NN O
01 NN NN O
) NN NN O
, NN NN O
while NN NN O
fractional NN NN O
shortening NN NN O
at NN NN O
the NN NN O
LV NN NN O
base NN NN O
increased NN NN O
from NN NN O
7 NN NN O
. NN NN O
7 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
4 NN NN O
. NN NN O
5 NN NN O
% NN NN O
to NN NN O
9 NN NN O
. NN NN O
4 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
4 NN NN O
. NN NN O
5 NN NN O
% NN NN O
( NN NN O
p NN NN O
= NN NN O
0 NN NN O
. NN NN O
045 NN NN O
) NN NN O
. NN NN O
   
After NN NN O
MAP NN NN O
, NN NN O
increases NN NN O
were NN NN O
identified NN NN O
in NN NN O
both NN NN O
cardiac NN NN O
output NN NN O
( NN NN O
from NN NN O
1 NN NN O
. NN NN O
54 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
0 NN NN O
. NN NN O
57 NN NN O
to NN NN O
1 NN NN O
. NN NN O
65 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
0 NN NN O
. NN NN O
57 NN NN O
1 NN NN O
/ NN NN O
min NN NN O
) NN NN O
and NN NN O
Emax NN NN O
( NN NN O
from NN NN O
1 NN NN O
. NN NN O
86 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
0 NN NN O
. NN NN O
9 NN NN O
to NN NN O
2 NN NN O
. NN NN O
41 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
1 NN NN O
. NN NN O
31 NN NN O
mmHg NN NN O
/ NN NN O
ml NN NN O
) NN NN O
. NN NN O
   
CONCLUSION NN NN O
: NN NN O
The NN NN O
data NN NN O
acquired NN NN O
suggest NN NN O
that NN NN O
isolated NN NN O
MAP NN NN O
may NN NN O
have NN NN O
certain NN NN O
benefits NN NN O
on NN NN O
LV NN NN O
dimension NN NN O
/ NN NN O
function NN NN O
in NN NN O
acute NN NN O
heart NN NN B-Disease
failure NN NN I-Disease
, NN NN O
even NN NN O
in NN NN O
the NN NN O
absence NN NN O
of NN NN O
MR NN NN B-Disease
. NN NN O
   
However NN NN O
, NN NN O
further NN NN O
investigations NN NN O
are NN NN O
warranted NN NN O
in NN NN O
a NN NN O
model NN NN O
of NN NN O
chronic NN NN O
heart NN NN B-Disease
failure NN NN I-Disease
. NN NN O
   
Piperacillin NN NN O
/ NN NN O
tazobactam NN NN O
- NN NN O
induced NN NN O
seizure NN NN B-Disease
rapidly NN NN O
reversed NN NN O
by NN NN O
high NN NN O
flux NN NN O
hemodialysis NN NN O
in NN NN O
a NN NN O
patient NN NN O
on NN NN O
peritoneal NN NN O
dialysis NN NN O
. NN NN O
   
Despite NN NN O
popular NN NN O
use NN NN O
of NN NN O
piperacillin NN NN O
, NN NN O
the NN NN O
dire NN NN O
neurotoxicity NN NN B-Disease
associated NN NN O
with NN NN O
piperacillin NN NN O
still NN NN O
goes NN NN O
unrecognized NN NN O
, NN NN O
leading NN NN O
to NN NN O
a NN NN O
delay NN NN O
in NN NN O
appropriate NN NN O
management NN NN O
. NN NN O
   
We NN NN O
report NN NN O
a NN NN O
57 NN NN O
- NN NN O
year NN NN O
- NN NN O
old NN NN O
woman NN NN O
with NN NN O
end NN NN B-Disease
- NN NN I-Disease
stage NN NN I-Disease
renal NN NN I-Disease
disease NN NN I-Disease
receiving NN NN O
continuous NN NN O
ambulatory NN NN O
peritoneal NN NN O
dialysis NN NN O
( NN NN O
CAPD NN NN O
) NN NN O
, NN NN O
who NN NN O
developed NN NN O
slurred NN NN O
speech NN NN O
, NN NN O
tremor NN NN B-Disease
, NN NN O
bizarre NN NN O
behavior NN NN O
, NN NN O
progressive NN NN O
mental NN NN O
confusion NN NN B-Disease
, NN NN O
and NN NN O
2 NN NN O
episodes NN NN O
of NN NN O
generalized NN NN O
tonic NN NN B-Disease
- NN NN I-Disease
clonic NN NN I-Disease
seizure NN NN I-Disease
( NN NN O
GTCS NN NN B-Disease
) NN NN O
after NN NN O
5 NN NN O
doses NN NN O
of NN NN O
piperacillin NN NN O
/ NN NN O
tazobactam NN NN O
( NN NN O
2 NN NN O
g NN NN O
/ NN NN O
250 NN NN O
mg NN NN O
) NN NN O
were NN NN O
given NN NN O
for NN NN O
bronchiectasis NN NN B-Disease
with NN NN O
secondary NN NN B-Disease
infection NN NN I-Disease
. NN NN O
   
The NN NN O
laboratory NN NN O
data NN NN O
revealed NN NN O
normal NN NN O
plasma NN NN O
electrolyte NN NN O
and NN NN O
ammonia NN NN O
levels NN NN O
but NN NN O
leukocytosis NN NN B-Disease
. NN NN O
   
Neurologic NN NN O
examinations NN NN O
showed NN NN O
dysarthria NN NN B-Disease
and NN NN O
bilateral NN NN O
Babinski NN NN O
sign NN NN O
. NN NN O
   
Computed NN NN O
tomography NN NN O
of NN NN O
brain NN NN O
and NN NN O
electroencephalogram NN NN O
were NN NN O
unremarkable NN NN O
. NN NN O
   
Despite NN NN O
the NN NN O
use NN NN O
of NN NN O
antiepileptic NN NN O
agents NN NN O
, NN NN O
another NN NN O
GTCS NN NN B-Disease
episode NN NN O
recurred NN NN O
after NN NN O
the NN NN O
sixth NN NN O
dose NN NN O
of NN NN O
piperacillin NN NN O
/ NN NN O
tazobactam NN NN O
. NN NN O
   
Brain NN NN O
magnetic NN NN O
resonance NN NN O
imaging NN NN O
did NN NN O
not NN NN O
demonstrate NN NN O
acute NN NN O
infarction NN NN B-Disease
and NN NN O
organic NN NN B-Disease
brain NN NN I-Disease
lesions NN NN I-Disease
. NN NN O
   
Initiation NN NN O
of NN NN O
high NN NN O
- NN NN O
flux NN NN O
hemodialysis NN NN O
rapidly NN NN O
reversed NN NN O
the NN NN O
neurologic NN NN O
symptoms NN NN O
within NN NN O
4 NN NN O
hours NN NN O
. NN NN O
   
Piperacillin NN NN O
- NN NN O
induced NN NN O
encephalopathy NN NN B-Disease
should NN NN O
be NN NN O
considered NN NN O
in NN NN O
any NN NN O
uremic NN NN B-Disease
patients NN NN O
with NN NN O
unexplained NN NN O
neurological NN NN O
manifestations NN NN O
. NN NN O
   
CAPD NN NN O
is NN NN O
inefficient NN NN O
in NN NN O
removing NN NN O
piperacillin NN NN O
, NN NN O
whereas NN NN O
hemodialysis NN NN O
can NN NN O
rapidly NN NN O
terminate NN NN O
the NN NN O
piperacillin NN NN O
- NN NN O
induced NN NN O
encephalopathy NN NN B-Disease
. NN NN O
   
Frequency NN NN O
of NN NN O
transient NN NN O
ipsilateral NN NN O
vocal NN NN B-Disease
cord NN NN I-Disease
paralysis NN NN I-Disease
in NN NN O
patients NN NN O
undergoing NN NN O
carotid NN NN O
endarterectomy NN NN O
under NN NN O
local NN NN O
anesthesia NN NN O
. NN NN O
   
BACKGROUND NN NN O
: NN NN O
Especially NN NN O
because NN NN O
of NN NN O
improvements NN NN O
in NN NN O
clinical NN NN O
neurologic NN NN O
monitoring NN NN O
, NN NN O
carotid NN NN O
endarterectomy NN NN O
done NN NN O
under NN NN O
local NN NN O
anesthesia NN NN O
has NN NN O
become NN NN O
the NN NN O
technique NN NN O
of NN NN O
choice NN NN O
in NN NN O
several NN NN O
centers NN NN O
. NN NN O
   
Temporary NN NN O
ipsilateral NN NN O
vocal NN NN B-Disease
nerve NN NN I-Disease
palsies NN NN I-Disease
due NN NN O
to NN NN O
local NN NN O
anesthetics NN NN O
have NN NN O
been NN NN O
described NN NN O
, NN NN O
however NN NN O
. NN NN O
   
Such NN NN O
complications NN NN O
are NN NN O
most NN NN O
important NN NN O
in NN NN O
situations NN NN O
where NN NN O
there NN NN O
is NN NN O
a NN NN O
pre NN NN O
- NN NN O
existing NN NN O
contralateral NN NN O
paralysis NN NN B-Disease
. NN NN O
   
We NN NN O
therefore NN NN O
examined NN NN O
the NN NN O
effect NN NN O
of NN NN O
local NN NN O
anesthesia NN NN O
on NN NN O
vocal NN NN O
cord NN NN O
function NN NN O
to NN NN O
better NN NN O
understand NN NN O
its NN NN O
possible NN NN O
consequences NN NN O
. NN NN O
   
METHODS NN NN O
: NN NN O
This NN NN O
prospective NN NN O
study NN NN O
included NN NN O
28 NN NN O
patients NN NN O
undergoing NN NN O
carotid NN NN O
endarterectomy NN NN O
under NN NN O
local NN NN O
anesthesia NN NN O
. NN NN O
   
Vocal NN NN O
cord NN NN O
function NN NN O
was NN NN O
evaluated NN NN O
before NN NN O
, NN NN O
during NN NN O
, NN NN O
and NN NN O
after NN NN O
surgery NN NN O
( NN NN O
postoperative NN NN O
day NN NN O
1 NN NN O
) NN NN O
using NN NN O
flexible NN NN O
laryngoscopy NN NN O
. NN NN O
   
Anesthesia NN NN O
was NN NN O
performed NN NN O
by NN NN O
injecting NN NN O
20 NN NN O
to NN NN O
40 NN NN O
mL NN NN O
of NN NN O
a NN NN O
mixture NN NN O
of NN NN O
long NN NN O
- NN NN O
acting NN NN O
( NN NN O
ropivacaine NN NN O
) NN NN O
and NN NN O
short NN NN O
- NN NN O
acting NN NN O
( NN NN O
prilocaine NN NN O
) NN NN O
anesthetic NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
All NN NN O
patients NN NN O
had NN NN O
normal NN NN O
vocal NN NN O
cord NN NN O
function NN NN O
preoperatively NN NN O
. NN NN O
   
Twelve NN NN O
patients NN NN O
( NN NN O
43 NN NN O
% NN NN O
) NN NN O
were NN NN O
found NN NN O
to NN NN O
have NN NN O
intraoperative NN NN O
ipsilateral NN NN O
vocal NN NN B-Disease
cord NN NN I-Disease
paralysis NN NN I-Disease
. NN NN O
   
It NN NN O
resolved NN NN O
in NN NN O
all NN NN O
cases NN NN O
< NN NN O
or NN NN O
= NN NN O
24 NN NN O
hours NN NN O
. NN NN O
   
There NN NN O
were NN NN O
no NN NN O
significant NN NN O
differences NN NN O
in NN NN O
operating NN NN O
time NN NN O
or NN NN O
volume NN NN O
or NN NN O
frequency NN NN O
of NN NN O
anesthetic NN NN O
administration NN NN O
in NN NN O
patients NN NN O
with NN NN O
temporary NN NN O
vocal NN NN B-Disease
cord NN NN I-Disease
paralysis NN NN I-Disease
compared NN NN O
with NN NN O
those NN NN O
without NN NN O
. NN NN O
   
CONCLUSION NN NN O
: NN NN O
Local NN NN O
anesthesia NN NN O
led NN NN O
to NN NN O
temporary NN NN O
ipsilateral NN NN O
vocal NN NN B-Disease
cord NN NN I-Disease
paralysis NN NN I-Disease
in NN NN O
almost NN NN O
half NN NN O
of NN NN O
these NN NN O
patients NN NN O
. NN NN O
   
Because NN NN O
pre NN NN O
- NN NN O
existing NN NN O
paralysis NN NN B-Disease
is NN NN O
of NN NN O
a NN NN O
relevant NN NN O
frequency NN NN O
( NN NN O
up NN NN O
to NN NN O
3 NN NN O
% NN NN O
) NN NN O
, NN NN O
a NN NN O
preoperative NN NN O
evaluation NN NN O
of NN NN O
vocal NN NN O
cord NN NN O
function NN NN O
before NN NN O
carotid NN NN O
endarterectomy NN NN O
under NN NN O
local NN NN O
anesthesia NN NN O
is NN NN O
recommended NN NN O
to NN NN O
avoid NN NN O
intraoperative NN NN O
bilateral NN NN O
paralysis NN NN B-Disease
. NN NN O
   
In NN NN O
patients NN NN O
with NN NN O
preoperative NN NN O
contralateral NN NN O
vocal NN NN B-Disease
cord NN NN I-Disease
paralysis NN NN I-Disease
, NN NN O
surgery NN NN O
under NN NN O
general NN NN O
anesthesia NN NN O
should NN NN O
be NN NN O
considered NN NN O
. NN NN O
   
Impaired NN NN B-Disease
fear NN NN I-Disease
recognition NN NN I-Disease
in NN NN O
regular NN NN O
recreational NN NN O
cocaine NN NN O
users NN NN O
. NN NN O
   
INTRODUCTION NN NN O
: NN NN O
The NN NN O
ability NN NN O
to NN NN O
read NN NN O
facial NN NN O
expressions NN NN O
is NN NN O
essential NN NN O
for NN NN O
normal NN NN O
human NN NN O
social NN NN O
interaction NN NN O
. NN NN O
   
The NN NN O
aim NN NN O
of NN NN O
the NN NN O
present NN NN O
study NN NN O
was NN NN O
to NN NN O
conduct NN NN O
the NN NN O
first NN NN O
investigation NN NN O
of NN NN O
facial NN NN O
expression NN NN O
recognition NN NN O
performance NN NN O
in NN NN O
recreational NN NN O
cocaine NN NN O
users NN NN O
. NN NN O
   
MATERIALS NN NN O
AND NN NN O
METHODS NN NN O
: NN NN O
Three NN NN O
groups NN NN O
, NN NN O
comprised NN NN O
of NN NN O
21 NN NN O
cocaine NN NN O
naive NN NN O
participants NN NN O
( NN NN O
CN NN NN O
) NN NN O
, NN NN O
30 NN NN O
occasional NN NN O
cocaine NN NN O
( NN NN O
OC NN NN O
) NN NN O
, NN NN O
and NN NN O
48 NN NN O
regular NN NN O
recreational NN NN O
cocaine NN NN O
( NN NN O
RC NN NN O
) NN NN O
users NN NN O
, NN NN O
were NN NN O
compared NN NN O
. NN NN O
   
An NN NN O
emotional NN NN O
facial NN NN O
expression NN NN O
( NN NN O
EFE NN NN O
) NN NN O
task NN NN O
consisting NN NN O
of NN NN O
a NN NN O
male NN NN O
and NN NN O
female NN NN O
face NN NN O
expressing NN NN O
six NN NN O
basic NN NN O
emotions NN NN O
( NN NN O
happiness NN NN O
, NN NN O
surprise NN NN O
, NN NN O
sadness NN NN O
, NN NN O
anger NN NN O
, NN NN O
fear NN NN O
, NN NN O
and NN NN O
disgust NN NN O
) NN NN O
was NN NN O
administered NN NN O
. NN NN O
   
Mean NN NN O
percent NN NN O
accuracy NN NN O
and NN NN O
latencies NN NN O
for NN NN O
correct NN NN O
responses NN NN O
across NN NN O
eight NN NN O
presentations NN NN O
of NN NN O
each NN NN O
basic NN NN O
emotion NN NN O
were NN NN O
derived NN NN O
. NN NN O
   
Participants NN NN O
were NN NN O
also NN NN O
assessed NN NN O
with NN NN O
the NN NN O
"""""""" NN NN O
Eyes NN NN O
task NN NN O
"""""""" NN NN O
to NN NN O
investigate NN NN O
their NN NN O
ability NN NN O
to NN NN O
recognize NN NN O
more NN NN O
complex NN NN O
emotional NN NN O
states NN NN O
and NN NN O
the NN NN O
Symptom NN NN O
CheckList NN NN O
- NN NN O
90 NN NN O
- NN NN O
Revised NN NN O
to NN NN O
measure NN NN O
psychopathology NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
There NN NN O
were NN NN O
no NN NN O
group NN NN O
differences NN NN O
in NN NN O
psychopathology NN NN O
or NN NN O
"""""""" NN NN O
eyes NN NN O
task NN NN O
"""""""" NN NN O
performance NN NN O
, NN NN O
but NN NN O
the NN NN O
RC NN NN O
group NN NN O
, NN NN O
who NN NN O
otherwise NN NN O
had NN NN O
similar NN NN O
illicit NN NN O
substance NN NN O
use NN NN O
histories NN NN O
to NN NN O
the NN NN O
OC NN NN O
group NN NN O
, NN NN O
exhibited NN NN O
impaired NN NN B-Disease
fear NN NN I-Disease
recognition NN NN I-Disease
accuracy NN NN O
compared NN NN O
to NN NN O
the NN NN O
OC NN NN O
and NN NN O
CN NN NN O
groups NN NN O
. NN NN O
   
The NN NN O
RC NN NN O
group NN NN O
also NN NN O
correctly NN NN O
identified NN NN O
anger NN NN O
, NN NN O
fear NN NN O
, NN NN O
happiness NN NN O
, NN NN O
and NN NN O
surprise NN NN O
, NN NN O
more NN NN O
slowly NN NN O
than NN NN O
CN NN NN O
, NN NN O
but NN NN O
not NN NN O
OC NN NN O
participants NN NN O
. NN NN O
   
The NN NN O
OC NN NN O
group NN NN O
was NN NN O
slower NN NN O
than NN NN O
CN NN NN O
when NN NN O
correctly NN NN O
identifying NN NN O
disgust NN NN O
. NN NN O
   
The NN NN O
selective NN NN O
deficit NN NN B-Disease
in NN NN I-Disease
fear NN NN I-Disease
recognition NN NN I-Disease
accuracy NN NN O
manifested NN NN O
by NN NN O
the NN NN O
RC NN NN O
group NN NN O
cannot NN NN O
be NN NN O
explained NN NN O
by NN NN O
the NN NN O
subacute NN NN O
effects NN NN O
of NN NN O
cocaine NN NN O
, NN NN O
or NN NN O
ecstasy NN NN O
, NN NN O
because NN NN O
recent NN NN O
and NN NN O
less NN NN O
recent NN NN O
users NN NN O
of NN NN O
these NN NN O
drugs NN NN O
within NN NN O
this NN NN O
group NN NN O
were NN NN O
similarly NN NN O
impaired NN NN O
. NN NN O
   
Possible NN NN O
parallels NN NN O
between NN NN O
RC NN NN O
users NN NN O
and NN NN O
psychopaths NN NN B-Disease
with NN NN O
respect NN NN O
to NN NN O
impaired NN NN B-Disease
fear NN NN I-Disease
recognition NN NN I-Disease
, NN NN O
amygdala NN NN B-Disease
dysfunction NN NN I-Disease
, NN NN O
and NN NN O
etiology NN NN O
are NN NN O
discussed NN NN O
. NN NN O
   
Damage NN NN B-Disease
of NN NN I-Disease
substantia NN NN I-Disease
nigra NN NN I-Disease
pars NN NN I-Disease
reticulata NN NN I-Disease
during NN NN O
pilocarpine NN NN O
- NN NN O
induced NN NN O
status NN NN B-Disease
epilepticus NN NN I-Disease
in NN NN O
the NN NN O
rat NN NN O
: NN NN O
immunohistochemical NN NN O
study NN NN O
of NN NN O
neurons NN NN O
, NN NN O
astrocytes NN NN O
and NN NN O
serum NN NN O
- NN NN O
protein NN NN O
extravasation NN NN O
. NN NN O
   
The NN NN O
substantia NN NN O
nigra NN NN O
has NN NN O
a NN NN O
gating NN NN O
function NN NN O
controlling NN NN O
the NN NN O
spread NN NN O
of NN NN O
epileptic NN NN B-Disease
seizure NN NN I-Disease
activity NN NN O
. NN NN O
   
Additionally NN NN O
, NN NN O
in NN NN O
models NN NN O
of NN NN O
prolonged NN NN B-Disease
status NN NN I-Disease
epilepticus NN NN I-Disease
the NN NN O
pars NN NN O
reticulata NN NN O
of NN NN O
substantia NN NN O
nigra NN NN O
( NN NN O
SNR NN NN O
) NN NN O
suffers NN NN O
from NN NN O
a NN NN O
massive NN NN O
lesion NN NN O
which NN NN O
may NN NN O
arise NN NN O
from NN NN O
a NN NN O
massive NN NN O
metabolic NN NN B-Disease
derangement NN NN I-Disease
and NN NN O
hyperexcitation NN NN O
developing NN NN O
in NN NN O
the NN NN O
activated NN NN O
SNR NN NN O
. NN NN O
   
In NN NN O
this NN NN O
study NN NN O
, NN NN O
status NN NN B-Disease
epilepticus NN NN I-Disease
was NN NN O
induced NN NN O
by NN NN O
systemic NN NN O
injection NN NN O
of NN NN O
pilocarpine NN NN O
in NN NN O
rats NN NN O
. NN NN O
   
The NN NN O
neuropathology NN NN O
of NN NN O
SNR NN NN O
was NN NN O
investigated NN NN O
using NN NN O
immunohistochemical NN NN O
techniques NN NN O
with NN NN O
the NN NN O
major NN NN O
emphasis NN NN O
on NN NN O
the NN NN O
time NN NN O
- NN NN O
course NN NN O
of NN NN O
changes NN NN O
in NN NN O
neurons NN NN O
and NN NN O
astrocytes NN NN O
. NN NN O
   
Animals NN NN O
surviving NN NN O
20 NN NN O
, NN NN O
30 NN NN O
, NN NN O
40 NN NN O
, NN NN O
60 NN NN O
min NN NN O
, NN NN O
2 NN NN O
, NN NN O
3 NN NN O
, NN NN O
6 NN NN O
hours NN NN O
, NN NN O
1 NN NN O
, NN NN O
2 NN NN O
, NN NN O
and NN NN O
3 NN NN O
days NN NN O
after NN NN O
induction NN NN O
of NN NN O
status NN NN B-Disease
epilepticus NN NN I-Disease
were NN NN O
perfusion NN NN O
- NN NN O
fixed NN NN O
, NN NN O
and NN NN O
brains NN NN O
processed NN NN O
for NN NN O
immunohistochemical NN NN O
staining NN NN O
of NN NN O
SNR NN NN O
. NN NN O
   
Nissl NN NN O
- NN NN O
staining NN NN O
and NN NN O
antibodies NN NN O
against NN NN O
the NN NN O
neuron NN NN O
- NN NN O
specific NN NN O
calcium NN NN O
- NN NN O
binding NN NN O
protein NN NN O
, NN NN O
parvalbumin NN NN O
, NN NN O
served NN NN O
to NN NN O
detect NN NN O
neuronal NN NN B-Disease
damage NN NN I-Disease
in NN NN O
SNR NN NN O
. NN NN O
   
Antibodies NN NN O
against NN NN O
the NN NN O
astroglia NN NN O
- NN NN O
specific NN NN O
cytoskeletal NN NN O
protein NN NN O
, NN NN O
glial NN NN O
fibrillary NN NN O
acidic NN NN O
protein NN NN O
( NN NN O
GFAP NN NN O
) NN NN O
, NN NN O
and NN NN O
against NN NN O
the NN NN O
glial NN NN O
calcium NN NN O
- NN NN O
binding NN NN O
protein NN NN O
, NN NN O
S NN NN O
- NN NN O
100 NN NN O
protein NN NN O
, NN NN O
were NN NN O
used NN NN O
to NN NN O
assess NN NN O
the NN NN O
status NN NN O
of NN NN O
astrocytes NN NN O
. NN NN O
   
Immunohistochemical NN NN O
staining NN NN O
for NN NN O
serum NN NN O
- NN NN O
albumin NN NN O
and NN NN O
immunoglobulins NN NN O
in NN NN O
brain NN NN O
tissue NN NN O
was NN NN O
taken NN NN O
as NN NN O
indicator NN NN O
of NN NN O
blood NN NN O
- NN NN O
brain NN NN O
barrier NN NN O
disturbances NN NN O
and NN NN O
vasogenic NN NN B-Disease
edema NN NN I-Disease
formation NN NN O
. NN NN O
   
Immunohistochemical NN NN O
staining NN NN O
indicated NN NN O
loss NN NN O
of NN NN O
GFAP NN NN O
- NN NN O
staining NN NN O
already NN NN O
at NN NN O
30 NN NN O
min NN NN O
after NN NN O
induction NN NN O
of NN NN O
seizures NN NN B-Disease
in NN NN O
an NN NN O
oval NN NN O
focus NN NN O
situated NN NN O
in NN NN O
the NN NN O
center NN NN O
of NN NN O
SNR NN NN O
while NN NN O
sparing NN NN O
medial NN NN O
and NN NN O
lateral NN NN O
aspects NN NN O
. NN NN O
   
At NN NN O
1 NN NN O
h NN NN O
there NN NN O
was NN NN O
additional NN NN O
vacuolation NN NN O
in NN NN O
S NN NN O
- NN NN O
100 NN NN O
protein NN NN O
staining NN NN O
. NN NN O
   
By NN NN O
2 NN NN O
hours NN NN O
, NN NN O
parvalbumin NN NN O
- NN NN O
staining NN NN O
changed NN NN O
in NN NN O
the NN NN O
central NN NN O
SNR NN NN O
indicating NN NN O
neuronal NN NN B-Disease
damage NN NN I-Disease
, NN NN O
and NN NN O
Nissl NN NN O
- NN NN O
staining NN NN O
visualized NN NN O
some NN NN O
neuronal NN NN O
distortion NN NN O
. NN NN O
   
Staining NN NN O
for NN NN O
serum NN NN O
- NN NN O
proteins NN NN O
occurred NN NN O
in NN NN O
a NN NN O
patchy NN NN O
manner NN NN O
throughout NN NN O
the NN NN O
forebrain NN NN O
during NN NN O
the NN NN O
first NN NN O
hours NN NN O
. NN NN O
   
By NN NN O
6 NN NN O
h NN NN O
, NN NN O
vasogenic NN NN B-Disease
edema NN NN I-Disease
covered NN NN O
the NN NN O
lesioned NN NN B-Disease
SNR NN NN I-Disease
. NN NN O
   
By NN NN O
24 NN NN O
h NN NN O
, NN NN O
glial NN NN O
and NN NN O
neuronal NN NN O
markers NN NN O
indicated NN NN O
a NN NN O
massive NN NN O
lesion NN NN O
in NN NN O
the NN NN O
center NN NN O
of NN NN O
SNR NN NN O
. NN NN O
   
By NN NN O
48 NN NN O
- NN NN O
72 NN NN O
h NN NN O
, NN NN O
astrocytes NN NN O
surrounding NN NN O
the NN NN O
lesion NN NN O
increased NN NN O
in NN NN O
size NN NN O
, NN NN O
and NN NN O
polymorphic NN NN O
phagocytotic NN NN O
cells NN NN O
invaded NN NN O
the NN NN O
damaged NN NN O
area NN NN O
. NN NN O
   
In NN NN O
a NN NN O
further NN NN O
group NN NN O
of NN NN O
animals NN NN O
surviving NN NN O
1 NN NN O
to NN NN O
5 NN NN O
days NN NN O
, NN NN O
conventional NN NN O
paraffin NN NN O
- NN NN O
sections NN NN O
confirmed NN NN O
the NN NN O
neuronal NN NN O
and NN NN O
glial NN NN O
damage NN NN B-Disease
of NN NN I-Disease
SNR NN NN I-Disease
. NN NN O
   
Additional NN NN O
pathology NN NN O
of NN NN O
similar NN NN O
quality NN NN O
was NN NN O
found NN NN O
in NN NN O
the NN NN O
globus NN NN O
pallidus NN NN O
. NN NN O
   
Since NN NN O
astrocytes NN NN O
were NN NN O
always NN NN O
damaged NN NN O
in NN NN O
parallel NN NN O
with NN NN O
neurons NN NN O
in NN NN O
SNR NN NN O
it NN NN O
is NN NN O
proposed NN NN O
that NN NN O
the NN NN O
anatomical NN NN O
and NN NN O
functional NN NN O
interrelationship NN NN O
between NN NN O
neurons NN NN O
and NN NN O
astrocytes NN NN O
is NN NN O
particularly NN NN O
tight NN NN O
in NN NN O
SNR NN NN O
. NN NN O
   
Both NN NN O
cell NN NN O
elements NN NN O
may NN NN O
suffer NN NN O
in NN NN O
common NN NN O
from NN NN O
metabolic NN NN O
disturbance NN NN O
and NN NN O
neurotransmitter NN NN B-Disease
dysfunction NN NN I-Disease
as NN NN O
occur NN NN O
during NN NN O
massive NN NN O
status NN NN B-Disease
epilepticus NN NN I-Disease
. NN NN O
   
Neuroprotective NN NN O
effects NN NN O
of NN NN O
melatonin NN NN O
upon NN NN O
the NN NN O
offspring NN NN O
cerebellar NN NN O
cortex NN NN O
in NN NN O
the NN NN O
rat NN NN O
model NN NN O
of NN NN O
BCNU NN NN O
- NN NN O
induced NN NN O
cortical NN NN B-Disease
dysplasia NN NN I-Disease
. NN NN O
   
Cortical NN NN B-Disease
dysplasia NN NN I-Disease
is NN NN O
a NN NN O
malformation NN NN O
characterized NN NN O
by NN NN O
defects NN NN O
in NN NN O
proliferation NN NN O
, NN NN O
migration NN NN O
and NN NN O
maturation NN NN O
. NN NN O
   
This NN NN O
study NN NN O
was NN NN O
designed NN NN O
to NN NN O
evaluate NN NN O
the NN NN O
alterations NN NN O
in NN NN O
offspring NN NN O
rat NN NN O
cerebellum NN NN O
induced NN NN O
by NN NN O
maternal NN NN O
exposure NN NN O
to NN NN O
carmustine NN NN O
- NN NN O
[ NN NN O
1 NN NN O
, NN NN O
3 NN NN O
- NN NN O
bis NN NN O
( NN NN O
2 NN NN O
- NN NN O
chloroethyl NN NN O
) NN NN O
- NN NN O
1 NN NN O
- NN NN O
nitrosoure NN NN O
] NN NN O
( NN NN O
BCNU NN NN O
) NN NN O
and NN NN O
to NN NN O
investigate NN NN O
the NN NN O
effects NN NN O
of NN NN O
exogenous NN NN O
melatonin NN NN O
upon NN NN O
cerebellar NN NN O
BCNU NN NN O
- NN NN O
induced NN NN O
cortical NN NN B-Disease
dysplasia NN NN I-Disease
, NN NN O
using NN NN O
histological NN NN O
and NN NN O
biochemical NN NN O
analyses NN NN O
. NN NN O
   
Pregnant NN NN O
Wistar NN NN O
rats NN NN O
were NN NN O
assigned NN NN O
to NN NN O
five NN NN O
groups NN NN O
: NN NN O
intact NN NN O
- NN NN O
control NN NN O
, NN NN O
saline NN NN O
- NN NN O
control NN NN O
, NN NN O
melatonin NN NN O
- NN NN O
treated NN NN O
, NN NN O
BCNU NN NN O
- NN NN O
exposed NN NN O
and NN NN O
BCNU NN NN O
- NN NN O
exposed NN NN O
plus NN NN O
melatonin NN NN O
. NN NN O
   
Rats NN NN O
were NN NN O
exposed NN NN O
to NN NN O
BCNU NN NN O
on NN NN O
embryonic NN NN O
day NN NN O
15 NN NN O
and NN NN O
melatonin NN NN O
was NN NN O
given NN NN O
until NN NN O
delivery NN NN O
. NN NN O
   
Immuno NN NN O
/ NN NN O
histochemistry NN NN O
and NN NN O
electron NN NN O
microscopy NN NN O
were NN NN O
carried NN NN O
out NN NN O
on NN NN O
the NN NN O
offspring NN NN O
cerebellum NN NN O
, NN NN O
and NN NN O
levels NN NN O
of NN NN O
malondialdehyde NN NN O
and NN NN O
superoxide NN NN O
dismutase NN NN O
were NN NN O
determined NN NN O
. NN NN O
   
Histopathologically NN NN O
, NN NN O
typical NN NN O
findings NN NN O
were NN NN O
observed NN NN O
in NN NN O
the NN NN O
cerebella NN NN O
from NN NN O
the NN NN O
control NN NN O
groups NN NN O
, NN NN O
but NN NN O
the NN NN O
findings NN NN O
consistent NN NN O
with NN NN O
early NN NN O
embryonic NN NN O
development NN NN O
were NN NN O
noted NN NN O
in NN NN O
BCNU NN NN O
- NN NN O
exposed NN NN O
cortical NN NN B-Disease
dysplasia NN NN I-Disease
group NN NN O
. NN NN O
   
There NN NN O
was NN NN O
a NN NN O
marked NN NN O
increase NN NN O
in NN NN O
the NN NN O
number NN NN O
of NN NN O
TUNEL NN NN O
positive NN NN O
cells NN NN O
and NN NN O
nestin NN NN O
positive NN NN O
cells NN NN O
in NN NN O
BCNU NN NN O
- NN NN O
exposed NN NN O
group NN NN O
, NN NN O
but NN NN O
a NN NN O
decreased NN NN O
immunoreactivity NN NN O
to NN NN O
glial NN NN O
fibrillary NN NN O
acidic NN NN O
protein NN NN O
, NN NN O
synaptophysin NN NN O
and NN NN O
transforming NN NN O
growth NN NN O
factor NN NN O
beta1 NN NN O
was NN NN O
observed NN NN O
, NN NN O
indicating NN NN O
a NN NN O
delayed NN NN O
maturation NN NN O
, NN NN O
and NN NN O
melatonin NN NN O
significantly NN NN O
reversed NN NN O
these NN NN O
changes NN NN O
. NN NN O
   
Malondialdehyde NN NN O
level NN NN O
in NN NN O
BCNU NN NN O
- NN NN O
exposed NN NN O
group NN NN O
was NN NN O
higher NN NN O
than NN NN O
those NN NN O
in NN NN O
control NN NN O
groups NN NN O
and NN NN O
melatonin NN NN O
decreased NN NN O
malondialdehyde NN NN O
levels NN NN O
in NN NN O
BCNU NN NN O
group NN NN O
( NN NN O
P NN NN O
< NN NN O
0 NN NN O
. NN NN O
01 NN NN O
) NN NN O
, NN NN O
while NN NN O
there NN NN O
were NN NN O
no NN NN O
significant NN NN O
differences NN NN O
in NN NN O
the NN NN O
superoxide NN NN O
dismutase NN NN O
levels NN NN O
between NN NN O
these NN NN O
groups NN NN O
. NN NN O
   
These NN NN O
data NN NN O
suggest NN NN O
that NN NN O
exposure NN NN O
of NN NN O
animals NN NN O
to NN NN O
BCNU NN NN O
during NN NN O
pregnancy NN NN O
leads NN NN O
to NN NN O
delayed NN NN O
maturation NN NN O
of NN NN O
offspring NN NN O
cerebellum NN NN O
and NN NN O
melatonin NN NN O
protects NN NN O
the NN NN O
cerebellum NN NN O
against NN NN O
the NN NN O
effects NN NN O
of NN NN O
BCNU NN NN O
. NN NN O
   
Reduced NN NN O
cardiotoxicity NN NN B-Disease
of NN NN O
doxorubicin NN NN O
given NN NN O
in NN NN O
the NN NN O
form NN NN O
of NN NN O
N NN NN O
- NN NN O
( NN NN O
2 NN NN O
- NN NN O
hydroxypropyl NN NN O
) NN NN O
methacrylamide NN NN O
conjugates NN NN O
: NN NN O
and NN NN O
experimental NN NN O
study NN NN O
in NN NN O
the NN NN O
rat NN NN O
. NN NN O
   
A NN NN O
rat NN NN O
model NN NN O
was NN NN O
used NN NN O
to NN NN O
evaluate NN NN O
the NN NN O
general NN NN O
acute NN NN O
toxicity NN NN B-Disease
and NN NN O
the NN NN O
late NN NN O
cardiotoxicity NN NN B-Disease
of NN NN O
4 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
doxorubicin NN NN O
( NN NN O
DOX NN NN O
) NN NN O
given NN NN O
either NN NN O
as NN NN O
free NN NN O
drug NN NN O
or NN NN O
in NN NN O
the NN NN O
form NN NN O
of NN NN O
three NN NN O
N NN NN O
- NN NN O
( NN NN O
2 NN NN O
- NN NN O
hydroxypropyl NN NN O
) NN NN O
methacrylamide NN NN O
( NN NN O
HPMA NN NN O
) NN NN O
copolymer NN NN O
conjugates NN NN O
. NN NN O
   
In NN NN O
these NN NN O
HPMA NN NN O
copolymers NN NN O
, NN NN O
DOX NN NN O
was NN NN O
covalently NN NN O
bound NN NN O
via NN NN O
peptide NN NN O
linkages NN NN O
that NN NN O
were NN NN O
either NN NN O
non NN NN O
- NN NN O
biodegradable NN NN O
( NN NN O
Gly NN NN O
- NN NN O
Gly NN NN O
) NN NN O
or NN NN O
degradable NN NN O
by NN NN O
lysosomal NN NN O
proteinases NN NN O
( NN NN O
Gly NN NN O
- NN NN O
Phe NN NN O
- NN NN O
Leu NN NN O
- NN NN O
Gly NN NN O
) NN NN O
. NN NN O
   
In NN NN O
addition NN NN O
, NN NN O
one NN NN O
biodegradable NN NN O
conjugate NN NN O
containing NN NN O
galactosamine NN NN O
was NN NN O
used NN NN O
; NN NN O
this NN NN O
residue NN NN O
was NN NN O
targeted NN NN O
to NN NN O
the NN NN O
liver NN NN O
. NN NN O
   
Over NN NN O
the NN NN O
first NN NN O
3 NN NN O
weeks NN NN O
after NN NN O
the NN NN O
i NN NN O
. NN NN O
v NN NN O
. NN NN O
administration NN NN O
of NN NN O
free NN NN O
and NN NN O
polymer NN NN O
- NN NN O
bound NN NN O
DOX NN NN O
, NN NN O
all NN NN O
animals NN NN O
showed NN NN O
a NN NN O
transient NN NN O
reduction NN NN O
in NN NN O
body NN NN O
weight NN NN O
. NN NN O
   
However NN NN O
, NN NN O
the NN NN O
maximal NN NN O
reduction NN NN O
in NN NN O
body NN NN O
weight NN NN O
seen NN NN O
in NN NN O
animals NN NN O
that NN NN O
received NN NN O
polymer NN NN O
- NN NN O
bound NN NN O
DOX NN NN O
( NN NN O
4 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
) NN NN O
was NN NN O
significantly NN NN O
lower NN NN O
than NN NN O
that NN NN O
observed NN NN O
in NN NN O
those NN NN O
that NN NN O
received NN NN O
free NN NN O
DOX NN NN O
( NN NN O
4 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
) NN NN O
or NN NN O
a NN NN O
mixture NN NN O
of NN NN O
the NN NN O
unmodified NN NN O
parent NN NN O
HPMA NN NN O
copolymer NN NN O
and NN NN O
free NN NN O
DOX NN NN O
( NN NN O
4 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
; NN NN O
P NN NN O
less NN NN O
than NN NN O
0 NN NN O
. NN NN O
01 NN NN O
) NN NN O
. NN NN O
   
Throughout NN NN O
the NN NN O
study NN NN O
( NN NN O
20 NN NN O
weeks NN NN O
) NN NN O
, NN NN O
deaths NN NN O
related NN NN O
to NN NN O
cardiotoxicity NN NN B-Disease
were NN NN O
observed NN NN O
only NN NN O
in NN NN O
animals NN NN O
that NN NN O
received NN NN O
either NN NN O
free NN NN O
DOX NN NN O
or NN NN O
the NN NN O
mixture NN NN O
of NN NN O
HPMA NN NN O
copolymer NN NN O
and NN NN O
free NN NN O
DOX NN NN O
; NN NN O
in NN NN O
these NN NN O
cases NN NN O
, NN NN O
histological NN NN O
investigations NN NN O
revealed NN NN O
marked NN NN O
changes NN NN O
in NN NN O
the NN NN O
heart NN NN O
that NN NN O
were NN NN O
consistent NN NN O
with NN NN O
DOX NN NN O
- NN NN O
induced NN NN O
cardiotoxicity NN NN B-Disease
. NN NN O
   
Sequential NN NN O
measurements NN NN O
of NN NN O
cardiac NN NN O
output NN NN O
in NN NN O
surviving NN NN O
animals NN NN O
that NN NN O
received NN NN O
either NN NN O
free NN NN O
DOX NN NN O
or NN NN O
the NN NN O
mixture NN NN O
of NN NN O
HPMA NN NN O
copolymer NN NN O
and NN NN O
free NN NN O
DOX NN NN O
showed NN NN O
a NN NN O
reduction NN NN O
of NN NN O
approximately NN NN O
30 NN NN O
% NN NN O
in NN NN O
function NN NN O
beginning NN NN O
at NN NN O
the NN NN O
4th NN NN O
week NN NN O
after NN NN O
drug NN NN O
administration NN NN O
. NN NN O
   
The NN NN O
heart NN NN O
rate NN NN O
in NN NN O
these NN NN O
animals NN NN O
was NN NN O
approximately NN NN O
12 NN NN O
% NN NN O
lower NN NN O
than NN NN O
that NN NN O
measured NN NN O
in NN NN O
age NN NN O
- NN NN O
matched NN NN O
control NN NN O
rats NN NN O
( NN NN O
P NN NN O
less NN NN O
than NN NN O
0 NN NN O
. NN NN O
05 NN NN O
) NN NN O
. NN NN O
   
Animals NN NN O
that NN NN O
were NN NN O
given NN NN O
the NN NN O
HPMA NN NN O
copolymer NN NN O
conjugates NN NN O
containing NN NN O
DOX NN NN O
exhibited NN NN O
no NN NN O
significant NN NN O
change NN NN O
in NN NN O
cardiac NN NN O
output NN NN O
throughout NN NN O
the NN NN O
study NN NN O
( NN NN O
P NN NN O
less NN NN O
than NN NN O
0 NN NN O
. NN NN O
05 NN NN O
) NN NN O
. NN NN O
   
In NN NN O
addition NN NN O
, NN NN O
no NN NN O
significant NN NN O
histological NN NN O
change NN NN O
was NN NN O
observed NN NN O
in NN NN O
the NN NN O
heart NN NN O
of NN NN O
animals NN NN O
that NN NN O
received NN NN O
DOX NN NN O
in NN NN O
the NN NN O
form NN NN O
of NN NN O
HPMA NN NN O
copolymer NN NN O
conjugates NN NN O
and NN NN O
were NN NN O
killed NN NN O
at NN NN O
the NN NN O
end NN NN O
of NN NN O
the NN NN O
study NN NN O
. NN NN O
   
However NN NN O
, NN NN O
these NN NN O
animals NN NN O
had NN NN O
shown NN NN O
a NN NN O
significant NN NN O
increase NN NN O
in NN NN O
heart NN NN O
rate NN NN O
beginning NN NN O
at NN NN O
8 NN NN O
weeks NN NN O
after NN NN O
drug NN NN O
administration NN NN O
( NN NN O
P NN NN O
less NN NN O
than NN NN O
0 NN NN O
. NN NN O
01 NN NN O
) NN NN O
. NN NN O
( NN NN O
ABSTRACT NN NN O
TRUNCATED NN NN O
AT NN NN O
400 NN NN O
WORDS NN NN O
) NN NN O
   
Corneal NN NN B-Disease
ulcers NN NN I-Disease
associated NN NN O
with NN NN O
aerosolized NN NN O
crack NN NN O
cocaine NN NN O
use NN NN O
. NN NN O
   
PURPOSE NN NN O
: NN NN O
We NN NN O
report NN NN O
4 NN NN O
cases NN NN O
of NN NN O
corneal NN NN B-Disease
ulcers NN NN I-Disease
associated NN NN O
with NN NN O
drug NN NN B-Disease
abuse NN NN I-Disease
. NN NN O
   
The NN NN O
pathogenesis NN NN O
of NN NN O
these NN NN O
ulcers NN NN B-Disease
and NN NN O
management NN NN O
of NN NN O
these NN NN O
patients NN NN O
are NN NN O
also NN NN O
reviewed NN NN O
. NN NN O
   
METHODS NN NN O
: NN NN O
Review NN NN O
of NN NN O
all NN NN O
cases NN NN O
of NN NN O
corneal NN NN B-Disease
ulcers NN NN I-Disease
associated NN NN O
with NN NN O
drug NN NN B-Disease
abuse NN NN I-Disease
seen NN NN O
at NN NN O
our NN NN O
institution NN NN O
from NN NN O
July NN NN O
2006 NN NN O
to NN NN O
December NN NN O
2006 NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
Four NN NN O
patients NN NN O
with NN NN O
corneal NN NN B-Disease
ulcers NN NN I-Disease
associated NN NN O
with NN NN O
crack NN NN O
cocaine NN NN O
use NN NN O
were NN NN O
reviewed NN NN O
. NN NN O
   
All NN NN O
corneal NN NN B-Disease
ulcers NN NN I-Disease
were NN NN O
cultured NN NN O
, NN NN O
and NN NN O
the NN NN O
patients NN NN O
were NN NN O
admitted NN NN O
to NN NN O
the NN NN O
hospital NN NN O
for NN NN O
intensive NN NN O
topical NN NN O
antibiotic NN NN O
treatment NN NN O
. NN NN O
   
Each NN NN O
patient NN NN O
received NN NN O
comprehensive NN NN O
health NN NN O
care NN NN O
, NN NN O
including NN NN O
medical NN NN O
and NN NN O
substance NN NN B-Disease
abuse NN NN I-Disease
consultations NN NN O
. NN NN O
   
Streptococcal NN NN O
organisms NN NN O
were NN NN O
found NN NN O
in NN NN O
3 NN NN O
cases NN NN O
and NN NN O
Capnocytophaga NN NN O
and NN NN O
Brevibacterium NN NN O
casei NN NN O
in NN NN O
1 NN NN O
patient NN NN O
. NN NN O
   
The NN NN O
infections NN NN B-Disease
responded NN NN O
to NN NN O
antibiotic NN NN O
treatment NN NN O
. NN NN O
   
Two NN NN O
patients NN NN O
needed NN NN O
a NN NN O
lateral NN NN O
tarsorrhaphy NN NN O
for NN NN O
persistent NN NN O
epithelial NN NN B-Disease
defects NN NN I-Disease
. NN NN O
   
CONCLUSIONS NN NN O
: NN NN O
Aerosolized NN NN O
crack NN NN O
cocaine NN NN O
use NN NN O
can NN NN O
be NN NN O
associated NN NN O
with NN NN O
the NN NN O
development NN NN O
of NN NN O
corneal NN NN B-Disease
ulcers NN NN I-Disease
. NN NN O
   
Drug NN NN B-Disease
abuse NN NN I-Disease
provides NN NN O
additional NN NN O
challenges NN NN O
for NN NN O
management NN NN O
. NN NN O
   
Not NN NN O
only NN NN O
treatment NN NN O
of NN NN O
their NN NN O
infections NN NN B-Disease
but NN NN O
also NN NN O
the NN NN O
overall NN NN O
poor NN NN O
health NN NN O
of NN NN O
the NN NN O
patients NN NN O
and NN NN O
increased NN NN O
risk NN NN O
of NN NN O
noncompliance NN NN O
need NN NN O
to NN NN O
be NN NN O
addressed NN NN O
. NN NN O
   
Comprehensive NN NN O
care NN NN O
may NN NN O
provide NN NN O
the NN NN O
patient NN NN O
the NN NN O
opportunity NN NN O
to NN NN O
discontinue NN NN O
their NN NN O
substance NN NN B-Disease
abuse NN NN I-Disease
, NN NN O
improve NN NN O
their NN NN O
overall NN NN O
health NN NN O
, NN NN O
and NN NN O
prevent NN NN O
future NN NN O
corneal NN NN O
complications NN NN O
. NN NN O
   
Topical NN NN O
0 NN NN O
. NN NN O
025 NN NN O
% NN NN O
capsaicin NN NN O
in NN NN O
chronic NN NN O
post NN NN B-Disease
- NN NN I-Disease
herpetic NN NN I-Disease
neuralgia NN NN I-Disease
: NN NN O
efficacy NN NN O
, NN NN O
predictors NN NN O
of NN NN O
response NN NN O
and NN NN O
long NN NN O
- NN NN O
term NN NN O
course NN NN O
. NN NN O
   
In NN NN O
order NN NN O
to NN NN O
evaluate NN NN O
the NN NN O
efficacy NN NN O
, NN NN O
time NN NN O
- NN NN O
course NN NN O
of NN NN O
action NN NN O
and NN NN O
predictors NN NN O
of NN NN O
response NN NN O
to NN NN O
topical NN NN O
capsaicin NN NN O
, NN NN O
39 NN NN O
patients NN NN O
with NN NN O
chronic NN NN O
post NN NN B-Disease
- NN NN I-Disease
herpetic NN NN I-Disease
neuralgia NN NN I-Disease
( NN NN O
PHN NN NN B-Disease
) NN NN O
, NN NN O
median NN NN O
duration NN NN O
24 NN NN O
months NN NN O
, NN NN O
were NN NN O
treated NN NN O
with NN NN O
0 NN NN O
. NN NN O
025 NN NN O
% NN NN O
capsaicin NN NN O
cream NN NN O
for NN NN O
8 NN NN O
weeks NN NN O
. NN NN O
   
During NN NN O
therapy NN NN O
the NN NN O
patients NN NN O
rated NN NN O
their NN NN O
pain NN NN B-Disease
on NN NN O
a NN NN O
visual NN NN O
analogue NN NN O
scale NN NN O
( NN NN O
VAS NN NN O
) NN NN O
and NN NN O
a NN NN O
verbal NN NN O
outcome NN NN O
scale NN NN O
. NN NN O
   
A NN NN O
follow NN NN O
- NN NN O
up NN NN O
investigation NN NN O
was NN NN O
performed NN NN O
10 NN NN O
- NN NN O
12 NN NN O
months NN NN O
after NN NN O
study NN NN O
onset NN NN O
on NN NN O
the NN NN O
patients NN NN O
who NN NN O
had NN NN O
improved NN NN O
. NN NN O
   
Nineteen NN NN O
patients NN NN O
( NN NN O
48 NN NN O
. NN NN O
7 NN NN O
% NN NN O
) NN NN O
substantially NN NN O
improved NN NN O
after NN NN O
the NN NN O
8 NN NN O
- NN NN O
week NN NN O
trial NN NN O
; NN NN O
5 NN NN O
( NN NN O
12 NN NN O
. NN NN O
8 NN NN O
% NN NN O
) NN NN O
discontinued NN NN O
therapy NN NN O
due NN NN O
to NN NN O
side NN NN O
- NN NN O
effects NN NN O
such NN NN O
as NN NN O
intolerable NN NN O
capsaicin NN NN O
- NN NN O
induced NN NN O
burning NN NN O
sensations NN NN O
( NN NN O
4 NN NN O
) NN NN O
or NN NN O
mastitis NN NN B-Disease
( NN NN O
1 NN NN O
) NN NN O
; NN NN O
15 NN NN O
( NN NN O
38 NN NN O
. NN NN O
5 NN NN O
% NN NN O
) NN NN O
reported NN NN O
no NN NN O
benefit NN NN O
. NN NN O
   
The NN NN O
decrease NN NN O
in NN NN O
VAS NN NN O
ratings NN NN O
was NN NN O
significant NN NN O
after NN NN O
2 NN NN O
weeks NN NN O
of NN NN O
continuous NN NN O
application NN NN O
. NN NN O
   
Of NN NN O
the NN NN O
responders NN NN O
72 NN NN O
. NN NN O
2 NN NN O
% NN NN O
were NN NN O
still NN NN O
improved NN NN O
at NN NN O
the NN NN O
follow NN NN O
- NN NN O
up NN NN O
; NN NN O
only NN NN O
one NN NN O
- NN NN O
third NN NN O
of NN NN O
them NN NN O
had NN NN O
continued NN NN O
application NN NN O
irregularly NN NN O
. NN NN O
   
Treatment NN NN O
effect NN NN O
was NN NN O
not NN NN O
dependent NN NN O
on NN NN O
patient NN NN O
' NN NN O
s NN NN O
age NN NN O
, NN NN O
duration NN NN O
or NN NN O
localization NN NN O
of NN NN O
PHN NN NN B-Disease
( NN NN O
trigeminal NN NN O
involvement NN NN O
was NN NN O
excluded NN NN O
) NN NN O
, NN NN O
sensory NN NN B-Disease
disturbance NN NN I-Disease
or NN NN O
pain NN NN B-Disease
character NN NN O
. NN NN O
   
Treatment NN NN O
response NN NN O
was NN NN O
not NN NN O
correlated NN NN O
with NN NN O
the NN NN O
incidence NN NN O
, NN NN O
time NN NN O
- NN NN O
course NN NN O
or NN NN O
severity NN NN O
of NN NN O
capsaicin NN NN O
- NN NN O
induced NN NN O
burning NN NN O
. NN NN O
   
If NN NN O
confirmed NN NN O
in NN NN O
controlled NN NN O
trials NN NN O
, NN NN O
the NN NN O
long NN NN O
- NN NN O
term NN NN O
results NN NN O
of NN NN O
this NN NN O
open NN NN O
, NN NN O
non NN NN O
- NN NN O
randomized NN NN O
study NN NN O
might NN NN O
indicate NN NN O
that NN NN O
the NN NN O
analgesic NN NN O
effect NN NN O
of NN NN O
capsaicin NN NN O
in NN NN O
PHN NN NN B-Disease
is NN NN O
mediated NN NN O
by NN NN O
both NN NN O
interference NN NN O
with NN NN O
neuropeptide NN NN O
metabolism NN NN O
and NN NN O
morphological NN NN O
changes NN NN O
( NN NN O
perhaps NN NN O
degeneration NN NN O
) NN NN O
of NN NN O
nociceptive NN NN O
afferents NN NN O
. NN NN O
   
Myo NN NN O
- NN NN O
inositol NN NN O
- NN NN O
1 NN NN O
- NN NN O
phosphate NN NN O
( NN NN O
MIP NN NN O
) NN NN O
synthase NN NN O
inhibition NN NN O
: NN NN O
in NN NN O
- NN NN O
vivo NN NN O
study NN NN O
in NN NN O
rats NN NN O
. NN NN O
   
Lithium NN NN O
and NN NN O
valproate NN NN O
are NN NN O
the NN NN O
prototypic NN NN O
mood NN NN O
stabilizers NN NN O
and NN NN O
have NN NN O
diverse NN NN O
structures NN NN O
and NN NN O
targets NN NN O
. NN NN O
   
Both NN NN O
drugs NN NN O
influence NN NN O
inositol NN NN O
metabolism NN NN O
. NN NN O
   
Lithium NN NN O
inhibits NN NN O
IMPase NN NN O
and NN NN O
valproate NN NN O
inhibits NN NN O
MIP NN NN O
synthase NN NN O
. NN NN O
   
This NN NN O
study NN NN O
shows NN NN O
that NN NN O
MIP NN NN O
synthase NN NN O
inhibition NN NN O
does NN NN O
not NN NN O
replicate NN NN O
or NN NN O
augment NN NN O
the NN NN O
effects NN NN O
of NN NN O
lithium NN NN O
in NN NN O
the NN NN O
inositol NN NN O
sensitive NN NN O
pilocarpine NN NN O
- NN NN O
induced NN NN O
seizures NN NN B-Disease
model NN NN O
. NN NN O
   
This NN NN O
lack NN NN O
of NN NN O
effects NN NN O
may NN NN O
stem NN NN O
from NN NN O
the NN NN O
low NN NN O
contribution NN NN O
of NN NN O
de NN NN O
- NN NN O
novo NN NN O
synthesis NN NN O
to NN NN O
cellular NN NN O
inositol NN NN O
supply NN NN O
or NN NN O
to NN NN O
the NN NN O
inhibition NN NN O
of NN NN O
the NN NN O
de NN NN O
- NN NN O
novo NN NN O
synthesis NN NN O
by NN NN O
lithium NN NN O
itself NN NN O
. NN NN O
   
Non NN NN O
- NN NN O
steroidal NN NN O
anti NN NN O
- NN NN O
inflammatory NN NN O
drugs NN NN O
- NN NN O
associated NN NN O
acute NN NN O
interstitial NN NN B-Disease
nephritis NN NN I-Disease
with NN NN O
granular NN NN O
tubular NN NN O
basement NN NN O
membrane NN NN O
deposits NN NN O
. NN NN O
   
Acute NN NN B-Disease
tubulo NN NN I-Disease
- NN NN I-Disease
interstitial NN NN I-Disease
nephritis NN NN I-Disease
( NN NN O
ATIN NN NN B-Disease
) NN NN O
is NN NN O
an NN NN O
important NN NN O
cause NN NN O
of NN NN O
acute NN NN B-Disease
renal NN NN I-Disease
failure NN NN I-Disease
resulting NN NN O
from NN NN O
a NN NN O
variety NN NN O
of NN NN O
insults NN NN O
, NN NN O
including NN NN O
immune NN NN O
complex NN NN O
- NN NN O
mediated NN NN O
tubulo NN NN B-Disease
- NN NN I-Disease
interstitial NN NN I-Disease
injury NN NN I-Disease
, NN NN O
but NN NN O
drugs NN NN O
such NN NN O
as NN NN O
non NN NN O
- NN NN O
steroidal NN NN O
anti NN NN O
- NN NN O
inflammatory NN NN O
drugs NN NN O
( NN NN O
NSAIDs NN NN O
) NN NN O
are NN NN O
a NN NN O
far NN NN O
more NN NN O
frequent NN NN O
cause NN NN O
. NN NN O
   
Overall NN NN O
, NN NN O
as NN NN O
an NN NN O
entity NN NN O
, NN NN O
ATIN NN NN B-Disease
remains NN NN O
under NN NN O
- NN NN O
diagnosed NN NN O
, NN NN O
as NN NN O
symptoms NN NN O
resolve NN NN O
spontaneously NN NN O
if NN NN O
the NN NN O
medication NN NN O
is NN NN O
stopped NN NN O
. NN NN O
   
We NN NN O
report NN NN O
on NN NN O
a NN NN O
14 NN NN O
- NN NN O
year NN NN O
- NN NN O
old NN NN O
boy NN NN O
who NN NN O
developed NN NN O
acute NN NN B-Disease
renal NN NN I-Disease
failure NN NN I-Disease
2 NN NN O
weeks NN NN O
after NN NN O
aortic NN NN O
valve NN NN O
surgery NN NN O
. NN NN O
   
He NN NN O
was NN NN O
put NN NN O
on NN NN O
aspirin NN NN O
following NN NN O
surgery NN NN O
and NN NN O
took NN NN O
ibuprofen NN NN O
for NN NN O
fever NN NN B-Disease
for NN NN O
nearly NN NN O
a NN NN O
week NN NN O
prior NN NN O
to NN NN O
presentation NN NN O
. NN NN O
   
He NN NN O
then NN NN O
presented NN NN O
to NN NN O
the NN NN O
emergency NN NN O
department NN NN O
feeling NN NN O
quite NN NN O
ill NN NN O
and NN NN O
was NN NN O
found NN NN O
to NN NN O
have NN NN O
a NN NN O
blood NN NN O
urea NN NN O
nitrogen NN NN O
( NN NN O
BUN NN NN O
) NN NN O
concentration NN NN O
of NN NN O
of NN NN O
147 NN NN O
mg NN NN O
/ NN NN O
dl NN NN O
, NN NN O
creatinine NN NN O
of NN NN O
15 NN NN O
. NN NN O
3 NN NN O
mg NN NN O
/ NN NN O
dl NN NN O
and NN NN O
serum NN NN O
potassium NN NN O
of NN NN O
8 NN NN O
. NN NN O
7 NN NN O
mEq NN NN O
/ NN NN O
l NN NN O
. NN NN O
   
Dialysis NN NN O
was NN NN O
immediately NN NN O
initiated NN NN O
. NN NN O
   
A NN NN O
kidney NN NN O
biopsy NN NN O
showed NN NN O
inflammatory NN NN O
infiltrate NN NN O
consistent NN NN O
with NN NN O
ATIN NN NN B-Disease
. NN NN O
   
However NN NN O
, NN NN O
in NN NN O
the NN NN O
tubular NN NN O
basement NN NN O
membrane NN NN O
( NN NN O
TBM NN NN O
) NN NN O
, NN NN O
very NN NN O
intense NN NN O
granular NN NN O
deposits NN NN O
of NN NN O
polyclonal NN NN O
IgG NN NN O
and NN NN O
C3 NN NN O
were NN NN O
noted NN NN O
. NN NN O
   
He NN NN O
needed NN NN O
dialysis NN NN O
for NN NN O
2 NN NN O
weeks NN NN O
and NN NN O
was NN NN O
treated NN NN O
successfully NN NN O
with NN NN O
steroids NN NN O
for NN NN O
6 NN NN O
months NN NN O
. NN NN O
   
His NN NN O
renal NN NN O
recovery NN NN O
and NN NN O
disappearance NN NN O
of NN NN O
proteinuria NN NN B-Disease
took NN NN O
a NN NN O
year NN NN O
. NN NN O
   
In NN NN O
conclusion NN NN O
, NN NN O
this NN NN O
is NN NN O
a NN NN O
first NN NN O
report NN NN O
of NN NN O
NSAIDs NN NN O
- NN NN O
associated NN NN O
ATIN NN NN B-Disease
, NN NN O
showing NN NN O
deposits NN NN O
of NN NN O
granular NN NN O
immune NN NN O
complex NN NN O
present NN NN O
only NN NN O
in NN NN O
the NN NN O
TBM NN NN O
and NN NN O
not NN NN O
in NN NN O
the NN NN O
glomeruli NN NN O
. NN NN O
   
Rifampicin NN NN O
- NN NN O
associated NN NN O
segmental NN NN O
necrotizing NN NN O
glomerulonephritis NN NN B-Disease
in NN NN O
staphylococcal NN NN B-Disease
endocarditis NN NN I-Disease
. NN NN O
   
Segmental NN NN O
necrotising NN NN O
glomerulonephritis NN NN B-Disease
has NN NN O
been NN NN O
reported NN NN O
as NN NN O
complication NN NN O
of NN NN O
rifampicin NN NN O
therapy NN NN O
in NN NN O
patients NN NN O
receiving NN NN O
treatment NN NN O
for NN NN O
tuberculosis NN NN B-Disease
. NN NN O
   
Changing NN NN O
epidemiology NN NN O
of NN NN O
infections NN NN B-Disease
such NN NN O
as NN NN O
infective NN NN B-Disease
endocarditis NN NN I-Disease
( NN NN O
IE NN NN B-Disease
) NN NN O
has NN NN O
led NN NN O
to NN NN O
an NN NN O
increase NN NN O
in NN NN O
the NN NN O
use NN NN O
of NN NN O
rifampicin NN NN O
for NN NN O
Staphylococcal NN NN B-Disease
infections NN NN I-Disease
. NN NN O
   
We NN NN O
describe NN NN O
a NN NN O
case NN NN O
of NN NN O
a NN NN O
patient NN NN O
with NN NN O
Staphylococcal NN NN B-Disease
IE NN NN I-Disease
who NN NN O
developed NN NN O
acute NN NN B-Disease
renal NN NN I-Disease
failure NN NN I-Disease
secondary NN NN O
to NN NN O
a NN NN O
segmental NN NN O
necrotising NN NN O
glomerulonephritis NN NN B-Disease
while NN NN O
being NN NN O
treated NN NN O
with NN NN O
rifampicin NN NN O
, NN NN O
and NN NN O
review NN NN O
the NN NN O
literature NN NN O
regarding NN NN O
this NN NN O
complication NN NN O
of NN NN O
rifampicin NN NN O
therapy NN NN O
. NN NN O
   
Rate NN NN O
of NN NN O
YMDD NN NN O
motif NN NN O
mutants NN NN O
in NN NN O
lamivudine NN NN O
- NN NN O
untreated NN NN O
Iranian NN NN O
patients NN NN O
with NN NN O
chronic NN NN B-Disease
hepatitis NN NN I-Disease
B NN NN I-Disease
virus NN NN I-Disease
infection NN NN I-Disease
. NN NN O
   
BACKGROUND NN NN O
: NN NN O
Lamivudine NN NN O
is NN NN O
used NN NN O
for NN NN O
the NN NN O
treatment NN NN O
of NN NN O
chronic NN NN B-Disease
hepatitis NN NN I-Disease
B NN NN I-Disease
patients NN NN O
. NN NN O
   
Recent NN NN O
studies NN NN O
show NN NN O
that NN NN O
the NN NN O
YMDD NN NN O
motif NN NN O
mutants NN NN O
( NN NN O
resistant NN NN O
hepatitis NN NN B-Disease
B NN NN I-Disease
virus NN NN O
) NN NN O
occur NN NN O
as NN NN O
natural NN NN O
genome NN NN O
variability NN NN O
in NN NN O
lamivudine NN NN O
- NN NN O
untreated NN NN O
chronic NN NN B-Disease
hepatitis NN NN I-Disease
B NN NN I-Disease
patients NN NN O
. NN NN O
   
In NN NN O
this NN NN O
study NN NN O
we NN NN O
aimed NN NN O
to NN NN O
determine NN NN O
the NN NN O
rate NN NN O
of NN NN O
YMDD NN NN O
motif NN NN O
mutants NN NN O
in NN NN O
lamivudine NN NN O
- NN NN O
untreated NN NN O
chronic NN NN B-Disease
hepatitis NN NN I-Disease
B NN NN I-Disease
patients NN NN O
in NN NN O
Iran NN NN O
. NN NN O
   
PATIENTS NN NN O
AND NN NN O
METHODS NN NN O
: NN NN O
A NN NN O
total NN NN O
of NN NN O
77 NN NN O
chronic NN NN B-Disease
hepatitis NN NN I-Disease
B NN NN I-Disease
patients NN NN O
who NN NN O
had NN NN O
not NN NN O
been NN NN O
treated NN NN O
with NN NN O
lamivudine NN NN O
were NN NN O
included NN NN O
in NN NN O
the NN NN O
study NN NN O
. NN NN O
   
Serum NN NN O
samples NN NN O
from NN NN O
patients NN NN O
were NN NN O
tested NN NN O
by NN NN O
polymerase NN NN O
chain NN NN O
reaction NN NN O
- NN NN O
restriction NN NN O
fragment NN NN O
length NN NN O
polymorphism NN NN O
( NN NN O
PCR NN NN O
- NN NN O
RFLP NN NN O
) NN NN O
for NN NN O
detection NN NN O
of NN NN O
YMDD NN NN O
motif NN NN O
mutants NN NN O
. NN NN O
   
All NN NN O
patients NN NN O
were NN NN O
also NN NN O
tested NN NN O
for NN NN O
liver NN NN O
enzymes NN NN O
, NN NN O
anti NN NN O
- NN NN O
HCV NN NN O
, NN NN O
HBeAg NN NN O
, NN NN O
and NN NN O
anti NN NN O
- NN NN O
HBe NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
Of NN NN O
the NN NN O
77 NN NN O
patients NN NN O
enrolled NN NN O
in NN NN O
the NN NN O
study NN NN O
, NN NN O
73 NN NN O
% NN NN O
were NN NN O
male NN NN O
and NN NN O
27 NN NN O
% NN NN O
were NN NN O
female NN NN O
. NN NN O
   
Mean NN NN O
ALT NN NN O
and NN NN O
AST NN NN O
levels NN NN O
were NN NN O
124 NN NN O
. NN NN O
4 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
73 NN NN O
. NN NN O
4 NN NN O
and NN NN O
103 NN NN O
. NN NN O
1 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
81 NN NN O
IU NN NN O
/ NN NN O
l NN NN O
, NN NN O
respectively NN NN O
. NN NN O
   
HBeAg NN NN O
was NN NN O
positive NN NN O
in NN NN O
40 NN NN O
% NN NN O
and NN NN O
anti NN NN O
- NN NN O
HBe NN NN O
in NN NN O
60 NN NN O
% NN NN O
of NN NN O
the NN NN O
patients NN NN O
. NN NN O
   
Anti NN NN O
- NN NN O
HCV NN NN O
was NN NN O
negative NN NN O
in NN NN O
all NN NN O
of NN NN O
them NN NN O
. NN NN O
   
YMDD NN NN O
motif NN NN O
mutants NN NN O
were NN NN O
not NN NN O
detected NN NN O
in NN NN O
any NN NN O
of NN NN O
the NN NN O
patients NN NN O
despite NN NN O
the NN NN O
liver NN NN O
enzyme NN NN O
levels NN NN O
and NN NN O
the NN NN O
presence NN NN O
of NN NN O
HBeAg NN NN O
or NN NN O
anti NN NN O
- NN NN O
HBe NN NN O
. NN NN O
   
CONCLUSION NN NN O
: NN NN O
Although NN NN O
the NN NN O
natural NN NN O
occurrence NN NN O
of NN NN O
YMDD NN NN O
motif NN NN O
mutants NN NN O
in NN NN O
lamivudine NN NN O
- NN NN O
untreated NN NN O
patients NN NN O
with NN NN O
chronic NN NN B-Disease
hepatitis NN NN I-Disease
B NN NN I-Disease
has NN NN O
been NN NN O
reported NN NN O
, NN NN O
these NN NN O
mutants NN NN O
were NN NN O
not NN NN O
detected NN NN O
in NN NN O
Iranian NN NN O
lamivudine NN NN O
- NN NN O
untreated NN NN O
chronic NN NN B-Disease
hepatitis NN NN I-Disease
B NN NN I-Disease
patients NN NN O
. NN NN O
   
Branch NN NN O
retinal NN NN B-Disease
vein NN NN I-Disease
occlusion NN NN I-Disease
and NN NN O
fluoxetine NN NN O
. NN NN O
   
A NN NN O
case NN NN O
of NN NN O
branch NN NN O
retinal NN NN B-Disease
vein NN NN I-Disease
occlusion NN NN I-Disease
associated NN NN O
with NN NN O
fluoxetine NN NN O
- NN NN O
induced NN NN O
secondary NN NN O
hypertension NN NN B-Disease
is NN NN O
described NN NN O
. NN NN O
   
Although NN NN O
an NN NN O
infrequent NN NN O
complication NN NN O
of NN NN O
selective NN NN O
serotonin NN NN O
reuptake NN NN O
inhibitor NN NN O
therapy NN NN O
, NN NN O
it NN NN O
is NN NN O
important NN NN O
that NN NN O
ophthalmologists NN NN O
are NN NN O
aware NN NN O
that NN NN O
these NN NN O
agents NN NN O
can NN NN O
cause NN NN O
hypertension NN NN B-Disease
because NN NN O
this NN NN O
class NN NN O
of NN NN O
drugs NN NN O
is NN NN O
widely NN NN O
prescribed NN NN O
. NN NN O
   
The NN NN O
differential NN NN O
effects NN NN O
of NN NN O
bupivacaine NN NN O
and NN NN O
lidocaine NN NN O
on NN NN O
prostaglandin NN NN O
E2 NN NN O
release NN NN O
, NN NN O
cyclooxygenase NN NN O
gene NN NN O
expression NN NN O
and NN NN O
pain NN NN B-Disease
in NN NN O
a NN NN O
clinical NN NN O
pain NN NN B-Disease
model NN NN O
. NN NN O
   
BACKGROUND NN NN O
: NN NN O
In NN NN O
addition NN NN O
to NN NN O
blocking NN NN O
nociceptive NN NN O
input NN NN O
from NN NN O
surgical NN NN O
sites NN NN O
, NN NN O
long NN NN O
- NN NN O
acting NN NN O
local NN NN O
anesthetics NN NN O
might NN NN O
directly NN NN O
modulate NN NN O
inflammation NN NN B-Disease
. NN NN O
   
In NN NN O
the NN NN O
present NN NN O
study NN NN O
, NN NN O
we NN NN O
describe NN NN O
the NN NN O
proinflammatory NN NN O
effects NN NN O
of NN NN O
bupivacaine NN NN O
on NN NN O
local NN NN O
prostaglandin NN NN O
E2 NN NN O
( NN NN O
PGE2 NN NN O
) NN NN O
production NN NN O
and NN NN O
cyclooxygenase NN NN O
( NN NN O
COX NN NN O
) NN NN O
gene NN NN O
expression NN NN O
that NN NN O
increases NN NN O
postoperative NN NN B-Disease
pain NN NN I-Disease
in NN NN O
human NN NN O
subjects NN NN O
. NN NN O
   
METHODS NN NN O
: NN NN O
Subjects NN NN O
( NN NN O
n NN NN O
= NN NN O
114 NN NN O
) NN NN O
undergoing NN NN O
extraction NN NN O
of NN NN O
impacted NN NN O
third NN NN O
molars NN NN O
received NN NN O
either NN NN O
2 NN NN O
% NN NN O
lidocaine NN NN O
or NN NN O
0 NN NN O
. NN NN O
5 NN NN O
% NN NN O
bupivacaine NN NN O
before NN NN O
surgery NN NN O
and NN NN O
either NN NN O
rofecoxib NN NN O
50 NN NN O
mg NN NN O
or NN NN O
placebo NN NN O
orally NN NN O
90 NN NN O
min NN NN O
before NN NN O
surgery NN NN O
and NN NN O
for NN NN O
the NN NN O
following NN NN O
48 NN NN O
h NN NN O
. NN NN O
   
Oral NN NN O
mucosal NN NN O
biopsies NN NN O
were NN NN O
taken NN NN O
before NN NN O
surgery NN NN O
and NN NN O
48 NN NN O
h NN NN O
after NN NN O
surgery NN NN O
. NN NN O
   
After NN NN O
extraction NN NN O
, NN NN O
a NN NN O
microdialysis NN NN O
probe NN NN O
was NN NN O
placed NN NN O
at NN NN O
the NN NN O
surgical NN NN O
site NN NN O
for NN NN O
PGE2 NN NN O
and NN NN O
thromboxane NN NN O
B2 NN NN O
( NN NN O
TXB2 NN NN O
) NN NN O
measurements NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
The NN NN O
bupivacaine NN NN O
/ NN NN O
rofecoxib NN NN O
group NN NN O
reported NN NN O
significantly NN NN O
less NN NN O
pain NN NN B-Disease
, NN NN O
as NN NN O
assessed NN NN O
by NN NN O
a NN NN O
visual NN NN O
analog NN NN O
scale NN NN O
, NN NN O
compared NN NN O
with NN NN O
the NN NN O
other NN NN O
three NN NN O
treatment NN NN O
groups NN NN O
over NN NN O
the NN NN O
first NN NN O
4 NN NN O
h NN NN O
. NN NN O
   
However NN NN O
, NN NN O
the NN NN O
bupivacaine NN NN O
/ NN NN O
placebo NN NN O
group NN NN O
reported NN NN O
significantly NN NN O
more NN NN O
pain NN NN B-Disease
at NN NN O
24 NN NN O
h NN NN O
and NN NN O
PGE2 NN NN O
levels NN NN O
during NN NN O
the NN NN O
first NN NN O
4 NN NN O
h NN NN O
were NN NN O
significantly NN NN O
higher NN NN O
than NN NN O
the NN NN O
other NN NN O
three NN NN O
treatment NN NN O
groups NN NN O
. NN NN O
   
Moreover NN NN O
, NN NN O
bupivacaine NN NN O
significantly NN NN O
increased NN NN O
COX NN NN O
- NN NN O
2 NN NN O
gene NN NN O
expression NN NN O
at NN NN O
48 NN NN O
h NN NN O
as NN NN O
compared NN NN O
with NN NN O
the NN NN O
lidocaine NN NN O
/ NN NN O
placebo NN NN O
group NN NN O
. NN NN O
   
Thromboxane NN NN O
levels NN NN O
were NN NN O
not NN NN O
significantly NN NN O
affected NN NN O
by NN NN O
any NN NN O
of NN NN O
the NN NN O
treatments NN NN O
, NN NN O
indicating NN NN O
that NN NN O
the NN NN O
effects NN NN O
seen NN NN O
were NN NN O
attributable NN NN O
to NN NN O
inhibition NN NN O
of NN NN O
COX NN NN O
- NN NN O
2 NN NN O
, NN NN O
but NN NN O
not NN NN O
COX NN NN O
- NN NN O
1 NN NN O
. NN NN O
   
CONCLUSIONS NN NN O
: NN NN O
These NN NN O
results NN NN O
suggest NN NN O
that NN NN O
bupivacaine NN NN O
stimulates NN NN O
COX NN NN O
- NN NN O
2 NN NN O
gene NN NN O
expression NN NN O
after NN NN O
tissue NN NN B-Disease
injury NN NN I-Disease
, NN NN O
which NN NN O
is NN NN O
associated NN NN O
with NN NN O
higher NN NN O
PGE2 NN NN O
production NN NN O
and NN NN O
pain NN NN B-Disease
after NN NN O
the NN NN O
local NN NN O
anesthetic NN NN O
effect NN NN O
dissipates NN NN O
. NN NN O
   
p75NTR NN NN O
expression NN NN O
in NN NN O
rat NN NN O
urinary NN NN O
bladder NN NN O
sensory NN NN O
neurons NN NN O
and NN NN O
spinal NN NN O
cord NN NN O
with NN NN O
cyclophosphamide NN NN O
- NN NN O
induced NN NN O
cystitis NN NN B-Disease
. NN NN O
   
A NN NN O
role NN NN O
for NN NN O
nerve NN NN O
growth NN NN O
factor NN NN O
( NN NN O
NGF NN NN O
) NN NN O
in NN NN O
contributing NN NN O
to NN NN O
increased NN NN O
voiding NN NN O
frequency NN NN O
and NN NN O
altered NN NN O
sensation NN NN O
from NN NN O
the NN NN O
urinary NN NN O
bladder NN NN O
has NN NN O
been NN NN O
suggested NN NN O
. NN NN O
   
Previous NN NN O
studies NN NN O
have NN NN O
examined NN NN O
the NN NN O
expression NN NN O
and NN NN O
regulation NN NN O
of NN NN O
tyrosine NN NN O
kinase NN NN O
receptors NN NN O
( NN NN O
Trks NN NN O
) NN NN O
in NN NN O
micturition NN NN O
reflexes NN NN O
with NN NN O
urinary NN NN B-Disease
bladder NN NN I-Disease
inflammation NN NN I-Disease
. NN NN O
   
The NN NN O
present NN NN O
studies NN NN O
examine NN NN O
the NN NN O
expression NN NN O
and NN NN O
regulation NN NN O
of NN NN O
another NN NN O
receptor NN NN O
known NN NN O
to NN NN O
bind NN NN O
NGF NN NN O
, NN NN O
p75 NN NN O
( NN NN O
NTR NN NN O
) NN NN O
, NN NN O
after NN NN O
various NN NN O
durations NN NN O
of NN NN O
bladder NN NN B-Disease
inflammation NN NN I-Disease
induced NN NN O
by NN NN O
cyclophosphamide NN NN O
( NN NN O
CYP NN NN O
) NN NN O
. NN NN O
   
CYP NN NN O
- NN NN O
induced NN NN O
cystitis NN NN B-Disease
increased NN NN O
( NN NN O
P NN NN O
< NN NN O
or NN NN O
= NN NN O
0 NN NN O
. NN NN O
001 NN NN O
) NN NN O
p75 NN NN O
( NN NN O
NTR NN NN O
) NN NN O
expression NN NN O
in NN NN O
the NN NN O
superficial NN NN O
lateral NN NN O
and NN NN O
medial NN NN O
dorsal NN NN O
horn NN NN O
in NN NN O
L1 NN NN O
- NN NN O
L2 NN NN O
and NN NN O
L6 NN NN O
- NN NN O
S1 NN NN O
spinal NN NN O
segments NN NN O
. NN NN O
   
The NN NN O
number NN NN O
of NN NN O
p75 NN NN O
( NN NN O
NTR NN NN O
) NN NN O
- NN NN O
immunoreactive NN NN O
( NN NN O
- NN NN O
IR NN NN O
) NN NN O
cells NN NN O
in NN NN O
the NN NN O
lumbosacral NN NN O
dorsal NN NN O
root NN NN O
ganglia NN NN O
( NN NN O
DRG NN NN O
) NN NN O
also NN NN O
increased NN NN O
( NN NN O
P NN NN O
< NN NN O
or NN NN O
= NN NN O
0 NN NN O
. NN NN O
05 NN NN O
) NN NN O
with NN NN O
CYP NN NN O
- NN NN O
induced NN NN O
cystitis NN NN B-Disease
( NN NN O
acute NN NN O
, NN NN O
intermediate NN NN O
, NN NN O
and NN NN O
chronic NN NN O
) NN NN O
. NN NN O
   
Quantitative NN NN O
, NN NN O
real NN NN O
- NN NN O
time NN NN O
polymerase NN NN O
chain NN NN O
reaction NN NN O
also NN NN O
demonstrated NN NN O
significant NN NN O
increases NN NN O
( NN NN O
P NN NN O
< NN NN O
or NN NN O
= NN NN O
0 NN NN O
. NN NN O
01 NN NN O
) NN NN O
in NN NN O
p75 NN NN O
( NN NN O
NTR NN NN O
) NN NN O
mRNA NN NN O
in NN NN O
DRG NN NN O
with NN NN O
intermediate NN NN O
and NN NN O
chronic NN NN O
CYP NN NN O
- NN NN O
induced NN NN O
cystitis NN NN B-Disease
. NN NN O
   
Retrograde NN NN O
dye NN NN O
- NN NN O
tracing NN NN O
techniques NN NN O
with NN NN O
Fastblue NN NN O
were NN NN O
used NN NN O
to NN NN O
identify NN NN O
presumptive NN NN O
bladder NN NN O
afferent NN NN O
cells NN NN O
in NN NN O
the NN NN O
lumbosacral NN NN O
DRG NN NN O
. NN NN O
   
In NN NN O
bladder NN NN O
afferent NN NN O
cells NN NN O
in NN NN O
DRG NN NN O
, NN NN O
p75 NN NN O
( NN NN O
NTR NN NN O
) NN NN O
- NN NN O
IR NN NN O
was NN NN O
also NN NN O
increased NN NN O
( NN NN O
P NN NN O
< NN NN O
or NN NN O
= NN NN O
0 NN NN O
. NN NN O
01 NN NN O
) NN NN O
with NN NN O
cystitis NN NN B-Disease
. NN NN O
   
In NN NN O
addition NN NN O
to NN NN O
increases NN NN O
in NN NN O
p75 NN NN O
( NN NN O
NTR NN NN O
) NN NN O
- NN NN O
IR NN NN O
in NN NN O
DRG NN NN O
cell NN NN O
bodies NN NN O
, NN NN O
increases NN NN O
( NN NN O
P NN NN O
< NN NN O
or NN NN O
= NN NN O
0 NN NN O
. NN NN O
001 NN NN O
) NN NN O
in NN NN O
pericellular NN NN O
( NN NN O
encircling NN NN O
DRG NN NN O
cells NN NN O
) NN NN O
p75 NN NN O
( NN NN O
NTR NN NN O
) NN NN O
- NN NN O
IR NN NN O
in NN NN O
DRG NN NN O
also NN NN O
increased NN NN O
. NN NN O
   
Confocal NN NN O
analyses NN NN O
demonstrated NN NN O
that NN NN O
pericellular NN NN O
p75 NN NN O
( NN NN O
NTR NN NN O
) NN NN O
- NN NN O
IR NN NN O
was NN NN O
not NN NN O
colocalized NN NN O
with NN NN O
the NN NN O
glial NN NN O
marker NN NN O
, NN NN O
glial NN NN O
fibrillary NN NN O
acidic NN NN O
protein NN NN O
( NN NN O
GFAP NN NN O
) NN NN O
. NN NN O
   
These NN NN O
studies NN NN O
demonstrate NN NN O
that NN NN O
p75 NN NN O
( NN NN O
NTR NN NN O
) NN NN O
expression NN NN O
in NN NN O
micturition NN NN O
reflexes NN NN O
is NN NN O
present NN NN O
constitutively NN NN O
and NN NN O
modified NN NN O
by NN NN O
bladder NN NN B-Disease
inflammation NN NN I-Disease
. NN NN O
   
The NN NN O
functional NN NN O
significance NN NN O
of NN NN O
p75 NN NN O
( NN NN O
NTR NN NN O
) NN NN O
expression NN NN O
in NN NN O
micturition NN NN O
reflexes NN NN O
remains NN NN O
to NN NN O
be NN NN O
determined NN NN O
. NN NN O
   
Azathioprine NN NN O
- NN NN O
induced NN NN O
suicidal NN NN O
erythrocyte NN NN O
death NN NN O
. NN NN O
   
BACKGROUND NN NN O
: NN NN O
Azathioprine NN NN O
is NN NN O
widely NN NN O
used NN NN O
as NN NN O
an NN NN O
immunosuppressive NN NN O
drug NN NN O
. NN NN O
   
The NN NN O
side NN NN O
effects NN NN O
of NN NN O
azathioprine NN NN O
include NN NN O
anemia NN NN B-Disease
, NN NN O
which NN NN O
has NN NN O
been NN NN O
attributed NN NN O
to NN NN O
bone NN NN O
marrow NN NN O
suppression NN NN O
. NN NN O
   
Alternatively NN NN O
, NN NN O
anemia NN NN B-Disease
could NN NN O
result NN NN O
from NN NN O
accelerated NN NN O
suicidal NN NN O
erythrocyte NN NN O
death NN NN O
or NN NN O
eryptosis NN NN O
, NN NN O
which NN NN O
is NN NN O
characterized NN NN O
by NN NN O
exposure NN NN O
of NN NN O
phosphatidylserine NN NN O
( NN NN O
PS NN NN O
) NN NN O
at NN NN O
the NN NN O
erythrocyte NN NN O
surface NN NN O
and NN NN O
by NN NN O
cell NN NN O
shrinkage NN NN O
. NN NN O
   
METHODS NN NN O
: NN NN O
The NN NN O
present NN NN O
experiments NN NN O
explored NN NN O
whether NN NN O
azathioprine NN NN O
influences NN NN O
eryptosis NN NN O
. NN NN O
   
According NN NN O
to NN NN O
annexin NN NN O
V NN NN O
binding NN NN O
, NN NN O
erythrocytes NN NN O
from NN NN O
patients NN NN O
indeed NN NN O
showed NN NN O
a NN NN O
significant NN NN O
increase NN NN O
of NN NN O
PS NN NN O
exposure NN NN O
within NN NN O
1 NN NN O
week NN NN O
of NN NN O
treatment NN NN O
with NN NN O
azathioprine NN NN O
. NN NN O
   
In NN NN O
a NN NN O
second NN NN O
series NN NN O
, NN NN O
cytosolic NN NN O
Ca2 NN NN O
+ NN NN O
activity NN NN O
( NN NN O
Fluo3 NN NN O
fluorescence NN NN O
) NN NN O
, NN NN O
cell NN NN O
volume NN NN O
( NN NN O
forward NN NN O
scatter NN NN O
) NN NN O
, NN NN O
and NN NN O
PS NN NN O
- NN NN O
exposure NN NN O
( NN NN O
annexin NN NN O
V NN NN O
binding NN NN O
) NN NN O
were NN NN O
determined NN NN O
by NN NN O
FACS NN NN O
analysis NN NN O
in NN NN O
erythrocytes NN NN O
from NN NN O
healthy NN NN O
volunteers NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
Exposure NN NN O
to NN NN O
azathioprine NN NN O
( NN NN O
> NN NN O
or NN NN O
= NN NN O
2 NN NN O
microg NN NN O
/ NN NN O
mL NN NN O
) NN NN O
for NN NN O
48 NN NN O
hours NN NN O
increased NN NN O
cytosolic NN NN O
Ca2 NN NN O
+ NN NN O
activity NN NN O
and NN NN O
annexin NN NN O
V NN NN O
binding NN NN O
and NN NN O
decreased NN NN O
forward NN NN O
scatter NN NN O
. NN NN O
   
The NN NN O
effect NN NN O
of NN NN O
azathioprine NN NN O
on NN NN O
both NN NN O
annexin NN NN O
V NN NN O
binding NN NN O
and NN NN O
forward NN NN O
scatter NN NN O
was NN NN O
significantly NN NN O
blunted NN NN O
in NN NN O
the NN NN O
nominal NN NN O
absence NN NN O
of NN NN O
extracellular NN NN O
Ca2 NN NN O
+ NN NN O
. NN NN O
   
CONCLUSIONS NN NN O
: NN NN O
Azathioprine NN NN O
triggers NN NN O
suicidal NN NN O
erythrocyte NN NN O
death NN NN O
, NN NN O
an NN NN O
effect NN NN O
presumably NN NN O
contributing NN NN O
to NN NN O
azathioprine NN NN O
- NN NN O
induced NN NN O
anemia NN NN B-Disease
. NN NN O
   
Levetiracetam NN NN O
as NN NN O
an NN NN O
adjunct NN NN O
to NN NN O
phenobarbital NN NN O
treatment NN NN O
in NN NN O
cats NN NN O
with NN NN O
suspected NN NN O
idiopathic NN NN B-Disease
epilepsy NN NN I-Disease
. NN NN O
   
OBJECTIVE NN NN O
: NN NN O
To NN NN O
assess NN NN O
pharmacokinetics NN NN O
, NN NN O
efficacy NN NN O
, NN NN O
and NN NN O
tolerability NN NN O
of NN NN O
oral NN NN O
levetiracetam NN NN O
administered NN NN O
as NN NN O
an NN NN O
adjunct NN NN O
to NN NN O
phenobarbital NN NN O
treatment NN NN O
in NN NN O
cats NN NN O
with NN NN O
poorly NN NN O
controlled NN NN O
suspected NN NN O
idiopathic NN NN B-Disease
epilepsy NN NN I-Disease
. NN NN O
   
DESIGN NN NN O
- NN NN O
Open NN NN O
- NN NN O
label NN NN O
, NN NN O
noncomparative NN NN O
clinical NN NN O
trial NN NN O
. NN NN O
   
ANIMALS NN NN O
: NN NN O
12 NN NN O
cats NN NN O
suspected NN NN O
to NN NN O
have NN NN O
idiopathic NN NN B-Disease
epilepsy NN NN I-Disease
that NN NN O
was NN NN O
poorly NN NN O
controlled NN NN O
with NN NN O
phenobarbital NN NN O
or NN NN O
that NN NN O
had NN NN O
unacceptable NN NN O
adverse NN NN O
effects NN NN O
when NN NN O
treated NN NN O
with NN NN O
phenobarbital NN NN O
. NN NN O
   
PROCEDURES NN NN O
: NN NN O
Cats NN NN O
were NN NN O
treated NN NN O
with NN NN O
levetiracetam NN NN O
( NN NN O
20 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
[ NN NN O
9 NN NN O
. NN NN O
1 NN NN O
mg NN NN O
/ NN NN O
lb NN NN O
] NN NN O
, NN NN O
PO NN NN O
, NN NN O
q NN NN O
8 NN NN O
h NN NN O
) NN NN O
. NN NN O
   
After NN NN O
a NN NN O
minimum NN NN O
of NN NN O
1 NN NN O
week NN NN O
of NN NN O
treatment NN NN O
, NN NN O
serum NN NN O
levetiracetam NN NN O
concentrations NN NN O
were NN NN O
measured NN NN O
before NN NN O
and NN NN O
2 NN NN O
, NN NN O
4 NN NN O
, NN NN O
and NN NN O
6 NN NN O
hours NN NN O
after NN NN O
drug NN NN O
administration NN NN O
, NN NN O
and NN NN O
maximum NN NN O
and NN NN O
minimum NN NN O
serum NN NN O
concentrations NN NN O
and NN NN O
elimination NN NN O
half NN NN O
- NN NN O
life NN NN O
were NN NN O
calculated NN NN O
. NN NN O
   
Seizure NN NN B-Disease
frequencies NN NN O
before NN NN O
and NN NN O
after NN NN O
initiation NN NN O
of NN NN O
levetiracetam NN NN O
treatment NN NN O
were NN NN O
compared NN NN O
, NN NN O
and NN NN O
adverse NN NN O
effects NN NN O
were NN NN O
recorded NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
Median NN NN O
maximum NN NN O
serum NN NN O
levetiracetam NN NN O
concentration NN NN O
was NN NN O
25 NN NN O
. NN NN O
5 NN NN O
microg NN NN O
/ NN NN O
mL NN NN O
, NN NN O
median NN NN O
minimum NN NN O
serum NN NN O
levetiracetam NN NN O
concentration NN NN O
was NN NN O
8 NN NN O
. NN NN O
3 NN NN O
microg NN NN O
/ NN NN O
mL NN NN O
, NN NN O
and NN NN O
median NN NN O
elimination NN NN O
half NN NN O
- NN NN O
life NN NN O
was NN NN O
2 NN NN O
. NN NN O
9 NN NN O
hours NN NN O
. NN NN O
   
Median NN NN O
seizure NN NN B-Disease
frequency NN NN O
prior NN NN O
to NN NN O
treatment NN NN O
with NN NN O
levetiracetam NN NN O
( NN NN O
2 NN NN O
. NN NN O
1 NN NN O
seizures NN NN B-Disease
/ NN NN O
mo NN NN O
) NN NN O
was NN NN O
significantly NN NN O
higher NN NN O
than NN NN O
median NN NN O
seizure NN NN B-Disease
frequency NN NN O
after NN NN O
initiation NN NN O
of NN NN O
levetiracetam NN NN O
treatment NN NN O
( NN NN O
0 NN NN O
. NN NN O
42 NN NN O
seizures NN NN B-Disease
/ NN NN O
mo NN NN O
) NN NN O
, NN NN O
and NN NN O
7 NN NN O
of NN NN O
10 NN NN O
cats NN NN O
were NN NN O
classified NN NN O
as NN NN O
having NN NN O
responded NN NN O
to NN NN O
levetiracetam NN NN O
treatment NN NN O
( NN NN O
ie NN NN O
, NN NN O
reduction NN NN O
in NN NN O
seizure NN NN B-Disease
frequency NN NN O
of NN NN O
> NN NN O
or NN NN O
= NN NN O
50 NN NN O
% NN NN O
) NN NN O
. NN NN O
   
Two NN NN O
cats NN NN O
had NN NN O
transient NN NN O
lethargy NN NN B-Disease
and NN NN O
inappetence NN NN B-Disease
. NN NN O
   
CONCLUSIONS NN NN O
AND NN NN O
CLINICAL NN NN O
RELEVANCE NN NN O
: NN NN O
Results NN NN O
suggested NN NN O
that NN NN O
levetiracetam NN NN O
is NN NN O
well NN NN O
tolerated NN NN O
in NN NN O
cats NN NN O
and NN NN O
may NN NN O
be NN NN O
useful NN NN O
as NN NN O
an NN NN O
adjunct NN NN O
to NN NN O
phenobarbital NN NN O
treatment NN NN O
in NN NN O
cats NN NN O
with NN NN O
idiopathic NN NN B-Disease
epilepsy NN NN I-Disease
. NN NN O
   
Serotonin NN NN O
reuptake NN NN O
inhibitors NN NN O
, NN NN O
paranoia NN NN B-Disease
, NN NN O
and NN NN O
the NN NN O
ventral NN NN O
basal NN NN O
ganglia NN NN O
. NN NN O
   
Antidepressants NN NN O
have NN NN O
previously NN NN O
been NN NN O
associated NN NN O
with NN NN O
paranoid NN NN B-Disease
reactions NN NN O
in NN NN O
psychiatric NN NN O
patients NN NN O
. NN NN O
   
Five NN NN O
cases NN NN O
of NN NN O
paranoid NN NN B-Disease
exacerbation NN NN O
with NN NN O
the NN NN O
serotonin NN NN O
reuptake NN NN O
inhibitors NN NN O
fluoxetine NN NN O
and NN NN O
amitriptyline NN NN O
are NN NN O
reported NN NN O
here NN NN O
. NN NN O
   
Elements NN NN O
common NN NN O
to NN NN O
these NN NN O
cases NN NN O
included NN NN O
a NN NN O
history NN NN O
of NN NN O
paranoid NN NN B-Disease
symptomatology NN NN O
and NN NN O
the NN NN O
concomitant NN NN O
occurrence NN NN O
of NN NN O
depressive NN NN B-Disease
and NN NN I-Disease
psychotic NN NN I-Disease
symptoms NN NN I-Disease
. NN NN O
   
Complicated NN NN O
depressive NN NN B-Disease
disorders NN NN I-Disease
( NN NN O
including NN NN O
atypicality NN NN O
of NN NN O
course NN NN O
and NN NN O
symptomatology NN NN O
, NN NN O
chronicity NN NN O
, NN NN O
psychosis NN NN B-Disease
, NN NN O
bipolarity NN NN O
, NN NN O
and NN NN O
secondary NN NN O
onset NN NN O
in NN NN O
the NN NN O
course NN NN O
of NN NN O
a NN NN O
primary NN NN O
psychosis NN NN B-Disease
) NN NN O
may NN NN O
present NN NN O
particular NN NN O
vulnerability NN NN O
to NN NN O
paranoid NN NN B-Disease
exacerbations NN NN O
associated NN NN O
with NN NN O
serotonin NN NN O
reuptake NN NN O
inhibitors NN NN O
. NN NN O
   
Although NN NN O
the NN NN O
pharmacology NN NN O
and NN NN O
neurobiology NN NN O
of NN NN O
paranoia NN NN B-Disease
remain NN NN O
cryptic NN NN O
, NN NN O
several NN NN O
mechanisms NN NN O
, NN NN O
including NN NN O
5HT3 NN NN O
receptor NN NN O
- NN NN O
mediated NN NN O
dopamine NN NN O
release NN NN O
, NN NN O
beta NN NN O
- NN NN O
noradrenergic NN NN O
receptor NN NN O
downregulation NN NN O
, NN NN O
or NN NN O
GABAB NN NN O
receptor NN NN O
upregulation NN NN O
acting NN NN O
in NN NN O
the NN NN O
vicinity NN NN O
of NN NN O
the NN NN O
ventral NN NN O
basal NN NN O
ganglia NN NN O
( NN NN O
possibly NN NN O
in NN NN O
lateral NN NN O
orbitofrontal NN NN O
or NN NN O
anterior NN NN O
cingulate NN NN O
circuits NN NN O
) NN NN O
, NN NN O
might NN NN O
apply NN NN O
to NN NN O
this NN NN O
phenomenon NN NN O
. NN NN O
   
These NN NN O
cases NN NN O
call NN NN O
attention NN NN O
to NN NN O
possible NN NN O
paranoid NN NN B-Disease
exacerbations NN NN O
with NN NN O
serotonin NN NN O
reuptake NN NN O
blockers NN NN O
in NN NN O
select NN NN O
patients NN NN O
and NN NN O
raise NN NN O
neurobiological NN NN O
considerations NN NN O
regarding NN NN O
paranoia NN NN B-Disease
. NN NN O
   
Clinical NN NN O
comparison NN NN O
of NN NN O
cardiorespiratory NN NN O
effects NN NN O
during NN NN O
unilateral NN NN O
and NN NN O
conventional NN NN O
spinal NN NN O
anaesthesia NN NN O
. NN NN O
   
BACKGROUND NN NN O
: NN NN O
Spinal NN NN O
anaesthesia NN NN O
is NN NN O
widely NN NN O
employed NN NN O
in NN NN O
clinical NN NN O
practice NN NN O
but NN NN O
has NN NN O
the NN NN O
main NN NN O
drawback NN NN O
of NN NN O
post NN NN O
- NN NN O
spinal NN NN O
block NN NN O
hypotension NN NN B-Disease
. NN NN O
   
Efforts NN NN O
must NN NN O
therefore NN NN O
continue NN NN O
to NN NN O
be NN NN O
made NN NN O
to NN NN O
obviate NN NN O
this NN NN O
setback NN NN O
OBJECTIVE NN NN O
: NN NN O
To NN NN O
evaluate NN NN O
the NN NN O
cardiovascular NN NN O
and NN NN O
respiratory NN NN O
changes NN NN O
during NN NN O
unilateral NN NN O
and NN NN O
conventional NN NN O
spinal NN NN O
anaesthesia NN NN O
. NN NN O
   
METHODS NN NN O
: NN NN O
With NN NN O
ethical NN NN O
approval NN NN O
, NN NN O
we NN NN O
studied NN NN O
74 NN NN O
American NN NN O
Society NN NN O
of NN NN O
Anesthesiologists NN NN O
( NN NN O
ASA NN NN O
) NN NN O
, NN NN O
physical NN NN O
status NN NN O
class NN NN O
1 NN NN O
and NN NN O
2 NN NN O
patients NN NN O
scheduled NN NN O
for NN NN O
elective NN NN O
unilateral NN NN O
lower NN NN O
limb NN NN O
surgery NN NN O
. NN NN O
   
Patients NN NN O
were NN NN O
randomly NN NN O
allocated NN NN O
into NN NN O
one NN NN O
of NN NN O
two NN NN O
groups NN NN O
: NN NN O
lateral NN NN O
and NN NN O
conventional NN NN O
spinal NN NN O
anaesthesia NN NN O
groups NN NN O
. NN NN O
   
In NN NN O
the NN NN O
lateral NN NN O
position NN NN O
with NN NN O
operative NN NN O
side NN NN O
down NN NN O
, NN NN O
patients NN NN O
recived NN NN O
10 NN NN O
mg NN NN O
( NN NN O
2mls NN NN O
) NN NN O
of NN NN O
0 NN NN O
. NN NN O
5 NN NN O
% NN NN O
hyperbaric NN NN O
bupivacaine NN NN O
through NN NN O
a NN NN O
25 NN NN O
- NN NN O
gauge NN NN O
spinal NN NN O
needle NN NN O
. NN NN O
   
Patients NN NN O
in NN NN O
the NN NN O
unilateral NN NN O
group NN NN O
were NN NN O
maintained NN NN O
in NN NN O
the NN NN O
lateral NN NN O
position NN NN O
for NN NN O
15 NN NN O
minutes NN NN O
following NN NN O
spinal NN NN O
injection NN NN O
while NN NN O
those NN NN O
in NN NN O
the NN NN O
conventional NN NN O
group NN NN O
were NN NN O
turned NN NN O
supine NN NN O
immediately NN NN O
after NN NN O
injection NN NN O
. NN NN O
   
Blood NN NN O
pressure NN NN O
, NN NN O
heart NN NN O
rate NN NN O
, NN NN O
respiratory NN NN O
rate NN NN O
and NN NN O
oxygen NN NN O
saturation NN NN O
were NN NN O
monitored NN NN O
over NN NN O
1 NN NN O
hour NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
Three NN NN O
patients NN NN O
( NN NN O
8 NN NN O
. NN NN O
1 NN NN O
% NN NN O
) NN NN O
in NN NN O
the NN NN O
unilateral NN NN O
group NN NN O
and NN NN O
5 NN NN O
( NN NN O
13 NN NN O
. NN NN O
5 NN NN O
% NN NN O
) NN NN O
in NN NN O
the NN NN O
conventional NN NN O
group NN NN O
developed NN NN O
hypotension NN NN B-Disease
, NN NN O
P NN NN O
= NN NN O
0 NN NN O
. NN NN O
71 NN NN O
. NN NN O
   
Four NN NN O
( NN NN O
10 NN NN O
. NN NN O
8 NN NN O
% NN NN O
) NN NN O
patients NN NN O
in NN NN O
the NN NN O
conventional NN NN O
group NN NN O
and NN NN O
1 NN NN O
( NN NN O
2 NN NN O
. NN NN O
7 NN NN O
% NN NN O
) NN NN O
in NN NN O
the NN NN O
unilateral NN NN O
group NN NN O
, NN NN O
P NN NN O
= NN NN O
0 NN NN O
. NN NN O
17 NN NN O
required NN NN O
epinephrine NN NN O
infusion NN NN O
to NN NN O
treat NN NN O
hypotension NN NN B-Disease
. NN NN O
   
Patients NN NN O
in NN NN O
the NN NN O
conventional NN NN O
group NN NN O
had NN NN O
statistically NN NN O
significant NN NN O
greater NN NN O
fall NN NN O
in NN NN O
the NN NN O
systolic NN NN O
blood NN NN O
pressures NN NN O
at NN NN O
15 NN NN O
, NN NN O
30 NN NN O
and NN NN O
45 NN NN O
minutes NN NN O
when NN NN O
compared NN NN O
to NN NN O
the NN NN O
baseline NN NN O
( NN NN O
P NN NN O
= NN NN O
0 NN NN O
. NN NN O
003 NN NN O
, NN NN O
0 NN NN O
. NN NN O
001 NN NN O
and NN NN O
0 NN NN O
. NN NN O
004 NN NN O
) NN NN O
. NN NN O
   
The NN NN O
mean NN NN O
respiratory NN NN O
rate NN NN O
and NN NN O
oxygen NN NN O
saturations NN NN O
in NN NN O
the NN NN O
two NN NN O
groups NN NN O
were NN NN O
similar NN NN O
. NN NN O
   
CONCLUSION NN NN O
: NN NN O
Compared NN NN O
to NN NN O
conventional NN NN O
spinal NN NN O
anaesthesia NN NN O
, NN NN O
unilateral NN NN O
spinal NN NN O
anaesthesia NN NN O
was NN NN O
associated NN NN O
with NN NN O
fewer NN NN O
cardiovascular NN NN O
perturbations NN NN O
. NN NN O
   
Also NN NN O
, NN NN O
the NN NN O
type NN NN O
of NN NN O
spinal NN NN O
block NN NN O
instituted NN NN O
affected NN NN O
neither NN NN O
the NN NN O
respiratory NN NN O
rate NN NN O
nor NN NN O
the NN NN O
arterial NN NN O
oxygen NN NN O
saturation NN NN O
. NN NN O
   
Spectrum NN NN O
of NN NN O
adverse NN NN O
events NN NN O
after NN NN O
generic NN NN O
HAART NN NN O
in NN NN O
southern NN NN O
Indian NN NN O
HIV NN NN B-Disease
- NN NN I-Disease
infected NN NN I-Disease
patients NN NN O
. NN NN O
   
To NN NN O
determine NN NN O
the NN NN O
incidence NN NN O
of NN NN O
clinically NN NN O
significant NN NN O
adverse NN NN O
events NN NN O
after NN NN O
long NN NN O
- NN NN O
term NN NN O
, NN NN O
fixed NN NN O
- NN NN O
dose NN NN O
, NN NN O
generic NN NN O
highly NN NN O
active NN NN O
antiretroviral NN NN O
therapy NN NN O
( NN NN O
HAART NN NN O
) NN NN O
use NN NN O
among NN NN O
HIV NN NN B-Disease
- NN NN I-Disease
infected NN NN I-Disease
individuals NN NN O
in NN NN O
South NN NN O
India NN NN O
, NN NN O
we NN NN O
examined NN NN O
the NN NN O
experiences NN NN O
of NN NN O
3154 NN NN O
HIV NN NN B-Disease
- NN NN I-Disease
infected NN NN I-Disease
individuals NN NN O
who NN NN O
received NN NN O
a NN NN O
minimum NN NN O
of NN NN O
3 NN NN O
months NN NN O
of NN NN O
generic NN NN O
HAART NN NN O
between NN NN O
February NN NN O
1996 NN NN O
and NN NN O
December NN NN O
2006 NN NN O
at NN NN O
a NN NN O
tertiary NN NN O
HIV NN NN O
care NN NN O
referral NN NN O
center NN NN O
in NN NN O
South NN NN O
India NN NN O
. NN NN O
   
The NN NN O
most NN NN O
common NN NN O
regimens NN NN O
were NN NN O
3TC NN NN O
+ NN NN O
d4T NN NN O
+ NN NN O
nevirapine NN NN O
( NN NN O
NVP NN NN O
) NN NN O
( NN NN O
54 NN NN O
. NN NN O
8 NN NN O
% NN NN O
) NN NN O
, NN NN O
zidovudine NN NN O
( NN NN O
AZT NN NN O
) NN NN O
+ NN NN O
3TC NN NN O
+ NN NN O
NVP NN NN O
( NN NN O
14 NN NN O
. NN NN O
5 NN NN O
% NN NN O
) NN NN O
, NN NN O
3TC NN NN O
+ NN NN O
d4T NN NN O
+ NN NN O
efavirenz NN NN O
( NN NN O
EFV NN NN O
) NN NN O
( NN NN O
20 NN NN O
. NN NN O
1 NN NN O
% NN NN O
) NN NN O
, NN NN O
and NN NN O
AZT NN NN O
+ NN NN O
3TC NN NN O
+ NN NN O
EFV NN NN O
( NN NN O
5 NN NN O
. NN NN O
4 NN NN O
% NN NN O
) NN NN O
. NN NN O
   
The NN NN O
most NN NN O
common NN NN O
adverse NN NN O
events NN NN O
and NN NN O
median NN NN O
CD4 NN NN O
at NN NN O
time NN NN O
of NN NN O
event NN NN O
were NN NN O
rash NN NN B-Disease
( NN NN O
15 NN NN O
. NN NN O
2 NN NN O
% NN NN O
; NN NN O
CD4 NN NN O
, NN NN O
285 NN NN O
cells NN NN O
/ NN NN O
microL NN NN O
) NN NN O
and NN NN O
peripheral NN NN B-Disease
neuropathy NN NN I-Disease
( NN NN O
9 NN NN O
. NN NN O
0 NN NN O
% NN NN O
and NN NN O
348 NN NN O
cells NN NN O
/ NN NN O
microL NN NN O
) NN NN O
. NN NN O
   
Clinically NN NN O
significant NN NN O
anemia NN NN B-Disease
( NN NN O
hemoglobin NN NN O
< NN NN O
7 NN NN O
g NN NN O
/ NN NN O
dL NN NN O
) NN NN O
was NN NN O
observed NN NN O
in NN NN O
5 NN NN O
. NN NN O
4 NN NN O
% NN NN O
of NN NN O
patients NN NN O
( NN NN O
CD4 NN NN O
, NN NN O
165 NN NN O
cells NN NN O
/ NN NN O
microL NN NN O
) NN NN O
and NN NN O
hepatitis NN NN B-Disease
( NN NN O
clinical NN NN O
jaundice NN NN B-Disease
with NN NN O
alanine NN NN O
aminotransferase NN NN O
> NN NN O
5 NN NN O
times NN NN O
upper NN NN O
limits NN NN O
of NN NN O
normal NN NN O
) NN NN O
in NN NN O
3 NN NN O
. NN NN O
5 NN NN O
% NN NN O
of NN NN O
patients NN NN O
( NN NN O
CD4 NN NN O
, NN NN O
260 NN NN O
cells NN NN O
/ NN NN O
microL NN NN O
) NN NN O
. NN NN O
   
Women NN NN O
were NN NN O
significantly NN NN O
more NN NN O
likely NN NN O
to NN NN O
experience NN NN O
lactic NN NN B-Disease
acidosis NN NN I-Disease
, NN NN O
while NN NN O
men NN NN O
were NN NN O
significantly NN NN O
more NN NN O
likely NN NN O
to NN NN O
experience NN NN O
immune NN NN B-Disease
reconstitution NN NN I-Disease
syndrome NN NN I-Disease
( NN NN O
p NN NN O
< NN NN O
0 NN NN O
. NN NN O
05 NN NN O
) NN NN O
. NN NN O
   
Among NN NN O
the NN NN O
patients NN NN O
with NN NN O
1 NN NN O
year NN NN O
of NN NN O
follow NN NN O
- NN NN O
up NN NN O
, NN NN O
NVP NN NN O
therapy NN NN O
was NN NN O
significantly NN NN O
associated NN NN O
with NN NN O
developing NN NN O
rash NN NN B-Disease
and NN NN O
d4T NN NN O
therapy NN NN O
with NN NN O
developing NN NN O
peripheral NN NN B-Disease
neuropathy NN NN I-Disease
( NN NN O
p NN NN O
< NN NN O
0 NN NN O
. NN NN O
05 NN NN O
) NN NN O
. NN NN O
   
Anemia NN NN B-Disease
and NN NN O
hepatitis NN NN B-Disease
often NN NN O
occur NN NN O
within NN NN O
12 NN NN O
weeks NN NN O
of NN NN O
initiating NN NN O
generic NN NN O
HAART NN NN O
. NN NN O
   
Frequent NN NN O
and NN NN O
early NN NN O
monitoring NN NN O
for NN NN O
these NN NN O
toxicities NN NN B-Disease
is NN NN O
warranted NN NN O
in NN NN O
developing NN NN O
countries NN NN O
where NN NN O
generic NN NN O
HAART NN NN O
is NN NN O
increasingly NN NN O
available NN NN O
. NN NN O
   
Thalidomide NN NN O
and NN NN O
sensory NN NN B-Disease
neurotoxicity NN NN I-Disease
: NN NN O
a NN NN O
neurophysiological NN NN O
study NN NN O
. NN NN O
   
BACKGROUND NN NN O
: NN NN O
Recent NN NN O
studies NN NN O
confirmed NN NN O
a NN NN O
high NN NN O
incidence NN NN O
of NN NN O
sensory NN NN B-Disease
axonal NN NN I-Disease
neuropathy NN NN I-Disease
in NN NN O
patients NN NN O
treated NN NN O
with NN NN O
different NN NN O
doses NN NN O
of NN NN O
thalidomide NN NN O
. NN NN O
   
The NN NN O
study NN NN O
' NN NN O
s NN NN O
aims NN NN O
were NN NN O
to NN NN O
measure NN NN O
variations NN NN O
in NN NN O
sural NN NN O
nerve NN NN O
sensory NN NN O
action NN NN O
potential NN NN O
( NN NN O
SAP NN NN O
) NN NN O
amplitude NN NN O
in NN NN O
patients NN NN O
with NN NN O
refractory NN NN O
cutaneous NN NN B-Disease
lupus NN NN I-Disease
erythematosus NN NN I-Disease
( NN NN O
CLE NN NN B-Disease
) NN NN O
treated NN NN O
with NN NN O
thalidomide NN NN O
and NN NN O
use NN NN O
these NN NN O
findings NN NN O
to NN NN O
identify NN NN O
the NN NN O
neurotoxic NN NN B-Disease
potential NN NN O
of NN NN O
thalidomide NN NN O
and NN NN O
the NN NN O
recovery NN NN O
capacity NN NN O
of NN NN O
sensory NN NN O
fibres NN NN O
after NN NN O
discontinuation NN NN O
of NN NN O
treatment NN NN O
. NN NN O
   
PATIENTS NN NN O
AND NN NN O
METHODS NN NN O
: NN NN O
Clinical NN NN O
and NN NN O
electrophysiological NN NN O
data NN NN O
in NN NN O
12 NN NN O
female NN NN O
patients NN NN O
with NN NN O
CLE NN NN B-Disease
during NN NN O
treatment NN NN O
with NN NN O
thalidomide NN NN O
and NN NN O
up NN NN O
to NN NN O
47 NN NN O
months NN NN O
after NN NN O
discontinuation NN NN O
of NN NN O
treatment NN NN O
were NN NN O
analysed NN NN O
. NN NN O
   
Sural NN NN O
nerve NN NN O
SAP NN NN O
amplitude NN NN O
reduction NN NN O
> NN NN O
or NN NN O
= NN NN O
40 NN NN O
% NN NN O
was NN NN O
the NN NN O
criteria NN NN O
for NN NN O
discontinuing NN NN O
therapy NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
During NN NN O
treatment NN NN O
, NN NN O
11 NN NN O
patients NN NN O
showed NN NN O
a NN NN O
reduction NN NN O
in NN NN O
sural NN NN O
nerve NN NN O
SAP NN NN O
amplitude NN NN O
compared NN NN O
to NN NN O
baseline NN NN O
values NN NN O
( NN NN O
9 NN NN O
with NN NN O
a NN NN O
reduction NN NN O
> NN NN O
or NN NN O
= NN NN O
50 NN NN O
% NN NN O
and NN NN O
2 NN NN O
< NN NN O
50 NN NN O
% NN NN O
) NN NN O
. NN NN O
   
One NN NN O
patient NN NN O
showed NN NN O
no NN NN O
changes NN NN O
in NN NN O
SAP NN NN O
amplitude NN NN O
. NN NN O
   
Five NN NN O
patients NN NN O
complained NN NN O
of NN NN O
paresthesias NN NN B-Disease
and NN NN O
leg NN NN O
cramps NN NN B-Disease
. NN NN O
   
After NN NN O
thalidomide NN NN O
treatment NN NN O
, NN NN O
sural NN NN O
SAP NN NN O
amplitude NN NN O
recovered NN NN O
in NN NN O
3 NN NN O
patients NN NN O
. NN NN O
   
At NN NN O
detection NN NN O
of NN NN O
reduction NN NN O
in NN NN O
sural NN NN O
nerve NN NN O
SAP NN NN O
amplitude NN NN O
, NN NN O
the NN NN O
median NN NN O
thalidomide NN NN O
cumulative NN NN O
dose NN NN O
was NN NN O
21 NN NN O
. NN NN O
4 NN NN O
g NN NN O
. NN NN O
   
The NN NN O
threshold NN NN O
neurotoxic NN NN B-Disease
dosage NN NN O
is NN NN O
lower NN NN O
than NN NN O
previously NN NN O
reported NN NN O
. NN NN O
   
CONCLUSIONS NN NN O
: NN NN O
Sural NN NN O
nerve NN NN O
SAP NN NN O
amplitude NN NN O
reduction NN NN O
is NN NN O
a NN NN O
reliable NN NN O
and NN NN O
sensitive NN NN O
marker NN NN O
of NN NN O
degeneration NN NN O
and NN NN O
recovery NN NN O
of NN NN O
sensory NN NN O
fibres NN NN O
. NN NN O
   
This NN NN O
electrophysiological NN NN O
parameter NN NN O
provides NN NN O
information NN NN O
about NN NN O
subclinical NN NN O
neurotoxic NN NN B-Disease
potential NN NN O
of NN NN O
thalidomide NN NN O
but NN NN O
is NN NN O
not NN NN O
helpful NN NN O
in NN NN O
predicting NN NN O
the NN NN O
appearance NN NN O
of NN NN O
sensory NN NN O
symptoms NN NN O
. NN NN O
   
Five NN NN O
cases NN NN O
of NN NN O
encephalitis NN NN B-Disease
during NN NN O
treatment NN NN O
of NN NN O
loiasis NN NN B-Disease
with NN NN O
diethylcarbamazine NN NN O
. NN NN O
   
Five NN NN O
cases NN NN O
of NN NN O
encephalitis NN NN B-Disease
following NN NN O
treatment NN NN O
with NN NN O
diethylcarbamazine NN NN O
( NN NN O
DEC NN NN O
) NN NN O
were NN NN O
observed NN NN O
in NN NN O
Congolese NN NN O
patients NN NN O
with NN NN O
Loa NN NN O
loa NN NN O
filariasis NN NN B-Disease
. NN NN O
   
Two NN NN O
cases NN NN O
had NN NN O
a NN NN O
fatal NN NN O
outcome NN NN O
and NN NN O
one NN NN O
resulted NN NN O
in NN NN O
severe NN NN O
sequelae NN NN O
. NN NN O
   
The NN NN O
notable NN NN O
fact NN NN O
was NN NN O
that NN NN O
this NN NN O
complication NN NN O
occurred NN NN O
in NN NN O
three NN NN O
patients NN NN O
hospitalized NN NN O
before NN NN O
treatment NN NN O
began NN NN O
, NN NN O
with NN NN O
whom NN NN O
particularly NN NN O
strict NN NN O
therapeutic NN NN O
precautions NN NN O
were NN NN O
taken NN NN O
, NN NN O
i NN NN O
. NN NN O
e NN NN O
. NN NN O
, NN NN O
initial NN NN O
dose NN NN O
less NN NN O
than NN NN O
10 NN NN O
mg NN NN O
of NN NN O
DEC NN NN O
, NN NN O
very NN NN O
gradual NN NN O
dose NN NN O
increases NN NN O
, NN NN O
and NN NN O
associated NN NN O
anti NN NN O
- NN NN O
allergic NN NN O
treatment NN NN O
. NN NN O
   
This NN NN O
type NN NN O
of NN NN O
drug NN NN O
- NN NN O
induced NN NN O
complication NN NN O
may NN NN O
not NN NN O
be NN NN O
that NN NN O
uncommon NN NN O
in NN NN O
highly NN NN O
endemic NN NN O
regions NN NN O
. NN NN O
   
It NN NN O
occurs NN NN O
primarily NN NN O
, NN NN O
but NN NN O
not NN NN O
exclusively NN NN O
, NN NN O
in NN NN O
subjects NN NN O
presenting NN NN O
with NN NN O
a NN NN O
high NN NN O
microfilarial NN NN O
load NN NN O
. NN NN O
   
The NN NN O
relationship NN NN O
between NN NN O
the NN NN O
occurrence NN NN O
of NN NN O
encephalitis NN NN B-Disease
and NN NN O
the NN NN O
decrease NN NN O
in NN NN O
microfilaremia NN NN B-Disease
is NN NN O
evident NN NN O
. NN NN O
   
The NN NN O
pathophysiological NN NN O
mechanisms NN NN O
are NN NN O
discussed NN NN O
in NN NN O
the NN NN O
light NN NN O
of NN NN O
these NN NN O
observations NN NN O
and NN NN O
the NN NN O
few NN NN O
other NN NN O
comments NN NN O
on NN NN O
this NN NN O
subject NN NN O
published NN NN O
in NN NN O
the NN NN O
literature NN NN O
. NN NN O
   
Amiodarone NN NN O
- NN NN O
related NN NN O
pulmonary NN NN B-Disease
mass NN NN I-Disease
and NN NN O
unique NN NN O
membranous NN NN B-Disease
glomerulonephritis NN NN I-Disease
in NN NN O
a NN NN O
patient NN NN O
with NN NN O
valvular NN NN B-Disease
heart NN NN I-Disease
disease NN NN I-Disease
: NN NN O
Diagnostic NN NN O
pitfall NN NN O
and NN NN O
new NN NN O
findings NN NN O
. NN NN O
   
Amiodarone NN NN O
is NN NN O
an NN NN O
anti NN NN O
- NN NN O
arrhythmic NN NN B-Disease
drug NN NN O
for NN NN O
life NN NN O
- NN NN O
threatening NN NN O
tachycardia NN NN B-Disease
, NN NN O
but NN NN O
various NN NN O
adverse NN NN O
effects NN NN O
have NN NN O
been NN NN O
reported NN NN O
. NN NN O
   
Reported NN NN O
herein NN NN O
is NN NN O
an NN NN O
autopsy NN NN O
case NN NN O
of NN NN O
valvular NN NN B-Disease
heart NN NN I-Disease
disease NN NN I-Disease
, NN NN O
in NN NN O
a NN NN O
patient NN NN O
who NN NN O
developed NN NN O
a NN NN O
lung NN NN B-Disease
mass NN NN I-Disease
( NN NN O
1 NN NN O
. NN NN O
5 NN NN O
cm NN NN O
in NN NN O
diameter NN NN O
) NN NN O
and NN NN O
proteinuria NN NN B-Disease
( NN NN O
2 NN NN O
. NN NN O
76 NN NN O
g NN NN O
/ NN NN O
day NN NN O
) NN NN O
after NN NN O
treatment NN NN O
with NN NN O
amiodarone NN NN O
for NN NN O
a NN NN O
long NN NN O
time NN NN O
. NN NN O
   
The NN NN O
lung NN NN B-Disease
mass NN NN I-Disease
was NN NN O
highly NN NN O
suspected NN NN O
to NN NN O
be NN NN O
lung NN NN B-Disease
cancer NN NN I-Disease
on NN NN O
CT NN NN O
and NN NN O
positron NN NN O
emission NN NN O
tomography NN NN O
, NN NN O
but NN NN O
histologically NN NN O
the NN NN O
lesion NN NN O
was NN NN O
composed NN NN O
of NN NN O
lymphoplasmacytic NN NN O
infiltrates NN NN O
in NN NN O
alveolar NN NN O
walls NN NN O
and NN NN O
intra NN NN O
- NN NN O
alveolar NN NN O
accumulation NN NN O
of NN NN O
foamy NN NN O
macrophages NN NN O
containing NN NN O
characteristic NN NN O
myelinoid NN NN O
bodies NN NN O
, NN NN O
indicating NN NN O
that NN NN O
it NN NN O
was NN NN O
an NN NN O
amiodarone NN NN O
- NN NN O
related NN NN O
lesion NN NN O
. NN NN O
   
In NN NN O
addition NN NN O
, NN NN O
the NN NN O
lung NN NN O
tissue NN NN O
had NN NN O
unevenly NN NN O
distributed NN NN O
hemosiderin NN NN B-Disease
deposition NN NN O
, NN NN O
and NN NN O
abnormally NN NN O
tortuous NN NN O
capillaries NN NN O
were NN NN O
seen NN NN O
in NN NN O
the NN NN O
mass NN NN O
and NN NN O
in NN NN O
heavily NN NN O
hemosiderotic NN NN B-Disease
lung NN NN O
portions NN NN O
outside NN NN O
the NN NN O
mass NN NN O
. NN NN O
   
In NN NN O
the NN NN O
kidneys NN NN O
, NN NN O
glomeruli NN NN O
had NN NN O
membrane NN NN O
spikes NN NN O
, NN NN O
prominent NN NN O
swelling NN NN O
of NN NN O
podocytes NN NN O
and NN NN O
subepithelial NN NN O
deposits NN NN O
, NN NN O
which NN NN O
were NN NN O
sometimes NN NN O
large NN NN O
and NN NN O
hump NN NN O
- NN NN O
like NN NN O
. NN NN O
   
Autoimmune NN NN B-Disease
diseases NN NN I-Disease
, NN NN O
viral NN NN B-Disease
hepatitis NN NN I-Disease
, NN NN O
malignant NN NN O
neoplasms NN NN B-Disease
or NN NN O
other NN NN O
diseases NN NN O
with NN NN O
a NN NN O
known NN NN O
relationship NN NN O
to NN NN O
membranous NN NN B-Disease
glomerulonephritis NN NN I-Disease
were NN NN O
not NN NN O
found NN NN O
. NN NN O
   
The NN NN O
present NN NN O
case NN NN O
highlights NN NN O
the NN NN O
possibility NN NN O
that NN NN O
differential NN NN O
diagnosis NN NN O
between NN NN O
an NN NN O
amiodarone NN NN O
- NN NN O
related NN NN O
pulmonary NN NN B-Disease
lesion NN NN I-Disease
and NN NN O
a NN NN O
neoplasm NN NN B-Disease
can NN NN O
be NN NN O
very NN NN O
difficult NN NN O
radiologically NN NN O
, NN NN O
and NN NN O
suggests NN NN O
that NN NN O
membranous NN NN B-Disease
glomerulonephritis NN NN I-Disease
might NN NN O
be NN NN O
another NN NN O
possible NN NN O
complication NN NN O
of NN NN O
amiodarone NN NN O
treatment NN NN O
. NN NN O
   
Risk NN NN O
of NN NN O
coronary NN NN B-Disease
artery NN NN I-Disease
disease NN NN I-Disease
associated NN NN O
with NN NN O
initial NN NN O
sulphonylurea NN NN O
treatment NN NN O
of NN NN O
patients NN NN O
with NN NN O
type NN NN B-Disease
2 NN NN I-Disease
diabetes NN NN I-Disease
: NN NN O
a NN NN O
matched NN NN O
case NN NN O
- NN NN O
control NN NN O
study NN NN O
. NN NN O
   
AIMS NN NN O
: NN NN O
This NN NN O
study NN NN O
sought NN NN O
to NN NN O
assess NN NN O
the NN NN O
risk NN NN O
of NN NN O
developing NN NN O
coronary NN NN B-Disease
artery NN NN I-Disease
disease NN NN I-Disease
( NN NN O
CAD NN NN B-Disease
) NN NN O
associated NN NN O
with NN NN O
initial NN NN O
treatment NN NN O
of NN NN O
type NN NN B-Disease
2 NN NN I-Disease
diabetes NN NN I-Disease
with NN NN O
different NN NN O
sulphonylureas NN NN O
. NN NN O
   
METHODS NN NN O
: NN NN O
In NN NN O
type NN NN B-Disease
2 NN NN I-Disease
diabetic NN NN I-Disease
patients NN NN O
, NN NN O
cases NN NN O
who NN NN O
developed NN NN O
CAD NN NN B-Disease
were NN NN O
compared NN NN O
retrospectively NN NN O
with NN NN O
controls NN NN O
that NN NN O
did NN NN O
not NN NN O
. NN NN O
   
The NN NN O
20 NN NN O
- NN NN O
year NN NN O
risk NN NN O
of NN NN O
CAD NN NN B-Disease
at NN NN O
diagnosis NN NN O
of NN NN O
diabetes NN NN B-Disease
, NN NN O
using NN NN O
the NN NN O
UKPDS NN NN O
risk NN NN O
engine NN NN O
, NN NN O
was NN NN O
used NN NN O
to NN NN O
match NN NN O
cases NN NN O
with NN NN O
controls NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
The NN NN O
76 NN NN O
cases NN NN O
of NN NN O
CAD NN NN B-Disease
were NN NN O
compared NN NN O
with NN NN O
152 NN NN O
controls NN NN O
. NN NN O
   
The NN NN O
hazard NN NN O
of NN NN O
developing NN NN O
CAD NN NN B-Disease
( NN NN O
95 NN NN O
% NN NN O
CI NN NN O
) NN NN O
associated NN NN O
with NN NN O
initial NN NN O
treatment NN NN O
increased NN NN O
by NN NN O
2 NN NN O
. NN NN O
4 NN NN O
- NN NN O
fold NN NN O
( NN NN O
1 NN NN O
. NN NN O
3 NN NN O
- NN NN O
4 NN NN O
. NN NN O
3 NN NN O
, NN NN O
P NN NN O
= NN NN O
0 NN NN O
. NN NN O
004 NN NN O
) NN NN O
with NN NN O
glibenclamide NN NN O
; NN NN O
2 NN NN O
- NN NN O
fold NN NN O
( NN NN O
0 NN NN O
. NN NN O
9 NN NN O
- NN NN O
4 NN NN O
. NN NN O
6 NN NN O
, NN NN O
P NN NN O
= NN NN O
0 NN NN O
. NN NN O
099 NN NN O
) NN NN O
with NN NN O
glipizide NN NN O
; NN NN O
2 NN NN O
. NN NN O
9 NN NN O
- NN NN O
fold NN NN O
( NN NN O
1 NN NN O
. NN NN O
6 NN NN O
- NN NN O
5 NN NN O
. NN NN O
1 NN NN O
, NN NN O
P NN NN O
= NN NN O
0 NN NN O
. NN NN O
000 NN NN O
) NN NN O
with NN NN O
either NN NN O
, NN NN O
and NN NN O
was NN NN O
unchanged NN NN O
with NN NN O
metformin NN NN O
. NN NN O
   
The NN NN O
hazard NN NN O
decreased NN NN O
0 NN NN O
. NN NN O
3 NN NN O
- NN NN O
fold NN NN O
( NN NN O
0 NN NN O
. NN NN O
7 NN NN O
- NN NN O
1 NN NN O
. NN NN O
7 NN NN O
, NN NN O
P NN NN O
= NN NN O
0 NN NN O
. NN NN O
385 NN NN O
) NN NN O
with NN NN O
glimepiride NN NN O
, NN NN O
0 NN NN O
. NN NN O
4 NN NN O
- NN NN O
fold NN NN O
( NN NN O
0 NN NN O
. NN NN O
7 NN NN O
- NN NN O
1 NN NN O
. NN NN O
3 NN NN O
, NN NN O
P NN NN O
= NN NN O
0 NN NN O
. NN NN O
192 NN NN O
) NN NN O
with NN NN O
gliclazide NN NN O
, NN NN O
and NN NN O
0 NN NN O
. NN NN O
4 NN NN O
- NN NN O
fold NN NN O
( NN NN O
0 NN NN O
. NN NN O
7 NN NN O
- NN NN O
1 NN NN O
. NN NN O
1 NN NN O
, NN NN O
P NN NN O
= NN NN O
0 NN NN O
. NN NN O
09 NN NN O
) NN NN O
with NN NN O
either NN NN O
. NN NN O
   
CONCLUSIONS NN NN O
: NN NN O
Initiating NN NN O
treatment NN NN O
of NN NN O
type NN NN B-Disease
2 NN NN I-Disease
diabetes NN NN I-Disease
with NN NN O
glibenclamide NN NN O
or NN NN O
glipizide NN NN O
is NN NN O
associated NN NN O
with NN NN O
increased NN NN O
risk NN NN O
of NN NN O
CAD NN NN B-Disease
in NN NN O
comparison NN NN O
to NN NN O
gliclazide NN NN O
or NN NN O
glimepiride NN NN O
. NN NN O
   
If NN NN O
confirmed NN NN O
, NN NN O
this NN NN O
may NN NN O
be NN NN O
important NN NN O
because NN NN O
most NN NN O
Indian NN NN O
patients NN NN O
receive NN NN O
the NN NN O
cheaper NN NN O
older NN NN O
sulphonylureas NN NN O
, NN NN O
and NN NN O
present NN NN O
guidelines NN NN O
do NN NN O
not NN NN O
distinguish NN NN O
between NN NN O
individual NN NN O
agents NN NN O
. NN NN O
   
Reduced NN NN O
progression NN NN O
of NN NN O
adriamycin NN NN O
nephropathy NN NN B-Disease
in NN NN O
spontaneously NN NN O
hypertensive NN NN B-Disease
rats NN NN O
treated NN NN O
by NN NN O
losartan NN NN O
. NN NN O
   
BACKGROUND NN NN O
: NN NN O
The NN NN O
aim NN NN O
of NN NN O
the NN NN O
study NN NN O
was NN NN O
to NN NN O
investigate NN NN O
the NN NN O
antihypertensive NN NN O
effects NN NN O
of NN NN O
angiotensin NN NN O
II NN NN O
type NN NN O
- NN NN O
1 NN NN O
receptor NN NN O
blocker NN NN O
, NN NN O
losartan NN NN O
, NN NN O
and NN NN O
its NN NN O
potential NN NN O
in NN NN O
slowing NN NN O
down NN NN O
renal NN NN B-Disease
disease NN NN I-Disease
progression NN NN O
in NN NN O
spontaneously NN NN O
hypertensive NN NN B-Disease
rats NN NN O
( NN NN O
SHR NN NN O
) NN NN O
with NN NN O
adriamycin NN NN O
( NN NN O
ADR NN NN O
) NN NN O
nephropathy NN NN B-Disease
. NN NN O
   
METHODS NN NN O
: NN NN O
Six NN NN O
- NN NN O
month NN NN O
- NN NN O
old NN NN O
female NN NN O
SHR NN NN O
were NN NN O
randomly NN NN O
selected NN NN O
in NN NN O
six NN NN O
groups NN NN O
. NN NN O
   
Two NN NN O
control NN NN O
groups NN NN O
( NN NN O
SH NN NN O
( NN NN O
6 NN NN O
) NN NN O
, NN NN O
SH NN NN O
( NN NN O
12 NN NN O
) NN NN O
) NN NN O
received NN NN O
vehicle NN NN O
. NN NN O
   
Groups NN NN O
ADR NN NN O
( NN NN O
6 NN NN O
) NN NN O
, NN NN O
ADR NN NN O
+ NN NN O
LOS NN NN O
( NN NN O
6 NN NN O
) NN NN O
and NN NN O
ADR NN NN O
( NN NN O
12 NN NN O
) NN NN O
, NN NN O
and NN NN O
ADR NN NN O
+ NN NN O
LOS NN NN O
( NN NN O
12 NN NN O
) NN NN O
received NN NN O
ADR NN NN O
( NN NN O
2 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
/ NN NN O
b NN NN O
. NN NN O
w NN NN O
. NN NN O
i NN NN O
. NN NN O
v NN NN O
. NN NN O
) NN NN O
twice NN NN O
in NN NN O
a NN NN O
3 NN NN O
- NN NN O
week NN NN O
interval NN NN O
. NN NN O
   
Group NN NN O
ADR NN NN O
+ NN NN O
LOS NN NN O
( NN NN O
6 NN NN O
) NN NN O
received NN NN O
losartan NN NN O
( NN NN O
10 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
/ NN NN O
b NN NN O
. NN NN O
w NN NN O
. NN NN O
/ NN NN O
day NN NN O
by NN NN O
gavages NN NN O
) NN NN O
for NN NN O
6 NN NN O
weeks NN NN O
and NN NN O
group NN NN O
ADR NN NN O
+ NN NN O
LOS NN NN O
( NN NN O
12 NN NN O
) NN NN O
for NN NN O
12 NN NN O
weeks NN NN O
after NN NN O
second NN NN O
injection NN NN O
of NN NN O
ADR NN NN O
. NN NN O
   
Animals NN NN O
were NN NN O
killed NN NN O
after NN NN O
6 NN NN O
or NN NN O
12 NN NN O
weeks NN NN O
, NN NN O
respectively NN NN O
. NN NN O
   
Haemodynamic NN NN O
measurements NN NN O
were NN NN O
performed NN NN O
on NN NN O
anaesthetized NN NN O
animals NN NN O
, NN NN O
blood NN NN O
and NN NN O
urine NN NN O
samples NN NN O
were NN NN O
taken NN NN O
for NN NN O
biochemical NN NN O
analysis NN NN O
and NN NN O
the NN NN O
left NN NN O
kidney NN NN O
was NN NN O
processed NN NN O
for NN NN O
morphological NN NN O
studies NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
Short NN NN O
- NN NN O
term NN NN O
losartan NN NN O
treatment NN NN O
, NN NN O
besides NN NN O
antihypertensive NN NN O
effect NN NN O
, NN NN O
improved NN NN O
glomerular NN NN O
filtration NN NN O
rate NN NN O
and NN NN O
ameliorated NN NN O
glomerulosclerosis NN NN B-Disease
resulting NN NN O
in NN NN O
decreased NN NN O
proteinuria NN NN B-Disease
. NN NN O
   
Prolonged NN NN O
treatment NN NN O
with NN NN O
losartan NN NN O
showed NN NN O
further NN NN O
reduction NN NN O
of NN NN O
glomerulosclerosis NN NN B-Disease
associated NN NN O
with NN NN O
reduced NN NN O
progression NN NN O
of NN NN O
tubular NN NN O
atrophy NN NN B-Disease
and NN NN O
interstitial NN NN B-Disease
fibrosis NN NN I-Disease
, NN NN O
thus NN NN O
preventing NN NN O
heavy NN NN O
proteinuria NN NN B-Disease
and NN NN O
chronic NN NN B-Disease
renal NN NN I-Disease
failure NN NN I-Disease
. NN NN O
   
Losartan NN NN O
reduced NN NN O
uraemia NN NN B-Disease
and NN NN O
increased NN NN O
urea NN NN O
clearance NN NN O
in NN NN O
advanced NN NN O
ADR NN NN O
nephropathy NN NN B-Disease
in NN NN O
SHR NN NN O
. NN NN O
   
Histological NN NN O
examination NN NN O
showed NN NN O
that NN NN O
losartan NN NN O
could NN NN O
prevent NN NN O
tubular NN NN O
atrophy NN NN B-Disease
, NN NN O
interstitial NN NN O
infiltration NN NN O
and NN NN O
fibrosis NN NN B-Disease
in NN NN O
ADR NN NN O
nephropathy NN NN B-Disease
. NN NN O
   
CONCLUSION NN NN O
: NN NN O
Losartan NN NN O
reduces NN NN O
the NN NN O
rate NN NN O
of NN NN O
progression NN NN O
of NN NN O
ADR NN NN O
- NN NN O
induced NN NN O
focal NN NN B-Disease
segmental NN NN I-Disease
glomerulosclerosis NN NN I-Disease
to NN NN O
end NN NN B-Disease
- NN NN I-Disease
stage NN NN I-Disease
renal NN NN I-Disease
disease NN NN I-Disease
in NN NN O
SHR NN NN O
. NN NN O
   
The NN NN O
risks NN NN O
of NN NN O
aprotinin NN NN O
and NN NN O
tranexamic NN NN O
acid NN NN O
in NN NN O
cardiac NN NN O
surgery NN NN O
: NN NN O
a NN NN O
one NN NN O
- NN NN O
year NN NN O
follow NN NN O
- NN NN O
up NN NN O
of NN NN O
1188 NN NN O
consecutive NN NN O
patients NN NN O
. NN NN O
   
BACKGROUND NN NN O
: NN NN O
Our NN NN O
aim NN NN O
was NN NN O
to NN NN O
investigate NN NN O
postoperative NN NN O
complications NN NN O
and NN NN O
mortality NN NN O
after NN NN O
administration NN NN O
of NN NN O
aprotinin NN NN O
compared NN NN O
to NN NN O
tranexamic NN NN O
acid NN NN O
in NN NN O
an NN NN O
unselected NN NN O
, NN NN O
consecutive NN NN O
cohort NN NN O
. NN NN O
   
METHODS NN NN O
: NN NN O
Perioperative NN NN O
data NN NN O
from NN NN O
consecutive NN NN O
cardiac NN NN O
surgery NN NN O
patients NN NN O
were NN NN O
prospectively NN NN O
collected NN NN O
between NN NN O
September NN NN O
2005 NN NN O
and NN NN O
June NN NN O
2006 NN NN O
in NN NN O
a NN NN O
university NN NN O
- NN NN O
affiliated NN NN O
clinic NN NN O
( NN NN O
n NN NN O
= NN NN O
1188 NN NN O
) NN NN O
. NN NN O
   
During NN NN O
the NN NN O
first NN NN O
5 NN NN O
mo NN NN O
, NN NN O
596 NN NN O
patients NN NN O
received NN NN O
aprotinin NN NN O
( NN NN O
Group NN NN O
A NN NN O
) NN NN O
; NN NN O
in NN NN O
the NN NN O
next NN NN O
5 NN NN O
mo NN NN O
, NN NN O
592 NN NN O
patients NN NN O
were NN NN O
treated NN NN O
with NN NN O
tranexamic NN NN O
acid NN NN O
( NN NN O
Group NN NN O
T NN NN O
) NN NN O
. NN NN O
   
Except NN NN O
for NN NN O
antifibrinolytic NN NN O
therapy NN NN O
, NN NN O
the NN NN O
anesthetic NN NN O
and NN NN O
surgical NN NN O
protocols NN NN O
remained NN NN O
unchanged NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
The NN NN O
pre NN NN O
- NN NN O
and NN NN O
intraoperative NN NN O
variables NN NN O
were NN NN O
comparable NN NN O
between NN NN O
the NN NN O
treatment NN NN O
groups NN NN O
. NN NN O
   
Postoperatively NN NN O
, NN NN O
a NN NN O
significantly NN NN O
higher NN NN O
incidence NN NN O
of NN NN O
seizures NN NN B-Disease
was NN NN O
found NN NN O
in NN NN O
Group NN NN O
T NN NN O
( NN NN O
4 NN NN O
. NN NN O
6 NN NN O
% NN NN O
vs NN NN O
1 NN NN O
. NN NN O
2 NN NN O
% NN NN O
, NN NN O
P NN NN O
< NN NN O
0 NN NN O
. NN NN O
001 NN NN O
) NN NN O
. NN NN O
   
This NN NN O
difference NN NN O
was NN NN O
also NN NN O
significant NN NN O
in NN NN O
the NN NN O
primary NN NN O
valve NN NN O
surgery NN NN O
and NN NN O
the NN NN O
high NN NN O
risk NN NN O
surgery NN NN O
subgroups NN NN O
( NN NN O
7 NN NN O
. NN NN O
9 NN NN O
% NN NN O
vs NN NN O
1 NN NN O
. NN NN O
2 NN NN O
% NN NN O
, NN NN O
P NN NN O
= NN NN O
0 NN NN O
. NN NN O
003 NN NN O
; NN NN O
7 NN NN O
. NN NN O
3 NN NN O
% NN NN O
vs NN NN O
2 NN NN O
. NN NN O
4 NN NN O
% NN NN O
, NN NN O
P NN NN O
= NN NN O
0 NN NN O
. NN NN O
035 NN NN O
, NN NN O
respectively NN NN O
) NN NN O
. NN NN O
   
Persistent NN NN O
atrial NN NN O
fibrillation NN NN O
( NN NN O
7 NN NN O
. NN NN O
9 NN NN O
% NN NN O
vs NN NN O
2 NN NN O
. NN NN O
3 NN NN O
% NN NN O
, NN NN O
P NN NN O
= NN NN O
0 NN NN O
. NN NN O
020 NN NN O
) NN NN O
and NN NN O
renal NN NN B-Disease
failure NN NN I-Disease
( NN NN O
9 NN NN O
. NN NN O
7 NN NN O
% NN NN O
vs NN NN O
1 NN NN O
. NN NN O
7 NN NN O
% NN NN O
, NN NN O
P NN NN O
= NN NN O
0 NN NN O
. NN NN O
002 NN NN O
) NN NN O
were NN NN O
also NN NN O
more NN NN O
common NN NN O
in NN NN O
Group NN NN O
T NN NN O
, NN NN O
in NN NN O
the NN NN O
primary NN NN O
valve NN NN O
surgery NN NN O
subgroup NN NN O
. NN NN O
   
On NN NN O
the NN NN O
contrary NN NN O
, NN NN O
among NN NN O
primary NN NN O
coronary NN NN O
artery NN NN O
bypass NN NN O
surgery NN NN O
patients NN NN O
, NN NN O
there NN NN O
were NN NN O
more NN NN O
acute NN NN O
myocardial NN NN B-Disease
infarctions NN NN I-Disease
and NN NN O
renal NN NN B-Disease
dysfunction NN NN I-Disease
in NN NN O
Group NN NN O
A NN NN O
( NN NN O
5 NN NN O
. NN NN O
8 NN NN O
% NN NN O
vs NN NN O
2 NN NN O
. NN NN O
0 NN NN O
% NN NN O
, NN NN O
P NN NN O
= NN NN O
0 NN NN O
. NN NN O
027 NN NN O
; NN NN O
22 NN NN O
. NN NN O
5 NN NN O
% NN NN O
vs NN NN O
15 NN NN O
. NN NN O
2 NN NN O
% NN NN O
, NN NN O
P NN NN O
= NN NN O
0 NN NN O
. NN NN O
036 NN NN O
, NN NN O
respectively NN NN O
) NN NN O
. NN NN O
   
The NN NN O
1 NN NN O
- NN NN O
yr NN NN O
mortality NN NN O
was NN NN O
significantly NN NN O
higher NN NN O
after NN NN O
aprotinin NN NN O
treatment NN NN O
in NN NN O
the NN NN O
high NN NN O
risk NN NN O
surgery NN NN O
group NN NN O
( NN NN O
17 NN NN O
. NN NN O
7 NN NN O
% NN NN O
vs NN NN O
9 NN NN O
. NN NN O
8 NN NN O
% NN NN O
, NN NN O
P NN NN O
= NN NN O
0 NN NN O
. NN NN O
034 NN NN O
) NN NN O
. NN NN O
   
CONCLUSION NN NN O
: NN NN O
Both NN NN O
antifibrinolytic NN NN O
drugs NN NN O
bear NN NN O
the NN NN O
risk NN NN O
of NN NN O
adverse NN NN O
outcome NN NN O
depending NN NN O
on NN NN O
the NN NN O
type NN NN O
of NN NN O
cardiac NN NN O
surgery NN NN O
. NN NN O
   
Administration NN NN O
of NN NN O
aprotinin NN NN O
should NN NN O
be NN NN O
avoided NN NN O
in NN NN O
coronary NN NN O
artery NN NN O
bypass NN NN O
graft NN NN O
and NN NN O
high NN NN O
risk NN NN O
patients NN NN O
, NN NN O
whereas NN NN O
administration NN NN O
of NN NN O
tranexamic NN NN O
acid NN NN O
is NN NN O
not NN NN O
recommended NN NN O
in NN NN O
valve NN NN O
surgery NN NN O
. NN NN O
   
Delirium NN NN B-Disease
in NN NN O
an NN NN O
elderly NN NN O
woman NN NN O
possibly NN NN O
associated NN NN O
with NN NN O
administration NN NN O
of NN NN O
misoprostol NN NN O
. NN NN O
   
Misoprostol NN NN O
has NN NN O
been NN NN O
associated NN NN O
with NN NN O
adverse NN NN O
reactions NN NN O
, NN NN O
including NN NN O
gastrointestinal NN NN O
symptoms NN NN O
, NN NN O
gynecologic NN NN O
problems NN NN O
, NN NN O
and NN NN O
headache NN NN B-Disease
. NN NN O
   
Changes NN NN O
in NN NN O
mental NN NN O
status NN NN O
, NN NN O
however NN NN O
, NN NN O
have NN NN O
not NN NN O
been NN NN O
reported NN NN O
. NN NN O
   
We NN NN O
present NN NN O
a NN NN O
case NN NN O
in NN NN O
which NN NN O
an NN NN O
89 NN NN O
- NN NN O
year NN NN O
- NN NN O
old NN NN O
woman NN NN O
in NN NN O
a NN NN O
long NN NN O
- NN NN O
term NN NN O
care NN NN O
facility NN NN O
became NN NN O
confused NN NN O
after NN NN O
the NN NN O
initiation NN NN O
of NN NN O
misoprostol NN NN O
therapy NN NN O
. NN NN O
   
The NN NN O
patient NN NN O
' NN NN O
s NN NN O
change NN NN O
in NN NN O
mental NN NN O
status NN NN O
was NN NN O
first NN NN O
reported NN NN O
nine NN NN O
days NN NN O
after NN NN O
the NN NN O
initiation NN NN O
of NN NN O
therapy NN NN O
. NN NN O
   
Her NN NN O
delirium NN NN B-Disease
significantly NN NN O
improved NN NN O
after NN NN O
misoprostol NN NN O
was NN NN O
discontinued NN NN O
and NN NN O
her NN NN O
mental NN NN O
status NN NN O
returned NN NN O
to NN NN O
normal NN NN O
within NN NN O
a NN NN O
week NN NN O
. NN NN O
   
Because NN NN O
no NN NN O
other NN NN O
factors NN NN O
related NN NN O
to NN NN O
this NN NN O
patient NN NN O
changed NN NN O
significantly NN NN O
, NN NN O
the NN NN O
delirium NN NN B-Disease
experienced NN NN O
by NN NN O
this NN NN O
patient NN NN O
possibly NN NN O
resulted NN NN O
from NN NN O
misoprostol NN NN O
therapy NN NN O
. NN NN O
   
The NN NN O
biological NN NN O
properties NN NN O
of NN NN O
the NN NN O
optical NN NN O
isomers NN NN O
of NN NN O
propranolol NN NN O
and NN NN O
their NN NN O
effects NN NN O
on NN NN O
cardiac NN NN B-Disease
arrhythmias NN NN I-Disease
. NN NN O
   
1 NN NN O
. NN NN O
   
The NN NN O
optical NN NN O
isomers NN NN O
of NN NN O
propranolol NN NN O
have NN NN O
been NN NN O
compared NN NN O
for NN NN O
their NN NN O
beta NN NN O
- NN NN O
blocking NN NN O
and NN NN O
antiarrhythmic NN NN O
activities NN NN O
. NN NN O
2 NN NN O
. NN NN O
   
In NN NN O
blocking NN NN O
the NN NN O
positive NN NN O
inotropic NN NN O
and NN NN O
chronotropic NN NN O
responses NN NN O
to NN NN O
isoprenaline NN NN O
, NN NN O
( NN NN O
+ NN NN O
) NN NN O
- NN NN O
propranolol NN NN O
had NN NN O
less NN NN O
than NN NN O
one NN NN O
hundredth NN NN O
the NN NN O
potency NN NN O
of NN NN O
( NN NN O
- NN NN O
) NN NN O
- NN NN O
propranolol NN NN O
. NN NN O
   
At NN NN O
dose NN NN O
levels NN NN O
of NN NN O
( NN NN O
+ NN NN O
) NN NN O
- NN NN O
propranolol NN NN O
which NN NN O
attenuated NN NN O
the NN NN O
responses NN NN O
to NN NN O
isoprenaline NN NN O
, NN NN O
there NN NN O
was NN NN O
a NN NN O
significant NN NN O
prolongation NN NN O
of NN NN O
the NN NN O
PR NN NN O
interval NN NN O
of NN NN O
the NN NN O
electrocardiogram NN NN O
. NN NN O
3 NN NN O
. NN NN O
   
The NN NN O
metabolic NN NN O
responses NN NN O
to NN NN O
isoprenaline NN NN O
in NN NN O
dogs NN NN O
( NN NN O
an NN NN O
increase NN NN O
in NN NN O
circulating NN NN O
glucose NN NN O
, NN NN O
lactate NN NN O
and NN NN O
free NN NN O
fatty NN NN O
acids NN NN O
) NN NN O
were NN NN O
all NN NN O
blocked NN NN O
by NN NN O
( NN NN O
- NN NN O
) NN NN O
- NN NN O
propranolol NN NN O
. NN NN O
   
( NN NN O
+ NN NN O
) NN NN O
- NN NN O
Propranolol NN NN O
had NN NN O
no NN NN O
effect NN NN O
on NN NN O
fatty NN NN O
acid NN NN O
mobilization NN NN O
but NN NN O
significantly NN NN O
reduced NN NN O
the NN NN O
increments NN NN O
in NN NN O
both NN NN O
lactate NN NN O
and NN NN O
glucose NN NN O
. NN NN O
4 NN NN O
. NN NN O
   
Both NN NN O
isomers NN NN O
of NN NN O
propranolol NN NN O
possessed NN NN O
similar NN NN O
depressant NN NN O
potency NN NN O
on NN NN O
isolated NN NN O
atrial NN NN O
muscle NN NN O
taken NN NN O
from NN NN O
guinea NN NN O
- NN NN O
pigs NN NN O
. NN NN O
5 NN NN O
. NN NN O
   
The NN NN O
isomers NN NN O
of NN NN O
propranolol NN NN O
exhibited NN NN O
similar NN NN O
local NN NN O
anaesthetic NN NN O
potencies NN NN O
on NN NN O
an NN NN O
isolated NN NN O
frog NN NN O
nerve NN NN O
preparation NN NN O
at NN NN O
a NN NN O
level NN NN O
approximately NN NN O
three NN NN O
times NN NN O
that NN NN O
of NN NN O
procaine NN NN O
. NN NN O
   
The NN NN O
racemic NN NN O
compound NN NN O
was NN NN O
significantly NN NN O
less NN NN O
potent NN NN O
than NN NN O
either NN NN O
isomer NN NN O
. NN NN O
6 NN NN O
. NN NN O
   
Both NN NN O
isomers NN NN O
of NN NN O
propranolol NN NN O
were NN NN O
capable NN NN O
of NN NN O
preventing NN NN O
adrenaline NN NN O
- NN NN O
induced NN NN O
cardiac NN NN B-Disease
arrhythmias NN NN I-Disease
in NN NN O
cats NN NN O
anaesthetized NN NN O
with NN NN O
halothane NN NN O
, NN NN O
but NN NN O
the NN NN O
mean NN NN O
dose NN NN O
of NN NN O
( NN NN O
- NN NN O
) NN NN O
- NN NN O
propranolol NN NN O
was NN NN O
0 NN NN O
. NN NN O
09 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
0 NN NN O
. NN NN O
02 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
whereas NN NN O
that NN NN O
of NN NN O
( NN NN O
+ NN NN O
) NN NN O
- NN NN O
propranolol NN NN O
was NN NN O
4 NN NN O
. NN NN O
2 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
1 NN NN O
. NN NN O
2 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
. NN NN O
   
At NN NN O
the NN NN O
effective NN NN O
dose NN NN O
level NN NN O
of NN NN O
( NN NN O
+ NN NN O
) NN NN O
- NN NN O
propranolol NN NN O
there NN NN O
was NN NN O
a NN NN O
significant NN NN O
prolongation NN NN O
of NN NN O
the NN NN O
PR NN NN O
interval NN NN O
of NN NN O
the NN NN O
electrocardiogram NN NN O
. NN NN O
   
Blockade NN NN O
of NN NN O
arrhythmias NN NN B-Disease
with NN NN O
both NN NN O
isomers NN NN O
was NN NN O
surmountable NN NN O
by NN NN O
increasing NN NN O
the NN NN O
dose NN NN O
of NN NN O
adrenaline NN NN O
. NN NN O
7 NN NN O
. NN NN O
   
Both NN NN O
isomers NN NN O
of NN NN O
propranolol NN NN O
were NN NN O
also NN NN O
capable NN NN O
of NN NN O
reversing NN NN O
ventricular NN NN B-Disease
tachycardia NN NN I-Disease
caused NN NN O
by NN NN O
ouabain NN NN O
in NN NN O
anaesthetized NN NN O
cats NN NN O
and NN NN O
dogs NN NN O
. NN NN O
   
The NN NN O
dose NN NN O
of NN NN O
( NN NN O
- NN NN O
) NN NN O
- NN NN O
propranolol NN NN O
was NN NN O
significantly NN NN O
smaller NN NN O
than NN NN O
that NN NN O
of NN NN O
( NN NN O
+ NN NN O
) NN NN O
- NN NN O
propranolol NN NN O
in NN NN O
both NN NN O
species NN NN O
but NN NN O
much NN NN O
higher NN NN O
than NN NN O
that NN NN O
required NN NN O
to NN NN O
produce NN NN O
evidence NN NN O
of NN NN O
beta NN NN O
- NN NN O
blockade NN NN O
. NN NN O
8 NN NN O
. NN NN O
   
The NN NN O
implications NN NN O
of NN NN O
these NN NN O
results NN NN O
are NN NN O
discussed NN NN O
. NN NN O
   
Topotecan NN NN O
in NN NN O
combination NN NN O
with NN NN O
radiotherapy NN NN O
in NN NN O
unresectable NN NN O
glioblastoma NN NN B-Disease
: NN NN O
a NN NN O
phase NN NN O
2 NN NN O
study NN NN O
. NN NN O
   
Improving NN NN O
glioblastoma NN NN B-Disease
multiforme NN NN I-Disease
( NN NN O
GBM NN NN B-Disease
) NN NN O
treatment NN NN O
with NN NN O
radio NN NN O
- NN NN O
chemotherapy NN NN O
remains NN NN O
a NN NN O
challenge NN NN O
. NN NN O
   
Topotecan NN NN O
is NN NN O
an NN NN O
attractive NN NN O
option NN NN O
as NN NN O
it NN NN O
exhibits NN NN O
growth NN NN O
inhibition NN NN O
of NN NN O
human NN NN O
glioma NN NN B-Disease
as NN NN O
well NN NN O
as NN NN O
brain NN NN O
penetration NN NN O
. NN NN O
   
The NN NN O
present NN NN O
study NN NN O
assessed NN NN O
the NN NN O
combination NN NN O
of NN NN O
radiotherapy NN NN O
( NN NN O
60 NN NN O
Gy NN NN O
/ NN NN O
30 NN NN O
fractions NN NN O
/ NN NN O
40 NN NN O
days NN NN O
) NN NN O
and NN NN O
topotecan NN NN O
( NN NN O
0 NN NN O
. NN NN O
9 NN NN O
mg NN NN O
/ NN NN O
m NN NN O
( NN NN O
2 NN NN O
) NN NN O
/ NN NN O
day NN NN O
on NN NN O
days NN NN O
1 NN NN O
- NN NN O
5 NN NN O
on NN NN O
weeks NN NN O
1 NN NN O
, NN NN O
3 NN NN O
and NN NN O
5 NN NN O
) NN NN O
in NN NN O
50 NN NN O
adults NN NN O
with NN NN O
histologically NN NN O
proven NN NN O
and NN NN O
untreated NN NN O
GBM NN NN B-Disease
. NN NN O
   
The NN NN O
incidence NN NN O
of NN NN O
non NN NN O
- NN NN O
hematological NN NN O
toxicities NN NN B-Disease
was NN NN O
low NN NN O
and NN NN O
grade NN NN O
3 NN NN O
- NN NN O
4 NN NN O
hematological NN NN O
toxicities NN NN B-Disease
were NN NN O
reported NN NN O
in NN NN O
20 NN NN O
patients NN NN O
( NN NN O
mainly NN NN O
lymphopenia NN NN B-Disease
and NN NN O
neutropenia NN NN B-Disease
) NN NN O
. NN NN O
   
Partial NN NN O
response NN NN O
and NN NN O
stabilization NN NN O
rates NN NN O
were NN NN O
2 NN NN O
% NN NN O
and NN NN O
32 NN NN O
% NN NN O
, NN NN O
respectively NN NN O
, NN NN O
with NN NN O
an NN NN O
overall NN NN O
time NN NN O
to NN NN O
progression NN NN O
of NN NN O
12 NN NN O
weeks NN NN O
. NN NN O
   
One NN NN O
- NN NN O
year NN NN O
overall NN NN O
survival NN NN O
( NN NN O
OS NN NN O
) NN NN O
rate NN NN O
was NN NN O
42 NN NN O
% NN NN O
, NN NN O
with NN NN O
a NN NN O
median NN NN O
OS NN NN O
of NN NN O
40 NN NN O
weeks NN NN O
. NN NN O
   
Topotecan NN NN O
in NN NN O
combination NN NN O
with NN NN O
radiotherapy NN NN O
was NN NN O
well NN NN O
tolerated NN NN O
. NN NN O
   
However NN NN O
, NN NN O
while NN NN O
response NN NN O
and NN NN O
stabilization NN NN O
concerned NN NN O
one NN NN O
- NN NN O
third NN NN O
of NN NN O
the NN NN O
patients NN NN O
, NN NN O
the NN NN O
study NN NN O
did NN NN O
not NN NN O
show NN NN O
increased NN NN O
benefits NN NN O
in NN NN O
terms NN NN O
of NN NN O
survival NN NN O
in NN NN O
patients NN NN O
with NN NN O
unresectable NN NN O
GBM NN NN B-Disease
. NN NN O
   
Long NN NN O
- NN NN O
term NN NN O
lithium NN NN O
therapy NN NN O
leading NN NN O
to NN NN O
hyperparathyroidism NN NN B-Disease
: NN NN O
a NN NN O
case NN NN O
report NN NN O
. NN NN O
   
PURPOSE NN NN O
: NN NN O
This NN NN O
paper NN NN O
reviews NN NN O
the NN NN O
effect NN NN O
of NN NN O
chronic NN NN O
lithium NN NN O
therapy NN NN O
on NN NN O
serum NN NN O
calcium NN NN O
level NN NN O
and NN NN O
parathyroid NN NN O
glands NN NN O
, NN NN O
its NN NN O
pathogenesis NN NN O
, NN NN O
and NN NN O
treatment NN NN O
options NN NN O
. NN NN O
   
We NN NN O
examined NN NN O
the NN NN O
case NN NN O
of NN NN O
a NN NN O
lithium NN NN O
- NN NN O
treated NN NN O
patient NN NN O
who NN NN O
had NN NN O
recurrent NN NN O
hypercalcemia NN NN B-Disease
to NN NN O
better NN NN O
understand NN NN O
the NN NN O
disease NN NN O
process NN NN O
. NN NN O
   
CONCLUSION NN NN O
: NN NN O
Primary NN NN B-Disease
hyperparathyroidism NN NN I-Disease
is NN NN O
a NN NN O
rare NN NN O
but NN NN O
potentially NN NN O
life NN NN O
- NN NN O
threatening NN NN O
side NN NN O
effect NN NN O
of NN NN O
long NN NN O
- NN NN O
term NN NN O
lithium NN NN O
therapy NN NN O
. NN NN O
   
Careful NN NN O
patient NN NN O
selection NN NN O
and NN NN O
long NN NN O
- NN NN O
term NN NN O
follow NN NN O
- NN NN O
up NN NN O
can NN NN O
reduce NN NN O
morbidity NN NN O
. NN NN O
   
PRACTICAL NN NN O
IMPLICATIONS NN NN O
: NN NN O
As NN NN O
much NN NN O
as NN NN O
15 NN NN O
% NN NN O
of NN NN O
lithium NN NN O
- NN NN O
treated NN NN O
patients NN NN O
become NN NN O
hypercalcemic NN NN B-Disease
. NN NN O
   
By NN NN O
routinely NN NN O
monitoring NN NN O
serum NN NN O
calcium NN NN O
levels NN NN O
, NN NN O
healthcare NN NN O
providers NN NN O
can NN NN O
improve NN NN O
the NN NN O
quality NN NN O
of NN NN O
life NN NN O
of NN NN O
this NN NN O
patient NN NN O
group NN NN O
. NN NN O
   
Comparison NN NN O
of NN NN O
laryngeal NN NN O
mask NN NN O
with NN NN O
endotracheal NN NN O
tube NN NN O
for NN NN O
anesthesia NN NN O
in NN NN O
endoscopic NN NN O
sinus NN NN O
surgery NN NN O
. NN NN O
   
BACKGROUND NN NN O
: NN NN O
The NN NN O
purpose NN NN O
of NN NN O
this NN NN O
study NN NN O
was NN NN O
to NN NN O
compare NN NN O
surgical NN NN O
conditions NN NN O
, NN NN O
including NN NN O
the NN NN O
amount NN NN O
of NN NN O
intraoperative NN NN O
bleeding NN NN B-Disease
as NN NN O
well NN NN O
as NN NN O
intraoperative NN NN O
blood NN NN O
pressure NN NN O
, NN NN O
during NN NN O
functional NN NN O
endoscopic NN NN O
sinus NN NN O
surgery NN NN O
( NN NN O
FESS NN NN O
) NN NN O
using NN NN O
flexible NN NN O
reinforced NN NN O
laryngeal NN NN O
mask NN NN O
airway NN NN O
( NN NN O
FRLMA NN NN O
) NN NN O
versus NN NN O
endotracheal NN NN O
tube NN NN O
( NN NN O
ETT NN NN O
) NN NN O
in NN NN O
maintaining NN NN O
controlled NN NN O
hypotension NN NN B-Disease
anesthesia NN NN O
induced NN NN O
by NN NN O
propofol NN NN O
- NN NN O
remifentanil NN NN O
total NN NN O
i NN NN O
. NN NN O
v NN NN O
. NN NN O
anesthesia NN NN O
( NN NN O
TIVA NN NN O
) NN NN O
. NN NN O
   
METHODS NN NN O
: NN NN O
Sixty NN NN O
normotensive NN NN O
American NN NN O
Society NN NN O
of NN NN O
Anesthesiologists NN NN O
I NN NN O
- NN NN O
II NN NN O
adult NN NN O
patients NN NN O
undergoing NN NN O
FESS NN NN O
under NN NN O
controlled NN NN O
hypotension NN NN B-Disease
anesthesia NN NN O
caused NN NN O
by NN NN O
propofol NN NN O
- NN NN O
remifentanil NN NN O
- NN NN O
TIVA NN NN O
were NN NN O
randomly NN NN O
assigned NN NN O
into NN NN O
two NN NN O
groups NN NN O
: NN NN O
group NN NN O
I NN NN O
, NN NN O
FRLMA NN NN O
; NN NN O
group NN NN O
II NN NN O
, NN NN O
ETT NN NN O
. NN NN O
   
Hemorrhage NN NN B-Disease
was NN NN O
measured NN NN O
and NN NN O
the NN NN O
visibility NN NN O
of NN NN O
the NN NN O
operative NN NN O
field NN NN O
was NN NN O
evaluated NN NN O
according NN NN O
to NN NN O
a NN NN O
six NN NN O
- NN NN O
point NN NN O
scale NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
Controlled NN NN O
hypotension NN NN B-Disease
was NN NN O
achieved NN NN O
within NN NN O
a NN NN O
shorter NN NN O
period NN NN O
using NN NN O
laryngeal NN NN O
mask NN NN O
using NN NN O
lower NN NN O
rates NN NN O
of NN NN O
remifentanil NN NN O
infusion NN NN O
and NN NN O
lower NN NN O
total NN NN O
dose NN NN O
of NN NN O
remifentanil NN NN O
. NN NN O
   
CONCLUSION NN NN O
: NN NN O
In NN NN O
summary NN NN O
, NN NN O
our NN NN O
results NN NN O
indicate NN NN O
that NN NN O
airway NN NN O
management NN NN O
using NN NN O
FRLMA NN NN O
during NN NN O
controlled NN NN O
hypotension NN NN B-Disease
anesthesia NN NN O
provided NN NN O
better NN NN O
surgical NN NN O
conditions NN NN O
in NN NN O
terms NN NN O
of NN NN O
quality NN NN O
of NN NN O
operative NN NN O
field NN NN O
and NN NN O
blood NN NN O
loss NN NN O
and NN NN O
allowed NN NN O
for NN NN O
convenient NN NN O
induced NN NN O
hypotension NN NN B-Disease
with NN NN O
low NN NN O
doses NN NN O
of NN NN O
remifentanil NN NN O
during NN NN O
TIVA NN NN O
in NN NN O
patients NN NN O
undergoing NN NN O
FESS NN NN O
. NN NN O
   
Nonalcoholic NN NN B-Disease
fatty NN NN I-Disease
liver NN NN I-Disease
disease NN NN I-Disease
during NN NN O
valproate NN NN O
therapy NN NN O
. NN NN O
   
Valproic NN NN O
acid NN NN O
( NN NN O
VPA NN NN O
) NN NN O
is NN NN O
effective NN NN O
for NN NN O
the NN NN O
treatment NN NN O
of NN NN O
many NN NN O
types NN NN O
of NN NN O
epilepsy NN NN B-Disease
, NN NN O
but NN NN O
its NN NN O
use NN NN O
can NN NN O
be NN NN O
associated NN NN O
with NN NN O
an NN NN O
increase NN NN O
in NN NN O
body NN NN O
weight NN NN O
. NN NN O
   
We NN NN O
report NN NN O
a NN NN O
case NN NN O
of NN NN O
nonalcoholic NN NN B-Disease
fatty NN NN I-Disease
liver NN NN I-Disease
disease NN NN I-Disease
( NN NN O
NAFLD NN NN B-Disease
) NN NN O
arising NN NN O
in NN NN O
a NN NN O
child NN NN O
who NN NN O
developed NN NN O
obesity NN NN B-Disease
during NN NN O
VPA NN NN O
treatment NN NN O
. NN NN O
   
Laboratory NN NN O
data NN NN O
revealed NN NN O
hyperinsulinemia NN NN B-Disease
with NN NN O
insulin NN NN B-Disease
resistance NN NN I-Disease
. NN NN O
   
After NN NN O
the NN NN O
withdrawal NN NN O
of NN NN O
VPA NN NN O
therapy NN NN O
, NN NN O
our NN NN O
patient NN NN O
showed NN NN O
a NN NN O
significant NN NN O
weight NN NN B-Disease
loss NN NN I-Disease
, NN NN O
a NN NN O
decrease NN NN O
of NN NN O
body NN NN O
mass NN NN O
index NN NN O
, NN NN O
and NN NN O
normalization NN NN O
of NN NN O
metabolic NN NN O
and NN NN O
endocrine NN NN O
parameters NN NN O
; NN NN O
moreover NN NN O
, NN NN O
ultrasound NN NN O
measurements NN NN O
showed NN NN O
a NN NN O
complete NN NN O
normalization NN NN O
. NN NN O
   
The NN NN O
present NN NN O
case NN NN O
suggests NN NN O
that NN NN O
obesity NN NN B-Disease
, NN NN O
hyperinsulinemia NN NN B-Disease
, NN NN O
insulin NN NN B-Disease
resistance NN NN I-Disease
, NN NN O
and NN NN O
long NN NN O
- NN NN O
term NN NN O
treatment NN NN O
with NN NN O
VPA NN NN O
may NN NN O
be NN NN O
all NN NN O
associated NN NN O
with NN NN O
the NN NN O
development NN NN O
of NN NN O
NAFLD NN NN B-Disease
; NN NN O
this NN NN O
side NN NN O
effect NN NN O
is NN NN O
reversible NN NN O
after NN NN O
VPA NN NN O
withdrawal NN NN O
. NN NN O
   
Carbimazole NN NN O
induced NN NN O
ANCA NN NN B-Disease
positive NN NN I-Disease
vasculitis NN NN I-Disease
. NN NN O
   
Anti NN NN O
- NN NN O
thyroid NN NN O
drugs NN NN O
, NN NN O
like NN NN O
carbimazole NN NN O
and NN NN O
propylthiouracil NN NN O
( NN NN O
PTU NN NN O
) NN NN O
are NN NN O
commonly NN NN O
prescribed NN NN O
for NN NN O
the NN NN O
treatment NN NN O
of NN NN O
hyperthyroidism NN NN B-Disease
. NN NN O
   
One NN NN O
should NN NN O
be NN NN O
aware NN NN O
of NN NN O
the NN NN O
side NN NN O
effects NN NN O
of NN NN O
antithyroid NN NN O
medications NN NN O
. NN NN O
   
Antineutrophil NN NN B-Disease
cytoplasmic NN NN I-Disease
antibody NN NN I-Disease
( NN NN I-Disease
ANCA NN NN I-Disease
) NN NN I-Disease
- NN NN I-Disease
- NN NN I-Disease
associated NN NN I-Disease
vasculitis NN NN I-Disease
is NN NN O
a NN NN O
potentially NN NN O
life NN NN O
- NN NN O
threatening NN NN O
adverse NN NN O
effect NN NN O
of NN NN O
antithyroidmedications NN NN O
. NN NN O
   
We NN NN O
report NN NN O
a NN NN O
patient NN NN O
with NN NN O
Graves NN NN B-Disease
' NN NN I-Disease
disease NN NN I-Disease
who NN NN O
developed NN NN O
ANCA NN NN O
positive NN NN O
carbimazole NN NN O
induced NN NN O
vasculitis NN NN B-Disease
. NN NN O
   
The NN NN O
episode NN NN O
was NN NN O
characterized NN NN O
by NN NN O
a NN NN O
vasculitic NN NN B-Disease
skin NN NN B-Disease
rash NN NN I-Disease
associated NN NN O
with NN NN O
large NN NN O
joint NN NN O
arthritis NN NN B-Disease
, NN NN O
pyrexia NN NN B-Disease
and NN NN O
parotiditis NN NN B-Disease
but NN NN O
no NN NN O
renal NN NN O
or NN NN O
pulmonary NN NN O
involvement NN NN O
. NN NN O
   
He NN NN O
was NN NN O
referred NN NN O
to NN NN O
us NN NN O
for NN NN O
neurological NN NN O
evaluation NN NN O
because NN NN O
he NN NN O
had NN NN O
difficulty NN NN O
in NN NN O
getting NN NN O
up NN NN O
from NN NN O
squatting NN NN O
position NN NN O
and NN NN O
was NN NN O
suspected NN NN O
to NN NN O
have NN NN O
myositis NN NN B-Disease
. NN NN O
   
Carbimazole NN NN O
and NN NN O
methimazole NN NN O
have NN NN O
a NN NN O
lower NN NN O
incidence NN NN O
of NN NN O
reported NN NN O
ANCA NN NN O
positive NN NN O
side NN NN O
effects NN NN O
than NN NN O
PUT NN NN O
. NN NN O
   
To NN NN O
the NN NN O
best NN NN O
of NN NN O
our NN NN O
knowledge NN NN O
this NN NN O
is NN NN O
the NN NN O
first NN NN O
ANCA NN NN O
positive NN NN O
carbimazole NN NN O
induced NN NN O
vasculitis NN NN B-Disease
case NN NN O
reported NN NN O
from NN NN O
India NN NN O
. NN NN O
   
Aspirin NN NN O
for NN NN O
the NN NN O
primary NN NN O
prevention NN NN O
of NN NN O
cardiovascular NN NN O
events NN NN O
: NN NN O
an NN NN O
update NN NN O
of NN NN O
the NN NN O
evidence NN NN O
for NN NN O
the NN NN O
U NN NN O
. NN NN O
S NN NN O
. NN NN O
   
Preventive NN NN O
Services NN NN O
Task NN NN O
Force NN NN O
. NN NN O
   
BACKGROUND NN NN O
: NN NN O
Coronary NN NN B-Disease
heart NN NN I-Disease
disease NN NN I-Disease
and NN NN O
cerebrovascular NN NN B-Disease
disease NN NN I-Disease
are NN NN O
leading NN NN O
causes NN NN O
of NN NN O
death NN NN O
in NN NN O
the NN NN O
United NN NN O
States NN NN O
. NN NN O
   
In NN NN O
2002 NN NN O
, NN NN O
the NN NN O
U NN NN O
. NN NN O
S NN NN O
. NN NN O
   
Preventive NN NN O
Services NN NN O
Task NN NN O
Force NN NN O
( NN NN O
USPSTF NN NN O
) NN NN O
strongly NN NN O
recommended NN NN O
that NN NN O
clinicians NN NN O
discuss NN NN O
aspirin NN NN O
with NN NN O
adults NN NN O
who NN NN O
are NN NN O
at NN NN O
increased NN NN O
risk NN NN O
for NN NN O
coronary NN NN B-Disease
heart NN NN I-Disease
disease NN NN I-Disease
. NN NN O
   
PURPOSE NN NN O
: NN NN O
To NN NN O
determine NN NN O
the NN NN O
benefits NN NN O
and NN NN O
harms NN NN O
of NN NN O
taking NN NN O
aspirin NN NN O
for NN NN O
the NN NN O
primary NN NN O
prevention NN NN O
of NN NN O
myocardial NN NN B-Disease
infarctions NN NN I-Disease
, NN NN O
strokes NN NN B-Disease
, NN NN O
and NN NN O
death NN NN O
. NN NN O
   
DATA NN NN O
SOURCES NN NN O
: NN NN O
MEDLINE NN NN O
and NN NN O
Cochrane NN NN O
Library NN NN O
( NN NN O
search NN NN O
dates NN NN O
, NN NN O
1 NN NN O
January NN NN O
2001 NN NN O
to NN NN O
28 NN NN O
August NN NN O
2008 NN NN O
) NN NN O
, NN NN O
recent NN NN O
systematic NN NN O
reviews NN NN O
, NN NN O
reference NN NN O
lists NN NN O
of NN NN O
retrieved NN NN O
articles NN NN O
, NN NN O
and NN NN O
suggestions NN NN O
from NN NN O
experts NN NN O
. NN NN O
   
STUDY NN NN O
SELECTION NN NN O
: NN NN O
English NN NN O
- NN NN O
language NN NN O
randomized NN NN O
, NN NN O
controlled NN NN O
trials NN NN O
( NN NN O
RCTs NN NN O
) NN NN O
; NN NN O
case NN NN O
- NN NN O
control NN NN O
studies NN NN O
; NN NN O
meta NN NN O
- NN NN O
analyses NN NN O
; NN NN O
and NN NN O
systematic NN NN O
reviews NN NN O
of NN NN O
aspirin NN NN O
versus NN NN O
control NN NN O
for NN NN O
the NN NN O
primary NN NN O
prevention NN NN O
of NN NN O
cardiovascular NN NN B-Disease
disease NN NN I-Disease
( NN NN O
CVD NN NN B-Disease
) NN NN O
were NN NN O
selected NN NN O
to NN NN O
answer NN NN O
the NN NN O
following NN NN O
questions NN NN O
: NN NN O
Does NN NN O
aspirin NN NN O
decrease NN NN O
coronary NN NN O
heart NN NN O
events NN NN O
, NN NN O
strokes NN NN B-Disease
, NN NN O
death NN NN O
from NN NN O
coronary NN NN O
heart NN NN O
events NN NN O
or NN NN O
stroke NN NN B-Disease
, NN NN O
or NN NN O
all NN NN O
- NN NN O
cause NN NN O
mortality NN NN O
in NN NN O
adults NN NN O
without NN NN O
known NN NN O
CVD NN NN B-Disease
? NN NN O
   
Does NN NN O
aspirin NN NN O
increase NN NN O
gastrointestinal NN NN B-Disease
bleeding NN NN I-Disease
or NN NN O
hemorrhagic NN NN B-Disease
strokes NN NN I-Disease
? NN NN O
   
DATA NN NN O
EXTRACTION NN NN O
: NN NN O
All NN NN O
studies NN NN O
were NN NN O
reviewed NN NN O
, NN NN O
abstracted NN NN O
, NN NN O
and NN NN O
rated NN NN O
for NN NN O
quality NN NN O
by NN NN O
using NN NN O
predefined NN NN O
USPSTF NN NN O
criteria NN NN O
. NN NN O
   
DATA NN NN O
SYNTHESIS NN NN O
: NN NN O
New NN NN O
evidence NN NN O
from NN NN O
1 NN NN O
good NN NN O
- NN NN O
quality NN NN O
RCT NN NN O
, NN NN O
1 NN NN O
good NN NN O
- NN NN O
quality NN NN O
meta NN NN O
- NN NN O
analysis NN NN O
, NN NN O
and NN NN O
2 NN NN O
fair NN NN O
- NN NN O
quality NN NN O
subanalyses NN NN O
of NN NN O
RCTs NN NN O
demonstrates NN NN O
that NN NN O
aspirin NN NN O
use NN NN O
reduces NN NN O
the NN NN O
number NN NN O
of NN NN O
CVD NN NN B-Disease
events NN NN O
in NN NN O
patients NN NN O
without NN NN O
known NN NN O
CVD NN NN B-Disease
. NN NN O
   
Men NN NN O
in NN NN O
these NN NN O
studies NN NN O
experienced NN NN O
fewer NN NN O
myocardial NN NN B-Disease
infarctions NN NN I-Disease
and NN NN O
women NN NN O
experienced NN NN O
fewer NN NN O
ischemic NN NN O
strokes NN NN B-Disease
. NN NN O
   
Aspirin NN NN O
does NN NN O
not NN NN O
seem NN NN O
to NN NN O
affect NN NN O
CVD NN NN B-Disease
mortality NN NN O
or NN NN O
all NN NN O
- NN NN O
cause NN NN O
mortality NN NN O
in NN NN O
either NN NN O
men NN NN O
or NN NN O
women NN NN O
. NN NN O
   
The NN NN O
use NN NN O
of NN NN O
aspirin NN NN O
for NN NN O
primary NN NN O
prevention NN NN O
increases NN NN O
the NN NN O
risk NN NN O
for NN NN O
major NN NN O
bleeding NN NN B-Disease
events NN NN O
, NN NN O
primarily NN NN O
gastrointestinal NN NN B-Disease
bleeding NN NN I-Disease
events NN NN O
, NN NN O
in NN NN O
both NN NN O
men NN NN O
and NN NN O
women NN NN O
. NN NN O
   
Men NN NN O
have NN NN O
an NN NN O
increased NN NN O
risk NN NN O
for NN NN O
hemorrhagic NN NN B-Disease
strokes NN NN I-Disease
with NN NN O
aspirin NN NN O
use NN NN O
. NN NN O
   
A NN NN O
new NN NN O
RCT NN NN O
and NN NN O
meta NN NN O
- NN NN O
analysis NN NN O
suggest NN NN O
that NN NN O
the NN NN O
risk NN NN O
for NN NN O
hemorrhagic NN NN B-Disease
strokes NN NN I-Disease
in NN NN O
women NN NN O
is NN NN O
not NN NN O
statistically NN NN O
significantly NN NN O
increased NN NN O
. NN NN O
   
LIMITATIONS NN NN O
: NN NN O
New NN NN O
evidence NN NN O
on NN NN O
aspirin NN NN O
for NN NN O
the NN NN O
primary NN NN O
prevention NN NN O
of NN NN O
CVD NN NN B-Disease
is NN NN O
limited NN NN O
. NN NN O
   
The NN NN O
dose NN NN O
of NN NN O
aspirin NN NN O
used NN NN O
in NN NN O
the NN NN O
RCTs NN NN O
varied NN NN O
, NN NN O
which NN NN O
prevented NN NN O
the NN NN O
estimation NN NN O
of NN NN O
the NN NN O
most NN NN O
appropriate NN NN O
dose NN NN O
for NN NN O
primary NN NN O
prevention NN NN O
. NN NN O
   
Several NN NN O
of NN NN O
the NN NN O
RCTs NN NN O
were NN NN O
conducted NN NN O
within NN NN O
populations NN NN O
of NN NN O
health NN NN O
professionals NN NN O
, NN NN O
which NN NN O
potentially NN NN O
limits NN NN O
generalizability NN NN O
. NN NN O
   
CONCLUSION NN NN O
: NN NN O
Aspirin NN NN O
reduces NN NN O
the NN NN O
risk NN NN O
for NN NN O
myocardial NN NN B-Disease
infarction NN NN I-Disease
in NN NN O
men NN NN O
and NN NN O
strokes NN NN B-Disease
in NN NN O
women NN NN O
. NN NN O
   
Aspirin NN NN O
use NN NN O
increases NN NN O
the NN NN O
risk NN NN O
for NN NN O
serious NN NN O
bleeding NN NN B-Disease
events NN NN O
. NN NN O
   
Reducing NN NN O
harm NN NN O
associated NN NN O
with NN NN O
anticoagulation NN NN O
: NN NN O
practical NN NN O
considerations NN NN O
of NN NN O
argatroban NN NN O
therapy NN NN O
in NN NN O
heparin NN NN O
- NN NN O
induced NN NN O
thrombocytopenia NN NN B-Disease
. NN NN O
   
Argatroban NN NN O
is NN NN O
a NN NN O
hepatically NN NN O
metabolized NN NN O
, NN NN O
direct NN NN O
thrombin NN NN O
inhibitor NN NN O
used NN NN O
for NN NN O
prophylaxis NN NN O
or NN NN O
treatment NN NN O
of NN NN O
thrombosis NN NN B-Disease
in NN NN O
heparin NN NN O
- NN NN O
induced NN NN O
thrombocytopenia NN NN B-Disease
( NN NN O
HIT NN NN B-Disease
) NN NN O
and NN NN O
for NN NN O
patients NN NN O
with NN NN O
or NN NN O
at NN NN O
risk NN NN O
of NN NN O
HIT NN NN B-Disease
undergoing NN NN O
percutaneous NN NN O
coronary NN NN O
intervention NN NN O
( NN NN O
PCI NN NN O
) NN NN O
. NN NN O
   
The NN NN O
objective NN NN O
of NN NN O
this NN NN O
review NN NN O
is NN NN O
to NN NN O
summarize NN NN O
practical NN NN O
considerations NN NN O
of NN NN O
argatroban NN NN O
therapy NN NN O
in NN NN O
HIT NN NN B-Disease
. NN NN O
   
The NN NN O
US NN NN O
FDA NN NN O
- NN NN O
recommended NN NN O
argatroban NN NN O
dose NN NN O
in NN NN O
HIT NN NN B-Disease
is NN NN O
2 NN NN O
microg NN NN O
/ NN NN O
kg NN NN O
/ NN NN O
min NN NN O
( NN NN O
reduced NN NN O
in NN NN O
patients NN NN O
with NN NN O
hepatic NN NN B-Disease
impairment NN NN I-Disease
and NN NN O
in NN NN O
paediatric NN NN O
patients NN NN O
) NN NN O
, NN NN O
adjusted NN NN O
to NN NN O
achieve NN NN O
activated NN NN O
partial NN NN O
thromboplastin NN NN O
times NN NN O
( NN NN O
aPTTs NN NN O
) NN NN O
1 NN NN O
. NN NN O
5 NN NN O
- NN NN O
3 NN NN O
times NN NN O
baseline NN NN O
( NN NN O
not NN NN O
> NN NN O
100 NN NN O
seconds NN NN O
) NN NN O
. NN NN O
   
Contemporary NN NN O
experiences NN NN O
indicate NN NN O
that NN NN O
reduced NN NN O
doses NN NN O
are NN NN O
also NN NN O
needed NN NN O
in NN NN O
patients NN NN O
with NN NN O
conditions NN NN O
associated NN NN O
with NN NN O
hepatic NN NN O
hypoperfusion NN NN O
, NN NN O
e NN NN O
. NN NN O
g NN NN O
. NN NN O
heart NN NN B-Disease
failure NN NN I-Disease
, NN NN O
yet NN NN O
are NN NN O
unnecessary NN NN O
for NN NN O
renal NN NN B-Disease
dysfunction NN NN I-Disease
, NN NN O
adult NN NN O
age NN NN O
, NN NN O
sex NN NN O
, NN NN O
race NN NN O
/ NN NN O
ethnicity NN NN O
or NN NN O
obesity NN NN B-Disease
. NN NN O
   
Argatroban NN NN O
0 NN NN O
. NN NN O
5 NN NN O
- NN NN O
1 NN NN O
. NN NN O
2 NN NN O
microg NN NN O
/ NN NN O
kg NN NN O
/ NN NN O
min NN NN O
typically NN NN O
supports NN NN O
therapeutic NN NN O
aPTTs NN NN O
. NN NN O
   
The NN NN O
FDA NN NN O
- NN NN O
recommended NN NN O
dose NN NN O
during NN NN O
PCI NN NN O
is NN NN O
25 NN NN O
microg NN NN O
/ NN NN O
kg NN NN O
/ NN NN O
min NN NN O
( NN NN O
350 NN NN O
microg NN NN O
/ NN NN O
kg NN NN O
initial NN NN O
bolus NN NN O
) NN NN O
, NN NN O
adjusted NN NN O
to NN NN O
achieve NN NN O
activated NN NN O
clotting NN NN O
times NN NN O
( NN NN O
ACTs NN NN O
) NN NN O
of NN NN O
300 NN NN O
- NN NN O
450 NN NN O
sec NN NN O
. NN NN O
   
For NN NN O
PCI NN NN O
, NN NN O
argatroban NN NN O
has NN NN O
not NN NN O
been NN NN O
investigated NN NN O
in NN NN O
hepatically NN NN O
impaired NN NN O
patients NN NN O
; NN NN O
dose NN NN O
adjustment NN NN O
is NN NN O
unnecessary NN NN O
for NN NN O
adult NN NN O
age NN NN O
, NN NN O
sex NN NN O
, NN NN O
race NN NN O
/ NN NN O
ethnicity NN NN O
or NN NN O
obesity NN NN B-Disease
, NN NN O
and NN NN O
lesser NN NN O
doses NN NN O
may NN NN O
be NN NN O
adequate NN NN O
with NN NN O
concurrent NN NN O
glycoprotein NN NN O
IIb NN NN O
/ NN NN O
IIIa NN NN O
inhibition NN NN O
. NN NN O
   
Argatroban NN NN O
prolongs NN NN O
the NN NN O
International NN NN O
Normalized NN NN O
Ratio NN NN O
, NN NN O
and NN NN O
published NN NN O
approaches NN NN O
for NN NN O
monitoring NN NN O
the NN NN O
argatroban NN NN O
- NN NN O
to NN NN O
- NN NN O
warfarin NN NN O
transition NN NN O
should NN NN O
be NN NN O
followed NN NN O
. NN NN O
   
Major NN NN O
bleeding NN NN B-Disease
with NN NN O
argatroban NN NN O
is NN NN O
0 NN NN O
- NN NN O
10 NN NN O
% NN NN O
in NN NN O
the NN NN O
non NN NN O
- NN NN O
interventional NN NN O
setting NN NN O
and NN NN O
0 NN NN O
- NN NN O
5 NN NN O
. NN NN O
8 NN NN O
% NN NN O
periprocedurally NN NN O
. NN NN O
   
Argatroban NN NN O
has NN NN O
no NN NN O
specific NN NN O
antidote NN NN O
, NN NN O
and NN NN O
if NN NN O
excessive NN NN O
anticoagulation NN NN O
occurs NN NN O
, NN NN O
argatroban NN NN O
infusion NN NN O
should NN NN O
be NN NN O
stopped NN NN O
or NN NN O
reduced NN NN O
. NN NN O
   
Improved NN NN O
familiarity NN NN O
of NN NN O
healthcare NN NN O
professionals NN NN O
with NN NN O
argatroban NN NN O
therapy NN NN O
in NN NN O
HIT NN NN B-Disease
, NN NN O
including NN NN O
in NN NN O
special NN NN O
populations NN NN O
and NN NN O
during NN NN O
PCI NN NN O
, NN NN O
may NN NN O
facilitate NN NN O
reduction NN NN O
of NN NN O
harm NN NN O
associated NN NN O
with NN NN O
HIT NN NN B-Disease
( NN NN O
e NN NN O
. NN NN O
g NN NN O
. NN NN O
fewer NN NN O
thromboses NN NN O
) NN NN O
or NN NN O
its NN NN O
treatment NN NN O
( NN NN O
e NN NN O
. NN NN O
g NN NN O
. NN NN O
fewer NN NN O
argatroban NN NN O
medication NN NN O
errors NN NN O
) NN NN O
. NN NN O
   
Rhabdomyolysis NN NN B-Disease
and NN NN O
brain NN NN O
ischemic NN NN B-Disease
stroke NN NN I-Disease
in NN NN O
a NN NN O
heroin NN NN O
- NN NN O
dependent NN NN O
male NN NN O
under NN NN O
methadone NN NN O
maintenance NN NN O
therapy NN NN O
. NN NN O
   
OBJECTIVE NN NN O
: NN NN O
There NN NN O
are NN NN O
several NN NN O
complications NN NN O
associated NN NN O
with NN NN O
heroin NN NN B-Disease
abuse NN NN I-Disease
, NN NN O
some NN NN O
of NN NN O
which NN NN O
are NN NN O
life NN NN O
- NN NN O
threatening NN NN O
. NN NN O
   
Methadone NN NN O
may NN NN O
aggravate NN NN O
this NN NN O
problem NN NN O
. NN NN O
   
METHOD NN NN O
: NN NN O
A NN NN O
clinical NN NN O
case NN NN O
description NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
A NN NN O
33 NN NN O
- NN NN O
year NN NN O
- NN NN O
old NN NN O
man NN NN O
presented NN NN O
with NN NN O
rhabdomyolysis NN NN B-Disease
and NN NN O
cerebral NN NN O
ischemic NN NN B-Disease
stroke NN NN I-Disease
after NN NN O
intravenous NN NN O
heroin NN NN O
. NN NN O
   
He NN NN O
had NN NN O
used NN NN O
heroin NN NN O
since NN NN O
age NN NN O
20 NN NN O
, NN NN O
and NN NN O
had NN NN O
used NN NN O
150 NN NN O
mg NN NN O
methadone NN NN O
daily NN NN O
for NN NN O
6 NN NN O
months NN NN O
. NN NN O
   
He NN NN O
was NN NN O
found NN NN O
unconsciousness NN NN B-Disease
at NN NN O
home NN NN O
and NN NN O
was NN NN O
sent NN NN O
to NN NN O
our NN NN O
hospital NN NN O
. NN NN O
   
In NN NN O
the NN NN O
ER NN NN O
, NN NN O
his NN NN O
opiate NN NN O
level NN NN O
was NN NN O
4497 NN NN O
ng NN NN O
/ NN NN O
ml NN NN O
. NN NN O
   
In NN NN O
the NN NN O
ICU NN NN O
, NN NN O
we NN NN O
found NN NN O
rhabdomyolysis NN NN B-Disease
, NN NN O
acute NN NN B-Disease
renal NN NN I-Disease
failure NN NN I-Disease
and NN NN O
acute NN NN O
respiratory NN NN B-Disease
failure NN NN I-Disease
. NN NN O
   
After NN NN O
transfer NN NN O
to NN NN O
an NN NN O
internal NN NN O
ward NN NN O
, NN NN O
we NN NN O
noted NN NN O
aphasia NN NN B-Disease
and NN NN O
weakness NN NN B-Disease
of NN NN O
his NN NN O
left NN NN O
limbs NN NN O
. NN NN O
   
After NN NN O
MRI NN NN O
, NN NN O
we NN NN O
found NN NN O
cerebral NN NN B-Disease
ischemic NN NN I-Disease
infarction NN NN I-Disease
. NN NN O
   
CONCLUSION NN NN O
: NN NN O
Those NN NN O
using NN NN O
methadone NN NN O
and NN NN O
heroin NN NN O
simultaneously NN NN O
may NN NN O
increase NN NN O
risk NN NN O
of NN NN O
rhabdomyolysis NN NN B-Disease
and NN NN O
ischemic NN NN B-Disease
stroke NN NN I-Disease
. NN NN O
   
Patients NN NN O
under NN NN O
methadone NN NN O
maintenance NN NN O
therapy NN NN O
should NN NN O
be NN NN O
warned NN NN O
regarding NN NN O
these NN NN O
serious NN NN O
adverse NN NN O
events NN NN O
. NN NN O
   
Hypotheses NN NN O
of NN NN O
heroin NN NN O
- NN NN O
related NN NN O
rhabdomyolysis NN NN B-Disease
and NN NN O
stroke NN NN B-Disease
in NN NN O
heroin NN NN O
abusers NN NN O
are NN NN O
discussed NN NN O
. NN NN O
   
Increased NN NN O
vulnerability NN NN O
to NN NN O
6 NN NN O
- NN NN O
hydroxydopamine NN NN O
lesion NN NN O
and NN NN O
reduced NN NN O
development NN NN O
of NN NN O
dyskinesias NN NN B-Disease
in NN NN O
mice NN NN O
lacking NN NN O
CB1 NN NN O
cannabinoid NN NN O
receptors NN NN O
. NN NN O
   
Motor NN NN O
impairment NN NN O
, NN NN O
dopamine NN NN O
( NN NN O
DA NN NN O
) NN NN O
neuronal NN NN O
activity NN NN O
and NN NN O
proenkephalin NN NN O
( NN NN O
PENK NN NN O
) NN NN O
gene NN NN O
expression NN NN O
in NN NN O
the NN NN O
caudate NN NN O
- NN NN O
putamen NN NN O
( NN NN O
CPu NN NN O
) NN NN O
were NN NN O
measured NN NN O
in NN NN O
6 NN NN O
- NN NN O
OHDA NN NN O
- NN NN O
lesioned NN NN O
and NN NN O
treated NN NN O
( NN NN O
L NN NN O
- NN NN O
DOPA NN NN O
+ NN NN O
benserazide NN NN O
) NN NN O
CB1 NN NN O
KO NN NN O
and NN NN O
WT NN NN O
mice NN NN O
. NN NN O
   
A NN NN O
lesion NN NN O
induced NN NN O
by NN NN O
6 NN NN O
- NN NN O
OHDA NN NN O
produced NN NN O
more NN NN O
severe NN NN O
motor NN NN O
deterioration NN NN O
in NN NN O
CB1 NN NN O
KO NN NN O
mice NN NN O
accompanied NN NN O
by NN NN O
more NN NN O
loss NN NN O
of NN NN O
DA NN NN O
neurons NN NN O
and NN NN O
increased NN NN O
PENK NN NN O
gene NN NN O
expression NN NN O
in NN NN O
the NN NN O
CPu NN NN O
. NN NN O
   
Oxidative NN NN O
/ NN NN O
nitrosative NN NN O
and NN NN O
neuroinflammatory NN NN O
parameters NN NN O
were NN NN O
estimated NN NN O
in NN NN O
the NN NN O
CPu NN NN O
and NN NN O
cingulate NN NN O
cortex NN NN O
( NN NN O
Cg NN NN O
) NN NN O
. NN NN O
   
CB1 NN NN O
KO NN NN O
mice NN NN O
exhibited NN NN O
higher NN NN O
MDA NN NN O
levels NN NN O
and NN NN O
iNOS NN NN O
protein NN NN O
expression NN NN O
in NN NN O
the NN NN O
CPu NN NN O
and NN NN O
Cg NN NN O
compared NN NN O
to NN NN O
WT NN NN O
mice NN NN O
. NN NN O
   
Treatment NN NN O
with NN NN O
L NN NN O
- NN NN O
DOPA NN NN O
+ NN NN O
benserazide NN NN O
( NN NN O
12 NN NN O
weeks NN NN O
) NN NN O
resulted NN NN O
in NN NN O
less NN NN O
severe NN NN O
dyskinesias NN NN B-Disease
in NN NN O
CB1 NN NN O
KO NN NN O
than NN NN O
in NN NN O
WT NN NN O
mice NN NN O
. NN NN O
   
The NN NN O
results NN NN O
revealed NN NN O
that NN NN O
the NN NN O
lack NN NN O
of NN NN O
cannabinoid NN NN O
CB1 NN NN O
receptors NN NN O
increased NN NN O
the NN NN O
severity NN NN O
of NN NN O
motor NN NN O
impairment NN NN O
and NN NN O
DA NN NN O
lesion NN NN O
, NN NN O
and NN NN O
reduced NN NN O
L NN NN O
- NN NN O
DOPA NN NN O
- NN NN O
induced NN NN O
dyskinesias NN NN B-Disease
. NN NN O
   
These NN NN O
results NN NN O
suggest NN NN O
that NN NN O
activation NN NN O
of NN NN O
CB1 NN NN O
receptors NN NN O
offers NN NN O
neuroprotection NN NN O
against NN NN O
dopaminergic NN NN O
lesion NN NN O
and NN NN O
the NN NN O
development NN NN O
of NN NN O
L NN NN O
- NN NN O
DOPA NN NN O
- NN NN O
induced NN NN O
dyskinesias NN NN B-Disease
. NN NN O
   
Hepatocellular NN NN O
oxidant NN NN O
stress NN NN O
following NN NN O
intestinal NN NN O
ischemia NN NN B-Disease
- NN NN O
reperfusion NN NN B-Disease
injury NN NN I-Disease
. NN NN O
   
Reperfusion NN NN O
of NN NN O
ischemic NN NN B-Disease
intestine NN NN O
results NN NN O
in NN NN O
acute NN NN O
liver NN NN B-Disease
dysfunction NN NN I-Disease
characterized NN NN O
by NN NN O
hepatocellular NN NN O
enzyme NN NN O
release NN NN O
into NN NN O
plasma NN NN O
, NN NN O
reduction NN NN O
in NN NN O
bile NN NN O
flow NN NN O
rate NN NN O
, NN NN O
and NN NN O
neutrophil NN NN O
sequestration NN NN O
within NN NN O
the NN NN O
liver NN NN O
. NN NN O
   
The NN NN O
pathophysiology NN NN O
underlying NN NN O
this NN NN O
acute NN NN O
hepatic NN NN B-Disease
injury NN NN I-Disease
is NN NN O
unknown NN NN O
. NN NN O
   
This NN NN O
study NN NN O
was NN NN O
undertaken NN NN O
to NN NN O
determine NN NN O
whether NN NN O
oxidants NN NN O
are NN NN O
associated NN NN O
with NN NN O
the NN NN O
hepatic NN NN B-Disease
injury NN NN I-Disease
and NN NN O
to NN NN O
determine NN NN O
the NN NN O
relative NN NN O
value NN NN O
of NN NN O
several NN NN O
indirect NN NN O
methods NN NN O
of NN NN O
assessing NN NN O
oxidant NN NN O
exposure NN NN O
in NN NN O
vivo NN NN O
. NN NN O
   
Rats NN NN O
were NN NN O
subjected NN NN O
to NN NN O
a NN NN O
standardized NN NN O
intestinal NN NN O
ischemia NN NN B-Disease
- NN NN O
reperfusion NN NN B-Disease
injury NN NN I-Disease
. NN NN O
   
Hepatic NN NN O
tissue NN NN O
was NN NN O
assayed NN NN O
for NN NN O
lipid NN NN O
peroxidation NN NN O
products NN NN O
and NN NN O
oxidized NN NN O
and NN NN O
reduced NN NN O
glutathione NN NN O
. NN NN O
   
There NN NN O
was NN NN O
no NN NN O
change NN NN O
in NN NN O
hepatic NN NN O
tissue NN NN O
total NN NN O
glutathione NN NN O
following NN NN O
intestinal NN NN O
ischemia NN NN B-Disease
- NN NN O
reperfusion NN NN B-Disease
injury NN NN I-Disease
. NN NN O
   
Oxidized NN NN O
glutathione NN NN O
( NN NN O
GSSG NN NN O
) NN NN O
increased NN NN O
significantly NN NN O
following NN NN O
30 NN NN O
and NN NN O
60 NN NN O
min NN NN O
of NN NN O
reperfusion NN NN O
. NN NN O
   
There NN NN O
was NN NN O
no NN NN O
increase NN NN O
in NN NN O
any NN NN O
of NN NN O
the NN NN O
products NN NN O
of NN NN O
lipid NN NN O
peroxidation NN NN O
associated NN NN O
with NN NN O
this NN NN O
injury NN NN O
. NN NN O
   
An NN NN O
increase NN NN O
in NN NN O
GSSG NN NN O
within NN NN O
hepatic NN NN O
tissue NN NN O
during NN NN O
intestinal NN NN O
reperfusion NN NN O
suggests NN NN O
exposure NN NN O
of NN NN O
hepatocytes NN NN O
to NN NN O
an NN NN O
oxidant NN NN O
stress NN NN O
. NN NN O
   
The NN NN O
lack NN NN O
of NN NN O
a NN NN O
significant NN NN O
increase NN NN O
in NN NN O
products NN NN O
of NN NN O
lipid NN NN O
peroxidation NN NN O
suggests NN NN O
that NN NN O
the NN NN O
oxidant NN NN O
stress NN NN O
is NN NN O
of NN NN O
insufficient NN NN O
magnitude NN NN O
to NN NN O
result NN NN O
in NN NN O
irreversible NN NN O
injury NN NN O
to NN NN O
hepatocyte NN NN O
cell NN NN O
membranes NN NN O
. NN NN O
   
These NN NN O
data NN NN O
also NN NN O
suggest NN NN O
that NN NN O
the NN NN O
measurement NN NN O
of NN NN O
tissue NN NN O
GSSG NN NN O
may NN NN O
be NN NN O
a NN NN O
more NN NN O
sensitive NN NN O
indicator NN NN O
of NN NN O
oxidant NN NN O
stress NN NN O
than NN NN O
measurement NN NN O
of NN NN O
products NN NN O
of NN NN O
lipid NN NN O
peroxidation NN NN O
. NN NN O
   
Animal NN NN O
model NN NN O
of NN NN O
mania NN NN B-Disease
induced NN NN O
by NN NN O
ouabain NN NN O
: NN NN O
Evidence NN NN O
of NN NN O
oxidative NN NN O
stress NN NN O
in NN NN O
submitochondrial NN NN O
particles NN NN O
of NN NN O
the NN NN O
rat NN NN O
brain NN NN O
. NN NN O
   
The NN NN O
intracerebroventricular NN NN O
( NN NN O
ICV NN NN O
) NN NN O
administration NN NN O
of NN NN O
ouabain NN NN O
( NN NN O
a NN NN O
Na NN NN O
( NN NN O
+ NN NN O
) NN NN O
/ NN NN O
K NN NN O
( NN NN O
+ NN NN O
) NN NN O
- NN NN O
ATPase NN NN O
inhibitor NN NN O
) NN NN O
in NN NN O
rats NN NN O
has NN NN O
been NN NN O
suggested NN NN O
to NN NN O
mimic NN NN O
some NN NN O
symptoms NN NN O
of NN NN O
human NN NN O
bipolar NN NN B-Disease
mania NN NN I-Disease
. NN NN O
   
Clinical NN NN O
studies NN NN O
have NN NN O
shown NN NN O
that NN NN O
bipolar NN NN B-Disease
disorder NN NN I-Disease
may NN NN O
be NN NN O
related NN NN O
to NN NN O
mitochondrial NN NN B-Disease
dysfunction NN NN I-Disease
. NN NN O
   
Herein NN NN O
, NN NN O
we NN NN O
investigated NN NN O
the NN NN O
behavioral NN NN O
and NN NN O
biochemical NN NN O
effects NN NN O
induced NN NN O
by NN NN O
the NN NN O
ICV NN NN O
administration NN NN O
of NN NN O
ouabain NN NN O
in NN NN O
rats NN NN O
. NN NN O
   
To NN NN O
achieve NN NN O
this NN NN O
aim NN NN O
, NN NN O
the NN NN O
effects NN NN O
of NN NN O
ouabain NN NN O
injection NN NN O
immediately NN NN O
after NN NN O
and NN NN O
7 NN NN O
days NN NN O
following NN NN O
a NN NN O
single NN NN O
ICV NN NN O
administration NN NN O
( NN NN O
at NN NN O
concentrations NN NN O
of NN NN O
10 NN NN O
( NN NN O
- NN NN O
2 NN NN O
) NN NN O
and NN NN O
10 NN NN O
( NN NN O
- NN NN O
3 NN NN O
) NN NN O
M NN NN O
) NN NN O
on NN NN O
locomotion NN NN O
was NN NN O
measured NN NN O
using NN NN O
the NN NN O
open NN NN O
- NN NN O
field NN NN O
test NN NN O
. NN NN O
   
Additionally NN NN O
, NN NN O
thiobarbituric NN NN O
acid NN NN O
reactive NN NN O
substances NN NN O
( NN NN O
TBARSs NN NN O
) NN NN O
and NN NN O
superoxide NN NN O
production NN NN O
were NN NN O
measured NN NN O
in NN NN O
submitochondrial NN NN O
particles NN NN O
of NN NN O
the NN NN O
prefrontal NN NN O
cortex NN NN O
, NN NN O
hippocampus NN NN O
, NN NN O
striatum NN NN O
and NN NN O
amygdala NN NN O
. NN NN O
   
Our NN NN O
findings NN NN O
demonstrated NN NN O
that NN NN O
ouabain NN NN O
at NN NN O
10 NN NN O
( NN NN O
- NN NN O
2 NN NN O
) NN NN O
and NN NN O
10 NN NN O
( NN NN O
- NN NN O
3 NN NN O
) NN NN O
M NN NN O
induced NN NN O
hyperlocomotion NN NN B-Disease
in NN NN O
rats NN NN O
, NN NN O
and NN NN O
this NN NN O
response NN NN O
remained NN NN O
up NN NN O
to NN NN O
7 NN NN O
days NN NN O
following NN NN O
a NN NN O
single NN NN O
ICV NN NN O
injection NN NN O
. NN NN O
   
In NN NN O
addition NN NN O
, NN NN O
we NN NN O
observed NN NN O
that NN NN O
the NN NN O
persistent NN NN O
increase NN NN O
in NN NN O
the NN NN O
rat NN NN O
spontaneous NN NN O
locomotion NN NN O
is NN NN O
associated NN NN O
with NN NN O
increased NN NN O
TBARS NN NN O
levels NN NN O
and NN NN O
superoxide NN NN O
generation NN NN O
in NN NN O
submitochondrial NN NN O
particles NN NN O
in NN NN O
the NN NN O
prefrontal NN NN O
cortex NN NN O
, NN NN O
striatum NN NN O
and NN NN O
amygdala NN NN O
. NN NN O
   
In NN NN O
conclusion NN NN O
, NN NN O
ouabain NN NN O
- NN NN O
induced NN NN O
mania NN NN B-Disease
- NN NN O
like NN NN O
behavior NN NN O
may NN NN O
provide NN NN O
a NN NN O
useful NN NN O
animal NN NN O
model NN NN O
to NN NN O
test NN NN O
the NN NN O
hypothesis NN NN O
of NN NN O
the NN NN O
involvement NN NN O
of NN NN O
oxidative NN NN O
stress NN NN O
in NN NN O
bipolar NN NN B-Disease
disorder NN NN I-Disease
. NN NN O
   
Intraoperative NN NN O
dialysis NN NN O
during NN NN O
liver NN NN O
transplantation NN NN O
with NN NN O
citrate NN NN O
dialysate NN NN O
. NN NN O
   
Liver NN NN O
transplantation NN NN O
for NN NN O
acutely NN NN O
ill NN NN O
patients NN NN O
with NN NN O
fulminant NN NN B-Disease
liver NN NN I-Disease
failure NN NN I-Disease
carries NN NN O
high NN NN O
intraoperative NN NN O
and NN NN O
immediate NN NN O
postoperative NN NN O
risks NN NN O
. NN NN O
   
These NN NN O
are NN NN O
increased NN NN O
with NN NN O
the NN NN O
presence NN NN O
of NN NN O
concomitant NN NN O
acute NN NN B-Disease
kidney NN NN I-Disease
injury NN NN I-Disease
( NN NN O
AKI NN NN B-Disease
) NN NN O
and NN NN O
intraoperative NN NN O
dialysis NN NN O
is NN NN O
sometimes NN NN O
required NN NN O
to NN NN O
allow NN NN O
the NN NN O
transplant NN NN O
to NN NN O
proceed NN NN O
. NN NN O
   
The NN NN O
derangements NN NN O
in NN NN O
the NN NN O
procoagulant NN NN O
and NN NN O
anticoagulant NN NN O
pathways NN NN O
during NN NN O
fulminant NN NN B-Disease
liver NN NN I-Disease
failure NN NN I-Disease
can NN NN O
lead NN NN O
to NN NN O
difficulties NN NN O
with NN NN O
anticoagulation NN NN O
during NN NN O
dialysis NN NN O
, NN NN O
especially NN NN O
when NN NN O
continued NN NN O
in NN NN O
the NN NN O
operating NN NN O
room NN NN O
. NN NN O
   
Systemic NN NN O
anticoagulation NN NN O
is NN NN O
unsafe NN NN O
and NN NN O
regional NN NN O
citrate NN NN O
anticoagulation NN NN O
in NN NN O
the NN NN O
absence NN NN O
of NN NN O
a NN NN O
functional NN NN O
liver NN NN O
carries NN NN O
the NN NN O
risk NN NN O
of NN NN O
citrate NN NN O
toxicity NN NN B-Disease
. NN NN O
   
Citrate NN NN O
dialysate NN NN O
, NN NN O
a NN NN O
new NN NN O
dialysate NN NN O
with NN NN O
citric NN NN O
acid NN NN O
can NN NN O
be NN NN O
used NN NN O
for NN NN O
anticoagulation NN NN O
in NN NN O
patients NN NN O
who NN NN O
cannot NN NN O
tolerate NN NN O
heparin NN NN O
or NN NN O
regional NN NN O
citrate NN NN O
. NN NN O
   
We NN NN O
report NN NN O
a NN NN O
case NN NN O
of NN NN O
a NN NN O
40 NN NN O
- NN NN O
year NN NN O
- NN NN O
old NN NN O
female NN NN O
with NN NN O
acetaminophen NN NN O
- NN NN O
induced NN NN O
fulminant NN NN B-Disease
liver NN NN I-Disease
failure NN NN I-Disease
with NN NN O
associated NN NN O
AKI NN NN B-Disease
who NN NN O
underwent NN NN O
intraoperative NN NN O
dialytic NN NN O
support NN NN O
during NN NN O
liver NN NN O
transplantation NN NN O
anticoagulated NN NN O
with NN NN O
citrate NN NN O
dialysate NN NN O
during NN NN O
the NN NN O
entire NN NN O
procedure NN NN O
. NN NN O
   
The NN NN O
patient NN NN O
tolerated NN NN O
the NN NN O
procedure NN NN O
well NN NN O
without NN NN O
any NN NN O
signs NN NN O
of NN NN O
citrate NN NN O
toxicity NN NN B-Disease
and NN NN O
maintained NN NN O
adequate NN NN O
anticoagulation NN NN O
for NN NN O
patency NN NN O
of NN NN O
the NN NN O
dialysis NN NN O
circuit NN NN O
. NN NN O
   
Citrate NN NN O
dialysate NN NN O
is NN NN O
a NN NN O
safe NN NN O
alternative NN NN O
for NN NN O
intradialytic NN NN O
support NN NN O
of NN NN O
liver NN NN O
transplantation NN NN O
in NN NN O
fulminant NN NN B-Disease
liver NN NN I-Disease
failure NN NN I-Disease
. NN NN O
   
Delirium NN NN B-Disease
in NN NN O
a NN NN O
patient NN NN O
with NN NN O
toxic NN NN O
flecainide NN NN O
plasma NN NN O
concentrations NN NN O
: NN NN O
the NN NN O
role NN NN O
of NN NN O
a NN NN O
pharmacokinetic NN NN O
drug NN NN O
interaction NN NN O
with NN NN O
paroxetine NN NN O
. NN NN O
   
OBJECTIVE NN NN O
: NN NN O
To NN NN O
describe NN NN O
a NN NN O
case NN NN O
of NN NN O
flecainide NN NN O
- NN NN O
induced NN NN O
delirium NN NN B-Disease
associated NN NN O
with NN NN O
a NN NN O
pharmacokinetic NN NN O
drug NN NN O
interaction NN NN O
with NN NN O
paroxetine NN NN O
. NN NN O
   
CASE NN NN O
SUMMARY NN NN O
: NN NN O
A NN NN O
69 NN NN O
- NN NN O
year NN NN O
- NN NN O
old NN NN O
white NN NN O
female NN NN O
presented NN NN O
to NN NN O
the NN NN O
emergency NN NN O
department NN NN O
with NN NN O
a NN NN O
history NN NN O
of NN NN O
confusion NN NN B-Disease
and NN NN O
paranoia NN NN B-Disease
over NN NN O
the NN NN O
past NN NN O
several NN NN O
days NN NN O
. NN NN O
   
On NN NN O
admission NN NN O
the NN NN O
patient NN NN O
was NN NN O
taking NN NN O
carvedilol NN NN O
12 NN NN O
mg NN NN O
twice NN NN O
daily NN NN O
, NN NN O
warfarin NN NN O
2 NN NN O
mg NN NN O
/ NN NN O
day NN NN O
, NN NN O
folic NN NN O
acid NN NN O
1 NN NN O
mg NN NN O
/ NN NN O
day NN NN O
, NN NN O
levothyroxine NN NN O
100 NN NN O
microg NN NN O
/ NN NN O
day NN NN O
, NN NN O
pantoprazole NN NN O
40 NN NN O
mg NN NN O
/ NN NN O
day NN NN O
, NN NN O
paroxetine NN NN O
40 NN NN O
mg NN NN O
/ NN NN O
day NN NN O
, NN NN O
and NN NN O
flecainide NN NN O
100 NN NN O
mg NN NN O
twice NN NN O
daily NN NN O
. NN NN O
   
Flecainide NN NN O
had NN NN O
been NN NN O
started NN NN O
2 NN NN O
weeks NN NN O
prior NN NN O
for NN NN O
atrial NN NN B-Disease
fibrillation NN NN I-Disease
. NN NN O
   
Laboratory NN NN O
test NN NN O
findings NN NN O
on NN NN O
admission NN NN O
were NN NN O
notable NN NN O
only NN NN O
for NN NN O
a NN NN O
flecainide NN NN O
plasma NN NN O
concentration NN NN O
of NN NN O
1360 NN NN O
microg NN NN O
/ NN NN O
L NN NN O
( NN NN O
reference NN NN O
range NN NN O
200 NN NN O
- NN NN O
1000 NN NN O
) NN NN O
. NN NN O
   
A NN NN O
metabolic NN NN O
drug NN NN O
interaction NN NN O
between NN NN O
flecainide NN NN O
and NN NN O
paroxetine NN NN O
, NN NN O
which NN NN O
the NN NN O
patient NN NN O
had NN NN O
been NN NN O
taking NN NN O
for NN NN O
more NN NN O
than NN NN O
5 NN NN O
years NN NN O
, NN NN O
was NN NN O
considered NN NN O
. NN NN O
   
Paroxetine NN NN O
was NN NN O
discontinued NN NN O
and NN NN O
the NN NN O
dose NN NN O
of NN NN O
flecainide NN NN O
was NN NN O
reduced NN NN O
to NN NN O
50 NN NN O
mg NN NN O
twice NN NN O
daily NN NN O
. NN NN O
   
Her NN NN O
delirium NN NN B-Disease
resolved NN NN O
3 NN NN O
days NN NN O
later NN NN O
. NN NN O
   
DISCUSSION NN NN O
: NN NN O
Flecainide NN NN O
and NN NN O
pharmacologically NN NN O
similar NN NN O
agents NN NN O
that NN NN O
interact NN NN O
with NN NN O
sodium NN NN O
channels NN NN O
may NN NN O
cause NN NN O
delirium NN NN B-Disease
in NN NN O
susceptible NN NN O
patients NN NN O
. NN NN O
   
A NN NN O
MEDLINE NN NN O
search NN NN O
( NN NN O
1966 NN NN O
- NN NN O
January NN NN O
2009 NN NN O
) NN NN O
revealed NN NN O
one NN NN O
in NN NN O
vivo NN NN O
pharmacokinetic NN NN O
study NN NN O
on NN NN O
the NN NN O
interaction NN NN O
between NN NN O
flecainide NN NN O
, NN NN O
a NN NN O
CYP2D6 NN NN O
substrate NN NN O
, NN NN O
and NN NN O
paroxetine NN NN O
, NN NN O
a NN NN O
CYP2D6 NN NN O
inhibitor NN NN O
, NN NN O
as NN NN O
well NN NN O
as NN NN O
3 NN NN O
case NN NN O
reports NN NN O
of NN NN O
flecainide NN NN O
- NN NN O
induced NN NN O
delirium NN NN B-Disease
. NN NN O
   
According NN NN O
to NN NN O
the NN NN O
Naranjo NN NN O
probability NN NN O
scale NN NN O
, NN NN O
flecainide NN NN O
was NN NN O
the NN NN O
probable NN NN O
cause NN NN O
of NN NN O
the NN NN O
patient NN NN O
' NN NN O
s NN NN O
delirium NN NN B-Disease
; NN NN O
the NN NN O
Horn NN NN O
Drug NN NN O
Interaction NN NN O
Probability NN NN O
Scale NN NN O
indicates NN NN O
a NN NN O
possible NN NN O
pharmacokinetic NN NN O
drug NN NN O
interaction NN NN O
between NN NN O
flecainide NN NN O
and NN NN O
paroxetine NN NN O
. NN NN O
   
CONCLUSIONS NN NN O
: NN NN O
Supratherapeutic NN NN O
flecainide NN NN O
plasma NN NN O
concentrations NN NN O
may NN NN O
cause NN NN O
delirium NN NN B-Disease
. NN NN O
   
Because NN NN O
toxicity NN NN B-Disease
may NN NN O
occur NN NN O
when NN NN O
flecainide NN NN O
is NN NN O
prescribed NN NN O
with NN NN O
paroxetine NN NN O
and NN NN O
other NN NN O
potent NN NN O
CYP2D6 NN NN O
inhibitors NN NN O
, NN NN O
flecainide NN NN O
plasma NN NN O
concentrations NN NN O
should NN NN O
be NN NN O
monitored NN NN O
closely NN NN O
with NN NN O
commencement NN NN O
of NN NN O
CYP2D6 NN NN O
inhibitors NN NN O
. NN NN O
   
Efficacy NN NN O
of NN NN O
everolimus NN NN O
( NN NN O
RAD001 NN NN O
) NN NN O
in NN NN O
patients NN NN O
with NN NN O
advanced NN NN O
NSCLC NN NN B-Disease
previously NN NN O
treated NN NN O
with NN NN O
chemotherapy NN NN O
alone NN NN O
or NN NN O
with NN NN O
chemotherapy NN NN O
and NN NN O
EGFR NN NN O
inhibitors NN NN O
. NN NN O
   
BACKGROUND NN NN O
: NN NN O
Treatment NN NN O
options NN NN O
are NN NN O
scarce NN NN O
in NN NN O
pretreated NN NN O
advanced NN NN O
non NN NN B-Disease
- NN NN I-Disease
small NN NN I-Disease
- NN NN I-Disease
cell NN NN I-Disease
lung NN NN I-Disease
cancer NN NN I-Disease
( NN NN O
NSCLC NN NN B-Disease
) NN NN O
patients NN NN O
. NN NN O
   
RAD001 NN NN O
, NN NN O
an NN NN O
oral NN NN O
inhibitor NN NN O
of NN NN O
the NN NN O
mammalian NN NN O
target NN NN O
of NN NN O
rapamycin NN NN O
( NN NN O
mTOR NN NN O
) NN NN O
, NN NN O
has NN NN O
shown NN NN O
phase NN NN O
I NN NN O
efficacy NN NN O
in NN NN O
NSCLC NN NN B-Disease
. NN NN O
   
METHODS NN NN O
: NN NN O
Stage NN NN O
IIIb NN NN O
or NN NN O
IV NN NN O
NSCLC NN NN B-Disease
patients NN NN O
, NN NN O
with NN NN O
two NN NN O
or NN NN O
fewer NN NN O
prior NN NN O
chemotherapy NN NN O
regimens NN NN O
, NN NN O
one NN NN O
platinum NN NN O
based NN NN O
( NN NN O
stratum NN NN O
1 NN NN O
) NN NN O
or NN NN O
both NN NN O
chemotherapy NN NN O
and NN NN O
epidermal NN NN O
growth NN NN O
factor NN NN O
receptor NN NN O
tyrosine NN NN O
kinase NN NN O
inhibitors NN NN O
( NN NN O
stratum NN NN O
2 NN NN O
) NN NN O
, NN NN O
received NN NN O
RAD001 NN NN O
10 NN NN O
mg NN NN O
/ NN NN O
day NN NN O
until NN NN O
progression NN NN O
or NN NN O
unacceptable NN NN O
toxicity NN NN B-Disease
. NN NN O
   
Primary NN NN O
objective NN NN O
was NN NN O
overall NN NN O
response NN NN O
rate NN NN O
( NN NN O
ORR NN NN O
) NN NN O
. NN NN O
   
Analyses NN NN O
of NN NN O
markers NN NN O
associated NN NN O
with NN NN O
the NN NN O
mTOR NN NN O
pathway NN NN O
were NN NN O
carried NN NN O
out NN NN O
on NN NN O
archival NN NN O
tumor NN NN B-Disease
from NN NN O
a NN NN O
subgroup NN NN O
using NN NN O
immunohistochemistry NN NN O
( NN NN O
IHC NN NN O
) NN NN O
and NN NN O
direct NN NN O
mutation NN NN O
sequencing NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
Eighty NN NN O
- NN NN O
five NN NN O
patients NN NN O
were NN NN O
enrolled NN NN O
, NN NN O
42 NN NN O
in NN NN O
stratum NN NN O
1 NN NN O
and NN NN O
43 NN NN O
in NN NN O
stratum NN NN O
. NN NN O
   
ORR NN NN O
was NN NN O
4 NN NN O
. NN NN O
7 NN NN O
% NN NN O
( NN NN O
7 NN NN O
. NN NN O
1 NN NN O
% NN NN O
stratum NN NN O
1 NN NN O
; NN NN O
2 NN NN O
. NN NN O
3 NN NN O
% NN NN O
stratum NN NN O
2 NN NN O
) NN NN O
. NN NN O
   
Overall NN NN O
disease NN NN O
control NN NN O
rate NN NN O
was NN NN O
47 NN NN O
. NN NN O
1 NN NN O
% NN NN O
. NN NN O
   
Median NN NN O
progression NN NN O
- NN NN O
free NN NN O
survivals NN NN O
( NN NN O
PFSs NN NN O
) NN NN O
were NN NN O
2 NN NN O
. NN NN O
6 NN NN O
( NN NN O
stratum NN NN O
1 NN NN O
) NN NN O
and NN NN O
2 NN NN O
. NN NN O
7 NN NN O
months NN NN O
( NN NN O
stratum NN NN O
2 NN NN O
) NN NN O
. NN NN O
   
Common NN NN O
> NN NN O
or NN NN O
= NN NN O
grade NN NN O
3 NN NN O
events NN NN O
were NN NN O
fatigue NN NN B-Disease
, NN NN O
dyspnea NN NN B-Disease
, NN NN O
stomatitis NN NN B-Disease
, NN NN O
anemia NN NN B-Disease
, NN NN O
and NN NN O
thrombocytopenia NN NN B-Disease
. NN NN O
   
Pneumonitis NN NN B-Disease
, NN NN O
probably NN NN O
or NN NN O
possibly NN NN O
related NN NN O
, NN NN O
mainly NN NN O
grade NN NN O
1 NN NN O
/ NN NN O
2 NN NN O
, NN NN O
occurred NN NN O
in NN NN O
25 NN NN O
% NN NN O
. NN NN O
   
Cox NN NN O
regression NN NN O
analysis NN NN O
of NN NN O
IHC NN NN O
scores NN NN O
found NN NN O
that NN NN O
only NN NN O
phospho NN NN O
AKT NN NN O
( NN NN O
pAKT NN NN O
) NN NN O
was NN NN O
a NN NN O
significant NN NN O
independent NN NN O
predictor NN NN O
of NN NN O
worse NN NN O
PFS NN NN O
. NN NN O
   
CONCLUSIONS NN NN O
: NN NN O
RAD001 NN NN O
10 NN NN O
mg NN NN O
/ NN NN O
day NN NN O
was NN NN O
well NN NN O
tolerated NN NN O
, NN NN O
showing NN NN O
modest NN NN O
clinical NN NN O
activity NN NN O
in NN NN O
pretreated NN NN O
NSCLC NN NN B-Disease
. NN NN O
   
Evaluation NN NN O
of NN NN O
RAD001 NN NN O
plus NN NN O
standard NN NN O
therapy NN NN O
for NN NN O
metastatic NN NN O
NSCLC NN NN B-Disease
continues NN NN O
. NN NN O
   
Posttransplant NN NN O
anemia NN NN B-Disease
: NN NN O
the NN NN O
role NN NN O
of NN NN O
sirolimus NN NN O
. NN NN O
   
Posttransplant NN NN O
anemia NN NN B-Disease
is NN NN O
a NN NN O
common NN NN O
problem NN NN O
that NN NN O
may NN NN O
hinder NN NN O
patients NN NN O
' NN NN O
quality NN NN O
of NN NN O
life NN NN O
. NN NN O
   
It NN NN O
occurs NN NN O
in NN NN O
12 NN NN O
to NN NN O
76 NN NN O
% NN NN O
of NN NN O
patients NN NN O
, NN NN O
and NN NN O
is NN NN O
most NN NN O
common NN NN O
in NN NN O
the NN NN O
immediate NN NN O
posttransplant NN NN O
period NN NN O
. NN NN O
   
A NN NN O
variety NN NN O
of NN NN O
factors NN NN O
have NN NN O
been NN NN O
identified NN NN O
that NN NN O
increase NN NN O
the NN NN O
risk NN NN O
of NN NN O
posttransplant NN NN O
anemia NN NN B-Disease
, NN NN O
of NN NN O
which NN NN O
the NN NN O
level NN NN O
of NN NN O
renal NN NN O
function NN NN O
is NN NN O
most NN NN O
important NN NN O
. NN NN O
   
Sirolimus NN NN O
, NN NN O
a NN NN O
mammalian NN NN O
target NN NN O
of NN NN O
rapamycin NN NN O
inhibitor NN NN O
, NN NN O
has NN NN O
been NN NN O
implicated NN NN O
as NN NN O
playing NN NN O
a NN NN O
special NN NN O
role NN NN O
in NN NN O
posttransplant NN NN O
anemia NN NN B-Disease
. NN NN O
   
This NN NN O
review NN NN O
considers NN NN O
anemia NN NN B-Disease
associated NN NN O
with NN NN O
sirolimus NN NN O
, NN NN O
including NN NN O
its NN NN O
presentation NN NN O
, NN NN O
mechanisms NN NN O
, NN NN O
and NN NN O
management NN NN O
. NN NN O
   
Coronary NN NN O
computerized NN NN O
tomography NN NN O
angiography NN NN O
for NN NN O
rapid NN NN O
discharge NN NN O
of NN NN O
low NN NN O
- NN NN O
risk NN NN O
patients NN NN O
with NN NN O
cocaine NN NN O
- NN NN O
associated NN NN O
chest NN NN B-Disease
pain NN NN I-Disease
. NN NN O
   
BACKGROUND NN NN O
: NN NN O
Most NN NN O
patients NN NN O
presenting NN NN O
to NN NN O
emergency NN NN O
departments NN NN O
( NN NN O
EDs NN NN O
) NN NN O
with NN NN O
cocaine NN NN O
- NN NN O
associated NN NN O
chest NN NN B-Disease
pain NN NN I-Disease
are NN NN O
admitted NN NN O
for NN NN O
at NN NN O
least NN NN O
12 NN NN O
hours NN NN O
and NN NN O
receive NN NN O
a NN NN O
"""""""" NN NN O
rule NN NN O
out NN NN O
acute NN NN B-Disease
coronary NN NN I-Disease
syndrome NN NN I-Disease
"""""""" NN NN O
protocol NN NN O
, NN NN O
often NN NN O
with NN NN O
noninvasive NN NN O
testing NN NN O
prior NN NN O
to NN NN O
discharge NN NN O
. NN NN O
   
In NN NN O
patients NN NN O
without NN NN O
cocaine NN NN O
use NN NN O
, NN NN O
coronary NN NN O
computerized NN NN O
tomography NN NN O
angiography NN NN O
( NN NN O
CTA NN NN O
) NN NN O
has NN NN O
been NN NN O
shown NN NN O
to NN NN O
be NN NN O
useful NN NN O
for NN NN O
identifying NN NN O
a NN NN O
group NN NN O
of NN NN O
patients NN NN O
at NN NN O
low NN NN O
risk NN NN O
for NN NN O
cardiac NN NN O
events NN NN O
who NN NN O
can NN NN O
be NN NN O
safely NN NN O
discharged NN NN O
. NN NN O
   
It NN NN O
is NN NN O
unclear NN NN O
whether NN NN O
a NN NN O
coronary NN NN O
CTA NN NN O
strategy NN NN O
would NN NN O
be NN NN O
efficacious NN NN O
in NN NN O
cocaine NN NN O
- NN NN O
associated NN NN O
chest NN NN B-Disease
pain NN NN I-Disease
, NN NN O
as NN NN O
coronary NN NN B-Disease
vasospasm NN NN I-Disease
may NN NN O
account NN NN O
for NN NN O
some NN NN O
of NN NN O
the NN NN O
ischemia NN NN B-Disease
. NN NN O
   
We NN NN O
studied NN NN O
whether NN NN O
a NN NN O
negative NN NN O
coronary NN NN O
CTA NN NN O
in NN NN O
patients NN NN O
with NN NN O
cocaine NN NN O
- NN NN O
associated NN NN O
chest NN NN B-Disease
pain NN NN I-Disease
could NN NN O
identify NN NN O
a NN NN O
subset NN NN O
safe NN NN O
for NN NN O
discharge NN NN O
. NN NN O
   
METHODS NN NN O
: NN NN O
We NN NN O
prospectively NN NN O
evaluated NN NN O
the NN NN O
safety NN NN O
of NN NN O
coronary NN NN O
CTA NN NN O
for NN NN O
low NN NN O
- NN NN O
risk NN NN O
patients NN NN O
who NN NN O
presented NN NN O
to NN NN O
the NN NN O
ED NN NN O
with NN NN O
cocaineassociated NN NN O
chest NN NN B-Disease
pain NN NN I-Disease
( NN NN O
self NN NN O
- NN NN O
reported NN NN O
or NN NN O
positive NN NN O
urine NN NN O
test NN NN O
) NN NN O
. NN NN O
   
Consecutive NN NN O
patients NN NN O
received NN NN O
either NN NN O
immediate NN NN O
coronary NN NN O
CTA NN NN O
in NN NN O
the NN NN O
ED NN NN O
( NN NN O
without NN NN O
serial NN NN O
markers NN NN O
) NN NN O
or NN NN O
underwent NN NN O
coronary NN NN O
CTA NN NN O
after NN NN O
a NN NN O
brief NN NN O
observation NN NN O
period NN NN O
with NN NN O
serial NN NN O
cardiac NN NN O
marker NN NN O
measurements NN NN O
. NN NN O
   
Patients NN NN O
with NN NN O
negative NN NN O
coronary NN NN O
CTA NN NN O
( NN NN O
maximal NN NN O
stenosis NN NN B-Disease
less NN NN O
than NN NN O
50 NN NN O
% NN NN O
) NN NN O
were NN NN O
discharged NN NN O
. NN NN O
   
The NN NN O
main NN NN O
outcome NN NN O
was NN NN O
30 NN NN O
- NN NN O
day NN NN O
cardiovascular NN NN O
death NN NN O
or NN NN O
myocardial NN NN B-Disease
infarction NN NN I-Disease
. NN NN O
   
RESULTS NN NN O
: NN NN O
A NN NN O
total NN NN O
of NN NN O
59 NN NN O
patients NN NN O
with NN NN O
cocaine NN NN O
- NN NN O
associated NN NN O
chest NN NN B-Disease
pain NN NN I-Disease
were NN NN O
evaluated NN NN O
. NN NN O
   
Patients NN NN O
had NN NN O
a NN NN O
mean NN NN O
age NN NN O
of NN NN O
45 NN NN O
. NN NN O
6 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
6 NN NN O
. NN NN O
6 NN NN O
yrs NN NN O
and NN NN O
were NN NN O
86 NN NN O
% NN NN O
black NN NN O
, NN NN O
66 NN NN O
% NN NN O
male NN NN O
. NN NN O
   
Seventy NN NN O
- NN NN O
nine NN NN O
percent NN NN O
had NN NN O
a NN NN O
normal NN NN O
or NN NN O
nonspecific NN NN O
ECG NN NN O
and NN NN O
85 NN NN O
% NN NN O
had NN NN O
a NN NN O
TIMI NN NN O
score NN NN O
< NN NN O
2 NN NN O
. NN NN O
   
Twenty NN NN O
patients NN NN O
received NN NN O
coronary NN NN O
CTA NN NN O
immediately NN NN O
in NN NN O
the NN NN O
ED NN NN O
, NN NN O
18 NN NN O
of NN NN O
whom NN NN O
were NN NN O
discharged NN NN O
following NN NN O
CTA NN NN O
( NN NN O
90 NN NN O
% NN NN O
) NN NN O
. NN NN O
   
Thirty NN NN O
- NN NN O
nine NN NN O
received NN NN O
coronary NN NN O
CTA NN NN O
after NN NN O
a NN NN O
brief NN NN O
observation NN NN O
period NN NN O
, NN NN O
with NN NN O
37 NN NN O
discharged NN NN O
home NN NN O
following NN NN O
CTA NN NN O
( NN NN O
95 NN NN O
% NN NN O
) NN NN O
. NN NN O
   
Six NN NN O
patients NN NN O
had NN NN O
coronary NN NN B-Disease
stenosis NN NN I-Disease
> NN NN O
or NN NN O
= NN NN O
50 NN NN O
% NN NN O
. NN NN O
   
During NN NN O
the NN NN O
30 NN NN O
- NN NN O
day NN NN O
follow NN NN O
- NN NN O
up NN NN O
period NN NN O
, NN NN O
no NN NN O
patients NN NN O
died NN NN O
of NN NN O
a NN NN O
cardiovascular NN NN O
event NN NN O
( NN NN O
0 NN NN O
% NN NN O
; NN NN O
95 NN NN O
% NN NN O
CI NN NN O
, NN NN O
0 NN NN O
- NN NN O
6 NN NN O
. NN NN O
1 NN NN O
% NN NN O
) NN NN O
and NN NN O
no NN NN O
patient NN NN O
sustained NN NN O
a NN NN O
nonfatal NN NN O
myocardial NN NN B-Disease
infarction NN NN I-Disease
( NN NN O
0 NN NN O
% NN NN O
; NN NN O
95 NN NN O
% NN NN O
CI NN NN O
, NN NN O
0 NN NN O
- NN NN O
6 NN NN O
. NN NN O
1 NN NN O
% NN NN O
) NN NN O
. NN NN O
   
CONCLUSIONS NN NN O
: NN NN O
Although NN NN O
cocaine NN NN O
- NN NN O
associated NN NN O
myocardial NN NN B-Disease
ischemia NN NN I-Disease
can NN NN O
result NN NN O
from NN NN O
coronary NN NN O
vasoconstriction NN NN O
, NN NN O
patients NN NN O
with NN NN O
cocaine NN NN O
associated NN NN O
chest NN NN B-Disease
pain NN NN I-Disease
, NN NN O
a NN NN O
non NN NN O
- NN NN O
ischemic NN NN B-Disease
ECG NN NN O
, NN NN O
and NN NN O
a NN NN O
TIMI NN NN O
risk NN NN O
score NN NN O
< NN NN O
2 NN NN O
may NN NN O
be NN NN O
safely NN NN O
discharged NN NN O
from NN NN O
the NN NN O
ED NN NN O
after NN NN O
a NN NN O
negative NN NN O
coronary NN NN O
CTA NN NN O
with NN NN O
a NN NN O
low NN NN O
risk NN NN O
of NN NN O
30 NN NN O
- NN NN O
day NN NN O
adverse NN NN O
events NN NN O
. NN NN O
   
Bilateral NN NN O
haemorrhagic NN NN B-Disease
infarction NN NN I-Disease
of NN NN I-Disease
the NN NN I-Disease
globus NN NN I-Disease
pallidus NN NN I-Disease
after NN NN O
cocaine NN NN O
and NN NN O
alcohol NN NN O
intoxication NN NN O
. NN NN O
   
Cocaine NN NN O
is NN NN O
a NN NN O
risk NN NN O
factor NN NN O
for NN NN O
both NN NN O
ischemic NN NN B-Disease
and NN NN I-Disease
haemorrhagic NN NN I-Disease
stroke NN NN I-Disease
. NN NN O
   
We NN NN O
present NN NN O
the NN NN O
case NN NN O
of NN NN O
a NN NN O
31 NN NN O
- NN NN O
year NN NN O
- NN NN O
old NN NN O
man NN NN O
with NN NN O
bilateral NN NN O
ischemia NN NN B-Disease
of NN NN I-Disease
the NN NN I-Disease
globus NN NN I-Disease
pallidus NN NN I-Disease
after NN NN O
excessive NN NN O
alcohol NN NN O
and NN NN O
intranasal NN NN O
cocaine NN NN O
use NN NN O
. NN NN O
   
Drug NN NN O
- NN NN O
related NN NN O
globus NN NN B-Disease
pallidus NN NN I-Disease
infarctions NN NN I-Disease
are NN NN O
most NN NN O
often NN NN O
associated NN NN O
with NN NN O
heroin NN NN O
. NN NN O
   
Bilateral NN NN O
basal NN NN B-Disease
ganglia NN NN I-Disease
infarcts NN NN I-Disease
after NN NN O
the NN NN O
use NN NN O
of NN NN O
cocaine NN NN O
, NN NN O
without NN NN O
concurrent NN NN O
heroin NN NN O
use NN NN O
, NN NN O
have NN NN O
never NN NN O
been NN NN O
reported NN NN O
. NN NN O
   
In NN NN O
our NN NN O
patient NN NN O
, NN NN O
transient NN NN O
cardiac NN NN B-Disease
arrhythmia NN NN I-Disease
or NN NN O
respiratory NN NN B-Disease
dysfunction NN NN I-Disease
related NN NN O
to NN NN O
cocaine NN NN O
and NN NN O
/ NN NN O
or NN NN O
ethanol NN NN O
use NN NN O
were NN NN O
the NN NN O
most NN NN O
likely NN NN O
causes NN NN O
of NN NN O
cerebral NN NN B-Disease
hypoperfusion NN NN I-Disease
. NN NN O
   
Late NN NN O
fulminant NN NN O
posterior NN NN B-Disease
reversible NN NN I-Disease
encephalopathy NN NN I-Disease
syndrome NN NN I-Disease
after NN NN O
liver NN NN O
transplant NN NN O
. NN NN O
   
OBJECTIVES NN NN O
: NN NN O
Posterior NN NN B-Disease
leukoencephalopathy NN NN I-Disease
due NN NN O
to NN NN O
calcineurin NN NN O
- NN NN O
inhibitor NN NN O
- NN NN O
related NN NN O
neurotoxicity NN NN B-Disease
is NN NN O
a NN NN O
rare NN NN O
but NN NN O
severe NN NN O
complication NN NN O
that NN NN O
results NN NN O
from NN NN O
treatment NN NN O
with NN NN O
immunosuppressive NN NN O
agents NN NN O
( NN NN O
primarily NN NN O
those NN NN O
administered NN NN O
after NN NN O
a NN NN O
liver NN NN O
or NN NN O
kidney NN NN O
transplant NN NN O
) NN NN O
. NN NN O
   
The NN NN O
pathophysiologic NN NN O
mechanisms NN NN O
of NN NN O
that NN NN O
disorder NN NN O
remain NN NN O
unknown NN NN O
. NN NN O
   
CASE NN NN O
: NN NN O
We NN NN O
report NN NN O
the NN NN O
case NN NN O
of NN NN O
a NN NN O
46 NN NN O
- NN NN O
year NN NN O
- NN NN O
old NN NN O
woman NN NN O
who NN NN O
received NN NN O
a NN NN O
liver NN NN O
transplant NN NN O
in NN NN O
our NN NN O
center NN NN O
as NN NN O
treatment NN NN O
for NN NN O
alcoholic NN NN B-Disease
cirrhosis NN NN I-Disease
and NN NN O
in NN NN O
whom NN NN O
either NN NN O
a NN NN O
fulminant NN NN O
course NN NN O
of NN NN O
posterior NN NN B-Disease
leukoencephalopathy NN NN I-Disease
or NN NN O
posterior NN NN B-Disease
reversible NN NN I-Disease
encephalopathy NN NN I-Disease
syndrome NN NN I-Disease
developed NN NN O
110 NN NN O
days NN NN O
after NN NN O
transplant NN NN O
. NN NN O
   
After NN NN O
an NN NN O
initially NN NN O
uneventful NN NN O
course NN NN O
after NN NN O
the NN NN O
transplant NN NN O
, NN NN O
the NN NN O
patient NN NN O
rapidly NN NN O
fell NN NN O
into NN NN O
deep NN NN O
coma NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
Cerebral NN NN O
MRI NN NN O
scan NN NN O
showed NN NN O
typical NN NN O
signs NN NN O
of NN NN O
enhancement NN NN O
in NN NN O
the NN NN O
pontine NN NN O
and NN NN O
posterior NN NN O
regions NN NN O
. NN NN O
   
Switching NN NN O
the NN NN O
immunosuppressive NN NN O
regimen NN NN O
from NN NN O
tacrolimus NN NN O
to NN NN O
cyclosporine NN NN O
did NN NN O
not NN NN O
improve NN NN O
the NN NN O
clinical NN NN O
situation NN NN O
. NN NN O
   
The NN NN O
termination NN NN O
of NN NN O
treatment NN NN O
with NN NN O
any NN NN O
calcineurin NN NN O
inhibitor NN NN O
resulted NN NN O
in NN NN O
a NN NN O
complete NN NN O
resolution NN NN O
of NN NN O
that NN NN O
complication NN NN O
. NN NN O
   
CONCLUSIONS NN NN O
: NN NN O
Posterior NN NN B-Disease
reversible NN NN I-Disease
encephalopathy NN NN I-Disease
syndrome NN NN I-Disease
after NN NN O
liver NN NN O
transplant NN NN O
is NN NN O
rare NN NN O
. NN NN O
   
We NN NN O
recommend NN NN O
a NN NN O
complete NN NN O
cessation NN NN O
of NN NN O
any NN NN O
calcineurin NN NN O
inhibitor NN NN O
rather NN NN O
than NN NN O
a NN NN O
dose NN NN O
reduction NN NN O
. NN NN O
   
Prolonged NN NN O
hypothermia NN NN B-Disease
as NN NN O
a NN NN O
bridge NN NN O
to NN NN O
recovery NN NN O
for NN NN O
cerebral NN NN B-Disease
edema NN NN I-Disease
and NN NN O
intracranial NN NN B-Disease
hypertension NN NN I-Disease
associated NN NN O
with NN NN O
fulminant NN NN B-Disease
hepatic NN NN I-Disease
failure NN NN I-Disease
. NN NN O
   
BACKGROUND NN NN O
: NN NN O
To NN NN O
review NN NN O
evidence NN NN O
- NN NN O
based NN NN O
treatment NN NN O
options NN NN O
in NN NN O
patients NN NN O
with NN NN O
cerebral NN NN B-Disease
edema NN NN I-Disease
complicating NN NN O
fulminant NN NN B-Disease
hepatic NN NN I-Disease
failure NN NN I-Disease
( NN NN O
FHF NN NN B-Disease
) NN NN O
and NN NN O
discuss NN NN O
the NN NN O
potential NN NN O
applications NN NN O
of NN NN O
hypothermia NN NN B-Disease
. NN NN O
   
METHOD NN NN O
: NN NN O
Case NN NN O
- NN NN O
based NN NN O
observations NN NN O
from NN NN O
a NN NN O
medical NN NN O
intensive NN NN O
care NN NN O
unit NN NN O
( NN NN O
MICU NN NN O
) NN NN O
in NN NN O
a NN NN O
tertiary NN NN O
care NN NN O
facility NN NN O
in NN NN O
a NN NN O
27 NN NN O
- NN NN O
year NN NN O
- NN NN O
old NN NN O
female NN NN O
with NN NN O
FHF NN NN B-Disease
from NN NN O
acetaminophen NN NN O
and NN NN O
resultant NN NN O
cerebral NN NN B-Disease
edema NN NN I-Disease
. NN NN O
   
RESULTS NN NN O
: NN NN O
Our NN NN O
patient NN NN O
was NN NN O
admitted NN NN O
to NN NN O
the NN NN O
MICU NN NN O
after NN NN O
being NN NN O
found NN NN O
unresponsive NN NN O
with NN NN O
presumed NN NN O
toxicity NN NN B-Disease
from NN NN O
acetaminophen NN NN O
which NN NN O
was NN NN O
ingested NN NN O
over NN NN O
a NN NN O
2 NN NN O
- NN NN O
day NN NN O
period NN NN O
. NN NN O
   
The NN NN O
patient NN NN O
had NN NN O
depressed NN NN O
of NN NN O
mental NN NN O
status NN NN O
lasting NN NN O
at NN NN O
least NN NN O
24 NN NN O
h NN NN O
prior NN NN O
to NN NN O
admission NN NN O
. NN NN O
   
Initial NN NN O
evaluation NN NN O
confirmed NN NN O
FHF NN NN B-Disease
from NN NN O
acetaminophen NN NN O
and NN NN O
cerebral NN NN B-Disease
edema NN NN I-Disease
. NN NN O
   
The NN NN O
patient NN NN O
was NN NN O
treated NN NN O
with NN NN O
hyperosmolar NN NN O
therapy NN NN O
, NN NN O
hyperventilation NN NN B-Disease
, NN NN O
sedation NN NN O
, NN NN O
and NN NN O
chemical NN NN O
paralysis NN NN B-Disease
. NN NN O
   
Her NN NN O
intracranial NN NN O
pressure NN NN O
remained NN NN O
elevated NN NN O
despite NN NN O
maximal NN NN O
medical NN NN O
therapy NN NN O
. NN NN O
   
We NN NN O
then NN NN O
initiated NN NN O
therapeutic NN NN O
hypothermia NN NN B-Disease
which NN NN O
was NN NN O
continued NN NN O
for NN NN O
5 NN NN O
days NN NN O
. NN NN O
   
At NN NN O
re NN NN O
- NN NN O
warming NN NN O
, NN NN O
patient NN NN O
had NN NN O
resolution NN NN O
of NN NN O
her NN NN O
cerebral NN NN B-Disease
edema NN NN I-Disease
and NN NN O
intracranial NN NN B-Disease
hypertension NN NN I-Disease
. NN NN O
   
At NN NN O
discharge NN NN O
, NN NN O
she NN NN O
had NN NN O
complete NN NN O
recovery NN NN O
of NN NN O
neurological NN NN O
and NN NN O
hepatic NN NN O
functions NN NN O
. NN NN O
   
CONCLUSION NN NN O
: NN NN O
In NN NN O
patients NN NN O
with NN NN O
FHF NN NN B-Disease
and NN NN O
cerebral NN NN B-Disease
edema NN NN I-Disease
from NN NN O
acetaminophen NN NN O
overdose NN NN B-Disease
, NN NN O
prolonged NN NN O
therapeutic NN NN O
hypothermia NN NN B-Disease
could NN NN O
potentially NN NN O
be NN NN O
used NN NN O
as NN NN O
a NN NN O
life NN NN O
saving NN NN O
therapy NN NN O
and NN NN O
a NN NN O
bridge NN NN O
to NN NN O
hepatic NN NN O
and NN NN O
neurological NN NN O
recovery NN NN O
. NN NN O
   
A NN NN O
clinical NN NN O
trial NN NN O
of NN NN O
hypothermia NN NN B-Disease
in NN NN O
patients NN NN O
with NN NN O
this NN NN O
condition NN NN O
is NN NN O
warranted NN NN O
. NN NN O
   
Binasal NN NN B-Disease
visual NN NN I-Disease
field NN NN I-Disease
defects NN NN I-Disease
are NN NN O
not NN NN O
specific NN NN O
to NN NN O
vigabatrin NN NN O
. NN NN O
   
This NN NN O
study NN NN O
investigated NN NN O
the NN NN O
visual NN NN B-Disease
defects NN NN I-Disease
associated NN NN O
with NN NN O
the NN NN O
antiepileptic NN NN O
drug NN NN O
vigabatrin NN NN O
( NN NN O
VGB NN NN O
) NN NN O
. NN NN O
   
Two NN NN O
hundred NN NN O
four NN NN O
people NN NN O
with NN NN O
epilepsy NN NN B-Disease
were NN NN O
grouped NN NN O
on NN NN O
the NN NN O
basis NN NN O
of NN NN O
antiepileptic NN NN O
drug NN NN O
therapy NN NN O
( NN NN O
current NN NN O
, NN NN O
previous NN NN O
, NN NN O
or NN NN O
no NN NN O
exposure NN NN O
to NN NN O
VGB NN NN O
) NN NN O
. NN NN O
   
Groups NN NN O
were NN NN O
matched NN NN O
with NN NN O
respect NN NN O
to NN NN O
age NN NN O
, NN NN O
gender NN NN O
, NN NN O
and NN NN O
seizure NN NN B-Disease
frequency NN NN O
. NN NN O
   
All NN NN O
patients NN NN O
underwent NN NN O
objective NN NN O
assessment NN NN O
of NN NN O
electrophysiological NN NN O
function NN NN O
( NN NN O
wide NN NN O
- NN NN O
field NN NN O
multifocal NN NN O
electroretinography NN NN O
) NN NN O
and NN NN O
conventional NN NN O
visual NN NN O
field NN NN O
testing NN NN O
( NN NN O
static NN NN O
perimetry NN NN O
) NN NN O
. NN NN O
   
Bilateral NN NN O
visual NN NN O
field NN NN O
constriction NN NN O
was NN NN O
observed NN NN O
in NN NN O
59 NN NN O
% NN NN O
of NN NN O
patients NN NN O
currently NN NN O
taking NN NN O
VGB NN NN O
, NN NN O
43 NN NN O
% NN NN O
of NN NN O
patients NN NN O
who NN NN O
previously NN NN O
took NN NN O
VGB NN NN O
, NN NN O
and NN NN O
24 NN NN O
% NN NN O
of NN NN O
patients NN NN O
with NN NN O
no NN NN O
exposure NN NN O
to NN NN O
VGB NN NN O
. NN NN O
   
Assessment NN NN O
of NN NN O
retinal NN NN O
function NN NN O
revealed NN NN O
abnormal NN NN O
responses NN NN O
in NN NN O
48 NN NN O
% NN NN O
of NN NN O
current NN NN O
VGB NN NN O
users NN NN O
and NN NN O
22 NN NN O
% NN NN O
of NN NN O
prior NN NN O
VGB NN NN O
users NN NN O
, NN NN O
but NN NN O
in NN NN O
none NN NN O
of NN NN O
the NN NN O
patients NN NN O
without NN NN O
previous NN NN O
exposure NN NN O
to NN NN O
VGB NN NN O
. NN NN O
   
Bilateral NN NN B-Disease
visual NN NN I-Disease
field NN NN I-Disease
abnormalities NN NN I-Disease
are NN NN O
common NN NN O
in NN NN O
the NN NN O
treated NN NN O
epilepsy NN NN B-Disease
population NN NN O
, NN NN O
irrespective NN NN O
of NN NN O
drug NN NN O
history NN NN O
. NN NN O
   
Assessment NN NN O
by NN NN O
conventional NN NN O
static NN NN O
perimetry NN NN O
may NN NN O
neither NN NN O
be NN NN O
sufficiently NN NN O
sensitive NN NN O
nor NN NN O
specific NN NN O
to NN NN O
reliably NN NN O
identify NN NN O
retinal NN NN B-Disease
toxicity NN NN I-Disease
associated NN NN O
with NN NN O
VGB NN NN O
. NN NN O
   
Smoking NN NN O
of NN NN O
crack NN NN O
cocaine NN NN O
as NN NN O
a NN NN O
risk NN NN O
factor NN NN O
for NN NN O
HIV NN NN B-Disease
infection NN NN I-Disease
among NN NN O
people NN NN O
who NN NN O
use NN NN O
injection NN NN O
drugs NN NN O
. NN NN O
   
BACKGROUND NN NN O
: NN NN O
Little NN NN O
is NN NN O
known NN NN O
about NN NN O
the NN NN O
possible NN NN O
role NN NN O
that NN NN O
smoking NN NN O
crack NN NN O
cocaine NN NN O
has NN NN O
on NN NN O
the NN NN O
incidence NN NN O
of NN NN O
HIV NN NN B-Disease
infection NN NN I-Disease
. NN NN O
   
Given NN NN O
the NN NN O
increasing NN NN O
use NN NN O
of NN NN O
crack NN NN O
cocaine NN NN O
, NN NN O
we NN NN O
sought NN NN O
to NN NN O
examine NN NN O
whether NN NN O
use NN NN O
of NN NN O
this NN NN O
illicit NN NN O
drug NN NN O
has NN NN O
become NN NN O
a NN NN O
risk NN NN O
factor NN NN O
for NN NN O
HIV NN NN B-Disease
infection NN NN I-Disease
. NN NN O
   
METHODS NN NN O
: NN NN O
We NN NN O
included NN NN O
data NN NN O
from NN NN O
people NN NN O
participating NN NN O
in NN NN O
the NN NN O
Vancouver NN NN O
Injection NN NN O
Drug NN NN O
Users NN NN O
Study NN NN O
who NN NN O
reported NN NN O
injecting NN NN O
illicit NN NN O
drugs NN NN O
at NN NN O
least NN NN O
once NN NN O
in NN NN O
the NN NN O
month NN NN O
before NN NN O
enrolment NN NN O
, NN NN O
lived NN NN O
in NN NN O
the NN NN O
greater NN NN O
Vancouver NN NN O
area NN NN O
, NN NN O
were NN NN O
HIV NN NN O
- NN NN O
negative NN NN O
at NN NN O
enrolment NN NN O
and NN NN O
completed NN NN O
at NN NN O
least NN NN O
1 NN NN O
follow NN NN O
- NN NN O
up NN NN O
study NN NN O
visit NN NN O
. NN NN O
   
To NN NN O
determine NN NN O
whether NN NN O
the NN NN O
risk NN NN O
of NN NN O
HIV NN NN B-Disease
seroconversion NN NN I-Disease
among NN NN O
daily NN NN O
smokers NN NN O
of NN NN O
crack NN NN O
cocaine NN NN O
changed NN NN O
over NN NN O
time NN NN O
, NN NN O
we NN NN O
used NN NN O
Cox NN NN O
proportional NN NN O
hazards NN NN O
regression NN NN O
and NN NN O
divided NN NN O
the NN NN O
study NN NN O
into NN NN O
3 NN NN O
periods NN NN O
: NN NN O
May NN NN O
1 NN NN O
, NN NN O
1996 NN NN O
- NN NN O
Nov NN NN O
. NN NN O
   
30 NN NN O
, NN NN O
1999 NN NN O
( NN NN O
period NN NN O
1 NN NN O
) NN NN O
, NN NN O
Dec NN NN O
. NN NN O
   
1 NN NN O
, NN NN O
1999 NN NN O
- NN NN O
Nov NN NN O
. NN NN O
   
30 NN NN O
, NN NN O
2002 NN NN O
( NN NN O
period NN NN O
2 NN NN O
) NN NN O
, NN NN O
and NN NN O
Dec NN NN O
. NN NN O
   
1 NN NN O
, NN NN O
2002 NN NN O
- NN NN O
Dec NN NN O
. NN NN O
   
30 NN NN O
, NN NN O
2005 NN NN O
( NN NN O
period NN NN O
3 NN NN O
) NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
Overall NN NN O
, NN NN O
1048 NN NN O
eligible NN NN O
injection NN NN O
drug NN NN O
users NN NN O
were NN NN O
included NN NN O
in NN NN O
our NN NN O
study NN NN O
. NN NN O
   
Of NN NN O
these NN NN O
, NN NN O
137 NN NN O
acquired NN NN O
HIV NN NN B-Disease
infection NN NN I-Disease
during NN NN O
follow NN NN O
- NN NN O
up NN NN O
. NN NN O
   
The NN NN O
mean NN NN O
proportion NN NN O
of NN NN O
participants NN NN O
who NN NN O
reported NN NN O
daily NN NN O
smoking NN NN O
of NN NN O
crack NN NN O
cocaine NN NN O
increased NN NN O
from NN NN O
11 NN NN O
. NN NN O
6 NN NN O
% NN NN O
in NN NN O
period NN NN O
1 NN NN O
to NN NN O
39 NN NN O
. NN NN O
7 NN NN O
% NN NN O
in NN NN O
period NN NN O
3 NN NN O
. NN NN O
   
After NN NN O
adjusting NN NN O
for NN NN O
potential NN NN O
confounders NN NN O
, NN NN O
we NN NN O
found NN NN O
that NN NN O
the NN NN O
risk NN NN O
of NN NN O
HIV NN NN B-Disease
seroconversion NN NN I-Disease
among NN NN O
participants NN NN O
who NN NN O
were NN NN O
daily NN NN O
smokers NN NN O
of NN NN O
crack NN NN O
cocaine NN NN O
increased NN NN O
over NN NN O
time NN NN O
( NN NN O
period NN NN O
1 NN NN O
: NN NN O
hazard NN NN O
ratio NN NN O
[ NN NN O
HR NN NN O
] NN NN O
1 NN NN O
. NN NN O
03 NN NN O
, NN NN O
95 NN NN O
% NN NN O
confidence NN NN O
interval NN NN O
[ NN NN O
CI NN NN O
] NN NN O
0 NN NN O
. NN NN O
57 NN NN O
- NN NN O
1 NN NN O
. NN NN O
85 NN NN O
; NN NN O
period NN NN O
2 NN NN O
: NN NN O
HR NN NN O
1 NN NN O
. NN NN O
68 NN NN O
, NN NN O
95 NN NN O
% NN NN O
CI NN NN O
1 NN NN O
. NN NN O
01 NN NN O
- NN NN O
2 NN NN O
. NN NN O
80 NN NN O
; NN NN O
and NN NN O
period NN NN O
3 NN NN O
: NN NN O
HR NN NN O
2 NN NN O
. NN NN O
74 NN NN O
, NN NN O
95 NN NN O
% NN NN O
CI NN NN O
1 NN NN O
. NN NN O
06 NN NN O
- NN NN O
7 NN NN O
. NN NN O
11 NN NN O
) NN NN O
. NN NN O
   
INTERPRETATION NN NN O
: NN NN O
Smoking NN NN O
of NN NN O
crack NN NN O
cocaine NN NN O
was NN NN O
found NN NN O
to NN NN O
be NN NN O
an NN NN O
independent NN NN O
risk NN NN O
factor NN NN O
for NN NN O
HIV NN NN B-Disease
seroconversion NN NN I-Disease
among NN NN O
people NN NN O
who NN NN O
were NN NN O
injection NN NN O
drug NN NN O
users NN NN O
. NN NN O
   
This NN NN O
finding NN NN O
points NN NN O
to NN NN O
the NN NN O
urgent NN NN O
need NN NN O
for NN NN O
evidence NN NN O
- NN NN O
based NN NN O
public NN NN O
health NN NN O
initiatives NN NN O
targeted NN NN O
at NN NN O
people NN NN O
who NN NN O
smoke NN NN O
crack NN NN O
cocaine NN NN O
. NN NN O
   
Fluoxetine NN NN O
improves NN NN O
the NN NN O
memory NN NN B-Disease
deficits NN NN I-Disease
caused NN NN O
by NN NN O
the NN NN O
chemotherapy NN NN O
agent NN NN O
5 NN NN O
- NN NN O
fluorouracil NN NN O
. NN NN O
   
Cancer NN NN B-Disease
patients NN NN O
who NN NN O
have NN NN O
been NN NN O
treated NN NN O
with NN NN O
systemic NN NN O
adjuvant NN NN O
chemotherapy NN NN O
have NN NN O
described NN NN O
experiencing NN NN O
deteriorations NN NN O
in NN NN O
cognition NN NN O
. NN NN O
   
A NN NN O
widely NN NN O
used NN NN O
chemotherapeutic NN NN O
agent NN NN O
, NN NN O
5 NN NN O
- NN NN O
fluorouracil NN NN O
( NN NN O
5 NN NN O
- NN NN O
FU NN NN O
) NN NN O
, NN NN O
readily NN NN O
crosses NN NN O
the NN NN O
blood NN NN O
- NN NN O
brain NN NN O
barrier NN NN O
and NN NN O
so NN NN O
could NN NN O
have NN NN O
a NN NN O
direct NN NN O
effect NN NN O
on NN NN O
brain NN NN O
function NN NN O
. NN NN O
   
In NN NN O
particular NN NN O
this NN NN O
anti NN NN O
mitotic NN NN O
drug NN NN O
could NN NN O
reduce NN NN O
cell NN NN O
proliferation NN NN O
in NN NN O
the NN NN O
neurogenic NN NN O
regions NN NN O
of NN NN O
the NN NN O
adult NN NN O
brain NN NN O
. NN NN O
   
In NN NN O
contrast NN NN O
reports NN NN O
indicate NN NN O
that NN NN O
hippocampal NN NN O
dependent NN NN O
neurogenesis NN NN O
and NN NN O
cognition NN NN O
are NN NN O
enhanced NN NN O
by NN NN O
the NN NN O
SSRI NN NN O
antidepressant NN NN O
Fluoxetine NN NN O
. NN NN O
   
In NN NN O
this NN NN O
investigation NN NN O
the NN NN O
behavioural NN NN O
effects NN NN O
of NN NN O
chronic NN NN O
( NN NN O
two NN NN O
week NN NN O
) NN NN O
treatment NN NN O
with NN NN O
5 NN NN O
- NN NN O
FU NN NN O
and NN NN O
( NN NN O
three NN NN O
weeks NN NN O
) NN NN O
with NN NN O
Fluoxetine NN NN O
either NN NN O
separately NN NN O
or NN NN O
in NN NN O
combination NN NN O
with NN NN O
5 NN NN O
- NN NN O
FU NN NN O
were NN NN O
tested NN NN O
on NN NN O
adult NN NN O
Lister NN NN O
hooded NN NN O
rats NN NN O
. NN NN O
   
Behavioural NN NN O
effects NN NN O
were NN NN O
tested NN NN O
using NN NN O
a NN NN O
context NN NN O
dependent NN NN O
conditioned NN NN O
emotional NN NN O
response NN NN O
test NN NN O
( NN NN O
CER NN NN O
) NN NN O
which NN NN O
showed NN NN O
that NN NN O
animals NN NN O
treated NN NN O
with NN NN O
5 NN NN O
- NN NN O
FU NN NN O
had NN NN O
a NN NN O
significant NN NN O
reduction NN NN O
in NN NN O
freezing NN NN O
time NN NN O
compared NN NN O
to NN NN O
controls NN NN O
. NN NN O
   
A NN NN O
separate NN NN O
group NN NN O
of NN NN O
animals NN NN O
was NN NN O
tested NN NN O
using NN NN O
a NN NN O
hippocampal NN NN O
dependent NN NN O
spatial NN NN O
working NN NN O
memory NN NN O
test NN NN O
, NN NN O
the NN NN O
object NN NN O
location NN NN O
recognition NN NN O
test NN NN O
( NN NN O
OLR NN NN O
) NN NN O
. NN NN O
   
Animals NN NN O
treated NN NN O
only NN NN O
with NN NN O
5 NN NN O
- NN NN O
FU NN NN O
showed NN NN O
significant NN NN O
deficits NN NN O
in NN NN O
their NN NN O
ability NN NN O
to NN NN O
carry NN NN O
out NN NN O
the NN NN O
OLR NN NN O
task NN NN O
but NN NN O
co NN NN O
administration NN NN O
of NN NN O
Fluoxetine NN NN O
improved NN NN O
their NN NN O
performance NN NN O
. NN NN O
   
5 NN NN O
- NN NN O
FU NN NN O
chemotherapy NN NN O
caused NN NN O
a NN NN O
significant NN NN O
reduction NN NN O
in NN NN O
the NN NN O
number NN NN O
of NN NN O
proliferating NN NN O
cells NN NN O
in NN NN O
the NN NN O
sub NN NN O
granular NN NN O
zone NN NN O
of NN NN O
the NN NN O
dentate NN NN O
gyrus NN NN O
compared NN NN O
to NN NN O
controls NN NN O
. NN NN O
   
This NN NN O
reduction NN NN O
was NN NN O
eliminated NN NN O
when NN NN O
Fluoxetine NN NN O
was NN NN O
co NN NN O
administered NN NN O
with NN NN O
5 NN NN O
- NN NN O
FU NN NN O
. NN NN O
   
Fluoxetine NN NN O
on NN NN O
its NN NN O
own NN NN O
had NN NN O
no NN NN O
effect NN NN O
on NN NN O
proliferating NN NN O
cell NN NN O
number NN NN O
or NN NN O
behaviour NN NN O
. NN NN O
   
These NN NN O
findings NN NN O
suggest NN NN O
that NN NN O
5 NN NN O
- NN NN O
FU NN NN O
can NN NN O
negatively NN NN O
affect NN NN O
both NN NN O
cell NN NN O
proliferation NN NN O
and NN NN O
hippocampal NN NN O
dependent NN NN O
working NN NN O
memory NN NN O
and NN NN O
that NN NN O
these NN NN O
deficits NN NN O
can NN NN O
be NN NN O
reversed NN NN O
by NN NN O
the NN NN O
simultaneous NN NN O
administration NN NN O
of NN NN O
the NN NN O
antidepressant NN NN O
Fluoxetine NN NN O
. NN NN O
   
Liver NN NN O
- NN NN O
specific NN NN O
ablation NN NN O
of NN NN O
integrin NN NN O
- NN NN O
linked NN NN O
kinase NN NN O
in NN NN O
mice NN NN O
results NN NN O
in NN NN O
enhanced NN NN O
and NN NN O
prolonged NN NN O
cell NN NN O
proliferation NN NN O
and NN NN O
hepatomegaly NN NN B-Disease
after NN NN O
phenobarbital NN NN O
administration NN NN O
. NN NN O
   
We NN NN O
have NN NN O
recently NN NN O
demonstrated NN NN O
that NN NN O
disruption NN NN O
of NN NN O
extracellular NN NN O
matrix NN NN O
( NN NN O
ECM NN NN O
) NN NN O
/ NN NN O
integrin NN NN O
signaling NN NN O
via NN NN O
elimination NN NN O
of NN NN O
integrin NN NN O
- NN NN O
linked NN NN O
kinase NN NN O
( NN NN O
ILK NN NN O
) NN NN O
in NN NN O
hepatocytes NN NN O
interferes NN NN O
with NN NN O
signals NN NN O
leading NN NN O
to NN NN O
termination NN NN O
of NN NN O
liver NN NN O
regeneration NN NN O
. NN NN O
   
This NN NN O
study NN NN O
investigates NN NN O
the NN NN O
role NN NN O
of NN NN O
ILK NN NN O
in NN NN O
liver NN NN O
enlargement NN NN O
induced NN NN O
by NN NN O
phenobarbital NN NN O
( NN NN O
PB NN NN O
) NN NN O
. NN NN O
   
Wild NN NN O
- NN NN O
type NN NN O
( NN NN O
WT NN NN O
) NN NN O
and NN NN O
ILK NN NN O
: NN NN O
liver NN NN O
- NN NN O
/ NN NN O
- NN NN O
mice NN NN O
were NN NN O
given NN NN O
PB NN NN O
( NN NN O
0 NN NN O
. NN NN O
1 NN NN O
% NN NN O
in NN NN O
drinking NN NN O
water NN NN O
) NN NN O
for NN NN O
10 NN NN O
days NN NN O
. NN NN O
   
Livers NN NN O
were NN NN O
harvested NN NN O
on NN NN O
2 NN NN O
, NN NN O
5 NN NN O
, NN NN O
and NN NN O
10 NN NN O
days NN NN O
during NN NN O
PB NN NN O
administration NN NN O
. NN NN O
   
In NN NN O
the NN NN O
hepatocyte NN NN O
- NN NN O
specific NN NN O
ILK NN NN O
/ NN NN O
liver NN NN O
- NN NN O
/ NN NN O
- NN NN O
mice NN NN O
, NN NN O
the NN NN O
liver NN NN O
: NN NN O
body NN NN O
weight NN NN O
ratio NN NN O
was NN NN O
more NN NN O
than NN NN O
double NN NN O
as NN NN O
compared NN NN O
to NN NN O
0 NN NN O
h NN NN O
at NN NN O
day NN NN O
2 NN NN O
( NN NN O
2 NN NN O
. NN NN O
5 NN NN O
times NN NN O
) NN NN O
, NN NN O
while NN NN O
at NN NN O
days NN NN O
5 NN NN O
and NN NN O
10 NN NN O
, NN NN O
it NN NN O
was NN NN O
enlarged NN NN O
three NN NN O
times NN NN O
. NN NN O
   
In NN NN O
the NN NN O
WT NN NN O
mice NN NN O
, NN NN O
the NN NN O
increase NN NN O
was NN NN O
as NN NN O
expected NN NN O
from NN NN O
previous NN NN O
literature NN NN O
( NN NN O
1 NN NN O
. NN NN O
8 NN NN O
times NN NN O
) NN NN O
and NN NN O
seems NN NN O
to NN NN O
have NN NN O
leveled NN NN O
off NN NN O
after NN NN O
day NN NN O
2 NN NN O
. NN NN O
   
There NN NN O
were NN NN O
slightly NN NN O
increased NN NN O
proliferating NN NN O
cell NN NN O
nuclear NN NN O
antigen NN NN O
- NN NN O
positive NN NN O
cells NN NN O
in NN NN O
the NN NN O
ILK NN NN O
/ NN NN O
liver NN NN O
- NN NN O
/ NN NN O
- NN NN O
animals NN NN O
at NN NN O
day NN NN O
2 NN NN O
as NN NN O
compared NN NN O
to NN NN O
WT NN NN O
after NN NN O
PB NN NN O
administration NN NN O
. NN NN O
   
In NN NN O
the NN NN O
WT NN NN O
animals NN NN O
, NN NN O
the NN NN O
proliferative NN NN O
response NN NN O
had NN NN O
come NN NN O
back NN NN O
to NN NN O
normal NN NN O
by NN NN O
days NN NN O
5 NN NN O
and NN NN O
10 NN NN O
. NN NN O
   
Hepatocytes NN NN O
of NN NN O
the NN NN O
ILK NN NN O
/ NN NN O
liver NN NN O
- NN NN O
/ NN NN O
- NN NN O
mice NN NN O
continued NN NN O
to NN NN O
proliferate NN NN O
up NN NN O
until NN NN O
day NN NN O
10 NN NN O
. NN NN O
   
ILK NN NN O
/ NN NN O
liver NN NN O
- NN NN O
/ NN NN O
- NN NN O
mice NN NN O
also NN NN O
showed NN NN O
increased NN NN O
expression NN NN O
of NN NN O
key NN NN O
genes NN NN O
involved NN NN O
in NN NN O
hepatocyte NN NN O
proliferation NN NN O
at NN NN O
different NN NN O
time NN NN O
points NN NN O
during NN NN O
PB NN NN O
administration NN NN O
. NN NN O
   
In NN NN O
summary NN NN O
, NN NN O
ECM NN NN O
proteins NN NN O
communicate NN NN O
with NN NN O
the NN NN O
signaling NN NN O
machinery NN NN O
of NN NN O
dividing NN NN O
cells NN NN O
via NN NN O
ILK NN NN O
to NN NN O
regulate NN NN O
hepatocyte NN NN O
proliferation NN NN O
and NN NN O
termination NN NN O
of NN NN O
the NN NN O
proliferative NN NN O
response NN NN O
. NN NN O
   
Lack NN NN O
of NN NN O
ILK NN NN O
in NN NN O
the NN NN O
hepatocytes NN NN O
imparts NN NN O
prolonged NN NN O
proliferative NN NN O
response NN NN O
not NN NN O
only NN NN O
to NN NN O
stimuli NN NN O
related NN NN O
to NN NN O
liver NN NN O
regeneration NN NN O
but NN NN O
also NN NN O
to NN NN O
xenobiotic NN NN O
chemical NN NN O
mitogens NN NN O
, NN NN O
such NN NN O
as NN NN O
PB NN NN O
. NN NN O
   
Decreased NN NN O
Expression NN NN O
of NN NN O
Na NN NN O
/ NN NN O
K NN NN O
- NN NN O
ATPase NN NN O
, NN NN O
NHE3 NN NN O
, NN NN O
NBC1 NN NN O
, NN NN O
AQP1 NN NN O
and NN NN O
OAT NN NN O
in NN NN O
Gentamicin NN NN O
- NN NN O
induced NN NN O
Nephropathy NN NN B-Disease
. NN NN O
   
The NN NN O
present NN NN O
study NN NN O
was NN NN O
aimed NN NN O
to NN NN O
determine NN NN O
whether NN NN O
there NN NN O
is NN NN O
an NN NN O
altered NN NN O
regulation NN NN O
of NN NN O
tubular NN NN O
transporters NN NN O
in NN NN O
gentamicin NN NN O
- NN NN O
induced NN NN O
nephropathy NN NN B-Disease
. NN NN O
   
Sprague NN NN O
- NN NN O
Dawley NN NN O
male NN NN O
rats NN NN O
( NN NN O
200 NN NN O
~ NN NN O
250 NN NN O
g NN NN O
) NN NN O
were NN NN O
subcutaneously NN NN O
injected NN NN O
with NN NN O
gentamicin NN NN O
( NN NN O
100 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
per NN NN O
day NN NN O
) NN NN O
for NN NN O
7 NN NN O
days NN NN O
, NN NN O
and NN NN O
the NN NN O
expression NN NN O
of NN NN O
tubular NN NN O
transporters NN NN O
was NN NN O
determined NN NN O
by NN NN O
immunoblotting NN NN O
and NN NN O
immunohistochemistry NN NN O
. NN NN O
   
The NN NN O
mRNA NN NN O
and NN NN O
protein NN NN O
expression NN NN O
of NN NN O
OAT NN NN O
was NN NN O
also NN NN O
determined NN NN O
. NN NN O
   
Gentamicin NN NN O
- NN NN O
treated NN NN O
rats NN NN O
exhibited NN NN O
significantly NN NN O
decreased NN NN O
creatinine NN NN O
clearance NN NN O
along NN NN O
with NN NN O
increased NN NN O
plasma NN NN O
creatinine NN NN O
levels NN NN O
. NN NN O
   
Accordingly NN NN O
, NN NN O
the NN NN O
fractional NN NN O
excretion NN NN O
of NN NN O
sodium NN NN O
increased NN NN O
. NN NN O
   
Urine NN NN O
volume NN NN O
was NN NN O
increased NN NN O
, NN NN O
while NN NN O
urine NN NN O
osmolality NN NN O
and NN NN O
free NN NN O
water NN NN O
reabsorption NN NN O
were NN NN O
decreased NN NN O
. NN NN O
   
Immunoblotting NN NN O
and NN NN O
immunohistochemistry NN NN O
revealed NN NN O
decreased NN NN O
expression NN NN O
of NN NN O
Na NN NN O
( NN NN O
+ NN NN O
) NN NN O
/ NN NN O
K NN NN O
( NN NN O
+ NN NN O
) NN NN O
- NN NN O
ATPase NN NN O
, NN NN O
NHE3 NN NN O
, NN NN O
NBC1 NN NN O
, NN NN O
and NN NN O
AQP1 NN NN O
in NN NN O
the NN NN O
kidney NN NN O
of NN NN O
gentamicin NN NN O
- NN NN O
treated NN NN O
rats NN NN O
. NN NN O
   
The NN NN O
expression NN NN O
of NN NN O
OAT1 NN NN O
and NN NN O
OAT3 NN NN O
was NN NN O
also NN NN O
decreased NN NN O
. NN NN O
   
Gentamicin NN NN O
- NN NN O
induced NN NN O
nephropathy NN NN B-Disease
may NN NN O
at NN NN O
least NN NN O
in NN NN O
part NN NN O
be NN NN O
causally NN NN O
related NN NN O
with NN NN O
a NN NN O
decreased NN NN O
expression NN NN O
of NN NN O
Na NN NN O
( NN NN O
+ NN NN O
) NN NN O
/ NN NN O
K NN NN O
( NN NN O
+ NN NN O
) NN NN O
- NN NN O
ATPase NN NN O
, NN NN O
NHE3 NN NN O
, NN NN O
NBC1 NN NN O
, NN NN O
AQP1 NN NN O
and NN NN O
OAT NN NN O
. NN NN O
   
Acute NN NN B-Disease
renal NN NN I-Disease
failure NN NN I-Disease
after NN NN O
high NN NN O
- NN NN O
dose NN NN O
methotrexate NN NN O
therapy NN NN O
in NN NN O
a NN NN O
patient NN NN O
with NN NN O
ileostomy NN NN O
. NN NN O
   
High NN NN O
- NN NN O
dose NN NN O
methotrexate NN NN O
( NN NN O
HD NN NN O
- NN NN O
MTX NN NN O
) NN NN O
is NN NN O
an NN NN O
important NN NN O
treatment NN NN O
for NN NN O
Burkitt NN NN B-Disease
lymphoma NN NN I-Disease
, NN NN O
but NN NN O
can NN NN O
cause NN NN O
hepatic NN NN B-Disease
and NN NN I-Disease
renal NN NN I-Disease
toxicity NN NN I-Disease
when NN NN O
its NN NN O
clearance NN NN O
is NN NN O
delayed NN NN O
. NN NN O
   
We NN NN O
report NN NN O
a NN NN O
case NN NN O
of NN NN O
acute NN NN B-Disease
renal NN NN I-Disease
failure NN NN I-Disease
after NN NN O
HD NN NN O
- NN NN O
MTX NN NN O
therapy NN NN O
in NN NN O
a NN NN O
patient NN NN O
with NN NN O
ileostomy NN NN O
, NN NN O
The NN NN O
patient NN NN O
was NN NN O
a NN NN O
3 NN NN O
- NN NN O
year NN NN O
- NN NN O
old NN NN O
boy NN NN O
who NN NN O
had NN NN O
received NN NN O
a NN NN O
living NN NN O
- NN NN O
related NN NN O
liver NN NN O
transplantation NN NN O
for NN NN O
congenital NN NN O
biliary NN NN B-Disease
atresia NN NN I-Disease
. NN NN O
   
At NN NN O
day NN NN O
833 NN NN O
after NN NN O
the NN NN O
transplantation NN NN O
, NN NN O
he NN NN O
was NN NN O
diagnosed NN NN O
with NN NN O
PTLD NN NN B-Disease
( NN NN O
post NN NN B-Disease
- NN NN I-Disease
transplantation NN NN I-Disease
lymphoproliferative NN NN I-Disease
disorder NN NN I-Disease
, NN NN O
Burkitt NN NN B-Disease
- NN NN I-Disease
type NN NN I-Disease
malignant NN NN I-Disease
lymphoma NN NN I-Disease
) NN NN O
. NN NN O
   
During NN NN O
induction NN NN O
therapy NN NN O
, NN NN O
he NN NN O
suffered NN NN O
ileal NN NN O
perforation NN NN O
and NN NN O
ileostomy NN NN O
was NN NN O
performed NN NN O
. NN NN O
   
Subsequent NN NN O
HD NN NN O
- NN NN O
MTX NN NN O
therapy NN NN O
caused NN NN O
acute NN NN B-Disease
renal NN NN I-Disease
failure NN NN I-Disease
that NN NN O
required NN NN O
continuous NN NN O
hemodialysis NN NN O
. NN NN O
   
We NN NN O
supposed NN NN O
that NN NN O
intravascular NN NN O
hypovolemia NN NN B-Disease
due NN NN O
to NN NN O
substantial NN NN O
drainage NN NN O
from NN NN O
the NN NN O
ileostoma NN NN O
caused NN NN O
acute NN NN B-Disease
prerenal NN NN I-Disease
failure NN NN I-Disease
. NN NN O
   
After NN NN O
recovery NN NN O
of NN NN O
his NN NN O
renal NN NN O
function NN NN O
, NN NN O
we NN NN O
could NN NN O
safely NN NN O
treat NN NN O
the NN NN O
patient NN NN O
with NN NN O
HD NN NN O
- NN NN O
MTX NN NN O
therapy NN NN O
by NN NN O
controlling NN NN O
drainage NN NN O
from NN NN O
ileostoma NN NN O
with NN NN O
total NN NN O
parenteral NN NN O
nutrition NN NN O
. NN NN O
   
Longitudinal NN NN O
association NN NN O
of NN NN O
alcohol NN NN O
use NN NN O
with NN NN O
HIV NN NN B-Disease
disease NN NN I-Disease
progression NN NN O
and NN NN O
psychological NN NN O
health NN NN O
of NN NN O
women NN NN O
with NN NN O
HIV NN NN O
. NN NN O
   
We NN NN O
evaluated NN NN O
the NN NN O
association NN NN O
of NN NN O
alcohol NN NN O
consumption NN NN O
and NN NN O
depression NN NN B-Disease
, NN NN O
and NN NN O
their NN NN O
effects NN NN O
on NN NN O
HIV NN NN B-Disease
disease NN NN I-Disease
progression NN NN O
among NN NN O
women NN NN O
with NN NN O
HIV NN NN O
. NN NN O
   
The NN NN O
study NN NN O
included NN NN O
871 NN NN O
women NN NN O
with NN NN O
HIV NN NN O
who NN NN O
were NN NN O
recruited NN NN O
from NN NN O
1993 NN NN O
- NN NN O
1995 NN NN O
in NN NN O
four NN NN O
US NN NN O
cities NN NN O
. NN NN O
   
The NN NN O
participants NN NN O
had NN NN O
physical NN NN O
examination NN NN O
, NN NN O
medical NN NN O
record NN NN O
extraction NN NN O
, NN NN O
and NN NN O
venipuncture NN NN O
, NN NN O
CD4 NN NN O
+ NN NN O
T NN NN O
- NN NN O
cell NN NN O
counts NN NN O
determination NN NN O
, NN NN O
measurement NN NN O
of NN NN O
depression NN NN B-Disease
symptoms NN NN O
( NN NN O
using NN NN O
the NN NN O
self NN NN O
- NN NN O
report NN NN O
Center NN NN O
for NN NN O
Epidemiological NN NN O
Studies NN NN O
- NN NN O
Depression NN NN B-Disease
Scale NN NN O
) NN NN O
, NN NN O
and NN NN O
alcohol NN NN O
use NN NN O
assessment NN NN O
at NN NN O
enrollment NN NN O
, NN NN O
and NN NN O
semiannually NN NN O
until NN NN O
March NN NN O
2000 NN NN O
. NN NN O
   
Multilevel NN NN O
random NN NN O
coefficient NN NN O
ordinal NN NN O
models NN NN O
as NN NN O
well NN NN O
as NN NN O
multilevel NN NN O
models NN NN O
with NN NN O
joint NN NN O
responses NN NN O
were NN NN O
used NN NN O
in NN NN O
the NN NN O
analysis NN NN O
. NN NN O
   
There NN NN O
was NN NN O
no NN NN O
significant NN NN O
association NN NN O
between NN NN O
level NN NN O
of NN NN O
alcohol NN NN O
use NN NN O
and NN NN O
CD4 NN NN O
+ NN NN O
T NN NN O
- NN NN O
cell NN NN O
counts NN NN O
. NN NN O
   
When NN NN O
participants NN NN O
were NN NN O
stratified NN NN O
by NN NN O
antiretroviral NN NN O
therapy NN NN O
( NN NN O
ART NN NN O
) NN NN O
use NN NN O
, NN NN O
the NN NN O
association NN NN O
between NN NN O
alcohol NN NN O
and NN NN O
CD4 NN NN O
+ NN NN O
T NN NN O
- NN NN O
cell NN NN O
did NN NN O
not NN NN O
reach NN NN O
statistical NN NN O
significance NN NN O
. NN NN O
   
The NN NN O
association NN NN O
between NN NN O
alcohol NN NN O
consumption NN NN O
and NN NN O
depression NN NN B-Disease
was NN NN O
significant NN NN O
( NN NN O
p NN NN O
< NN NN O
0 NN NN O
. NN NN O
001 NN NN O
) NN NN O
. NN NN O
   
Depression NN NN B-Disease
had NN NN O
a NN NN O
significant NN NN O
negative NN NN O
effect NN NN O
on NN NN O
CD4 NN NN O
+ NN NN O
T NN NN O
- NN NN O
cell NN NN O
counts NN NN O
over NN NN O
time NN NN O
regardless NN NN O
of NN NN O
ART NN NN O
use NN NN O
. NN NN O
   
Our NN NN O
findings NN NN O
suggest NN NN O
that NN NN O
alcohol NN NN O
consumption NN NN O
has NN NN O
a NN NN O
direct NN NN O
association NN NN O
with NN NN O
depression NN NN B-Disease
. NN NN O
   
Moreover NN NN O
, NN NN O
depression NN NN B-Disease
is NN NN O
associated NN NN O
with NN NN O
HIV NN NN B-Disease
disease NN NN I-Disease
progression NN NN O
. NN NN O
   
Our NN NN O
findings NN NN O
have NN NN O
implications NN NN O
for NN NN O
the NN NN O
provision NN NN O
of NN NN O
alcohol NN NN O
use NN NN O
interventions NN NN O
and NN NN O
psychological NN NN O
resources NN NN O
to NN NN O
improve NN NN O
the NN NN O
health NN NN O
of NN NN O
women NN NN O
with NN NN O
HIV NN NN O
. NN NN O
   
Chemokine NN NN O
CCL2 NN NN O
and NN NN O
its NN NN O
receptor NN NN O
CCR2 NN NN O
are NN NN O
increased NN NN O
in NN NN O
the NN NN O
hippocampus NN NN O
following NN NN O
pilocarpine NN NN O
- NN NN O
induced NN NN O
status NN NN B-Disease
epilepticus NN NN I-Disease
. NN NN O
   
BACKGROUND NN NN O
: NN NN O
Neuroinflammation NN NN B-Disease
occurs NN NN O
after NN NN O
seizures NN NN B-Disease
and NN NN O
is NN NN O
implicated NN NN O
in NN NN O
epileptogenesis NN NN O
. NN NN O
   
CCR2 NN NN O
is NN NN O
a NN NN O
chemokine NN NN O
receptor NN NN O
for NN NN O
CCL2 NN NN O
and NN NN O
their NN NN O
interaction NN NN O
mediates NN NN O
monocyte NN NN O
infiltration NN NN O
in NN NN O
the NN NN O
neuroinflammatory NN NN B-Disease
cascade NN NN O
triggered NN NN O
in NN NN O
different NN NN O
brain NN NN O
pathologies NN NN O
. NN NN O
   
In NN NN O
this NN NN O
work NN NN O
CCR2 NN NN O
and NN NN O
CCL2 NN NN O
expression NN NN O
were NN NN O
examined NN NN O
following NN NN O
status NN NN B-Disease
epilepticus NN NN I-Disease
( NN NN O
SE NN NN B-Disease
) NN NN O
induced NN NN O
by NN NN O
pilocarpine NN NN O
injection NN NN O
. NN NN O
   
METHODS NN NN O
: NN NN O
SE NN NN B-Disease
was NN NN O
induced NN NN O
by NN NN O
pilocarpine NN NN O
injection NN NN O
. NN NN O
   
Control NN NN O
rats NN NN O
were NN NN O
injected NN NN O
with NN NN O
saline NN NN O
instead NN NN O
of NN NN O
pilocarpine NN NN O
. NN NN O
   
Five NN NN O
days NN NN O
after NN NN O
SE NN NN B-Disease
, NN NN O
CCR2 NN NN O
staining NN NN O
in NN NN O
neurons NN NN O
and NN NN O
glial NN NN O
cells NN NN O
was NN NN O
examined NN NN O
using NN NN O
imunohistochemical NN NN O
analyses NN NN O
. NN NN O
   
The NN NN O
number NN NN O
of NN NN O
CCR2 NN NN O
positive NN NN O
cells NN NN O
was NN NN O
determined NN NN O
using NN NN O
stereology NN NN O
probes NN NN O
in NN NN O
the NN NN O
hippocampus NN NN O
. NN NN O
   
CCL2 NN NN O
expression NN NN O
in NN NN O
the NN NN O
hippocampus NN NN O
was NN NN O
examined NN NN O
by NN NN O
molecular NN NN O
assay NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
Increased NN NN O
CCR2 NN NN O
was NN NN O
observed NN NN O
in NN NN O
the NN NN O
hippocampus NN NN O
after NN NN O
SE NN NN B-Disease
. NN NN O
   
Seizures NN NN B-Disease
also NN NN O
resulted NN NN O
in NN NN O
alterations NN NN O
to NN NN O
the NN NN O
cell NN NN O
types NN NN O
expressing NN NN O
CCR2 NN NN O
. NN NN O
   
Increased NN NN O
numbers NN NN O
of NN NN O
neurons NN NN O
that NN NN O
expressed NN NN O
CCR2 NN NN O
was NN NN O
observed NN NN O
following NN NN O
SE NN NN B-Disease
. NN NN O
   
Microglial NN NN O
cells NN NN O
were NN NN O
more NN NN O
closely NN NN O
apposed NN NN O
to NN NN O
the NN NN O
CCR2 NN NN O
- NN NN O
labeled NN NN O
cells NN NN O
in NN NN O
SE NN NN B-Disease
rats NN NN O
. NN NN O
   
In NN NN O
addition NN NN O
, NN NN O
rats NN NN O
that NN NN O
experienced NN NN O
SE NN NN B-Disease
exhibited NN NN O
CCR2 NN NN O
- NN NN O
labeling NN NN O
in NN NN O
populations NN NN O
of NN NN O
hypertrophied NN NN B-Disease
astrocytes NN NN O
, NN NN O
especially NN NN O
in NN NN O
CA1 NN NN O
and NN NN O
dentate NN NN O
gyrus NN NN O
. NN NN O
   
These NN NN O
CCR2 NN NN O
+ NN NN O
astroctytes NN NN O
were NN NN O
not NN NN O
observed NN NN O
in NN NN O
control NN NN O
rats NN NN O
. NN NN O
   
Examination NN NN O
of NN NN O
CCL2 NN NN O
expression NN NN O
showed NN NN O
that NN NN O
it NN NN O
was NN NN O
elevated NN NN O
in NN NN O
the NN NN O
hippocampus NN NN O
following NN NN O
SE NN NN B-Disease
. NN NN O
   
CONCLUSION NN NN O
: NN NN O
The NN NN O
data NN NN O
show NN NN O
that NN NN O
CCR2 NN NN O
and NN NN O
CCL2 NN NN O
are NN NN O
up NN NN O
- NN NN O
regulated NN NN O
in NN NN O
the NN NN O
hippocampus NN NN O
after NN NN O
pilocarpine NN NN O
- NN NN O
induced NN NN O
SE NN NN B-Disease
. NN NN O
   
Seizures NN NN B-Disease
also NN NN O
result NN NN O
in NN NN O
changes NN NN O
to NN NN O
CCR2 NN NN O
receptor NN NN O
expression NN NN O
in NN NN O
neurons NN NN O
and NN NN O
astrocytes NN NN O
. NN NN O
   
These NN NN O
changes NN NN O
might NN NN O
be NN NN O
involved NN NN O
in NN NN O
detrimental NN NN O
neuroplasticity NN NN O
and NN NN O
neuroinflammatory NN NN B-Disease
changes NN NN O
that NN NN O
occur NN NN O
following NN NN O
seizures NN NN B-Disease
. NN NN O
   
Metallothionein NN NN O
induction NN NN O
reduces NN NN O
caspase NN NN O
- NN NN O
3 NN NN O
activity NN NN O
and NN NN O
TNFalpha NN NN O
levels NN NN O
with NN NN O
preservation NN NN O
of NN NN O
cognitive NN NN O
function NN NN O
and NN NN O
intact NN NN O
hippocampal NN NN O
neurons NN NN O
in NN NN O
carmustine NN NN O
- NN NN O
treated NN NN O
rats NN NN O
. NN NN O
   
Hippocampal NN NN O
integrity NN NN O
is NN NN O
essential NN NN O
for NN NN O
cognitive NN NN O
functions NN NN O
. NN NN O
   
On NN NN O
the NN NN O
other NN NN O
hand NN NN O
, NN NN O
induction NN NN O
of NN NN O
metallothionein NN NN O
( NN NN O
MT NN NN O
) NN NN O
by NN NN O
ZnSO NN NN O
( NN NN O
4 NN NN O
) NN NN O
and NN NN O
its NN NN O
role NN NN O
in NN NN O
neuroprotection NN NN O
has NN NN O
been NN NN O
documented NN NN O
. NN NN O
   
The NN NN O
present NN NN O
study NN NN O
aimed NN NN O
to NN NN O
explore NN NN O
the NN NN O
effect NN NN O
of NN NN O
MT NN NN O
induction NN NN O
on NN NN O
carmustine NN NN O
( NN NN O
BCNU NN NN O
) NN NN O
- NN NN O
induced NN NN O
hippocampal NN NN O
cognitive NN NN B-Disease
dysfunction NN NN I-Disease
in NN NN O
rats NN NN O
. NN NN O
   
A NN NN O
total NN NN O
of NN NN O
60 NN NN O
male NN NN O
Wistar NN NN O
albino NN NN O
rats NN NN O
were NN NN O
randomly NN NN O
divided NN NN O
into NN NN O
four NN NN O
groups NN NN O
( NN NN O
15 NN NN O
/ NN NN O
group NN NN O
) NN NN O
: NN NN O
The NN NN O
control NN NN O
group NN NN O
injected NN NN O
with NN NN O
single NN NN O
doses NN NN O
of NN NN O
normal NN NN O
saline NN NN O
( NN NN O
i NN NN O
. NN NN O
c NN NN O
. NN NN O
v NN NN O
) NN NN O
followed NN NN O
24 NN NN O
h NN NN O
later NN NN O
by NN NN O
BCNU NN NN O
solvent NN NN O
( NN NN O
i NN NN O
. NN NN O
v NN NN O
) NN NN O
. NN NN O
   
The NN NN O
second NN NN O
group NN NN O
administered NN NN O
ZnSO NN NN O
( NN NN O
4 NN NN O
) NN NN O
( NN NN O
0 NN NN O
. NN NN O
1 NN NN O
micromol NN NN O
/ NN NN O
10 NN NN O
microl NN NN O
normal NN NN O
saline NN NN O
, NN NN O
i NN NN O
. NN NN O
c NN NN O
. NN NN O
v NN NN O
, NN NN O
once NN NN O
) NN NN O
then NN NN O
BCNU NN NN O
solvent NN NN O
( NN NN O
i NN NN O
. NN NN O
v NN NN O
) NN NN O
after NN NN O
24 NN NN O
h NN NN O
. NN NN O
   
Third NN NN O
group NN NN O
received NN NN O
BCNU NN NN O
( NN NN O
20 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
, NN NN O
i NN NN O
. NN NN O
v NN NN O
, NN NN O
once NN NN O
) NN NN O
24 NN NN O
h NN NN O
after NN NN O
injection NN NN O
with NN NN O
normal NN NN O
saline NN NN O
( NN NN O
i NN NN O
. NN NN O
c NN NN O
. NN NN O
v NN NN O
) NN NN O
. NN NN O
   
Fourth NN NN O
group NN NN O
received NN NN O
a NN NN O
single NN NN O
dose NN NN O
of NN NN O
ZnSO NN NN O
( NN NN O
4 NN NN O
) NN NN O
( NN NN O
0 NN NN O
. NN NN O
1 NN NN O
micromol NN NN O
/ NN NN O
10 NN NN O
microl NN NN O
normal NN NN O
saline NN NN O
, NN NN O
i NN NN O
. NN NN O
c NN NN O
. NN NN O
v NN NN O
) NN NN O
then NN NN O
BCNU NN NN O
( NN NN O
20 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
, NN NN O
i NN NN O
. NN NN O
v NN NN O
, NN NN O
once NN NN O
) NN NN O
after NN NN O
24 NN NN O
h NN NN O
. NN NN O
   
The NN NN O
obtained NN NN O
data NN NN O
revealed NN NN O
that NN NN O
BCNU NN NN O
administration NN NN O
resulted NN NN O
in NN NN O
deterioration NN NN B-Disease
of NN NN I-Disease
learning NN NN I-Disease
and NN NN I-Disease
short NN NN I-Disease
- NN NN I-Disease
term NN NN I-Disease
memory NN NN I-Disease
( NN NN O
STM NN NN O
) NN NN O
, NN NN O
as NN NN O
measured NN NN O
by NN NN O
using NN NN O
radial NN NN O
arm NN NN O
water NN NN O
maze NN NN O
, NN NN O
accompanied NN NN O
with NN NN O
decreased NN NN O
hippocampal NN NN O
glutathione NN NN O
reductase NN NN O
( NN NN O
GR NN NN O
) NN NN O
activity NN NN O
and NN NN O
reduced NN NN O
glutathione NN NN O
( NN NN O
GSH NN NN O
) NN NN O
content NN NN O
. NN NN O
   
Also NN NN O
, NN NN O
BCNU NN NN O
administration NN NN O
increased NN NN O
serum NN NN O
tumor NN NN B-Disease
necrosis NN NN B-Disease
factor NN NN O
- NN NN O
alpha NN NN O
( NN NN O
TNFalpha NN NN O
) NN NN O
, NN NN O
hippocampal NN NN O
MT NN NN O
and NN NN O
malondialdehyde NN NN O
( NN NN O
MDA NN NN O
) NN NN O
contents NN NN O
as NN NN O
well NN NN O
as NN NN O
caspase NN NN O
- NN NN O
3 NN NN O
activity NN NN O
in NN NN O
addition NN NN O
to NN NN O
histological NN NN O
alterations NN NN O
. NN NN O
   
ZnSO NN NN O
( NN NN O
4 NN NN O
) NN NN O
pretreatment NN NN O
counteracted NN NN O
BCNU NN NN O
- NN NN O
induced NN NN O
inhibition NN NN O
of NN NN O
GR NN NN O
and NN NN O
depletion NN NN O
of NN NN O
GSH NN NN O
and NN NN O
resulted NN NN O
in NN NN O
significant NN NN O
reduction NN NN O
in NN NN O
the NN NN O
levels NN NN O
of NN NN O
MDA NN NN O
and NN NN O
TNFalpha NN NN O
as NN NN O
well NN NN O
as NN NN O
the NN NN O
activity NN NN O
of NN NN O
caspase NN NN O
- NN NN O
3 NN NN O
. NN NN O
   
The NN NN O
histological NN NN O
features NN NN O
were NN NN O
improved NN NN O
in NN NN O
hippocampus NN NN O
of NN NN O
rats NN NN O
treated NN NN O
with NN NN O
ZnSO NN NN O
( NN NN O
4 NN NN O
) NN NN O
+ NN NN O
BCNU NN NN O
compared NN NN O
to NN NN O
only NN NN O
BCNU NN NN O
- NN NN O
treated NN NN O
animals NN NN O
. NN NN O
   
In NN NN O
conclusion NN NN O
, NN NN O
MT NN NN O
induction NN NN O
halts NN NN O
BCNU NN NN O
- NN NN O
induced NN NN O
hippocampal NN NN O
toxicity NN NN B-Disease
as NN NN O
it NN NN O
prevented NN NN O
GR NN NN O
inhibition NN NN O
and NN NN O
GSH NN NN O
depletion NN NN O
and NN NN O
counteracted NN NN O
the NN NN O
increased NN NN O
levels NN NN O
of NN NN O
TNFalpha NN NN O
, NN NN O
MDA NN NN O
and NN NN O
caspase NN NN O
- NN NN O
3 NN NN O
activity NN NN O
with NN NN O
subsequent NN NN O
preservation NN NN O
of NN NN O
cognition NN NN O
. NN NN O
   
Fatal NN NN O
carbamazepine NN NN O
induced NN NN O
fulminant NN NN B-Disease
eosinophilic NN NN I-Disease
( NN NN O
hypersensitivity NN NN B-Disease
) NN NN O
myocarditis NN NN B-Disease
: NN NN O
emphasis NN NN O
on NN NN O
anatomical NN NN O
and NN NN O
histological NN NN O
characteristics NN NN O
, NN NN O
mechanisms NN NN O
and NN NN O
genetics NN NN O
of NN NN O
drug NN NN B-Disease
hypersensitivity NN NN I-Disease
and NN NN O
differential NN NN O
diagnosis NN NN O
. NN NN O
   
The NN NN O
most NN NN O
severe NN NN O
adverse NN NN O
reactions NN NN O
to NN NN O
carbamazepine NN NN O
have NN NN O
been NN NN O
observed NN NN O
in NN NN O
the NN NN O
haemopoietic NN NN O
system NN NN O
, NN NN O
the NN NN O
liver NN NN O
and NN NN O
the NN NN O
cardiovascular NN NN O
system NN NN O
. NN NN O
   
A NN NN O
frequently NN NN O
fatal NN NN O
, NN NN O
although NN NN O
exceptionally NN NN O
rare NN NN O
side NN NN O
effect NN NN O
of NN NN O
carbamazepine NN NN O
is NN NN O
necrotizing NN NN O
eosinophilic NN NN O
( NN NN O
hypersensitivity NN NN B-Disease
) NN NN O
myocarditis NN NN B-Disease
. NN NN O
   
We NN NN O
report NN NN O
a NN NN O
case NN NN O
of NN NN O
hypersensitivity NN NN B-Disease
myocarditis NN NN B-Disease
secondary NN NN O
to NN NN O
administration NN NN O
of NN NN O
carbamazepine NN NN O
. NN NN O
   
Acute NN NN O
hypersensitivity NN NN B-Disease
myocarditis NN NN B-Disease
was NN NN O
not NN NN O
suspected NN NN O
clinically NN NN O
, NN NN O
and NN NN O
the NN NN O
diagnosis NN NN O
was NN NN O
made NN NN O
post NN NN O
- NN NN O
mortem NN NN O
. NN NN O
   
Histology NN NN O
revealed NN NN O
diffuse NN NN O
infiltration NN NN O
of NN NN O
the NN NN O
myocardium NN NN O
by NN NN O
eosinophils NN NN O
and NN NN O
lymphocytes NN NN O
with NN NN O
myocyte NN NN O
damage NN NN O
. NN NN O
   
Clinically NN NN O
, NN NN O
death NN NN O
was NN NN O
due NN NN O
to NN NN O
cardiogenic NN NN B-Disease
shock NN NN I-Disease
. NN NN O
   
To NN NN O
best NN NN O
of NN NN O
our NN NN O
knowledge NN NN O
this NN NN O
is NN NN O
the NN NN O
second NN NN O
case NN NN O
of NN NN O
fatal NN NN O
carbamazepine NN NN O
induced NN NN O
myocarditis NN NN B-Disease
reported NN NN O
in NN NN O
English NN NN O
literature NN NN O
. NN NN O
   
Neuropsychiatric NN NN O
behaviors NN NN O
in NN NN O
the NN NN O
MPTP NN NN O
marmoset NN NN O
model NN NN O
of NN NN O
Parkinson NN NN B-Disease
' NN NN I-Disease
s NN NN I-Disease
disease NN NN I-Disease
. NN NN O
   
OBJECTIVES NN NN O
: NN NN O
Neuropsychiatric NN NN O
symptoms NN NN O
are NN NN O
increasingly NN NN O
recognised NN NN O
as NN NN O
a NN NN O
significant NN NN O
problem NN NN O
in NN NN O
patients NN NN O
with NN NN O
Parkinson NN NN B-Disease
' NN NN I-Disease
s NN NN I-Disease
disease NN NN I-Disease
( NN NN O
PD NN NN B-Disease
) NN NN O
. NN NN O
   
These NN NN O
symptoms NN NN O
may NN NN O
be NN NN O
due NN NN O
to NN NN O
' NN NN O
sensitisation NN NN O
' NN NN O
following NN NN O
repeated NN NN O
levodopa NN NN O
treatment NN NN O
or NN NN O
a NN NN O
direct NN NN O
effect NN NN O
of NN NN O
dopamine NN NN O
on NN NN O
the NN NN O
disease NN NN O
state NN NN O
. NN NN O
   
The NN NN O
levodopa NN NN O
- NN NN O
treated NN NN O
MPTP NN NN O
- NN NN O
lesioned NN NN O
marmoset NN NN O
was NN NN O
used NN NN O
as NN NN O
a NN NN O
model NN NN O
of NN NN O
neuropsychiatric NN NN B-Disease
symptoms NN NN I-Disease
in NN NN O
PD NN NN B-Disease
patients NN NN O
. NN NN O
   
Here NN NN O
we NN NN O
compare NN NN O
the NN NN O
time NN NN O
course NN NN O
of NN NN O
levodopa NN NN O
- NN NN O
induced NN NN O
motor NN NN O
fluctuations NN NN O
and NN NN O
neuropsychiatric NN NN B-Disease
- NN NN I-Disease
like NN NN I-Disease
behaviors NN NN I-Disease
to NN NN O
determine NN NN O
the NN NN O
relationship NN NN O
between NN NN O
duration NN NN O
of NN NN O
treatment NN NN O
and NN NN O
onset NN NN O
of NN NN O
symptoms NN NN O
. NN NN O
   
METHODS NN NN O
: NN NN O
Marmosets NN NN O
were NN NN O
administered NN NN O
1 NN NN O
- NN NN O
methyl NN NN O
- NN NN O
4 NN NN O
- NN NN O
phenyl NN NN O
- NN NN O
1 NN NN O
, NN NN O
2 NN NN O
, NN NN O
3 NN NN O
, NN NN O
6 NN NN O
- NN NN O
tetrahydropyridine NN NN O
( NN NN O
2 NN NN O
. NN NN O
0 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
s NN NN O
. NN NN O
c NN NN O
. NN NN O
) NN NN O
for NN NN O
five NN NN O
days NN NN O
, NN NN O
resulting NN NN O
in NN NN O
stable NN NN O
parkinsonism NN NN B-Disease
. NN NN O
   
Levodopa NN NN O
( NN NN O
15 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
and NN NN O
benserazide NN NN O
, NN NN O
3 NN NN O
. NN NN O
75 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
) NN NN O
p NN NN O
. NN NN O
o NN NN O
. NN NN O
   
b NN NN O
. NN NN O
i NN NN O
. NN NN O
d NN NN O
, NN NN O
was NN NN O
administered NN NN O
for NN NN O
30 NN NN O
days NN NN O
. NN NN O
   
Animals NN NN O
were NN NN O
evaluated NN NN O
for NN NN O
parkinsonian NN NN B-Disease
disability NN NN I-Disease
, NN NN O
dyskinesia NN NN B-Disease
and NN NN O
on NN NN O
- NN NN O
time NN NN O
( NN NN O
motor NN NN O
fluctuations NN NN O
) NN NN O
and NN NN O
neuropsychiatric NN NN B-Disease
- NN NN I-Disease
like NN NN I-Disease
behaviors NN NN I-Disease
on NN NN O
Day NN NN O
0 NN NN O
( NN NN O
prior NN NN O
to NN NN O
levodopa NN NN O
) NN NN O
and NN NN O
on NN NN O
Days NN NN O
1 NN NN O
, NN NN O
7 NN NN O
, NN NN O
13 NN NN O
, NN NN O
27 NN NN O
and NN NN O
30 NN NN O
of NN NN O
treatment NN NN O
using NN NN O
post NN NN O
hoc NN NN O
DVD NN NN O
analysis NN NN O
by NN NN O
a NN NN O
trained NN NN O
rater NN NN O
, NN NN O
blind NN NN O
to NN NN O
the NN NN O
treatment NN NN O
day NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
The NN NN O
neuropsychiatric NN NN B-Disease
- NN NN I-Disease
like NN NN I-Disease
behavior NN NN I-Disease
rating NN NN O
scale NN NN O
demonstrated NN NN O
high NN NN O
interrater NN NN O
reliability NN NN O
between NN NN O
three NN NN O
trained NN NN O
raters NN NN O
of NN NN O
differing NN NN O
professional NN NN O
backgrounds NN NN O
. NN NN O
   
As NN NN O
anticipated NN NN O
, NN NN O
animals NN NN O
exhibited NN NN O
a NN NN O
progressive NN NN O
increase NN NN O
in NN NN O
levodopa NN NN O
- NN NN O
induced NN NN O
motor NN NN O
fluctuations NN NN O
, NN NN O
dyskinesia NN NN B-Disease
and NN NN O
wearing NN NN O
- NN NN O
off NN NN O
, NN NN O
that NN NN O
correlated NN NN O
with NN NN O
the NN NN O
duration NN NN O
of NN NN O
levodopa NN NN O
therapy NN NN O
. NN NN O
   
In NN NN O
contrast NN NN O
, NN NN O
levodopa NN NN O
- NN NN O
induced NN NN O
neuropsychiatric NN NN B-Disease
- NN NN I-Disease
like NN NN I-Disease
behaviors NN NN I-Disease
were NN NN O
present NN NN O
on NN NN O
Day NN NN O
1 NN NN O
of NN NN O
levodopa NN NN O
treatment NN NN O
and NN NN O
their NN NN O
severity NN NN O
did NN NN O
not NN NN O
correlate NN NN O
with NN NN O
duration NN NN O
of NN NN O
treatment NN NN O
. NN NN O
   
CONCLUSIONS NN NN O
: NN NN O
The NN NN O
data NN NN O
suggest NN NN O
that NN NN O
neuropsychiatric NN NN B-Disease
disorders NN NN I-Disease
in NN NN O
PD NN NN B-Disease
are NN NN O
more NN NN O
likely NN NN O
an NN NN O
interaction NN NN O
between NN NN O
levodopa NN NN O
and NN NN O
the NN NN O
disease NN NN O
state NN NN O
than NN NN O
a NN NN O
consequence NN NN O
of NN NN O
sensitisation NN NN O
to NN NN O
repeated NN NN O
dopaminergic NN NN O
therapy NN NN O
. NN NN O
   
Contrast NN NN O
medium NN NN O
nephrotoxicity NN NN B-Disease
after NN NN O
renal NN NN O
artery NN NN O
and NN NN O
coronary NN NN O
angioplasty NN NN O
. NN NN O
   
BACKGROUND NN NN O
: NN NN O
Renal NN NN B-Disease
dysfunction NN NN I-Disease
induced NN NN O
by NN NN O
iodinated NN NN O
contrast NN NN O
medium NN NN O
( NN NN O
CM NN NN O
) NN NN O
administration NN NN O
can NN NN O
minimize NN NN O
the NN NN O
benefit NN NN O
of NN NN O
the NN NN O
interventional NN NN O
procedure NN NN O
in NN NN O
patients NN NN O
undergoing NN NN O
renal NN NN O
angioplasty NN NN O
( NN NN O
PTRA NN NN O
) NN NN O
. NN NN O
   
PURPOSE NN NN O
: NN NN O
To NN NN O
compare NN NN O
the NN NN O
susceptibility NN NN O
to NN NN O
nephrotoxic NN NN B-Disease
effect NN NN O
of NN NN O
CM NN NN O
in NN NN O
patients NN NN O
undergoing NN NN O
PTRA NN NN O
with NN NN O
that NN NN O
of NN NN O
patients NN NN O
submitted NN NN O
to NN NN O
percutaneous NN NN O
coronary NN NN O
intervention NN NN O
( NN NN O
PCI NN NN O
) NN NN O
. NN NN O
   
MATERIAL NN NN O
AND NN NN O
METHODS NN NN O
: NN NN O
A NN NN O
total NN NN O
of NN NN O
33 NN NN O
patients NN NN O
successfully NN NN O
treated NN NN O
with NN NN O
PTRA NN NN O
( NN NN O
PTRA NN NN O
group NN NN O
, NN NN O
mean NN NN O
age NN NN O
70 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
12 NN NN O
years NN NN O
, NN NN O
23 NN NN O
female NN NN O
, NN NN O
basal NN NN O
creatinine NN NN O
1 NN NN O
. NN NN O
46 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
0 NN NN O
. NN NN O
79 NN NN O
, NN NN O
range NN NN O
0 NN NN O
. NN NN O
7 NN NN O
- NN NN O
4 NN NN O
. NN NN O
9 NN NN O
mg NN NN O
/ NN NN O
dl NN NN O
) NN NN O
were NN NN O
compared NN NN O
with NN NN O
33 NN NN O
patients NN NN O
undergoing NN NN O
successful NN NN O
PCI NN NN O
( NN NN O
PCI NN NN O
group NN NN O
) NN NN O
, NN NN O
matched NN NN O
for NN NN O
basal NN NN O
creatinine NN NN O
( NN NN O
1 NN NN O
. NN NN O
44 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
0 NN NN O
. NN NN O
6 NN NN O
, NN NN O
range NN NN O
0 NN NN O
. NN NN O
7 NN NN O
- NN NN O
3 NN NN O
. NN NN O
4 NN NN O
mg NN NN O
/ NN NN O
dl NN NN O
) NN NN O
, NN NN O
gender NN NN O
, NN NN O
and NN NN O
age NN NN O
. NN NN O
   
In NN NN O
both NN NN O
groups NN NN O
postprocedural NN NN O
( NN NN O
48 NN NN O
h NN NN O
) NN NN O
serum NN NN O
creatinine NN NN O
was NN NN O
measured NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
Postprocedural NN NN O
creatinine NN NN O
level NN NN O
decreased NN NN O
nonsignificantly NN NN O
in NN NN O
the NN NN O
PTRA NN NN O
group NN NN O
( NN NN O
1 NN NN O
. NN NN O
46 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
0 NN NN O
. NN NN O
8 NN NN O
vs NN NN O
. NN NN O
1 NN NN O
. NN NN O
34 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
0 NN NN O
. NN NN O
5 NN NN O
mg NN NN O
/ NN NN O
dl NN NN O
, NN NN O
P NN NN O
= NN NN O
NS NN NN O
) NN NN O
and NN NN O
increased NN NN O
significantly NN NN O
in NN NN O
the NN NN O
PCI NN NN O
group NN NN O
( NN NN O
1 NN NN O
. NN NN O
44 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
0 NN NN O
. NN NN O
6 NN NN O
vs NN NN O
. NN NN O
1 NN NN O
. NN NN O
57 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
0 NN NN O
. NN NN O
7 NN NN O
mg NN NN O
/ NN NN O
dl NN NN O
, NN NN O
P NN NN O
< NN NN O
0 NN NN O
. NN NN O
02 NN NN O
) NN NN O
. NN NN O
   
Changes NN NN O
in NN NN O
serum NN NN O
creatinine NN NN O
after NN NN O
intervention NN NN O
( NN NN O
after NN NN O
- NN NN O
before NN NN O
) NN NN O
were NN NN O
significantly NN NN O
different NN NN O
between NN NN O
the NN NN O
PTRA NN NN O
and NN NN O
PCI NN NN O
groups NN NN O
( NN NN O
- NN NN O
0 NN NN O
. NN NN O
12 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
0 NN NN O
. NN NN O
5 NN NN O
vs NN NN O
. NN NN O
0 NN NN O
. NN NN O
13 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
0 NN NN O
. NN NN O
3 NN NN O
, NN NN O
P NN NN O
= NN NN O
0 NN NN O
. NN NN O
014 NN NN O
) NN NN O
. NN NN O
   
This NN NN O
difference NN NN O
was NN NN O
not NN NN O
related NN NN O
to NN NN O
either NN NN O
a NN NN O
different NN NN O
clinical NN NN O
risk NN NN O
profile NN NN O
or NN NN O
to NN NN O
the NN NN O
volume NN NN O
of NN NN O
CM NN NN O
administered NN NN O
. NN NN O
   
CONCLUSION NN NN O
: NN NN O
In NN NN O
this NN NN O
preliminary NN NN O
study NN NN O
patients NN NN O
submitted NN NN O
to NN NN O
PTRA NN NN O
showed NN NN O
a NN NN O
lower NN NN O
susceptibility NN NN O
to NN NN O
renal NN NN B-Disease
damage NN NN I-Disease
induced NN NN O
by NN NN O
CM NN NN O
administration NN NN O
than NN NN O
PCI NN NN O
patients NN NN O
. NN NN O
   
The NN NN O
effectiveness NN NN O
of NN NN O
PTRA NN NN O
on NN NN O
renal NN NN O
function NN NN O
seems NN NN O
to NN NN O
be NN NN O
barely NN NN O
influenced NN NN O
by NN NN O
CM NN NN O
toxicity NN NN B-Disease
. NN NN O
   
Diphenhydramine NN NN O
prevents NN NN O
the NN NN O
haemodynamic NN NN O
changes NN NN O
of NN NN O
cimetidine NN NN O
in NN NN O
ICU NN NN O
patients NN NN O
. NN NN O
   
Cimetidine NN NN O
, NN NN O
a NN NN O
histamine NN NN O
2 NN NN O
( NN NN O
H2 NN NN O
) NN NN O
antagonist NN NN O
, NN NN O
produces NN NN O
a NN NN O
decrease NN NN O
in NN NN O
arterial NN NN O
pressure NN NN O
due NN NN O
to NN NN O
vasodilatation NN NN O
, NN NN O
especially NN NN O
in NN NN O
critically NN NN O
ill NN NN O
patients NN NN O
. NN NN O
   
This NN NN O
may NN NN O
be NN NN O
because NN NN O
cimetidine NN NN O
acts NN NN O
as NN NN O
a NN NN O
histamine NN NN O
agonist NN NN O
. NN NN O
   
We NN NN O
, NN NN O
therefore NN NN O
, NN NN O
investigated NN NN O
the NN NN O
effects NN NN O
of NN NN O
the NN NN O
histamine NN NN O
1 NN NN O
( NN NN O
H1 NN NN O
) NN NN O
receptor NN NN O
antagonist NN NN O
, NN NN O
diphenhydramine NN NN O
, NN NN O
on NN NN O
the NN NN O
haemodynamic NN NN O
changes NN NN O
observed NN NN O
after NN NN O
cimetidine NN NN O
in NN NN O
ICU NN NN O
patients NN NN O
. NN NN O
   
Each NN NN O
patient NN NN O
was NN NN O
studied NN NN O
on NN NN O
two NN NN O
separate NN NN O
days NN NN O
. NN NN O
   
In NN NN O
a NN NN O
random NN NN O
fashion NN NN O
, NN NN O
they NN NN O
received NN NN O
cimetidine NN NN O
200 NN NN O
mg NN NN O
iv NN NN O
on NN NN O
one NN NN O
day NN NN O
, NN NN O
and NN NN O
on NN NN O
the NN NN O
other NN NN O
, NN NN O
a NN NN O
pretreatment NN NN O
of NN NN O
diphenhydramine NN NN O
40 NN NN O
mg NN NN O
iv NN NN O
with NN NN O
cimetidine NN NN O
200 NN NN O
mg NN NN O
iv NN NN O
. NN NN O
   
In NN NN O
the NN NN O
non NN NN O
- NN NN O
pretreatment NN NN O
group NN NN O
, NN NN O
mean NN NN O
arterial NN NN O
pressure NN NN O
( NN NN O
MAP NN NN O
) NN NN O
decreased NN NN O
from NN NN O
107 NN NN O
. NN NN O
4 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
8 NN NN O
. NN NN O
4 NN NN O
mmHg NN NN O
to NN NN O
86 NN NN O
. NN NN O
7 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
11 NN NN O
. NN NN O
4 NN NN O
mmHg NN NN O
( NN NN O
P NN NN O
less NN NN O
than NN NN O
0 NN NN O
. NN NN O
01 NN NN O
) NN NN O
two NN NN O
minutes NN NN O
after NN NN O
cimetidine NN NN O
. NN NN O
   
Also NN NN O
, NN NN O
systemic NN NN O
vascular NN NN O
resistance NN NN O
( NN NN O
SVR NN NN O
) NN NN O
decreased NN NN O
during NN NN O
the NN NN O
eight NN NN O
- NN NN O
minute NN NN O
observation NN NN O
period NN NN O
( NN NN O
P NN NN O
less NN NN O
than NN NN O
0 NN NN O
. NN NN O
01 NN NN O
) NN NN O
. NN NN O
   
In NN NN O
contrast NN NN O
, NN NN O
in NN NN O
the NN NN O
pretreatment NN NN O
group NN NN O
, NN NN O
little NN NN O
haemodynamic NN NN O
change NN NN O
was NN NN O
seen NN NN O
. NN NN O
   
We NN NN O
conclude NN NN O
that NN NN O
an NN NN O
H1 NN NN O
antagonist NN NN O
may NN NN O
be NN NN O
useful NN NN O
in NN NN O
preventing NN NN O
hypotension NN NN B-Disease
caused NN NN O
by NN NN O
iv NN NN O
cimetidine NN NN O
, NN NN O
since NN NN O
the NN NN O
vasodilating NN NN O
activity NN NN O
of NN NN O
cimetidine NN NN O
is NN NN O
mediated NN NN O
, NN NN O
in NN NN O
part NN NN O
, NN NN O
through NN NN O
the NN NN O
H1 NN NN O
receptor NN NN O
. NN NN O
   
Medical NN NN O
and NN NN O
psychiatric NN NN O
outcomes NN NN O
for NN NN O
patients NN NN O
transplanted NN NN O
for NN NN O
acetaminophen NN NN O
- NN NN O
induced NN NN O
acute NN NN B-Disease
liver NN NN I-Disease
failure NN NN I-Disease
: NN NN O
a NN NN O
case NN NN O
- NN NN O
control NN NN O
study NN NN O
. NN NN O
   
BACKGROUND NN NN O
: NN NN O
Acetaminophen NN NN O
- NN NN O
induced NN NN O
hepatotoxicity NN NN B-Disease
is NN NN O
the NN NN O
most NN NN O
common NN NN O
cause NN NN O
of NN NN O
acute NN NN B-Disease
liver NN NN I-Disease
failure NN NN I-Disease
( NN NN O
ALF NN NN B-Disease
) NN NN O
in NN NN O
the NN NN O
UK NN NN O
. NN NN O
   
Patients NN NN O
often NN NN O
consume NN NN O
the NN NN O
drug NN NN O
with NN NN O
suicidal NN NN O
intent NN NN O
or NN NN O
with NN NN O
a NN NN O
background NN NN O
of NN NN O
substance NN NN O
dependence NN NN O
. NN NN O
   
AIMS NN NN O
AND NN NN O
METHODS NN NN O
: NN NN O
We NN NN O
compared NN NN O
the NN NN O
severity NN NN O
of NN NN O
pretransplant NN NN O
illness NN NN O
, NN NN O
psychiatric NN NN O
co NN NN O
- NN NN O
morbidity NN NN O
, NN NN O
medical NN NN O
and NN NN O
psychosocial NN NN O
outcomes NN NN O
of NN NN O
all NN NN O
patients NN NN O
who NN NN O
had NN NN O
undergone NN NN O
liver NN NN O
transplantation NN NN O
( NN NN O
LT NN NN O
) NN NN O
emergently NN NN O
between NN NN O
1999 NN NN O
- NN NN O
2004 NN NN O
for NN NN O
acetaminophen NN NN O
- NN NN O
induced NN NN O
ALF NN NN B-Disease
( NN NN O
n NN NN O
= NN NN O
36 NN NN O
) NN NN O
with NN NN O
age NN NN O
- NN NN O
and NN NN O
sex NN NN O
- NN NN O
matched NN NN O
patients NN NN O
undergoing NN NN O
emergent NN NN O
LT NN NN O
for NN NN O
non NN NN O
- NN NN O
acetaminophen NN NN O
- NN NN O
induced NN NN O
ALF NN NN B-Disease
( NN NN O
n NN NN O
= NN NN O
35 NN NN O
) NN NN O
and NN NN O
elective NN NN O
LT NN NN O
for NN NN O
chronic NN NN B-Disease
liver NN NN I-Disease
disease NN NN I-Disease
( NN NN O
CLD NN NN B-Disease
, NN NN O
n NN NN O
= NN NN O
34 NN NN O
) NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
Acetaminophen NN NN O
- NN NN O
induced NN NN O
ALF NN NN B-Disease
patients NN NN O
undergoing NN NN O
LT NN NN O
had NN NN O
a NN NN O
greater NN NN O
severity NN NN O
of NN NN O
pre NN NN O
- NN NN O
LT NN NN O
illness NN NN O
reflected NN NN O
by NN NN O
higher NN NN O
Acute NN NN O
Physiology NN NN O
and NN NN O
Chronic NN NN O
Health NN NN O
Evaluation NN NN O
II NN NN O
scores NN NN O
and NN NN O
requirement NN NN O
for NN NN O
organ NN NN O
support NN NN O
compared NN NN O
with NN NN O
the NN NN O
other NN NN O
two NN NN O
groups NN NN O
. NN NN O
   
Twenty NN NN O
( NN NN O
56 NN NN O
% NN NN O
) NN NN O
acetaminophen NN NN O
- NN NN O
induced NN NN O
ALF NN NN B-Disease
patients NN NN O
had NN NN O
a NN NN O
formal NN NN O
psychiatric NN NN O
diagnosis NN NN O
before NN NN O
LT NN NN O
( NN NN O
non NN NN O
- NN NN O
acetaminophen NN NN O
- NN NN O
induced NN NN O
ALF NN NN B-Disease
= NN NN O
0 NN NN O
/ NN NN O
35 NN NN O
, NN NN O
CLD NN NN B-Disease
= NN NN O
2 NN NN O
/ NN NN O
34 NN NN O
; NN NN O
P NN NN O
< NN NN O
0 NN NN O
. NN NN O
01 NN NN O
for NN NN O
all NN NN O
) NN NN O
and NN NN O
nine NN NN O
( NN NN O
25 NN NN O
% NN NN O
) NN NN O
had NN NN O
a NN NN O
previous NN NN O
suicide NN NN O
attempt NN NN O
. NN NN O
   
During NN NN O
follow NN NN O
- NN NN O
up NN NN O
( NN NN O
median NN NN O
5 NN NN O
years NN NN O
) NN NN O
, NN NN O
there NN NN O
were NN NN O
no NN NN O
significant NN NN O
differences NN NN O
in NN NN O
rejection NN NN O
( NN NN O
acute NN NN O
and NN NN O
chronic NN NN O
) NN NN O
, NN NN O
graft NN NN O
failure NN NN O
or NN NN O
survival NN NN O
between NN NN O
the NN NN O
groups NN NN O
( NN NN O
acetaminophen NN NN O
- NN NN O
induced NN NN O
ALF NN NN B-Disease
1 NN NN O
year NN NN O
87 NN NN O
% NN NN O
, NN NN O
5 NN NN O
years NN NN O
75 NN NN O
% NN NN O
; NN NN O
non NN NN O
- NN NN O
acetaminophen NN NN O
- NN NN O
induced NN NN O
ALF NN NN B-Disease
88 NN NN O
% NN NN O
, NN NN O
78 NN NN O
% NN NN O
; NN NN O
CLD NN NN B-Disease
93 NN NN O
% NN NN O
, NN NN O
82 NN NN O
% NN NN O
: NN NN O
P NN NN O
> NN NN O
0 NN NN O
. NN NN O
6 NN NN O
log NN NN O
rank NN NN O
) NN NN O
. NN NN O
   
Two NN NN O
acetaminophen NN NN O
- NN NN O
induced NN NN O
ALF NN NN B-Disease
patients NN NN O
reattempted NN NN O
suicide NN NN O
post NN NN O
- NN NN O
LT NN NN O
( NN NN O
one NN NN O
died NN NN O
8 NN NN O
years NN NN O
post NN NN O
- NN NN O
LT NN NN O
) NN NN O
. NN NN O
   
CONCLUSIONS NN NN O
: NN NN O
Despite NN NN O
a NN NN O
high NN NN O
prevalence NN NN O
of NN NN O
psychiatric NN NN O
disturbance NN NN O
, NN NN O
outcomes NN NN O
for NN NN O
patients NN NN O
transplanted NN NN O
emergently NN NN O
for NN NN O
acetaminophen NN NN O
- NN NN O
induced NN NN O
ALF NN NN B-Disease
were NN NN O
comparable NN NN O
to NN NN O
those NN NN O
transplanted NN NN O
for NN NN O
non NN NN O
- NN NN O
acetaminophen NN NN O
- NN NN O
induced NN NN O
ALF NN NN B-Disease
and NN NN O
electively NN NN O
for NN NN O
CLD NN NN B-Disease
. NN NN O
   
Multidisciplinary NN NN O
approaches NN NN O
with NN NN O
long NN NN O
- NN NN O
term NN NN O
psychiatric NN NN O
follow NN NN O
- NN NN O
up NN NN O
may NN NN O
contribute NN NN O
to NN NN O
low NN NN O
post NN NN O
- NN NN O
transplant NN NN O
suicide NN NN O
rates NN NN O
seen NN NN O
and NN NN O
low NN NN O
rates NN NN O
of NN NN O
graft NN NN O
loss NN NN O
because NN NN O
of NN NN O
non NN NN O
- NN NN O
compliance NN NN O
. NN NN O
   
Antithrombotic NN NN O
drug NN NN O
use NN NN O
, NN NN O
cerebral NN NN B-Disease
microbleeds NN NN I-Disease
, NN NN O
and NN NN O
intracerebral NN NN B-Disease
hemorrhage NN NN I-Disease
: NN NN O
a NN NN O
systematic NN NN O
review NN NN O
of NN NN O
published NN NN O
and NN NN O
unpublished NN NN O
studies NN NN O
. NN NN O
   
BACKGROUND NN NN O
AND NN NN O
PURPOSE NN NN O
: NN NN O
Cerebral NN NN B-Disease
microbleeds NN NN I-Disease
( NN NN O
MB NN NN B-Disease
) NN NN O
are NN NN O
potential NN NN O
risk NN NN O
factors NN NN O
for NN NN O
intracerebral NN NN B-Disease
hemorrhage NN NN I-Disease
( NN NN O
ICH NN NN B-Disease
) NN NN O
, NN NN O
but NN NN O
it NN NN O
is NN NN O
unclear NN NN O
if NN NN O
they NN NN O
are NN NN O
a NN NN O
contraindication NN NN O
to NN NN O
using NN NN O
antithrombotic NN NN O
drugs NN NN O
. NN NN O
   
Insights NN NN O
could NN NN O
be NN NN O
gained NN NN O
by NN NN O
pooling NN NN O
data NN NN O
on NN NN O
MB NN NN B-Disease
frequency NN NN O
stratified NN NN O
by NN NN O
antithrombotic NN NN O
use NN NN O
in NN NN O
cohorts NN NN O
with NN NN O
ICH NN NN B-Disease
and NN NN O
ischemic NN NN B-Disease
stroke NN NN I-Disease
( NN NN O
IS NN NN B-Disease
) NN NN O
/ NN NN O
transient NN NN B-Disease
ischemic NN NN I-Disease
attack NN NN I-Disease
( NN NN O
TIA NN NN B-Disease
) NN NN O
. NN NN O
   
METHODS NN NN O
: NN NN O
We NN NN O
performed NN NN O
a NN NN O
systematic NN NN O
review NN NN O
of NN NN O
published NN NN O
and NN NN O
unpublished NN NN O
data NN NN O
from NN NN O
cohorts NN NN O
with NN NN O
stroke NN NN B-Disease
or NN NN O
TIA NN NN B-Disease
to NN NN O
compare NN NN O
the NN NN O
presence NN NN O
of NN NN O
MB NN NN B-Disease
in NN NN O
: NN NN O
( NN NN O
1 NN NN O
) NN NN O
antithrombotic NN NN O
users NN NN O
vs NN NN O
nonantithrombotic NN NN O
users NN NN O
with NN NN O
ICH NN NN B-Disease
; NN NN O
( NN NN O
2 NN NN O
) NN NN O
antithrombotic NN NN O
users NN NN O
vs NN NN O
nonusers NN NN O
with NN NN O
IS NN NN B-Disease
/ NN NN O
TIA NN NN B-Disease
; NN NN O
and NN NN O
( NN NN O
3 NN NN O
) NN NN O
ICH NN NN B-Disease
vs NN NN O
ischemic NN NN B-Disease
events NN NN O
stratified NN NN O
by NN NN O
antithrombotic NN NN O
use NN NN O
. NN NN O
   
We NN NN O
also NN NN O
analyzed NN NN O
published NN NN O
and NN NN O
unpublished NN NN O
follow NN NN O
- NN NN O
up NN NN O
data NN NN O
to NN NN O
determine NN NN O
the NN NN O
risk NN NN O
of NN NN O
ICH NN NN B-Disease
in NN NN O
antithrombotic NN NN O
users NN NN O
with NN NN O
MB NN NN B-Disease
. NN NN O
   
RESULTS NN NN O
: NN NN O
In NN NN O
a NN NN O
pooled NN NN O
analysis NN NN O
of NN NN O
1460 NN NN O
ICH NN NN B-Disease
and NN NN O
3817 NN NN O
IS NN NN B-Disease
/ NN NN O
TIA NN NN B-Disease
, NN NN O
MB NN NN B-Disease
were NN NN O
more NN NN O
frequent NN NN O
in NN NN O
ICH NN NN B-Disease
vs NN NN O
IS NN NN B-Disease
/ NN NN O
TIA NN NN B-Disease
in NN NN O
all NN NN O
treatment NN NN O
groups NN NN O
, NN NN O
but NN NN O
the NN NN O
excess NN NN O
increased NN NN O
from NN NN O
2 NN NN O
. NN NN O
8 NN NN O
( NN NN O
odds NN NN O
ratio NN NN O
; NN NN O
range NN NN O
, NN NN O
2 NN NN O
. NN NN O
3 NN NN O
- NN NN O
3 NN NN O
. NN NN O
5 NN NN O
) NN NN O
in NN NN O
nonantithrombotic NN NN O
users NN NN O
to NN NN O
5 NN NN O
. NN NN O
7 NN NN O
( NN NN O
range NN NN O
, NN NN O
3 NN NN O
. NN NN O
4 NN NN O
- NN NN O
9 NN NN O
. NN NN O
7 NN NN O
) NN NN O
in NN NN O
antiplatelet NN NN O
users NN NN O
and NN NN O
8 NN NN O
. NN NN O
0 NN NN O
( NN NN O
range NN NN O
, NN NN O
3 NN NN O
. NN NN O
5 NN NN O
- NN NN O
17 NN NN O
. NN NN O
8 NN NN O
) NN NN O
in NN NN O
warfarin NN NN O
users NN NN O
( NN NN O
P NN NN O
difference NN NN O
= NN NN O
0 NN NN O
. NN NN O
01 NN NN O
) NN NN O
. NN NN O
   
There NN NN O
was NN NN O
also NN NN O
an NN NN O
excess NN NN O
of NN NN O
MB NN NN B-Disease
in NN NN O
warfarin NN NN O
users NN NN O
vs NN NN O
nonusers NN NN O
with NN NN O
ICH NN NN B-Disease
( NN NN O
OR NN NN O
, NN NN O
2 NN NN O
. NN NN O
7 NN NN O
; NN NN O
95 NN NN O
% NN NN O
CI NN NN O
, NN NN O
1 NN NN O
. NN NN O
6 NN NN O
- NN NN O
4 NN NN O
. NN NN O
4 NN NN O
; NN NN O
P NN NN O
< NN NN O
0 NN NN O
. NN NN O
001 NN NN O
) NN NN O
but NN NN O
none NN NN O
in NN NN O
warfarin NN NN O
users NN NN O
with NN NN O
IS NN NN B-Disease
/ NN NN O
TIA NN NN B-Disease
( NN NN O
OR NN NN O
, NN NN O
1 NN NN O
. NN NN O
3 NN NN O
; NN NN O
95 NN NN O
% NN NN O
CI NN NN O
, NN NN O
0 NN NN O
. NN NN O
9 NN NN O
- NN NN O
1 NN NN O
. NN NN O
7 NN NN O
; NN NN O
P NN NN O
= NN NN O
0 NN NN O
. NN NN O
33 NN NN O
; NN NN O
P NN NN O
difference NN NN O
= NN NN O
0 NN NN O
. NN NN O
01 NN NN O
) NN NN O
. NN NN O
   
There NN NN O
was NN NN O
a NN NN O
smaller NN NN O
excess NN NN O
of NN NN O
MB NN NN B-Disease
in NN NN O
antiplatelet NN NN O
users NN NN O
vs NN NN O
nonusers NN NN O
with NN NN O
ICH NN NN B-Disease
( NN NN O
OR NN NN O
, NN NN O
1 NN NN O
. NN NN O
7 NN NN O
; NN NN O
95 NN NN O
% NN NN O
CI NN NN O
, NN NN O
1 NN NN O
. NN NN O
3 NN NN O
- NN NN O
2 NN NN O
. NN NN O
3 NN NN O
; NN NN O
P NN NN O
< NN NN O
0 NN NN O
. NN NN O
001 NN NN O
) NN NN O
, NN NN O
but NN NN O
findings NN NN O
were NN NN O
similar NN NN O
for NN NN O
antiplatelet NN NN O
users NN NN O
with NN NN O
IS NN NN B-Disease
/ NN NN O
TIA NN NN B-Disease
( NN NN O
OR NN NN O
, NN NN O
1 NN NN O
. NN NN O
4 NN NN O
; NN NN O
95 NN NN O
% NN NN O
CI NN NN O
, NN NN O
1 NN NN O
. NN NN O
2 NN NN O
- NN NN O
1 NN NN O
. NN NN O
7 NN NN O
; NN NN O
P NN NN O
< NN NN O
0 NN NN O
. NN NN O
001 NN NN O
; NN NN O
P NN NN O
difference NN NN O
= NN NN O
0 NN NN O
. NN NN O
25 NN NN O
) NN NN O
. NN NN O
   
In NN NN O
pooled NN NN O
follow NN NN O
- NN NN O
up NN NN O
data NN NN O
for NN NN O
768 NN NN O
antithrombotic NN NN O
users NN NN O
, NN NN O
presence NN NN O
of NN NN O
MB NN NN B-Disease
at NN NN O
baseline NN NN O
was NN NN O
associated NN NN O
with NN NN O
a NN NN O
substantially NN NN O
increased NN NN O
risk NN NN O
of NN NN O
subsequent NN NN O
ICH NN NN B-Disease
( NN NN O
OR NN NN O
, NN NN O
12 NN NN O
. NN NN O
1 NN NN O
; NN NN O
95 NN NN O
% NN NN O
CI NN NN O
, NN NN O
3 NN NN O
. NN NN O
4 NN NN O
- NN NN O
42 NN NN O
. NN NN O
5 NN NN O
; NN NN O
P NN NN O
< NN NN O
0 NN NN O
. NN NN O
001 NN NN O
) NN NN O
. NN NN O
   
CONCLUSIONS NN NN O
: NN NN O
The NN NN O
excess NN NN O
of NN NN O
MB NN NN B-Disease
in NN NN O
warfarin NN NN O
users NN NN O
with NN NN O
ICH NN NN B-Disease
compared NN NN O
to NN NN O
other NN NN O
groups NN NN O
suggests NN NN O
that NN NN O
MB NN NN B-Disease
increase NN NN O
the NN NN O
risk NN NN O
of NN NN O
warfarin NN NN O
- NN NN O
associated NN NN O
ICH NN NN B-Disease
. NN NN O
   
Limited NN NN O
prospective NN NN O
data NN NN O
corroborate NN NN O
these NN NN O
findings NN NN O
, NN NN O
but NN NN O
larger NN NN O
prospective NN NN O
studies NN NN O
are NN NN O
urgently NN NN O
required NN NN O
. NN NN O
   
Studies NN NN O
of NN NN O
synergy NN NN O
between NN NN O
morphine NN NN O
and NN NN O
a NN NN O
novel NN NN O
sodium NN NN O
channel NN NN O
blocker NN NN O
, NN NN O
CNSB002 NN NN O
, NN NN O
in NN NN O
rat NN NN O
models NN NN O
of NN NN O
inflammatory NN NN O
and NN NN O
neuropathic NN NN B-Disease
pain NN NN I-Disease
. NN NN O
   
OBJECTIVE NN NN O
: NN NN O
This NN NN O
study NN NN O
determined NN NN O
the NN NN O
antihyperalgesic NN NN O
effect NN NN O
of NN NN O
CNSB002 NN NN O
, NN NN O
a NN NN O
sodium NN NN O
channel NN NN O
blocker NN NN O
with NN NN O
antioxidant NN NN O
properties NN NN O
given NN NN O
alone NN NN O
and NN NN O
in NN NN O
combinations NN NN O
with NN NN O
morphine NN NN O
in NN NN O
rat NN NN O
models NN NN O
of NN NN O
inflammatory NN NN O
and NN NN O
neuropathic NN NN B-Disease
pain NN NN I-Disease
. NN NN O
   
DESIGN NN NN O
: NN NN O
Dose NN NN O
response NN NN O
curves NN NN O
for NN NN O
nonsedating NN NN O
doses NN NN O
of NN NN O
morphine NN NN O
and NN NN O
CNSB002 NN NN O
given NN NN O
intraperitoneally NN NN O
alone NN NN O
and NN NN O
together NN NN O
in NN NN O
combinations NN NN O
were NN NN O
constructed NN NN O
for NN NN O
antihyperalgesic NN NN O
effect NN NN O
using NN NN O
paw NN NN O
withdrawal NN NN O
from NN NN O
noxious NN NN O
heat NN NN O
in NN NN O
two NN NN O
rat NN NN O
pain NN NN B-Disease
models NN NN O
: NN NN O
carrageenan NN NN O
- NN NN O
induced NN NN O
paw NN NN O
inflammation NN NN B-Disease
and NN NN O
streptozotocin NN NN O
( NN NN O
STZ NN NN O
) NN NN O
- NN NN O
induced NN NN O
diabetic NN NN B-Disease
neuropathy NN NN I-Disease
. NN NN O
   
RESULTS NN NN O
: NN NN O
The NN NN O
maximum NN NN O
nonsedating NN NN O
doses NN NN O
were NN NN O
: NN NN O
morphine NN NN O
, NN NN O
3 NN NN O
. NN NN O
2 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
; NN NN O
CNSB002 NN NN O
10 NN NN O
. NN NN O
0 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
; NN NN O
5 NN NN O
. NN NN O
0 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
CNSB002 NN NN O
with NN NN O
morphine NN NN O
3 NN NN O
. NN NN O
2 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
in NN NN O
combination NN NN O
. NN NN O
   
The NN NN O
doses NN NN O
calculated NN NN O
to NN NN O
cause NN NN O
50 NN NN O
% NN NN O
reversal NN NN O
of NN NN O
hyperalgesia NN NN B-Disease
( NN NN O
ED50 NN NN O
) NN NN O
were NN NN O
7 NN NN O
. NN NN O
54 NN NN O
( NN NN O
1 NN NN O
. NN NN O
81 NN NN O
) NN NN O
and NN NN O
4 NN NN O
. NN NN O
83 NN NN O
( NN NN O
1 NN NN O
. NN NN O
54 NN NN O
) NN NN O
in NN NN O
the NN NN O
carrageenan NN NN O
model NN NN O
and NN NN O
44 NN NN O
. NN NN O
18 NN NN O
( NN NN O
1 NN NN O
. NN NN O
37 NN NN O
) NN NN O
and NN NN O
9 NN NN O
. NN NN O
14 NN NN O
( NN NN O
1 NN NN O
. NN NN O
24 NN NN O
) NN NN O
in NN NN O
the NN NN O
STZ NN NN O
- NN NN O
induced NN NN O
neuropathy NN NN B-Disease
model NN NN O
for NN NN O
CNSB002 NN NN O
and NN NN O
morphine NN NN O
, NN NN O
respectively NN NN O
( NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
; NN NN O
mean NN NN O
, NN NN O
SEM NN NN O
) NN NN O
. NN NN O
   
These NN NN O
values NN NN O
were NN NN O
greater NN NN O
than NN NN O
the NN NN O
maximum NN NN O
nonsedating NN NN O
doses NN NN O
. NN NN O
   
The NN NN O
ED50 NN NN O
values NN NN O
for NN NN O
morphine NN NN O
when NN NN O
given NN NN O
in NN NN O
combination NN NN O
with NN NN O
CNSB002 NN NN O
( NN NN O
5 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
) NN NN O
were NN NN O
less NN NN O
than NN NN O
the NN NN O
maximum NN NN O
nonsedating NN NN O
dose NN NN O
: NN NN O
0 NN NN O
. NN NN O
56 NN NN O
( NN NN O
1 NN NN O
. NN NN O
55 NN NN O
) NN NN O
in NN NN O
the NN NN O
carrageenan NN NN O
model NN NN O
and NN NN O
1 NN NN O
. NN NN O
37 NN NN O
( NN NN O
1 NN NN O
. NN NN O
23 NN NN O
) NN NN O
in NN NN O
the NN NN O
neuropathy NN NN B-Disease
model NN NN O
( NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
; NN NN O
mean NN NN O
, NN NN O
SEM NN NN O
) NN NN O
. NN NN O
   
The NN NN O
antinociception NN NN O
after NN NN O
morphine NN NN O
( NN NN O
3 NN NN O
. NN NN O
2 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
) NN NN O
was NN NN O
increased NN NN O
by NN NN O
co NN NN O
- NN NN O
administration NN NN O
with NN NN O
CNSB002 NN NN O
from NN NN O
28 NN NN O
. NN NN O
0 NN NN O
and NN NN O
31 NN NN O
. NN NN O
7 NN NN O
% NN NN O
to NN NN O
114 NN NN O
. NN NN O
6 NN NN O
and NN NN O
56 NN NN O
. NN NN O
9 NN NN O
% NN NN O
reversal NN NN O
of NN NN O
hyperalgesia NN NN B-Disease
in NN NN O
the NN NN O
inflammatory NN NN O
and NN NN O
neuropathic NN NN B-Disease
models NN NN O
, NN NN O
respectively NN NN O
( NN NN O
P NN NN O
< NN NN O
0 NN NN O
. NN NN O
01 NN NN O
; NN NN O
one NN NN O
- NN NN O
way NN NN O
analysis NN NN O
of NN NN O
variance NN NN O
- NN NN O
significantly NN NN O
greater NN NN O
than NN NN O
either NN NN O
drug NN NN O
given NN NN O
alone NN NN O
) NN NN O
. NN NN O
   
CONCLUSIONS NN NN O
: NN NN O
The NN NN O
maximum NN NN O
antihyperalgesic NN NN O
effect NN NN O
achievable NN NN O
with NN NN O
nonsedating NN NN O
doses NN NN O
of NN NN O
morphine NN NN O
may NN NN O
be NN NN O
increased NN NN O
significantly NN NN O
when NN NN O
the NN NN O
drug NN NN O
is NN NN O
used NN NN O
in NN NN O
combination NN NN O
with NN NN O
CNSB002 NN NN O
. NN NN O
   
Heparin NN NN O
- NN NN O
induced NN NN O
thrombocytopenia NN NN B-Disease
: NN NN O
a NN NN O
practical NN NN O
review NN NN O
. NN NN O
   
Heparin NN NN O
- NN NN O
induced NN NN O
thrombocytopenia NN NN B-Disease
( NN NN O
HIT NN NN B-Disease
) NN NN O
remains NN NN O
under NN NN O
- NN NN O
recognized NN NN O
despite NN NN O
its NN NN O
potentially NN NN O
devastating NN NN O
outcomes NN NN O
. NN NN O
   
It NN NN O
begins NN NN O
when NN NN O
heparin NN NN O
exposure NN NN O
stimulates NN NN O
the NN NN O
formation NN NN O
of NN NN O
heparin NN NN O
- NN NN O
platelet NN NN O
factor NN NN O
4 NN NN O
antibodies NN NN O
, NN NN O
which NN NN O
in NN NN O
turn NN NN O
triggers NN NN O
the NN NN O
release NN NN O
of NN NN O
procoagulant NN NN O
platelet NN NN O
particles NN NN O
. NN NN O
   
Thrombosis NN NN B-Disease
and NN NN O
thrombocytopenia NN NN B-Disease
that NN NN O
follow NN NN O
comprise NN NN O
the NN NN O
2 NN NN O
hallmark NN NN O
traits NN NN O
of NN NN O
HIT NN NN B-Disease
, NN NN O
with NN NN O
the NN NN O
former NN NN O
largely NN NN O
responsible NN NN O
for NN NN O
significant NN NN O
vascular NN NN O
complications NN NN O
. NN NN O
   
The NN NN O
prevalence NN NN O
of NN NN O
HIT NN NN B-Disease
varies NN NN O
among NN NN O
several NN NN O
subgroups NN NN O
, NN NN O
with NN NN O
greater NN NN O
incidence NN NN O
in NN NN O
surgical NN NN O
as NN NN O
compared NN NN O
with NN NN O
medical NN NN O
populations NN NN O
. NN NN O
   
HIT NN NN B-Disease
must NN NN O
be NN NN O
acknowledged NN NN O
for NN NN O
its NN NN O
intense NN NN O
predilection NN NN O
for NN NN O
thrombosis NN NN B-Disease
and NN NN O
suspected NN NN O
whenever NN NN O
thrombosis NN NN B-Disease
occurs NN NN O
after NN NN O
heparin NN NN O
exposure NN NN O
. NN NN O
   
Early NN NN O
recognition NN NN O
that NN NN O
incorporates NN NN O
the NN NN O
clinical NN NN O
and NN NN O
serologic NN NN O
clues NN NN O
is NN NN O
paramount NN NN O
to NN NN O
timely NN NN O
institution NN NN O
of NN NN O
treatment NN NN O
, NN NN O
as NN NN O
its NN NN O
delay NN NN O
may NN NN O
result NN NN O
in NN NN O
catastrophic NN NN O
outcomes NN NN O
. NN NN O
   
The NN NN O
treatment NN NN O
of NN NN O
HIT NN NN B-Disease
mandates NN NN O
an NN NN O
immediate NN NN O
cessation NN NN O
of NN NN O
all NN NN O
heparin NN NN O
exposure NN NN O
and NN NN O
the NN NN O
institution NN NN O
of NN NN O
an NN NN O
antithrombotic NN NN O
therapy NN NN O
, NN NN O
most NN NN O
commonly NN NN O
using NN NN O
a NN NN O
direct NN NN O
thrombin NN NN O
inhibitor NN NN O
. NN NN O
   
Current NN NN O
"""""""" NN NN O
diagnostic NN NN O
"""""""" NN NN O
tests NN NN O
, NN NN O
which NN NN O
primarily NN NN O
include NN NN O
functional NN NN O
and NN NN O
antigenic NN NN O
assays NN NN O
, NN NN O
have NN NN O
more NN NN O
of NN NN O
a NN NN O
confirmatory NN NN O
than NN NN O
diagnostic NN NN O
role NN NN O
in NN NN O
the NN NN O
management NN NN O
of NN NN O
HIT NN NN B-Disease
. NN NN O
   
Special NN NN O
attention NN NN O
must NN NN O
be NN NN O
paid NN NN O
to NN NN O
cardiac NN NN O
patients NN NN O
who NN NN O
are NN NN O
often NN NN O
exposed NN NN O
to NN NN O
heparin NN NN O
multiple NN NN O
times NN NN O
during NN NN O
their NN NN O
course NN NN O
of NN NN O
treatment NN NN O
. NN NN O
   
Direct NN NN O
thrombin NN NN O
inhibitors NN NN O
are NN NN O
appropriate NN NN O
, NN NN O
evidence NN NN O
- NN NN O
based NN NN O
alternatives NN NN O
to NN NN O
heparin NN NN O
in NN NN O
patients NN NN O
with NN NN O
a NN NN O
history NN NN O
of NN NN O
HIT NN NN B-Disease
, NN NN O
who NN NN O
need NN NN O
to NN NN O
undergo NN NN O
percutaneous NN NN O
coronary NN NN O
intervention NN NN O
. NN NN O
   
As NN NN O
heparin NN NN O
remains NN NN O
one NN NN O
of NN NN O
the NN NN O
most NN NN O
frequently NN NN O
used NN NN O
medications NN NN O
today NN NN O
with NN NN O
potential NN NN O
for NN NN O
HIT NN NN B-Disease
with NN NN O
every NN NN O
heparin NN NN O
exposure NN NN O
, NN NN O
a NN NN O
close NN NN O
vigilance NN NN O
of NN NN O
platelet NN NN O
counts NN NN O
must NN NN O
be NN NN O
practiced NN NN O
whenever NN NN O
heparin NN NN O
is NN NN O
initiated NN NN O
. NN NN O
   
Abductor NN NN O
paralysis NN NN B-Disease
after NN NN O
botox NN NN O
injection NN NN O
for NN NN O
adductor NN NN B-Disease
spasmodic NN NN I-Disease
dysphonia NN NN I-Disease
. NN NN O
   
OBJECTIVES NN NN O
/ NN NN O
HYPOTHESIS NN NN O
: NN NN O
Botulinum NN NN O
toxin NN NN O
( NN NN O
Botox NN NN O
) NN NN O
injections NN NN O
into NN NN O
the NN NN O
thyroarytenoid NN NN O
muscles NN NN O
are NN NN O
the NN NN O
current NN NN O
standard NN NN O
of NN NN O
care NN NN O
for NN NN O
adductor NN NN B-Disease
spasmodic NN NN I-Disease
dysphonia NN NN I-Disease
( NN NN O
ADSD NN NN B-Disease
) NN NN O
. NN NN O
   
Reported NN NN O
adverse NN NN O
effects NN NN O
include NN NN O
a NN NN O
period NN NN O
of NN NN O
breathiness NN NN O
, NN NN O
throat NN NN B-Disease
pain NN NN I-Disease
, NN NN O
and NN NN O
difficulty NN NN O
with NN NN O
swallowing NN NN O
liquids NN NN O
. NN NN O
   
Here NN NN O
we NN NN O
report NN NN O
multiple NN NN O
cases NN NN O
of NN NN O
bilateral NN NN O
abductor NN NN O
paralysis NN NN B-Disease
following NN NN O
Botox NN NN O
injections NN NN O
for NN NN O
ADSD NN NN B-Disease
, NN NN O
a NN NN O
complication NN NN O
previously NN NN O
unreported NN NN O
. NN NN O
   
STUDY NN NN O
DESIGN NN NN O
: NN NN O
Retrospective NN NN O
case NN NN O
series NN NN O
. NN NN O
   
METHODS NN NN O
: NN NN O
Patients NN NN O
that NN NN O
received NN NN O
Botox NN NN O
injections NN NN O
for NN NN O
spasmodic NN NN B-Disease
dysphonia NN NN I-Disease
between NN NN O
January NN NN O
2000 NN NN O
and NN NN O
October NN NN O
2009 NN NN O
were NN NN O
evaluated NN NN O
. NN NN O
   
Patients NN NN O
with NN NN O
ADSD NN NN B-Disease
were NN NN O
identified NN NN O
. NN NN O
   
The NN NN O
number NN NN O
of NN NN O
treatments NN NN O
received NN NN O
and NN NN O
adverse NN NN O
effects NN NN O
were NN NN O
noted NN NN O
. NN NN O
   
For NN NN O
patients NN NN O
with NN NN O
bilateral NN NN O
abductor NN NN O
paralysis NN NN B-Disease
, NN NN O
age NN NN O
, NN NN O
sex NN NN O
, NN NN O
paralytic NN NN O
Botox NN NN O
dose NN NN O
, NN NN O
prior NN NN O
Botox NN NN O
dose NN NN O
, NN NN O
and NN NN O
course NN NN O
following NN NN O
paralysis NN NN B-Disease
were NN NN O
noted NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
From NN NN O
a NN NN O
database NN NN O
of NN NN O
452 NN NN O
patients NN NN O
receiving NN NN O
Botox NN NN O
, NN NN O
352 NN NN O
patients NN NN O
had NN NN O
been NN NN O
diagnosed NN NN O
with NN NN O
ADSD NN NN B-Disease
. NN NN O
   
Of NN NN O
these NN NN O
352 NN NN O
patients NN NN O
, NN NN O
eight NN NN O
patients NN NN O
suffered NN NN O
bilateral NN NN O
abductor NN NN O
paralysis NN NN B-Disease
, NN NN O
and NN NN O
two NN NN O
suffered NN NN O
this NN NN O
complication NN NN O
twice NN NN O
. NN NN O
   
All NN NN O
affected NN NN O
patients NN NN O
were NN NN O
females NN NN O
over NN NN O
the NN NN O
age NN NN O
of NN NN O
50 NN NN O
years NN NN O
. NN NN O
   
Most NN NN O
patients NN NN O
had NN NN O
received NN NN O
treatments NN NN O
prior NN NN O
to NN NN O
abductor NN NN O
paralysis NN NN B-Disease
and NN NN O
continued NN NN O
receiving NN NN O
after NN NN O
paralysis NN NN B-Disease
. NN NN O
   
Seven NN NN O
patients NN NN O
recovered NN NN O
after NN NN O
a NN NN O
brief NN NN O
period NN NN O
of NN NN O
activity NN NN O
restrictions NN NN O
, NN NN O
and NN NN O
one NN NN O
underwent NN NN O
a NN NN O
tracheotomy NN NN O
. NN NN O
   
The NN NN O
incidence NN NN O
of NN NN O
abductor NN NN O
paralysis NN NN B-Disease
after NN NN O
Botox NN NN O
injection NN NN O
for NN NN O
ADSD NN NN B-Disease
was NN NN O
0 NN NN O
. NN NN O
34 NN NN O
% NN NN O
. NN NN O
   
CONCLUSIONS NN NN O
: NN NN O
Bilateral NN NN O
abductor NN NN O
paralysis NN NN B-Disease
is NN NN O
a NN NN O
rare NN NN O
complication NN NN O
of NN NN O
Botox NN NN O
injections NN NN O
for NN NN O
ADSD NN NN B-Disease
, NN NN O
causing NN NN O
difficulty NN NN O
with NN NN O
breathing NN NN O
upon NN NN O
exertion NN NN O
. NN NN O
   
The NN NN O
likely NN NN O
mechanism NN NN O
of NN NN O
paralysis NN NN B-Disease
is NN NN O
diffusion NN NN O
of NN NN O
Botox NN NN O
around NN NN O
the NN NN O
muscular NN NN O
process NN NN O
of NN NN O
the NN NN O
arytenoid NN NN O
to NN NN O
the NN NN O
posterior NN NN O
cricoarytenoid NN NN O
muscles NN NN O
. NN NN O
   
The NN NN O
paralysis NN NN B-Disease
is NN NN O
temporary NN NN O
, NN NN O
and NN NN O
watchful NN NN O
waiting NN NN O
with NN NN O
restriction NN NN O
of NN NN O
activity NN NN O
is NN NN O
the NN NN O
recommended NN NN O
management NN NN O
. NN NN O
   
Mitochondrial NN NN B-Disease
impairment NN NN I-Disease
contributes NN NN O
to NN NN O
cocaine NN NN O
- NN NN O
induced NN NN O
cardiac NN NN B-Disease
dysfunction NN NN I-Disease
: NN NN O
Prevention NN NN O
by NN NN O
the NN NN O
targeted NN NN O
antioxidant NN NN O
MitoQ NN NN O
. NN NN O
   
The NN NN O
goal NN NN O
of NN NN O
this NN NN O
study NN NN O
was NN NN O
to NN NN O
assess NN NN O
mitochondrial NN NN O
function NN NN O
and NN NN O
ROS NN NN O
production NN NN O
in NN NN O
an NN NN O
experimental NN NN O
model NN NN O
of NN NN O
cocaine NN NN O
- NN NN O
induced NN NN O
cardiac NN NN B-Disease
dysfunction NN NN I-Disease
. NN NN O
   
We NN NN O
hypothesized NN NN O
that NN NN O
cocaine NN NN B-Disease
abuse NN NN I-Disease
may NN NN O
lead NN NN O
to NN NN O
altered NN NN O
mitochondrial NN NN O
function NN NN O
that NN NN O
in NN NN O
turn NN NN O
may NN NN O
cause NN NN O
left NN NN B-Disease
ventricular NN NN I-Disease
dysfunction NN NN I-Disease
. NN NN O
   
Seven NN NN O
days NN NN O
of NN NN O
cocaine NN NN O
administration NN NN O
to NN NN O
rats NN NN O
led NN NN O
to NN NN O
an NN NN O
increased NN NN O
oxygen NN NN O
consumption NN NN O
detected NN NN O
in NN NN O
cardiac NN NN O
fibers NN NN O
, NN NN O
specifically NN NN O
through NN NN O
complex NN NN O
I NN NN O
and NN NN O
complex NN NN O
III NN NN O
. NN NN O
   
ROS NN NN O
levels NN NN O
were NN NN O
increased NN NN O
, NN NN O
specifically NN NN O
in NN NN O
interfibrillar NN NN O
mitochondria NN NN O
. NN NN O
   
In NN NN O
parallel NN NN O
there NN NN O
was NN NN O
a NN NN O
decrease NN NN O
in NN NN O
ATP NN NN O
synthesis NN NN O
, NN NN O
whereas NN NN O
no NN NN O
difference NN NN O
was NN NN O
observed NN NN O
in NN NN O
subsarcolemmal NN NN O
mitochondria NN NN O
. NN NN O
   
This NN NN O
uncoupling NN NN O
effect NN NN O
on NN NN O
oxidative NN NN O
phosphorylation NN NN O
was NN NN O
not NN NN O
detectable NN NN O
after NN NN O
short NN NN O
- NN NN O
term NN NN O
exposure NN NN O
to NN NN O
cocaine NN NN O
, NN NN O
suggesting NN NN O
that NN NN O
these NN NN O
mitochondrial NN NN B-Disease
abnormalities NN NN I-Disease
were NN NN O
a NN NN O
late NN NN O
rather NN NN O
than NN NN O
a NN NN O
primary NN NN O
event NN NN O
in NN NN O
the NN NN O
pathological NN NN O
response NN NN O
to NN NN O
cocaine NN NN O
. NN NN O
   
MitoQ NN NN O
, NN NN O
a NN NN O
mitochondrial NN NN O
- NN NN O
targeted NN NN O
antioxidant NN NN O
, NN NN O
was NN NN O
shown NN NN O
to NN NN O
completely NN NN O
prevent NN NN O
these NN NN O
mitochondrial NN NN B-Disease
abnormalities NN NN I-Disease
as NN NN O
well NN NN O
as NN NN O
cardiac NN NN B-Disease
dysfunction NN NN I-Disease
characterized NN NN O
here NN NN O
by NN NN O
a NN NN O
diastolic NN NN B-Disease
dysfunction NN NN I-Disease
studied NN NN O
with NN NN O
a NN NN O
conductance NN NN O
catheter NN NN O
to NN NN O
obtain NN NN O
pressure NN NN O
- NN NN O
volume NN NN O
data NN NN O
. NN NN O
   
Taken NN NN O
together NN NN O
, NN NN O
these NN NN O
results NN NN O
extend NN NN O
previous NN NN O
studies NN NN O
and NN NN O
demonstrate NN NN O
that NN NN O
cocaine NN NN O
- NN NN O
induced NN NN O
cardiac NN NN B-Disease
dysfunction NN NN I-Disease
may NN NN O
be NN NN O
due NN NN O
to NN NN O
a NN NN O
mitochondrial NN NN B-Disease
defect NN NN I-Disease
. NN NN O
   
Trimethoprim NN NN O
- NN NN O
induced NN NN O
immune NN NN O
hemolytic NN NN B-Disease
anemia NN NN I-Disease
in NN NN O
a NN NN O
pediatric NN NN O
oncology NN NN O
patient NN NN O
presenting NN NN O
as NN NN O
an NN NN O
acute NN NN O
hemolytic NN NN O
transfusion NN NN O
reaction NN NN O
. NN NN O
   
A NN NN O
10 NN NN O
- NN NN O
year NN NN O
- NN NN O
old NN NN O
male NN NN O
with NN NN O
acute NN NN B-Disease
leukemia NN NN I-Disease
presented NN NN O
with NN NN O
post NN NN O
- NN NN O
chemotherapy NN NN O
anemia NN NN B-Disease
. NN NN O
   
During NN NN O
red NN NN O
cell NN NN O
transfusion NN NN O
, NN NN O
he NN NN O
developed NN NN O
hemoglobinuria NN NN B-Disease
. NN NN O
   
Transfusion NN NN O
reaction NN NN O
workup NN NN O
was NN NN O
negative NN NN O
. NN NN O
   
Drug NN NN O
- NN NN O
induced NN NN O
immune NN NN O
hemolytic NN NN B-Disease
anemia NN NN I-Disease
was NN NN O
suspected NN NN O
because NN NN O
of NN NN O
positive NN NN O
direct NN NN O
antiglobulin NN NN O
test NN NN O
, NN NN O
negative NN NN O
eluate NN NN O
, NN NN O
and NN NN O
microspherocytes NN NN O
on NN NN O
smear NN NN O
pre NN NN O
- NN NN O
and NN NN O
post NN NN O
- NN NN O
transfusion NN NN O
. NN NN O
   
Drug NN NN O
studies NN NN O
using NN NN O
the NN NN O
indirect NN NN O
antiglobulin NN NN O
test NN NN O
were NN NN O
strongly NN NN O
positive NN NN O
with NN NN O
trimethoprim NN NN O
and NN NN O
trimethoprim NN NN O
- NN NN O
sulfamethoxazole NN NN O
but NN NN O
negative NN NN O
with NN NN O
sulfamethoxazole NN NN O
. NN NN O
   
The NN NN O
patient NN NN O
recovered NN NN O
after NN NN O
discontinuing NN NN O
the NN NN O
drug NN NN O
, NN NN O
with NN NN O
no NN NN O
recurrence NN NN O
in NN NN O
2 NN NN O
years NN NN O
. NN NN O
   
Other NN NN O
causes NN NN O
of NN NN O
anemia NN NN B-Disease
should NN NN O
be NN NN O
considered NN NN O
in NN NN O
patients NN NN O
with NN NN O
worse NN NN O
- NN NN O
than NN NN O
- NN NN O
expected NN NN O
anemia NN NN B-Disease
after NN NN O
chemotherapy NN NN O
. NN NN O
   
Furthermore NN NN O
, NN NN O
hemolysis NN NN B-Disease
during NN NN O
transfusion NN NN O
is NN NN O
not NN NN O
always NN NN O
a NN NN O
transfusion NN NN O
reaction NN NN O
. NN NN O
   
Verapamil NN NN O
stimulation NN NN O
test NN NN O
in NN NN O
hyperprolactinemia NN NN B-Disease
: NN NN O
loss NN NN O
of NN NN O
prolactin NN NN O
response NN NN O
in NN NN O
anatomic NN NN O
or NN NN O
functional NN NN O
stalk NN NN O
effect NN NN O
. NN NN O
   
AIM NN NN O
: NN NN O
Verapamil NN NN O
stimulation NN NN O
test NN NN O
was NN NN O
previously NN NN O
investigated NN NN O
as NN NN O
a NN NN O
tool NN NN O
for NN NN O
differential NN NN O
diagnosis NN NN O
of NN NN O
hyperprolactinemia NN NN B-Disease
, NN NN O
but NN NN O
with NN NN O
conflicting NN NN O
results NN NN O
. NN NN O
   
Macroprolactinemia NN NN B-Disease
was NN NN O
never NN NN O
considered NN NN O
in NN NN O
those NN NN O
previous NN NN O
studies NN NN O
. NN NN O
   
Here NN NN O
, NN NN O
we NN NN O
aimed NN NN O
to NN NN O
re NN NN O
- NN NN O
investigate NN NN O
the NN NN O
diagnostic NN NN O
value NN NN O
of NN NN O
verapamil NN NN O
in NN NN O
a NN NN O
population NN NN O
who NN NN O
were NN NN O
all NN NN O
screened NN NN O
for NN NN O
macroprolactinemia NN NN B-Disease
. NN NN O
   
Prolactin NN NN O
responses NN NN O
to NN NN O
verapamil NN NN O
in NN NN O
65 NN NN O
female NN NN O
patients NN NN O
( NN NN O
age NN NN O
: NN NN O
29 NN NN O
. NN NN O
9 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
8 NN NN O
. NN NN O
1 NN NN O
years NN NN O
) NN NN O
with NN NN O
hyperprolactinemia NN NN B-Disease
were NN NN O
tested NN NN O
in NN NN O
a NN NN O
descriptive NN NN O
, NN NN O
matched NN NN O
case NN NN O
- NN NN O
control NN NN O
study NN NN O
. NN NN O
   
METHODS NN NN O
: NN NN O
Verapamil NN NN O
80 NN NN O
mg NN NN O
, NN NN O
p NN NN O
. NN NN O
o NN NN O
. NN NN O
was NN NN O
administered NN NN O
, NN NN O
and NN NN O
then NN NN O
PRL NN NN O
levels NN NN O
were NN NN O
measured NN NN O
at NN NN O
8th NN NN O
and NN NN O
16th NN NN O
hours NN NN O
, NN NN O
by NN NN O
immunometric NN NN O
chemiluminescence NN NN O
. NN NN O
   
Verapamil NN NN O
responsiveness NN NN O
was NN NN O
determined NN NN O
by NN NN O
peak NN NN O
percent NN NN O
change NN NN O
in NN NN O
basal NN NN O
prolactin NN NN O
levels NN NN O
( NN NN O
PRL NN NN O
) NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
Verapamil NN NN O
significantly NN NN O
increased NN NN O
PRL NN NN O
levels NN NN O
in NN NN O
healthy NN NN O
controls NN NN O
( NN NN O
N NN NN O
. NN NN O
8 NN NN O
, NN NN O
PRL NN NN O
: NN NN O
183 NN NN O
% NN NN O
) NN NN O
, NN NN O
macroprolactinoma NN NN B-Disease
( NN NN O
N NN NN O
. NN NN O
8 NN NN O
, NN NN O
PRL NN NN O
: NN NN O
7 NN NN O
% NN NN O
) NN NN O
, NN NN O
microprolactinoma NN NN B-Disease
( NN NN O
N NN NN O
. NN NN O
19 NN NN O
, NN NN O
PRL NN NN O
: NN NN O
21 NN NN O
% NN NN O
) NN NN O
, NN NN O
macroprolactinemia NN NN B-Disease
( NN NN O
N NN NN O
. NN NN O
23 NN NN O
, NN NN O
PRL NN NN O
: NN NN O
126 NN NN O
% NN NN O
) NN NN O
, NN NN O
but NN NN O
not NN NN O
in NN NN O
pseudoprolactinoma NN NN B-Disease
( NN NN O
N NN NN O
. NN NN O
8 NN NN O
, NN NN O
PRL NN NN O
: NN NN O
0 NN NN O
. NN NN O
8 NN NN O
% NN NN O
) NN NN O
, NN NN O
and NN NN O
risperidone NN NN O
- NN NN O
induced NN NN O
hyperprolactinemia NN NN B-Disease
( NN NN O
N NN NN O
. NN NN O
7 NN NN O
, NN NN O
PRL NN NN O
: NN NN O
3 NN NN O
% NN NN O
) NN NN O
. NN NN O
   
ROC NN NN O
curve NN NN O
analysis NN NN O
revealed NN NN O
that NN NN O
unresponsiveness NN NN O
to NN NN O
verapamil NN NN O
defined NN NN O
as NN NN O
PRL NN NN O
< NN NN O
7 NN NN O
% NN NN O
, NN NN O
discriminated NN NN O
anatomical NN NN O
or NN NN O
functional NN NN O
stalk NN NN O
effect NN NN O
( NN NN O
sensitivity NN NN O
: NN NN O
74 NN NN O
% NN NN O
, NN NN O
specificity NN NN O
: NN NN O
73 NN NN O
% NN NN O
, NN NN O
AUC NN NN O
: NN NN O
0 NN NN O
. NN NN O
855 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
0 NN NN O
. NN NN O
04 NN NN O
, NN NN O
P NN NN O
< NN NN O
0 NN NN O
. NN NN O
001 NN NN O
, NN NN O
CI NN NN O
: NN NN O
0 NN NN O
. NN NN O
768 NN NN O
- NN NN O
0 NN NN O
. NN NN O
942 NN NN O
) NN NN O
associated NN NN O
with NN NN O
pseudoprolactinoma NN NN B-Disease
or NN NN O
risperidone NN NN O
- NN NN O
induced NN NN O
hyperprolactinemia NN NN B-Disease
, NN NN O
respectively NN NN O
. NN NN O
   
CONCLUSION NN NN O
: NN NN O
Verapamil NN NN O
responsiveness NN NN O
is NN NN O
not NN NN O
a NN NN O
reliable NN NN O
finding NN NN O
for NN NN O
the NN NN O
differential NN NN O
diagnosis NN NN O
of NN NN O
hyperprolactinemia NN NN B-Disease
. NN NN O
   
However NN NN O
, NN NN O
verapamil NN NN O
unresponsiveness NN NN O
discriminates NN NN O
stalk NN NN O
effect NN NN O
( NN NN O
i NN NN O
. NN NN O
e NN NN O
. NN NN O
, NN NN O
anatomically NN NN O
or NN NN O
functionally NN NN O
inhibited NN NN O
dopaminergic NN NN O
tonus NN NN O
) NN NN O
from NN NN O
other NN NN O
causes NN NN O
of NN NN O
hyperprolactinemia NN NN B-Disease
with NN NN O
varying NN NN O
degrees NN NN O
of NN NN O
responsiveness NN NN O
. NN NN O
   
Blockade NN NN O
of NN NN O
endothelial NN NN O
- NN NN O
mesenchymal NN NN O
transition NN NN O
by NN NN O
a NN NN O
Smad3 NN NN O
inhibitor NN NN O
delays NN NN O
the NN NN O
early NN NN O
development NN NN O
of NN NN O
streptozotocin NN NN O
- NN NN O
induced NN NN O
diabetic NN NN B-Disease
nephropathy NN NN I-Disease
. NN NN O
   
OBJECTIVE NN NN O
: NN NN O
A NN NN O
multicenter NN NN O
, NN NN O
controlled NN NN O
trial NN NN O
showed NN NN O
that NN NN O
early NN NN O
blockade NN NN O
of NN NN O
the NN NN O
renin NN NN O
- NN NN O
angiotensin NN NN O
system NN NN O
in NN NN O
patients NN NN O
with NN NN O
type NN NN B-Disease
1 NN NN I-Disease
diabetes NN NN I-Disease
and NN NN O
normoalbuminuria NN NN O
did NN NN O
not NN NN O
retard NN NN O
the NN NN O
progression NN NN O
of NN NN O
nephropathy NN NN B-Disease
, NN NN O
suggesting NN NN O
that NN NN O
other NN NN O
mechanism NN NN O
( NN NN O
s NN NN O
) NN NN O
are NN NN O
involved NN NN O
in NN NN O
the NN NN O
pathogenesis NN NN O
of NN NN O
early NN NN O
diabetic NN NN B-Disease
nephropathy NN NN I-Disease
( NN NN O
diabetic NN NN B-Disease
nephropathy NN NN I-Disease
) NN NN O
. NN NN O
   
We NN NN O
have NN NN O
previously NN NN O
demonstrated NN NN O
that NN NN O
endothelial NN NN O
- NN NN O
mesenchymal NN NN O
- NN NN O
transition NN NN O
( NN NN O
EndoMT NN NN O
) NN NN O
contributes NN NN O
to NN NN O
the NN NN O
early NN NN O
development NN NN O
of NN NN O
renal NN NN O
interstitial NN NN O
fibrosis NN NN B-Disease
independently NN NN O
of NN NN O
microalbuminuria NN NN O
in NN NN O
mice NN NN O
with NN NN O
streptozotocin NN NN O
( NN NN O
STZ NN NN O
) NN NN O
- NN NN O
induced NN NN O
diabetes NN NN B-Disease
. NN NN O
   
In NN NN O
the NN NN O
present NN NN O
study NN NN O
, NN NN O
we NN NN O
hypothesized NN NN O
that NN NN O
blocking NN NN O
EndoMT NN NN O
reduces NN NN O
the NN NN O
early NN NN O
development NN NN O
of NN NN O
diabetic NN NN B-Disease
nephropathy NN NN I-Disease
. NN NN O
   
RESEARCH NN NN O
DESIGN NN NN O
AND NN NN O
METHODS NN NN O
: NN NN O
EndoMT NN NN O
was NN NN O
induced NN NN O
in NN NN O
a NN NN O
mouse NN NN O
pancreatic NN NN O
microvascular NN NN O
endothelial NN NN O
cell NN NN O
line NN NN O
( NN NN O
MMEC NN NN O
) NN NN O
in NN NN O
the NN NN O
presence NN NN O
of NN NN O
advanced NN NN O
glycation NN NN O
end NN NN O
products NN NN O
( NN NN O
AGEs NN NN O
) NN NN O
and NN NN O
in NN NN O
the NN NN O
endothelial NN NN O
lineage NN NN O
- NN NN O
traceble NN NN O
mouse NN NN O
line NN NN O
Tie2 NN NN O
- NN NN O
Cre NN NN O
; NN NN O
Loxp NN NN O
- NN NN O
EGFP NN NN O
by NN NN O
administration NN NN O
of NN NN O
AGEs NN NN O
, NN NN O
with NN NN O
nonglycated NN NN O
mouse NN NN O
albumin NN NN O
serving NN NN O
as NN NN O
a NN NN O
control NN NN O
. NN NN O
   
Phosphorylated NN NN O
Smad3 NN NN O
was NN NN O
detected NN NN O
by NN NN O
immunoprecipitation NN NN O
/ NN NN O
Western NN NN O
blotting NN NN O
and NN NN O
confocal NN NN O
microscopy NN NN O
. NN NN O
   
Blocking NN NN O
studies NN NN O
using NN NN O
receptor NN NN O
for NN NN O
AGE NN NN O
siRNA NN NN O
and NN NN O
a NN NN O
specific NN NN O
inhibitor NN NN O
of NN NN O
Smad3 NN NN O
( NN NN O
SIS3 NN NN O
) NN NN O
were NN NN O
performed NN NN O
in NN NN O
MMECs NN NN O
and NN NN O
in NN NN O
STZ NN NN O
- NN NN O
induced NN NN O
diabetic NN NN B-Disease
nephropathy NN NN I-Disease
in NN NN O
Tie2 NN NN O
- NN NN O
Cre NN NN O
; NN NN O
Loxp NN NN O
- NN NN O
EGFP NN NN O
mice NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
Confocal NN NN O
microscopy NN NN O
and NN NN O
real NN NN O
- NN NN O
time NN NN O
PCR NN NN O
demonstrated NN NN O
that NN NN O
AGEs NN NN O
induced NN NN O
EndoMT NN NN O
in NN NN O
MMECs NN NN O
and NN NN O
in NN NN O
Tie2 NN NN O
- NN NN O
Cre NN NN O
; NN NN O
Loxp NN NN O
- NN NN O
EGFP NN NN O
mice NN NN O
. NN NN O
   
Immunoprecipitation NN NN O
/ NN NN O
Western NN NN O
blotting NN NN O
showed NN NN O
that NN NN O
Smad3 NN NN O
was NN NN O
activated NN NN O
by NN NN O
AGEs NN NN O
but NN NN O
was NN NN O
inhibited NN NN O
by NN NN O
SIS3 NN NN O
in NN NN O
MMECs NN NN O
and NN NN O
in NN NN O
STZ NN NN O
- NN NN O
induced NN NN O
diabetic NN NN B-Disease
nephropathy NN NN I-Disease
. NN NN O
   
Confocal NN NN O
microscopy NN NN O
and NN NN O
real NN NN O
- NN NN O
time NN NN O
PCR NN NN O
further NN NN O
demonstrated NN NN O
that NN NN O
SIS3 NN NN O
abrogated NN NN O
EndoMT NN NN O
, NN NN O
reduced NN NN O
renal NN NN O
fibrosis NN NN B-Disease
, NN NN O
and NN NN O
retarded NN NN O
progression NN NN O
of NN NN O
nephropathy NN NN B-Disease
. NN NN O
   
CONCLUSIONS NN NN O
: NN NN O
EndoMT NN NN O
is NN NN O
a NN NN O
novel NN NN O
pathway NN NN O
leading NN NN O
to NN NN O
early NN NN O
development NN NN O
of NN NN O
diabetic NN NN B-Disease
nephropathy NN NN I-Disease
. NN NN O
   
Blockade NN NN O
of NN NN O
EndoMT NN NN O
by NN NN O
SIS3 NN NN O
may NN NN O
provide NN NN O
a NN NN O
new NN NN O
strategy NN NN O
to NN NN O
retard NN NN O
the NN NN O
progression NN NN O
of NN NN O
diabetic NN NN B-Disease
nephropathy NN NN I-Disease
and NN NN O
other NN NN O
diabetes NN NN B-Disease
complications NN NN I-Disease
. NN NN O
   
Cytostatic NN NN O
and NN NN O
anti NN NN O
- NN NN O
angiogenic NN NN O
effects NN NN O
of NN NN O
temsirolimus NN NN O
in NN NN O
refractory NN NN O
mantle NN NN B-Disease
cell NN NN I-Disease
lymphoma NN NN I-Disease
. NN NN O
   
Mantle NN NN B-Disease
cell NN NN I-Disease
lymphoma NN NN I-Disease
( NN NN O
MCL NN NN B-Disease
) NN NN O
is NN NN O
a NN NN O
rare NN NN O
and NN NN O
aggressive NN NN O
type NN NN O
of NN NN O
B NN NN B-Disease
- NN NN I-Disease
cell NN NN I-Disease
non NN NN I-Disease
- NN NN I-Disease
Hodgkin NN NN I-Disease
' NN NN I-Disease
s NN NN I-Disease
lymphoma NN NN I-Disease
. NN NN O
   
Patients NN NN O
become NN NN O
progressively NN NN O
refractory NN NN O
to NN NN O
conventional NN NN O
chemotherapy NN NN O
, NN NN O
and NN NN O
their NN NN O
prognosis NN NN O
is NN NN O
poor NN NN O
. NN NN O
   
However NN NN O
, NN NN O
a NN NN O
38 NN NN O
% NN NN O
remission NN NN O
rate NN NN O
has NN NN O
been NN NN O
recently NN NN O
reported NN NN O
in NN NN O
refractory NN NN O
MCL NN NN B-Disease
treated NN NN O
with NN NN O
temsirolimus NN NN O
, NN NN O
a NN NN O
mTOR NN NN O
inhibitor NN NN O
. NN NN O
Here NN NN O
we NN NN O
had NN NN O
the NN NN O
opportunity NN NN O
to NN NN O
study NN NN O
a NN NN O
case NN NN O
of NN NN O
refractory NN NN O
MCL NN NN B-Disease
who NN NN O
had NN NN O
tumor NN NN B-Disease
regression NN NN O
two NN NN O
months NN NN O
after NN NN O
temsirolimus NN NN O
treatment NN NN O
, NN NN O
and NN NN O
a NN NN O
progression NN NN O
- NN NN O
free NN NN O
survival NN NN O
of NN NN O
10 NN NN O
months NN NN O
. NN NN O
   
In NN NN O
this NN NN O
case NN NN O
, NN NN O
lymph NN NN O
node NN NN O
biopsies NN NN O
were NN NN O
performed NN NN O
before NN NN O
and NN NN O
six NN NN O
months NN NN O
after NN NN O
temsirolimus NN NN O
therapy NN NN O
. NN NN O
   
Comparison NN NN O
of NN NN O
the NN NN O
two NN NN O
biopsies NN NN O
showed NN NN O
that NN NN O
temsirolimus NN NN O
inhibited NN NN O
tumor NN NN B-Disease
cell NN NN O
proliferation NN NN O
through NN NN O
cell NN NN O
cycle NN NN O
arrest NN NN O
, NN NN O
but NN NN O
did NN NN O
not NN NN O
induce NN NN O
any NN NN O
change NN NN O
in NN NN O
the NN NN O
number NN NN O
of NN NN O
apoptotic NN NN O
tumor NN NN B-Disease
cells NN NN O
. NN NN O
   
Apart NN NN O
from NN NN O
this NN NN O
cytostatic NN NN O
effect NN NN O
, NN NN O
temsirolimus NN NN O
had NN NN O
an NN NN O
antiangiogenic NN NN O
effect NN NN O
with NN NN O
decrease NN NN O
of NN NN O
tumor NN NN B-Disease
microvessel NN NN O
density NN NN O
and NN NN O
of NN NN O
VEGF NN NN O
expression NN NN O
. NN NN O
   
Moreover NN NN O
, NN NN O
numerous NN NN O
patchy NN NN O
, NN NN O
well NN NN O
- NN NN O
limited NN NN O
fibrotic NN NN O
areas NN NN O
, NN NN O
compatible NN NN O
with NN NN O
post NN NN O
- NN NN O
necrotic NN NN B-Disease
tissue NN NN O
repair NN NN O
, NN NN O
were NN NN O
found NN NN O
after NN NN O
6 NN NN O
- NN NN O
month NN NN O
temsirolimus NN NN O
therapy NN NN O
. NN NN O
   
Thus NN NN O
, NN NN O
temsirolimus NN NN O
reduced NN NN O
tumor NN NN B-Disease
burden NN NN O
through NN NN O
associated NN NN O
cytostatic NN NN O
and NN NN O
anti NN NN O
- NN NN O
angiogenic NN NN O
effects NN NN O
. NN NN O
This NN NN O
dual NN NN O
effect NN NN O
of NN NN O
temsirolimus NN NN O
on NN NN O
tumor NN NN B-Disease
tissue NN NN O
could NN NN O
contribute NN NN O
to NN NN O
its NN NN O
recently NN NN O
reported NN NN O
efficiency NN NN O
in NN NN O
refractory NN NN O
MCL NN NN B-Disease
resistant NN NN O
to NN NN O
conventional NN NN O
chemotherapy NN NN O
. NN NN O
   
Acute NN NN B-Disease
renal NN NN I-Disease
failure NN NN I-Disease
due NN NN O
to NN NN O
rifampicin NN NN O
. NN NN O
   
A NN NN O
23 NN NN O
- NN NN O
year NN NN O
- NN NN O
old NN NN O
male NN NN O
patient NN NN O
with NN NN O
bacteriologically NN NN O
proven NN NN O
pulmonary NN NN B-Disease
tuberculosis NN NN I-Disease
was NN NN O
treated NN NN O
with NN NN O
the NN NN O
various NN NN O
regimens NN NN O
of NN NN O
antituberculosis NN NN O
drugs NN NN O
for NN NN O
nearly NN NN O
15 NN NN O
months NN NN O
. NN NN O
   
Rifampicin NN NN O
was NN NN O
administered NN NN O
thrice NN NN O
as NN NN O
one NN NN O
of NN NN O
the NN NN O
3 NN NN O
- NN NN O
4 NN NN O
drug NN NN O
regimen NN NN O
and NN NN O
each NN NN O
time NN NN O
he NN NN O
developed NN NN O
untoward NN NN O
side NN NN O
effects NN NN O
like NN NN O
nausea NN NN B-Disease
, NN NN O
vomiting NN NN B-Disease
and NN NN O
fever NN NN B-Disease
with NN NN O
chills NN NN O
and NN NN O
rigors NN NN O
. NN NN O
   
The NN NN O
last NN NN O
such NN NN O
episode NN NN O
was NN NN O
of NN NN O
acute NN NN O
renal NN NN O
failure NN NN O
at NN NN O
which NN NN O
stage NN NN O
the NN NN O
patient NN NN O
was NN NN O
seen NN NN O
by NN NN O
the NN NN O
authors NN NN O
of NN NN O
this NN NN O
report NN NN O
. NN NN O
   
The NN NN O
patient NN NN O
, NN NN O
however NN NN O
, NN NN O
made NN NN O
a NN NN O
full NN NN O
recovery NN NN O
. NN NN O
   
Syncope NN NN B-Disease
caused NN NN O
by NN NN O
hyperkalemia NN NN B-Disease
during NN NN O
use NN NN O
of NN NN O
a NN NN O
combined NN NN O
therapy NN NN O
with NN NN O
the NN NN O
angiotensin NN NN O
- NN NN O
converting NN NN O
enzyme NN NN O
inhibitor NN NN O
and NN NN O
spironolactone NN NN O
. NN NN O
   
A NN NN O
76 NN NN O
year NN NN O
- NN NN O
old NN NN O
woman NN NN O
with NN NN O
a NN NN O
history NN NN O
of NN NN O
coronary NN NN O
artery NN NN O
bypass NN NN O
grafting NN NN O
and NN NN O
prior NN NN O
myocardial NN NN B-Disease
infarction NN NN I-Disease
was NN NN O
transferred NN NN O
to NN NN O
the NN NN O
emergency NN NN O
room NN NN O
with NN NN O
loss NN NN B-Disease
of NN NN I-Disease
consciousness NN NN I-Disease
due NN NN O
to NN NN O
marked NN NN O
bradycardia NN NN B-Disease
caused NN NN O
by NN NN O
hyperkalemia NN NN B-Disease
. NN NN O
   
The NN NN O
concentration NN NN O
of NN NN O
serum NN NN O
potassium NN NN O
was NN NN O
high NN NN O
, NN NN O
and NN NN O
normal NN NN O
sinus NN NN O
rhythm NN NN O
was NN NN O
restored NN NN O
after NN NN O
correction NN NN O
of NN NN O
the NN NN O
serum NN NN O
potassium NN NN O
level NN NN O
. NN NN O
   
The NN NN O
cause NN NN O
of NN NN O
hyperkalemia NN NN B-Disease
was NN NN O
considered NN NN O
to NN NN O
be NN NN O
several NN NN O
doses NN NN O
of NN NN O
spiranolactone NN NN O
, NN NN O
an NN NN O
aldosterone NN NN O
antagonist NN NN O
, NN NN O
in NN NN O
addition NN NN O
to NN NN O
the NN NN O
long NN NN O
- NN NN O
term NN NN O
intake NN NN O
of NN NN O
ramipril NN NN O
, NN NN O
an NN NN O
ACE NN NN O
inhibitor NN NN O
. NN NN O
   
This NN NN O
case NN NN O
is NN NN O
a NN NN O
good NN NN O
example NN NN O
of NN NN O
electrolyte NN NN O
imbalance NN NN O
causing NN NN O
acute NN NN O
life NN NN O
- NN NN O
threatening NN NN O
cardiac NN NN O
events NN NN O
. NN NN O
   
Clinicians NN NN O
should NN NN O
be NN NN O
alert NN NN O
to NN NN O
the NN NN O
possibility NN NN O
of NN NN O
hyperkalemia NN NN B-Disease
, NN NN O
especially NN NN O
in NN NN O
elderly NN NN O
patients NN NN O
using NN NN O
ACE NN NN O
/ NN NN O
ARB NN NN O
in NN NN O
combination NN NN O
with NN NN O
potassium NN NN O
sparing NN NN O
agents NN NN O
and NN NN O
who NN NN O
have NN NN O
mild NN NN O
renal NN NN B-Disease
disturbance NN NN I-Disease
. NN NN O
   
Diffuse NN NN O
skeletal NN NN O
pain NN NN B-Disease
after NN NN O
administration NN NN O
of NN NN O
alendronate NN NN O
. NN NN O
   
BACKGROUND NN NN O
: NN NN O
Osteoporosis NN NN B-Disease
is NN NN O
caused NN NN O
by NN NN O
bone NN NN O
resorption NN NN O
in NN NN O
excess NN NN O
of NN NN O
bone NN NN O
formation NN NN O
, NN NN O
and NN NN O
bisphosphonates NN NN O
, NN NN O
are NN NN O
used NN NN O
to NN NN O
inhibit NN NN O
bone NN NN O
resorption NN NN O
. NN NN O
   
Alendronate NN NN O
, NN NN O
a NN NN O
biphosphonate NN NN O
, NN NN O
is NN NN O
effective NN NN O
for NN NN O
both NN NN O
the NN NN O
treatment NN NN O
and NN NN O
prevention NN NN O
of NN NN O
osteoporosis NN NN B-Disease
in NN NN O
postmenopausal NN NN O
women NN NN O
. NN NN O
   
Side NN NN O
effects NN NN O
are NN NN O
relatively NN NN O
few NN NN O
and NN NN O
prominently NN NN O
gastrointestinal NN NN O
. NN NN O
   
Musculoskeletal NN NN B-Disease
pain NN NN I-Disease
may NN NN O
be NN NN O
an NN NN O
important NN NN O
side NN NN O
effect NN NN O
in NN NN O
these NN NN O
patients NN NN O
. NN NN O
   
We NN NN O
presented NN NN O
a NN NN O
patient NN NN O
admitted NN NN O
to NN NN O
our NN NN O
out NN NN O
- NN NN O
patient NN NN O
clinic NN NN O
with NN NN O
diffuse NN NN O
skeletal NN NN O
pain NN NN B-Disease
after NN NN O
three NN NN O
consecutive NN NN O
administration NN NN O
of NN NN O
alendronate NN NN O
. NN NN O
   
CONCLUSION NN NN O
: NN NN O
We NN NN O
conclude NN NN O
that NN NN O
patients NN NN O
with NN NN O
osteoporosis NN NN B-Disease
can NN NN O
report NN NN O
pain NN NN B-Disease
, NN NN O
and NN NN O
bisphosphonate NN NN O
- NN NN O
related NN NN O
pain NN NN B-Disease
should NN NN O
also NN NN O
be NN NN O
considered NN NN O
before NN NN O
ascribing NN NN O
this NN NN O
complaint NN NN O
to NN NN O
osteoporosis NN NN B-Disease
. NN NN O
   
Cerebrospinal NN NN O
fluid NN NN O
penetration NN NN O
of NN NN O
high NN NN O
- NN NN O
dose NN NN O
daptomycin NN NN O
in NN NN O
suspected NN NN O
Staphylococcus NN NN O
aureus NN NN O
meningitis NN NN B-Disease
. NN NN O
   
OBJECTIVE NN NN O
: NN NN O
To NN NN O
report NN NN O
a NN NN O
case NN NN O
of NN NN O
methicillin NN NN O
- NN NN O
sensitive NN NN O
Staphylococcus NN NN O
aureus NN NN O
( NN NN O
MSSA NN NN O
) NN NN O
bacteremia NN NN B-Disease
with NN NN O
suspected NN NN O
MSSA NN NN O
meningitis NN NN B-Disease
treated NN NN O
with NN NN O
high NN NN O
- NN NN O
dose NN NN O
daptomycin NN NN O
assessed NN NN O
with NN NN O
concurrent NN NN O
serum NN NN O
and NN NN O
cerebrospinal NN NN O
fluid NN NN O
( NN NN O
CSF NN NN O
) NN NN O
concentrations NN NN O
. NN NN O
   
CASE NN NN O
SUMMARY NN NN O
: NN NN O
A NN NN O
54 NN NN O
- NN NN O
year NN NN O
- NN NN O
old NN NN O
male NN NN O
presented NN NN O
to NN NN O
the NN NN O
emergency NN NN O
department NN NN O
with NN NN O
generalized NN NN O
weakness NN NN B-Disease
and NN NN O
presumed NN NN O
health NN NN O
- NN NN O
care NN NN O
- NN NN O
associated NN NN O
pneumonia NN NN B-Disease
shown NN NN O
on NN NN O
chest NN NN O
radiograph NN NN O
. NN NN O
   
Treatment NN NN O
was NN NN O
empirically NN NN O
initiated NN NN O
with NN NN O
vancomycin NN NN O
, NN NN O
levofloxacin NN NN O
, NN NN O
and NN NN O
piperacillin NN NN O
/ NN NN O
tazobactam NN NN O
. NN NN O
   
Blood NN NN O
cultures NN NN O
revealed NN NN O
S NN NN O
. NN NN O
aureus NN NN O
susceptible NN NN O
to NN NN O
oxacillin NN NN O
. NN NN O
   
Empiric NN NN O
antibiotic NN NN O
treatment NN NN O
was NN NN O
narrowed NN NN O
to NN NN O
nafcillin NN NN O
on NN NN O
day NN NN O
4 NN NN O
. NN NN O
   
On NN NN O
day NN NN O
8 NN NN O
, NN NN O
the NN NN O
patient NN NN O
developed NN NN O
acute NN NN B-Disease
renal NN NN I-Disease
failure NN NN I-Disease
( NN NN O
serum NN NN O
creatinine NN NN O
1 NN NN O
. NN NN O
9 NN NN O
mg NN NN O
/ NN NN O
dL NN NN O
, NN NN O
increased NN NN O
from NN NN O
1 NN NN O
. NN NN O
2 NN NN O
mg NN NN O
/ NN NN O
dL NN NN O
the NN NN O
previous NN NN O
day NN NN O
and NN NN O
0 NN NN O
. NN NN O
8 NN NN O
mg NN NN O
/ NN NN O
dL NN NN O
on NN NN O
admission NN NN O
) NN NN O
. NN NN O
   
The NN NN O
patient NN NN O
' NN NN O
s NN NN O
Glasgow NN NN O
Coma NN NN O
Score NN NN O
was NN NN O
3 NN NN O
, NN NN O
with NN NN O
normal NN NN O
findings NN NN O
shown NN NN O
on NN NN O
computed NN NN O
tomography NN NN O
scan NN NN O
of NN NN O
the NN NN O
head NN NN O
72 NN NN O
hours NN NN O
following NN NN O
an NN NN O
episode NN NN O
of NN NN O
cardiac NN NN B-Disease
arrest NN NN I-Disease
on NN NN O
day NN NN O
10 NN NN O
. NN NN O
   
The NN NN O
patient NN NN O
experienced NN NN O
relapsing NN NN O
MSSA NN NN O
bacteremia NN NN B-Disease
on NN NN O
day NN NN O
9 NN NN O
, NN NN O
increasing NN NN O
the NN NN O
suspicion NN NN O
for NN NN O
a NN NN O
central NN NN O
nervous NN NN O
system NN NN O
( NN NN O
CNS NN NN O
) NN NN O
infection NN NN B-Disease
. NN NN O
   
Nafcillin NN NN O
was NN NN O
discontinued NN NN O
and NN NN O
daptomycin NN NN O
9 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
daily NN NN O
was NN NN O
initiated NN NN O
for NN NN O
suspected NN NN O
meningitis NN NN B-Disease
and NN NN O
was NN NN O
continued NN NN O
until NN NN O
the NN NN O
patient NN NN O
' NN NN O
s NN NN O
death NN NN O
on NN NN O
day NN NN O
16 NN NN O
. NN NN O
   
Daptomycin NN NN O
serum NN NN O
and NN NN O
CSF NN NN O
trough NN NN O
concentrations NN NN O
were NN NN O
11 NN NN O
. NN NN O
21 NN NN O
ug NN NN O
/ NN NN O
mL NN NN O
and NN NN O
0 NN NN O
. NN NN O
52 NN NN O
ug NN NN O
/ NN NN O
mL NN NN O
, NN NN O
respectively NN NN O
, NN NN O
prior NN NN O
to NN NN O
the NN NN O
third NN NN O
dose NN NN O
. NN NN O
   
Lumbar NN NN O
puncture NN NN O
results NN NN O
were NN NN O
inconclusive NN NN O
and NN NN O
no NN NN O
further NN NN O
blood NN NN O
cultures NN NN O
were NN NN O
positive NN NN O
for NN NN O
MSSA NN NN O
. NN NN O
   
Creatine NN NN O
kinase NN NN O
levels NN NN O
were NN NN O
normal NN NN O
prior NN NN O
to NN NN O
daptomycin NN NN O
therapy NN NN O
and NN NN O
were NN NN O
not NN NN O
reassessed NN NN O
. NN NN O
   
DISCUSSION NN NN O
: NN NN O
Daptomycin NN NN O
was NN NN O
initiated NN NN O
in NN NN O
our NN NN O
patient NN NN O
secondary NN NN O
to NN NN O
possible NN NN O
nafcillin NN NN O
- NN NN O
induced NN NN O
acute NN NN O
interstitial NN NN B-Disease
nephritis NN NN I-Disease
and NN NN O
relapsing NN NN O
bacteremia NN NN B-Disease
. NN NN O
   
At NN NN O
a NN NN O
dose NN NN O
of NN NN O
9 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
, NN NN O
resultant NN NN O
penetration NN NN O
of NN NN O
5 NN NN O
% NN NN O
was NN NN O
higher NN NN O
than NN NN O
in NN NN O
previous NN NN O
reports NN NN O
, NN NN O
more NN NN O
consistent NN NN O
with NN NN O
inflamed NN NN O
meninges NN NN O
. NN NN O
   
CONCLUSIONS NN NN O
: NN NN O
High NN NN O
- NN NN O
dose NN NN O
daptomycin NN NN O
may NN NN O
be NN NN O
an NN NN O
alternative NN NN O
option NN NN O
for NN NN O
MSSA NN NN O
bacteremia NN NN B-Disease
with NN NN O
or NN NN O
without NN NN O
a NN NN O
CNS NN NN O
source NN NN O
in NN NN O
patients NN NN O
who NN NN O
have NN NN O
failed NN NN O
or NN NN O
cannot NN NN O
tolerate NN NN O
standard NN NN O
therapy NN NN O
. NN NN O
   
Further NN NN O
clinical NN NN O
evaluation NN NN O
in NN NN O
patients NN NN O
with NN NN O
confirmed NN NN O
meningitis NN NN B-Disease
is NN NN O
warranted NN NN O
. NN NN O
   
The NN NN O
role NN NN O
of NN NN O
nitric NN NN O
oxide NN NN O
in NN NN O
convulsions NN NN B-Disease
induced NN NN O
by NN NN O
lindane NN NN O
in NN NN O
rats NN NN O
. NN NN O
   
Lindane NN NN O
is NN NN O
an NN NN O
organochloride NN NN O
pesticide NN NN O
and NN NN O
scabicide NN NN O
. NN NN O
   
It NN NN O
evokes NN NN O
convulsions NN NN B-Disease
mainly NN NN O
trough NN NN O
the NN NN O
blockage NN NN O
of NN NN O
GABA NN NN O
( NN NN O
A NN NN O
) NN NN O
receptors NN NN O
. NN NN O
   
Nitric NN NN O
oxide NN NN O
( NN NN O
NO NN NN O
) NN NN O
, NN NN O
gaseous NN NN O
neurotransmitter NN NN O
, NN NN O
has NN NN O
contradictor NN NN O
role NN NN O
in NN NN O
epileptogenesis NN NN O
due NN NN O
to NN NN O
opposite NN NN O
effects NN NN O
of NN NN O
L NN NN O
- NN NN O
arginine NN NN O
, NN NN O
precursor NN NN O
of NN NN O
NO NN NN O
syntheses NN NN O
( NN NN O
NOS NN NN O
) NN NN O
, NN NN O
and NN NN O
L NN NN O
- NN NN O
NAME NN NN O
( NN NN O
NOS NN NN O
inhibitor NN NN O
) NN NN O
observed NN NN O
in NN NN O
different NN NN O
epilepsy NN NN B-Disease
models NN NN O
. NN NN O
   
The NN NN O
aim NN NN O
of NN NN O
the NN NN O
current NN NN O
study NN NN O
was NN NN O
to NN NN O
determine NN NN O
the NN NN O
effects NN NN O
of NN NN O
NO NN NN O
on NN NN O
the NN NN O
behavioral NN NN O
and NN NN O
EEG NN NN O
characteristics NN NN O
of NN NN O
lindane NN NN O
- NN NN O
induced NN NN O
epilepsy NN NN B-Disease
in NN NN O
male NN NN O
Wistar NN NN O
albino NN NN O
rats NN NN O
. NN NN O
   
The NN NN O
administration NN NN O
of NN NN O
L NN NN O
- NN NN O
arginine NN NN O
( NN NN O
600 NN NN O
, NN NN O
800 NN NN O
and NN NN O
1000 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
, NN NN O
i NN NN O
. NN NN O
p NN NN O
. NN NN O
) NN NN O
in NN NN O
dose NN NN O
- NN NN O
dependent NN NN O
manner NN NN O
significantly NN NN O
increased NN NN O
convulsion NN NN B-Disease
incidence NN NN O
and NN NN O
severity NN NN O
and NN NN O
shortened NN NN O
latency NN NN O
time NN NN O
to NN NN O
first NN NN O
convulsion NN NN B-Disease
elicited NN NN O
by NN NN O
lower NN NN O
lindane NN NN O
dose NN NN O
( NN NN O
4 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
, NN NN O
i NN NN O
. NN NN O
p NN NN O
. NN NN O
) NN NN O
. NN NN O
   
On NN NN O
the NN NN O
contrary NN NN O
, NN NN O
pretreatment NN NN O
with NN NN O
L NN NN O
- NN NN O
NAME NN NN O
( NN NN O
500 NN NN O
, NN NN O
700 NN NN O
and NN NN O
900 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
, NN NN O
i NN NN O
. NN NN O
p NN NN O
. NN NN O
) NN NN O
decreased NN NN O
convulsion NN NN B-Disease
incidence NN NN O
and NN NN O
severity NN NN O
and NN NN O
prolonged NN NN O
latency NN NN O
time NN NN O
to NN NN O
convulsion NN NN B-Disease
following NN NN O
injection NN NN O
with NN NN O
a NN NN O
convulsive NN NN B-Disease
dose NN NN O
of NN NN O
lindane NN NN O
( NN NN O
8 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
, NN NN O
i NN NN O
. NN NN O
p NN NN O
. NN NN O
) NN NN O
. NN NN O
   
EEG NN NN O
analyses NN NN O
showed NN NN O
increase NN NN O
of NN NN O
number NN NN O
and NN NN O
duration NN NN O
of NN NN O
ictal NN NN O
periods NN NN O
in NN NN O
EEG NN NN O
of NN NN O
rats NN NN O
receiving NN NN O
l NN NN O
- NN NN O
arginine NN NN O
prior NN NN O
to NN NN O
lindane NN NN O
and NN NN O
decrease NN NN O
of NN NN O
this NN NN O
number NN NN O
in NN NN O
rats NN NN O
pretreated NN NN O
with NN NN O
L NN NN O
- NN NN O
NAME NN NN O
. NN NN O
   
These NN NN O
results NN NN O
support NN NN O
the NN NN O
conclusion NN NN O
that NN NN O
NO NN NN O
plays NN NN O
a NN NN O
role NN NN O
of NN NN O
endogenous NN NN O
convulsant NN NN O
in NN NN O
rat NN NN O
model NN NN O
of NN NN O
lindane NN NN O
seizures NN NN B-Disease
. NN NN O
   
Severe NN NN O
polyneuropathy NN NN B-Disease
and NN NN O
motor NN NN O
loss NN NN O
after NN NN O
intrathecal NN NN O
thiotepa NN NN O
combination NN NN O
chemotherapy NN NN O
: NN NN O
description NN NN O
of NN NN O
two NN NN O
cases NN NN O
. NN NN O
   
Two NN NN O
cases NN NN O
of NN NN O
severe NN NN O
delayed NN NN O
neurologic NN NN B-Disease
toxicity NN NN I-Disease
related NN NN O
to NN NN O
the NN NN O
administration NN NN O
of NN NN O
intrathecal NN NN O
( NN NN O
IT NN NN O
) NN NN O
combination NN NN O
chemotherapy NN NN O
including NN NN O
thiotepa NN NN O
( NN NN O
TSPA NN NN O
) NN NN O
are NN NN O
presented NN NN O
. NN NN O
   
Both NN NN O
cases NN NN O
developed NN NN O
axonal NN NN B-Disease
neuropathy NN NN I-Disease
with NN NN O
motor NN NN O
predominance NN NN O
in NN NN O
the NN NN O
lower NN NN O
extremities NN NN O
1 NN NN O
and NN NN O
6 NN NN O
months NN NN O
after NN NN O
IT NN NN O
chemotherapy NN NN O
was NN NN O
administered NN NN O
. NN NN O
   
Neurologic NN NN B-Disease
toxicities NN NN I-Disease
have NN NN O
been NN NN O
described NN NN O
with NN NN O
IT NN NN O
- NN NN O
methotrexate NN NN O
, NN NN O
IT NN NN O
- NN NN O
cytosine NN NN O
arabinoside NN NN O
and NN NN O
IT NN NN O
- NN NN O
TSPA NN NN O
. NN NN O
   
To NN NN O
our NN NN O
knowledge NN NN O
, NN NN O
however NN NN O
, NN NN O
axonal NN NN B-Disease
neuropathy NN NN I-Disease
following NN NN O
administration NN NN O
of NN NN O
these NN NN O
three NN NN O
agents NN NN O
has NN NN O
not NN NN O
been NN NN O
previously NN NN O
described NN NN O
. NN NN O
   
In NN NN O
spite NN NN O
of NN NN O
the NN NN O
fact NN NN O
that NN NN O
TSPA NN NN O
is NN NN O
a NN NN O
useful NN NN O
IT NN NN O
agent NN NN O
, NN NN O
its NN NN O
combination NN NN O
with NN NN O
MTX NN NN O
, NN NN O
ara NN NN O
- NN NN O
C NN NN O
and NN NN O
radiotherapy NN NN O
could NN NN O
cause NN NN O
severe NN NN O
neurotoxicity NN NN B-Disease
. NN NN O
   
This NN NN O
unexpected NN NN O
complication NN NN O
indicates NN NN O
the NN NN O
need NN NN O
for NN NN O
further NN NN O
toxicology NN NN O
research NN NN O
on NN NN O
IT NN NN O
- NN NN O
TSPA NN NN O
. NN NN O
   
Effects NN NN O
of NN NN O
cromakalim NN NN O
and NN NN O
pinacidil NN NN O
on NN NN O
large NN NN O
epicardial NN NN O
and NN NN O
small NN NN O
coronary NN NN O
arteries NN NN O
in NN NN O
conscious NN NN O
dogs NN NN O
. NN NN O
   
The NN NN O
effects NN NN O
of NN NN O
i NN NN O
. NN NN O
v NN NN O
. NN NN O
bolus NN NN O
administration NN NN O
of NN NN O
cromakalim NN NN O
( NN NN O
1 NN NN O
- NN NN O
10 NN NN O
micrograms NN NN O
/ NN NN O
kg NN NN O
) NN NN O
and NN NN O
pinacidil NN NN O
( NN NN O
3 NN NN O
- NN NN O
100 NN NN O
micrograms NN NN O
/ NN NN O
kg NN NN O
) NN NN O
on NN NN O
large NN NN O
( NN NN O
circumflex NN NN O
artery NN NN O
) NN NN O
and NN NN O
small NN NN O
coronary NN NN O
arteries NN NN O
and NN NN O
on NN NN O
systemic NN NN O
hemodynamics NN NN O
were NN NN O
investigated NN NN O
in NN NN O
chronically NN NN O
instrumented NN NN O
conscious NN NN O
dogs NN NN O
and NN NN O
compared NN NN O
to NN NN O
those NN NN O
of NN NN O
nitroglycerin NN NN O
( NN NN O
0 NN NN O
. NN NN O
03 NN NN O
- NN NN O
10 NN NN O
micrograms NN NN O
/ NN NN O
kg NN NN O
) NN NN O
. NN NN O
   
Nitroglycerin NN NN O
, NN NN O
up NN NN O
to NN NN O
0 NN NN O
. NN NN O
3 NN NN O
micrograms NN NN O
/ NN NN O
kg NN NN O
, NN NN O
selectively NN NN O
increased NN NN O
circumflex NN NN O
artery NN NN O
diameter NN NN O
( NN NN O
CxAD NN NN O
) NN NN O
without NN NN O
simultaneously NN NN O
affecting NN NN O
any NN NN O
other NN NN O
cardiac NN NN O
or NN NN O
systemic NN NN O
hemodynamic NN NN O
parameter NN NN O
. NN NN O
   
In NN NN O
contrast NN NN O
, NN NN O
cromakalim NN NN O
and NN NN O
pinacidil NN NN O
at NN NN O
all NN NN O
doses NN NN O
and NN NN O
nitroglycerin NN NN O
at NN NN O
doses NN NN O
higher NN NN O
than NN NN O
0 NN NN O
. NN NN O
3 NN NN O
micrograms NN NN O
/ NN NN O
kg NN NN O
simultaneously NN NN O
and NN NN O
dose NN NN O
- NN NN O
dependently NN NN O
increased NN NN O
CxAD NN NN O
, NN NN O
coronary NN NN O
blood NN NN O
flow NN NN O
and NN NN O
heart NN NN O
rate NN NN O
and NN NN O
decreased NN NN O
coronary NN NN O
vascular NN NN O
resistance NN NN O
and NN NN O
aortic NN NN O
pressure NN NN O
. NN NN O
   
Cromakalim NN NN O
was NN NN O
approximately NN NN O
8 NN NN O
- NN NN O
to NN NN O
9 NN NN O
. NN NN O
5 NN NN O
- NN NN O
fold NN NN O
more NN NN O
potent NN NN O
than NN NN O
pinacidil NN NN O
in NN NN O
increasing NN NN O
CxAD NN NN O
. NN NN O
   
Vasodilation NN NN O
of NN NN O
large NN NN O
and NN NN O
small NN NN O
coronary NN NN O
vessels NN NN O
and NN NN O
hypotension NN NN B-Disease
induced NN NN O
by NN NN O
cromakalim NN NN O
and NN NN O
pinacidil NN NN O
were NN NN O
not NN NN O
affected NN NN O
by NN NN O
prior NN NN O
combined NN NN O
beta NN NN O
adrenergic NN NN O
and NN NN O
muscarinic NN NN O
receptors NN NN O
blockade NN NN O
but NN NN O
drug NN NN O
- NN NN O
induced NN NN O
tachycardia NN NN B-Disease
was NN NN O
abolished NN NN O
. NN NN O
   
When NN NN O
circumflex NN NN O
artery NN NN O
blood NN NN O
flow NN NN O
was NN NN O
maintained NN NN O
constant NN NN O
, NN NN O
the NN NN O
increases NN NN O
in NN NN O
CxAD NN NN O
induced NN NN O
by NN NN O
cromakalim NN NN O
( NN NN O
10 NN NN O
micrograms NN NN O
/ NN NN O
kg NN NN O
) NN NN O
, NN NN O
pinacidil NN NN O
( NN NN O
30 NN NN O
micrograms NN NN O
/ NN NN O
kg NN NN O
) NN NN O
and NN NN O
nitroglycerin NN NN O
( NN NN O
10 NN NN O
micrograms NN NN O
/ NN NN O
kg NN NN O
) NN NN O
were NN NN O
reduced NN NN O
by NN NN O
68 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
7 NN NN O
, NN NN O
54 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
9 NN NN O
and NN NN O
1 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
1 NN NN O
% NN NN O
, NN NN O
respectively NN NN O
. NN NN O
   
Thus NN NN O
, NN NN O
whereas NN NN O
nitroglycerin NN NN O
preferentially NN NN O
and NN NN O
flow NN NN O
- NN NN O
independently NN NN O
dilates NN NN O
large NN NN O
coronary NN NN O
arteries NN NN O
, NN NN O
cromakalim NN NN O
and NN NN O
pinacidil NN NN O
dilate NN NN O
both NN NN O
large NN NN O
and NN NN O
small NN NN O
coronary NN NN O
arteries NN NN O
and NN NN O
this NN NN O
effect NN NN O
is NN NN O
not NN NN O
dependent NN NN O
upon NN NN O
the NN NN O
simultaneous NN NN O
beta NN NN O
adrenoceptors NN NN O
- NN NN O
mediated NN NN O
rise NN NN O
in NN NN O
myocardial NN NN O
metabolic NN NN O
demand NN NN O
. NN NN O
   
Finally NN NN O
, NN NN O
two NN NN O
mechanisms NN NN O
at NN NN O
least NN NN O
, NN NN O
direct NN NN O
vasodilation NN NN O
and NN NN O
flow NN NN O
dependency NN NN O
, NN NN O
are NN NN O
involved NN NN O
in NN NN O
the NN NN O
cromakalim NN NN O
- NN NN O
and NN NN O
pinacidil NN NN O
- NN NN O
induced NN NN O
increase NN NN O
in NN NN O
CxAD NN NN O
. NN NN O
   
Mefenamic NN NN O
acid NN NN O
- NN NN O
induced NN NN O
neutropenia NN NN B-Disease
and NN NN O
renal NN NN B-Disease
failure NN NN I-Disease
in NN NN O
elderly NN NN O
females NN NN O
with NN NN O
hypothyroidism NN NN B-Disease
. NN NN O
   
We NN NN O
report NN NN O
mefenamic NN NN O
acid NN NN O
- NN NN O
induced NN NN O
non NN NN O
- NN NN O
oliguric NN NN O
renal NN NN B-Disease
failure NN NN I-Disease
and NN NN O
severe NN NN O
neutropenia NN NN B-Disease
occurring NN NN O
simultaneously NN NN O
in NN NN O
two NN NN O
elderly NN NN O
females NN NN O
. NN NN O
   
The NN NN O
neutropenia NN NN B-Disease
was NN NN O
due NN NN O
to NN NN O
maturation NN NN O
arrest NN NN O
of NN NN O
the NN NN O
myeloid NN NN O
series NN NN O
in NN NN O
one NN NN O
patient NN NN O
. NN NN O
   
Both NN NN O
patients NN NN O
were NN NN O
also NN NN O
hypothyroid NN NN B-Disease
, NN NN O
but NN NN O
it NN NN O
is NN NN O
not NN NN O
clear NN NN O
whether NN NN O
this NN NN O
was NN NN O
a NN NN O
predisposing NN NN O
factor NN NN O
to NN NN O
the NN NN O
development NN NN O
of NN NN O
these NN NN O
adverse NN NN O
reactions NN NN O
. NN NN O
   
However NN NN O
, NN NN O
it NN NN O
would NN NN O
seem NN NN O
prudent NN NN O
not NN NN O
to NN NN O
use NN NN O
mefenamic NN NN O
acid NN NN O
in NN NN O
hypothyroid NN NN B-Disease
patients NN NN O
until NN NN O
the NN NN O
hypothyroidism NN NN B-Disease
has NN NN O
been NN NN O
corrected NN NN O
. NN NN O
   
Etiology NN NN O
of NN NN O
hypercalcemia NN NN B-Disease
in NN NN O
hemodialysis NN NN O
patients NN NN O
on NN NN O
calcium NN NN O
carbonate NN NN O
therapy NN NN O
. NN NN O
   
Fourteen NN NN O
of NN NN O
39 NN NN O
dialysis NN NN O
patients NN NN O
( NN NN O
36 NN NN O
% NN NN O
) NN NN O
became NN NN O
hypercalcemic NN NN B-Disease
after NN NN O
switching NN NN O
to NN NN O
calcium NN NN O
carbonate NN NN O
as NN NN O
their NN NN O
principal NN NN O
phosphate NN NN O
binder NN NN O
. NN NN O
   
In NN NN O
order NN NN O
to NN NN O
identify NN NN O
risk NN NN O
factors NN NN O
associated NN NN O
with NN NN O
the NN NN O
development NN NN O
of NN NN O
hypercalcemia NN NN B-Disease
, NN NN O
indirect NN NN O
parameters NN NN O
of NN NN O
intestinal NN NN O
calcium NN NN O
reabsorption NN NN O
and NN NN O
bone NN NN O
turnover NN NN O
rate NN NN O
in NN NN O
these NN NN O
14 NN NN O
patients NN NN O
were NN NN O
compared NN NN O
with NN NN O
results NN NN O
in NN NN O
14 NN NN O
eucalcemic NN NN O
patients NN NN O
matched NN NN O
for NN NN O
age NN NN O
, NN NN O
sex NN NN O
, NN NN O
length NN NN O
of NN NN O
time NN NN O
on NN NN O
dialysis NN NN O
, NN NN O
and NN NN O
etiology NN NN O
of NN NN O
renal NN NN B-Disease
disease NN NN I-Disease
. NN NN O
   
In NN NN O
addition NN NN O
to NN NN O
experiencing NN NN O
hypercalcemic NN NN B-Disease
episodes NN NN O
with NN NN O
peak NN NN O
calcium NN NN O
values NN NN O
of NN NN O
2 NN NN O
. NN NN O
7 NN NN O
to NN NN O
3 NN NN O
. NN NN O
8 NN NN O
mmol NN NN O
/ NN NN O
L NN NN O
( NN NN O
10 NN NN O
. NN NN O
7 NN NN O
to NN NN O
15 NN NN O
. NN NN O
0 NN NN O
mg NN NN O
/ NN NN O
dL NN NN O
) NN NN O
, NN NN O
patients NN NN O
in NN NN O
the NN NN O
hypercalcemic NN NN B-Disease
group NN NN O
exhibited NN NN O
a NN NN O
significant NN NN O
increase NN NN O
in NN NN O
the NN NN O
mean NN NN O
calcium NN NN O
concentration NN NN O
obtained NN NN O
during NN NN O
6 NN NN O
months NN NN O
before NN NN O
the NN NN O
switch NN NN O
, NN NN O
compared NN NN O
with NN NN O
the NN NN O
mean NN NN O
value NN NN O
obtained NN NN O
during NN NN O
the NN NN O
7 NN NN O
months NN NN O
of NN NN O
observation NN NN O
after NN NN O
the NN NN O
switch NN NN O
( NN NN O
2 NN NN O
. NN NN O
4 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
0 NN NN O
. NN NN O
03 NN NN O
to NN NN O
2 NN NN O
. NN NN O
5 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
0 NN NN O
. NN NN O
03 NN NN O
mmol NN NN O
/ NN NN O
L NN NN O
[ NN NN O
9 NN NN O
. NN NN O
7 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
0 NN NN O
. NN NN O
2 NN NN O
to NN NN O
10 NN NN O
. NN NN O
2 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
0 NN NN O
. NN NN O
1 NN NN O
mg NN NN O
/ NN NN O
dL NN NN O
] NN NN O
, NN NN O
P NN NN O
= NN NN O
0 NN NN O
. NN NN O
006 NN NN O
) NN NN O
. NN NN O
   
In NN NN O
contrast NN NN O
, NN NN O
eucalcemic NN NN O
patients NN NN O
exhibited NN NN O
no NN NN O
change NN NN O
in NN NN O
mean NN NN O
calcium NN NN O
values NN NN O
over NN NN O
the NN NN O
same NN NN O
time NN NN O
period NN NN O
( NN NN O
2 NN NN O
. NN NN O
3 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
0 NN NN O
. NN NN O
05 NN NN O
to NN NN O
2 NN NN O
. NN NN O
3 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
0 NN NN O
. NN NN O
05 NN NN O
mmol NN NN O
/ NN NN O
L NN NN O
[ NN NN O
9 NN NN O
. NN NN O
2 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
0 NN NN O
. NN NN O
2 NN NN O
to NN NN O
9 NN NN O
. NN NN O
2 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
0 NN NN O
. NN NN O
2 NN NN O
mg NN NN O
/ NN NN O
dL NN NN O
] NN NN O
) NN NN O
. NN NN O
   
CaCO3 NN NN O
dosage NN NN O
, NN NN O
calculated NN NN O
dietary NN NN O
calcium NN NN O
intake NN NN O
, NN NN O
and NN NN O
circulating NN NN O
levels NN NN O
of NN NN O
vitamin NN NN O
D NN NN O
metabolites NN NN O
were NN NN O
similar NN NN O
in NN NN O
both NN NN O
groups NN NN O
. NN NN O
   
Physical NN NN O
activity NN NN O
index NN NN O
and NN NN O
predialysis NN NN O
serum NN NN O
bicarbonate NN NN O
levels NN NN O
also NN NN O
were NN NN O
similar NN NN O
in NN NN O
both NN NN O
groups NN NN O
. NN NN O
   
However NN NN O
, NN NN O
there NN NN O
was NN NN O
a NN NN O
significant NN NN O
difference NN NN O
in NN NN O
parameters NN NN O
reflecting NN NN O
bone NN NN O
turnover NN NN O
rates NN NN O
between NN NN O
groups NN NN O
. NN NN O
( NN NN O
ABSTRACT NN NN O
TRUNCATED NN NN O
AT NN NN O
250 NN NN O
WORDS NN NN O
) NN NN O
   
Late NN NN O
- NN NN O
onset NN NN O
scleroderma NN NN B-Disease
renal NN NN I-Disease
crisis NN NN I-Disease
induced NN NN O
by NN NN O
tacrolimus NN NN O
and NN NN O
prednisolone NN NN O
: NN NN O
a NN NN O
case NN NN O
report NN NN O
. NN NN O
   
Scleroderma NN NN B-Disease
renal NN NN I-Disease
crisis NN NN I-Disease
( NN NN O
SRC NN NN B-Disease
) NN NN O
is NN NN O
a NN NN O
rare NN NN O
complication NN NN O
of NN NN O
systemic NN NN B-Disease
sclerosis NN NN I-Disease
( NN NN O
SSc NN NN B-Disease
) NN NN O
but NN NN O
can NN NN O
be NN NN O
severe NN NN O
enough NN NN O
to NN NN O
require NN NN O
temporary NN NN O
or NN NN O
permanent NN NN O
renal NN NN O
replacement NN NN O
therapy NN NN O
. NN NN O
   
Moderate NN NN O
to NN NN O
high NN NN O
dose NN NN O
corticosteroid NN NN O
use NN NN O
is NN NN O
recognized NN NN O
as NN NN O
a NN NN O
major NN NN O
risk NN NN O
factor NN NN O
for NN NN O
SRC NN NN B-Disease
. NN NN O
   
Furthermore NN NN O
, NN NN O
there NN NN O
have NN NN O
been NN NN O
reports NN NN O
of NN NN O
thrombotic NN NN B-Disease
microangiopathy NN NN I-Disease
precipitated NN NN O
by NN NN O
cyclosporine NN NN O
in NN NN O
patients NN NN O
with NN NN O
SSc NN NN B-Disease
. NN NN O
   
In NN NN O
this NN NN O
article NN NN O
, NN NN O
we NN NN O
report NN NN O
a NN NN O
patient NN NN O
with NN NN O
SRC NN NN B-Disease
induced NN NN O
by NN NN O
tacrolimus NN NN O
and NN NN O
corticosteroids NN NN O
. NN NN O
   
The NN NN O
aim NN NN O
of NN NN O
this NN NN O
work NN NN O
is NN NN O
to NN NN O
call NN NN O
attention NN NN O
to NN NN O
the NN NN O
risk NN NN O
of NN NN O
tacrolimus NN NN O
use NN NN O
in NN NN O
patients NN NN O
with NN NN O
SSc NN NN B-Disease
. NN NN O
   
Methyldopa NN NN O
- NN NN O
induced NN NN O
hemolytic NN NN B-Disease
anemia NN NN I-Disease
in NN NN O
a NN NN O
15 NN NN O
year NN NN O
old NN NN O
presenting NN NN O
as NN NN O
near NN NN O
- NN NN O
syncope NN NN B-Disease
. NN NN O
   
Methyldopa NN NN O
is NN NN O
an NN NN O
antihypertensive NN NN O
medication NN NN O
which NN NN O
is NN NN O
available NN NN O
generically NN NN O
and NN NN O
under NN NN O
the NN NN O
trade NN NN O
name NN NN O
Aldomet NN NN O
that NN NN O
is NN NN O
widely NN NN O
prescribed NN NN O
in NN NN O
the NN NN O
adult NN NN O
population NN NN O
and NN NN O
infrequently NN NN O
used NN NN O
in NN NN O
children NN NN O
. NN NN O
   
Methyldopa NN NN O
causes NN NN O
an NN NN O
autoimmune NN NN B-Disease
hemolytic NN NN I-Disease
anemia NN NN I-Disease
in NN NN O
a NN NN O
small NN NN O
percentage NN NN O
of NN NN O
patients NN NN O
who NN NN O
take NN NN O
the NN NN O
drug NN NN O
. NN NN O
   
We NN NN O
report NN NN O
a NN NN O
case NN NN O
of NN NN O
methyldopa NN NN O
- NN NN O
induced NN NN O
hemolytic NN NN B-Disease
anemia NN NN I-Disease
in NN NN O
a NN NN O
15 NN NN O
- NN NN O
year NN NN O
- NN NN O
old NN NN O
boy NN NN O
who NN NN O
presented NN NN O
to NN NN O
the NN NN O
emergency NN NN B-Disease
department NN NN I-Disease
with NN NN O
near NN NN O
- NN NN O
syncope NN NN B-Disease
. NN NN O
   
The NN NN O
boy NN NN O
had NN NN O
been NN NN O
treated NN NN O
with NN NN O
intravenous NN NN O
methyldopa NN NN O
during NN NN O
a NN NN O
trauma NN NN B-Disease
admission NN NN O
seven NN NN O
weeks NN NN O
prior NN NN O
to NN NN O
presentation NN NN O
. NN NN O
   
Evaluation NN NN O
revealed NN NN O
a NN NN O
hemoglobin NN NN O
of NN NN O
three NN NN O
grams NN NN O
, NN NN O
3 NN NN O
+ NN NN O
Coombs NN NN O
' NN NN O
test NN NN O
with NN NN O
polyspecific NN NN O
anti NN NN O
- NN NN O
human NN NN O
globulin NN NN O
and NN NN O
monospecific NN NN O
IgG NN NN O
reagents NN NN O
, NN NN O
and NN NN O
a NN NN O
warm NN NN O
reacting NN NN O
autoantibody NN NN O
. NN NN O
   
Transfusion NN NN O
and NN NN O
corticosteroid NN NN O
therapy NN NN O
resulted NN NN O
in NN NN O
a NN NN O
complete NN NN O
recovery NN NN O
of NN NN O
the NN NN O
patient NN NN O
. NN NN O
   
Emergency NN NN O
physicians NN NN O
treating NN NN O
children NN NN O
must NN NN O
be NN NN O
aware NN NN O
of NN NN O
this NN NN O
syndrome NN NN O
in NN NN O
order NN NN O
to NN NN O
diagnose NN NN O
and NN NN O
treat NN NN O
it NN NN O
correctly NN NN O
. NN NN O
   
A NN NN O
brief NN NN O
review NN NN O
of NN NN O
autoimmune NN NN O
and NN NN O
drug NN NN O
- NN NN O
induced NN NN O
hemolytic NN NN B-Disease
anemias NN NN I-Disease
is NN NN O
provided NN NN O
. NN NN O
   
The NN NN O
risk NN NN O
and NN NN O
associated NN NN O
factors NN NN O
of NN NN O
methamphetamine NN NN O
psychosis NN NN B-Disease
in NN NN O
methamphetamine NN NN O
- NN NN O
dependent NN NN O
patients NN NN O
in NN NN O
Malaysia NN NN O
. NN NN O
   
OBJECTIVE NN NN O
: NN NN O
The NN NN O
objective NN NN O
of NN NN O
this NN NN O
study NN NN O
was NN NN O
to NN NN O
determine NN NN O
the NN NN O
risk NN NN O
of NN NN O
lifetime NN NN O
and NN NN O
current NN NN O
methamphetamine NN NN O
- NN NN O
induced NN NN O
psychosis NN NN B-Disease
in NN NN O
patients NN NN O
with NN NN O
methamphetamine NN NN O
dependence NN NN O
. NN NN O
   
The NN NN O
association NN NN O
between NN NN O
psychiatric NN NN O
co NN NN O
- NN NN O
morbidity NN NN O
and NN NN O
methamphetamine NN NN O
- NN NN O
induced NN NN O
psychosis NN NN B-Disease
was NN NN O
also NN NN O
studied NN NN O
. NN NN O
   
METHODS NN NN O
: NN NN O
This NN NN O
was NN NN O
a NN NN O
cross NN NN O
- NN NN O
sectional NN NN O
study NN NN O
conducted NN NN O
concurrently NN NN O
at NN NN O
a NN NN O
teaching NN NN O
hospital NN NN O
and NN NN O
a NN NN O
drug NN NN O
rehabilitation NN NN O
center NN NN O
in NN NN O
Malaysia NN NN O
. NN NN O
   
Patients NN NN O
with NN NN O
the NN NN O
diagnosis NN NN O
of NN NN O
methamphetamine NN NN O
based NN NN O
on NN NN O
DSM NN NN O
- NN NN O
IV NN NN O
were NN NN O
interviewed NN NN O
using NN NN O
the NN NN O
Mini NN NN O
International NN NN O
Neuropsychiatric NN NN O
Interview NN NN O
( NN NN O
M NN NN O
. NN NN O
I NN NN O
. NN NN O
N NN NN O
. NN NN O
I NN NN O
. NN NN O
) NN NN O
for NN NN O
methamphetamine NN NN O
- NN NN O
induced NN NN O
psychosis NN NN B-Disease
and NN NN O
other NN NN O
Axis NN NN O
I NN NN O
psychiatric NN NN B-Disease
disorders NN NN I-Disease
. NN NN O
   
The NN NN O
information NN NN O
on NN NN O
sociodemographic NN NN O
background NN NN O
and NN NN O
drug NN NN O
use NN NN O
history NN NN O
was NN NN O
obtained NN NN O
from NN NN O
interview NN NN O
or NN NN O
medical NN NN O
records NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
Of NN NN O
292 NN NN O
subjects NN NN O
, NN NN O
47 NN NN O
. NN NN O
9 NN NN O
% NN NN O
of NN NN O
the NN NN O
subjects NN NN O
had NN NN O
a NN NN O
past NN NN O
history NN NN O
of NN NN O
psychotic NN NN B-Disease
symptoms NN NN I-Disease
and NN NN O
13 NN NN O
. NN NN O
0 NN NN O
% NN NN O
of NN NN O
the NN NN O
patients NN NN O
were NN NN O
having NN NN O
current NN NN O
psychotic NN NN B-Disease
symptoms NN NN I-Disease
. NN NN O
   
Co NN NN O
- NN NN O
morbid NN NN O
major NN NN O
depressive NN NN B-Disease
disorder NN NN I-Disease
( NN NN O
OR NN NN O
= NN NN O
7 NN NN O
. NN NN O
18 NN NN O
, NN NN O
95 NN NN O
CI NN NN O
= NN NN O
2 NN NN O
. NN NN O
612 NN NN O
- NN NN O
19 NN NN O
. NN NN O
708 NN NN O
) NN NN O
, NN NN O
bipolar NN NN B-Disease
disorder NN NN I-Disease
( NN NN O
OR NN NN O
= NN NN O
13 NN NN O
. NN NN O
807 NN NN O
, NN NN O
95 NN NN O
CI NN NN O
= NN NN O
5 NN NN O
. NN NN O
194 NN NN O
- NN NN O
36 NN NN O
. NN NN O
706 NN NN O
) NN NN O
, NN NN O
antisocial NN NN B-Disease
personality NN NN I-Disease
disorder NN NN I-Disease
( NN NN O
OR NN NN O
= NN NN O
12 NN NN O
. NN NN O
619 NN NN O
, NN NN O
95 NN NN O
CI NN NN O
= NN NN O
6 NN NN O
. NN NN O
702 NN NN O
- NN NN O
23 NN NN O
. NN NN O
759 NN NN O
) NN NN O
and NN NN O
heavy NN NN O
methamphetamine NN NN O
uses NN NN O
were NN NN O
significantly NN NN O
associated NN NN O
with NN NN O
lifetime NN NN O
methamphetamine NN NN O
- NN NN O
induced NN NN O
psychosis NN NN B-Disease
after NN NN O
adjusted NN NN O
for NN NN O
other NN NN O
factors NN NN O
. NN NN O
   
Major NN NN B-Disease
depressive NN NN I-Disease
disorder NN NN I-Disease
( NN NN O
OR NN NN O
= NN NN O
2 NN NN O
. NN NN O
870 NN NN O
, NN NN O
CI NN NN O
= NN NN O
1 NN NN O
. NN NN O
154 NN NN O
- NN NN O
7 NN NN O
. NN NN O
142 NN NN O
) NN NN O
and NN NN O
antisocial NN NN B-Disease
personality NN NN I-Disease
disorder NN NN I-Disease
( NN NN O
OR NN NN O
= NN NN O
3 NN NN O
. NN NN O
299 NN NN O
, NN NN O
95 NN NN O
CI NN NN O
= NN NN O
1 NN NN O
. NN NN O
375 NN NN O
- NN NN O
7 NN NN O
. NN NN O
914 NN NN O
) NN NN O
were NN NN O
the NN NN O
only NN NN O
factors NN NN O
associated NN NN O
with NN NN O
current NN NN O
psychosis NN NN B-Disease
. NN NN O
   
CONCLUSION NN NN O
: NN NN O
There NN NN O
was NN NN O
a NN NN O
high NN NN O
risk NN NN O
of NN NN O
psychosis NN NN B-Disease
in NN NN O
patients NN NN O
with NN NN O
methamphetamine NN NN O
dependence NN NN O
. NN NN O
   
It NN NN O
was NN NN O
associated NN NN O
with NN NN O
co NN NN O
- NN NN O
morbid NN NN O
affective NN NN B-Disease
disorder NN NN I-Disease
, NN NN O
antisocial NN NN B-Disease
personality NN NN I-Disease
, NN NN O
and NN NN O
heavy NN NN O
methamphetamine NN NN O
use NN NN O
. NN NN O
   
It NN NN O
is NN NN O
recommended NN NN O
that NN NN O
all NN NN O
cases NN NN O
of NN NN O
methamphetamine NN NN O
dependence NN NN O
should NN NN O
be NN NN O
screened NN NN O
for NN NN O
psychotic NN NN B-Disease
symptoms NN NN I-Disease
. NN NN O
   
Cerebellar NN NN O
sensory NN NN O
processing NN NN O
alterations NN NN O
impact NN NN O
motor NN NN O
cortical NN NN O
plasticity NN NN O
in NN NN O
Parkinson NN NN B-Disease
' NN NN I-Disease
s NN NN I-Disease
disease NN NN I-Disease
: NN NN O
clues NN NN O
from NN NN O
dyskinetic NN NN B-Disease
patients NN NN O
. NN NN O
   
The NN NN O
plasticity NN NN O
of NN NN O
primary NN NN O
motor NN NN O
cortex NN NN O
( NN NN O
M1 NN NN O
) NN NN O
in NN NN O
patients NN NN O
with NN NN O
Parkinson NN NN B-Disease
' NN NN I-Disease
s NN NN I-Disease
disease NN NN I-Disease
( NN NN O
PD NN NN B-Disease
) NN NN O
and NN NN O
levodopa NN NN O
- NN NN O
induced NN NN O
dyskinesias NN NN B-Disease
( NN NN O
LIDs NN NN B-Disease
) NN NN O
is NN NN O
severely NN NN O
impaired NN NN O
. NN NN O
   
We NN NN O
recently NN NN O
reported NN NN O
in NN NN O
young NN NN O
healthy NN NN O
subjects NN NN O
that NN NN O
inhibitory NN NN O
cerebellar NN NN O
stimulation NN NN O
enhanced NN NN O
the NN NN O
sensorimotor NN NN O
plasticity NN NN O
of NN NN O
M1 NN NN O
that NN NN O
was NN NN O
induced NN NN O
by NN NN O
paired NN NN O
associative NN NN O
stimulation NN NN O
( NN NN O
PAS NN NN O
) NN NN O
. NN NN O
   
This NN NN O
study NN NN O
demonstrates NN NN O
that NN NN O
the NN NN O
deficient NN NN O
sensorimotor NN NN O
M1 NN NN O
plasticity NN NN O
in NN NN O
16 NN NN O
patients NN NN O
with NN NN O
LIDs NN NN B-Disease
could NN NN O
be NN NN O
reinstated NN NN O
by NN NN O
a NN NN O
single NN NN O
session NN NN O
of NN NN O
real NN NN O
inhibitory NN NN O
cerebellar NN NN O
stimulation NN NN O
but NN NN O
not NN NN O
sham NN NN O
stimulation NN NN O
. NN NN O
   
This NN NN O
was NN NN O
evident NN NN O
only NN NN O
when NN NN O
a NN NN O
sensory NN NN O
component NN NN O
was NN NN O
involved NN NN O
in NN NN O
the NN NN O
induction NN NN O
of NN NN O
plasticity NN NN O
, NN NN O
indicating NN NN O
that NN NN O
cerebellar NN NN O
sensory NN NN O
processing NN NN O
function NN NN O
is NN NN O
involved NN NN O
in NN NN O
the NN NN O
resurgence NN NN O
of NN NN O
M1 NN NN O
plasticity NN NN O
. NN NN O
   
The NN NN O
benefit NN NN O
of NN NN O
inhibitory NN NN O
cerebellar NN NN O
stimulation NN NN O
on NN NN O
LIDs NN NN B-Disease
is NN NN O
known NN NN O
. NN NN O
   
To NN NN O
explore NN NN O
whether NN NN O
this NN NN O
benefit NN NN O
is NN NN O
linked NN NN O
to NN NN O
the NN NN O
restoration NN NN O
of NN NN O
sensorimotor NN NN O
plasticity NN NN O
of NN NN O
M1 NN NN O
, NN NN O
we NN NN O
conducted NN NN O
an NN NN O
additional NN NN O
study NN NN O
looking NN NN O
at NN NN O
changes NN NN O
in NN NN O
LIDs NN NN B-Disease
and NN NN O
PAS NN NN O
- NN NN O
induced NN NN O
plasticity NN NN O
after NN NN O
10 NN NN O
sessions NN NN O
of NN NN O
either NN NN O
bilateral NN NN O
, NN NN O
real NN NN O
inhibitory NN NN O
cerebellar NN NN O
stimulation NN NN O
or NN NN O
sham NN NN O
stimulation NN NN O
. NN NN O
   
Only NN NN O
real NN NN O
and NN NN O
not NN NN O
sham NN NN O
stimulation NN NN O
had NN NN O
an NN NN O
antidyskinetic NN NN O
effect NN NN O
and NN NN O
it NN NN O
was NN NN O
paralleled NN NN O
by NN NN O
a NN NN O
resurgence NN NN O
in NN NN O
the NN NN O
sensorimotor NN NN O
plasticity NN NN O
of NN NN O
M1 NN NN O
. NN NN O
   
These NN NN O
results NN NN O
suggest NN NN O
that NN NN O
alterations NN NN O
in NN NN O
cerebellar NN NN O
sensory NN NN O
processing NN NN O
function NN NN O
, NN NN O
occurring NN NN O
secondary NN NN O
to NN NN O
abnormal NN NN O
basal NN NN O
ganglia NN NN O
signals NN NN O
reaching NN NN O
it NN NN O
, NN NN O
may NN NN O
be NN NN O
an NN NN O
important NN NN O
element NN NN O
contributing NN NN O
to NN NN O
the NN NN O
maladaptive NN NN O
sensorimotor NN NN O
plasticity NN NN O
of NN NN O
M1 NN NN O
and NN NN O
the NN NN O
emergence NN NN O
of NN NN O
abnormal NN NN B-Disease
involuntary NN NN I-Disease
movements NN NN I-Disease
. NN NN O
   
The NN NN O
long NN NN O
- NN NN O
term NN NN O
safety NN NN O
of NN NN O
danazol NN NN O
in NN NN O
women NN NN O
with NN NN O
hereditary NN NN B-Disease
angioedema NN NN I-Disease
. NN NN O
   
Although NN NN O
the NN NN O
short NN NN O
- NN NN O
term NN NN O
safety NN NN O
( NN NN O
less NN NN O
than NN NN O
or NN NN O
equal NN NN O
to NN NN O
6 NN NN O
months NN NN O
) NN NN O
of NN NN O
danazol NN NN O
has NN NN O
been NN NN O
established NN NN O
in NN NN O
a NN NN O
variety NN NN O
of NN NN O
settings NN NN O
, NN NN O
no NN NN O
information NN NN O
exists NN NN O
as NN NN O
to NN NN O
its NN NN O
long NN NN O
- NN NN O
term NN NN O
safety NN NN O
. NN NN O
   
We NN NN O
therefore NN NN O
investigated NN NN O
the NN NN O
long NN NN O
- NN NN O
term NN NN O
safety NN NN O
of NN NN O
danazol NN NN O
by NN NN O
performing NN NN O
a NN NN O
retrospective NN NN O
chart NN NN O
review NN NN O
of NN NN O
60 NN NN O
female NN NN O
patients NN NN O
with NN NN O
hereditary NN NN B-Disease
angioedema NN NN I-Disease
treated NN NN O
with NN NN O
danazol NN NN O
for NN NN O
a NN NN O
continuous NN NN O
period NN NN O
of NN NN O
6 NN NN O
months NN NN O
or NN NN O
longer NN NN O
. NN NN O
   
The NN NN O
mean NN NN O
age NN NN O
of NN NN O
the NN NN O
patients NN NN O
was NN NN O
35 NN NN O
. NN NN O
2 NN NN O
years NN NN O
and NN NN O
the NN NN O
mean NN NN O
duration NN NN O
of NN NN O
therapy NN NN O
was NN NN O
59 NN NN O
. NN NN O
7 NN NN O
months NN NN O
. NN NN O
   
Virtually NN NN O
all NN NN O
patients NN NN O
experienced NN NN O
one NN NN O
or NN NN O
more NN NN O
adverse NN NN O
reactions NN NN O
. NN NN O
   
Menstrual NN NN B-Disease
abnormalities NN NN I-Disease
( NN NN O
79 NN NN O
% NN NN O
) NN NN O
, NN NN O
weight NN NN B-Disease
gain NN NN I-Disease
( NN NN O
60 NN NN O
% NN NN O
) NN NN O
, NN NN O
muscle NN NN B-Disease
cramps NN NN I-Disease
/ NN NN O
myalgias NN NN B-Disease
( NN NN O
40 NN NN O
% NN NN O
) NN NN O
, NN NN O
and NN NN O
transaminase NN NN O
elevations NN NN O
( NN NN O
40 NN NN O
% NN NN O
) NN NN O
were NN NN O
the NN NN O
most NN NN O
common NN NN O
adverse NN NN O
reactions NN NN O
. NN NN O
   
The NN NN O
drug NN NN O
was NN NN O
discontinued NN NN O
due NN NN O
to NN NN O
adverse NN NN O
reactions NN NN O
in NN NN O
8 NN NN O
patients NN NN O
. NN NN O
   
No NN NN O
patient NN NN O
has NN NN O
died NN NN O
or NN NN O
suffered NN NN O
any NN NN O
apparent NN NN O
long NN NN O
- NN NN O
term NN NN O
sequelae NN NN O
that NN NN O
were NN NN O
directly NN NN O
attributable NN NN O
to NN NN O
the NN NN O
drug NN NN O
. NN NN O
   
We NN NN O
conclude NN NN O
that NN NN O
, NN NN O
despite NN NN O
a NN NN O
relatively NN NN O
high NN NN O
incidence NN NN O
of NN NN O
adverse NN NN O
reactions NN NN O
, NN NN O
danazol NN NN O
has NN NN O
proven NN NN O
to NN NN O
be NN NN O
remarkably NN NN O
safe NN NN O
over NN NN O
the NN NN O
long NN NN O
- NN NN O
term NN NN O
in NN NN O
this NN NN O
group NN NN O
of NN NN O
patients NN NN O
. NN NN O
   
The NN NN O
function NN NN O
of NN NN O
P2X3 NN NN O
receptor NN NN O
and NN NN O
NK1 NN NN O
receptor NN NN O
antagonists NN NN O
on NN NN O
cyclophosphamide NN NN O
- NN NN O
induced NN NN O
cystitis NN NN B-Disease
in NN NN O
rats NN NN O
. NN NN O
   
PURPOSE NN NN O
: NN NN O
The NN NN O
purpose NN NN O
of NN NN O
the NN NN O
study NN NN O
is NN NN O
to NN NN O
explore NN NN O
the NN NN O
function NN NN O
of NN NN O
P2X3 NN NN O
and NN NN O
NK1 NN NN O
receptors NN NN O
antagonists NN NN O
on NN NN O
cyclophosphamide NN NN O
( NN NN O
CYP NN NN O
) NN NN O
- NN NN O
induced NN NN O
cystitis NN NN B-Disease
in NN NN O
rats NN NN O
. NN NN O
   
METHODS NN NN O
: NN NN O
Sixty NN NN O
female NN NN O
Sprague NN NN O
- NN NN O
Dawley NN NN O
( NN NN O
SD NN NN O
) NN NN O
rats NN NN O
were NN NN O
randomly NN NN O
divided NN NN O
into NN NN O
three NN NN O
groups NN NN O
. NN NN O
   
The NN NN O
rats NN NN O
in NN NN O
the NN NN O
control NN NN O
group NN NN O
were NN NN O
intraperitoneally NN NN O
( NN NN O
i NN NN O
. NN NN O
p NN NN O
. NN NN O
) NN NN O
injected NN NN O
with NN NN O
0 NN NN O
. NN NN O
9 NN NN O
% NN NN O
saline NN NN O
( NN NN O
4 NN NN O
ml NN NN O
/ NN NN O
kg NN NN O
) NN NN O
; NN NN O
the NN NN O
rats NN NN O
in NN NN O
the NN NN O
model NN NN O
group NN NN O
were NN NN O
i NN NN O
. NN NN O
p NN NN O
. NN NN O
injected NN NN O
with NN NN O
CYP NN NN O
( NN NN O
150 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
) NN NN O
; NN NN O
and NN NN O
the NN NN O
rats NN NN O
in NN NN O
the NN NN O
intervention NN NN O
group NN NN O
were NN NN O
i NN NN O
. NN NN O
p NN NN O
. NN NN O
injected NN NN O
with NN NN O
CYP NN NN O
with NN NN O
subsequently NN NN O
perfusion NN NN O
of NN NN O
bladder NN NN O
with NN NN O
P2X3 NN NN O
and NN NN O
NK1 NN NN O
receptors NN NN O
' NN NN O
antagonists NN NN O
, NN NN O
Suramin NN NN O
and NN NN O
GR NN NN O
82334 NN NN O
. NN NN O
   
Spontaneous NN NN O
pain NN NN B-Disease
behaviors NN NN O
following NN NN O
the NN NN O
administration NN NN O
of NN NN O
CYP NN NN O
were NN NN O
observed NN NN O
. NN NN O
   
Urodynamic NN NN O
parameters NN NN O
, NN NN O
bladder NN NN O
pressure NN NN O
- NN NN O
volume NN NN O
curve NN NN O
, NN NN O
maximum NN NN O
voiding NN NN O
pressure NN NN O
( NN NN O
MVP NN NN O
) NN NN O
, NN NN O
and NN NN O
maximum NN NN O
cystometric NN NN O
capacity NN NN O
( NN NN O
MCC NN NN O
) NN NN O
, NN NN O
were NN NN O
recorded NN NN O
. NN NN O
   
Pathological NN NN O
changes NN NN O
in NN NN O
bladder NN NN O
tissue NN NN O
were NN NN O
observed NN NN O
. NN NN O
   
Immunofluorescence NN NN O
was NN NN O
used NN NN O
to NN NN O
detect NN NN O
the NN NN O
expression NN NN O
of NN NN O
P2X3 NN NN O
and NN NN O
NK1 NN NN O
receptors NN NN O
in NN NN O
bladder NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
Cyclophosphamide NN NN O
treatment NN NN O
increased NN NN O
the NN NN O
spontaneous NN NN O
pain NN NN B-Disease
behaviors NN NN O
scores NN NN O
. NN NN O
   
The NN NN O
incidence NN NN O
of NN NN O
bladder NN NN O
instability NN NN O
during NN NN O
urine NN NN O
storage NN NN O
period NN NN O
of NN NN O
model NN NN O
group NN NN O
was NN NN O
significantly NN NN O
higher NN NN O
than NN NN O
intervention NN NN O
group NN NN O
( NN NN O
X NN NN O
( NN NN O
2 NN NN O
) NN NN O
= NN NN O
7 NN NN O
. NN NN O
619 NN NN O
, NN NN O
P NN NN O
= NN NN O
0 NN NN O
. NN NN O
007 NN NN O
) NN NN O
and NN NN O
control NN NN O
group NN NN O
( NN NN O
X NN NN O
( NN NN O
2 NN NN O
) NN NN O
= NN NN O
13 NN NN O
. NN NN O
755 NN NN O
, NN NN O
P NN NN O
= NN NN O
0 NN NN O
. NN NN O
000 NN NN O
) NN NN O
. NN NN O
   
MCC NN NN O
in NN NN O
the NN NN O
model NN NN O
group NN NN O
was NN NN O
lower NN NN O
than NN NN O
the NN NN O
control NN NN O
and NN NN O
intervention NN NN O
groups NN NN O
( NN NN O
P NN NN O
< NN NN O
0 NN NN O
. NN NN O
01 NN NN O
) NN NN O
. NN NN O
   
Histological NN NN O
changes NN NN O
evident NN NN O
in NN NN O
model NN NN O
and NN NN O
intervention NN NN O
groups NN NN O
rats NN NN O
' NN NN O
bladder NN NN O
included NN NN O
edema NN NN B-Disease
, NN NN O
vasodilation NN NN O
, NN NN O
and NN NN O
infiltration NN NN O
of NN NN O
inflammatory NN NN O
cells NN NN O
. NN NN O
   
In NN NN O
model NN NN O
group NN NN O
, NN NN O
the NN NN O
expression NN NN O
of NN NN O
P2X3 NN NN O
receptor NN NN O
increased NN NN O
in NN NN O
urothelium NN NN O
and NN NN O
suburothelium NN NN O
, NN NN O
and NN NN O
NK1 NN NN O
receptor NN NN O
increased NN NN O
in NN NN O
suburothelium NN NN O
, NN NN O
while NN NN O
the NN NN O
expression NN NN O
of NN NN O
them NN NN O
in NN NN O
intervention NN NN O
group NN NN O
was NN NN O
lower NN NN O
. NN NN O
   
CONCLUSIONS NN NN O
: NN NN O
In NN NN O
CYP NN NN O
- NN NN O
induced NN NN O
cystitis NN NN B-Disease
, NN NN O
the NN NN O
expression NN NN O
of NN NN O
P2X3 NN NN O
and NN NN O
NK1 NN NN O
receptors NN NN O
increased NN NN O
in NN NN O
urothelium NN NN O
and NN NN O
/ NN NN O
or NN NN O
suburothelium NN NN O
. NN NN O
   
Perfusion NN NN O
of NN NN O
bladder NN NN O
with NN NN O
P2X3 NN NN O
and NN NN O
NK1 NN NN O
receptors NN NN O
antagonists NN NN O
ameliorated NN NN O
the NN NN O
bladder NN NN O
function NN NN O
. NN NN O
   
Patient NN NN O
tolerance NN NN O
study NN NN O
of NN NN O
topical NN NN O
chlorhexidine NN NN O
diphosphanilate NN NN O
: NN NN O
a NN NN O
new NN NN O
topical NN NN O
agent NN NN O
for NN NN O
burns NN NN B-Disease
. NN NN O
   
Effective NN NN O
topical NN NN O
antimicrobial NN NN O
agents NN NN O
decrease NN NN O
infection NN NN B-Disease
and NN NN O
mortality NN NN O
in NN NN O
burn NN NN B-Disease
patients NN NN O
. NN NN O
   
Chlorhexidine NN NN O
phosphanilate NN NN O
( NN NN O
CHP NN NN O
) NN NN O
, NN NN O
a NN NN O
new NN NN O
broad NN NN O
- NN NN O
spectrum NN NN O
antimicrobial NN NN O
agent NN NN O
, NN NN O
has NN NN O
been NN NN O
evaluated NN NN O
as NN NN O
a NN NN O
topical NN NN O
burn NN NN B-Disease
wound NN NN O
dressing NN NN O
in NN NN O
cream NN NN O
form NN NN O
, NN NN O
but NN NN O
preliminary NN NN O
clinical NN NN O
trials NN NN O
reported NN NN O
that NN NN O
it NN NN O
was NN NN O
painful NN NN O
upon NN NN O
application NN NN O
. NN NN O
   
This NN NN O
study NN NN O
compared NN NN O
various NN NN O
concentrations NN NN O
of NN NN O
CHP NN NN O
to NN NN O
determine NN NN O
if NN NN O
a NN NN O
tolerable NN NN O
concentration NN NN O
could NN NN O
be NN NN O
identified NN NN O
with NN NN O
retention NN NN O
of NN NN O
antimicrobial NN NN O
efficacy NN NN O
. NN NN O
   
Twenty NN NN O
- NN NN O
nine NN NN O
burn NN NN B-Disease
patients NN NN O
, NN NN O
each NN NN O
with NN NN O
two NN NN O
similar NN NN O
burns NN NN B-Disease
which NN NN O
could NN NN O
be NN NN O
separately NN NN O
treated NN NN O
, NN NN O
were NN NN O
given NN NN O
pairs NN NN O
of NN NN O
treatments NN NN O
at NN NN O
successive NN NN O
12 NN NN O
- NN NN O
h NN NN O
intervals NN NN O
over NN NN O
a NN NN O
3 NN NN O
- NN NN O
day NN NN O
period NN NN O
. NN NN O
   
One NN NN O
burn NN NN B-Disease
site NN NN O
was NN NN O
treated NN NN O
with NN NN O
each NN NN O
of NN NN O
four NN NN O
different NN NN O
CHP NN NN O
concentrations NN NN O
, NN NN O
from NN NN O
0 NN NN O
. NN NN O
25 NN NN O
per NN NN O
cent NN NN O
to NN NN O
2 NN NN O
per NN NN O
cent NN NN O
, NN NN O
their NN NN O
vehicle NN NN O
, NN NN O
and NN NN O
1 NN NN O
per NN NN O
cent NN NN O
silver NN NN O
sulphadiazine NN NN O
( NN NN O
AgSD NN NN O
) NN NN O
cream NN NN O
, NN NN O
an NN NN O
antimicrobial NN NN O
agent NN NN O
frequently NN NN O
used NN NN O
for NN NN O
topical NN NN O
treatment NN NN O
of NN NN O
burn NN NN B-Disease
wounds NN NN O
. NN NN O
   
The NN NN O
other NN NN O
site NN NN O
was NN NN O
always NN NN O
treated NN NN O
with NN NN O
AgSD NN NN O
cream NN NN O
. NN NN O
   
There NN NN O
was NN NN O
a NN NN O
direct NN NN O
relationship NN NN O
between NN NN O
CHP NN NN O
concentration NN NN O
and NN NN O
patients NN NN O
' NN NN O
ratings NN NN O
of NN NN O
pain NN NN B-Disease
on NN NN O
an NN NN O
analogue NN NN O
scale NN NN O
. NN NN O
   
The NN NN O
0 NN NN O
. NN NN O
25 NN NN O
per NN NN O
cent NN NN O
CHP NN NN O
cream NN NN O
was NN NN O
closest NN NN O
to NN NN O
AgSD NN NN O
in NN NN O
pain NN NN B-Disease
tolerance NN NN O
; NN NN O
however NN NN O
, NN NN O
none NN NN O
of NN NN O
the NN NN O
treatments NN NN O
differed NN NN O
statistically NN NN O
from NN NN O
AgSD NN NN O
or NN NN O
from NN NN O
each NN NN O
other NN NN O
. NN NN O
   
In NN NN O
addition NN NN O
, NN NN O
ease NN NN O
of NN NN O
application NN NN O
of NN NN O
CHP NN NN O
creams NN NN O
was NN NN O
less NN NN O
satisfactory NN NN O
than NN NN O
that NN NN O
of NN NN O
AgSD NN NN O
. NN NN O
   
It NN NN O
was NN NN O
concluded NN NN O
that NN NN O
formulations NN NN O
at NN NN O
or NN NN O
below NN NN O
0 NN NN O
. NN NN O
5 NN NN O
per NN NN O
cent NN NN O
CHP NN NN O
may NN NN O
prove NN NN O
acceptable NN NN O
for NN NN O
wound NN NN O
care NN NN O
, NN NN O
but NN NN O
the NN NN O
vehicle NN NN O
system NN NN O
needs NN NN O
pharmaceutical NN NN O
improvement NN NN O
to NN NN O
render NN NN O
it NN NN O
more NN NN O
tolerable NN NN O
and NN NN O
easier NN NN O
to NN NN O
use NN NN O
. NN NN O
   
Acute NN NN O
hepatitis NN NN B-Disease
associated NN NN O
with NN NN O
clopidogrel NN NN O
: NN NN O
a NN NN O
case NN NN O
report NN NN O
and NN NN O
review NN NN O
of NN NN O
the NN NN O
literature NN NN O
. NN NN O
   
Drug NN NN O
- NN NN O
induced NN NN O
hepatotoxicity NN NN B-Disease
is NN NN O
a NN NN O
common NN NN O
cause NN NN O
of NN NN O
acute NN NN O
hepatitis NN NN B-Disease
, NN NN O
and NN NN O
the NN NN O
recognition NN NN O
of NN NN O
the NN NN O
responsible NN NN O
drug NN NN O
may NN NN O
be NN NN O
difficult NN NN O
. NN NN O
   
We NN NN O
describe NN NN O
a NN NN O
case NN NN O
of NN NN O
clopidogrel NN NN O
- NN NN O
related NN NN O
acute NN NN O
hepatitis NN NN B-Disease
. NN NN O
   
The NN NN O
diagnosis NN NN O
is NN NN O
strongly NN NN O
suggested NN NN O
by NN NN O
an NN NN O
accurate NN NN O
medical NN NN O
history NN NN O
and NN NN O
liver NN NN O
biopsy NN NN O
. NN NN O
   
Reports NN NN O
about NN NN O
cases NN NN O
of NN NN O
hepatotoxicity NN NN B-Disease
due NN NN O
to NN NN O
clopidogrel NN NN O
are NN NN O
increasing NN NN O
in NN NN O
the NN NN O
last NN NN O
few NN NN O
years NN NN O
, NN NN O
after NN NN O
the NN NN O
increased NN NN O
use NN NN O
of NN NN O
this NN NN O
drug NN NN O
. NN NN O
   
In NN NN O
conclusion NN NN O
, NN NN O
we NN NN O
believe NN NN O
that NN NN O
physicians NN NN O
should NN NN O
carefully NN NN O
consider NN NN O
the NN NN O
risk NN NN O
of NN NN O
drug NN NN O
- NN NN O
induced NN NN O
hepatic NN NN B-Disease
injury NN NN I-Disease
when NN NN O
clopidogrel NN NN O
is NN NN O
prescribed NN NN O
. NN NN O
   
Bortezomib NN NN O
and NN NN O
dexamethasone NN NN O
as NN NN O
salvage NN NN O
therapy NN NN O
in NN NN O
patients NN NN O
with NN NN O
relapsed NN NN O
/ NN NN O
refractory NN NN O
multiple NN NN B-Disease
myeloma NN NN I-Disease
: NN NN O
analysis NN NN O
of NN NN O
long NN NN O
- NN NN O
term NN NN O
clinical NN NN O
outcomes NN NN O
. NN NN O
   
Bortezomib NN NN O
( NN NN O
bort NN NN O
) NN NN O
- NN NN O
dexamethasone NN NN O
( NN NN O
dex NN NN O
) NN NN O
is NN NN O
an NN NN O
effective NN NN O
therapy NN NN O
for NN NN O
relapsed NN NN O
/ NN NN O
refractory NN NN O
( NN NN O
R NN NN O
/ NN NN O
R NN NN O
) NN NN O
multiple NN NN B-Disease
myeloma NN NN I-Disease
( NN NN O
MM NN NN B-Disease
) NN NN O
. NN NN O
   
This NN NN O
retrospective NN NN O
study NN NN O
investigated NN NN O
the NN NN O
combination NN NN O
of NN NN O
bort NN NN O
( NN NN O
1 NN NN O
. NN NN O
3 NN NN O
mg NN NN O
/ NN NN O
m NN NN O
( NN NN O
2 NN NN O
) NN NN O
on NN NN O
days NN NN O
1 NN NN O
, NN NN O
4 NN NN O
, NN NN O
8 NN NN O
, NN NN O
and NN NN O
11 NN NN O
every NN NN O
3 NN NN O
weeks NN NN O
) NN NN O
and NN NN O
dex NN NN O
( NN NN O
20 NN NN O
mg NN NN O
on NN NN O
the NN NN O
day NN NN O
of NN NN O
and NN NN O
the NN NN O
day NN NN O
after NN NN O
bort NN NN O
) NN NN O
as NN NN O
salvage NN NN O
treatment NN NN O
in NN NN O
85 NN NN O
patients NN NN O
with NN NN O
R NN NN O
/ NN NN O
R NN NN O
MM NN NN B-Disease
after NN NN O
prior NN NN O
autologous NN NN O
stem NN NN O
cell NN NN O
transplantation NN NN O
or NN NN O
conventional NN NN O
chemotherapy NN NN O
. NN NN O
   
The NN NN O
median NN NN O
number NN NN O
of NN NN O
prior NN NN O
lines NN NN O
of NN NN O
therapy NN NN O
was NN NN O
2 NN NN O
. NN NN O
   
Eighty NN NN O
- NN NN O
seven NN NN O
percent NN NN O
of NN NN O
the NN NN O
patients NN NN O
had NN NN O
received NN NN O
immunomodulatory NN NN O
drugs NN NN O
included NN NN O
in NN NN O
some NN NN O
line NN NN O
of NN NN O
therapy NN NN O
before NN NN O
bort NN NN O
- NN NN O
dex NN NN O
. NN NN O
   
The NN NN O
median NN NN O
number NN NN O
of NN NN O
bort NN NN O
- NN NN O
dex NN NN O
cycles NN NN O
was NN NN O
6 NN NN O
, NN NN O
up NN NN O
to NN NN O
a NN NN O
maximum NN NN O
of NN NN O
12 NN NN O
cycles NN NN O
. NN NN O
   
On NN NN O
an NN NN O
intention NN NN O
- NN NN O
to NN NN O
- NN NN O
treat NN NN O
basis NN NN O
, NN NN O
55 NN NN O
% NN NN O
of NN NN O
the NN NN O
patients NN NN O
achieved NN NN O
at NN NN O
least NN NN O
partial NN NN O
response NN NN O
, NN NN O
including NN NN O
19 NN NN O
% NN NN O
CR NN NN O
and NN NN O
35 NN NN O
% NN NN O
achieved NN NN O
at NN NN O
least NN NN O
very NN NN O
good NN NN O
partial NN NN O
response NN NN O
. NN NN O
   
Median NN NN O
durations NN NN O
of NN NN O
response NN NN O
, NN NN O
time NN NN O
to NN NN O
next NN NN O
therapy NN NN O
and NN NN O
treatment NN NN O
- NN NN O
free NN NN O
interval NN NN O
were NN NN O
8 NN NN O
, NN NN O
11 NN NN O
. NN NN O
2 NN NN O
, NN NN O
and NN NN O
5 NN NN O
. NN NN O
1 NN NN O
months NN NN O
, NN NN O
respectively NN NN O
. NN NN O
   
The NN NN O
most NN NN O
relevant NN NN O
adverse NN NN O
event NN NN O
was NN NN O
peripheral NN NN B-Disease
neuropathy NN NN I-Disease
, NN NN O
which NN NN O
occurred NN NN O
in NN NN O
78 NN NN O
% NN NN O
of NN NN O
the NN NN O
patients NN NN O
( NN NN O
grade NN NN O
II NN NN O
, NN NN O
38 NN NN O
% NN NN O
; NN NN O
grade NN NN O
III NN NN O
, NN NN O
21 NN NN O
% NN NN O
) NN NN O
and NN NN O
led NN NN O
to NN NN O
treatment NN NN O
discontinuation NN NN O
in NN NN O
6 NN NN O
% NN NN O
. NN NN O
   
With NN NN O
a NN NN O
median NN NN O
follow NN NN O
up NN NN O
of NN NN O
22 NN NN O
months NN NN O
, NN NN O
median NN NN O
time NN NN O
to NN NN O
progression NN NN O
, NN NN O
progression NN NN O
- NN NN O
free NN NN O
survival NN NN O
( NN NN O
PFS NN NN O
) NN NN O
and NN NN O
overall NN NN O
survival NN NN O
( NN NN O
OS NN NN O
) NN NN O
were NN NN O
8 NN NN O
. NN NN O
9 NN NN O
, NN NN O
8 NN NN O
. NN NN O
7 NN NN O
, NN NN O
and NN NN O
22 NN NN O
months NN NN O
, NN NN O
respectively NN NN O
. NN NN O
   
Prolonged NN NN O
PFS NN NN O
and NN NN O
OS NN NN O
were NN NN O
observed NN NN O
in NN NN O
patients NN NN O
achieving NN NN O
CR NN NN O
and NN NN O
receiving NN NN O
bort NN NN O
- NN NN O
dex NN NN O
a NN NN O
single NN NN O
line NN NN O
of NN NN O
prior NN NN O
therapy NN NN O
. NN NN O
   
Bort NN NN O
- NN NN O
dex NN NN O
was NN NN O
an NN NN O
effective NN NN O
salvage NN NN O
treatment NN NN O
for NN NN O
MM NN NN B-Disease
patients NN NN O
, NN NN O
particularly NN NN O
for NN NN O
those NN NN O
in NN NN O
first NN NN O
relapse NN NN O
. NN NN O
   
Pubertal NN NN O
exposure NN NN O
to NN NN O
Bisphenol NN NN O
A NN NN O
increases NN NN O
anxiety NN NN B-Disease
- NN NN O
like NN NN O
behavior NN NN O
and NN NN O
decreases NN NN O
acetylcholinesterase NN NN O
activity NN NN O
of NN NN O
hippocampus NN NN O
in NN NN O
adult NN NN O
male NN NN O
mice NN NN O
. NN NN O
   
The NN NN O
negative NN NN O
effects NN NN O
of NN NN O
Bisphenol NN NN O
A NN NN O
( NN NN O
BPA NN NN O
) NN NN O
on NN NN O
neurodevelopment NN NN O
and NN NN O
behaviors NN NN O
have NN NN O
been NN NN O
well NN NN O
established NN NN O
. NN NN O
   
Acetylcholinesterase NN NN O
( NN NN O
AChE NN NN O
) NN NN O
is NN NN O
a NN NN O
regulatory NN NN O
enzyme NN NN O
which NN NN O
is NN NN O
involved NN NN O
in NN NN O
anxiety NN NN B-Disease
- NN NN O
like NN NN O
behavior NN NN O
. NN NN O
   
This NN NN O
study NN NN O
investigated NN NN O
behavioral NN NN O
phenotypes NN NN O
and NN NN O
AChE NN NN O
activity NN NN O
in NN NN O
male NN NN O
mice NN NN O
following NN NN O
BPA NN NN O
exposure NN NN O
during NN NN O
puberty NN NN O
. NN NN O
   
On NN NN O
postnatal NN NN O
day NN NN O
( NN NN O
PND NN NN O
) NN NN O
35 NN NN O
, NN NN O
male NN NN O
mice NN NN O
were NN NN O
exposed NN NN O
to NN NN O
50mg NN NN O
BPA NN NN O
/ NN NN O
kg NN NN O
diet NN NN O
per NN NN O
day NN NN O
for NN NN O
a NN NN O
period NN NN O
of NN NN O
35 NN NN O
days NN NN O
. NN NN O
   
On NN NN O
PND71 NN NN O
, NN NN O
a NN NN O
behavioral NN NN O
assay NN NN O
was NN NN O
performed NN NN O
using NN NN O
the NN NN O
elevated NN NN O
plus NN NN O
maze NN NN O
( NN NN O
EPM NN NN O
) NN NN O
and NN NN O
the NN NN O
light NN NN O
/ NN NN O
dark NN NN O
test NN NN O
. NN NN O
   
In NN NN O
addition NN NN O
, NN NN O
AChE NN NN O
activity NN NN O
was NN NN O
measured NN NN O
in NN NN O
the NN NN O
prefrontal NN NN O
cortex NN NN O
, NN NN O
hypothalamus NN NN O
, NN NN O
cerebellum NN NN O
and NN NN O
hippocampus NN NN O
. NN NN O
   
Results NN NN O
from NN NN O
our NN NN O
behavioral NN NN O
phenotyping NN NN O
indicated NN NN O
that NN NN O
anxiety NN NN B-Disease
- NN NN O
like NN NN O
behavior NN NN O
was NN NN O
increased NN NN O
in NN NN O
mice NN NN O
exposed NN NN O
to NN NN O
BPA NN NN O
. NN NN O
   
AChE NN NN O
activity NN NN O
was NN NN O
significantly NN NN O
decreased NN NN O
in NN NN O
the NN NN O
hippocampus NN NN O
of NN NN O
mice NN NN O
with NN NN O
BPA NN NN O
compared NN NN O
to NN NN O
control NN NN O
mice NN NN O
, NN NN O
whereas NN NN O
no NN NN O
difference NN NN O
was NN NN O
found NN NN O
in NN NN O
the NN NN O
prefrontal NN NN O
cortex NN NN O
, NN NN O
hypothalamus NN NN O
and NN NN O
cerebellum NN NN O
. NN NN O
   
Our NN NN O
findings NN NN O
showed NN NN O
that NN NN O
pubertal NN NN O
BPA NN NN O
exposure NN NN O
increased NN NN O
anxiety NN NN B-Disease
- NN NN O
like NN NN O
behavior NN NN O
, NN NN O
which NN NN O
may NN NN O
be NN NN O
associated NN NN O
with NN NN O
decreased NN NN O
AChE NN NN O
activity NN NN O
of NN NN O
the NN NN O
hippocampus NN NN O
in NN NN O
adult NN NN O
male NN NN O
mice NN NN O
. NN NN O
   
Further NN NN O
studies NN NN O
are NN NN O
necessary NN NN O
to NN NN O
investigate NN NN O
the NN NN O
cholinergic NN NN O
signaling NN NN O
of NN NN O
the NN NN O
hippocampus NN NN O
in NN NN O
PBE NN NN O
induced NN NN O
anxiety NN NN B-Disease
- NN NN O
like NN NN O
behaviors NN NN O
. NN NN O
   
Biochemical NN NN O
effects NN NN O
of NN NN O
Solidago NN NN O
virgaurea NN NN O
extract NN NN O
on NN NN O
experimental NN NN O
cardiotoxicity NN NN B-Disease
. NN NN O
   
Cardiovascular NN NN B-Disease
diseases NN NN I-Disease
( NN NN O
CVDs NN NN B-Disease
) NN NN O
are NN NN O
the NN NN O
major NN NN O
health NN NN O
problem NN NN O
of NN NN O
advanced NN NN O
as NN NN O
well NN NN O
as NN NN O
developing NN NN O
countries NN NN O
of NN NN O
the NN NN O
world NN NN O
. NN NN O
   
The NN NN O
aim NN NN O
of NN NN O
the NN NN O
present NN NN O
study NN NN O
was NN NN O
to NN NN O
investigate NN NN O
the NN NN O
protective NN NN O
effect NN NN O
of NN NN O
the NN NN O
Solidago NN NN O
virgaurea NN NN O
extract NN NN O
on NN NN O
isoproterenol NN NN O
- NN NN O
induced NN NN O
cardiotoxicity NN NN B-Disease
in NN NN O
rats NN NN O
. NN NN O
   
The NN NN O
subcutaneous NN NN O
injection NN NN O
of NN NN O
isoproterenol NN NN O
( NN NN O
30 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
) NN NN O
into NN NN O
rats NN NN O
twice NN NN O
at NN NN O
an NN NN O
interval NN NN O
of NN NN O
24 NN NN O
h NN NN O
, NN NN O
for NN NN O
two NN NN O
consecutive NN NN O
days NN NN O
, NN NN O
led NN NN O
to NN NN O
a NN NN O
significant NN NN O
increase NN NN O
in NN NN O
serum NN NN O
lactate NN NN O
dehydrogenase NN NN O
, NN NN O
creatine NN NN O
phosphokinase NN NN O
, NN NN O
alanine NN NN O
transaminase NN NN O
, NN NN O
aspartate NN NN O
transaminase NN NN O
, NN NN O
and NN NN O
angiotensin NN NN O
- NN NN O
converting NN NN O
enzyme NN NN O
activities NN NN O
, NN NN O
total NN NN O
cholesterol NN NN O
, NN NN O
triglycerides NN NN O
, NN NN O
free NN NN O
serum NN NN O
fatty NN NN O
acid NN NN O
, NN NN O
cardiac NN NN O
tissue NN NN O
malondialdehyde NN NN O
( NN NN O
MDA NN NN O
) NN NN O
, NN NN O
and NN NN O
nitric NN NN O
oxide NN NN O
levels NN NN O
and NN NN O
a NN NN O
significant NN NN O
decrease NN NN O
in NN NN O
levels NN NN O
of NN NN O
glutathione NN NN O
and NN NN O
superoxide NN NN O
dismutase NN NN O
in NN NN O
cardiac NN NN O
tissue NN NN O
as NN NN O
compared NN NN O
to NN NN O
the NN NN O
normal NN NN O
control NN NN O
group NN NN O
( NN NN O
P NN NN O
< NN NN O
0 NN NN O
. NN NN O
05 NN NN O
) NN NN O
. NN NN O
   
Pretreatment NN NN O
with NN NN O
S NN NN O
. NN NN O
virgaurea NN NN O
extract NN NN O
for NN NN O
5 NN NN O
weeks NN NN O
at NN NN O
a NN NN O
dose NN NN O
of NN NN O
250 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
followed NN NN O
by NN NN O
isoproterenol NN NN O
injection NN NN O
significantly NN NN O
prevented NN NN O
the NN NN O
observed NN NN O
alterations NN NN O
. NN NN O
   
Captopril NN NN O
( NN NN O
50 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
/ NN NN O
day NN NN O
, NN NN O
given NN NN O
orally NN NN O
) NN NN O
, NN NN O
an NN NN O
inhibitor NN NN O
of NN NN O
angiotensin NN NN O
- NN NN O
converting NN NN O
enzyme NN NN O
used NN NN O
as NN NN O
a NN NN O
standard NN NN O
cardioprotective NN NN O
drug NN NN O
, NN NN O
was NN NN O
used NN NN O
as NN NN O
a NN NN O
positive NN NN O
control NN NN O
in NN NN O
this NN NN O
study NN NN O
. NN NN O
   
The NN NN O
data NN NN O
of NN NN O
the NN NN O
present NN NN O
study NN NN O
suggest NN NN O
that NN NN O
S NN NN O
. NN NN O
virgaurea NN NN O
extract NN NN O
exerts NN NN O
its NN NN O
protective NN NN O
effect NN NN O
by NN NN O
decreasing NN NN O
MDA NN NN O
level NN NN O
and NN NN O
increasing NN NN O
the NN NN O
antioxidant NN NN O
status NN NN O
in NN NN O
isoproterenol NN NN O
- NN NN O
treated NN NN O
rats NN NN O
. NN NN O
   
The NN NN O
study NN NN O
emphasizes NN NN O
the NN NN O
beneficial NN NN O
action NN NN O
of NN NN O
S NN NN O
. NN NN O
virgaurea NN NN O
extract NN NN O
as NN NN O
a NN NN O
cardioprotective NN NN O
agent NN NN O
. NN NN O
   
"""""""" NN NN O
Real NN NN O
- NN NN O
world NN NN O
"""""""" NN NN O
data NN NN O
on NN NN O
the NN NN O
efficacy NN NN O
and NN NN O
safety NN NN O
of NN NN O
lenalidomide NN NN O
and NN NN O
dexamethasone NN NN O
in NN NN O
patients NN NN O
with NN NN O
relapsed NN NN O
/ NN NN O
refractory NN NN O
multiple NN NN B-Disease
myeloma NN NN I-Disease
who NN NN O
were NN NN O
treated NN NN O
according NN NN O
to NN NN O
the NN NN O
standard NN NN O
clinical NN NN O
practice NN NN O
: NN NN O
a NN NN O
study NN NN O
of NN NN O
the NN NN O
Greek NN NN O
Myeloma NN NN B-Disease
Study NN NN O
Group NN NN O
. NN NN O
   
Lenalidomide NN NN O
and NN NN O
dexamethasone NN NN O
( NN NN O
RD NN NN O
) NN NN O
is NN NN O
a NN NN O
standard NN NN O
of NN NN O
care NN NN O
for NN NN O
relapsed NN NN O
/ NN NN O
refractory NN NN O
multiple NN NN B-Disease
myeloma NN NN I-Disease
( NN NN O
RRMM NN NN B-Disease
) NN NN O
, NN NN O
but NN NN O
there NN NN O
is NN NN O
limited NN NN O
published NN NN O
data NN NN O
on NN NN O
its NN NN O
efficacy NN NN O
and NN NN O
safety NN NN O
in NN NN O
the NN NN O
"""""""" NN NN O
real NN NN O
world NN NN O
"""""""" NN NN O
( NN NN O
RW NN NN O
) NN NN O
, NN NN O
according NN NN O
to NN NN O
the NN NN O
International NN NN O
Society NN NN O
of NN NN O
Pharmacoeconomics NN NN O
and NN NN O
Outcomes NN NN O
Research NN NN O
definition NN NN O
. NN NN O
   
We NN NN O
studied NN NN O
212 NN NN O
RRMM NN NN B-Disease
patients NN NN O
who NN NN O
received NN NN O
RD NN NN O
in NN NN O
RW NN NN O
. NN NN O
   
Objective NN NN O
response NN NN O
( NN NN O
> NN NN O
PR NN NN O
( NN NN O
partial NN NN O
response NN NN O
) NN NN O
) NN NN O
rate NN NN O
was NN NN O
77 NN NN O
. NN NN O
4 NN NN O
% NN NN O
( NN NN O
complete NN NN O
response NN NN O
( NN NN O
CR NN NN O
) NN NN O
, NN NN O
20 NN NN O
. NN NN O
2 NN NN O
% NN NN O
) NN NN O
. NN NN O
   
Median NN NN O
time NN NN O
to NN NN O
first NN NN O
and NN NN O
best NN NN O
response NN NN O
was NN NN O
2 NN NN O
and NN NN O
5 NN NN O
months NN NN O
, NN NN O
respectively NN NN O
. NN NN O
   
Median NN NN O
time NN NN O
to NN NN O
CR NN NN O
when NN NN O
RD NN NN O
was NN NN O
given NN NN O
as NN NN O
2nd NN NN O
or NN NN O
> NN NN O
2 NN NN O
( NN NN O
nd NN NN O
) NN NN O
- NN NN O
line NN NN O
treatment NN NN O
at NN NN O
4 NN NN O
and NN NN O
11 NN NN O
months NN NN O
, NN NN O
respectively NN NN O
. NN NN O
   
Quality NN NN O
of NN NN O
response NN NN O
was NN NN O
independent NN NN O
of NN NN O
previous NN NN O
lines NN NN O
of NN NN O
therapies NN NN O
or NN NN O
previous NN NN O
exposure NN NN O
to NN NN O
thalidomide NN NN O
or NN NN O
bortezomib NN NN O
. NN NN O
   
Median NN NN O
duration NN NN O
of NN NN O
response NN NN O
was NN NN O
34 NN NN O
. NN NN O
4 NN NN O
months NN NN O
, NN NN O
and NN NN O
it NN NN O
was NN NN O
higher NN NN O
in NN NN O
patients NN NN O
who NN NN O
received NN NN O
RD NN NN O
until NN NN O
progression NN NN O
( NN NN O
not NN NN O
reached NN NN O
versus NN NN O
19 NN NN O
months NN NN O
, NN NN O
p NN NN O
< NN NN O
0 NN NN O
. NN NN O
001 NN NN O
) NN NN O
. NN NN O
   
Improvement NN NN O
of NN NN O
humoral NN NN O
immunity NN NN O
occurred NN NN O
in NN NN O
60 NN NN O
% NN NN O
of NN NN O
responders NN NN O
( NN NN O
p NN NN O
< NN NN O
0 NN NN O
. NN NN O
001 NN NN O
) NN NN O
and NN NN O
in NN NN O
the NN NN O
majority NN NN O
of NN NN O
patients NN NN O
who NN NN O
achieved NN NN O
stable NN NN O
disease NN NN O
. NN NN O
   
Adverse NN NN O
events NN NN O
were NN NN O
reported NN NN O
in NN NN O
68 NN NN O
. NN NN O
9 NN NN O
% NN NN O
of NN NN O
patients NN NN O
( NN NN O
myelosuppression NN NN B-Disease
in NN NN O
49 NN NN O
. NN NN O
4 NN NN O
% NN NN O
) NN NN O
and NN NN O
12 NN NN O
. NN NN O
7 NN NN O
% NN NN O
of NN NN O
patients NN NN O
needed NN NN O
hospitalization NN NN O
. NN NN O
   
Peripheral NN NN B-Disease
neuropathy NN NN I-Disease
was NN NN O
observed NN NN O
only NN NN O
in NN NN O
2 NN NN O
. NN NN O
5 NN NN O
% NN NN O
of NN NN O
patients NN NN O
and NN NN O
deep NN NN B-Disease
vein NN NN I-Disease
thrombosis NN NN I-Disease
in NN NN O
5 NN NN O
. NN NN O
7 NN NN O
% NN NN O
. NN NN O
   
Dose NN NN O
reductions NN NN O
were NN NN O
needed NN NN O
in NN NN O
31 NN NN O
% NN NN O
of NN NN O
patients NN NN O
and NN NN O
permanent NN NN O
discontinuation NN NN O
in NN NN O
38 NN NN O
. NN NN O
9 NN NN O
% NN NN O
. NN NN O
   
Median NN NN O
time NN NN O
to NN NN O
treatment NN NN O
discontinuation NN NN O
was NN NN O
16 NN NN O
. NN NN O
8 NN NN O
months NN NN O
. NN NN O
   
Performance NN NN O
status NN NN O
( NN NN O
PS NN NN O
) NN NN O
and NN NN O
initial NN NN O
lenalidomide NN NN O
dose NN NN O
predicted NN NN O
for NN NN O
treatment NN NN O
discontinuation NN NN O
. NN NN O
   
Extra NN NN O
- NN NN O
medullary NN NN O
relapses NN NN O
occurred NN NN O
in NN NN O
3 NN NN O
. NN NN O
8 NN NN O
% NN NN O
of NN NN O
patients NN NN O
. NN NN O
   
Our NN NN O
study NN NN O
confirms NN NN O
that NN NN O
RD NN NN O
is NN NN O
effective NN NN O
and NN NN O
safe NN NN O
in NN NN O
RRMM NN NN B-Disease
in NN NN O
the NN NN O
RW NN NN O
; NN NN O
it NN NN O
produces NN NN O
durable NN NN O
responses NN NN O
especially NN NN O
in NN NN O
patients NN NN O
who NN NN O
continue NN NN O
on NN NN O
treatment NN NN O
till NN NN O
progression NN NN O
and NN NN O
improves NN NN O
humoral NN NN O
immunity NN NN O
even NN NN O
in NN NN O
patients NN NN O
with NN NN O
stable NN NN O
disease NN NN O
. NN NN O
   
The NN NN O
cytogenetic NN NN O
action NN NN O
of NN NN O
ifosfamide NN NN O
, NN NN O
mesna NN NN O
, NN NN O
and NN NN O
their NN NN O
combination NN NN O
on NN NN O
peripheral NN NN O
rabbit NN NN O
lymphocytes NN NN O
: NN NN O
an NN NN O
in NN NN O
vivo NN NN O
/ NN NN O
in NN NN O
vitro NN NN O
cytogenetic NN NN O
study NN NN O
. NN NN O
   
Ifosfamide NN NN O
( NN NN O
IFO NN NN O
) NN NN O
is NN NN O
an NN NN O
alkylating NN NN O
nitrogen NN NN O
mustard NN NN O
, NN NN O
administrated NN NN O
as NN NN O
an NN NN O
antineoplasmic NN NN O
agent NN NN O
. NN NN O
   
It NN NN O
is NN NN O
characterized NN NN O
by NN NN O
its NN NN O
intense NN NN O
urotoxic NN NN O
action NN NN O
, NN NN O
leading NN NN O
to NN NN O
hemorrhagic NN NN B-Disease
cystitis NN NN I-Disease
. NN NN O
   
This NN NN O
side NN NN O
effect NN NN O
of NN NN O
IFO NN NN O
raises NN NN O
the NN NN O
requirement NN NN O
for NN NN O
the NN NN O
co NN NN O
- NN NN O
administration NN NN O
with NN NN O
sodium NN NN O
2 NN NN O
- NN NN O
sulfanylethanesulfonate NN NN O
( NN NN O
Mesna NN NN O
) NN NN O
aiming NN NN O
to NN NN O
avoid NN NN O
or NN NN O
minimize NN NN O
this NN NN O
effect NN NN O
. NN NN O
   
IFO NN NN O
and NN NN O
Mesna NN NN O
were NN NN O
administrated NN NN O
separately NN NN O
on NN NN O
rabbit NN NN O
' NN NN O
s NN NN O
lymphocytes NN NN O
in NN NN O
vivo NN NN O
, NN NN O
which NN NN O
were NN NN O
later NN NN O
developed NN NN O
in NN NN O
vitro NN NN O
. NN NN O
   
Cytogenetic NN NN O
markers NN NN O
for NN NN O
sister NN NN O
chromatid NN NN O
exchanges NN NN O
( NN NN O
SCEs NN NN O
) NN NN O
, NN NN O
proliferation NN NN O
rate NN NN O
index NN NN O
( NN NN O
PRI NN NN O
) NN NN O
and NN NN O
Mitotic NN NN O
Index NN NN O
were NN NN O
recorded NN NN O
. NN NN O
   
Mesna NN NN O
' NN NN O
s NN NN O
action NN NN O
, NN NN O
in NN NN O
conjunction NN NN O
with NN NN O
IFO NN NN O
reduces NN NN O
the NN NN O
frequency NN NN O
of NN NN O
SCEs NN NN O
, NN NN O
in NN NN O
comparison NN NN O
with NN NN O
the NN NN O
SCEs NN NN O
recordings NN NN O
obtained NN NN O
when NN NN O
IFO NN NN O
is NN NN O
administered NN NN O
alone NN NN O
. NN NN O
   
In NN NN O
addition NN NN O
to NN NN O
this NN NN O
, NN NN O
when NN NN O
high NN NN O
concentrations NN NN O
of NN NN O
Mesna NN NN O
were NN NN O
administered NN NN O
alone NN NN O
significant NN NN O
reductions NN NN O
of NN NN O
the NN NN O
PRI NN NN O
were NN NN O
noted NN NN O
, NN NN O
than NN NN O
with NN NN O
IFO NN NN O
acting NN NN O
at NN NN O
the NN NN O
same NN NN O
concentration NN NN O
on NN NN O
the NN NN O
lymphocytes NN NN O
. NN NN O
   
Mesna NN NN O
significantly NN NN O
reduces NN NN O
IFO NN NN O
' NN NN O
s NN NN O
genotoxicity NN NN B-Disease
, NN NN O
while NN NN O
when NN NN O
administered NN NN O
in NN NN O
high NN NN O
concentrations NN NN O
it NN NN O
acts NN NN O
in NN NN O
an NN NN O
inhibitory NN NN O
fashion NN NN O
on NN NN O
the NN NN O
cytostatic NN NN O
action NN NN O
of NN NN O
the NN NN O
drug NN NN O
. NN NN O
   
Risk NN NN O
factors NN NN O
and NN NN O
predictors NN NN O
of NN NN O
levodopa NN NN O
- NN NN O
induced NN NN O
dyskinesia NN NN B-Disease
among NN NN O
multiethnic NN NN O
Malaysians NN NN O
with NN NN O
Parkinson NN NN B-Disease
' NN NN I-Disease
s NN NN I-Disease
disease NN NN I-Disease
. NN NN O
   
Chronic NN NN O
pulsatile NN NN O
levodopa NN NN O
therapy NN NN O
for NN NN O
Parkinson NN NN B-Disease
' NN NN I-Disease
s NN NN I-Disease
disease NN NN I-Disease
( NN NN O
PD NN NN B-Disease
) NN NN O
leads NN NN O
to NN NN O
the NN NN O
development NN NN O
of NN NN O
motor NN NN O
fluctuations NN NN O
and NN NN O
dyskinesia NN NN B-Disease
. NN NN O
   
We NN NN O
studied NN NN O
the NN NN O
prevalence NN NN O
and NN NN O
predictors NN NN O
of NN NN O
levodopa NN NN O
- NN NN O
induced NN NN O
dyskinesia NN NN B-Disease
among NN NN O
multiethnic NN NN O
Malaysian NN NN O
patients NN NN O
with NN NN O
PD NN NN B-Disease
. NN NN O
   
METHODS NN NN O
: NN NN O
This NN NN O
is NN NN O
a NN NN O
cross NN NN O
- NN NN O
sectional NN NN O
study NN NN O
involving NN NN O
95 NN NN O
patients NN NN O
with NN NN O
PD NN NN B-Disease
on NN NN O
uninterrupted NN NN O
levodopa NN NN O
therapy NN NN O
for NN NN O
at NN NN O
least NN NN O
6 NN NN O
months NN NN O
. NN NN O
   
The NN NN O
instrument NN NN O
used NN NN O
was NN NN O
the NN NN O
UPDRS NN NN O
questionnaires NN NN O
. NN NN O
   
The NN NN O
predictors NN NN O
of NN NN O
dyskinesia NN NN B-Disease
were NN NN O
determined NN NN O
using NN NN O
multivariate NN NN O
logistic NN NN O
regression NN NN O
analysis NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
The NN NN O
mean NN NN O
age NN NN O
was NN NN O
65 NN NN O
. NN NN O
6 NN NN O
+ NN NN O
8 NN NN O
. NN NN O
5 NN NN O
years NN NN O
. NN NN O
   
The NN NN O
mean NN NN O
onset NN NN O
age NN NN O
was NN NN O
58 NN NN O
. NN NN O
5 NN NN O
+ NN NN O
9 NN NN O
. NN NN O
8 NN NN O
years NN NN O
. NN NN O
   
The NN NN O
median NN NN O
disease NN NN O
duration NN NN O
was NN NN O
6 NN NN O
( NN NN O
7 NN NN O
) NN NN O
years NN NN O
. NN NN O
   
Dyskinesia NN NN B-Disease
was NN NN O
present NN NN O
in NN NN O
44 NN NN O
% NN NN O
( NN NN O
n NN NN O
= NN NN O
42 NN NN O
) NN NN O
with NN NN O
median NN NN O
levodopa NN NN O
therapy NN NN O
of NN NN O
3 NN NN O
years NN NN O
. NN NN O
   
There NN NN O
were NN NN O
64 NN NN O
. NN NN O
3 NN NN O
% NN NN O
Chinese NN NN O
, NN NN O
31 NN NN O
% NN NN O
Malays NN NN O
, NN NN O
and NN NN O
3 NN NN O
. NN NN O
7 NN NN O
% NN NN O
Indians NN NN O
and NN NN O
other NN NN O
ethnic NN NN O
groups NN NN O
. NN NN O
   
Eighty NN NN O
- NN NN O
one NN NN O
percent NN NN O
of NN NN O
patients NN NN O
with NN NN O
dyskinesia NN NN B-Disease
had NN NN O
clinical NN NN O
fluctuations NN NN O
. NN NN O
   
Patients NN NN O
with NN NN O
dyskinesia NN NN B-Disease
had NN NN O
lower NN NN O
onset NN NN O
age NN NN O
( NN NN O
p NN NN O
< NN NN O
0 NN NN O
. NN NN O
001 NN NN O
) NN NN O
, NN NN O
longer NN NN O
duration NN NN O
of NN NN O
levodopa NN NN O
therapy NN NN O
( NN NN O
p NN NN O
< NN NN O
0 NN NN O
. NN NN O
001 NN NN O
) NN NN O
, NN NN O
longer NN NN O
disease NN NN O
duration NN NN O
( NN NN O
p NN NN O
< NN NN O
0 NN NN O
. NN NN O
001 NN NN O
) NN NN O
, NN NN O
higher NN NN O
total NN NN O
daily NN NN O
levodopa NN NN O
dose NN NN O
( NN NN O
p NN NN O
< NN NN O
0 NN NN O
. NN NN O
001 NN NN O
) NN NN O
, NN NN O
and NN NN O
higher NN NN O
total NN NN O
UPDRS NN NN O
scores NN NN O
( NN NN O
p NN NN O
= NN NN O
0 NN NN O
. NN NN O
005 NN NN O
) NN NN O
than NN NN O
patients NN NN O
without NN NN O
dyskinesia NN NN B-Disease
. NN NN O
   
The NN NN O
three NN NN O
significant NN NN O
predictors NN NN O
of NN NN O
dyskinesia NN NN B-Disease
were NN NN O
duration NN NN O
of NN NN O
levodopa NN NN O
therapy NN NN O
, NN NN O
onset NN NN O
age NN NN O
, NN NN O
and NN NN O
total NN NN O
daily NN NN O
levodopa NN NN O
dose NN NN O
. NN NN O
   
CONCLUSIONS NN NN O
: NN NN O
The NN NN O
prevalence NN NN O
of NN NN O
levodopa NN NN O
- NN NN O
induced NN NN O
dyskinesia NN NN B-Disease
in NN NN O
our NN NN O
patients NN NN O
was NN NN O
44 NN NN O
% NN NN O
. NN NN O
   
The NN NN O
most NN NN O
significant NN NN O
predictors NN NN O
were NN NN O
duration NN NN O
of NN NN O
levodopa NN NN O
therapy NN NN O
, NN NN O
total NN NN O
daily NN NN O
levodopa NN NN O
dose NN NN O
, NN NN O
and NN NN O
onset NN NN O
age NN NN O
. NN NN O
   
Dose NN NN O
- NN NN O
dependent NN NN O
neurotoxicity NN NN B-Disease
of NN NN O
high NN NN O
- NN NN O
dose NN NN O
busulfan NN NN O
in NN NN O
children NN NN O
: NN NN O
a NN NN O
clinical NN NN O
and NN NN O
pharmacological NN NN O
study NN NN O
. NN NN O
   
Busulfan NN NN O
is NN NN O
known NN NN O
to NN NN O
be NN NN O
neurotoxic NN NN B-Disease
in NN NN O
animals NN NN O
and NN NN O
humans NN NN O
, NN NN O
but NN NN O
its NN NN O
acute NN NN O
neurotoxicity NN NN B-Disease
remains NN NN O
poorly NN NN O
characterized NN NN O
in NN NN O
children NN NN O
. NN NN O
   
We NN NN O
report NN NN O
here NN NN O
a NN NN O
retrospective NN NN O
study NN NN O
of NN NN O
123 NN NN O
children NN NN O
( NN NN O
median NN NN O
age NN NN O
, NN NN O
6 NN NN O
. NN NN O
5 NN NN O
years NN NN O
) NN NN O
receiving NN NN O
high NN NN O
- NN NN O
dose NN NN O
busulfan NN NN O
in NN NN O
combined NN NN O
chemotherapy NN NN O
before NN NN O
bone NN NN O
marrow NN NN O
transplantation NN NN O
for NN NN O
malignant NN NN O
solid NN NN O
tumors NN NN B-Disease
, NN NN O
brain NN NN B-Disease
tumors NN NN I-Disease
excluded NN NN O
. NN NN O
   
Busulfan NN NN O
was NN NN O
given NN NN O
p NN NN O
. NN NN O
o NN NN O
. NN NN O
, NN NN O
every NN NN O
6 NN NN O
hours NN NN O
for NN NN O
16 NN NN O
doses NN NN O
over NN NN O
4 NN NN O
days NN NN O
. NN NN O
   
Two NN NN O
total NN NN O
doses NN NN O
were NN NN O
consecutively NN NN O
used NN NN O
: NN NN O
16 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
, NN NN O
then NN NN O
600 NN NN O
mg NN NN O
/ NN NN O
m2 NN NN O
. NN NN O
   
The NN NN O
dose NN NN O
calculation NN NN O
on NN NN O
the NN NN O
basis NN NN O
of NN NN O
body NN NN O
surface NN NN O
area NN NN O
results NN NN O
in NN NN O
higher NN NN O
doses NN NN O
in NN NN O
young NN NN O
children NN NN O
than NN NN O
in NN NN O
older NN NN O
patients NN NN O
( NN NN O
16 NN NN O
to NN NN O
28 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
) NN NN O
. NN NN O
   
Ninety NN NN O
- NN NN O
six NN NN O
patients NN NN O
were NN NN O
not NN NN O
given NN NN O
anticonvulsive NN NN O
prophylaxis NN NN O
; NN NN O
7 NN NN O
( NN NN O
7 NN NN O
. NN NN O
5 NN NN O
% NN NN O
) NN NN O
developed NN NN O
seizures NN NN B-Disease
during NN NN O
the NN NN O
4 NN NN O
days NN NN O
of NN NN O
the NN NN O
busulfan NN NN O
course NN NN O
or NN NN O
within NN NN O
24 NN NN O
h NN NN O
after NN NN O
the NN NN O
last NN NN O
dosing NN NN O
. NN NN O
   
When NN NN O
the NN NN O
total NN NN O
busulfan NN NN O
dose NN NN O
was NN NN O
taken NN NN O
into NN NN O
account NN NN O
, NN NN O
there NN NN O
was NN NN O
a NN NN O
significant NN NN O
difference NN NN O
in NN NN O
terms NN NN O
of NN NN O
neurotoxicity NN NN B-Disease
incidence NN NN O
among NN NN O
patients NN NN O
under NN NN O
16 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
( NN NN O
1 NN NN O
of NN NN O
57 NN NN O
, NN NN O
1 NN NN O
. NN NN O
7 NN NN O
% NN NN O
) NN NN O
and NN NN O
patients NN NN O
under NN NN O
600 NN NN O
mg NN NN O
/ NN NN O
m2 NN NN O
( NN NN O
6 NN NN O
of NN NN O
39 NN NN O
, NN NN O
15 NN NN O
. NN NN O
4 NN NN O
% NN NN O
) NN NN O
( NN NN O
P NN NN O
less NN NN O
than NN NN O
0 NN NN O
. NN NN O
02 NN NN O
) NN NN O
. NN NN O
   
Twenty NN NN O
- NN NN O
seven NN NN O
patients NN NN O
were NN NN O
given NN NN O
a NN NN O
600 NN NN O
- NN NN O
mg NN NN O
/ NN NN O
m2 NN NN O
busulfan NN NN O
total NN NN O
dose NN NN O
with NN NN O
continuous NN NN O
i NN NN O
. NN NN O
v NN NN O
. NN NN O
infusion NN NN O
of NN NN O
clonazepam NN NN O
; NN NN O
none NN NN O
had NN NN O
any NN NN O
neurological NN NN B-Disease
symptoms NN NN I-Disease
. NN NN O
   
Busulfan NN NN O
levels NN NN O
were NN NN O
measured NN NN O
by NN NN O
a NN NN O
gas NN NN O
chromatographic NN NN O
- NN NN O
mass NN NN O
spectrometry NN NN O
assay NN NN O
in NN NN O
the NN NN O
plasma NN NN O
and NN NN O
cerebrospinal NN NN O
fluid NN NN O
of NN NN O
9 NN NN O
children NN NN O
without NN NN O
central NN NN B-Disease
nervous NN NN I-Disease
system NN NN I-Disease
disease NN NN I-Disease
under NN NN O
600 NN NN O
mg NN NN O
/ NN NN O
m2 NN NN O
busulfan NN NN O
with NN NN O
clonazepam NN NN O
: NN NN O
busulfan NN NN O
cerebrospinal NN NN O
fluid NN NN O
: NN NN O
plasma NN NN O
ratio NN NN O
was NN NN O
1 NN NN O
. NN NN O
39 NN NN O
. NN NN O
   
This NN NN O
was NN NN O
significantly NN NN O
different NN NN O
( NN NN O
P NN NN O
less NN NN O
than NN NN O
0 NN NN O
. NN NN O
02 NN NN O
) NN NN O
from NN NN O
the NN NN O
cerebrospinal NN NN O
fluid NN NN O
: NN NN O
plasma NN NN O
ratio NN NN O
previously NN NN O
defined NN NN O
in NN NN O
children NN NN O
receiving NN NN O
a NN NN O
16 NN NN O
- NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
total NN NN O
dose NN NN O
of NN NN O
busulfan NN NN O
. NN NN O
   
This NN NN O
study NN NN O
shows NN NN O
that NN NN O
busulfan NN NN O
neurotoxicity NN NN B-Disease
is NN NN O
dose NN NN O
- NN NN O
dependent NN NN O
in NN NN O
children NN NN O
and NN NN O
efficiently NN NN O
prevented NN NN O
by NN NN O
clonazepam NN NN O
. NN NN O
   
A NN NN O
busulfan NN NN O
dose NN NN O
calculated NN NN O
on NN NN O
the NN NN O
basis NN NN O
of NN NN O
body NN NN O
surface NN NN O
area NN NN O
, NN NN O
resulting NN NN O
in NN NN O
higher NN NN O
doses NN NN O
in NN NN O
young NN NN O
children NN NN O
, NN NN O
was NN NN O
followed NN NN O
by NN NN O
increased NN NN O
neurotoxicity NN NN B-Disease
, NN NN O
close NN NN O
to NN NN O
neurotoxicity NN NN B-Disease
incidence NN NN O
observed NN NN O
in NN NN O
adults NN NN O
. NN NN O
   
Since NN NN O
plasma NN NN O
pharmacokinetic NN NN O
studies NN NN O
showed NN NN O
a NN NN O
faster NN NN O
busulfan NN NN O
clearance NN NN O
in NN NN O
children NN NN O
than NN NN O
in NN NN O
adults NN NN O
, NN NN O
this NN NN O
new NN NN O
dose NN NN O
may NN NN O
approximate NN NN O
more NN NN O
closely NN NN O
the NN NN O
adult NN NN O
systemic NN NN O
exposure NN NN O
obtained NN NN O
after NN NN O
the NN NN O
usual NN NN O
16 NN NN O
- NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
total NN NN O
dose NN NN O
, NN NN O
with NN NN O
potential NN NN O
inferences NN NN O
in NN NN O
terms NN NN O
of NN NN O
anticancer NN NN O
or NN NN O
myeloablative NN NN O
effects NN NN O
. NN NN O
   
The NN NN O
busulfan NN NN O
dose NN NN O
in NN NN O
children NN NN O
and NN NN O
infants NN NN O
undergoing NN NN O
bone NN NN O
marrow NN NN O
transplantation NN NN O
should NN NN O
be NN NN O
reconsidered NN NN O
on NN NN O
the NN NN O
basis NN NN O
of NN NN O
pharmacokinetic NN NN O
studies NN NN O
. NN NN O
   
An NN NN O
unexpected NN NN O
diagnosis NN NN O
in NN NN O
a NN NN O
renal NN NN O
- NN NN O
transplant NN NN O
patient NN NN O
with NN NN O
proteinuria NN NN B-Disease
treated NN NN O
with NN NN O
everolimus NN NN O
: NN NN O
AL NN NN B-Disease
amyloidosis NN NN B-Disease
. NN NN O
   
Proteinuria NN NN B-Disease
is NN NN O
an NN NN O
expected NN NN O
complication NN NN O
in NN NN O
transplant NN NN O
patients NN NN O
treated NN NN O
with NN NN O
mammalian NN NN O
target NN NN O
of NN NN O
rapamycin NN NN O
inhibitors NN NN O
( NN NN O
mTOR NN NN O
- NN NN O
i NN NN O
) NN NN O
. NN NN O
   
However NN NN O
, NN NN O
clinical NN NN O
suspicion NN NN O
should NN NN O
always NN NN O
be NN NN O
supported NN NN O
by NN NN O
histological NN NN O
evidence NN NN O
in NN NN O
order NN NN O
to NN NN O
investigate NN NN O
potential NN NN O
alternate NN NN O
diagnoses NN NN O
such NN NN O
as NN NN O
acute NN NN O
or NN NN O
chronic NN NN O
rejection NN NN O
, NN NN O
interstitial NN NN O
fibrosis NN NN B-Disease
and NN NN O
tubular NN NN O
atrophy NN NN B-Disease
, NN NN O
or NN NN O
recurrent NN NN O
or NN NN O
de NN NN O
novo NN NN O
glomerulopathy NN NN B-Disease
. NN NN O
   
In NN NN O
this NN NN O
case NN NN O
we NN NN O
report NN NN O
the NN NN O
unexpected NN NN O
diagnosis NN NN O
of NN NN O
amyloidosis NN NN B-Disease
in NN NN O
a NN NN O
renal NN NN O
- NN NN O
transplant NN NN O
patient NN NN O
with NN NN O
pre NN NN O
- NN NN O
transplant NN NN O
monoclonal NN NN O
gammapathy NN NN O
of NN NN O
undetermined NN NN O
significance NN NN O
who NN NN O
developed NN NN O
proteinuria NN NN B-Disease
after NN NN O
conversion NN NN O
from NN NN O
tacrolimus NN NN O
to NN NN O
everolimus NN NN O
. NN NN O
   
Long NN NN O
- NN NN O
term NN NN O
oral NN NN O
galactose NN NN O
treatment NN NN O
prevents NN NN O
cognitive NN NN B-Disease
deficits NN NN I-Disease
in NN NN O
male NN NN O
Wistar NN NN O
rats NN NN O
treated NN NN O
intracerebroventricularly NN NN O
with NN NN O
streptozotocin NN NN O
. NN NN O
   
Basic NN NN O
and NN NN O
clinical NN NN O
research NN NN O
has NN NN O
demonstrated NN NN O
that NN NN O
dementia NN NN B-Disease
of NN NN O
sporadic NN NN O
Alzheimer NN NN B-Disease
' NN NN I-Disease
s NN NN I-Disease
disease NN NN I-Disease
( NN NN O
sAD NN NN O
) NN NN O
type NN NN O
is NN NN O
associated NN NN O
with NN NN O
dysfunction NN NN O
of NN NN O
the NN NN O
insulin NN NN O
- NN NN O
receptor NN NN O
( NN NN O
IR NN NN O
) NN NN O
system NN NN O
followed NN NN O
by NN NN O
decreased NN NN O
glucose NN NN O
transport NN NN O
via NN NN O
glucose NN NN O
transporter NN NN O
GLUT4 NN NN O
and NN NN O
decreased NN NN O
glucose NN NN O
metabolism NN NN O
in NN NN O
brain NN NN O
cells NN NN O
. NN NN O
   
An NN NN O
alternative NN NN O
source NN NN O
of NN NN O
energy NN NN O
is NN NN O
d NN NN O
- NN NN O
galactose NN NN O
( NN NN O
the NN NN O
C NN NN O
- NN NN O
4 NN NN O
- NN NN O
epimer NN NN O
of NN NN O
d NN NN O
- NN NN O
glucose NN NN O
) NN NN O
which NN NN O
is NN NN O
transported NN NN O
into NN NN O
the NN NN O
brain NN NN O
by NN NN O
insulin NN NN O
- NN NN O
independent NN NN O
GLUT3 NN NN O
transporter NN NN O
where NN NN O
it NN NN O
might NN NN O
be NN NN O
metabolized NN NN O
to NN NN O
glucose NN NN O
via NN NN O
the NN NN O
Leloir NN NN O
pathway NN NN O
. NN NN O
   
Exclusively NN NN O
parenteral NN NN O
daily NN NN O
injections NN NN O
of NN NN O
galactose NN NN O
induce NN NN O
memory NN NN B-Disease
deterioration NN NN I-Disease
in NN NN O
rodents NN NN O
and NN NN O
are NN NN O
used NN NN O
to NN NN O
generate NN NN O
animal NN NN O
aging NN NN O
model NN NN O
, NN NN O
but NN NN O
the NN NN O
effects NN NN O
of NN NN O
oral NN NN O
galactose NN NN O
treatment NN NN O
on NN NN O
cognitive NN NN O
functions NN NN O
have NN NN O
never NN NN O
been NN NN O
tested NN NN O
. NN NN O
   
We NN NN O
have NN NN O
investigated NN NN O
the NN NN O
effects NN NN O
of NN NN O
continuous NN NN O
daily NN NN O
oral NN NN O
galactose NN NN O
( NN NN O
200 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
/ NN NN O
day NN NN O
) NN NN O
treatment NN NN O
on NN NN O
cognitive NN NN B-Disease
deficits NN NN I-Disease
in NN NN O
streptozotocin NN NN O
- NN NN O
induced NN NN O
( NN NN O
STZ NN NN O
- NN NN O
icv NN NN O
) NN NN O
rat NN NN O
model NN NN O
of NN NN O
sAD NN NN O
, NN NN O
tested NN NN O
by NN NN O
Morris NN NN O
Water NN NN O
Maze NN NN O
and NN NN O
Passive NN NN O
Avoidance NN NN O
test NN NN O
, NN NN O
respectively NN NN O
. NN NN O
   
One NN NN O
month NN NN O
of NN NN O
oral NN NN O
galactose NN NN O
treatment NN NN O
initiated NN NN O
immediately NN NN O
after NN NN O
the NN NN O
STZ NN NN O
- NN NN O
icv NN NN O
administration NN NN O
, NN NN O
successfully NN NN O
prevented NN NN O
development NN NN O
of NN NN O
the NN NN O
STZ NN NN O
- NN NN O
icv NN NN O
- NN NN O
induced NN NN O
cognitive NN NN B-Disease
deficits NN NN I-Disease
. NN NN O
   
Beneficial NN NN O
effect NN NN O
of NN NN O
oral NN NN O
galactose NN NN O
was NN NN O
independent NN NN O
of NN NN O
the NN NN O
rat NN NN O
age NN NN O
and NN NN O
of NN NN O
the NN NN O
galactose NN NN O
dose NN NN O
ranging NN NN O
from NN NN O
100 NN NN O
to NN NN O
300 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
/ NN NN O
day NN NN O
. NN NN O
   
Additionally NN NN O
, NN NN O
oral NN NN O
galactose NN NN O
administration NN NN O
led NN NN O
to NN NN O
the NN NN O
appearance NN NN O
of NN NN O
galactose NN NN O
in NN NN O
the NN NN O
blood NN NN O
. NN NN O
   
The NN NN O
increase NN NN O
of NN NN O
galactose NN NN O
concentration NN NN O
in NN NN O
the NN NN O
cerebrospinal NN NN O
fluid NN NN O
was NN NN O
several NN NN O
times NN NN O
lower NN NN O
after NN NN O
oral NN NN O
than NN NN O
after NN NN O
parenteral NN NN O
administration NN NN O
of NN NN O
the NN NN O
same NN NN O
galactose NN NN O
dose NN NN O
. NN NN O
   
Oral NN NN O
galactose NN NN O
exposure NN NN O
might NN NN O
have NN NN O
beneficial NN NN O
effects NN NN O
on NN NN O
learning NN NN O
and NN NN O
memory NN NN O
ability NN NN O
and NN NN O
could NN NN O
be NN NN O
worth NN NN O
investigating NN NN O
for NN NN O
improvement NN NN O
of NN NN O
cognitive NN NN B-Disease
deficits NN NN I-Disease
associated NN NN O
with NN NN O
glucose NN NN B-Disease
hypometabolism NN NN I-Disease
in NN NN O
AD NN NN B-Disease
. NN NN O
   
An NN NN O
investigation NN NN O
of NN NN O
the NN NN O
pattern NN NN O
of NN NN O
kidney NN NN B-Disease
injury NN NN I-Disease
in NN NN O
HIV NN NN O
- NN NN O
positive NN NN O
persons NN NN O
exposed NN NN O
to NN NN O
tenofovir NN NN O
disoproxil NN NN O
fumarate NN NN O
: NN NN O
an NN NN O
examination NN NN O
of NN NN O
a NN NN O
large NN NN O
population NN NN O
database NN NN O
( NN NN O
MHRA NN NN O
database NN NN O
) NN NN O
. NN NN O
   
The NN NN O
potential NN NN O
for NN NN O
tenofovir NN NN O
to NN NN O
cause NN NN O
a NN NN O
range NN NN O
of NN NN O
kidney NN NN O
syndromes NN NN O
has NN NN O
been NN NN O
established NN NN O
from NN NN O
mechanistic NN NN O
and NN NN O
randomised NN NN O
clinical NN NN O
trials NN NN O
. NN NN O
   
However NN NN O
, NN NN O
the NN NN O
exact NN NN O
pattern NN NN O
of NN NN O
kidney NN NN O
involvement NN NN O
is NN NN O
still NN NN O
uncertain NN NN O
. NN NN O
   
We NN NN O
undertook NN NN O
a NN NN O
descriptive NN NN O
analysis NN NN O
of NN NN O
Yellow NN NN O
Card NN NN O
records NN NN O
of NN NN O
407 NN NN O
HIV NN NN O
- NN NN O
positive NN NN O
persons NN NN O
taking NN NN O
tenofovir NN NN O
disoproxil NN NN O
fumarate NN NN O
( NN NN O
TDF NN NN O
) NN NN O
as NN NN O
part NN NN O
of NN NN O
their NN NN O
antiretroviral NN NN O
therapy NN NN O
regimen NN NN O
and NN NN O
submitted NN NN O
to NN NN O
the NN NN O
Medicines NN NN O
and NN NN O
Healthcare NN NN O
Products NN NN O
Regulatory NN NN O
Agency NN NN O
( NN NN O
MHRA NN NN O
) NN NN O
with NN NN O
suspected NN NN O
kidney NN NN O
adverse NN NN O
effects NN NN O
. NN NN O
   
Reports NN NN O
that NN NN O
satisfy NN NN O
defined NN NN O
criteria NN NN O
were NN NN O
classified NN NN O
as NN NN O
acute NN NN B-Disease
kidney NN NN I-Disease
injury NN NN I-Disease
, NN NN O
kidney NN NN B-Disease
tubular NN NN I-Disease
dysfunction NN NN I-Disease
and NN NN O
Fanconi NN NN B-Disease
syndrome NN NN I-Disease
. NN NN O
   
Of NN NN O
the NN NN O
407 NN NN O
Yellow NN NN O
Card NN NN O
records NN NN O
analysed NN NN O
, NN NN O
106 NN NN O
satisfied NN NN O
criteria NN NN O
for NN NN O
TDF NN NN O
- NN NN O
related NN NN O
kidney NN NN B-Disease
disease NN NN I-Disease
, NN NN O
of NN NN O
which NN NN O
53 NN NN O
( NN NN O
50 NN NN O
% NN NN O
) NN NN O
had NN NN O
features NN NN O
of NN NN O
kidney NN NN B-Disease
tubular NN NN I-Disease
dysfunction NN NN I-Disease
, NN NN O
35 NN NN O
( NN NN O
33 NN NN O
% NN NN O
) NN NN O
were NN NN O
found NN NN O
to NN NN O
have NN NN O
features NN NN O
of NN NN O
glomerular NN NN B-Disease
dysfunction NN NN I-Disease
and NN NN O
18 NN NN O
( NN NN O
17 NN NN O
% NN NN O
) NN NN O
had NN NN O
Fanconi NN NN B-Disease
syndrome NN NN I-Disease
. NN NN O
   
The NN NN O
median NN NN O
TDF NN NN O
exposure NN NN O
was NN NN O
316 NN NN O
days NN NN O
( NN NN O
interquartile NN NN O
range NN NN O
120 NN NN O
- NN NN O
740 NN NN O
) NN NN O
. NN NN O
   
The NN NN O
incidence NN NN O
of NN NN O
hospitalisation NN NN O
for NN NN O
TDF NN NN O
kidney NN NN O
adverse NN NN O
effects NN NN O
was NN NN O
high NN NN O
, NN NN O
particularly NN NN O
amongst NN NN O
patients NN NN O
with NN NN O
features NN NN O
of NN NN O
Fanconi NN NN B-Disease
syndrome NN NN I-Disease
. NN NN O
   
The NN NN O
pattern NN NN O
of NN NN O
kidney NN NN O
syndromes NN NN O
in NN NN O
this NN NN O
population NN NN O
series NN NN O
mirrors NN NN O
that NN NN O
reported NN NN O
in NN NN O
randomised NN NN O
clinical NN NN O
trials NN NN O
. NN NN O
   
Cessation NN NN O
of NN NN O
TDF NN NN O
was NN NN O
associated NN NN O
with NN NN O
complete NN NN O
restoration NN NN O
of NN NN O
kidney NN NN O
function NN NN O
in NN NN O
up NN NN O
half NN NN O
of NN NN O
the NN NN O
patients NN NN O
in NN NN O
this NN NN O
report NN NN O
. NN NN O
   
Incidence NN NN O
of NN NN O
postoperative NN NN B-Disease
delirium NN NN I-Disease
is NN NN O
high NN NN O
even NN NN O
in NN NN O
a NN NN O
population NN NN O
without NN NN O
known NN NN O
risk NN NN O
factors NN NN O
. NN NN O
   
PURPOSE NN NN O
: NN NN O
Postoperative NN NN B-Disease
delirium NN NN I-Disease
is NN NN O
a NN NN O
recognized NN NN O
complication NN NN O
in NN NN O
populations NN NN O
at NN NN O
risk NN NN O
. NN NN O
   
The NN NN O
aim NN NN O
of NN NN O
this NN NN O
study NN NN O
is NN NN O
to NN NN O
assess NN NN O
the NN NN O
prevalence NN NN O
of NN NN O
early NN NN O
postoperative NN NN B-Disease
delirium NN NN I-Disease
in NN NN O
a NN NN O
population NN NN O
without NN NN O
known NN NN O
risk NN NN O
factors NN NN O
admitted NN NN O
to NN NN O
the NN NN O
ICU NN NN O
for NN NN O
postoperative NN NN O
monitoring NN NN O
after NN NN O
elective NN NN O
major NN NN O
surgery NN NN O
. NN NN O
   
The NN NN O
secondary NN NN O
outcome NN NN O
investigated NN NN O
is NN NN O
to NN NN O
identify NN NN O
eventual NN NN O
independent NN NN O
risk NN NN O
factors NN NN O
among NN NN O
demographic NN NN O
data NN NN O
and NN NN O
anesthetic NN NN O
drugs NN NN O
used NN NN O
. NN NN O
   
METHODS NN NN O
: NN NN O
An NN NN O
observational NN NN O
, NN NN O
prospective NN NN O
study NN NN O
was NN NN O
conducted NN NN O
on NN NN O
a NN NN O
consecutive NN NN O
cohort NN NN O
of NN NN O
patients NN NN O
admitted NN NN O
to NN NN O
our NN NN O
ICU NN NN O
within NN NN O
and NN NN O
for NN NN O
at NN NN O
least NN NN O
24 NN NN O
h NN NN O
after NN NN O
major NN NN O
surgical NN NN O
procedures NN NN O
. NN NN O
   
Exclusion NN NN O
criteria NN NN O
were NN NN O
any NN NN O
preexisting NN NN O
predisposing NN NN O
factor NN NN O
for NN NN O
delirium NN NN B-Disease
or NN NN O
other NN NN O
potentially NN NN O
confounding NN NN O
neurological NN NN B-Disease
dysfunctions NN NN I-Disease
. NN NN O
   
Patients NN NN O
were NN NN O
assessed NN NN O
daily NN NN O
using NN NN O
the NN NN O
confusion NN NN B-Disease
assessment NN NN O
method NN NN O
for NN NN O
the NN NN O
ICU NN NN O
scale NN NN O
for NN NN O
3 NN NN O
days NN NN O
after NN NN O
the NN NN O
surgical NN NN O
procedure NN NN O
. NN NN O
   
Early NN NN O
postoperative NN NN B-Disease
delirium NN NN I-Disease
incidence NN NN O
risk NN NN O
factors NN NN O
were NN NN O
then NN NN O
assessed NN NN O
through NN NN O
three NN NN O
different NN NN O
multiple NN NN O
regression NN NN O
models NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
According NN NN O
to NN NN O
the NN NN O
confusion NN NN O
assessment NN NN O
method NN NN O
for NN NN O
the NN NN O
ICU NN NN O
scale NN NN O
, NN NN O
28 NN NN O
% NN NN O
of NN NN O
patients NN NN O
were NN NN O
diagnosed NN NN O
with NN NN O
early NN NN O
postoperative NN NN B-Disease
delirium NN NN I-Disease
. NN NN O
   
The NN NN O
use NN NN O
of NN NN O
thiopentone NN NN O
was NN NN O
significantly NN NN O
associated NN NN O
with NN NN O
an NN NN O
eight NN NN O
- NN NN O
fold NN NN O
- NN NN O
higher NN NN O
risk NN NN O
for NN NN O
delirium NN NN B-Disease
compared NN NN O
to NN NN O
propofol NN NN O
( NN NN O
57 NN NN O
. NN NN O
1 NN NN O
% NN NN O
vs NN NN O
. NN NN O
7 NN NN O
. NN NN O
1 NN NN O
% NN NN O
, NN NN O
RR NN NN O
= NN NN O
8 NN NN O
. NN NN O
0 NN NN O
, NN NN O
X2 NN NN O
= NN NN O
4 NN NN O
. NN NN O
256 NN NN O
; NN NN O
df NN NN O
= NN NN O
1 NN NN O
; NN NN O
0 NN NN O
. NN NN O
05 NN NN O
< NN NN O
p NN NN O
< NN NN O
0 NN NN O
. NN NN O
02 NN NN O
) NN NN O
. NN NN O
   
CONCLUSION NN NN O
: NN NN O
In NN NN O
this NN NN O
study NN NN O
early NN NN O
postoperative NN NN B-Disease
delirium NN NN I-Disease
was NN NN O
found NN NN O
to NN NN O
be NN NN O
a NN NN O
very NN NN O
common NN NN O
complication NN NN O
after NN NN O
major NN NN O
surgery NN NN O
, NN NN O
even NN NN O
in NN NN O
a NN NN O
population NN NN O
without NN NN O
known NN NN O
risk NN NN O
factors NN NN O
. NN NN O
   
Thiopentone NN NN O
was NN NN O
independently NN NN O
associated NN NN O
with NN NN O
an NN NN O
increase NN NN O
in NN NN O
its NN NN O
relative NN NN O
risk NN NN O
. NN NN O
   
A NN NN O
single NN NN O
neurotoxic NN NN B-Disease
dose NN NN O
of NN NN O
methamphetamine NN NN O
induces NN NN O
a NN NN O
long NN NN O
- NN NN O
lasting NN NN O
depressive NN NN B-Disease
- NN NN O
like NN NN O
behaviour NN NN O
in NN NN O
mice NN NN O
. NN NN O
   
Methamphetamine NN NN O
( NN NN O
METH NN NN O
) NN NN O
triggers NN NN O
a NN NN O
disruption NN NN O
of NN NN O
the NN NN O
monoaminergic NN NN O
system NN NN O
and NN NN O
METH NN NN O
abuse NN NN O
leads NN NN O
to NN NN O
negative NN NN O
emotional NN NN O
states NN NN O
including NN NN O
depressive NN NN B-Disease
symptoms NN NN I-Disease
during NN NN O
drug NN NN O
withdrawal NN NN O
. NN NN O
   
However NN NN O
, NN NN O
it NN NN O
is NN NN O
currently NN NN O
unknown NN NN O
if NN NN O
the NN NN O
acute NN NN O
toxic NN NN O
dosage NN NN O
of NN NN O
METH NN NN O
also NN NN O
causes NN NN O
a NN NN O
long NN NN O
- NN NN O
lasting NN NN O
depressive NN NN B-Disease
phenotype NN NN O
and NN NN O
persistent NN NN O
monoaminergic NN NN O
deficits NN NN O
. NN NN O
   
Thus NN NN O
, NN NN O
we NN NN O
now NN NN O
assessed NN NN O
the NN NN O
depressive NN NN B-Disease
- NN NN O
like NN NN O
behaviour NN NN O
in NN NN O
mice NN NN O
at NN NN O
early NN NN O
and NN NN O
long NN NN O
- NN NN O
term NN NN O
periods NN NN O
following NN NN O
a NN NN O
single NN NN O
high NN NN O
METH NN NN O
dose NN NN O
( NN NN O
30 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
, NN NN O
i NN NN O
. NN NN O
p NN NN O
. NN NN O
) NN NN O
. NN NN O
   
METH NN NN O
did NN NN O
not NN NN O
alter NN NN O
the NN NN O
motor NN NN O
function NN NN O
and NN NN O
procedural NN NN O
memory NN NN O
of NN NN O
mice NN NN O
as NN NN O
assessed NN NN O
by NN NN O
swimming NN NN O
speed NN NN O
and NN NN O
escape NN NN O
latency NN NN O
to NN NN O
find NN NN O
the NN NN O
platform NN NN O
in NN NN O
a NN NN O
cued NN NN O
version NN NN O
of NN NN O
the NN NN O
water NN NN O
maze NN NN O
task NN NN O
. NN NN O
   
However NN NN O
, NN NN O
METH NN NN O
significantly NN NN O
increased NN NN O
the NN NN O
immobility NN NN O
time NN NN O
in NN NN O
the NN NN O
tail NN NN O
suspension NN NN O
test NN NN O
at NN NN O
3 NN NN O
and NN NN O
49 NN NN O
days NN NN O
post NN NN O
- NN NN O
administration NN NN O
. NN NN O
   
This NN NN O
depressive NN NN B-Disease
- NN NN O
like NN NN O
profile NN NN O
induced NN NN O
by NN NN O
METH NN NN O
was NN NN O
accompanied NN NN O
by NN NN O
a NN NN O
marked NN NN O
depletion NN NN O
of NN NN O
frontostriatal NN NN O
dopaminergic NN NN O
and NN NN O
serotonergic NN NN O
neurotransmission NN NN O
, NN NN O
indicated NN NN O
by NN NN O
a NN NN O
reduction NN NN O
in NN NN O
the NN NN O
levels NN NN O
of NN NN O
dopamine NN NN O
, NN NN O
DOPAC NN NN O
and NN NN O
HVA NN NN O
, NN NN O
tyrosine NN NN O
hydroxylase NN NN O
and NN NN O
serotonin NN NN O
, NN NN O
observed NN NN O
at NN NN O
both NN NN O
3 NN NN O
and NN NN O
49 NN NN O
days NN NN O
post NN NN O
- NN NN O
administration NN NN O
. NN NN O
   
In NN NN O
parallel NN NN O
, NN NN O
another NN NN O
neurochemical NN NN O
feature NN NN O
of NN NN O
depression NN NN B-Disease
- NN NN O
- NN NN O
astroglial NN NN O
dysfunction NN NN O
- NN NN O
- NN NN O
was NN NN O
unaffected NN NN O
in NN NN O
the NN NN O
cortex NN NN O
and NN NN O
the NN NN O
striatal NN NN O
levels NN NN O
of NN NN O
the NN NN O
astrocytic NN NN O
protein NN NN O
marker NN NN O
, NN NN O
glial NN NN O
fibrillary NN NN O
acidic NN NN O
protein NN NN O
, NN NN O
were NN NN O
only NN NN O
transiently NN NN O
increased NN NN O
at NN NN O
3 NN NN O
days NN NN O
. NN NN O
   
These NN NN O
findings NN NN O
demonstrate NN NN O
for NN NN O
the NN NN O
first NN NN O
time NN NN O
that NN NN O
a NN NN O
single NN NN O
high NN NN O
dose NN NN O
of NN NN O
METH NN NN O
induces NN NN O
long NN NN O
- NN NN O
lasting NN NN O
depressive NN NN B-Disease
- NN NN O
like NN NN O
behaviour NN NN O
in NN NN O
mice NN NN O
associated NN NN O
with NN NN O
a NN NN O
persistent NN NN O
disruption NN NN O
of NN NN O
frontostriatal NN NN O
dopaminergic NN NN O
and NN NN O
serotonergic NN NN O
homoeostasis NN NN O
. NN NN O
   
Linezolid NN NN O
- NN NN O
induced NN NN O
optic NN NN B-Disease
neuropathy NN NN I-Disease
. NN NN O
   
Many NN NN O
systemic NN NN O
antimicrobials NN NN O
have NN NN O
been NN NN O
implicated NN NN O
to NN NN O
cause NN NN O
ocular NN NN O
adverse NN NN O
effects NN NN O
. NN NN O
   
This NN NN O
is NN NN O
especially NN NN O
relevant NN NN O
in NN NN O
multidrug NN NN O
therapy NN NN O
where NN NN O
more NN NN O
than NN NN O
one NN NN O
drug NN NN O
can NN NN O
cause NN NN O
a NN NN O
similar NN NN O
ocular NN NN O
adverse NN NN O
effect NN NN O
. NN NN O
   
We NN NN O
describe NN NN O
a NN NN O
case NN NN O
of NN NN O
progressive NN NN O
loss NN NN B-Disease
of NN NN I-Disease
vision NN NN I-Disease
associated NN NN O
with NN NN O
linezolid NN NN O
therapy NN NN O
. NN NN O
   
A NN NN O
45 NN NN O
- NN NN O
year NN NN O
- NN NN O
old NN NN O
male NN NN O
patient NN NN O
who NN NN O
was NN NN O
on NN NN O
treatment NN NN O
with NN NN O
multiple NN NN O
second NN NN O
- NN NN O
line NN NN O
anti NN NN O
- NN NN O
tuberculous NN NN O
drugs NN NN O
including NN NN O
linezolid NN NN O
and NN NN O
ethambutol NN NN O
for NN NN O
extensively NN NN B-Disease
drug NN NN I-Disease
- NN NN I-Disease
resistant NN NN I-Disease
tuberculosis NN NN I-Disease
( NN NN O
XDR NN NN B-Disease
- NN NN I-Disease
TB NN NN I-Disease
) NN NN O
presented NN NN O
to NN NN O
us NN NN O
with NN NN O
painless NN NN O
progressive NN NN O
loss NN NN B-Disease
of NN NN I-Disease
vision NN NN I-Disease
in NN NN O
both NN NN O
eyes NN NN O
. NN NN O
   
Color NN NN O
vision NN NN O
was NN NN O
defective NN NN O
and NN NN O
fundus NN NN O
examination NN NN O
revealed NN NN O
optic NN NN B-Disease
disc NN NN I-Disease
edema NN NN I-Disease
in NN NN O
both NN NN O
eyes NN NN O
. NN NN O
   
Ethambutol NN NN O
- NN NN O
induced NN NN O
toxic NN NN B-Disease
optic NN NN I-Disease
neuropathy NN NN I-Disease
was NN NN O
suspected NN NN O
and NN NN O
tablet NN NN O
ethambutol NN NN O
was NN NN O
withdrawn NN NN O
. NN NN O
   
Deterioration NN NN B-Disease
of NN NN I-Disease
vision NN NN I-Disease
occurred NN NN O
despite NN NN O
withdrawal NN NN O
of NN NN O
ethambutol NN NN O
. NN NN O
   
Discontinuation NN NN O
of NN NN O
linezolid NN NN O
resulted NN NN O
in NN NN O
marked NN NN O
improvement NN NN O
of NN NN O
vision NN NN O
. NN NN O
   
Our NN NN O
report NN NN O
emphasizes NN NN O
the NN NN O
need NN NN O
for NN NN O
monitoring NN NN O
of NN NN O
visual NN NN O
function NN NN O
in NN NN O
patients NN NN O
on NN NN O
long NN NN O
- NN NN O
term NN NN O
linezolid NN NN O
treatment NN NN O
. NN NN O
   
Resuscitation NN NN O
with NN NN O
lipid NN NN O
, NN NN O
epinephrine NN NN O
, NN NN O
or NN NN O
both NN NN O
in NN NN O
levobupivacaine NN NN O
- NN NN O
induced NN NN O
cardiac NN NN B-Disease
toxicity NN NN I-Disease
in NN NN O
newborn NN NN O
piglets NN NN O
. NN NN O
   
BACKGROUND NN NN O
: NN NN O
The NN NN O
optimal NN NN O
dosing NN NN O
regimens NN NN O
of NN NN O
lipid NN NN O
emulsion NN NN O
, NN NN O
epinephrine NN NN O
, NN NN O
or NN NN O
both NN NN O
are NN NN O
not NN NN O
yet NN NN O
determined NN NN O
in NN NN O
neonates NN NN O
in NN NN O
cases NN NN O
of NN NN O
local NN NN O
anaesthetic NN NN O
systemic NN NN O
toxicity NN NN B-Disease
( NN NN O
LAST NN NN O
) NN NN O
. NN NN O
   
METHODS NN NN O
: NN NN O
Newborn NN NN O
piglets NN NN O
received NN NN O
levobupivacaine NN NN O
until NN NN O
cardiovascular NN NN B-Disease
collapse NN NN I-Disease
occurred NN NN O
. NN NN O
   
Standard NN NN O
cardiopulmonary NN NN O
resuscitation NN NN O
was NN NN O
started NN NN O
and NN NN O
electrocardiogram NN NN O
( NN NN O
ECG NN NN O
) NN NN O
was NN NN O
monitored NN NN O
for NN NN O
ventricular NN NN B-Disease
tachycardia NN NN I-Disease
, NN NN O
fibrillation NN NN B-Disease
, NN NN O
or NN NN O
QRS NN NN O
prolongation NN NN O
. NN NN O
   
Piglets NN NN O
were NN NN O
then NN NN O
randomly NN NN O
allocated NN NN O
to NN NN O
four NN NN O
groups NN NN O
: NN NN O
control NN NN O
( NN NN O
saline NN NN O
) NN NN O
, NN NN O
Intralipid NN NN O
( NN NN O
) NN NN O
alone NN NN O
, NN NN O
epinephrine NN NN O
alone NN NN O
, NN NN O
or NN NN O
a NN NN O
combination NN NN O
of NN NN O
Intralipd NN NN O
plus NN NN O
epinephrine NN NN O
. NN NN O
   
Resuscitation NN NN O
continued NN NN O
for NN NN O
30 NN NN O
min NN NN O
or NN NN O
until NN NN O
there NN NN O
was NN NN O
a NN NN O
return NN NN O
of NN NN O
spontaneous NN NN O
circulation NN NN O
( NN NN O
ROSC NN NN O
) NN NN O
accompanied NN NN O
by NN NN O
a NN NN O
mean NN NN O
arterial NN NN O
pressure NN NN O
at NN NN O
or NN NN O
superior NN NN O
to NN NN O
the NN NN O
baseline NN NN O
pressure NN NN O
and NN NN O
normal NN NN O
sinus NN NN O
rhythm NN NN O
for NN NN O
a NN NN O
period NN NN O
of NN NN O
30 NN NN O
min NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
ROSC NN NN O
was NN NN O
achieved NN NN O
in NN NN O
only NN NN O
one NN NN O
of NN NN O
the NN NN O
control NN NN O
piglets NN NN O
compared NN NN O
with NN NN O
most NN NN O
of NN NN O
the NN NN O
treated NN NN O
piglets NN NN O
. NN NN O
   
Mortality NN NN O
was NN NN O
not NN NN O
significantly NN NN O
different NN NN O
between NN NN O
the NN NN O
three NN NN O
treatment NN NN O
groups NN NN O
, NN NN O
but NN NN O
was NN NN O
significantly NN NN O
lower NN NN O
in NN NN O
all NN NN O
the NN NN O
treatment NN NN O
groups NN NN O
compared NN NN O
with NN NN O
control NN NN O
. NN NN O
   
The NN NN O
number NN NN O
of NN NN O
ECG NN NN O
abnormalities NN NN O
was NN NN O
zero NN NN O
in NN NN O
the NN NN O
Intralipid NN NN O
only NN NN O
group NN NN O
, NN NN O
but NN NN O
14 NN NN O
and NN NN O
17 NN NN O
, NN NN O
respectively NN NN O
, NN NN O
in NN NN O
the NN NN O
epinephrine NN NN O
and NN NN O
epinephrine NN NN O
plus NN NN O
lipid NN NN O
groups NN NN O
( NN NN O
P NN NN O
< NN NN O
0 NN NN O
. NN NN O
05 NN NN O
) NN NN O
. NN NN O
   
CONCLUSIONS NN NN O
: NN NN O
Lipid NN NN O
emulsion NN NN O
with NN NN O
or NN NN O
without NN NN O
epinephrine NN NN O
, NN NN O
or NN NN O
epinephrine NN NN O
alone NN NN O
were NN NN O
equally NN NN O
effective NN NN O
in NN NN O
achieving NN NN O
a NN NN O
return NN NN O
to NN NN O
spontaneous NN NN O
circulation NN NN O
in NN NN O
this NN NN O
model NN NN O
of NN NN O
LAST NN NN O
. NN NN O
   
Epinephrine NN NN O
alone NN NN O
or NN NN O
in NN NN O
combination NN NN O
with NN NN O
lipid NN NN O
was NN NN O
associated NN NN O
with NN NN O
an NN NN O
increased NN NN O
number NN NN O
of NN NN O
ECG NN NN O
abnormalities NN NN O
compared NN NN O
with NN NN O
lipid NN NN O
emulsion NN NN O
alone NN NN O
. NN NN O
   
Incidence NN NN O
of NN NN O
heparin NN NN O
- NN NN O
induced NN NN O
thrombocytopenia NN NN B-Disease
type NN NN I-Disease
II NN NN I-Disease
and NN NN O
postoperative NN NN O
recovery NN NN O
of NN NN O
platelet NN NN O
count NN NN O
in NN NN O
liver NN NN O
graft NN NN O
recipients NN NN O
: NN NN O
a NN NN O
retrospective NN NN O
cohort NN NN O
analysis NN NN O
. NN NN O
   
BACKGROUND NN NN O
: NN NN O
Thrombocytopenia NN NN B-Disease
in NN NN O
patients NN NN O
with NN NN O
end NN NN B-Disease
- NN NN I-Disease
stage NN NN I-Disease
liver NN NN I-Disease
disease NN NN I-Disease
is NN NN O
a NN NN O
common NN NN O
disorder NN NN O
caused NN NN O
mainly NN NN O
by NN NN O
portal NN NN B-Disease
hypertension NN NN I-Disease
, NN NN O
low NN NN O
levels NN NN O
of NN NN O
thrombopoetin NN NN O
, NN NN O
and NN NN O
endotoxemia NN NN B-Disease
. NN NN O
   
The NN NN O
impact NN NN O
of NN NN O
immune NN NN O
- NN NN O
mediated NN NN O
heparin NN NN O
- NN NN O
induced NN NN O
thrombocytopenia NN NN B-Disease
type NN NN I-Disease
II NN NN I-Disease
( NN NN O
HIT NN NN B-Disease
type NN NN I-Disease
II NN NN I-Disease
) NN NN O
as NN NN O
a NN NN O
cause NN NN O
of NN NN O
thrombocytopenia NN NN B-Disease
after NN NN O
liver NN NN O
transplantation NN NN O
is NN NN O
not NN NN O
yet NN NN O
understood NN NN O
, NN NN O
with NN NN O
few NN NN O
literature NN NN O
citations NN NN O
reporting NN NN O
contradictory NN NN O
results NN NN O
. NN NN O
   
The NN NN O
aim NN NN O
of NN NN O
our NN NN O
study NN NN O
was NN NN O
to NN NN O
demonstrate NN NN O
the NN NN O
perioperative NN NN O
course NN NN O
of NN NN O
thrombocytopenia NN NN B-Disease
after NN NN O
liver NN NN O
transplantation NN NN O
and NN NN O
determine NN NN O
the NN NN O
occurrence NN NN O
of NN NN O
clinical NN NN O
HIT NN NN B-Disease
type NN NN I-Disease
II NN NN I-Disease
. NN NN O
   
METHOD NN NN O
: NN NN O
We NN NN O
retrospectively NN NN O
evaluated NN NN O
the NN NN O
medical NN NN O
records NN NN O
of NN NN O
205 NN NN O
consecutive NN NN O
adult NN NN O
patients NN NN O
who NN NN O
underwent NN NN O
full NN NN O
- NN NN O
size NN NN O
liver NN NN O
transplantation NN NN O
between NN NN O
January NN NN O
2006 NN NN O
and NN NN O
December NN NN O
2010 NN NN O
due NN NN O
to NN NN O
end NN NN B-Disease
- NN NN I-Disease
stage NN NN I-Disease
or NN NN I-Disease
malignant NN NN I-Disease
liver NN NN I-Disease
disease NN NN I-Disease
. NN NN O
   
Preoperative NN NN O
platelet NN NN O
count NN NN O
, NN NN O
postoperative NN NN O
course NN NN O
of NN NN O
platelets NN NN O
, NN NN O
and NN NN O
clinical NN NN O
signs NN NN O
of NN NN O
HIT NN NN B-Disease
type NN NN I-Disease
II NN NN I-Disease
were NN NN O
analyzed NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
A NN NN O
total NN NN O
of NN NN O
155 NN NN O
( NN NN O
75 NN NN O
. NN NN O
6 NN NN O
% NN NN O
) NN NN O
of NN NN O
205 NN NN O
patients NN NN O
had NN NN O
thrombocytopenia NN NN B-Disease
before NN NN O
transplantation NN NN O
, NN NN O
significantly NN NN O
influenced NN NN O
by NN NN O
Model NN NN O
of NN NN O
End NN NN B-Disease
- NN NN I-Disease
Stage NN NN I-Disease
Liver NN NN I-Disease
Disease NN NN I-Disease
score NN NN O
and NN NN O
liver NN NN B-Disease
cirrhosis NN NN I-Disease
. NN NN O
   
The NN NN O
platelet NN NN O
count NN NN O
exceeded NN NN O
100 NN NN O
, NN NN O
000 NN NN O
/ NN NN O
uL NN NN O
in NN NN O
most NN NN O
of NN NN O
the NN NN O
patients NN NN O
( NN NN O
n NN NN O
= NN NN O
193 NN NN O
) NN NN O
at NN NN O
a NN NN O
medium NN NN O
of NN NN O
7 NN NN O
d NN NN O
. NN NN O
   
Regarding NN NN O
HIT NN NN B-Disease
II NN NN I-Disease
, NN NN O
there NN NN O
were NN NN O
four NN NN O
( NN NN O
1 NN NN O
. NN NN O
95 NN NN O
% NN NN O
) NN NN O
patients NN NN O
with NN NN O
a NN NN O
background NN NN O
of NN NN O
HIT NN NN B-Disease
type NN NN I-Disease
II NN NN I-Disease
. NN NN O
   
CONCLUSIONS NN NN O
: NN NN O
The NN NN O
incidence NN NN O
of NN NN O
HIT NN NN B-Disease
in NN NN O
patients NN NN O
with NN NN O
end NN NN B-Disease
- NN NN I-Disease
stage NN NN I-Disease
hepatic NN NN I-Disease
failure NN NN I-Disease
is NN NN O
, NN NN O
with NN NN O
about NN NN O
1 NN NN O
. NN NN O
95 NN NN O
% NN NN O
, NN NN O
rare NN NN O
. NN NN O
   
For NN NN O
further NN NN O
reduction NN NN O
of NN NN O
HIT NN NN B-Disease
type NN NN I-Disease
II NN NN I-Disease
, NN NN O
the NN NN O
use NN NN O
of NN NN O
intravenous NN NN O
heparin NN NN O
should NN NN O
be NN NN O
avoided NN NN O
and NN NN O
the NN NN O
prophylactic NN NN O
anticoagulation NN NN O
should NN NN O
be NN NN O
performed NN NN O
with NN NN O
low NN NN O
- NN NN O
molecular NN NN O
- NN NN O
weight NN NN O
heparin NN NN O
after NN NN O
normalization NN NN O
of NN NN O
platelet NN NN O
count NN NN O
. NN NN O
   
Takotsubo NN NN B-Disease
syndrome NN NN I-Disease
( NN NN O
or NN NN O
apical NN NN B-Disease
ballooning NN NN I-Disease
syndrome NN NN I-Disease
) NN NN O
secondary NN NN O
to NN NN O
Zolmitriptan NN NN O
. NN NN O
   
Takotsubo NN NN B-Disease
syndrome NN NN I-Disease
( NN NN O
TS NN NN B-Disease
) NN NN O
, NN NN O
also NN NN O
known NN NN O
as NN NN O
broken NN NN B-Disease
heart NN NN I-Disease
syndrome NN NN I-Disease
, NN NN O
is NN NN O
characterized NN NN O
by NN NN O
left NN NN O
ventricle NN NN O
apical NN NN O
ballooning NN NN O
with NN NN O
elevated NN NN O
cardiac NN NN O
biomarkers NN NN O
and NN NN O
electrocardiographic NN NN O
changes NN NN O
suggestive NN NN O
of NN NN O
an NN NN O
acute NN NN B-Disease
coronary NN NN I-Disease
syndrome NN NN I-Disease
( NN NN O
ie NN NN O
, NN NN O
ST NN NN O
- NN NN O
segment NN NN O
elevation NN NN O
, NN NN O
T NN NN O
wave NN NN O
inversions NN NN O
, NN NN O
and NN NN O
pathologic NN NN O
Q NN NN O
waves NN NN O
) NN NN O
. NN NN O
   
We NN NN O
report NN NN O
a NN NN O
case NN NN O
of NN NN O
54 NN NN O
- NN NN O
year NN NN O
- NN NN O
old NN NN O
woman NN NN O
with NN NN O
medical NN NN O
history NN NN O
of NN NN O
mitral NN NN B-Disease
valve NN NN I-Disease
prolapse NN NN I-Disease
and NN NN O
migraines NN NN B-Disease
, NN NN O
who NN NN O
was NN NN O
admitted NN NN O
to NN NN O
the NN NN O
hospital NN NN O
for NN NN O
substernal NN NN O
chest NN NN B-Disease
pain NN NN I-Disease
and NN NN O
electrocardiogram NN NN O
demonstrated NN NN O
1 NN NN O
/ NN NN O
2 NN NN O
mm NN NN O
ST NN NN O
- NN NN O
segment NN NN O
elevation NN NN O
in NN NN O
leads NN NN O
II NN NN O
, NN NN O
III NN NN O
, NN NN O
aVF NN NN O
, NN NN O
V5 NN NN O
, NN NN O
and NN NN O
V6 NN NN O
and NN NN O
positive NN NN O
troponin NN NN O
I NN NN O
. NN NN O
   
Emergent NN NN O
coronary NN NN O
angiogram NN NN O
revealed NN NN O
normal NN NN O
coronary NN NN O
arteries NN NN O
with NN NN O
moderately NN NN O
reduced NN NN O
left NN NN O
ventricular NN NN O
ejection NN NN O
fraction NN NN O
with NN NN O
wall NN NN O
motion NN NN O
abnormalities NN NN O
consistent NN NN O
with NN NN O
TS NN NN B-Disease
. NN NN O
   
Detailed NN NN O
history NN NN O
obtained NN NN O
retrospectively NN NN O
revealed NN NN O
that NN NN O
the NN NN O
patient NN NN O
took NN NN O
zolmitriptan NN NN O
sparingly NN NN O
only NN NN O
when NN NN O
she NN NN O
had NN NN O
migraines NN NN B-Disease
. NN NN O
   
But NN NN O
before NN NN O
this NN NN O
event NN NN O
, NN NN O
she NN NN O
was NN NN O
taking NN NN O
zolmitriptan NN NN O
2 NN NN O
- NN NN O
3 NN NN O
times NN NN O
daily NN NN O
for NN NN O
several NN NN O
days NN NN O
because NN NN O
of NN NN O
a NN NN O
persistent NN NN O
migraine NN NN B-Disease
headache NN NN I-Disease
. NN NN O
   
She NN NN O
otherwise NN NN O
reported NN NN O
that NN NN O
she NN NN O
is NN NN O
quite NN NN O
active NN NN O
, NN NN O
rides NN NN O
horses NN NN O
, NN NN O
and NN NN O
does NN NN O
show NN NN O
jumping NN NN O
without NN NN O
any NN NN O
limitations NN NN O
in NN NN O
her NN NN O
physical NN NN O
activity NN NN O
. NN NN O
   
There NN NN O
was NN NN O
no NN NN O
evidence NN NN O
of NN NN O
any NN NN O
recent NN NN O
stress NN NN O
or NN NN O
status NN NN B-Disease
migrainosus NN NN I-Disease
. NN NN O
   
Extensive NN NN O
literature NN NN O
search NN NN O
revealed NN NN O
multiple NN NN O
cases NN NN O
of NN NN O
coronary NN NN B-Disease
artery NN NN I-Disease
vasospasm NN NN I-Disease
secondary NN NN O
to NN NN O
zolmitriptan NN NN O
, NN NN O
but NN NN O
none NN NN O
of NN NN O
the NN NN O
cases NN NN O
were NN NN O
associated NN NN O
with NN NN O
TS NN NN B-Disease
. NN NN O
   
Depression NN NN B-Disease
, NN NN O
impulsiveness NN NN B-Disease
, NN NN O
sleep NN NN O
, NN NN O
and NN NN O
memory NN NN O
in NN NN O
past NN NN O
and NN NN O
present NN NN O
polydrug NN NN O
users NN NN O
of NN NN O
3 NN NN O
, NN NN O
4 NN NN O
- NN NN O
methylenedioxymethamphetamine NN NN O
( NN NN O
MDMA NN NN O
, NN NN O
ecstasy NN NN O
) NN NN O
. NN NN O
   
RATIONALE NN NN O
: NN NN O
Ecstasy NN NN O
( NN NN O
3 NN NN O
, NN NN O
4 NN NN O
- NN NN O
methylenedioxymethamphetamine NN NN O
, NN NN O
MDMA NN NN O
) NN NN O
is NN NN O
a NN NN O
worldwide NN NN O
recreational NN NN O
drug NN NN O
of NN NN O
abuse NN NN O
. NN NN O
   
Unfortunately NN NN O
, NN NN O
the NN NN O
results NN NN O
from NN NN O
human NN NN O
research NN NN O
investigating NN NN O
its NN NN O
psychological NN NN O
effects NN NN O
have NN NN O
been NN NN O
inconsistent NN NN O
. NN NN O
   
OBJECTIVES NN NN O
: NN NN O
The NN NN O
present NN NN O
study NN NN O
aimed NN NN O
to NN NN O
be NN NN O
the NN NN O
largest NN NN O
to NN NN O
date NN NN O
in NN NN O
sample NN NN O
size NN NN O
and NN NN O
5HT NN NN O
- NN NN O
related NN NN O
behaviors NN NN O
; NN NN O
the NN NN O
first NN NN O
to NN NN O
compare NN NN O
present NN NN O
ecstasy NN NN O
users NN NN O
with NN NN O
past NN NN O
users NN NN O
after NN NN O
an NN NN O
abstinence NN NN O
of NN NN O
4 NN NN O
or NN NN O
more NN NN O
years NN NN O
, NN NN O
and NN NN O
the NN NN O
first NN NN O
to NN NN O
include NN NN O
robust NN NN O
controls NN NN O
for NN NN O
other NN NN O
recreational NN NN O
substances NN NN O
. NN NN O
   
METHODS NN NN O
: NN NN O
A NN NN O
sample NN NN O
of NN NN O
997 NN NN O
participants NN NN O
( NN NN O
52 NN NN O
% NN NN O
male NN NN O
) NN NN O
was NN NN O
recruited NN NN O
to NN NN O
four NN NN O
control NN NN O
groups NN NN O
( NN NN O
non NN NN O
- NN NN O
drug NN NN O
( NN NN O
ND NN NN O
) NN NN O
, NN NN O
alcohol NN NN O
/ NN NN O
nicotine NN NN O
( NN NN O
AN NN NN O
) NN NN O
, NN NN O
cannabis NN NN O
/ NN NN O
alcohol NN NN O
/ NN NN O
nicotine NN NN O
( NN NN O
CAN NN NN O
) NN NN O
, NN NN O
non NN NN O
- NN NN O
ecstasy NN NN O
polydrug NN NN O
( NN NN O
PD NN NN O
) NN NN O
) NN NN O
, NN NN O
and NN NN O
two NN NN O
ecstasy NN NN O
polydrug NN NN O
groups NN NN O
( NN NN O
present NN NN O
( NN NN O
MDMA NN NN O
) NN NN O
and NN NN O
past NN NN O
users NN NN O
( NN NN O
EX NN NN O
- NN NN O
MDMA NN NN O
) NN NN O
. NN NN O
   
Participants NN NN O
completed NN NN O
a NN NN O
drug NN NN O
history NN NN O
questionnaire NN NN O
, NN NN O
Beck NN NN O
Depression NN NN B-Disease
Inventory NN NN O
, NN NN O
Barratt NN NN O
Impulsiveness NN NN B-Disease
Scale NN NN O
, NN NN O
Pittsburgh NN NN O
Sleep NN NN O
Quality NN NN O
Index NN NN O
, NN NN O
and NN NN O
Wechsler NN NN O
Memory NN NN O
Scale NN NN O
- NN NN O
Revised NN NN O
which NN NN O
, NN NN O
in NN NN O
total NN NN O
, NN NN O
provided NN NN O
13 NN NN O
psychometric NN NN O
measures NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
While NN NN O
the NN NN O
CAN NN NN O
and NN NN O
PD NN NN O
groups NN NN O
tended NN NN O
to NN NN O
record NN NN O
greater NN NN O
deficits NN NN O
than NN NN O
the NN NN O
non NN NN O
- NN NN O
drug NN NN O
controls NN NN O
, NN NN O
the NN NN O
MDMA NN NN O
and NN NN O
EX NN NN O
- NN NN O
MDMA NN NN O
groups NN NN O
recorded NN NN O
greater NN NN O
deficits NN NN O
than NN NN O
all NN NN O
the NN NN O
control NN NN O
groups NN NN O
on NN NN O
ten NN NN O
of NN NN O
the NN NN O
13 NN NN O
psychometric NN NN O
measures NN NN O
. NN NN O
   
Strikingly NN NN O
, NN NN O
despite NN NN O
prolonged NN NN O
abstinence NN NN O
( NN NN O
mean NN NN O
, NN NN O
4 NN NN O
. NN NN O
98 NN NN O
; NN NN O
range NN NN O
, NN NN O
4 NN NN O
- NN NN O
9 NN NN O
years NN NN O
) NN NN O
, NN NN O
past NN NN O
ecstasy NN NN O
users NN NN O
showed NN NN O
few NN NN O
signs NN NN O
of NN NN O
recovery NN NN O
. NN NN O
   
Compared NN NN O
with NN NN O
present NN NN O
ecstasy NN NN O
users NN NN O
, NN NN O
the NN NN O
past NN NN O
users NN NN O
showed NN NN O
no NN NN O
change NN NN O
for NN NN O
ten NN NN O
measures NN NN O
, NN NN O
increased NN NN O
impairment NN NN O
for NN NN O
two NN NN O
measures NN NN O
, NN NN O
and NN NN O
improvement NN NN O
on NN NN O
just NN NN O
one NN NN O
measure NN NN O
. NN NN O
   
CONCLUSIONS NN NN O
: NN NN O
Given NN NN O
this NN NN O
record NN NN O
of NN NN O
impaired NN NN B-Disease
memory NN NN I-Disease
and NN NN O
clinically NN NN O
significant NN NN O
levels NN NN O
of NN NN O
depression NN NN B-Disease
, NN NN O
impulsiveness NN NN B-Disease
, NN NN O
and NN NN O
sleep NN NN B-Disease
disturbance NN NN I-Disease
, NN NN O
the NN NN O
prognosis NN NN O
for NN NN O
the NN NN O
current NN NN O
generation NN NN O
of NN NN O
ecstasy NN NN O
users NN NN O
is NN NN O
a NN NN O
major NN NN O
cause NN NN O
for NN NN O
concern NN NN O
. NN NN O
   
Association NN NN O
of NN NN O
common NN NN O
genetic NN NN O
variants NN NN O
of NN NN O
HOMER1 NN NN O
gene NN NN O
with NN NN O
levodopa NN NN O
adverse NN NN O
effects NN NN O
in NN NN O
Parkinson NN NN B-Disease
' NN NN I-Disease
s NN NN I-Disease
disease NN NN I-Disease
patients NN NN O
. NN NN O
   
Levodopa NN NN O
is NN NN O
the NN NN O
most NN NN O
effective NN NN O
symptomatic NN NN O
therapy NN NN O
for NN NN O
Parkinson NN NN B-Disease
' NN NN I-Disease
s NN NN I-Disease
disease NN NN I-Disease
, NN NN O
but NN NN O
its NN NN O
chronic NN NN O
use NN NN O
could NN NN O
lead NN NN O
to NN NN O
chronic NN NN O
adverse NN NN O
outcomes NN NN O
, NN NN O
such NN NN O
as NN NN O
motor NN NN O
fluctuations NN NN O
, NN NN O
dyskinesia NN NN B-Disease
and NN NN O
visual NN NN B-Disease
hallucinations NN NN I-Disease
. NN NN O
   
HOMER1 NN NN O
is NN NN O
a NN NN O
protein NN NN O
with NN NN O
pivotal NN NN O
function NN NN O
in NN NN O
glutamate NN NN O
transmission NN NN O
, NN NN O
which NN NN O
has NN NN O
been NN NN O
related NN NN O
to NN NN O
the NN NN O
pathogenesis NN NN O
of NN NN O
these NN NN O
complications NN NN O
. NN NN O
   
This NN NN O
study NN NN O
investigates NN NN O
whether NN NN O
polymorphisms NN NN O
in NN NN O
the NN NN O
HOMER1 NN NN O
gene NN NN O
promoter NN NN O
region NN NN O
are NN NN O
associated NN NN O
with NN NN O
the NN NN O
occurrence NN NN O
of NN NN O
the NN NN O
chronic NN NN O
complications NN NN O
of NN NN O
levodopa NN NN O
therapy NN NN O
. NN NN O
   
A NN NN O
total NN NN O
of NN NN O
205 NN NN O
patients NN NN O
with NN NN O
idiopathic NN NN B-Disease
Parkinson NN NN I-Disease
' NN NN I-Disease
s NN NN I-Disease
disease NN NN I-Disease
were NN NN O
investigated NN NN O
. NN NN O
   
Patients NN NN O
were NN NN O
genotyped NN NN O
for NN NN O
rs4704559 NN NN O
, NN NN O
rs10942891 NN NN O
and NN NN O
rs4704560 NN NN O
by NN NN O
allelic NN NN O
discrimination NN NN O
with NN NN O
Taqman NN NN O
assays NN NN O
. NN NN O
   
The NN NN O
rs4704559 NN NN O
G NN NN O
allele NN NN O
was NN NN O
associated NN NN O
with NN NN O
a NN NN O
lower NN NN O
prevalence NN NN O
of NN NN O
dyskinesia NN NN B-Disease
( NN NN O
prevalence NN NN O
ratio NN NN O
( NN NN O
PR NN NN O
) NN NN O
= NN NN O
0 NN NN O
. NN NN O
615 NN NN O
, NN NN O
95 NN NN O
% NN NN O
confidence NN NN O
interval NN NN O
( NN NN O
CI NN NN O
) NN NN O
0 NN NN O
. NN NN O
426 NN NN O
- NN NN O
0 NN NN O
. NN NN O
887 NN NN O
, NN NN O
P NN NN O
= NN NN O
0 NN NN O
. NN NN O
009 NN NN O
) NN NN O
and NN NN O
visual NN NN B-Disease
hallucinations NN NN I-Disease
( NN NN O
PR NN NN O
= NN NN O
0 NN NN O
. NN NN O
515 NN NN O
, NN NN O
95 NN NN O
% NN NN O
CI NN NN O
0 NN NN O
. NN NN O
295 NN NN O
- NN NN O
0 NN NN O
. NN NN O
899 NN NN O
, NN NN O
P NN NN O
= NN NN O
0 NN NN O
. NN NN O
020 NN NN O
) NN NN O
. NN NN O
   
Our NN NN O
data NN NN O
suggest NN NN O
that NN NN O
HOMER1 NN NN O
rs4704559 NN NN O
G NN NN O
allele NN NN O
has NN NN O
a NN NN O
protective NN NN O
role NN NN O
for NN NN O
the NN NN O
development NN NN O
of NN NN O
levodopa NN NN O
adverse NN NN O
effects NN NN O
. NN NN O
   
Crocin NN NN O
improves NN NN O
lipid NN NN O
dysregulation NN NN O
in NN NN O
subacute NN NN O
diazinon NN NN O
exposure NN NN O
through NN NN O
ERK1 NN NN O
/ NN NN O
2 NN NN O
pathway NN NN O
in NN NN O
rat NN NN O
liver NN NN O
. NN NN O
   
INTRODUCTION NN NN O
: NN NN O
Diazinon NN NN O
Yis NN NN O
one NN NN O
of NN NN O
the NN NN O
most NN NN O
broadly NN NN O
used NN NN O
organophosphorus NN NN O
insecticides NN NN O
in NN NN O
agriculture NN NN O
. NN NN O
   
It NN NN O
has NN NN O
been NN NN O
shown NN NN O
that NN NN O
exposure NN NN O
to NN NN O
diazinon NN NN O
may NN NN O
interfere NN NN O
with NN NN O
lipid NN NN O
metabolism NN NN O
. NN NN O
   
Moreover NN NN O
, NN NN O
the NN NN O
hypolipidemic NN NN O
effect NN NN O
of NN NN O
crocin NN NN O
has NN NN O
been NN NN O
established NN NN O
. NN NN O
   
Earlier NN NN O
studies NN NN O
revealed NN NN O
the NN NN O
major NN NN O
role NN NN O
of NN NN O
Extracellular NN NN O
signal NN NN O
- NN NN O
regulated NN NN O
kinase NN NN O
( NN NN O
ERK NN NN O
) NN NN O
pathways NN NN O
in NN NN O
low NN NN O
- NN NN O
density NN NN O
lipoprotein NN NN O
receptor NN NN O
( NN NN O
LDLr NN NN O
) NN NN O
expression NN NN O
. NN NN O
   
The NN NN O
aim NN NN O
of NN NN O
this NN NN O
study NN NN O
was NN NN O
to NN NN O
evaluate NN NN O
changes NN NN O
in NN NN O
the NN NN O
regulation NN NN O
of NN NN O
lipid NN NN O
metabolism NN NN O
, NN NN O
ERK NN NN O
and NN NN O
LDLr NN NN O
expression NN NN O
in NN NN O
the NN NN O
liver NN NN O
of NN NN O
rats NN NN O
exposed NN NN O
to NN NN O
subacute NN NN O
diazinon NN NN O
. NN NN O
   
Furthermore NN NN O
ameliorating NN NN O
effect NN NN O
of NN NN O
crocin NN NN O
on NN NN O
diazinon NN NN O
induced NN NN O
disturbed NN NN O
cholesterol NN NN O
homeostasis NN NN O
was NN NN O
studied NN NN O
. NN NN O
   
METHODS NN NN O
: NN NN O
24 NN NN O
Rats NN NN O
were NN NN O
divided NN NN O
into NN NN O
4 NN NN O
groups NN NN O
and NN NN O
received NN NN O
following NN NN O
treatments NN NN O
for NN NN O
4 NN NN O
weeks NN NN O
; NN NN O
Corn NN NN O
oil NN NN O
( NN NN O
control NN NN O
) NN NN O
, NN NN O
diazinon NN NN O
( NN NN O
15mg NN NN O
/ NN NN O
kg NN NN O
per NN NN O
day NN NN O
, NN NN O
orally NN NN O
) NN NN O
and NN NN O
crocin NN NN O
( NN NN O
12 NN NN O
. NN NN O
5 NN NN O
and NN NN O
25mg NN NN O
/ NN NN O
kg NN NN O
per NN NN O
day NN NN O
, NN NN O
intraperitoneally NN NN O
) NN NN O
in NN NN O
combination NN NN O
with NN NN O
diazinon NN NN O
( NN NN O
15 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
) NN NN O
. NN NN O
   
The NN NN O
levels NN NN O
of NN NN O
cholesterol NN NN O
, NN NN O
triglyceride NN NN O
and NN NN O
LDL NN NN O
in NN NN O
blood NN NN O
of NN NN O
rats NN NN O
were NN NN O
analyzed NN NN O
. NN NN O
   
Moreover NN NN O
mRNA NN NN O
levels NN NN O
of NN NN O
LDLr NN NN O
and NN NN O
ERK1 NN NN O
/ NN NN O
2 NN NN O
as NN NN O
well NN NN O
as NN NN O
protein NN NN O
levels NN NN O
of NN NN O
total NN NN O
and NN NN O
activated NN NN O
forms NN NN O
of NN NN O
ERK1 NN NN O
/ NN NN O
2 NN NN O
in NN NN O
rat NN NN O
liver NN NN O
were NN NN O
evaluated NN NN O
by NN NN O
Western NN NN O
blotting NN NN O
and NN NN O
quantitative NN NN O
real NN NN O
time NN NN O
polymerase NN NN O
chain NN NN O
reaction NN NN O
analysis NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
Our NN NN O
data NN NN O
showed NN NN O
that NN NN O
subacute NN NN O
exposure NN NN O
to NN NN O
diazinon NN NN O
significantly NN NN O
increased NN NN O
concentrations NN NN O
of NN NN O
cholesterol NN NN O
, NN NN O
triglyceride NN NN O
and NN NN O
LDL NN NN O
. NN NN O
   
Moreover NN NN O
diazinon NN NN O
decreased NN NN O
ERK1 NN NN O
/ NN NN O
2 NN NN O
protein NN NN O
phosphorylation NN NN O
and NN NN O
LDLr NN NN O
transcript NN NN O
. NN NN O
   
Crocin NN NN O
reduced NN NN O
inhibition NN NN O
of NN NN O
ERK NN NN O
activation NN NN O
and NN NN O
diazinon NN NN O
- NN NN O
induced NN NN O
hyperlipemia NN NN B-Disease
and NN NN O
increased NN NN O
levels NN NN O
of NN NN O
LDLr NN NN O
transcript NN NN O
. NN NN O
   
CONCLUSIONS NN NN O
: NN NN O
Crocin NN NN O
may NN NN O
be NN NN O
considered NN NN O
as NN NN O
a NN NN O
novel NN NN O
protective NN NN O
agent NN NN O
in NN NN O
diazinon NN NN O
- NN NN O
induced NN NN O
hyperlipemia NN NN B-Disease
through NN NN O
modulating NN NN O
of NN NN O
ERK NN NN O
pathway NN NN O
and NN NN O
increase NN NN O
of NN NN O
LDLr NN NN O
expression NN NN O
. NN NN O
   
GEM NN NN O
- NN NN O
P NN NN O
chemotherapy NN NN O
is NN NN O
active NN NN O
in NN NN O
the NN NN O
treatment NN NN O
of NN NN O
relapsed NN NN O
Hodgkin NN NN B-Disease
lymphoma NN NN I-Disease
. NN NN O
   
Hodgkin NN NN B-Disease
lymphoma NN NN I-Disease
( NN NN O
HL NN NN B-Disease
) NN NN O
is NN NN O
a NN NN O
relatively NN NN O
chemosensitive NN NN O
malignancy NN NN B-Disease
. NN NN O
   
However NN NN O
, NN NN O
for NN NN O
those NN NN O
who NN NN O
relapse NN NN O
, NN NN O
high NN NN O
- NN NN O
dose NN NN O
chemotherapy NN NN O
with NN NN O
autologous NN NN O
stem NN NN O
cell NN NN O
transplant NN NN O
is NN NN O
the NN NN O
treatment NN NN O
of NN NN O
choice NN NN O
which NN NN O
relies NN NN O
on NN NN O
adequate NN NN O
disease NN NN O
control NN NN O
with NN NN O
salvage NN NN O
chemotherapy NN NN O
. NN NN O
   
Regimens NN NN O
commonly NN NN O
used NN NN O
often NN NN O
require NN NN O
inpatient NN NN O
administration NN NN O
and NN NN O
can NN NN O
be NN NN O
difficult NN NN O
to NN NN O
deliver NN NN O
due NN NN O
to NN NN O
toxicity NN NN B-Disease
. NN NN O
   
Gemcitabine NN NN O
and NN NN O
cisplatin NN NN O
have NN NN O
activity NN NN O
in NN NN O
HL NN NN B-Disease
, NN NN O
non NN NN O
- NN NN O
overlapping NN NN O
toxicity NN NN B-Disease
with NN NN O
first NN NN O
- NN NN O
line NN NN O
chemotherapeutics NN NN O
, NN NN O
and NN NN O
may NN NN O
be NN NN O
delivered NN NN O
in NN NN O
an NN NN O
outpatient NN NN O
setting NN NN O
. NN NN O
   
In NN NN O
this NN NN O
retrospective NN NN O
single NN NN O
- NN NN O
centre NN NN O
analysis NN NN O
, NN NN O
patients NN NN O
with NN NN O
relapsed NN NN O
or NN NN O
refractory NN NN O
HL NN NN B-Disease
treated NN NN O
with NN NN O
gemcitabine NN NN O
1 NN NN O
, NN NN O
000 NN NN O
mg NN NN O
/ NN NN O
m NN NN O
( NN NN O
2 NN NN O
) NN NN O
day NN NN O
( NN NN O
D NN NN O
) NN NN O
1 NN NN O
, NN NN O
D8 NN NN O
and NN NN O
D15 NN NN O
; NN NN O
methylprednisolone NN NN O
1 NN NN O
, NN NN O
000 NN NN O
mg NN NN O
D1 NN NN O
- NN NN O
5 NN NN O
; NN NN O
and NN NN O
cisplatin NN NN O
100 NN NN O
mg NN NN O
/ NN NN O
m NN NN O
( NN NN O
2 NN NN O
) NN NN O
D15 NN NN O
, NN NN O
every NN NN O
28 NN NN O
days NN NN O
( NN NN O
GEM NN NN O
- NN NN O
P NN NN O
) NN NN O
were NN NN O
included NN NN O
. NN NN O
   
Demographic NN NN O
, NN NN O
survival NN NN O
, NN NN O
response NN NN O
and NN NN O
toxicity NN NN B-Disease
data NN NN O
were NN NN O
recorded NN NN O
. NN NN O
   
Forty NN NN O
- NN NN O
one NN NN O
eligible NN NN O
patients NN NN O
were NN NN O
identified NN NN O
: NN NN O
median NN NN O
age NN NN O
27 NN NN O
. NN NN O
   
One NN NN O
hundred NN NN O
and NN NN O
twenty NN NN O
- NN NN O
two NN NN O
cycles NN NN O
of NN NN O
GEM NN NN O
- NN NN O
P NN NN O
were NN NN O
administered NN NN O
in NN NN O
total NN NN O
( NN NN O
median NN NN O
3 NN NN O
cycles NN NN O
; NN NN O
range NN NN O
1 NN NN O
- NN NN O
6 NN NN O
) NN NN O
. NN NN O
   
Twenty NN NN O
of NN NN O
41 NN NN O
( NN NN O
48 NN NN O
% NN NN O
) NN NN O
patients NN NN O
received NN NN O
GEM NN NN O
- NN NN O
P NN NN O
as NN NN O
second NN NN O
- NN NN O
line NN NN O
treatment NN NN O
and NN NN O
11 NN NN O
/ NN NN O
41 NN NN O
( NN NN O
27 NN NN O
% NN NN O
) NN NN O
as NN NN O
third NN NN O
- NN NN O
line NN NN O
therapy NN NN O
. NN NN O
   
Overall NN NN O
response NN NN O
rate NN NN O
( NN NN O
ORR NN NN O
) NN NN O
to NN NN O
GEM NN NN O
- NN NN O
P NN NN O
in NN NN O
the NN NN O
entire NN NN O
cohort NN NN O
was NN NN O
80 NN NN O
% NN NN O
( NN NN O
complete NN NN O
response NN NN O
( NN NN O
CR NN NN O
) NN NN O
37 NN NN O
% NN NN O
, NN NN O
partial NN NN O
response NN NN O
44 NN NN O
% NN NN O
) NN NN O
with NN NN O
14 NN NN O
/ NN NN O
15 NN NN O
CR NN NN O
confirmed NN NN O
as NN NN O
a NN NN O
metabolic NN NN O
CR NN NN O
on NN NN O
PET NN NN O
and NN NN O
ORR NN NN O
of NN NN O
85 NN NN O
% NN NN O
in NN NN O
the NN NN O
20 NN NN O
second NN NN O
- NN NN O
line NN NN O
patients NN NN O
. NN NN O
   
The NN NN O
most NN NN O
common NN NN O
grade NN NN O
3 NN NN O
/ NN NN O
4 NN NN O
toxicities NN NN B-Disease
were NN NN O
haematological NN NN O
: NN NN O
neutropenia NN NN B-Disease
54 NN NN O
% NN NN O
and NN NN O
thrombocytopenia NN NN B-Disease
51 NN NN O
% NN NN O
. NN NN O
   
Median NN NN O
follow NN NN O
- NN NN O
up NN NN O
from NN NN O
the NN NN O
start NN NN O
of NN NN O
GEM NN NN O
- NN NN O
P NN NN O
was NN NN O
4 NN NN O
. NN NN O
5 NN NN O
years NN NN O
. NN NN O
   
Following NN NN O
GEM NN NN O
- NN NN O
P NN NN O
, NN NN O
5 NN NN O
- NN NN O
year NN NN O
progression NN NN O
- NN NN O
free NN NN O
survival NN NN O
was NN NN O
46 NN NN O
% NN NN O
( NN NN O
95 NN NN O
% NN NN O
confidence NN NN O
interval NN NN O
( NN NN O
CI NN NN O
) NN NN O
, NN NN O
30 NN NN O
- NN NN O
62 NN NN O
% NN NN O
) NN NN O
and NN NN O
5 NN NN O
- NN NN O
year NN NN O
overall NN NN O
survival NN NN O
was NN NN O
59 NN NN O
% NN NN O
( NN NN O
95 NN NN O
% NN NN O
CI NN NN O
, NN NN O
43 NN NN O
- NN NN O
74 NN NN O
% NN NN O
) NN NN O
. NN NN O
   
Fourteen NN NN O
of NN NN O
41 NN NN O
patients NN NN O
proceeded NN NN O
directly NN NN O
to NN NN O
autologous NN NN O
transplant NN NN O
. NN NN O
   
GEM NN NN O
- NN NN O
P NN NN O
is NN NN O
a NN NN O
salvage NN NN O
chemotherapy NN NN O
with NN NN O
relatively NN NN O
high NN NN O
response NN NN O
rates NN NN O
, NN NN O
leading NN NN O
to NN NN O
successful NN NN O
transplantation NN NN O
in NN NN O
appropriate NN NN O
patients NN NN O
, NN NN O
in NN NN O
the NN NN O
treatment NN NN O
of NN NN O
relapsed NN NN O
or NN NN O
refractory NN NN O
HL NN NN B-Disease
. NN NN O
   
Basal NN NN O
functioning NN NN O
of NN NN O
the NN NN O
hypothalamic NN NN O
- NN NN O
pituitary NN NN O
- NN NN O
adrenal NN NN O
( NN NN O
HPA NN NN O
) NN NN O
axis NN NN O
and NN NN O
psychological NN NN O
distress NN NN O
in NN NN O
recreational NN NN O
ecstasy NN NN O
polydrug NN NN O
users NN NN O
. NN NN O
   
RATIONALE NN NN O
: NN NN O
Ecstasy NN NN O
( NN NN O
MDMA NN NN O
) NN NN O
is NN NN O
a NN NN O
psychostimulant NN NN O
drug NN NN O
which NN NN O
is NN NN O
increasingly NN NN O
associated NN NN O
with NN NN O
psychobiological NN NN B-Disease
dysfunction NN NN I-Disease
. NN NN O
   
While NN NN O
some NN NN O
recent NN NN O
studies NN NN O
suggest NN NN O
acute NN NN O
changes NN NN O
in NN NN O
neuroendocrine NN NN O
function NN NN O
, NN NN O
less NN NN O
is NN NN O
known NN NN O
about NN NN O
long NN NN O
- NN NN O
term NN NN O
changes NN NN O
in NN NN O
HPA NN NN O
functionality NN NN O
in NN NN O
recreational NN NN O
users NN NN O
. NN NN O
   
OBJECTIVES NN NN O
: NN NN O
The NN NN O
current NN NN O
study NN NN O
is NN NN O
the NN NN O
first NN NN O
to NN NN O
explore NN NN O
the NN NN O
effects NN NN O
of NN NN O
ecstasy NN NN O
- NN NN O
polydrug NN NN O
use NN NN O
on NN NN O
psychological NN NN O
distress NN NN O
and NN NN O
basal NN NN O
functioning NN NN O
of NN NN O
the NN NN O
HPA NN NN O
axis NN NN O
through NN NN O
assessing NN NN O
the NN NN O
secretion NN NN O
of NN NN O
cortisol NN NN O
across NN NN O
the NN NN O
diurnal NN NN O
period NN NN O
. NN NN O
   
METHOD NN NN O
: NN NN O
Seventy NN NN O
- NN NN O
six NN NN O
participants NN NN O
( NN NN O
21 NN NN O
nonusers NN NN O
, NN NN O
29 NN NN O
light NN NN O
ecstasy NN NN O
- NN NN O
polydrug NN NN O
users NN NN O
, NN NN O
26 NN NN O
heavy NN NN O
ecstasy NN NN O
- NN NN O
polydrug NN NN O
users NN NN O
) NN NN O
completed NN NN O
a NN NN O
substance NN NN O
use NN NN O
inventory NN NN O
and NN NN O
measures NN NN O
of NN NN O
psychological NN NN O
distress NN NN O
at NN NN O
baseline NN NN O
, NN NN O
then NN NN O
two NN NN O
consecutive NN NN O
days NN NN O
of NN NN O
cortisol NN NN O
sampling NN NN O
( NN NN O
on NN NN O
awakening NN NN O
, NN NN O
30 NN NN O
min NN NN O
post NN NN O
awakening NN NN O
, NN NN O
between NN NN O
1400 NN NN O
and NN NN O
1600 NN NN O
hours NN NN O
and NN NN O
pre NN NN O
bedtime NN NN O
) NN NN O
. NN NN O
   
On NN NN O
day NN NN O
2 NN NN O
, NN NN O
participants NN NN O
also NN NN O
attended NN NN O
the NN NN O
laboratory NN NN O
to NN NN O
complete NN NN O
a NN NN O
20 NN NN O
- NN NN O
min NN NN O
multitasking NN NN O
stressor NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
Both NN NN O
user NN NN O
groups NN NN O
exhibited NN NN O
significantly NN NN O
greater NN NN O
levels NN NN O
of NN NN O
anxiety NN NN B-Disease
and NN NN O
depression NN NN B-Disease
than NN NN O
nonusers NN NN O
. NN NN O
   
On NN NN O
day NN NN O
1 NN NN O
, NN NN O
all NN NN O
participants NN NN O
exhibited NN NN O
a NN NN O
typical NN NN O
cortisol NN NN O
profile NN NN O
, NN NN O
though NN NN O
light NN NN O
users NN NN O
had NN NN O
significantly NN NN O
elevated NN NN O
levels NN NN O
pre NN NN O
- NN NN O
bed NN NN O
. NN NN O
   
On NN NN O
day NN NN O
2 NN NN O
, NN NN O
heavy NN NN O
users NN NN O
demonstrated NN NN O
elevated NN NN O
levels NN NN O
upon NN NN O
awakening NN NN O
and NN NN O
all NN NN O
ecstasy NN NN O
- NN NN O
polydrug NN NN O
users NN NN O
demonstrated NN NN O
elevated NN NN O
pre NN NN O
- NN NN O
bed NN NN O
levels NN NN O
compared NN NN O
to NN NN O
non NN NN O
- NN NN O
users NN NN O
. NN NN O
   
Significant NN NN O
between NN NN O
group NN NN O
differences NN NN O
were NN NN O
also NN NN O
observed NN NN O
in NN NN O
afternoon NN NN O
cortisol NN NN O
levels NN NN O
and NN NN O
in NN NN O
overall NN NN O
cortisol NN NN O
secretion NN NN O
across NN NN O
the NN NN O
day NN NN O
. NN NN O
   
CONCLUSIONS NN NN O
: NN NN O
The NN NN O
increases NN NN O
in NN NN O
anxiety NN NN B-Disease
and NN NN O
depression NN NN B-Disease
are NN NN O
in NN NN O
line NN NN O
with NN NN O
previous NN NN O
observations NN NN O
in NN NN O
recreational NN NN O
ecstasy NN NN O
- NN NN O
polydrug NN NN O
users NN NN O
. NN NN O
   
Dysregulated NN NN O
diurnal NN NN O
cortisol NN NN O
may NN NN O
be NN NN O
indicative NN NN O
of NN NN O
inappropriate NN NN O
anticipation NN NN O
of NN NN O
forthcoming NN NN O
demands NN NN O
and NN NN O
hypersecretion NN NN O
may NN NN O
lead NN NN O
to NN NN O
the NN NN O
increased NN NN O
psychological NN NN O
and NN NN O
physical NN NN O
morbidity NN NN O
associated NN NN O
with NN NN O
heavy NN NN O
recreational NN NN O
use NN NN O
of NN NN O
ecstasy NN NN O
. NN NN O
   
Ifosfamide NN NN O
related NN NN O
encephalopathy NN NN B-Disease
: NN NN O
the NN NN O
need NN NN O
for NN NN O
a NN NN O
timely NN NN O
EEG NN NN O
evaluation NN NN O
. NN NN O
   
BACKGROUND NN NN O
: NN NN O
Ifosfamide NN NN O
is NN NN O
an NN NN O
alkylating NN NN O
agent NN NN O
useful NN NN O
in NN NN O
the NN NN O
treatment NN NN O
of NN NN O
a NN NN O
wide NN NN O
range NN NN O
of NN NN O
cancers NN NN B-Disease
including NN NN O
sarcomas NN NN B-Disease
, NN NN O
lymphoma NN NN B-Disease
, NN NN O
gynecologic NN NN B-Disease
and NN NN I-Disease
testicular NN NN I-Disease
cancers NN NN I-Disease
. NN NN O
   
Encephalopathy NN NN B-Disease
has NN NN O
been NN NN O
reported NN NN O
in NN NN O
10 NN NN O
- NN NN O
40 NN NN O
% NN NN O
of NN NN O
patients NN NN O
receiving NN NN O
high NN NN O
- NN NN O
dose NN NN O
IV NN NN O
ifosfamide NN NN O
. NN NN O
   
OBJECTIVE NN NN O
: NN NN O
To NN NN O
highlight NN NN O
the NN NN O
role NN NN O
of NN NN O
electroencephalogram NN NN O
( NN NN O
EEG NN NN O
) NN NN O
in NN NN O
the NN NN O
early NN NN O
detection NN NN O
and NN NN O
management NN NN O
of NN NN O
ifosfamide NN NN O
related NN NN O
encephalopathy NN NN B-Disease
. NN NN O
   
METHODS NN NN O
: NN NN O
Retrospective NN NN O
chart NN NN O
review NN NN O
including NN NN O
clinical NN NN O
data NN NN O
and NN NN O
EEG NN NN O
recordings NN NN O
was NN NN O
done NN NN O
on NN NN O
five NN NN O
patients NN NN O
, NN NN O
admitted NN NN O
to NN NN O
MD NN NN O
Anderson NN NN O
Cancer NN NN B-Disease
Center NN NN O
between NN NN O
years NN NN O
2009 NN NN O
and NN NN O
2012 NN NN O
, NN NN O
who NN NN O
developed NN NN O
ifosfamide NN NN O
related NN NN O
acute NN NN O
encephalopathy NN NN B-Disease
. NN NN O
   
RESULTS NN NN O
: NN NN O
All NN NN O
five NN NN O
patients NN NN O
experienced NN NN O
symptoms NN NN O
of NN NN O
encephalopathy NN NN B-Disease
soon NN NN O
after NN NN O
( NN NN O
within NN NN O
12 NN NN O
h NN NN O
- NN NN O
2 NN NN O
days NN NN O
) NN NN O
receiving NN NN O
ifosfamide NN NN O
. NN NN O
   
Two NN NN O
patients NN NN O
developed NN NN O
generalized NN NN O
convulsions NN NN B-Disease
while NN NN O
one NN NN O
patient NN NN O
developed NN NN O
continuous NN NN O
non NN NN B-Disease
- NN NN I-Disease
convulsive NN NN I-Disease
status NN NN I-Disease
epilepticus NN NN I-Disease
( NN NN O
NCSE NN NN B-Disease
) NN NN O
that NN NN O
required NN NN O
ICU NN NN O
admission NN NN O
and NN NN O
intubation NN NN O
. NN NN O
   
Initial NN NN O
EEG NN NN O
showed NN NN O
epileptiform NN NN O
discharges NN NN O
in NN NN O
three NN NN O
patients NN NN O
; NN NN O
run NN NN O
of NN NN O
triphasic NN NN O
waves NN NN O
in NN NN O
one NN NN O
patient NN NN O
and NN NN O
moderate NN NN O
degree NN NN O
diffuse NN NN O
generalized NN NN O
slowing NN NN O
. NN NN O
   
Mixed NN NN O
pattern NN NN O
with NN NN O
the NN NN O
presence NN NN O
of NN NN O
both NN NN O
sharps NN NN O
and NN NN O
triphasic NN NN O
waves NN NN O
were NN NN O
also NN NN O
noted NN NN O
. NN NN O
   
Repeat NN NN O
EEGs NN NN O
within NN NN O
24 NN NN O
_ NN NN O
h NN NN O
of NN NN O
symptom NN NN O
onset NN NN O
showed NN NN O
marked NN NN O
improvement NN NN O
that NN NN O
was NN NN O
correlated NN NN O
with NN NN O
clinical NN NN O
improvement NN NN O
. NN NN O
   
CONCLUSIONS NN NN O
: NN NN O
Severity NN NN O
of NN NN O
ifosfamide NN NN O
related NN NN O
encephalopathy NN NN B-Disease
correlates NN NN O
with NN NN O
EEG NN NN O
changes NN NN O
. NN NN O
   
We NN NN O
suggest NN NN O
a NN NN O
timely NN NN O
EEG NN NN O
evaluation NN NN O
for NN NN O
patients NN NN O
receiving NN NN O
ifosfamide NN NN O
who NN NN O
develop NN NN O
features NN NN O
of NN NN O
encephalopathy NN NN B-Disease
. NN NN O
   
Incidence NN NN O
of NN NN O
contrast NN NN O
- NN NN O
induced NN NN O
nephropathy NN NN B-Disease
in NN NN O
hospitalised NN NN O
patients NN NN O
with NN NN O
cancer NN NN B-Disease
. NN NN O
   
OBJECTIVES NN NN O
: NN NN O
To NN NN O
determine NN NN O
the NN NN O
frequency NN NN O
of NN NN O
and NN NN O
possible NN NN O
factors NN NN O
related NN NN O
to NN NN O
contrast NN NN O
- NN NN O
induced NN NN O
nephropathy NN NN B-Disease
( NN NN O
CIN NN NN O
) NN NN O
in NN NN O
hospitalised NN NN O
patients NN NN O
with NN NN O
cancer NN NN B-Disease
. NN NN O
   
METHODS NN NN O
: NN NN O
Ninety NN NN O
adult NN NN O
patients NN NN O
were NN NN O
enrolled NN NN O
. NN NN O
   
Patients NN NN O
with NN NN O
risk NN NN O
factors NN NN O
for NN NN O
acute NN NN B-Disease
renal NN NN I-Disease
failure NN NN I-Disease
were NN NN O
excluded NN NN O
. NN NN O
   
Blood NN NN O
samples NN NN O
were NN NN O
examined NN NN O
the NN NN O
day NN NN O
before NN NN O
contrast NN NN O
- NN NN O
enhanced NN NN O
computed NN NN O
tomography NN NN O
( NN NN O
CT NN NN O
) NN NN O
and NN NN O
serially NN NN O
for NN NN O
3 NN NN O
days NN NN O
thereafter NN NN O
. NN NN O
   
CIN NN NN O
was NN NN O
defined NN NN O
as NN NN O
an NN NN O
increase NN NN O
in NN NN O
serum NN NN O
creatinine NN NN O
( NN NN O
Cr NN NN O
) NN NN O
of NN NN O
0 NN NN O
. NN NN O
5 NN NN O
mg NN NN O
/ NN NN O
dl NN NN O
or NN NN O
more NN NN O
, NN NN O
or NN NN O
elevation NN NN O
of NN NN O
Cr NN NN O
to NN NN O
25 NN NN O
% NN NN O
over NN NN O
baseline NN NN O
. NN NN O
   
Relationships NN NN O
between NN NN O
CIN NN NN O
and NN NN O
possible NN NN O
risk NN NN O
factors NN NN O
were NN NN O
investigated NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
CIN NN NN O
was NN NN O
detected NN NN O
in NN NN O
18 NN NN O
/ NN NN O
90 NN NN O
( NN NN O
20 NN NN O
% NN NN O
) NN NN O
patients NN NN O
. NN NN O
   
CIN NN NN O
developed NN NN O
in NN NN O
25 NN NN O
. NN NN O
5 NN NN O
% NN NN O
patients NN NN O
who NN NN O
underwent NN NN O
chemotherapy NN NN O
and NN NN O
in NN NN O
11 NN NN O
% NN NN O
patients NN NN O
who NN NN O
did NN NN O
not NN NN O
( NN NN O
P NN NN O
= NN NN O
0 NN NN O
. NN NN O
1 NN NN O
) NN NN O
. NN NN O
   
CIN NN NN O
more NN NN O
frequently NN NN O
developed NN NN O
in NN NN O
patients NN NN O
who NN NN O
had NN NN O
undergone NN NN O
CT NN NN O
within NN NN O
45 NN NN O
days NN NN O
after NN NN O
the NN NN O
last NN NN O
chemotherapy NN NN O
( NN NN O
P NN NN O
= NN NN O
0 NN NN O
. NN NN O
005 NN NN O
) NN NN O
; NN NN O
it NN NN O
was NN NN O
also NN NN O
an NN NN O
independent NN NN O
risk NN NN O
factor NN NN O
( NN NN O
P NN NN O
= NN NN O
0 NN NN O
. NN NN O
017 NN NN O
) NN NN O
. NN NN O
   
CIN NN NN O
was NN NN O
significantly NN NN O
more NN NN O
after NN NN O
treatment NN NN O
with NN NN O
bevacizumab NN NN O
/ NN NN O
irinotecan NN NN O
( NN NN O
P NN NN O
= NN NN O
0 NN NN O
. NN NN O
021 NN NN O
) NN NN O
and NN NN O
in NN NN O
patients NN NN O
with NN NN O
hypertension NN NN B-Disease
( NN NN O
P NN NN O
= NN NN O
0 NN NN O
. NN NN O
044 NN NN O
) NN NN O
. NN NN O
   
CONCLUSIONS NN NN O
: NN NN O
The NN NN O
incidence NN NN O
of NN NN O
CIN NN NN O
after NN NN O
CT NN NN O
in NN NN O
hospitalised NN NN O
oncological NN NN O
patients NN NN O
was NN NN O
20 NN NN O
% NN NN O
. NN NN O
   
CIN NN NN O
developed NN NN O
4 NN NN O
. NN NN O
5 NN NN O
- NN NN O
times NN NN O
more NN NN O
frequently NN NN O
in NN NN O
patients NN NN O
with NN NN O
cancer NN NN B-Disease
who NN NN O
had NN NN O
undergone NN NN O
recent NN NN O
chemotherapy NN NN O
. NN NN O
   
Hypertension NN NN B-Disease
and NN NN O
the NN NN O
combination NN NN O
of NN NN O
bevacizumab NN NN O
/ NN NN O
irinotecan NN NN O
may NN NN O
be NN NN O
additional NN NN O
risk NN NN O
factors NN NN O
for NN NN O
CIN NN NN O
development NN NN O
. NN NN O
   
KEY NN NN O
POINTS NN NN O
: NN NN O
. NN NN O
   
Contrast NN NN O
- NN NN O
induced NN NN O
nephropathy NN NN B-Disease
( NN NN O
CIN NN NN O
) NN NN O
is NN NN O
a NN NN O
concern NN NN O
for NN NN O
oncological NN NN O
patients NN NN O
undergoing NN NN O
CT NN NN O
. NN NN O
   
. NN NN O
CIN NN NN O
occurs NN NN O
more NN NN O
often NN NN O
when NN NN O
CT NN NN O
is NN NN O
performed NN NN O
< NN NN O
45 NN NN O
days NN NN O
after NN NN O
chemotherapy NN NN O
. NN NN O
   
. NN NN O
Hypertension NN NN B-Disease
and NN NN O
treatment NN NN O
with NN NN O
bevacizumab NN NN O
appear NN NN O
to NN NN O
be NN NN O
additional NN NN O
risk NN NN O
factors NN NN O
. NN NN O
   
Syndrome NN NN B-Disease
of NN NN I-Disease
inappropriate NN NN I-Disease
antidiuretic NN NN I-Disease
hormone NN NN I-Disease
secretion NN NN O
associated NN NN O
with NN NN O
desvenlafaxine NN NN O
. NN NN O
   
OBJECTIVE NN NN O
: NN NN O
To NN NN O
report NN NN O
a NN NN O
case NN NN O
of NN NN O
syndrome NN NN B-Disease
of NN NN I-Disease
inappropriate NN NN I-Disease
anti NN NN I-Disease
- NN NN I-Disease
diuretic NN NN I-Disease
hormone NN NN I-Disease
( NN NN O
SIADH NN NN B-Disease
) NN NN O
secretion NN NN O
associated NN NN O
with NN NN O
desvenlafaxine NN NN O
. NN NN O
   
CASE NN NN O
SUMMARY NN NN O
: NN NN O
A NN NN O
57 NN NN O
- NN NN O
year NN NN O
old NN NN O
female NN NN O
with NN NN O
hyponatraemia NN NN B-Disease
. NN NN O
   
Her NN NN O
medications NN NN O
included NN NN O
desvenlafaxine NN NN O
, NN NN O
and NN NN O
symptoms NN NN O
included NN NN O
nausea NN NN B-Disease
, NN NN O
anxiety NN NN B-Disease
and NN NN O
confusion NN NN B-Disease
. NN NN O
   
The NN NN O
serum NN NN O
sodium NN NN O
at NN NN O
this NN NN O
time NN NN O
was NN NN O
120 NN NN O
mmol NN NN O
/ NN NN O
L NN NN O
, NN NN O
serum NN NN O
osmolality NN NN O
was NN NN O
263 NN NN O
mosmol NN NN O
/ NN NN O
kg NN NN O
, NN NN O
urine NN NN O
osmolality NN NN O
410 NN NN O
mosmol NN NN O
/ NN NN O
kg NN NN O
and NN NN O
urine NN NN O
sodium NN NN O
63 NN NN O
mmol NN NN O
/ NN NN O
L NN NN O
, NN NN O
consistent NN NN O
with NN NN O
a NN NN O
diagnosis NN NN O
of NN NN O
SIADH NN NN B-Disease
. NN NN O
   
Desvenlafaxine NN NN O
was NN NN O
ceased NN NN O
and NN NN O
fluid NN NN O
restriction NN NN O
implemented NN NN O
. NN NN O
   
After NN NN O
4 NN NN O
days NN NN O
the NN NN O
sodium NN NN O
increased NN NN O
to NN NN O
128 NN NN O
mmol NN NN O
/ NN NN O
L NN NN O
and NN NN O
fluid NN NN O
restriction NN NN O
was NN NN O
relaxed NN NN O
. NN NN O
   
During NN NN O
her NN NN O
further NN NN O
3 NN NN O
weeks NN NN O
inpatient NN NN O
admission NN NN O
the NN NN O
serum NN NN O
sodium NN NN O
ranged NN NN O
from NN NN O
134 NN NN O
to NN NN O
137 NN NN O
mmol NN NN O
/ NN NN O
L NN NN O
during NN NN O
treatment NN NN O
with NN NN O
mirtazapine NN NN O
. NN NN O
   
DISCUSSION NN NN O
: NN NN O
SIADH NN NN B-Disease
has NN NN O
been NN NN O
widely NN NN O
reported NN NN O
with NN NN O
a NN NN O
range NN NN O
of NN NN O
antidepressants NN NN O
. NN NN O
   
This NN NN O
case NN NN O
report NN NN O
suggests NN NN O
that NN NN O
desvenlafaxine NN NN O
might NN NN O
cause NN NN O
clinically NN NN O
significant NN NN O
hyponatremia NN NN B-Disease
. NN NN O
   
CONCLUSIONS NN NN O
: NN NN O
Clinicians NN NN O
should NN NN O
be NN NN O
aware NN NN O
of NN NN O
the NN NN O
potential NN NN O
for NN NN O
antidepressants NN NN O
to NN NN O
cause NN NN O
hyponatremia NN NN B-Disease
, NN NN O
and NN NN O
take NN NN O
appropriate NN NN O
corrective NN NN O
action NN NN O
where NN NN O
necessary NN NN O
. NN NN O
   
Oxidative NN NN O
stress NN NN O
on NN NN O
cardiotoxicity NN NN B-Disease
after NN NN O
treatment NN NN O
with NN NN O
single NN NN O
and NN NN O
multiple NN NN O
doses NN NN O
of NN NN O
doxorubicin NN NN O
. NN NN O
   
The NN NN O
mechanism NN NN O
of NN NN O
doxorubicin NN NN O
( NN NN O
DOX NN NN O
) NN NN O
- NN NN O
induced NN NN O
cardiotoxicity NN NN B-Disease
remains NN NN O
controversial NN NN O
. NN NN O
   
Wistar NN NN O
rats NN NN O
( NN NN O
n NN NN O
= NN NN O
66 NN NN O
) NN NN O
received NN NN O
DOX NN NN O
injections NN NN O
intraperitoneally NN NN O
and NN NN O
were NN NN O
randomly NN NN O
assigned NN NN O
to NN NN O
2 NN NN O
experimental NN NN O
protocols NN NN O
: NN NN O
( NN NN O
1 NN NN O
) NN NN O
rats NN NN O
were NN NN O
killed NN NN O
before NN NN O
( NN NN O
- NN NN O
24 NN NN O
h NN NN O
, NN NN O
n NN NN O
= NN NN O
8 NN NN O
) NN NN O
and NN NN O
24 NN NN O
h NN NN O
after NN NN O
( NN NN O
+ NN NN O
24 NN NN O
h NN NN O
, NN NN O
n NN NN O
= NN NN O
8 NN NN O
) NN NN O
a NN NN O
single NN NN O
dose NN NN O
of NN NN O
DOX NN NN O
( NN NN O
4 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
body NN NN O
weight NN NN O
) NN NN O
to NN NN O
determine NN NN O
the NN NN O
DOX NN NN O
acute NN NN O
effect NN NN O
and NN NN O
( NN NN O
2 NN NN O
) NN NN O
rats NN NN O
( NN NN O
n NN NN O
= NN NN O
58 NN NN O
) NN NN O
received NN NN O
4 NN NN O
injections NN NN O
of NN NN O
DOX NN NN O
( NN NN O
4 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
body NN NN O
weight NN NN O
/ NN NN O
week NN NN O
) NN NN O
and NN NN O
were NN NN O
killed NN NN O
before NN NN O
the NN NN O
first NN NN O
injection NN NN O
( NN NN O
M0 NN NN O
) NN NN O
and NN NN O
1 NN NN O
week NN NN O
after NN NN O
each NN NN O
injection NN NN O
( NN NN O
M1 NN NN O
, NN NN O
M2 NN NN O
, NN NN O
M3 NN NN O
, NN NN O
and NN NN O
M4 NN NN O
) NN NN O
to NN NN O
determine NN NN O
the NN NN O
chronological NN NN O
effects NN NN O
. NN NN O
   
Animals NN NN O
used NN NN O
at NN NN O
M0 NN NN O
( NN NN O
n NN NN O
= NN NN O
8 NN NN O
) NN NN O
were NN NN O
also NN NN O
used NN NN O
at NN NN O
moment NN NN O
- NN NN O
24 NN NN O
h NN NN O
of NN NN O
acute NN NN O
study NN NN O
. NN NN O
   
Cardiac NN NN O
total NN NN O
antioxidant NN NN O
performance NN NN O
( NN NN O
TAP NN NN O
) NN NN O
, NN NN O
DNA NN NN O
damage NN NN O
, NN NN O
and NN NN O
morphology NN NN O
analyses NN NN O
were NN NN O
carried NN NN O
out NN NN O
at NN NN O
each NN NN O
time NN NN O
point NN NN O
. NN NN O
   
Single NN NN O
dose NN NN O
of NN NN O
DOX NN NN O
was NN NN O
associated NN NN O
with NN NN O
increased NN NN O
cardiac NN NN B-Disease
disarrangement NN NN I-Disease
, NN NN O
necrosis NN NN B-Disease
, NN NN O
and NN NN O
DNA NN NN O
damage NN NN O
( NN NN O
strand NN NN O
breaks NN NN O
( NN NN O
SBs NN NN O
) NN NN O
and NN NN O
oxidized NN NN O
pyrimidines NN NN O
) NN NN O
and NN NN O
decreased NN NN O
TAP NN NN O
. NN NN O
   
The NN NN O
chronological NN NN O
study NN NN O
showed NN NN O
an NN NN O
effect NN NN O
of NN NN O
a NN NN O
cumulative NN NN O
dose NN NN O
on NN NN O
body NN NN O
weight NN NN O
( NN NN O
R NN NN O
= NN NN O
- NN NN O
0 NN NN O
. NN NN O
99 NN NN O
, NN NN O
p NN NN O
= NN NN O
0 NN NN O
. NN NN O
011 NN NN O
) NN NN O
, NN NN O
necrosis NN NN B-Disease
( NN NN O
R NN NN O
= NN NN O
1 NN NN O
. NN NN O
00 NN NN O
, NN NN O
p NN NN O
= NN NN O
0 NN NN O
. NN NN O
004 NN NN O
) NN NN O
, NN NN O
TAP NN NN O
( NN NN O
R NN NN O
= NN NN O
0 NN NN O
. NN NN O
95 NN NN O
, NN NN O
p NN NN O
= NN NN O
0 NN NN O
. NN NN O
049 NN NN O
) NN NN O
, NN NN O
and NN NN O
DNA NN NN O
SBs NN NN O
( NN NN O
R NN NN O
= NN NN O
- NN NN O
0 NN NN O
. NN NN O
95 NN NN O
, NN NN O
p NN NN O
= NN NN O
0 NN NN O
. NN NN O
049 NN NN O
) NN NN O
. NN NN O
   
DNA NN NN O
SBs NN NN O
damage NN NN O
was NN NN O
negatively NN NN O
associated NN NN O
with NN NN O
TAP NN NN O
( NN NN O
R NN NN O
= NN NN O
- NN NN O
0 NN NN O
. NN NN O
98 NN NN O
, NN NN O
p NN NN O
= NN NN O
0 NN NN O
. NN NN O
018 NN NN O
) NN NN O
, NN NN O
and NN NN O
necrosis NN NN B-Disease
( NN NN O
R NN NN O
= NN NN O
- NN NN O
0 NN NN O
. NN NN O
97 NN NN O
, NN NN O
p NN NN O
= NN NN O
0 NN NN O
. NN NN O
027 NN NN O
) NN NN O
. NN NN O
   
Our NN NN O
results NN NN O
suggest NN NN O
that NN NN O
oxidative NN NN O
damage NN NN O
is NN NN O
associated NN NN O
with NN NN O
acute NN NN O
cardiotoxicity NN NN B-Disease
induced NN NN O
by NN NN O
a NN NN O
single NN NN O
dose NN NN O
of NN NN O
DOX NN NN O
only NN NN O
. NN NN O
   
Increased NN NN O
resistance NN NN O
to NN NN O
the NN NN O
oxidative NN NN O
stress NN NN O
is NN NN O
plausible NN NN O
for NN NN O
the NN NN O
multiple NN NN O
dose NN NN O
of NN NN O
DOX NN NN O
. NN NN O
   
Thus NN NN O
, NN NN O
different NN NN O
mechanisms NN NN O
may NN NN O
be NN NN O
involved NN NN O
in NN NN O
acute NN NN O
toxicity NN NN B-Disease
versus NN NN O
chronic NN NN O
toxicity NN NN B-Disease
. NN NN O
   
Tacrolimus NN NN O
- NN NN O
related NN NN O
seizure NN NN B-Disease
after NN NN O
pediatric NN NN O
liver NN NN O
transplantation NN NN O
- NN NN O
- NN NN O
a NN NN O
single NN NN O
- NN NN O
center NN NN O
experience NN NN O
. NN NN O
   
To NN NN O
identify NN NN O
the NN NN O
risk NN NN O
factors NN NN O
for NN NN O
new NN NN O
- NN NN O
onset NN NN O
seizures NN NN B-Disease
after NN NN O
pediatric NN NN O
LT NN NN O
and NN NN O
to NN NN O
assess NN NN O
their NN NN O
clinical NN NN O
implications NN NN O
and NN NN O
long NN NN O
- NN NN O
term NN NN O
prognosis NN NN O
. NN NN O
   
The NN NN O
clinical NN NN O
and NN NN O
laboratory NN NN O
data NN NN O
of NN NN O
27 NN NN O
consecutive NN NN O
children NN NN O
who NN NN O
underwent NN NN O
LT NN NN O
from NN NN O
January NN NN O
2007 NN NN O
to NN NN O
December NN NN O
2010 NN NN O
in NN NN O
our NN NN O
center NN NN O
were NN NN O
analyzed NN NN O
retrospectively NN NN O
. NN NN O
   
Patients NN NN O
were NN NN O
divided NN NN O
into NN NN O
seizures NN NN B-Disease
group NN NN O
and NN NN O
a NN NN O
non NN NN O
- NN NN O
seizures NN NN B-Disease
group NN NN O
. NN NN O
   
Pre NN NN O
- NN NN O
operative NN NN O
, NN NN O
intra NN NN O
- NN NN O
operative NN NN O
, NN NN O
and NN NN O
post NN NN O
- NN NN O
operative NN NN O
data NN NN O
were NN NN O
collected NN NN O
. NN NN O
   
Seizures NN NN B-Disease
occurred NN NN O
in NN NN O
four NN NN O
children NN NN O
, NN NN O
an NN NN O
incidence NN NN O
of NN NN O
14 NN NN O
. NN NN O
8 NN NN O
% NN NN O
. NN NN O
   
All NN NN O
exhibited NN NN O
generalized NN NN O
tonic NN NN B-Disease
- NN NN I-Disease
clonic NN NN I-Disease
seizures NN NN I-Disease
within NN NN O
the NN NN O
first NN NN O
two NN NN O
wk NN NN O
after NN NN O
LT NN NN O
. NN NN O
   
Univariate NN NN O
analysis NN NN O
showed NN NN O
that NN NN O
the NN NN O
risk NN NN O
factors NN NN O
associated NN NN O
with NN NN O
seizures NN NN B-Disease
after NN NN O
pediatric NN NN O
LT NN NN O
included NN NN O
gender NN NN O
, NN NN O
pediatric NN NN O
end NN NN B-Disease
- NN NN I-Disease
stage NN NN I-Disease
liver NN NN I-Disease
disease NN NN I-Disease
score NN NN O
before NN NN O
surgery NN NN O
, NN NN O
Child NN NN O
- NN NN O
Pugh NN NN O
score NN NN O
before NN NN O
surgery NN NN O
, NN NN O
serum NN NN O
total NN NN O
bilirubin NN NN O
after NN NN O
surgery NN NN O
, NN NN O
and NN NN O
trough NN NN O
TAC NN NN O
level NN NN O
. NN NN O
   
Multivariate NN NN O
analysis NN NN O
showed NN NN O
that NN NN O
trough NN NN O
TAC NN NN O
level NN NN O
was NN NN O
the NN NN O
only NN NN O
independent NN NN O
risk NN NN O
factor NN NN O
associated NN NN O
with NN NN O
the NN NN O
seizures NN NN B-Disease
. NN NN O
   
All NN NN O
children NN NN O
who NN NN O
experienced NN NN O
seizures NN NN B-Disease
survived NN NN O
with NN NN O
good NN NN O
graft NN NN O
function NN NN O
and NN NN O
remained NN NN O
seizure NN NN B-Disease
- NN NN O
free NN NN O
without NN NN O
anti NN NN O
- NN NN O
epileptic NN NN B-Disease
drugs NN NN O
over NN NN O
a NN NN O
mean NN NN O
follow NN NN O
- NN NN O
up NN NN O
period NN NN O
of NN NN O
33 NN NN O
. NN NN O
7 NN NN O
+ NN NN O
14 NN NN O
. NN NN O
6 NN NN O
months NN NN O
. NN NN O
   
High NN NN O
trough NN NN O
TAC NN NN O
level NN NN O
was NN NN O
the NN NN O
predominant NN NN O
factor NN NN O
that NN NN O
contributed NN NN O
to NN NN O
seizures NN NN B-Disease
in NN NN O
the NN NN O
early NN NN O
post NN NN O
- NN NN O
operative NN NN O
period NN NN O
after NN NN O
pediatric NN NN O
LT NN NN O
. NN NN O
   
High NN NN O
PELD NN NN O
and NN NN O
Child NN NN O
- NN NN O
Pugh NN NN O
scores NN NN O
before NN NN O
LT NN NN O
and NN NN O
high NN NN O
post NN NN O
- NN NN O
operative NN NN O
serum NN NN O
Tbil NN NN O
may NN NN O
be NN NN O
contributory NN NN O
risk NN NN O
factors NN NN O
for NN NN O
TAC NN NN O
- NN NN O
related NN NN O
seizures NN NN B-Disease
. NN NN O
   
The NN NN O
flavonoid NN NN O
apigenin NN NN O
delays NN NN O
forgetting NN NN O
of NN NN O
passive NN NN O
avoidance NN NN O
conditioning NN NN O
in NN NN O
rats NN NN O
. NN NN O
   
The NN NN O
present NN NN O
experiments NN NN O
were NN NN O
performed NN NN O
to NN NN O
study NN NN O
the NN NN O
effect NN NN O
of NN NN O
the NN NN O
flavonoid NN NN O
apigenin NN NN O
( NN NN O
20 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
intraperitoneally NN NN O
( NN NN O
i NN NN O
. NN NN O
p NN NN O
. NN NN O
) NN NN O
, NN NN O
1 NN NN O
h NN NN O
before NN NN O
acquisition NN NN O
) NN NN O
, NN NN O
on NN NN O
24 NN NN O
h NN NN O
retention NN NN O
performance NN NN O
and NN NN O
forgetting NN NN O
of NN NN O
a NN NN O
step NN NN O
- NN NN O
through NN NN O
passive NN NN O
avoidance NN NN O
task NN NN O
, NN NN O
in NN NN O
young NN NN O
male NN NN O
Wistar NN NN O
rats NN NN O
. NN NN O
   
There NN NN O
were NN NN O
no NN NN O
differences NN NN O
between NN NN O
saline NN NN O
- NN NN O
and NN NN O
apigenin NN NN O
- NN NN O
treated NN NN O
groups NN NN O
in NN NN O
the NN NN O
24 NN NN O
h NN NN O
retention NN NN O
trial NN NN O
. NN NN O
   
Furthermore NN NN O
, NN NN O
apigenin NN NN O
did NN NN O
not NN NN O
prevent NN NN O
the NN NN O
amnesia NN NN B-Disease
induced NN NN O
by NN NN O
scopolamine NN NN O
( NN NN O
1mg NN NN O
/ NN NN O
kg NN NN O
, NN NN O
i NN NN O
. NN NN O
p NN NN O
. NN NN O
, NN NN O
30 NN NN O
min NN NN O
before NN NN O
the NN NN O
acquisition NN NN O
) NN NN O
. NN NN O
   
The NN NN O
saline NN NN O
- NN NN O
and NN NN O
apigenin NN NN O
- NN NN O
treated NN NN O
rats NN NN O
that NN NN O
did NN NN O
not NN NN O
step NN NN O
through NN NN O
into NN NN O
the NN NN O
dark NN NN O
compartment NN NN O
during NN NN O
the NN NN O
cut NN NN O
- NN NN O
off NN NN O
time NN NN O
( NN NN O
540 NN NN O
s NN NN O
) NN NN O
were NN NN O
retested NN NN O
weekly NN NN O
for NN NN O
up NN NN O
to NN NN O
eight NN NN O
weeks NN NN O
. NN NN O
   
In NN NN O
the NN NN O
saline NN NN O
treated NN NN O
group NN NN O
, NN NN O
the NN NN O
first NN NN O
significant NN NN O
decline NN NN O
in NN NN O
passive NN NN O
avoidance NN NN O
response NN NN O
was NN NN O
observed NN NN O
at NN NN O
four NN NN O
weeks NN NN O
, NN NN O
and NN NN O
complete NN NN O
memory NN NN B-Disease
loss NN NN I-Disease
was NN NN O
found NN NN O
five NN NN O
weeks NN NN O
after NN NN O
the NN NN O
acquisition NN NN O
of NN NN O
the NN NN O
passive NN NN O
avoidance NN NN O
task NN NN O
. NN NN O
   
At NN NN O
the NN NN O
end NN NN O
of NN NN O
the NN NN O
experimental NN NN O
period NN NN O
, NN NN O
60 NN NN O
% NN NN O
of NN NN O
the NN NN O
animals NN NN O
treated NN NN O
with NN NN O
apigenin NN NN O
still NN NN O
did NN NN O
not NN NN O
step NN NN O
through NN NN O
. NN NN O
   
These NN NN O
data NN NN O
suggest NN NN O
that NN NN O
1 NN NN O
) NN NN O
apigenin NN NN O
delays NN NN O
the NN NN O
long NN NN O
- NN NN O
term NN NN O
forgetting NN NN O
but NN NN O
did NN NN O
not NN NN O
modulate NN NN O
the NN NN O
24 NN NN O
h NN NN O
retention NN NN O
of NN NN O
fear NN NN O
memory NN NN O
and NN NN O
2 NN NN O
) NN NN O
the NN NN O
obtained NN NN O
beneficial NN NN O
effect NN NN O
of NN NN O
apigenin NN NN O
on NN NN O
the NN NN O
passive NN NN O
avoidance NN NN O
conditioning NN NN O
is NN NN O
mediated NN NN O
by NN NN O
mechanisms NN NN O
that NN NN O
do NN NN O
not NN NN O
implicate NN NN O
its NN NN O
action NN NN O
on NN NN O
the NN NN O
muscarinic NN NN O
cholinergic NN NN O
system NN NN O
. NN NN O
   
Histamine NN NN O
antagonists NN NN O
and NN NN O
d NN NN O
- NN NN O
tubocurarine NN NN O
- NN NN O
induced NN NN O
hypotension NN NN B-Disease
in NN NN O
cardiac NN NN O
surgical NN NN O
patients NN NN O
. NN NN O
   
Hemodynamic NN NN O
effects NN NN O
and NN NN O
histamine NN NN O
release NN NN O
by NN NN O
bolus NN NN O
injection NN NN O
of NN NN O
0 NN NN O
. NN NN O
35 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
of NN NN O
d NN NN O
- NN NN O
tubocurarine NN NN O
were NN NN O
studied NN NN O
in NN NN O
24 NN NN O
patients NN NN O
. NN NN O
   
H1 NN NN O
- NN NN O
and NN NN O
H2 NN NN O
- NN NN O
histamine NN NN O
antagonists NN NN O
or NN NN O
placebo NN NN O
were NN NN O
given NN NN O
before NN NN O
dosing NN NN O
with NN NN O
d NN NN O
- NN NN O
tubocurarine NN NN O
in NN NN O
a NN NN O
randomized NN NN O
double NN NN O
- NN NN O
blind NN NN O
fashion NN NN O
to NN NN O
four NN NN O
groups NN NN O
: NN NN O
group NN NN O
1 NN NN O
- NN NN O
- NN NN O
placebo NN NN O
; NN NN O
group NN NN O
2 NN NN O
- NN NN O
- NN NN O
cimetidine NN NN O
, NN NN O
4 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
, NN NN O
plus NN NN O
placebo NN NN O
; NN NN O
group NN NN O
3 NN NN O
- NN NN O
- NN NN O
chlorpheniramine NN NN O
, NN NN O
0 NN NN O
. NN NN O
1 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
, NN NN O
plus NN NN O
placebo NN NN O
; NN NN O
and NN NN O
group NN NN O
4 NN NN O
- NN NN O
- NN NN O
cimetidine NN NN O
plus NN NN O
chlorpheniramine NN NN O
. NN NN O
   
Histamine NN NN O
release NN NN O
occurred NN NN O
in NN NN O
most NN NN O
patients NN NN O
, NN NN O
the NN NN O
highest NN NN O
level NN NN O
2 NN NN O
minutes NN NN O
after NN NN O
d NN NN O
- NN NN O
tubocurarine NN NN O
dosing NN NN O
. NN NN O
   
Group NN NN O
1 NN NN O
had NN NN O
a NN NN O
moderate NN NN O
negative NN NN O
correlation NN NN O
between NN NN O
plasma NN NN O
histamine NN NN O
change NN NN O
and NN NN O
systemic NN NN O
vascular NN NN O
resistance NN NN O
( NN NN O
r NN NN O
= NN NN O
0 NN NN O
. NN NN O
58 NN NN O
; NN NN O
P NN NN O
less NN NN O
than NN NN O
0 NN NN O
. NN NN O
05 NN NN O
) NN NN O
not NN NN O
present NN NN O
in NN NN O
group NN NN O
4 NN NN O
. NN NN O
   
Prior NN NN O
dosing NN NN O
with NN NN O
antagonists NN NN O
partially NN NN O
prevented NN NN O
the NN NN O
fall NN NN O
in NN NN O
systemic NN NN O
vascular NN NN O
resistance NN NN O
. NN NN O
   
These NN NN O
data NN NN O
demonstrate NN NN O
that NN NN O
the NN NN O
hemodynamic NN NN O
changes NN NN O
associated NN NN O
with NN NN O
d NN NN O
- NN NN O
tubocurarine NN NN O
dosing NN NN O
are NN NN O
only NN NN O
partially NN NN O
explained NN NN O
by NN NN O
histamine NN NN O
release NN NN O
. NN NN O
   
Thus NN NN O
prior NN NN O
dosing NN NN O
with NN NN O
H1 NN NN O
- NN NN O
and NN NN O
H2 NN NN O
- NN NN O
antagonists NN NN O
provides NN NN O
only NN NN O
partial NN NN O
protection NN NN O
. NN NN O
   
Cholecystokinin NN NN O
- NN NN O
octapeptide NN NN O
restored NN NN O
morphine NN NN O
- NN NN O
induced NN NN O
hippocampal NN NN O
long NN NN O
- NN NN O
term NN NN O
potentiation NN NN O
impairment NN NN O
in NN NN O
rats NN NN O
. NN NN O
   
Cholecystokinin NN NN O
- NN NN O
octapeptide NN NN O
( NN NN O
CCK NN NN O
- NN NN O
8 NN NN O
) NN NN O
, NN NN O
which NN NN O
is NN NN O
a NN NN O
typical NN NN O
brain NN NN O
- NN NN O
gut NN NN O
peptide NN NN O
, NN NN O
exerts NN NN O
a NN NN O
wide NN NN O
range NN NN O
of NN NN O
biological NN NN O
activities NN NN O
on NN NN O
the NN NN O
central NN NN O
nervous NN NN O
system NN NN O
. NN NN O
   
We NN NN O
have NN NN O
previously NN NN O
reported NN NN O
that NN NN O
CCK NN NN O
- NN NN O
8 NN NN O
significantly NN NN O
alleviated NN NN O
morphine NN NN O
- NN NN O
induced NN NN O
amnesia NN NN B-Disease
and NN NN O
reversed NN NN O
spine NN NN O
density NN NN O
decreases NN NN O
in NN NN O
the NN NN O
CA1 NN NN O
region NN NN O
of NN NN O
the NN NN O
hippocampus NN NN O
in NN NN O
morphine NN NN O
- NN NN O
treated NN NN O
animals NN NN O
. NN NN O
   
Here NN NN O
, NN NN O
we NN NN O
investigated NN NN O
the NN NN O
effects NN NN O
of NN NN O
CCK NN NN O
- NN NN O
8 NN NN O
on NN NN O
long NN NN O
- NN NN O
term NN NN O
potentiation NN NN O
( NN NN O
LTP NN NN O
) NN NN O
in NN NN O
the NN NN O
lateral NN NN O
perforant NN NN O
path NN NN O
( NN NN O
LPP NN NN O
) NN NN O
- NN NN O
granule NN NN O
cell NN NN O
synapse NN NN O
of NN NN O
rat NN NN O
dentate NN NN O
gyrus NN NN O
( NN NN O
DG NN NN O
) NN NN O
in NN NN O
acute NN NN O
saline NN NN O
or NN NN O
morphine NN NN O
- NN NN O
treated NN NN O
rats NN NN O
. NN NN O
   
Population NN NN O
spikes NN NN O
( NN NN O
PS NN NN O
) NN NN O
, NN NN O
which NN NN O
were NN NN O
evoked NN NN O
by NN NN O
stimulation NN NN O
of NN NN O
the NN NN O
LPP NN NN O
, NN NN O
were NN NN O
recorded NN NN O
in NN NN O
the NN NN O
DG NN NN O
region NN NN O
. NN NN O
   
Acute NN NN O
morphine NN NN O
( NN NN O
30mg NN NN O
/ NN NN O
kg NN NN O
, NN NN O
s NN NN O
. NN NN O
c NN NN O
. NN NN O
) NN NN O
treatment NN NN O
significantly NN NN O
attenuated NN NN O
hippocampal NN NN O
LTP NN NN O
and NN NN O
CCK NN NN O
- NN NN O
8 NN NN O
( NN NN O
1ug NN NN O
, NN NN O
i NN NN O
. NN NN O
c NN NN O
. NN NN O
v NN NN O
. NN NN O
) NN NN O
restored NN NN O
the NN NN O
amplitude NN NN O
of NN NN O
PS NN NN O
that NN NN O
was NN NN O
attenuated NN NN O
by NN NN O
morphine NN NN O
injection NN NN O
. NN NN O
   
Furthermore NN NN O
, NN NN O
microinjection NN NN O
of NN NN O
CCK NN NN O
- NN NN O
8 NN NN O
( NN NN O
0 NN NN O
. NN NN O
1 NN NN O
and NN NN O
1ug NN NN O
, NN NN O
i NN NN O
. NN NN O
c NN NN O
. NN NN O
v NN NN O
. NN NN O
) NN NN O
also NN NN O
significantly NN NN O
augmented NN NN O
hippocampal NN NN O
LTP NN NN O
in NN NN O
saline NN NN O
- NN NN O
treated NN NN O
( NN NN O
1ml NN NN O
/ NN NN O
kg NN NN O
, NN NN O
s NN NN O
. NN NN O
c NN NN O
. NN NN O
) NN NN O
rats NN NN O
. NN NN O
   
Pre NN NN O
- NN NN O
treatment NN NN O
of NN NN O
the NN NN O
CCK2 NN NN O
receptor NN NN O
antagonist NN NN O
L NN NN O
- NN NN O
365 NN NN O
, NN NN O
260 NN NN O
( NN NN O
10ug NN NN O
, NN NN O
i NN NN O
. NN NN O
c NN NN O
. NN NN O
v NN NN O
) NN NN O
reversed NN NN O
the NN NN O
effects NN NN O
of NN NN O
CCK NN NN O
- NN NN O
8 NN NN O
, NN NN O
but NN NN O
the NN NN O
CCK1 NN NN O
receptor NN NN O
antagonist NN NN O
L NN NN O
- NN NN O
364 NN NN O
, NN NN O
718 NN NN O
( NN NN O
10ug NN NN O
, NN NN O
i NN NN O
. NN NN O
c NN NN O
. NN NN O
v NN NN O
) NN NN O
did NN NN O
not NN NN O
. NN NN O
   
The NN NN O
present NN NN O
results NN NN O
demonstrate NN NN O
that NN NN O
CCK NN NN O
- NN NN O
8 NN NN O
attenuates NN NN O
the NN NN O
effect NN NN O
of NN NN O
morphine NN NN O
on NN NN O
hippocampal NN NN O
LTP NN NN O
through NN NN O
CCK2 NN NN O
receptors NN NN O
and NN NN O
suggest NN NN O
an NN NN O
ameliorative NN NN O
function NN NN O
of NN NN O
CCK NN NN O
- NN NN O
8 NN NN O
on NN NN O
morphine NN NN O
- NN NN O
induced NN NN O
memory NN NN B-Disease
impairment NN NN I-Disease
. NN NN O
   
Glial NN NN O
activation NN NN O
and NN NN O
post NN NN O
- NN NN O
synaptic NN NN O
neurotoxicity NN NN B-Disease
: NN NN O
the NN NN O
key NN NN O
events NN NN O
in NN NN O
Streptozotocin NN NN O
( NN NN O
ICV NN NN O
) NN NN O
induced NN NN O
memory NN NN B-Disease
impairment NN NN I-Disease
in NN NN O
rats NN NN O
. NN NN O
   
In NN NN O
the NN NN O
present NN NN O
study NN NN O
the NN NN O
role NN NN O
of NN NN O
glial NN NN O
activation NN NN O
and NN NN O
post NN NN O
synaptic NN NN O
toxicity NN NN B-Disease
in NN NN O
ICV NN NN O
Streptozotocin NN NN O
( NN NN O
STZ NN NN O
) NN NN O
induced NN NN O
memory NN NN B-Disease
impaired NN NN I-Disease
rats NN NN O
was NN NN O
explored NN NN O
. NN NN O
   
In NN NN O
experiment NN NN O
set NN NN O
up NN NN O
1 NN NN O
: NN NN O
Memory NN NN B-Disease
deficit NN NN I-Disease
was NN NN O
found NN NN O
in NN NN O
Morris NN NN O
water NN NN O
maze NN NN O
test NN NN O
on NN NN O
14 NN NN O
- NN NN O
16 NN NN O
days NN NN O
after NN NN O
STZ NN NN O
( NN NN O
ICV NN NN O
; NN NN O
3mg NN NN O
/ NN NN O
Kg NN NN O
) NN NN O
administration NN NN O
. NN NN O
   
STZ NN NN O
causes NN NN O
increased NN NN O
expression NN NN O
of NN NN O
GFAP NN NN O
, NN NN O
CD11b NN NN O
and NN NN O
TNF NN NN O
- NN NN O
a NN NN O
indicating NN NN O
glial NN NN O
activation NN NN O
and NN NN O
neuroinflammation NN NN B-Disease
. NN NN O
   
STZ NN NN O
also NN NN O
significantly NN NN O
increased NN NN O
the NN NN O
level NN NN O
of NN NN O
ROS NN NN O
, NN NN O
nitrite NN NN O
, NN NN O
Ca NN NN O
( NN NN O
2 NN NN O
+ NN NN O
) NN NN O
and NN NN O
reduced NN NN O
the NN NN O
mitochondrial NN NN O
activity NN NN O
in NN NN O
synaptosomal NN NN O
preparation NN NN O
illustrating NN NN O
free NN NN O
radical NN NN O
generation NN NN O
and NN NN O
excitotoxicity NN NN B-Disease
. NN NN O
   
Increased NN NN O
expression NN NN O
and NN NN O
activity NN NN O
of NN NN O
Caspase NN NN O
- NN NN O
3 NN NN O
was NN NN O
also NN NN O
observed NN NN O
in NN NN O
STZ NN NN O
treated NN NN O
rat NN NN O
which NN NN O
specify NN NN O
apoptotic NN NN O
cell NN NN O
death NN NN O
in NN NN O
hippocampus NN NN O
and NN NN O
cortex NN NN O
. NN NN O
   
STZ NN NN O
treatment NN NN O
showed NN NN O
decrease NN NN O
expression NN NN O
of NN NN O
post NN NN O
synaptic NN NN O
markers NN NN O
CaMKIIa NN NN O
and NN NN O
PSD NN NN O
- NN NN O
95 NN NN O
, NN NN O
while NN NN O
, NN NN O
expression NN NN O
of NN NN O
pre NN NN O
synaptic NN NN O
markers NN NN O
( NN NN O
synaptophysin NN NN O
and NN NN O
SNAP NN NN O
- NN NN O
25 NN NN O
) NN NN O
remains NN NN O
unaltered NN NN O
indicating NN NN O
selective NN NN O
post NN NN O
synaptic NN NN O
neurotoxicity NN NN B-Disease
. NN NN O
   
Oral NN NN O
treatment NN NN O
with NN NN O
Memantine NN NN O
( NN NN O
10mg NN NN O
/ NN NN O
kg NN NN O
) NN NN O
and NN NN O
Ibuprofen NN NN O
( NN NN O
50 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
) NN NN O
daily NN NN O
for NN NN O
13 NN NN O
days NN NN O
attenuated NN NN O
STZ NN NN O
induced NN NN O
glial NN NN O
activation NN NN O
, NN NN O
apoptotic NN NN O
cell NN NN O
death NN NN O
and NN NN O
post NN NN O
synaptic NN NN O
neurotoxicity NN NN B-Disease
in NN NN O
rat NN NN O
brain NN NN O
. NN NN O
   
Further NN NN O
, NN NN O
in NN NN O
experiment NN NN O
set NN NN O
up NN NN O
2 NN NN O
: NN NN O
where NN NN O
memory NN NN O
function NN NN O
was NN NN O
not NN NN O
affected NN NN O
i NN NN O
. NN NN O
e NN NN O
. NN NN O
7 NN NN O
- NN NN O
9 NN NN O
days NN NN O
after NN NN O
STZ NN NN O
treatment NN NN O
. NN NN O
   
The NN NN O
level NN NN O
of NN NN O
GFAP NN NN O
, NN NN O
CD11b NN NN O
, NN NN O
TNF NN NN O
- NN NN O
a NN NN O
, NN NN O
ROS NN NN O
and NN NN O
nitrite NN NN O
levels NN NN O
were NN NN O
increased NN NN O
. NN NN O
   
On NN NN O
the NN NN O
other NN NN O
hand NN NN O
, NN NN O
apoptotic NN NN O
marker NN NN O
, NN NN O
synaptic NN NN O
markers NN NN O
, NN NN O
mitochondrial NN NN O
activity NN NN O
and NN NN O
Ca NN NN O
( NN NN O
2 NN NN O
+ NN NN O
) NN NN O
levels NN NN O
remained NN NN O
unaffected NN NN O
. NN NN O
   
Collective NN NN O
data NN NN O
indicates NN NN O
that NN NN O
neuroinflammatory NN NN B-Disease
process NN NN O
and NN NN O
oxidative NN NN O
stress NN NN O
occurs NN NN O
earlier NN NN O
to NN NN O
apoptosis NN NN O
and NN NN O
does NN NN O
not NN NN O
affect NN NN O
memory NN NN O
function NN NN O
. NN NN O
   
Present NN NN O
study NN NN O
clearly NN NN O
suggests NN NN O
that NN NN O
glial NN NN O
activation NN NN O
and NN NN O
post NN NN O
synaptic NN NN O
neurotoxicity NN NN B-Disease
are NN NN O
the NN NN O
key NN NN O
factors NN NN O
in NN NN O
STZ NN NN O
induced NN NN O
memory NN NN B-Disease
impairment NN NN I-Disease
and NN NN O
neuronal NN NN O
cell NN NN O
death NN NN O
. NN NN O
   
Comparison NN NN O
of NN NN O
effects NN NN O
of NN NN O
isotonic NN NN O
sodium NN NN O
chloride NN NN O
with NN NN O
diltiazem NN NN O
in NN NN O
prevention NN NN O
of NN NN O
contrast NN NN O
- NN NN O
induced NN NN O
nephropathy NN NN B-Disease
. NN NN O
   
INTRODUCTION NN NN O
AND NN NN O
OBJECTIVE NN NN O
: NN NN O
Contrast NN NN O
- NN NN O
induced NN NN O
nephropathy NN NN B-Disease
( NN NN O
CIN NN NN O
) NN NN O
significantly NN NN O
increases NN NN O
the NN NN O
morbidity NN NN O
and NN NN O
mortality NN NN O
of NN NN O
patients NN NN O
. NN NN O
   
The NN NN O
aim NN NN O
of NN NN O
this NN NN O
study NN NN O
is NN NN O
to NN NN O
investigate NN NN O
and NN NN O
compare NN NN O
the NN NN O
protective NN NN O
effects NN NN O
of NN NN O
isotonic NN NN O
sodium NN NN O
chloride NN NN O
with NN NN O
sodium NN NN O
bicarbonate NN NN O
infusion NN NN O
and NN NN O
isotonic NN NN O
sodium NN NN O
chloride NN NN O
infusion NN NN O
with NN NN O
diltiazem NN NN O
, NN NN O
a NN NN O
calcium NN NN O
channel NN NN O
blocker NN NN O
, NN NN O
in NN NN O
preventing NN NN O
CIN NN NN O
. NN NN O
   
MATERIALS NN NN O
AND NN NN O
METHODS NN NN O
: NN NN O
Our NN NN O
study NN NN O
included NN NN O
patients NN NN O
who NN NN O
were NN NN O
administered NN NN O
30 NN NN O
- NN NN O
60 NN NN O
mL NN NN O
of NN NN O
iodinated NN NN O
contrast NN NN O
agent NN NN O
for NN NN O
percutaneous NN NN O
coronary NN NN O
angiography NN NN O
( NN NN O
PCAG NN NN O
) NN NN O
, NN NN O
all NN NN O
with NN NN O
creatinine NN NN O
values NN NN O
between NN NN O
1 NN NN O
. NN NN O
1 NN NN O
and NN NN O
3 NN NN O
. NN NN O
1 NN NN O
mg NN NN O
/ NN NN O
dL NN NN O
. NN NN O
   
Patients NN NN O
were NN NN O
divided NN NN O
into NN NN O
three NN NN O
groups NN NN O
and NN NN O
each NN NN O
group NN NN O
had NN NN O
20 NN NN O
patients NN NN O
. NN NN O
   
The NN NN O
first NN NN O
group NN NN O
of NN NN O
patients NN NN O
was NN NN O
administered NN NN O
isotonic NN NN O
sodium NN NN O
chloride NN NN O
; NN NN O
the NN NN O
second NN NN O
group NN NN O
was NN NN O
administered NN NN O
a NN NN O
solution NN NN O
that NN NN O
of NN NN O
5 NN NN O
% NN NN O
dextrose NN NN O
and NN NN O
sodium NN NN O
bicarbonate NN NN O
, NN NN O
while NN NN O
the NN NN O
third NN NN O
group NN NN O
was NN NN O
administered NN NN O
isotonic NN NN O
sodium NN NN O
chloride NN NN O
before NN NN O
and NN NN O
after NN NN O
the NN NN O
contrast NN NN O
injection NN NN O
. NN NN O
   
The NN NN O
third NN NN O
group NN NN O
received NN NN O
an NN NN O
additional NN NN O
injection NN NN O
of NN NN O
diltiazem NN NN O
the NN NN O
day NN NN O
before NN NN O
and NN NN O
first NN NN O
2 NN NN O
days NN NN O
after NN NN O
the NN NN O
contrast NN NN O
injection NN NN O
. NN NN O
   
All NN NN O
of NN NN O
the NN NN O
patients NN NN O
' NN NN O
plasma NN NN O
blood NN NN O
urea NN NN O
nitrogen NN NN O
( NN NN O
BUN NN NN O
) NN NN O
and NN NN O
creatinine NN NN O
levels NN NN O
were NN NN O
measured NN NN O
on NN NN O
the NN NN O
second NN NN O
and NN NN O
seventh NN NN O
day NN NN O
after NN NN O
the NN NN O
administration NN NN O
of NN NN O
intravenous NN NN O
contrast NN NN O
material NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
The NN NN O
basal NN NN O
creatinine NN NN O
levels NN NN O
were NN NN O
similar NN NN O
for NN NN O
all NN NN O
three NN NN O
groups NN NN O
( NN NN O
p NN NN O
> NN NN O
0 NN NN O
. NN NN O
05 NN NN O
) NN NN O
. NN NN O
   
Among NN NN O
a NN NN O
total NN NN O
of NN NN O
60 NN NN O
patients NN NN O
included NN NN O
in NN NN O
the NN NN O
study NN NN O
, NN NN O
16 NN NN O
patients NN NN O
developed NN NN O
acute NN NN B-Disease
renal NN NN I-Disease
failure NN NN I-Disease
( NN NN O
ARF NN NN B-Disease
) NN NN O
on NN NN O
the NN NN O
second NN NN O
day NN NN O
after NN NN O
contrast NN NN O
material NN NN O
was NN NN O
injected NN NN O
( NN NN O
26 NN NN O
. NN NN O
6 NN NN O
% NN NN O
) NN NN O
. NN NN O
   
The NN NN O
number NN NN O
of NN NN O
patients NN NN O
who NN NN O
developed NN NN O
ARF NN NN B-Disease
on NN NN O
the NN NN O
second NN NN O
day NN NN O
after NN NN O
the NN NN O
injection NN NN O
in NN NN O
the NN NN O
first NN NN O
group NN NN O
was NN NN O
five NN NN O
( NN NN O
25 NN NN O
% NN NN O
) NN NN O
, NN NN O
in NN NN O
the NN NN O
second NN NN O
group NN NN O
was NN NN O
six NN NN O
( NN NN O
30 NN NN O
% NN NN O
) NN NN O
and NN NN O
the NN NN O
third NN NN O
group NN NN O
was NN NN O
five NN NN O
( NN NN O
25 NN NN O
% NN NN O
) NN NN O
( NN NN O
p NN NN O
> NN NN O
0 NN NN O
. NN NN O
05 NN NN O
) NN NN O
. NN NN O
   
CONCLUSION NN NN O
: NN NN O
There NN NN O
was NN NN O
no NN NN O
significant NN NN O
difference NN NN O
between NN NN O
isotonic NN NN O
sodium NN NN O
chloride NN NN O
, NN NN O
sodium NN NN O
bicarbonate NN NN O
and NN NN O
isotonic NN NN O
sodium NN NN O
chloride NN NN O
with NN NN O
diltiazem NN NN O
application NN NN O
in NN NN O
prevention NN NN O
of NN NN O
CIN NN NN O
. NN NN O
   
Neurocognitive NN NN O
and NN NN O
neuroradiologic NN NN O
central NN NN O
nervous NN NN O
system NN NN O
late NN NN O
effects NN NN O
in NN NN O
children NN NN O
treated NN NN O
on NN NN O
Pediatric NN NN O
Oncology NN NN O
Group NN NN O
( NN NN O
POG NN NN O
) NN NN O
P9605 NN NN O
( NN NN O
standard NN NN O
risk NN NN O
) NN NN O
and NN NN O
P9201 NN NN O
( NN NN O
lesser NN NN O
risk NN NN O
) NN NN O
acute NN NN B-Disease
lymphoblastic NN NN I-Disease
leukemia NN NN I-Disease
protocols NN NN O
( NN NN O
ACCL0131 NN NN O
) NN NN O
: NN NN O
a NN NN O
methotrexate NN NN O
consequence NN NN O
? NN NN O
   
A NN NN O
report NN NN O
from NN NN O
the NN NN O
Children NN NN O
' NN NN O
s NN NN O
Oncology NN NN O
Group NN NN O
. NN NN O
   
Concerns NN NN O
about NN NN O
long NN NN O
- NN NN O
term NN NN O
methotrexate NN NN O
( NN NN O
MTX NN NN O
) NN NN O
neurotoxicity NN NN B-Disease
in NN NN O
the NN NN O
1990s NN NN O
led NN NN O
to NN NN O
modifications NN NN O
in NN NN O
intrathecal NN NN O
( NN NN O
IT NN NN O
) NN NN O
therapy NN NN O
, NN NN O
leucovorin NN NN O
rescue NN NN O
, NN NN O
and NN NN O
frequency NN NN O
of NN NN O
systemic NN NN O
MTX NN NN O
administration NN NN O
in NN NN O
children NN NN O
with NN NN O
acute NN NN B-Disease
lymphoblastic NN NN I-Disease
leukemia NN NN I-Disease
. NN NN O
   
In NN NN O
this NN NN O
study NN NN O
, NN NN O
neurocognitive NN NN O
outcomes NN NN O
and NN NN O
neuroradiologic NN NN O
evidence NN NN O
of NN NN O
leukoencephalopathy NN NN B-Disease
were NN NN O
compared NN NN O
in NN NN O
children NN NN O
treated NN NN O
with NN NN O
intense NN NN O
central NN NN O
nervous NN NN O
system NN NN O
( NN NN O
CNS NN NN O
) NN NN O
- NN NN O
directed NN NN O
therapy NN NN O
( NN NN O
P9605 NN NN O
) NN NN O
versus NN NN O
those NN NN O
receiving NN NN O
fewer NN NN O
CNS NN NN O
- NN NN O
directed NN NN O
treatment NN NN O
days NN NN O
during NN NN O
intensive NN NN O
consolidation NN NN O
( NN NN O
P9201 NN NN O
) NN NN O
. NN NN O
   
A NN NN O
total NN NN O
of NN NN O
66 NN NN O
children NN NN O
from NN NN O
16 NN NN O
Pediatric NN NN O
Oncology NN NN O
Group NN NN O
institutions NN NN O
with NN NN O
"""""""" NN NN O
standard NN NN O
- NN NN O
risk NN NN O
"""""""" NN NN O
acute NN NN B-Disease
lymphoblastic NN NN I-Disease
leukemia NN NN I-Disease
, NN NN O
1 NN NN O
. NN NN O
00 NN NN O
to NN NN O
9 NN NN O
. NN NN O
99 NN NN O
years NN NN O
at NN NN O
diagnosis NN NN O
, NN NN O
without NN NN O
evidence NN NN O
of NN NN O
CNS NN NN O
leukemia NN NN B-Disease
at NN NN O
diagnosis NN NN O
were NN NN O
enrolled NN NN O
on NN NN O
ACCL0131 NN NN O
: NN NN O
28 NN NN O
from NN NN O
P9201 NN NN O
and NN NN O
38 NN NN O
from NN NN O
P9605 NN NN O
. NN NN O
   
Magnetic NN NN O
resonance NN NN O
imaging NN NN O
scans NN NN O
and NN NN O
standard NN NN O
neuropsychological NN NN O
tests NN NN O
were NN NN O
performed NN NN O
> NN NN O
2 NN NN O
. NN NN O
6 NN NN O
years NN NN O
after NN NN O
the NN NN O
end NN NN O
of NN NN O
treatment NN NN O
. NN NN O
   
Significantly NN NN O
more NN NN O
P9605 NN NN O
patients NN NN O
developed NN NN O
leukoencephalopathy NN NN B-Disease
compared NN NN O
with NN NN O
P9201 NN NN O
patients NN NN O
( NN NN O
68 NN NN O
% NN NN O
, NN NN O
95 NN NN O
% NN NN O
confidence NN NN O
interval NN NN O
49 NN NN O
% NN NN O
- NN NN O
83 NN NN O
% NN NN O
vs NN NN O
. NN NN O
22 NN NN O
% NN NN O
, NN NN O
95 NN NN O
% NN NN O
confidence NN NN O
interval NN NN O
5 NN NN O
% NN NN O
- NN NN O
44 NN NN O
% NN NN O
; NN NN O
P NN NN O
= NN NN O
0 NN NN O
. NN NN O
001 NN NN O
) NN NN O
identified NN NN O
as NN NN O
late NN NN O
as NN NN O
7 NN NN O
. NN NN O
7 NN NN O
years NN NN O
after NN NN O
the NN NN O
end NN NN O
of NN NN O
treatment NN NN O
. NN NN O
   
Overall NN NN O
, NN NN O
40 NN NN O
% NN NN O
of NN NN O
patients NN NN O
scored NN NN O
< NN NN O
85 NN NN O
on NN NN O
either NN NN O
Verbal NN NN O
or NN NN O
Performance NN NN O
IQ NN NN O
. NN NN O
   
Children NN NN O
on NN NN O
both NN NN O
studies NN NN O
had NN NN O
significant NN NN O
attention NN NN B-Disease
problems NN NN I-Disease
, NN NN O
but NN NN O
P9605 NN NN O
children NN NN O
scored NN NN O
below NN NN O
average NN NN O
on NN NN O
more NN NN O
neurocognitive NN NN O
measures NN NN O
than NN NN O
those NN NN O
treated NN NN O
on NN NN O
P9201 NN NN O
( NN NN O
82 NN NN O
% NN NN O
, NN NN O
14 NN NN O
/ NN NN O
17 NN NN O
measures NN NN O
vs NN NN O
. NN NN O
24 NN NN O
% NN NN O
, NN NN O
4 NN NN O
/ NN NN O
17 NN NN O
measures NN NN O
) NN NN O
. NN NN O
   
This NN NN O
supports NN NN O
ongoing NN NN O
concerns NN NN O
about NN NN O
intensive NN NN O
MTX NN NN O
exposure NN NN O
as NN NN O
a NN NN O
major NN NN O
contributor NN NN O
to NN NN O
CNS NN NN O
late NN NN O
effects NN NN O
. NN NN O
   
Tranexamic NN NN O
acid NN NN O
overdosage NN NN O
- NN NN O
induced NN NN O
generalized NN NN O
seizure NN NN B-Disease
in NN NN O
renal NN NN B-Disease
failure NN NN I-Disease
. NN NN O
   
We NN NN O
report NN NN O
a NN NN O
45 NN NN O
- NN NN O
year NN NN O
- NN NN O
old NN NN O
lady NN NN O
with NN NN O
chronic NN NN B-Disease
kidney NN NN I-Disease
disease NN NN I-Disease
stage NN NN O
4 NN NN O
due NN NN O
to NN NN O
chronic NN NN O
tubulointerstial NN NN B-Disease
disease NN NN I-Disease
. NN NN O
   
She NN NN O
was NN NN O
admitted NN NN O
to NN NN O
our NN NN O
center NN NN O
for NN NN O
severe NN NN O
anemia NN NN B-Disease
due NN NN O
to NN NN O
menorrhagia NN NN B-Disease
and NN NN O
deterioration NN NN B-Disease
of NN NN I-Disease
renal NN NN I-Disease
function NN NN I-Disease
. NN NN O
   
She NN NN O
was NN NN O
infused NN NN O
three NN NN O
units NN NN O
of NN NN O
packed NN NN O
cells NN NN O
during NN NN O
a NN NN O
session NN NN O
of NN NN O
hemodialysis NN NN O
. NN NN O
   
Tranexamic NN NN O
acid NN NN O
( NN NN O
TNA NN NN O
) NN NN O
1 NN NN O
g NN NN O
8 NN NN O
- NN NN O
hourly NN NN O
was NN NN O
administered NN NN O
to NN NN O
her NN NN O
to NN NN O
control NN NN O
bleeding NN NN B-Disease
per NN NN O
vaginum NN NN O
. NN NN O
   
Two NN NN O
hours NN NN O
after NN NN O
the NN NN O
sixth NN NN O
dose NN NN O
of NN NN O
TNA NN NN O
, NN NN O
she NN NN O
had NN NN O
an NN NN O
episode NN NN O
of NN NN O
generalized NN NN O
tonic NN NN B-Disease
clonic NN NN I-Disease
convulsions NN NN I-Disease
. NN NN O
   
TNA NN NN O
was NN NN O
discontinued NN NN O
. NN NN O
   
Investigations NN NN O
of NN NN O
the NN NN O
patient NN NN O
revealed NN NN O
no NN NN O
biochemical NN NN O
or NN NN O
structural NN NN O
central NN NN O
nervous NN NN B-Disease
system NN NN I-Disease
abnormalities NN NN I-Disease
that NN NN O
could NN NN O
have NN NN O
provoked NN NN O
the NN NN O
convulsions NN NN B-Disease
. NN NN O
   
She NN NN O
did NN NN O
not NN NN O
require NN NN O
any NN NN O
further NN NN O
dialytic NN NN O
support NN NN O
. NN NN O
   
She NN NN O
had NN NN O
no NN NN O
further NN NN O
episodes NN NN O
of NN NN O
convulsion NN NN B-Disease
till NN NN O
dis NN NN O
- NN NN O
charge NN NN O
and NN NN O
during NN NN O
the NN NN O
two NN NN O
months NN NN O
of NN NN O
follow NN NN O
- NN NN O
up NN NN O
. NN NN O
   
Thus NN NN O
, NN NN O
the NN NN O
precipitating NN NN O
cause NN NN O
of NN NN O
convulsions NN NN B-Disease
was NN NN O
believed NN NN O
to NN NN O
be NN NN O
an NN NN O
overdose NN NN B-Disease
of NN NN O
TNA NN NN O
. NN NN O
   
Pre NN NN O
- NN NN O
treatment NN NN O
of NN NN O
bupivacaine NN NN O
- NN NN O
induced NN NN O
cardiovascular NN NN B-Disease
depression NN NN I-Disease
using NN NN O
different NN NN O
lipid NN NN O
formulations NN NN O
of NN NN O
propofol NN NN O
. NN NN O
   
BACKGROUND NN NN O
: NN NN O
Pre NN NN O
- NN NN O
treatment NN NN O
with NN NN O
lipid NN NN O
emulsions NN NN O
has NN NN O
been NN NN O
shown NN NN O
to NN NN O
increase NN NN O
lethal NN NN O
doses NN NN O
of NN NN O
bupivacaine NN NN O
, NN NN O
and NN NN O
the NN NN O
lipid NN NN O
content NN NN O
of NN NN O
propofol NN NN O
may NN NN O
alleviate NN NN O
bupivacaine NN NN O
- NN NN O
induced NN NN O
cardiotoxicity NN NN B-Disease
. NN NN O
   
The NN NN O
aim NN NN O
of NN NN O
this NN NN O
study NN NN O
is NN NN O
to NN NN O
investigate NN NN O
the NN NN O
effects NN NN O
of NN NN O
propofol NN NN O
in NN NN O
intralipid NN NN O
or NN NN O
medialipid NN NN O
emulsions NN NN O
on NN NN O
bupivacaine NN NN O
- NN NN O
induced NN NN O
cardiotoxicity NN NN B-Disease
. NN NN O
   
METHODS NN NN O
: NN NN O
Rats NN NN O
were NN NN O
anaesthetised NN NN O
with NN NN O
ketamine NN NN O
and NN NN O
were NN NN O
given NN NN O
0 NN NN O
. NN NN O
5 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
/ NN NN O
min NN NN O
propofol NN NN O
in NN NN O
intralipid NN NN O
( NN NN O
Group NN NN O
P NN NN O
) NN NN O
, NN NN O
propofol NN NN O
in NN NN O
medialipid NN NN O
( NN NN O
Group NN NN O
L NN NN O
) NN NN O
, NN NN O
or NN NN O
saline NN NN O
( NN NN O
Group NN NN O
C NN NN O
) NN NN O
over NN NN O
20 NN NN O
min NN NN O
. NN NN O
   
Thereafter NN NN O
, NN NN O
2 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
/ NN NN O
min NN NN O
bupivacaine NN NN O
0 NN NN O
. NN NN O
5 NN NN O
% NN NN O
was NN NN O
infused NN NN O
. NN NN O
   
We NN NN O
recorded NN NN O
time NN NN O
to NN NN O
first NN NN O
dysrhythmia NN NN B-Disease
occurrence NN NN O
, NN NN O
respective NN NN O
times NN NN O
to NN NN O
25 NN NN O
% NN NN O
and NN NN O
50 NN NN O
% NN NN O
reduction NN NN O
of NN NN O
the NN NN O
heart NN NN O
rate NN NN O
( NN NN O
HR NN NN O
) NN NN O
and NN NN O
mean NN NN O
arterial NN NN O
pressure NN NN O
, NN NN O
and NN NN O
time NN NN O
to NN NN O
asystole NN NN B-Disease
and NN NN O
total NN NN O
amount NN NN O
of NN NN O
bupivacaine NN NN O
consumption NN NN O
. NN NN O
   
Blood NN NN O
and NN NN O
tissue NN NN O
samples NN NN O
were NN NN O
collected NN NN O
following NN NN O
asystole NN NN B-Disease
. NN NN O
   
RESULTS NN NN O
: NN NN O
The NN NN O
time NN NN O
to NN NN O
first NN NN O
dysrhythmia NN NN B-Disease
occurrence NN NN O
, NN NN O
time NN NN O
to NN NN O
25 NN NN O
% NN NN O
and NN NN O
50 NN NN O
% NN NN O
reductions NN NN O
in NN NN O
HR NN NN O
, NN NN O
and NN NN O
time NN NN O
to NN NN O
asystole NN NN B-Disease
were NN NN O
longer NN NN O
in NN NN O
Group NN NN O
P NN NN O
than NN NN O
the NN NN O
other NN NN O
groups NN NN O
. NN NN O
   
The NN NN O
cumulative NN NN O
bupivacaine NN NN O
dose NN NN O
given NN NN O
at NN NN O
those NN NN O
time NN NN O
points NN NN O
was NN NN O
higher NN NN O
in NN NN O
Group NN NN O
P NN NN O
. NN NN O
Plasma NN NN O
bupivacaine NN NN O
levels NN NN O
were NN NN O
significantly NN NN O
lower NN NN O
in NN NN O
Group NN NN O
P NN NN O
than NN NN O
in NN NN O
Group NN NN O
C NN NN O
. NN NN O
Bupivacaine NN NN O
levels NN NN O
in NN NN O
the NN NN O
brain NN NN O
and NN NN O
heart NN NN O
were NN NN O
significantly NN NN O
lower NN NN O
in NN NN O
Group NN NN O
P NN NN O
and NN NN O
Group NN NN O
L NN NN O
than NN NN O
in NN NN O
Group NN NN O
C NN NN O
. NN NN O
   
CONCLUSION NN NN O
: NN NN O
We NN NN O
conclude NN NN O
that NN NN O
pre NN NN O
- NN NN O
treatment NN NN O
with NN NN O
propofol NN NN O
in NN NN O
intralipid NN NN O
, NN NN O
compared NN NN O
with NN NN O
propofol NN NN O
in NN NN O
medialipid NN NN O
or NN NN O
saline NN NN O
, NN NN O
delayed NN NN O
the NN NN O
onset NN NN O
of NN NN O
bupivacaine NN NN O
- NN NN O
induced NN NN O
cardiotoxic NN NN B-Disease
effects NN NN O
as NN NN O
well NN NN O
as NN NN O
reduced NN NN O
plasma NN NN O
bupivacaine NN NN O
levels NN NN O
. NN NN O
   
Further NN NN O
studies NN NN O
are NN NN O
needed NN NN O
to NN NN O
explore NN NN O
tissue NN NN O
bupivacaine NN NN O
levels NN NN O
of NN NN O
propofol NN NN O
in NN NN O
medialipid NN NN O
and NN NN O
adapt NN NN O
these NN NN O
results NN NN O
to NN NN O
clinical NN NN O
practice NN NN O
. NN NN O
   
Drug NN NN B-Disease
- NN NN I-Disease
Induced NN NN I-Disease
Acute NN NN I-Disease
Liver NN NN I-Disease
Injury NN NN I-Disease
Within NN NN O
12 NN NN O
Hours NN NN O
After NN NN O
Fluvastatin NN NN O
Therapy NN NN O
. NN NN O
   
Although NN NN O
statins NN NN O
are NN NN O
generally NN NN O
well NN NN O
- NN NN O
tolerated NN NN O
drugs NN NN O
, NN NN O
recent NN NN O
cases NN NN O
of NN NN O
drug NN NN B-Disease
- NN NN I-Disease
induced NN NN I-Disease
liver NN NN I-Disease
injury NN NN I-Disease
associated NN NN O
with NN NN O
their NN NN O
use NN NN O
have NN NN O
been NN NN O
reported NN NN O
. NN NN O
   
A NN NN O
52 NN NN O
- NN NN O
year NN NN O
- NN NN O
old NN NN O
Chinese NN NN O
man NN NN O
reported NN NN O
with NN NN O
liver NN NN B-Disease
damage NN NN I-Disease
, NN NN O
which NN NN O
appeared NN NN O
12 NN NN O
hours NN NN O
after NN NN O
beginning NN NN O
treatment NN NN O
with NN NN O
fluvastatin NN NN O
. NN NN O
   
Patient NN NN O
presented NN NN O
with NN NN O
complaints NN NN O
of NN NN O
increasing NN NN O
nausea NN NN B-Disease
, NN NN O
anorexia NN NN B-Disease
, NN NN O
and NN NN O
upper NN NN O
abdominal NN NN B-Disease
pain NN NN I-Disease
. NN NN O
   
His NN NN O
laboratory NN NN O
values NN NN O
showed NN NN O
elevated NN NN O
creatine NN NN O
kinase NN NN O
and NN NN O
transaminases NN NN O
. NN NN O
   
Testing NN NN O
for NN NN O
autoantibodies NN NN O
was NN NN O
also NN NN O
negative NN NN O
. NN NN O
   
The NN NN O
liver NN NN O
biochemistries NN NN O
eventually NN NN O
normalized NN NN O
within NN NN O
3 NN NN O
weeks NN NN O
of NN NN O
stopping NN NN O
the NN NN O
fluvastatin NN NN O
. NN NN O
   
Therefore NN NN O
, NN NN O
when NN NN O
prescribing NN NN O
statins NN NN O
, NN NN O
the NN NN O
possibility NN NN O
of NN NN O
hepatic NN NN B-Disease
damage NN NN I-Disease
should NN NN O
be NN NN O
taken NN NN O
into NN NN O
account NN NN O
. NN NN O
   
Fluconazole NN NN O
associated NN NN O
agranulocytosis NN NN B-Disease
and NN NN O
thrombocytopenia NN NN B-Disease
. NN NN O
   
CASE NN NN O
: NN NN O
We NN NN O
describe NN NN O
a NN NN O
second NN NN O
case NN NN O
of NN NN O
fluconazole NN NN O
associated NN NN O
agranulocytosis NN NN B-Disease
with NN NN O
thrombocytopenia NN NN B-Disease
and NN NN O
recovery NN NN O
upon NN NN O
discontinuation NN NN O
of NN NN O
therapy NN NN O
. NN NN O
   
The NN NN O
patient NN NN O
began NN NN O
to NN NN O
have NN NN O
changes NN NN O
in NN NN O
white NN NN O
blood NN NN O
cells NN NN O
and NN NN O
platelets NN NN O
within NN NN O
48 NN NN O
h NN NN O
of NN NN O
administration NN NN O
of NN NN O
fluconazole NN NN O
and NN NN O
began NN NN O
to NN NN O
recover NN NN O
with NN NN O
48 NN NN O
h NN NN O
of NN NN O
discontinuation NN NN O
. NN NN O
   
This NN NN O
case NN NN O
highlights NN NN O
that NN NN O
drug NN NN O
- NN NN O
induced NN NN O
blood NN NN B-Disease
dyscrasias NN NN I-Disease
can NN NN O
occur NN NN O
unexpectedly NN NN O
as NN NN O
a NN NN O
result NN NN O
of NN NN O
treatment NN NN O
with NN NN O
a NN NN O
commonly NN NN O
used NN NN O
drug NN NN O
thought NN NN O
to NN NN O
be NN NN O
"""""""" NN NN O
safe NN NN O
"""""""" NN NN O
. NN NN O
   
CONCLUSION NN NN O
: NN NN O
According NN NN O
to NN NN O
Naranjo NN NN O
' NN NN O
s NN NN O
algorithm NN NN O
the NN NN O
likelihood NN NN O
that NN NN O
our NN NN O
patient NN NN O
' NN NN O
s NN NN O
agranulocytosis NN NN B-Disease
and NN NN O
thrombocytopenia NN NN B-Disease
occurred NN NN O
as NN NN O
a NN NN O
result NN NN O
of NN NN O
therapy NN NN O
with NN NN O
fluconazole NN NN O
is NN NN O
probable NN NN O
, NN NN O
with NN NN O
a NN NN O
total NN NN O
of NN NN O
six NN NN O
points NN NN O
. NN NN O
   
We NN NN O
feel NN NN O
that NN NN O
the NN NN O
weight NN NN O
of NN NN O
the NN NN O
overall NN NN O
evidence NN NN O
of NN NN O
this NN NN O
evidence NN NN O
is NN NN O
strong NN NN O
. NN NN O
   
In NN NN O
particular NN NN O
the NN NN O
temporal NN NN O
relationship NN NN O
of NN NN O
bone NN NN B-Disease
marrow NN NN I-Disease
suppression NN NN I-Disease
to NN NN O
the NN NN O
initiation NN NN O
of NN NN O
fluconazole NN NN O
and NN NN O
the NN NN O
abatement NN NN O
of NN NN O
symptoms NN NN O
that NN NN O
rapidly NN NN O
reversed NN NN O
immediately NN NN O
following NN NN O
discontinuation NN NN O
. NN NN O
   
Two NN NN O
- NN NN O
dimensional NN NN O
speckle NN NN O
tracking NN NN O
echocardiography NN NN O
combined NN NN O
with NN NN O
high NN NN O
- NN NN O
sensitive NN NN O
cardiac NN NN O
troponin NN NN O
T NN NN O
in NN NN O
early NN NN O
detection NN NN O
and NN NN O
prediction NN NN O
of NN NN O
cardiotoxicity NN NN B-Disease
during NN NN O
epirubicine NN NN O
- NN NN O
based NN NN O
chemotherapy NN NN O
. NN NN O
   
AIMS NN NN O
: NN NN O
To NN NN O
investigate NN NN O
whether NN NN O
alterations NN NN O
of NN NN O
myocardial NN NN B-Disease
strain NN NN I-Disease
and NN NN O
high NN NN O
- NN NN O
sensitive NN NN O
cardiac NN NN O
troponin NN NN O
T NN NN O
( NN NN O
cTnT NN NN O
) NN NN O
could NN NN O
predict NN NN O
future NN NN O
cardiac NN NN B-Disease
dysfunction NN NN I-Disease
in NN NN O
patients NN NN O
after NN NN O
epirubicin NN NN O
exposure NN NN O
. NN NN O
   
METHODS NN NN O
: NN NN O
Seventy NN NN O
- NN NN O
five NN NN O
patients NN NN O
with NN NN O
non NN NN B-Disease
- NN NN I-Disease
Hodgkin NN NN I-Disease
lymphoma NN NN I-Disease
treated NN NN O
with NN NN O
epirubicin NN NN O
were NN NN O
studied NN NN O
. NN NN O
   
Blood NN NN O
collection NN NN O
and NN NN O
echocardiography NN NN O
were NN NN O
performed NN NN O
at NN NN O
baseline NN NN O
, NN NN O
1 NN NN O
day NN NN O
after NN NN O
the NN NN O
third NN NN O
cycle NN NN O
, NN NN O
and NN NN O
1 NN NN O
day NN NN O
after NN NN O
completion NN NN O
of NN NN O
chemotherapy NN NN O
. NN NN O
   
Patients NN NN O
were NN NN O
studied NN NN O
using NN NN O
echocardiography NN NN O
during NN NN O
follow NN NN O
- NN NN O
up NN NN O
. NN NN O
   
Global NN NN O
longitudinal NN NN O
( NN NN O
GLS NN NN O
) NN NN O
, NN NN O
circumferential NN NN O
( NN NN O
GCS NN NN O
) NN NN O
, NN NN O
and NN NN O
radial NN NN O
strain NN NN O
( NN NN O
GRS NN NN O
) NN NN O
were NN NN O
calculated NN NN O
using NN NN O
speckle NN NN O
tracking NN NN O
echocardiography NN NN O
. NN NN O
   
Left NN NN O
ventricular NN NN O
ejection NN NN O
fraction NN NN O
was NN NN O
analysed NN NN O
by NN NN O
real NN NN O
- NN NN O
time NN NN O
3D NN NN O
echocardiography NN NN O
. NN NN O
   
Cardiotoxicity NN NN B-Disease
was NN NN O
defined NN NN O
as NN NN O
a NN NN O
reduction NN NN O
of NN NN O
the NN NN O
LVEF NN NN O
of NN NN O
> NN NN O
5 NN NN O
% NN NN O
to NN NN O
< NN NN O
55 NN NN O
% NN NN O
with NN NN O
symptoms NN NN O
of NN NN O
heart NN NN B-Disease
failure NN NN I-Disease
or NN NN O
an NN NN O
asymptomatic NN NN O
reduction NN NN O
of NN NN O
the NN NN O
LVEF NN NN O
of NN NN O
> NN NN O
10 NN NN O
% NN NN O
to NN NN O
< NN NN O
55 NN NN O
% NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
Fourteen NN NN O
patients NN NN O
( NN NN O
18 NN NN O
. NN NN O
67 NN NN O
% NN NN O
) NN NN O
developed NN NN O
cardiotoxicity NN NN B-Disease
after NN NN O
treatment NN NN O
. NN NN O
   
GLS NN NN O
( NN NN O
- NN NN O
18 NN NN O
. NN NN O
48 NN NN O
+ NN NN O
1 NN NN O
. NN NN O
72 NN NN O
% NN NN O
vs NN NN O
. NN NN O
- NN NN O
15 NN NN O
. NN NN O
96 NN NN O
+ NN NN O
1 NN NN O
. NN NN O
6 NN NN O
% NN NN O
) NN NN O
, NN NN O
GCS NN NN O
( NN NN O
- NN NN O
20 NN NN O
. NN NN O
93 NN NN O
+ NN NN O
2 NN NN O
. NN NN O
86 NN NN O
% NN NN O
vs NN NN O
. NN NN O
- NN NN O
19 NN NN O
. NN NN O
20 NN NN O
+ NN NN O
3 NN NN O
. NN NN O
21 NN NN O
% NN NN O
) NN NN O
, NN NN O
and NN NN O
GRS NN NN O
( NN NN O
39 NN NN O
. NN NN O
23 NN NN O
+ NN NN O
6 NN NN O
. NN NN O
44 NN NN O
% NN NN O
vs NN NN O
. NN NN O
34 NN NN O
. NN NN O
98 NN NN O
+ NN NN O
6 NN NN O
. NN NN O
2 NN NN O
% NN NN O
) NN NN O
were NN NN O
markedly NN NN O
reduced NN NN O
and NN NN O
cTnT NN NN O
was NN NN O
elevated NN NN O
from NN NN O
0 NN NN O
. NN NN O
0010 NN NN O
+ NN NN O
0 NN NN O
. NN NN O
0020 NN NN O
to NN NN O
0 NN NN O
. NN NN O
0073 NN NN O
+ NN NN O
0 NN NN O
. NN NN O
0038 NN NN O
ng NN NN O
/ NN NN O
mL NN NN O
( NN NN O
P NN NN O
all NN NN O
< NN NN O
0 NN NN O
. NN NN O
01 NN NN O
) NN NN O
at NN NN O
the NN NN O
completion NN NN O
of NN NN O
chemotherapy NN NN O
compared NN NN O
with NN NN O
baseline NN NN O
values NN NN O
. NN NN O
   
A NN NN O
> NN NN O
15 NN NN O
. NN NN O
9 NN NN O
% NN NN O
decrease NN NN O
in NN NN O
GLS NN NN O
[ NN NN O
sensitivity NN NN O
, NN NN O
86 NN NN O
% NN NN O
; NN NN O
specificity NN NN O
, NN NN O
75 NN NN O
% NN NN O
; NN NN O
area NN NN O
under NN NN O
the NN NN O
curve NN NN O
( NN NN O
AUC NN NN O
) NN NN O
= NN NN O
0 NN NN O
. NN NN O
815 NN NN O
; NN NN O
P NN NN O
= NN NN O
0 NN NN O
. NN NN O
001 NN NN O
] NN NN O
and NN NN O
a NN NN O
> NN NN O
0 NN NN O
. NN NN O
004 NN NN O
ng NN NN O
/ NN NN O
mL NN NN O
elevation NN NN O
in NN NN O
cTnT NN NN O
( NN NN O
sensitivity NN NN O
, NN NN O
79 NN NN O
% NN NN O
; NN NN O
specificity NN NN O
, NN NN O
64 NN NN O
% NN NN O
; NN NN O
AUC NN NN O
= NN NN O
0 NN NN O
. NN NN O
757 NN NN O
; NN NN O
P NN NN O
= NN NN O
0 NN NN O
. NN NN O
005 NN NN O
) NN NN O
from NN NN O
baseline NN NN O
to NN NN O
the NN NN O
third NN NN O
cycle NN NN O
of NN NN O
chemotherapy NN NN O
predicted NN NN O
later NN NN O
cardiotoxicity NN NN B-Disease
. NN NN O
   
The NN NN O
decrease NN NN O
in NN NN O
GLS NN NN O
remained NN NN O
the NN NN O
only NN NN O
independent NN NN O
predictor NN NN O
of NN NN O
cardiotoxicity NN NN B-Disease
( NN NN O
P NN NN O
= NN NN O
0 NN NN O
. NN NN O
000 NN NN O
) NN NN O
. NN NN O
   
CONCLUSIONS NN NN O
: NN NN O
GLS NN NN O
combined NN NN O
with NN NN O
cTnT NN NN O
may NN NN O
provide NN NN O
a NN NN O
reliable NN NN O
and NN NN O
non NN NN O
- NN NN O
invasive NN NN O
method NN NN O
to NN NN O
predict NN NN O
cardiac NN NN B-Disease
dysfunction NN NN I-Disease
in NN NN O
patients NN NN O
receiving NN NN O
anthracycline NN NN O
- NN NN O
based NN NN O
chemotherapy NN NN O
. NN NN O
   
Prevention NN NN O
of NN NN O
etomidate NN NN O
- NN NN O
induced NN NN O
myoclonus NN NN B-Disease
: NN NN O
which NN NN O
is NN NN O
superior NN NN O
: NN NN O
Fentanyl NN NN O
, NN NN O
midazolam NN NN O
, NN NN O
or NN NN O
a NN NN O
combination NN NN O
? NN NN O
   
A NN NN O
Retrospective NN NN O
comparative NN NN O
study NN NN O
. NN NN O
   
BACKGROUND NN NN O
: NN NN O
In NN NN O
this NN NN O
retrospective NN NN O
comparative NN NN O
study NN NN O
, NN NN O
we NN NN O
aimed NN NN O
to NN NN O
compare NN NN O
the NN NN O
effectiveness NN NN O
of NN NN O
fentanyl NN NN O
, NN NN O
midazolam NN NN O
, NN NN O
and NN NN O
a NN NN O
combination NN NN O
of NN NN O
fentanyl NN NN O
and NN NN O
midazolam NN NN O
to NN NN O
prevent NN NN O
etomidate NN NN O
- NN NN O
induced NN NN O
myoclonus NN NN B-Disease
. NN NN O
   
MATERIAL NN NN O
AND NN NN O
METHODS NN NN O
: NN NN O
This NN NN O
study NN NN O
was NN NN O
performed NN NN O
based NN NN O
on NN NN O
anesthesia NN NN O
records NN NN O
. NN NN O
   
Depending NN NN O
on NN NN O
the NN NN O
drugs NN NN O
that NN NN O
would NN NN O
be NN NN O
given NN NN O
before NN NN O
the NN NN O
induction NN NN O
of NN NN O
anesthesia NN NN O
with NN NN O
etomidate NN NN O
, NN NN O
the NN NN O
patients NN NN O
were NN NN O
separated NN NN O
into NN NN O
4 NN NN O
groups NN NN O
: NN NN O
no NN NN O
pretreatment NN NN O
( NN NN O
Group NN NN O
NP NN NN O
) NN NN O
, NN NN O
fentanyl NN NN O
1 NN NN O
ug NN NN O
. NN NN O
kg NN NN O
- NN NN O
1 NN NN O
( NN NN O
Group NN NN O
F NN NN O
) NN NN O
, NN NN O
midazolam NN NN O
0 NN NN O
. NN NN O
03 NN NN O
mg NN NN O
. NN NN O
kg NN NN O
- NN NN O
1 NN NN O
( NN NN O
Group NN NN O
M NN NN O
) NN NN O
, NN NN O
and NN NN O
midazolam NN NN O
0 NN NN O
. NN NN O
015 NN NN O
mg NN NN O
. NN NN O
kg NN NN O
- NN NN O
1 NN NN O
+ NN NN O
fentanyl NN NN O
0 NN NN O
. NN NN O
5 NN NN O
ug NN NN O
. NN NN O
kg NN NN O
- NN NN O
1 NN NN O
( NN NN O
Group NN NN O
FM NN NN O
) NN NN O
. NN NN O
   
Patients NN NN O
who NN NN O
received NN NN O
the NN NN O
same NN NN O
anesthetic NN NN O
procedure NN NN O
were NN NN O
selected NN NN O
: NN NN O
2 NN NN O
minutes NN NN O
after NN NN O
intravenous NN NN O
injections NN NN O
of NN NN O
the NN NN O
pretreatment NN NN O
drugs NN NN O
, NN NN O
anesthesia NN NN O
is NN NN O
induced NN NN O
with NN NN O
0 NN NN O
. NN NN O
3 NN NN O
mg NN NN O
. NN NN O
kg NN NN O
- NN NN O
1 NN NN O
etomidate NN NN O
injected NN NN O
intravenously NN NN O
over NN NN O
a NN NN O
period NN NN O
of NN NN O
20 NN NN O
- NN NN O
30 NN NN O
seconds NN NN O
. NN NN O
   
Myoclonic NN NN B-Disease
movements NN NN I-Disease
are NN NN O
evaluated NN NN O
, NN NN O
which NN NN O
were NN NN O
observed NN NN O
and NN NN O
graded NN NN O
according NN NN O
to NN NN O
clinical NN NN O
severity NN NN O
during NN NN O
the NN NN O
2 NN NN O
minutes NN NN O
after NN NN O
etomidate NN NN O
injection NN NN O
. NN NN O
   
The NN NN O
severity NN NN O
of NN NN O
pain NN NN B-Disease
due NN NN O
to NN NN O
etomidate NN NN O
injection NN NN O
, NN NN O
mean NN NN O
arterial NN NN O
pressure NN NN O
, NN NN O
heart NN NN O
rate NN NN O
, NN NN O
and NN NN O
adverse NN NN O
effects NN NN O
were NN NN O
also NN NN O
evaluated NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
Study NN NN O
results NN NN O
showed NN NN O
that NN NN O
myoclonus NN NN B-Disease
incidence NN NN O
was NN NN O
85 NN NN O
% NN NN O
, NN NN O
40 NN NN O
% NN NN O
, NN NN O
70 NN NN O
% NN NN O
, NN NN O
and NN NN O
25 NN NN O
% NN NN O
in NN NN O
Group NN NN O
NP NN NN O
, NN NN O
Group NN NN O
F NN NN O
, NN NN O
Group NN NN O
M NN NN O
, NN NN O
and NN NN O
Group NN NN O
FM NN NN O
, NN NN O
respectively NN NN O
, NN NN O
and NN NN O
were NN NN O
significantly NN NN O
lower NN NN O
in NN NN O
Group NN NN O
F NN NN O
and NN NN O
Group NN NN O
FM NN NN O
. NN NN O
   
CONCLUSIONS NN NN O
: NN NN O
We NN NN O
conclude NN NN O
that NN NN O
pretreatment NN NN O
with NN NN O
fentanyl NN NN O
or NN NN O
combination NN NN O
of NN NN O
fentanyl NN NN O
and NN NN O
midazolam NN NN O
was NN NN O
effective NN NN O
in NN NN O
preventing NN NN O
etomidate NN NN O
- NN NN O
induced NN NN O
myoclonus NN NN B-Disease
. NN NN O
   
Convulsant NN NN O
effect NN NN O
of NN NN O
lindane NN NN O
and NN NN O
regional NN NN O
brain NN NN O
concentration NN NN O
of NN NN O
GABA NN NN O
and NN NN O
dopamine NN NN O
. NN NN O
   
Lindane NN NN O
( NN NN O
gamma NN NN O
- NN NN O
hexachlorocyclohexane NN NN O
) NN NN O
is NN NN O
an NN NN O
organochlorine NN NN O
insecticide NN NN O
with NN NN O
known NN NN O
neurotoxic NN NN B-Disease
effects NN NN O
. NN NN O
   
Its NN NN O
mechanism NN NN O
of NN NN O
action NN NN O
is NN NN O
not NN NN O
well NN NN O
understood NN NN O
although NN NN O
it NN NN O
has NN NN O
been NN NN O
proposed NN NN O
that NN NN O
lindane NN NN O
acts NN NN O
as NN NN O
a NN NN O
non NN NN O
- NN NN O
competitive NN NN O
antagonist NN NN O
at NN NN O
the NN NN O
gamma NN NN O
- NN NN O
aminobutyric NN NN O
acid NN NN O
( NN NN O
GABA NN NN O
) NN NN O
- NN NN O
A NN NN O
receptor NN NN O
. NN NN O
   
We NN NN O
studied NN NN O
the NN NN O
effect NN NN O
of NN NN O
lindane NN NN O
( NN NN O
150 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
) NN NN O
on NN NN O
the NN NN O
GABAergic NN NN O
and NN NN O
dopaminergic NN NN O
systems NN NN O
by NN NN O
measuring NN NN O
the NN NN O
concentration NN NN O
of NN NN O
GABA NN NN O
, NN NN O
dopamine NN NN O
and NN NN O
its NN NN O
metabolites NN NN O
in NN NN O
7 NN NN O
brain NN NN O
areas NN NN O
at NN NN O
the NN NN O
onset NN NN O
of NN NN O
seizures NN NN B-Disease
. NN NN O
   
All NN NN O
animals NN NN O
suffered NN NN O
tonic NN NN O
convulsions NN NN B-Disease
at NN NN O
18 NN NN O
. NN NN O
3 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
1 NN NN O
. NN NN O
4 NN NN O
min NN NN O
after NN NN O
lindane NN NN O
administration NN NN O
. NN NN O
   
The NN NN O
concentration NN NN O
of NN NN O
GABA NN NN O
was NN NN O
only NN NN O
slightly NN NN O
but NN NN O
significantly NN NN O
decreased NN NN O
in NN NN O
the NN NN O
colliculi NN NN O
without NN NN O
modifications NN NN O
in NN NN O
the NN NN O
other NN NN O
areas NN NN O
. NN NN O
   
The NN NN O
concentration NN NN O
of NN NN O
dopamine NN NN O
was NN NN O
increased NN NN O
in NN NN O
the NN NN O
mesencephalon NN NN O
and NN NN O
that NN NN O
of NN NN O
its NN NN O
metabolite NN NN O
DOPAC NN NN O
was NN NN O
also NN NN O
increased NN NN O
in NN NN O
the NN NN O
mesencephalon NN NN O
and NN NN O
the NN NN O
striatum NN NN O
. NN NN O
   
Cholestatic NN NN B-Disease
presentation NN NN O
of NN NN O
yellow NN NN O
phosphorus NN NN O
poisoning NN NN B-Disease
. NN NN O
   
Yellow NN NN O
phosphorus NN NN O
, NN NN O
a NN NN O
component NN NN O
of NN NN O
certain NN NN O
pesticide NN NN O
pastes NN NN O
and NN NN O
fireworks NN NN O
, NN NN O
is NN NN O
well NN NN O
known NN NN O
to NN NN O
cause NN NN O
hepatotoxicity NN NN B-Disease
. NN NN O
   
Poisoning NN NN B-Disease
with NN NN O
yellow NN NN O
phosphorus NN NN O
classically NN NN O
manifests NN NN O
with NN NN O
acute NN NN B-Disease
hepatitis NN NN I-Disease
leading NN NN O
to NN NN O
acute NN NN B-Disease
liver NN NN I-Disease
failure NN NN I-Disease
which NN NN O
may NN NN O
need NN NN O
liver NN NN O
transplantation NN NN O
. NN NN O
   
We NN NN O
present NN NN O
a NN NN O
case NN NN O
of NN NN O
yellow NN NN O
phosphorus NN NN O
poisoning NN NN B-Disease
in NN NN O
which NN NN O
a NN NN O
patient NN NN O
presented NN NN O
with NN NN O
florid NN NN O
clinical NN NN O
features NN NN O
of NN NN O
cholestasis NN NN B-Disease
highlighting NN NN O
the NN NN O
fact NN NN O
that NN NN O
cholestasis NN NN B-Disease
can NN NN O
rarely NN NN O
be NN NN O
a NN NN O
presenting NN NN O
feature NN NN O
of NN NN O
yellow NN NN O
phosphorus NN NN O
hepatotoxicity NN NN B-Disease
. NN NN O
   
Vasovagal NN NN B-Disease
syncope NN NN I-Disease
and NN NN O
severe NN NN O
bradycardia NN NN B-Disease
following NN NN O
intranasal NN NN O
dexmedetomidine NN NN O
for NN NN O
pediatric NN NN O
procedural NN NN O
sedation NN NN O
. NN NN O
   
We NN NN O
report NN NN O
syncope NN NN B-Disease
and NN NN O
bradycardia NN NN B-Disease
in NN NN O
an NN NN O
11 NN NN O
- NN NN O
year NN NN O
- NN NN O
old NN NN O
girl NN NN O
following NN NN O
administration NN NN O
of NN NN O
intranasal NN NN O
dexmedetomidine NN NN O
for NN NN O
sedation NN NN O
for NN NN O
a NN NN O
voiding NN NN O
cystourethrogram NN NN O
. NN NN O
   
Following NN NN O
successful NN NN O
completion NN NN O
of NN NN O
VCUG NN NN O
and NN NN O
a NN NN O
60 NN NN O
- NN NN O
min NN NN O
recovery NN NN O
period NN NN O
, NN NN O
the NN NN O
patient NN NN O
' NN NN O
s NN NN O
level NN NN O
of NN NN O
consciousness NN NN O
and NN NN O
vital NN NN O
signs NN NN O
returned NN NN O
to NN NN O
presedation NN NN O
levels NN NN O
. NN NN O
   
Upon NN NN O
leaving NN NN O
the NN NN O
sedation NN NN O
area NN NN O
, NN NN O
the NN NN O
patient NN NN O
collapsed NN NN O
, NN NN O
with NN NN O
no NN NN O
apparent NN NN O
inciting NN NN O
event NN NN O
. NN NN O
   
The NN NN O
patient NN NN O
quickly NN NN O
regained NN NN O
consciousness NN NN O
and NN NN O
no NN NN O
injury NN NN O
occurred NN NN O
. NN NN O
   
The NN NN O
primary NN NN O
abnormality NN NN O
found NN NN O
was NN NN O
persistent NN NN O
bradycardia NN NN B-Disease
, NN NN O
and NN NN O
she NN NN O
was NN NN O
admitted NN NN O
to NN NN O
the NN NN O
hospital NN NN O
for NN NN O
telemetric NN NN O
observation NN NN O
. NN NN O
   
The NN NN O
bradycardia NN NN B-Disease
lasted NN NN O
~ NN NN O
2 NN NN O
h NN NN O
, NN NN O
and NN NN O
further NN NN O
cardiac NN NN O
workup NN NN O
revealed NN NN O
no NN NN O
underlying NN NN O
abnormality NN NN O
. NN NN O
   
Unanticipated NN NN O
and NN NN O
previously NN NN O
unreported NN NN O
outcomes NN NN O
may NN NN O
be NN NN O
witnessed NN NN O
as NN NN O
we NN NN O
expand NN NN O
the NN NN O
use NN NN O
of NN NN O
certain NN NN O
sedatives NN NN O
to NN NN O
alternative NN NN O
routes NN NN O
of NN NN O
administration NN NN O
. NN NN O
   
Paradoxical NN NN O
severe NN NN O
agitation NN NN B-Disease
induced NN NN O
by NN NN O
add NN NN O
- NN NN O
on NN NN O
high NN NN O
- NN NN O
doses NN NN O
quetiapine NN NN O
in NN NN O
schizo NN NN B-Disease
- NN NN I-Disease
affective NN NN I-Disease
disorder NN NN I-Disease
. NN NN O
   
We NN NN O
report NN NN O
the NN NN O
case NN NN O
of NN NN O
a NN NN O
35 NN NN O
- NN NN O
year NN NN O
- NN NN O
old NN NN O
patient NN NN O
suffering NN NN O
from NN NN O
schizo NN NN B-Disease
- NN NN I-Disease
affective NN NN I-Disease
disorder NN NN I-Disease
since NN NN O
the NN NN O
age NN NN O
of NN NN O
19 NN NN O
years NN NN O
, NN NN O
treated NN NN O
by NN NN O
a NN NN O
combination NN NN O
of NN NN O
first NN NN O
- NN NN O
generation NN NN O
antipsychotics NN NN O
, NN NN O
zuclopenthixol NN NN O
( NN NN O
100 NN NN O
mg NN NN O
/ NN NN O
day NN NN O
) NN NN O
and NN NN O
lithium NN NN O
( NN NN O
1200 NN NN O
mg NN NN O
/ NN NN O
day NN NN O
) NN NN O
( NN NN O
serum NN NN O
lithium NN NN O
= NN NN O
0 NN NN O
. NN NN O
85 NN NN O
mEq NN NN O
/ NN NN O
l NN NN O
) NN NN O
. NN NN O
   
This NN NN O
patient NN NN O
had NN NN O
no NN NN O
associated NN NN O
personality NN NN B-Disease
disorder NN NN I-Disease
( NN NN O
particularly NN NN O
no NN NN O
antisocial NN NN B-Disease
disorder NN NN I-Disease
) NN NN O
and NN NN O
no NN NN O
substance NN NN B-Disease
abuse NN NN I-Disease
disorder NN NN I-Disease
. NN NN O
   
Within NN NN O
the NN NN O
48 NN NN O
h NN NN O
following NN NN O
the NN NN O
gradual NN NN O
introduction NN NN O
of NN NN O
quetiapine NN NN O
( NN NN O
up NN NN O
to NN NN O
600 NN NN O
mg NN NN O
/ NN NN O
day NN NN O
) NN NN O
, NN NN O
the NN NN O
patient NN NN O
presented NN NN O
severe NN NN O
agitation NN NN B-Disease
without NN NN O
an NN NN O
environmental NN NN O
explanation NN NN O
, NN NN O
contrasting NN NN O
with NN NN O
the NN NN O
absence NN NN O
of NN NN O
a NN NN O
history NN NN O
of NN NN O
aggressiveness NN NN B-Disease
or NN NN O
personality NN NN B-Disease
disorder NN NN I-Disease
. NN NN O
   
The NN NN O
diagnoses NN NN O
of NN NN O
manic NN NN B-Disease
shift NN NN O
and NN NN O
akathisia NN NN B-Disease
were NN NN O
dismissed NN NN O
. NN NN O
   
The NN NN O
withdrawal NN NN O
and NN NN O
the NN NN O
gradual NN NN O
reintroduction NN NN O
of NN NN O
quetiapine NN NN O
2 NN NN O
weeks NN NN O
later NN NN O
, NN NN O
which NN NN O
led NN NN O
to NN NN O
another NN NN O
severe NN NN O
agitation NN NN B-Disease
, NN NN O
enabled NN NN O
us NN NN O
to NN NN O
attribute NN NN O
the NN NN O
agitation NN NN B-Disease
specifically NN NN O
to NN NN O
quetiapine NN NN O
. NN NN O
   
Antioxidant NN NN O
effects NN NN O
of NN NN O
bovine NN NN O
lactoferrin NN NN O
on NN NN O
dexamethasone NN NN O
- NN NN O
induced NN NN O
hypertension NN NN B-Disease
in NN NN O
rat NN NN O
. NN NN O
   
Dexamethasone NN NN O
- NN NN O
( NN NN O
Dex NN NN O
- NN NN O
) NN NN O
induced NN NN O
hypertension NN NN B-Disease
is NN NN O
associated NN NN O
with NN NN O
enhanced NN NN O
oxidative NN NN O
stress NN NN O
. NN NN O
   
Lactoferrin NN NN O
( NN NN O
LF NN NN O
) NN NN O
is NN NN O
an NN NN O
iron NN NN O
- NN NN O
binding NN NN O
glycoprotein NN NN O
with NN NN O
antihypertensive NN NN O
properties NN NN O
. NN NN O
   
In NN NN O
this NN NN O
study NN NN O
, NN NN O
we NN NN O
investigated NN NN O
the NN NN O
effect NN NN O
of NN NN O
chronic NN NN O
administration NN NN O
of NN NN O
LF NN NN O
on NN NN O
oxidative NN NN O
stress NN NN O
and NN NN O
hypertension NN NN B-Disease
upon NN NN O
Dex NN NN O
administration NN NN O
. NN NN O
   
Male NN NN O
Wistar NN NN O
rats NN NN O
were NN NN O
treated NN NN O
by NN NN O
Dex NN NN O
( NN NN O
30 NN NN O
u NN NN O
g NN NN O
/ NN NN O
kg NN NN O
/ NN NN O
day NN NN O
subcutaneously NN NN O
) NN NN O
or NN NN O
saline NN NN O
for NN NN O
14 NN NN O
days NN NN O
. NN NN O
   
Oral NN NN O
bovine NN NN O
LF NN NN O
( NN NN O
30 NN NN O
, NN NN O
100 NN NN O
, NN NN O
300 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
) NN NN O
was NN NN O
given NN NN O
from NN NN O
day NN NN O
8 NN NN O
to NN NN O
14 NN NN O
in NN NN O
a NN NN O
reversal NN NN O
study NN NN O
. NN NN O
   
In NN NN O
a NN NN O
prevention NN NN O
study NN NN O
, NN NN O
rats NN NN O
received NN NN O
4 NN NN O
days NN NN O
of NN NN O
LF NN NN O
treatment NN NN O
followed NN NN O
by NN NN O
Dex NN NN O
and NN NN O
continued NN NN O
during NN NN O
the NN NN O
test NN NN O
period NN NN O
. NN NN O
   
Systolic NN NN O
blood NN NN O
pressure NN NN O
( NN NN O
SBP NN NN O
) NN NN O
was NN NN O
measured NN NN O
using NN NN O
tail NN NN O
- NN NN O
cuff NN NN O
method NN NN O
. NN NN O
   
Thymus NN NN O
weight NN NN O
was NN NN O
used NN NN O
as NN NN O
a NN NN O
marker NN NN O
of NN NN O
glucocorticoid NN NN O
activity NN NN O
. NN NN O
   
Plasma NN NN O
hydrogen NN NN O
peroxide NN NN O
( NN NN O
H2O2 NN NN O
) NN NN O
concentration NN NN O
and NN NN O
ferric NN NN O
reducing NN NN O
antioxidant NN NN O
power NN NN O
( NN NN O
FRAP NN NN O
) NN NN O
value NN NN O
were NN NN O
determined NN NN O
. NN NN O
   
Dexamethasone NN NN O
significantly NN NN O
increased NN NN O
SBP NN NN O
and NN NN O
plasma NN NN O
H2O2 NN NN O
level NN NN O
and NN NN O
decreased NN NN O
thymus NN NN O
and NN NN O
body NN NN O
weights NN NN O
. NN NN O
   
LF NN NN O
lowered NN NN O
( NN NN O
P NN NN O
< NN NN O
0 NN NN O
. NN NN O
01 NN NN O
) NN NN O
and NN NN O
dose NN NN O
dependently NN NN O
prevented NN NN O
( NN NN O
P NN NN O
< NN NN O
0 NN NN O
. NN NN O
001 NN NN O
) NN NN O
Dex NN NN O
- NN NN O
induced NN NN O
hypertension NN NN B-Disease
. NN NN O
   
LF NN NN O
prevented NN NN O
body NN NN O
weight NN NN B-Disease
loss NN NN I-Disease
and NN NN O
significantly NN NN O
reduced NN NN O
the NN NN O
elevated NN NN O
plasma NN NN O
H2O2 NN NN O
and NN NN O
increased NN NN O
FRAP NN NN O
values NN NN O
. NN NN O
   
Chronic NN NN O
administration NN NN O
of NN NN O
LF NN NN O
strongly NN NN O
reduced NN NN O
the NN NN O
blood NN NN O
pressure NN NN O
and NN NN O
production NN NN O
of NN NN O
ROS NN NN O
and NN NN O
improved NN NN O
antioxidant NN NN O
capacity NN NN O
in NN NN O
Dex NN NN O
- NN NN O
induced NN NN O
hypertension NN NN B-Disease
, NN NN O
suggesting NN NN O
the NN NN O
role NN NN O
of NN NN O
inhibition NN NN O
of NN NN O
oxidative NN NN O
stress NN NN O
as NN NN O
another NN NN O
mechanism NN NN O
of NN NN O
antihypertensive NN NN O
action NN NN O
of NN NN O
LF NN NN O
. NN NN O
   
The NN NN O
association NN NN O
between NN NN O
tranexamic NN NN O
acid NN NN O
and NN NN O
convulsive NN NN B-Disease
seizures NN NN B-Disease
after NN NN O
cardiac NN NN O
surgery NN NN O
: NN NN O
a NN NN O
multivariate NN NN O
analysis NN NN O
in NN NN O
11 NN NN O
529 NN NN O
patients NN NN O
. NN NN O
   
Because NN NN O
of NN NN O
a NN NN O
lack NN NN O
of NN NN O
contemporary NN NN O
data NN NN O
regarding NN NN O
seizures NN NN B-Disease
after NN NN O
cardiac NN NN O
surgery NN NN O
, NN NN O
we NN NN O
undertook NN NN O
a NN NN O
retrospective NN NN O
analysis NN NN O
of NN NN O
prospectively NN NN O
collected NN NN O
data NN NN O
from NN NN O
11 NN NN O
529 NN NN O
patients NN NN O
in NN NN O
whom NN NN O
cardiopulmonary NN NN O
bypass NN NN O
was NN NN O
used NN NN O
from NN NN O
January NN NN O
2004 NN NN O
to NN NN O
December NN NN O
2010 NN NN O
. NN NN O
   
A NN NN O
convulsive NN NN B-Disease
seizure NN NN B-Disease
was NN NN O
defined NN NN O
as NN NN O
a NN NN O
transient NN NN O
episode NN NN O
of NN NN O
disturbed NN NN O
brain NN NN O
function NN NN O
characterised NN NN O
by NN NN O
abnormal NN NN B-Disease
involuntary NN NN I-Disease
motor NN NN I-Disease
movements NN NN I-Disease
. NN NN O
   
Multivariate NN NN O
regression NN NN O
analysis NN NN O
was NN NN O
performed NN NN O
to NN NN O
identify NN NN O
independent NN NN O
predictors NN NN O
of NN NN O
postoperative NN NN O
seizures NN NN B-Disease
. NN NN O
   
A NN NN O
total NN NN O
of NN NN O
100 NN NN O
( NN NN O
0 NN NN O
. NN NN O
9 NN NN O
% NN NN O
) NN NN O
patients NN NN O
developed NN NN O
postoperative NN NN O
convulsive NN NN B-Disease
seizures NN NN B-Disease
. NN NN O
   
Generalised NN NN B-Disease
and NN NN I-Disease
focal NN NN I-Disease
seizures NN NN I-Disease
were NN NN O
identified NN NN O
in NN NN O
68 NN NN O
and NN NN O
32 NN NN O
patients NN NN O
, NN NN O
respectively NN NN O
. NN NN O
   
The NN NN O
median NN NN O
( NN NN O
IQR NN NN O
[ NN NN O
range NN NN O
] NN NN O
) NN NN O
time NN NN O
after NN NN O
surgery NN NN O
when NN NN O
the NN NN O
seizure NN NN B-Disease
occurred NN NN O
was NN NN O
7 NN NN O
( NN NN O
6 NN NN O
- NN NN O
12 NN NN O
[ NN NN O
1 NN NN O
- NN NN O
216 NN NN O
] NN NN O
) NN NN O
h NN NN O
and NN NN O
8 NN NN O
( NN NN O
6 NN NN O
- NN NN O
11 NN NN O
[ NN NN O
4 NN NN O
- NN NN O
18 NN NN O
] NN NN O
) NN NN O
h NN NN O
, NN NN O
respectively NN NN O
. NN NN O
   
Epileptiform NN NN O
findings NN NN O
on NN NN O
electroencephalography NN NN O
were NN NN O
seen NN NN O
in NN NN O
19 NN NN O
patients NN NN O
. NN NN O
   
Independent NN NN O
predictors NN NN O
of NN NN O
postoperative NN NN O
seizures NN NN B-Disease
included NN NN O
age NN NN O
, NN NN O
female NN NN O
sex NN NN O
, NN NN O
redo NN NN O
cardiac NN NN O
surgery NN NN O
, NN NN O
calcification NN NN O
of NN NN O
ascending NN NN O
aorta NN NN O
, NN NN O
congestive NN NN B-Disease
heart NN NN I-Disease
failure NN NN I-Disease
, NN NN O
deep NN NN O
hypothermic NN NN B-Disease
circulatory NN NN O
arrest NN NN O
, NN NN O
duration NN NN O
of NN NN O
aortic NN NN O
cross NN NN O
- NN NN O
clamp NN NN O
and NN NN O
tranexamic NN NN O
acid NN NN O
. NN NN O
   
When NN NN O
tested NN NN O
in NN NN O
a NN NN O
multivariate NN NN O
regression NN NN O
analysis NN NN O
, NN NN O
tranexamic NN NN O
acid NN NN O
was NN NN O
a NN NN O
strong NN NN O
independent NN NN O
predictor NN NN O
of NN NN O
seizures NN NN B-Disease
( NN NN O
OR NN NN O
14 NN NN O
. NN NN O
3 NN NN O
, NN NN O
95 NN NN O
% NN NN O
CI NN NN O
5 NN NN O
. NN NN O
5 NN NN O
- NN NN O
36 NN NN O
. NN NN O
7 NN NN O
; NN NN O
p NN NN O
< NN NN O
0 NN NN O
. NN NN O
001 NN NN O
) NN NN O
. NN NN O
   
Patients NN NN O
with NN NN O
convulsive NN NN B-Disease
seizures NN NN B-Disease
had NN NN O
2 NN NN O
. NN NN O
5 NN NN O
times NN NN O
higher NN NN O
in NN NN O
- NN NN O
hospital NN NN O
mortality NN NN O
rates NN NN O
and NN NN O
twice NN NN O
the NN NN O
length NN NN O
of NN NN O
hospital NN NN O
stay NN NN O
compared NN NN O
with NN NN O
patients NN NN O
without NN NN O
convulsive NN NN B-Disease
seizures NN NN B-Disease
. NN NN O
   
Mean NN NN O
( NN NN O
IQR NN NN O
[ NN NN O
range NN NN O
] NN NN O
) NN NN O
length NN NN O
of NN NN O
stay NN NN O
in NN NN O
the NN NN O
intensive NN NN O
care NN NN O
unit NN NN O
was NN NN O
115 NN NN O
( NN NN O
49 NN NN O
- NN NN O
228 NN NN O
[ NN NN O
32 NN NN O
- NN NN O
481 NN NN O
] NN NN O
) NN NN O
h NN NN O
in NN NN O
patients NN NN O
with NN NN O
convulsive NN NN B-Disease
seizures NN NN B-Disease
compared NN NN O
with NN NN O
26 NN NN O
( NN NN O
22 NN NN O
- NN NN O
69 NN NN O
[ NN NN O
14 NN NN O
- NN NN O
1080 NN NN O
] NN NN O
) NN NN O
h NN NN O
in NN NN O
patients NN NN O
without NN NN O
seizures NN NN B-Disease
( NN NN O
p NN NN O
< NN NN O
0 NN NN O
. NN NN O
001 NN NN O
) NN NN O
. NN NN O
   
Convulsive NN NN B-Disease
seizures NN NN B-Disease
are NN NN O
a NN NN O
serious NN NN O
postoperative NN NN B-Disease
complication NN NN I-Disease
after NN NN O
cardiac NN NN O
surgery NN NN O
. NN NN O
   
As NN NN O
tranexamic NN NN O
acid NN NN O
is NN NN O
the NN NN O
only NN NN O
modifiable NN NN O
factor NN NN O
, NN NN O
its NN NN O
administration NN NN O
, NN NN O
particularly NN NN O
in NN NN O
doses NN NN O
exceeding NN NN O
80 NN NN O
mg NN NN O
. NN NN O
kg NN NN O
( NN NN O
- NN NN O
1 NN NN O
) NN NN O
, NN NN O
should NN NN O
be NN NN O
weighed NN NN O
against NN NN O
the NN NN O
risk NN NN O
of NN NN O
postoperative NN NN O
seizures NN NN B-Disease
. NN NN O
   
Dysfunctional NN NN B-Disease
overnight NN NN I-Disease
memory NN NN I-Disease
consolidation NN NN O
in NN NN O
ecstasy NN NN O
users NN NN O
. NN NN O
   
Sleep NN NN O
plays NN NN O
an NN NN O
important NN NN O
role NN NN O
in NN NN O
the NN NN O
consolidation NN NN O
and NN NN O
integration NN NN O
of NN NN O
memory NN NN O
in NN NN O
a NN NN O
process NN NN O
called NN NN O
overnight NN NN O
memory NN NN O
consolidation NN NN O
. NN NN O
   
Previous NN NN O
studies NN NN O
indicate NN NN O
that NN NN O
ecstasy NN NN O
users NN NN O
have NN NN O
marked NN NN O
and NN NN O
persistent NN NN O
neurocognitive NN NN O
and NN NN O
sleep NN NN B-Disease
- NN NN I-Disease
related NN NN I-Disease
impairments NN NN I-Disease
. NN NN O
   
We NN NN O
extend NN NN O
past NN NN O
research NN NN O
by NN NN O
examining NN NN O
overnight NN NN O
memory NN NN O
consolidation NN NN O
among NN NN O
regular NN NN O
ecstasy NN NN O
users NN NN O
( NN NN O
n NN NN O
= NN NN O
12 NN NN O
) NN NN O
and NN NN O
drug NN NN O
naive NN NN O
healthy NN NN O
controls NN NN O
( NN NN O
n NN NN O
= NN NN O
26 NN NN O
) NN NN O
. NN NN O
   
Memory NN NN O
recall NN NN O
of NN NN O
word NN NN O
pairs NN NN O
was NN NN O
evaluated NN NN O
before NN NN O
and NN NN O
after NN NN O
a NN NN O
period NN NN O
of NN NN O
sleep NN NN O
, NN NN O
with NN NN O
and NN NN O
without NN NN O
interference NN NN O
prior NN NN O
to NN NN O
testing NN NN O
. NN NN O
   
In NN NN O
addition NN NN O
, NN NN O
we NN NN O
assessed NN NN O
neurocognitive NN NN O
performances NN NN O
across NN NN O
tasks NN NN O
of NN NN O
learning NN NN O
, NN NN O
memory NN NN O
and NN NN O
executive NN NN O
functioning NN NN O
. NN NN O
   
Ecstasy NN NN O
users NN NN O
demonstrated NN NN O
impaired NN NN B-Disease
overnight NN NN I-Disease
memory NN NN I-Disease
consolidation NN NN O
, NN NN O
a NN NN O
finding NN NN O
that NN NN O
was NN NN O
more NN NN O
pronounced NN NN O
following NN NN O
associative NN NN O
interference NN NN O
. NN NN O
   
Additionally NN NN O
, NN NN O
ecstasy NN NN O
users NN NN O
demonstrated NN NN O
impairments NN NN O
on NN NN O
tasks NN NN O
recruiting NN NN O
frontostriatal NN NN O
and NN NN O
hippocampal NN NN O
neural NN NN O
circuitry NN NN O
, NN NN O
in NN NN O
the NN NN O
domains NN NN O
of NN NN O
proactive NN NN O
interference NN NN O
memory NN NN O
, NN NN O
long NN NN O
- NN NN O
term NN NN O
memory NN NN O
, NN NN O
encoding NN NN O
, NN NN O
working NN NN O
memory NN NN O
and NN NN O
complex NN NN O
planning NN NN O
. NN NN O
   
We NN NN O
suggest NN NN O
that NN NN O
ecstasy NN NN O
- NN NN O
associated NN NN O
dysfunction NN NN O
in NN NN O
fronto NN NN O
- NN NN O
temporal NN NN O
circuitry NN NN O
may NN NN O
underlie NN NN O
overnight NN NN O
consolidation NN NN O
memory NN NN B-Disease
impairments NN NN I-Disease
in NN NN O
regular NN NN O
ecstasy NN NN O
users NN NN O
. NN NN O
   
Normoammonemic NN NN O
encephalopathy NN NN B-Disease
: NN NN O
solely NN NN O
valproate NN NN O
induced NN NN O
or NN NN O
multiple NN NN O
mechanisms NN NN O
? NN NN O
   
A NN NN O
77 NN NN O
- NN NN O
year NN NN O
- NN NN O
old NN NN O
woman NN NN O
presented NN NN O
with NN NN O
subacute NN NN O
onset NN NN O
progressive NN NN O
confusion NN NN B-Disease
, NN NN O
aggression NN NN B-Disease
, NN NN O
auditory NN NN B-Disease
hallucinations NN NN I-Disease
and NN NN O
delusions NN NN B-Disease
. NN NN O
   
In NN NN O
the NN NN O
preceding NN NN O
months NN NN O
, NN NN O
the NN NN O
patient NN NN O
had NN NN O
a NN NN O
number NN NN O
of NN NN O
admissions NN NN O
with NN NN O
transient NN NN O
unilateral NN NN O
hemiparesis NN NN B-Disease
with NN NN O
facial NN NN O
droop NN NN O
, NN NN O
and NN NN O
had NN NN O
been NN NN O
started NN NN O
on NN NN O
valproate NN NN O
for NN NN O
presumed NN NN O
hemiplegic NN NN B-Disease
migraine NN NN I-Disease
. NN NN O
   
Valproate NN NN O
was NN NN O
withdrawn NN NN O
soon NN NN O
after NN NN O
admission NN NN O
and NN NN O
her NN NN O
cognitive NN NN O
abilities NN NN O
have NN NN O
gradually NN NN O
improved NN NN O
over NN NN O
3 NN NN O
months NN NN O
of NN NN O
follow NN NN O
- NN NN O
up NN NN O
. NN NN O
   
Valproate NN NN O
levels NN NN O
taken NN NN O
prior NN NN O
to NN NN O
withdrawal NN NN O
were NN NN O
subtherapeutic NN NN O
and NN NN O
the NN NN O
patient NN NN O
was NN NN O
normoammonaemic NN NN O
. NN NN O
   
EEG NN NN O
undertaken NN NN O
during NN NN O
inpatient NN NN O
stay NN NN O
showed NN NN O
changes NN NN O
consistent NN NN O
with NN NN O
encephalopathy NN NN B-Disease
, NN NN O
and NN NN O
low NN NN O
titre NN NN O
N NN NN O
- NN NN O
methyl NN NN O
- NN NN O
D NN NN O
- NN NN O
aspartate NN NN O
( NN NN O
NMDA NN NN O
) NN NN O
receptor NN NN O
antibodies NN NN O
were NN NN O
present NN NN O
in NN NN O
this NN NN O
patient NN NN O
. NN NN O
   
The NN NN O
possible NN NN O
aetiologies NN NN O
of NN NN O
valproate NN NN O
- NN NN O
induced NN NN O
encephalopathy NN NN B-Disease
and NN NN O
NMDA NN NN O
receptor NN NN O
- NN NN O
associated NN NN O
encephalitis NN NN B-Disease
present NN NN O
a NN NN O
diagnostic NN NN O
dilemma NN NN O
. NN NN O
   
We NN NN O
present NN NN O
a NN NN O
putative NN NN O
combinatorial NN NN O
hypothesis NN NN O
to NN NN O
explain NN NN O
this NN NN O
patient NN NN O
' NN NN O
s NN NN O
symptoms NN NN O
. NN NN O
   
Cerebellar NN NN B-Disease
and NN NN I-Disease
oculomotor NN NN I-Disease
dysfunction NN NN I-Disease
induced NN NN O
by NN NN O
rapid NN NN O
infusion NN NN O
of NN NN O
pethidine NN NN O
. NN NN O
   
Pethidine NN NN O
is NN NN O
an NN NN O
opioid NN NN O
that NN NN O
gains NN NN O
its NN NN O
popularity NN NN O
for NN NN O
the NN NN O
effective NN NN O
pain NN NN B-Disease
control NN NN O
through NN NN O
acting NN NN O
on NN NN O
the NN NN O
opioid NN NN O
- NN NN O
receptors NN NN O
. NN NN O
   
However NN NN O
, NN NN O
rapid NN NN O
pain NN NN B-Disease
relief NN NN O
sometimes NN NN O
brings NN NN O
about NN NN O
unfavourable NN NN O
side NN NN O
effects NN NN O
that NN NN O
largely NN NN O
limit NN NN O
its NN NN O
clinical NN NN O
utility NN NN O
. NN NN O
   
Common NN NN O
side NN NN O
effects NN NN O
include NN NN O
nausea NN NN B-Disease
, NN NN O
vomiting NN NN B-Disease
and NN NN O
hypotension NN NN B-Disease
. NN NN O
   
In NN NN O
patients NN NN O
with NN NN O
impaired NN NN B-Disease
renal NN NN I-Disease
and NN NN I-Disease
liver NN NN I-Disease
function NN NN I-Disease
, NN NN O
and NN NN O
those NN NN O
who NN NN O
need NN NN O
long NN NN O
- NN NN O
term NN NN O
pain NN NN B-Disease
control NN NN O
, NN NN O
pethidine NN NN O
may NN NN O
cause NN NN O
excitatory NN NN O
central NN NN O
nervous NN NN O
system NN NN O
( NN NN O
CNS NN NN O
) NN NN O
effects NN NN O
through NN NN O
its NN NN O
neurotoxic NN NN B-Disease
metabolite NN NN O
, NN NN O
norpethidine NN NN O
, NN NN O
resulting NN NN O
in NN NN O
irritability NN NN B-Disease
and NN NN O
seizure NN NN B-Disease
attack NN NN O
. NN NN O
   
On NN NN O
the NN NN O
contrary NN NN O
, NN NN O
though NN NN O
not NN NN O
clinically NN NN O
apparent NN NN O
, NN NN O
pethidine NN NN O
potentially NN NN O
causes NN NN O
inhibitory NN NN O
impacts NN NN O
on NN NN O
the NN NN O
CNS NN NN O
and NN NN O
impairs NN NN O
normal NN NN O
cerebellar NN NN O
and NN NN O
oculomotor NN NN O
function NN NN O
in NN NN O
the NN NN O
short NN NN O
term NN NN O
. NN NN O
   
In NN NN O
this NN NN O
case NN NN O
report NN NN O
, NN NN O
we NN NN O
highlight NN NN O
opioid NN NN O
' NN NN O
s NN NN O
inhibitory NN NN O
side NN NN O
effects NN NN O
on NN NN O
the NN NN O
cerebellar NN NN O
structure NN NN O
that NN NN O
causes NN NN O
dysmetria NN NN B-Disease
, NN NN O
dysarthria NN NN B-Disease
, NN NN O
reduced NN NN O
smooth NN NN O
pursuit NN NN O
gain NN NN O
and NN NN O
decreased NN NN O
saccadic NN NN O
velocity NN NN O
. NN NN O
   
Baboon NN NN B-Disease
syndrome NN NN I-Disease
induced NN NN O
by NN NN O
ketoconazole NN NN O
. NN NN O
   
A NN NN O
27 NN NN O
- NN NN O
year NN NN O
- NN NN O
old NN NN O
male NN NN O
patient NN NN O
presented NN NN O
with NN NN O
a NN NN O
maculopapular NN NN B-Disease
eruption NN NN I-Disease
on NN NN O
the NN NN O
flexural NN NN O
areas NN NN O
and NN NN O
buttocks NN NN O
after NN NN O
using NN NN O
oral NN NN O
ketoconazole NN NN O
. NN NN O
   
The NN NN O
patient NN NN O
was NN NN O
diagnosed NN NN O
with NN NN O
drug NN NN O
- NN NN O
induced NN NN O
baboon NN NN B-Disease
syndrome NN NN I-Disease
based NN NN O
on NN NN O
his NN NN O
history NN NN O
, NN NN O
which NN NN O
included NN NN O
prior NN NN O
sensitivity NN NN O
to NN NN O
topical NN NN O
ketoconazole NN NN O
, NN NN O
a NN NN O
physical NN NN O
examination NN NN O
, NN NN O
and NN NN O
histopathological NN NN O
findings NN NN O
. NN NN O
   
Baboon NN NN B-Disease
syndrome NN NN I-Disease
is NN NN O
a NN NN O
drug NN NN O
- NN NN O
or NN NN O
contact NN NN O
allergen NN NN O
- NN NN O
related NN NN O
maculopapular NN NN B-Disease
eruption NN NN I-Disease
that NN NN O
typically NN NN O
involves NN NN O
the NN NN O
flexural NN NN O
and NN NN O
gluteal NN NN O
areas NN NN O
. NN NN O
   
To NN NN O
the NN NN O
best NN NN O
of NN NN O
our NN NN O
knowledge NN NN O
, NN NN O
this NN NN O
is NN NN O
the NN NN O
first NN NN O
reported NN NN O
case NN NN O
of NN NN O
ketoconazole NN NN O
- NN NN O
induced NN NN O
baboon NN NN B-Disease
syndrome NN NN I-Disease
in NN NN O
the NN NN O
English NN NN O
literature NN NN O
. NN NN O
   
A NN NN O
Case NN NN O
of NN NN O
Sudden NN NN B-Disease
Cardiac NN NN I-Disease
Death NN NN I-Disease
due NN NN O
to NN NN O
Pilsicainide NN NN O
- NN NN O
Induced NN NN O
Torsades NN NN B-Disease
de NN NN I-Disease
Pointes NN NN I-Disease
. NN NN O
   
An NN NN O
84 NN NN O
- NN NN O
year NN NN O
- NN NN O
old NN NN O
male NN NN O
received NN NN O
oral NN NN O
pilsicainide NN NN O
, NN NN O
a NN NN O
pure NN NN O
sodium NN NN O
channel NN NN O
blocker NN NN O
with NN NN O
slow NN NN O
recovery NN NN O
kinetics NN NN O
, NN NN O
to NN NN O
convert NN NN O
his NN NN O
paroxysmal NN NN O
atrial NN NN B-Disease
fibrillation NN NN I-Disease
to NN NN O
a NN NN O
sinus NN NN O
rhythm NN NN O
; NN NN O
the NN NN O
patient NN NN O
developed NN NN O
sudden NN NN B-Disease
cardiac NN NN I-Disease
death NN NN I-Disease
two NN NN O
days NN NN O
later NN NN O
. NN NN O
   
The NN NN O
Holter NN NN O
electrocardiogram NN NN O
, NN NN O
which NN NN O
was NN NN O
worn NN NN O
by NN NN O
chance NN NN O
, NN NN O
revealed NN NN O
torsade NN NN B-Disease
de NN NN I-Disease
pointes NN NN I-Disease
with NN NN O
gradually NN NN O
prolonged NN NN O
QT NN NN O
intervals NN NN O
. NN NN O
   
This NN NN O
drug NN NN O
is NN NN O
rapidly NN NN O
absorbed NN NN O
from NN NN O
the NN NN O
gastrointestinal NN NN O
tract NN NN O
, NN NN O
and NN NN O
most NN NN O
of NN NN O
it NN NN O
is NN NN O
excreted NN NN O
from NN NN O
the NN NN O
kidney NN NN O
. NN NN O
   
Although NN NN O
the NN NN O
patient NN NN O
' NN NN O
s NN NN O
renal NN NN O
function NN NN O
was NN NN O
not NN NN O
highly NN NN O
impaired NN NN O
and NN NN O
the NN NN O
dose NN NN O
of NN NN O
pilsicainide NN NN O
was NN NN O
low NN NN O
, NN NN O
the NN NN O
plasma NN NN O
concentration NN NN O
of NN NN O
pilsicainide NN NN O
may NN NN O
have NN NN O
been NN NN O
high NN NN O
, NN NN O
which NN NN O
can NN NN O
produce NN NN O
torsades NN NN B-Disease
de NN NN I-Disease
pointes NN NN I-Disease
in NN NN O
the NN NN O
octogenarian NN NN O
. NN NN O
   
Although NN NN O
the NN NN O
oral NN NN O
administration NN NN O
of NN NN O
class NN NN O
IC NN NN O
drugs NN NN O
, NN NN O
including NN NN O
pilsicainide NN NN O
, NN NN O
is NN NN O
effective NN NN O
to NN NN O
terminate NN NN O
atrial NN NN B-Disease
fibrillation NN NN I-Disease
, NN NN O
careful NN NN O
consideration NN NN O
must NN NN O
be NN NN O
taken NN NN O
before NN NN O
giving NN NN O
these NN NN O
drugs NN NN O
to NN NN O
octogenarians NN NN O
. NN NN O
   
All NN NN O
- NN NN O
trans NN NN O
retinoic NN NN O
acid NN NN O
- NN NN O
induced NN NN O
inflammatory NN NN O
myositis NN NN B-Disease
in NN NN O
a NN NN O
patient NN NN O
with NN NN O
acute NN NN B-Disease
promyelocytic NN NN I-Disease
leukemia NN NN I-Disease
. NN NN O
   
All NN NN O
- NN NN O
trans NN NN O
retinoic NN NN O
acid NN NN O
( NN NN O
ATRA NN NN O
) NN NN O
, NN NN O
a NN NN O
component NN NN O
of NN NN O
standard NN NN O
therapy NN NN O
for NN NN O
acute NN NN B-Disease
promyelocytic NN NN I-Disease
leukemia NN NN I-Disease
( NN NN O
APL NN NN B-Disease
) NN NN O
, NN NN O
is NN NN O
associated NN NN O
with NN NN O
potentially NN NN O
serious NN NN O
but NN NN O
treatable NN NN O
adverse NN NN O
effects NN NN O
involving NN NN O
numerous NN NN O
organ NN NN O
systems NN NN O
, NN NN O
including NN NN O
rare NN NN O
skeletal NN NN O
muscle NN NN O
involvement NN NN O
. NN NN O
   
Only NN NN O
a NN NN O
handful NN NN O
of NN NN O
cases NN NN O
of NN NN O
ATRA NN NN O
- NN NN O
induced NN NN O
myositis NN NN B-Disease
in NN NN O
children NN NN O
have NN NN O
been NN NN O
reported NN NN O
, NN NN O
and NN NN O
none NN NN O
in NN NN O
the NN NN O
radiology NN NN O
literature NN NN O
. NN NN O
   
We NN NN O
present NN NN O
such NN NN O
a NN NN O
case NN NN O
in NN NN O
a NN NN O
15 NN NN O
- NN NN O
year NN NN O
- NN NN O
old NN NN O
boy NN NN O
with NN NN O
APL NN NN B-Disease
, NN NN O
where NN NN O
recognition NN NN O
of NN NN O
imaging NN NN O
findings NN NN O
played NN NN O
a NN NN O
crucial NN NN O
role NN NN O
in NN NN O
making NN NN O
the NN NN O
diagnosis NN NN O
and NN NN O
facilitated NN NN O
prompt NN NN O
, NN NN O
effective NN NN O
treatment NN NN O
. NN NN O
   
Tolerability NN NN O
of NN NN O
lomustine NN NN O
in NN NN O
combination NN NN O
with NN NN O
cyclophosphamide NN NN O
in NN NN O
dogs NN NN O
with NN NN O
lymphoma NN NN B-Disease
. NN NN O
   
This NN NN O
retrospective NN NN O
study NN NN O
describes NN NN O
toxicity NN NN B-Disease
associated NN NN O
with NN NN O
a NN NN O
protocol NN NN O
of NN NN O
lomustine NN NN O
( NN NN O
CCNU NN NN O
) NN NN O
and NN NN O
cyclophosphamide NN NN O
( NN NN O
CTX NN NN O
) NN NN O
in NN NN O
dogs NN NN O
with NN NN O
lymphoma NN NN B-Disease
. NN NN O
   
CCNU NN NN O
was NN NN O
administered NN NN O
per NN NN O
os NN NN O
( NN NN O
PO NN NN O
) NN NN O
at NN NN O
a NN NN O
targeted NN NN O
dosage NN NN O
of NN NN O
60 NN NN O
mg NN NN O
/ NN NN O
m NN NN O
( NN NN O
2 NN NN O
) NN NN O
body NN NN O
surface NN NN O
area NN NN O
on NN NN O
day NN NN O
0 NN NN O
, NN NN O
CTX NN NN O
was NN NN O
administered NN NN O
PO NN NN O
at NN NN O
a NN NN O
targeted NN NN O
dosage NN NN O
of NN NN O
250 NN NN O
mg NN NN O
/ NN NN O
m NN NN O
( NN NN O
2 NN NN O
) NN NN O
divided NN NN O
over NN NN O
days NN NN O
0 NN NN O
through NN NN O
4 NN NN O
, NN NN O
and NN NN O
all NN NN O
dogs NN NN O
received NN NN O
prophylactic NN NN O
antibiotics NN NN O
. NN NN O
   
Ninety NN NN O
treatments NN NN O
were NN NN O
given NN NN O
to NN NN O
the NN NN O
57 NN NN O
dogs NN NN O
included NN NN O
in NN NN O
the NN NN O
study NN NN O
. NN NN O
   
Neutropenia NN NN B-Disease
was NN NN O
the NN NN O
principal NN NN O
toxic NN NN O
effect NN NN O
, NN NN O
and NN NN O
the NN NN O
overall NN NN O
frequency NN NN O
of NN NN O
grade NN NN O
4 NN NN O
neutropenia NN NN B-Disease
after NN NN O
the NN NN O
first NN NN O
treatment NN NN O
of NN NN O
CCNU NN NN O
/ NN NN O
CTX NN NN O
was NN NN O
30 NN NN O
% NN NN O
( NN NN O
95 NN NN O
% NN NN O
confidence NN NN O
interval NN NN O
, NN NN O
19 NN NN O
- NN NN O
43 NN NN O
% NN NN O
) NN NN O
. NN NN O
   
The NN NN O
mean NN NN O
body NN NN O
weight NN NN O
of NN NN O
dogs NN NN O
with NN NN O
grade NN NN O
4 NN NN O
neutropenia NN NN B-Disease
( NN NN O
19 NN NN O
. NN NN O
7 NN NN O
kg NN NN O
+ NN NN O
13 NN NN O
. NN NN O
4 NN NN O
kg NN NN O
) NN NN O
was NN NN O
significantly NN NN O
less NN NN O
than NN NN O
the NN NN O
mean NN NN O
body NN NN O
weight NN NN O
of NN NN O
dogs NN NN O
that NN NN O
did NN NN O
not NN NN O
develop NN NN O
grade NN NN O
4 NN NN O
neutropenia NN NN B-Disease
( NN NN O
31 NN NN O
. NN NN O
7 NN NN O
kg NN NN O
+ NN NN O
12 NN NN O
. NN NN O
4 NN NN O
kg NN NN O
; NN NN O
P NN NN O
= NN NN O
. NN NN O
005 NN NN O
) NN NN O
. NN NN O
   
One NN NN O
dog NN NN O
( NN NN O
3 NN NN O
% NN NN O
) NN NN O
developed NN NN O
hematologic NN NN O
changes NN NN O
suggestive NN NN O
of NN NN O
hepatotoxicity NN NN B-Disease
. NN NN O
   
No NN NN O
dogs NN NN O
had NN NN O
evidence NN NN O
of NN NN O
either NN NN O
renal NN NN B-Disease
toxicity NN NN I-Disease
or NN NN O
hemorrhagic NN NN B-Disease
cystitis NN NN I-Disease
. NN NN O
   
Adverse NN NN O
gastrointestinal NN NN O
effects NN NN O
were NN NN O
uncommon NN NN O
. NN NN O
   
On NN NN O
the NN NN O
basis NN NN O
of NN NN O
the NN NN O
findings NN NN O
reported NN NN O
herein NN NN O
, NN NN O
a NN NN O
dose NN NN O
of NN NN O
60 NN NN O
mg NN NN O
/ NN NN O
m NN NN O
( NN NN O
2 NN NN O
) NN NN O
of NN NN O
CCNU NN NN O
combined NN NN O
with NN NN O
250 NN NN O
mg NN NN O
/ NN NN O
m NN NN O
( NN NN O
2 NN NN O
) NN NN O
of NN NN O
CTX NN NN O
( NN NN O
divided NN NN O
over NN NN O
5 NN NN O
days NN NN O
) NN NN O
q NN NN O
4 NN NN O
wk NN NN O
is NN NN O
tolerable NN NN O
in NN NN O
tumor NN NN B-Disease
- NN NN O
bearing NN NN O
dogs NN NN O
. NN NN O
   
Nelarabine NN NN O
neurotoxicity NN NN B-Disease
with NN NN O
concurrent NN NN O
intrathecal NN NN O
chemotherapy NN NN O
: NN NN O
Case NN NN O
report NN NN O
and NN NN O
review NN NN O
of NN NN O
literature NN NN O
. NN NN O
   
Severe NN NN O
nelarabine NN NN O
neurotoxicity NN NN B-Disease
in NN NN O
a NN NN O
patient NN NN O
who NN NN O
received NN NN O
concurrent NN NN O
intrathecal NN NN O
( NN NN O
IT NN NN O
) NN NN O
chemotherapy NN NN O
is NN NN O
reported NN NN O
. NN NN O
   
A NN NN O
37 NN NN O
- NN NN O
year NN NN O
- NN NN O
old NN NN O
Caucasian NN NN O
woman NN NN O
with NN NN O
a NN NN O
history NN NN O
of NN NN O
T NN NN B-Disease
- NN NN I-Disease
cell NN NN I-Disease
lymphoblastic NN NN I-Disease
lymphoma NN NN I-Disease
was NN NN O
admitted NN NN O
for NN NN O
relapsed NN NN O
disease NN NN O
. NN NN O
   
She NN NN O
was NN NN O
originally NN NN O
treated NN NN O
with NN NN O
induction NN NN O
chemotherapy NN NN O
followed NN NN O
by NN NN O
an NN NN O
autologous NN NN O
transplant NN NN O
. NN NN O
   
She NN NN O
developed NN NN O
relapsed NN NN O
disease NN NN O
10 NN NN O
months NN NN O
later NN NN O
with NN NN O
leukemic NN NN B-Disease
involvement NN NN O
. NN NN O
   
She NN NN O
was NN NN O
re NN NN O
- NN NN O
induced NN NN O
with NN NN O
nelarabine NN NN O
1500 NN NN O
mg NN NN O
/ NN NN O
m NN NN O
( NN NN O
2 NN NN O
) NN NN O
on NN NN O
days NN NN O
1 NN NN O
, NN NN O
3 NN NN O
, NN NN O
and NN NN O
5 NN NN O
with NN NN O
1 NN NN O
dose NN NN O
of NN NN O
IT NN NN O
cytarabine NN NN O
100 NN NN O
mg NN NN O
on NN NN O
day NN NN O
2 NN NN O
as NN NN O
central NN NN O
nervous NN NN O
system NN NN O
( NN NN O
CNS NN NN O
) NN NN O
prophylaxis NN NN O
. NN NN O
   
At NN NN O
the NN NN O
time NN NN O
of NN NN O
treatment NN NN O
, NN NN O
she NN NN O
was NN NN O
on NN NN O
continuous NN NN O
renal NN NN O
replacement NN NN O
therapy NN NN O
due NN NN O
to NN NN O
sequelae NN NN O
of NN NN O
tumor NN NN B-Disease
lysis NN NN I-Disease
syndrome NN NN I-Disease
( NN NN O
TLS NN NN B-Disease
) NN NN O
. NN NN O
   
She NN NN O
tolerated NN NN O
therapy NN NN O
well NN NN O
, NN NN O
entered NN NN O
a NN NN O
complete NN NN O
remission NN NN O
, NN NN O
and NN NN O
recovered NN NN O
her NN NN O
renal NN NN O
function NN NN O
. NN NN O
   
She NN NN O
received NN NN O
a NN NN O
second NN NN O
cycle NN NN O
of NN NN O
nelarabine NN NN O
without NN NN O
additional NN NN O
IT NN NN O
prophylaxis NN NN O
one NN NN O
month NN NN O
later NN NN O
. NN NN O
   
A NN NN O
week NN NN O
after NN NN O
this NN NN O
second NN NN O
cycle NN NN O
, NN NN O
she NN NN O
noted NN NN O
numbness NN NN O
in NN NN O
her NN NN O
lower NN NN O
extremities NN NN O
. NN NN O
   
Predominantly NN NN O
sensory NN NN O
, NN NN O
though NN NN O
also NN NN O
motor NN NN O
and NN NN O
autonomic NN NN O
, NN NN O
peripheral NN NN B-Disease
neuropathy NN NN I-Disease
started NN NN O
in NN NN O
her NN NN O
feet NN NN O
, NN NN O
ascended NN NN O
proximally NN NN O
to NN NN O
the NN NN O
mid NN NN O
- NN NN O
thoracic NN NN O
region NN NN O
, NN NN O
and NN NN O
eventually NN NN O
included NN NN O
her NN NN O
distal NN NN O
upper NN NN O
extremities NN NN O
. NN NN O
   
A NN NN O
magnetic NN NN O
resonance NN NN O
imaging NN NN O
( NN NN O
MRI NN NN O
) NN NN O
of NN NN O
her NN NN O
spine NN NN O
demonstrated NN NN O
changes NN NN O
from NN NN O
C2 NN NN O
to NN NN O
C6 NN NN O
consistent NN NN O
with NN NN O
subacute NN NN O
combined NN NN O
degeneration NN NN O
. NN NN O
   
Nelarabine NN NN O
was NN NN O
felt NN NN O
to NN NN O
be NN NN O
the NN NN O
cause NN NN O
of NN NN O
her NN NN O
symptoms NN NN O
. NN NN O
   
Her NN NN O
neuropathy NN NN B-Disease
stabilized NN NN O
and NN NN O
showed NN NN O
slight NN NN O
improvement NN NN O
and NN NN O
ultimately NN NN O
received NN NN O
an NN NN O
unrelated NN NN O
, NN NN O
reduced NN NN O
- NN NN O
intensity NN NN O
allogeneic NN NN O
transplant NN NN O
while NN NN O
in NN NN O
complete NN NN O
remission NN NN O
, NN NN O
but NN NN O
relapsed NN NN O
disease NN NN O
10 NN NN O
weeks NN NN O
later NN NN O
. NN NN O
   
She NN NN O
is NN NN O
currently NN NN O
being NN NN O
treated NN NN O
with NN NN O
best NN NN O
supportive NN NN O
care NN NN O
. NN NN O
   
To NN NN O
our NN NN O
knowledge NN NN O
, NN NN O
this NN NN O
is NN NN O
the NN NN O
first NN NN O
published NN NN O
case NN NN O
report NN NN O
of NN NN O
severe NN NN O
neurotoxicity NN NN B-Disease
caused NN NN O
by NN NN O
nelarabine NN NN O
in NN NN O
a NN NN O
patient NN NN O
who NN NN O
received NN NN O
concurrent NN NN O
IT NN NN O
chemotherapy NN NN O
. NN NN O
   
Valproate NN NN O
- NN NN O
induced NN NN O
hyperammonemic NN NN B-Disease
encephalopathy NN NN B-Disease
in NN NN O
a NN NN O
renal NN NN O
transplanted NN NN O
patient NN NN O
. NN NN O
   
Neurological NN NN B-Disease
complications NN NN I-Disease
after NN NN O
renal NN NN O
transplantation NN NN O
constitute NN NN O
an NN NN O
important NN NN O
cause NN NN O
of NN NN O
morbidity NN NN O
and NN NN O
mortality NN NN O
. NN NN O
   
Their NN NN O
differential NN NN O
diagnosis NN NN O
is NN NN O
difficult NN NN O
and NN NN O
essential NN NN O
for NN NN O
subsequent NN NN O
patient NN NN O
' NN NN O
s NN NN O
management NN NN O
. NN NN O
   
Valproate NN NN O
- NN NN O
induced NN NN O
hyperammonemic NN NN B-Disease
encephalopathy NN NN B-Disease
is NN NN O
an NN NN O
uncommon NN NN O
but NN NN O
serious NN NN O
effect NN NN O
of NN NN O
valproate NN NN O
treatment NN NN O
. NN NN O
   
Here NN NN O
, NN NN O
we NN NN O
describe NN NN O
the NN NN O
case NN NN O
of NN NN O
a NN NN O
15 NN NN O
- NN NN O
year NN NN O
- NN NN O
old NN NN O
girl NN NN O
who NN NN O
was NN NN O
on NN NN O
a NN NN O
long NN NN O
- NN NN O
term NN NN O
therapy NN NN O
with NN NN O
valproate NN NN O
due NN NN O
to NN NN O
epilepsy NN NN B-Disease
and NN NN O
revealed NN NN O
impaired NN NN B-Disease
consciousness NN NN I-Disease
with NN NN O
hyperammonemia NN NN B-Disease
12 NN NN O
days NN NN O
after NN NN O
renal NN NN O
transplantation NN NN O
. NN NN O
   
After NN NN O
withdraw NN NN O
of NN NN O
valproate NN NN O
, NN NN O
patients NN NN O
' NN NN O
symptoms NN NN O
resolved NN NN O
within NN NN O
24 NN NN O
h NN NN O
. NN NN O
   
Clinicians NN NN O
should NN NN O
increase NN NN O
their NN NN O
awareness NN NN O
for NN NN O
potential NN NN O
complication NN NN O
of NN NN O
valproate NN NN O
, NN NN O
especially NN NN O
in NN NN O
transplanted NN NN O
patients NN NN O
. NN NN O
   
Necrotising NN NN B-Disease
fasciitis NN NN I-Disease
after NN NN O
bortezomib NN NN O
and NN NN O
dexamethasone NN NN O
- NN NN O
containing NN NN O
regimen NN NN O
in NN NN O
an NN NN O
elderly NN NN O
patient NN NN O
of NN NN O
Waldenstrom NN NN B-Disease
macroglobulinaemia NN NN I-Disease
. NN NN O
   
Bortezomib NN NN O
and NN NN O
high NN NN O
- NN NN O
dose NN NN O
dexamethasone NN NN O
- NN NN O
containing NN NN O
regimens NN NN O
are NN NN O
considered NN NN O
to NN NN O
be NN NN O
generally NN NN O
tolerable NN NN O
with NN NN O
few NN NN O
severe NN NN O
bacterial NN NN B-Disease
infections NN NN I-Disease
in NN NN O
patients NN NN O
with NN NN O
B NN NN O
- NN NN O
cell NN NN O
malignancies NN NN B-Disease
. NN NN O
   
However NN NN O
, NN NN O
information NN NN O
is NN NN O
limited NN NN O
concerning NN NN O
the NN NN O
safety NN NN O
of NN NN O
the NN NN O
regimen NN NN O
in NN NN O
elderly NN NN O
patients NN NN O
. NN NN O
   
We NN NN O
report NN NN O
a NN NN O
case NN NN O
of NN NN O
a NN NN O
76 NN NN O
- NN NN O
year NN NN O
- NN NN O
old NN NN O
man NN NN O
with NN NN O
Waldenstrom NN NN B-Disease
macroglobulinaemia NN NN I-Disease
who NN NN O
suffered NN NN O
necrotising NN NN B-Disease
fasciitis NN NN I-Disease
without NN NN O
neutropenia NN NN B-Disease
after NN NN O
the NN NN O
combination NN NN O
treatment NN NN O
with NN NN O
bortezomib NN NN O
, NN NN O
high NN NN O
- NN NN O
dose NN NN O
dexamethasone NN NN O
and NN NN O
rituximab NN NN O
. NN NN O
   
Despite NN NN O
immediate NN NN O
intravenous NN NN O
antimicrobial NN NN O
therapy NN NN O
, NN NN O
he NN NN O
succumbed NN NN O
23 NN NN O
h NN NN O
after NN NN O
the NN NN O
onset NN NN O
. NN NN O
   
Physicians NN NN O
should NN NN O
recognise NN NN O
the NN NN O
possibility NN NN O
of NN NN O
fatal NN NN O
bacterial NN NN B-Disease
infections NN NN I-Disease
related NN NN O
to NN NN O
bortezomib NN NN O
plus NN NN O
high NN NN O
- NN NN O
dose NN NN O
dexamethasone NN NN O
in NN NN O
elderly NN NN O
patients NN NN O
, NN NN O
and NN NN O
we NN NN O
believe NN NN O
this NN NN O
case NN NN O
warrants NN NN O
further NN NN O
investigation NN NN O
. NN NN O
   
An NN NN O
integrated NN NN O
characterization NN NN O
of NN NN O
serological NN NN O
, NN NN O
pathological NN NN O
, NN NN O
and NN NN O
functional NN NN O
events NN NN O
in NN NN O
doxorubicin NN NN O
- NN NN O
induced NN NN O
cardiotoxicity NN NN B-Disease
. NN NN O
   
Many NN NN O
efficacious NN NN O
cancer NN NN B-Disease
treatments NN NN O
cause NN NN O
significant NN NN O
cardiac NN NN O
morbidity NN NN O
, NN NN O
yet NN NN O
biomarkers NN NN O
or NN NN O
functional NN NN O
indices NN NN O
of NN NN O
early NN NN O
damage NN NN O
, NN NN O
which NN NN O
would NN NN O
allow NN NN O
monitoring NN NN O
and NN NN O
intervention NN NN O
, NN NN O
are NN NN O
lacking NN NN O
. NN NN O
   
In NN NN O
this NN NN O
study NN NN O
, NN NN O
we NN NN O
have NN NN O
utilized NN NN O
a NN NN O
rat NN NN O
model NN NN O
of NN NN O
progressive NN NN O
doxorubicin NN NN O
( NN NN O
DOX NN NN O
) NN NN O
- NN NN O
induced NN NN O
cardiomyopathy NN NN B-Disease
, NN NN O
applying NN NN O
multiple NN NN O
approaches NN NN O
, NN NN O
including NN NN O
cardiac NN NN O
magnetic NN NN O
resonance NN NN O
imaging NN NN O
( NN NN O
MRI NN NN O
) NN NN O
, NN NN O
to NN NN O
provide NN NN O
the NN NN O
most NN NN O
comprehensive NN NN O
characterization NN NN O
to NN NN O
date NN NN O
of NN NN O
the NN NN O
timecourse NN NN O
of NN NN O
serological NN NN O
, NN NN O
pathological NN NN O
, NN NN O
and NN NN O
functional NN NN O
events NN NN O
underlying NN NN O
this NN NN O
toxicity NN NN B-Disease
. NN NN O
   
Hannover NN NN O
Wistar NN NN O
rats NN NN O
were NN NN O
dosed NN NN O
with NN NN O
1 NN NN O
. NN NN O
25 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
DOX NN NN O
weekly NN NN O
for NN NN O
8 NN NN O
weeks NN NN O
followed NN NN O
by NN NN O
a NN NN O
4 NN NN O
week NN NN O
off NN NN O
- NN NN O
dosing NN NN O
"""""""" NN NN O
recovery NN NN O
"""""""" NN NN O
period NN NN O
. NN NN O
   
Electron NN NN O
microscopy NN NN O
of NN NN O
the NN NN O
myocardium NN NN O
revealed NN NN O
subcellular NN NN B-Disease
degeneration NN NN I-Disease
and NN NN O
marked NN NN O
mitochondrial NN NN O
changes NN NN O
after NN NN O
a NN NN O
single NN NN O
dose NN NN O
. NN NN O
   
Histopathological NN NN O
analysis NN NN O
revealed NN NN O
progressive NN NN O
cardiomyocyte NN NN B-Disease
degeneration NN NN I-Disease
, NN NN O
hypertrophy NN NN B-Disease
/ NN NN O
cytomegaly NN NN O
, NN NN O
and NN NN O
extensive NN NN O
vacuolation NN NN O
after NN NN O
two NN NN O
doses NN NN O
. NN NN O
   
Extensive NN NN O
replacement NN NN O
fibrosis NN NN B-Disease
( NN NN O
quantified NN NN O
by NN NN O
Sirius NN NN O
red NN NN O
staining NN NN O
) NN NN O
developed NN NN O
during NN NN O
the NN NN O
off NN NN O
- NN NN O
dosing NN NN O
period NN NN O
. NN NN O
   
Functional NN NN O
indices NN NN O
assessed NN NN O
by NN NN O
cardiac NN NN O
MRI NN NN O
( NN NN O
including NN NN O
left NN NN O
ventricular NN NN O
ejection NN NN O
fraction NN NN O
( NN NN O
LVEF NN NN O
) NN NN O
, NN NN O
cardiac NN NN O
output NN NN O
, NN NN O
and NN NN O
E NN NN O
/ NN NN O
A NN NN O
ratio NN NN O
) NN NN O
declined NN NN O
progressively NN NN O
, NN NN O
reaching NN NN O
statistical NN NN O
significance NN NN O
after NN NN O
two NN NN O
doses NN NN O
and NN NN O
culminating NN NN O
in NN NN O
"""""""" NN NN O
clinical NN NN O
"""""""" NN NN O
LV NN NN B-Disease
dysfunction NN NN I-Disease
by NN NN O
12 NN NN O
weeks NN NN O
. NN NN O
   
Significant NN NN O
increases NN NN O
in NN NN O
peak NN NN O
myocardial NN NN O
contrast NN NN O
enhancement NN NN O
and NN NN O
serological NN NN O
cardiac NN NN O
troponin NN NN O
I NN NN O
( NN NN O
cTnI NN NN O
) NN NN O
emerged NN NN O
after NN NN O
eight NN NN O
doses NN NN O
, NN NN O
importantly NN NN O
preceding NN NN O
the NN NN O
LVEF NN NN O
decline NN NN O
to NN NN O
< NN NN O
50 NN NN O
% NN NN O
. NN NN O
   
Troponin NN NN O
I NN NN O
levels NN NN O
positively NN NN O
correlated NN NN O
with NN NN O
delayed NN NN O
and NN NN O
peak NN NN O
gadolinium NN NN O
contrast NN NN O
enhancement NN NN O
, NN NN O
histopathological NN NN O
grading NN NN O
, NN NN O
and NN NN O
diastolic NN NN B-Disease
dysfunction NN NN I-Disease
. NN NN O
   
In NN NN O
summary NN NN O
, NN NN O
subcellular NN NN O
cardiomyocyte NN NN B-Disease
degeneration NN NN I-Disease
was NN NN O
the NN NN O
earliest NN NN O
marker NN NN O
, NN NN O
followed NN NN O
by NN NN O
progressive NN NN O
functional NN NN O
decline NN NN O
and NN NN O
histopathological NN NN O
manifestations NN NN O
. NN NN O
   
Myocardial NN NN O
contrast NN NN O
enhancement NN NN O
and NN NN O
elevations NN NN O
in NN NN O
cTnI NN NN O
occurred NN NN O
later NN NN O
. NN NN O
   
However NN NN O
, NN NN O
all NN NN O
indices NN NN O
predated NN NN O
"""""""" NN NN O
clinical NN NN O
"""""""" NN NN O
LV NN NN B-Disease
dysfunction NN NN I-Disease
and NN NN O
thus NN NN O
warrant NN NN O
further NN NN O
evaluation NN NN O
as NN NN O
predictive NN NN O
biomarkers NN NN O
. NN NN O
   
Intradermal NN NN O
glutamate NN NN O
and NN NN O
capsaicin NN NN O
injections NN NN O
: NN NN O
intra NN NN O
- NN NN O
and NN NN O
interindividual NN NN O
variability NN NN O
of NN NN O
provoked NN NN O
hyperalgesia NN NN B-Disease
and NN NN O
allodynia NN NN B-Disease
. NN NN O
   
Intradermal NN NN O
injections NN NN O
of NN NN O
glutamate NN NN O
and NN NN O
capsaicin NN NN O
are NN NN O
attractive NN NN O
to NN NN O
use NN NN O
in NN NN O
human NN NN O
experimental NN NN O
pain NN NN B-Disease
models NN NN O
because NN NN O
hyperalgesia NN NN B-Disease
and NN NN O
allodynia NN NN B-Disease
mimic NN NN O
isolated NN NN O
aspects NN NN O
of NN NN O
clinical NN NN O
pain NN NN B-Disease
disorders NN NN I-Disease
. NN NN O
   
The NN NN O
aim NN NN O
of NN NN O
the NN NN O
present NN NN O
study NN NN O
was NN NN O
to NN NN O
investigate NN NN O
the NN NN O
reproducibility NN NN O
of NN NN O
these NN NN O
models NN NN O
. NN NN O
   
Twenty NN NN O
healthy NN NN O
male NN NN O
volunteers NN NN O
( NN NN O
mean NN NN O
age NN NN O
24 NN NN O
years NN NN O
; NN NN O
range NN NN O
18 NN NN O
- NN NN O
38 NN NN O
years NN NN O
) NN NN O
received NN NN O
intradermal NN NN O
injections NN NN O
of NN NN O
glutamate NN NN O
and NN NN O
capsaicin NN NN O
in NN NN O
the NN NN O
volar NN NN O
forearm NN NN O
. NN NN O
   
Magnitudes NN NN O
of NN NN O
secondary NN NN O
pinprick NN NN O
hyperalgesia NN NN B-Disease
and NN NN O
brush NN NN O
- NN NN O
evoked NN NN O
allodynia NN NN B-Disease
were NN NN O
investigated NN NN O
using NN NN O
von NN NN O
Frey NN NN O
filaments NN NN O
( NN NN O
gauges NN NN O
10 NN NN O
, NN NN O
15 NN NN O
, NN NN O
60 NN NN O
and NN NN O
100 NN NN O
g NN NN O
) NN NN O
and NN NN O
brush NN NN O
strokes NN NN O
. NN NN O
   
Areas NN NN O
of NN NN O
secondary NN NN B-Disease
hyperalgesia NN NN I-Disease
and NN NN O
allodynia NN NN B-Disease
were NN NN O
quantified NN NN O
immediately NN NN O
after NN NN O
injection NN NN O
and NN NN O
after NN NN O
15 NN NN O
, NN NN O
30 NN NN O
and NN NN O
60 NN NN O
min NN NN O
. NN NN O
   
Two NN NN O
identical NN NN O
experiments NN NN O
separated NN NN O
by NN NN O
at NN NN O
least NN NN O
7 NN NN O
days NN NN O
were NN NN O
performed NN NN O
. NN NN O
   
Reproducibility NN NN O
across NN NN O
and NN NN O
within NN NN O
volunteers NN NN O
( NN NN O
inter NN NN O
- NN NN O
and NN NN O
intra NN NN O
- NN NN O
individual NN NN O
variation NN NN O
, NN NN O
respectively NN NN O
) NN NN O
was NN NN O
assessed NN NN O
using NN NN O
intraclass NN NN O
correlation NN NN O
coefficient NN NN O
( NN NN O
ICC NN NN O
) NN NN O
and NN NN O
coefficient NN NN O
of NN NN O
variation NN NN O
( NN NN O
CV NN NN O
) NN NN O
. NN NN O
   
Secondary NN NN O
pinprick NN NN O
hyperalgesia NN NN B-Disease
was NN NN O
observed NN NN O
as NN NN O
a NN NN O
marked NN NN O
increase NN NN O
in NN NN O
the NN NN O
visual NN NN O
analogue NN NN O
scale NN NN O
( NN NN O
VAS NN NN O
) NN NN O
response NN NN O
to NN NN O
von NN NN O
Frey NN NN O
gauges NN NN O
60 NN NN O
and NN NN O
100 NN NN O
g NN NN O
( NN NN O
P NN NN O
< NN NN O
0 NN NN O
. NN NN O
001 NN NN O
) NN NN O
after NN NN O
glutamate NN NN O
injection NN NN O
. NN NN O
   
For NN NN O
capsaicin NN NN O
, NN NN O
secondary NN NN O
pinprick NN NN O
hyperalgesia NN NN B-Disease
was NN NN O
detected NN NN O
with NN NN O
all NN NN O
von NN NN O
Frey NN NN O
gauges NN NN O
( NN NN O
P NN NN O
< NN NN O
0 NN NN O
. NN NN O
001 NN NN O
) NN NN O
. NN NN O
   
Glutamate NN NN O
evoked NN NN O
reproducible NN NN O
VAS NN NN O
response NN NN O
to NN NN O
all NN NN O
von NN NN O
Frey NN NN O
gauges NN NN O
( NN NN O
ICC NN NN O
> NN NN O
0 NN NN O
. NN NN O
60 NN NN O
) NN NN O
and NN NN O
brush NN NN O
strokes NN NN O
( NN NN O
ICC NN NN O
> NN NN O
0 NN NN O
. NN NN O
83 NN NN O
) NN NN O
. NN NN O
   
Capsaicin NN NN O
injection NN NN O
was NN NN O
reproducible NN NN O
for NN NN O
secondary NN NN B-Disease
hyperalgesia NN NN I-Disease
( NN NN O
ICC NN NN O
> NN NN O
0 NN NN O
. NN NN O
70 NN NN O
) NN NN O
and NN NN O
allodynia NN NN B-Disease
( NN NN O
ICC NN NN O
> NN NN O
0 NN NN O
. NN NN O
71 NN NN O
) NN NN O
. NN NN O
   
Intra NN NN O
- NN NN O
individual NN NN O
variability NN NN O
was NN NN O
generally NN NN O
lower NN NN O
for NN NN O
the NN NN O
VAS NN NN O
response NN NN O
to NN NN O
von NN NN O
Frey NN NN O
and NN NN O
brush NN NN O
compared NN NN O
with NN NN O
areas NN NN O
of NN NN O
secondary NN NN B-Disease
hyperalgesia NN NN I-Disease
and NN NN O
allodynia NN NN B-Disease
. NN NN O
   
In NN NN O
conclusion NN NN O
, NN NN O
glutamate NN NN O
and NN NN O
capsaicin NN NN O
yield NN NN O
reproducible NN NN O
hyperalgesic NN NN B-Disease
and NN NN O
allodynic NN NN B-Disease
responses NN NN O
, NN NN O
and NN NN O
the NN NN O
present NN NN O
model NN NN O
is NN NN O
well NN NN O
suited NN NN O
for NN NN O
basic NN NN O
research NN NN O
, NN NN O
as NN NN O
well NN NN O
as NN NN O
for NN NN O
assessing NN NN O
the NN NN O
modulation NN NN O
of NN NN O
central NN NN O
phenomena NN NN O
. NN NN O
   
Ocular NN NN O
- NN NN O
specific NN NN O
ER NN NN O
stress NN NN O
reduction NN NN O
rescues NN NN O
glaucoma NN NN B-Disease
in NN NN O
murine NN NN O
glucocorticoid NN NN O
- NN NN O
induced NN NN O
glaucoma NN NN B-Disease
. NN NN O
   
Administration NN NN O
of NN NN O
glucocorticoids NN NN O
induces NN NN O
ocular NN NN B-Disease
hypertension NN NN I-Disease
in NN NN O
some NN NN O
patients NN NN O
. NN NN O
   
If NN NN O
untreated NN NN O
, NN NN O
these NN NN O
patients NN NN O
can NN NN O
develop NN NN O
a NN NN O
secondary NN NN O
glaucoma NN NN B-Disease
that NN NN O
resembles NN NN O
primary NN NN B-Disease
open NN NN I-Disease
- NN NN I-Disease
angle NN NN I-Disease
glaucoma NN NN I-Disease
( NN NN O
POAG NN NN B-Disease
) NN NN O
. NN NN O
   
The NN NN O
underlying NN NN O
pathology NN NN O
of NN NN O
glucocorticoid NN NN O
- NN NN O
induced NN NN O
glaucoma NN NN B-Disease
is NN NN O
not NN NN O
fully NN NN O
understood NN NN O
, NN NN O
due NN NN O
in NN NN O
part NN NN O
to NN NN O
lack NN NN O
of NN NN O
an NN NN O
appropriate NN NN O
animal NN NN O
model NN NN O
. NN NN O
   
Here NN NN O
, NN NN O
we NN NN O
developed NN NN O
a NN NN O
murine NN NN O
model NN NN O
of NN NN O
glucocorticoid NN NN O
- NN NN O
induced NN NN O
glaucoma NN NN B-Disease
that NN NN O
exhibits NN NN O
glaucoma NN NN B-Disease
features NN NN O
that NN NN O
are NN NN O
observed NN NN O
in NN NN O
patients NN NN O
. NN NN O
   
Treatment NN NN O
of NN NN O
WT NN NN O
mice NN NN O
with NN NN O
topical NN NN O
ocular NN NN O
0 NN NN O
. NN NN O
1 NN NN O
% NN NN O
dexamethasone NN NN O
led NN NN O
to NN NN O
elevation NN NN O
of NN NN O
intraocular NN NN O
pressure NN NN O
( NN NN O
IOP NN NN O
) NN NN O
, NN NN O
functional NN NN O
and NN NN O
structural NN NN O
loss NN NN O
of NN NN O
retinal NN NN B-Disease
ganglion NN NN I-Disease
cells NN NN O
, NN NN O
and NN NN O
axonal NN NN B-Disease
degeneration NN NN I-Disease
, NN NN O
resembling NN NN O
glucocorticoid NN NN O
- NN NN O
induced NN NN O
glaucoma NN NN B-Disease
in NN NN O
human NN NN O
patients NN NN O
. NN NN O
   
Furthermore NN NN O
, NN NN O
dexamethasone NN NN O
- NN NN O
induced NN NN O
ocular NN NN B-Disease
hypertension NN NN I-Disease
was NN NN O
associated NN NN O
with NN NN O
chronic NN NN O
ER NN NN O
stress NN NN O
of NN NN O
the NN NN O
trabecular NN NN O
meshwork NN NN O
( NN NN O
TM NN NN O
) NN NN O
. NN NN O
   
Similar NN NN O
to NN NN O
patients NN NN O
, NN NN O
withdrawal NN NN O
of NN NN O
dexamethasone NN NN O
treatment NN NN O
reduced NN NN O
elevated NN NN O
IOP NN NN O
and NN NN O
ER NN NN O
stress NN NN O
in NN NN O
this NN NN O
animal NN NN O
model NN NN O
. NN NN O
   
Dexamethasone NN NN O
induced NN NN O
the NN NN O
transcriptional NN NN O
factor NN NN O
CHOP NN NN O
, NN NN O
a NN NN O
marker NN NN O
for NN NN O
chronic NN NN O
ER NN NN O
stress NN NN O
, NN NN O
in NN NN O
the NN NN O
anterior NN NN O
segment NN NN O
tissues NN NN O
, NN NN O
and NN NN O
Chop NN NN O
deletion NN NN O
reduced NN NN O
ER NN NN O
stress NN NN O
in NN NN O
these NN NN O
tissues NN NN O
and NN NN O
prevented NN NN O
dexamethasone NN NN O
- NN NN O
induced NN NN O
ocular NN NN B-Disease
hypertension NN NN I-Disease
. NN NN O
   
Furthermore NN NN O
, NN NN O
reduction NN NN O
of NN NN O
ER NN NN O
stress NN NN O
in NN NN O
the NN NN O
TM NN NN O
with NN NN O
sodium NN NN O
4 NN NN O
- NN NN O
phenylbutyrate NN NN O
prevented NN NN O
dexamethasone NN NN O
- NN NN O
induced NN NN O
ocular NN NN B-Disease
hypertension NN NN I-Disease
in NN NN O
WT NN NN O
mice NN NN O
. NN NN O
   
Our NN NN O
data NN NN O
indicate NN NN O
that NN NN O
ER NN NN O
stress NN NN O
contributes NN NN O
to NN NN O
glucocorticoid NN NN O
- NN NN O
induced NN NN O
ocular NN NN B-Disease
hypertension NN NN I-Disease
and NN NN O
suggest NN NN O
that NN NN O
reducing NN NN O
ER NN NN O
stress NN NN O
has NN NN O
potential NN NN O
as NN NN O
a NN NN O
therapeutic NN NN O
strategy NN NN O
for NN NN O
treating NN NN O
glucocorticoid NN NN O
- NN NN O
induced NN NN O
glaucoma NN NN B-Disease
. NN NN O
   
Effects NN NN O
of NN NN O
ginsenosides NN NN O
on NN NN O
opioid NN NN O
- NN NN O
induced NN NN O
hyperalgesia NN NN B-Disease
in NN NN O
mice NN NN O
. NN NN O
   
Opioid NN NN O
- NN NN O
induced NN NN O
hyperalgesia NN NN B-Disease
( NN NN O
OIH NN NN B-Disease
) NN NN O
is NN NN O
characterized NN NN O
by NN NN O
nociceptive NN NN O
sensitization NN NN O
caused NN NN O
by NN NN O
the NN NN O
cessation NN NN O
of NN NN O
chronic NN NN O
opioid NN NN O
use NN NN O
. NN NN O
   
OIH NN NN B-Disease
can NN NN O
limit NN NN O
the NN NN O
clinical NN NN O
use NN NN O
of NN NN O
opioid NN NN O
analgesics NN NN O
and NN NN O
complicate NN NN O
withdrawal NN NN O
from NN NN O
opioid NN NN B-Disease
addiction NN NN I-Disease
. NN NN O
   
In NN NN O
this NN NN O
study NN NN O
, NN NN O
we NN NN O
investigated NN NN O
the NN NN O
effects NN NN O
of NN NN O
Re NN NN O
, NN NN O
Rg1 NN NN O
, NN NN O
and NN NN O
Rb1 NN NN O
ginsenosides NN NN O
, NN NN O
the NN NN O
bioactive NN NN O
components NN NN O
of NN NN O
ginseng NN NN O
, NN NN O
on NN NN O
OIH NN NN B-Disease
. NN NN O
   
OIH NN NN B-Disease
was NN NN O
achieved NN NN O
in NN NN O
mice NN NN O
after NN NN O
subcutaneous NN NN O
administration NN NN O
of NN NN O
morphine NN NN O
for NN NN O
7 NN NN O
consecutive NN NN O
days NN NN O
three NN NN O
times NN NN O
per NN NN O
day NN NN O
. NN NN O
   
During NN NN O
withdrawal NN NN O
( NN NN O
days NN NN O
8 NN NN O
and NN NN O
9 NN NN O
) NN NN O
, NN NN O
these NN NN O
mice NN NN O
were NN NN O
administered NN NN O
Re NN NN O
, NN NN O
Rg1 NN NN O
, NN NN O
or NN NN O
Rb1 NN NN O
intragastrically NN NN O
two NN NN O
times NN NN O
per NN NN O
day NN NN O
. NN NN O
   
On NN NN O
the NN NN O
test NN NN O
day NN NN O
( NN NN O
day NN NN O
10 NN NN O
) NN NN O
, NN NN O
mice NN NN O
were NN NN O
subjected NN NN O
to NN NN O
the NN NN O
thermal NN NN O
sensitivity NN NN O
test NN NN O
and NN NN O
the NN NN O
acetic NN NN O
acid NN NN O
- NN NN O
induced NN NN O
writhing NN NN O
test NN NN O
. NN NN O
   
Re NN NN O
( NN NN O
300 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
) NN NN O
inhibited NN NN O
OIH NN NN B-Disease
in NN NN O
both NN NN O
the NN NN O
thermal NN NN O
sensitivity NN NN O
test NN NN O
and NN NN O
the NN NN O
acetic NN NN O
acid NN NN O
- NN NN O
induced NN NN O
writhing NN NN O
test NN NN O
. NN NN O
   
However NN NN O
, NN NN O
the NN NN O
Rg1 NN NN O
and NN NN O
Rb1 NN NN O
ginsenosides NN NN O
failed NN NN O
to NN NN O
prevent NN NN O
OIH NN NN B-Disease
in NN NN O
either NN NN O
test NN NN O
. NN NN O
   
Furthermore NN NN O
, NN NN O
Rg1 NN NN O
showed NN NN O
a NN NN O
tendency NN NN O
to NN NN O
aggravate NN NN O
OIH NN NN B-Disease
in NN NN O
the NN NN O
acetic NN NN O
acid NN NN O
- NN NN O
induced NN NN O
writhing NN NN O
test NN NN O
. NN NN O
   
Our NN NN O
data NN NN O
suggested NN NN O
that NN NN O
the NN NN O
ginsenoside NN NN O
Re NN NN O
, NN NN O
but NN NN O
not NN NN O
Rg1 NN NN O
or NN NN O
Rb1 NN NN O
, NN NN O
may NN NN O
contribute NN NN O
toward NN NN O
reversal NN NN O
of NN NN O
OIH NN NN B-Disease
. NN NN O
   
A NN NN O
comparison NN NN O
of NN NN O
severe NN NN O
hemodynamic NN NN O
disturbances NN NN O
between NN NN O
dexmedetomidine NN NN O
and NN NN O
propofol NN NN O
for NN NN O
sedation NN NN O
in NN NN O
neurocritical NN NN O
care NN NN O
patients NN NN O
. NN NN O
   
OBJECTIVE NN NN O
: NN NN O
Dexmedetomidine NN NN O
and NN NN O
propofol NN NN O
are NN NN O
commonly NN NN O
used NN NN O
sedatives NN NN O
in NN NN O
neurocritical NN NN O
care NN NN O
as NN NN O
they NN NN O
allow NN NN O
for NN NN O
frequent NN NN O
neurologic NN NN O
examinations NN NN O
. NN NN O
   
However NN NN O
, NN NN O
both NN NN O
agents NN NN O
are NN NN O
associated NN NN O
with NN NN O
significant NN NN O
hemodynamic NN NN O
side NN NN O
effects NN NN O
. NN NN O
   
The NN NN O
primary NN NN O
objective NN NN O
of NN NN O
this NN NN O
study NN NN O
is NN NN O
to NN NN O
compare NN NN O
the NN NN O
prevalence NN NN O
of NN NN O
severe NN NN O
hemodynamic NN NN O
effects NN NN O
in NN NN O
neurocritical NN NN O
care NN NN O
patients NN NN O
receiving NN NN O
dexmedetomidine NN NN O
and NN NN O
propofol NN NN O
. NN NN O
   
DESIGN NN NN O
: NN NN O
Multicenter NN NN O
, NN NN O
retrospective NN NN O
, NN NN O
propensity NN NN O
- NN NN O
matched NN NN O
cohort NN NN O
study NN NN O
. NN NN O
   
SETTING NN NN O
: NN NN O
Neurocritical NN NN O
care NN NN O
units NN NN O
at NN NN O
two NN NN O
academic NN NN O
medical NN NN O
centers NN NN O
with NN NN O
dedicated NN NN O
neurocritical NN NN O
care NN NN O
teams NN NN O
and NN NN O
board NN NN O
- NN NN O
certified NN NN O
neurointensivists NN NN O
. NN NN O
   
PATIENTS NN NN O
: NN NN O
Neurocritical NN NN O
care NN NN O
patients NN NN O
admitted NN NN O
between NN NN O
July NN NN O
2009 NN NN O
and NN NN O
September NN NN O
2012 NN NN O
were NN NN O
evaluated NN NN O
and NN NN O
then NN NN O
matched NN NN O
1 NN NN O
: NN NN O
1 NN NN O
based NN NN O
on NN NN O
propensity NN NN O
scoring NN NN O
of NN NN O
baseline NN NN O
characteristics NN NN O
. NN NN O
   
INTERVENTIONS NN NN O
: NN NN O
Continuous NN NN O
sedation NN NN O
with NN NN O
dexmedetomidine NN NN O
or NN NN O
propofol NN NN O
. NN NN O
   
MEASUREMENTS NN NN O
AND NN NN O
MAIN NN NN O
RESULTS NN NN O
: NN NN O
A NN NN O
total NN NN O
of NN NN O
342 NN NN O
patients NN NN O
( NN NN O
105 NN NN O
dexmedetomidine NN NN O
and NN NN O
237 NN NN O
propofol NN NN O
) NN NN O
were NN NN O
included NN NN O
in NN NN O
the NN NN O
analysis NN NN O
, NN NN O
with NN NN O
190 NN NN O
matched NN NN O
( NN NN O
95 NN NN O
in NN NN O
each NN NN O
group NN NN O
) NN NN O
by NN NN O
propensity NN NN O
score NN NN O
. NN NN O
   
The NN NN O
primary NN NN O
outcome NN NN O
of NN NN O
this NN NN O
study NN NN O
was NN NN O
a NN NN O
composite NN NN O
of NN NN O
severe NN NN O
hypotension NN NN B-Disease
( NN NN O
mean NN NN O
arterial NN NN O
pressure NN NN O
< NN NN O
60 NN NN O
mm NN NN O
Hg NN NN O
) NN NN O
and NN NN O
bradycardia NN NN B-Disease
( NN NN O
heart NN NN O
rate NN NN O
< NN NN O
50 NN NN O
beats NN NN O
/ NN NN O
min NN NN O
) NN NN O
during NN NN O
sedative NN NN O
infusion NN NN O
. NN NN O
   
No NN NN O
difference NN NN O
in NN NN O
the NN NN O
primary NN NN O
composite NN NN O
outcome NN NN O
in NN NN O
both NN NN O
the NN NN O
unmatched NN NN O
( NN NN O
30 NN NN O
% NN NN O
vs NN NN O
30 NN NN O
% NN NN O
, NN NN O
p NN NN O
= NN NN O
0 NN NN O
. NN NN O
94 NN NN O
) NN NN O
or NN NN O
matched NN NN O
cohorts NN NN O
( NN NN O
28 NN NN O
% NN NN O
vs NN NN O
34 NN NN O
% NN NN O
, NN NN O
p NN NN O
= NN NN O
0 NN NN O
. NN NN O
35 NN NN O
) NN NN O
could NN NN O
be NN NN O
found NN NN O
. NN NN O
   
When NN NN O
analyzed NN NN O
separately NN NN O
, NN NN O
no NN NN O
differences NN NN O
could NN NN O
be NN NN O
found NN NN O
in NN NN O
the NN NN O
prevalence NN NN O
of NN NN O
severe NN NN O
hypotension NN NN B-Disease
or NN NN O
bradycardia NN NN B-Disease
in NN NN O
either NN NN O
the NN NN O
unmatched NN NN O
or NN NN O
matched NN NN O
cohorts NN NN O
. NN NN O
   
CONCLUSIONS NN NN O
: NN NN O
Severe NN NN O
hypotension NN NN B-Disease
and NN NN O
bradycardia NN NN B-Disease
occur NN NN O
at NN NN O
similar NN NN O
prevalence NN NN O
in NN NN O
neurocritical NN NN O
care NN NN O
patients NN NN O
who NN NN O
receive NN NN O
dexmedetomidine NN NN O
or NN NN O
propofol NN NN O
. NN NN O
   
Providers NN NN O
should NN NN O
similarly NN NN O
consider NN NN O
the NN NN O
likelihood NN NN O
of NN NN O
hypotension NN NN B-Disease
or NN NN O
bradycardia NN NN B-Disease
before NN NN O
starting NN NN O
either NN NN O
sedative NN NN O
. NN NN O
   
Hydroxytyrosol NN NN O
ameliorates NN NN O
oxidative NN NN O
stress NN NN O
and NN NN O
mitochondrial NN NN B-Disease
dysfunction NN NN I-Disease
in NN NN O
doxorubicin NN NN O
- NN NN O
induced NN NN O
cardiotoxicity NN NN B-Disease
in NN NN O
rats NN NN O
with NN NN O
breast NN NN B-Disease
cancer NN NN I-Disease
. NN NN O
   
Oxidative NN NN O
stress NN NN O
is NN NN O
involved NN NN O
in NN NN O
several NN NN O
processes NN NN O
including NN NN O
cancer NN NN B-Disease
, NN NN O
aging NN NN O
and NN NN O
cardiovascular NN NN B-Disease
disease NN NN I-Disease
, NN NN O
and NN NN O
has NN NN O
been NN NN O
shown NN NN O
to NN NN O
potentiate NN NN O
the NN NN O
therapeutic NN NN O
effect NN NN O
of NN NN O
drugs NN NN O
such NN NN O
as NN NN O
doxorubicin NN NN O
. NN NN O
   
Doxorubicin NN NN O
causes NN NN O
significant NN NN O
cardiotoxicity NN NN B-Disease
characterized NN NN O
by NN NN O
marked NN NN O
increases NN NN O
in NN NN O
oxidative NN NN O
stress NN NN O
and NN NN O
mitochondrial NN NN B-Disease
dysfunction NN NN I-Disease
. NN NN O
   
Herein NN NN O
, NN NN O
we NN NN O
investigate NN NN O
whether NN NN O
doxorubicin NN NN O
- NN NN O
associated NN NN O
chronic NN NN O
cardiac NN NN B-Disease
toxicity NN NN I-Disease
can NN NN O
be NN NN O
ameliorated NN NN O
with NN NN O
the NN NN O
antioxidant NN NN O
hydroxytyrosol NN NN O
in NN NN O
rats NN NN O
with NN NN O
breast NN NN B-Disease
cancer NN NN I-Disease
. NN NN O
   
Thirty NN NN O
- NN NN O
six NN NN O
rats NN NN O
bearing NN NN O
breast NN NN B-Disease
tumors NN NN I-Disease
induced NN NN O
chemically NN NN O
were NN NN O
divided NN NN O
into NN NN O
4 NN NN O
groups NN NN O
: NN NN O
control NN NN O
, NN NN O
hydroxytyrosol NN NN O
( NN NN O
0 NN NN O
. NN NN O
5mg NN NN O
/ NN NN O
kg NN NN O
, NN NN O
5days NN NN O
/ NN NN O
week NN NN O
) NN NN O
, NN NN O
doxorubicin NN NN O
( NN NN O
1mg NN NN O
/ NN NN O
kg NN NN O
/ NN NN O
week NN NN O
) NN NN O
, NN NN O
and NN NN O
doxorubicin NN NN O
plus NN NN O
hydroxytyrosol NN NN O
. NN NN O
   
Cardiac NN NN B-Disease
disturbances NN NN I-Disease
at NN NN O
the NN NN O
cellular NN NN O
and NN NN O
mitochondrial NN NN O
level NN NN O
, NN NN O
mitochondrial NN NN O
electron NN NN O
transport NN NN O
chain NN NN O
complexes NN NN O
I NN NN O
- NN NN O
IV NN NN O
and NN NN O
apoptosis NN NN O
- NN NN O
inducing NN NN O
factor NN NN O
, NN NN O
and NN NN O
oxidative NN NN O
stress NN NN O
markers NN NN O
have NN NN O
been NN NN O
analyzed NN NN O
. NN NN O
   
Hydroxytyrosol NN NN O
improved NN NN O
the NN NN O
cardiac NN NN B-Disease
disturbances NN NN I-Disease
enhanced NN NN O
by NN NN O
doxorubicin NN NN O
by NN NN O
significantly NN NN O
reducing NN NN O
the NN NN O
percentage NN NN O
of NN NN O
altered NN NN O
mitochondria NN NN O
and NN NN O
oxidative NN NN O
damage NN NN O
. NN NN O
   
These NN NN O
results NN NN O
suggest NN NN O
that NN NN O
hydroxytyrosol NN NN O
improve NN NN O
the NN NN O
mitochondrial NN NN O
electron NN NN O
transport NN NN O
chain NN NN O
. NN NN O
   
This NN NN O
study NN NN O
demonstrates NN NN O
that NN NN O
hydroxytyrosol NN NN O
protect NN NN O
rat NN NN O
heart NN NN B-Disease
damage NN NN I-Disease
provoked NN NN O
by NN NN O
doxorubicin NN NN O
decreasing NN NN O
oxidative NN NN O
damage NN NN O
and NN NN O
mitochondrial NN NN O
alterations NN NN O
. NN NN O
   
Amiodarone NN NN O
- NN NN O
induced NN NN O
myxoedema NN NN B-Disease
coma NN NN I-Disease
. NN NN O
   
A NN NN O
62 NN NN O
- NN NN O
year NN NN O
- NN NN O
old NN NN O
man NN NN O
was NN NN O
found NN NN O
to NN NN O
have NN NN O
bradycardia NN NN B-Disease
, NN NN O
hypothermia NN NN B-Disease
and NN NN O
respiratory NN NN B-Disease
failure NN NN I-Disease
3 NN NN O
weeks NN NN O
after NN NN O
initiation NN NN O
of NN NN O
amiodarone NN NN O
therapy NN NN O
for NN NN O
atrial NN NN B-Disease
fibrillation NN NN I-Disease
. NN NN O
   
Thyroid NN NN O
- NN NN O
stimulating NN NN O
hormone NN NN O
was NN NN O
found NN NN O
to NN NN O
be NN NN O
168 NN NN O
uIU NN NN O
/ NN NN O
mL NN NN O
( NN NN O
nl NN NN O
. NN NN O
0 NN NN O
. NN NN O
3 NN NN O
- NN NN O
5 NN NN O
uIU NN NN O
/ NN NN O
mL NN NN O
) NN NN O
and NN NN O
free NN NN O
thyroxine NN NN O
( NN NN O
FT4 NN NN O
) NN NN O
was NN NN O
< NN NN O
0 NN NN O
. NN NN O
2 NN NN O
ng NN NN O
/ NN NN O
dL NN NN O
( NN NN O
nl NN NN O
. NN NN O
0 NN NN O
. NN NN O
8 NN NN O
- NN NN O
1 NN NN O
. NN NN O
8 NN NN O
ng NN NN O
/ NN NN O
dL NN NN O
) NN NN O
. NN NN O
   
He NN NN O
received NN NN O
intravenous NN NN O
fluids NN NN O
, NN NN O
vasopressor NN NN O
therapy NN NN O
and NN NN O
stress NN NN O
dose NN NN O
steroids NN NN O
; NN NN O
he NN NN O
was NN NN O
intubated NN NN O
and NN NN O
admitted NN NN O
to NN NN O
the NN NN O
intensive NN NN O
care NN NN O
unit NN NN O
. NN NN O
   
He NN NN O
received NN NN O
500 NN NN O
ug NN NN O
of NN NN O
intravenous NN NN O
levothyroxine NN NN O
in NN NN O
the NN NN O
first NN NN O
18 NN NN O
h NN NN O
of NN NN O
therapy NN NN O
, NN NN O
and NN NN O
150 NN NN O
ug NN NN O
intravenous NN NN O
daily NN NN O
thereafter NN NN O
. NN NN O
   
Haemodynamic NN NN O
improvement NN NN O
, NN NN O
along NN NN O
with NN NN O
complete NN NN O
recovery NN NN O
of NN NN O
mental NN NN O
status NN NN O
, NN NN O
occurred NN NN O
after NN NN O
48 NN NN O
h NN NN O
. NN NN O
   
Twelve NN NN O
hours NN NN O
after NN NN O
the NN NN O
initiation NN NN O
of NN NN O
therapy NN NN O
, NN NN O
FT4 NN NN O
was NN NN O
0 NN NN O
. NN NN O
96 NN NN O
ng NN NN O
/ NN NN O
dL NN NN O
. NN NN O
   
The NN NN O
patient NN NN O
was NN NN O
maintained NN NN O
on NN NN O
levothyroxine NN NN O
175 NN NN O
( NN NN O
g NN NN O
POorally NN NN O
daily NN NN O
. NN NN O
   
A NN NN O
thyroid NN NN O
ultrasound NN NN O
showed NN NN O
diffuse NN NN O
heterogeneity NN NN O
. NN NN O
   
The NN NN O
24 NN NN O
hour NN NN O
excretion NN NN O
of NN NN O
iodine NN NN O
was NN NN O
3657 NN NN O
( NN NN O
mcg NN NN O
( NN NN O
25 NN NN O
- NN NN O
756 NN NN O
( NN NN O
mcg NN NN O
) NN NN O
. NN NN O
   
The NN NN O
only NN NN O
two NN NN O
cases NN NN O
of NN NN O
amiodarone NN NN O
- NN NN O
induced NN NN O
myxoedema NN NN B-Disease
coma NN NN I-Disease
in NN NN O
the NN NN O
literature NN NN O
report NN NN O
patient NN NN O
death NN NN O
despite NN NN O
supportive NN NN O
therapy NN NN O
and NN NN O
thyroid NN NN O
hormone NN NN O
replacement NN NN O
. NN NN O
   
This NN NN O
case NN NN O
represents NN NN O
the NN NN O
most NN NN O
thoroughly NN NN O
investigated NN NN O
case NN NN O
of NN NN O
amiodarone NN NN O
- NN NN O
induced NN NN O
myxoedema NN NN B-Disease
coma NN NN I-Disease
with NN NN O
a NN NN O
history NN NN O
significant NN NN O
for NN NN O
subclinical NN NN O
thyroid NN NN B-Disease
disease NN NN I-Disease
. NN NN O
   
Use NN NN O
of NN NN O
argatroban NN NN O
and NN NN O
catheter NN NN O
- NN NN O
directed NN NN O
thrombolysis NN NN B-Disease
with NN NN O
alteplase NN NN O
in NN NN O
an NN NN O
oncology NN NN O
patient NN NN O
with NN NN O
heparin NN NN O
- NN NN O
induced NN NN O
thrombocytopenia NN NN B-Disease
with NN NN O
thrombosis NN NN B-Disease
. NN NN O
   
PURPOSE NN NN O
: NN NN O
The NN NN O
case NN NN O
of NN NN O
an NN NN O
oncology NN NN O
patient NN NN O
who NN NN O
developed NN NN O
heparin NN NN O
- NN NN O
induced NN NN O
thrombocytopenia NN NN B-Disease
with NN NN O
thrombosis NN NN B-Disease
( NN NN O
HITT NN NN B-Disease
) NN NN O
and NN NN O
was NN NN O
treated NN NN O
with NN NN O
argatroban NN NN O
plus NN NN O
catheter NN NN O
- NN NN O
directed NN NN O
thrombolysis NN NN B-Disease
( NN NN O
CDT NN NN O
) NN NN O
with NN NN O
alteplase NN NN O
is NN NN O
presented NN NN O
. NN NN O
   
SUMMARY NN NN O
: NN NN O
A NN NN O
63 NN NN O
- NN NN O
year NN NN O
- NN NN O
old NN NN O
Caucasian NN NN O
man NN NN O
with NN NN O
renal NN NN O
amyloidosis NN NN B-Disease
undergoing NN NN O
peripheral NN NN O
blood NN NN O
stem NN NN O
cell NN NN O
collection NN NN O
for NN NN O
an NN NN O
autologous NN NN O
stem NN NN O
cell NN NN O
transplant NN NN O
developed NN NN O
extensive NN NN O
bilateral NN NN O
upper NN NN B-Disease
- NN NN I-Disease
extremity NN NN I-Disease
deep NN NN I-Disease
venous NN NN I-Disease
thrombosis NN NN I-Disease
( NN NN O
DVT NN NN B-Disease
) NN NN O
and NN NN O
pulmonary NN NN B-Disease
embolism NN NN I-Disease
secondary NN NN O
to NN NN O
heparin NN NN O
- NN NN O
induced NN NN O
thrombocytopenia NN NN B-Disease
. NN NN O
   
A NN NN O
continuous NN NN O
i NN NN O
. NN NN O
v NN NN O
. NN NN O
infusion NN NN O
of NN NN O
argatroban NN NN O
was NN NN O
initiated NN NN O
, NN NN O
and NN NN O
the NN NN O
patient NN NN O
was NN NN O
managed NN NN O
on NN NN O
the NN NN O
general NN NN O
medical NN NN O
floor NN NN O
. NN NN O
   
After NN NN O
one NN NN O
week NN NN O
of NN NN O
therapy NN NN O
, NN NN O
he NN NN O
was NN NN O
transferred NN NN O
to NN NN O
the NN NN O
intensive NN NN O
care NN NN O
unit NN NN O
with NN NN O
cardiopulmonary NN NN O
compromise NN NN O
related NN NN O
to NN NN O
superior NN NN B-Disease
vena NN NN I-Disease
cava NN NN I-Disease
( NN NN I-Disease
SVC NN NN I-Disease
) NN NN I-Disease
syndrome NN NN I-Disease
. NN NN O
   
A NN NN O
percutaneous NN NN O
mechanical NN NN O
thrombectomy NN NN O
and NN NN O
CDT NN NN O
with NN NN O
alteplase NN NN O
were NN NN O
attempted NN NN O
, NN NN O
but NN NN O
the NN NN O
procedure NN NN O
was NN NN O
aborted NN NN O
due NN NN O
to NN NN O
epistaxis NN NN B-Disease
. NN NN O
   
The NN NN O
epistaxis NN NN B-Disease
resolved NN NN O
the NN NN O
next NN NN O
day NN NN O
, NN NN O
and NN NN O
the NN NN O
patient NN NN O
was NN NN O
restarted NN NN O
on NN NN O
argatroban NN NN O
. NN NN O
   
A NN NN O
second NN NN O
percutaneous NN NN O
mechanical NN NN O
thrombectomy NN NN O
was NN NN O
performed NN NN O
six NN NN O
days NN NN O
later NN NN O
and NN NN O
resulted NN NN O
in NN NN O
partial NN NN O
revascularization NN NN O
of NN NN O
the NN NN O
SVC NN NN O
and NN NN O
central NN NN O
veins NN NN O
. NN NN O
   
Postthrombectomy NN NN O
continuous NN NN O
CDT NN NN O
with NN NN O
alteplase NN NN O
was NN NN O
commenced NN NN O
while NN NN O
argatroban NN NN O
was NN NN O
withheld NN NN O
, NN NN O
and NN NN O
complete NN NN O
patency NN NN O
of NN NN O
the NN NN O
SVC NN NN O
and NN NN O
central NN NN O
veins NN NN O
was NN NN O
achieved NN NN O
after NN NN O
three NN NN O
days NN NN O
of NN NN O
therapy NN NN O
. NN NN O
   
Alteplase NN NN O
was NN NN O
discontinued NN NN O
, NN NN O
and NN NN O
the NN NN O
patient NN NN O
was NN NN O
reinitiated NN NN O
on NN NN O
argatroban NN NN O
; NN NN O
ultimately NN NN O
, NN NN O
he NN NN O
was NN NN O
transitioned NN NN O
to NN NN O
warfarin NN NN O
for NN NN O
long NN NN O
- NN NN O
term NN NN O
anticoagulation NN NN O
. NN NN O
   
Although NN NN O
the NN NN O
patient NN NN O
recovered NN NN O
, NN NN O
he NN NN O
experienced NN NN O
permanent NN NN O
vision NN NN B-Disease
and NN NN I-Disease
hearing NN NN I-Disease
loss NN NN I-Disease
, NN NN O
as NN NN O
well NN NN O
as NN NN O
end NN NN B-Disease
- NN NN I-Disease
stage NN NN I-Disease
renal NN NN I-Disease
disease NN NN I-Disease
. NN NN O
   
CONCLUSION NN NN O
: NN NN O
A NN NN O
63 NN NN O
- NN NN O
year NN NN O
- NN NN O
old NN NN O
man NN NN O
with NN NN O
renal NN NN O
amyloidosis NN NN B-Disease
and NN NN O
SVC NN NN B-Disease
syndrome NN NN I-Disease
secondary NN NN O
to NN NN O
HITT NN NN B-Disease
was NN NN O
successfully NN NN O
treated NN NN O
with NN NN O
argatroban NN NN O
and NN NN O
CDT NN NN O
with NN NN O
alteplase NN NN O
. NN NN O
   
Effects NN NN O
of NN NN O
dehydroepiandrosterone NN NN O
in NN NN O
amphetamine NN NN O
- NN NN O
induced NN NN O
schizophrenia NN NN B-Disease
models NN NN O
in NN NN O
mice NN NN O
. NN NN O
   
OBJECTIVE NN NN O
: NN NN O
To NN NN O
examine NN NN O
the NN NN O
effects NN NN O
of NN NN O
dehydroepiandrosterone NN NN O
( NN NN O
DHEA NN NN O
) NN NN O
on NN NN O
animal NN NN O
models NN NN O
of NN NN O
schizophrenia NN NN B-Disease
. NN NN O
   
METHODS NN NN O
: NN NN O
Seventy NN NN O
Swiss NN NN O
albino NN NN O
female NN NN O
mice NN NN O
( NN NN O
25 NN NN O
- NN NN O
35 NN NN O
g NN NN O
) NN NN O
were NN NN O
divided NN NN O
into NN NN O
4 NN NN O
groups NN NN O
: NN NN O
amphetamine NN NN O
- NN NN O
free NN NN O
( NN NN O
control NN NN O
) NN NN O
, NN NN O
amphetamine NN NN O
, NN NN O
50 NN NN O
, NN NN O
and NN NN O
100 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
DHEA NN NN O
. NN NN O
   
The NN NN O
DHEA NN NN O
was NN NN O
administered NN NN O
intraperitoneally NN NN O
( NN NN O
ip NN NN O
) NN NN O
for NN NN O
5 NN NN O
days NN NN O
. NN NN O
   
Amphetamine NN NN O
( NN NN O
3 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
ip NN NN O
) NN NN O
induced NN NN O
hyper NN NN B-Disease
locomotion NN NN O
, NN NN O
apomorphine NN NN O
( NN NN O
1 NN NN O
. NN NN O
5 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
subcutaneously NN NN O
[ NN NN O
sc NN NN O
] NN NN O
) NN NN O
induced NN NN O
climbing NN NN O
, NN NN O
and NN NN O
haloperidol NN NN O
( NN NN O
1 NN NN O
. NN NN O
5 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
sc NN NN O
) NN NN O
induced NN NN O
catalepsy NN NN B-Disease
tests NN NN O
were NN NN O
used NN NN O
as NN NN O
animal NN NN O
models NN NN O
of NN NN O
schizophrenia NN NN B-Disease
. NN NN O
   
The NN NN O
study NN NN O
was NN NN O
conducted NN NN O
at NN NN O
the NN NN O
Animal NN NN O
Experiment NN NN O
Laboratories NN NN O
, NN NN O
Department NN NN O
of NN NN O
Pharmacology NN NN O
, NN NN O
Medical NN NN O
School NN NN O
, NN NN O
Eskisehir NN NN O
Osmangazi NN NN O
University NN NN O
, NN NN O
Eskisehir NN NN O
, NN NN O
Turkey NN NN O
between NN NN O
March NN NN O
and NN NN O
May NN NN O
2012 NN NN O
. NN NN O
   
Statistical NN NN O
analysis NN NN O
was NN NN O
carried NN NN O
out NN NN O
using NN NN O
Kruskal NN NN O
- NN NN O
Wallis NN NN O
test NN NN O
for NN NN O
hyper NN NN B-Disease
locomotion NN NN O
, NN NN O
and NN NN O
one NN NN O
- NN NN O
way NN NN O
ANOVA NN NN O
for NN NN O
climbing NN NN O
and NN NN O
catalepsy NN NN B-Disease
tests NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
In NN NN O
the NN NN O
amphetamine NN NN O
- NN NN O
induced NN NN O
locomotion NN NN O
test NN NN O
, NN NN O
there NN NN O
were NN NN O
significant NN NN O
increases NN NN O
in NN NN O
all NN NN O
movements NN NN O
compared NN NN O
with NN NN O
the NN NN O
amphetamine NN NN O
- NN NN O
free NN NN O
group NN NN O
. NN NN O
   
Both NN NN O
DHEA NN NN O
50 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
( NN NN O
p NN NN O
< NN NN O
0 NN NN O
. NN NN O
05 NN NN O
) NN NN O
, NN NN O
and NN NN O
100 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
( NN NN O
p NN NN O
< NN NN O
0 NN NN O
. NN NN O
01 NN NN O
) NN NN O
significantly NN NN O
decreased NN NN O
all NN NN O
movements NN NN O
compared NN NN O
with NN NN O
the NN NN O
amphetamine NN NN O
- NN NN O
induced NN NN O
locomotion NN NN O
group NN NN O
. NN NN O
   
There NN NN O
was NN NN O
a NN NN O
significant NN NN O
difference NN NN O
between NN NN O
groups NN NN O
in NN NN O
the NN NN O
haloperidol NN NN O
- NN NN O
induced NN NN O
catalepsy NN NN B-Disease
test NN NN O
( NN NN O
p NN NN O
< NN NN O
0 NN NN O
. NN NN O
05 NN NN O
) NN NN O
. NN NN O
   
There NN NN O
was NN NN O
no NN NN O
significant NN NN O
difference NN NN O
between NN NN O
groups NN NN O
in NN NN O
terms NN NN O
of NN NN O
total NN NN O
climbing NN NN O
time NN NN O
in NN NN O
the NN NN O
apomorphine NN NN O
- NN NN O
induced NN NN O
climbing NN NN O
test NN NN O
( NN NN O
p NN NN O
> NN NN O
0 NN NN O
. NN NN O
05 NN NN O
) NN NN O
. NN NN O
   
CONCLUSION NN NN O
: NN NN O
We NN NN O
observed NN NN O
that NN NN O
DHEA NN NN O
reduced NN NN O
locomotor NN NN O
activity NN NN O
and NN NN O
increased NN NN O
catalepsy NN NN B-Disease
at NN NN O
both NN NN O
doses NN NN O
, NN NN O
while NN NN O
it NN NN O
had NN NN O
no NN NN O
effect NN NN O
on NN NN O
climbing NN NN O
behavior NN NN O
. NN NN O
   
We NN NN O
suggest NN NN O
that NN NN O
DHEA NN NN O
displays NN NN O
typical NN NN O
neuroleptic NN NN O
- NN NN O
like NN NN O
effects NN NN O
, NN NN O
and NN NN O
may NN NN O
be NN NN O
used NN NN O
in NN NN O
the NN NN O
treatment NN NN O
of NN NN O
schizophrenia NN NN B-Disease
. NN NN O
   
Availability NN NN O
of NN NN O
human NN NN O
induced NN NN O
pluripotent NN NN O
stem NN NN O
cell NN NN O
- NN NN O
derived NN NN O
cardiomyocytes NN NN O
in NN NN O
assessment NN NN O
of NN NN O
drug NN NN O
potential NN NN O
for NN NN O
QT NN NN B-Disease
prolongation NN NN I-Disease
. NN NN O
   
Field NN NN O
potential NN NN O
duration NN NN O
( NN NN O
FPD NN NN O
) NN NN O
in NN NN O
human NN NN O
- NN NN O
induced NN NN O
pluripotent NN NN O
stem NN NN O
cell NN NN O
- NN NN O
derived NN NN O
cardiomyocytes NN NN O
( NN NN O
hiPS NN NN O
- NN NN O
CMs NN NN O
) NN NN O
, NN NN O
which NN NN O
can NN NN O
express NN NN O
QT NN NN O
interval NN NN O
in NN NN O
an NN NN O
electrocardiogram NN NN O
, NN NN O
is NN NN O
reported NN NN O
to NN NN O
be NN NN O
a NN NN O
useful NN NN O
tool NN NN O
to NN NN O
predict NN NN O
K NN NN O
( NN NN O
+ NN NN O
) NN NN O
channel NN NN O
and NN NN O
Ca NN NN O
( NN NN O
2 NN NN O
+ NN NN O
) NN NN O
channel NN NN O
blocker NN NN O
effects NN NN O
on NN NN O
QT NN NN O
interval NN NN O
. NN NN O
   
However NN NN O
, NN NN O
there NN NN O
is NN NN O
no NN NN O
report NN NN O
showing NN NN O
that NN NN O
this NN NN O
technique NN NN O
can NN NN O
be NN NN O
used NN NN O
to NN NN O
predict NN NN O
multichannel NN NN O
blocker NN NN O
potential NN NN O
for NN NN O
QT NN NN B-Disease
prolongation NN NN I-Disease
. NN NN O
   
The NN NN O
aim NN NN O
of NN NN O
this NN NN O
study NN NN O
is NN NN O
to NN NN O
show NN NN O
that NN NN O
FPD NN NN O
from NN NN O
MEA NN NN O
( NN NN O
Multielectrode NN NN O
array NN NN O
) NN NN O
of NN NN O
hiPS NN NN O
- NN NN O
CMs NN NN O
can NN NN O
detect NN NN O
QT NN NN B-Disease
prolongation NN NN I-Disease
induced NN NN O
by NN NN O
multichannel NN NN O
blockers NN NN O
. NN NN O
   
hiPS NN NN O
- NN NN O
CMs NN NN O
were NN NN O
seeded NN NN O
onto NN NN O
MEA NN NN O
and NN NN O
FPD NN NN O
was NN NN O
measured NN NN O
for NN NN O
2min NN NN O
every NN NN O
10min NN NN O
for NN NN O
30min NN NN O
after NN NN O
drug NN NN O
exposure NN NN O
for NN NN O
the NN NN O
vehicle NN NN O
and NN NN O
each NN NN O
drug NN NN O
concentration NN NN O
. NN NN O
   
IKr NN NN O
and NN NN O
IKs NN NN O
blockers NN NN O
concentration NN NN O
- NN NN O
dependently NN NN O
prolonged NN NN O
corrected NN NN O
FPD NN NN O
( NN NN O
FPDc NN NN O
) NN NN O
, NN NN O
whereas NN NN O
Ca NN NN O
( NN NN O
2 NN NN O
+ NN NN O
) NN NN O
channel NN NN O
blockers NN NN O
concentration NN NN O
- NN NN O
dependently NN NN O
shortened NN NN O
FPDc NN NN O
. NN NN O
   
Also NN NN O
, NN NN O
the NN NN O
multichannel NN NN O
blockers NN NN O
Amiodarone NN NN O
, NN NN O
Paroxetine NN NN O
, NN NN O
Terfenadine NN NN O
and NN NN O
Citalopram NN NN O
prolonged NN NN O
FPDc NN NN O
in NN NN O
a NN NN O
concentration NN NN O
dependent NN NN O
manner NN NN O
. NN NN O
   
Finally NN NN O
, NN NN O
the NN NN O
IKr NN NN O
blockers NN NN O
, NN NN O
Terfenadine NN NN O
and NN NN O
Citalopram NN NN O
, NN NN O
which NN NN O
are NN NN O
reported NN NN O
to NN NN O
cause NN NN O
Torsade NN NN B-Disease
de NN NN I-Disease
Pointes NN NN I-Disease
( NN NN O
TdP NN NN B-Disease
) NN NN O
in NN NN O
clinical NN NN O
practice NN NN O
, NN NN O
produced NN NN O
early NN NN O
afterdepolarization NN NN O
( NN NN O
EAD NN NN O
) NN NN O
. NN NN O
   
hiPS NN NN O
- NN NN O
CMs NN NN O
using NN NN O
MEA NN NN O
system NN NN O
and NN NN O
FPDc NN NN O
can NN NN O
predict NN NN O
the NN NN O
effects NN NN O
of NN NN O
drug NN NN O
candidates NN NN O
on NN NN O
QT NN NN O
interval NN NN O
. NN NN O
   
This NN NN O
study NN NN O
also NN NN O
shows NN NN O
that NN NN O
this NN NN O
assay NN NN O
can NN NN O
help NN NN O
detect NN NN O
EAD NN NN O
for NN NN O
drugs NN NN O
with NN NN O
TdP NN NN B-Disease
potential NN NN O
. NN NN O
   
Dermal NN NN O
developmental NN NN O
toxicity NN NN B-Disease
of NN NN O
N NN NN O
- NN NN O
phenylimide NN NN O
herbicides NN NN O
in NN NN O
rats NN NN O
. NN NN O
   
BACKGROUND NN NN O
: NN NN O
S NN NN O
- NN NN O
53482 NN NN O
and NN NN O
S NN NN O
- NN NN O
23121 NN NN O
are NN NN O
N NN NN O
- NN NN O
phenylimide NN NN O
herbicides NN NN O
and NN NN O
produced NN NN O
embryolethality NN NN B-Disease
, NN NN O
teratogenicity NN NN B-Disease
( NN NN O
mainly NN NN O
ventricular NN NN B-Disease
septal NN NN I-Disease
defects NN NN I-Disease
and NN NN O
wavy NN NN O
ribs NN NN O
) NN NN O
, NN NN O
and NN NN O
growth NN NN B-Disease
retardation NN NN I-Disease
in NN NN O
rats NN NN O
in NN NN O
conventional NN NN O
oral NN NN O
developmental NN NN O
toxicity NN NN B-Disease
studies NN NN O
. NN NN O
   
Our NN NN O
objective NN NN O
in NN NN O
this NN NN O
study NN NN O
was NN NN O
to NN NN O
investigate NN NN O
whether NN NN O
the NN NN O
compounds NN NN O
induce NN NN O
developmental NN NN O
toxicity NN NN B-Disease
via NN NN O
the NN NN O
dermal NN NN O
route NN NN O
, NN NN O
which NN NN O
is NN NN O
more NN NN O
relevant NN NN O
to NN NN O
occupational NN NN O
exposure NN NN O
, NN NN O
hence NN NN O
better NN NN O
addressing NN NN O
human NN NN O
health NN NN O
risks NN NN O
. NN NN O
   
METHODS NN NN O
: NN NN O
S NN NN O
- NN NN O
53482 NN NN O
was NN NN O
administered NN NN O
dermally NN NN O
to NN NN O
rats NN NN O
at NN NN O
30 NN NN O
, NN NN O
100 NN NN O
, NN NN O
and NN NN O
300 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
during NN NN O
organogenesis NN NN O
, NN NN O
and NN NN O
S NN NN O
- NN NN O
23121 NN NN O
was NN NN O
administered NN NN O
at NN NN O
200 NN NN O
, NN NN O
400 NN NN O
, NN NN O
and NN NN O
800 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
( NN NN O
the NN NN O
maximum NN NN O
applicable NN NN O
dose NN NN O
level NN NN O
) NN NN O
. NN NN O
   
Fetuses NN NN O
were NN NN O
obtained NN NN O
by NN NN O
a NN NN O
Cesarean NN NN O
section NN NN O
and NN NN O
examined NN NN O
for NN NN O
external NN NN O
, NN NN O
visceral NN NN O
, NN NN O
and NN NN O
skeletal NN NN O
alterations NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
Dermal NN NN O
exposure NN NN O
of NN NN O
rats NN NN O
to NN NN O
S NN NN O
- NN NN O
53482 NN NN O
at NN NN O
300 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
produced NN NN O
patterns NN NN O
of NN NN O
developmental NN NN O
toxicity NN NN B-Disease
similar NN NN O
to NN NN O
those NN NN O
resulting NN NN O
from NN NN O
oral NN NN O
exposure NN NN O
. NN NN O
   
Toxicity NN NN B-Disease
included NN NN O
embryolethality NN NN B-Disease
, NN NN O
teratogenicity NN NN B-Disease
, NN NN O
and NN NN O
growth NN NN B-Disease
retardation NN NN I-Disease
. NN NN O
   
Dermal NN NN O
administration NN NN O
of NN NN O
S NN NN O
- NN NN O
23121 NN NN O
at NN NN O
800 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
resulted NN NN O
in NN NN O
an NN NN O
increased NN NN O
incidence NN NN O
of NN NN O
embryonic NN NN B-Disease
death NN NN I-Disease
and NN NN O
ventricular NN NN B-Disease
septal NN NN I-Disease
defect NN NN I-Disease
, NN NN O
but NN NN O
retarded NN NN O
fetal NN NN O
growth NN NN O
was NN NN O
not NN NN O
observed NN NN O
as NN NN O
it NN NN O
was NN NN O
following NN NN O
oral NN NN O
exposure NN NN O
to NN NN O
S NN NN O
- NN NN O
23121 NN NN O
. NN NN O
   
CONCLUSIONS NN NN O
: NN NN O
Based NN NN O
on NN NN O
the NN NN O
results NN NN O
, NN NN O
S NN NN O
- NN NN O
53482 NN NN O
and NN NN O
S NN NN O
- NN NN O
23121 NN NN O
were NN NN O
teratogenic NN NN B-Disease
when NN NN O
administered NN NN O
dermally NN NN O
to NN NN O
pregnant NN NN O
rats NN NN O
as NN NN O
were NN NN O
the NN NN O
compounds NN NN O
administered NN NN O
orally NN NN O
. NN NN O
   
Thus NN NN O
, NN NN O
investigation NN NN O
of NN NN O
the NN NN O
mechanism NN NN O
and NN NN O
its NN NN O
human NN NN O
relevancy NN NN O
become NN NN O
more NN NN O
important NN NN O
. NN NN O
   
Rates NN NN O
of NN NN O
Renal NN NN B-Disease
Toxicity NN NN I-Disease
in NN NN O
Cancer NN NN B-Disease
Patients NN NN O
Receiving NN NN O
Cisplatin NN NN O
With NN NN O
and NN NN O
Without NN NN O
Mannitol NN NN O
. NN NN O
   
BACKGROUND NN NN O
: NN NN O
Cisplatin NN NN O
is NN NN O
a NN NN O
widely NN NN O
used NN NN O
antineoplastic NN NN O
. NN NN O
   
One NN NN O
of NN NN O
the NN NN O
major NN NN O
complications NN NN O
of NN NN O
cisplatin NN NN O
use NN NN O
is NN NN O
dose NN NN O
- NN NN O
limiting NN NN O
nephrotoxicity NN NN B-Disease
. NN NN O
   
There NN NN O
are NN NN O
many NN NN O
strategies NN NN O
to NN NN O
prevent NN NN O
this NN NN O
toxicity NN NN B-Disease
, NN NN O
including NN NN O
the NN NN O
use NN NN O
of NN NN O
mannitol NN NN O
as NN NN O
a NN NN O
nephroprotectant NN NN O
in NN NN O
combination NN NN O
with NN NN O
hydration NN NN O
. NN NN O
   
OBJECTIVE NN NN O
: NN NN O
We NN NN O
aimed NN NN O
to NN NN O
evaluate NN NN O
the NN NN O
rates NN NN O
of NN NN O
cisplatin NN NN O
- NN NN O
induced NN NN O
nephrotoxicity NN NN B-Disease
in NN NN O
cancer NN NN B-Disease
patients NN NN O
receiving NN NN O
single NN NN O
- NN NN O
agent NN NN O
cisplatin NN NN O
with NN NN O
and NN NN O
without NN NN O
mannitol NN NN O
. NN NN O
   
METHODS NN NN O
: NN NN O
This NN NN O
single NN NN O
- NN NN O
center NN NN O
retrospective NN NN O
analysis NN NN O
was NN NN O
a NN NN O
quasi NN NN O
experiment NN NN O
created NN NN O
by NN NN O
the NN NN O
national NN NN O
mannitol NN NN O
shortage NN NN O
. NN NN O
   
Data NN NN O
were NN NN O
collected NN NN O
on NN NN O
adult NN NN O
cancer NN NN B-Disease
patients NN NN O
receiving NN NN O
single NN NN O
- NN NN O
agent NN NN O
cisplatin NN NN O
as NN NN O
an NN NN O
outpatient NN NN O
from NN NN O
January NN NN O
2011 NN NN O
to NN NN O
September NN NN O
2012 NN NN O
. NN NN O
   
The NN NN O
primary NN NN O
outcome NN NN O
was NN NN O
acute NN NN B-Disease
kidney NN NN I-Disease
injury NN NN I-Disease
( NN NN O
AKI NN NN B-Disease
) NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
We NN NN O
evaluated NN NN O
143 NN NN O
patients NN NN O
who NN NN O
received NN NN O
single NN NN O
- NN NN O
agent NN NN O
cisplatin NN NN O
; NN NN O
97 NN NN O
. NN NN O
2 NN NN O
% NN NN O
of NN NN O
patients NN NN O
had NN NN O
head NN NN B-Disease
and NN NN I-Disease
neck NN NN I-Disease
cancer NN NN I-Disease
as NN NN O
their NN NN O
primary NN NN O
malignancy NN NN B-Disease
. NN NN O
   
Patients NN NN O
who NN NN O
did NN NN O
not NN NN O
receive NN NN O
mannitol NN NN O
were NN NN O
more NN NN O
likely NN NN O
to NN NN O
develop NN NN O
nephrotoxicity NN NN B-Disease
: NN NN O
odds NN NN O
ratio NN NN O
[ NN NN O
OR NN NN O
] NN NN O
= NN NN O
2 NN NN O
. NN NN O
646 NN NN O
( NN NN O
95 NN NN O
% NN NN O
CI NN NN O
= NN NN O
1 NN NN O
. NN NN O
008 NN NN O
, NN NN O
6 NN NN O
. NN NN O
944 NN NN O
; NN NN O
P NN NN O
= NN NN O
0 NN NN O
. NN NN O
048 NN NN O
) NN NN O
. NN NN O
   
Patients NN NN O
who NN NN O
received NN NN O
the NN NN O
100 NN NN O
mg NN NN O
/ NN NN O
m NN NN O
( NN NN O
2 NN NN O
) NN NN O
dosing NN NN O
and NN NN O
patients NN NN O
who NN NN O
had NN NN O
a NN NN O
history NN NN O
of NN NN O
hypertension NN NN B-Disease
also NN NN O
had NN NN O
a NN NN O
higher NN NN O
likelihood NN NN O
of NN NN O
developing NN NN O
nephrotoxicity NN NN B-Disease
: NN NN O
OR NN NN O
= NN NN O
11 NN NN O
. NN NN O
494 NN NN O
( NN NN O
95 NN NN O
% NN NN O
CI NN NN O
= NN NN O
4 NN NN O
. NN NN O
149 NN NN O
, NN NN O
32 NN NN O
. NN NN O
258 NN NN O
; NN NN O
P NN NN O
< NN NN O
0 NN NN O
. NN NN O
0001 NN NN O
) NN NN O
and NN NN O
OR NN NN O
= NN NN O
3 NN NN O
. NN NN O
219 NN NN O
( NN NN O
95 NN NN O
% NN NN O
CI NN NN O
= NN NN O
1 NN NN O
. NN NN O
228 NN NN O
, NN NN O
8 NN NN O
. NN NN O
439 NN NN O
; NN NN O
P NN NN O
= NN NN O
0 NN NN O
. NN NN O
017 NN NN O
) NN NN O
, NN NN O
respectively NN NN O
. NN NN O
   
CONCLUSIONS NN NN O
: NN NN O
When NN NN O
limited NN NN O
quantities NN NN O
of NN NN O
mannitol NN NN O
are NN NN O
available NN NN O
, NN NN O
it NN NN O
should NN NN O
preferentially NN NN O
be NN NN O
given NN NN O
to NN NN O
patients NN NN O
at NN NN O
particularly NN NN O
high NN NN O
risk NN NN O
of NN NN O
nephrotoxicity NN NN B-Disease
. NN NN O
   
Our NN NN O
analysis NN NN O
suggests NN NN O
that NN NN O
those NN NN O
patients NN NN O
receiving NN NN O
the NN NN O
dosing NN NN O
schedule NN NN O
of NN NN O
100 NN NN O
mg NN NN O
/ NN NN O
m NN NN O
( NN NN O
2 NN NN O
) NN NN O
cisplatin NN NN O
every NN NN O
3 NN NN O
weeks NN NN O
and NN NN O
those NN NN O
with NN NN O
hypertension NN NN B-Disease
are NN NN O
at NN NN O
the NN NN O
greatest NN NN O
risk NN NN O
of NN NN O
nephrotoxicity NN NN B-Disease
and NN NN O
would NN NN O
benefit NN NN O
from NN NN O
the NN NN O
addition NN NN O
of NN NN O
mannitol NN NN O
. NN NN O
   
Metformin NN NN O
protects NN NN O
against NN NN O
seizures NN NN B-Disease
, NN NN O
learning NN NN B-Disease
and NN NN I-Disease
memory NN NN I-Disease
impairments NN NN I-Disease
and NN NN O
oxidative NN NN O
damage NN NN O
induced NN NN O
by NN NN O
pentylenetetrazole NN NN O
- NN NN O
induced NN NN O
kindling NN NN O
in NN NN O
mice NN NN O
. NN NN O
   
Cognitive NN NN B-Disease
impairment NN NN I-Disease
, NN NN O
the NN NN O
most NN NN O
common NN NN O
and NN NN O
severe NN NN O
comorbidity NN NN O
of NN NN O
epilepsy NN NN B-Disease
, NN NN O
greatly NN NN O
diminishes NN NN O
the NN NN O
quality NN NN O
of NN NN O
life NN NN O
. NN NN O
   
However NN NN O
, NN NN O
current NN NN O
therapeutic NN NN O
interventions NN NN O
for NN NN O
epilepsy NN NN B-Disease
can NN NN O
also NN NN O
cause NN NN O
untoward NN NN O
cognitive NN NN O
effects NN NN O
. NN NN O
   
Thus NN NN O
, NN NN O
there NN NN O
is NN NN O
an NN NN O
urgent NN NN O
need NN NN O
for NN NN O
new NN NN O
kinds NN NN O
of NN NN O
agents NN NN O
targeting NN NN O
both NN NN O
seizures NN NN B-Disease
and NN NN O
cognition NN NN B-Disease
deficits NN NN I-Disease
. NN NN O
   
Oxidative NN NN O
stress NN NN O
is NN NN O
considered NN NN O
to NN NN O
play NN NN O
an NN NN O
important NN NN O
role NN NN O
in NN NN O
epileptogenesis NN NN O
and NN NN O
cognitive NN NN B-Disease
deficits NN NN I-Disease
, NN NN O
and NN NN O
antioxidants NN NN O
have NN NN O
a NN NN O
putative NN NN O
antiepileptic NN NN O
potential NN NN O
. NN NN O
   
Metformin NN NN O
, NN NN O
the NN NN O
most NN NN O
commonly NN NN O
prescribed NN NN O
antidiabetic NN NN O
oral NN NN O
drug NN NN O
, NN NN O
has NN NN O
antioxidant NN NN O
properties NN NN O
. NN NN O
   
This NN NN O
study NN NN O
was NN NN O
designed NN NN O
to NN NN O
evaluate NN NN O
the NN NN O
ameliorative NN NN O
effects NN NN O
of NN NN O
metformin NN NN O
on NN NN O
seizures NN NN B-Disease
, NN NN O
cognitive NN NN B-Disease
impairment NN NN I-Disease
and NN NN O
brain NN NN O
oxidative NN NN O
stress NN NN O
markers NN NN O
observed NN NN O
in NN NN O
pentylenetetrazole NN NN O
- NN NN O
induced NN NN O
kindling NN NN O
animals NN NN O
. NN NN O
   
Male NN NN O
C57BL NN NN O
/ NN NN O
6 NN NN O
mice NN NN O
were NN NN O
administered NN NN O
with NN NN O
subconvulsive NN NN O
dose NN NN O
of NN NN O
pentylenetetrazole NN NN O
( NN NN O
37 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
, NN NN O
i NN NN O
. NN NN O
p NN NN O
. NN NN O
) NN NN O
every NN NN O
other NN NN O
day NN NN O
for NN NN O
14 NN NN O
injections NN NN O
. NN NN O
   
Metformin NN NN O
was NN NN O
injected NN NN O
intraperitoneally NN NN O
in NN NN O
dose NN NN O
of NN NN O
200mg NN NN O
/ NN NN O
kg NN NN O
along NN NN O
with NN NN O
alternate NN NN O
- NN NN O
day NN NN O
PTZ NN NN O
. NN NN O
   
We NN NN O
found NN NN O
that NN NN O
metformin NN NN O
suppressed NN NN O
the NN NN O
progression NN NN O
of NN NN O
kindling NN NN O
, NN NN O
ameliorated NN NN O
the NN NN O
cognitive NN NN B-Disease
impairment NN NN I-Disease
and NN NN O
decreased NN NN O
brain NN NN O
oxidative NN NN O
stress NN NN O
. NN NN O
   
Thus NN NN O
the NN NN O
present NN NN O
study NN NN O
concluded NN NN O
that NN NN O
metformin NN NN O
may NN NN O
be NN NN O
a NN NN O
potential NN NN O
agent NN NN O
for NN NN O
the NN NN O
treatment NN NN O
of NN NN O
epilepsy NN NN B-Disease
as NN NN O
well NN NN O
as NN NN O
a NN NN O
protective NN NN O
medicine NN NN O
against NN NN O
cognitive NN NN B-Disease
impairment NN NN I-Disease
induced NN NN O
by NN NN O
seizures NN NN B-Disease
. NN NN O
   
P53 NN NN O
inhibition NN NN O
exacerbates NN NN O
late NN NN O
- NN NN O
stage NN NN O
anthracycline NN NN O
cardiotoxicity NN NN B-Disease
. NN NN O
   
AIMS NN NN O
: NN NN O
Doxorubicin NN NN O
( NN NN O
DOX NN NN O
) NN NN O
is NN NN O
an NN NN O
effective NN NN O
anti NN NN O
- NN NN O
cancer NN NN B-Disease
therapeutic NN NN O
, NN NN O
but NN NN O
is NN NN O
associated NN NN O
with NN NN O
both NN NN O
acute NN NN O
and NN NN O
late NN NN O
- NN NN O
stage NN NN O
cardiotoxicity NN NN B-Disease
. NN NN O
   
Children NN NN O
are NN NN O
particularly NN NN O
sensitive NN NN O
to NN NN O
DOX NN NN O
- NN NN O
induced NN NN O
heart NN NN B-Disease
failure NN NN I-Disease
. NN NN O
   
Here NN NN O
, NN NN O
the NN NN O
impact NN NN O
of NN NN O
p53 NN NN O
inhibition NN NN O
on NN NN O
acute NN NN O
vs NN NN O
. NN NN O
late NN NN O
- NN NN O
stage NN NN O
DOX NN NN O
cardiotoxicity NN NN B-Disease
was NN NN O
examined NN NN O
in NN NN O
a NN NN O
juvenile NN NN O
model NN NN O
. NN NN O
   
METHODS NN NN O
AND NN NN O
RESULTS NN NN O
: NN NN O
Two NN NN O
- NN NN O
week NN NN O
- NN NN O
old NN NN O
MHC NN NN O
- NN NN O
CB7 NN NN O
mice NN NN O
( NN NN O
which NN NN O
express NN NN O
dominant NN NN O
- NN NN O
interfering NN NN O
p53 NN NN O
in NN NN O
cardiomyocytes NN NN O
) NN NN O
and NN NN O
their NN NN O
non NN NN O
- NN NN O
transgenic NN NN O
( NN NN O
NON NN NN O
- NN NN O
TXG NN NN O
) NN NN O
littermates NN NN O
received NN NN O
weekly NN NN O
DOX NN NN O
injections NN NN O
for NN NN O
5 NN NN O
weeks NN NN O
( NN NN O
25 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
cumulative NN NN O
dose NN NN O
) NN NN O
. NN NN O
   
One NN NN O
week NN NN O
after NN NN O
the NN NN O
last NN NN O
DOX NN NN O
treatment NN NN O
( NN NN O
acute NN NN O
stage NN NN O
) NN NN O
, NN NN O
MHC NN NN O
- NN NN O
CB7 NN NN O
mice NN NN O
exhibited NN NN O
improved NN NN O
cardiac NN NN O
function NN NN O
and NN NN O
lower NN NN O
levels NN NN O
of NN NN O
cardiomyocyte NN NN O
apoptosis NN NN O
when NN NN O
compared NN NN O
with NN NN O
the NN NN O
NON NN NN O
- NN NN O
TXG NN NN O
mice NN NN O
. NN NN O
   
Surprisingly NN NN O
, NN NN O
by NN NN O
13 NN NN O
weeks NN NN O
following NN NN O
the NN NN O
last NN NN O
DOX NN NN O
treatment NN NN O
( NN NN O
late NN NN O
stage NN NN O
) NN NN O
, NN NN O
MHC NN NN O
- NN NN O
CB7 NN NN O
exhibited NN NN O
a NN NN O
progressive NN NN O
decrease NN NN O
in NN NN O
cardiac NN NN O
function NN NN O
and NN NN O
higher NN NN O
rates NN NN O
of NN NN O
cardiomyocyte NN NN O
apoptosis NN NN O
when NN NN O
compared NN NN O
with NN NN O
NON NN NN O
- NN NN O
TXG NN NN O
mice NN NN O
. NN NN O
   
p53 NN NN O
inhibition NN NN O
blocked NN NN O
transient NN NN O
DOX NN NN O
- NN NN O
induced NN NN O
STAT3 NN NN O
activation NN NN O
in NN NN O
MHC NN NN O
- NN NN O
CB7 NN NN O
mice NN NN O
, NN NN O
which NN NN O
was NN NN O
associated NN NN O
with NN NN O
enhanced NN NN O
induction NN NN O
of NN NN O
the NN NN O
DNA NN NN O
repair NN NN O
proteins NN NN O
Ku70 NN NN O
and NN NN O
Ku80 NN NN O
. NN NN O
   
Mice NN NN O
with NN NN O
cardiomyocyte NN NN O
- NN NN O
restricted NN NN O
deletion NN NN O
of NN NN O
STAT3 NN NN O
exhibited NN NN O
worse NN NN O
cardiac NN NN O
function NN NN O
, NN NN O
higher NN NN O
levels NN NN O
of NN NN O
cardiomyocyte NN NN O
apoptosis NN NN O
, NN NN O
and NN NN O
a NN NN O
greater NN NN O
induction NN NN O
of NN NN O
Ku70 NN NN O
and NN NN O
Ku80 NN NN O
in NN NN O
response NN NN O
to NN NN O
DOX NN NN O
treatment NN NN O
during NN NN O
the NN NN O
acute NN NN O
stage NN NN O
when NN NN O
compared NN NN O
with NN NN O
control NN NN O
animals NN NN O
. NN NN O
   
CONCLUSION NN NN O
: NN NN O
These NN NN O
data NN NN O
support NN NN O
a NN NN O
model NN NN O
wherein NN NN O
a NN NN O
p53 NN NN O
- NN NN O
dependent NN NN O
cardioprotective NN NN O
pathway NN NN O
, NN NN O
mediated NN NN O
via NN NN O
STAT3 NN NN O
activation NN NN O
, NN NN O
mitigates NN NN O
DOX NN NN O
- NN NN O
induced NN NN O
myocardial NN NN O
stress NN NN O
during NN NN O
drug NN NN O
delivery NN NN O
. NN NN O
   
Furthermore NN NN O
, NN NN O
these NN NN O
data NN NN O
suggest NN NN O
an NN NN O
explanation NN NN O
as NN NN O
to NN NN O
how NN NN O
p53 NN NN O
inhibition NN NN O
can NN NN O
result NN NN O
in NN NN O
cardioprotection NN NN O
during NN NN O
drug NN NN O
treatment NN NN O
and NN NN O
, NN NN O
paradoxically NN NN O
, NN NN O
enhanced NN NN O
cardiotoxicity NN NN B-Disease
long NN NN O
after NN NN O
the NN NN O
cessation NN NN O
of NN NN O
drug NN NN O
treatment NN NN O
. NN NN O
   
Metronidazole NN NN O
- NN NN O
induced NN NN O
encephalopathy NN NN B-Disease
: NN NN O
an NN NN O
uncommon NN NN O
scenario NN NN O
. NN NN O
   
Metronidazole NN NN O
can NN NN O
produce NN NN O
neurological NN NN O
complications NN NN O
although NN NN O
it NN NN O
is NN NN O
not NN NN O
a NN NN O
common NN NN O
scenario NN NN O
. NN NN O
   
We NN NN O
present NN NN O
a NN NN O
case NN NN O
where NN NN O
a NN NN O
patient NN NN O
developed NN NN O
features NN NN O
of NN NN O
encephalopathy NN NN B-Disease
following NN NN O
prolonged NN NN O
metronidazole NN NN O
intake NN NN O
. NN NN O
   
Magnetic NN NN O
resonance NN NN O
imaging NN NN O
( NN NN O
MRI NN NN O
) NN NN O
brain NN NN O
showed NN NN O
abnormal NN NN O
signal NN NN O
intensity NN NN O
involving NN NN O
both NN NN O
dentate NN NN O
nuclei NN NN O
of NN NN O
cerebellum NN NN O
and NN NN O
splenium NN NN O
of NN NN O
corpus NN NN O
callosum NN NN O
. NN NN O
   
The NN NN O
diagnosis NN NN O
of NN NN O
metronidazole NN NN O
toxicity NN NN B-Disease
was NN NN O
made NN NN O
by NN NN O
the NN NN O
MRI NN NN O
findings NN NN O
and NN NN O
supported NN NN O
clinically NN NN O
. NN NN O
   
Aconitine NN NN O
- NN NN O
induced NN NN O
Ca2 NN NN O
+ NN NN O
overload NN NN O
causes NN NN O
arrhythmia NN NN B-Disease
and NN NN O
triggers NN NN O
apoptosis NN NN O
through NN NN O
p38 NN NN O
MAPK NN NN O
signaling NN NN O
pathway NN NN O
in NN NN O
rats NN NN O
. NN NN O
   
Aconitine NN NN O
is NN NN O
a NN NN O
major NN NN O
bioactive NN NN O
diterpenoid NN NN O
alkaloid NN NN O
with NN NN O
high NN NN O
content NN NN O
derived NN NN O
from NN NN O
herbal NN NN O
aconitum NN NN O
plants NN NN O
. NN NN O
   
Emerging NN NN O
evidence NN NN O
indicates NN NN O
that NN NN O
voltage NN NN O
- NN NN O
dependent NN NN O
Na NN NN O
( NN NN O
+ NN NN O
) NN NN O
channels NN NN O
have NN NN O
pivotal NN NN O
roles NN NN O
in NN NN O
the NN NN O
cardiotoxicity NN NN B-Disease
of NN NN O
aconitine NN NN O
. NN NN O
   
However NN NN O
, NN NN O
no NN NN O
reports NN NN O
are NN NN O
available NN NN O
on NN NN O
the NN NN O
role NN NN O
of NN NN O
Ca NN NN O
( NN NN O
2 NN NN O
+ NN NN O
) NN NN O
in NN NN O
aconitine NN NN O
poisoning NN NN B-Disease
. NN NN O
   
In NN NN O
this NN NN O
study NN NN O
, NN NN O
we NN NN O
explored NN NN O
the NN NN O
importance NN NN O
of NN NN O
pathological NN NN O
Ca NN NN O
( NN NN O
2 NN NN O
+ NN NN O
) NN NN O
signaling NN NN O
in NN NN O
aconitine NN NN O
poisoning NN NN B-Disease
in NN NN O
vitro NN NN O
and NN NN O
in NN NN O
vivo NN NN O
. NN NN O
   
We NN NN O
found NN NN O
that NN NN O
Ca NN NN O
( NN NN O
2 NN NN O
+ NN NN O
) NN NN O
overload NN NN O
lead NN NN O
to NN NN O
accelerated NN NN O
beating NN NN O
rhythm NN NN O
in NN NN O
adult NN NN O
rat NN NN O
ventricular NN NN O
myocytes NN NN O
and NN NN O
caused NN NN O
arrhythmia NN NN B-Disease
in NN NN O
conscious NN NN O
freely NN NN O
moving NN NN O
rats NN NN O
. NN NN O
   
To NN NN O
investigate NN NN O
effects NN NN O
of NN NN O
aconitine NN NN O
on NN NN O
myocardial NN NN B-Disease
injury NN NN I-Disease
, NN NN O
we NN NN O
performed NN NN O
cytotoxicity NN NN B-Disease
assay NN NN O
in NN NN O
neonatal NN NN O
rat NN NN O
ventricular NN NN O
myocytes NN NN O
( NN NN O
NRVMs NN NN O
) NN NN O
, NN NN O
as NN NN O
well NN NN O
as NN NN O
measured NN NN O
lactate NN NN O
dehydrogenase NN NN O
level NN NN O
in NN NN O
the NN NN O
culture NN NN O
medium NN NN O
of NN NN O
NRVMs NN NN O
and NN NN O
activities NN NN O
of NN NN O
serum NN NN O
cardiac NN NN O
enzymes NN NN O
in NN NN O
rats NN NN O
. NN NN O
   
The NN NN O
results NN NN O
showed NN NN O
that NN NN O
aconitine NN NN O
resulted NN NN O
in NN NN O
myocardial NN NN B-Disease
injury NN NN I-Disease
and NN NN O
reduced NN NN O
NRVMs NN NN O
viability NN NN O
dose NN NN O
- NN NN O
dependently NN NN O
. NN NN O
   
To NN NN O
confirm NN NN O
the NN NN O
pro NN NN O
- NN NN O
apoptotic NN NN O
effects NN NN O
, NN NN O
we NN NN O
performed NN NN O
flow NN NN O
cytometric NN NN O
detection NN NN O
, NN NN O
cardiac NN NN O
histology NN NN O
, NN NN O
transmission NN NN O
electron NN NN O
microscopy NN NN O
and NN NN O
terminal NN NN O
deoxynucleotidyl NN NN O
transferase NN NN O
- NN NN O
mediated NN NN O
dUTP NN NN O
- NN NN O
biotin NN NN O
nick NN NN O
end NN NN O
labeling NN NN O
assay NN NN O
. NN NN O
   
The NN NN O
results NN NN O
showed NN NN O
that NN NN O
aconitine NN NN O
stimulated NN NN O
apoptosis NN NN O
time NN NN O
- NN NN O
dependently NN NN O
. NN NN O
   
The NN NN O
expression NN NN O
analysis NN NN O
of NN NN O
Ca NN NN O
( NN NN O
2 NN NN O
+ NN NN O
) NN NN O
handling NN NN O
proteins NN NN O
demonstrated NN NN O
that NN NN O
aconitine NN NN O
promoted NN NN O
Ca NN NN O
( NN NN O
2 NN NN O
+ NN NN O
) NN NN O
overload NN NN O
through NN NN O
the NN NN O
expression NN NN O
regulation NN NN O
of NN NN O
Ca NN NN O
( NN NN O
2 NN NN O
+ NN NN O
) NN NN O
handling NN NN O
proteins NN NN O
. NN NN O
   
The NN NN O
expression NN NN O
analysis NN NN O
of NN NN O
apoptosis NN NN O
- NN NN O
related NN NN O
proteins NN NN O
revealed NN NN O
that NN NN O
pro NN NN O
- NN NN O
apoptotic NN NN O
protein NN NN O
expression NN NN O
was NN NN O
upregulated NN NN O
, NN NN O
and NN NN O
anti NN NN O
- NN NN O
apoptotic NN NN O
protein NN NN O
BCL NN NN O
- NN NN O
2 NN NN O
expression NN NN O
was NN NN O
downregulated NN NN O
. NN NN O
   
Furthermore NN NN O
, NN NN O
increased NN NN O
phosphorylation NN NN O
of NN NN O
MAPK NN NN O
family NN NN O
members NN NN O
, NN NN O
especially NN NN O
the NN NN O
P NN NN O
- NN NN O
P38 NN NN O
/ NN NN O
P38 NN NN O
ratio NN NN O
was NN NN O
found NN NN O
in NN NN O
cardiac NN NN O
tissues NN NN O
. NN NN O
   
Hence NN NN O
, NN NN O
our NN NN O
results NN NN O
suggest NN NN O
that NN NN O
aconitine NN NN O
significantly NN NN O
aggravates NN NN O
Ca NN NN O
( NN NN O
2 NN NN O
+ NN NN O
) NN NN O
overload NN NN O
and NN NN O
causes NN NN O
arrhythmia NN NN B-Disease
and NN NN O
finally NN NN O
promotes NN NN O
apoptotic NN NN O
development NN NN O
via NN NN O
phosphorylation NN NN O
of NN NN O
P38 NN NN O
mitogen NN NN O
- NN NN O
activated NN NN O
protein NN NN O
kinase NN NN O
. NN NN O
   
Chronic NN NN O
treatment NN NN O
with NN NN O
metformin NN NN O
suppresses NN NN O
toll NN NN O
- NN NN O
like NN NN O
receptor NN NN O
4 NN NN O
signaling NN NN O
and NN NN O
attenuates NN NN O
left NN NN B-Disease
ventricular NN NN I-Disease
dysfunction NN NN I-Disease
following NN NN O
myocardial NN NN B-Disease
infarction NN NN I-Disease
. NN NN O
   
Acute NN NN O
treatment NN NN O
with NN NN O
metformin NN NN O
has NN NN O
a NN NN O
protective NN NN O
effect NN NN O
in NN NN O
myocardial NN NN B-Disease
infarction NN NN I-Disease
by NN NN O
suppression NN NN O
of NN NN O
inflammatory NN NN O
responses NN NN O
due NN NN O
to NN NN O
activation NN NN O
of NN NN O
AMP NN NN O
- NN NN O
activated NN NN O
protein NN NN O
kinase NN NN O
( NN NN O
AMPK NN NN O
) NN NN O
. NN NN O
   
In NN NN O
the NN NN O
present NN NN O
study NN NN O
, NN NN O
the NN NN O
effect NN NN O
of NN NN O
chronic NN NN O
pre NN NN O
- NN NN O
treatment NN NN O
with NN NN O
metformin NN NN O
on NN NN O
cardiac NN NN B-Disease
dysfunction NN NN I-Disease
and NN NN O
toll NN NN O
- NN NN O
like NN NN O
receptor NN NN O
4 NN NN O
( NN NN O
TLR4 NN NN O
) NN NN O
activities NN NN O
following NN NN O
myocardial NN NN B-Disease
infarction NN NN I-Disease
and NN NN O
their NN NN O
relation NN NN O
with NN NN O
AMPK NN NN O
were NN NN O
assessed NN NN O
. NN NN O
   
Male NN NN O
Wistar NN NN O
rats NN NN O
were NN NN O
randomly NN NN O
assigned NN NN O
to NN NN O
one NN NN O
of NN NN O
5 NN NN O
groups NN NN O
( NN NN O
n NN NN O
= NN NN O
6 NN NN O
) NN NN O
: NN NN O
normal NN NN O
control NN NN O
and NN NN O
groups NN NN O
were NN NN O
injected NN NN O
isoproterenol NN NN O
after NN NN O
chronic NN NN O
pre NN NN O
- NN NN O
treatment NN NN O
with NN NN O
0 NN NN O
, NN NN O
25 NN NN O
, NN NN O
50 NN NN O
, NN NN O
or NN NN O
100mg NN NN O
/ NN NN O
kg NN NN O
of NN NN O
metformin NN NN O
twice NN NN O
daily NN NN O
for NN NN O
14 NN NN O
days NN NN O
. NN NN O
   
Isoproterenol NN NN O
( NN NN O
100mg NN NN O
/ NN NN O
kg NN NN O
) NN NN O
was NN NN O
injected NN NN O
subcutaneously NN NN O
on NN NN O
the NN NN O
13th NN NN O
and NN NN O
14th NN NN O
days NN NN O
to NN NN O
induce NN NN O
acute NN NN B-Disease
myocardial NN NN I-Disease
infarction NN NN I-Disease
. NN NN O
   
Isoproterenol NN NN O
alone NN NN O
decreased NN NN O
left NN NN O
ventricular NN NN O
systolic NN NN O
pressure NN NN O
and NN NN O
myocardial NN NN O
contractility NN NN O
indexed NN NN O
as NN NN O
LVdp NN NN O
/ NN NN O
dtmax NN NN O
and NN NN O
LVdp NN NN O
/ NN NN O
dtmin NN NN O
. NN NN O
   
The NN NN O
left NN NN B-Disease
ventricular NN NN I-Disease
dysfunction NN NN I-Disease
was NN NN O
significantly NN NN O
lower NN NN O
in NN NN O
the NN NN O
groups NN NN O
treated NN NN O
with NN NN O
25 NN NN O
and NN NN O
50mg NN NN O
/ NN NN O
kg NN NN O
of NN NN O
metformin NN NN O
. NN NN O
   
Metfromin NN NN O
markedly NN NN O
lowered NN NN O
isoproterenol NN NN O
- NN NN O
induced NN NN O
elevation NN NN O
in NN NN O
the NN NN O
levels NN NN O
of NN NN O
TLR4 NN NN O
mRNA NN NN O
, NN NN O
myeloid NN NN O
differentiation NN NN O
protein NN NN O
88 NN NN O
( NN NN O
MyD88 NN NN O
) NN NN O
, NN NN O
tumor NN NN B-Disease
necrosis NN NN B-Disease
factor NN NN O
- NN NN O
alpha NN NN O
( NN NN O
TNF NN NN O
- NN NN O
a NN NN O
) NN NN O
, NN NN O
and NN NN O
interleukin NN NN O
6 NN NN O
( NN NN O
IL NN NN O
- NN NN O
6 NN NN O
) NN NN O
in NN NN O
the NN NN O
heart NN NN O
tissues NN NN O
. NN NN O
   
Similar NN NN O
changes NN NN O
were NN NN O
also NN NN O
seen NN NN O
in NN NN O
the NN NN O
serum NN NN O
levels NN NN O
of NN NN O
TNF NN NN O
- NN NN O
a NN NN O
and NN NN O
IL NN NN O
- NN NN O
6 NN NN O
. NN NN O
   
However NN NN O
, NN NN O
the NN NN O
lower NN NN O
doses NN NN O
of NN NN O
25 NN NN O
and NN NN O
50mg NN NN O
/ NN NN O
kg NN NN O
were NN NN O
more NN NN O
effective NN NN O
than NN NN O
100mg NN NN O
/ NN NN O
kg NN NN O
. NN NN O
   
Phosphorylated NN NN O
AMPKa NN NN O
( NN NN O
p NN NN O
- NN NN O
AMPK NN NN O
) NN NN O
in NN NN O
the NN NN O
myocardium NN NN O
was NN NN O
significantly NN NN O
elevated NN NN O
by NN NN O
25mg NN NN O
/ NN NN O
kg NN NN O
of NN NN O
metformin NN NN O
, NN NN O
slightly NN NN O
by NN NN O
50mg NN NN O
/ NN NN O
kg NN NN O
, NN NN O
but NN NN O
not NN NN O
by NN NN O
100mg NN NN O
/ NN NN O
kg NN NN O
. NN NN O
   
Chronic NN NN O
pre NN NN O
- NN NN O
treatment NN NN O
with NN NN O
metformin NN NN O
reduces NN NN O
post NN NN O
- NN NN O
myocardial NN NN B-Disease
infarction NN NN I-Disease
cardiac NN NN O
dysfunction NN NN O
and NN NN O
suppresses NN NN O
inflammatory NN NN O
responses NN NN O
, NN NN O
possibly NN NN O
through NN NN O
inhibition NN NN O
of NN NN O
TLR4 NN NN O
activities NN NN O
. NN NN O
   
This NN NN O
mechanism NN NN O
can NN NN O
be NN NN O
considered NN NN O
as NN NN O
a NN NN O
target NN NN O
to NN NN O
protect NN NN O
infarcted NN NN O
myocardium NN NN O
. NN NN O
   
Unusual NN NN O
complications NN NN O
of NN NN O
antithyroid NN NN O
drug NN NN O
therapy NN NN O
: NN NN O
four NN NN O
case NN NN O
reports NN NN O
and NN NN O
review NN NN O
of NN NN O
literature NN NN O
. NN NN O
   
Two NN NN O
cases NN NN O
of NN NN O
propylthiouracil NN NN O
- NN NN O
associated NN NN O
acute NN NN O
hepatitis NN NN B-Disease
, NN NN O
one NN NN O
case NN NN O
of NN NN O
fatal NN NN O
methimazole NN NN O
- NN NN O
associated NN NN O
hepatocellular NN NN B-Disease
necrosis NN NN I-Disease
and NN NN O
one NN NN O
case NN NN O
of NN NN O
propylthiouracil NN NN O
- NN NN O
associated NN NN O
lupus NN NN B-Disease
- NN NN I-Disease
like NN NN I-Disease
syndrome NN NN I-Disease
are NN NN O
described NN NN O
. NN NN O
   
The NN NN O
literature NN NN O
related NN NN O
to NN NN O
antithyroid NN NN O
drug NN NN O
side NN NN O
effects NN NN O
and NN NN O
the NN NN O
mechanisms NN NN O
for NN NN O
their NN NN O
occurrence NN NN O
are NN NN O
reviewed NN NN O
and NN NN O
the NN NN O
efficacy NN NN O
and NN NN O
complications NN NN O
of NN NN O
thyroidectomy NN NN O
and NN NN O
radioiodine NN NN O
compared NN NN O
to NN NN O
those NN NN O
of NN NN O
antithyroid NN NN O
drugs NN NN O
. NN NN O
   
It NN NN O
is NN NN O
concluded NN NN O
that NN NN O
in NN NN O
most NN NN O
circumstances NN NN O
131I NN NN O
is NN NN O
the NN NN O
therapy NN NN O
of NN NN O
choice NN NN O
for NN NN O
hyperthyroidism NN NN B-Disease
. NN NN O
   
Neuroleptic NN NN B-Disease
malignant NN NN I-Disease
syndrome NN NN I-Disease
induced NN NN O
by NN NN O
combination NN NN O
therapy NN NN O
with NN NN O
tetrabenazine NN NN O
and NN NN O
tiapride NN NN O
in NN NN O
a NN NN O
Japanese NN NN O
patient NN NN O
with NN NN O
Huntington NN NN B-Disease
' NN NN I-Disease
s NN NN I-Disease
disease NN NN I-Disease
at NN NN O
the NN NN O
terminal NN NN O
stage NN NN O
of NN NN O
recurrent NN NN O
breast NN NN B-Disease
cancer NN NN I-Disease
. NN NN O
   
We NN NN O
herein NN NN O
describe NN NN O
the NN NN O
case NN NN O
of NN NN O
an NN NN O
81 NN NN O
- NN NN O
year NN NN O
- NN NN O
old NN NN O
Japanese NN NN O
woman NN NN O
with NN NN O
neuroleptic NN NN B-Disease
malignant NN NN I-Disease
syndrome NN NN I-Disease
that NN NN O
occurred NN NN O
36 NN NN O
days NN NN O
after NN NN O
the NN NN O
initiation NN NN O
of NN NN O
combination NN NN O
therapy NN NN O
with NN NN O
tiapride NN NN O
( NN NN O
75 NN NN O
mg NN NN O
/ NN NN O
day NN NN O
) NN NN O
and NN NN O
tetrabenazine NN NN O
( NN NN O
12 NN NN O
. NN NN O
5 NN NN O
mg NN NN O
/ NN NN O
day NN NN O
) NN NN O
for NN NN O
Huntington NN NN B-Disease
' NN NN I-Disease
s NN NN I-Disease
disease NN NN I-Disease
. NN NN O
   
The NN NN O
patient NN NN O
had NN NN O
been NN NN O
treated NN NN O
with NN NN O
tiapride NN NN O
or NN NN O
tetrabenazine NN NN O
alone NN NN O
without NN NN O
any NN NN O
adverse NN NN O
effects NN NN O
before NN NN O
the NN NN O
administration NN NN O
of NN NN O
the NN NN O
combination NN NN O
therapy NN NN O
. NN NN O
   
She NN NN O
also NN NN O
had NN NN O
advanced NN NN O
breast NN NN B-Disease
cancer NN NN I-Disease
when NN NN O
the NN NN O
combination NN NN O
therapy NN NN O
was NN NN O
initiated NN NN O
. NN NN O
   
To NN NN O
the NN NN O
best NN NN O
of NN NN O
our NN NN O
knowledge NN NN O
, NN NN O
the NN NN O
occurrence NN NN O
of NN NN O
neuroleptic NN NN B-Disease
malignant NN NN I-Disease
syndrome NN NN I-Disease
due NN NN O
to NN NN O
combination NN NN O
therapy NN NN O
with NN NN O
tetrabenazine NN NN O
and NN NN O
tiapride NN NN O
has NN NN O
not NN NN O
been NN NN O
previously NN NN O
reported NN NN O
. NN NN O
   
Tetrabenazine NN NN O
should NN NN O
be NN NN O
administered NN NN O
very NN NN O
carefully NN NN O
in NN NN O
combination NN NN O
with NN NN O
other NN NN O
neuroleptic NN NN O
drugs NN NN O
, NN NN O
particularly NN NN O
in NN NN O
patients NN NN O
with NN NN O
a NN NN O
worsening NN NN O
general NN NN O
condition NN NN O
. NN NN O
   
A NN NN O
metoprolol NN NN O
- NN NN O
terbinafine NN NN O
combination NN NN O
induced NN NN O
bradycardia NN NN B-Disease
. NN NN O
   
To NN NN O
report NN NN O
a NN NN O
sinus NN NN B-Disease
bradycardia NN NN I-Disease
induced NN NN O
by NN NN O
metoprolol NN NN O
and NN NN O
terbinafine NN NN O
drug NN NN O
- NN NN O
drug NN NN O
interaction NN NN O
and NN NN O
its NN NN O
management NN NN O
. NN NN O
   
A NN NN O
63 NN NN O
year NN NN O
- NN NN O
old NN NN O
Caucasian NN NN O
man NN NN O
on NN NN O
metoprolol NN NN O
200 NN NN O
mg NN NN O
/ NN NN O
day NN NN O
for NN NN O
stable NN NN O
coronary NN NN B-Disease
artery NN NN I-Disease
disease NN NN I-Disease
was NN NN O
prescribed NN NN O
a NN NN O
90 NN NN O
- NN NN O
day NN NN O
course NN NN O
of NN NN O
oral NN NN O
terbinafine NN NN O
250 NN NN O
mg NN NN O
/ NN NN O
day NN NN O
for NN NN O
onychomycosis NN NN B-Disease
. NN NN O
   
On NN NN O
the NN NN O
49th NN NN O
day NN NN O
of NN NN O
terbinafine NN NN O
therapy NN NN O
, NN NN O
he NN NN O
was NN NN O
brought NN NN O
to NN NN O
the NN NN O
emergency NN NN O
room NN NN O
for NN NN O
a NN NN O
decrease NN NN O
of NN NN O
his NN NN O
global NN NN O
health NN NN O
status NN NN O
, NN NN O
confusion NN NN B-Disease
and NN NN O
falls NN NN O
. NN NN O
   
The NN NN O
electrocardiogram NN NN O
revealed NN NN O
a NN NN O
37 NN NN O
beats NN NN O
/ NN NN O
min NN NN O
sinus NN NN B-Disease
bradycardia NN NN I-Disease
. NN NN O
   
A NN NN O
score NN NN O
of NN NN O
7 NN NN O
on NN NN O
the NN NN O
Naranjo NN NN O
adverse NN NN B-Disease
drug NN NN I-Disease
reaction NN NN I-Disease
probability NN NN O
scale NN NN O
indicates NN NN O
a NN NN O
probable NN NN O
relationship NN NN O
between NN NN O
the NN NN O
patient NN NN O
' NN NN O
s NN NN O
sinus NN NN B-Disease
bradycardia NN NN I-Disease
and NN NN O
the NN NN O
drug NN NN O
interaction NN NN O
between NN NN O
metoprolol NN NN O
and NN NN O
terbinafine NN NN O
. NN NN O
   
The NN NN O
heart NN NN O
rate NN NN O
ameliorated NN NN O
first NN NN O
with NN NN O
a NN NN O
decrease NN NN O
in NN NN O
the NN NN O
dose NN NN O
of NN NN O
metoprolol NN NN O
. NN NN O
   
It NN NN O
was NN NN O
subsequently NN NN O
changed NN NN O
to NN NN O
bisoprolol NN NN O
and NN NN O
the NN NN O
heart NN NN O
rate NN NN O
remained NN NN O
normal NN NN O
. NN NN O
   
By NN NN O
inhibiting NN NN O
the NN NN O
cytochrome NN NN O
P450 NN NN O
2D6 NN NN O
, NN NN O
terbinafine NN NN O
had NN NN O
decreased NN NN O
metoprolol NN NN O
' NN NN O
s NN NN O
clearance NN NN O
, NN NN O
leading NN NN O
in NN NN O
metoprolol NN NN O
accumulation NN NN O
which NN NN O
has NN NN O
resulted NN NN O
in NN NN O
clinically NN NN O
significant NN NN O
sinus NN NN B-Disease
bradycardia NN NN I-Disease
. NN NN O
   
Optochiasmatic NN NN O
and NN NN O
peripheral NN NN B-Disease
neuropathy NN NN I-Disease
due NN NN O
to NN NN O
ethambutol NN NN O
overtreatment NN NN O
. NN NN O
   
Ethambutol NN NN O
is NN NN O
known NN NN O
to NN NN O
cause NN NN O
optic NN NN B-Disease
neuropathy NN NN I-Disease
and NN NN O
, NN NN O
more NN NN O
rarely NN NN O
, NN NN O
axonal NN NN O
polyneuropathy NN NN B-Disease
. NN NN O
   
We NN NN O
characterize NN NN O
the NN NN O
clinical NN NN O
, NN NN O
neurophysiological NN NN O
, NN NN O
and NN NN O
neuroimaging NN NN O
findings NN NN O
in NN NN O
a NN NN O
72 NN NN O
- NN NN O
year NN NN O
- NN NN O
old NN NN O
man NN NN O
who NN NN O
developed NN NN O
visual NN NN B-Disease
loss NN NN I-Disease
and NN NN O
paresthesias NN NN B-Disease
after NN NN O
11 NN NN O
weeks NN NN O
of NN NN O
exposure NN NN O
to NN NN O
a NN NN O
supratherapeutic NN NN O
dose NN NN O
of NN NN O
ethambutol NN NN O
. NN NN O
   
This NN NN O
case NN NN O
demonstrates NN NN O
the NN NN O
selective NN NN O
vulnerability NN NN O
of NN NN O
the NN NN O
anterior NN NN O
visual NN NN O
pathways NN NN O
and NN NN O
peripheral NN NN O
nerves NN NN O
to NN NN O
ethambutol NN NN O
toxicity NN NN B-Disease
. NN NN O
   
Testosterone NN NN O
ameliorates NN NN O
streptozotocin NN NN O
- NN NN O
induced NN NN O
memory NN NN B-Disease
impairment NN NN I-Disease
in NN NN O
male NN NN O
rats NN NN O
. NN NN O
   
AIM NN NN O
: NN NN O
To NN NN O
study NN NN O
the NN NN O
effects NN NN O
of NN NN O
testosterone NN NN O
on NN NN O
streptozotocin NN NN O
( NN NN O
STZ NN NN O
) NN NN O
- NN NN O
induced NN NN O
memory NN NN B-Disease
impairment NN NN I-Disease
in NN NN O
male NN NN O
rats NN NN O
. NN NN O
   
METHODS NN NN O
: NN NN O
Adult NN NN O
male NN NN O
Wistar NN NN O
rats NN NN O
were NN NN O
intracerebroventricularly NN NN O
( NN NN O
icv NN NN O
) NN NN O
infused NN NN O
with NN NN O
STZ NN NN O
( NN NN O
750 NN NN O
ug NN NN O
) NN NN O
on NN NN O
d NN NN O
1 NN NN O
and NN NN O
d NN NN O
3 NN NN O
, NN NN O
and NN NN O
a NN NN O
passive NN NN O
avoidance NN NN O
task NN NN O
was NN NN O
assessed NN NN O
2 NN NN O
weeks NN NN O
after NN NN O
the NN NN O
first NN NN O
injection NN NN O
of NN NN O
STZ NN NN O
. NN NN O
   
Castration NN NN O
surgery NN NN O
was NN NN O
performed NN NN O
in NN NN O
another NN NN O
group NN NN O
of NN NN O
rats NN NN O
, NN NN O
and NN NN O
the NN NN O
passive NN NN O
avoidance NN NN O
task NN NN O
was NN NN O
assessed NN NN O
4 NN NN O
weeks NN NN O
after NN NN O
the NN NN O
operation NN NN O
. NN NN O
   
Testosterone NN NN O
( NN NN O
1 NN NN O
mg NN NN O
. NN NN O
kg NN NN O
( NN NN O
- NN NN O
1 NN NN O
) NN NN O
. NN NN O
d NN NN O
( NN NN O
- NN NN O
1 NN NN O
) NN NN O
, NN NN O
sc NN NN O
) NN NN O
, NN NN O
the NN NN O
androgen NN NN O
receptor NN NN O
antagonist NN NN O
flutamide NN NN O
( NN NN O
10 NN NN O
mg NN NN O
. NN NN O
kg NN NN O
( NN NN O
- NN NN O
1 NN NN O
) NN NN O
. NN NN O
d NN NN O
( NN NN O
- NN NN O
1 NN NN O
) NN NN O
, NN NN O
ip NN NN O
) NN NN O
, NN NN O
the NN NN O
estrogen NN NN O
receptor NN NN O
antagonist NN NN O
tamoxifen NN NN O
( NN NN O
1 NN NN O
mg NN NN O
. NN NN O
kg NN NN O
( NN NN O
- NN NN O
1 NN NN O
) NN NN O
. NN NN O
d NN NN O
( NN NN O
- NN NN O
1 NN NN O
) NN NN O
, NN NN O
ip NN NN O
) NN NN O
or NN NN O
the NN NN O
aromatase NN NN O
inhibitor NN NN O
letrozole NN NN O
( NN NN O
4 NN NN O
mg NN NN O
. NN NN O
kg NN NN O
( NN NN O
- NN NN O
1 NN NN O
) NN NN O
. NN NN O
d NN NN O
( NN NN O
- NN NN O
1 NN NN O
) NN NN O
, NN NN O
ip NN NN O
) NN NN O
were NN NN O
administered NN NN O
for NN NN O
6 NN NN O
d NN NN O
after NN NN O
the NN NN O
first NN NN O
injection NN NN O
of NN NN O
STZ NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
STZ NN NN O
administration NN NN O
and NN NN O
castration NN NN O
markedly NN NN O
decreased NN NN O
both NN NN O
STL1 NN NN O
( NN NN O
the NN NN O
short NN NN O
memory NN NN O
) NN NN O
and NN NN O
STL2 NN NN O
( NN NN O
the NN NN O
long NN NN O
memory NN NN O
) NN NN O
in NN NN O
passive NN NN O
avoidance NN NN O
tests NN NN O
. NN NN O
   
Testosterone NN NN O
replacement NN NN O
almost NN NN O
restored NN NN O
the NN NN O
STL1 NN NN O
and NN NN O
STL2 NN NN O
in NN NN O
castrated NN NN O
rats NN NN O
, NN NN O
and NN NN O
significantly NN NN O
prolonged NN NN O
the NN NN O
STL1 NN NN O
and NN NN O
STL2 NN NN O
in NN NN O
STZ NN NN O
- NN NN O
treated NN NN O
rats NN NN O
. NN NN O
   
Administration NN NN O
of NN NN O
flutamide NN NN O
, NN NN O
letrozole NN NN O
or NN NN O
tamoxifen NN NN O
significantly NN NN O
impaired NN NN B-Disease
the NN NN I-Disease
memory NN NN I-Disease
in NN NN O
intact NN NN O
rats NN NN O
, NN NN O
and NN NN O
significantly NN NN O
attenuated NN NN O
the NN NN O
testosterone NN NN O
replacement NN NN O
in NN NN O
improving NN NN O
STZ NN NN O
- NN NN O
and NN NN O
castration NN NN O
- NN NN O
induced NN NN O
memory NN NN B-Disease
impairment NN NN I-Disease
. NN NN O
   
CONCLUSION NN NN O
: NN NN O
Testosterone NN NN O
administration NN NN O
ameliorates NN NN O
STZ NN NN O
- NN NN O
and NN NN O
castration NN NN O
- NN NN O
induced NN NN O
memory NN NN B-Disease
impairment NN NN I-Disease
in NN NN O
male NN NN O
Wistar NN NN O
rats NN NN O
. NN NN O
   
Behavioral NN NN O
and NN NN O
neurochemical NN NN O
studies NN NN O
in NN NN O
mice NN NN O
pretreated NN NN O
with NN NN O
garcinielliptone NN NN O
FC NN NN O
in NN NN O
pilocarpine NN NN O
- NN NN O
induced NN NN O
seizures NN NN B-Disease
. NN NN O
   
Garcinielliptone NN NN O
FC NN NN O
( NN NN O
GFC NN NN O
) NN NN O
isolated NN NN O
from NN NN O
hexanic NN NN O
fraction NN NN O
seed NN NN O
extract NN NN O
of NN NN O
species NN NN O
Platonia NN NN O
insignis NN NN O
Mart NN NN O
. NN NN O
   
It NN NN O
is NN NN O
widely NN NN O
used NN NN O
in NN NN O
folk NN NN O
medicine NN NN O
to NN NN O
treat NN NN O
skin NN NN B-Disease
diseases NN NN I-Disease
in NN NN O
both NN NN O
humans NN NN O
and NN NN O
animals NN NN O
as NN NN O
well NN NN O
as NN NN O
the NN NN O
seed NN NN O
decoction NN NN O
has NN NN O
been NN NN O
used NN NN O
to NN NN O
treat NN NN O
diarrheas NN NN B-Disease
and NN NN O
inflammatory NN NN B-Disease
diseases NN NN I-Disease
. NN NN O
   
However NN NN O
, NN NN O
there NN NN O
is NN NN O
no NN NN O
research NN NN O
on NN NN O
GFC NN NN O
effects NN NN O
in NN NN O
the NN NN O
central NN NN O
nervous NN NN O
system NN NN O
of NN NN O
rodents NN NN O
. NN NN O
   
The NN NN O
present NN NN O
study NN NN O
aimed NN NN O
to NN NN O
evaluate NN NN O
the NN NN O
GFC NN NN O
effects NN NN O
at NN NN O
doses NN NN O
of NN NN O
25 NN NN O
, NN NN O
50 NN NN O
or NN NN O
75 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
on NN NN O
seizure NN NN B-Disease
parameters NN NN O
to NN NN O
determine NN NN O
their NN NN O
anticonvulsant NN NN O
activity NN NN O
and NN NN O
its NN NN O
effects NN NN O
on NN NN O
amino NN NN O
acid NN NN O
( NN NN O
r NN NN O
- NN NN O
aminobutyric NN NN O
acid NN NN O
( NN NN O
GABA NN NN O
) NN NN O
, NN NN O
glutamine NN NN O
, NN NN O
aspartate NN NN O
and NN NN O
glutathione NN NN O
) NN NN O
levels NN NN O
as NN NN O
well NN NN O
as NN NN O
on NN NN O
acetylcholinesterase NN NN O
( NN NN O
AChE NN NN O
) NN NN O
activity NN NN O
in NN NN O
mice NN NN O
hippocampus NN NN O
after NN NN O
seizures NN NN B-Disease
. NN NN O
   
GFC NN NN O
produced NN NN O
an NN NN O
increased NN NN O
latency NN NN O
to NN NN O
first NN NN O
seizure NN NN B-Disease
, NN NN O
at NN NN O
doses NN NN O
25mg NN NN O
/ NN NN O
kg NN NN O
( NN NN O
20 NN NN O
. NN NN O
12 NN NN O
+ NN NN O
2 NN NN O
. NN NN O
20 NN NN O
min NN NN O
) NN NN O
, NN NN O
50mg NN NN O
/ NN NN O
kg NN NN O
( NN NN O
20 NN NN O
. NN NN O
95 NN NN O
+ NN NN O
2 NN NN O
. NN NN O
21 NN NN O
min NN NN O
) NN NN O
or NN NN O
75 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
( NN NN O
23 NN NN O
. NN NN O
43 NN NN O
+ NN NN O
1 NN NN O
. NN NN O
99 NN NN O
min NN NN O
) NN NN O
when NN NN O
compared NN NN O
with NN NN O
seized NN NN O
mice NN NN O
. NN NN O
   
In NN NN O
addition NN NN O
, NN NN O
GABA NN NN O
content NN NN O
of NN NN O
mice NN NN O
hippocampus NN NN O
treated NN NN O
with NN NN O
GFC75 NN NN O
plus NN NN O
P400 NN NN O
showed NN NN O
an NN NN O
increase NN NN O
of NN NN O
46 NN NN O
. NN NN O
90 NN NN O
% NN NN O
when NN NN O
compared NN NN O
with NN NN O
seized NN NN O
mice NN NN O
. NN NN O
   
In NN NN O
aspartate NN NN O
, NN NN O
glutamine NN NN O
and NN NN O
glutamate NN NN O
levels NN NN O
detected NN NN O
a NN NN O
decrease NN NN O
of NN NN O
5 NN NN O
. NN NN O
21 NN NN O
% NN NN O
, NN NN O
13 NN NN O
. NN NN O
55 NN NN O
% NN NN O
and NN NN O
21 NN NN O
. NN NN O
80 NN NN O
% NN NN O
, NN NN O
respectively NN NN O
in NN NN O
mice NN NN O
hippocampus NN NN O
treated NN NN O
with NN NN O
GFC75 NN NN O
plus NN NN O
P400 NN NN O
when NN NN O
compared NN NN O
with NN NN O
seized NN NN O
mice NN NN O
. NN NN O
   
Hippocampus NN NN O
mice NN NN O
treated NN NN O
with NN NN O
GFC75 NN NN O
plus NN NN O
P400 NN NN O
showed NN NN O
an NN NN O
increase NN NN O
in NN NN O
AChE NN NN O
activity NN NN O
( NN NN O
63 NN NN O
. NN NN O
30 NN NN O
% NN NN O
) NN NN O
when NN NN O
compared NN NN O
with NN NN O
seized NN NN O
mice NN NN O
. NN NN O
   
The NN NN O
results NN NN O
indicate NN NN O
that NN NN O
GFC NN NN O
can NN NN O
exert NN NN O
anticonvulsant NN NN O
activity NN NN O
and NN NN O
reduce NN NN O
the NN NN O
frequency NN NN O
of NN NN O
installation NN NN O
of NN NN O
pilocarpine NN NN O
- NN NN O
induced NN NN O
status NN NN B-Disease
epilepticus NN NN I-Disease
, NN NN O
as NN NN O
demonstrated NN NN O
by NN NN O
increase NN NN O
in NN NN O
latency NN NN O
to NN NN O
first NN NN O
seizure NN NN B-Disease
and NN NN O
decrease NN NN O
in NN NN O
mortality NN NN O
rate NN NN O
of NN NN O
animals NN NN O
. NN NN O
   
In NN NN O
conclusion NN NN O
, NN NN O
our NN NN O
data NN NN O
suggest NN NN O
that NN NN O
GFC NN NN O
may NN NN O
influence NN NN O
in NN NN O
epileptogenesis NN NN O
and NN NN O
promote NN NN O
anticonvulsant NN NN O
actions NN NN O
in NN NN O
pilocarpine NN NN O
model NN NN O
by NN NN O
modulating NN NN O
the NN NN O
GABA NN NN O
and NN NN O
glutamate NN NN O
contents NN NN O
and NN NN O
of NN NN O
AChE NN NN O
activity NN NN O
in NN NN O
seized NN NN O
mice NN NN O
hippocampus NN NN O
. NN NN O
   
This NN NN O
compound NN NN O
may NN NN O
be NN NN O
useful NN NN O
to NN NN O
produce NN NN O
neuronal NN NN O
protection NN NN O
and NN NN O
it NN NN O
can NN NN O
be NN NN O
considered NN NN O
as NN NN O
an NN NN O
anticonvulsant NN NN O
agent NN NN O
. NN NN O
   
Standard NN NN O
operating NN NN O
procedures NN NN O
for NN NN O
antibiotic NN NN O
therapy NN NN O
and NN NN O
the NN NN O
occurrence NN NN O
of NN NN O
acute NN NN B-Disease
kidney NN NN I-Disease
injury NN NN I-Disease
: NN NN O
a NN NN O
prospective NN NN O
, NN NN O
clinical NN NN O
, NN NN O
non NN NN O
- NN NN O
interventional NN NN O
, NN NN O
observational NN NN O
study NN NN O
. NN NN O
   
INTRODUCTION NN NN O
: NN NN O
Acute NN NN B-Disease
kidney NN NN I-Disease
injury NN NN I-Disease
( NN NN O
AKI NN NN B-Disease
) NN NN O
occurs NN NN O
in NN NN O
7 NN NN O
% NN NN O
of NN NN O
hospitalized NN NN O
and NN NN O
66 NN NN O
% NN NN O
of NN NN O
Intensive NN NN O
Care NN NN O
Unit NN NN O
( NN NN O
ICU NN NN O
) NN NN O
patients NN NN O
. NN NN O
   
It NN NN O
increases NN NN O
mortality NN NN O
, NN NN O
hospital NN NN O
length NN NN O
of NN NN O
stay NN NN O
, NN NN O
and NN NN O
costs NN NN O
. NN NN O
   
The NN NN O
aim NN NN O
of NN NN O
this NN NN O
study NN NN O
was NN NN O
to NN NN O
investigate NN NN O
, NN NN O
whether NN NN O
there NN NN O
is NN NN O
an NN NN O
association NN NN O
between NN NN O
adherence NN NN O
to NN NN O
guidelines NN NN O
( NN NN O
standard NN NN O
operating NN NN O
procedures NN NN O
( NN NN O
SOP NN NN O
) NN NN O
) NN NN O
for NN NN O
potentially NN NN O
nephrotoxic NN NN B-Disease
antibiotics NN NN O
and NN NN O
the NN NN O
occurrence NN NN O
of NN NN O
AKI NN NN B-Disease
. NN NN O
   
METHODS NN NN O
: NN NN O
This NN NN O
study NN NN O
was NN NN O
carried NN NN O
out NN NN O
as NN NN O
a NN NN O
prospective NN NN O
, NN NN O
clinical NN NN O
, NN NN O
non NN NN O
- NN NN O
interventional NN NN O
, NN NN O
observational NN NN O
study NN NN O
. NN NN O
   
Data NN NN O
collection NN NN O
was NN NN O
performed NN NN O
over NN NN O
a NN NN O
total NN NN O
of NN NN O
170 NN NN O
days NN NN O
in NN NN O
three NN NN O
ICUs NN NN O
at NN NN O
Charite NN NN O
- NN NN O
Universitaetsmedizin NN NN O
Berlin NN NN O
. NN NN O
   
A NN NN O
total NN NN O
of NN NN O
675 NN NN O
patients NN NN O
were NN NN O
included NN NN O
; NN NN O
163 NN NN O
of NN NN O
these NN NN O
had NN NN O
therapy NN NN O
with NN NN O
vancomycin NN NN O
, NN NN O
gentamicin NN NN O
, NN NN O
or NN NN O
tobramycin NN NN O
; NN NN O
were NN NN O
> NN NN O
18 NN NN O
years NN NN O
; NN NN O
and NN NN O
treated NN NN O
in NN NN O
the NN NN O
ICU NN NN O
for NN NN O
> NN NN O
24 NN NN O
hours NN NN O
. NN NN O
   
Patients NN NN O
with NN NN O
an NN NN O
adherence NN NN O
to NN NN O
SOP NN NN O
> NN NN O
70 NN NN O
% NN NN O
were NN NN O
classified NN NN O
into NN NN O
the NN NN O
high NN NN O
adherence NN NN O
group NN NN O
( NN NN O
HAG NN NN O
) NN NN O
and NN NN O
patients NN NN O
with NN NN O
an NN NN O
adherence NN NN O
of NN NN O
< NN NN O
70 NN NN O
% NN NN O
into NN NN O
the NN NN O
low NN NN O
adherence NN NN O
group NN NN O
( NN NN O
LAG NN NN O
) NN NN O
. NN NN O
   
AKI NN NN B-Disease
was NN NN O
defined NN NN O
according NN NN O
to NN NN O
RIFLE NN NN O
criteria NN NN O
. NN NN O
   
Adherence NN NN O
to NN NN O
SOPs NN NN O
was NN NN O
evaluated NN NN O
by NN NN O
retrospective NN NN O
expert NN NN O
audit NN NN O
. NN NN O
   
Development NN NN O
of NN NN O
AKI NN NN B-Disease
was NN NN O
compared NN NN O
between NN NN O
groups NN NN O
with NN NN O
exact NN NN O
Chi2 NN NN O
- NN NN O
test NN NN O
and NN NN O
multivariate NN NN O
logistic NN NN O
regression NN NN O
analysis NN NN O
( NN NN O
two NN NN O
- NN NN O
sided NN NN O
P NN NN O
< NN NN O
0 NN NN O
. NN NN O
05 NN NN O
) NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
LAG NN NN O
consisted NN NN O
of NN NN O
75 NN NN O
patients NN NN O
( NN NN O
46 NN NN O
% NN NN O
) NN NN O
versus NN NN O
88 NN NN O
HAG NN NN O
patients NN NN O
( NN NN O
54 NN NN O
% NN NN O
) NN NN O
. NN NN O
   
AKI NN NN B-Disease
occurred NN NN O
significantly NN NN O
more NN NN O
often NN NN O
in NN NN O
LAG NN NN O
with NN NN O
36 NN NN O
% NN NN O
versus NN NN O
21 NN NN O
% NN NN O
in NN NN O
HAG NN NN O
( NN NN O
P NN NN O
= NN NN O
0 NN NN O
. NN NN O
035 NN NN O
) NN NN O
. NN NN O
   
Basic NN NN O
characteristics NN NN O
were NN NN O
comparable NN NN O
, NN NN O
except NN NN O
an NN NN O
increased NN NN O
rate NN NN O
of NN NN O
soft NN NN O
tissue NN NN O
infections NN NN B-Disease
in NN NN O
LAG NN NN O
. NN NN O
   
Multivariate NN NN O
analysis NN NN O
revealed NN NN O
an NN NN O
odds NN NN O
ratio NN NN O
of NN NN O
2 NN NN O
. NN NN O
5 NN NN O
- NN NN O
fold NN NN O
for NN NN O
LAG NN NN O
to NN NN O
develop NN NN O
AKI NN NN B-Disease
compared NN NN O
with NN NN O
HAG NN NN O
( NN NN O
95 NN NN O
% NN NN O
confidence NN NN O
interval NN NN O
1 NN NN O
. NN NN O
195 NN NN O
to NN NN O
5 NN NN O
. NN NN O
124 NN NN O
, NN NN O
P NN NN O
= NN NN O
0 NN NN O
. NN NN O
039 NN NN O
) NN NN O
. NN NN O
   
CONCLUSION NN NN O
: NN NN O
Low NN NN O
adherence NN NN O
to NN NN O
SOPs NN NN O
for NN NN O
potentially NN NN O
nephrotoxic NN NN B-Disease
antibiotics NN NN O
was NN NN O
associated NN NN O
with NN NN O
a NN NN O
higher NN NN O
occurrence NN NN O
of NN NN O
AKI NN NN B-Disease
. NN NN O
   
TRIAL NN NN O
REGISTRATION NN NN O
: NN NN O
Current NN NN O
Controlled NN NN O
Trials NN NN O
ISRCTN54598675 NN NN O
. NN NN O
   
Registered NN NN O
17 NN NN O
August NN NN O
2007 NN NN O
. NN NN O
   
Rhabdomyolysis NN NN B-Disease
in NN NN O
a NN NN O
hepatitis NN NN B-Disease
C NN NN I-Disease
virus NN NN I-Disease
infected NN NN I-Disease
patient NN NN O
treated NN NN O
with NN NN O
telaprevir NN NN O
and NN NN O
simvastatin NN NN O
. NN NN O
   
A NN NN O
46 NN NN O
- NN NN O
year NN NN O
old NN NN O
man NN NN O
with NN NN O
a NN NN O
chronic NN NN O
hepatitis NN NN B-Disease
C NN NN I-Disease
virus NN NN I-Disease
infection NN NN I-Disease
received NN NN O
triple NN NN O
therapy NN NN O
with NN NN O
ribavirin NN NN O
, NN NN O
pegylated NN NN O
interferon NN NN O
and NN NN O
telaprevir NN NN O
. NN NN O
   
The NN NN O
patient NN NN O
also NN NN O
received NN NN O
simvastatin NN NN O
. NN NN O
   
One NN NN O
month NN NN O
after NN NN O
starting NN NN O
the NN NN O
antiviral NN NN O
therapy NN NN O
, NN NN O
the NN NN O
patient NN NN O
was NN NN O
admitted NN NN O
to NN NN O
the NN NN O
hospital NN NN O
because NN NN O
he NN NN O
developed NN NN O
rhabdomyolysis NN NN B-Disease
. NN NN O
   
At NN NN O
admission NN NN O
simvastatin NN NN O
and NN NN O
all NN NN O
antiviral NN NN O
drugs NN NN O
were NN NN O
discontinued NN NN O
because NN NN O
toxicity NN NN B-Disease
due NN NN O
to NN NN O
a NN NN O
drug NN NN O
- NN NN O
drug NN NN O
interaction NN NN O
was NN NN O
suspected NN NN O
. NN NN O
   
The NN NN O
creatine NN NN O
kinase NN NN O
peaked NN NN O
at NN NN O
62 NN NN O
, NN NN O
246 NN NN O
IU NN NN O
/ NN NN O
L NN NN O
and NN NN O
the NN NN O
patient NN NN O
was NN NN O
treated NN NN O
with NN NN O
intravenous NN NN O
normal NN NN O
saline NN NN O
. NN NN O
   
The NN NN O
patient NN NN O
' NN NN O
s NN NN O
renal NN NN O
function NN NN O
remained NN NN O
unaffected NN NN O
. NN NN O
   
Fourteen NN NN O
days NN NN O
after NN NN O
hospitalization NN NN O
, NN NN O
creatine NN NN O
kinase NN NN O
level NN NN O
had NN NN O
returned NN NN O
to NN NN O
230 NN NN O
IU NN NN O
/ NN NN O
L NN NN O
and NN NN O
the NN NN O
patient NN NN O
was NN NN O
discharged NN NN O
. NN NN O
   
Telaprevir NN NN O
was NN NN O
considered NN NN O
the NN NN O
probable NN NN O
causative NN NN O
agent NN NN O
of NN NN O
an NN NN O
interaction NN NN O
with NN NN O
simvastatin NN NN O
according NN NN O
to NN NN O
the NN NN O
Drug NN NN O
Interaction NN NN O
Probability NN NN O
Scale NN NN O
. NN NN O
   
The NN NN O
interaction NN NN O
is NN NN O
due NN NN O
to NN NN O
inhibition NN NN O
of NN NN O
CYP3A4 NN NN O
- NN NN O
mediated NN NN O
simvastatin NN NN O
clearance NN NN O
. NN NN O
   
Simvastatin NN NN O
plasma NN NN O
concentration NN NN O
increased NN NN O
30 NN NN O
times NN NN O
in NN NN O
this NN NN O
patient NN NN O
and NN NN O
statin NN NN O
induced NN NN O
muscle NN NN B-Disease
toxicity NN NN I-Disease
is NN NN O
related NN NN O
to NN NN O
the NN NN O
concentration NN NN O
of NN NN O
the NN NN O
statin NN NN O
in NN NN O
blood NN NN O
. NN NN O
   
In NN NN O
conclusion NN NN O
, NN NN O
with NN NN O
this NN NN O
case NN NN O
we NN NN O
illustrate NN NN O
that NN NN O
telaprevir NN NN O
as NN NN O
well NN NN O
as NN NN O
statins NN NN O
are NN NN O
susceptible NN NN O
to NN NN O
clinical NN NN O
relevant NN NN O
drug NN NN O
- NN NN O
drug NN NN O
interactions NN NN O
. NN NN O
   
Combination NN NN O
of NN NN O
bortezomib NN NN O
, NN NN O
thalidomide NN NN O
, NN NN O
and NN NN O
dexamethasone NN NN O
( NN NN O
VTD NN NN O
) NN NN O
as NN NN O
a NN NN O
consolidation NN NN O
therapy NN NN O
after NN NN O
autologous NN NN O
stem NN NN O
cell NN NN O
transplantation NN NN O
for NN NN O
symptomatic NN NN O
multiple NN NN B-Disease
myeloma NN NN I-Disease
in NN NN O
Japanese NN NN O
patients NN NN O
. NN NN O
   
Consolidation NN NN O
therapy NN NN O
for NN NN O
patients NN NN O
with NN NN O
multiple NN NN B-Disease
myeloma NN NN I-Disease
( NN NN O
MM NN NN B-Disease
) NN NN O
has NN NN O
been NN NN O
widely NN NN O
adopted NN NN O
to NN NN O
improve NN NN O
treatment NN NN O
response NN NN O
following NN NN O
autologous NN NN O
stem NN NN O
cell NN NN O
transplantation NN NN O
. NN NN O
   
In NN NN O
this NN NN O
study NN NN O
, NN NN O
we NN NN O
retrospectively NN NN O
analyzed NN NN O
the NN NN O
safety NN NN O
and NN NN O
efficacy NN NN O
of NN NN O
combination NN NN O
regimen NN NN O
of NN NN O
bortezomib NN NN O
, NN NN O
thalidomide NN NN O
, NN NN O
and NN NN O
dexamethasone NN NN O
( NN NN O
VTD NN NN O
) NN NN O
as NN NN O
consolidation NN NN O
therapy NN NN O
in NN NN O
24 NN NN O
Japanese NN NN O
patients NN NN O
with NN NN O
newly NN NN O
diagnosed NN NN O
MM NN NN B-Disease
. NN NN O
   
VTD NN NN O
consisted NN NN O
of NN NN O
bortezomib NN NN O
at NN NN O
a NN NN O
dose NN NN O
of NN NN O
1 NN NN O
. NN NN O
3 NN NN O
mg NN NN O
/ NN NN O
m NN NN O
( NN NN O
2 NN NN O
) NN NN O
and NN NN O
dexamethasone NN NN O
at NN NN O
a NN NN O
dose NN NN O
of NN NN O
40 NN NN O
mg NN NN O
/ NN NN O
day NN NN O
on NN NN O
days NN NN O
1 NN NN O
, NN NN O
8 NN NN O
, NN NN O
15 NN NN O
, NN NN O
and NN NN O
22 NN NN O
of NN NN O
a NN NN O
35 NN NN O
- NN NN O
day NN NN O
cycle NN NN O
, NN NN O
with NN NN O
daily NN NN O
oral NN NN O
thalidomide NN NN O
at NN NN O
a NN NN O
dose NN NN O
of NN NN O
100 NN NN O
mg NN NN O
/ NN NN O
day NN NN O
. NN NN O
   
Grade NN NN O
3 NN NN O
- NN NN O
4 NN NN O
neutropenia NN NN B-Disease
and NN NN O
thrombocytopenia NN NN B-Disease
were NN NN O
documented NN NN O
in NN NN O
four NN NN O
and NN NN O
three NN NN O
patients NN NN O
( NN NN O
17 NN NN O
and NN NN O
13 NN NN O
% NN NN O
) NN NN O
, NN NN O
respectively NN NN O
, NN NN O
but NN NN O
drug NN NN O
dose NN NN O
reduction NN NN O
due NN NN O
to NN NN O
cytopenia NN NN B-Disease
was NN NN O
not NN NN O
required NN NN O
in NN NN O
any NN NN O
case NN NN O
. NN NN O
   
Peripheral NN NN B-Disease
neuropathy NN NN I-Disease
was NN NN O
common NN NN O
( NN NN O
63 NN NN O
% NN NN O
) NN NN O
, NN NN O
but NN NN O
severe NN NN O
grade NN NN O
3 NN NN O
- NN NN O
4 NN NN O
peripheral NN NN B-Disease
neuropathy NN NN I-Disease
was NN NN O
not NN NN O
observed NN NN O
. NN NN O
   
Very NN NN O
good NN NN O
partial NN NN O
response NN NN O
or NN NN O
better NN NN O
response NN NN O
( NN NN O
> NN NN O
VGPR NN NN O
) NN NN O
rates NN NN O
before NN NN O
and NN NN O
after NN NN O
consolidation NN NN O
therapy NN NN O
were NN NN O
54 NN NN O
and NN NN O
79 NN NN O
% NN NN O
, NN NN O
respectively NN NN O
. NN NN O
   
Patients NN NN O
had NN NN O
a NN NN O
significant NN NN O
probability NN NN O
of NN NN O
improving NN NN O
from NN NN O
< NN NN O
VGPR NN NN O
before NN NN O
consolidation NN NN O
therapy NN NN O
to NN NN O
> NN NN O
VGPR NN NN O
after NN NN O
consolidation NN NN O
therapy NN NN O
( NN NN O
p NN NN O
= NN NN O
0 NN NN O
. NN NN O
041 NN NN O
) NN NN O
. NN NN O
   
The NN NN O
VTD NN NN O
regimen NN NN O
may NN NN O
be NN NN O
safe NN NN O
and NN NN O
effective NN NN O
as NN NN O
a NN NN O
consolidation NN NN O
therapy NN NN O
in NN NN O
the NN NN O
treatment NN NN O
of NN NN O
MM NN NN O
in NN NN O
Japanese NN NN O
population NN NN O
. NN NN O
   
Conversion NN NN O
to NN NN O
sirolimus NN NN O
ameliorates NN NN O
cyclosporine NN NN O
- NN NN O
induced NN NN O
nephropathy NN NN B-Disease
in NN NN O
the NN NN O
rat NN NN O
: NN NN O
focus NN NN O
on NN NN O
serum NN NN O
, NN NN O
urine NN NN O
, NN NN O
gene NN NN O
, NN NN O
and NN NN O
protein NN NN O
renal NN NN O
expression NN NN O
biomarkers NN NN O
. NN NN O
   
Protocols NN NN O
of NN NN O
conversion NN NN O
from NN NN O
cyclosporin NN NN O
A NN NN O
( NN NN O
CsA NN NN O
) NN NN O
to NN NN O
sirolimus NN NN O
( NN NN O
SRL NN NN O
) NN NN O
have NN NN O
been NN NN O
widely NN NN O
used NN NN O
in NN NN O
immunotherapy NN NN O
after NN NN O
transplantation NN NN O
to NN NN O
prevent NN NN O
CsA NN NN O
- NN NN O
induced NN NN O
nephropathy NN NN B-Disease
, NN NN O
but NN NN O
the NN NN O
molecular NN NN O
mechanisms NN NN O
underlying NN NN O
these NN NN O
protocols NN NN O
remain NN NN O
nuclear NN NN O
. NN NN O
   
This NN NN O
study NN NN O
aimed NN NN O
to NN NN O
identify NN NN O
the NN NN O
molecular NN NN O
pathways NN NN O
and NN NN O
putative NN NN O
biomarkers NN NN O
of NN NN O
CsA NN NN O
- NN NN O
to NN NN O
- NN NN O
SRL NN NN O
conversion NN NN O
in NN NN O
a NN NN O
rat NN NN O
model NN NN O
. NN NN O
   
Four NN NN O
animal NN NN O
groups NN NN O
( NN NN O
n NN NN O
= NN NN O
6 NN NN O
) NN NN O
were NN NN O
tested NN NN O
during NN NN O
9 NN NN O
weeks NN NN O
: NN NN O
control NN NN O
, NN NN O
CsA NN NN O
, NN NN O
SRL NN NN O
, NN NN O
and NN NN O
conversion NN NN O
( NN NN O
CsA NN NN O
for NN NN O
3 NN NN O
weeks NN NN O
followed NN NN O
by NN NN O
SRL NN NN O
for NN NN O
6 NN NN O
weeks NN NN O
) NN NN O
. NN NN O
   
Classical NN NN O
and NN NN O
emergent NN NN O
serum NN NN O
, NN NN O
urinary NN NN O
, NN NN O
and NN NN O
kidney NN NN O
tissue NN NN O
( NN NN O
gene NN NN O
and NN NN O
protein NN NN O
expression NN NN O
) NN NN O
markers NN NN O
were NN NN O
assessed NN NN O
. NN NN O
   
Renal NN NN B-Disease
lesions NN NN I-Disease
were NN NN O
analyzed NN NN O
in NN NN O
hematoxylin NN NN O
and NN NN O
eosin NN NN O
, NN NN O
periodic NN NN O
acid NN NN O
- NN NN O
Schiff NN NN O
, NN NN O
and NN NN O
Masson NN NN O
' NN NN O
s NN NN O
trichrome NN NN O
stains NN NN O
. NN NN O
   
SRL NN NN O
- NN NN O
treated NN NN O
rats NN NN O
presented NN NN O
proteinuria NN NN B-Disease
and NN NN O
NGAL NN NN O
( NN NN O
serum NN NN O
and NN NN O
urinary NN NN O
) NN NN O
as NN NN O
the NN NN O
best NN NN O
markers NN NN O
of NN NN O
renal NN NN B-Disease
impairment NN NN I-Disease
. NN NN O
   
Short NN NN O
CsA NN NN O
treatment NN NN O
presented NN NN O
slight NN NN O
or NN NN O
even NN NN O
absent NN NN O
kidney NN NN B-Disease
lesions NN NN I-Disease
and NN NN O
TGF NN NN O
- NN NN O
b NN NN O
, NN NN O
NF NN NN O
- NN NN O
kb NN NN O
, NN NN O
mTOR NN NN O
, NN NN O
PCNA NN NN O
, NN NN O
TP53 NN NN O
, NN NN O
KIM NN NN O
- NN NN O
1 NN NN O
, NN NN O
and NN NN O
CTGF NN NN O
as NN NN O
relevant NN NN O
gene NN NN O
and NN NN O
protein NN NN O
changes NN NN O
. NN NN O
   
Prolonged NN NN O
CsA NN NN O
exposure NN NN O
aggravated NN NN O
renal NN NN B-Disease
damage NN NN I-Disease
, NN NN O
without NN NN O
clear NN NN O
changes NN NN O
on NN NN O
the NN NN O
traditional NN NN O
markers NN NN O
, NN NN O
but NN NN O
with NN NN O
changes NN NN O
in NN NN O
serums NN NN O
TGF NN NN O
- NN NN O
b NN NN O
and NN NN O
IL NN NN O
- NN NN O
7 NN NN O
, NN NN O
TBARs NN NN O
clearance NN NN O
, NN NN O
and NN NN O
kidney NN NN O
TGF NN NN O
- NN NN O
b NN NN O
and NN NN O
mTOR NN NN O
. NN NN O
   
Conversion NN NN O
to NN NN O
SRL NN NN O
prevented NN NN O
CsA NN NN O
- NN NN O
induced NN NN O
renal NN NN B-Disease
damage NN NN I-Disease
evolution NN NN O
( NN NN O
absent NN NN O
/ NN NN O
mild NN NN O
grade NN NN O
lesions NN NN O
) NN NN O
, NN NN O
while NN NN O
NGAL NN NN O
( NN NN O
serum NN NN O
versus NN NN O
urine NN NN O
) NN NN O
seems NN NN O
to NN NN O
be NN NN O
a NN NN O
feasible NN NN O
biomarker NN NN O
of NN NN O
CsA NN NN O
replacement NN NN O
to NN NN O
SRL NN NN O
. NN NN O
   
Kinin NN NN O
B2 NN NN O
receptor NN NN O
deletion NN NN O
and NN NN O
blockage NN NN O
ameliorates NN NN O
cisplatin NN NN O
- NN NN O
induced NN NN O
acute NN NN B-Disease
renal NN NN I-Disease
injury NN NN I-Disease
. NN NN O
   
Cisplatin NN NN O
treatment NN NN O
has NN NN O
been NN NN O
adopted NN NN O
in NN NN O
some NN NN O
chemotherapies NN NN O
; NN NN O
however NN NN O
, NN NN O
this NN NN O
drug NN NN O
can NN NN O
induce NN NN O
acute NN NN B-Disease
kidney NN NN I-Disease
injury NN NN I-Disease
due NN NN O
its NN NN O
ability NN NN O
to NN NN O
negatively NN NN O
affect NN NN O
renal NN NN O
function NN NN O
, NN NN O
augment NN NN O
serum NN NN O
levels NN NN O
of NN NN O
creatinine NN NN O
and NN NN O
urea NN NN O
, NN NN O
increase NN NN O
the NN NN O
acute NN NN B-Disease
tubular NN NN I-Disease
necrosis NN NN I-Disease
score NN NN O
and NN NN O
up NN NN O
- NN NN O
regulate NN NN O
cytokines NN NN O
( NN NN O
e NN NN O
. NN NN O
g NN NN O
. NN NN O
, NN NN O
IL NN NN O
- NN NN O
1b NN NN O
and NN NN O
TNF NN NN O
- NN NN O
a NN NN O
) NN NN O
. NN NN O
   
The NN NN O
kinin NN NN O
B2 NN NN O
receptor NN NN O
has NN NN O
been NN NN O
associated NN NN O
with NN NN O
the NN NN O
inflammation NN NN B-Disease
process NN NN O
, NN NN O
as NN NN O
well NN NN O
as NN NN O
the NN NN O
regulation NN NN O
of NN NN O
cytokine NN NN O
expression NN NN O
, NN NN O
and NN NN O
its NN NN O
deletion NN NN O
resulted NN NN O
in NN NN O
an NN NN O
improvement NN NN O
in NN NN O
the NN NN O
diabetic NN NN B-Disease
nephropathy NN NN I-Disease
status NN NN O
. NN NN O
   
To NN NN O
examine NN NN O
the NN NN O
role NN NN O
of NN NN O
the NN NN O
kinin NN NN O
B2 NN NN O
receptor NN NN O
in NN NN O
cisplatin NN NN O
- NN NN O
induced NN NN O
acute NN NN B-Disease
kidney NN NN I-Disease
injury NN NN I-Disease
, NN NN O
kinin NN NN O
B2 NN NN O
receptor NN NN O
knockout NN NN O
mice NN NN O
were NN NN O
challenged NN NN O
with NN NN O
cisplatin NN NN O
. NN NN O
   
Additionally NN NN O
, NN NN O
WT NN NN O
mice NN NN O
were NN NN O
treated NN NN O
with NN NN O
a NN NN O
B2 NN NN O
receptor NN NN O
antagonist NN NN O
after NN NN O
cisplatin NN NN O
administration NN NN O
. NN NN O
   
B2 NN NN O
receptor NN NN O
- NN NN O
deficient NN NN O
mice NN NN O
were NN NN O
less NN NN O
sensitive NN NN O
to NN NN O
this NN NN O
drug NN NN O
than NN NN O
the NN NN O
WT NN NN O
mice NN NN O
, NN NN O
as NN NN O
shown NN NN O
by NN NN O
reduced NN NN O
weight NN NN B-Disease
loss NN NN I-Disease
, NN NN O
better NN NN O
preservation NN NN O
of NN NN O
kidney NN NN O
function NN NN O
, NN NN O
down NN NN O
regulation NN NN O
of NN NN O
inflammatory NN NN O
cytokines NN NN O
and NN NN O
less NN NN O
acute NN NN B-Disease
tubular NN NN I-Disease
necrosis NN NN I-Disease
. NN NN O
   
Moreover NN NN O
, NN NN O
treatment NN NN O
with NN NN O
the NN NN O
kinin NN NN O
B2 NN NN O
receptor NN NN O
antagonist NN NN O
effectively NN NN O
reduced NN NN O
the NN NN O
levels NN NN O
of NN NN O
serum NN NN O
creatinine NN NN O
and NN NN O
blood NN NN O
urea NN NN O
after NN NN O
cisplatin NN NN O
administration NN NN O
. NN NN O
   
Thus NN NN O
, NN NN O
our NN NN O
data NN NN O
suggest NN NN O
that NN NN O
the NN NN O
kinin NN NN O
B2 NN NN O
receptor NN NN O
is NN NN O
involved NN NN O
in NN NN O
cisplatin NN NN O
- NN NN O
induced NN NN O
acute NN NN B-Disease
kidney NN NN I-Disease
injury NN NN I-Disease
by NN NN O
mediating NN NN O
the NN NN O
necrotic NN NN B-Disease
process NN NN O
and NN NN O
the NN NN O
expression NN NN O
of NN NN O
inflammatory NN NN O
cytokines NN NN O
, NN NN O
thus NN NN O
resulting NN NN O
in NN NN O
declined NN NN O
renal NN NN O
function NN NN O
. NN NN O
   
These NN NN O
results NN NN O
highlight NN NN O
the NN NN O
kinin NN NN O
B2 NN NN O
receptor NN NN O
antagonist NN NN O
treatment NN NN O
in NN NN O
amelioration NN NN O
of NN NN O
nephrotoxicity NN NN B-Disease
induced NN NN O
by NN NN O
cisplatin NN NN O
therapy NN NN O
. NN NN O
   
Safety NN NN O
and NN NN O
efficacy NN NN O
of NN NN O
fluocinolone NN NN O
acetonide NN NN O
intravitreal NN NN O
implant NN NN O
( NN NN O
0 NN NN O
. NN NN O
59 NN NN O
mg NN NN O
) NN NN O
in NN NN O
birdshot NN NN B-Disease
retinochoroidopathy NN NN I-Disease
. NN NN O
   
PURPOSE NN NN O
: NN NN O
To NN NN O
report NN NN O
the NN NN O
treatment NN NN O
outcomes NN NN O
of NN NN O
the NN NN O
fluocinolone NN NN O
acetonide NN NN O
intravitreal NN NN O
implant NN NN O
( NN NN O
0 NN NN O
. NN NN O
59 NN NN O
mg NN NN O
) NN NN O
in NN NN O
patients NN NN O
with NN NN O
birdshot NN NN B-Disease
retinochoroidopathy NN NN I-Disease
whose NN NN O
disease NN NN O
is NN NN O
refractory NN NN O
or NN NN O
intolerant NN NN O
to NN NN O
conventional NN NN O
immunomodulatory NN NN O
therapy NN NN O
. NN NN O
   
METHODS NN NN O
: NN NN O
A NN NN O
retrospective NN NN O
case NN NN O
series NN NN O
involving NN NN O
11 NN NN O
birdshot NN NN B-Disease
retinochoroidopathy NN NN I-Disease
patients NN NN O
( NN NN O
11 NN NN O
eyes NN NN O
) NN NN O
. NN NN O
   
Eleven NN NN O
patients NN NN O
( NN NN O
11 NN NN O
eyes NN NN O
) NN NN O
underwent NN NN O
surgery NN NN O
for NN NN O
fluocinolone NN NN O
acetonide NN NN O
implant NN NN O
( NN NN O
0 NN NN O
. NN NN O
59 NN NN O
mg NN NN O
) NN NN O
. NN NN O
   
Treatment NN NN O
outcomes NN NN O
of NN NN O
interest NN NN O
were NN NN O
noted NN NN O
at NN NN O
baseline NN NN O
, NN NN O
before NN NN O
fluocinolone NN NN O
acetonide NN NN O
implant NN NN O
, NN NN O
and NN NN O
then NN NN O
at NN NN O
6 NN NN O
months NN NN O
, NN NN O
1 NN NN O
year NN NN O
, NN NN O
2 NN NN O
years NN NN O
, NN NN O
3 NN NN O
years NN NN O
, NN NN O
and NN NN O
beyond NN NN O
3 NN NN O
years NN NN O
. NN NN O
   
Disease NN NN O
activity NN NN O
markers NN NN O
, NN NN O
including NN NN O
signs NN NN O
of NN NN O
ocular NN NN O
inflammation NN NN B-Disease
, NN NN O
evidence NN NN O
of NN NN O
retinal NN NN B-Disease
vasculitis NN NN I-Disease
, NN NN O
Swedish NN NN O
interactive NN NN O
threshold NN NN O
algorithm NN NN O
- NN NN O
short NN NN O
wavelength NN NN O
automated NN NN O
perimetry NN NN O
Humphrey NN NN O
visual NN NN O
field NN NN O
analysis NN NN O
, NN NN O
electroretinographic NN NN O
parameters NN NN O
, NN NN O
and NN NN O
optical NN NN O
coherence NN NN O
tomography NN NN O
were NN NN O
recorded NN NN O
. NN NN O
   
Data NN NN O
on NN NN O
occurrence NN NN O
of NN NN O
cataract NN NN B-Disease
and NN NN O
raised NN NN B-Disease
intraocular NN NN I-Disease
pressure NN NN I-Disease
were NN NN O
collected NN NN O
in NN NN O
all NN NN O
eyes NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
Intraocular NN NN O
inflammation NN NN B-Disease
was NN NN O
present NN NN O
in NN NN O
54 NN NN O
. NN NN O
5 NN NN O
, NN NN O
9 NN NN O
. NN NN O
9 NN NN O
, NN NN O
11 NN NN O
. NN NN O
1 NN NN O
, NN NN O
and NN NN O
0 NN NN O
% NN NN O
of NN NN O
patients NN NN O
at NN NN O
baseline NN NN O
, NN NN O
6 NN NN O
months NN NN O
, NN NN O
1 NN NN O
year NN NN O
, NN NN O
2 NN NN O
years NN NN O
, NN NN O
3 NN NN O
years NN NN O
, NN NN O
and NN NN O
beyond NN NN O
3 NN NN O
years NN NN O
after NN NN O
receiving NN NN O
the NN NN O
implant NN NN O
, NN NN O
respectively NN NN O
. NN NN O
   
Active NN NN O
vasculitis NN NN B-Disease
was NN NN O
noted NN NN O
in NN NN O
36 NN NN O
. NN NN O
3 NN NN O
% NN NN O
patients NN NN O
at NN NN O
baseline NN NN O
and NN NN O
0 NN NN O
% NN NN O
at NN NN O
3 NN NN O
years NN NN O
of NN NN O
follow NN NN O
- NN NN O
up NN NN O
. NN NN O
   
More NN NN O
than NN NN O
20 NN NN O
% NN NN O
( NN NN O
47 NN NN O
. NN NN O
61 NN NN O
- NN NN O
67 NN NN O
. NN NN O
2 NN NN O
% NN NN O
) NN NN O
reduction NN NN O
in NN NN O
central NN NN O
retinal NN NN O
thickness NN NN O
was NN NN O
noted NN NN O
in NN NN O
all NN NN O
patients NN NN O
with NN NN O
cystoid NN NN B-Disease
macular NN NN I-Disease
edema NN NN I-Disease
at NN NN O
6 NN NN O
months NN NN O
, NN NN O
1 NN NN O
year NN NN O
, NN NN O
2 NN NN O
years NN NN O
, NN NN O
and NN NN O
3 NN NN O
years NN NN O
postimplant NN NN O
. NN NN O
   
At NN NN O
baseline NN NN O
, NN NN O
54 NN NN O
. NN NN O
5 NN NN O
% NN NN O
patients NN NN O
were NN NN O
on NN NN O
immunomodulatory NN NN O
agents NN NN O
. NN NN O
   
This NN NN O
percentage NN NN O
decreased NN NN O
to NN NN O
45 NN NN O
. NN NN O
45 NN NN O
, NN NN O
44 NN NN O
. NN NN O
4 NN NN O
, NN NN O
and NN NN O
14 NN NN O
. NN NN O
28 NN NN O
% NN NN O
at NN NN O
1 NN NN O
year NN NN O
, NN NN O
2 NN NN O
years NN NN O
, NN NN O
and NN NN O
3 NN NN O
years NN NN O
postimplant NN NN O
, NN NN O
respectively NN NN O
. NN NN O
   
Adverse NN NN O
events NN NN O
included NN NN O
increased NN NN B-Disease
intraocular NN NN I-Disease
pressure NN NN I-Disease
( NN NN O
54 NN NN O
. NN NN O
5 NN NN O
% NN NN O
) NN NN O
and NN NN O
cataract NN NN B-Disease
formation NN NN O
( NN NN O
100 NN NN O
% NN NN O
) NN NN O
. NN NN O
   
CONCLUSION NN NN O
: NN NN O
The NN NN O
data NN NN O
suggest NN NN O
that NN NN O
fluocinolone NN NN O
acetonide NN NN O
implant NN NN O
( NN NN O
0 NN NN O
. NN NN O
59 NN NN O
mg NN NN O
) NN NN O
helps NN NN O
to NN NN O
control NN NN O
inflammation NN NN B-Disease
in NN NN O
otherwise NN NN O
treatment NN NN O
- NN NN O
refractory NN NN O
cases NN NN O
of NN NN O
birdshot NN NN B-Disease
retinochoroidopathy NN NN I-Disease
. NN NN O
   
It NN NN O
is NN NN O
associated NN NN O
with NN NN O
significant NN NN O
side NN NN O
effects NN NN O
of NN NN O
cataract NN NN B-Disease
and NN NN O
ocular NN NN B-Disease
hypertension NN NN I-Disease
requiring NN NN O
treatment NN NN O
. NN NN O
   
Optimal NN NN O
precurarizing NN NN O
dose NN NN O
of NN NN O
rocuronium NN NN O
to NN NN O
decrease NN NN O
fasciculation NN NN B-Disease
and NN NN O
myalgia NN NN B-Disease
following NN NN O
succinylcholine NN NN O
administration NN NN O
. NN NN O
   
BACKGROUND NN NN O
: NN NN O
Succinylcholine NN NN O
commonly NN NN O
produces NN NN O
frequent NN NN O
adverse NN NN O
effects NN NN O
, NN NN O
including NN NN O
muscle NN NN B-Disease
fasciculation NN NN I-Disease
and NN NN O
myalgia NN NN B-Disease
. NN NN O
   
The NN NN O
current NN NN O
study NN NN O
identified NN NN O
the NN NN O
optimal NN NN O
dose NN NN O
of NN NN O
rocuronium NN NN O
to NN NN O
prevent NN NN O
succinylcholine NN NN O
- NN NN O
induced NN NN O
fasciculation NN NN B-Disease
and NN NN O
myalgia NN NN B-Disease
and NN NN O
evaluated NN NN O
the NN NN O
influence NN NN O
of NN NN O
rocuronium NN NN O
on NN NN O
the NN NN O
speed NN NN O
of NN NN O
onset NN NN O
produced NN NN O
by NN NN O
succinylcholine NN NN O
. NN NN O
   
METHODS NN NN O
: NN NN O
This NN NN O
randomized NN NN O
, NN NN O
double NN NN O
- NN NN O
blinded NN NN O
study NN NN O
was NN NN O
conducted NN NN O
in NN NN O
100 NN NN O
patients NN NN O
randomly NN NN O
allocated NN NN O
into NN NN O
five NN NN O
groups NN NN O
of NN NN O
20 NN NN O
patients NN NN O
each NN NN O
. NN NN O
   
Patients NN NN O
were NN NN O
randomized NN NN O
to NN NN O
receive NN NN O
0 NN NN O
. NN NN O
02 NN NN O
, NN NN O
0 NN NN O
. NN NN O
03 NN NN O
, NN NN O
0 NN NN O
. NN NN O
04 NN NN O
, NN NN O
0 NN NN O
. NN NN O
05 NN NN O
and NN NN O
0 NN NN O
. NN NN O
06 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
rocuronium NN NN O
as NN NN O
a NN NN O
precurarizing NN NN O
dose NN NN O
. NN NN O
   
Neuromuscular NN NN O
monitoring NN NN O
after NN NN O
each NN NN O
precurarizing NN NN O
dose NN NN O
was NN NN O
recorded NN NN O
from NN NN O
the NN NN O
adductor NN NN O
pollicis NN NN O
muscle NN NN O
using NN NN O
acceleromyography NN NN O
with NN NN O
train NN NN O
- NN NN O
of NN NN O
- NN NN O
four NN NN O
stimulation NN NN O
of NN NN O
the NN NN O
ulnar NN NN O
nerve NN NN O
. NN NN O
   
All NN NN O
patients NN NN O
received NN NN O
succinylcholine NN NN O
1 NN NN O
. NN NN O
5 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
at NN NN O
2 NN NN O
minutes NN NN O
after NN NN O
the NN NN O
precurarization NN NN O
, NN NN O
and NN NN O
were NN NN O
assessed NN NN O
the NN NN O
incidence NN NN O
and NN NN O
severity NN NN O
of NN NN O
fasciculations NN NN B-Disease
, NN NN O
while NN NN O
myalgia NN NN B-Disease
was NN NN O
assessed NN NN O
at NN NN O
24 NN NN O
hours NN NN O
after NN NN O
surgery NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
The NN NN O
incidence NN NN O
and NN NN O
severity NN NN O
of NN NN O
visible NN NN O
muscle NN NN B-Disease
fasciculation NN NN I-Disease
was NN NN O
significantly NN NN O
less NN NN O
with NN NN O
increasing NN NN O
the NN NN O
amount NN NN O
of NN NN O
precurarizing NN NN O
dose NN NN O
of NN NN O
rocuronium NN NN O
( NN NN O
P NN NN O
< NN NN O
0 NN NN O
. NN NN O
001 NN NN O
) NN NN O
. NN NN O
   
Those NN NN O
of NN NN O
myalgia NN NN B-Disease
tend NN NN O
to NN NN O
decrease NN NN O
according NN NN O
to NN NN O
increasing NN NN O
the NN NN O
amount NN NN O
of NN NN O
precurarizing NN NN O
dose NN NN O
of NN NN O
rocuronium NN NN O
, NN NN O
but NN NN O
there NN NN O
was NN NN O
no NN NN O
significance NN NN O
( NN NN O
P NN NN O
= NN NN O
0 NN NN O
. NN NN O
072 NN NN O
) NN NN O
. NN NN O
   
The NN NN O
onset NN NN O
time NN NN O
of NN NN O
succinylcholine NN NN O
was NN NN O
significantly NN NN O
longer NN NN O
with NN NN O
increasing NN NN O
the NN NN O
amount NN NN O
of NN NN O
precurarizing NN NN O
dose NN NN O
of NN NN O
rocuronium NN NN O
( NN NN O
P NN NN O
< NN NN O
0 NN NN O
. NN NN O
001 NN NN O
) NN NN O
. NN NN O
   
CONCLUSIONS NN NN O
: NN NN O
Precurarization NN NN O
with NN NN O
0 NN NN O
. NN NN O
04 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
rocuronium NN NN O
was NN NN O
the NN NN O
optimal NN NN O
dose NN NN O
considering NN NN O
the NN NN O
reduction NN NN O
in NN NN O
the NN NN O
incidence NN NN O
and NN NN O
severity NN NN O
of NN NN O
fasciculation NN NN B-Disease
and NN NN O
myalgia NN NN B-Disease
with NN NN O
acceptable NN NN O
onset NN NN O
time NN NN O
, NN NN O
and NN NN O
the NN NN O
safe NN NN O
and NN NN O
effective NN NN O
precurarization NN NN O
. NN NN O
   
Absence NN NN O
of NN NN O
PKC NN NN O
- NN NN O
alpha NN NN O
attenuates NN NN O
lithium NN NN O
- NN NN O
induced NN NN O
nephrogenic NN NN B-Disease
diabetes NN NN I-Disease
insipidus NN NN I-Disease
. NN NN O
   
Lithium NN NN O
, NN NN O
an NN NN O
effective NN NN O
antipsychotic NN NN O
, NN NN O
induces NN NN O
nephrogenic NN NN B-Disease
diabetes NN NN I-Disease
insipidus NN NN I-Disease
( NN NN O
NDI NN NN B-Disease
) NN NN O
in NN NN O
40 NN NN O
% NN NN O
of NN NN O
patients NN NN O
. NN NN O
   
The NN NN O
decreased NN NN O
capacity NN NN O
to NN NN O
concentrate NN NN O
urine NN NN O
is NN NN O
likely NN NN O
due NN NN O
to NN NN O
lithium NN NN O
acutely NN NN O
disrupting NN NN O
the NN NN O
cAMP NN NN O
pathway NN NN O
and NN NN O
chronically NN NN O
reducing NN NN O
urea NN NN O
transporter NN NN O
( NN NN O
UT NN NN O
- NN NN O
A1 NN NN O
) NN NN O
and NN NN O
water NN NN O
channel NN NN O
( NN NN O
AQP2 NN NN O
) NN NN O
expression NN NN O
in NN NN O
the NN NN O
inner NN NN O
medulla NN NN O
. NN NN O
   
Targeting NN NN O
an NN NN O
alternative NN NN O
signaling NN NN O
pathway NN NN O
, NN NN O
such NN NN O
as NN NN O
PKC NN NN O
- NN NN O
mediated NN NN O
signaling NN NN O
, NN NN O
may NN NN O
be NN NN O
an NN NN O
effective NN NN O
method NN NN O
of NN NN O
treating NN NN O
lithium NN NN O
- NN NN O
induced NN NN O
polyuria NN NN B-Disease
. NN NN O
   
PKC NN NN O
- NN NN O
alpha NN NN O
null NN NN O
mice NN NN O
( NN NN O
PKCa NN NN O
KO NN NN O
) NN NN O
and NN NN O
strain NN NN O
- NN NN O
matched NN NN O
wild NN NN O
type NN NN O
( NN NN O
WT NN NN O
) NN NN O
controls NN NN O
were NN NN O
treated NN NN O
with NN NN O
lithium NN NN O
for NN NN O
0 NN NN O
, NN NN O
3 NN NN O
or NN NN O
5 NN NN O
days NN NN O
. NN NN O
   
WT NN NN O
mice NN NN O
had NN NN O
increased NN NN O
urine NN NN O
output NN NN O
and NN NN O
lowered NN NN O
urine NN NN O
osmolality NN NN O
after NN NN O
3 NN NN O
and NN NN O
5 NN NN O
days NN NN O
of NN NN O
treatment NN NN O
whereas NN NN O
PKCa NN NN O
KO NN NN O
mice NN NN O
had NN NN O
no NN NN O
change NN NN O
in NN NN O
urine NN NN O
output NN NN O
or NN NN O
concentration NN NN O
. NN NN O
   
Western NN NN O
blot NN NN O
analysis NN NN O
revealed NN NN O
that NN NN O
AQP2 NN NN O
expression NN NN O
in NN NN O
medullary NN NN O
tissues NN NN O
was NN NN O
lowered NN NN O
after NN NN O
3 NN NN O
and NN NN O
5 NN NN O
days NN NN O
in NN NN O
WT NN NN O
mice NN NN O
; NN NN O
however NN NN O
, NN NN O
AQP2 NN NN O
was NN NN O
unchanged NN NN O
in NN NN O
PKCa NN NN O
KO NN NN O
. NN NN O
   
Similar NN NN O
results NN NN O
were NN NN O
observed NN NN O
with NN NN O
UT NN NN O
- NN NN O
A1 NN NN O
expression NN NN O
. NN NN O
   
Animals NN NN O
were NN NN O
also NN NN O
treated NN NN O
with NN NN O
lithium NN NN O
for NN NN O
6 NN NN O
weeks NN NN O
. NN NN O
   
Lithium NN NN O
- NN NN O
treated NN NN O
WT NN NN O
mice NN NN O
had NN NN O
19 NN NN O
- NN NN O
fold NN NN O
increased NN NN O
urine NN NN O
output NN NN O
whereas NN NN O
treated NN NN O
PKCa NN NN O
KO NN NN O
animals NN NN O
had NN NN O
a NN NN O
4 NN NN O
- NN NN O
fold NN NN O
increase NN NN O
in NN NN O
output NN NN O
. NN NN O
   
AQP2 NN NN O
and NN NN O
UT NN NN O
- NN NN O
A1 NN NN O
expression NN NN O
was NN NN O
lowered NN NN O
in NN NN O
6 NN NN O
week NN NN O
lithium NN NN O
- NN NN O
treated NN NN O
WT NN NN O
animals NN NN O
whereas NN NN O
in NN NN O
treated NN NN O
PKCa NN NN O
KO NN NN O
mice NN NN O
, NN NN O
AQP2 NN NN O
was NN NN O
only NN NN O
reduced NN NN O
by NN NN O
2 NN NN O
- NN NN O
fold NN NN O
and NN NN O
UT NN NN O
- NN NN O
A1 NN NN O
expression NN NN O
was NN NN O
unaffected NN NN O
. NN NN O
   
Urinary NN NN O
sodium NN NN O
, NN NN O
potassium NN NN O
and NN NN O
calcium NN NN O
were NN NN O
elevated NN NN O
in NN NN O
lithium NN NN O
- NN NN O
fed NN NN O
WT NN NN O
but NN NN O
not NN NN O
in NN NN O
lithium NN NN O
- NN NN O
fed NN NN O
PKCa NN NN O
KO NN NN O
mice NN NN O
. NN NN O
   
Our NN NN O
data NN NN O
show NN NN O
that NN NN O
ablation NN NN O
of NN NN O
PKCa NN NN O
preserves NN NN O
AQP2 NN NN O
and NN NN O
UT NN NN O
- NN NN O
A1 NN NN O
protein NN NN O
expression NN NN O
and NN NN O
localization NN NN O
in NN NN O
lithium NN NN O
- NN NN O
induced NN NN O
NDI NN NN B-Disease
, NN NN O
and NN NN O
prevents NN NN O
the NN NN O
development NN NN O
of NN NN O
the NN NN O
severe NN NN O
polyuria NN NN B-Disease
associated NN NN O
with NN NN O
lithium NN NN O
therapy NN NN O
. NN NN O
   
Is NN NN O
Dysguesia NN NN B-Disease
Going NN NN O
to NN NN O
be NN NN O
a NN NN O
Rare NN NN O
or NN NN O
a NN NN O
Common NN NN O
Side NN NN O
- NN NN O
effect NN NN O
of NN NN O
Amlodipine NN NN O
? NN NN O
   
A NN NN O
very NN NN O
rare NN NN O
side NN NN O
- NN NN O
effect NN NN O
of NN NN O
amlodipine NN NN O
is NN NN O
dysguesia NN NN B-Disease
. NN NN O
   
A NN NN O
review NN NN O
of NN NN O
the NN NN O
literature NN NN O
produced NN NN O
only NN NN O
one NN NN O
case NN NN O
. NN NN O
   
We NN NN O
report NN NN O
a NN NN O
case NN NN O
about NN NN O
a NN NN O
female NN NN O
with NN NN O
essential NN NN O
hypertension NN NN B-Disease
on NN NN O
drug NN NN O
treatment NN NN O
with NN NN O
amlodipine NN NN O
developed NN NN O
loss NN NN B-Disease
of NN NN I-Disease
taste NN NN I-Disease
sensation NN NN I-Disease
. NN NN O
   
Condition NN NN O
moderately NN NN O
improved NN NN O
on NN NN O
stoppage NN NN O
of NN NN O
the NN NN O
drug NN NN O
for NN NN O
25 NN NN O
days NN NN O
. NN NN O
   
We NN NN O
conclude NN NN O
that NN NN O
amlodipine NN NN O
can NN NN O
cause NN NN O
dysguesia NN NN B-Disease
. NN NN O
   
Here NN NN O
, NN NN O
we NN NN O
describe NN NN O
the NN NN O
clinical NN NN O
presentation NN NN O
and NN NN O
review NN NN O
the NN NN O
relevant NN NN O
literature NN NN O
on NN NN O
amlodipine NN NN O
and NN NN O
dysguesia NN NN B-Disease
. NN NN O
   
Rhabdomyolysis NN NN B-Disease
in NN NN O
association NN NN O
with NN NN O
simvastatin NN NN O
and NN NN O
dosage NN NN O
increment NN NN O
in NN NN O
clarithromycin NN NN O
. NN NN O
   
Clarithromycin NN NN O
is NN NN O
the NN NN O
most NN NN O
documented NN NN O
cytochrome NN NN O
P450 NN NN O
3A4 NN NN O
( NN NN O
CYP3A4 NN NN O
) NN NN O
inhibitor NN NN O
to NN NN O
cause NN NN O
an NN NN O
adverse NN NN O
interaction NN NN O
with NN NN O
simvastatin NN NN O
. NN NN O
   
This NN NN O
particular NN NN O
case NN NN O
is NN NN O
of NN NN O
interest NN NN O
as NN NN O
rhabdomyolysis NN NN B-Disease
only NN NN O
occurred NN NN O
after NN NN O
an NN NN O
increase NN NN O
in NN NN O
the NN NN O
dose NN NN O
of NN NN O
clarithromycin NN NN O
. NN NN O
   
The NN NN O
patient NN NN O
developed NN NN O
raised NN NN O
cardiac NN NN O
biomarkers NN NN O
without NN NN O
any NN NN O
obvious NN NN O
cardiac NN NN O
issues NN NN O
, NN NN O
a NN NN O
phenomenon NN NN O
that NN NN O
has NN NN O
been NN NN O
linked NN NN O
to NN NN O
rhabdomyolysis NN NN B-Disease
previously NN NN O
. NN NN O
   
To NN NN O
date NN NN O
, NN NN O
there NN NN O
has NN NN O
been NN NN O
no NN NN O
reported NN NN O
effect NN NN O
of NN NN O
rhabdomyolysis NN NN B-Disease
on NN NN O
the NN NN O
structure NN NN O
and NN NN O
function NN NN O
of NN NN O
cardiac NN NN O
muscle NN NN O
. NN NN O
   
Clinicians NN NN O
need NN NN O
to NN NN O
be NN NN O
aware NN NN O
of NN NN O
prescribing NN NN O
concomitant NN NN O
medications NN NN O
that NN NN O
increase NN NN O
the NN NN O
risk NN NN O
of NN NN O
myopathy NN NN B-Disease
or NN NN O
inhibit NN NN O
the NN NN O
CYP3A4 NN NN O
enzyme NN NN O
. NN NN O
   
Our NN NN O
case NN NN O
suggests NN NN O
that NN NN O
troponin NN NN O
elevation NN NN O
could NN NN O
be NN NN O
associated NN NN O
with NN NN O
statin NN NN O
induced NN NN O
rhabdomyolysis NN NN B-Disease
, NN NN O
which NN NN O
may NN NN O
warrant NN NN O
further NN NN O
studies NN NN O
. NN NN O
   
Characterization NN NN O
of NN NN O
a NN NN O
novel NN NN O
BCHE NN NN O
"""""""" NN NN O
silent NN NN O
"""""""" NN NN O
allele NN NN O
: NN NN O
point NN NN O
mutation NN NN O
( NN NN O
p NN NN O
. NN NN O
Val204Asp NN NN O
) NN NN O
causes NN NN O
loss NN NN O
of NN NN O
activity NN NN O
and NN NN O
prolonged NN NN O
apnea NN NN B-Disease
with NN NN O
suxamethonium NN NN O
. NN NN O
   
Butyrylcholinesterase NN NN B-Disease
deficiency NN NN I-Disease
is NN NN O
characterized NN NN O
by NN NN O
prolonged NN NN O
apnea NN NN B-Disease
after NN NN O
the NN NN O
use NN NN O
of NN NN O
muscle NN NN O
relaxants NN NN O
( NN NN O
suxamethonium NN NN O
or NN NN O
mivacurium NN NN O
) NN NN O
in NN NN O
patients NN NN O
who NN NN O
have NN NN O
mutations NN NN O
in NN NN O
the NN NN O
BCHE NN NN O
gene NN NN O
. NN NN O
   
Here NN NN O
, NN NN O
we NN NN O
report NN NN O
a NN NN O
case NN NN O
of NN NN O
prolonged NN NN O
neuromuscular NN NN O
block NN NN O
after NN NN O
administration NN NN O
of NN NN O
suxamethonium NN NN O
leading NN NN O
to NN NN O
the NN NN O
discovery NN NN O
of NN NN O
a NN NN O
novel NN NN O
BCHE NN NN O
variant NN NN O
( NN NN O
c NN NN O
. NN NN O
695T NN NN O
> NN NN O
A NN NN O
, NN NN O
p NN NN O
. NN NN O
Val204Asp NN NN O
) NN NN O
. NN NN O
   
Inhibition NN NN O
studies NN NN O
, NN NN O
kinetic NN NN O
analysis NN NN O
and NN NN O
molecular NN NN O
dynamics NN NN O
were NN NN O
undertaken NN NN O
to NN NN O
understand NN NN O
how NN NN O
this NN NN O
mutation NN NN O
disrupts NN NN O
the NN NN O
catalytic NN NN O
triad NN NN O
and NN NN O
determines NN NN O
a NN NN O
"""""""" NN NN O
silent NN NN O
"""""""" NN NN O
phenotype NN NN O
. NN NN O
   
Low NN NN O
activity NN NN O
of NN NN O
patient NN NN O
plasma NN NN O
butyrylcholinesterase NN NN O
with NN NN O
butyrylthiocholine NN NN O
( NN NN O
BTC NN NN O
) NN NN O
and NN NN O
benzoylcholine NN NN O
, NN NN O
and NN NN O
values NN NN O
of NN NN O
dibucaine NN NN O
and NN NN O
fluoride NN NN O
numbers NN NN O
fit NN NN O
with NN NN O
heterozygous NN NN O
atypical NN NN O
silent NN NN O
genotype NN NN O
. NN NN O
   
Electrophoretic NN NN O
analysis NN NN O
of NN NN O
plasma NN NN O
BChE NN NN O
of NN NN O
the NN NN O
proband NN NN O
and NN NN O
his NN NN O
mother NN NN O
showed NN NN O
that NN NN O
patient NN NN O
has NN NN O
a NN NN O
reduced NN NN O
amount NN NN O
of NN NN O
tetrameric NN NN O
enzyme NN NN O
in NN NN O
plasma NN NN O
and NN NN O
that NN NN O
minor NN NN O
fast NN NN O
- NN NN O
moving NN NN O
BChE NN NN O
components NN NN O
: NN NN O
monomer NN NN O
, NN NN O
dimer NN NN O
, NN NN O
and NN NN O
monomer NN NN O
- NN NN O
albumin NN NN O
conjugate NN NN O
are NN NN O
missing NN NN O
. NN NN O
   
Kinetic NN NN O
analysis NN NN O
showed NN NN O
that NN NN O
the NN NN O
p NN NN O
. NN NN O
Val204Asp NN NN O
/ NN NN O
p NN NN O
. NN NN O
Asp70Gly NN NN O
- NN NN O
p NN NN O
. NN NN O
Ala539Thr NN NN O
BChE NN NN O
displays NN NN O
a NN NN O
pure NN NN O
Michaelian NN NN O
behavior NN NN O
with NN NN O
BTC NN NN O
as NN NN O
the NN NN O
substrate NN NN O
. NN NN O
   
Both NN NN O
catalytic NN NN O
parameters NN NN O
Km NN NN O
= NN NN O
265 NN NN O
uM NN NN O
for NN NN O
BTC NN NN O
, NN NN O
two NN NN O
times NN NN O
higher NN NN O
than NN NN O
that NN NN O
of NN NN O
the NN NN O
atypical NN NN O
enzyme NN NN O
, NN NN O
and NN NN O
a NN NN O
low NN NN O
Vmax NN NN O
are NN NN O
consistent NN NN O
with NN NN O
the NN NN O
absence NN NN O
of NN NN O
activity NN NN O
against NN NN O
suxamethonium NN NN O
. NN NN O
   
Molecular NN NN O
dynamic NN NN O
( NN NN O
MD NN NN O
) NN NN O
simulations NN NN O
showed NN NN O
that NN NN O
the NN NN O
overall NN NN O
effect NN NN O
of NN NN O
the NN NN O
mutation NN NN O
p NN NN O
. NN NN O
Val204Asp NN NN O
is NN NN O
disruption NN NN O
of NN NN O
hydrogen NN NN O
bonding NN NN O
between NN NN O
Gln223 NN NN O
and NN NN O
Glu441 NN NN O
, NN NN O
leading NN NN O
Ser198 NN NN O
and NN NN O
His438 NN NN O
to NN NN O
move NN NN O
away NN NN O
from NN NN O
each NN NN O
other NN NN O
with NN NN O
subsequent NN NN O
disruption NN NN O
of NN NN O
the NN NN O
catalytic NN NN O
triad NN NN O
functionality NN NN O
regardless NN NN O
of NN NN O
the NN NN O
type NN NN O
of NN NN O
substrate NN NN O
. NN NN O
   
MD NN NN O
also NN NN O
showed NN NN O
that NN NN O
the NN NN O
enzyme NN NN O
volume NN NN O
is NN NN O
increased NN NN O
, NN NN O
suggesting NN NN O
a NN NN O
pre NN NN O
- NN NN O
denaturation NN NN O
state NN NN O
. NN NN O
   
This NN NN O
fits NN NN O
with NN NN O
the NN NN O
reduced NN NN O
concentration NN NN O
of NN NN O
p NN NN O
. NN NN O
Ala204Asp NN NN O
/ NN NN O
p NN NN O
. NN NN O
Asp70Gly NN NN O
- NN NN O
p NN NN O
. NN NN O
Ala539Thr NN NN O
tetrameric NN NN O
enzyme NN NN O
in NN NN O
the NN NN O
plasma NN NN O
and NN NN O
non NN NN O
- NN NN O
detectable NN NN O
fast NN NN O
moving NN NN O
- NN NN O
bands NN NN O
on NN NN O
electrophoresis NN NN O
gels NN NN O
. NN NN O
   
Delayed NN NN O
anemia NN NN B-Disease
after NN NN O
treatment NN NN O
with NN NN O
injectable NN NN O
artesunate NN NN O
in NN NN O
the NN NN O
Democratic NN NN O
Republic NN NN O
of NN NN O
the NN NN O
Congo NN NN O
: NN NN O
a NN NN O
manageable NN NN O
issue NN NN O
. NN NN O
   
Cases NN NN O
of NN NN O
delayed NN NN O
hemolytic NN NN B-Disease
anemia NN NN I-Disease
have NN NN O
been NN NN O
described NN NN O
after NN NN O
treatment NN NN O
with NN NN O
injectable NN NN O
artesunate NN NN O
, NN NN O
the NN NN O
current NN NN O
World NN NN O
Health NN NN O
Organization NN NN O
( NN NN O
WHO NN NN O
) NN NN O
- NN NN O
recommended NN NN O
first NN NN O
- NN NN O
line NN NN O
drug NN NN O
for NN NN O
the NN NN O
treatment NN NN O
of NN NN O
severe NN NN O
malaria NN NN B-Disease
. NN NN O
   
A NN NN O
total NN NN O
of NN NN O
350 NN NN O
patients NN NN O
( NN NN O
215 NN NN O
[ NN NN O
61 NN NN O
. NN NN O
4 NN NN O
% NN NN O
] NN NN O
< NN NN O
5 NN NN O
years NN NN O
of NN NN O
age NN NN O
and NN NN O
135 NN NN O
[ NN NN O
38 NN NN O
. NN NN O
6 NN NN O
% NN NN O
] NN NN O
> NN NN O
5 NN NN O
years NN NN O
of NN NN O
age NN NN O
) NN NN O
were NN NN O
followed NN NN O
- NN NN O
up NN NN O
after NN NN O
treatment NN NN O
with NN NN O
injectable NN NN O
artesunate NN NN O
for NN NN O
severe NN NN O
malaria NN NN B-Disease
in NN NN O
hospitals NN NN O
and NN NN O
health NN NN O
centers NN NN O
of NN NN O
the NN NN O
Democratic NN NN O
Republic NN NN O
of NN NN O
the NN NN O
Congo NN NN O
. NN NN O
   
Complete NN NN O
series NN NN O
of NN NN O
hemoglobin NN NN O
( NN NN O
Hb NN NN O
) NN NN O
measurements NN NN O
were NN NN O
available NN NN O
for NN NN O
201 NN NN O
patients NN NN O
. NN NN O
   
A NN NN O
decrease NN NN O
in NN NN O
Hb NN NN O
levels NN NN O
between NN NN O
2 NN NN O
and NN NN O
5 NN NN O
g NN NN O
/ NN NN O
dL NN NN O
was NN NN O
detected NN NN O
in NN NN O
23 NN NN O
( NN NN O
11 NN NN O
. NN NN O
4 NN NN O
% NN NN O
) NN NN O
patients NN NN O
during NN NN O
the NN NN O
follow NN NN O
- NN NN O
up NN NN O
period NN NN O
. NN NN O
   
For NN NN O
five NN NN O
patients NN NN O
, NN NN O
Hb NN NN O
levels NN NN O
decreased NN NN O
below NN NN O
5 NN NN O
g NN NN O
/ NN NN O
dL NN NN O
during NN NN O
at NN NN O
least NN NN O
one NN NN O
follow NN NN O
- NN NN O
up NN NN O
visit NN NN O
. NN NN O
   
All NN NN O
cases NN NN O
of NN NN O
delayed NN NN O
anemia NN NN B-Disease
were NN NN O
clinically NN NN O
manageable NN NN O
and NN NN O
resolved NN NN O
within NN NN O
one NN NN O
month NN NN O
. NN NN O
   
Regulation NN NN O
of NN NN O
signal NN NN O
transducer NN NN O
and NN NN O
activator NN NN O
of NN NN O
transcription NN NN O
3 NN NN O
and NN NN O
apoptotic NN NN O
pathways NN NN O
by NN NN O
betaine NN NN O
attenuates NN NN O
isoproterenol NN NN O
- NN NN O
induced NN NN O
acute NN NN O
myocardial NN NN B-Disease
injury NN NN I-Disease
in NN NN O
rats NN NN O
. NN NN O
   
The NN NN O
present NN NN O
study NN NN O
was NN NN O
designed NN NN O
to NN NN O
investigate NN NN O
the NN NN O
cardioprotective NN NN O
effects NN NN O
of NN NN O
betaine NN NN O
on NN NN O
acute NN NN O
myocardial NN NN B-Disease
ischemia NN NN I-Disease
induced NN NN O
experimentally NN NN O
in NN NN O
rats NN NN O
focusing NN NN O
on NN NN O
regulation NN NN O
of NN NN O
signal NN NN O
transducer NN NN O
and NN NN O
activator NN NN O
of NN NN O
transcription NN NN O
3 NN NN O
( NN NN O
STAT3 NN NN O
) NN NN O
and NN NN O
apoptotic NN NN O
pathways NN NN O
as NN NN O
the NN NN O
potential NN NN O
mechanism NN NN O
underlying NN NN O
the NN NN O
drug NN NN O
effect NN NN O
. NN NN O
   
Male NN NN O
Sprague NN NN O
Dawley NN NN O
rats NN NN O
were NN NN O
treated NN NN O
with NN NN O
betaine NN NN O
( NN NN O
100 NN NN O
, NN NN O
200 NN NN O
, NN NN O
and NN NN O
400 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
) NN NN O
orally NN NN O
for NN NN O
40 NN NN O
days NN NN O
. NN NN O
   
Acute NN NN O
myocardial NN NN B-Disease
ischemic NN NN I-Disease
injury NN NN I-Disease
was NN NN O
induced NN NN O
in NN NN O
rats NN NN O
by NN NN O
subcutaneous NN NN O
injection NN NN O
of NN NN O
isoproterenol NN NN O
( NN NN O
85 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
) NN NN O
, NN NN O
for NN NN O
two NN NN O
consecutive NN NN O
days NN NN O
. NN NN O
   
Serum NN NN O
cardiac NN NN O
marker NN NN O
enzyme NN NN O
, NN NN O
histopathological NN NN O
variables NN NN O
and NN NN O
expression NN NN O
of NN NN O
protein NN NN O
levels NN NN O
were NN NN O
analyzed NN NN O
. NN NN O
   
Oral NN NN O
administration NN NN O
of NN NN O
betaine NN NN O
( NN NN O
200 NN NN O
and NN NN O
400 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
) NN NN O
significantly NN NN O
reduced NN NN O
the NN NN O
level NN NN O
of NN NN O
cardiac NN NN O
marker NN NN O
enzyme NN NN O
in NN NN O
the NN NN O
serum NN NN O
and NN NN O
prevented NN NN O
left NN NN O
ventricular NN NN B-Disease
remodeling NN NN I-Disease
. NN NN O
   
Western NN NN O
blot NN NN O
analysis NN NN O
showed NN NN O
that NN NN O
isoproterenol NN NN O
- NN NN O
induced NN NN O
phosphorylation NN NN O
of NN NN O
STAT3 NN NN O
was NN NN O
maintained NN NN O
or NN NN O
further NN NN O
enhanced NN NN O
by NN NN O
betaine NN NN O
treatment NN NN O
in NN NN O
myocardium NN NN O
. NN NN O
   
Furthermore NN NN O
, NN NN O
betaine NN NN O
( NN NN O
200 NN NN O
and NN NN O
400 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
) NN NN O
treatment NN NN O
increased NN NN O
the NN NN O
ventricular NN NN O
expression NN NN O
of NN NN O
Bcl NN NN O
- NN NN O
2 NN NN O
and NN NN O
reduced NN NN O
the NN NN O
level NN NN O
of NN NN O
Bax NN NN O
, NN NN O
therefore NN NN O
causing NN NN O
a NN NN O
significant NN NN O
increase NN NN O
in NN NN O
the NN NN O
ratio NN NN O
of NN NN O
Bcl NN NN O
- NN NN O
2 NN NN O
/ NN NN O
Bax NN NN O
. NN NN O
   
The NN NN O
protective NN NN O
role NN NN O
of NN NN O
betaine NN NN O
on NN NN O
myocardial NN NN B-Disease
damage NN NN I-Disease
was NN NN O
further NN NN O
confirmed NN NN O
by NN NN O
histopathological NN NN O
examination NN NN O
. NN NN O
   
In NN NN O
summary NN NN O
, NN NN O
our NN NN O
results NN NN O
showed NN NN O
that NN NN O
betaine NN NN O
pretreatment NN NN O
attenuated NN NN O
isoproterenol NN NN O
- NN NN O
induced NN NN O
acute NN NN O
myocardial NN NN B-Disease
ischemia NN NN I-Disease
via NN NN O
the NN NN O
regulation NN NN O
of NN NN O
STAT3 NN NN O
and NN NN O
apoptotic NN NN O
pathways NN NN O
. NN NN O
   
Quetiapine NN NN O
- NN NN O
induced NN NN O
neutropenia NN NN B-Disease
in NN NN O
a NN NN O
bipolar NN NN B-Disease
patient NN NN O
with NN NN O
hepatocellular NN NN B-Disease
carcinoma NN NN I-Disease
. NN NN O
   
OBJECTIVE NN NN O
: NN NN O
Quetiapine NN NN O
is NN NN O
a NN NN O
dibenzothiazepine NN NN O
derivative NN NN O
, NN NN O
similar NN NN O
to NN NN O
clozapine NN NN O
, NN NN O
which NN NN O
has NN NN O
the NN NN O
highest NN NN O
risk NN NN O
of NN NN O
causing NN NN O
blood NN NN B-Disease
dyscrasias NN NN I-Disease
, NN NN O
especially NN NN O
neutropenia NN NN B-Disease
. NN NN O
   
There NN NN O
are NN NN O
some NN NN O
case NN NN O
reports NN NN O
about NN NN O
this NN NN O
side NN NN O
effect NN NN O
of NN NN O
quetiapine NN NN O
, NN NN O
but NN NN O
possible NN NN O
risk NN NN O
factors NN NN O
are NN NN O
seldom NN NN O
discussed NN NN O
and NN NN O
identified NN NN O
. NN NN O
   
A NN NN O
case NN NN O
of NN NN O
a NN NN O
patient NN NN O
with NN NN O
hepatocellular NN NN B-Disease
carcinoma NN NN I-Disease
that NN NN O
developed NN NN O
neutropenia NN NN B-Disease
after NN NN O
treatment NN NN O
with NN NN O
quetiapine NN NN O
is NN NN O
described NN NN O
here NN NN O
. NN NN O
   
CASE NN NN O
REPORT NN NN O
: NN NN O
A NN NN O
62 NN NN O
- NN NN O
year NN NN O
- NN NN O
old NN NN O
Taiwanese NN NN O
widow NN NN O
with NN NN O
bipolar NN NN B-Disease
disorder NN NN I-Disease
was NN NN O
diagnosed NN NN O
with NN NN O
hepatocellular NN NN B-Disease
carcinoma NN NN I-Disease
at NN NN O
age NN NN O
60 NN NN O
. NN NN O
   
She NN NN O
developed NN NN O
leucopenia NN NN B-Disease
after NN NN O
being NN NN O
treated NN NN O
with NN NN O
quetiapine NN NN O
. NN NN O
   
After NN NN O
quetiapine NN NN O
was NN NN O
discontinued NN NN O
, NN NN O
her NN NN O
white NN NN O
blood NN NN O
cell NN NN O
count NN NN O
returned NN NN O
to NN NN O
normal NN NN O
. NN NN O
   
CONCLUSIONS NN NN O
: NN NN O
Although NN NN O
neutropenia NN NN B-Disease
is NN NN O
not NN NN O
a NN NN O
common NN NN O
side NN NN O
effect NN NN O
of NN NN O
quetiapine NN NN O
, NN NN O
physicians NN NN O
should NN NN O
be NN NN O
cautious NN NN O
about NN NN O
its NN NN O
presentation NN NN O
and NN NN O
associated NN NN O
risk NN NN O
factors NN NN O
. NN NN O
   
Hepatic NN NN B-Disease
dysfunction NN NN I-Disease
may NN NN O
be NN NN O
one NN NN O
of NN NN O
the NN NN O
possible NN NN O
risk NN NN O
factors NN NN O
, NN NN O
and NN NN O
concomitant NN NN O
fever NN NN B-Disease
may NN NN O
be NN NN O
a NN NN O
diagnostic NN NN O
marker NN NN O
for NN NN O
adverse NN NN O
reaction NN NN O
to NN NN O
quetiapine NN NN O
. NN NN O
   
Lateral NN NN O
antebrachial NN NN O
cutaneous NN NN O
neuropathy NN NN B-Disease
after NN NN O
steroid NN NN O
injection NN NN O
at NN NN O
lateral NN NN O
epicondyle NN NN O
. NN NN O
   
BACKGROUND NN NN O
AND NN NN O
OBJECTIVES NN NN O
: NN NN O
This NN NN O
report NN NN O
aimed NN NN O
to NN NN O
present NN NN O
a NN NN O
case NN NN O
of NN NN O
lateral NN NN O
antebrachial NN NN O
cutaneous NN NN O
neuropathy NN NN B-Disease
( NN NN O
LACNP NN NN O
) NN NN O
that NN NN O
occurred NN NN O
after NN NN O
a NN NN O
steroid NN NN O
injection NN NN O
in NN NN O
the NN NN O
lateral NN NN O
epicondyle NN NN O
to NN NN O
treat NN NN O
lateral NN NN B-Disease
epicondylitis NN NN I-Disease
in NN NN O
a NN NN O
40 NN NN O
- NN NN O
year NN NN O
- NN NN O
old NN NN O
woman NN NN O
. NN NN O
   
MATERIAL NN NN O
AND NN NN O
METHOD NN NN O
: NN NN O
A NN NN O
40 NN NN O
- NN NN O
year NN NN O
- NN NN O
old NN NN O
woman NN NN O
presented NN NN O
with NN NN O
decreased NN NN O
sensation NN NN O
and NN NN O
paresthesia NN NN B-Disease
over NN NN O
her NN NN O
right NN NN O
lateral NN NN O
forearm NN NN O
; NN NN O
the NN NN O
paresthesia NN NN B-Disease
had NN NN O
occurred NN NN O
after NN NN O
a NN NN O
steroid NN NN O
injection NN NN O
in NN NN O
the NN NN O
right NN NN O
lateral NN NN O
epicondyle NN NN O
3 NN NN O
months NN NN O
before NN NN O
. NN NN O
   
Her NN NN O
sensation NN NN O
of NN NN O
light NN NN O
touch NN NN O
and NN NN O
pain NN NN B-Disease
was NN NN O
diminished NN NN O
over NN NN O
the NN NN O
lateral NN NN O
side NN NN O
of NN NN O
the NN NN O
right NN NN O
forearm NN NN O
and NN NN O
wrist NN NN O
area NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
The NN NN O
sensory NN NN O
action NN NN O
potential NN NN O
amplitude NN NN O
of NN NN O
the NN NN O
right NN NN O
lateral NN NN O
antebrachial NN NN O
cutaneous NN NN O
nerve NN NN O
( NN NN O
LACN NN NN O
) NN NN O
( NN NN O
6 NN NN O
. NN NN O
2 NN NN O
uV NN NN O
) NN NN O
was NN NN O
lower NN NN O
than NN NN O
that NN NN O
of NN NN O
the NN NN O
left NN NN O
( NN NN O
13 NN NN O
. NN NN O
1 NN NN O
uV NN NN O
) NN NN O
. NN NN O
   
The NN NN O
difference NN NN O
of NN NN O
amplitude NN NN O
between NN NN O
both NN NN O
sides NN NN O
was NN NN O
significant NN NN O
because NN NN O
there NN NN O
was NN NN O
more NN NN O
than NN NN O
a NN NN O
50 NN NN O
% NN NN O
reduction NN NN O
. NN NN O
   
She NN NN O
was NN NN O
diagnosed NN NN O
with NN NN O
right NN NN O
LACNP NN NN O
( NN NN O
mainly NN NN O
axonal NN NN O
involvement NN NN O
) NN NN O
on NN NN O
the NN NN O
basis NN NN O
of NN NN O
the NN NN O
clinical NN NN O
manifestation NN NN O
and NN NN O
the NN NN O
electrodiagnostic NN NN O
findings NN NN O
. NN NN O
   
Her NN NN O
symptoms NN NN O
improved NN NN O
through NN NN O
physical NN NN O
therapy NN NN O
but NN NN O
persisted NN NN O
to NN NN O
some NN NN O
degree NN NN O
. NN NN O
   
CONCLUSION NN NN O
: NN NN O
This NN NN O
report NN NN O
describes NN NN O
the NN NN O
case NN NN O
of NN NN O
a NN NN O
woman NN NN O
with NN NN O
LACNP NN NN O
that NN NN O
developed NN NN O
after NN NN O
a NN NN O
steroid NN NN O
injection NN NN O
for NN NN O
the NN NN O
treatment NN NN O
of NN NN O
lateral NN NN B-Disease
epicondylitis NN NN I-Disease
. NN NN O
   
An NN NN O
electrodiagnostic NN NN O
study NN NN O
, NN NN O
including NN NN O
a NN NN O
nerve NN NN O
conduction NN NN O
study NN NN O
of NN NN O
the NN NN O
LACN NN NN O
, NN NN O
was NN NN O
helpful NN NN O
to NN NN O
diagnose NN NN O
right NN NN O
LACNP NN NN O
and NN NN O
to NN NN O
find NN NN O
the NN NN O
passage NN NN O
of NN NN O
the NN NN O
LACN NN NN O
on NN NN O
the NN NN O
lateral NN NN O
epicondyle NN NN O
. NN NN O
   
Curcumin NN NN O
prevents NN NN O
maleate NN NN O
- NN NN O
induced NN NN O
nephrotoxicity NN NN B-Disease
: NN NN O
relation NN NN O
to NN NN O
hemodynamic NN NN O
alterations NN NN O
, NN NN O
oxidative NN NN O
stress NN NN O
, NN NN O
mitochondrial NN NN O
oxygen NN NN O
consumption NN NN O
and NN NN O
activity NN NN O
of NN NN O
respiratory NN NN O
complex NN NN O
I NN NN O
. NN NN O
   
The NN NN O
potential NN NN O
protective NN NN O
effect NN NN O
of NN NN O
the NN NN O
dietary NN NN O
antioxidant NN NN O
curcumin NN NN O
( NN NN O
120 NN NN O
mg NN NN O
/ NN NN O
Kg NN NN O
/ NN NN O
day NN NN O
for NN NN O
6 NN NN O
days NN NN O
) NN NN O
against NN NN O
the NN NN O
renal NN NN B-Disease
injury NN NN I-Disease
induced NN NN O
by NN NN O
maleate NN NN O
was NN NN O
evaluated NN NN O
. NN NN O
   
Tubular NN NN O
proteinuria NN NN B-Disease
and NN NN O
oxidative NN NN O
stress NN NN O
were NN NN O
induced NN NN O
by NN NN O
a NN NN O
single NN NN O
injection NN NN O
of NN NN O
maleate NN NN O
( NN NN O
400 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
) NN NN O
in NN NN O
rats NN NN O
. NN NN O
   
Maleate NN NN O
- NN NN O
induced NN NN O
renal NN NN B-Disease
injury NN NN I-Disease
included NN NN O
increase NN NN O
in NN NN O
renal NN NN O
vascular NN NN O
resistance NN NN O
and NN NN O
in NN NN O
the NN NN O
urinary NN NN O
excretion NN NN O
of NN NN O
total NN NN O
protein NN NN O
, NN NN O
glucose NN NN O
, NN NN O
sodium NN NN O
, NN NN O
neutrophil NN NN O
gelatinase NN NN O
- NN NN O
associated NN NN O
lipocalin NN NN O
( NN NN O
NGAL NN NN O
) NN NN O
and NN NN O
N NN NN O
- NN NN O
acetyl NN NN O
b NN NN O
- NN NN O
D NN NN O
- NN NN O
glucosaminidase NN NN O
( NN NN O
NAG NN NN O
) NN NN O
, NN NN O
upregulation NN NN O
of NN NN O
kidney NN NN B-Disease
injury NN NN I-Disease
molecule NN NN O
( NN NN O
KIM NN NN O
) NN NN O
- NN NN O
1 NN NN O
, NN NN O
decrease NN NN O
in NN NN O
renal NN NN O
blood NN NN O
flow NN NN O
and NN NN O
claudin NN NN O
- NN NN O
2 NN NN O
expression NN NN O
besides NN NN O
of NN NN O
necrosis NN NN B-Disease
and NN NN O
apoptosis NN NN O
of NN NN O
tubular NN NN O
cells NN NN O
on NN NN O
24 NN NN O
h NN NN O
. NN NN O
   
Oxidative NN NN O
stress NN NN O
was NN NN O
determined NN NN O
by NN NN O
measuring NN NN O
the NN NN O
oxidation NN NN O
of NN NN O
lipids NN NN O
and NN NN O
proteins NN NN O
and NN NN O
diminution NN NN O
in NN NN O
renal NN NN O
Nrf2 NN NN O
levels NN NN O
. NN NN O
   
Studies NN NN O
were NN NN O
also NN NN O
conducted NN NN O
in NN NN O
renal NN NN O
epithelial NN NN O
LLC NN NN O
- NN NN O
PK1 NN NN O
cells NN NN O
and NN NN O
in NN NN O
mitochondria NN NN O
isolated NN NN O
from NN NN O
kidneys NN NN O
of NN NN O
all NN NN O
the NN NN O
experimental NN NN O
groups NN NN O
. NN NN O
   
Maleate NN NN O
induced NN NN O
cell NN NN O
damage NN NN O
and NN NN O
reactive NN NN O
oxygen NN NN O
species NN NN O
( NN NN O
ROS NN NN O
) NN NN O
production NN NN O
in NN NN O
LLC NN NN O
- NN NN O
PK1 NN NN O
cells NN NN O
in NN NN O
culture NN NN O
. NN NN O
   
In NN NN O
addition NN NN O
, NN NN O
maleate NN NN O
treatment NN NN O
reduced NN NN O
oxygen NN NN O
consumption NN NN O
in NN NN O
ADP NN NN O
- NN NN O
stimulated NN NN O
mitochondria NN NN O
and NN NN O
diminished NN NN O
respiratory NN NN O
control NN NN O
index NN NN O
when NN NN O
using NN NN O
malate NN NN O
/ NN NN O
glutamate NN NN O
as NN NN O
substrate NN NN O
. NN NN O
   
The NN NN O
activities NN NN O
of NN NN O
both NN NN O
complex NN NN O
I NN NN O
and NN NN O
aconitase NN NN O
were NN NN O
also NN NN O
diminished NN NN O
. NN NN O
   
All NN NN O
the NN NN O
above NN NN O
- NN NN O
described NN NN O
alterations NN NN O
were NN NN O
prevented NN NN O
by NN NN O
curcumin NN NN O
. NN NN O
   
It NN NN O
is NN NN O
concluded NN NN O
that NN NN O
curcumin NN NN O
is NN NN O
able NN NN O
to NN NN O
attenuate NN NN O
in NN NN O
vivo NN NN O
maleate NN NN O
- NN NN O
induced NN NN O
nephropathy NN NN B-Disease
and NN NN O
in NN NN O
vitro NN NN O
cell NN NN O
damage NN NN O
. NN NN O
   
The NN NN O
in NN NN O
vivo NN NN O
protection NN NN O
was NN NN O
associated NN NN O
to NN NN O
the NN NN O
prevention NN NN O
of NN NN O
oxidative NN NN O
stress NN NN O
and NN NN O
preservation NN NN O
of NN NN O
mitochondrial NN NN O
oxygen NN NN O
consumption NN NN O
and NN NN O
activity NN NN O
of NN NN O
respiratory NN NN O
complex NN NN O
I NN NN O
, NN NN O
and NN NN O
the NN NN O
in NN NN O
vitro NN NN O
protection NN NN O
was NN NN O
associated NN NN O
to NN NN O
the NN NN O
prevention NN NN O
of NN NN O
ROS NN NN O
production NN NN O
. NN NN O
   
Anticonvulsant NN NN O
actions NN NN O
of NN NN O
MK NN NN O
- NN NN O
801 NN NN O
on NN NN O
the NN NN O
lithium NN NN O
- NN NN O
pilocarpine NN NN O
model NN NN O
of NN NN O
status NN NN B-Disease
epilepticus NN NN I-Disease
in NN NN O
rats NN NN O
. NN NN O
   
MK NN NN O
- NN NN O
801 NN NN O
, NN NN O
a NN NN O
noncompetitive NN NN O
N NN NN O
- NN NN O
methyl NN NN O
- NN NN O
D NN NN O
- NN NN O
aspartate NN NN O
( NN NN O
NMDA NN NN O
) NN NN O
receptor NN NN O
antagonist NN NN O
, NN NN O
was NN NN O
tested NN NN O
for NN NN O
anticonvulsant NN NN O
effects NN NN O
in NN NN O
rats NN NN O
using NN NN O
two NN NN O
seizure NN NN B-Disease
models NN NN O
, NN NN O
coadministration NN NN O
of NN NN O
lithium NN NN O
and NN NN O
pilocarpine NN NN O
and NN NN O
administration NN NN O
of NN NN O
a NN NN O
high NN NN O
dose NN NN O
of NN NN O
pilocarpine NN NN O
alone NN NN O
. NN NN O
   
Three NN NN O
major NN NN O
results NN NN O
are NN NN O
reported NN NN O
. NN NN O
   
First NN NN O
, NN NN O
pretreatment NN NN O
with NN NN O
MK NN NN O
- NN NN O
801 NN NN O
produced NN NN O
an NN NN O
effective NN NN O
and NN NN O
dose NN NN O
- NN NN O
dependent NN NN O
anticonvulsant NN NN O
action NN NN O
with NN NN O
the NN NN O
lithium NN NN O
- NN NN O
pilocarpine NN NN O
model NN NN O
but NN NN O
not NN NN O
with NN NN O
rats NN NN O
treated NN NN O
with NN NN O
pilocarpine NN NN O
alone NN NN O
, NN NN O
suggesting NN NN O
that NN NN O
different NN NN O
biochemical NN NN O
mechanisms NN NN O
control NN NN O
seizures NN NN B-Disease
in NN NN O
these NN NN O
two NN NN O
models NN NN O
. NN NN O
   
Second NN NN O
, NN NN O
the NN NN O
anticonvulsant NN NN O
effect NN NN O
of NN NN O
MK NN NN O
- NN NN O
801 NN NN O
in NN NN O
the NN NN O
lithium NN NN O
- NN NN O
pilocarpine NN NN O
model NN NN O
only NN NN O
occurred NN NN O
after NN NN O
initial NN NN O
periods NN NN O
of NN NN O
seizure NN NN B-Disease
activity NN NN O
. NN NN O
   
This NN NN O
observation NN NN O
is NN NN O
suggested NN NN O
to NN NN O
be NN NN O
an NN NN O
in NN NN O
vivo NN NN O
demonstration NN NN O
of NN NN O
the NN NN O
conclusion NN NN O
derived NN NN O
from NN NN O
in NN NN O
vitro NN NN O
experiments NN NN O
that NN NN O
MK NN NN O
- NN NN O
801 NN NN O
binding NN NN O
requires NN NN O
agonist NN NN O
- NN NN O
induced NN NN O
opening NN NN O
of NN NN O
the NN NN O
channel NN NN O
sites NN NN O
of NN NN O
the NN NN O
NMDA NN NN O
receptor NN NN O
. NN NN O
   
Third NN NN O
, NN NN O
although NN NN O
it NN NN O
is NN NN O
relatively NN NN O
easy NN NN O
to NN NN O
block NN NN O
seizures NN NN B-Disease
induced NN NN O
by NN NN O
lithium NN NN O
and NN NN O
pilocarpine NN NN O
by NN NN O
administration NN NN O
of NN NN O
anticonvulsants NN NN O
prior NN NN O
to NN NN O
pilocarpine NN NN O
, NN NN O
it NN NN O
is NN NN O
more NN NN O
difficult NN NN O
to NN NN O
terminate NN NN O
ongoing NN NN O
status NN NN B-Disease
epilepticus NN NN I-Disease
and NN NN O
block NN NN O
the NN NN O
lethality NN NN O
of NN NN O
the NN NN O
seizures NN NN B-Disease
. NN NN O
   
Administration NN NN O
of NN NN O
MK NN NN O
- NN NN O
801 NN NN O
30 NN NN O
or NN NN O
60 NN NN O
min NN NN O
after NN NN O
pilocarpine NN NN O
, NN NN O
i NN NN O
. NN NN O
e NN NN O
. NN NN O
, NN NN O
during NN NN O
status NN NN B-Disease
epilepticus NN NN I-Disease
, NN NN O
gradually NN NN O
reduced NN NN O
electrical NN NN O
and NN NN O
behavioral NN NN O
seizure NN NN B-Disease
activity NN NN O
and NN NN O
greatly NN NN O
enhanced NN NN O
the NN NN O
survival NN NN O
rate NN NN O
. NN NN O
   
These NN NN O
results NN NN O
suggest NN NN O
that NN NN O
activation NN NN O
of NN NN O
NMDA NN NN O
receptors NN NN O
plays NN NN O
an NN NN O
important NN NN O
role NN NN O
in NN NN O
status NN NN B-Disease
epilepticus NN NN I-Disease
and NN NN O
brain NN NN B-Disease
damage NN NN I-Disease
in NN NN O
the NN NN O
lithium NN NN O
- NN NN O
pilocarpine NN NN O
model NN NN O
. NN NN O
   
This NN NN O
was NN NN O
further NN NN O
supported NN NN O
by NN NN O
results NN NN O
showing NN NN O
that NN NN O
nonconvulsive NN NN O
doses NN NN O
of NN NN O
NMDA NN NN O
and NN NN O
pilocarpine NN NN O
were NN NN O
synergistic NN NN O
, NN NN O
resulting NN NN O
in NN NN O
status NN NN B-Disease
epilepticus NN NN I-Disease
and NN NN O
subsequent NN NN O
mortality NN NN O
. NN NN O
   
Continuous NN NN O
infusion NN NN O
tobramycin NN NN O
combined NN NN O
with NN NN O
carbenicillin NN NN O
for NN NN O
infections NN NN B-Disease
in NN NN O
cancer NN NN B-Disease
patients NN NN O
. NN NN O
   
The NN NN O
cure NN NN O
rate NN NN O
of NN NN O
infections NN NN B-Disease
in NN NN O
cancer NN NN B-Disease
patients NN NN O
is NN NN O
adversely NN NN O
affected NN NN O
by NN NN O
neutropenia NN NN B-Disease
( NN NN O
less NN NN O
than NN NN O
1 NN NN O
, NN NN O
000 NN NN O
/ NN NN O
mm3 NN NN O
) NN NN O
. NN NN O
   
In NN NN O
particular NN NN O
, NN NN O
patients NN NN O
with NN NN O
severe NN NN O
neutropenia NN NN B-Disease
( NN NN O
less NN NN O
than NN NN O
100 NN NN O
/ NN NN O
mm3 NN NN O
) NN NN O
have NN NN O
shown NN NN O
a NN NN O
poor NN NN O
response NN NN O
to NN NN O
antibiotics NN NN O
. NN NN O
   
To NN NN O
overcome NN NN O
the NN NN O
adverse NN NN O
effects NN NN O
of NN NN O
neutropenia NN NN B-Disease
, NN NN O
tobramycin NN NN O
was NN NN O
given NN NN O
by NN NN O
continuous NN NN O
infusion NN NN O
and NN NN O
combined NN NN O
with NN NN O
intermittent NN NN O
carbenicillin NN NN O
. NN NN O
   
Tobramycin NN NN O
was NN NN O
given NN NN O
to NN NN O
a NN NN O
total NN NN O
daily NN NN O
dose NN NN O
of NN NN O
300 NN NN O
mg NN NN O
/ NN NN O
m2 NN NN O
and NN NN O
carbenicillin NN NN O
was NN NN O
given NN NN O
at NN NN O
a NN NN O
dose NN NN O
of NN NN O
5 NN NN O
gm NN NN O
every NN NN O
four NN NN O
hours NN NN O
. NN NN O
   
There NN NN O
were NN NN O
125 NN NN O
infectious NN NN O
episodes NN NN O
in NN NN O
116 NN NN O
cancer NN NN B-Disease
patients NN NN O
receiving NN NN O
myelosuppressive NN NN O
chemotherapy NN NN O
. NN NN O
   
The NN NN O
overall NN NN O
cure NN NN O
rate NN NN O
was NN NN O
70 NN NN O
% NN NN O
. NN NN O
   
Pneumonia NN NN B-Disease
was NN NN O
the NN NN O
most NN NN O
common NN NN O
infection NN NN B-Disease
and NN NN O
61 NN NN O
% NN NN O
of NN NN O
59 NN NN O
episodes NN NN O
were NN NN O
cured NN NN O
. NN NN O
   
Gram NN NN O
- NN NN O
negative NN NN O
bacilli NN NN O
were NN NN O
the NN NN O
most NN NN O
common NN NN O
causative NN NN O
organisms NN NN O
and NN NN O
69 NN NN O
% NN NN O
of NN NN O
these NN NN O
infections NN NN B-Disease
were NN NN O
cured NN NN O
. NN NN O
   
The NN NN O
most NN NN O
common NN NN O
pathogen NN NN O
was NN NN O
Klebsiella NN NN O
pneumoniae NN NN B-Disease
and NN NN O
this NN NN O
, NN NN O
together NN NN O
with NN NN O
Escherichia NN NN O
coli NN NN O
and NN NN O
Pseudomonas NN NN O
aeruginosa NN NN O
, NN NN O
accounted NN NN O
for NN NN O
74 NN NN O
% NN NN O
of NN NN O
all NN NN O
gram NN NN B-Disease
- NN NN I-Disease
negative NN NN I-Disease
bacillary NN NN I-Disease
infections NN NN I-Disease
. NN NN O
   
Response NN NN O
was NN NN O
not NN NN O
influenced NN NN O
by NN NN O
the NN NN O
initial NN NN O
neutrophil NN NN O
count NN NN O
, NN NN O
with NN NN O
a NN NN O
62 NN NN O
% NN NN O
cure NN NN O
rate NN NN O
for NN NN O
39 NN NN O
episodes NN NN O
associated NN NN O
with NN NN O
severe NN NN O
neutropenia NN NN B-Disease
. NN NN O
   
However NN NN O
, NN NN O
failure NN NN O
of NN NN O
the NN NN O
neutrophil NN NN O
count NN NN O
to NN NN O
increase NN NN O
during NN NN O
therapy NN NN O
adversely NN NN O
affected NN NN O
response NN NN O
. NN NN O
   
Azotemia NN NN B-Disease
was NN NN O
the NN NN O
major NN NN O
side NN NN O
effect NN NN O
recognized NN NN O
, NN NN O
and NN NN O
it NN NN O
occurred NN NN O
in NN NN O
11 NN NN O
% NN NN O
of NN NN O
episodes NN NN O
. NN NN O
   
Major NN NN O
azotemia NN NN B-Disease
( NN NN O
serum NN NN O
creatinine NN NN O
greater NN NN O
than NN NN O
2 NN NN O
. NN NN O
5 NN NN O
mg NN NN O
/ NN NN O
dl NN NN O
or NN NN O
BUN NN NN O
greater NN NN O
than NN NN O
50 NN NN O
mg NN NN O
/ NN NN O
dl NN NN O
) NN NN O
occurred NN NN O
in NN NN O
only NN NN O
2 NN NN O
% NN NN O
. NN NN O
   
Azotemia NN NN B-Disease
was NN NN O
not NN NN O
related NN NN O
to NN NN O
duration NN NN O
of NN NN O
therapy NN NN O
or NN NN O
serum NN NN O
tobramycin NN NN O
concentration NN NN O
. NN NN O
   
This NN NN O
antibiotic NN NN O
regimen NN NN O
showed NN NN O
both NN NN O
therapeutic NN NN O
efficacy NN NN O
and NN NN O
acceptable NN NN O
renal NN NN B-Disease
toxicity NN NN I-Disease
for NN NN O
these NN NN O
patients NN NN O
. NN NN O
   
Incidence NN NN O
of NN NN O
solid NN NN O
tumours NN NN B-Disease
among NN NN O
pesticide NN NN O
applicators NN NN O
exposed NN NN O
to NN NN O
the NN NN O
organophosphate NN NN O
insecticide NN NN O
diazinon NN NN O
in NN NN O
the NN NN O
Agricultural NN NN O
Health NN NN O
Study NN NN O
: NN NN O
an NN NN O
updated NN NN O
analysis NN NN O
. NN NN O
   
OBJECTIVE NN NN O
: NN NN O
Diazinon NN NN O
, NN NN O
a NN NN O
common NN NN O
organophosphate NN NN O
insecticide NN NN O
with NN NN O
genotoxic NN NN O
properties NN NN O
, NN NN O
was NN NN O
previously NN NN O
associated NN NN O
with NN NN O
lung NN NN B-Disease
cancer NN NN I-Disease
in NN NN O
the NN NN O
Agricultural NN NN O
Health NN NN O
Study NN NN O
( NN NN O
AHS NN NN O
) NN NN O
cohort NN NN O
, NN NN O
but NN NN O
few NN NN O
other NN NN O
epidemiological NN NN O
studies NN NN O
have NN NN O
examined NN NN O
diazinon NN NN O
- NN NN O
associated NN NN O
cancer NN NN B-Disease
risk NN NN O
. NN NN O
   
We NN NN O
used NN NN O
updated NN NN O
diazinon NN NN O
exposure NN NN O
and NN NN O
cancer NN NN B-Disease
incidence NN NN O
information NN NN O
to NN NN O
evaluate NN NN O
solid NN NN O
tumour NN NN B-Disease
risk NN NN O
in NN NN O
the NN NN O
AHS NN NN O
. NN NN O
   
METHODS NN NN O
: NN NN O
Male NN NN O
pesticide NN NN O
applicators NN NN O
in NN NN O
Iowa NN NN O
and NN NN O
North NN NN O
Carolina NN NN O
reported NN NN O
lifetime NN NN O
diazinon NN NN O
use NN NN O
at NN NN O
enrolment NN NN O
( NN NN O
1993 NN NN O
- NN NN O
1997 NN NN O
) NN NN O
and NN NN O
follow NN NN O
- NN NN O
up NN NN O
( NN NN O
1998 NN NN O
- NN NN O
2005 NN NN O
) NN NN O
; NN NN O
cancer NN NN B-Disease
incidence NN NN O
was NN NN O
assessed NN NN O
through NN NN O
2010 NN NN O
( NN NN O
North NN NN O
Carolina NN NN O
) NN NN O
/ NN NN O
2011 NN NN O
( NN NN O
Iowa NN NN O
) NN NN O
. NN NN O
   
Among NN NN O
applicators NN NN O
with NN NN O
usage NN NN O
information NN NN O
sufficient NN NN O
to NN NN O
evaluate NN NN O
exposure NN NN O
- NN NN O
response NN NN O
patterns NN NN O
, NN NN O
we NN NN O
used NN NN O
Poisson NN NN O
regression NN NN O
to NN NN O
estimate NN NN O
adjusted NN NN O
rate NN NN O
ratios NN NN O
( NN NN O
RRs NN NN O
) NN NN O
and NN NN O
95 NN NN O
% NN NN O
CI NN NN O
for NN NN O
cancer NN NN B-Disease
sites NN NN O
with NN NN O
> NN NN O
10 NN NN O
exposed NN NN O
cases NN NN O
for NN NN O
both NN NN O
lifetime NN NN O
( NN NN O
LT NN NN O
) NN NN O
exposure NN NN O
days NN NN O
and NN NN O
intensity NN NN O
- NN NN O
weighted NN NN O
( NN NN O
IW NN NN O
) NN NN O
lifetime NN NN O
exposure NN NN O
days NN NN O
( NN NN O
accounting NN NN O
for NN NN O
factors NN NN O
impacting NN NN O
exposure NN NN O
) NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
We NN NN O
observed NN NN O
elevated NN NN O
lung NN NN B-Disease
cancer NN NN I-Disease
risks NN NN O
( NN NN O
N NN NN O
= NN NN O
283 NN NN O
) NN NN O
among NN NN O
applicators NN NN O
with NN NN O
the NN NN O
greatest NN NN O
number NN NN O
of NN NN O
LT NN NN O
( NN NN O
RR NN NN O
= NN NN O
1 NN NN O
. NN NN O
60 NN NN O
; NN NN O
95 NN NN O
% NN NN O
CI NN NN O
1 NN NN O
. NN NN O
11 NN NN O
to NN NN O
2 NN NN O
. NN NN O
31 NN NN O
; NN NN O
Ptrend NN NN O
= NN NN O
0 NN NN O
. NN NN O
02 NN NN O
) NN NN O
and NN NN O
IW NN NN O
days NN NN O
of NN NN O
diazinon NN NN O
use NN NN O
( NN NN O
RR NN NN O
= NN NN O
1 NN NN O
. NN NN O
41 NN NN O
; NN NN O
95 NN NN O
% NN NN O
CI NN NN O
0 NN NN O
. NN NN O
98 NN NN O
to NN NN O
2 NN NN O
. NN NN O
04 NN NN O
; NN NN O
Ptrend NN NN O
= NN NN O
0 NN NN O
. NN NN O
08 NN NN O
) NN NN O
. NN NN O
   
Kidney NN NN B-Disease
cancer NN NN I-Disease
( NN NN O
N NN NN O
= NN NN O
94 NN NN O
) NN NN O
risks NN NN O
were NN NN O
non NN NN O
- NN NN O
significantly NN NN O
elevated NN NN O
( NN NN O
RRLT NN NN O
days NN NN O
= NN NN O
1 NN NN O
. NN NN O
77 NN NN O
; NN NN O
95 NN NN O
% NN NN O
CI NN NN O
0 NN NN O
. NN NN O
90 NN NN O
to NN NN O
3 NN NN O
. NN NN O
51 NN NN O
; NN NN O
Ptrend NN NN O
= NN NN O
0 NN NN O
. NN NN O
09 NN NN O
; NN NN O
RRIW NN NN O
days NN NN O
1 NN NN O
. NN NN O
37 NN NN O
; NN NN O
95 NN NN O
% NN NN O
CI NN NN O
0 NN NN O
. NN NN O
64 NN NN O
to NN NN O
2 NN NN O
. NN NN O
92 NN NN O
; NN NN O
Ptrend NN NN O
= NN NN O
0 NN NN O
. NN NN O
50 NN NN O
) NN NN O
, NN NN O
as NN NN O
were NN NN O
risks NN NN O
for NN NN O
aggressive NN NN O
prostate NN NN B-Disease
cancer NN NN I-Disease
( NN NN O
N NN NN O
= NN NN O
656 NN NN O
) NN NN O
. NN NN O
   
CONCLUSIONS NN NN O
: NN NN O
Our NN NN O
updated NN NN O
evaluation NN NN O
of NN NN O
diazinon NN NN O
provides NN NN O
additional NN NN O
evidence NN NN O
of NN NN O
an NN NN O
association NN NN O
with NN NN O
lung NN NN B-Disease
cancer NN NN I-Disease
risk NN NN O
. NN NN O
   
Newly NN NN O
identified NN NN O
links NN NN O
to NN NN O
kidney NN NN B-Disease
cancer NN NN I-Disease
and NN NN O
associations NN NN O
with NN NN O
aggressive NN NN O
prostate NN NN B-Disease
cancer NN NN I-Disease
require NN NN O
further NN NN O
evaluation NN NN O
. NN NN O
   
Associations NN NN O
of NN NN O
Ozone NN NN O
and NN NN O
PM2 NN NN O
. NN NN O
5 NN NN O
Concentrations NN NN O
With NN NN O
Parkinson NN NN B-Disease
' NN NN I-Disease
s NN NN I-Disease
Disease NN NN I-Disease
Among NN NN O
Participants NN NN O
in NN NN O
the NN NN O
Agricultural NN NN O
Health NN NN O
Study NN NN O
. NN NN O
   
OBJECTIVE NN NN O
: NN NN O
This NN NN O
study NN NN O
describes NN NN O
associations NN NN O
of NN NN O
ozone NN NN O
and NN NN O
fine NN NN O
particulate NN NN O
matter NN NN O
with NN NN O
Parkinson NN NN B-Disease
' NN NN I-Disease
s NN NN I-Disease
disease NN NN I-Disease
observed NN NN O
among NN NN O
farmers NN NN O
in NN NN O
North NN NN O
Carolina NN NN O
and NN NN O
Iowa NN NN O
. NN NN O
   
METHODS NN NN O
: NN NN O
We NN NN O
used NN NN O
logistic NN NN O
regression NN NN O
to NN NN O
determine NN NN O
the NN NN O
associations NN NN O
of NN NN O
these NN NN O
pollutants NN NN O
with NN NN O
self NN NN O
- NN NN O
reported NN NN O
, NN NN O
doctor NN NN O
- NN NN O
diagnosed NN NN O
Parkinson NN NN B-Disease
' NN NN I-Disease
s NN NN I-Disease
disease NN NN I-Disease
. NN NN O
   
Daily NN NN O
predicted NN NN O
pollutant NN NN O
concentrations NN NN O
were NN NN O
used NN NN O
to NN NN O
derive NN NN O
surrogates NN NN O
of NN NN O
long NN NN O
- NN NN O
term NN NN O
exposure NN NN O
and NN NN O
link NN NN O
them NN NN O
to NN NN O
study NN NN O
participants NN NN O
' NN NN O
geocoded NN NN O
addresses NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
We NN NN O
observed NN NN O
positive NN NN O
associations NN NN O
of NN NN O
Parkinson NN NN B-Disease
' NN NN I-Disease
s NN NN I-Disease
disease NN NN I-Disease
with NN NN O
ozone NN NN O
( NN NN O
odds NN NN O
ratio NN NN O
= NN NN O
1 NN NN O
. NN NN O
39 NN NN O
; NN NN O
95 NN NN O
% NN NN O
CI NN NN O
: NN NN O
0 NN NN O
. NN NN O
98 NN NN O
to NN NN O
1 NN NN O
. NN NN O
98 NN NN O
) NN NN O
and NN NN O
fine NN NN O
particulate NN NN O
matter NN NN O
( NN NN O
odds NN NN O
ratio NN NN O
= NN NN O
1 NN NN O
. NN NN O
34 NN NN O
; NN NN O
95 NN NN O
% NN NN O
CI NN NN O
: NN NN O
0 NN NN O
. NN NN O
93 NN NN O
to NN NN O
1 NN NN O
. NN NN O
93 NN NN O
) NN NN O
in NN NN O
North NN NN O
Carolina NN NN O
but NN NN O
not NN NN O
in NN NN O
Iowa NN NN O
. NN NN O
   
CONCLUSIONS NN NN O
: NN NN O
The NN NN O
plausibility NN NN O
of NN NN O
an NN NN O
effect NN NN O
of NN NN O
ambient NN NN O
concentrations NN NN O
of NN NN O
these NN NN O
pollutants NN NN O
on NN NN O
Parkinson NN NN B-Disease
' NN NN I-Disease
s NN NN I-Disease
disease NN NN I-Disease
risk NN NN O
is NN NN O
supported NN NN O
by NN NN O
experimental NN NN O
data NN NN O
demonstrating NN NN O
damage NN NN O
to NN NN O
dopaminergic NN NN O
neurons NN NN O
at NN NN O
relevant NN NN O
concentrations NN NN O
. NN NN O
   
Additional NN NN O
studies NN NN O
are NN NN O
needed NN NN O
to NN NN O
address NN NN O
uncertainties NN NN O
related NN NN O
to NN NN O
confounding NN NN O
and NN NN O
to NN NN O
examine NN NN O
temporal NN NN O
aspects NN NN O
of NN NN O
the NN NN O
associations NN NN O
we NN NN O
observed NN NN O
. NN NN O
   
Low NN NN O
functional NN NN O
programming NN NN O
of NN NN O
renal NN NN O
AT2R NN NN O
mediates NN NN O
the NN NN O
developmental NN NN O
origin NN NN O
of NN NN O
glomerulosclerosis NN NN B-Disease
in NN NN O
adult NN NN O
offspring NN NN O
induced NN NN O
by NN NN O
prenatal NN NN O
caffeine NN NN O
exposure NN NN O
. NN NN O
   
UNASSIGNED NN NN O
: NN NN O
Our NN NN O
previous NN NN O
study NN NN O
has NN NN O
indicated NN NN O
that NN NN O
prenatal NN NN O
caffeine NN NN O
exposure NN NN O
( NN NN O
PCE NN NN O
) NN NN O
could NN NN O
induce NN NN O
intrauterine NN NN B-Disease
growth NN NN I-Disease
retardation NN NN I-Disease
( NN NN O
IUGR NN NN B-Disease
) NN NN O
of NN NN O
offspring NN NN O
. NN NN O
   
Recent NN NN O
research NN NN O
suggested NN NN O
that NN NN O
IUGR NN NN B-Disease
is NN NN O
a NN NN O
risk NN NN O
factor NN NN O
for NN NN O
glomerulosclerosis NN NN B-Disease
. NN NN O
   
However NN NN O
, NN NN O
whether NN NN O
PCE NN NN O
could NN NN O
induce NN NN O
glomerulosclerosis NN NN B-Disease
and NN NN O
its NN NN O
underlying NN NN O
mechanisms NN NN O
remain NN NN O
unknown NN NN O
. NN NN O
   
This NN NN O
study NN NN O
aimed NN NN O
to NN NN O
demonstrate NN NN O
the NN NN O
induction NN NN O
to NN NN O
glomerulosclerosis NN NN B-Disease
in NN NN O
adult NN NN O
offspring NN NN O
by NN NN O
PCE NN NN O
and NN NN O
its NN NN O
intrauterine NN NN O
programming NN NN O
mechanisms NN NN O
. NN NN O
   
A NN NN O
rat NN NN O
model NN NN O
of NN NN O
IUGR NN NN B-Disease
was NN NN O
established NN NN O
by NN NN O
PCE NN NN O
, NN NN O
male NN NN O
fetuses NN NN O
and NN NN O
adult NN NN O
offspring NN NN O
at NN NN O
the NN NN O
age NN NN O
of NN NN O
postnatal NN NN O
week NN NN O
24 NN NN O
were NN NN O
euthanized NN NN O
. NN NN O
   
The NN NN O
results NN NN O
revealed NN NN O
that NN NN O
the NN NN O
adult NN NN O
offspring NN NN O
kidneys NN NN O
in NN NN O
the NN NN O
PCE NN NN O
group NN NN O
exhibited NN NN O
glomerulosclerosis NN NN B-Disease
as NN NN O
well NN NN O
as NN NN O
interstitial NN NN B-Disease
fibrosis NN NN I-Disease
, NN NN O
accompanied NN NN O
by NN NN O
elevated NN NN O
levels NN NN O
of NN NN O
serum NN NN O
creatinine NN NN O
and NN NN O
urine NN NN O
protein NN NN O
. NN NN O
   
Renal NN NN O
angiotensin NN NN O
II NN NN O
receptor NN NN O
type NN NN O
2 NN NN O
( NN NN O
AT2R NN NN O
) NN NN O
gene NN NN O
expression NN NN O
in NN NN O
adult NN NN O
offspring NN NN O
was NN NN O
reduced NN NN O
by NN NN O
PCE NN NN O
, NN NN O
whereas NN NN O
the NN NN O
renal NN NN O
angiotensin NN NN O
II NN NN O
receptor NN NN O
type NN NN O
1a NN NN O
( NN NN O
AT1aR NN NN O
) NN NN O
/ NN NN O
AT2R NN NN O
expression NN NN O
ratio NN NN O
was NN NN O
increased NN NN O
. NN NN O
   
The NN NN O
fetal NN NN O
kidneys NN NN O
in NN NN O
the NN NN O
PCE NN NN O
group NN NN O
displayed NN NN O
an NN NN O
enlarged NN NN O
Bowman NN NN O
' NN NN O
s NN NN O
space NN NN O
and NN NN O
a NN NN O
shrunken NN NN O
glomerular NN NN O
tuft NN NN O
, NN NN O
accompanied NN NN O
by NN NN O
a NN NN O
reduced NN NN O
cortex NN NN O
width NN NN O
and NN NN O
an NN NN O
increase NN NN O
in NN NN O
the NN NN O
nephrogenic NN NN O
zone NN NN O
/ NN NN O
cortical NN NN O
zone NN NN O
ratio NN NN O
. NN NN O
   
Observation NN NN O
by NN NN O
electronic NN NN O
microscope NN NN O
revealed NN NN O
structural NN NN O
damage NN NN O
of NN NN O
podocytes NN NN O
; NN NN O
the NN NN O
reduced NN NN O
expression NN NN O
level NN NN O
of NN NN O
podocyte NN NN O
marker NN NN O
genes NN NN O
, NN NN O
nephrin NN NN O
and NN NN O
podocin NN NN O
, NN NN O
was NN NN O
also NN NN O
detected NN NN O
by NN NN O
q NN NN O
- NN NN O
PCR NN NN O
. NN NN O
   
Moreover NN NN O
, NN NN O
AT2R NN NN O
gene NN NN O
and NN NN O
protein NN NN O
expressions NN NN O
in NN NN O
fetal NN NN O
kidneys NN NN O
were NN NN O
inhibited NN NN O
by NN NN O
PCE NN NN O
, NN NN O
associated NN NN O
with NN NN O
the NN NN O
repression NN NN O
of NN NN O
the NN NN O
gene NN NN O
expression NN NN O
of NN NN O
glial NN NN O
- NN NN O
cell NN NN O
- NN NN O
line NN NN O
- NN NN O
derived NN NN O
neurotrophic NN NN O
factor NN NN O
( NN NN O
GDNF NN NN O
) NN NN O
/ NN NN O
tyrosine NN NN O
kinase NN NN O
receptor NN NN O
( NN NN O
c NN NN O
- NN NN O
Ret NN NN O
) NN NN O
signaling NN NN O
pathway NN NN O
. NN NN O
   
These NN NN O
results NN NN O
demonstrated NN NN O
that NN NN O
PCE NN NN O
could NN NN O
induce NN NN O
dysplasia NN NN B-Disease
of NN NN I-Disease
fetal NN NN I-Disease
kidneys NN NN I-Disease
as NN NN O
well NN NN O
as NN NN O
glomerulosclerosis NN NN B-Disease
of NN NN O
adult NN NN O
offspring NN NN O
, NN NN O
and NN NN O
the NN NN O
low NN NN O
functional NN NN O
programming NN NN O
of NN NN O
renal NN NN O
AT2R NN NN O
might NN NN O
mediate NN NN O
the NN NN O
developmental NN NN O
origin NN NN O
of NN NN O
adult NN NN O
glomerulosclerosis NN NN B-Disease
. NN NN O
   
1 NN NN O
, NN NN O
3 NN NN O
- NN NN O
Butadiene NN NN O
, NN NN O
CML NN NN B-Disease
and NN NN O
the NN NN O
t NN NN O
( NN NN O
9 NN NN O
: NN NN O
22 NN NN O
) NN NN O
translocation NN NN O
: NN NN O
A NN NN O
reality NN NN O
check NN NN O
. NN NN O
   
UNASSIGNED NN NN O
: NN NN O
Epidemiological NN NN O
studies NN NN O
of NN NN O
1 NN NN O
, NN NN O
3 NN NN O
- NN NN O
butadiene NN NN O
have NN NN O
suggest NN NN O
that NN NN O
exposures NN NN O
to NN NN O
humans NN NN O
are NN NN O
associated NN NN O
with NN NN O
chronic NN NN B-Disease
myeloid NN NN I-Disease
leukemia NN NN I-Disease
( NN NN O
CML NN NN B-Disease
) NN NN O
. NN NN O
   
CML NN NN B-Disease
has NN NN O
a NN NN O
well NN NN O
- NN NN O
documented NN NN O
association NN NN O
with NN NN O
ionizing NN NN O
radiation NN NN O
, NN NN O
but NN NN O
reports NN NN O
of NN NN O
associations NN NN O
with NN NN O
chemical NN NN O
exposures NN NN O
have NN NN O
been NN NN O
questioned NN NN O
. NN NN O
   
Ionizing NN NN O
radiation NN NN O
is NN NN O
capable NN NN O
of NN NN O
inducing NN NN O
the NN NN O
requisite NN NN O
CML NN NN B-Disease
- NN NN O
associated NN NN O
t NN NN O
( NN NN O
9 NN NN O
: NN NN O
22 NN NN O
) NN NN O
translocation NN NN O
( NN NN O
Philadelphia NN NN B-Disease
chromosome NN NN I-Disease
) NN NN O
in NN NN O
appropriate NN NN O
cells NN NN O
in NN NN O
vitro NN NN O
but NN NN O
, NN NN O
thus NN NN O
far NN NN O
, NN NN O
chemicals NN NN O
have NN NN O
not NN NN O
shown NN NN O
this NN NN O
capacity NN NN O
. NN NN O
   
We NN NN O
have NN NN O
proposed NN NN O
that NN NN O
1 NN NN O
, NN NN O
3 NN NN O
- NN NN O
butadiene NN NN O
metabolites NN NN O
be NN NN O
so NN NN O
tested NN NN O
as NN NN O
a NN NN O
reality NN NN O
check NN NN O
on NN NN O
the NN NN O
epidemiological NN NN O
reports NN NN O
. NN NN O
   
In NN NN O
order NN NN O
to NN NN O
conduct NN NN O
reliable NN NN O
testing NN NN O
in NN NN O
this NN NN O
regard NN NN O
, NN NN O
it NN NN O
is NN NN O
essential NN NN O
that NN NN O
a NN NN O
positive NN NN O
control NN NN O
for NN NN O
induction NN NN O
be NN NN O
available NN NN O
. NN NN O
   
We NN NN O
have NN NN O
used NN NN O
ionizing NN NN O
radiation NN NN O
to NN NN O
develop NN NN O
such NN NN O
a NN NN O
control NN NN O
. NN NN O
   
Results NN NN O
described NN NN O
here NN NN O
demonstrate NN NN O
that NN NN O
this NN NN O
agent NN NN O
does NN NN O
in NN NN O
fact NN NN O
induce NN NN O
pathogenic NN NN O
t NN NN O
( NN NN O
9 NN NN O
: NN NN O
22 NN NN O
) NN NN O
translocations NN NN O
in NN NN O
a NN NN O
human NN NN O
myeloid NN NN O
cell NN NN O
line NN NN O
in NN NN O
vitro NN NN O
, NN NN O
but NN NN O
does NN NN O
so NN NN O
at NN NN O
low NN NN O
frequencies NN NN O
. NN NN O
   
Conditions NN NN O
that NN NN O
will NN NN O
be NN NN O
required NN NN O
for NN NN O
studies NN NN O
of NN NN O
1 NN NN O
, NN NN O
3 NN NN O
- NN NN O
butadiene NN NN O
are NN NN O
discussed NN NN O
. NN NN O
   
Cancer NN NN B-Disease
incidence NN NN O
and NN NN O
metolachlor NN NN O
use NN NN O
in NN NN O
the NN NN O
Agricultural NN NN O
Health NN NN O
Study NN NN O
: NN NN O
An NN NN O
update NN NN O
. NN NN O
   
UNASSIGNED NN NN O
: NN NN O
Metolachlor NN NN O
, NN NN O
a NN NN O
widely NN NN O
used NN NN O
herbicide NN NN O
, NN NN O
is NN NN O
classified NN NN O
as NN NN O
a NN NN O
Group NN NN O
C NN NN O
carcinogen NN NN O
by NN NN O
the NN NN O
U NN NN O
. NN NN O
S NN NN O
. NN NN O
   
Environmental NN NN O
Protection NN NN O
Agency NN NN O
based NN NN O
on NN NN O
increased NN NN O
liver NN NN B-Disease
neoplasms NN NN I-Disease
in NN NN O
female NN NN O
rats NN NN O
. NN NN O
   
Epidemiologic NN NN O
studies NN NN O
of NN NN O
the NN NN O
health NN NN O
effects NN NN O
of NN NN O
metolachlor NN NN O
have NN NN O
been NN NN O
limited NN NN O
. NN NN O
   
The NN NN O
Agricultural NN NN O
Health NN NN O
Study NN NN O
( NN NN O
AHS NN NN O
) NN NN O
is NN NN O
a NN NN O
prospective NN NN O
cohort NN NN O
study NN NN O
including NN NN O
licensed NN NN O
private NN NN O
and NN NN O
commercial NN NN O
pesticide NN NN O
applicators NN NN O
in NN NN O
Iowa NN NN O
and NN NN O
North NN NN O
Carolina NN NN O
enrolled NN NN O
1993 NN NN O
- NN NN O
1997 NN NN O
. NN NN O
   
We NN NN O
evaluated NN NN O
cancer NN NN B-Disease
incidence NN NN O
through NN NN O
2010 NN NN O
/ NN NN O
2011 NN NN O
( NN NN O
NC NN NN O
/ NN NN O
IA NN NN O
) NN NN O
for NN NN O
49 NN NN O
, NN NN O
616 NN NN O
applicators NN NN O
, NN NN O
53 NN NN O
% NN NN O
of NN NN O
whom NN NN O
reported NN NN O
ever NN NN O
using NN NN O
metolachlor NN NN O
. NN NN O
   
We NN NN O
used NN NN O
Poisson NN NN O
regression NN NN O
to NN NN O
evaluate NN NN O
relations NN NN O
between NN NN O
two NN NN O
metrics NN NN O
of NN NN O
metolachlor NN NN O
use NN NN O
( NN NN O
lifetime NN NN O
days NN NN O
, NN NN O
intensity NN NN O
- NN NN O
weighted NN NN O
lifetime NN NN O
days NN NN O
) NN NN O
and NN NN O
cancer NN NN B-Disease
incidence NN NN O
. NN NN O
   
We NN NN O
saw NN NN O
no NN NN O
association NN NN O
between NN NN O
metolachlor NN NN O
use NN NN O
and NN NN O
incidence NN NN O
of NN NN O
all NN NN O
cancers NN NN B-Disease
combined NN NN O
( NN NN O
n NN NN O
= NN NN O
5 NN NN O
, NN NN O
701 NN NN O
with NN NN O
a NN NN O
5 NN NN O
- NN NN O
year NN NN O
lag NN NN O
) NN NN O
or NN NN O
most NN NN O
site NN NN O
- NN NN O
specific NN NN O
cancers NN NN B-Disease
. NN NN O
   
For NN NN O
liver NN NN B-Disease
cancer NN NN I-Disease
, NN NN O
in NN NN O
analyses NN NN O
restricted NN NN O
to NN NN O
exposed NN NN O
workers NN NN O
, NN NN O
elevations NN NN O
observed NN NN O
at NN NN O
higher NN NN O
categories NN NN O
of NN NN O
use NN NN O
were NN NN O
not NN NN O
statistically NN NN O
significant NN NN O
. NN NN O
   
However NN NN O
, NN NN O
trends NN NN O
for NN NN O
both NN NN O
lifetime NN NN O
and NN NN O
intensity NN NN O
- NN NN O
weighted NN NN O
lifetime NN NN O
days NN NN O
of NN NN O
metolachor NN NN O
use NN NN O
were NN NN O
positive NN NN O
and NN NN O
statistically NN NN O
significant NN NN O
with NN NN O
an NN NN O
unexposed NN NN O
reference NN NN O
group NN NN O
. NN NN O
   
A NN NN O
similar NN NN O
pattern NN NN O
was NN NN O
observed NN NN O
for NN NN O
follicular NN NN B-Disease
cell NN NN I-Disease
lymphoma NN NN I-Disease
, NN NN O
but NN NN O
no NN NN O
other NN NN O
lymphoma NN NN B-Disease
subtypes NN NN O
. NN NN O
   
An NN NN O
earlier NN NN O
suggestion NN NN O
of NN NN O
increased NN NN O
lung NN NN B-Disease
cancer NN NN I-Disease
risk NN NN O
at NN NN O
high NN NN O
levels NN NN O
of NN NN O
metolachlor NN NN O
use NN NN O
in NN NN O
this NN NN O
cohort NN NN O
was NN NN O
not NN NN O
confirmed NN NN O
in NN NN O
this NN NN O
update NN NN O
. NN NN O
   
This NN NN O
suggestion NN NN O
of NN NN O
an NN NN O
association NN NN O
between NN NN O
metolachlor NN NN O
and NN NN O
liver NN NN B-Disease
cancer NN NN I-Disease
among NN NN O
pesticide NN NN O
applicators NN NN O
is NN NN O
a NN NN O
novel NN NN O
finding NN NN O
and NN NN O
echoes NN NN O
observation NN NN O
of NN NN O
increased NN NN O
liver NN NN B-Disease
neoplasms NN NN I-Disease
in NN NN O
some NN NN O
animal NN NN O
studies NN NN O
. NN NN O
   
However NN NN O
, NN NN O
our NN NN O
findings NN NN O
for NN NN O
both NN NN O
liver NN NN B-Disease
cancer NN NN I-Disease
and NN NN O
follicular NN NN O
cell NN NN O
lymphoma NN NN B-Disease
warrant NN NN O
follow NN NN O
- NN NN O
up NN NN O
to NN NN O
better NN NN O
differentiate NN NN O
effects NN NN O
of NN NN O
metolachlor NN NN O
use NN NN O
from NN NN O
other NN NN O
factors NN NN O
. NN NN O
   
Mechanisms NN NN O
Underlying NN NN O
Latent NN NN O
Disease NN NN O
Risk NN NN O
Associated NN NN O
with NN NN O
Early NN NN O
- NN NN O
Life NN NN O
Arsenic NN NN O
Exposure NN NN O
: NN NN O
Current NN NN O
Research NN NN O
Trends NN NN O
and NN NN O
Scientific NN NN O
Gaps NN NN O
. NN NN O
   
BACKGROUND NN NN O
: NN NN O
Millions NN NN O
of NN NN O
individuals NN NN O
worldwide NN NN O
, NN NN O
particularly NN NN O
those NN NN O
living NN NN O
in NN NN O
rural NN NN O
and NN NN O
developing NN NN O
areas NN NN O
, NN NN O
are NN NN O
exposed NN NN O
to NN NN O
harmful NN NN O
levels NN NN O
of NN NN O
inorganic NN NN O
arsenic NN NN O
( NN NN O
iAs NN NN O
) NN NN O
in NN NN O
their NN NN O
drinking NN NN O
water NN NN O
. NN NN O
   
Inorganic NN NN O
As NN NN O
exposure NN NN O
during NN NN O
key NN NN O
developmental NN NN O
periods NN NN O
is NN NN O
associated NN NN O
with NN NN O
a NN NN O
variety NN NN O
of NN NN O
adverse NN NN O
health NN NN O
effects NN NN O
including NN NN O
those NN NN O
that NN NN O
are NN NN O
evident NN NN O
in NN NN O
adulthood NN NN O
. NN NN O
   
There NN NN O
is NN NN O
considerable NN NN O
interest NN NN O
in NN NN O
identifying NN NN O
the NN NN O
molecular NN NN O
mechanisms NN NN O
that NN NN O
relate NN NN O
early NN NN O
- NN NN O
life NN NN O
iAs NN NN O
exposure NN NN O
to NN NN O
the NN NN O
development NN NN O
of NN NN O
these NN NN O
latent NN NN O
diseases NN NN O
, NN NN O
particularly NN NN O
in NN NN O
relationship NN NN O
to NN NN O
cancer NN NN B-Disease
. NN NN O
   
OBJECTIVES NN NN O
: NN NN O
This NN NN O
work NN NN O
summarizes NN NN O
research NN NN O
on NN NN O
the NN NN O
molecular NN NN O
mechanisms NN NN O
that NN NN O
underlie NN NN O
the NN NN O
increased NN NN O
risk NN NN O
of NN NN O
cancer NN NN B-Disease
development NN NN O
in NN NN O
adulthood NN NN O
that NN NN O
is NN NN O
associated NN NN O
with NN NN O
early NN NN O
- NN NN O
life NN NN O
iAs NN NN O
exposure NN NN O
. NN NN O
   
DISCUSSION NN NN O
: NN NN O
Epigenetic NN NN O
reprogramming NN NN O
that NN NN O
imparts NN NN O
functional NN NN O
changes NN NN O
in NN NN O
gene NN NN O
expression NN NN O
, NN NN O
the NN NN O
development NN NN O
of NN NN O
cancer NN NN B-Disease
stem NN NN O
cells NN NN O
, NN NN O
and NN NN O
immunomodulation NN NN O
are NN NN O
plausible NN NN O
underlying NN NN O
mechanisms NN NN O
by NN NN O
which NN NN O
early NN NN O
- NN NN O
life NN NN O
iAs NN NN O
exposure NN NN O
elicits NN NN O
latent NN NN O
carcinogenic NN NN O
effects NN NN O
. NN NN O
   
CONCLUSIONS NN NN O
: NN NN O
Evidence NN NN O
is NN NN O
mounting NN NN O
that NN NN O
relates NN NN O
early NN NN O
- NN NN O
life NN NN O
iAs NN NN O
exposure NN NN O
and NN NN O
cancer NN NN B-Disease
development NN NN O
later NN NN O
in NN NN O
life NN NN O
. NN NN O
   
Future NN NN O
research NN NN O
should NN NN O
include NN NN O
animal NN NN O
studies NN NN O
that NN NN O
address NN NN O
mechanistic NN NN O
hypotheses NN NN O
and NN NN O
studies NN NN O
of NN NN O
human NN NN O
populations NN NN O
that NN NN O
integrate NN NN O
early NN NN O
- NN NN O
life NN NN O
exposure NN NN O
, NN NN O
molecular NN NN O
alterations NN NN O
, NN NN O
and NN NN O
latent NN NN O
disease NN NN O
outcomes NN NN O
. NN NN O
   
Nifedipine NN NN O
induced NN NN O
bradycardia NN NN B-Disease
in NN NN O
a NN NN O
patient NN NN O
with NN NN O
autonomic NN NN B-Disease
neuropathy NN NN I-Disease
. NN NN O
   
An NN NN O
80 NN NN O
year NN NN O
old NN NN O
diabetic NN NN B-Disease
male NN NN O
with NN NN O
evidence NN NN O
of NN NN O
peripheral NN NN B-Disease
and NN NN I-Disease
autonomic NN NN I-Disease
neuropathy NN NN I-Disease
was NN NN O
admitted NN NN O
with NN NN O
chest NN NN B-Disease
pain NN NN I-Disease
. NN NN O
   
He NN NN O
was NN NN O
found NN NN O
to NN NN O
have NN NN O
atrial NN NN B-Disease
flutter NN NN I-Disease
at NN NN O
a NN NN O
ventricular NN NN O
rate NN NN O
of NN NN O
70 NN NN O
/ NN NN O
min NN NN O
which NN NN O
slowed NN NN O
down NN NN O
to NN NN O
30 NN NN O
- NN NN O
40 NN NN O
/ NN NN O
min NN NN O
when NN NN O
nifedipine NN NN O
( NN NN O
60 NN NN O
mg NN NN O
) NN NN O
in NN NN O
3 NN NN O
divided NN NN O
doses NN NN O
, NN NN O
during NN NN O
which NN NN O
he NN NN O
was NN NN O
paced NN NN O
at NN NN O
a NN NN O
rate NN NN O
of NN NN O
70 NN NN O
/ NN NN O
min NN NN O
. NN NN O
   
This NN NN O
is NN NN O
inconsistent NN NN O
with NN NN O
the NN NN O
well NN NN O
- NN NN O
established NN NN O
finding NN NN O
that NN NN O
nifedipine NN NN O
induces NN NN O
tachycardia NN NN B-Disease
in NN NN O
normally NN NN O
innervated NN NN O
hearts NN NN O
. NN NN O
   
However NN NN O
, NN NN O
in NN NN O
hearts NN NN O
deprived NN NN O
of NN NN O
compensatory NN NN O
sympathetic NN NN O
drive NN NN O
, NN NN O
it NN NN O
may NN NN O
lead NN NN O
to NN NN O
bradycardia NN NN B-Disease
. NN NN O
   
The NN NN O
effect NN NN O
of NN NN O
haloperidol NN NN O
in NN NN O
cocaine NN NN O
and NN NN O
amphetamine NN NN O
intoxication NN NN O
. NN NN O
   
The NN NN O
effectiveness NN NN O
of NN NN O
haloperidol NN NN O
pretreatment NN NN O
in NN NN O
preventing NN NN O
the NN NN O
toxic NN NN O
effects NN NN O
of NN NN O
high NN NN O
doses NN NN O
of NN NN O
amphetamine NN NN O
and NN NN O
cocaine NN NN O
was NN NN O
studied NN NN O
in NN NN O
rats NN NN O
. NN NN O
   
In NN NN O
this NN NN O
model NN NN O
, NN NN O
toxic NN NN O
effects NN NN O
were NN NN O
induced NN NN O
by NN NN O
intraperitoneal NN NN O
( NN NN O
i NN NN O
. NN NN O
p NN NN O
. NN NN O
) NN NN O
injection NN NN O
of NN NN O
amphetamine NN NN O
75 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
( NN NN O
100 NN NN O
% NN NN O
death NN NN O
rate NN NN O
) NN NN O
or NN NN O
cocaine NN NN O
70 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
( NN NN O
82 NN NN O
% NN NN O
death NN NN O
rate NN NN O
) NN NN O
. NN NN O
   
Haloperidol NN NN O
failed NN NN O
to NN NN O
prevent NN NN O
amphetamine NN NN O
- NN NN O
induced NN NN O
seizures NN NN B-Disease
, NN NN O
but NN NN O
did NN NN O
lower NN NN O
the NN NN O
mortality NN NN O
rate NN NN O
at NN NN O
most NN NN O
doses NN NN O
tested NN NN O
. NN NN O
   
Haloperidol NN NN O
decreased NN NN O
the NN NN O
incidence NN NN O
of NN NN O
cocaine NN NN O
- NN NN O
induced NN NN O
seizures NN NN B-Disease
at NN NN O
the NN NN O
two NN NN O
highest NN NN O
doses NN NN O
, NN NN O
but NN NN O
the NN NN O
lowering NN NN O
of NN NN O
the NN NN O
mortality NN NN O
rate NN NN O
did NN NN O
not NN NN O
reach NN NN O
statistical NN NN O
significance NN NN O
at NN NN O
any NN NN O
dose NN NN O
. NN NN O
   
These NN NN O
data NN NN O
suggest NN NN O
a NN NN O
protective NN NN O
role NN NN O
for NN NN O
the NN NN O
central NN NN O
dopamine NN NN O
blocker NN NN O
haloperidol NN NN O
against NN NN O
death NN NN O
from NN NN O
high NN NN O
- NN NN O
dose NN NN O
amphetamine NN NN O
exposure NN NN O
without NN NN O
reducing NN NN O
the NN NN O
incidence NN NN O
of NN NN O
seizures NN NN B-Disease
. NN NN O
   
In NN NN O
contrast NN NN O
, NN NN O
haloperidol NN NN O
demonstrated NN NN O
an NN NN O
ability NN NN O
to NN NN O
reduce NN NN O
cocaine NN NN O
- NN NN O
induced NN NN O
seizures NN NN B-Disease
without NN NN O
significantly NN NN O
reducing NN NN O
mortality NN NN O
. NN NN O
   
Autoradiographic NN NN O
evidence NN NN O
of NN NN O
estrogen NN NN O
binding NN NN O
sites NN NN O
in NN NN O
nuclei NN NN O
of NN NN O
diethylstilbesterol NN NN O
induced NN NN O
hamster NN NN O
renal NN NN B-Disease
carcinomas NN NN I-Disease
. NN NN O
   
Estrogen NN NN O
binding NN NN O
sites NN NN O
were NN NN O
demonstrated NN NN O
by NN NN O
autoradiography NN NN O
in NN NN O
one NN NN O
transplantable NN NN O
and NN NN O
five NN NN O
primary NN NN O
diethylstilbesterol NN NN O
induced NN NN O
renal NN NN B-Disease
carcinomas NN NN I-Disease
in NN NN O
three NN NN O
hamsters NN NN O
. NN NN O
   
Radiolabelling NN NN O
, NN NN O
following NN NN O
the NN NN O
in NN NN O
vivo NN NN O
injection NN NN O
of NN NN O
3H NN NN O
- NN NN O
17 NN NN O
beta NN NN O
estradiol NN NN O
, NN NN O
was NN NN O
increased NN NN O
only NN NN O
over NN NN O
the NN NN O
nuclei NN NN O
of NN NN O
tumor NN NN B-Disease
cells NN NN O
; NN NN O
stereologic NN NN O
analysis NN NN O
revealed NN NN O
a NN NN O
4 NN NN O
. NN NN O
5 NN NN O
- NN NN O
to NN NN O
6 NN NN O
. NN NN O
7 NN NN O
- NN NN O
times NN NN O
higher NN NN O
concentration NN NN O
of NN NN O
reduced NN NN O
silver NN NN O
grains NN NN O
over NN NN O
nuclei NN NN O
than NN NN O
cytoplasm NN NN O
of NN NN O
these NN NN O
cells NN NN O
. NN NN O
   
Despite NN NN O
rapid NN NN O
tubular NN NN O
excretion NN NN O
of NN NN O
estradiol NN NN O
which NN NN O
peaked NN NN O
in NN NN O
less NN NN O
than NN NN O
1 NN NN O
h NN NN O
, NN NN O
the NN NN O
normal NN NN O
cells NN NN O
did NN NN O
not NN NN O
appear NN NN O
to NN NN O
bind NN NN O
the NN NN O
ligand NN NN O
. NN NN O
   
This NN NN O
is NN NN O
the NN NN O
first NN NN O
published NN NN O
report NN NN O
documenting NN NN O
the NN NN O
preferential NN NN O
in NN NN O
vivo NN NN O
binding NN NN O
of NN NN O
estrogen NN NN O
to NN NN O
nuclei NN NN O
of NN NN O
cells NN NN O
in NN NN O
estrogen NN NN O
induced NN NN O
hamster NN NN O
renal NN NN B-Disease
carcinomas NN NN I-Disease
. NN NN O
   
Bradycardia NN NN B-Disease
due NN NN O
to NN NN O
biperiden NN NN O
. NN NN O
   
In NN NN O
a NN NN O
38 NN NN O
- NN NN O
year NN NN O
- NN NN O
old NN NN O
male NN NN O
patient NN NN O
suffering NN NN O
from NN NN O
a NN NN O
severe NN NN O
postzosteric NN NN B-Disease
trigeminal NN NN B-Disease
neuralgia NN NN I-Disease
, NN NN O
intravenous NN NN O
application NN NN O
of NN NN O
10 NN NN O
mg NN NN O
biperiden NN NN O
lactate NN NN O
led NN NN O
to NN NN O
a NN NN O
long NN NN O
- NN NN O
lasting NN NN O
paradoxical NN NN O
reaction NN NN O
characterized NN NN O
by NN NN O
considerable NN NN O
bradycardia NN NN B-Disease
, NN NN O
dysarthria NN NN B-Disease
, NN NN O
and NN NN O
dysphagia NN NN B-Disease
. NN NN O
   
The NN NN O
heart NN NN O
rate NN NN O
was NN NN O
back NN NN O
to NN NN O
normal NN NN O
within NN NN O
12 NN NN O
hours NN NN O
upon NN NN O
administration NN NN O
of NN NN O
orciprenaline NN NN O
under NN NN O
cardiac NN NN O
monitoring NN NN O
in NN NN O
an NN NN O
intensive NN NN O
care NN NN O
unit NN NN O
. NN NN O
   
Bradycardia NN NN B-Disease
induced NN NN O
by NN NN O
biperiden NN NN O
is NN NN O
attributed NN NN O
to NN NN O
the NN NN O
speed NN NN O
of NN NN O
injection NN NN O
and NN NN O
to NN NN O
a NN NN O
dose NN NN O
- NN NN O
related NN NN O
dual NN NN O
effect NN NN O
of NN NN O
atropine NN NN O
- NN NN O
like NN NN O
drugs NN NN O
on NN NN O
muscarine NN NN O
receptors NN NN O
. NN NN O
   
Deliberate NN NN O
hypotension NN NN B-Disease
induced NN NN O
by NN NN O
labetalol NN NN O
with NN NN O
halothane NN NN O
, NN NN O
enflurane NN NN O
or NN NN O
isoflurane NN NN O
for NN NN O
middle NN NN O
- NN NN O
ear NN NN O
surgery NN NN O
. NN NN O
   
The NN NN O
feasibility NN NN O
of NN NN O
using NN NN O
labetalol NN NN O
, NN NN O
an NN NN O
alpha NN NN O
- NN NN O
and NN NN O
beta NN NN O
- NN NN O
adrenergic NN NN O
blocking NN NN O
agent NN NN O
, NN NN O
as NN NN O
a NN NN O
hypotensive NN NN B-Disease
agent NN NN O
in NN NN O
combination NN NN O
with NN NN O
inhalation NN NN O
anaesthetics NN NN O
( NN NN O
halothane NN NN O
, NN NN O
enflurane NN NN O
or NN NN O
isoflurane NN NN O
) NN NN O
was NN NN O
studied NN NN O
in NN NN O
23 NN NN O
adult NN NN O
patients NN NN O
undergoing NN NN O
middle NN NN O
- NN NN O
ear NN NN O
surgery NN NN O
. NN NN O
   
The NN NN O
mean NN NN O
arterial NN NN O
pressure NN NN O
was NN NN O
decreased NN NN O
from NN NN O
86 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
5 NN NN O
( NN NN O
s NN NN O
. NN NN O
e NN NN O
. NN NN O
mean NN NN O
) NN NN O
mmHg NN NN O
to NN NN O
52 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
1 NN NN O
mmHg NN NN O
( NN NN O
11 NN NN O
. NN NN O
5 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
0 NN NN O
. NN NN O
7 NN NN O
to NN NN O
6 NN NN O
. NN NN O
9 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
0 NN NN O
. NN NN O
1 NN NN O
kPa NN NN O
) NN NN O
for NN NN O
98 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
10 NN NN O
min NN NN O
in NN NN O
the NN NN O
halothane NN NN O
( NN NN O
H NN NN O
) NN NN O
group NN NN O
, NN NN O
from NN NN O
79 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
5 NN NN O
to NN NN O
53 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
1 NN NN O
mmHg NN NN O
( NN NN O
10 NN NN O
. NN NN O
5 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
0 NN NN O
. NN NN O
7 NN NN O
to NN NN O
7 NN NN O
. NN NN O
1 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
0 NN NN O
. NN NN O
1 NN NN O
kPa NN NN O
) NN NN O
for NN NN O
129 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
11 NN NN O
min NN NN O
in NN NN O
the NN NN O
enflurane NN NN O
( NN NN O
E NN NN O
) NN NN O
group NN NN O
, NN NN O
and NN NN O
from NN NN O
80 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
4 NN NN O
to NN NN O
49 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
1 NN NN O
mmHg NN NN O
( NN NN O
10 NN NN O
. NN NN O
7 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
0 NN NN O
. NN NN O
5 NN NN O
to NN NN O
6 NN NN O
. NN NN O
5 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
0 NN NN O
. NN NN O
1 NN NN O
kPa NN NN O
) NN NN O
for NN NN O
135 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
15 NN NN O
min NN NN O
in NN NN O
the NN NN O
isoflurane NN NN O
( NN NN O
I NN NN O
) NN NN O
group NN NN O
. NN NN O
   
The NN NN O
mean NN NN O
H NN NN O
concentration NN NN O
during NN NN O
hypotension NN NN B-Disease
in NN NN O
the NN NN O
inspiratory NN NN O
gas NN NN O
was NN NN O
0 NN NN O
. NN NN O
7 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
0 NN NN O
. NN NN O
1 NN NN O
vol NN NN O
% NN NN O
, NN NN O
the NN NN O
mean NN NN O
E NN NN O
concentration NN NN O
1 NN NN O
. NN NN O
6 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
0 NN NN O
. NN NN O
2 NN NN O
vol NN NN O
% NN NN O
, NN NN O
and NN NN O
the NN NN O
mean NN NN O
I NN NN O
concentration NN NN O
1 NN NN O
. NN NN O
0 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
0 NN NN O
. NN NN O
1 NN NN O
vol NN NN O
% NN NN O
. NN NN O
   
In NN NN O
addition NN NN O
, NN NN O
the NN NN O
patients NN NN O
received NN NN O
fentanyl NN NN O
and NN NN O
d NN NN O
- NN NN O
tubocurarine NN NN O
. NN NN O
   
The NN NN O
initial NN NN O
dose NN NN O
of NN NN O
labetalol NN NN O
for NN NN O
lowering NN NN O
blood NN NN O
pressure NN NN O
was NN NN O
similar NN NN O
, NN NN O
0 NN NN O
. NN NN O
52 NN NN O
- NN NN O
0 NN NN O
. NN NN O
59 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
, NN NN O
in NN NN O
all NN NN O
the NN NN O
groups NN NN O
. NN NN O
   
During NN NN O
hypotension NN NN B-Disease
, NN NN O
the NN NN O
heart NN NN O
rate NN NN O
was NN NN O
stable NN NN O
without NN NN O
tachy NN NN B-Disease
- NN NN I-Disease
or NN NN I-Disease
bradycardia NN NN I-Disease
. NN NN O
   
The NN NN O
operating NN NN O
conditions NN NN O
regarding NN NN O
bleeding NN NN B-Disease
were NN NN O
estimated NN NN O
in NN NN O
a NN NN O
double NN NN O
- NN NN O
blind NN NN O
manner NN NN O
, NN NN O
and NN NN O
did NN NN O
not NN NN O
differ NN NN O
significantly NN NN O
between NN NN O
the NN NN O
groups NN NN O
. NN NN O
   
During NN NN O
hypotension NN NN B-Disease
, NN NN O
the NN NN O
serum NN NN O
creatinine NN NN O
concentration NN NN O
rose NN NN O
significantly NN NN O
in NN NN O
all NN NN O
groups NN NN O
from NN NN O
the NN NN O
values NN NN O
before NN NN O
hypotension NN NN B-Disease
and NN NN O
returned NN NN O
postoperatively NN NN O
to NN NN O
the NN NN O
initial NN NN O
level NN NN O
in NN NN O
the NN NN O
other NN NN O
groups NN NN O
, NN NN O
except NN NN O
the NN NN O
isoflurane NN NN O
group NN NN O
. NN NN O
   
After NN NN O
hypotension NN NN B-Disease
there NN NN O
was NN NN O
no NN NN O
rebound NN NN O
phenomenon NN NN O
in NN NN O
either NN NN O
blood NN NN O
pressure NN NN O
or NN NN O
heart NN NN O
rate NN NN O
. NN NN O
   
These NN NN O
results NN NN O
indicate NN NN O
that NN NN O
labetalol NN NN O
induces NN NN O
easily NN NN O
adjustable NN NN O
hypotension NN NN B-Disease
without NN NN O
compensatory NN NN O
tachycardia NN NN B-Disease
and NN NN O
rebound NN NN O
hypertension NN NN B-Disease
. NN NN O
   
Convulsion NN NN B-Disease
following NN NN O
intravenous NN NN O
fluorescein NN NN O
angiography NN NN O
. NN NN O
   
Tonic NN NN B-Disease
- NN NN I-Disease
clonic NN NN I-Disease
seizures NN NN I-Disease
followed NN NN O
intravenous NN NN O
fluorescein NN NN O
injection NN NN O
for NN NN O
fundus NN NN O
angiography NN NN O
in NN NN O
a NN NN O
47 NN NN O
- NN NN O
year NN NN O
- NN NN O
old NN NN O
male NN NN O
. NN NN O
   
Despite NN NN O
precautions NN NN O
this NN NN O
adverse NN NN O
reaction NN NN O
recurred NN NN O
on NN NN O
re NN NN O
- NN NN O
exposure NN NN O
to NN NN O
intravenous NN NN O
fluorescein NN NN O
. NN NN O
   
Pharmacology NN NN O
of NN NN O
ACC NN NN O
- NN NN O
9653 NN NN O
( NN NN O
phenytoin NN NN O
prodrug NN NN O
) NN NN O
. NN NN O
   
ACC NN NN O
- NN NN O
9653 NN NN O
, NN NN O
the NN NN O
disodium NN NN O
phosphate NN NN O
ester NN NN O
of NN NN O
3 NN NN O
- NN NN O
hydroxymethyl NN NN O
- NN NN O
5 NN NN O
, NN NN O
5 NN NN O
- NN NN O
diphenylhydantoin NN NN O
, NN NN O
is NN NN O
a NN NN O
prodrug NN NN O
of NN NN O
phenytoin NN NN O
with NN NN O
advantageous NN NN O
physicochemical NN NN O
properties NN NN O
. NN NN O
   
ACC NN NN O
- NN NN O
9653 NN NN O
is NN NN O
rapidly NN NN O
converted NN NN O
enzymatically NN NN O
to NN NN O
phenytoin NN NN O
in NN NN O
vivo NN NN O
. NN NN O
   
ACC NN NN O
- NN NN O
9653 NN NN O
and NN NN O
phenytoin NN NN O
sodium NN NN O
have NN NN O
equivalent NN NN O
anticonvulsant NN NN O
activity NN NN O
against NN NN O
seizures NN NN B-Disease
induced NN NN O
by NN NN O
maximal NN NN O
electroshock NN NN O
( NN NN O
MES NN NN O
) NN NN O
in NN NN O
mice NN NN O
following NN NN O
i NN NN O
. NN NN O
p NN NN O
. NN NN O
, NN NN O
oral NN NN O
, NN NN O
or NN NN O
i NN NN O
. NN NN O
v NN NN O
. NN NN O
administration NN NN O
. NN NN O
   
The NN NN O
ED50 NN NN O
doses NN NN O
were NN NN O
16 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
for NN NN O
i NN NN O
. NN NN O
v NN NN O
. NN NN O
ACC NN NN O
- NN NN O
9653 NN NN O
and NN NN O
8 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
for NN NN O
i NN NN O
. NN NN O
v NN NN O
. NN NN O
phenytoin NN NN O
sodium NN NN O
. NN NN O
   
ACC NN NN O
- NN NN O
9653 NN NN O
and NN NN O
phenytoin NN NN O
sodium NN NN O
have NN NN O
similar NN NN O
antiarrhythmic NN NN O
activity NN NN O
against NN NN O
ouabain NN NN O
- NN NN O
induced NN NN O
ventricular NN NN B-Disease
tachycardia NN NN I-Disease
in NN NN O
anesthetized NN NN O
dogs NN NN O
. NN NN O
   
The NN NN O
total NN NN O
doses NN NN O
of NN NN O
ACC NN NN O
- NN NN O
9653 NN NN O
or NN NN O
phenytoin NN NN O
sodium NN NN O
necessary NN NN O
to NN NN O
convert NN NN O
the NN NN O
arrhythmia NN NN B-Disease
to NN NN O
a NN NN O
normal NN NN O
sinus NN NN O
rhythm NN NN O
were NN NN O
24 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
6 NN NN O
and NN NN O
14 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
3 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
, NN NN O
respectively NN NN O
. NN NN O
   
Only NN NN O
phenytoin NN NN O
sodium NN NN O
displayed NN NN O
in NN NN O
vitro NN NN O
antiarrhythmic NN NN O
activity NN NN O
against NN NN O
strophanthidin NN NN O
- NN NN O
induced NN NN O
arrhythmias NN NN B-Disease
in NN NN O
guinea NN NN O
pig NN NN O
right NN NN O
atria NN NN O
. NN NN O
   
In NN NN O
anesthetized NN NN O
dogs NN NN O
, NN NN O
a NN NN O
high NN NN O
dose NN NN O
of NN NN O
ACC NN NN O
- NN NN O
9653 NN NN O
( NN NN O
31 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
) NN NN O
was NN NN O
infused NN NN O
over NN NN O
15 NN NN O
, NN NN O
20 NN NN O
, NN NN O
and NN NN O
30 NN NN O
min NN NN O
and NN NN O
the NN NN O
responses NN NN O
were NN NN O
compared NN NN O
to NN NN O
an NN NN O
equimolar NN NN O
dose NN NN O
of NN NN O
phenytoin NN NN O
sodium NN NN O
( NN NN O
21 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
) NN NN O
. NN NN O
   
The NN NN O
ACC NN NN O
- NN NN O
9653 NN NN O
and NN NN O
phenytoin NN NN O
sodium NN NN O
treatments NN NN O
produced NN NN O
similar NN NN O
marked NN NN O
reductions NN NN O
in NN NN O
diastolic NN NN O
blood NN NN O
pressure NN NN O
and NN NN O
contractile NN NN O
force NN NN O
( NN NN O
LVdP NN NN O
/ NN NN O
dt NN NN O
) NN NN O
. NN NN O
   
The NN NN O
maximum NN NN O
effects NN NN O
of NN NN O
each NN NN O
treatment NN NN O
occurred NN NN O
at NN NN O
the NN NN O
time NN NN O
of NN NN O
maximum NN NN O
phenytoin NN NN O
sodium NN NN O
levels NN NN O
. NN NN O
   
Acute NN NN O
toxicity NN NN B-Disease
studies NN NN O
of NN NN O
ACC NN NN O
- NN NN O
9653 NN NN O
and NN NN O
phenytoin NN NN O
sodium NN NN O
were NN NN O
carried NN NN O
out NN NN O
in NN NN O
mice NN NN O
, NN NN O
rats NN NN O
, NN NN O
rabbits NN NN O
, NN NN O
and NN NN O
dogs NN NN O
by NN NN O
i NN NN O
. NN NN O
v NN NN O
. NN NN O
, NN NN O
i NN NN O
. NN NN O
m NN NN O
. NN NN O
, NN NN O
and NN NN O
i NN NN O
. NN NN O
p NN NN O
. NN NN O
routes NN NN O
of NN NN O
administration NN NN O
. NN NN O
   
The NN NN O
systemic NN NN O
toxic NN NN O
signs NN NN O
of NN NN O
both NN NN O
agents NN NN O
were NN NN O
similar NN NN O
and NN NN O
occurred NN NN O
at NN NN O
approximately NN NN O
equivalent NN NN O
doses NN NN O
. NN NN O
   
Importantly NN NN O
, NN NN O
the NN NN O
local NN NN O
irritation NN NN O
of NN NN O
ACC NN NN O
- NN NN O
9653 NN NN O
was NN NN O
markedly NN NN O
less NN NN O
than NN NN O
phenytoin NN NN O
sodium NN NN O
following NN NN O
i NN NN O
. NN NN O
m NN NN O
. NN NN O
administration NN NN O
. NN NN O
( NN NN O
ABSTRACT NN NN O
TRUNCATED NN NN O
AT NN NN O
250 NN NN O
WORDS NN NN O
) NN NN O
   
Tachyphylaxis NN NN O
to NN NN O
systemic NN NN O
but NN NN O
not NN NN O
to NN NN O
airway NN NN O
responses NN NN O
during NN NN O
prolonged NN NN O
therapy NN NN O
with NN NN O
high NN NN O
dose NN NN O
inhaled NN NN O
salbutamol NN NN O
in NN NN O
asthmatics NN NN B-Disease
. NN NN O
   
High NN NN O
doses NN NN O
of NN NN O
inhaled NN NN O
salbutamol NN NN O
produce NN NN O
substantial NN NN O
improvements NN NN O
in NN NN O
airway NN NN O
response NN NN O
in NN NN O
patients NN NN O
with NN NN O
asthma NN NN B-Disease
, NN NN O
and NN NN O
are NN NN O
associated NN NN O
with NN NN O
dose NN NN O
- NN NN O
dependent NN NN O
systemic NN NN O
beta NN NN O
- NN NN O
adrenoceptor NN NN O
responses NN NN O
. NN NN O
   
The NN NN O
purpose NN NN O
of NN NN O
the NN NN O
present NN NN O
study NN NN O
was NN NN O
to NN NN O
investigate NN NN O
whether NN NN O
tachyphylaxis NN NN O
occurs NN NN O
during NN NN O
prolonged NN NN O
treatment NN NN O
with NN NN O
high NN NN O
dose NN NN O
inhaled NN NN O
salbutamol NN NN O
. NN NN O
   
Twelve NN NN O
asthmatic NN NN B-Disease
patients NN NN O
( NN NN O
FEV1 NN NN O
, NN NN O
81 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
4 NN NN O
% NN NN O
predicted NN NN O
) NN NN O
, NN NN O
requiring NN NN O
only NN NN O
occasional NN NN O
inhaled NN NN O
beta NN NN O
- NN NN O
agonists NN NN O
as NN NN O
their NN NN O
sole NN NN O
therapy NN NN O
, NN NN O
were NN NN O
given NN NN O
a NN NN O
14 NN NN O
- NN NN O
day NN NN O
treatment NN NN O
with NN NN O
high NN NN O
dose NN NN O
inhaled NN NN O
salbutamol NN NN O
( NN NN O
HDS NN NN O
) NN NN O
, NN NN O
4 NN NN O
, NN NN O
000 NN NN O
micrograms NN NN O
daily NN NN O
, NN NN O
low NN NN O
dose NN NN O
inhaled NN NN O
salbutamol NN NN O
( NN NN O
LDS NN NN O
) NN NN O
, NN NN O
800 NN NN O
micrograms NN NN O
daily NN NN O
, NN NN O
or NN NN O
placebo NN NN O
( NN NN O
PI NN NN O
) NN NN O
by NN NN O
metered NN NN O
- NN NN O
dose NN NN O
inhaler NN NN O
in NN NN O
a NN NN O
double NN NN O
- NN NN O
blind NN NN O
, NN NN O
randomized NN NN O
crossover NN NN O
design NN NN O
. NN NN O
   
During NN NN O
the NN NN O
14 NN NN O
- NN NN O
day NN NN O
run NN NN O
- NN NN O
in NN NN O
and NN NN O
during NN NN O
washout NN NN O
periods NN NN O
, NN NN O
inhaled NN NN O
beta NN NN O
- NN NN O
agonists NN NN O
were NN NN O
withheld NN NN O
and NN NN O
ipratropium NN NN O
bromide NN NN O
was NN NN O
substituted NN NN O
for NN NN O
rescue NN NN O
purposes NN NN O
. NN NN O
   
At NN NN O
the NN NN O
end NN NN O
of NN NN O
each NN NN O
14 NN NN O
- NN NN O
day NN NN O
treatment NN NN O
, NN NN O
a NN NN O
dose NN NN O
- NN NN O
response NN NN O
curve NN NN O
( NN NN O
DRC NN NN O
) NN NN O
was NN NN O
performed NN NN O
, NN NN O
and NN NN O
airway NN NN O
( NN NN O
FEV1 NN NN O
, NN NN O
FEF25 NN NN O
- NN NN O
75 NN NN O
) NN NN O
chronotropic NN NN O
( NN NN O
HR NN NN O
) NN NN O
, NN NN O
tremor NN NN B-Disease
, NN NN O
and NN NN O
metabolic NN NN O
( NN NN O
K NN NN O
, NN NN O
Glu NN NN O
) NN NN O
responses NN NN O
were NN NN O
measured NN NN O
at NN NN O
each NN NN O
step NN NN O
( NN NN O
from NN NN O
100 NN NN O
to NN NN O
4 NN NN O
, NN NN O
000 NN NN O
micrograms NN NN O
) NN NN O
. NN NN O
   
Treatment NN NN O
had NN NN O
no NN NN O
significant NN NN O
effect NN NN O
on NN NN O
baseline NN NN O
values NN NN O
. NN NN O
   
There NN NN O
were NN NN O
dose NN NN O
- NN NN O
dependent NN NN O
increases NN NN O
in NN NN O
FEV1 NN NN O
and NN NN O
FEF25 NN NN O
- NN NN O
75 NN NN O
( NN NN O
p NN NN O
less NN NN O
than NN NN O
0 NN NN O
. NN NN O
001 NN NN O
) NN NN O
, NN NN O
and NN NN O
pretreatment NN NN O
with NN NN O
HDS NN NN O
did NN NN O
not NN NN O
displace NN NN O
the NN NN O
DRC NN NN O
to NN NN O
the NN NN O
right NN NN O
. NN NN O
   
DRC NN NN O
for NN NN O
HR NN NN O
( NN NN O
p NN NN O
less NN NN O
than NN NN O
0 NN NN O
. NN NN O
001 NN NN O
) NN NN O
, NN NN O
K NN NN O
( NN NN O
p NN NN O
less NN NN O
than NN NN O
0 NN NN O
. NN NN O
001 NN NN O
) NN NN O
, NN NN O
and NN NN O
Glu NN NN O
( NN NN O
p NN NN O
less NN NN O
than NN NN O
0 NN NN O
. NN NN O
005 NN NN O
) NN NN O
were NN NN O
attenuated NN NN O
after NN NN O
treatment NN NN O
with NN NN O
HDS NN NN O
compared NN NN O
with NN NN O
PI NN NN O
. NN NN O
   
There NN NN O
were NN NN O
also NN NN O
differences NN NN O
between NN NN O
HDS NN NN O
and NN NN O
LDS NN NN O
for NN NN O
HR NN NN O
( NN NN O
p NN NN O
less NN NN O
than NN NN O
0 NN NN O
. NN NN O
001 NN NN O
) NN NN O
and NN NN O
Glu NN NN O
( NN NN O
p NN NN O
less NN NN O
than NN NN O
0 NN NN O
. NN NN O
05 NN NN O
) NN NN O
responses NN NN O
. NN NN O
   
Frequency NN NN O
and NN NN O
severity NN NN O
of NN NN O
subjective NN NN O
adverse NN NN O
effects NN NN O
were NN NN O
also NN NN O
reduced NN NN O
after NN NN O
HDS NN NN O
: NN NN O
tremor NN NN B-Disease
( NN NN O
p NN NN O
less NN NN O
than NN NN O
0 NN NN O
. NN NN O
001 NN NN O
) NN NN O
, NN NN O
palpitations NN NN B-Disease
( NN NN O
p NN NN O
less NN NN O
than NN NN O
0 NN NN O
. NN NN O
001 NN NN O
) NN NN O
. NN NN O
( NN NN O
ABSTRACT NN NN O
TRUNCATED NN NN O
AT NN NN O
250 NN NN O
WORDS NN NN O
) NN NN O
   
Phenytoin NN NN O
induced NN NN O
fatal NN NN O
hepatic NN NN B-Disease
injury NN NN I-Disease
. NN NN O
   
A NN NN O
61 NN NN O
year NN NN O
old NN NN O
female NN NN O
developed NN NN O
fatal NN NN O
hepatic NN NN B-Disease
failure NN NN I-Disease
after NN NN O
phenytoin NN NN O
administration NN NN O
. NN NN O
   
A NN NN O
typical NN NN O
multisystem NN NN O
clinical NN NN O
pattern NN NN O
precedes NN NN O
the NN NN O
manifestations NN NN O
of NN NN O
hepatic NN NN B-Disease
injury NN NN I-Disease
. NN NN O
   
The NN NN O
hematologic NN NN O
, NN NN O
biochemical NN NN O
and NN NN O
pathologic NN NN O
features NN NN O
indicate NN NN O
a NN NN O
mixed NN NN O
hepatocellular NN NN B-Disease
damage NN NN I-Disease
due NN NN O
to NN NN O
drug NN NN B-Disease
hypersensitivity NN NN I-Disease
. NN NN O
   
In NN NN O
a NN NN O
patient NN NN O
receiving NN NN O
phenytoin NN NN O
who NN NN O
presents NN NN O
a NN NN O
viral NN NN O
- NN NN O
like NN NN O
illness NN NN O
, NN NN O
early NN NN O
recognition NN NN O
and NN NN O
discontinuation NN NN O
of NN NN O
the NN NN O
drug NN NN O
are NN NN O
mandatory NN NN O
. NN NN O
   
Treatment NN NN O
of NN NN O
lethal NN NN O
pertussis NN NN O
vaccine NN NN O
reaction NN NN O
with NN NN O
histamine NN NN O
H1 NN NN O
antagonists NN NN O
. NN NN O
   
We NN NN O
studied NN NN O
mortality NN NN O
after NN NN O
pertussis NN NN B-Disease
immunization NN NN O
in NN NN O
the NN NN O
mouse NN NN O
. NN NN O
   
Without NN NN O
treatment NN NN O
, NN NN O
73 NN NN O
of NN NN O
92 NN NN O
animals NN NN O
( NN NN O
80 NN NN O
% NN NN O
) NN NN O
died NN NN O
after NN NN O
injection NN NN O
of NN NN O
bovine NN NN O
serum NN NN O
albumin NN NN O
( NN NN O
BSA NN NN O
) NN NN O
on NN NN O
day NN NN O
+ NN NN O
7 NN NN O
of NN NN O
pertussis NN NN B-Disease
immunization NN NN O
. NN NN O
   
After NN NN O
pretreatment NN NN O
with NN NN O
3 NN NN O
mg NN NN O
of NN NN O
cyproheptadine NN NN O
, NN NN O
2 NN NN O
mg NN NN O
mianserin NN NN O
, NN NN O
or NN NN O
2 NN NN O
mg NN NN O
chlorpheniramine NN NN O
, NN NN O
only NN NN O
5 NN NN O
of NN NN O
105 NN NN O
animals NN NN O
( NN NN O
5 NN NN O
% NN NN O
) NN NN O
died NN NN O
after NN NN O
receiving NN NN O
BSA NN NN O
on NN NN O
day NN NN O
+ NN NN O
7 NN NN O
( NN NN O
p NN NN O
less NN NN O
than NN NN O
0 NN NN O
. NN NN O
001 NN NN O
) NN NN O
. NN NN O
   
Blockade NN NN O
of NN NN O
histamine NN NN O
H1 NN NN O
receptors NN NN O
may NN NN O
reduce NN NN O
mortality NN NN O
in NN NN O
pertussis NN NN B-Disease
immunization NN NN O
- NN NN O
induced NN NN O
encephalopathy NN NN B-Disease
in NN NN O
mice NN NN O
. NN NN O
   
Support NN NN O
for NN NN O
adrenaline NN NN O
- NN NN O
hypertension NN NN B-Disease
hypothesis NN NN O
: NN NN O
18 NN NN O
hour NN NN O
pressor NN NN O
effect NN NN O
after NN NN O
6 NN NN O
hours NN NN O
adrenaline NN NN O
infusion NN NN O
. NN NN O
   
In NN NN O
a NN NN O
double NN NN O
blind NN NN O
, NN NN O
crossover NN NN O
study NN NN O
6 NN NN O
h NN NN O
infusions NN NN O
of NN NN O
adrenaline NN NN O
( NN NN O
15 NN NN O
ng NN NN O
/ NN NN O
kg NN NN O
/ NN NN O
min NN NN O
; NN NN O
1 NN NN O
ng NN NN O
= NN NN O
5 NN NN O
. NN NN O
458 NN NN O
pmol NN NN O
) NN NN O
, NN NN O
noradrenaline NN NN O
( NN NN O
30 NN NN O
ng NN NN O
/ NN NN O
kg NN NN O
/ NN NN O
min NN NN O
; NN NN O
1 NN NN O
ng NN NN O
= NN NN O
5 NN NN O
. NN NN O
911 NN NN O
pmol NN NN O
) NN NN O
, NN NN O
and NN NN O
a NN NN O
5 NN NN O
% NN NN O
dextrose NN NN O
solution NN NN O
( NN NN O
5 NN NN O
. NN NN O
4 NN NN O
ml NN NN O
/ NN NN O
h NN NN O
) NN NN O
, NN NN O
were NN NN O
given NN NN O
to NN NN O
ten NN NN O
healthy NN NN O
volunteers NN NN O
in NN NN O
random NN NN O
order NN NN O
2 NN NN O
weeks NN NN O
apart NN NN O
. NN NN O
   
By NN NN O
means NN NN O
of NN NN O
intra NN NN O
- NN NN O
arterial NN NN O
ambulatory NN NN O
monitoring NN NN O
the NN NN O
haemodynamic NN NN O
effects NN NN O
were NN NN O
followed NN NN O
for NN NN O
18 NN NN O
h NN NN O
after NN NN O
the NN NN O
infusions NN NN O
were NN NN O
stopped NN NN O
. NN NN O
   
Adrenaline NN NN O
, NN NN O
but NN NN O
not NN NN O
noradrenaline NN NN O
, NN NN O
caused NN NN O
a NN NN O
delayed NN NN O
and NN NN O
protracted NN NN O
pressor NN NN O
effect NN NN O
. NN NN O
   
Over NN NN O
the NN NN O
total NN NN O
postinfusion NN NN O
period NN NN O
systolic NN NN O
and NN NN O
diastolic NN NN O
arterial NN NN O
pressure NN NN O
were NN NN O
6 NN NN O
( NN NN O
SEM NN NN O
2 NN NN O
) NN NN O
% NN NN O
and NN NN O
7 NN NN O
( NN NN O
2 NN NN O
) NN NN O
% NN NN O
, NN NN O
respectively NN NN O
, NN NN O
higher NN NN O
than NN NN O
after NN NN O
dextrose NN NN O
infusion NN NN O
( NN NN O
ANOVA NN NN O
, NN NN O
p NN NN O
less NN NN O
than NN NN O
0 NN NN O
. NN NN O
001 NN NN O
) NN NN O
. NN NN O
   
Thus NN NN O
, NN NN O
"""""""" NN NN O
stress NN NN O
"""""""" NN NN O
levels NN NN O
of NN NN O
adrenaline NN NN O
( NN NN O
230 NN NN O
pg NN NN O
/ NN NN O
ml NN NN O
) NN NN O
for NN NN O
6 NN NN O
h NN NN O
cause NN NN O
a NN NN O
delayed NN NN O
and NN NN O
protracted NN NN O
pressor NN NN O
effect NN NN O
. NN NN O
   
These NN NN O
findings NN NN O
are NN NN O
strong NN NN O
support NN NN O
for NN NN O
the NN NN O
adrenaline NN NN O
- NN NN O
hypertension NN NN B-Disease
hypothesis NN NN O
in NN NN O
man NN NN O
. NN NN O
   
Effect NN NN O
of NN NN O
alkylxanthines NN NN O
on NN NN O
gentamicin NN NN O
- NN NN O
induced NN NN O
acute NN NN B-Disease
renal NN NN I-Disease
failure NN NN I-Disease
in NN NN O
the NN NN O
rat NN NN O
. NN NN O
   
Adenosine NN NN O
antagonists NN NN O
have NN NN O
been NN NN O
previously NN NN O
shown NN NN O
to NN NN O
be NN NN O
of NN NN O
benefit NN NN O
in NN NN O
some NN NN O
ischaemic NN NN B-Disease
and NN NN O
nephrotoxic NN NN B-Disease
models NN NN O
of NN NN O
acute NN NN B-Disease
renal NN NN I-Disease
failure NN NN I-Disease
( NN NN O
ARF NN NN B-Disease
) NN NN O
. NN NN O
   
In NN NN O
the NN NN O
present NN NN O
study NN NN O
, NN NN O
the NN NN O
effects NN NN O
of NN NN O
three NN NN O
alkylxanthines NN NN O
with NN NN O
different NN NN O
potencies NN NN O
as NN NN O
adenosine NN NN O
antagonists NN NN O
8 NN NN O
- NN NN O
phenyltheophylline NN NN O
, NN NN O
theophylline NN NN O
and NN NN O
enprofylline NN NN O
, NN NN O
were NN NN O
examined NN NN O
in NN NN O
rats NN NN O
developing NN NN O
acute NN NN B-Disease
renal NN NN I-Disease
failure NN NN I-Disease
after NN NN O
4 NN NN O
daily NN NN O
injections NN NN O
of NN NN O
gentamicin NN NN O
( NN NN O
200 NN NN O
mg NN NN O
kg NN NN O
- NN NN O
1 NN NN O
) NN NN O
. NN NN O
   
Renal NN NN O
function NN NN O
was NN NN O
assessed NN NN O
by NN NN O
biochemical NN NN O
( NN NN O
plasma NN NN O
urea NN NN O
and NN NN O
creatinine NN NN O
) NN NN O
, NN NN O
functional NN NN O
( NN NN O
urine NN NN O
analysis NN NN O
and NN NN O
[ NN NN O
3H NN NN O
] NN NN O
inulin NN NN O
and NN NN O
[ NN NN O
14C NN NN O
] NN NN O
p NN NN O
- NN NN O
aminohippuric NN NN O
acid NN NN O
clearances NN NN O
) NN NN O
and NN NN O
morphological NN NN O
( NN NN O
degree NN NN O
of NN NN O
necrosis NN NN B-Disease
) NN NN O
indices NN NN O
. NN NN O
   
The NN NN O
various NN NN O
drug NN NN O
treatments NN NN O
produced NN NN O
improvements NN NN O
in NN NN O
some NN NN O
, NN NN O
but NN NN O
not NN NN O
all NN NN O
, NN NN O
measurements NN NN O
of NN NN O
renal NN NN O
function NN NN O
. NN NN O
   
However NN NN O
, NN NN O
any NN NN O
improvement NN NN O
produced NN NN O
by NN NN O
drug NN NN O
treatment NN NN O
was NN NN O
largely NN NN O
a NN NN O
result NN NN O
of NN NN O
a NN NN O
beneficial NN NN O
effect NN NN O
exerted NN NN O
by NN NN O
its NN NN O
vehicle NN NN O
( NN NN O
polyethylene NN NN O
glycol NN NN O
and NN NN O
NaOH NN NN O
) NN NN O
. NN NN O
   
The NN NN O
lack NN NN O
of NN NN O
any NN NN O
consistent NN NN O
protective NN NN O
effect NN NN O
noted NN NN O
with NN NN O
the NN NN O
alkylxanthines NN NN O
tested NN NN O
in NN NN O
the NN NN O
present NN NN O
study NN NN O
indicates NN NN O
that NN NN O
adenosine NN NN O
plays NN NN O
little NN NN O
, NN NN O
if NN NN O
any NN NN O
, NN NN O
pathophysiological NN NN O
role NN NN O
in NN NN O
gentamicin NN NN O
- NN NN O
induced NN NN O
ARF NN NN B-Disease
. NN NN O
   
Adverse NN NN O
ocular NN NN O
reactions NN NN O
possibly NN NN O
associated NN NN O
with NN NN O
isotretinoin NN NN O
. NN NN O
   
A NN NN O
total NN NN O
of NN NN O
261 NN NN O
adverse NN NN O
ocular NN NN O
reactions NN NN O
occurred NN NN O
in NN NN O
237 NN NN O
patients NN NN O
who NN NN O
received NN NN O
isotretinoin NN NN O
, NN NN O
a NN NN O
commonly NN NN O
used NN NN O
drug NN NN O
in NN NN O
the NN NN O
treatment NN NN O
of NN NN O
severe NN NN O
cystic NN NN O
acne NN NN B-Disease
. NN NN O
   
Blepharoconjunctivitis NN NN B-Disease
, NN NN O
subjective NN NN O
complaints NN NN O
of NN NN O
dry NN NN B-Disease
eyes NN NN I-Disease
, NN NN O
blurred NN NN B-Disease
vision NN NN I-Disease
, NN NN O
contact NN NN O
lens NN NN O
intolerance NN NN O
, NN NN O
and NN NN O
photodermatitis NN NN B-Disease
are NN NN O
reversible NN NN O
side NN NN O
effects NN NN O
. NN NN O
   
More NN NN O
serious NN NN O
ocular NN NN O
adverse NN NN O
reactions NN NN O
include NN NN O
papilledema NN NN B-Disease
, NN NN O
pseudotumor NN NN B-Disease
cerebri NN NN I-Disease
, NN NN O
and NN NN O
white NN NN O
or NN NN O
gray NN NN O
subepithelial NN NN O
corneal NN NN B-Disease
opacities NN NN I-Disease
; NN NN O
all NN NN O
of NN NN O
these NN NN O
are NN NN O
reversible NN NN O
if NN NN O
the NN NN O
drug NN NN O
is NN NN O
discontinued NN NN O
. NN NN O
   
Reported NN NN O
cases NN NN O
of NN NN O
decreased NN NN O
dark NN NN O
adaptation NN NN O
are NN NN O
under NN NN O
investigation NN NN O
. NN NN O
   
Isotretinoin NN NN O
is NN NN O
contraindicated NN NN O
in NN NN O
pregnancy NN NN O
because NN NN O
of NN NN O
the NN NN O
many NN NN O
reported NN NN O
congenital NN NN B-Disease
abnormalities NN NN I-Disease
after NN NN O
maternal NN NN O
use NN NN O
( NN NN O
including NN NN O
microphthalmos NN NN B-Disease
, NN NN O
orbital NN NN O
hypertelorism NN NN B-Disease
, NN NN O
and NN NN O
optic NN NN B-Disease
nerve NN NN I-Disease
hypoplasia NN NN I-Disease
) NN NN O
. NN NN O
   
Procaterol NN NN O
and NN NN O
terbutaline NN NN O
in NN NN O
bronchial NN NN B-Disease
asthma NN NN I-Disease
. NN NN O
   
A NN NN O
double NN NN O
- NN NN O
blind NN NN O
, NN NN O
placebo NN NN O
- NN NN O
controlled NN NN O
, NN NN O
cross NN NN O
- NN NN O
over NN NN O
study NN NN O
. NN NN O
   
Procaterol NN NN O
, NN NN O
a NN NN O
new NN NN O
beta NN NN O
- NN NN O
2 NN NN O
adrenoceptor NN NN O
stimulant NN NN O
, NN NN O
was NN NN O
studied NN NN O
in NN NN O
a NN NN O
double NN NN O
- NN NN O
blind NN NN O
, NN NN O
placebo NN NN O
- NN NN O
controlled NN NN O
, NN NN O
cross NN NN O
- NN NN O
over NN NN O
trial NN NN O
in NN NN O
patients NN NN O
with NN NN O
bronchial NN NN B-Disease
asthma NN NN I-Disease
. NN NN O
   
Oral NN NN O
procaterol NN NN O
50 NN NN O
micrograms NN NN O
b NN NN O
. NN NN O
d NN NN O
. NN NN O
, NN NN O
procaterol NN NN O
100 NN NN O
micrograms NN NN O
b NN NN O
. NN NN O
d NN NN O
. NN NN O
, NN NN O
and NN NN O
terbutaline NN NN O
5 NN NN O
mg NN NN O
t NN NN O
. NN NN O
i NN NN O
. NN NN O
d NN NN O
. NN NN O
, NN NN O
were NN NN O
compared NN NN O
when NN NN O
given NN NN O
randomly NN NN O
in NN NN O
1 NN NN O
- NN NN O
week NN NN O
treatment NN NN O
periods NN NN O
. NN NN O
   
The NN NN O
best NN NN O
clinical NN NN O
effect NN NN O
was NN NN O
found NN NN O
with NN NN O
terbutaline NN NN O
. NN NN O
   
Both NN NN O
anti NN NN O
- NN NN O
asthmatic NN NN B-Disease
and NN NN O
tremorgenic NN NN B-Disease
effects NN NN O
of NN NN O
procaterol NN NN O
were NN NN O
dose NN NN O
- NN NN O
related NN NN O
. NN NN O
   
Procaterol NN NN O
appeared NN NN O
effective NN NN O
in NN NN O
the NN NN O
doses NN NN O
tested NN NN O
, NN NN O
and NN NN O
a NN NN O
twice NN NN O
daily NN NN O
regimen NN NN O
would NN NN O
appear NN NN O
to NN NN O
be NN NN O
suitable NN NN O
with NN NN O
this NN NN O
drug NN NN O
. NN NN O
   
Subacute NN NN O
effects NN NN O
of NN NN O
propranolol NN NN O
and NN NN O
B NN NN O
24 NN NN O
/ NN NN O
76 NN NN O
on NN NN O
isoproterenol NN NN O
- NN NN O
induced NN NN O
rat NN NN O
heart NN NN B-Disease
hypertrophy NN NN I-Disease
in NN NN O
correlation NN NN O
with NN NN O
blood NN NN O
pressure NN NN O
. NN NN O
   
We NN NN O
compared NN NN O
the NN NN O
potential NN NN O
beta NN NN O
- NN NN O
receptor NN NN O
blocker NN NN O
, NN NN O
B NN NN O
24 NN NN O
/ NN NN O
76 NN NN O
i NN NN O
. NN NN O
e NN NN O
. NN NN O
1 NN NN O
- NN NN O
( NN NN O
2 NN NN O
, NN NN O
4 NN NN O
- NN NN O
dichlorophenoxy NN NN O
) NN NN O
- NN NN O
3 NN NN O
[ NN NN O
2 NN NN O
- NN NN O
3 NN NN O
, NN NN O
4 NN NN O
- NN NN O
dimethoxyphenyl NN NN O
) NN NN O
ethanolamino NN NN O
] NN NN O
- NN NN O
prop NN NN O
an NN NN O
- NN NN O
2 NN NN O
- NN NN O
ol NN NN O
, NN NN O
which NN NN O
is NN NN O
characterized NN NN O
by NN NN O
beta NN NN O
1 NN NN O
- NN NN O
adrenoceptor NN NN O
blocking NN NN O
and NN NN O
beta NN NN O
2 NN NN O
- NN NN O
adrenoceptor NN NN O
stimulating NN NN O
properties NN NN O
with NN NN O
propranolol NN NN O
. NN NN O
   
The NN NN O
studies NN NN O
were NN NN O
performed NN NN O
using NN NN O
an NN NN O
experimental NN NN O
model NN NN O
of NN NN O
isoproterenol NN NN O
- NN NN O
induced NN NN O
heart NN NN B-Disease
hypertrophy NN NN I-Disease
in NN NN O
rats NN NN O
. NN NN O
   
A NN NN O
correlation NN NN O
of NN NN O
the NN NN O
blood NN NN O
pressure NN NN O
was NN NN O
neither NN NN O
found NN NN O
in NN NN O
the NN NN O
development NN NN O
nor NN NN O
in NN NN O
the NN NN O
attempt NN NN O
to NN NN O
suppress NN NN O
the NN NN O
development NN NN O
of NN NN O
heart NN NN B-Disease
hypertrophy NN NN I-Disease
with NN NN O
the NN NN O
two NN NN O
beta NN NN O
- NN NN O
receptor NN NN O
blockers NN NN O
. NN NN O
   
Both NN NN O
beta NN NN O
- NN NN O
blockers NN NN O
influenced NN NN O
the NN NN O
development NN NN O
of NN NN O
hypertrophy NN NN B-Disease
to NN NN O
a NN NN O
different NN NN O
, NN NN O
but NN NN O
not NN NN O
reproducible NN NN O
extent NN NN O
. NN NN O
   
It NN NN O
was NN NN O
possible NN NN O
to NN NN O
suppress NN NN O
the NN NN O
increased NN NN O
ornithine NN NN O
decarboxylase NN NN O
activity NN NN O
with NN NN O
both NN NN O
beta NN NN O
- NN NN O
blockers NN NN O
in NN NN O
hypertrophied NN NN B-Disease
hearts NN NN I-Disease
, NN NN O
but NN NN O
there NN NN O
was NN NN O
no NN NN O
effect NN NN O
on NN NN O
the NN NN O
heart NN NN O
mass NN NN O
. NN NN O
   
Neither NN NN O
propranolol NN NN O
nor NN NN O
B NN NN O
24 NN NN O
/ NN NN O
76 NN NN O
could NN NN O
stop NN NN O
the NN NN O
changes NN NN O
in NN NN O
the NN NN O
characteristic NN NN O
myosin NN NN O
isoenzyme NN NN O
pattern NN NN O
of NN NN O
the NN NN O
hypertrophied NN NN B-Disease
rat NN NN O
heart NN NN O
. NN NN O
   
Thus NN NN O
, NN NN O
the NN NN O
investigations NN NN O
did NN NN O
not NN NN O
provide NN NN O
any NN NN O
evidence NN NN O
that NN NN O
the NN NN O
beta NN NN O
- NN NN O
receptor NN NN O
blockers NN NN O
propranolol NN NN O
and NN NN O
B NN NN O
24 NN NN O
/ NN NN O
76 NN NN O
have NN NN O
the NN NN O
potency NN NN O
to NN NN O
prevent NN NN O
isoproterenol NN NN O
from NN NN O
producing NN NN O
heart NN NN B-Disease
hypertrophy NN NN I-Disease
. NN NN O
   
Increased NN NN O
anxiogenic NN NN O
effects NN NN O
of NN NN O
caffeine NN NN O
in NN NN O
panic NN NN B-Disease
disorders NN NN I-Disease
. NN NN O
   
The NN NN O
effects NN NN O
of NN NN O
oral NN NN O
administration NN NN O
of NN NN O
caffeine NN NN O
( NN NN O
10 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
) NN NN O
on NN NN O
behavioral NN NN O
ratings NN NN O
, NN NN O
somatic NN NN O
symptoms NN NN O
, NN NN O
blood NN NN O
pressure NN NN O
and NN NN O
plasma NN NN O
levels NN NN O
of NN NN O
3 NN NN O
- NN NN O
methoxy NN NN O
- NN NN O
4 NN NN O
- NN NN O
hydroxyphenethyleneglycol NN NN O
( NN NN O
MHPG NN NN O
) NN NN O
and NN NN O
cortisol NN NN O
were NN NN O
determined NN NN O
in NN NN O
17 NN NN O
healthy NN NN O
subjects NN NN O
and NN NN O
21 NN NN O
patients NN NN O
meeting NN NN O
DSM NN NN O
- NN NN O
III NN NN O
criteria NN NN O
for NN NN O
agoraphobia NN NN B-Disease
with NN NN O
panic NN NN B-Disease
attacks NN NN I-Disease
or NN NN O
panic NN NN B-Disease
disorder NN NN I-Disease
. NN NN O
   
Caffeine NN NN O
produced NN NN O
significantly NN NN O
greater NN NN O
increases NN NN O
in NN NN O
subject NN NN O
- NN NN O
rated NN NN O
anxiety NN NN B-Disease
, NN NN O
nervousness NN NN O
, NN NN O
fear NN NN O
, NN NN O
nausea NN NN B-Disease
, NN NN O
palpitations NN NN B-Disease
, NN NN O
restlessness NN NN B-Disease
, NN NN O
and NN NN O
tremors NN NN B-Disease
in NN NN O
the NN NN O
patients NN NN O
compared NN NN O
with NN NN O
healthy NN NN O
subjects NN NN O
. NN NN O
   
In NN NN O
the NN NN O
patients NN NN O
, NN NN O
but NN NN O
not NN NN O
the NN NN O
healthy NN NN O
subjects NN NN O
, NN NN O
these NN NN O
symptoms NN NN O
were NN NN O
significantly NN NN O
correlated NN NN O
with NN NN O
plasma NN NN O
caffeine NN NN O
levels NN NN O
. NN NN O
   
Seventy NN NN O
- NN NN O
one NN NN O
percent NN NN O
of NN NN O
the NN NN O
patients NN NN O
reported NN NN O
that NN NN O
the NN NN O
behavioral NN NN O
effects NN NN O
of NN NN O
caffeine NN NN O
were NN NN O
similar NN NN O
to NN NN O
those NN NN O
experienced NN NN O
during NN NN O
panic NN NN B-Disease
attacks NN NN I-Disease
. NN NN O
   
Caffeine NN NN O
did NN NN O
not NN NN O
alter NN NN O
plasma NN NN O
MHPG NN NN O
levels NN NN O
in NN NN O
either NN NN O
the NN NN O
healthy NN NN O
subjects NN NN O
or NN NN O
patients NN NN O
. NN NN O
   
Caffeine NN NN O
increased NN NN O
plasma NN NN O
cortisol NN NN O
levels NN NN O
equally NN NN O
in NN NN O
the NN NN O
patient NN NN O
and NN NN O
healthy NN NN O
groups NN NN O
. NN NN O
   
Because NN NN O
caffeine NN NN O
is NN NN O
an NN NN O
adenosine NN NN O
receptor NN NN O
antagonist NN NN O
, NN NN O
these NN NN O
results NN NN O
suggest NN NN O
that NN NN O
some NN NN O
panic NN NN B-Disease
disorder NN NN I-Disease
patients NN NN O
may NN NN O
have NN NN O
abnormalities NN NN B-Disease
in NN NN I-Disease
neuronal NN NN I-Disease
systems NN NN I-Disease
involving NN NN O
adenosine NN NN O
. NN NN O
   
Patients NN NN O
with NN NN O
anxiety NN NN B-Disease
disorders NN NN I-Disease
may NN NN O
benefit NN NN O
by NN NN O
avoiding NN NN O
caffeine NN NN O
- NN NN O
containing NN NN O
foods NN NN O
and NN NN O
beverages NN NN O
. NN NN O
   
Comparison NN NN O
of NN NN O
the NN NN O
effect NN NN O
of NN NN O
oxitropium NN NN O
bromide NN NN O
and NN NN O
of NN NN O
slow NN NN O
- NN NN O
release NN NN O
theophylline NN NN O
on NN NN O
nocturnal NN NN O
asthma NN NN B-Disease
. NN NN O
   
The NN NN O
effects NN NN O
of NN NN O
a NN NN O
new NN NN O
inhaled NN NN O
antimuscarinic NN NN O
drug NN NN O
, NN NN O
oxitropium NN NN O
bromide NN NN O
, NN NN O
and NN NN O
of NN NN O
a NN NN O
slow NN NN O
- NN NN O
release NN NN O
theophylline NN NN O
preparation NN NN O
upon NN NN O
nocturnal NN NN O
asthma NN NN B-Disease
were NN NN O
compared NN NN O
in NN NN O
a NN NN O
placebo NN NN O
- NN NN O
controlled NN NN O
double NN NN O
- NN NN O
blind NN NN O
study NN NN O
. NN NN O
   
Two NN NN O
samples NN NN O
were NN NN O
studied NN NN O
: NN NN O
12 NN NN O
patients NN NN O
received NN NN O
oxitropium NN NN O
at NN NN O
600 NN NN O
micrograms NN NN O
( NN NN O
6 NN NN O
subjects NN NN O
) NN NN O
or NN NN O
at NN NN O
400 NN NN O
micrograms NN NN O
t NN NN O
. NN NN O
i NN NN O
. NN NN O
d NN NN O
. NN NN O
   
( NN NN O
6 NN NN O
subjects NN NN O
) NN NN O
whereas NN NN O
11 NN NN O
received NN NN O
theophylline NN NN O
at NN NN O
300 NN NN O
mg NN NN O
b NN NN O
. NN NN O
i NN NN O
. NN NN O
d NN NN O
. NN NN O
   
Morning NN NN O
dipping NN NN O
, NN NN O
assessed NN NN O
by NN NN O
the NN NN O
fall NN NN O
in NN NN O
peak NN NN O
flow NN NN O
overnight NN NN O
, NN NN O
was NN NN O
significantly NN NN O
reduced NN NN O
in NN NN O
the NN NN O
periods NN NN O
when NN NN O
either NN NN O
active NN NN O
drug NN NN O
was NN NN O
taken NN NN O
, NN NN O
whereas NN NN O
no NN NN O
difference NN NN O
was NN NN O
noticed NN NN O
during NN NN O
the NN NN O
placebo NN NN O
administration NN NN O
. NN NN O
   
No NN NN O
significant NN NN O
difference NN NN O
was NN NN O
noticed NN NN O
between NN NN O
results NN NN O
obtained NN NN O
with NN NN O
either NN NN O
active NN NN O
drug NN NN O
, NN NN O
as NN NN O
well NN NN O
as NN NN O
with NN NN O
either NN NN O
dosage NN NN O
of NN NN O
oxitropium NN NN O
. NN NN O
   
No NN NN O
subject NN NN O
reported NN NN O
side NN NN O
effects NN NN O
of NN NN O
oxitropium NN NN O
, NN NN O
as NN NN O
compared NN NN O
to NN NN O
three NN NN O
subjects NN NN O
reporting NN NN O
nausea NN NN B-Disease
, NN NN O
vomiting NN NN B-Disease
and NN NN O
tremors NN NN B-Disease
after NN NN O
theophylline NN NN O
. NN NN O
   
Oxitropium NN NN O
proves NN NN O
to NN NN O
be NN NN O
a NN NN O
valuable NN NN O
alternative NN NN O
to NN NN O
theophylline NN NN O
in NN NN O
nocturnal NN NN O
asthma NN NN B-Disease
, NN NN O
since NN NN O
it NN NN O
is NN NN O
equally NN NN O
potent NN NN O
, NN NN O
safer NN NN O
and NN NN O
does NN NN O
not NN NN O
require NN NN O
the NN NN O
titration NN NN O
of NN NN O
dosage NN NN O
. NN NN O
   
Penicillin NN NN O
anaphylaxis NN NN B-Disease
. NN NN O
   
A NN NN O
case NN NN O
of NN NN O
oral NN NN O
penicillin NN NN O
anaphylaxis NN NN B-Disease
is NN NN O
described NN NN O
, NN NN O
and NN NN O
the NN NN O
terminology NN NN O
, NN NN O
occurrence NN NN O
, NN NN O
clinical NN NN O
manifestations NN NN O
, NN NN O
pathogenesis NN NN O
, NN NN O
prevention NN NN O
, NN NN O
and NN NN O
treatment NN NN O
of NN NN O
anaphylaxis NN NN B-Disease
are NN NN O
reviewed NN NN O
. NN NN O
   
Emergency NN NN O
physicians NN NN O
should NN NN O
be NN NN O
aware NN NN O
of NN NN O
oral NN NN O
penicillin NN NN O
anaphylaxis NN NN B-Disease
in NN NN O
order NN NN O
to NN NN O
prevent NN NN O
its NN NN O
occurrence NN NN O
by NN NN O
prescribing NN NN O
the NN NN O
antibiotic NN NN O
judiciously NN NN O
and NN NN O
knowledgeably NN NN O
and NN NN O
to NN NN O
offer NN NN O
optimal NN NN O
medical NN NN O
therapy NN NN O
once NN NN O
this NN NN O
life NN NN O
- NN NN O
threatening NN NN O
reaction NN NN O
has NN NN O
begun NN NN O
. NN NN O
   
Reversible NN NN O
valproic NN NN O
acid NN NN O
- NN NN O
induced NN NN O
dementia NN NN B-Disease
: NN NN O
a NN NN O
case NN NN O
report NN NN O
. NN NN O
   
Reversible NN NN O
valproic NN NN O
acid NN NN O
- NN NN O
induced NN NN O
dementia NN NN B-Disease
was NN NN O
documented NN NN O
in NN NN O
a NN NN O
21 NN NN O
- NN NN O
year NN NN O
- NN NN O
old NN NN O
man NN NN O
with NN NN O
epilepsy NN NN B-Disease
who NN NN O
had NN NN O
a NN NN O
3 NN NN O
- NN NN O
year NN NN O
history NN NN O
of NN NN O
insidious NN NN O
progressive NN NN O
decline NN NN O
in NN NN O
global NN NN O
cognitive NN NN O
abilities NN NN O
documented NN NN O
by NN NN O
serial NN NN O
neuropsychological NN NN O
studies NN NN O
. NN NN O
   
Repeat NN NN O
neuropsychological NN NN O
testing NN NN O
7 NN NN O
weeks NN NN O
after NN NN O
discontinuation NN NN O
of NN NN O
the NN NN O
drug NN NN O
revealed NN NN O
dramatic NN NN O
improvement NN NN O
in NN NN O
IQ NN NN O
, NN NN O
memory NN NN O
, NN NN O
naming NN NN O
, NN NN O
and NN NN O
other NN NN O
tasks NN NN O
commensurate NN NN O
with NN NN O
clinical NN NN O
recovery NN NN O
in NN NN O
his NN NN O
intellectual NN NN O
capacity NN NN O
. NN NN O
   
Possible NN NN O
pathophysiological NN NN O
mechanisms NN NN O
which NN NN O
may NN NN O
have NN NN O
been NN NN O
operative NN NN O
in NN NN O
this NN NN O
case NN NN O
include NN NN O
: NN NN O
a NN NN O
direct NN NN O
central NN NN O
nervous NN NN O
system NN NN O
( NN NN O
CNS NN NN O
) NN NN O
toxic NN NN O
effect NN NN O
of NN NN O
valproic NN NN O
acid NN NN O
; NN NN O
a NN NN O
paradoxical NN NN O
epileptogenic NN NN O
effect NN NN O
secondary NN NN O
to NN NN O
the NN NN O
drug NN NN O
; NN NN O
and NN NN O
an NN NN O
indirect NN NN O
CNS NN NN O
toxic NN NN O
effect NN NN O
mediated NN NN O
through NN NN O
valproic NN NN O
acid NN NN O
- NN NN O
induced NN NN O
hyperammonemia NN NN B-Disease
. NN NN O
   
Reversal NN NN O
of NN NN O
scopolamine NN NN O
- NN NN O
induced NN NN O
amnesia NN NN B-Disease
of NN NN O
passive NN NN O
avoidance NN NN O
by NN NN O
pre NN NN O
- NN NN O
and NN NN O
post NN NN O
- NN NN O
training NN NN O
naloxone NN NN O
. NN NN O
   
In NN NN O
a NN NN O
series NN NN O
of NN NN O
five NN NN O
experiments NN NN O
, NN NN O
the NN NN O
modulating NN NN O
role NN NN O
of NN NN O
naloxone NN NN O
on NN NN O
a NN NN O
scopolamine NN NN O
- NN NN O
induced NN NN O
retention NN NN B-Disease
deficit NN NN I-Disease
in NN NN O
a NN NN O
passive NN NN O
avoidance NN NN O
paradigm NN NN O
was NN NN O
investigated NN NN O
in NN NN O
mice NN NN O
. NN NN O
   
Scopolamine NN NN O
, NN NN O
but NN NN O
not NN NN O
methyl NN NN O
scopolamine NN NN O
( NN NN O
1 NN NN O
and NN NN O
3 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
) NN NN O
, NN NN O
induced NN NN O
an NN NN O
amnesia NN NN B-Disease
as NN NN O
measured NN NN O
by NN NN O
latency NN NN O
and NN NN O
duration NN NN O
parameters NN NN O
. NN NN O
   
Naloxone NN NN O
( NN NN O
0 NN NN O
. NN NN O
3 NN NN O
, NN NN O
1 NN NN O
, NN NN O
3 NN NN O
, NN NN O
and NN NN O
10 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
) NN NN O
injected NN NN O
prior NN NN O
to NN NN O
training NN NN O
attenuated NN NN O
the NN NN O
retention NN NN B-Disease
deficit NN NN I-Disease
with NN NN O
a NN NN O
peak NN NN O
of NN NN O
activity NN NN O
at NN NN O
3 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
. NN NN O
   
The NN NN O
effect NN NN O
of NN NN O
naloxone NN NN O
could NN NN O
be NN NN O
antagonized NN NN O
with NN NN O
morphine NN NN O
( NN NN O
1 NN NN O
, NN NN O
3 NN NN O
, NN NN O
and NN NN O
10 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
) NN NN O
, NN NN O
demonstrating NN NN O
the NN NN O
opioid NN NN O
specificity NN NN O
of NN NN O
the NN NN O
naloxone NN NN O
effect NN NN O
. NN NN O
   
Post NN NN O
- NN NN O
training NN NN O
administration NN NN O
of NN NN O
naloxone NN NN O
( NN NN O
3 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
) NN NN O
as NN NN O
a NN NN O
single NN NN O
or NN NN O
as NN NN O
a NN NN O
split NN NN O
dose NN NN O
also NN NN O
attenuated NN NN O
the NN NN O
scopolamine NN NN O
- NN NN O
induced NN NN O
amnesia NN NN B-Disease
. NN NN O
   
Control NN NN O
experiments NN NN O
indicated NN NN O
that NN NN O
neither NN NN O
an NN NN O
increase NN NN O
in NN NN O
pain NN NN B-Disease
sensitivity NN NN O
( NN NN O
pre NN NN O
- NN NN O
training NN NN O
naloxone NN NN O
) NN NN O
nor NN NN O
an NN NN O
induced NN NN O
aversive NN NN O
state NN NN O
( NN NN O
post NN NN O
- NN NN O
training NN NN O
naloxone NN NN O
) NN NN O
appear NN NN O
to NN NN O
be NN NN O
responsible NN NN O
for NN NN O
the NN NN O
influence NN NN O
of NN NN O
naloxone NN NN O
on NN NN O
the NN NN O
scopolamine NN NN O
- NN NN O
induced NN NN O
retention NN NN B-Disease
deficit NN NN I-Disease
. NN NN O
   
These NN NN O
results NN NN O
extend NN NN O
previous NN NN O
findings NN NN O
implicating NN NN O
a NN NN O
cholinergic NN NN O
- NN NN O
opioid NN NN O
interaction NN NN O
in NN NN O
memory NN NN O
processes NN NN O
. NN NN O
   
A NN NN O
possible NN NN O
mechanism NN NN O
for NN NN O
this NN NN O
interaction NN NN O
involving NN NN O
the NN NN O
septo NN NN O
- NN NN O
hippocampal NN NN O
cholinergic NN NN O
pathway NN NN O
is NN NN O
discussed NN NN O
. NN NN O
   
Electron NN NN O
microscopic NN NN O
investigations NN NN O
of NN NN O
the NN NN O
cyclophosphamide NN NN O
- NN NN O
induced NN NN O
lesions NN NN B-Disease
of NN NN I-Disease
the NN NN I-Disease
urinary NN NN I-Disease
bladder NN NN I-Disease
of NN NN O
the NN NN O
rat NN NN O
and NN NN O
their NN NN O
prevention NN NN O
by NN NN O
mesna NN NN O
. NN NN O
   
Fully NN NN O
developed NN NN O
cyclophosphamide NN NN O
- NN NN O
induced NN NN O
cystitis NN NN B-Disease
is NN NN O
characterized NN NN O
by NN NN O
nearly NN NN O
complete NN NN O
detachment NN NN O
of NN NN O
the NN NN O
urothelium NN NN O
, NN NN O
severe NN NN O
submucosal NN NN O
edema NN NN B-Disease
owing NN NN O
to NN NN O
damage NN NN O
to NN NN O
the NN NN O
microvascular NN NN O
bed NN NN O
and NN NN O
focal NN NN O
muscle NN NN O
necroses NN NN B-Disease
. NN NN O
   
The NN NN O
initial NN NN O
response NN NN O
to NN NN O
the NN NN O
primary NN NN O
attack NN NN O
by NN NN O
the NN NN O
cyclophosphamide NN NN O
metabolites NN NN O
seems NN NN O
to NN NN O
be NN NN O
fragmentation NN NN O
of NN NN O
the NN NN O
luminal NN NN O
membrane NN NN O
. NN NN O
   
This NN NN O
damages NN NN O
the NN NN O
cellular NN NN O
barrier NN NN O
against NN NN O
the NN NN O
hypertonic NN NN O
urine NN NN O
. NN NN O
   
Subsequent NN NN O
breaks NN NN O
in NN NN O
the NN NN O
lateral NN NN O
cell NN NN O
membranes NN NN O
of NN NN O
the NN NN O
superficial NN NN O
cells NN NN O
and NN NN O
in NN NN O
all NN NN O
the NN NN O
plasma NN NN O
membranes NN NN O
of NN NN O
the NN NN O
intermediate NN NN O
and NN NN O
basal NN NN O
cells NN NN O
, NN NN O
intercellular NN NN O
and NN NN O
intracellular NN NN O
edema NN NN B-Disease
and NN NN O
disintegration NN NN O
of NN NN O
the NN NN O
desmosomes NN NN O
and NN NN O
hemidesmosomes NN NN O
lead NN NN O
to NN NN O
progressive NN NN O
degeneration NN NN O
and NN NN O
detachment NN NN O
of NN NN O
the NN NN O
epithelial NN NN O
cells NN NN O
with NN NN O
exposure NN NN O
and NN NN O
splitting NN NN O
of NN NN O
the NN NN O
basal NN NN O
membrane NN NN O
. NN NN O
   
The NN NN O
morphological NN NN O
changes NN NN O
of NN NN O
the NN NN O
endothelial NN NN O
cells NN NN O
, NN NN O
which NN NN O
become NN NN O
more NN NN O
pronounced NN NN O
in NN NN O
the NN NN O
later NN NN O
stages NN NN O
of NN NN O
the NN NN O
experiment NN NN O
, NN NN O
the NN NN O
involvement NN NN O
of NN NN O
blood NN NN O
vessels NN NN O
regardless NN NN O
of NN NN O
their NN NN O
diameter NN NN O
and NN NN O
the NN NN O
location NN NN O
- NN NN O
dependent NN NN O
extent NN NN O
of NN NN O
the NN NN O
damage NN NN O
indicate NN NN O
a NN NN O
direct NN NN O
type NN NN O
of NN NN O
damage NN NN O
which NN NN O
is NN NN O
preceded NN NN O
by NN NN O
a NN NN O
mediator NN NN O
- NN NN O
induced NN NN O
increase NN NN O
in NN NN O
permeability NN NN O
, NN NN O
the NN NN O
morphological NN NN O
correlate NN NN O
of NN NN O
which NN NN O
is NN NN O
the NN NN O
formation NN NN O
of NN NN O
gaps NN NN O
in NN NN O
the NN NN O
interendothelial NN NN O
cell NN NN O
connections NN NN O
on NN NN O
the NN NN O
venules NN NN O
. NN NN O
   
These NN NN O
changes NN NN O
can NN NN O
be NN NN O
effectively NN NN O
prevented NN NN O
by NN NN O
mesna NN NN O
. NN NN O
   
The NN NN O
only NN NN O
sign NN NN O
of NN NN O
a NN NN O
possible NN NN O
involvement NN NN O
is NN NN O
the NN NN O
increase NN NN O
in NN NN O
the NN NN O
number NN NN O
of NN NN O
specific NN NN O
granules NN NN O
with NN NN O
a NN NN O
presumed NN NN O
lysosomal NN NN O
function NN NN O
in NN NN O
the NN NN O
superficial NN NN O
cells NN NN O
. NN NN O
   
Increase NN NN O
in NN NN O
intragastric NN NN O
pressure NN NN O
during NN NN O
suxamethonium NN NN O
- NN NN O
induced NN NN O
muscle NN NN B-Disease
fasciculations NN NN I-Disease
in NN NN O
children NN NN O
: NN NN O
inhibition NN NN O
by NN NN O
alfentanil NN NN O
. NN NN O
   
Changes NN NN O
in NN NN O
intragastric NN NN O
pressure NN NN O
after NN NN O
the NN NN O
administration NN NN O
of NN NN O
suxamethonium NN NN O
1 NN NN O
. NN NN O
5 NN NN O
mg NN NN O
kg NN NN O
- NN NN O
1 NN NN O
i NN NN O
. NN NN O
v NN NN O
. NN NN O
were NN NN O
studied NN NN O
in NN NN O
32 NN NN O
children NN NN O
( NN NN O
mean NN NN O
age NN NN O
6 NN NN O
. NN NN O
9 NN NN O
yr NN NN O
) NN NN O
pretreated NN NN O
with NN NN O
either NN NN O
physiological NN NN O
saline NN NN O
or NN NN O
alfentanil NN NN O
50 NN NN O
micrograms NN NN O
kg NN NN O
- NN NN O
1 NN NN O
. NN NN O
   
Anaesthesia NN NN O
was NN NN O
induced NN NN O
with NN NN O
thiopentone NN NN O
5 NN NN O
mg NN NN O
kg NN NN O
- NN NN O
1 NN NN O
. NN NN O
   
The NN NN O
incidence NN NN O
and NN NN O
intensity NN NN O
of NN NN O
muscle NN NN B-Disease
fasciculations NN NN I-Disease
caused NN NN O
by NN NN O
suxamethonium NN NN O
were NN NN O
significantly NN NN O
greater NN NN O
in NN NN O
the NN NN O
control NN NN O
than NN NN O
in NN NN O
the NN NN O
alfentanil NN NN O
group NN NN O
. NN NN O
   
The NN NN O
intragastric NN NN O
pressure NN NN O
during NN NN O
muscle NN NN B-Disease
fasciculations NN NN I-Disease
was NN NN O
significantly NN NN O
higher NN NN O
in NN NN O
the NN NN O
control NN NN O
group NN NN O
( NN NN O
16 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
0 NN NN O
. NN NN O
7 NN NN O
( NN NN O
SEM NN NN O
) NN NN O
cm NN NN O
H2O NN NN O
) NN NN O
than NN NN O
in NN NN O
the NN NN O
alfentanil NN NN O
group NN NN O
( NN NN O
7 NN NN O
. NN NN O
7 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
1 NN NN O
. NN NN O
5 NN NN O
( NN NN O
SEM NN NN O
) NN NN O
cm NN NN O
H2O NN NN O
) NN NN O
. NN NN O
   
The NN NN O
increase NN NN O
in NN NN O
intragastric NN NN O
pressure NN NN O
was NN NN O
directly NN NN O
related NN NN O
to NN NN O
the NN NN O
intensity NN NN O
of NN NN O
muscle NN NN B-Disease
fasciculations NN NN I-Disease
( NN NN O
regression NN NN O
line NN NN O
: NN NN O
y NN NN O
= NN NN O
0 NN NN O
. NN NN O
5 NN NN O
+ NN NN O
4 NN NN O
. NN NN O
78x NN NN O
with NN NN O
r NN NN O
of NN NN O
0 NN NN O
. NN NN O
78 NN NN O
) NN NN O
. NN NN O
   
It NN NN O
is NN NN O
concluded NN NN O
that NN NN O
intragastric NN NN O
pressure NN NN O
increases NN NN O
significantly NN NN O
during NN NN O
muscle NN NN B-Disease
fasciculations NN NN I-Disease
caused NN NN O
by NN NN O
suxamethonium NN NN O
in NN NN O
healthy NN NN O
children NN NN O
. NN NN O
   
Alfentanil NN NN O
50 NN NN O
micrograms NN NN O
kg NN NN O
- NN NN O
1 NN NN O
effectively NN NN O
inhibits NN NN O
the NN NN O
incidence NN NN O
and NN NN O
intensity NN NN O
of NN NN O
suxamethonium NN NN O
- NN NN O
induced NN NN O
muscle NN NN B-Disease
fasciculations NN NN I-Disease
; NN NN O
moreover NN NN O
, NN NN O
intragastric NN NN O
pressure NN NN O
remains NN NN O
at NN NN O
its NN NN O
control NN NN O
value NN NN O
. NN NN O
   
Acute NN NN O
insulin NN NN O
treatment NN NN O
normalizes NN NN O
the NN NN O
resistance NN NN O
to NN NN O
the NN NN O
cardiotoxic NN NN B-Disease
effect NN NN O
of NN NN O
isoproterenol NN NN O
in NN NN O
streptozotocin NN NN O
diabetic NN NN B-Disease
rats NN NN O
. NN NN O
   
A NN NN O
morphometric NN NN O
study NN NN O
of NN NN O
isoproterenol NN NN O
induced NN NN O
myocardial NN NN O
fibrosis NN NN B-Disease
. NN NN O
   
The NN NN O
acute NN NN O
effect NN NN O
of NN NN O
insulin NN NN O
treatment NN NN O
on NN NN O
the NN NN O
earlier NN NN O
reported NN NN O
protective NN NN O
effect NN NN O
of NN NN O
streptozotocin NN NN O
diabetes NN NN B-Disease
against NN NN O
the NN NN O
cardiotoxic NN NN B-Disease
effect NN NN O
of NN NN O
high NN NN O
doses NN NN O
of NN NN O
isoproterenol NN NN O
( NN NN O
ISO NN NN O
) NN NN O
was NN NN O
investigated NN NN O
in NN NN O
rats NN NN O
. NN NN O
   
Thirty NN NN O
to NN NN O
135 NN NN O
min NN NN O
after NN NN O
the NN NN O
injection NN NN O
of NN NN O
crystalline NN NN O
insulin NN NN O
, NN NN O
ISO NN NN O
was NN NN O
given NN NN O
subcutaneously NN NN O
and NN NN O
when NN NN O
ISO NN NN O
induced NN NN O
fibrosis NN NN B-Disease
in NN NN O
the NN NN O
myocardium NN NN O
was NN NN O
morphometrically NN NN O
analyzed NN NN O
7 NN NN O
days NN NN O
later NN NN O
, NN NN O
a NN NN O
highly NN NN O
significant NN NN O
correlation NN NN O
( NN NN O
r NN NN O
= NN NN O
0 NN NN O
. NN NN O
83 NN NN O
, NN NN O
2 NN NN O
p NN NN O
= NN NN O
0 NN NN O
. NN NN O
006 NN NN O
) NN NN O
to NN NN O
the NN NN O
slope NN NN O
of NN NN O
the NN NN O
fall NN NN O
in NN NN O
blood NN NN O
glucose NN NN O
after NN NN O
insulin NN NN O
treatment NN NN O
appeared NN NN O
. NN NN O
   
The NN NN O
myocardial NN NN O
content NN NN O
of NN NN O
catecholamines NN NN O
was NN NN O
estimated NN NN O
in NN NN O
these NN NN O
8 NN NN O
day NN NN O
diabetic NN NN B-Disease
rats NN NN O
. NN NN O
   
The NN NN O
norepinephrine NN NN O
content NN NN O
was NN NN O
significantly NN NN O
increased NN NN O
while NN NN O
epinephrine NN NN O
remained NN NN O
unchanged NN NN O
. NN NN O
   
An NN NN O
enhanced NN NN O
sympathetic NN NN O
nervous NN NN O
system NN NN O
activity NN NN O
with NN NN O
a NN NN O
consequent NN NN O
down NN NN O
regulation NN NN O
of NN NN O
the NN NN O
myocardial NN NN O
beta NN NN O
- NN NN O
adrenergic NN NN O
receptors NN NN O
could NN NN O
, NN NN O
therefore NN NN O
, NN NN O
explain NN NN O
this NN NN O
catecholamine NN NN O
resistance NN NN O
. NN NN O
   
The NN NN O
rapid NN NN O
reversion NN NN O
after NN NN O
insulin NN NN O
treatment NN NN O
excludes NN NN O
the NN NN O
possibility NN NN O
that NN NN O
streptozotocin NN NN O
in NN NN O
itself NN NN O
causes NN NN O
the NN NN O
ISO NN NN O
resistance NN NN O
and NN NN O
points NN NN O
towards NN NN O
a NN NN O
direct NN NN O
insulin NN NN O
effect NN NN O
on NN NN O
myocardial NN NN O
catecholamine NN NN O
sensitivity NN NN O
in NN NN O
diabetic NN NN B-Disease
rats NN NN O
. NN NN O
   
The NN NN O
phenomenon NN NN O
described NN NN O
might NN NN O
elucidate NN NN O
pathogenetic NN NN O
mechanisms NN NN O
behind NN NN O
toxic NN NN O
myocardial NN NN O
cell NN NN O
degeneration NN NN O
and NN NN O
may NN NN O
possibly NN NN O
have NN NN O
relevance NN NN O
for NN NN O
acute NN NN O
cardiovascular NN NN O
complications NN NN O
in NN NN O
diabetic NN NN B-Disease
patients NN NN O
. NN NN O
   
Differential NN NN O
effects NN NN O
of NN NN O
non NN NN O
- NN NN O
steroidal NN NN O
anti NN NN O
- NN NN O
inflammatory NN NN O
drugs NN NN O
on NN NN O
seizures NN NN B-Disease
produced NN NN O
by NN NN O
pilocarpine NN NN O
in NN NN O
rats NN NN O
. NN NN O
   
The NN NN O
muscarinic NN NN O
cholinergic NN NN O
agonist NN NN O
pilocarpine NN NN O
induces NN NN O
in NN NN O
rats NN NN O
seizures NN NN B-Disease
and NN NN O
status NN NN B-Disease
epilepticus NN NN I-Disease
followed NN NN O
by NN NN O
widespread NN NN O
damage NN NN O
to NN NN O
the NN NN O
forebrain NN NN O
. NN NN O
   
The NN NN O
present NN NN O
study NN NN O
was NN NN O
designed NN NN O
to NN NN O
investigate NN NN O
the NN NN O
effect NN NN O
of NN NN O
5 NN NN O
non NN NN O
- NN NN O
steroidal NN NN O
anti NN NN O
- NN NN O
inflammatory NN NN O
drugs NN NN O
, NN NN O
sodium NN NN O
salicylate NN NN O
, NN NN O
phenylbutazone NN NN O
, NN NN O
indomethacin NN NN O
, NN NN O
ibuprofen NN NN O
and NN NN O
mefenamic NN NN O
acid NN NN O
, NN NN O
on NN NN O
seizures NN NN B-Disease
produced NN NN O
by NN NN O
pilocarpine NN NN O
. NN NN O
   
Pretreatment NN NN O
of NN NN O
rats NN NN O
with NN NN O
sodium NN NN O
salicylate NN NN O
, NN NN O
ED50 NN NN O
103 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
( NN NN O
60 NN NN O
- NN NN O
174 NN NN O
) NN NN O
, NN NN O
and NN NN O
phenylbutazone NN NN O
, NN NN O
59 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
( NN NN O
50 NN NN O
- NN NN O
70 NN NN O
) NN NN O
converted NN NN O
the NN NN O
non NN NN O
- NN NN O
convulsant NN NN O
dose NN NN O
of NN NN O
pilocarpine NN NN O
, NN NN O
200 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
, NN NN O
to NN NN O
a NN NN O
convulsant NN NN O
one NN NN O
. NN NN O
   
Indomethacin NN NN O
, NN NN O
1 NN NN O
- NN NN O
10 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
, NN NN O
and NN NN O
ibuprofen NN NN O
, NN NN O
10 NN NN O
- NN NN O
100 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
, NN NN O
failed NN NN O
to NN NN O
modulate NN NN O
seizures NN NN B-Disease
produced NN NN O
by NN NN O
pilocarpine NN NN O
. NN NN O
   
Mefenamic NN NN O
acid NN NN O
, NN NN O
26 NN NN O
( NN NN O
22 NN NN O
- NN NN O
30 NN NN O
) NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
, NN NN O
prevented NN NN O
seizures NN NN B-Disease
and NN NN O
protected NN NN O
rats NN NN O
from NN NN O
seizure NN NN B-Disease
- NN NN O
related NN NN O
brain NN NN B-Disease
damage NN NN I-Disease
induced NN NN O
by NN NN O
pilocarpine NN NN O
, NN NN O
380 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
. NN NN O
   
These NN NN O
results NN NN O
indicate NN NN O
that NN NN O
non NN NN O
- NN NN O
steroidal NN NN O
anti NN NN O
- NN NN O
inflammatory NN NN O
drugs NN NN O
differentially NN NN O
modulate NN NN O
the NN NN O
threshold NN NN O
for NN NN O
pilocarpine NN NN O
- NN NN O
induced NN NN O
seizures NN NN B-Disease
. NN NN O
   
Acute NN NN B-Disease
neurologic NN NN I-Disease
dysfunction NN NN I-Disease
after NN NN O
high NN NN O
- NN NN O
dose NN NN O
etoposide NN NN O
therapy NN NN O
for NN NN O
malignant NN NN B-Disease
glioma NN NN I-Disease
. NN NN O
   
Etoposide NN NN O
( NN NN O
VP NN NN O
- NN NN O
16 NN NN O
- NN NN O
213 NN NN O
) NN NN O
has NN NN O
been NN NN O
used NN NN O
in NN NN O
the NN NN O
treatment NN NN O
of NN NN O
many NN NN O
solid NN NN O
tumors NN NN B-Disease
and NN NN O
hematologic NN NN B-Disease
malignancies NN NN I-Disease
. NN NN O
   
When NN NN O
used NN NN O
in NN NN O
high NN NN O
doses NN NN O
and NN NN O
in NN NN O
conjunction NN NN O
with NN NN O
autologous NN NN O
bone NN NN O
marrow NN NN O
transplantation NN NN O
, NN NN O
this NN NN O
agent NN NN O
has NN NN O
activity NN NN O
against NN NN O
several NN NN O
treatment NN NN O
- NN NN O
resistant NN NN O
cancers NN NN B-Disease
including NN NN O
malignant NN NN B-Disease
glioma NN NN I-Disease
. NN NN O
   
In NN NN O
six NN NN O
of NN NN O
eight NN NN O
patients NN NN O
( NN NN O
75 NN NN O
% NN NN O
) NN NN O
who NN NN O
we NN NN O
treated NN NN O
for NN NN O
recurrent NN NN O
or NN NN O
resistant NN NN O
glioma NN NN B-Disease
, NN NN O
sudden NN NN O
severe NN NN O
neurologic NN NN B-Disease
deterioration NN NN I-Disease
occurred NN NN O
. NN NN O
   
This NN NN O
developed NN NN O
a NN NN O
median NN NN O
of NN NN O
9 NN NN O
days NN NN O
after NN NN O
initiation NN NN O
of NN NN O
high NN NN O
- NN NN O
dose NN NN O
etoposide NN NN O
therapy NN NN O
. NN NN O
   
Significant NN NN O
clinical NN NN O
manifestations NN NN O
have NN NN O
included NN NN O
confusion NN NN B-Disease
, NN NN O
papilledema NN NN B-Disease
, NN NN O
somnolence NN NN B-Disease
, NN NN O
exacerbation NN NN O
of NN NN O
motor NN NN B-Disease
deficits NN NN I-Disease
, NN NN O
and NN NN O
sharp NN NN O
increase NN NN O
in NN NN O
seizure NN NN B-Disease
activity NN NN O
. NN NN O
   
These NN NN O
abnormalities NN NN O
resolved NN NN O
rapidly NN NN O
after NN NN O
initiation NN NN O
of NN NN O
high NN NN O
- NN NN O
dose NN NN O
intravenous NN NN O
dexamethasone NN NN O
therapy NN NN O
. NN NN O
   
In NN NN O
all NN NN O
patients NN NN O
, NN NN O
computerized NN NN O
tomographic NN NN O
( NN NN O
CT NN NN O
) NN NN O
brain NN NN O
scans NN NN O
demonstrated NN NN O
stability NN NN O
in NN NN O
tumor NN NN B-Disease
size NN NN O
and NN NN O
peritumor NN NN O
edema NN NN B-Disease
when NN NN O
compared NN NN O
with NN NN O
pretransplant NN NN O
scans NN NN O
. NN NN O
   
This NN NN O
complication NN NN O
appears NN NN O
to NN NN O
represent NN NN O
a NN NN O
significant NN NN O
new NN NN O
toxicity NN NN B-Disease
of NN NN O
high NN NN O
- NN NN O
dose NN NN O
etoposide NN NN O
therapy NN NN O
for NN NN O
malignant NN NN B-Disease
glioma NN NN I-Disease
. NN NN O
   
Progressive NN NN O
bile NN NN B-Disease
duct NN NN I-Disease
injury NN NN I-Disease
after NN NN O
thiabendazole NN NN O
administration NN NN O
. NN NN O
   
A NN NN O
27 NN NN O
- NN NN O
yr NN NN O
- NN NN O
old NN NN O
man NN NN O
developed NN NN O
jaundice NN NN B-Disease
2 NN NN O
wk NN NN O
after NN NN O
exposure NN NN O
to NN NN O
thiabendazole NN NN O
. NN NN O
   
Cholestasis NN NN B-Disease
persisted NN NN O
for NN NN O
3 NN NN O
yr NN NN O
, NN NN O
at NN NN O
which NN NN O
time NN NN O
a NN NN O
liver NN NN O
transplant NN NN O
was NN NN O
performed NN NN O
. NN NN O
   
Two NN NN O
liver NN NN O
biopsy NN NN O
specimens NN NN O
and NN NN O
the NN NN O
hepatectomy NN NN O
specimen NN NN O
were NN NN O
remarkable NN NN O
for NN NN O
almost NN NN O
complete NN NN O
disappearance NN NN O
of NN NN O
interlobular NN NN O
bile NN NN O
ducts NN NN O
. NN NN O
   
Prominent NN NN O
fibrosis NN NN B-Disease
and NN NN O
hepatocellular NN NN O
regeneration NN NN O
were NN NN O
also NN NN O
present NN NN O
; NN NN O
however NN NN O
, NN NN O
the NN NN O
lobular NN NN O
architecture NN NN O
was NN NN O
preserved NN NN O
. NN NN O
   
This NN NN O
case NN NN O
represents NN NN O
an NN NN O
example NN NN O
of NN NN O
"""""""" NN NN O
idiosyncratic NN NN O
"""""""" NN NN O
drug NN NN B-Disease
- NN NN I-Disease
induced NN NN I-Disease
liver NN NN I-Disease
damage NN NN I-Disease
in NN NN O
which NN NN O
the NN NN O
primary NN NN O
target NN NN O
of NN NN O
injury NN NN O
is NN NN O
the NN NN O
bile NN NN O
duct NN NN O
. NN NN O
   
An NN NN O
autoimmune NN NN O
pathogenesis NN NN O
of NN NN O
the NN NN O
bile NN NN B-Disease
duct NN NN I-Disease
destruction NN NN I-Disease
is NN NN O
suggested NN NN O
. NN NN O
   
Differential NN NN O
effects NN NN O
of NN NN O
1 NN NN O
, NN NN O
4 NN NN O
- NN NN O
dihydropyridine NN NN O
calcium NN NN O
channel NN NN O
blockers NN NN O
: NN NN O
therapeutic NN NN O
implications NN NN O
. NN NN O
   
Increasing NN NN O
recognition NN NN O
of NN NN O
the NN NN O
importance NN NN O
of NN NN O
calcium NN NN O
in NN NN O
the NN NN O
pathogenesis NN NN O
of NN NN O
cardiovascular NN NN B-Disease
disease NN NN I-Disease
has NN NN O
stimulated NN NN O
research NN NN O
into NN NN O
the NN NN O
use NN NN O
of NN NN O
calcium NN NN O
channel NN NN O
blocking NN NN O
agents NN NN O
for NN NN O
treatment NN NN O
of NN NN O
a NN NN O
variety NN NN O
of NN NN O
cardiovascular NN NN B-Disease
diseases NN NN I-Disease
. NN NN O
   
The NN NN O
favorable NN NN O
efficacy NN NN O
and NN NN O
tolerability NN NN O
profiles NN NN O
of NN NN O
these NN NN O
agents NN NN O
make NN NN O
them NN NN O
attractive NN NN O
therapeutic NN NN O
modalities NN NN O
. NN NN O
   
Clinical NN NN O
applications NN NN O
of NN NN O
calcium NN NN O
channel NN NN O
blockers NN NN O
parallel NN NN O
their NN NN O
tissue NN NN O
selectivity NN NN O
. NN NN O
   
In NN NN O
contrast NN NN O
to NN NN O
verapamil NN NN O
and NN NN O
diltiazem NN NN O
, NN NN O
which NN NN O
are NN NN O
roughly NN NN O
equipotent NN NN O
in NN NN O
their NN NN O
actions NN NN O
on NN NN O
the NN NN O
heart NN NN O
and NN NN O
vascular NN NN O
smooth NN NN O
muscle NN NN O
, NN NN O
the NN NN O
dihydropyridine NN NN O
calcium NN NN O
channel NN NN O
blockers NN NN O
are NN NN O
a NN NN O
group NN NN O
of NN NN O
potent NN NN O
peripheral NN NN O
vasodilator NN NN O
agents NN NN O
that NN NN O
exert NN NN O
minimal NN NN O
electrophysiologic NN NN O
effects NN NN O
on NN NN O
cardiac NN NN O
nodal NN NN O
or NN NN O
conduction NN NN O
tissue NN NN O
. NN NN O
   
As NN NN O
the NN NN O
first NN NN O
dihydropyridine NN NN O
available NN NN O
for NN NN O
use NN NN O
in NN NN O
the NN NN O
United NN NN O
States NN NN O
, NN NN O
nifedipine NN NN O
controls NN NN O
angina NN NN B-Disease
and NN NN O
hypertension NN NN B-Disease
with NN NN O
minimal NN NN O
depression NN NN O
of NN NN O
cardiac NN NN O
function NN NN O
. NN NN O
   
Additional NN NN O
members NN NN O
of NN NN O
this NN NN O
group NN NN O
of NN NN O
calcium NN NN O
channel NN NN O
blockers NN NN O
have NN NN O
been NN NN O
studied NN NN O
for NN NN O
a NN NN O
variety NN NN O
of NN NN O
indications NN NN O
for NN NN O
which NN NN O
they NN NN O
may NN NN O
offer NN NN O
advantages NN NN O
over NN NN O
current NN NN O
therapy NN NN O
. NN NN O
   
Once NN NN O
or NN NN O
twice NN NN O
daily NN NN O
dosage NN NN O
possible NN NN O
with NN NN O
nitrendipine NN NN O
and NN NN O
nisoldipine NN NN O
offers NN NN O
a NN NN O
convenient NN NN O
administration NN NN O
schedule NN NN O
, NN NN O
which NN NN O
encourages NN NN O
patient NN NN O
compliance NN NN O
in NN NN O
long NN NN O
- NN NN O
term NN NN O
therapy NN NN O
of NN NN O
hypertension NN NN B-Disease
. NN NN O
   
The NN NN O
coronary NN NN O
vasodilating NN NN O
properties NN NN O
of NN NN O
nisoldipine NN NN O
have NN NN O
led NN NN O
to NN NN O
the NN NN O
investigation NN NN O
of NN NN O
this NN NN O
agent NN NN O
for NN NN O
use NN NN O
in NN NN O
angina NN NN B-Disease
. NN NN O
   
Selectivity NN NN O
for NN NN O
the NN NN O
cerebrovascular NN NN O
bed NN NN O
makes NN NN O
nimodipine NN NN O
potentially NN NN O
useful NN NN O
in NN NN O
the NN NN O
treatment NN NN O
of NN NN O
subarachnoid NN NN B-Disease
hemorrhage NN NN I-Disease
, NN NN O
migraine NN NN B-Disease
headache NN NN I-Disease
, NN NN O
dementia NN NN B-Disease
, NN NN O
and NN NN O
stroke NN NN B-Disease
. NN NN O
   
In NN NN O
general NN NN O
, NN NN O
the NN NN O
dihydropyridine NN NN O
calcium NN NN O
channel NN NN O
blockers NN NN O
are NN NN O
usually NN NN O
well NN NN O
tolerated NN NN O
, NN NN O
with NN NN O
headache NN NN B-Disease
, NN NN O
facial NN NN O
flushing NN NN B-Disease
, NN NN O
palpitations NN NN B-Disease
, NN NN O
edema NN NN B-Disease
, NN NN O
nausea NN NN B-Disease
, NN NN O
anorexia NN NN B-Disease
, NN NN O
and NN NN O
dizziness NN NN B-Disease
being NN NN O
the NN NN O
more NN NN O
common NN NN O
adverse NN NN O
effects NN NN O
. NN NN O
   
The NN NN O
enhancement NN NN O
of NN NN O
aminonucleoside NN NN O
nephrosis NN NN B-Disease
by NN NN O
the NN NN O
co NN NN O
- NN NN O
administration NN NN O
of NN NN O
protamine NN NN O
. NN NN O
   
An NN NN O
experimental NN NN O
model NN NN O
of NN NN O
focal NN NN B-Disease
segmental NN NN I-Disease
glomerular NN NN I-Disease
sclerosis NN NN I-Disease
( NN NN O
FSGS NN NN B-Disease
) NN NN O
was NN NN O
developed NN NN O
in NN NN O
rats NN NN O
by NN NN O
the NN NN O
combined NN NN O
administration NN NN O
of NN NN O
puromycin NN NN O
- NN NN O
aminonucleoside NN NN O
( NN NN O
AMNS NN NN O
) NN NN O
and NN NN O
protamine NN NN O
sulfate NN NN O
( NN NN O
PS NN NN O
) NN NN O
. NN NN O
   
Male NN NN O
Sprague NN NN O
- NN NN O
Dawley NN NN O
rats NN NN O
, NN NN O
uninephrectomized NN NN O
three NN NN O
weeks NN NN O
before NN NN O
, NN NN O
received NN NN O
daily NN NN O
injections NN NN O
of NN NN O
subcutaneous NN NN O
AMNS NN NN O
( NN NN O
1 NN NN O
mg NN NN O
/ NN NN O
100 NN NN O
g NN NN O
body NN NN O
wt NN NN O
) NN NN O
and NN NN O
intravenous NN NN O
PS NN NN O
( NN NN O
2 NN NN O
separated NN NN O
doses NN NN O
of NN NN O
2 NN NN O
. NN NN O
5 NN NN O
mg NN NN O
/ NN NN O
100 NN NN O
g NN NN O
body NN NN O
wt NN NN O
) NN NN O
for NN NN O
four NN NN O
days NN NN O
. NN NN O
   
The NN NN O
series NN NN O
of NN NN O
injections NN NN O
were NN NN O
repeated NN NN O
another NN NN O
three NN NN O
times NN NN O
at NN NN O
10 NN NN O
day NN NN O
intervals NN NN O
. NN NN O
   
The NN NN O
animals NN NN O
were NN NN O
sacrificed NN NN O
on NN NN O
days NN NN O
24 NN NN O
, NN NN O
52 NN NN O
, NN NN O
and NN NN O
80 NN NN O
. NN NN O
   
They NN NN O
developed NN NN O
nephrotic NN NN B-Disease
syndrome NN NN I-Disease
and NN NN O
finally NN NN O
renal NN NN B-Disease
failure NN NN I-Disease
. NN NN O
   
The NN NN O
time NN NN O
- NN NN O
course NN NN O
curve NN NN O
of NN NN O
creatinine NN NN O
clearance NN NN O
dropped NN NN O
and NN NN O
showed NN NN O
significant NN NN O
difference NN NN O
( NN NN O
P NN NN O
less NN NN O
than NN NN O
0 NN NN O
. NN NN O
01 NN NN O
) NN NN O
from NN NN O
that NN NN O
of NN NN O
each NN NN O
control NN NN O
group NN NN O
, NN NN O
such NN NN O
as NN NN O
, NN NN O
AMNS NN NN O
alone NN NN O
, NN NN O
PS NN NN O
alone NN NN O
or NN NN O
saline NN NN O
injected NN NN O
. NN NN O
   
Their NN NN O
glomeruli NN NN O
showed NN NN O
changes NN NN O
of NN NN O
progressive NN NN O
FSGS NN NN B-Disease
. NN NN O
   
The NN NN O
ultrastructural NN NN O
studies NN NN O
in NN NN O
the NN NN O
initial NN NN O
stage NN NN O
revealed NN NN O
significant NN NN O
lack NN NN O
of NN NN O
particles NN NN O
of NN NN O
perfused NN NN O
ruthenium NN NN O
red NN NN O
on NN NN O
the NN NN O
lamina NN NN O
rara NN NN O
externa NN NN O
and NN NN O
marked NN NN O
changes NN NN O
in NN NN O
epithelial NN NN O
cell NN NN O
cytoplasm NN NN O
. NN NN O
   
Therefore NN NN O
, NN NN O
it NN NN O
is NN NN O
suggested NN NN O
that NN NN O
the NN NN O
administration NN NN O
of NN NN O
PS NN NN O
enhances NN NN O
the NN NN O
toxicity NN NN B-Disease
of NN NN O
AMNS NN NN O
on NN NN O
the NN NN O
glomerulus NN NN O
and NN NN O
readily NN NN O
produces NN NN O
progressive NN NN O
FSGS NN NN B-Disease
in NN NN O
rats NN NN O
resulting NN NN O
in NN NN O
the NN NN O
end NN NN B-Disease
- NN NN I-Disease
stage NN NN I-Disease
renal NN NN I-Disease
disease NN NN I-Disease
. NN NN O
   
Theophylline NN NN O
neurotoxicity NN NN B-Disease
in NN NN O
pregnant NN NN O
rats NN NN O
. NN NN O
   
The NN NN O
purpose NN NN O
of NN NN O
this NN NN O
investigation NN NN O
was NN NN O
to NN NN O
determine NN NN O
whether NN NN O
the NN NN O
neurotoxicity NN NN B-Disease
of NN NN O
theophylline NN NN O
is NN NN O
altered NN NN O
in NN NN O
advanced NN NN O
pregnancy NN NN O
. NN NN O
   
Sprague NN NN O
- NN NN O
Dawley NN NN O
rats NN NN O
that NN NN O
were NN NN O
20 NN NN O
days NN NN O
pregnant NN NN O
and NN NN O
nonpregnant NN NN O
rats NN NN O
of NN NN O
the NN NN O
same NN NN O
age NN NN O
and NN NN O
strain NN NN O
received NN NN O
infusions NN NN O
of NN NN O
aminophylline NN NN O
until NN NN O
onset NN NN O
of NN NN O
maximal NN NN O
seizures NN NN B-Disease
which NN NN O
occurred NN NN O
after NN NN O
28 NN NN O
and NN NN O
30 NN NN O
minutes NN NN O
respectively NN NN O
. NN NN O
   
Theophylline NN NN O
concentrations NN NN O
at NN NN O
this NN NN O
endpoint NN NN O
in NN NN O
serum NN NN O
( NN NN O
total NN NN O
) NN NN O
and NN NN O
CSF NN NN O
were NN NN O
similar NN NN O
but NN NN O
serum NN NN O
( NN NN O
free NN NN O
) NN NN O
and NN NN O
brain NN NN O
concentrations NN NN O
were NN NN O
slightly NN NN O
different NN NN O
in NN NN O
pregnant NN NN O
rats NN NN O
. NN NN O
   
Theophylline NN NN O
serum NN NN O
protein NN NN O
binding NN NN O
determined NN NN O
by NN NN O
equilibrium NN NN O
dialysis NN NN O
was NN NN O
lower NN NN O
in NN NN O
pregnant NN NN O
rats NN NN O
. NN NN O
   
Fetal NN NN O
serum NN NN O
concentrations NN NN O
at NN NN O
onset NN NN O
of NN NN O
seizures NN NN B-Disease
in NN NN O
the NN NN O
mother NN NN O
were NN NN O
similar NN NN O
to NN NN O
maternal NN NN O
brain NN NN O
and NN NN O
CSF NN NN O
concentrations NN NN O
and NN NN O
correlated NN NN O
significantly NN NN O
with NN NN O
the NN NN O
former NN NN O
. NN NN O
   
It NN NN O
is NN NN O
concluded NN NN O
that NN NN O
advanced NN NN O
pregnancy NN NN O
has NN NN O
a NN NN O
negligible NN NN O
effect NN NN O
on NN NN O
the NN NN O
neurotoxic NN NN B-Disease
response NN NN O
to NN NN O
theophylline NN NN O
in NN NN O
rats NN NN O
. NN NN O
   
Hyperkalemia NN NN B-Disease
induced NN NN O
by NN NN O
indomethacin NN NN O
and NN NN O
naproxen NN NN O
and NN NN O
reversed NN NN O
by NN NN O
fludrocortisone NN NN O
. NN NN O
   
We NN NN O
have NN NN O
described NN NN O
a NN NN O
patient NN NN O
with NN NN O
severe NN NN O
rheumatoid NN NN B-Disease
arthritis NN NN I-Disease
and NN NN O
a NN NN O
history NN NN O
of NN NN O
mefenamic NN NN O
acid NN NN O
nephropathy NN NN B-Disease
in NN NN O
whom NN NN O
hyperkalemia NN NN B-Disease
and NN NN O
inappropriate NN NN O
hypoaldosteronism NN NN B-Disease
were NN NN O
caused NN NN O
by NN NN O
both NN NN O
indomethacin NN NN O
and NN NN O
naproxen NN NN O
, NN NN O
without NN NN O
major NN NN O
decline NN NN O
in NN NN O
renal NN NN O
function NN NN O
. NN NN O
   
It NN NN O
is NN NN O
likely NN NN O
that NN NN O
preexisting NN NN O
renal NN NN B-Disease
disease NN NN I-Disease
predisposed NN NN O
this NN NN O
patient NN NN O
to NN NN O
type NN NN B-Disease
IV NN NN I-Disease
renal NN NN I-Disease
tubular NN NN I-Disease
acidosis NN NN I-Disease
with NN NN O
prostaglandin NN NN O
synthetase NN NN O
inhibitors NN NN O
. NN NN O
   
Because NN NN O
he NN NN O
was NN NN O
unable NN NN O
to NN NN O
discontinue NN NN O
nonsteroidal NN NN O
anti NN NN O
- NN NN O
inflammatory NN NN O
drug NN NN O
therapy NN NN O
, NN NN O
fludrocortisone NN NN O
was NN NN O
added NN NN O
, NN NN O
correcting NN NN O
the NN NN O
hyperkalemia NN NN B-Disease
and NN NN O
allowing NN NN O
indomethacin NN NN O
therapy NN NN O
to NN NN O
be NN NN O
continued NN NN O
safely NN NN O
. NN NN O
   
Hypotension NN NN B-Disease
as NN NN O
a NN NN O
manifestation NN NN O
of NN NN O
cardiotoxicity NN NN B-Disease
in NN NN O
three NN NN O
patients NN NN O
receiving NN NN O
cisplatin NN NN O
and NN NN O
5 NN NN O
- NN NN O
fluorouracil NN NN O
. NN NN O
   
Cardiac NN NN O
symptoms NN NN O
, NN NN O
including NN NN O
hypotension NN NN B-Disease
, NN NN O
developed NN NN O
in NN NN O
three NN NN O
patients NN NN O
with NN NN O
advanced NN NN O
colorectal NN NN B-Disease
carcinoma NN NN I-Disease
while NN NN O
being NN NN O
treated NN NN O
with NN NN O
cisplatin NN NN O
( NN NN O
CDDP NN NN O
) NN NN O
and NN NN O
5 NN NN O
- NN NN O
fluorouracil NN NN O
( NN NN O
5 NN NN O
- NN NN O
FU NN NN O
) NN NN O
. NN NN O
   
In NN NN O
two NN NN O
patients NN NN O
, NN NN O
hypotension NN NN B-Disease
was NN NN O
associated NN NN O
with NN NN O
severe NN NN O
left NN NN B-Disease
ventricular NN NN I-Disease
dysfunction NN NN I-Disease
. NN NN O
   
All NN NN O
three NN NN O
patients NN NN O
required NN NN O
therapy NN NN O
discontinuation NN NN O
. NN NN O
   
Cardiac NN NN O
enzymes NN NN O
remained NN NN O
normal NN NN O
despite NN NN O
transient NN NN O
electrocardiographic NN NN O
( NN NN O
EKG NN NN O
) NN NN O
changes NN NN O
. NN NN O
   
The NN NN O
presentation NN NN O
and NN NN O
cardiac NN NN O
evaluation NN NN O
( NN NN O
hemodynamic NN NN O
, NN NN O
echocardiographic NN NN O
, NN NN O
and NN NN O
scintigraphic NN NN O
) NN NN O
of NN NN O
these NN NN O
patients NN NN O
suggest NN NN O
new NN NN O
manifestations NN NN O
of NN NN O
5 NN NN O
- NN NN O
FU NN NN O
cardiotoxicity NN NN B-Disease
that NN NN O
may NN NN O
be NN NN O
influenced NN NN O
by NN NN O
CDDP NN NN O
. NN NN O
   
The NN NN O
possible NN NN O
pathophysiologic NN NN O
mechanisms NN NN O
are NN NN O
discussed NN NN O
. NN NN O
   
Fatal NN NN O
aplastic NN NN B-Disease
anemia NN NN I-Disease
in NN NN O
a NN NN O
patient NN NN O
treated NN NN O
with NN NN O
carbamazepine NN NN O
. NN NN O
   
A NN NN O
case NN NN O
of NN NN O
fatal NN NN O
aplastic NN NN B-Disease
anemia NN NN I-Disease
due NN NN O
to NN NN O
carbamazepine NN NN O
treatment NN NN O
in NN NN O
an NN NN O
epileptic NN NN B-Disease
woman NN NN O
is NN NN O
reported NN NN O
. NN NN O
   
Despite NN NN O
concerns NN NN O
of NN NN O
fatal NN NN O
bone NN NN B-Disease
marrow NN NN I-Disease
toxicity NN NN I-Disease
due NN NN O
to NN NN O
carbamazepine NN NN O
, NN NN O
this NN NN O
is NN NN O
only NN NN O
the NN NN O
fourth NN NN O
documented NN NN O
and NN NN O
published NN NN O
report NN NN O
. NN NN O
   
Carbamazepine NN NN O
is NN NN O
a NN NN O
safe NN NN O
drug NN NN O
, NN NN O
but NN NN O
physicians NN NN O
and NN NN O
patients NN NN O
should NN NN O
be NN NN O
aware NN NN O
of NN NN O
the NN NN O
exceedingly NN NN O
rare NN NN O
but NN NN O
potentially NN NN O
fatal NN NN O
side NN NN O
effects NN NN O
, NN NN O
better NN NN O
prevented NN NN O
by NN NN O
clinical NN NN O
than NN NN O
by NN NN O
laboratory NN NN O
monitoring NN NN O
. NN NN O
   
Participation NN NN O
of NN NN O
a NN NN O
bulbospinal NN NN O
serotonergic NN NN O
pathway NN NN O
in NN NN O
the NN NN O
rat NN NN O
brain NN NN O
in NN NN O
clonidine NN NN O
- NN NN O
induced NN NN O
hypotension NN NN B-Disease
and NN NN O
bradycardia NN NN B-Disease
. NN NN O
   
The NN NN O
effects NN NN O
of NN NN O
microinjection NN NN O
of NN NN O
clonidine NN NN O
( NN NN O
1 NN NN O
- NN NN O
10 NN NN O
micrograms NN NN O
in NN NN O
1 NN NN O
microliter NN NN O
) NN NN O
into NN NN O
a NN NN O
region NN NN O
adjacent NN NN O
to NN NN O
the NN NN O
ventrolateral NN NN O
surface NN NN O
of NN NN O
the NN NN O
medulla NN NN O
oblongata NN NN O
on NN NN O
cardiovascular NN NN O
function NN NN O
were NN NN O
assessed NN NN O
in NN NN O
urethane NN NN O
- NN NN O
anesthetized NN NN O
rats NN NN O
. NN NN O
   
Intramedullary NN NN O
administration NN NN O
of NN NN O
clonidine NN NN O
, NN NN O
but NN NN O
not NN NN O
saline NN NN O
vehicle NN NN O
, NN NN O
caused NN NN O
a NN NN O
dose NN NN O
- NN NN O
dependent NN NN O
decrease NN NN O
in NN NN O
both NN NN O
the NN NN O
mean NN NN O
arterial NN NN O
pressure NN NN O
and NN NN O
the NN NN O
heart NN NN O
rate NN NN O
. NN NN O
   
The NN NN O
clonidine NN NN O
- NN NN O
induced NN NN O
hypotension NN NN B-Disease
was NN NN O
antagonized NN NN O
by NN NN O
prior NN NN O
spinal NN NN O
transection NN NN O
, NN NN O
but NN NN O
not NN NN O
bilateral NN NN O
vagotomy NN NN O
. NN NN O
   
On NN NN O
the NN NN O
other NN NN O
hand NN NN O
, NN NN O
the NN NN O
clonidine NN NN O
- NN NN O
induced NN NN O
bradycardia NN NN B-Disease
was NN NN O
antagonized NN NN O
by NN NN O
prior NN NN O
bilateral NN NN O
vagotomy NN NN O
, NN NN O
but NN NN O
not NN NN O
spinal NN NN O
transection NN NN O
. NN NN O
   
Furthermore NN NN O
, NN NN O
selective NN NN O
destruction NN NN O
of NN NN O
the NN NN O
spinal NN NN O
5 NN NN O
- NN NN O
HT NN NN O
nerves NN NN O
, NN NN O
produced NN NN O
by NN NN O
bilateral NN NN O
spinal NN NN O
injection NN NN O
of NN NN O
5 NN NN O
, NN NN O
7 NN NN O
- NN NN O
dihydroxytryptamine NN NN O
, NN NN O
reduced NN NN O
the NN NN O
magnitude NN NN O
of NN NN O
the NN NN O
vasodepressor NN NN O
or NN NN O
the NN NN O
bradycardiac NN NN B-Disease
responses NN NN O
to NN NN O
clonidine NN NN O
microinjected NN NN O
into NN NN O
the NN NN O
area NN NN O
near NN NN O
the NN NN O
ventrolateral NN NN O
surface NN NN O
of NN NN O
the NN NN O
medulla NN NN O
oblongata NN NN O
in NN NN O
rats NN NN O
. NN NN O
   
The NN NN O
data NN NN O
indicate NN NN O
that NN NN O
a NN NN O
bulbospinal NN NN O
serotonergic NN NN O
pathway NN NN O
is NN NN O
involved NN NN O
in NN NN O
development NN NN O
of NN NN O
clonidine NN NN O
- NN NN O
induced NN NN O
hypotension NN NN B-Disease
and NN NN O
bradycardia NN NN B-Disease
. NN NN O
   
The NN NN O
induced NN NN O
hypotension NN NN B-Disease
is NN NN O
brought NN NN O
about NN NN O
by NN NN O
a NN NN O
decrease NN NN O
in NN NN O
sympathetic NN NN O
efferent NN NN O
activity NN NN O
, NN NN O
whereas NN NN O
the NN NN O
induced NN NN O
bradycardia NN NN B-Disease
was NN NN O
due NN NN O
to NN NN O
an NN NN O
increase NN NN O
in NN NN O
vagal NN NN O
efferent NN NN O
activity NN NN O
. NN NN O
   
Hypertension NN NN B-Disease
in NN NN O
neuroblastoma NN NN B-Disease
induced NN NN O
by NN NN O
imipramine NN NN O
. NN NN O
   
Hypertension NN NN B-Disease
is NN NN O
a NN NN O
well NN NN O
- NN NN O
known NN NN O
finding NN NN O
in NN NN O
some NN NN O
patients NN NN O
with NN NN O
neuroblastoma NN NN B-Disease
. NN NN O
   
However NN NN O
, NN NN O
it NN NN O
has NN NN O
not NN NN O
previously NN NN O
been NN NN O
described NN NN O
in NN NN O
association NN NN O
with NN NN O
the NN NN O
use NN NN O
of NN NN O
Imipramine NN NN O
. NN NN O
   
We NN NN O
report NN NN O
the NN NN O
occurrence NN NN O
of NN NN O
severe NN NN O
hypertension NN NN B-Disease
( NN NN O
blood NN NN O
pressure NN NN O
190 NN NN O
/ NN NN O
160 NN NN O
) NN NN O
in NN NN O
a NN NN O
4 NN NN O
- NN NN O
year NN NN O
- NN NN O
old NN NN O
girl NN NN O
with NN NN O
neuroblastoma NN NN B-Disease
who NN NN O
was NN NN O
given NN NN O
Imipramine NN NN O
to NN NN O
control NN NN O
a NN NN O
behavior NN NN B-Disease
disorder NN NN I-Disease
. NN NN O
   
It NN NN O
was NN NN O
determined NN NN O
later NN NN O
that NN NN O
this NN NN O
patient NN NN O
' NN NN O
s NN NN O
tumor NN NN B-Disease
was NN NN O
recurring NN NN O
at NN NN O
the NN NN O
time NN NN O
of NN NN O
her NN NN O
hypertensive NN NN B-Disease
episode NN NN O
. NN NN O
   
Since NN NN O
she NN NN O
had NN NN O
no NN NN O
blood NN NN O
pressure NN NN O
elevation NN NN O
at NN NN O
initial NN NN O
diagnosis NN NN O
and NN NN O
none NN NN O
following NN NN O
discontinuation NN NN O
of NN NN O
the NN NN O
Imipramine NN NN O
( NN NN O
when NN NN O
she NN NN O
was NN NN O
in NN NN O
florid NN NN O
relapse NN NN O
) NN NN O
, NN NN O
we NN NN O
believe NN NN O
that NN NN O
this NN NN O
drug NN NN O
rather NN NN O
than NN NN O
her NN NN O
underlying NN NN O
disease NN NN O
alone NN NN O
caused NN NN O
her NN NN O
hypertension NN NN B-Disease
. NN NN O
   
The NN NN O
mechanism NN NN O
for NN NN O
this NN NN O
reaction NN NN O
is NN NN O
believed NN NN O
to NN NN O
be NN NN O
increased NN NN O
levels NN NN O
of NN NN O
vasoactive NN NN O
catecholamines NN NN O
due NN NN O
to NN NN O
interference NN NN O
of NN NN O
their NN NN O
physiologic NN NN O
inactivation NN NN O
by NN NN O
Imipramine NN NN O
. NN NN O
   
From NN NN O
this NN NN O
experience NN NN O
, NN NN O
we NN NN O
urge NN NN O
extreme NN NN O
caution NN NN O
in NN NN O
the NN NN O
use NN NN O
of NN NN O
tricyclic NN NN O
antidepressants NN NN O
in NN NN O
children NN NN O
with NN NN O
active NN NN O
neuroblastoma NN NN B-Disease
. NN NN O
   
Rechallenge NN NN O
of NN NN O
patients NN NN O
who NN NN O
developed NN NN O
oral NN NN B-Disease
candidiasis NN NN I-Disease
or NN NN O
hoarseness NN NN B-Disease
with NN NN O
beclomethasone NN NN O
dipropionate NN NN O
. NN NN O
   
Of NN NN O
158 NN NN O
asthmatic NN NN B-Disease
patients NN NN O
who NN NN O
were NN NN O
placed NN NN O
on NN NN O
inhaled NN NN O
beclomethasone NN NN O
, NN NN O
15 NN NN O
( NN NN O
9 NN NN O
. NN NN O
5 NN NN O
% NN NN O
) NN NN O
developed NN NN O
either NN NN O
hoarseness NN NN B-Disease
( NN NN O
8 NN NN O
) NN NN O
, NN NN O
oral NN NN O
thrush NN NN B-Disease
( NN NN O
6 NN NN O
) NN NN O
, NN NN O
or NN NN O
both NN NN O
( NN NN O
1 NN NN O
) NN NN O
. NN NN O
   
When NN NN O
their NN NN O
adverse NN NN O
reactions NN NN O
subsided NN NN O
, NN NN O
seven NN NN O
of NN NN O
these NN NN O
15 NN NN O
patients NN NN O
were NN NN O
rechallenged NN NN O
with NN NN O
inhaled NN NN O
beclomethasone NN NN O
. NN NN O
   
These NN NN O
included NN NN O
five NN NN O
cases NN NN O
who NN NN O
developed NN NN O
hoarseness NN NN B-Disease
and NN NN O
three NN NN O
who NN NN O
developed NN NN O
Candidiasis NN NN B-Disease
. NN NN O
   
One NN NN O
patient NN NN O
had NN NN O
both NN NN O
. NN NN O
   
Oral NN NN O
thrush NN NN B-Disease
did NN NN O
not NN NN O
recur NN NN O
, NN NN O
but NN NN O
60 NN NN O
% NN NN O
( NN NN O
3 NN NN O
/ NN NN O
5 NN NN O
) NN NN O
of NN NN O
patients NN NN O
with NN NN O
hoarseness NN NN B-Disease
had NN NN O
recurrence NN NN O
. NN NN O
   
We NN NN O
conclude NN NN O
that NN NN O
patients NN NN O
may NN NN O
be NN NN O
restarted NN NN O
on NN NN O
inhaled NN NN O
beclomethasone NN NN O
when NN NN O
clinically NN NN O
indicated NN NN O
; NN NN O
however NN NN O
, NN NN O
because NN NN O
of NN NN O
the NN NN O
high NN NN O
recurrence NN NN O
rate NN NN O
, NN NN O
patients NN NN O
who NN NN O
develop NN NN O
hoarseness NN NN B-Disease
should NN NN O
not NN NN O
be NN NN O
re NN NN O
- NN NN O
challenged NN NN O
. NN NN O
   
Concomitant NN NN O
use NN NN O
of NN NN O
oral NN NN O
prednisone NN NN O
and NN NN O
topical NN NN O
beclomethasone NN NN O
may NN NN O
increase NN NN O
the NN NN O
risk NN NN O
of NN NN O
developing NN NN O
hoarseness NN NN B-Disease
or NN NN O
candidiasis NN NN B-Disease
. NN NN O
   
Cyclophosphamide NN NN O
cardiotoxicity NN NN B-Disease
: NN NN O
an NN NN O
analysis NN NN O
of NN NN O
dosing NN NN O
as NN NN O
a NN NN O
risk NN NN O
factor NN NN O
. NN NN O
   
Patients NN NN O
who NN NN O
undergo NN NN O
bone NN NN O
marrow NN NN O
transplantation NN NN O
are NN NN O
generally NN NN O
immunosuppressed NN NN O
with NN NN O
a NN NN O
dose NN NN O
of NN NN O
cyclophosphamide NN NN O
( NN NN O
CYA NN NN O
) NN NN O
which NN NN O
is NN NN O
usually NN NN O
calculated NN NN O
based NN NN O
on NN NN O
the NN NN O
patient NN NN O
' NN NN O
s NN NN O
weight NN NN O
. NN NN O
   
At NN NN O
these NN NN O
high NN NN O
doses NN NN O
of NN NN O
CYA NN NN O
, NN NN O
serious NN NN O
cardiotoxicity NN NN B-Disease
may NN NN O
occur NN NN O
, NN NN O
but NN NN O
definitive NN NN O
risk NN NN O
factors NN NN O
for NN NN O
the NN NN O
development NN NN O
of NN NN O
such NN NN O
cardiotoxicity NN NN B-Disease
have NN NN O
not NN NN O
been NN NN O
described NN NN O
. NN NN O
   
Since NN NN O
chemotherapeutic NN NN O
agent NN NN O
toxicity NN NN B-Disease
generally NN NN O
correlates NN NN O
with NN NN O
dose NN NN O
per NN NN O
body NN NN O
surface NN NN O
area NN NN O
, NN NN O
we NN NN O
retrospectively NN NN O
calculated NN NN O
the NN NN O
dose NN NN O
of NN NN O
CYA NN NN O
in NN NN O
patients NN NN O
transplanted NN NN O
at NN NN O
our NN NN O
institution NN NN O
to NN NN O
determine NN NN O
whether NN NN O
the NN NN O
incidence NN NN O
of NN NN O
CYA NN NN O
cardiotoxicity NN NN B-Disease
correlated NN NN O
with NN NN O
the NN NN O
dose NN NN O
per NN NN O
body NN NN O
surface NN NN O
area NN NN O
. NN NN O
   
Eighty NN NN O
patients NN NN O
who NN NN O
were NN NN O
to NN NN O
receive NN NN O
CYA NN NN O
50 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
/ NN NN O
d NN NN O
for NN NN O
four NN NN O
days NN NN O
as NN NN O
preparation NN NN O
for NN NN O
marrow NN NN O
grafting NN NN O
underwent NN NN O
a NN NN O
total NN NN O
of NN NN O
84 NN NN O
transplants NN NN O
for NN NN O
aplastic NN NN B-Disease
anemia NN NN I-Disease
, NN NN O
Wiskott NN NN B-Disease
- NN NN I-Disease
Aldrich NN NN I-Disease
syndrome NN NN I-Disease
, NN NN O
or NN NN O
severe NN NN B-Disease
combined NN NN I-Disease
immunodeficiency NN NN I-Disease
syndrome NN NN I-Disease
. NN NN O
   
Fourteen NN NN O
of NN NN O
84 NN NN O
( NN NN O
17 NN NN O
% NN NN O
) NN NN O
patients NN NN O
had NN NN O
symptoms NN NN O
and NN NN O
signs NN NN O
consistent NN NN O
with NN NN O
CYA NN NN O
cardiotoxicity NN NN B-Disease
within NN NN O
ten NN NN O
days NN NN O
of NN NN O
receiving NN NN O
1 NN NN O
to NN NN O
4 NN NN O
doses NN NN O
of NN NN O
CYA NN NN O
. NN NN O
   
Six NN NN O
of NN NN O
the NN NN O
14 NN NN O
patients NN NN O
died NN NN O
with NN NN O
congestive NN NN B-Disease
heart NN NN I-Disease
failure NN NN I-Disease
. NN NN O
   
The NN NN O
dose NN NN O
of NN NN O
CYA NN NN O
per NN NN O
body NN NN O
surface NN NN O
area NN NN O
was NN NN O
calculated NN NN O
for NN NN O
all NN NN O
patients NN NN O
and NN NN O
the NN NN O
patients NN NN O
were NN NN O
divided NN NN O
into NN NN O
two NN NN O
groups NN NN O
based NN NN O
on NN NN O
daily NN NN O
CYA NN NN O
dose NN NN O
: NN NN O
Group NN NN O
1 NN NN O
, NN NN O
CYA NN NN O
less NN NN O
than NN NN O
or NN NN O
equal NN NN O
to NN NN O
1 NN NN O
. NN NN O
55 NN NN O
g NN NN O
/ NN NN O
m2 NN NN O
/ NN NN O
d NN NN O
; NN NN O
Group NN NN O
2 NN NN O
, NN NN O
CYA NN NN O
greater NN NN O
than NN NN O
1 NN NN O
. NN NN O
55 NN NN O
g NN NN O
/ NN NN O
m2 NN NN O
/ NN NN O
d NN NN O
. NN NN O
   
Cardiotoxicity NN NN B-Disease
that NN NN O
was NN NN O
thought NN NN O
to NN NN O
be NN NN O
related NN NN O
to NN NN O
CYA NN NN O
occurred NN NN O
in NN NN O
1 NN NN O
/ NN NN O
32 NN NN O
( NN NN O
3 NN NN O
% NN NN O
) NN NN O
of NN NN O
patients NN NN O
in NN NN O
Group NN NN O
1 NN NN O
and NN NN O
in NN NN O
13 NN NN O
/ NN NN O
52 NN NN O
( NN NN O
25 NN NN O
% NN NN O
) NN NN O
patients NN NN O
in NN NN O
Group NN NN O
2 NN NN O
( NN NN O
P NN NN O
less NN NN O
than NN NN O
0 NN NN O
. NN NN O
025 NN NN O
) NN NN O
. NN NN O
   
Congestive NN NN B-Disease
heart NN NN I-Disease
failure NN NN I-Disease
caused NN NN O
or NN NN O
contributed NN NN O
to NN NN O
death NN NN O
in NN NN O
0 NN NN O
/ NN NN O
32 NN NN O
patients NN NN O
in NN NN O
Group NN NN O
1 NN NN O
v NN NN O
6 NN NN O
/ NN NN O
52 NN NN O
( NN NN O
12 NN NN O
% NN NN O
) NN NN O
of NN NN O
patients NN NN O
in NN NN O
Group NN NN O
2 NN NN O
( NN NN O
P NN NN O
less NN NN O
than NN NN O
0 NN NN O
. NN NN O
25 NN NN O
) NN NN O
. NN NN O
   
There NN NN O
was NN NN O
no NN NN O
difference NN NN O
in NN NN O
the NN NN O
rate NN NN O
of NN NN O
engraftment NN NN O
of NN NN O
evaluable NN NN O
patients NN NN O
in NN NN O
the NN NN O
two NN NN O
groups NN NN O
( NN NN O
P NN NN O
greater NN NN O
than NN NN O
0 NN NN O
. NN NN O
5 NN NN O
) NN NN O
. NN NN O
   
We NN NN O
conclude NN NN O
that NN NN O
the NN NN O
CYA NN NN O
cardiotoxicity NN NN B-Disease
correlates NN NN O
with NN NN O
CYA NN NN O
dosage NN NN O
as NN NN O
calculated NN NN O
by NN NN O
body NN NN O
surface NN NN O
area NN NN O
, NN NN O
and NN NN O
that NN NN O
patients NN NN O
with NN NN O
aplastic NN NN B-Disease
anemia NN NN I-Disease
and NN NN O
immunodeficiencies NN NN B-Disease
can NN NN O
be NN NN O
effectively NN NN O
prepared NN NN O
for NN NN O
bone NN NN O
marrow NN NN O
grafting NN NN O
at NN NN O
a NN NN O
CYA NN NN O
dose NN NN O
of NN NN O
1 NN NN O
. NN NN O
55 NN NN O
g NN NN O
/ NN NN O
m2 NN NN O
/ NN NN O
d NN NN O
for NN NN O
four NN NN O
days NN NN O
with NN NN O
a NN NN O
lower NN NN O
incidence NN NN O
of NN NN O
cardiotoxicity NN NN B-Disease
than NN NN O
patients NN NN O
whose NN NN O
CYA NN NN O
dosage NN NN O
is NN NN O
calculated NN NN O
based NN NN O
on NN NN O
weight NN NN O
. NN NN O
   
This NN NN O
study NN NN O
reaffirms NN NN O
the NN NN O
principle NN NN O
that NN NN O
drug NN NN O
toxicity NN NN B-Disease
correlates NN NN O
with NN NN O
dose NN NN O
per NN NN O
body NN NN O
surface NN NN O
area NN NN O
. NN NN O
   
Studies NN NN O
of NN NN O
risk NN NN O
factors NN NN O
for NN NN O
aminoglycoside NN NN O
nephrotoxicity NN NN B-Disease
. NN NN O
   
The NN NN O
epidemiology NN NN O
of NN NN O
aminoglycoside NN NN O
- NN NN O
induced NN NN O
nephrotoxicity NN NN B-Disease
is NN NN O
not NN NN O
fully NN NN O
understood NN NN O
. NN NN O
   
Experimental NN NN O
studies NN NN O
in NN NN O
healthy NN NN O
human NN NN O
volunteers NN NN O
indicate NN NN O
aminoglycosides NN NN O
cause NN NN O
proximal NN NN O
tubular NN NN O
damage NN NN O
in NN NN O
most NN NN O
patients NN NN O
, NN NN O
but NN NN O
rarely NN NN O
, NN NN O
if NN NN O
ever NN NN O
, NN NN O
cause NN NN O
glomerular NN NN B-Disease
or NN NN I-Disease
tubular NN NN I-Disease
dysfunction NN NN I-Disease
. NN NN O
   
Clinical NN NN O
trials NN NN O
of NN NN O
aminoglycosides NN NN O
in NN NN O
seriously NN NN O
ill NN NN O
patients NN NN O
indicate NN NN O
that NN NN O
the NN NN O
relative NN NN O
risk NN NN O
for NN NN O
developing NN NN O
acute NN NN B-Disease
renal NN NN I-Disease
failure NN NN I-Disease
during NN NN O
therapy NN NN O
ranges NN NN O
from NN NN O
8 NN NN O
to NN NN O
10 NN NN O
and NN NN O
that NN NN O
the NN NN O
attributable NN NN O
risk NN NN O
is NN NN O
70 NN NN O
% NN NN O
to NN NN O
80 NN NN O
% NN NN O
. NN NN O
   
Further NN NN O
analysis NN NN O
of NN NN O
these NN NN O
data NN NN O
suggests NN NN O
that NN NN O
the NN NN O
duration NN NN O
of NN NN O
therapy NN NN O
, NN NN O
plasma NN NN O
aminoglycoside NN NN O
levels NN NN O
, NN NN O
liver NN NN B-Disease
disease NN NN I-Disease
, NN NN O
advanced NN NN O
age NN NN O
, NN NN O
high NN NN O
initial NN NN O
estimated NN NN O
creatinine NN NN O
clearance NN NN O
and NN NN O
, NN NN O
possibly NN NN O
, NN NN O
female NN NN O
gender NN NN O
all NN NN O
increase NN NN O
the NN NN O
risk NN NN O
for NN NN O
nephrotoxicity NN NN B-Disease
. NN NN O
   
Other NN NN O
causes NN NN O
of NN NN O
acute NN NN B-Disease
renal NN NN I-Disease
failure NN NN I-Disease
, NN NN O
such NN NN O
as NN NN O
shock NN NN B-Disease
, NN NN O
appear NN NN O
to NN NN O
have NN NN O
an NN NN O
additive NN NN O
effect NN NN O
. NN NN O
   
Predictive NN NN O
models NN NN O
have NN NN O
been NN NN O
developed NN NN O
from NN NN O
these NN NN O
analyses NN NN O
that NN NN O
should NN NN O
be NN NN O
useful NN NN O
for NN NN O
identifying NN NN O
patients NN NN O
at NN NN O
high NN NN O
risk NN NN O
. NN NN O
   
These NN NN O
models NN NN O
may NN NN O
also NN NN O
be NN NN O
useful NN NN O
in NN NN O
developing NN NN O
insights NN NN O
into NN NN O
the NN NN O
pathophysiology NN NN O
of NN NN O
aminoglycoside NN NN O
- NN NN O
induced NN NN O
nephrotoxicity NN NN B-Disease
. NN NN O
   
Central NN NN O
action NN NN O
of NN NN O
narcotic NN NN O
analgesics NN NN O
. NN NN O
   
Part NN NN O
IV NN NN O
. NN NN O
   
Noradrenergic NN NN O
influences NN NN O
on NN NN O
the NN NN O
activity NN NN O
of NN NN O
analgesics NN NN O
in NN NN O
rats NN NN O
. NN NN O
   
The NN NN O
effect NN NN O
of NN NN O
clonidine NN NN O
, NN NN O
naphazoline NN NN O
and NN NN O
xylometazoline NN NN O
on NN NN O
analgesia NN NN O
induced NN NN O
by NN NN O
morphine NN NN O
, NN NN O
codeine NN NN O
, NN NN O
fentanyl NN NN O
and NN NN O
pentazocine NN NN O
, NN NN O
and NN NN O
on NN NN O
cataleptic NN NN B-Disease
effect NN NN O
of NN NN O
morphine NN NN O
, NN NN O
codine NN NN O
and NN NN O
fentanyl NN NN O
was NN NN O
studied NN NN O
in NN NN O
rats NN NN O
. NN NN O
   
The NN NN O
biochemical NN NN O
assays NN NN O
on NN NN O
the NN NN O
influence NN NN O
of NN NN O
four NN NN O
analgesics NN NN O
on NN NN O
the NN NN O
brain NN NN O
concentration NN NN O
and NN NN O
turnover NN NN O
of NN NN O
noradrenaline NN NN O
( NN NN O
NA NN NN O
) NN NN O
were NN NN O
also NN NN O
performed NN NN O
. NN NN O
   
It NN NN O
was NN NN O
found NN NN O
that NN NN O
three NN NN O
drugs NN NN O
stimulating NN NN O
central NN NN O
NA NN NN O
receptors NN NN O
failed NN NN O
to NN NN O
affect NN NN O
the NN NN O
analgesic NN NN O
ED50 NN NN O
of NN NN O
all NN NN O
antinociceptive NN NN O
agents NN NN O
and NN NN O
they NN NN O
enhanced NN NN O
catalepsy NN NN B-Disease
induced NN NN O
by NN NN O
morphine NN NN O
and NN NN O
fentanyl NN NN O
. NN NN O
   
Codeine NN NN O
catalepsy NN NN B-Disease
was NN NN O
increased NN NN O
by NN NN O
clonidine NN NN O
and NN NN O
decreased NN NN O
by NN NN O
naphazoline NN NN O
and NN NN O
xylometazoline NN NN O
. NN NN O
   
The NN NN O
brain NN NN O
concentration NN NN O
of NN NN O
NA NN NN O
was NN NN O
not NN NN O
changed NN NN O
by NN NN O
morphine NN NN O
and NN NN O
fentanyl NN NN O
, NN NN O
but NN NN O
one NN NN O
of NN NN O
the NN NN O
doses NN NN O
of NN NN O
codeine NN NN O
( NN NN O
45 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
) NN NN O
slightly NN NN O
enhanced NN NN O
it NN NN O
. NN NN O
   
Pentazocine NN NN O
dose NN NN O
- NN NN O
dependently NN NN O
decreased NN NN O
the NN NN O
brain NN NN O
level NN NN O
of NN NN O
NA NN NN O
. NN NN O
   
The NN NN O
rate NN NN O
of NN NN O
NA NN NN O
turnover NN NN O
was NN NN O
not NN NN O
altered NN NN O
by NN NN O
analgesics NN NN O
except NN NN O
for NN NN O
the NN NN O
higher NN NN O
dose NN NN O
of NN NN O
fentanyl NN NN O
( NN NN O
0 NN NN O
. NN NN O
2 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
) NN NN O
following NN NN O
which NN NN O
the NN NN O
disappearance NN NN O
of NN NN O
NA NN NN O
from NN NN O
the NN NN O
brain NN NN O
was NN NN O
diminished NN NN O
. NN NN O
   
The NN NN O
results NN NN O
are NN NN O
discussed NN NN O
in NN NN O
the NN NN O
light NN NN O
of NN NN O
various NN NN O
and NN NN O
non NN NN O
- NN NN O
uniform NN NN O
data NN NN O
from NN NN O
the NN NN O
literature NN NN O
. NN NN O
   
It NN NN O
is NN NN O
suggested NN NN O
that NN NN O
in NN NN O
rats NN NN O
the NN NN O
brain NN NN O
NA NN NN O
plays NN NN O
a NN NN O
less NN NN O
important NN NN O
function NN NN O
than NN NN O
the NN NN O
other NN NN O
monoamines NN NN O
in NN NN O
the NN NN O
behavioural NN NN O
activity NN NN O
of NN NN O
potent NN NN O
analgesics NN NN O
. NN NN O
   
Flurothyl NN NN O
seizure NN NN B-Disease
thresholds NN NN O
in NN NN O
mice NN NN O
treated NN NN O
neonatally NN NN O
with NN NN O
a NN NN O
single NN NN O
injection NN NN O
of NN NN O
monosodium NN NN O
glutamate NN NN O
( NN NN O
MSG NN NN O
) NN NN O
: NN NN O
evaluation NN NN O
of NN NN O
experimental NN NN O
parameters NN NN O
in NN NN O
flurothyl NN NN O
seizure NN NN B-Disease
testing NN NN O
. NN NN O
   
Monosodium NN NN O
glutamate NN NN O
( NN NN O
MSG NN NN O
) NN NN O
administration NN NN O
to NN NN O
neonatal NN NN O
rodents NN NN O
produces NN NN O
convulsions NN NN B-Disease
and NN NN O
results NN NN O
in NN NN O
numerous NN NN O
biochemical NN NN O
and NN NN O
behavioral NN NN O
deficits NN NN O
. NN NN O
   
These NN NN O
studies NN NN O
were NN NN O
undertaken NN NN O
to NN NN O
determine NN NN O
if NN NN O
neonatal NN NN O
administration NN NN O
of NN NN O
MSG NN NN O
produced NN NN O
permanent NN NN O
alterations NN NN O
in NN NN O
seizure NN NN B-Disease
susceptibility NN NN O
, NN NN O
since NN NN O
previous NN NN O
investigations NN NN O
were NN NN O
inconclusive NN NN O
. NN NN O
   
A NN NN O
flurothyl NN NN O
ether NN NN O
seizure NN NN B-Disease
screening NN NN O
technique NN NN O
was NN NN O
used NN NN O
to NN NN O
evaluate NN NN O
seizure NN NN B-Disease
susceptibility NN NN O
in NN NN O
adult NN NN O
mice NN NN O
that NN NN O
received NN NN O
neonatal NN NN O
injections NN NN O
of NN NN O
MSG NN NN O
( NN NN O
4 NN NN O
mg NN NN O
/ NN NN O
g NN NN O
and NN NN O
1 NN NN O
mg NN NN O
/ NN NN O
g NN NN O
) NN NN O
. NN NN O
   
MSG NN NN O
treatment NN NN O
resulted NN NN O
in NN NN O
significant NN NN O
reductions NN NN O
in NN NN O
whole NN NN O
brain NN NN O
weight NN NN O
but NN NN O
did NN NN O
not NN NN O
alter NN NN O
seizure NN NN B-Disease
threshold NN NN O
. NN NN O
   
A NN NN O
naloxone NN NN O
( NN NN O
5 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
) NN NN O
challenge NN NN O
was NN NN O
also NN NN O
ineffective NN NN O
in NN NN O
altering NN NN O
the NN NN O
seizure NN NN B-Disease
thresholds NN NN O
of NN NN O
either NN NN O
control NN NN O
of NN NN O
MSG NN NN O
- NN NN O
treated NN NN O
mice NN NN O
. NN NN O
   
Flurothyl NN NN O
ether NN NN O
produced NN NN O
hypothermia NN NN B-Disease
which NN NN O
was NN NN O
correlated NN NN O
with NN NN O
the NN NN O
duration NN NN O
of NN NN O
flurothyl NN NN O
exposure NN NN O
; NN NN O
however NN NN O
, NN NN O
the NN NN O
relationship NN NN O
of NN NN O
hypothermia NN NN B-Disease
to NN NN O
seizure NN NN B-Disease
induction NN NN O
was NN NN O
unclear NN NN O
. NN NN O
   
Flurothyl NN NN O
seizure NN NN B-Disease
testing NN NN O
proved NN NN O
to NN NN O
be NN NN O
a NN NN O
rapid NN NN O
and NN NN O
reliable NN NN O
technique NN NN O
with NN NN O
which NN NN O
to NN NN O
evaluate NN NN O
seizure NN NN B-Disease
susceptibility NN NN O
. NN NN O
   
Susceptibility NN NN O
to NN NN O
seizures NN NN B-Disease
produced NN NN O
by NN NN O
pilocarpine NN NN O
in NN NN O
rats NN NN O
after NN NN O
microinjection NN NN O
of NN NN O
isoniazid NN NN O
or NN NN O
gamma NN NN O
- NN NN O
vinyl NN NN O
- NN NN O
GABA NN NN O
into NN NN O
the NN NN O
substantia NN NN O
nigra NN NN O
. NN NN O
   
Pilocarpine NN NN O
, NN NN O
given NN NN O
intraperitoneally NN NN O
to NN NN O
rats NN NN O
, NN NN O
reproduces NN NN O
the NN NN O
neuropathological NN NN O
sequelae NN NN O
of NN NN O
temporal NN NN B-Disease
lobe NN NN I-Disease
epilepsy NN NN I-Disease
and NN NN O
provides NN NN O
a NN NN O
relevant NN NN O
animal NN NN O
model NN NN O
for NN NN O
studying NN NN O
mechanisms NN NN O
of NN NN O
buildup NN NN O
of NN NN O
convulsive NN NN B-Disease
activity NN NN O
and NN NN O
pathways NN NN O
operative NN NN O
in NN NN O
the NN NN O
generalization NN NN O
and NN NN O
propagation NN NN O
of NN NN O
seizures NN NN B-Disease
within NN NN O
the NN NN O
forebrain NN NN O
. NN NN O
   
In NN NN O
the NN NN O
present NN NN O
study NN NN O
, NN NN O
the NN NN O
effects NN NN O
of NN NN O
manipulating NN NN O
the NN NN O
activity NN NN O
of NN NN O
the NN NN O
gamma NN NN O
- NN NN O
aminobutyric NN NN O
acid NN NN O
( NN NN O
GABA NN NN O
) NN NN O
- NN NN O
mediated NN NN O
synaptic NN NN O
inhibition NN NN O
within NN NN O
the NN NN O
substantia NN NN O
nigra NN NN O
on NN NN O
seizures NN NN B-Disease
produced NN NN O
by NN NN O
pilocarpine NN NN O
in NN NN O
rats NN NN O
, NN NN O
were NN NN O
investigated NN NN O
. NN NN O
   
In NN NN O
animals NN NN O
pretreated NN NN O
with NN NN O
microinjections NN NN O
of NN NN O
isoniazid NN NN O
, NN NN O
150 NN NN O
micrograms NN NN O
, NN NN O
an NN NN O
inhibitor NN NN O
of NN NN O
activity NN NN O
of NN NN O
the NN NN O
GABA NN NN O
- NN NN O
synthesizing NN NN O
enzyme NN NN O
, NN NN O
L NN NN O
- NN NN O
glutamic NN NN O
acid NN NN O
decarboxylase NN NN O
, NN NN O
into NN NN O
the NN NN O
substantia NN NN O
nigra NN NN O
pars NN NN O
reticulata NN NN O
( NN NN O
SNR NN NN O
) NN NN O
, NN NN O
bilaterally NN NN O
, NN NN O
non NN NN O
- NN NN O
convulsant NN NN O
doses NN NN O
of NN NN O
pilocarpine NN NN O
, NN NN O
100 NN NN O
and NN NN O
200 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
, NN NN O
resulted NN NN O
in NN NN O
severe NN NN O
motor NN NN O
limbic NN NN O
seizures NN NN B-Disease
and NN NN O
status NN NN B-Disease
epilepticus NN NN I-Disease
. NN NN O
   
Electroencephalographic NN NN O
and NN NN O
behavioral NN NN O
monitoring NN NN O
revealed NN NN O
a NN NN O
profound NN NN O
reduction NN NN O
of NN NN O
the NN NN O
threshold NN NN O
for NN NN O
pilocarpine NN NN O
- NN NN O
induced NN NN O
convulsions NN NN B-Disease
. NN NN O
   
Morphological NN NN O
analysis NN NN O
of NN NN O
frontal NN NN O
forebrain NN NN O
sections NN NN O
with NN NN O
light NN NN O
microscopy NN NN O
revealed NN NN O
seizure NN NN B-Disease
- NN NN O
related NN NN O
damage NN NN O
to NN NN O
the NN NN O
hippocampal NN NN O
formation NN NN O
, NN NN O
thalamus NN NN O
, NN NN O
amygdala NN NN O
, NN NN O
olfactory NN NN O
cortex NN NN O
, NN NN O
substantia NN NN O
nigra NN NN O
and NN NN O
neocortex NN NN O
, NN NN O
which NN NN O
is NN NN O
typically NN NN O
observed NN NN O
with NN NN O
pilocarpine NN NN O
in NN NN O
doses NN NN O
exceeding NN NN O
350 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
. NN NN O
   
Bilateral NN NN O
intrastriatal NN NN O
injections NN NN O
of NN NN O
isoniazid NN NN O
did NN NN O
not NN NN O
augment NN NN O
seizures NN NN B-Disease
produced NN NN O
by NN NN O
pilocarpine NN NN O
, NN NN O
200 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
. NN NN O
   
Application NN NN O
of NN NN O
an NN NN O
irreversible NN NN O
inhibitor NN NN O
of NN NN O
GABA NN NN O
transaminase NN NN O
, NN NN O
gamma NN NN O
- NN NN O
vinyl NN NN O
- NN NN O
GABA NN NN O
( NN NN O
D NN NN O
, NN NN O
L NN NN O
- NN NN O
4 NN NN O
- NN NN O
amino NN NN O
- NN NN O
hex NN NN O
- NN NN O
5 NN NN O
- NN NN O
enoic NN NN O
acid NN NN O
) NN NN O
, NN NN O
5 NN NN O
micrograms NN NN O
, NN NN O
into NN NN O
the NN NN O
SNR NN NN O
, NN NN O
bilaterally NN NN O
, NN NN O
suppressed NN NN O
the NN NN O
appearance NN NN O
of NN NN O
electrographic NN NN O
and NN NN O
behavioral NN NN O
seizures NN NN B-Disease
produced NN NN O
by NN NN O
pilocarpine NN NN O
, NN NN O
380 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
. NN NN O
   
This NN NN O
treatment NN NN O
was NN NN O
also NN NN O
sufficient NN NN O
to NN NN O
protect NN NN O
animals NN NN O
from NN NN O
the NN NN O
occurrence NN NN O
of NN NN O
brain NN NN B-Disease
damage NN NN I-Disease
. NN NN O
   
Microinjections NN NN O
of NN NN O
gamma NN NN O
- NN NN O
vinyl NN NN O
- NN NN O
GABA NN NN O
, NN NN O
5 NN NN O
micrograms NN NN O
, NN NN O
into NN NN O
the NN NN O
dorsal NN NN O
striatum NN NN O
, NN NN O
bilaterally NN NN O
, NN NN O
failed NN NN O
to NN NN O
prevent NN NN O
the NN NN O
development NN NN O
of NN NN O
convulsions NN NN B-Disease
produced NN NN O
by NN NN O
pilocarpine NN NN O
, NN NN O
380 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
. NN NN O
   
The NN NN O
results NN NN O
demonstrate NN NN O
that NN NN O
the NN NN O
threshold NN NN O
for NN NN O
pilocarpine NN NN O
- NN NN O
induced NN NN O
seizures NN NN B-Disease
in NN NN O
rats NN NN O
is NN NN O
subjected NN NN O
to NN NN O
the NN NN O
regulation NN NN O
of NN NN O
the NN NN O
GABA NN NN O
- NN NN O
mediated NN NN O
synaptic NN NN O
inhibition NN NN O
within NN NN O
the NN NN O
substantia NN NN O
nigra NN NN O
. NN NN O
   
Human NN NN O
and NN NN O
canine NN NN O
ventricular NN NN O
vasoactive NN NN O
intestinal NN NN O
polypeptide NN NN O
: NN NN O
decrease NN NN O
with NN NN O
heart NN NN B-Disease
failure NN NN I-Disease
. NN NN O
   
Vasoactive NN NN O
intestinal NN NN O
polypeptide NN NN O
( NN NN O
VIP NN NN O
) NN NN O
is NN NN O
a NN NN O
systemic NN NN O
and NN NN O
coronary NN NN O
vasodilator NN NN O
that NN NN O
may NN NN O
have NN NN O
positive NN NN O
inotropic NN NN O
properties NN NN O
. NN NN O
   
Myocardial NN NN O
levels NN NN O
of NN NN O
VIP NN NN O
were NN NN O
assayed NN NN O
before NN NN O
and NN NN O
after NN NN O
the NN NN O
development NN NN O
of NN NN O
heart NN NN B-Disease
failure NN NN I-Disease
in NN NN O
two NN NN O
canine NN NN O
models NN NN O
. NN NN O
   
In NN NN O
the NN NN O
first NN NN O
, NN NN O
cobalt NN NN O
cardiomyopathy NN NN B-Disease
was NN NN O
induced NN NN O
in NN NN O
eight NN NN O
dogs NN NN O
; NN NN O
VIP NN NN O
( NN NN O
by NN NN O
radioimmunoassay NN NN O
) NN NN O
decreased NN NN O
from NN NN O
35 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
11 NN NN O
pg NN NN O
/ NN NN O
mg NN NN O
protein NN NN O
( NN NN O
mean NN NN O
+ NN NN O
/ NN NN O
- NN NN O
SD NN NN O
) NN NN O
to NN NN O
5 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
4 NN NN O
pg NN NN O
/ NN NN O
mg NN NN O
protein NN NN O
( NN NN O
P NN NN O
less NN NN O
than NN NN O
0 NN NN O
. NN NN O
05 NN NN O
) NN NN O
. NN NN O
   
In NN NN O
six NN NN O
dogs NN NN O
with NN NN O
doxorubicin NN NN O
- NN NN O
induced NN NN O
heart NN NN B-Disease
failure NN NN I-Disease
, NN NN O
VIP NN NN O
decreased NN NN O
from NN NN O
31 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
7 NN NN O
to NN NN O
11 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
4 NN NN O
pg NN NN O
/ NN NN O
mg NN NN O
protein NN NN O
( NN NN O
P NN NN O
less NN NN O
than NN NN O
0 NN NN O
. NN NN O
05 NN NN O
) NN NN O
. NN NN O
   
In NN NN O
addition NN NN O
, NN NN O
VIP NN NN O
content NN NN O
of NN NN O
left NN NN O
ventricular NN NN O
muscle NN NN O
of NN NN O
resected NN NN O
failing NN NN O
hearts NN NN O
in NN NN O
10 NN NN O
patients NN NN O
receiving NN NN O
a NN NN O
heart NN NN O
transplant NN NN O
was NN NN O
compared NN NN O
with NN NN O
the NN NN O
papillary NN NN O
muscles NN NN O
in NN NN O
14 NN NN O
patients NN NN O
( NN NN O
five NN NN O
with NN NN O
rheumatic NN NN B-Disease
disease NN NN I-Disease
, NN NN O
nine NN NN O
with NN NN O
myxomatous NN NN B-Disease
degeneration NN NN I-Disease
) NN NN O
receiving NN NN O
mitral NN NN O
valve NN NN O
prostheses NN NN O
. NN NN O
   
The NN NN O
lowest NN NN O
myocardial NN NN O
VIP NN NN O
concentration NN NN O
was NN NN O
found NN NN O
in NN NN O
the NN NN O
hearts NN NN O
of NN NN O
patients NN NN O
with NN NN O
coronary NN NN B-Disease
disease NN NN I-Disease
( NN NN O
one NN NN O
patient NN NN O
receiving NN NN O
a NN NN O
transplant NN NN O
and NN NN O
three NN NN O
receiving NN NN O
mitral NN NN O
prostheses NN NN O
) NN NN O
( NN NN O
6 NN NN O
. NN NN O
3 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
1 NN NN O
. NN NN O
9 NN NN O
pg NN NN O
/ NN NN O
mg NN NN O
protein NN NN O
) NN NN O
. NN NN O
   
The NN NN O
other NN NN O
patients NN NN O
undergoing NN NN O
transplantation NN NN O
had NN NN O
an NN NN O
average NN NN O
ejection NN NN O
fraction NN NN O
of NN NN O
17 NN NN O
% NN NN O
+ NN NN O
/ NN NN O
- NN NN O
6 NN NN O
% NN NN O
and NN NN O
a NN NN O
VIP NN NN O
level NN NN O
of NN NN O
8 NN NN O
. NN NN O
8 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
3 NN NN O
. NN NN O
9 NN NN O
pg NN NN O
/ NN NN O
mg NN NN O
protein NN NN O
. NN NN O
   
The NN NN O
hearts NN NN O
without NN NN O
coronary NN NN B-Disease
artery NN NN I-Disease
disease NN NN I-Disease
( NN NN O
average NN NN O
ejection NN NN O
fraction NN NN O
of NN NN O
this NN NN O
group NN NN O
62 NN NN O
% NN NN O
+ NN NN O
/ NN NN O
- NN NN O
10 NN NN O
% NN NN O
) NN NN O
had NN NN O
a NN NN O
VIP NN NN O
concentration NN NN O
of NN NN O
14 NN NN O
. NN NN O
1 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
7 NN NN O
. NN NN O
9 NN NN O
pg NN NN O
/ NN NN O
mg NN NN O
protein NN NN O
, NN NN O
and NN NN O
this NN NN O
was NN NN O
greater NN NN O
than NN NN O
in NN NN O
hearts NN NN O
of NN NN O
the NN NN O
patients NN NN O
with NN NN O
coronary NN NN B-Disease
disease NN NN I-Disease
and NN NN O
the NN NN O
hearts NN NN O
of NN NN O
patients NN NN O
receiving NN NN O
a NN NN O
transplant NN NN O
( NN NN O
P NN NN O
less NN NN O
than NN NN O
0 NN NN O
. NN NN O
05 NN NN O
) NN NN O
. NN NN O
   
Myocardial NN NN O
catecholamines NN NN O
were NN NN O
also NN NN O
determined NN NN O
in NN NN O
14 NN NN O
subjects NN NN O
; NN NN O
a NN NN O
weak NN NN O
correlation NN NN O
( NN NN O
r NN NN O
= NN NN O
0 NN NN O
. NN NN O
57 NN NN O
, NN NN O
P NN NN O
less NN NN O
than NN NN O
0 NN NN O
. NN NN O
05 NN NN O
) NN NN O
between NN NN O
the NN NN O
tissue NN NN O
concentrations NN NN O
of NN NN O
VIP NN NN O
and NN NN O
norepinephrine NN NN O
was NN NN O
noted NN NN O
. NN NN O
( NN NN O
ABSTRACT NN NN O
TRUNCATED NN NN O
AT NN NN O
250 NN NN O
WORDS NN NN O
) NN NN O
   
Non NN NN O
- NN NN O
invasive NN NN O
detection NN NN O
of NN NN O
coronary NN NN B-Disease
artery NN NN I-Disease
disease NN NN I-Disease
by NN NN O
body NN NN O
surface NN NN O
electrocardiographic NN NN O
mapping NN NN O
after NN NN O
dipyridamole NN NN O
infusion NN NN O
. NN NN O
   
Electrocardiographic NN NN O
changes NN NN O
after NN NN O
dipyridamole NN NN O
infusion NN NN O
( NN NN O
0 NN NN O
. NN NN O
568 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
/ NN NN O
4 NN NN O
min NN NN O
) NN NN O
were NN NN O
studied NN NN O
in NN NN O
41 NN NN O
patients NN NN O
with NN NN O
coronary NN NN B-Disease
artery NN NN I-Disease
disease NN NN I-Disease
and NN NN O
compared NN NN O
with NN NN O
those NN NN O
after NN NN O
submaximal NN NN O
treadmill NN NN O
exercise NN NN O
by NN NN O
use NN NN O
of NN NN O
the NN NN O
body NN NN O
surface NN NN O
mapping NN NN O
technique NN NN O
. NN NN O
   
Patients NN NN O
were NN NN O
divided NN NN O
into NN NN O
three NN NN O
groups NN NN O
; NN NN O
19 NN NN O
patients NN NN O
without NN NN O
myocardial NN NN B-Disease
infarction NN NN I-Disease
( NN NN O
non NN NN O
- NN NN O
MI NN NN B-Disease
group NN NN O
) NN NN O
, NN NN O
14 NN NN O
with NN NN O
anterior NN NN B-Disease
infarction NN NN I-Disease
( NN NN O
ANT NN NN B-Disease
- NN NN I-Disease
MI NN NN I-Disease
) NN NN O
and NN NN O
eight NN NN O
with NN NN O
inferior NN NN B-Disease
infarction NN NN I-Disease
( NN NN O
INF NN NN B-Disease
- NN NN I-Disease
MI NN NN I-Disease
) NN NN O
. NN NN O
   
Eighty NN NN O
- NN NN O
seven NN NN O
unipolar NN NN O
electrocardiograms NN NN O
( NN NN O
ECGs NN NN O
) NN NN O
distributed NN NN O
over NN NN O
the NN NN O
entire NN NN O
thoracic NN NN O
surface NN NN O
were NN NN O
simultaneously NN NN O
recorded NN NN O
. NN NN O
   
After NN NN O
dipyridamole NN NN O
, NN NN O
ischemic NN NN B-Disease
ST NN NN O
- NN NN O
segment NN NN O
depression NN NN B-Disease
( NN NN O
0 NN NN O
. NN NN O
05 NN NN O
mV NN NN O
or NN NN O
more NN NN O
) NN NN O
was NN NN O
observed NN NN O
in NN NN O
84 NN NN O
% NN NN O
of NN NN O
the NN NN O
non NN NN O
- NN NN O
MI NN NN B-Disease
group NN NN O
, NN NN O
29 NN NN O
% NN NN O
of NN NN O
the NN NN O
ANT NN NN B-Disease
- NN NN I-Disease
MI NN NN I-Disease
group NN NN O
, NN NN O
63 NN NN O
% NN NN O
of NN NN O
the NN NN O
INF NN NN B-Disease
- NN NN I-Disease
MI NN NN I-Disease
group NN NN O
and NN NN O
61 NN NN O
% NN NN O
of NN NN O
the NN NN O
total NN NN O
population NN NN O
. NN NN O
   
Exercise NN NN O
- NN NN O
induced NN NN O
ST NN NN O
depression NN NN B-Disease
was NN NN O
observed NN NN O
in NN NN O
84 NN NN O
% NN NN O
of NN NN O
the NN NN O
non NN NN O
- NN NN O
MI NN NN B-Disease
group NN NN O
, NN NN O
43 NN NN O
% NN NN O
of NN NN O
the NN NN O
ANT NN NN B-Disease
- NN NN I-Disease
MI NN NN I-Disease
group NN NN O
, NN NN O
38 NN NN O
% NN NN O
of NN NN O
the NN NN O
INF NN NN B-Disease
- NN NN I-Disease
MI NN NN I-Disease
group NN NN O
and NN NN O
61 NN NN O
% NN NN O
of NN NN O
the NN NN O
total NN NN O
. NN NN O
   
For NN NN O
individual NN NN O
patients NN NN O
, NN NN O
there NN NN O
were NN NN O
no NN NN O
obvious NN NN O
differences NN NN O
between NN NN O
the NN NN O
body NN NN O
surface NN NN O
distribution NN NN O
of NN NN O
ST NN NN O
depression NN NN B-Disease
in NN NN O
both NN NN O
tests NN NN O
. NN NN O
   
The NN NN O
increase NN NN O
in NN NN O
pressure NN NN O
rate NN NN O
product NN NN O
after NN NN O
dipyridamole NN NN O
was NN NN O
significantly NN NN O
less NN NN O
than NN NN O
that NN NN O
during NN NN O
the NN NN O
treadmill NN NN O
exercise NN NN O
. NN NN O
   
The NN NN O
data NN NN O
suggest NN NN O
that NN NN O
the NN NN O
dipyridamole NN NN O
- NN NN O
induced NN NN O
myocardial NN NN B-Disease
ischemia NN NN I-Disease
is NN NN O
caused NN NN O
by NN NN O
the NN NN O
inhomogenous NN NN O
distribution NN NN O
of NN NN O
myocardial NN NN O
blood NN NN O
flow NN NN O
. NN NN O
   
We NN NN O
conclude NN NN O
that NN NN O
the NN NN O
dipyridamole NN NN O
ECG NN NN O
test NN NN O
is NN NN O
as NN NN O
useful NN NN O
as NN NN O
the NN NN O
exercise NN NN O
ECG NN NN O
test NN NN O
for NN NN O
the NN NN O
assessment NN NN O
of NN NN O
coronary NN NN B-Disease
artery NN NN I-Disease
disease NN NN I-Disease
. NN NN O
   
Bradycardia NN NN B-Disease
after NN NN O
high NN NN O
- NN NN O
dose NN NN O
intravenous NN NN O
methylprednisolone NN NN O
therapy NN NN O
. NN NN O
   
In NN NN O
5 NN NN O
consecutive NN NN O
patients NN NN O
with NN NN O
rheumatoid NN NN B-Disease
arthritis NN NN I-Disease
who NN NN O
received NN NN O
intravenous NN NN O
high NN NN O
- NN NN O
dose NN NN O
methylprednisolone NN NN O
( NN NN O
MP NN NN O
) NN NN O
therapy NN NN O
( NN NN O
1 NN NN O
g NN NN O
daily NN NN O
for NN NN O
2 NN NN O
or NN NN O
3 NN NN O
consecutive NN NN O
days NN NN O
) NN NN O
, NN NN O
a NN NN O
decline NN NN O
in NN NN O
pulse NN NN O
rate NN NN O
was NN NN O
observed NN NN O
, NN NN O
most NN NN O
pronounced NN NN O
on NN NN O
day NN NN O
4 NN NN O
. NN NN O
   
In NN NN O
one NN NN O
of NN NN O
the NN NN O
5 NN NN O
patients NN NN O
the NN NN O
bradycardia NN NN B-Disease
was NN NN O
associated NN NN O
with NN NN O
complaints NN NN O
of NN NN O
substernal NN NN O
pressure NN NN O
. NN NN O
   
Reversal NN NN O
to NN NN O
normal NN NN O
heart NN NN O
rate NN NN O
was NN NN O
found NN NN O
on NN NN O
day NN NN O
7 NN NN O
. NN NN O
   
Electrocardiographic NN NN O
registrations NN NN O
showed NN NN O
sinus NN NN B-Disease
bradycardia NN NN I-Disease
in NN NN O
all NN NN O
cases NN NN O
. NN NN O
   
No NN NN O
significant NN NN O
changes NN NN O
in NN NN O
plasma NN NN O
concentrations NN NN O
of NN NN O
electrolytes NN NN O
were NN NN O
found NN NN O
. NN NN O
   
Careful NN NN O
observation NN NN O
of NN NN O
patients NN NN O
receiving NN NN O
high NN NN O
- NN NN O
dose NN NN O
MP NN NN O
is NN NN O
recommended NN NN O
. NN NN O
   
High NN NN O
- NN NN O
dose NN NN O
MP NN NN O
may NN NN O
be NN NN O
contraindicated NN NN O
in NN NN O
patients NN NN O
with NN NN O
known NN NN O
heart NN NN B-Disease
disease NN NN I-Disease
. NN NN O
   
Two NN NN O
cases NN NN O
of NN NN O
downbeat NN NN B-Disease
nystagmus NN NN I-Disease
and NN NN O
oscillopsia NN NN B-Disease
associated NN NN O
with NN NN O
carbamazepine NN NN O
. NN NN O
   
Downbeat NN NN B-Disease
nystagmus NN NN I-Disease
is NN NN O
often NN NN O
associated NN NN O
with NN NN O
structural NN NN O
lesions NN NN O
at NN NN O
the NN NN O
craniocervical NN NN O
junction NN NN O
, NN NN O
but NN NN O
has NN NN O
occasionally NN NN O
been NN NN O
reported NN NN O
as NN NN O
a NN NN O
manifestation NN NN O
of NN NN O
metabolic NN NN O
imbalance NN NN O
or NN NN O
drug NN NN O
intoxication NN NN O
. NN NN O
   
We NN NN O
recorded NN NN O
the NN NN O
eye NN NN O
movements NN NN O
of NN NN O
two NN NN O
patients NN NN O
with NN NN O
reversible NN NN O
downbeat NN NN B-Disease
nystagmus NN NN I-Disease
related NN NN O
to NN NN O
carbamazepine NN NN O
therapy NN NN O
. NN NN O
   
The NN NN O
nystagmus NN NN B-Disease
of NN NN O
both NN NN O
patients NN NN O
resolved NN NN O
after NN NN O
reduction NN NN O
of NN NN O
the NN NN O
serum NN NN O
carbamazepine NN NN O
levels NN NN O
. NN NN O
   
Neuroradiologic NN NN O
investigations NN NN O
including NN NN O
magnetic NN NN O
resonance NN NN O
imaging NN NN O
scans NN NN O
in NN NN O
both NN NN O
patients NN NN O
showed NN NN O
no NN NN O
evidence NN NN O
of NN NN O
intracranial NN NN O
abnormality NN NN O
. NN NN O
   
In NN NN O
patients NN NN O
with NN NN O
downbeat NN NN B-Disease
nystagmus NN NN I-Disease
who NN NN O
are NN NN O
taking NN NN O
anticonvulsant NN NN O
medications NN NN O
, NN NN O
consideration NN NN O
should NN NN O
be NN NN O
given NN NN O
to NN NN O
reduction NN NN O
in NN NN O
dose NN NN O
before NN NN O
further NN NN O
investigation NN NN O
is NN NN O
undertaken NN NN O
. NN NN O
   
Improvement NN NN O
by NN NN O
denopamine NN NN O
( NN NN O
TA NN NN O
- NN NN O
064 NN NN O
) NN NN O
of NN NN O
pentobarbital NN NN O
- NN NN O
induced NN NN O
cardiac NN NN B-Disease
failure NN NN I-Disease
in NN NN O
the NN NN O
dog NN NN O
heart NN NN O
- NN NN O
lung NN NN O
preparation NN NN O
. NN NN O
   
The NN NN O
efficacy NN NN O
of NN NN O
denopamine NN NN O
, NN NN O
an NN NN O
orally NN NN O
active NN NN O
beta NN NN O
1 NN NN O
- NN NN O
adrenoceptor NN NN O
agonist NN NN O
, NN NN O
in NN NN O
improving NN NN O
cardiac NN NN B-Disease
failure NN NN I-Disease
was NN NN O
assessed NN NN O
in NN NN O
dog NN NN O
heart NN NN O
- NN NN O
lung NN NN O
preparations NN NN O
. NN NN O
   
Cardiac NN NN O
functions NN NN O
depressed NN NN O
by NN NN O
pentobarbital NN NN O
( NN NN O
118 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
28 NN NN O
mg NN NN O
; NN NN O
mean NN NN O
value NN NN O
+ NN NN O
/ NN NN O
- NN NN O
SD NN NN O
) NN NN O
such NN NN O
that NN NN O
cardiac NN NN O
output NN NN O
and NN NN O
maximum NN NN O
rate NN NN O
of NN NN O
rise NN NN O
of NN NN O
left NN NN O
ventricular NN NN O
pressure NN NN O
( NN NN O
LV NN NN O
dP NN NN O
/ NN NN O
dt NN NN O
max NN NN O
) NN NN O
had NN NN O
been NN NN O
reduced NN NN O
by NN NN O
about NN NN O
35 NN NN O
% NN NN O
and NN NN O
26 NN NN O
% NN NN O
of NN NN O
the NN NN O
respective NN NN O
controls NN NN O
were NN NN O
improved NN NN O
by NN NN O
denopamine NN NN O
( NN NN O
10 NN NN O
- NN NN O
300 NN NN O
micrograms NN NN O
) NN NN O
in NN NN O
a NN NN O
dose NN NN O
- NN NN O
dependent NN NN O
manner NN NN O
. NN NN O
   
With NN NN O
100 NN NN O
micrograms NN NN O
denopamine NN NN O
, NN NN O
almost NN NN O
complete NN NN O
restoration NN NN O
of NN NN O
cardiac NN NN O
performance NN NN O
was NN NN O
attained NN NN O
, NN NN O
associated NN NN O
with NN NN O
a NN NN O
slight NN NN O
increase NN NN O
in NN NN O
heart NN NN O
rate NN NN O
. NN NN O
   
No NN NN O
arrhythmias NN NN B-Disease
were NN NN O
induced NN NN O
by NN NN O
these NN NN O
doses NN NN O
of NN NN O
denopamine NN NN O
. NN NN O
   
The NN NN O
results NN NN O
warrant NN NN O
clinical NN NN O
trials NN NN O
of NN NN O
denopamine NN NN O
in NN NN O
the NN NN O
treatment NN NN O
of NN NN O
cardiac NN NN B-Disease
failure NN NN I-Disease
. NN NN O
   
Clonazepam NN NN O
monotherapy NN NN O
for NN NN O
epilepsy NN NN B-Disease
in NN NN O
childhood NN NN O
. NN NN O
   
Sixty NN NN O
patients NN NN O
( NN NN O
age NN NN O
- NN NN O
range NN NN O
one NN NN O
month NN NN O
to NN NN O
14 NN NN O
years NN NN O
) NN NN O
with NN NN O
other NN NN O
types NN NN O
of NN NN O
epilepsy NN NN B-Disease
than NN NN O
infantile NN NN B-Disease
spasms NN NN I-Disease
were NN NN O
treated NN NN O
with NN NN O
clonazepam NN NN O
. NN NN O
   
Disappearance NN NN O
of NN NN O
seizures NN NN B-Disease
and NN NN O
normalization NN NN O
of NN NN O
abnormal NN NN O
EEG NN NN O
with NN NN O
disappearance NN NN O
of NN NN O
seizures NN NN B-Disease
were NN NN O
recognized NN NN O
in NN NN O
77 NN NN O
% NN NN O
and NN NN O
50 NN NN O
% NN NN O
, NN NN O
respectively NN NN O
. NN NN O
   
Seizures NN NN B-Disease
disappeared NN NN O
in NN NN O
71 NN NN O
% NN NN O
of NN NN O
the NN NN O
patients NN NN O
with NN NN O
generalized NN NN O
seizures NN NN B-Disease
and NN NN O
89 NN NN O
% NN NN O
of NN NN O
partial NN NN O
seizures NN NN B-Disease
. NN NN O
   
Improvement NN NN O
of NN NN O
abnormal NN NN O
EEG NN NN O
was NN NN O
noticed NN NN O
in NN NN O
76 NN NN O
% NN NN O
of NN NN O
diffuse NN NN O
paroxysms NN NN O
and NN NN O
in NN NN O
67 NN NN O
% NN NN O
of NN NN O
focal NN NN O
paroxysms NN NN O
. NN NN O
   
In NN NN O
excellent NN NN O
cases NN NN O
, NN NN O
mean NN NN O
effective NN NN O
dosages NN NN O
were NN NN O
0 NN NN O
. NN NN O
086 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
0 NN NN O
. NN NN O
021 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
/ NN NN O
day NN NN O
in NN NN O
infants NN NN O
and NN NN O
0 NN NN O
. NN NN O
057 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
0 NN NN O
. NN NN O
022 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
/ NN NN O
day NN NN O
in NN NN O
schoolchildren NN NN O
, NN NN O
this NN NN O
difference NN NN O
was NN NN O
statistically NN NN O
significant NN NN O
( NN NN O
p NN NN O
less NN NN O
than NN NN O
0 NN NN O
. NN NN O
005 NN NN O
) NN NN O
. NN NN O
   
The NN NN O
incidence NN NN O
of NN NN O
side NN NN O
effects NN NN O
such NN NN O
as NN NN O
drowsiness NN NN B-Disease
and NN NN O
ataxia NN NN B-Disease
was NN NN O
only NN NN O
5 NN NN O
% NN NN O
. NN NN O
   
Postmarketing NN NN O
study NN NN O
of NN NN O
timolol NN NN O
- NN NN O
hydrochlorothiazide NN NN O
antihypertensive NN NN O
therapy NN NN O
. NN NN O
   
A NN NN O
postmarketing NN NN O
surveillance NN NN O
study NN NN O
was NN NN O
conducted NN NN O
to NN NN O
determine NN NN O
the NN NN O
safety NN NN O
and NN NN O
efficacy NN NN O
of NN NN O
a NN NN O
fixed NN NN O
- NN NN O
ratio NN NN O
combination NN NN O
containing NN NN O
10 NN NN O
mg NN NN O
of NN NN O
timolol NN NN O
maleate NN NN O
and NN NN O
25 NN NN O
mg NN NN O
of NN NN O
hydrochlorothiazide NN NN O
, NN NN O
administered NN NN O
twice NN NN O
daily NN NN O
for NN NN O
one NN NN O
month NN NN O
to NN NN O
hypertensive NN NN B-Disease
patients NN NN O
. NN NN O
   
Data NN NN O
on NN NN O
9 NN NN O
, NN NN O
037 NN NN O
patients NN NN O
were NN NN O
collected NN NN O
by NN NN O
1 NN NN O
, NN NN O
455 NN NN O
participating NN NN O
physicians NN NN O
. NN NN O
   
Mean NN NN O
systolic NN NN O
blood NN NN O
pressure NN NN O
decreased NN NN O
25 NN NN O
mmHg NN NN O
and NN NN O
mean NN NN O
diastolic NN NN O
blood NN NN O
pressure NN NN O
declined NN NN O
15 NN NN O
mmHg NN NN O
after NN NN O
one NN NN O
month NN NN O
of NN NN O
timolol NN NN O
- NN NN O
hydrochlorothiazide NN NN O
therapy NN NN O
( NN NN O
P NN NN O
less NN NN O
than NN NN O
0 NN NN O
. NN NN O
01 NN NN O
, NN NN O
both NN NN O
comparisons NN NN O
) NN NN O
. NN NN O
   
Age NN NN O
, NN NN O
race NN NN O
, NN NN O
and NN NN O
sex NN NN O
appeared NN NN O
to NN NN O
have NN NN O
no NN NN O
influence NN NN O
on NN NN O
the NN NN O
decrease NN NN O
in NN NN O
blood NN NN O
pressure NN NN O
. NN NN O
   
The NN NN O
antihypertensive NN NN O
effect NN NN O
of NN NN O
the NN NN O
drug NN NN O
was NN NN O
greater NN NN O
in NN NN O
patients NN NN O
with NN NN O
more NN NN O
severe NN NN O
hypertension NN NN B-Disease
. NN NN O
   
Overall NN NN O
, NN NN O
1 NN NN O
, NN NN O
453 NN NN O
patients NN NN O
experienced NN NN O
a NN NN O
total NN NN O
of NN NN O
2 NN NN O
, NN NN O
658 NN NN O
adverse NN NN O
events NN NN O
, NN NN O
the NN NN O
most NN NN O
common NN NN O
being NN NN O
fatigue NN NN B-Disease
, NN NN O
dizziness NN NN B-Disease
, NN NN O
and NN NN O
weakness NN NN B-Disease
. NN NN O
   
Treatment NN NN O
in NN NN O
590 NN NN O
patients NN NN O
was NN NN O
discontinued NN NN O
because NN NN O
of NN NN O
adverse NN NN O
events NN NN O
. NN NN O
   
Salicylate NN NN O
nephropathy NN NN B-Disease
in NN NN O
the NN NN O
Gunn NN NN O
rat NN NN O
: NN NN O
potential NN NN O
role NN NN O
of NN NN O
prostaglandins NN NN O
. NN NN O
   
We NN NN O
examined NN NN O
the NN NN O
potential NN NN O
role NN NN O
of NN NN O
prostaglandins NN NN O
in NN NN O
the NN NN O
development NN NN O
of NN NN O
analgesic NN NN O
nephropathy NN NN B-Disease
in NN NN O
the NN NN O
Gunn NN NN O
strain NN NN O
of NN NN O
rat NN NN O
. NN NN O
   
The NN NN O
homozygous NN NN O
Gunn NN NN O
rats NN NN O
have NN NN O
unconjugated NN NN O
hyperbilirubinemia NN NN B-Disease
due NN NN O
to NN NN O
the NN NN O
absence NN NN O
of NN NN O
glucuronyl NN NN O
transferase NN NN O
, NN NN O
leading NN NN O
to NN NN O
marked NN NN O
bilirubin NN NN O
deposition NN NN O
in NN NN O
renal NN NN O
medulla NN NN O
and NN NN O
papilla NN NN O
. NN NN O
   
These NN NN O
rats NN NN O
are NN NN O
also NN NN O
highly NN NN O
susceptible NN NN O
to NN NN O
develop NN NN O
papillary NN NN B-Disease
necrosis NN NN I-Disease
with NN NN O
analgesic NN NN O
administration NN NN O
. NN NN O
   
We NN NN O
used NN NN O
homozygous NN NN O
( NN NN O
jj NN NN O
) NN NN O
and NN NN O
phenotypically NN NN O
normal NN NN O
heterozygous NN NN O
( NN NN O
jJ NN NN O
) NN NN O
animals NN NN O
. NN NN O
   
Four NN NN O
groups NN NN O
of NN NN O
rats NN NN O
( NN NN O
n NN NN O
= NN NN O
7 NN NN O
) NN NN O
were NN NN O
studied NN NN O
: NN NN O
jj NN NN O
and NN NN O
jJ NN NN O
rats NN NN O
treated NN NN O
either NN NN O
with NN NN O
aspirin NN NN O
300 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
every NN NN O
other NN NN O
day NN NN O
or NN NN O
sham NN NN O
- NN NN O
treated NN NN O
. NN NN O
   
After NN NN O
one NN NN O
week NN NN O
, NN NN O
slices NN NN O
of NN NN O
cortex NN NN O
, NN NN O
outer NN NN O
and NN NN O
inner NN NN O
medulla NN NN O
from NN NN O
one NN NN O
kidney NN NN O
were NN NN O
incubated NN NN O
in NN NN O
buffer NN NN O
and NN NN O
prostaglandin NN NN O
synthesis NN NN O
was NN NN O
determined NN NN O
by NN NN O
radioimmunoassay NN NN O
. NN NN O
   
The NN NN O
other NN NN O
kidney NN NN O
was NN NN O
examined NN NN O
histologically NN NN O
. NN NN O
   
A NN NN O
marked NN NN O
corticomedullary NN NN O
gradient NN NN O
of NN NN O
prostaglandin NN NN O
synthesis NN NN O
was NN NN O
observed NN NN O
in NN NN O
all NN NN O
groups NN NN O
. NN NN O
   
PGE2 NN NN O
synthesis NN NN O
was NN NN O
significantly NN NN O
higher NN NN O
in NN NN O
outer NN NN O
medulla NN NN O
, NN NN O
but NN NN O
not NN NN O
cortex NN NN O
or NN NN O
inner NN NN O
medulla NN NN O
, NN NN O
of NN NN O
jj NN NN O
( NN NN O
38 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
6 NN NN O
ng NN NN O
/ NN NN O
mg NN NN O
prot NN NN O
) NN NN O
than NN NN O
jJ NN NN O
rats NN NN O
( NN NN O
15 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
3 NN NN O
) NN NN O
( NN NN O
p NN NN O
less NN NN O
than NN NN O
0 NN NN O
. NN NN O
01 NN NN O
) NN NN O
. NN NN O
   
Aspirin NN NN O
treatment NN NN O
reduced NN NN O
PGE2 NN NN O
synthesis NN NN O
in NN NN O
all NN NN O
regions NN NN O
, NN NN O
but NN NN O
outer NN NN O
medullary NN NN O
PGE2 NN NN O
remained NN NN O
higher NN NN O
in NN NN O
jj NN NN O
( NN NN O
18 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
3 NN NN O
) NN NN O
than NN NN O
jJ NN NN O
rats NN NN O
( NN NN O
9 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
2 NN NN O
) NN NN O
( NN NN O
p NN NN O
less NN NN O
than NN NN O
0 NN NN O
. NN NN O
05 NN NN O
) NN NN O
. NN NN O
   
PGF2 NN NN O
alpha NN NN O
was NN NN O
also NN NN O
significantly NN NN O
higher NN NN O
in NN NN O
the NN NN O
outer NN NN O
medulla NN NN O
of NN NN O
jj NN NN O
rats NN NN O
with NN NN O
and NN NN O
without NN NN O
aspirin NN NN O
administration NN NN O
( NN NN O
p NN NN O
less NN NN O
than NN NN O
0 NN NN O
. NN NN O
05 NN NN O
) NN NN O
. NN NN O
   
The NN NN O
changes NN NN O
in NN NN O
renal NN NN O
prostaglandin NN NN O
synthesis NN NN O
were NN NN O
accompanied NN NN O
by NN NN O
evidence NN NN O
of NN NN O
renal NN NN B-Disease
damage NN NN I-Disease
in NN NN O
aspirin NN NN O
- NN NN O
treated NN NN O
jj NN NN O
but NN NN O
not NN NN O
jJ NN NN O
rats NN NN O
as NN NN O
evidenced NN NN O
by NN NN O
: NN NN O
increased NN NN O
incidence NN NN O
and NN NN O
severity NN NN O
of NN NN O
hematuria NN NN B-Disease
( NN NN O
p NN NN O
less NN NN O
than NN NN O
0 NN NN O
. NN NN O
01 NN NN O
) NN NN O
; NN NN O
increased NN NN O
serum NN NN O
creatinine NN NN O
( NN NN O
p NN NN O
less NN NN O
than NN NN O
0 NN NN O
. NN NN O
05 NN NN O
) NN NN O
; NN NN O
and NN NN O
increase NN NN O
in NN NN O
outer NN NN O
medullary NN NN O
histopathologic NN NN O
lesions NN NN O
( NN NN O
p NN NN O
less NN NN O
than NN NN O
0 NN NN O
. NN NN O
005 NN NN O
compared NN NN O
to NN NN O
either NN NN O
sham NN NN O
- NN NN O
treated NN NN O
jj NN NN O
or NN NN O
aspirin NN NN O
- NN NN O
treated NN NN O
jJ NN NN O
) NN NN O
. NN NN O
   
These NN NN O
results NN NN O
suggest NN NN O
that NN NN O
enhanced NN NN O
prostaglandin NN NN O
synthesis NN NN O
contributes NN NN O
to NN NN O
maintenance NN NN O
of NN NN O
renal NN NN O
function NN NN O
and NN NN O
morphological NN NN O
integrity NN NN O
, NN NN O
and NN NN O
that NN NN O
inhibition NN NN O
of NN NN O
prostaglandin NN NN O
synthesis NN NN O
may NN NN O
lead NN NN O
to NN NN O
pathological NN NN B-Disease
renal NN NN I-Disease
medullary NN NN I-Disease
lesions NN NN I-Disease
and NN NN O
deterioration NN NN B-Disease
of NN NN I-Disease
renal NN NN I-Disease
function NN NN I-Disease
. NN NN O
   
Prophylactic NN NN O
lidocaine NN NN O
in NN NN O
the NN NN O
early NN NN O
phase NN NN O
of NN NN O
suspected NN NN O
myocardial NN NN B-Disease
infarction NN NN I-Disease
. NN NN O
   
Four NN NN O
hundred NN NN O
two NN NN O
patients NN NN O
with NN NN O
suspected NN NN O
myocardial NN NN B-Disease
infarction NN NN I-Disease
seen NN NN O
within NN NN O
6 NN NN O
hours NN NN O
of NN NN O
the NN NN O
onset NN NN O
of NN NN O
symptoms NN NN O
entered NN NN O
a NN NN O
double NN NN O
- NN NN O
blind NN NN O
randomized NN NN O
trial NN NN O
of NN NN O
lidocaine NN NN O
vs NN NN O
placebo NN NN O
. NN NN O
   
During NN NN O
the NN NN O
1 NN NN O
hour NN NN O
after NN NN O
administration NN NN O
of NN NN O
the NN NN O
drug NN NN O
the NN NN O
incidence NN NN O
of NN NN O
ventricular NN NN B-Disease
fibrillation NN NN I-Disease
or NN NN O
sustained NN NN O
ventricular NN NN B-Disease
tachycardia NN NN I-Disease
among NN NN O
the NN NN O
204 NN NN O
patients NN NN O
with NN NN O
acute NN NN O
myocardial NN NN B-Disease
infarction NN NN I-Disease
was NN NN O
low NN NN O
, NN NN O
1 NN NN O
. NN NN O
5 NN NN O
% NN NN O
. NN NN O
   
Lidocaine NN NN O
, NN NN O
given NN NN O
in NN NN O
a NN NN O
300 NN NN O
mg NN NN O
dose NN NN O
intramuscularly NN NN O
followed NN NN O
by NN NN O
100 NN NN O
mg NN NN O
intravenously NN NN O
, NN NN O
did NN NN O
not NN NN O
prevent NN NN O
sustained NN NN O
ventricular NN NN B-Disease
tachycardia NN NN I-Disease
, NN NN O
although NN NN O
there NN NN O
was NN NN O
a NN NN O
significant NN NN O
reduction NN NN O
in NN NN O
the NN NN O
number NN NN O
of NN NN O
patients NN NN O
with NN NN O
warning NN NN O
arrhythmias NN NN B-Disease
between NN NN O
15 NN NN O
and NN NN O
45 NN NN O
minutes NN NN O
after NN NN O
the NN NN O
administration NN NN O
of NN NN O
lidocaine NN NN O
( NN NN O
p NN NN O
less NN NN O
than NN NN O
0 NN NN O
. NN NN O
05 NN NN O
) NN NN O
. NN NN O
   
The NN NN O
average NN NN O
plasma NN NN O
lidocaine NN NN O
level NN NN O
10 NN NN O
minutes NN NN O
after NN NN O
administration NN NN O
for NN NN O
patients NN NN O
without NN NN O
a NN NN O
myocardial NN NN B-Disease
infarction NN NN I-Disease
was NN NN O
significantly NN NN O
higher NN NN O
than NN NN O
that NN NN O
for NN NN O
patients NN NN O
with NN NN O
an NN NN O
acute NN NN O
infarction NN NN B-Disease
. NN NN O
   
The NN NN O
mean NN NN O
plasma NN NN O
lidocaine NN NN O
level NN NN O
of NN NN O
patients NN NN O
on NN NN O
beta NN NN O
- NN NN O
blocking NN NN O
agents NN NN O
was NN NN O
no NN NN O
different NN NN O
from NN NN O
that NN NN O
in NN NN O
patients NN NN O
not NN NN O
on NN NN O
beta NN NN O
blocking NN NN O
agents NN NN O
. NN NN O
   
During NN NN O
the NN NN O
1 NN NN O
- NN NN O
hour NN NN O
study NN NN O
period NN NN O
, NN NN O
the NN NN O
incidence NN NN O
of NN NN O
central NN NN O
nervous NN NN O
system NN NN O
side NN NN O
effects NN NN O
was NN NN O
significantly NN NN O
greater NN NN O
in NN NN O
the NN NN O
lidocaine NN NN O
group NN NN O
, NN NN O
hypotension NN NN B-Disease
occurred NN NN O
in NN NN O
11 NN NN O
patients NN NN O
, NN NN O
nine NN NN O
of NN NN O
whom NN NN O
had NN NN O
received NN NN O
lidocaine NN NN O
, NN NN O
and NN NN O
four NN NN O
patients NN NN O
died NN NN O
from NN NN O
asystole NN NN B-Disease
, NN NN O
three NN NN O
of NN NN O
whom NN NN O
had NN NN O
had NN NN O
lidocaine NN NN O
. NN NN O
   
We NN NN O
cannot NN NN O
advocate NN NN O
the NN NN O
administration NN NN O
of NN NN O
lidocaine NN NN O
prophylactically NN NN O
in NN NN O
the NN NN O
early NN NN O
hours NN NN O
of NN NN O
suspected NN NN O
myocardial NN NN B-Disease
infarction NN NN I-Disease
. NN NN O
   
Evidence NN NN O
for NN NN O
a NN NN O
cholinergic NN NN O
role NN NN O
in NN NN O
haloperidol NN NN O
- NN NN O
induced NN NN O
catalepsy NN NN B-Disease
. NN NN O
   
Experiments NN NN O
in NN NN O
mice NN NN O
tested NN NN O
previous NN NN O
evidence NN NN O
that NN NN O
activation NN NN O
of NN NN O
cholinergic NN NN O
systems NN NN O
promotes NN NN O
catalepsy NN NN B-Disease
and NN NN O
that NN NN O
cholinergic NN NN O
mechanisms NN NN O
need NN NN O
to NN NN O
be NN NN O
intact NN NN O
for NN NN O
full NN NN O
expression NN NN O
of NN NN O
neuroleptic NN NN O
- NN NN O
induced NN NN O
catalepsy NN NN B-Disease
. NN NN O
   
Large NN NN O
doses NN NN O
of NN NN O
the NN NN O
cholinomimetic NN NN O
, NN NN O
pilocarpine NN NN O
, NN NN O
could NN NN O
induce NN NN O
catalepsy NN NN B-Disease
when NN NN O
peripheral NN NN O
cholinergic NN NN O
receptors NN NN O
were NN NN O
blocked NN NN O
. NN NN O
   
Low NN NN O
doses NN NN O
of NN NN O
pilocarpine NN NN O
caused NN NN O
a NN NN O
pronounced NN NN O
enhancement NN NN O
of NN NN O
the NN NN O
catalepsy NN NN B-Disease
that NN NN O
was NN NN O
induced NN NN O
by NN NN O
the NN NN O
dopaminergic NN NN O
blocker NN NN O
, NN NN O
haloperidol NN NN O
. NN NN O
   
A NN NN O
muscarinic NN NN O
receptor NN NN O
blocker NN NN O
, NN NN O
atropine NN NN O
, NN NN O
disrupted NN NN O
haloperidol NN NN O
- NN NN O
induced NN NN O
catalepsy NN NN B-Disease
. NN NN O
   
Intracranial NN NN O
injection NN NN O
of NN NN O
an NN NN O
acetylcholine NN NN O
- NN NN O
synthesis NN NN O
inhibitor NN NN O
, NN NN O
hemicholinium NN NN O
, NN NN O
prevented NN NN O
the NN NN O
catalepsy NN NN B-Disease
that NN NN O
is NN NN O
usually NN NN O
induced NN NN O
by NN NN O
haloperidol NN NN O
. NN NN O
   
These NN NN O
findings NN NN O
suggest NN NN O
the NN NN O
hypothesis NN NN O
that NN NN O
the NN NN O
catalepsy NN NN B-Disease
that NN NN O
is NN NN O
produced NN NN O
by NN NN O
neuroleptics NN NN O
such NN NN O
as NN NN O
haloperidol NN NN O
is NN NN O
actually NN NN O
mediated NN NN O
by NN NN O
intrinsic NN NN O
central NN NN O
cholinergic NN NN O
systems NN NN O
. NN NN O
   
Alternatively NN NN O
, NN NN O
activation NN NN O
of NN NN O
central NN NN O
cholinergic NN NN O
systems NN NN O
could NN NN O
promote NN NN O
catalepsy NN NN B-Disease
by NN NN O
suppression NN NN O
of NN NN O
dopaminergic NN NN O
systems NN NN O
. NN NN O
   
Cardiovascular NN NN B-Disease
dysfunction NN NN I-Disease
and NN NN O
hypersensitivity NN NN B-Disease
to NN NN O
sodium NN NN O
pentobarbital NN NN O
induced NN NN O
by NN NN O
chronic NN NN O
barium NN NN O
chloride NN NN O
ingestion NN NN O
. NN NN O
   
Barium NN NN O
- NN NN O
supplemented NN NN O
Long NN NN O
- NN NN O
Evans NN NN O
hooded NN NN O
rats NN NN O
were NN NN O
characterized NN NN O
by NN NN O
a NN NN O
persistent NN NN O
hypertension NN NN B-Disease
that NN NN O
was NN NN O
evident NN NN O
after NN NN O
1 NN NN O
month NN NN O
of NN NN O
barium NN NN O
( NN NN O
100 NN NN O
micrograms NN NN O
/ NN NN O
ml NN NN O
mineral NN NN O
fortified NN NN O
water NN NN O
) NN NN O
treatment NN NN O
. NN NN O
   
Analysis NN NN O
of NN NN O
in NN NN O
vivo NN NN O
myocardial NN NN O
excitability NN NN O
, NN NN O
contractility NN NN O
, NN NN O
and NN NN O
metabolic NN NN O
characteristics NN NN O
at NN NN O
16 NN NN O
months NN NN O
revealed NN NN O
other NN NN O
significant NN NN O
barium NN NN O
- NN NN O
induced NN NN O
disturbances NN NN B-Disease
within NN NN I-Disease
the NN NN I-Disease
cardiovascular NN NN I-Disease
system NN NN I-Disease
. NN NN O
   
The NN NN O
most NN NN O
distinctive NN NN O
aspect NN NN O
of NN NN O
the NN NN O
barium NN NN O
effect NN NN O
was NN NN O
a NN NN O
demonstrated NN NN O
hypersensitivity NN NN B-Disease
of NN NN O
the NN NN O
cardiovascular NN NN O
system NN NN O
to NN NN O
sodium NN NN O
pentobarbital NN NN O
. NN NN O
   
Under NN NN O
barbiturate NN NN O
anesthesia NN NN O
, NN NN O
virtually NN NN O
all NN NN O
of NN NN O
the NN NN O
myocardial NN NN O
contractile NN NN O
indices NN NN O
were NN NN O
depressed NN NN O
significantly NN NN O
in NN NN O
barium NN NN O
- NN NN O
exposed NN NN O
rats NN NN O
relative NN NN O
to NN NN O
the NN NN O
corresponding NN NN O
control NN NN O
- NN NN O
fed NN NN O
rats NN NN O
. NN NN O
   
The NN NN O
lack NN NN O
of NN NN O
a NN NN O
similar NN NN O
response NN NN O
to NN NN O
ketamine NN NN O
and NN NN O
xylazine NN NN O
anesthesia NN NN O
revealed NN NN O
that NN NN O
the NN NN O
cardiovascular NN NN O
actions NN NN O
of NN NN O
sodium NN NN O
pentobarbital NN NN O
in NN NN O
barium NN NN O
- NN NN O
treated NN NN O
rats NN NN O
were NN NN O
linked NN NN O
specifically NN NN O
to NN NN O
this NN NN O
anesthetic NN NN O
, NN NN O
and NN NN O
were NN NN O
not NN NN O
representative NN NN O
of NN NN O
a NN NN O
generalized NN NN O
anesthetic NN NN O
response NN NN O
. NN NN O
   
Other NN NN O
myocardial NN NN O
pathophysiologic NN NN O
and NN NN O
metabolic NN NN O
changes NN NN O
induced NN NN O
by NN NN O
barium NN NN O
were NN NN O
manifest NN NN O
, NN NN O
irrespective NN NN O
of NN NN O
the NN NN O
anesthetic NN NN O
employed NN NN O
. NN NN O
   
The NN NN O
contractile NN NN O
element NN NN O
shortening NN NN O
velocity NN NN O
of NN NN O
the NN NN O
cardiac NN NN O
muscle NN NN O
fibers NN NN O
was NN NN O
significantly NN NN O
slower NN NN O
in NN NN O
both NN NN O
groups NN NN O
of NN NN O
barium NN NN O
- NN NN O
treated NN NN O
rats NN NN O
relative NN NN O
to NN NN O
the NN NN O
control NN NN O
groups NN NN O
, NN NN O
irrespective NN NN O
of NN NN O
the NN NN O
anesthetic NN NN O
regimen NN NN O
. NN NN O
   
Similarly NN NN O
, NN NN O
significant NN NN O
disturbances NN NN O
in NN NN O
myocardial NN NN O
energy NN NN O
metabolism NN NN O
were NN NN O
detected NN NN O
in NN NN O
the NN NN O
barium NN NN O
- NN NN O
exposed NN NN O
rats NN NN O
which NN NN O
were NN NN O
consistent NN NN O
with NN NN O
the NN NN O
reduced NN NN O
contractile NN NN O
element NN NN O
shortening NN NN O
velocity NN NN O
. NN NN O
   
In NN NN O
addition NN NN O
, NN NN O
the NN NN O
excitability NN NN O
of NN NN O
the NN NN O
cardiac NN NN O
conduction NN NN O
system NN NN O
was NN NN O
depressed NN NN O
preferentially NN NN O
in NN NN O
the NN NN O
atrioventricular NN NN O
nodal NN NN O
region NN NN O
of NN NN O
hearts NN NN O
from NN NN O
barium NN NN O
- NN NN O
exposed NN NN O
rats NN NN O
. NN NN O
   
Overall NN NN O
, NN NN O
the NN NN O
altered NN NN O
cardiac NN NN O
contractility NN NN O
and NN NN O
excitability NN NN O
characteristics NN NN O
, NN NN O
the NN NN O
myocardial NN NN O
metabolic NN NN B-Disease
disturbances NN NN I-Disease
, NN NN O
and NN NN O
the NN NN O
hypersensitivity NN NN B-Disease
of NN NN O
the NN NN O
cardiovascular NN NN O
system NN NN O
to NN NN O
sodium NN NN O
pentobarbital NN NN O
suggest NN NN O
the NN NN O
existence NN NN O
of NN NN O
a NN NN O
heretofore NN NN O
undescribed NN NN O
cardiomyopathic NN NN B-Disease
disorder NN NN I-Disease
induced NN NN O
by NN NN O
chronic NN NN O
barium NN NN O
exposure NN NN O
. NN NN O
   
These NN NN O
experimental NN NN O
findings NN NN O
represent NN NN O
the NN NN O
first NN NN O
indication NN NN O
that NN NN O
life NN NN O
- NN NN O
long NN NN O
barium NN NN O
ingestion NN NN O
may NN NN O
have NN NN O
significant NN NN O
adverse NN NN O
effects NN NN O
on NN NN O
the NN NN O
mammalian NN NN O
cardiovascular NN NN O
system NN NN O
. NN NN O
   
Propranolol NN NN O
antagonism NN NN O
of NN NN O
phenylpropanolamine NN NN O
- NN NN O
induced NN NN O
hypertension NN NN B-Disease
. NN NN O
   
Phenylpropanolamine NN NN O
( NN NN O
PPA NN NN O
) NN NN O
overdose NN NN B-Disease
can NN NN O
cause NN NN O
severe NN NN O
hypertension NN NN B-Disease
, NN NN O
intracerebral NN NN B-Disease
hemorrhage NN NN I-Disease
, NN NN O
and NN NN O
death NN NN O
. NN NN O
   
We NN NN O
studied NN NN O
the NN NN O
efficacy NN NN O
and NN NN O
safety NN NN O
of NN NN O
propranolol NN NN O
in NN NN O
the NN NN O
treatment NN NN O
of NN NN O
PPA NN NN O
- NN NN O
induced NN NN O
hypertension NN NN B-Disease
. NN NN O
   
Subjects NN NN O
received NN NN O
propranolol NN NN O
either NN NN O
by NN NN O
mouth NN NN O
for NN NN O
48 NN NN O
hours NN NN O
before NN NN O
PPA NN NN O
or NN NN O
as NN NN O
a NN NN O
rapid NN NN O
intravenous NN NN O
infusion NN NN O
after NN NN O
PPA NN NN O
. NN NN O
   
PPA NN NN O
, NN NN O
75 NN NN O
mg NN NN O
alone NN NN O
, NN NN O
increased NN NN O
blood NN NN O
pressure NN NN O
( NN NN O
31 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
14 NN NN O
mm NN NN O
Hg NN NN O
systolic NN NN O
, NN NN O
20 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
5 NN NN O
mm NN NN O
Hg NN NN O
diastolic NN NN O
) NN NN O
, NN NN O
and NN NN O
propranolol NN NN O
pretreatment NN NN O
antagonized NN NN O
this NN NN O
increase NN NN O
( NN NN O
12 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
10 NN NN O
mm NN NN O
Hg NN NN O
systolic NN NN O
, NN NN O
10 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
7 NN NN O
mm NN NN O
Hg NN NN O
diastolic NN NN O
) NN NN O
. NN NN O
   
Intravenous NN NN O
propranolol NN NN O
after NN NN O
PPA NN NN O
also NN NN O
decreased NN NN O
blood NN NN O
pressure NN NN O
. NN NN O
   
Left NN NN O
ventricular NN NN O
function NN NN O
( NN NN O
assessed NN NN O
by NN NN O
echocardiography NN NN O
) NN NN O
showed NN NN O
that NN NN O
PPA NN NN O
increased NN NN O
the NN NN O
stroke NN NN B-Disease
volume NN NN O
30 NN NN O
% NN NN O
( NN NN O
from NN NN O
62 NN NN O
. NN NN O
5 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
20 NN NN O
. NN NN O
9 NN NN O
to NN NN O
80 NN NN O
. NN NN O
8 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
22 NN NN O
. NN NN O
4 NN NN O
ml NN NN O
) NN NN O
, NN NN O
the NN NN O
ejection NN NN O
fraction NN NN O
9 NN NN O
% NN NN O
( NN NN O
from NN NN O
64 NN NN O
% NN NN O
+ NN NN O
/ NN NN O
- NN NN O
10 NN NN O
% NN NN O
to NN NN O
70 NN NN O
% NN NN O
+ NN NN O
/ NN NN O
- NN NN O
7 NN NN O
% NN NN O
) NN NN O
, NN NN O
and NN NN O
cardiac NN NN O
output NN NN O
14 NN NN O
% NN NN O
( NN NN O
from NN NN O
3 NN NN O
. NN NN O
6 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
0 NN NN O
. NN NN O
6 NN NN O
to NN NN O
4 NN NN O
. NN NN O
1 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
1 NN NN O
. NN NN O
0 NN NN O
L NN NN O
/ NN NN O
min NN NN O
) NN NN O
. NN NN O
   
Intravenous NN NN O
propranolol NN NN O
reversed NN NN O
these NN NN O
effects NN NN O
. NN NN O
   
Systemic NN NN O
vascular NN NN O
resistance NN NN O
was NN NN O
increased NN NN O
by NN NN O
PPA NN NN O
28 NN NN O
% NN NN O
( NN NN O
from NN NN O
1710 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
200 NN NN O
to NN NN O
2190 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
700 NN NN O
dyne NN NN O
X NN NN O
sec NN NN O
/ NN NN O
cm5 NN NN O
) NN NN O
and NN NN O
was NN NN O
further NN NN O
increased NN NN O
by NN NN O
propranolol NN NN O
22 NN NN O
% NN NN O
( NN NN O
to NN NN O
2660 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
1200 NN NN O
dyne NN NN O
X NN NN O
sec NN NN O
/ NN NN O
cm5 NN NN O
) NN NN O
. NN NN O
   
We NN NN O
conclude NN NN O
that NN NN O
PPA NN NN O
increases NN NN O
blood NN NN O
pressure NN NN O
by NN NN O
increasing NN NN O
systemic NN NN O
vascular NN NN O
resistance NN NN O
and NN NN O
cardiac NN NN O
output NN NN O
, NN NN O
and NN NN O
that NN NN O
propranolol NN NN O
antagonizes NN NN O
this NN NN O
increase NN NN O
by NN NN O
reversing NN NN O
the NN NN O
effect NN NN O
of NN NN O
PPA NN NN O
on NN NN O
cardiac NN NN O
output NN NN O
. NN NN O
   
That NN NN O
propranolol NN NN O
antagonizes NN NN O
the NN NN O
pressor NN NN O
effect NN NN O
of NN NN O
PPA NN NN O
is NN NN O
in NN NN O
contrast NN NN O
to NN NN O
the NN NN O
interaction NN NN O
in NN NN O
which NN NN O
propranolol NN NN O
enhances NN NN O
the NN NN O
pressor NN NN O
effect NN NN O
of NN NN O
norepinephrine NN NN O
. NN NN O
   
This NN NN O
is NN NN O
probably NN NN O
because NN NN O
PPA NN NN O
has NN NN O
less NN NN O
beta NN NN O
2 NN NN O
activity NN NN O
than NN NN O
does NN NN O
norepinephrine NN NN O
. NN NN O
   
Mesangial NN NN O
function NN NN O
and NN NN O
glomerular NN NN B-Disease
sclerosis NN NN I-Disease
in NN NN O
rats NN NN O
with NN NN O
aminonucleoside NN NN O
nephrosis NN NN B-Disease
. NN NN O
   
The NN NN O
possible NN NN O
relationship NN NN O
between NN NN O
mesangial NN NN B-Disease
dysfunction NN NN I-Disease
and NN NN O
development NN NN O
of NN NN O
glomerular NN NN B-Disease
sclerosis NN NN I-Disease
was NN NN O
studied NN NN O
in NN NN O
the NN NN O
puromycin NN NN O
aminonucleoside NN NN O
( NN NN O
PAN NN NN O
) NN NN O
model NN NN O
. NN NN O
   
Five NN NN O
male NN NN O
Wistar NN NN O
rats NN NN O
received NN NN O
repeated NN NN O
subcutaneous NN NN O
PAN NN NN O
injections NN NN O
; NN NN O
five NN NN O
controls NN NN O
received NN NN O
saline NN NN O
only NN NN O
. NN NN O
   
After NN NN O
4 NN NN O
weeks NN NN O
the NN NN O
PAN NN NN O
rats NN NN O
were NN NN O
severely NN NN O
proteinuric NN NN B-Disease
( NN NN O
190 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
80 NN NN O
mg NN NN O
/ NN NN O
24 NN NN O
hr NN NN O
) NN NN O
, NN NN O
and NN NN O
all NN NN O
rats NN NN O
were NN NN O
given NN NN O
colloidal NN NN O
carbon NN NN O
( NN NN O
CC NN NN O
) NN NN O
intravenously NN NN O
. NN NN O
   
At NN NN O
5 NN NN O
months NN NN O
glomerular NN NN B-Disease
sclerosis NN NN I-Disease
was NN NN O
found NN NN O
in NN NN O
7 NN NN O
. NN NN O
6 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
3 NN NN O
. NN NN O
4 NN NN O
% NN NN O
of NN NN O
the NN NN O
glomeruli NN NN O
of NN NN O
PAN NN NN O
rats NN NN O
; NN NN O
glomeruli NN NN O
of NN NN O
the NN NN O
controls NN NN O
were NN NN O
normal NN NN O
. NN NN O
   
Glomeruli NN NN O
of NN NN O
PAN NN NN O
rats NN NN O
contained NN NN O
significantly NN NN O
more NN NN O
CC NN NN O
than NN NN O
glomeruli NN NN O
of NN NN O
controls NN NN O
. NN NN O
   
Glomeruli NN NN O
with NN NN O
sclerosis NN NN B-Disease
contained NN NN O
significantly NN NN O
more NN NN O
CC NN NN O
than NN NN O
non NN NN O
- NN NN O
sclerotic NN NN O
glomeruli NN NN O
in NN NN O
the NN NN O
same NN NN O
kidneys NN NN O
. NN NN O
   
CC NN NN O
was NN NN O
preferentially NN NN O
localized NN NN O
within NN NN O
the NN NN O
sclerotic NN NN O
areas NN NN O
of NN NN O
the NN NN O
affected NN NN O
glomeruli NN NN O
. NN NN O
   
Since NN NN O
mesangial NN NN O
CC NN NN O
clearance NN NN O
from NN NN O
the NN NN O
mesangium NN NN O
did NN NN O
not NN NN O
change NN NN O
during NN NN O
chronic NN NN O
PAN NN NN O
treatment NN NN O
, NN NN O
we NN NN O
conclude NN NN O
that NN NN O
this NN NN O
preferential NN NN O
CC NN NN O
localization NN NN O
within NN NN O
the NN NN O
lesions NN NN O
is NN NN O
caused NN NN O
by NN NN O
an NN NN O
increased NN NN O
CC NN NN O
uptake NN NN O
shortly NN NN O
after NN NN O
injection NN NN O
in NN NN O
apparent NN NN O
vulnerable NN NN O
areas NN NN O
where NN NN O
sclerosis NN NN B-Disease
will NN NN O
develop NN NN O
subsequently NN NN O
. NN NN O
   
Cluster NN NN O
analysis NN NN O
showed NN NN O
a NN NN O
random NN NN O
distribution NN NN O
of NN NN O
lesions NN NN O
in NN NN O
the NN NN O
PAN NN NN O
glomeruli NN NN O
in NN NN O
concordance NN NN O
with NN NN O
the NN NN O
random NN NN O
localization NN NN O
of NN NN O
mesangial NN NN O
areas NN NN O
with NN NN O
dysfunction NN NN O
in NN NN O
this NN NN O
model NN NN O
. NN NN O
   
Similar NN NN O
to NN NN O
the NN NN O
remnant NN NN O
kidney NN NN O
model NN NN O
in NN NN O
PAN NN NN O
nephrosis NN NN B-Disease
the NN NN O
development NN NN O
of NN NN O
glomerular NN NN B-Disease
sclerosis NN NN I-Disease
may NN NN O
be NN NN O
related NN NN O
to NN NN O
"""""""" NN NN O
mesangial NN NN O
overloading NN NN O
. NN NN O
"""""""" NN NN O
   
Relationship NN NN O
between NN NN O
nicotine NN NN O
- NN NN O
induced NN NN O
seizures NN NN B-Disease
and NN NN O
hippocampal NN NN O
nicotinic NN NN O
receptors NN NN O
. NN NN O
   
A NN NN O
controversy NN NN O
has NN NN O
existed NN NN O
for NN NN O
several NN NN O
years NN NN O
concerning NN NN O
the NN NN O
physiological NN NN O
relevance NN NN O
of NN NN O
the NN NN O
nicotinic NN NN O
receptor NN NN O
measured NN NN O
by NN NN O
alpha NN NN O
- NN NN O
bungarotoxin NN NN O
binding NN NN O
. NN NN O
   
Using NN NN O
mice NN NN O
derived NN NN O
from NN NN O
a NN NN O
classical NN NN O
F2 NN NN O
and NN NN O
backcross NN NN O
genetic NN NN O
design NN NN O
, NN NN O
a NN NN O
relationship NN NN O
between NN NN O
nicotine NN NN O
- NN NN O
induced NN NN O
seizures NN NN B-Disease
and NN NN O
alpha NN NN O
- NN NN O
bungarotoxin NN NN O
nicotinic NN NN O
receptor NN NN O
concentration NN NN O
was NN NN O
found NN NN O
. NN NN O
   
Mice NN NN O
sensitive NN NN O
to NN NN O
the NN NN O
convulsant NN NN O
effects NN NN O
of NN NN O
nicotine NN NN O
had NN NN O
greater NN NN O
alpha NN NN O
- NN NN O
bungarotoxin NN NN O
binding NN NN O
in NN NN O
the NN NN O
hippocampus NN NN O
than NN NN O
seizure NN NN B-Disease
insensitive NN NN O
mice NN NN O
. NN NN O
   
The NN NN O
binding NN NN O
sites NN NN O
from NN NN O
seizure NN NN B-Disease
sensitive NN NN O
and NN NN O
resistant NN NN O
mice NN NN O
were NN NN O
equally NN NN O
affected NN NN O
by NN NN O
treatment NN NN O
with NN NN O
dithiothreitol NN NN O
, NN NN O
trypsin NN NN O
or NN NN O
heat NN NN O
. NN NN O
   
Thus NN NN O
it NN NN O
appears NN NN O
that NN NN O
the NN NN O
difference NN NN O
between NN NN O
seizure NN NN B-Disease
sensitive NN NN O
and NN NN O
insensitive NN NN O
animals NN NN O
may NN NN O
be NN NN O
due NN NN O
to NN NN O
a NN NN O
difference NN NN O
in NN NN O
hippocampal NN NN O
nicotinic NN NN O
receptor NN NN O
concentration NN NN O
as NN NN O
measured NN NN O
with NN NN O
alpha NN NN O
- NN NN O
bungarotoxin NN NN O
binding NN NN O
. NN NN O
   
The NN NN O
role NN NN O
of NN NN O
p NN NN O
- NN NN O
aminophenol NN NN O
in NN NN O
acetaminophen NN NN O
- NN NN O
induced NN NN O
nephrotoxicity NN NN B-Disease
: NN NN O
effect NN NN O
of NN NN O
bis NN NN O
( NN NN O
p NN NN O
- NN NN O
nitrophenyl NN NN O
) NN NN O
phosphate NN NN O
on NN NN O
acetaminophen NN NN O
and NN NN O
p NN NN O
- NN NN O
aminophenol NN NN O
nephrotoxicity NN NN B-Disease
and NN NN O
metabolism NN NN O
in NN NN O
Fischer NN NN O
344 NN NN O
rats NN NN O
. NN NN O
   
Acetaminophen NN NN O
( NN NN O
APAP NN NN O
) NN NN O
produces NN NN O
proximal NN NN O
tubular NN NN B-Disease
necrosis NN NN I-Disease
in NN NN O
Fischer NN NN O
344 NN NN O
( NN NN O
F344 NN NN O
) NN NN O
rats NN NN O
. NN NN O
   
Recently NN NN O
, NN NN O
p NN NN O
- NN NN O
aminophenol NN NN O
( NN NN O
PAP NN NN O
) NN NN O
, NN NN O
a NN NN O
known NN NN O
potent NN NN O
nephrotoxicant NN NN O
, NN NN O
was NN NN O
identified NN NN O
as NN NN O
a NN NN O
metabolite NN NN O
of NN NN O
APAP NN NN O
in NN NN O
F344 NN NN O
rats NN NN O
. NN NN O
   
The NN NN O
purpose NN NN O
of NN NN O
this NN NN O
study NN NN O
was NN NN O
to NN NN O
determine NN NN O
if NN NN O
PAP NN NN O
formation NN NN O
is NN NN O
a NN NN O
requisite NN NN O
step NN NN O
in NN NN O
APAP NN NN O
- NN NN O
induced NN NN O
nephrotoxicity NN NN B-Disease
. NN NN O
   
Therefore NN NN O
, NN NN O
the NN NN O
effect NN NN O
of NN NN O
bis NN NN O
( NN NN O
p NN NN O
- NN NN O
nitrophenyl NN NN O
) NN NN O
phosphate NN NN O
( NN NN O
BNPP NN NN O
) NN NN O
, NN NN O
an NN NN O
acylamidase NN NN O
inhibitor NN NN O
, NN NN O
on NN NN O
APAP NN NN O
and NN NN O
PAP NN NN O
nephrotoxicity NN NN B-Disease
and NN NN O
metabolism NN NN O
was NN NN O
determined NN NN O
. NN NN O
   
BNPP NN NN O
( NN NN O
1 NN NN O
to NN NN O
8 NN NN O
mM NN NN O
) NN NN O
reduced NN NN O
APAP NN NN O
deacetylation NN NN O
and NN NN O
covalent NN NN O
binding NN NN O
in NN NN O
F344 NN NN O
renal NN NN O
cortical NN NN O
homogenates NN NN O
in NN NN O
a NN NN O
concentration NN NN O
- NN NN O
dependent NN NN O
manner NN NN O
. NN NN O
   
Pretreatment NN NN O
of NN NN O
animals NN NN O
with NN NN O
BNPP NN NN O
prior NN NN O
to NN NN O
APAP NN NN O
or NN NN O
PAP NN NN O
administration NN NN O
resulted NN NN O
in NN NN O
marked NN NN O
reduction NN NN O
of NN NN O
APAP NN NN O
( NN NN O
900 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
) NN NN O
nephrotoxicity NN NN B-Disease
but NN NN O
not NN NN O
PAP NN NN O
nephrotoxicity NN NN B-Disease
. NN NN O
   
This NN NN O
result NN NN O
was NN NN O
not NN NN O
due NN NN O
to NN NN O
altered NN NN O
disposition NN NN O
of NN NN O
either NN NN O
APAP NN NN O
or NN NN O
acetylated NN NN O
metabolites NN NN O
in NN NN O
plasma NN NN O
or NN NN O
renal NN NN O
cortical NN NN O
and NN NN O
hepatic NN NN O
tissue NN NN O
. NN NN O
   
Rather NN NN O
, NN NN O
BNPP NN NN O
pretreatment NN NN O
reduced NN NN O
the NN NN O
fraction NN NN O
of NN NN O
APAP NN NN O
excreted NN NN O
as NN NN O
PAP NN NN O
by NN NN O
64 NN NN O
and NN NN O
75 NN NN O
% NN NN O
after NN NN O
APAP NN NN O
doses NN NN O
of NN NN O
750 NN NN O
and NN NN O
900 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
. NN NN O
   
BNPP NN NN O
did NN NN O
not NN NN O
alter NN NN O
the NN NN O
excretion NN NN O
of NN NN O
APAP NN NN O
or NN NN O
any NN NN O
of NN NN O
its NN NN O
non NN NN O
- NN NN O
deacetylated NN NN O
metabolites NN NN O
nor NN NN O
did NN NN O
BNPP NN NN O
alter NN NN O
excretion NN NN O
of NN NN O
PAP NN NN O
or NN NN O
its NN NN O
metabolites NN NN O
after NN NN O
PAP NN NN O
doses NN NN O
of NN NN O
150 NN NN O
and NN NN O
300 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
. NN NN O
   
Therefore NN NN O
, NN NN O
the NN NN O
BNPP NN NN O
- NN NN O
induced NN NN O
reduction NN NN O
in NN NN O
APAP NN NN O
- NN NN O
induced NN NN O
nephrotoxicity NN NN B-Disease
appears NN NN O
to NN NN O
be NN NN O
due NN NN O
to NN NN O
inhibition NN NN O
of NN NN O
APAP NN NN O
deacetylation NN NN O
. NN NN O
   
It NN NN O
is NN NN O
concluded NN NN O
that NN NN O
PAP NN NN O
formation NN NN O
, NN NN O
in NN NN O
vivo NN NN O
, NN NN O
accounts NN NN O
, NN NN O
at NN NN O
least NN NN O
in NN NN O
part NN NN O
, NN NN O
for NN NN O
APAP NN NN O
- NN NN O
induced NN NN O
renal NN NN B-Disease
tubular NN NN I-Disease
necrosis NN NN I-Disease
. NN NN O
   
Morphine NN NN O
- NN NN O
induced NN NN O
seizures NN NN B-Disease
in NN NN O
newborn NN NN O
infants NN NN O
. NN NN O
   
Two NN NN O
neonates NN NN O
suffered NN NN O
from NN NN O
generalized NN NN O
seizures NN NN B-Disease
during NN NN O
the NN NN O
course NN NN O
of NN NN O
intravenous NN NN O
morphine NN NN O
sulfate NN NN O
for NN NN O
post NN NN O
- NN NN O
operative NN NN O
analgesia NN NN O
. NN NN O
   
They NN NN O
received NN NN O
morphine NN NN O
in NN NN O
doses NN NN O
of NN NN O
32 NN NN O
micrograms NN NN O
/ NN NN O
kg NN NN O
/ NN NN O
hr NN NN O
and NN NN O
40 NN NN O
micrograms NN NN O
/ NN NN O
kg NN NN O
/ NN NN O
hr NN NN O
larger NN NN O
than NN NN O
a NN NN O
group NN NN O
of NN NN O
10 NN NN O
neonates NN NN O
who NN NN O
received NN NN O
6 NN NN O
- NN NN O
24 NN NN O
micrograms NN NN O
/ NN NN O
kg NN NN O
/ NN NN O
hr NN NN O
and NN NN O
had NN NN O
no NN NN O
seizures NN NN B-Disease
. NN NN O
   
Plasma NN NN O
concentrations NN NN O
of NN NN O
morphine NN NN O
in NN NN O
these NN NN O
neonates NN NN O
was NN NN O
excessive NN NN O
( NN NN O
60 NN NN O
and NN NN O
90 NN NN O
mg NN NN O
/ NN NN O
ml NN NN O
) NN NN O
. NN NN O
   
Other NN NN O
known NN NN O
reasons NN NN O
for NN NN O
seizures NN NN B-Disease
were NN NN O
ruled NN NN O
out NN NN O
and NN NN O
the NN NN O
convulsions NN NN B-Disease
stopped NN NN O
a NN NN O
few NN NN O
hours NN NN O
after NN NN O
cessation NN NN O
of NN NN O
morphine NN NN O
and NN NN O
did NN NN O
not NN NN O
reoccur NN NN O
in NN NN O
the NN NN O
subsequent NN NN O
8 NN NN O
months NN NN O
. NN NN O
   
It NN NN O
is NN NN O
suggested NN NN O
that NN NN O
post NN NN O
- NN NN O
operative NN NN O
intravenous NN NN O
morphine NN NN O
should NN NN O
not NN NN O
exceed NN NN O
20 NN NN O
micrograms NN NN O
/ NN NN O
kg NN NN O
/ NN NN O
ml NN NN O
in NN NN O
neonates NN NN O
. NN NN O
   
Indomethacin NN NN O
induced NN NN O
hypotension NN NN B-Disease
in NN NN O
sodium NN NN O
and NN NN O
volume NN NN O
depleted NN NN O
rats NN NN O
. NN NN O
   
After NN NN O
a NN NN O
single NN NN O
oral NN NN O
dose NN NN O
of NN NN O
4 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
indomethacin NN NN O
( NN NN O
IDM NN NN O
) NN NN O
to NN NN O
sodium NN NN O
and NN NN O
volume NN NN O
depleted NN NN O
rats NN NN O
plasma NN NN O
renin NN NN O
activity NN NN O
( NN NN O
PRA NN NN O
) NN NN O
and NN NN O
systolic NN NN O
blood NN NN O
pressure NN NN O
fell NN NN O
significantly NN NN O
within NN NN O
four NN NN O
hours NN NN O
. NN NN O
   
In NN NN O
sodium NN NN O
repleted NN NN O
animals NN NN O
indomethacin NN NN O
did NN NN O
not NN NN O
change NN NN O
systolic NN NN O
blood NN NN O
pressure NN NN O
( NN NN O
BP NN NN O
) NN NN O
although NN NN O
plasma NN NN O
renin NN NN O
activity NN NN O
was NN NN O
decreased NN NN O
. NN NN O
   
Thus NN NN O
, NN NN O
indomethacin NN NN O
by NN NN O
inhibition NN NN O
of NN NN O
prostaglandin NN NN O
synthesis NN NN O
may NN NN O
diminish NN NN O
the NN NN O
blood NN NN O
pressure NN NN O
maintaining NN NN O
effect NN NN O
of NN NN O
the NN NN O
stimulated NN NN O
renin NN NN O
- NN NN O
angiotensin NN NN O
system NN NN O
in NN NN O
sodium NN NN O
and NN NN O
volume NN NN O
depletion NN NN O
. NN NN O
   
On NN NN O
the NN NN O
antiarrhythmic NN NN O
activity NN NN O
of NN NN O
one NN NN O
N NN NN O
- NN NN O
substituted NN NN O
piperazine NN NN O
derivative NN NN O
of NN NN O
trans NN NN O
- NN NN O
2 NN NN O
- NN NN O
amino NN NN O
- NN NN O
3 NN NN O
- NN NN O
hydroxy NN NN O
- NN NN O
1 NN NN O
, NN NN O
2 NN NN O
, NN NN O
3 NN NN O
, NN NN O
4 NN NN O
- NN NN O
tetrahydroanaphthalene NN NN O
. NN NN O
   
The NN NN O
antiarrhythmic NN NN O
activity NN NN O
of NN NN O
the NN NN O
compound NN NN O
N NN NN O
- NN NN O
( NN NN O
trans NN NN O
- NN NN O
3 NN NN O
- NN NN O
hydroxy NN NN O
- NN NN O
1 NN NN O
, NN NN O
2 NN NN O
, NN NN O
3 NN NN O
, NN NN O
4 NN NN O
- NN NN O
tetrahydro NN NN O
- NN NN O
2 NN NN O
- NN NN O
naphthyl NN NN O
) NN NN O
- NN NN O
N NN NN O
- NN NN O
( NN NN O
3 NN NN O
- NN NN O
oxo NN NN O
- NN NN O
3 NN NN O
- NN NN O
phenyl NN NN O
- NN NN O
2 NN NN O
- NN NN O
methylpropyl NN NN O
) NN NN O
- NN NN O
piperazine NN NN O
hydrochloride NN NN O
, NN NN O
referred NN NN O
to NN NN O
as NN NN O
P11 NN NN O
, NN NN O
is NN NN O
studied NN NN O
on NN NN O
anaesthesized NN NN O
cats NN NN O
and NN NN O
Wistar NN NN O
albino NN NN O
rats NN NN O
, NN NN O
as NN NN O
well NN NN O
as NN NN O
on NN NN O
non NN NN O
- NN NN O
anaesthesized NN NN O
rabbits NN NN O
. NN NN O
   
Four NN NN O
types NN NN O
of NN NN O
experimental NN NN O
arrhythmia NN NN B-Disease
are NN NN O
used NN NN O
- NN NN O
- NN NN O
with NN NN O
BaCl2 NN NN O
, NN NN O
with NN NN O
chloroform NN NN O
- NN NN O
adrenaline NN NN O
, NN NN O
with NN NN O
strophantine NN NN O
G NN NN O
and NN NN O
with NN NN O
aconitine NN NN O
. NN NN O
   
The NN NN O
compound NN NN O
P11 NN NN O
is NN NN O
introduced NN NN O
in NN NN O
doses NN NN O
of NN NN O
0 NN NN O
. NN NN O
25 NN NN O
and NN NN O
0 NN NN O
. NN NN O
50 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
intravenously NN NN O
and NN NN O
10 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
orally NN NN O
. NN NN O
   
The NN NN O
compound NN NN O
manifests NN NN O
antiarrhythmic NN NN O
activity NN NN O
in NN NN O
all NN NN O
models NN NN O
of NN NN O
experimental NN NN O
arrhythmia NN NN B-Disease
used NN NN O
, NN NN O
causing NN NN O
greatest NN NN O
inhibition NN NN O
on NN NN O
the NN NN O
arrhythmia NN NN B-Disease
induced NN NN O
by NN NN O
chloroform NN NN O
- NN NN O
adrenaline NN NN O
( NN NN O
in NN NN O
90 NN NN O
per NN NN O
cent NN NN O
) NN NN O
and NN NN O
with NN NN O
BaCl2 NN NN O
( NN NN O
in NN NN O
84 NN NN O
per NN NN O
cent NN NN O
) NN NN O
. NN NN O
   
The NN NN O
results NN NN O
obtained NN NN O
are NN NN O
associated NN NN O
with NN NN O
the NN NN O
beta NN NN O
- NN NN O
adrenoblocking NN NN O
and NN NN O
with NN NN O
the NN NN O
membrane NN NN O
- NN NN O
stabilizing NN NN O
action NN NN O
of NN NN O
the NN NN O
compound NN NN O
. NN NN O
   
Recurrent NN NN O
subarachnoid NN NN B-Disease
hemorrhage NN NN I-Disease
associated NN NN O
with NN NN O
aminocaproic NN NN O
acid NN NN O
therapy NN NN O
and NN NN O
acute NN NN B-Disease
renal NN NN I-Disease
artery NN NN I-Disease
thrombosis NN NN I-Disease
. NN NN O
   
Case NN NN O
report NN NN O
. NN NN O
   
Epsilon NN NN O
aminocaproic NN NN O
acid NN NN O
( NN NN O
EACA NN NN O
) NN NN O
has NN NN O
been NN NN O
used NN NN O
to NN NN O
prevent NN NN O
rebleeding NN NN O
in NN NN O
patients NN NN O
with NN NN O
subarachnoid NN NN B-Disease
hemorrhage NN NN I-Disease
( NN NN O
SAH NN NN B-Disease
) NN NN O
. NN NN O
   
Although NN NN O
this NN NN O
agent NN NN O
does NN NN O
decrease NN NN O
the NN NN O
frequency NN NN O
of NN NN O
rebleeding NN NN O
, NN NN O
several NN NN O
reports NN NN O
have NN NN O
described NN NN O
thrombotic NN NN B-Disease
complications NN NN O
of NN NN O
EACA NN NN O
therapy NN NN O
. NN NN O
   
These NN NN O
complications NN NN O
have NN NN O
included NN NN O
clinical NN NN O
deterioration NN NN O
and NN NN O
intracranial NN NN B-Disease
vascular NN NN I-Disease
thrombosis NN NN I-Disease
in NN NN O
patients NN NN O
with NN NN O
SAH NN NN B-Disease
, NN NN O
arteriolar NN NN O
and NN NN O
capillary NN NN O
fibrin NN NN O
thrombi NN NN B-Disease
in NN NN O
patients NN NN O
with NN NN O
fibrinolytic NN NN O
syndromes NN NN O
treated NN NN O
with NN NN O
EACA NN NN O
, NN NN O
or NN NN O
other NN NN O
thromboembolic NN NN B-Disease
phenomena NN NN I-Disease
. NN NN O
   
Since NN NN O
intravascular NN NN O
fibrin NN NN O
thrombi NN NN B-Disease
are NN NN O
often NN NN O
observed NN NN O
in NN NN O
patients NN NN O
with NN NN O
fibrinolytic NN NN O
disorders NN NN O
, NN NN O
EACA NN NN O
should NN NN O
not NN NN O
be NN NN O
implicated NN NN O
in NN NN O
the NN NN O
pathogenesis NN NN O
of NN NN O
fibrin NN NN O
thrombi NN NN B-Disease
in NN NN O
patients NN NN O
with NN NN O
disseminated NN NN B-Disease
intravascular NN NN I-Disease
coagulation NN NN I-Disease
or NN NN O
other NN NN O
"""""""" NN NN O
consumption NN NN B-Disease
coagulopathies NN NN I-Disease
. NN NN O
"""""""" NN NN O
This NN NN O
report NN NN O
describes NN NN O
subtotal NN NN O
infarction NN NN B-Disease
of NN NN O
the NN NN O
kidney NN NN O
due NN NN O
to NN NN O
thrombosis NN NN B-Disease
of NN NN I-Disease
a NN NN I-Disease
normal NN NN I-Disease
renal NN NN I-Disease
artery NN NN I-Disease
. NN NN O
   
This NN NN O
occlusion NN NN O
occurred NN NN O
after NN NN O
EACA NN NN O
therapy NN NN O
in NN NN O
a NN NN O
patient NN NN O
with NN NN O
SAH NN NN B-Disease
and NN NN O
histopathological NN NN O
documentation NN NN O
of NN NN O
recurrent NN NN O
SAH NN NN B-Disease
. NN NN O
   
The NN NN O
corresponding NN NN O
clinical NN NN O
event NN NN O
was NN NN O
characterized NN NN O
by NN NN O
marked NN NN O
hypertension NN NN B-Disease
and NN NN O
abrupt NN NN O
neurological NN NN O
deterioration NN NN O
. NN NN O
   
Effect NN NN O
of NN NN O
vincristine NN NN O
sulfate NN NN O
on NN NN O
Pseudomonas NN NN B-Disease
infections NN NN I-Disease
in NN NN O
monkeys NN NN O
. NN NN O
   
In NN NN O
rhesus NN NN O
monkeys NN NN O
, NN NN O
intravenous NN NN O
challenge NN NN O
with NN NN O
0 NN NN O
. NN NN O
6 NN NN O
x NN NN O
10 NN NN O
( NN NN O
10 NN NN O
) NN NN O
to NN NN O
2 NN NN O
. NN NN O
2 NN NN O
x NN NN O
10 NN NN O
( NN NN O
10 NN NN O
) NN NN O
Pseudomonas NN NN O
aeruginosa NN NN O
organisms NN NN O
caused NN NN O
acute NN NN O
illness NN NN O
of NN NN O
4 NN NN O
to NN NN O
5 NN NN O
days NN NN O
' NN NN O
duration NN NN O
with NN NN O
spontaneous NN NN O
recovery NN NN O
in NN NN O
13 NN NN O
of NN NN O
15 NN NN O
monkeys NN NN O
; NN NN O
blood NN NN O
cultures NN NN O
became NN NN O
negative NN NN O
3 NN NN O
to NN NN O
17 NN NN O
days NN NN O
after NN NN O
challenge NN NN O
. NN NN O
   
Leukocytosis NN NN B-Disease
was NN NN O
observed NN NN O
in NN NN O
all NN NN O
monkeys NN NN O
. NN NN O
   
Intravenous NN NN O
or NN NN O
intratracheal NN NN O
inoculation NN NN O
of NN NN O
2 NN NN O
. NN NN O
0 NN NN O
to NN NN O
2 NN NN O
. NN NN O
5 NN NN O
mg NN NN O
of NN NN O
vincristine NN NN O
sulfate NN NN O
was NN NN O
followed NN NN O
by NN NN O
leukopenia NN NN B-Disease
in NN NN O
4 NN NN O
to NN NN O
5 NN NN O
days NN NN O
. NN NN O
   
Intravenous NN NN O
inoculation NN NN O
of NN NN O
4 NN NN O
. NN NN O
2 NN NN O
x NN NN O
10 NN NN O
( NN NN O
10 NN NN O
) NN NN O
to NN NN O
7 NN NN O
. NN NN O
8 NN NN O
x NN NN O
10 NN NN O
( NN NN O
10 NN NN O
) NN NN O
pyocin NN NN O
type NN NN O
6 NN NN O
Pseudomonas NN NN O
organisms NN NN O
in NN NN O
monkeys NN NN O
given NN NN O
vincristine NN NN O
sulfate NN NN O
4 NN NN O
days NN NN O
previously NN NN O
resulted NN NN O
in NN NN O
fatal NN NN O
infection NN NN B-Disease
in NN NN O
11 NN NN O
of NN NN O
14 NN NN O
monkeys NN NN O
, NN NN O
whereas NN NN O
none NN NN O
of NN NN O
four NN NN O
receiving NN NN O
Pseudomonas NN NN O
alone NN NN O
died NN NN O
. NN NN O
   
These NN NN O
studies NN NN O
suggest NN NN O
that NN NN O
an NN NN O
antimetabolite NN NN O
- NN NN O
induced NN NN O
leukopenia NN NN B-Disease
predisposes NN NN O
to NN NN O
severe NN NN O
Pseudomonas NN NN O
sepsis NN NN B-Disease
and NN NN O
that NN NN O
such NN NN O
monkeys NN NN O
may NN NN O
serve NN NN O
as NN NN O
a NN NN O
biological NN NN O
model NN NN O
for NN NN O
study NN NN O
of NN NN O
comparative NN NN O
efficacy NN NN O
of NN NN O
antimicrobial NN NN O
agents NN NN O
. NN NN O
   
Modification NN NN O
by NN NN O
propranolol NN NN O
of NN NN O
cardiovascular NN NN O
effects NN NN O
of NN NN O
induced NN NN O
hypoglycaemia NN NN B-Disease
. NN NN O
   
The NN NN O
cardiovascular NN NN O
effects NN NN O
of NN NN O
hypoglycaemia NN NN B-Disease
, NN NN O
with NN NN O
and NN NN O
without NN NN O
beta NN NN O
- NN NN O
blockade NN NN O
, NN NN O
were NN NN O
compared NN NN O
in NN NN O
fourteen NN NN O
healthy NN NN O
men NN NN O
. NN NN O
   
Eight NN NN O
received NN NN O
insulin NN NN O
alone NN NN O
, NN NN O
and NN NN O
eight NN NN O
, NN NN O
including NN NN O
two NN NN O
of NN NN O
the NN NN O
original NN NN O
insulin NN NN O
- NN NN O
only NN NN O
group NN NN O
, NN NN O
were NN NN O
given NN NN O
propranolol NN NN O
and NN NN O
insulin NN NN O
. NN NN O
   
In NN NN O
the NN NN O
insulin NN NN O
- NN NN O
group NN NN O
the NN NN O
period NN NN O
of NN NN O
hypoglycaemia NN NN B-Disease
was NN NN O
associated NN NN O
with NN NN O
an NN NN O
increase NN NN O
in NN NN O
heart NN NN O
- NN NN O
rate NN NN O
and NN NN O
a NN NN O
fall NN NN O
in NN NN O
diastolic NN NN O
blood NN NN O
- NN NN O
pressure NN NN O
. NN NN O
   
In NN NN O
the NN NN O
propranolol NN NN O
- NN NN O
insulin NN NN O
group NN NN O
there NN NN O
was NN NN O
a NN NN O
significant NN NN O
fall NN NN O
in NN NN O
heart NN NN O
- NN NN O
rate NN NN O
in NN NN O
most NN NN O
subjects NN NN O
and NN NN O
an NN NN O
increase NN NN O
in NN NN O
diastolic NN NN O
pressure NN NN O
. NN NN O
   
Typical NN NN O
S NN NN O
- NN NN O
T NN NN O
/ NN NN O
T NN NN O
changes NN NN O
occurred NN NN O
in NN NN O
the NN NN O
insulin NN NN O
- NN NN O
group NN NN O
but NN NN O
in NN NN O
none NN NN O
of NN NN O
the NN NN O
propranolol NN NN O
- NN NN O
insulin NN NN O
group NN NN O
. NN NN O
   
Hypertension NN NN B-Disease
in NN NN O
diabetics NN NN B-Disease
prone NN NN O
to NN NN O
hypoglycaemia NN NN B-Disease
attacks NN NN O
should NN NN O
not NN NN O
be NN NN O
treated NN NN O
with NN NN O
beta NN NN O
- NN NN O
blockers NN NN O
because NN NN O
these NN NN O
drugs NN NN O
may NN NN O
cause NN NN O
a NN NN O
sharp NN NN O
rise NN NN O
in NN NN O
blood NN NN O
- NN NN O
pressure NN NN O
in NN NN O
such NN NN O
patients NN NN O
. NN NN O
   
Long NN NN O
- NN NN O
term NN NN O
propranolol NN NN O
therapy NN NN O
in NN NN O
pregnancy NN NN O
: NN NN O
maternal NN NN O
and NN NN O
fetal NN NN O
outcome NN NN O
. NN NN O
   
Propranolol NN NN O
, NN NN O
a NN NN O
beta NN NN O
- NN NN O
adrenergic NN NN O
blocking NN NN O
agent NN NN O
, NN NN O
has NN NN O
found NN NN O
an NN NN O
important NN NN O
position NN NN O
in NN NN O
the NN NN O
practice NN NN O
of NN NN O
medicine NN NN O
. NN NN O
   
Its NN NN O
use NN NN O
in NN NN O
pregnancy NN NN O
, NN NN O
however NN NN O
, NN NN O
is NN NN O
an NN NN O
open NN NN O
question NN NN O
as NN NN O
a NN NN O
number NN NN O
of NN NN O
detrimental NN NN O
side NN NN O
effects NN NN O
have NN NN O
been NN NN O
reported NN NN O
in NN NN O
the NN NN O
fetus NN NN O
and NN NN O
neonate NN NN O
. NN NN O
   
Ten NN NN O
patients NN NN O
and NN NN O
12 NN NN O
pregnancies NN NN O
are NN NN O
reported NN NN O
where NN NN O
chronic NN NN O
propranolol NN NN O
has NN NN O
been NN NN O
administered NN NN O
. NN NN O
   
Five NN NN O
patients NN NN O
with NN NN O
serial NN NN O
pregnancies NN NN O
with NN NN O
and NN NN O
without NN NN O
propranolol NN NN O
therapy NN NN O
are NN NN O
also NN NN O
examined NN NN O
. NN NN O
   
Maternal NN NN O
, NN NN O
fetal NN NN O
, NN NN O
and NN NN O
neonatal NN NN O
complications NN NN O
are NN NN O
examined NN NN O
. NN NN O
   
An NN NN O
attempt NN NN O
is NN NN O
made NN NN O
to NN NN O
differentiate NN NN O
drug NN NN O
- NN NN O
related NN NN O
complications NN NN O
from NN NN O
maternal NN NN O
disease NN NN O
- NN NN O
- NN NN O
related NN NN O
complications NN NN O
. NN NN O
   
We NN NN O
conclude NN NN O
that NN NN O
previously NN NN O
reported NN NN O
hypoglycemia NN NN B-Disease
, NN NN O
hyperbilirubinemia NN NN B-Disease
, NN NN O
polycythemia NN NN B-Disease
, NN NN O
neonatal NN NN B-Disease
apnea NN NN I-Disease
, NN NN O
and NN NN O
bradycardia NN NN B-Disease
are NN NN O
not NN NN O
invariable NN NN O
and NN NN O
cannot NN NN O
be NN NN O
statistically NN NN O
correlated NN NN O
with NN NN O
chronic NN NN O
propranolol NN NN O
therapy NN NN O
. NN NN O
   
Growth NN NN B-Disease
retardation NN NN I-Disease
, NN NN O
however NN NN O
, NN NN O
appears NN NN O
to NN NN O
be NN NN O
significant NN NN O
in NN NN O
both NN NN O
of NN NN O
our NN NN O
series NN NN O
. NN NN O
   
Central NN NN O
excitatory NN NN O
actions NN NN O
of NN NN O
flurazepam NN NN O
. NN NN O
   
Toxic NN NN O
actions NN NN O
of NN NN O
flurazepam NN NN O
( NN NN O
FZP NN NN O
) NN NN O
were NN NN O
studied NN NN O
in NN NN O
cats NN NN O
, NN NN O
mice NN NN O
and NN NN O
rats NN NN O
. NN NN O
   
High NN NN O
doses NN NN O
caused NN NN O
an NN NN O
apparent NN NN O
central NN NN O
excitation NN NN O
, NN NN O
most NN NN O
clearly NN NN O
seen NN NN O
as NN NN O
clonic NN NN O
convulsions NN NN B-Disease
, NN NN O
superimposed NN NN O
on NN NN O
general NN NN O
depression NN NN B-Disease
. NN NN O
   
Following NN NN O
a NN NN O
lethal NN NN O
dose NN NN O
, NN NN O
death NN NN O
was NN NN O
always NN NN O
associated NN NN O
with NN NN O
convulsions NN NN B-Disease
. NN NN O
   
Comparing NN NN O
the NN NN O
relative NN NN O
sensitivity NN NN O
to NN NN O
central NN NN O
depression NN NN B-Disease
and NN NN O
excitation NN NN O
revealed NN NN O
that NN NN O
rats NN NN O
were NN NN O
least NN NN O
likely NN NN O
to NN NN O
have NN NN O
convulsions NN NN B-Disease
at NN NN O
doses NN NN O
that NN NN O
did NN NN O
not NN NN O
first NN NN O
cause NN NN O
loss NN NN B-Disease
of NN NN I-Disease
consciousness NN NN I-Disease
, NN NN O
while NN NN O
cats NN NN O
most NN NN O
clearly NN NN O
showed NN NN O
marked NN NN O
central NN NN O
excitatory NN NN O
actions NN NN O
. NN NN O
   
Signs NN NN O
of NN NN O
FZP NN NN O
toxocity NN NN B-Disease
in NN NN O
cats NN NN O
included NN NN O
excessive NN NN O
salivation NN NN B-Disease
, NN NN O
extreme NN NN O
apprehensive NN NN O
behavior NN NN O
, NN NN O
retching NN NN O
, NN NN O
muscle NN NN B-Disease
tremors NN NN I-Disease
and NN NN O
convulsions NN NN B-Disease
. NN NN O
   
An NN NN O
interaction NN NN O
between NN NN O
FZP NN NN O
and NN NN O
pentylenetetrazol NN NN O
( NN NN O
PTZ NN NN O
) NN NN O
was NN NN O
shown NN NN O
by NN NN O
pretreating NN NN O
mice NN NN O
with NN NN O
FZP NN NN O
before NN NN O
PTZ NN NN O
challenge NN NN O
. NN NN O
   
As NN NN O
a NN NN O
function NN NN O
of NN NN O
dose NN NN O
, NN NN O
FZP NN NN O
first NN NN O
protected NN NN O
against NN NN O
convulsions NN NN B-Disease
and NN NN O
death NN NN O
. NN NN O
   
At NN NN O
higher NN NN O
doses NN NN O
, NN NN O
however NN NN O
, NN NN O
convulsions NN NN B-Disease
again NN NN O
emerged NN NN O
. NN NN O
   
These NN NN O
doses NN NN O
of NN NN O
FZP NN NN O
were NN NN O
lower NN NN O
than NN NN O
those NN NN O
that NN NN O
would NN NN O
alone NN NN O
cause NN NN O
convulsions NN NN B-Disease
. NN NN O
   
These NN NN O
results NN NN O
may NN NN O
be NN NN O
relevant NN NN O
to NN NN O
the NN NN O
use NN NN O
of NN NN O
FZP NN NN O
in NN NN O
clinical NN NN O
situations NN NN O
in NN NN O
which NN NN O
there NN NN O
is NN NN O
increased NN NN O
neural NN NN O
excitability NN NN O
, NN NN O
such NN NN O
as NN NN O
epilepsy NN NN B-Disease
or NN NN O
sedative NN NN O
- NN NN O
hypnotic NN NN O
drug NN NN O
withdrawal NN NN O
. NN NN O
   
Use NN NN O
of NN NN O
propranolol NN NN O
in NN NN O
the NN NN O
treatment NN NN O
of NN NN O
idiopathic NN NN B-Disease
orthostatic NN NN I-Disease
hypotension NN NN I-Disease
. NN NN O
   
Five NN NN O
patients NN NN O
with NN NN O
idiopathic NN NN B-Disease
orthostatic NN NN I-Disease
hypotension NN NN I-Disease
who NN NN O
had NN NN O
physiologic NN NN O
and NN NN O
biochemical NN NN O
evidence NN NN O
of NN NN O
severe NN NN O
autonomic NN NN O
dysfunction NN NN O
were NN NN O
included NN NN O
in NN NN O
the NN NN O
study NN NN O
. NN NN O
   
They NN NN O
all NN NN O
exhibited NN NN O
markedly NN NN O
reduced NN NN O
plasma NN NN O
catecholamines NN NN O
and NN NN O
plasma NN NN O
renin NN NN O
activity NN NN O
in NN NN O
both NN NN O
recumbent NN NN O
and NN NN O
upright NN NN O
positions NN NN O
and NN NN O
had NN NN O
marked NN NN O
hypersensitivity NN NN B-Disease
to NN NN O
the NN NN O
pressor NN NN O
effects NN NN O
of NN NN O
infused NN NN O
norepinephrine NN NN O
. NN NN O
   
Treatment NN NN O
with NN NN O
propanolol NN NN O
administered NN NN O
intravenously NN NN O
( NN NN O
1 NN NN O
- NN NN O
5 NN NN O
mg NN NN O
) NN NN O
produced NN NN O
increases NN NN O
in NN NN O
supine NN NN O
and NN NN O
upright NN NN O
blood NN NN O
pressure NN NN O
in NN NN O
4 NN NN O
of NN NN O
the NN NN O
5 NN NN O
individuals NN NN O
with NN NN O
rises NN NN O
ranging NN NN O
from NN NN O
11 NN NN O
/ NN NN O
6 NN NN O
to NN NN O
22 NN NN O
/ NN NN O
11 NN NN O
mmHg NN NN O
. NN NN O
   
Chronic NN NN O
oral NN NN O
administration NN NN O
of NN NN O
propranolol NN NN O
( NN NN O
40 NN NN O
- NN NN O
160 NN NN O
mg NN NN O
/ NN NN O
day NN NN O
) NN NN O
also NN NN O
elevated NN NN O
the NN NN O
blood NN NN O
pressures NN NN O
of NN NN O
these NN NN O
individuals NN NN O
with NN NN O
increases NN NN O
in NN NN O
the NN NN O
order NN NN O
of NN NN O
20 NN NN O
- NN NN O
35 NN NN O
/ NN NN O
15 NN NN O
- NN NN O
25 NN NN O
mmg NN NN O
being NN NN O
observed NN NN O
. NN NN O
   
In NN NN O
1 NN NN O
patient NN NN O
, NN NN O
marked NN NN O
hypertension NN NN B-Disease
was NN NN O
induced NN NN O
by NN NN O
propranolol NN NN O
and NN NN O
the NN NN O
drug NN NN O
had NN NN O
to NN NN O
be NN NN O
withdrawn NN NN O
. NN NN O
   
It NN NN O
otherwise NN NN O
was NN NN O
well NN NN O
tolerated NN NN O
and NN NN O
no NN NN O
important NN NN O
side NN NN O
effects NN NN O
were NN NN O
observed NN NN O
. NN NN O
   
Treatment NN NN O
has NN NN O
been NN NN O
continued NN NN O
in NN NN O
3 NN NN O
individuals NN NN O
for NN NN O
6 NN NN O
- NN NN O
13 NN NN O
months NN NN O
with NN NN O
persistence NN NN O
of NN NN O
the NN NN O
pressor NN NN O
effect NN NN O
, NN NN O
although NN NN O
there NN NN O
appears NN NN O
to NN NN O
have NN NN O
been NN NN O
some NN NN O
decrease NN NN O
in NN NN O
the NN NN O
degree NN NN O
of NN NN O
response NN NN O
with NN NN O
time NN NN O
. NN NN O
   
Hemodynamic NN NN O
measurements NN NN O
in NN NN O
1 NN NN O
of NN NN O
the NN NN O
patients NN NN O
demonstrated NN NN O
an NN NN O
increase NN NN O
in NN NN O
total NN NN O
peripheral NN NN O
resistance NN NN O
and NN NN O
essentially NN NN O
no NN NN O
change NN NN O
in NN NN O
cardiac NN NN O
output NN NN O
following NN NN O
propranolol NN NN O
therapy NN NN O
. NN NN O
   
The NN NN O
studies NN NN O
suggest NN NN O
that NN NN O
propranolol NN NN O
is NN NN O
a NN NN O
useful NN NN O
drug NN NN O
in NN NN O
selected NN NN O
patients NN NN O
with NN NN O
severe NN NN O
idiopathic NN NN B-Disease
orthostatic NN NN I-Disease
hypotension NN NN I-Disease
. NN NN O
   
Total NN NN O
intravenous NN NN O
anesthesia NN NN O
with NN NN O
etomidate NN NN O
. NN NN O
   
III NN NN O
. NN NN O
   
Some NN NN O
observations NN NN O
in NN NN O
adults NN NN O
. NN NN O
   
An NN NN O
investigation NN NN O
was NN NN O
undertaken NN NN O
to NN NN O
determine NN NN O
the NN NN O
dosage NN NN O
of NN NN O
etomidate NN NN O
required NN NN O
to NN NN O
maintain NN NN O
sleep NN NN O
in NN NN O
adults NN NN O
undergoing NN NN O
surgery NN NN O
under NN NN O
regional NN NN O
local NN NN O
anesthesia NN NN O
. NN NN O
   
Premedication NN NN O
of NN NN O
diazepam NN NN O
10 NN NN O
mg NN NN O
and NN NN O
atropine NN NN O
0 NN NN O
. NN NN O
5 NN NN O
mg NN NN O
was NN NN O
given NN NN O
, NN NN O
and NN NN O
sleep NN NN O
was NN NN O
induced NN NN O
and NN NN O
maintained NN NN O
by NN NN O
intermittent NN NN O
intravenous NN NN O
injections NN NN O
of NN NN O
etomidate NN NN O
0 NN NN O
. NN NN O
1 NN NN O
/ NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
, NN NN O
given NN NN O
whenever NN NN O
the NN NN O
patient NN NN O
would NN NN O
open NN NN O
his NN NN O
eyes NN NN O
on NN NN O
request NN NN O
. NN NN O
   
A NN NN O
mean NN NN O
overall NN NN O
dose NN NN O
of NN NN O
etomidate NN NN O
17 NN NN O
. NN NN O
4 NN NN O
microgram NN NN O
/ NN NN O
kg NN NN O
/ NN NN O
min NN NN O
. NN NN O
was NN NN O
required NN NN O
to NN NN O
maintain NN NN O
sleep NN NN O
, NN NN O
but NN NN O
great NN NN O
individual NN NN O
variation NN NN O
occurred NN NN O
, NN NN O
with NN NN O
older NN NN O
patients NN NN O
requiring NN NN O
less NN NN O
drug NN NN O
. NN NN O
   
The NN NN O
investigation NN NN O
was NN NN O
discontinued NN NN O
after NN NN O
18 NN NN O
patients NN NN O
because NN NN O
of NN NN O
the NN NN O
frequency NN NN O
and NN NN O
intensity NN NN O
of NN NN O
side NN NN O
- NN NN O
effects NN NN O
, NN NN O
particularly NN NN O
pain NN NN B-Disease
and NN NN O
myoclonia NN NN B-Disease
, NN NN O
which NN NN O
caused NN NN O
the NN NN O
technique NN NN O
to NN NN O
be NN NN O
abandoned NN NN O
in NN NN O
two NN NN O
cases NN NN O
. NN NN O
   
It NN NN O
is NN NN O
considered NN NN O
unlikely NN NN O
that NN NN O
etomidate NN NN O
will NN NN O
prove NN NN O
to NN NN O
be NN NN O
the NN NN O
hypnotic NN NN O
of NN NN O
choice NN NN O
for NN NN O
a NN NN O
totally NN NN O
intravenous NN NN O
anesthetic NN NN O
technique NN NN O
in NN NN O
adults NN NN O
because NN NN O
of NN NN O
the NN NN O
high NN NN O
incidence NN NN O
of NN NN O
myoclonia NN NN B-Disease
after NN NN O
prolonged NN NN O
administration NN NN O
. NN NN O
   
In NN NN O
several NN NN O
patients NN NN O
uncontrollable NN NN O
muscle NN NN O
movements NN NN O
persisted NN NN O
for NN NN O
many NN NN O
minutes NN NN O
after NN NN O
complete NN NN O
recovery NN NN O
of NN NN O
consciousness NN NN O
. NN NN O
   
Evidence NN NN O
for NN NN O
cardiac NN NN O
beta NN NN O
2 NN NN O
- NN NN O
adrenoceptors NN NN O
in NN NN O
man NN NN O
. NN NN O
   
We NN NN O
compared NN NN O
the NN NN O
effects NN NN O
of NN NN O
single NN NN O
doses NN NN O
of NN NN O
50 NN NN O
mg NN NN O
atenolol NN NN O
( NN NN O
cardioselective NN NN O
) NN NN O
, NN NN O
40 NN NN O
mg NN NN O
propranolol NN NN O
( NN NN O
nonselective NN NN O
) NN NN O
, NN NN O
and NN NN O
placebo NN NN O
on NN NN O
both NN NN O
exercise NN NN O
- NN NN O
and NN NN O
isoproterenol NN NN O
- NN NN O
induced NN NN O
tachycardia NN NN B-Disease
in NN NN O
two NN NN O
experiments NN NN O
involving NN NN O
nine NN NN O
normal NN NN O
subjects NN NN O
. NN NN O
   
Maximal NN NN O
exercise NN NN O
heart NN NN O
rate NN NN O
was NN NN O
reduced NN NN O
from NN NN O
187 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
4 NN NN O
( NN NN O
SEM NN NN O
) NN NN O
after NN NN O
placebo NN NN O
to NN NN O
146 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
7 NN NN O
bpm NN NN O
after NN NN O
atenolol NN NN O
and NN NN O
138 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
6 NN NN O
bpm NN NN O
after NN NN O
propranolol NN NN O
, NN NN O
but NN NN O
there NN NN O
were NN NN O
no NN NN O
differences NN NN O
between NN NN O
the NN NN O
drugs NN NN O
. NN NN O
   
The NN NN O
effects NN NN O
on NN NN O
isoproterenol NN NN O
tachycardia NN NN B-Disease
were NN NN O
determined NN NN O
before NN NN O
and NN NN O
after NN NN O
atropine NN NN O
( NN NN O
0 NN NN O
. NN NN O
04 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
IV NN NN O
) NN NN O
. NN NN O
   
Isoproterenol NN NN O
sensitivity NN NN O
was NN NN O
determined NN NN O
as NN NN O
the NN NN O
intravenous NN NN O
dose NN NN O
that NN NN O
increased NN NN O
heart NN NN O
rate NN NN O
by NN NN O
25 NN NN O
bpm NN NN O
( NN NN O
CD25 NN NN O
) NN NN O
and NN NN O
this NN NN O
was NN NN O
increased NN NN O
from NN NN O
1 NN NN O
. NN NN O
8 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
0 NN NN O
. NN NN O
3 NN NN O
micrograms NN NN O
after NN NN O
placebo NN NN O
to NN NN O
38 NN NN O
. NN NN O
9 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
8 NN NN O
. NN NN O
3 NN NN O
micrograms NN NN O
after NN NN O
propranolol NN NN O
and NN NN O
8 NN NN O
. NN NN O
3 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
1 NN NN O
. NN NN O
7 NN NN O
micrograms NN NN O
after NN NN O
atenolol NN NN O
. NN NN O
   
The NN NN O
difference NN NN O
in NN NN O
the NN NN O
effects NN NN O
of NN NN O
the NN NN O
two NN NN O
was NN NN O
significant NN NN O
. NN NN O
   
After NN NN O
atropine NN NN O
the NN NN O
CD25 NN NN O
was NN NN O
unchanged NN NN O
after NN NN O
placebo NN NN O
( NN NN O
2 NN NN O
. NN NN O
3 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
0 NN NN O
. NN NN O
3 NN NN O
micrograms NN NN O
) NN NN O
and NN NN O
atenolol NN NN O
( NN NN O
7 NN NN O
. NN NN O
7 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
1 NN NN O
. NN NN O
3 NN NN O
micrograms NN NN O
) NN NN O
; NN NN O
it NN NN O
was NN NN O
reduced NN NN O
after NN NN O
propranolol NN NN O
( NN NN O
24 NN NN O
. NN NN O
8 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
5 NN NN O
. NN NN O
0 NN NN O
micrograms NN NN O
) NN NN O
, NN NN O
but NN NN O
remained NN NN O
different NN NN O
from NN NN O
atenolol NN NN O
. NN NN O
   
This NN NN O
change NN NN O
with NN NN O
propranolol NN NN O
sensitivity NN NN O
was NN NN O
calculated NN NN O
as NN NN O
the NN NN O
apparent NN NN O
Ka NN NN O
, NN NN O
this NN NN O
was NN NN O
unchanged NN NN O
by NN NN O
atropine NN NN O
( NN NN O
11 NN NN O
. NN NN O
7 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
2 NN NN O
. NN NN O
1 NN NN O
and NN NN O
10 NN NN O
. NN NN O
1 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
2 NN NN O
. NN NN O
5 NN NN O
ml NN NN O
/ NN NN O
ng NN NN O
) NN NN O
. NN NN O
   
These NN NN O
data NN NN O
are NN NN O
consistent NN NN O
with NN NN O
the NN NN O
hypothesis NN NN O
that NN NN O
exercise NN NN O
- NN NN O
induced NN NN O
tachycardia NN NN B-Disease
results NN NN O
largely NN NN O
from NN NN O
beta NN NN O
1 NN NN O
- NN NN O
receptor NN NN O
activation NN NN O
that NN NN O
is NN NN O
blocked NN NN O
by NN NN O
both NN NN O
cardioselective NN NN O
and NN NN O
nonselective NN NN O
drugs NN NN O
, NN NN O
whereas NN NN O
isoproterenol NN NN O
activates NN NN O
both NN NN O
beta NN NN O
1 NN NN O
- NN NN O
and NN NN O
beta NN NN O
2 NN NN O
- NN NN O
receptors NN NN O
so NN NN O
that NN NN O
after NN NN O
cardioselective NN NN O
blockade NN NN O
there NN NN O
remains NN NN O
a NN NN O
beta NN NN O
2 NN NN O
- NN NN O
component NN NN O
that NN NN O
can NN NN O
be NN NN O
blocked NN NN O
with NN NN O
a NN NN O
nonselective NN NN O
drug NN NN O
. NN NN O
   
While NN NN O
there NN NN O
appear NN NN O
to NN NN O
be NN NN O
beta NN NN O
2 NN NN O
- NN NN O
receptors NN NN O
in NN NN O
the NN NN O
human NN NN O
heart NN NN O
, NN NN O
their NN NN O
physiologic NN NN O
or NN NN O
pathologic NN NN O
roles NN NN O
remain NN NN O
to NN NN O
be NN NN O
defined NN NN O
. NN NN O
   
Hormones NN NN O
and NN NN O
risk NN NN O
of NN NN O
breast NN NN B-Disease
cancer NN NN I-Disease
. NN NN O
   
This NN NN O
paper NN NN O
reports NN NN O
the NN NN O
results NN NN O
of NN NN O
a NN NN O
study NN NN O
of NN NN O
50 NN NN O
menopausal NN NN O
women NN NN O
receiving NN NN O
hormonal NN NN O
replacement NN NN O
therapy NN NN O
. NN NN O
   
The NN NN O
majority NN NN O
( NN NN O
29 NN NN O
) NN NN O
had NN NN O
surgical NN NN O
menopause NN NN O
; NN NN O
their NN NN O
mean NN NN O
age NN NN O
was NN NN O
45 NN NN O
. NN NN O
7 NN NN O
years NN NN O
. NN NN O
   
It NN NN O
was NN NN O
hypothesized NN NN O
that NN NN O
progestins NN NN O
could NN NN O
equilibrate NN NN O
the NN NN O
effects NN NN O
of NN NN O
the NN NN O
estrogenic NN NN O
stimulation NN NN O
on NN NN O
the NN NN O
mammary NN NN O
and NN NN O
endometrial NN NN O
target NN NN O
tissues NN NN O
of NN NN O
women NN NN O
on NN NN O
hormonal NN NN O
replacement NN NN O
therapy NN NN O
. NN NN O
   
The NN NN O
treatment NN NN O
schedule NN NN O
consisted NN NN O
of NN NN O
conjugated NN NN O
estrogens NN NN O
( NN NN O
Premarin NN NN O
) NN NN O
1 NN NN O
. NN NN O
25 NN NN O
mg NN NN O
/ NN NN O
day NN NN O
for NN NN O
21 NN NN O
days NN NN O
and NN NN O
Medroxyprogesterone NN NN O
acetate NN NN O
10 NN NN O
mg NN NN O
/ NN NN O
day NN NN O
for NN NN O
10 NN NN O
days NN NN O
in NN NN O
each NN NN O
month NN NN O
. NN NN O
   
The NN NN O
mean NN NN O
treatment NN NN O
period NN NN O
was NN NN O
18 NN NN O
months NN NN O
. NN NN O
   
During NN NN O
the NN NN O
follow NN NN O
- NN NN O
up NN NN O
period NN NN O
, NN NN O
attention NN NN O
was NN NN O
paid NN NN O
to NN NN O
breast NN NN O
modifications NN NN O
as NN NN O
evidenced NN NN O
by NN NN O
symptomatology NN NN O
, NN NN O
physical NN NN O
examination NN NN O
, NN NN O
and NN NN O
plate NN NN O
thermography NN NN O
. NN NN O
   
Mastodynia NN NN B-Disease
was NN NN O
reported NN NN O
by NN NN O
21 NN NN O
patients NN NN O
, NN NN O
and NN NN O
physical NN NN O
examination NN NN O
revealed NN NN O
a NN NN O
light NN NN O
increase NN NN O
in NN NN O
breast NN NN O
firmness NN NN O
in NN NN O
12 NN NN O
women NN NN O
and NN NN O
a NN NN O
moderate NN NN O
increase NN NN O
in NN NN O
breast NN NN O
nodularity NN NN O
in NN NN O
2 NN NN O
women NN NN O
. NN NN O
   
Themography NN NN O
confirmed NN NN O
the NN NN O
existence NN NN O
of NN NN O
an NN NN O
excessive NN NN O
breast NN NN O
stimulation NN NN O
in NN NN O
1 NN NN O
women NN NN O
who NN NN O
complained NN NN O
of NN NN O
moderate NN NN O
mastodynia NN NN B-Disease
and NN NN O
in NN NN O
5 NN NN O
of NN NN O
the NN NN O
7 NN NN O
women NN NN O
who NN NN O
complained NN NN O
of NN NN O
severe NN NN O
mastodynia NN NN B-Disease
. NN NN O
   
Normalization NN NN O
was NN NN O
obtained NN NN O
by NN NN O
halving NN NN O
the NN NN O
estrogen NN NN O
dose NN NN O
. NN NN O
   
These NN NN O
results NN NN O
suggest NN NN O
that NN NN O
hormonal NN NN O
replacement NN NN O
therapy NN NN O
can NN NN O
be NN NN O
safely NN NN O
prescribed NN NN O
if NN NN O
the NN NN O
following NN NN O
criteria NN NN O
are NN NN O
satisfied NN NN O
: NN NN O
1 NN NN O
) NN NN O
preliminary NN NN O
evaluation NN NN O
of NN NN O
patients NN NN O
from NN NN O
a NN NN O
clinical NN NN O
, NN NN O
metabolic NN NN O
, NN NN O
cytologic NN NN O
, NN NN O
and NN NN O
mammographic NN NN O
perspective NN NN O
; NN NN O
2 NN NN O
) NN NN O
cyclic NN NN O
treatment NN NN O
schedule NN NN O
, NN NN O
with NN NN O
a NN NN O
progestative NN NN O
phase NN NN O
of NN NN O
10 NN NN O
days NN NN O
; NN NN O
and NN NN O
3 NN NN O
) NN NN O
periodic NN NN O
complete NN NN O
follow NN NN O
- NN NN O
up NN NN O
, NN NN O
with NN NN O
accurate NN NN O
thermographic NN NN O
evaluation NN NN O
of NN NN O
the NN NN O
breast NN NN O
target NN NN O
tissues NN NN O
. NN NN O
   
Early NN NN O
infections NN NN B-Disease
in NN NN O
kidney NN NN O
, NN NN O
heart NN NN O
, NN NN O
and NN NN O
liver NN NN O
transplant NN NN O
recipients NN NN O
on NN NN O
cyclosporine NN NN O
. NN NN O
   
Eighty NN NN O
- NN NN O
one NN NN O
renal NN NN O
, NN NN O
seventeen NN NN O
heart NN NN O
, NN NN O
and NN NN O
twenty NN NN O
- NN NN O
four NN NN O
liver NN NN O
transplant NN NN O
patients NN NN O
were NN NN O
followed NN NN O
for NN NN O
infection NN NN B-Disease
. NN NN O
   
Seventeen NN NN O
renal NN NN O
patients NN NN O
received NN NN O
azathioprine NN NN O
( NN NN O
Aza NN NN O
) NN NN O
and NN NN O
prednisone NN NN O
as NN NN O
part NN NN O
of NN NN O
a NN NN O
randomized NN NN O
trial NN NN O
of NN NN O
immunosuppression NN NN O
with NN NN O
21 NN NN O
cyclosporine NN NN O
- NN NN O
and NN NN O
- NN NN O
prednisone NN NN O
- NN NN O
treated NN NN O
renal NN NN O
transplant NN NN O
patients NN NN O
. NN NN O
   
All NN NN O
others NN NN O
received NN NN O
cyclosporine NN NN O
and NN NN O
prednisone NN NN O
. NN NN O
   
The NN NN O
randomized NN NN O
Aza NN NN O
patients NN NN O
had NN NN O
more NN NN O
overall NN NN O
infections NN NN B-Disease
( NN NN O
P NN NN O
less NN NN O
than NN NN O
0 NN NN O
. NN NN O
05 NN NN O
) NN NN O
and NN NN O
more NN NN O
nonviral NN NN O
infections NN NN B-Disease
( NN NN O
P NN NN O
less NN NN O
than NN NN O
0 NN NN O
. NN NN O
02 NN NN O
) NN NN O
than NN NN O
the NN NN O
randomized NN NN O
cyclosporine NN NN O
patients NN NN O
. NN NN O
   
Heart NN NN O
and NN NN O
liver NN NN O
patients NN NN O
had NN NN O
more NN NN O
infections NN NN B-Disease
than NN NN O
cyclosporine NN NN O
renal NN NN O
patients NN NN O
but NN NN O
fewer NN NN O
infections NN NN B-Disease
than NN NN O
the NN NN O
Aza NN NN O
renal NN NN O
patients NN NN O
. NN NN O
   
There NN NN O
were NN NN O
no NN NN O
infectious NN NN O
deaths NN NN O
in NN NN O
renal NN NN O
transplant NN NN O
patients NN NN O
on NN NN O
cyclosporine NN NN O
or NN NN O
Aza NN NN O
, NN NN O
but NN NN O
infection NN NN B-Disease
played NN NN O
a NN NN O
major NN NN O
role NN NN O
in NN NN O
3 NN NN O
out NN NN O
of NN NN O
6 NN NN O
cardiac NN NN O
transplant NN NN O
deaths NN NN O
and NN NN O
in NN NN O
8 NN NN O
out NN NN O
of NN NN O
9 NN NN O
liver NN NN O
transplant NN NN O
deaths NN NN O
. NN NN O
   
Renal NN NN O
patients NN NN O
on NN NN O
cyclosporine NN NN O
had NN NN O
the NN NN O
fewest NN NN O
bacteremias NN NN B-Disease
. NN NN O
   
Analysis NN NN O
of NN NN O
site NN NN O
of NN NN O
infection NN NN B-Disease
showed NN NN O
a NN NN O
preponderance NN NN O
of NN NN O
abdominal NN NN B-Disease
infections NN NN I-Disease
in NN NN O
liver NN NN O
patients NN NN O
, NN NN O
intrathoracic NN NN O
infections NN NN B-Disease
in NN NN O
heart NN NN O
patients NN NN O
, NN NN O
and NN NN O
urinary NN NN B-Disease
tract NN NN I-Disease
infections NN NN I-Disease
in NN NN O
renal NN NN O
patients NN NN O
. NN NN O
   
Pulmonary NN NN O
infections NN NN B-Disease
were NN NN O
less NN NN O
common NN NN O
in NN NN O
cyclosporine NN NN O
- NN NN O
treated NN NN O
renal NN NN O
patients NN NN O
than NN NN O
in NN NN O
Aza NN NN O
- NN NN O
treated NN NN O
patients NN NN O
( NN NN O
P NN NN O
less NN NN O
than NN NN O
0 NN NN O
. NN NN O
05 NN NN O
) NN NN O
. NN NN O
   
Aza NN NN O
patients NN NN O
had NN NN O
significantly NN NN O
more NN NN O
staphylococcal NN NN B-Disease
infections NN NN I-Disease
than NN NN O
all NN NN O
other NN NN O
transplant NN NN O
groups NN NN O
( NN NN O
P NN NN O
less NN NN O
than NN NN O
0 NN NN O
. NN NN O
005 NN NN O
) NN NN O
, NN NN O
and NN NN O
systemic NN NN O
fungal NN NN B-Disease
infections NN NN I-Disease
occurred NN NN O
only NN NN O
in NN NN O
the NN NN O
liver NN NN O
transplant NN NN O
group NN NN O
. NN NN O
   
Cytomegalovirus NN NN O
( NN NN O
CMV NN NN O
) NN NN O
shedding NN NN O
or NN NN O
serological NN NN O
rises NN NN O
in NN NN O
antibody NN NN O
titer NN NN O
, NN NN O
or NN NN O
both NN NN O
occurred NN NN O
in NN NN O
78 NN NN O
% NN NN O
of NN NN O
cyclosporine NN NN O
patients NN NN O
and NN NN O
76 NN NN O
% NN NN O
of NN NN O
Aza NN NN O
patients NN NN O
. NN NN O
   
Of NN NN O
the NN NN O
cyclosporine NN NN O
patients NN NN O
, NN NN O
15 NN NN O
% NN NN O
had NN NN O
symptoms NN NN O
related NN NN O
to NN NN O
CMV NN NN B-Disease
infection NN NN I-Disease
. NN NN O
   
Serological NN NN O
evidence NN NN O
for NN NN O
Epstein NN NN B-Disease
Barr NN NN I-Disease
Virus NN NN I-Disease
infection NN NN I-Disease
was NN NN O
found NN NN O
in NN NN O
20 NN NN O
% NN NN O
of NN NN O
65 NN NN O
cyclosporine NN NN O
patients NN NN O
studied NN NN O
. NN NN O
   
Three NN NN O
had NN NN O
associated NN NN O
symptoms NN NN O
, NN NN O
and NN NN O
one NN NN O
developed NN NN O
a NN NN O
lymphoma NN NN B-Disease
. NN NN O
   
Structure NN NN O
- NN NN O
activity NN NN O
and NN NN O
dose NN NN O
- NN NN O
effect NN NN O
relationships NN NN O
of NN NN O
the NN NN O
antagonism NN NN O
of NN NN O
picrotoxin NN NN O
- NN NN O
induced NN NN O
seizures NN NN B-Disease
by NN NN O
cholecystokinin NN NN O
, NN NN O
fragments NN NN O
and NN NN O
analogues NN NN O
of NN NN O
cholecystokinin NN NN O
in NN NN O
mice NN NN O
. NN NN O
   
Intraperitoneal NN NN O
administration NN NN O
of NN NN O
cholecystokinin NN NN O
octapeptide NN NN O
sulphate NN NN O
ester NN NN O
( NN NN O
CCK NN NN O
- NN NN O
8 NN NN O
- NN NN O
SE NN NN O
) NN NN O
and NN NN O
nonsulphated NN NN O
cholecystokinin NN NN O
octapeptide NN NN O
( NN NN O
CCK NN NN O
- NN NN O
8 NN NN O
- NN NN O
NS NN NN O
) NN NN O
enhanced NN NN O
the NN NN O
latency NN NN O
of NN NN O
seizures NN NN B-Disease
induced NN NN O
by NN NN O
picrotoxin NN NN O
in NN NN O
mice NN NN O
. NN NN O
   
Experiments NN NN O
with NN NN O
N NN NN O
- NN NN O
and NN NN O
C NN NN O
- NN NN O
terminal NN NN O
fragments NN NN O
revealed NN NN O
that NN NN O
the NN NN O
C NN NN O
- NN NN O
terminal NN NN O
tetrapeptide NN NN O
( NN NN O
CCK NN NN O
- NN NN O
5 NN NN O
- NN NN O
8 NN NN O
) NN NN O
was NN NN O
the NN NN O
active NN NN O
centre NN NN O
of NN NN O
the NN NN O
CCK NN NN O
octapeptide NN NN O
molecule NN NN O
. NN NN O
   
The NN NN O
analogues NN NN O
CCK NN NN O
- NN NN O
8 NN NN O
- NN NN O
SE NN NN O
and NN NN O
CCK NN NN O
- NN NN O
8 NN NN O
- NN NN O
NS NN NN O
( NN NN O
dose NN NN O
range NN NN O
0 NN NN O
. NN NN O
2 NN NN O
- NN NN O
6 NN NN O
. NN NN O
4 NN NN O
mumol NN NN O
/ NN NN O
kg NN NN O
) NN NN O
and NN NN O
caerulein NN NN O
dose NN NN O
range NN NN O
0 NN NN O
. NN NN O
1 NN NN O
- NN NN O
0 NN NN O
. NN NN O
8 NN NN O
mumol NN NN O
/ NN NN O
kg NN NN O
) NN NN O
showed NN NN O
bell NN NN O
- NN NN O
shaped NN NN O
dose NN NN O
- NN NN O
effect NN NN O
curves NN NN O
, NN NN O
with NN NN O
the NN NN O
greatest NN NN O
maximum NN NN O
inhibition NN NN O
for NN NN O
CCK NN NN O
- NN NN O
8 NN NN O
- NN NN O
NS NN NN O
. NN NN O
   
The NN NN O
peptide NN NN O
CCK NN NN O
- NN NN O
5 NN NN O
- NN NN O
8 NN NN O
had NN NN O
weak NN NN O
anticonvulsant NN NN O
activity NN NN O
in NN NN O
comparison NN NN O
to NN NN O
the NN NN O
octapeptides NN NN O
, NN NN O
3 NN NN O
. NN NN O
2 NN NN O
mumol NN NN O
/ NN NN O
kg NN NN O
and NN NN O
larger NN NN O
doses NN NN O
of NN NN O
the NN NN O
reference NN NN O
drug NN NN O
, NN NN O
diazepam NN NN O
, NN NN O
totally NN NN O
prevented NN NN O
picrotoxin NN NN O
- NN NN O
induced NN NN O
seizures NN NN B-Disease
and NN NN O
mortality NN NN O
. NN NN O
   
The NN NN O
maximum NN NN O
effect NN NN O
of NN NN O
the NN NN O
peptides NN NN O
tested NN NN O
was NN NN O
less NN NN O
than NN NN O
that NN NN O
of NN NN O
diazepam NN NN O
. NN NN O
   
Experiments NN NN O
with NN NN O
analogues NN NN O
and NN NN O
derivatives NN NN O
of NN NN O
CCK NN NN O
- NN NN O
5 NN NN O
- NN NN O
8 NN NN O
demonstrated NN NN O
that NN NN O
the NN NN O
effectiveness NN NN O
of NN NN O
the NN NN O
beta NN NN O
- NN NN O
alanyl NN NN O
derivatives NN NN O
of NN NN O
CCK NN NN O
- NN NN O
5 NN NN O
- NN NN O
8 NN NN O
were NN NN O
enhanced NN NN O
and NN NN O
that NN NN O
they NN NN O
were NN NN O
equipotent NN NN O
with NN NN O
CCK NN NN O
- NN NN O
8 NN NN O
- NN NN O
SE NN NN O
. NN NN O
   
Of NN NN O
the NN NN O
CCK NN NN O
- NN NN O
2 NN NN O
- NN NN O
8 NN NN O
analogues NN NN O
, NN NN O
Ser NN NN O
( NN NN O
SO3H NN NN O
) NN NN O
7 NN NN O
- NN NN O
Ac NN NN O
- NN NN O
CCK NN NN O
- NN NN O
2 NN NN O
- NN NN O
8 NN NN O
- NN NN O
SE NN NN O
and NN NN O
Thr NN NN O
( NN NN O
SO3H NN NN O
) NN NN O
7 NN NN O
- NN NN O
Ac NN NN O
- NN NN O
CCK NN NN O
- NN NN O
2 NN NN O
- NN NN O
8 NN NN O
- NN NN O
SE NN NN O
and NN NN O
Hyp NN NN O
( NN NN O
SO3H NN NN O
) NN NN O
- NN NN O
Ac NN NN O
- NN NN O
CCK NN NN O
- NN NN O
2 NN NN O
- NN NN O
8 NN NN O
- NN NN O
SE NN NN O
were NN NN O
slightly NN NN O
more NN NN O
active NN NN O
than NN NN O
CCK NN NN O
- NN NN O
8 NN NN O
- NN NN O
SE NN NN O
. NN NN O
   
Vasopressin NN NN O
as NN NN O
a NN NN O
possible NN NN O
contributor NN NN O
to NN NN O
hypertension NN NN B-Disease
. NN NN O
   
The NN NN O
role NN NN O
of NN NN O
vasopressin NN NN O
as NN NN O
a NN NN O
pressor NN NN O
agent NN NN O
to NN NN O
the NN NN O
hypertensive NN NN B-Disease
process NN NN O
was NN NN O
examined NN NN O
. NN NN O
   
Vasopressin NN NN O
plays NN NN O
a NN NN O
major NN NN O
role NN NN O
in NN NN O
the NN NN O
pathogenesis NN NN O
of NN NN O
DOCA NN NN O
- NN NN O
salt NN NN O
hypertension NN NN B-Disease
, NN NN O
since NN NN O
the NN NN O
elevation NN NN O
of NN NN O
blood NN NN O
pressure NN NN O
was NN NN O
not NN NN O
substantial NN NN O
in NN NN O
the NN NN O
rats NN NN O
with NN NN O
lithium NN NN O
- NN NN O
treated NN NN O
diabetes NN NN B-Disease
insipidus NN NN I-Disease
after NN NN O
DOCA NN NN O
- NN NN O
salt NN NN O
treatment NN NN O
. NN NN O
   
Administration NN NN O
of NN NN O
DDAVP NN NN O
which NN NN O
has NN NN O
antidiuretic NN NN O
action NN NN O
but NN NN O
minimal NN NN O
vasopressor NN NN O
effect NN NN O
failed NN NN O
to NN NN O
increase NN NN O
blood NN NN O
pressure NN NN O
to NN NN O
the NN NN O
levels NN NN O
observed NN NN O
after NN NN O
administration NN NN O
of NN NN O
AVP NN NN O
. NN NN O
   
Furthermore NN NN O
, NN NN O
the NN NN O
pressor NN NN O
action NN NN O
of NN NN O
vasopressin NN NN O
appears NN NN O
to NN NN O
be NN NN O
important NN NN O
in NN NN O
the NN NN O
development NN NN O
of NN NN O
this NN NN O
model NN NN O
of NN NN O
hypertension NN NN B-Disease
, NN NN O
since NN NN O
the NN NN O
enhanced NN NN O
pressor NN NN O
responsiveness NN NN O
to NN NN O
the NN NN O
hormone NN NN O
was NN NN O
observed NN NN O
in NN NN O
the NN NN O
initial NN NN O
stage NN NN O
of NN NN O
hypertension NN NN B-Disease
. NN NN O
   
Increased NN NN O
secretion NN NN O
of NN NN O
vasopressin NN NN O
from NN NN O
neurohypophysis NN NN O
also NN NN O
promotes NN NN O
the NN NN O
function NN NN O
of NN NN O
the NN NN O
hormone NN NN O
as NN NN O
a NN NN O
pathogenetic NN NN O
factor NN NN O
in NN NN O
hypertension NN NN B-Disease
. NN NN O
   
An NN NN O
unproportional NN NN O
release NN NN O
of NN NN O
vasopressin NN NN O
compared NN NN O
to NN NN O
plasma NN NN O
osmolality NN NN O
may NN NN O
be NN NN O
induced NN NN O
by NN NN O
the NN NN O
absence NN NN O
of NN NN O
an NN NN O
adjusting NN NN O
control NN NN O
of NN NN O
angiotensin NN NN O
II NN NN O
forming NN NN O
and NN NN O
receptor NN NN O
binding NN NN O
capacity NN NN O
for NN NN O
sodium NN NN O
balance NN NN O
in NN NN O
the NN NN O
brain NN NN O
. NN NN O
   
However NN NN O
, NN NN O
the NN NN O
role NN NN O
of NN NN O
vasopressin NN NN O
remains NN NN O
to NN NN O
be NN NN O
determined NN NN O
in NN NN O
human NN NN O
essential NN NN O
hypertension NN NN B-Disease
. NN NN O
   
Toxic NN NN B-Disease
hepatitis NN NN I-Disease
induced NN NN O
by NN NN O
disulfiram NN NN O
in NN NN O
a NN NN O
non NN NN O
- NN NN O
alcoholic NN NN O
. NN NN O
   
A NN NN O
reversible NN NN O
toxic NN NN B-Disease
liver NN NN I-Disease
damage NN NN I-Disease
was NN NN O
observed NN NN O
in NN NN O
a NN NN O
non NN NN O
- NN NN O
alcoholic NN NN O
woman NN NN O
treated NN NN O
with NN NN O
disulfiram NN NN O
. NN NN O
   
The NN NN O
causative NN NN O
relationship NN NN O
was NN NN O
proven NN NN O
by NN NN O
challenge NN NN O
. NN NN O
   
Atrial NN NN B-Disease
thrombosis NN NN I-Disease
involving NN NN O
the NN NN O
heart NN NN O
of NN NN O
F NN NN O
- NN NN O
344 NN NN O
rats NN NN O
ingesting NN NN O
quinacrine NN NN O
hydrochloride NN NN O
. NN NN O
   
Quinacrine NN NN O
hydrochloride NN NN O
is NN NN O
toxic NN NN O
for NN NN O
the NN NN O
heart NN NN O
of NN NN O
F NN NN O
- NN NN O
344 NN NN O
rats NN NN O
. NN NN O
   
Rats NN NN O
treated NN NN O
with NN NN O
500 NN NN O
ppm NN NN O
quinacrine NN NN O
hydrochloride NN NN O
in NN NN O
the NN NN O
diet NN NN O
all NN NN O
developed NN NN O
a NN NN O
high NN NN O
incidence NN NN O
of NN NN O
left NN NN O
atrial NN NN B-Disease
thrombosis NN NN I-Disease
. NN NN O
   
The NN NN O
lesion NN NN O
was NN NN O
associated NN NN O
with NN NN O
cardiac NN NN B-Disease
hypertrophy NN NN I-Disease
and NN NN O
dilatation NN NN O
and NN NN O
focal NN NN O
myocardial NN NN B-Disease
degeneration NN NN I-Disease
. NN NN O
   
Rats NN NN O
died NN NN O
from NN NN O
cardiac NN NN B-Disease
hypertrophy NN NN I-Disease
with NN NN O
severe NN NN O
acute NN NN O
and NN NN O
chronic NN NN O
congestion NN NN O
of NN NN O
the NN NN O
lungs NN NN O
, NN NN O
liver NN NN O
, NN NN O
and NN NN O
other NN NN O
organs NN NN O
. NN NN O
   
Seventy NN NN O
percent NN NN O
of NN NN O
rats NN NN O
given NN NN O
250 NN NN O
ppm NN NN O
quinacrine NN NN O
hydrochloride NN NN O
and NN NN O
1 NN NN O
, NN NN O
000 NN NN O
ppm NN NN O
sodium NN NN O
nitrite NN NN O
simultaneously NN NN O
in NN NN O
the NN NN O
diet NN NN O
had NN NN O
thrombosis NN NN B-Disease
of NN NN O
the NN NN O
atria NN NN O
of NN NN O
the NN NN O
heart NN NN O
, NN NN O
while NN NN O
untreated NN NN O
control NN NN O
rats NN NN O
in NN NN O
this NN NN O
laboratory NN NN O
did NN NN O
not NN NN O
have NN NN O
atrial NN NN B-Disease
thrombosis NN NN I-Disease
. NN NN O
   
Sodium NN NN O
nitrite NN NN O
in NN NN O
combination NN NN O
with NN NN O
quinacrine NN NN O
hydrochloride NN NN O
appeared NN NN O
to NN NN O
have NN NN O
no NN NN O
additional NN NN O
effect NN NN O
. NN NN O
   
Alternating NN NN B-Disease
sinus NN NN I-Disease
rhythm NN NN I-Disease
and NN NN O
intermittent NN NN O
sinoatrial NN NN B-Disease
block NN NN I-Disease
induced NN NN O
by NN NN O
propranolol NN NN O
. NN NN O
   
Alternating NN NN B-Disease
sinus NN NN I-Disease
rhythm NN NN I-Disease
and NN NN O
intermittent NN NN O
sinoatrial NN NN B-Disease
( NN NN I-Disease
S NN NN I-Disease
- NN NN I-Disease
A NN NN I-Disease
) NN NN I-Disease
block NN NN I-Disease
was NN NN O
observed NN NN O
in NN NN O
a NN NN O
57 NN NN O
- NN NN O
year NN NN O
- NN NN O
old NN NN O
woman NN NN O
, NN NN O
under NN NN O
treatment NN NN O
for NN NN O
angina NN NN B-Disease
with NN NN O
80 NN NN O
mg NN NN O
propranolol NN NN O
daily NN NN O
. NN NN O
   
The NN NN O
electrocardiogram NN NN O
showed NN NN O
alternation NN NN O
of NN NN O
long NN NN O
and NN NN O
short NN NN O
P NN NN O
- NN NN O
P NN NN O
intervals NN NN O
and NN NN O
occasional NN NN O
pauses NN NN O
. NN NN O
   
These NN NN O
pauses NN NN O
were NN NN O
always NN NN O
preceded NN NN O
by NN NN O
the NN NN O
short NN NN O
P NN NN O
- NN NN O
P NN NN O
intervals NN NN O
and NN NN O
were NN NN O
usually NN NN O
followed NN NN O
by NN NN O
one NN NN O
or NN NN O
two NN NN O
P NN NN O
- NN NN O
P NN NN O
intervals NN NN O
of NN NN O
0 NN NN O
. NN NN O
92 NN NN O
- NN NN O
0 NN NN O
. NN NN O
95 NN NN O
s NN NN O
representing NN NN O
the NN NN O
basic NN NN O
sinus NN NN O
cycle NN NN O
. NN NN O
   
Following NN NN O
these NN NN O
basic NN NN O
sinus NN NN O
cycles NN NN O
, NN NN O
alternating NN NN B-Disease
rhythm NN NN I-Disease
started NN NN O
with NN NN O
the NN NN O
longer NN NN O
P NN NN O
- NN NN O
P NN NN O
interval NN NN O
. NN NN O
   
The NN NN O
long NN NN O
P NN NN O
- NN NN O
P NN NN O
intervals NN NN O
ranged NN NN O
between NN NN O
1 NN NN O
. NN NN O
04 NN NN O
- NN NN O
1 NN NN O
. NN NN O
12 NN NN O
s NN NN O
and NN NN O
the NN NN O
short NN NN O
P NN NN O
- NN NN O
P NN NN O
intervals NN NN O
between NN NN O
0 NN NN O
. NN NN O
80 NN NN O
- NN NN O
0 NN NN O
. NN NN O
84 NN NN O
s NN NN O
, NN NN O
respectively NN NN O
. NN NN O
   
The NN NN O
duration NN NN O
of NN NN O
the NN NN O
pauses NN NN O
were NN NN O
equal NN NN O
or NN NN O
almost NN NN O
equal NN NN O
to NN NN O
one NN NN O
short NN NN O
plus NN NN O
one NN NN O
long NN NN O
P NN NN O
- NN NN O
P NN NN O
interval NN NN O
or NN NN O
to NN NN O
twice NN NN O
the NN NN O
basic NN NN O
sinus NN NN O
cycle NN NN O
. NN NN O
   
In NN NN O
one NN NN O
recording NN NN O
a NN NN O
short NN NN O
period NN NN O
of NN NN O
regular NN NN O
sinus NN NN O
rhythm NN NN O
with NN NN O
intermittent NN NN O
2 NN NN O
/ NN NN O
1 NN NN O
S NN NN B-Disease
- NN NN I-Disease
A NN NN I-Disease
block NN NN I-Disease
was NN NN O
observed NN NN O
. NN NN O
   
This NN NN O
short NN NN O
period NN NN O
of NN NN O
sinus NN NN O
rhythm NN NN O
was NN NN O
interrupted NN NN O
by NN NN O
sudden NN NN O
prolongation NN NN O
of NN NN O
the NN NN O
P NN NN O
- NN NN O
P NN NN O
interval NN NN O
starting NN NN O
the NN NN O
alternative NN NN O
rhythm NN NN O
. NN NN O
   
There NN NN O
were NN NN O
small NN NN O
changes NN NN O
in NN NN O
the NN NN O
shape NN NN O
of NN NN O
the NN NN O
P NN NN O
waves NN NN O
and NN NN O
P NN NN O
- NN NN O
R NN NN O
intervals NN NN O
. NN NN O
   
S NN NN O
- NN NN O
A NN NN O
conduction NN NN O
through NN NN O
two NN NN O
pathways NN NN O
, NN NN O
the NN NN O
first NN NN O
with NN NN O
2 NN NN O
/ NN NN O
1 NN NN O
block NN NN O
the NN NN O
second NN NN O
having NN NN O
0 NN NN O
. NN NN O
12 NN NN O
- NN NN O
0 NN NN O
. NN NN O
14 NN NN O
s NN NN O
longer NN NN O
conduction NN NN O
time NN NN O
and NN NN O
with NN NN O
occasional NN NN O
2 NN NN O
/ NN NN O
1 NN NN O
block NN NN O
was NN NN O
proposed NN NN O
for NN NN O
the NN NN O
explanation NN NN O
of NN NN O
the NN NN O
alternating NN NN O
P NN NN O
- NN NN O
P NN NN O
interval NN NN O
and NN NN O
other NN NN O
electrocardiographic NN NN O
features NN NN O
seen NN NN O
. NN NN O
   
Atropine NN NN O
1 NN NN O
mg NN NN O
given NN NN O
intravenously NN NN O
resulted NN NN O
in NN NN O
shortening NN NN O
of NN NN O
all NN NN O
P NN NN O
- NN NN O
P NN NN O
intervals NN NN O
without NN NN O
changing NN NN O
the NN NN O
rhythm NN NN O
. NN NN O
   
The NN NN O
abnormal NN NN O
rhythm NN NN O
disappeared NN NN O
with NN NN O
the NN NN O
withdrawal NN NN O
of NN NN O
propranolol NN NN O
and NN NN O
when NN NN O
the NN NN O
drug NN NN O
was NN NN O
restarted NN NN O
a NN NN O
2 NN NN O
/ NN NN O
1 NN NN O
S NN NN B-Disease
- NN NN I-Disease
A NN NN I-Disease
block NN NN I-Disease
was NN NN O
seen NN NN O
. NN NN O
   
This NN NN O
was NN NN O
accepted NN NN O
as NN NN O
evidence NN NN O
for NN NN O
propranolol NN NN O
being NN NN O
the NN NN O
cause NN NN O
of NN NN O
this NN NN O
conduction NN NN B-Disease
disorder NN NN I-Disease
. NN NN O
   
Antitumor NN NN O
effect NN NN O
, NN NN O
cardiotoxicity NN NN B-Disease
, NN NN O
and NN NN O
nephrotoxicity NN NN B-Disease
of NN NN O
doxorubicin NN NN O
in NN NN O
the NN NN O
IgM NN NN O
solid NN NN O
immunocytoma NN NN B-Disease
- NN NN O
bearing NN NN O
LOU NN NN O
/ NN NN O
M NN NN O
/ NN NN O
WSL NN NN O
rat NN NN O
. NN NN O
   
Antitumor NN NN O
activity NN NN O
, NN NN O
cardiotoxicity NN NN B-Disease
, NN NN O
and NN NN O
nephrotoxicity NN NN B-Disease
induced NN NN O
by NN NN O
doxorubicin NN NN O
were NN NN O
studied NN NN O
in NN NN O
LOU NN NN O
/ NN NN O
M NN NN O
/ NN NN O
WSL NN NN O
inbred NN NN O
rats NN NN O
each NN NN O
bearing NN NN O
a NN NN O
transplantable NN NN O
solid NN NN O
IgM NN NN O
immunocytoma NN NN B-Disease
. NN NN O
   
Animals NN NN O
with NN NN O
a NN NN O
tumor NN NN B-Disease
( NN NN O
diameter NN NN O
, NN NN O
15 NN NN O
. NN NN O
8 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
3 NN NN O
. NN NN O
3 NN NN O
mm NN NN O
) NN NN O
were NN NN O
treated NN NN O
with NN NN O
iv NN NN O
injections NN NN O
of NN NN O
doxorubicin NN NN O
on NN NN O
5 NN NN O
consecutive NN NN O
days NN NN O
, NN NN O
followed NN NN O
by NN NN O
1 NN NN O
weekly NN NN O
injection NN NN O
for NN NN O
7 NN NN O
weeks NN NN O
( NN NN O
dose NN NN O
range NN NN O
, NN NN O
0 NN NN O
. NN NN O
015 NN NN O
- NN NN O
4 NN NN O
. NN NN O
0 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
body NN NN O
wt NN NN O
) NN NN O
. NN NN O
   
Tumor NN NN B-Disease
regression NN NN O
was NN NN O
observed NN NN O
with NN NN O
0 NN NN O
. NN NN O
5 NN NN O
mg NN NN O
doxorubicin NN NN O
/ NN NN O
kg NN NN O
. NN NN O
   
Complete NN NN O
disappearance NN NN O
of NN NN O
the NN NN O
tumor NN NN B-Disease
was NN NN O
induced NN NN O
with NN NN O
1 NN NN O
. NN NN O
0 NN NN O
mg NN NN O
doxorubicin NN NN O
/ NN NN O
kg NN NN O
. NN NN O
   
Histologic NN NN O
evidence NN NN O
of NN NN O
cardiotoxicity NN NN B-Disease
scored NN NN O
as NN NN O
grade NN NN O
III NN NN O
was NN NN O
only NN NN O
observed NN NN O
at NN NN O
a NN NN O
dose NN NN O
of NN NN O
1 NN NN O
. NN NN O
0 NN NN O
mg NN NN O
doxorubicin NN NN O
/ NN NN O
kg NN NN O
. NN NN O
   
Light NN NN O
microscopic NN NN O
evidence NN NN O
of NN NN O
renal NN NN B-Disease
damage NN NN I-Disease
was NN NN O
seen NN NN O
above NN NN O
a NN NN O
dose NN NN O
of NN NN O
0 NN NN O
. NN NN O
5 NN NN O
mg NN NN O
doxorubicin NN NN O
/ NN NN O
kg NN NN O
, NN NN O
which NN NN O
resulted NN NN O
in NN NN O
albuminuria NN NN B-Disease
and NN NN O
very NN NN O
low NN NN O
serum NN NN O
albumin NN NN O
levels NN NN O
. NN NN O
   
In NN NN O
the NN NN O
group NN NN O
that NN NN O
received NN NN O
1 NN NN O
. NN NN O
0 NN NN O
mg NN NN O
doxorubicin NN NN O
/ NN NN O
kg NN NN O
, NN NN O
the NN NN O
serum NN NN O
albumin NN NN O
level NN NN O
decreased NN NN O
from NN NN O
33 NN NN O
. NN NN O
6 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
4 NN NN O
. NN NN O
1 NN NN O
to NN NN O
1 NN NN O
. NN NN O
5 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
0 NN NN O
. NN NN O
5 NN NN O
g NN NN O
/ NN NN O
liter NN NN O
. NN NN O
   
Ascites NN NN B-Disease
and NN NN O
hydrothorax NN NN B-Disease
were NN NN O
observed NN NN O
simultaneously NN NN O
. NN NN O
   
The NN NN O
same NN NN O
experiments NN NN O
were NN NN O
performed NN NN O
with NN NN O
non NN NN O
- NN NN O
tumor NN NN B-Disease
- NN NN O
bearing NN NN O
rats NN NN O
, NN NN O
in NN NN O
which NN NN O
no NN NN O
major NN NN O
differences NN NN O
were NN NN O
observed NN NN O
. NN NN O
   
In NN NN O
conclusion NN NN O
, NN NN O
antitumor NN NN O
activity NN NN O
, NN NN O
cardiotoxicity NN NN B-Disease
, NN NN O
and NN NN O
nephrotoxicity NN NN B-Disease
were NN NN O
studied NN NN O
simultaneously NN NN O
in NN NN O
the NN NN O
same NN NN O
LOU NN NN O
/ NN NN O
M NN NN O
/ NN NN O
WSL NN NN O
rat NN NN O
. NN NN O
   
Albuminuria NN NN B-Disease
due NN NN O
to NN NN O
renal NN NN B-Disease
damage NN NN I-Disease
led NN NN O
to NN NN O
extremely NN NN O
low NN NN O
serum NN NN O
albumin NN NN O
levels NN NN O
, NN NN O
so NN NN O
ascites NN NN B-Disease
and NN NN O
hydrothorax NN NN B-Disease
were NN NN O
not NN NN O
necessarily NN NN O
a NN NN O
consequence NN NN O
of NN NN O
the NN NN O
observed NN NN O
cardiomyopathy NN NN B-Disease
. NN NN O
   
Intraoperative NN NN O
bradycardia NN NN B-Disease
and NN NN O
hypotension NN NN B-Disease
associated NN NN O
with NN NN O
timolol NN NN O
and NN NN O
pilocarpine NN NN O
eye NN NN O
drops NN NN O
. NN NN O
   
A NN NN O
69 NN NN O
- NN NN O
yr NN NN O
- NN NN O
old NN NN O
man NN NN O
, NN NN O
who NN NN O
was NN NN O
concurrently NN NN O
being NN NN O
treated NN NN O
with NN NN O
pilocarpine NN NN O
nitrate NN NN O
and NN NN O
timolol NN NN O
maleate NN NN O
eye NN NN O
drops NN NN O
, NN NN O
developed NN NN O
a NN NN O
bradycardia NN NN B-Disease
and NN NN O
became NN NN O
hypotensive NN NN B-Disease
during NN NN O
halothane NN NN O
anaesthesia NN NN O
. NN NN O
   
Both NN NN O
timolol NN NN O
and NN NN O
pilocarpine NN NN O
were NN NN O
subsequently NN NN O
identified NN NN O
in NN NN O
a NN NN O
24 NN NN O
- NN NN O
h NN NN O
collection NN NN O
of NN NN O
urine NN NN O
. NN NN O
   
Timolol NN NN O
( NN NN O
but NN NN O
not NN NN O
pilocarpine NN NN O
) NN NN O
was NN NN O
detected NN NN O
in NN NN O
a NN NN O
sample NN NN O
of NN NN O
plasma NN NN O
removed NN NN O
during NN NN O
surgery NN NN O
; NN NN O
the NN NN O
plasma NN NN O
concentration NN NN O
of NN NN O
timolol NN NN O
( NN NN O
2 NN NN O
. NN NN O
6 NN NN O
ng NN NN O
ml NN NN O
- NN NN O
1 NN NN O
) NN NN O
was NN NN O
consistent NN NN O
with NN NN O
partial NN NN O
beta NN NN O
- NN NN O
adrenoceptor NN NN O
blockade NN NN O
. NN NN O
   
It NN NN O
is NN NN O
postulated NN NN O
that NN NN O
this NN NN O
action NN NN O
may NN NN O
have NN NN O
been NN NN O
enhanced NN NN O
during NN NN O
halothane NN NN O
anaesthesia NN NN O
with NN NN O
resultant NN NN O
bradycardia NN NN B-Disease
and NN NN O
hypotension NN NN B-Disease
. NN NN O
   
Pilocarpine NN NN O
may NN NN O
have NN NN O
had NN NN O
a NN NN O
contributory NN NN O
effect NN NN O
. NN NN O
   
Succinylcholine NN NN O
apnoea NN NN B-Disease
: NN NN O
attempted NN NN O
reversal NN NN O
with NN NN O
anticholinesterases NN NN O
. NN NN O
   
Anticholinesterases NN NN O
were NN NN O
administered NN NN O
in NN NN O
an NN NN O
attempt NN NN O
to NN NN O
antagonize NN NN O
prolonged NN NN O
neuromuscular NN NN B-Disease
blockade NN NN I-Disease
following NN NN O
the NN NN O
administration NN NN O
of NN NN O
succinylcholine NN NN O
in NN NN O
a NN NN O
patient NN NN O
later NN NN O
found NN NN O
to NN NN O
be NN NN O
homozygous NN NN O
for NN NN O
atypical NN NN O
plasma NN NN O
cholinesterase NN NN O
. NN NN O
   
Edrophonium NN NN O
10 NN NN O
mg NN NN O
, NN NN O
given NN NN O
74 NN NN O
min NN NN O
after NN NN O
succinylcholine NN NN O
, NN NN O
when NN NN O
train NN NN O
- NN NN O
of NN NN O
- NN NN O
four NN NN O
stimulation NN NN O
was NN NN O
characteristic NN NN O
of NN NN O
phase NN NN O
II NN NN O
block NN NN O
, NN NN O
produced NN NN O
partial NN NN O
antagonism NN NN O
which NN NN O
was NN NN O
not NN NN O
sustained NN NN O
. NN NN O
   
Repeated NN NN O
doses NN NN O
of NN NN O
edrophonium NN NN O
to NN NN O
70 NN NN O
mg NN NN O
and NN NN O
neostigmine NN NN O
to NN NN O
2 NN NN O
. NN NN O
5 NN NN O
mg NN NN O
did NN NN O
not NN NN O
antagonize NN NN O
or NN NN O
augment NN NN O
the NN NN O
block NN NN O
. NN NN O
   
Spontaneous NN NN O
respiration NN NN O
recommenced NN NN O
200 NN NN O
min NN NN O
after NN NN O
succinylcholine NN NN O
administration NN NN O
. NN NN O
   
It NN NN O
is NN NN O
concluded NN NN O
that NN NN O
anticholinesterases NN NN O
are NN NN O
only NN NN O
partially NN NN O
effective NN NN O
in NN NN O
restoring NN NN O
neuromuscular NN NN O
function NN NN O
in NN NN O
succinylcholine NN NN O
apnoea NN NN B-Disease
despite NN NN O
muscle NN NN O
twitch NN NN O
activity NN NN O
typical NN NN O
of NN NN O
phase NN NN O
II NN NN O
block NN NN O
. NN NN O
   
Effect NN NN O
of NN NN O
doxorubicin NN NN O
on NN NN O
[ NN NN O
omega NN NN O
- NN NN O
I NN NN O
- NN NN O
131 NN NN O
] NN NN O
heptadecanoic NN NN O
acid NN NN O
myocardial NN NN O
scintigraphy NN NN O
and NN NN O
echocardiography NN NN O
in NN NN O
dogs NN NN O
. NN NN O
   
The NN NN O
effects NN NN O
of NN NN O
serial NN NN O
treatment NN NN O
with NN NN O
doxorubicin NN NN O
on NN NN O
dynamic NN NN O
myocardial NN NN O
scintigraphy NN NN O
with NN NN O
[ NN NN O
omega NN NN O
- NN NN O
I NN NN O
- NN NN O
131 NN NN O
] NN NN O
heptadecanoic NN NN O
acid NN NN O
( NN NN O
I NN NN O
- NN NN O
131 NN NN O
HA NN NN O
) NN NN O
, NN NN O
and NN NN O
on NN NN O
global NN NN O
left NN NN O
- NN NN O
ventricular NN NN O
function NN NN O
determined NN NN O
echocardiographically NN NN O
, NN NN O
were NN NN O
studied NN NN O
in NN NN O
a NN NN O
group NN NN O
of NN NN O
nine NN NN O
mongrel NN NN O
dogs NN NN O
. NN NN O
   
Total NN NN O
extractable NN NN O
myocardial NN NN O
lipid NN NN O
was NN NN O
compared NN NN O
postmortem NN NN O
between NN NN O
a NN NN O
group NN NN O
of NN NN O
control NN NN O
dogs NN NN O
and NN NN O
doxorubicin NN NN O
- NN NN O
treated NN NN O
dogs NN NN O
. NN NN O
   
A NN NN O
significant NN NN O
and NN NN O
then NN NN O
progressive NN NN O
fall NN NN O
in NN NN O
global NN NN O
LV NN NN O
function NN NN O
was NN NN O
observed NN NN O
at NN NN O
a NN NN O
cumulative NN NN O
doxorubicin NN NN O
dose NN NN O
of NN NN O
4 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
. NN NN O
   
A NN NN O
significant NN NN O
increase NN NN O
in NN NN O
the NN NN O
myocardial NN NN O
t1 NN NN O
/ NN NN O
2 NN NN O
of NN NN O
the NN NN O
I NN NN O
- NN NN O
131 NN NN O
HA NN NN O
was NN NN O
observed NN NN O
only NN NN O
at NN NN O
a NN NN O
higher NN NN O
cumulative NN NN O
dose NN NN O
, NN NN O
10 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
. NN NN O
   
No NN NN O
significant NN NN O
alteration NN NN O
in NN NN O
total NN NN O
extractable NN NN O
myocardial NN NN O
lipids NN NN O
was NN NN O
observed NN NN O
between NN NN O
control NN NN O
dogs NN NN O
and NN NN O
those NN NN O
treated NN NN O
with NN NN O
doxorubicin NN NN O
. NN NN O
   
Our NN NN O
findings NN NN O
suggest NN NN O
that NN NN O
the NN NN O
changes NN NN O
leading NN NN O
to NN NN O
an NN NN O
alteration NN NN O
of NN NN O
myocardial NN NN O
dynamic NN NN O
imaging NN NN O
with NN NN O
I NN NN O
- NN NN O
131 NN NN O
HA NN NN O
are NN NN O
not NN NN O
the NN NN O
initiating NN NN O
factor NN NN O
in NN NN O
doxorubicin NN NN O
cardiotoxicity NN NN B-Disease
. NN NN O
   
Hemodynamics NN NN O
and NN NN O
myocardial NN NN O
metabolism NN NN O
under NN NN O
deliberate NN NN O
hypotension NN NN B-Disease
. NN NN O
   
An NN NN O
experimental NN NN O
study NN NN O
in NN NN O
dogs NN NN O
. NN NN O
   
Coronary NN NN O
blood NN NN O
flow NN NN O
, NN NN O
cardiac NN NN O
work NN NN O
and NN NN O
metabolism NN NN O
were NN NN O
studied NN NN O
in NN NN O
dogs NN NN O
under NN NN O
sodium NN NN O
nitroprusside NN NN O
( NN NN O
SNP NN NN O
) NN NN O
and NN NN O
trimetaphan NN NN O
( NN NN O
TMP NN NN O
) NN NN O
deliberate NN NN O
hypotension NN NN B-Disease
( NN NN O
20 NN NN O
% NN NN O
and NN NN O
40 NN NN O
% NN NN O
mean NN NN O
pressure NN NN O
decrease NN NN O
from NN NN O
baseline NN NN O
) NN NN O
. NN NN O
   
Regarding NN NN O
the NN NN O
effects NN NN O
of NN NN O
drug NN NN O
- NN NN O
induced NN NN O
hypotension NN NN B-Disease
on NN NN O
coronary NN NN O
blood NN NN O
flow NN NN O
, NN NN O
aortic NN NN O
and NN NN O
coronary NN NN O
sinus NN NN O
metabolic NN NN O
data NN NN O
( NN NN O
pH NN NN O
, NN NN O
pO2 NN NN O
, NN NN O
pCO2 NN NN O
) NN NN O
we NN NN O
could NN NN O
confirm NN NN O
that NN NN O
nitroprusside NN NN O
hypotension NN NN B-Disease
could NN NN O
be NN NN O
safely NN NN O
used NN NN O
to NN NN O
30 NN NN O
% NN NN O
mean NN NN O
blood NN NN O
pressure NN NN O
decrease NN NN O
from NN NN O
control NN NN O
, NN NN O
trimetaphan NN NN O
hypotension NN NN B-Disease
to NN NN O
20 NN NN O
% NN NN O
mean NN NN O
blood NN NN O
pressure NN NN O
decrease NN NN O
. NN NN O
   
Cardiac NN NN O
work NN NN O
was NN NN O
significantly NN NN O
reduced NN NN O
during NN NN O
SNP NN NN O
hypotension NN NN B-Disease
. NN NN O
   
Myocardial NN NN O
O2 NN NN O
consumption NN NN O
and NN NN O
O2 NN NN O
availability NN NN O
were NN NN O
directly NN NN O
dependent NN NN O
on NN NN O
the NN NN O
coronary NN NN O
perfusion NN NN O
. NN NN O
   
Careful NN NN O
invasive NN NN O
monitoring NN NN O
of NN NN O
the NN NN O
blood NN NN O
pressure NN NN O
, NN NN O
blood NN NN O
gases NN NN O
and NN NN O
of NN NN O
the NN NN O
ECG NN NN O
ST NN NN O
- NN NN O
T NN NN O
segment NN NN O
is NN NN O
mandatory NN NN O
. NN NN O
   
Evidence NN NN O
for NN NN O
a NN NN O
selective NN NN O
brain NN NN O
noradrenergic NN NN O
involvement NN NN O
in NN NN O
the NN NN O
locomotor NN NN O
stimulant NN NN O
effects NN NN O
of NN NN O
amphetamine NN NN O
in NN NN O
the NN NN O
rat NN NN O
. NN NN O
   
Male NN NN O
rats NN NN O
received NN NN O
the NN NN O
noradrenaline NN NN O
neurotoxin NN NN O
DSP4 NN NN O
( NN NN O
50 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
) NN NN O
7 NN NN O
days NN NN O
prior NN NN O
to NN NN O
injection NN NN O
of NN NN O
D NN NN O
- NN NN O
amphetamine NN NN O
( NN NN O
10 NN NN O
or NN NN O
40 NN NN O
mumol NN NN O
/ NN NN O
kg NN NN O
i NN NN O
. NN NN O
p NN NN O
. NN NN O
) NN NN O
. NN NN O
   
The NN NN O
hyperactivity NN NN B-Disease
induced NN NN O
by NN NN O
D NN NN O
- NN NN O
amphetamine NN NN O
( NN NN O
10 NN NN O
mumol NN NN O
/ NN NN O
kg NN NN O
) NN NN O
was NN NN O
significantly NN NN O
reduced NN NN O
by NN NN O
DSP4 NN NN O
pretreatment NN NN O
. NN NN O
   
However NN NN O
, NN NN O
the NN NN O
increased NN NN O
rearings NN NN O
and NN NN O
the NN NN O
amphetamine NN NN O
- NN NN O
induced NN NN O
stereotypies NN NN B-Disease
were NN NN O
not NN NN O
blocked NN NN O
by NN NN O
pretreatment NN NN O
with NN NN O
DSP4 NN NN O
. NN NN O
   
The NN NN O
reduction NN NN O
of NN NN O
amphetamine NN NN O
hyperactivity NN NN B-Disease
induced NN NN O
by NN NN O
DSP4 NN NN O
was NN NN O
blocked NN NN O
by NN NN O
pretreatment NN NN O
with NN NN O
the NN NN O
noradrenaline NN NN O
- NN NN O
uptake NN NN O
blocking NN NN O
agent NN NN O
, NN NN O
desipramine NN NN O
, NN NN O
which NN NN O
prevents NN NN O
the NN NN O
neurotoxic NN NN B-Disease
action NN NN O
of NN NN O
DSP4 NN NN O
. NN NN O
   
The NN NN O
present NN NN O
results NN NN O
suggest NN NN O
a NN NN O
selective NN NN O
involvement NN NN O
of NN NN O
central NN NN O
noradrenergic NN NN O
neurones NN NN O
in NN NN O
the NN NN O
locomotor NN NN O
stimulant NN NN O
effect NN NN O
of NN NN O
amphetamine NN NN O
in NN NN O
the NN NN O
rat NN NN O
. NN NN O
   
Accelerated NN NN B-Disease
junctional NN NN I-Disease
rhythms NN NN I-Disease
during NN NN O
oral NN NN O
verapamil NN NN O
therapy NN NN O
. NN NN O
   
This NN NN O
study NN NN O
examined NN NN O
the NN NN O
frequency NN NN O
of NN NN O
atrioventricular NN NN O
( NN NN O
AV NN NN O
) NN NN O
dissociation NN NN O
and NN NN O
accelerated NN NN B-Disease
junctional NN NN I-Disease
rhythms NN NN I-Disease
in NN NN O
59 NN NN O
patients NN NN O
receiving NN NN O
oral NN NN O
verapamil NN NN O
. NN NN O
   
Accelerated NN NN B-Disease
junctional NN NN I-Disease
rhythms NN NN I-Disease
and NN NN O
AV NN NN O
dissociation NN NN O
were NN NN O
frequent NN NN O
in NN NN O
patients NN NN O
with NN NN O
supraventricular NN NN B-Disease
tachyarrhythmias NN NN I-Disease
, NN NN O
particularly NN NN O
AV NN NN O
nodal NN NN O
reentry NN NN O
. NN NN O
   
Verapamil NN NN O
administration NN NN O
to NN NN O
these NN NN O
patients NN NN O
led NN NN O
to NN NN O
an NN NN O
asymptomatic NN NN O
increase NN NN O
in NN NN O
activity NN NN O
of NN NN O
these NN NN O
junctional NN NN O
pacemakers NN NN O
. NN NN O
   
In NN NN O
patients NN NN O
with NN NN O
various NN NN O
chest NN NN B-Disease
pain NN NN I-Disease
syndromes NN NN O
, NN NN O
verapamil NN NN O
neither NN NN O
increased NN NN O
the NN NN O
frequency NN NN O
of NN NN O
junctional NN NN O
rhythms NN NN O
nor NN NN O
suppressed NN NN O
their NN NN O
role NN NN O
as NN NN O
escape NN NN O
rhythms NN NN O
under NN NN O
physiologically NN NN O
appropriate NN NN O
circumstances NN NN O
. NN NN O
   
Interstrain NN NN O
variation NN NN O
in NN NN O
acute NN NN O
toxic NN NN O
response NN NN O
to NN NN O
caffeine NN NN O
among NN NN O
inbred NN NN O
mice NN NN O
. NN NN O
   
Acute NN NN O
toxic NN NN O
dosage NN NN O
- NN NN O
dependent NN NN O
behavioral NN NN O
effects NN NN O
of NN NN O
caffeine NN NN O
were NN NN O
compared NN NN O
in NN NN O
adult NN NN O
males NN NN O
from NN NN O
seven NN NN O
inbred NN NN O
mouse NN NN O
strains NN NN O
( NN NN O
A NN NN O
/ NN NN O
J NN NN O
, NN NN O
BALB NN NN O
/ NN NN O
cJ NN NN O
, NN NN O
CBA NN NN O
/ NN NN O
J NN NN O
, NN NN O
C3H NN NN O
/ NN NN O
HeJ NN NN O
, NN NN O
C57BL NN NN O
/ NN NN O
6J NN NN O
, NN NN O
DBA NN NN O
/ NN NN O
2J NN NN O
, NN NN O
SWR NN NN O
/ NN NN O
J NN NN O
) NN NN O
. NN NN O
   
C57BL NN NN O
/ NN NN O
6J NN NN O
, NN NN O
chosen NN NN O
as NN NN O
a NN NN O
"""""""" NN NN O
prototypic NN NN O
"""""""" NN NN O
mouse NN NN O
strain NN NN O
, NN NN O
was NN NN O
used NN NN O
to NN NN O
determine NN NN O
behavioral NN NN O
responses NN NN O
to NN NN O
a NN NN O
broad NN NN O
range NN NN O
( NN NN O
5 NN NN O
- NN NN O
500 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
) NN NN O
of NN NN O
caffeine NN NN O
doses NN NN O
. NN NN O
   
Five NN NN O
phenotypic NN NN O
characteristics NN NN O
- NN NN O
- NN NN O
locomotor NN NN O
activity NN NN O
, NN NN O
righting NN NN O
ability NN NN O
, NN NN O
clonic NN NN B-Disease
seizure NN NN I-Disease
induction NN NN O
, NN NN O
stress NN NN O
- NN NN O
induced NN NN O
lethality NN NN O
, NN NN O
death NN NN O
without NN NN O
external NN NN O
stress NN NN O
- NN NN O
- NN NN O
were NN NN O
scored NN NN O
at NN NN O
various NN NN O
caffeine NN NN O
doses NN NN O
in NN NN O
drug NN NN O
- NN NN O
naive NN NN O
animals NN NN O
under NN NN O
empirically NN NN O
optimized NN NN O
, NN NN O
rigidly NN NN O
constant NN NN O
experimental NN NN O
conditions NN NN O
. NN NN O
   
Mice NN NN O
( NN NN O
n NN NN O
= NN NN O
12 NN NN O
for NN NN O
each NN NN O
point NN NN O
) NN NN O
received NN NN O
single NN NN O
IP NN NN O
injections NN NN O
of NN NN O
a NN NN O
fixed NN NN O
volume NN NN O
/ NN NN O
g NN NN O
body NN NN O
weight NN NN O
of NN NN O
physiological NN NN O
saline NN NN O
carrier NN NN O
with NN NN O
or NN NN O
without NN NN O
caffeine NN NN O
in NN NN O
doses NN NN O
ranging NN NN O
from NN NN O
125 NN NN O
- NN NN O
500 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
. NN NN O
   
Loss NN NN O
of NN NN O
righting NN NN O
ability NN NN O
was NN NN O
scored NN NN O
at NN NN O
1 NN NN O
, NN NN O
3 NN NN O
, NN NN O
5 NN NN O
min NN NN O
post NN NN O
dosing NN NN O
and NN NN O
at NN NN O
5 NN NN O
min NN NN O
intervals NN NN O
thereafter NN NN O
for NN NN O
20 NN NN O
min NN NN O
. NN NN O
   
In NN NN O
the NN NN O
same NN NN O
animals NN NN O
the NN NN O
occurrence NN NN O
of NN NN O
clonic NN NN B-Disease
seizures NN NN I-Disease
was NN NN O
scored NN NN O
as NN NN O
to NN NN O
time NN NN O
of NN NN O
onset NN NN O
and NN NN O
severity NN NN O
for NN NN O
20 NN NN O
min NN NN O
after NN NN O
drug NN NN O
administration NN NN O
. NN NN O
   
When NN NN O
these NN NN O
proceeded NN NN O
to NN NN O
tonic NN NN B-Disease
seizures NN NN I-Disease
, NN NN O
death NN NN O
occurred NN NN O
in NN NN O
less NN NN O
than NN NN O
20 NN NN O
min NN NN O
. NN NN O
   
Animals NN NN O
surviving NN NN O
for NN NN O
20 NN NN O
min NN NN O
were NN NN O
immediately NN NN O
stressed NN NN O
by NN NN O
a NN NN O
swim NN NN O
test NN NN O
in NN NN O
25 NN NN O
degrees NN NN O
C NN NN O
water NN NN O
, NN NN O
and NN NN O
death NN NN O
- NN NN O
producing NN NN O
tonic NN NN B-Disease
seizures NN NN I-Disease
were NN NN O
scored NN NN O
for NN NN O
2 NN NN O
min NN NN O
. NN NN O
   
In NN NN O
other NN NN O
animals NN NN O
locomotor NN NN O
activity NN NN O
was NN NN O
measured NN NN O
15 NN NN O
or NN NN O
60 NN NN O
min NN NN O
after NN NN O
caffeine NN NN O
administration NN NN O
. NN NN O
   
By NN NN O
any NN NN O
single NN NN O
behavioral NN NN O
criterion NN NN O
or NN NN O
a NN NN O
combination NN NN O
of NN NN O
these NN NN O
criteria NN NN O
, NN NN O
marked NN NN O
differences NN NN O
in NN NN O
response NN NN O
to NN NN O
toxic NN NN O
caffeine NN NN O
doses NN NN O
were NN NN O
observed NN NN O
between NN NN O
strains NN NN O
. NN NN O
   
These NN NN O
results NN NN O
indicate NN NN O
that NN NN O
behavioral NN NN O
toxicity NN NN B-Disease
testing NN NN O
of NN NN O
alkylxanthines NN NN O
in NN NN O
a NN NN O
single NN NN O
mouse NN NN O
strain NN NN O
may NN NN O
be NN NN O
misleading NN NN O
and NN NN O
suggest NN NN O
that NN NN O
toxic NN NN O
responses NN NN O
of NN NN O
the NN NN O
central NN NN O
nervous NN NN O
system NN NN O
to NN NN O
this NN NN O
class NN NN O
of NN NN O
compounds NN NN O
are NN NN O
genetically NN NN O
influenced NN NN O
in NN NN O
mammals NN NN O
. NN NN O
   
Treatment NN NN O
of NN NN O
ovarian NN NN B-Disease
cancer NN NN I-Disease
with NN NN O
a NN NN O
combination NN NN O
of NN NN O
cis NN NN O
- NN NN O
platinum NN NN O
, NN NN O
adriamycin NN NN O
, NN NN O
cyclophosphamide NN NN O
and NN NN O
hexamethylmelamine NN NN O
. NN NN O
   
During NN NN O
the NN NN O
last NN NN O
2 NN NN O
1 NN NN O
/ NN NN O
2 NN NN O
years NN NN O
, NN NN O
38 NN NN O
patients NN NN O
with NN NN O
ovarian NN NN B-Disease
cancer NN NN I-Disease
were NN NN O
treated NN NN O
with NN NN O
a NN NN O
combination NN NN O
of NN NN O
cisplatinum NN NN O
( NN NN O
CPDD NN NN O
) NN NN O
, NN NN O
50 NN NN O
mg NN NN O
/ NN NN O
m2 NN NN O
, NN NN O
adriamycin NN NN O
, NN NN O
30 NN NN O
mg NN NN O
/ NN NN O
m2 NN NN O
, NN NN O
cyclophosphamide NN NN O
, NN NN O
300 NN NN O
mg NN NN O
/ NN NN O
m2 NN NN O
, NN NN O
on NN NN O
day NN NN O
1 NN NN O
; NN NN O
and NN NN O
hexamethylmelamine NN NN O
( NN NN O
HMM NN NN O
) NN NN O
, NN NN O
6 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
daily NN NN O
, NN NN O
for NN NN O
14 NN NN O
days NN NN O
. NN NN O
   
Each NN NN O
course NN NN O
was NN NN O
repeated NN NN O
monthly NN NN O
. NN NN O
   
2 NN NN O
patients NN NN O
had NN NN O
stage NN NN O
II NN NN O
, NN NN O
14 NN NN O
stage NN NN O
III NN NN O
and NN NN O
22 NN NN O
stage NN NN O
IV NN NN O
disease NN NN O
. NN NN O
   
14 NN NN O
of NN NN O
the NN NN O
38 NN NN O
patients NN NN O
were NN NN O
previously NN NN O
treated NN NN O
with NN NN O
chemotherapy NN NN O
, NN NN O
1 NN NN O
with NN NN O
radiation NN NN O
, NN NN O
6 NN NN O
with NN NN O
both NN NN O
chemotherapy NN NN O
and NN NN O
radiation NN NN O
, NN NN O
and NN NN O
17 NN NN O
did NN NN O
not NN NN O
have NN NN O
any NN NN O
treatment NN NN O
before NN NN O
CPDD NN NN O
combination NN NN O
. NN NN O
   
31 NN NN O
of NN NN O
the NN NN O
38 NN NN O
cases NN NN O
( NN NN O
81 NN NN O
. NN NN O
5 NN NN O
% NN NN O
) NN NN O
demonstrated NN NN O
objective NN NN O
responses NN NN O
lasting NN NN O
for NN NN O
2 NN NN O
months NN NN O
or NN NN O
more NN NN O
. NN NN O
   
These NN NN O
responses NN NN O
were NN NN O
partial NN NN O
in NN NN O
19 NN NN O
and NN NN O
complete NN NN O
in NN NN O
12 NN NN O
cases NN NN O
. NN NN O
   
Hematologic NN NN B-Disease
toxicity NN NN I-Disease
was NN NN O
moderate NN NN O
and NN NN O
with NN NN O
reversible NN NN O
anemia NN NN B-Disease
developing NN NN O
in NN NN O
71 NN NN O
% NN NN O
of NN NN O
patients NN NN O
. NN NN O
   
Gastrointestinal NN NN O
side NN NN O
effects NN NN O
from NN NN O
CPDD NN NN O
were NN NN O
universal NN NN O
. NN NN O
   
HMM NN NN O
gastrointestinal NN NN B-Disease
toxicity NN NN I-Disease
necessitated NN NN O
discontinuation NN NN O
of NN NN O
the NN NN O
drug NN NN O
in NN NN O
5 NN NN O
patients NN NN O
. NN NN O
   
Severe NN NN O
nephrotoxicity NN NN B-Disease
was NN NN O
observed NN NN O
in NN NN O
2 NN NN O
patients NN NN O
but NN NN O
was NN NN O
reversible NN NN O
. NN NN O
   
There NN NN O
were NN NN O
no NN NN O
drug NN NN O
- NN NN O
related NN NN O
deaths NN NN O
. NN NN O
   
Nontraumatic NN NN O
dissecting NN NN B-Disease
aneurysm NN NN I-Disease
of NN NN O
the NN NN O
basilar NN NN O
artery NN NN O
. NN NN O
   
A NN NN O
case NN NN O
of NN NN O
nontraumatic NN NN O
dissecting NN NN B-Disease
aneurysm NN NN I-Disease
of NN NN O
the NN NN O
basilar NN NN O
artery NN NN O
in NN NN O
association NN NN O
with NN NN O
hypertension NN NN B-Disease
, NN NN O
smoke NN NN O
, NN NN O
and NN NN O
oral NN NN O
contraceptives NN NN O
is NN NN O
reported NN NN O
in NN NN O
a NN NN O
young NN NN O
female NN NN O
patient NN NN O
with NN NN O
a NN NN O
locked NN NN B-Disease
- NN NN I-Disease
in NN NN I-Disease
syndrome NN NN I-Disease
. NN NN O
   
A NN NN O
method NN NN O
for NN NN O
the NN NN O
measurement NN NN O
of NN NN O
tremor NN NN B-Disease
, NN NN O
and NN NN O
a NN NN O
comparison NN NN O
of NN NN O
the NN NN O
effects NN NN O
of NN NN O
tocolytic NN NN O
beta NN NN O
- NN NN O
mimetics NN NN O
. NN NN O
   
A NN NN O
method NN NN O
permitting NN NN O
measurement NN NN O
of NN NN O
finger NN NN O
tremor NN NN B-Disease
as NN NN O
a NN NN O
displacement NN NN O
- NN NN O
time NN NN O
curve NN NN O
is NN NN O
described NN NN O
, NN NN O
using NN NN O
a NN NN O
test NN NN O
system NN NN O
with NN NN O
simple NN NN O
amplitude NN NN O
calibration NN NN O
. NN NN O
   
The NN NN O
coordinates NN NN O
of NN NN O
the NN NN O
inversion NN NN O
points NN NN O
of NN NN O
the NN NN O
displacement NN NN O
- NN NN O
time NN NN O
curves NN NN O
were NN NN O
transferred NN NN O
through NN NN O
graphical NN NN O
input NN NN O
equipment NN NN O
to NN NN O
punched NN NN O
tape NN NN O
. NN NN O
   
By NN NN O
means NN NN O
of NN NN O
a NN NN O
computer NN NN O
program NN NN O
, NN NN O
periods NN NN O
and NN NN O
amplitudes NN NN O
of NN NN O
tremor NN NN B-Disease
oscillations NN NN O
were NN NN O
calculated NN NN O
and NN NN O
classified NN NN O
. NN NN O
   
The NN NN O
event NN NN O
frequency NN NN O
for NN NN O
each NN NN O
class NN NN O
of NN NN O
periods NN NN O
and NN NN O
amplitudes NN NN O
was NN NN O
determined NN NN O
. NN NN O
   
The NN NN O
actions NN NN O
of NN NN O
fenoterol NN NN O
- NN NN O
hydrobromide NN NN O
, NN NN O
ritodrin NN NN O
- NN NN O
HCl NN NN O
and NN NN O
placebo NN NN O
given NN NN O
to NN NN O
10 NN NN O
healthy NN NN O
subjects NN NN O
by NN NN O
intravenous NN NN O
infusion NN NN O
in NN NN O
a NN NN O
double NN NN O
- NN NN O
blind NN NN O
crossover NN NN O
study NN NN O
were NN NN O
tested NN NN O
by NN NN O
this NN NN O
method NN NN O
. NN NN O
   
At NN NN O
therapeutic NN NN O
doses NN NN O
both NN NN O
substances NN NN O
raised NN NN O
the NN NN O
mean NN NN O
tremor NN NN B-Disease
amplitude NN NN O
to NN NN O
about NN NN O
three NN NN O
times NN NN O
the NN NN O
control NN NN O
level NN NN O
. NN NN O
   
At NN NN O
the NN NN O
same NN NN O
time NN NN O
, NN NN O
the NN NN O
mean NN NN O
period NN NN O
within NN NN O
each NN NN O
class NN NN O
of NN NN O
amplitudes NN NN O
shortened NN NN O
by NN NN O
10 NN NN O
- NN NN O
- NN NN O
20 NN NN O
ms NN NN O
, NN NN O
whereas NN NN O
the NN NN O
mean NN NN O
periods NN NN O
calculated NN NN O
from NN NN O
all NN NN O
oscillations NN NN O
together NN NN O
did NN NN O
not NN NN O
change NN NN O
significantly NN NN O
. NN NN O
   
After NN NN O
the NN NN O
end NN NN O
of NN NN O
fenoterol NN NN O
- NN NN O
hydrobromide NN NN O
infusion NN NN O
, NN NN O
tremor NN NN B-Disease
amplitudes NN NN O
decreased NN NN O
significantly NN NN O
faster NN NN O
than NN NN O
those NN NN O
following NN NN O
ritodrin NN NN O
- NN NN O
HCl NN NN O
infusion NN NN O
. NN NN O
   
Propylthiouracil NN NN O
- NN NN O
induced NN NN O
hepatic NN NN B-Disease
damage NN NN I-Disease
. NN NN O
   
Two NN NN O
cases NN NN O
of NN NN O
propylthiouracil NN NN O
- NN NN O
induced NN NN O
liver NN NN B-Disease
damage NN NN I-Disease
have NN NN O
been NN NN O
observed NN NN O
. NN NN O
   
The NN NN O
first NN NN O
case NN NN O
is NN NN O
of NN NN O
an NN NN O
acute NN NN O
type NN NN O
of NN NN O
damage NN NN O
, NN NN O
proven NN NN O
by NN NN O
rechallenge NN NN O
; NN NN O
the NN NN O
second NN NN O
presents NN NN O
a NN NN O
clinical NN NN O
and NN NN O
histologic NN NN O
picture NN NN O
resembling NN NN O
chronic NN NN B-Disease
active NN NN I-Disease
hepatitis NN NN I-Disease
, NN NN O
with NN NN O
spontaneous NN NN O
remission NN NN O
. NN NN O
   
Studies NN NN O
on NN NN O
the NN NN O
bradycardia NN NN B-Disease
induced NN NN O
by NN NN O
bepridil NN NN O
. NN NN O
   
Bepridil NN NN O
, NN NN O
a NN NN O
novel NN NN O
active NN NN O
compound NN NN O
for NN NN O
prophylactic NN NN O
treatment NN NN O
of NN NN O
anginal NN NN B-Disease
attacks NN NN I-Disease
, NN NN O
induced NN NN O
persistent NN NN O
bradycardia NN NN B-Disease
and NN NN O
a NN NN O
non NN NN O
- NN NN O
specific NN NN O
anti NN NN O
- NN NN O
tachycardial NN NN B-Disease
effect NN NN O
, NN NN O
the NN NN O
mechanisms NN NN O
of NN NN O
which NN NN O
were NN NN O
investigated NN NN O
in NN NN O
vitro NN NN O
and NN NN O
in NN NN O
vivo NN NN O
. NN NN O
   
In NN NN O
vitro NN NN O
perfusion NN NN O
of NN NN O
bepridil NN NN O
in NN NN O
the NN NN O
life NN NN O
- NN NN O
support NN NN O
medium NN NN O
for NN NN O
isolated NN NN O
sino NN NN O
- NN NN O
atrial NN NN O
tissue NN NN O
from NN NN O
rabbit NN NN O
heart NN NN O
, NN NN O
caused NN NN O
a NN NN O
reduction NN NN O
in NN NN O
action NN NN O
potential NN NN O
( NN NN O
AP NN NN O
) NN NN O
spike NN NN O
frequency NN NN O
( NN NN O
recorded NN NN O
by NN NN O
KCl NN NN O
microelectrodes NN NN O
) NN NN O
starting NN NN O
at NN NN O
doses NN NN O
of NN NN O
5 NN NN O
X NN NN O
10 NN NN O
( NN NN O
- NN NN O
6 NN NN O
) NN NN O
M NN NN O
. NN NN O
   
This NN NN O
effect NN NN O
was NN NN O
dose NN NN O
- NN NN O
dependent NN NN O
up NN NN O
to NN NN O
concentrations NN NN O
of NN NN O
5 NN NN O
X NN NN O
10 NN NN O
( NN NN O
- NN NN O
5 NN NN O
) NN NN O
M NN NN O
, NN NN O
whereupon NN NN O
blockade NN NN O
of NN NN O
sinus NN NN O
activity NN NN O
set NN NN O
in NN NN O
. NN NN O
   
Bepridil NN NN O
at NN NN O
a NN NN O
dose NN NN O
of NN NN O
5 NN NN O
X NN NN O
10 NN NN O
( NN NN O
- NN NN O
6 NN NN O
) NN NN O
M NN NN O
, NN NN O
induced NN NN O
a NN NN O
concomitant NN NN O
reduction NN NN O
in NN NN O
AP NN NN O
amplitude NN NN O
( NN NN O
falling NN NN O
from NN NN O
71 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
8 NN NN O
mV NN NN O
to NN NN O
47 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
6 NN NN O
mV NN NN O
) NN NN O
, NN NN O
maximum NN NN O
systolic NN NN O
depolarization NN NN O
velocity NN NN O
( NN NN O
phase NN NN O
0 NN NN O
) NN NN O
which NN NN O
fell NN NN O
from NN NN O
1 NN NN O
. NN NN O
85 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
0 NN NN O
. NN NN O
35 NN NN O
V NN NN O
/ NN NN O
s NN NN O
to NN NN O
0 NN NN O
. NN NN O
84 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
0 NN NN O
. NN NN O
28 NN NN O
V NN NN O
/ NN NN O
s NN NN O
, NN NN O
together NN NN O
with NN NN O
maximum NN NN O
diastolic NN NN O
depolarization NN NN O
velocity NN NN O
( NN NN O
phase NN NN O
4 NN NN O
) NN NN O
which NN NN O
fell NN NN O
from NN NN O
38 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
3 NN NN O
mV NN NN O
/ NN NN O
s NN NN O
to NN NN O
24 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
5 NN NN O
mV NN NN O
/ NN NN O
s NN NN O
. NN NN O
   
In NN NN O
vivo NN NN O
injection NN NN O
of NN NN O
bepridil NN NN O
at NN NN O
a NN NN O
dose NN NN O
of NN NN O
5 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
( NN NN O
i NN NN O
. NN NN O
v NN NN O
. NN NN O
) NN NN O
into NN NN O
6 NN NN O
anaesthetized NN NN O
dogs NN NN O
which NN NN O
had NN NN O
undergone NN NN O
ablation NN NN O
of NN NN O
all NN NN O
the NN NN O
extrinsic NN NN O
cardiac NN NN O
afferent NN NN O
nerve NN NN O
supply NN NN O
, NN NN O
together NN NN O
with NN NN O
a NN NN O
bilateral NN NN O
medullo NN NN O
- NN NN O
adrenalectomy NN NN O
, NN NN O
caused NN NN O
a NN NN O
marked NN NN O
reduction NN NN O
in NN NN O
heart NN NN O
rate NN NN O
which NN NN O
fell NN NN O
from NN NN O
98 NN NN O
. NN NN O
7 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
4 NN NN O
. NN NN O
2 NN NN O
beats NN NN O
/ NN NN O
min NN NN O
to NN NN O
76 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
5 NN NN O
. NN NN O
3 NN NN O
beats NN NN O
/ NN NN O
min NN NN O
sustained NN NN O
for NN NN O
more NN NN O
than NN NN O
45 NN NN O
min NN NN O
. NN NN O
   
It NN NN O
is NN NN O
concluded NN NN O
that NN NN O
bepridil NN NN O
reduces NN NN O
heart NN NN O
rate NN NN O
by NN NN O
acting NN NN O
directly NN NN O
on NN NN O
the NN NN O
sinus NN NN O
node NN NN O
. NN NN O
   
This NN NN O
effect NN NN O
, NN NN O
which NN NN O
results NN NN O
in NN NN O
a NN NN O
flattening NN NN O
of NN NN O
the NN NN O
phase NN NN O
0 NN NN O
and NN NN O
phase NN NN O
4 NN NN O
slope NN NN O
, NN NN O
together NN NN O
with NN NN O
a NN NN O
longer NN NN O
AP NN NN O
duration NN NN O
, NN NN O
may NN NN O
be NN NN O
due NN NN O
to NN NN O
an NN NN O
increase NN NN O
in NN NN O
the NN NN O
time NN NN O
constants NN NN O
of NN NN O
slow NN NN O
inward NN NN O
ionic NN NN O
currents NN NN O
( NN NN O
already NN NN O
demonstrated NN NN O
elsewhere NN NN O
) NN NN O
, NN NN O
but NN NN O
also NN NN O
to NN NN O
an NN NN O
increased NN NN O
time NN NN O
constant NN NN O
for NN NN O
deactivation NN NN O
of NN NN O
the NN NN O
outward NN NN O
potassium NN NN O
current NN NN O
( NN NN O
Ip NN NN O
) NN NN O
. NN NN O
   
Hepatitis NN NN B-Disease
and NN NN O
renal NN NN B-Disease
tubular NN NN I-Disease
acidosis NN NN I-Disease
after NN NN O
anesthesia NN NN O
with NN NN O
methoxyflurane NN NN O
. NN NN O
   
A NN NN O
69 NN NN O
- NN NN O
year NN NN O
- NN NN O
old NN NN O
man NN NN O
operated NN NN O
for NN NN O
acute NN NN B-Disease
cholecystitis NN NN I-Disease
under NN NN O
methoxyflurane NN NN O
anesthesia NN NN O
developed NN NN O
postoperatively NN NN O
a NN NN O
hepatic NN NN B-Disease
insufficiency NN NN I-Disease
syndrome NN NN I-Disease
and NN NN O
renal NN NN B-Disease
tubular NN NN I-Disease
acidosis NN NN I-Disease
. NN NN O
   
Massive NN NN O
bleeding NN NN B-Disease
appeared NN NN O
during NN NN O
surgery NN NN O
which NN NN O
lasted NN NN O
for NN NN O
six NN NN O
hours NN NN O
. NN NN O
   
Postoperative NN NN O
evolution NN NN O
under NN NN O
supportive NN NN O
therapy NN NN O
was NN NN O
favourable NN NN O
. NN NN O
   
Complete NN NN O
recovery NN NN O
was NN NN O
confirmed NN NN O
by NN NN O
repeated NN NN O
controls NN NN O
performed NN NN O
over NN NN O
a NN NN O
period NN NN O
of NN NN O
one NN NN O
year NN NN O
after NN NN O
surgery NN NN O
. NN NN O
   
Pituitary NN NN O
response NN NN O
to NN NN O
luteinizing NN NN O
hormone NN NN O
- NN NN O
releasing NN NN O
hormone NN NN O
during NN NN O
haloperidol NN NN O
- NN NN O
induced NN NN O
hyperprolactinemia NN NN B-Disease
. NN NN O
   
The NN NN O
effects NN NN O
of NN NN O
a NN NN O
6 NN NN O
- NN NN O
hour NN NN O
infusion NN NN O
with NN NN O
haloperidol NN NN O
on NN NN O
serum NN NN O
prolactin NN NN O
and NN NN O
luteinizing NN NN O
hormone NN NN O
( NN NN O
LH NN NN O
) NN NN O
levels NN NN O
was NN NN O
studied NN NN O
in NN NN O
a NN NN O
group NN NN O
of NN NN O
male NN NN O
subjects NN NN O
. NN NN O
   
Five NN NN O
hours NN NN O
after NN NN O
starting NN NN O
the NN NN O
infusions NN NN O
, NN NN O
a NN NN O
study NN NN O
of NN NN O
the NN NN O
pituitary NN NN O
responses NN NN O
to NN NN O
LH NN NN O
- NN NN O
releasing NN NN O
hormone NN NN O
( NN NN O
LH NN NN O
- NN NN O
RH NN NN O
) NN NN O
was NN NN O
carried NN NN O
out NN NN O
. NN NN O
   
Control NN NN O
patients NN NN O
received NN NN O
infusions NN NN O
of NN NN O
0 NN NN O
. NN NN O
9 NN NN O
% NN NN O
NaCl NN NN O
solution NN NN O
. NN NN O
   
During NN NN O
the NN NN O
course NN NN O
of NN NN O
haloperidol NN NN O
infusions NN NN O
, NN NN O
significant NN NN O
hyperprolactinemia NN NN B-Disease
was NN NN O
found NN NN O
, NN NN O
together NN NN O
with NN NN O
an NN NN O
abolished NN NN O
pituitary NN NN O
response NN NN O
to NN NN O
LH NN NN O
- NN NN O
RH NN NN O
, NN NN O
as NN NN O
compared NN NN O
with NN NN O
responses NN NN O
of NN NN O
control NN NN O
subjects NN NN O
. NN NN O
   
Antirifampicin NN NN O
antibodies NN NN O
in NN NN O
acute NN NN O
rifampicin NN NN O
- NN NN O
associated NN NN O
renal NN NN B-Disease
failure NN NN I-Disease
. NN NN O
   
5 NN NN O
patients NN NN O
with NN NN O
acute NN NN B-Disease
renal NN NN I-Disease
failure NN NN I-Disease
( NN NN O
3 NN NN O
with NN NN O
thrombopenia NN NN B-Disease
and NN NN O
hemolysis NN NN B-Disease
) NN NN O
induced NN NN O
by NN NN O
the NN NN O
reintroduction NN NN O
of NN NN O
rifampicin NN NN O
are NN NN O
described NN NN O
. NN NN O
   
No NN NN O
correlation NN NN O
was NN NN O
found NN NN O
between NN NN O
the NN NN O
severity NN NN O
of NN NN O
clinical NN NN O
manifestations NN NN O
and NN NN O
the NN NN O
total NN NN O
dose NN NN O
taken NN NN O
by NN NN O
the NN NN O
patients NN NN O
. NN NN O
   
In NN NN O
all NN NN O
but NN NN O
1 NN NN O
patient NN NN O
, NN NN O
antirifampicin NN NN O
antibodies NN NN O
were NN NN O
detected NN NN O
. NN NN O
   
Antibodies NN NN O
suggested NN NN O
to NN NN O
be NN NN O
of NN NN O
the NN NN O
IgM NN NN O
class NN NN O
were NN NN O
detected NN NN O
in NN NN O
all NN NN O
3 NN NN O
patients NN NN O
with NN NN O
hematological NN NN B-Disease
disorders NN NN I-Disease
. NN NN O
   
The NN NN O
pattern NN NN O
of NN NN O
non NN NN O
- NN NN O
specific NN NN O
acute NN NN B-Disease
tubular NN NN I-Disease
necrosis NN NN I-Disease
found NN NN O
in NN NN O
the NN NN O
2 NN NN O
biopsied NN NN O
patients NN NN O
, NN NN O
indistinguishable NN NN O
from NN NN O
that NN NN O
of NN NN O
ischemic NN NN O
origin NN NN O
, NN NN O
raised NN NN O
the NN NN O
possibility NN NN O
of NN NN O
a NN NN O
vascular NN NN O
- NN NN O
mediated NN NN O
damage NN NN O
. NN NN O
   
In NN NN O
3 NN NN O
patients NN NN O
, NN NN O
the NN NN O
possibility NN NN O
of NN NN O
a NN NN O
triggering NN NN O
immunoallergic NN NN O
mechanism NN NN O
is NN NN O
discussed NN NN O
. NN NN O
   
Cardiovascular NN NN O
effects NN NN O
of NN NN O
hypotension NN NN B-Disease
induced NN NN O
by NN NN O
adenosine NN NN O
triphosphate NN NN O
and NN NN O
sodium NN NN O
nitroprusside NN NN O
on NN NN O
dogs NN NN O
with NN NN O
denervated NN NN O
hearts NN NN O
. NN NN O
   
Adenosine NN NN O
triphosphate NN NN O
( NN NN O
ATP NN NN O
) NN NN O
and NN NN O
sodium NN NN O
nitroprusside NN NN O
( NN NN O
SNP NN NN O
) NN NN O
are NN NN O
administered NN NN O
to NN NN O
patients NN NN O
to NN NN O
induce NN NN O
and NN NN O
control NN NN O
hypotension NN NN B-Disease
during NN NN O
anesthesia NN NN O
. NN NN O
   
SNP NN NN O
is NN NN O
authorized NN NN O
for NN NN O
clinical NN NN O
use NN NN O
in NN NN O
USA NN NN O
and NN NN O
UK NN NN O
, NN NN O
and NN NN O
ATP NN NN O
is NN NN O
clinically NN NN O
used NN NN O
in NN NN O
other NN NN O
countries NN NN O
such NN NN O
as NN NN O
Japan NN NN O
. NN NN O
   
We NN NN O
investigated NN NN O
how NN NN O
these NN NN O
two NN NN O
drugs NN NN O
act NN NN O
on NN NN O
the NN NN O
cardiovascular NN NN O
systems NN NN O
of NN NN O
20 NN NN O
dogs NN NN O
whose NN NN O
hearts NN NN O
had NN NN O
been NN NN O
denervated NN NN O
by NN NN O
a NN NN O
procedure NN NN O
we NN NN O
had NN NN O
devised NN NN O
. NN NN O
   
ATP NN NN O
( NN NN O
10 NN NN O
dogs NN NN O
) NN NN O
or NN NN O
SNP NN NN O
( NN NN O
10 NN NN O
dogs NN NN O
) NN NN O
was NN NN O
administered NN NN O
to NN NN O
reduce NN NN O
mean NN NN O
arterial NN NN O
pressure NN NN O
by NN NN O
30 NN NN O
% NN NN O
to NN NN O
70 NN NN O
% NN NN O
of NN NN O
control NN NN O
. NN NN O
   
Before NN NN O
, NN NN O
during NN NN O
and NN NN O
after NN NN O
induced NN NN O
hypotension NN NN B-Disease
, NN NN O
we NN NN O
measured NN NN O
major NN NN O
cardiovascular NN NN O
parameters NN NN O
. NN NN O
   
Hypotension NN NN B-Disease
induced NN NN O
by NN NN O
ATP NN NN O
was NN NN O
accompanied NN NN O
by NN NN O
significant NN NN O
decreases NN NN O
in NN NN O
mean NN NN O
pulmonary NN NN O
arterial NN NN O
pressure NN NN O
( NN NN O
p NN NN O
less NN NN O
than NN NN O
0 NN NN O
. NN NN O
001 NN NN O
) NN NN O
, NN NN O
central NN NN O
venous NN NN O
pressure NN NN O
( NN NN O
p NN NN O
less NN NN O
than NN NN O
0 NN NN O
. NN NN O
001 NN NN O
) NN NN O
, NN NN O
left NN NN O
ventricular NN NN O
end NN NN O
- NN NN O
diastolic NN NN O
pressure NN NN O
( NN NN O
p NN NN O
less NN NN O
than NN NN O
0 NN NN O
. NN NN O
001 NN NN O
) NN NN O
, NN NN O
total NN NN O
peripheral NN NN O
resistance NN NN O
( NN NN O
p NN NN O
less NN NN O
than NN NN O
0 NN NN O
. NN NN O
001 NN NN O
) NN NN O
, NN NN O
rate NN NN O
pressure NN NN O
product NN NN O
( NN NN O
p NN NN O
less NN NN O
than NN NN O
0 NN NN O
. NN NN O
001 NN NN O
) NN NN O
, NN NN O
total NN NN O
body NN NN O
oxygen NN NN O
consumption NN NN O
( NN NN O
p NN NN O
less NN NN O
than NN NN O
0 NN NN O
. NN NN O
05 NN NN O
) NN NN O
, NN NN O
and NN NN O
heart NN NN O
rate NN NN O
( NN NN O
p NN NN O
less NN NN O
than NN NN O
0 NN NN O
. NN NN O
001 NN NN O
) NN NN O
; NN NN O
all NN NN O
these NN NN O
variables NN NN O
returned NN NN O
normal NN NN O
within NN NN O
30 NN NN O
min NN NN O
after NN NN O
ATP NN NN O
was NN NN O
stopped NN NN O
. NN NN O
   
Cardiac NN NN O
output NN NN O
did NN NN O
not NN NN O
change NN NN O
. NN NN O
   
During NN NN O
hypotension NN NN B-Disease
produced NN NN O
by NN NN O
SNP NN NN O
similar NN NN O
decreases NN NN O
were NN NN O
observed NN NN O
in NN NN O
mean NN NN O
pulmonary NN NN O
arterial NN NN O
pressure NN NN O
( NN NN O
p NN NN O
less NN NN O
than NN NN O
0 NN NN O
. NN NN O
01 NN NN O
) NN NN O
, NN NN O
central NN NN O
venous NN NN O
pressure NN NN O
( NN NN O
p NN NN O
less NN NN O
than NN NN O
0 NN NN O
. NN NN O
001 NN NN O
) NN NN O
, NN NN O
left NN NN O
ventricular NN NN O
end NN NN O
- NN NN O
diastolic NN NN O
pressure NN NN O
( NN NN O
p NN NN O
less NN NN O
than NN NN O
0 NN NN O
. NN NN O
01 NN NN O
) NN NN O
, NN NN O
total NN NN O
peripheral NN NN O
resistance NN NN O
( NN NN O
p NN NN O
less NN NN O
than NN NN O
0 NN NN O
. NN NN O
001 NN NN O
) NN NN O
, NN NN O
rate NN NN O
pressure NN NN O
product NN NN O
( NN NN O
p NN NN O
less NN NN O
than NN NN O
0 NN NN O
. NN NN O
001 NN NN O
) NN NN O
, NN NN O
and NN NN O
oxygen NN NN O
content NN NN O
difference NN NN O
between NN NN O
arterial NN NN O
and NN NN O
mixed NN NN O
venous NN NN O
blood NN NN O
( NN NN O
p NN NN O
less NN NN O
than NN NN O
0 NN NN O
. NN NN O
05 NN NN O
) NN NN O
, NN NN O
while NN NN O
heart NN NN O
rate NN NN O
( NN NN O
p NN NN O
less NN NN O
than NN NN O
0 NN NN O
. NN NN O
001 NN NN O
) NN NN O
and NN NN O
cardiac NN NN O
output NN NN O
( NN NN O
p NN NN O
less NN NN O
than NN NN O
0 NN NN O
. NN NN O
05 NN NN O
) NN NN O
were NN NN O
increased NN NN O
. NN NN O
   
Recoveries NN NN O
of NN NN O
heart NN NN O
rate NN NN O
and NN NN O
left NN NN O
ventricular NN NN O
end NN NN O
- NN NN O
diastolic NN NN O
pressure NN NN O
were NN NN O
not NN NN O
shown NN NN O
within NN NN O
60 NN NN O
min NN NN O
after NN NN O
SNP NN NN O
had NN NN O
been NN NN O
stopped NN NN O
. NN NN O
   
Both NN NN O
ATP NN NN O
and NN NN O
SNP NN NN O
should NN NN O
act NN NN O
on NN NN O
the NN NN O
pacemaker NN NN O
tissue NN NN O
of NN NN O
the NN NN O
heart NN NN O
. NN NN O
   
Comparative NN NN O
study NN NN O
: NN NN O
Endografine NN NN O
( NN NN O
diatrizoate NN NN O
) NN NN O
, NN NN O
Vasurix NN NN O
polyvidone NN NN O
( NN NN O
acetrizoate NN NN O
) NN NN O
, NN NN O
Dimer NN NN O
- NN NN O
X NN NN O
( NN NN O
iocarmate NN NN O
) NN NN O
and NN NN O
Hexabrix NN NN O
( NN NN O
ioxaglate NN NN O
) NN NN O
in NN NN O
hysterosalpingography NN NN O
. NN NN O
   
Side NN NN O
effects NN NN O
of NN NN O
hysterosalpingography NN NN O
with NN NN O
Dimer NN NN O
- NN NN O
X NN NN O
, NN NN O
Hexabrix NN NN O
, NN NN O
Vasurix NN NN O
polyvidone NN NN O
and NN NN O
Endografine NN NN O
in NN NN O
142 NN NN O
consecutive NN NN O
patients NN NN O
, NN NN O
receiving NN NN O
one NN NN O
of NN NN O
the NN NN O
four NN NN O
tested NN NN O
media NN NN O
were NN NN O
evaluated NN NN O
from NN NN O
replies NN NN O
to NN NN O
postal NN NN O
questionnaires NN NN O
. NN NN O
   
The NN NN O
Dimer NN NN O
- NN NN O
X NN NN O
group NN NN O
had NN NN O
a NN NN O
higher NN NN O
incidence NN NN O
of NN NN O
nausea NN NN B-Disease
and NN NN O
dizziness NN NN B-Disease
. NN NN O
   
The NN NN O
Endografine NN NN O
group NN NN O
had NN NN O
a NN NN O
higher NN NN O
incidence NN NN O
of NN NN O
abdominal NN NN B-Disease
pain NN NN I-Disease
. NN NN O
   
These NN NN O
differences NN NN O
occur NN NN O
especially NN NN O
in NN NN O
the NN NN O
age NN NN O
groups NN NN O
under NN NN O
30 NN NN O
years NN NN O
. NN NN O
   
Hexabrix NN NN O
and NN NN O
Vasurix NN NN O
polyvidone NN NN O
are NN NN O
considered NN NN O
the NN NN O
best NN NN O
contrast NN NN O
media NN NN O
for NN NN O
hysterosalpingography NN NN O
and NN NN O
perhaps NN NN O
because NN NN O
of NN NN O
its NN NN O
low NN NN O
toxicity NN NN B-Disease
Hexabrix NN NN O
should NN NN O
be NN NN O
preferred NN NN O
. NN NN O
   
Post NN NN O
- NN NN O
suxamethonium NN NN O
pains NN NN B-Disease
in NN NN O
Nigerian NN NN O
surgical NN NN O
patients NN NN O
. NN NN O
   
Contrary NN NN O
to NN NN O
an NN NN O
earlier NN NN O
report NN NN O
by NN NN O
Coxon NN NN O
, NN NN O
scoline NN NN O
pain NN NN B-Disease
occurs NN NN O
in NN NN O
African NN NN O
negroes NN NN O
. NN NN O
   
Its NN NN O
incidence NN NN O
was NN NN O
determined NN NN O
in NN NN O
a NN NN O
prospective NN NN O
study NN NN O
involving NN NN O
a NN NN O
total NN NN O
of NN NN O
100 NN NN O
Nigerian NN NN O
patients NN NN O
( NN NN O
50 NN NN O
out NN NN O
- NN NN O
patients NN NN O
and NN NN O
50 NN NN O
in NN NN O
- NN NN O
patients NN NN O
) NN NN O
. NN NN O
   
About NN NN O
62 NN NN O
% NN NN O
of NN NN O
the NN NN O
out NN NN O
- NN NN O
patients NN NN O
developed NN NN O
scoline NN NN O
pain NN NN B-Disease
as NN NN O
compared NN NN O
with NN NN O
about NN NN O
26 NN NN O
% NN NN O
among NN NN O
the NN NN O
in NN NN O
- NN NN O
patients NN NN O
. NN NN O
   
The NN NN O
abolition NN NN O
of NN NN O
muscle NN NN O
fasciculations NN NN B-Disease
( NN NN O
by NN NN O
0 NN NN O
. NN NN O
075mg NN NN O
/ NN NN O
kg NN NN O
dose NN NN O
of NN NN O
Fazadinium NN NN O
) NN NN O
did NN NN O
not NN NN O
influence NN NN O
the NN NN O
occurrence NN NN O
of NN NN O
scoline NN NN O
pain NN NN B-Disease
. NN NN O
   
Neither NN NN O
the NN NN O
type NN NN O
of NN NN O
induction NN NN O
agent NN NN O
( NN NN O
Althesin NN NN O
or NN NN O
Thiopentone NN NN O
) NN NN O
nor NN NN O
the NN NN O
salt NN NN O
preparation NN NN O
of NN NN O
suxamethonium NN NN O
used NN NN O
( NN NN O
chloride NN NN O
or NN NN O
bromide NN NN O
) NN NN O
, NN NN O
affected NN NN O
the NN NN O
incidence NN NN O
of NN NN O
scoline NN NN O
pain NN NN B-Disease
. NN NN O
   
Invasive NN NN O
carcinoma NN NN B-Disease
of NN NN I-Disease
the NN NN I-Disease
renal NN NN I-Disease
pelvis NN NN I-Disease
following NN NN O
cyclophosphamide NN NN O
therapy NN NN O
for NN NN O
nonmalignant NN NN O
disease NN NN O
. NN NN O
   
A NN NN O
47 NN NN O
- NN NN O
year NN NN O
- NN NN O
old NN NN O
woman NN NN O
with NN NN O
right NN NN O
hydroureteronephrosis NN NN B-Disease
due NN NN O
to NN NN O
ureterovesical NN NN O
junction NN NN O
obstruction NN NN O
had NN NN O
gross NN NN O
hematuria NN NN B-Disease
after NN NN O
being NN NN O
treated NN NN O
for NN NN O
five NN NN O
years NN NN O
wtih NN NN O
cyclophosphamide NN NN O
for NN NN O
cerebral NN NN B-Disease
vasculitis NN NN I-Disease
. NN NN O
   
A NN NN O
right NN NN O
nephroureterectomy NN NN O
was NN NN O
required NN NN O
for NN NN O
control NN NN O
of NN NN O
bleeding NN NN B-Disease
. NN NN O
   
The NN NN O
pathology NN NN O
specimen NN NN O
contained NN NN O
clinically NN NN O
occult NN NN O
invasive NN NN O
carcinoma NN NN B-Disease
of NN NN I-Disease
the NN NN I-Disease
renal NN NN I-Disease
pelvis NN NN I-Disease
. NN NN O
   
Although NN NN O
the NN NN O
ability NN NN O
of NN NN O
cyclophosphamide NN NN O
to NN NN O
cause NN NN O
hemorrhagic NN NN B-Disease
cystitis NN NN I-Disease
and NN NN O
urine NN NN O
cytologic NN NN O
abnormalities NN NN O
indistinguishable NN NN O
from NN NN O
high NN NN O
grade NN NN O
carcinoma NN NN B-Disease
is NN NN O
well NN NN O
known NN NN O
, NN NN O
it NN NN O
is NN NN O
less NN NN O
widely NN NN O
appreciated NN NN O
that NN NN O
it NN NN O
is NN NN O
also NN NN O
associated NN NN O
with NN NN O
carcinoma NN NN B-Disease
of NN NN I-Disease
the NN NN I-Disease
urinary NN NN I-Disease
tract NN NN I-Disease
. NN NN O
   
Twenty NN NN O
carcinomas NN NN B-Disease
of NN NN I-Disease
the NN NN I-Disease
urinary NN NN I-Disease
bladder NN NN I-Disease
and NN NN O
one NN NN O
carcinoma NN NN B-Disease
of NN NN I-Disease
the NN NN I-Disease
prostate NN NN I-Disease
have NN NN O
been NN NN O
reported NN NN O
in NN NN O
association NN NN O
with NN NN O
its NN NN O
use NN NN O
. NN NN O
   
The NN NN O
present NN NN O
case NN NN O
is NN NN O
the NN NN O
first NN NN O
carcinoma NN NN B-Disease
of NN NN I-Disease
the NN NN I-Disease
renal NN NN I-Disease
pelvis NN NN I-Disease
reported NN NN O
in NN NN O
association NN NN O
with NN NN O
cyclophosphamide NN NN O
treatment NN NN O
. NN NN O
   
It NN NN O
is NN NN O
the NN NN O
third NN NN O
urinary NN NN B-Disease
tract NN NN I-Disease
cancer NN NN I-Disease
reported NN NN O
in NN NN O
association NN NN O
with NN NN O
cyclophosphamide NN NN O
treatment NN NN O
for NN NN O
nonmalignant NN NN O
disease NN NN O
. NN NN O
   
The NN NN O
association NN NN O
of NN NN O
the NN NN O
tumor NN NN B-Disease
with NN NN O
preexisting NN NN O
hydroureteronephrosis NN NN B-Disease
suggests NN NN O
that NN NN O
stasis NN NN O
prolonged NN NN O
and NN NN O
intensified NN NN O
exposure NN NN O
of NN NN O
upper NN NN O
urinary NN NN O
tract NN NN O
epithelium NN NN O
to NN NN O
cyclophosphamide NN NN O
. NN NN O
   
Patients NN NN O
who NN NN O
are NN NN O
candidates NN NN O
for NN NN O
long NN NN O
- NN NN O
term NN NN O
cyclophosphamide NN NN O
treatment NN NN O
should NN NN O
be NN NN O
routinely NN NN O
evaluated NN NN O
for NN NN O
obstructive NN NN B-Disease
uropathy NN NN I-Disease
. NN NN O
   
Medial NN NN O
changes NN NN O
in NN NN O
arterial NN NN O
spasm NN NN B-Disease
induced NN NN O
by NN NN O
L NN NN O
- NN NN O
norepinephrine NN NN O
. NN NN O
   
In NN NN O
normal NN NN O
rats NN NN O
, NN NN O
the NN NN O
media NN NN O
of NN NN O
small NN NN O
arteries NN NN O
( NN NN O
0 NN NN O
. NN NN O
4 NN NN O
- NN NN O
- NN NN O
0 NN NN O
. NN NN O
2 NN NN O
mm NN NN O
in NN NN O
diameter NN NN O
) NN NN O
previously NN NN O
was NN NN O
shown NN NN O
to NN NN O
contain NN NN O
intracellular NN NN O
vacuoles NN NN O
, NN NN O
identified NN NN O
ultrastructurally NN NN O
as NN NN O
herniations NN NN O
of NN NN O
one NN NN O
smooth NN NN O
muscle NN NN O
cell NN NN O
into NN NN O
another NN NN O
. NN NN O
   
The NN NN O
hypothesis NN NN O
that NN NN O
intense NN NN O
vasoconstriction NN NN O
would NN NN O
increase NN NN O
the NN NN O
number NN NN O
of NN NN O
such NN NN O
vacuoles NN NN O
has NN NN O
been NN NN O
tested NN NN O
. NN NN O
   
In NN NN O
the NN NN O
media NN NN O
of NN NN O
the NN NN O
saphenous NN NN O
artery NN NN O
and NN NN O
its NN NN O
distal NN NN O
branch NN NN O
, NN NN O
vasoconstriction NN NN O
induced NN NN O
by NN NN O
L NN NN O
- NN NN O
norepinephrine NN NN O
produced NN NN O
many NN NN O
cell NN NN O
- NN NN O
to NN NN O
- NN NN O
cell NN NN O
hernias NN NN B-Disease
within NN NN O
15 NN NN O
minutes NN NN O
. NN NN O
   
At NN NN O
1 NN NN O
day NN NN O
their NN NN O
number NN NN O
was NN NN O
reduced NN NN O
to NN NN O
about NN NN O
1 NN NN O
/ NN NN O
10 NN NN O
of NN NN O
the NN NN O
original NN NN O
number NN NN O
. NN NN O
   
By NN NN O
7 NN NN O
days NN NN O
the NN NN O
vessel NN NN O
was NN NN O
almost NN NN O
restored NN NN O
to NN NN O
normal NN NN O
. NN NN O
   
Triple NN NN O
stimulation NN NN O
over NN NN O
1 NN NN O
day NN NN O
induced NN NN O
more NN NN O
severe NN NN O
changes NN NN O
in NN NN O
the NN NN O
media NN NN O
. NN NN O
   
These NN NN O
findings NN NN O
suggest NN NN O
that NN NN O
smooth NN NN O
muscle NN NN O
cells NN NN O
are NN NN O
susceptible NN NN O
to NN NN O
damage NN NN O
in NN NN O
the NN NN O
course NN NN O
of NN NN O
their NN NN O
specific NN NN O
function NN NN O
. NN NN O
   
The NN NN O
experimental NN NN O
data NN NN O
are NN NN O
discussed NN NN O
in NN NN O
relation NN NN O
to NN NN O
medial NN NN O
changes NN NN O
observed NN NN O
in NN NN O
other NN NN O
instances NN NN O
of NN NN O
arterial NN NN O
spasm NN NN B-Disease
. NN NN O
   
Endothelial NN NN O
changes NN NN O
that NN NN O
developed NN NN O
in NN NN O
the NN NN O
same NN NN O
experimental NN NN O
model NN NN O
were NN NN O
described NN NN O
in NN NN O
a NN NN O
previous NN NN O
paper NN NN O
. NN NN O
   
Bilateral NN NN O
retinal NN NN B-Disease
artery NN NN I-Disease
and NN NN I-Disease
choriocapillaris NN NN I-Disease
occlusion NN NN I-Disease
following NN NN O
the NN NN O
injection NN NN O
of NN NN O
long NN NN O
- NN NN O
acting NN NN O
corticosteroid NN NN O
suspensions NN NN O
in NN NN O
combination NN NN O
with NN NN O
other NN NN O
drugs NN NN O
: NN NN O
I NN NN O
. NN NN O
   
Clinical NN NN O
studies NN NN O
. NN NN O
   
Two NN NN O
well NN NN O
- NN NN O
documented NN NN O
cases NN NN O
of NN NN O
bilateral NN NN O
retinal NN NN B-Disease
artery NN NN I-Disease
and NN NN I-Disease
choriocapillaris NN NN I-Disease
occlusions NN NN I-Disease
with NN NN O
blindness NN NN B-Disease
following NN NN O
head NN NN O
and NN NN O
neck NN NN O
soft NN NN O
- NN NN O
tissue NN NN O
injection NN NN O
with NN NN O
methylprednisolone NN NN O
acetate NN NN O
in NN NN O
combination NN NN O
with NN NN O
lidocaine NN NN O
, NN NN O
epinephrine NN NN O
, NN NN O
or NN NN O
penicillin NN NN O
are NN NN O
reported NN NN O
. NN NN O
   
One NN NN O
case NN NN O
had NN NN O
only NN NN O
a NN NN O
unilateral NN NN O
injection NN NN O
. NN NN O
   
The NN NN O
acute NN NN O
observations NN NN O
included NN NN O
hazy NN NN O
sensorium NN NN O
, NN NN O
superior NN NN O
gaze NN NN O
palsy NN NN B-Disease
, NN NN O
pupillary NN NN B-Disease
abnormalities NN NN I-Disease
, NN NN O
and NN NN O
conjunctival NN NN O
hemorrhages NN NN B-Disease
with NN NN O
edema NN NN B-Disease
. NN NN O
   
Follow NN NN O
- NN NN O
up NN NN O
changes NN NN O
showed NN NN O
marked NN NN O
visual NN NN B-Disease
loss NN NN I-Disease
, NN NN O
constricted NN NN O
visual NN NN O
fields NN NN O
, NN NN O
optic NN NN O
nerve NN NN O
pallor NN NN O
, NN NN O
vascular NN NN O
attenuation NN NN O
, NN NN O
and NN NN O
chorioretinal NN NN B-Disease
atrophy NN NN I-Disease
. NN NN O
   
The NN NN O
literature NN NN O
is NN NN O
reviewed NN NN O
, NN NN O
and NN NN O
possible NN NN O
causes NN NN O
are NN NN O
discussed NN NN O
. NN NN O
   
Abnormalities NN NN O
of NN NN O
the NN NN O
pupil NN NN O
and NN NN O
visual NN NN O
- NN NN O
evoked NN NN O
potential NN NN O
in NN NN O
quinine NN NN O
amblyopia NN NN B-Disease
. NN NN O
   
Total NN NN O
blindness NN NN B-Disease
with NN NN O
a NN NN O
transient NN NN O
tonic NN NN B-Disease
pupillary NN NN I-Disease
response NN NN O
, NN NN O
denervation NN NN O
supersensitivity NN NN O
, NN NN O
and NN NN O
abnormal NN NN O
visual NN NN O
- NN NN O
evoked NN NN O
potentials NN NN O
developed NN NN O
in NN NN O
a NN NN O
54 NN NN O
- NN NN O
year NN NN O
- NN NN O
old NN NN O
man NN NN O
after NN NN O
the NN NN O
use NN NN O
of NN NN O
quinine NN NN O
sulfate NN NN O
for NN NN O
leg NN NN B-Disease
cramps NN NN I-Disease
. NN NN O
   
He NN NN O
later NN NN O
recovered NN NN O
normal NN NN O
visual NN NN O
acuity NN NN O
. NN NN O
   
A NN NN O
transient NN NN O
tonic NN NN B-Disease
pupillary NN NN I-Disease
response NN NN O
, NN NN O
denervation NN NN O
supersensitivity NN NN O
, NN NN O
and NN NN O
abnormal NN NN O
visual NN NN O
- NN NN O
evoked NN NN O
potentials NN NN O
in NN NN O
quinine NN NN O
toxicity NN NN B-Disease
, NN NN O
to NN NN O
our NN NN O
knowledge NN NN O
, NN NN O
have NN NN O
not NN NN O
been NN NN O
previously NN NN O
reported NN NN O
. NN NN O
   
Suxamethonium NN NN O
- NN NN O
induced NN NN O
jaw NN NN B-Disease
stiffness NN NN I-Disease
and NN NN O
myalgia NN NN B-Disease
associated NN NN O
with NN NN O
atypical NN NN O
cholinesterase NN NN O
: NN NN O
case NN NN O
report NN NN O
. NN NN O
   
An NN NN O
11 NN NN O
- NN NN O
year NN NN O
- NN NN O
old NN NN O
boy NN NN O
was NN NN O
given NN NN O
halothane NN NN O
, NN NN O
nitrous NN NN O
oxide NN NN O
and NN NN O
oxygen NN NN O
, NN NN O
pancuronium NN NN O
0 NN NN O
. NN NN O
4 NN NN O
mg NN NN O
and NN NN O
suxamethonium NN NN O
100 NN NN O
mg NN NN O
for NN NN O
induction NN NN O
of NN NN O
anaesthesia NN NN O
. NN NN O
   
In NN NN O
response NN NN O
to NN NN O
this NN NN O
a NN NN O
marked NN NN O
jaw NN NN B-Disease
stiffness NN NN I-Disease
occurred NN NN O
which NN NN O
lasted NN NN O
for NN NN O
two NN NN O
minutes NN NN O
and NN NN O
the NN NN O
anaesthesia NN NN O
were NN NN O
terminated NN NN O
. NN NN O
   
Four NN NN O
hours NN NN O
of NN NN O
apnoea NN NN B-Disease
ensued NN NN O
and NN NN O
he NN NN O
suffered NN NN O
generalized NN NN O
severe NN NN O
myalgia NN NN B-Disease
lasting NN NN O
for NN NN O
one NN NN O
week NN NN O
. NN NN O
   
He NN NN O
was NN NN O
found NN NN O
to NN NN O
have NN NN O
atypical NN NN O
plasma NN NN O
cholinesterase NN NN O
with NN NN O
a NN NN O
dibucaine NN NN O
number NN NN O
of NN NN O
12 NN NN O
, NN NN O
indicating NN NN O
homozygocity NN NN O
. NN NN O
   
This NN NN O
was NN NN O
verified NN NN O
by NN NN O
study NN NN O
of NN NN O
the NN NN O
family NN NN O
. NN NN O
   
The NN NN O
case NN NN O
shows NN NN O
that NN NN O
prolonged NN NN B-Disease
jaw NN NN I-Disease
rigidity NN NN I-Disease
and NN NN O
myalgia NN NN B-Disease
may NN NN O
occur NN NN O
after NN NN O
suxamethonium NN NN O
in NN NN O
patients NN NN O
with NN NN O
atypical NN NN O
cholinesterase NN NN O
despite NN NN O
pretreatment NN NN O
with NN NN O
pancuronium NN NN O
. NN NN O
   
Indomethacin NN NN O
- NN NN O
induced NN NN O
hyperkalemia NN NN B-Disease
in NN NN O
three NN NN O
patients NN NN O
with NN NN O
gouty NN NN B-Disease
arthritis NN NN I-Disease
. NN NN O
   
We NN NN O
describe NN NN O
three NN NN O
patients NN NN O
in NN NN O
whom NN NN O
severe NN NN O
, NN NN O
life NN NN O
- NN NN O
threatening NN NN O
hyperkalemia NN NN B-Disease
and NN NN O
renal NN NN B-Disease
insufficiency NN NN I-Disease
developed NN NN O
after NN NN O
treatment NN NN O
of NN NN O
acute NN NN O
gouty NN NN B-Disease
arthritis NN NN I-Disease
with NN NN O
indomethacin NN NN O
. NN NN O
   
This NN NN O
complication NN NN O
may NN NN O
result NN NN O
from NN NN O
an NN NN O
inhibition NN NN O
of NN NN O
prostaglandin NN NN O
synthesis NN NN O
and NN NN O
consequent NN NN O
hyporeninemic NN NN B-Disease
hypoaidosteronism NN NN I-Disease
. NN NN O
   
Careful NN NN O
attention NN NN O
to NN NN O
renal NN NN O
function NN NN O
and NN NN O
potassium NN NN O
balance NN NN O
in NN NN O
patients NN NN O
receiving NN NN O
indomethacin NN NN O
or NN NN O
other NN NN O
nonsteroidal NN NN O
anti NN NN O
- NN NN O
inflammatory NN NN O
agents NN NN O
, NN NN O
particularly NN NN O
in NN NN O
those NN NN O
patients NN NN O
with NN NN O
diabetes NN NN B-Disease
mellitus NN NN I-Disease
or NN NN O
preexisting NN NN O
renal NN NN B-Disease
disease NN NN I-Disease
, NN NN O
will NN NN O
help NN NN O
prevent NN NN O
this NN NN O
potentially NN NN O
serious NN NN O
complication NN NN O
. NN NN O
   
Etomidate NN NN O
: NN NN O
a NN NN O
foreshortened NN NN O
clinical NN NN O
trial NN NN O
. NN NN O
   
A NN NN O
clinical NN NN O
evaluation NN NN O
of NN NN O
etomidate NN NN O
for NN NN O
outpatient NN NN O
cystoscopy NN NN O
was NN NN O
embarked NN NN O
upon NN NN O
. NN NN O
   
Unpremedicated NN NN O
patients NN NN O
were NN NN O
given NN NN O
fentanyl NN NN O
1 NN NN O
microgram NN NN O
/ NN NN O
kg NN NN O
followed NN NN O
by NN NN O
etomidate NN NN O
0 NN NN O
. NN NN O
3 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
. NN NN O
   
Anaesthesia NN NN O
was NN NN O
maintained NN NN O
with NN NN O
intermittent NN NN O
etomidate NN NN O
in NN NN O
2 NN NN O
- NN NN O
4 NN NN O
mg NN NN O
doses NN NN O
. NN NN O
   
Patients NN NN O
were NN NN O
interviewed NN NN O
personally NN NN O
later NN NN O
the NN NN O
same NN NN O
day NN NN O
, NN NN O
and NN NN O
by NN NN O
questionnaire NN NN O
three NN NN O
to NN NN O
four NN NN O
weeks NN NN O
later NN NN O
. NN NN O
   
The NN NN O
trial NN NN O
was NN NN O
discontinued NN NN O
after NN NN O
20 NN NN O
cases NN NN O
because NN NN O
of NN NN O
an NN NN O
unacceptable NN NN O
incidence NN NN O
of NN NN O
side NN NN O
effects NN NN O
. NN NN O
   
Venous NN NN O
pain NN NN B-Disease
occurred NN NN O
in NN NN O
68 NN NN O
% NN NN O
of NN NN O
patients NN NN O
and NN NN O
50 NN NN O
% NN NN O
had NN NN O
redness NN NN O
, NN NN O
pain NN NN B-Disease
or NN NN O
swelling NN NN B-Disease
related NN NN O
to NN NN O
the NN NN O
injection NN NN O
site NN NN O
, NN NN O
in NN NN O
some NN NN O
cases NN NN O
lasting NN NN O
up NN NN O
to NN NN O
three NN NN O
weeks NN NN O
after NN NN O
anaesthesia NN NN O
. NN NN O
   
Skeletal NN NN O
movements NN NN O
occurred NN NN O
in NN NN O
50 NN NN O
% NN NN O
of NN NN O
patients NN NN O
; NN NN O
30 NN NN O
% NN NN O
experienced NN NN O
respiratory NN NN B-Disease
upset NN NN I-Disease
, NN NN O
one NN NN O
sufficiently NN NN O
severe NN NN O
to NN NN O
necessitate NN NN O
abandoning NN NN O
the NN NN O
technique NN NN O
. NN NN O
   
Nausea NN NN B-Disease
and NN NN O
vomiting NN NN B-Disease
occurred NN NN O
in NN NN O
40 NN NN O
% NN NN O
and NN NN O
25 NN NN O
% NN NN O
had NN NN O
disturbing NN NN O
emergence NN NN O
psychoses NN NN B-Disease
. NN NN O
   
Levodopa NN NN O
- NN NN O
induced NN NN O
dyskinesias NN NN B-Disease
are NN NN O
improved NN NN O
by NN NN O
fluoxetine NN NN O
. NN NN O
   
We NN NN O
evaluated NN NN O
the NN NN O
severity NN NN O
of NN NN O
motor NN NN B-Disease
disability NN NN I-Disease
and NN NN O
dyskinesias NN NN B-Disease
in NN NN O
seven NN NN O
levodopa NN NN O
- NN NN O
responsive NN NN O
patients NN NN O
with NN NN O
Parkinson NN NN B-Disease
' NN NN I-Disease
s NN NN I-Disease
disease NN NN I-Disease
after NN NN O
an NN NN O
acute NN NN O
challenge NN NN O
with NN NN O
the NN NN O
mixed NN NN O
dopamine NN NN O
agonist NN NN O
, NN NN O
apomorphine NN NN O
, NN NN O
before NN NN O
and NN NN O
after NN NN O
the NN NN O
administration NN NN O
of NN NN O
fluoxetine NN NN O
( NN NN O
20 NN NN O
mg NN NN O
twice NN NN O
per NN NN O
day NN NN O
) NN NN O
for NN NN O
11 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
1 NN NN O
days NN NN O
. NN NN O
   
After NN NN O
fluoxetine NN NN O
treatment NN NN O
, NN NN O
there NN NN O
was NN NN O
a NN NN O
significant NN NN O
47 NN NN O
% NN NN O
improvement NN NN O
( NN NN O
p NN NN O
< NN NN O
0 NN NN O
. NN NN O
05 NN NN O
) NN NN O
of NN NN O
apomorphine NN NN O
- NN NN O
induced NN NN O
dyskinesias NN NN B-Disease
without NN NN O
modification NN NN O
of NN NN O
parkinsonian NN NN B-Disease
motor NN NN B-Disease
disability NN NN I-Disease
. NN NN O
   
The NN NN O
dyskinesias NN NN B-Disease
were NN NN O
reduced NN NN O
predominantly NN NN O
in NN NN O
the NN NN O
lower NN NN O
limbs NN NN O
during NN NN O
the NN NN O
onset NN NN O
and NN NN O
disappearance NN NN O
of NN NN O
dystonic NN NN B-Disease
dyskinesias NN NN I-Disease
( NN NN O
onset NN NN O
- NN NN O
and NN NN O
end NN NN O
- NN NN O
of NN NN O
- NN NN O
dose NN NN O
dyskinesias NN NN B-Disease
) NN NN O
and NN NN O
in NN NN O
the NN NN O
upper NN NN O
limbs NN NN O
during NN NN O
choreic NN NN B-Disease
mid NN NN I-Disease
- NN NN I-Disease
dose NN NN I-Disease
dyskinesias NN NN I-Disease
. NN NN O
   
The NN NN O
results NN NN O
suggest NN NN O
that NN NN O
increased NN NN O
brain NN NN O
serotoninergic NN NN O
transmission NN NN O
with NN NN O
fluoxetine NN NN O
may NN NN O
reduce NN NN O
levodopa NN NN O
- NN NN O
or NN NN O
dopamine NN NN O
agonist NN NN O
- NN NN O
induced NN NN O
dyskinesias NN NN B-Disease
without NN NN O
aggravating NN NN O
parkinsonian NN NN B-Disease
motor NN NN B-Disease
disability NN NN I-Disease
. NN NN O
   
A NN NN O
large NN NN O
population NN NN O
- NN NN O
based NN NN O
follow NN NN O
- NN NN O
up NN NN O
study NN NN O
of NN NN O
trimethoprim NN NN O
- NN NN O
sulfamethoxazole NN NN O
, NN NN O
trimethoprim NN NN O
, NN NN O
and NN NN O
cephalexin NN NN O
for NN NN O
uncommon NN NN O
serious NN NN O
drug NN NN B-Disease
toxicity NN NN I-Disease
. NN NN O
   
We NN NN O
conducted NN NN O
a NN NN O
population NN NN O
- NN NN O
based NN NN O
45 NN NN O
- NN NN O
day NN NN O
follow NN NN O
- NN NN O
up NN NN O
study NN NN O
of NN NN O
232 NN NN O
, NN NN O
390 NN NN O
people NN NN O
who NN NN O
were NN NN O
prescribed NN NN O
trimethoprim NN NN O
- NN NN O
sulfamethoxazole NN NN O
( NN NN O
TMP NN NN O
- NN NN O
SMZ NN NN O
) NN NN O
, NN NN O
266 NN NN O
, NN NN O
951 NN NN O
prescribed NN NN O
trimethoprim NN NN O
alone NN NN O
, NN NN O
and NN NN O
196 NN NN O
, NN NN O
397 NN NN O
prescribed NN NN O
cephalexin NN NN O
, NN NN O
to NN NN O
estimate NN NN O
the NN NN O
risk NN NN O
of NN NN O
serious NN NN O
liver NN NN B-Disease
, NN NN I-Disease
blood NN NN I-Disease
, NN NN I-Disease
skin NN NN I-Disease
, NN NN I-Disease
and NN NN I-Disease
renal NN NN I-Disease
disorders NN NN I-Disease
resulting NN NN O
in NN NN O
referral NN NN O
or NN NN O
hospitalization NN NN O
associated NN NN O
with NN NN O
these NN NN O
drugs NN NN O
. NN NN O
   
The NN NN O
results NN NN O
were NN NN O
based NN NN O
on NN NN O
information NN NN O
recorded NN NN O
on NN NN O
office NN NN O
computers NN NN O
by NN NN O
selected NN NN O
general NN NN O
practitioners NN NN O
in NN NN O
the NN NN O
United NN NN O
Kingdom NN NN O
, NN NN O
together NN NN O
with NN NN O
a NN NN O
review NN NN O
of NN NN O
clinical NN NN O
records NN NN O
. NN NN O
   
The NN NN O
risk NN NN O
of NN NN O
clinically NN NN O
important NN NN O
idiopathic NN NN O
liver NN NN B-Disease
disease NN NN I-Disease
was NN NN O
similar NN NN O
for NN NN O
persons NN NN O
prescribed NN NN O
TMP NN NN O
- NN NN O
SMZ NN NN O
( NN NN O
5 NN NN O
. NN NN O
2 NN NN O
/ NN NN O
100 NN NN O
, NN NN O
000 NN NN O
) NN NN O
and NN NN O
those NN NN O
prescribed NN NN O
trimethoprim NN NN O
alone NN NN O
( NN NN O
3 NN NN O
. NN NN O
8 NN NN O
/ NN NN O
100 NN NN O
, NN NN O
000 NN NN O
) NN NN O
. NN NN O
   
The NN NN O
risk NN NN O
for NN NN O
those NN NN O
prescribed NN NN O
cephalexin NN NN O
was NN NN O
somewhat NN NN O
lower NN NN O
( NN NN O
2 NN NN O
. NN NN O
0 NN NN O
/ NN NN O
100 NN NN O
, NN NN O
000 NN NN O
) NN NN O
. NN NN O
   
Only NN NN O
five NN NN O
patients NN NN O
experienced NN NN O
blood NN NN O
disorders NN NN O
, NN NN O
one NN NN O
of NN NN O
whom NN NN O
was NN NN O
exposed NN NN O
to NN NN O
TMP NN NN O
- NN NN O
SMZ NN NN O
; NN NN O
of NN NN O
seven NN NN O
with NN NN O
erythema NN NN B-Disease
multiforme NN NN I-Disease
and NN NN O
Stevens NN NN B-Disease
- NN NN I-Disease
Johnson NN NN I-Disease
syndrome NN NN I-Disease
, NN NN O
four NN NN O
were NN NN O
exposed NN NN O
to NN NN O
TMP NN NN O
- NN NN O
SMZ NN NN O
. NN NN O
   
The NN NN O
one NN NN O
case NN NN O
of NN NN O
toxic NN NN B-Disease
epidermal NN NN I-Disease
necrolysis NN NN I-Disease
occurred NN NN O
in NN NN O
a NN NN O
patient NN NN O
who NN NN O
took NN NN O
cephalexin NN NN O
. NN NN O
   
Finally NN NN O
, NN NN O
only NN NN O
five NN NN O
cases NN NN O
of NN NN O
acute NN NN O
parenchymal NN NN O
renal NN NN B-Disease
disease NN NN I-Disease
occurred NN NN O
, NN NN O
none NN NN O
likely NN NN O
to NN NN O
be NN NN O
caused NN NN O
by NN NN O
a NN NN O
study NN NN O
drug NN NN O
. NN NN O
   
We NN NN O
conclude NN NN O
that NN NN O
the NN NN O
risk NN NN O
of NN NN O
the NN NN O
serious NN NN O
diseases NN NN O
studied NN NN O
is NN NN O
small NN NN O
for NN NN O
the NN NN O
three NN NN O
agents NN NN O
, NN NN O
and NN NN O
compares NN NN O
reasonably NN NN O
with NN NN O
the NN NN O
risk NN NN O
for NN NN O
many NN NN O
other NN NN O
antibiotics NN NN O
. NN NN O
   
Clinical NN NN O
safety NN NN O
of NN NN O
lidocaine NN NN O
in NN NN O
patients NN NN O
with NN NN O
cocaine NN NN O
- NN NN O
associated NN NN O
myocardial NN NN B-Disease
infarction NN NN I-Disease
. NN NN O
   
STUDY NN NN O
OBJECTIVE NN NN O
: NN NN O
To NN NN O
evaluate NN NN O
the NN NN O
safety NN NN O
of NN NN O
lidocaine NN NN O
in NN NN O
the NN NN O
setting NN NN O
of NN NN O
cocaine NN NN O
- NN NN O
induced NN NN O
myocardial NN NN B-Disease
infarction NN NN I-Disease
( NN NN O
MI NN NN B-Disease
) NN NN O
. NN NN O
   
DESIGN NN NN O
: NN NN O
A NN NN O
retrospective NN NN O
, NN NN O
multicenter NN NN O
study NN NN O
. NN NN O
   
SETTING NN NN O
: NN NN O
Twenty NN NN O
- NN NN O
nine NN NN O
university NN NN O
, NN NN O
university NN NN O
- NN NN O
affiliated NN NN O
, NN NN O
or NN NN O
community NN NN O
hospitals NN NN O
during NN NN O
a NN NN O
6 NN NN O
- NN NN O
year NN NN O
period NN NN O
( NN NN O
total NN NN O
of NN NN O
117 NN NN O
cumulative NN NN O
hospital NN NN O
- NN NN O
years NN NN O
) NN NN O
. NN NN O
   
PARTICIPANTS NN NN O
: NN NN O
Patients NN NN O
with NN NN O
cocaine NN NN O
- NN NN O
associated NN NN O
MI NN NN B-Disease
who NN NN O
received NN NN O
lidocaine NN NN O
in NN NN O
the NN NN O
emergency NN NN O
department NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
Of NN NN O
29 NN NN O
patients NN NN O
who NN NN O
received NN NN O
lidocaine NN NN O
in NN NN O
the NN NN O
setting NN NN O
of NN NN O
cocaine NN NN O
- NN NN O
associated NN NN O
MI NN NN B-Disease
, NN NN O
no NN NN O
patient NN NN O
died NN NN O
; NN NN O
exhibited NN NN O
bradydysrhythmias NN NN B-Disease
, NN NN O
ventricular NN NN B-Disease
tachycardia NN NN I-Disease
, NN NN O
or NN NN O
ventricular NN NN B-Disease
fibrillation NN NN I-Disease
; NN NN O
or NN NN O
experienced NN NN O
seizures NN NN B-Disease
after NN NN O
administration NN NN O
of NN NN O
lidocaine NN NN O
( NN NN O
95 NN NN O
% NN NN O
confidence NN NN O
interval NN NN O
, NN NN O
0 NN NN O
% NN NN O
to NN NN O
11 NN NN O
% NN NN O
) NN NN O
. NN NN O
   
CONCLUSION NN NN O
: NN NN O
Despite NN NN O
theoretical NN NN O
concerns NN NN O
that NN NN O
lidocaine NN NN O
may NN NN O
enhance NN NN O
cocaine NN NN O
toxicity NN NN B-Disease
, NN NN O
the NN NN O
use NN NN O
of NN NN O
lidocaine NN NN O
in NN NN O
patients NN NN O
with NN NN O
cocaine NN NN O
- NN NN O
associated NN NN O
MI NN NN B-Disease
was NN NN O
not NN NN O
associated NN NN O
with NN NN O
significant NN NN O
cardiovascular NN NN B-Disease
or NN NN I-Disease
central NN NN I-Disease
nervous NN NN I-Disease
system NN NN I-Disease
toxicity NN NN I-Disease
. NN NN O
   
Experimental NN NN O
progressive NN NN O
muscular NN NN B-Disease
dystrophy NN NN I-Disease
and NN NN O
its NN NN O
treatment NN NN O
with NN NN O
high NN NN O
doses NN NN O
anabolizing NN NN O
agents NN NN O
. NN NN O
   
We NN NN O
are NN NN O
still NN NN O
a NN NN O
long NN NN O
way NN NN O
from NN NN O
discovering NN NN O
an NN NN O
unequivocal NN NN O
pathogenetic NN NN O
interpretation NN NN O
of NN NN O
progressive NN NN O
muscular NN NN B-Disease
dystrophy NN NN I-Disease
in NN NN O
man NN NN O
. NN NN O
   
Noteworthy NN NN O
efforts NN NN O
have NN NN O
been NN NN O
made NN NN O
in NN NN O
the NN NN O
experimental NN NN O
field NN NN O
; NN NN O
a NN NN O
recessive NN NN O
autosomic NN NN O
form NN NN O
found NN NN O
in NN NN O
the NN NN O
mouse NN NN O
seems NN NN O
to NN NN O
bear NN NN O
the NN NN O
closest NN NN O
resemblance NN NN O
to NN NN O
the NN NN O
human NN NN O
form NN NN O
from NN NN O
the NN NN O
genetic NN NN O
point NN NN O
of NN NN O
view NN NN O
. NN NN O
   
Myopathy NN NN B-Disease
due NN NN O
to NN NN O
lack NN NN O
of NN NN O
vitamin NN NN O
E NN NN O
and NN NN O
myopathy NN NN B-Disease
induced NN NN O
by NN NN O
certain NN NN O
viruses NN NN O
have NN NN O
much NN NN O
in NN NN O
common NN NN O
anatomically NN NN O
and NN NN O
pathologically NN NN O
with NN NN O
the NN NN O
human NN NN O
form NN NN O
. NN NN O
   
The NN NN O
authors NN NN O
induced NN NN O
myodystrophy NN NN B-Disease
in NN NN O
the NN NN O
rat NN NN O
by NN NN O
giving NN NN O
it NN NN O
a NN NN O
diet NN NN O
lacking NN NN O
in NN NN O
vitamin NN NN O
E NN NN O
. NN NN O
   
The NN NN O
pharmacological NN NN O
characteristics NN NN O
of NN NN O
vitamin NN NN O
E NN NN O
and NN NN O
the NN NN O
degenerative NN NN O
changes NN NN O
brought NN NN O
about NN NN O
by NN NN O
its NN NN O
deficiency NN NN O
, NN NN O
especially NN NN O
in NN NN O
the NN NN O
muscles NN NN O
, NN NN O
are NN NN O
illustrated NN NN O
. NN NN O
   
It NN NN O
is NN NN O
thus NN NN O
confirmed NN NN O
that NN NN O
the NN NN O
histological NN NN O
characteristics NN NN O
of NN NN O
myopathic NN NN B-Disease
rat NN NN O
muscle NN NN O
induced NN NN O
experimentally NN NN O
are NN NN O
extraordinarily NN NN O
similar NN NN O
to NN NN O
those NN NN O
of NN NN O
human NN NN O
myopathy NN NN B-Disease
as NN NN O
confirmed NN NN O
during NN NN O
biopsies NN NN O
performed NN NN O
at NN NN O
the NN NN O
Orthopaedic NN NN O
Traumatological NN NN O
Centre NN NN O
, NN NN O
Florence NN NN O
. NN NN O
   
The NN NN O
encouraging NN NN O
results NN NN O
obtained NN NN O
in NN NN O
various NN NN O
authoratative NN NN O
departments NN NN O
in NN NN O
myopathic NN NN B-Disease
patients NN NN O
by NN NN O
using NN NN O
anabolizing NN NN O
steroids NN NN O
have NN NN O
encouraged NN NN O
the NN NN O
authors NN NN O
to NN NN O
investigate NN NN O
the NN NN O
beneficial NN NN O
effects NN NN O
of NN NN O
one NN NN O
anabolizing NN NN O
agent NN NN O
( NN NN O
Dianabol NN NN O
, NN NN O
CIBA NN NN O
) NN NN O
at NN NN O
high NN NN O
doses NN NN O
in NN NN O
rats NN NN O
rendered NN NN O
myopathic NN NN B-Disease
by NN NN O
a NN NN O
diet NN NN O
deficient NN NN O
in NN NN O
vitamin NN NN O
E NN NN O
. NN NN O
   
In NN NN O
this NN NN O
way NN NN O
they NN NN O
obtained NN NN O
appreciable NN NN O
changes NN NN O
in NN NN O
body NN NN O
weight NN NN O
( NN NN O
increased NN NN O
from NN NN O
50 NN NN O
to NN NN O
70 NN NN O
g NN NN O
after NN NN O
forty NN NN O
days NN NN O
at NN NN O
a NN NN O
dose NN NN O
of NN NN O
5 NN NN O
mg NN NN O
per NN NN O
day NN NN O
of NN NN O
anabolizing NN NN O
agent NN NN O
) NN NN O
, NN NN O
but NN NN O
most NN NN O
of NN NN O
all NN NN O
they NN NN O
found NN NN O
histological NN NN O
changes NN NN O
due NN NN O
to NN NN O
"""""""" NN NN O
regenerative NN NN O
"""""""" NN NN O
changes NN NN O
in NN NN O
the NN NN O
muscle NN NN O
tissue NN NN O
, NN NN O
which NN NN O
however NN NN O
maintained NN NN O
its NN NN O
myopathic NN NN B-Disease
characteristics NN NN O
in NN NN O
the NN NN O
control NN NN O
animals NN NN O
that NN NN O
were NN NN O
not NN NN O
treated NN NN O
with NN NN O
the NN NN O
anabolizing NN NN O
agent NN NN O
. NN NN O
   
The NN NN O
authors NN NN O
conclude NN NN O
by NN NN O
affirming NN NN O
the NN NN O
undoubted NN NN O
efficacy NN NN O
of NN NN O
the NN NN O
anabolizing NN NN O
steroids NN NN O
in NN NN O
experimental NN NN O
myopathic NN NN B-Disease
disease NN NN I-Disease
, NN NN O
but NN NN O
they NN NN O
have NN NN O
reservations NN NN O
as NN NN O
to NN NN O
the NN NN O
transfer NN NN O
of NN NN O
the NN NN O
results NN NN O
into NN NN O
the NN NN O
human NN NN O
field NN NN O
, NN NN O
where NN NN O
high NN NN O
dosage NN NN O
cannot NN NN O
be NN NN O
carried NN NN O
out NN NN O
continuously NN NN O
because NN NN O
of NN NN O
the NN NN O
effects NN NN O
of NN NN O
the NN NN O
drug NN NN O
on NN NN O
virility NN NN O
; NN NN O
because NN NN O
the NN NN O
tissue NN NN O
injury NN NN O
too NN NN O
often NN NN O
occurs NN NN O
at NN NN O
an NN NN O
irreversible NN NN O
stage NN NN O
vis NN NN O
- NN NN O
a NN NN O
- NN NN O
vis NN NN O
the NN NN O
"""""""" NN NN O
regeneration NN NN O
"""""""" NN NN O
of NN NN O
the NN NN O
muscle NN NN O
tissue NN NN O
; NN NN O
and NN NN O
finally NN NN O
because NN NN O
the NN NN O
dystrophic NN NN O
injurious NN NN O
agent NN NN O
is NN NN O
certainly NN NN O
not NN NN O
the NN NN O
lack NN NN O
of NN NN O
vitamin NN NN O
E NN NN O
but NN NN O
something NN NN O
as NN NN O
yet NN NN O
unknown NN NN O
. NN NN O
   
Paclitaxel NN NN O
3 NN NN O
- NN NN O
hour NN NN O
infusion NN NN O
given NN NN O
alone NN NN O
and NN NN O
combined NN NN O
with NN NN O
carboplatin NN NN O
: NN NN O
preliminary NN NN O
results NN NN O
of NN NN O
dose NN NN O
- NN NN O
escalation NN NN O
trials NN NN O
. NN NN O
   
Paclitaxel NN NN O
( NN NN O
Taxol NN NN O
; NN NN O
Bristol NN NN O
- NN NN O
Myers NN NN O
Squibb NN NN O
Company NN NN O
, NN NN O
Princeton NN NN O
, NN NN O
NJ NN NN O
) NN NN O
by NN NN O
3 NN NN O
- NN NN O
hour NN NN O
infusion NN NN O
was NN NN O
combined NN NN O
with NN NN O
carboplatin NN NN O
in NN NN O
a NN NN O
phase NN NN O
I NN NN O
/ NN NN O
II NN NN O
study NN NN O
directed NN NN O
to NN NN O
patients NN NN O
with NN NN O
non NN NN B-Disease
- NN NN I-Disease
small NN NN I-Disease
cell NN NN I-Disease
lung NN NN I-Disease
cancer NN NN I-Disease
. NN NN O
   
Carboplatin NN NN O
was NN NN O
given NN NN O
at NN NN O
a NN NN O
fixed NN NN O
target NN NN O
area NN NN O
under NN NN O
the NN NN O
concentration NN NN O
- NN NN O
time NN NN O
curve NN NN O
of NN NN O
6 NN NN O
. NN NN O
0 NN NN O
by NN NN O
the NN NN O
Calvert NN NN O
formula NN NN O
, NN NN O
whereas NN NN O
paclitaxel NN NN O
was NN NN O
escalated NN NN O
in NN NN O
patient NN NN O
cohorts NN NN O
from NN NN O
150 NN NN O
mg NN NN O
/ NN NN O
m2 NN NN O
( NN NN O
dose NN NN O
level NN NN O
I NN NN O
) NN NN O
to NN NN O
175 NN NN O
, NN NN O
200 NN NN O
, NN NN O
225 NN NN O
, NN NN O
and NN NN O
250 NN NN O
mg NN NN O
/ NN NN O
m2 NN NN O
. NN NN O
   
The NN NN O
225 NN NN O
mg NN NN O
/ NN NN O
m2 NN NN O
level NN NN O
was NN NN O
expanded NN NN O
for NN NN O
the NN NN O
phase NN NN O
II NN NN O
study NN NN O
since NN NN O
the NN NN O
highest NN NN O
level NN NN O
achieved NN NN O
( NN NN O
250 NN NN O
mg NN NN O
/ NN NN O
m2 NN NN O
) NN NN O
required NN NN O
modification NN NN O
because NN NN O
of NN NN O
nonhematologic NN NN O
toxicities NN NN B-Disease
( NN NN O
arthralgia NN NN B-Disease
and NN NN O
sensory NN NN B-Disease
neuropathy NN NN I-Disease
) NN NN O
. NN NN O
   
Therapeutic NN NN O
effects NN NN O
were NN NN O
noted NN NN O
at NN NN O
all NN NN O
dose NN NN O
levels NN NN O
, NN NN O
with NN NN O
objective NN NN O
responses NN NN O
in NN NN O
17 NN NN O
( NN NN O
two NN NN O
complete NN NN O
and NN NN O
15 NN NN O
partial NN NN O
regressions NN NN O
) NN NN O
of NN NN O
41 NN NN O
previously NN NN O
untreated NN NN O
patients NN NN O
. NN NN O
   
Toxicities NN NN B-Disease
were NN NN O
compared NN NN O
with NN NN O
a NN NN O
cohort NN NN O
of NN NN O
patients NN NN O
in NN NN O
a NN NN O
phase NN NN O
I NN NN O
trial NN NN O
of NN NN O
paclitaxel NN NN O
alone NN NN O
at NN NN O
identical NN NN O
dose NN NN O
levels NN NN O
. NN NN O
   
Carboplatin NN NN O
did NN NN O
not NN NN O
appear NN NN O
to NN NN O
add NN NN O
to NN NN O
the NN NN O
hematologic NN NN B-Disease
toxicities NN NN I-Disease
observed NN NN O
, NN NN O
and NN NN O
the NN NN O
paclitaxel NN NN O
/ NN NN O
carboplatin NN NN O
combination NN NN O
could NN NN O
be NN NN O
dosed NN NN O
every NN NN O
3 NN NN O
weeks NN NN O
. NN NN O
   
The NN NN O
dose NN NN O
- NN NN O
dependent NN NN O
effect NN NN O
of NN NN O
misoprostol NN NN O
on NN NN O
indomethacin NN NN O
- NN NN O
induced NN NN O
renal NN NN B-Disease
dysfunction NN NN I-Disease
in NN NN O
well NN NN O
compensated NN NN O
cirrhosis NN NN B-Disease
. NN NN O
   
Misoprostol NN NN O
( NN NN O
200 NN NN O
micrograms NN NN O
) NN NN O
has NN NN O
been NN NN O
shown NN NN O
to NN NN O
acutely NN NN O
counteract NN NN O
the NN NN O
indomethacin NN NN O
- NN NN O
induced NN NN O
renal NN NN B-Disease
dysfunction NN NN I-Disease
in NN NN O
well NN NN O
compensated NN NN O
cirrhotic NN NN B-Disease
patients NN NN O
. NN NN O
   
The NN NN O
aim NN NN O
of NN NN O
this NN NN O
study NN NN O
was NN NN O
to NN NN O
determine NN NN O
if NN NN O
the NN NN O
prophylactic NN NN O
value NN NN O
of NN NN O
misoprostol NN NN O
was NN NN O
dose NN NN O
- NN NN O
dependent NN NN O
. NN NN O
   
Parameters NN NN O
of NN NN O
renal NN NN O
hemodynamics NN NN O
and NN NN O
tubular NN NN O
sodium NN NN O
and NN NN O
water NN NN O
handling NN NN O
were NN NN O
assessed NN NN O
by NN NN O
clearance NN NN O
techniques NN NN O
in NN NN O
26 NN NN O
well NN NN O
compensated NN NN O
cirrhotic NN NN B-Disease
patients NN NN O
before NN NN O
and NN NN O
after NN NN O
an NN NN O
oral NN NN O
combination NN NN O
of NN NN O
50 NN NN O
mg NN NN O
of NN NN O
indomethacin NN NN O
and NN NN O
various NN NN O
doses NN NN O
of NN NN O
misoprostol NN NN O
. NN NN O
   
The NN NN O
200 NN NN O
- NN NN O
micrograms NN NN O
dose NN NN O
was NN NN O
able NN NN O
to NN NN O
totally NN NN O
abolish NN NN O
the NN NN O
deleterious NN NN O
renal NN NN O
effects NN NN O
of NN NN O
indomethacin NN NN O
, NN NN O
whereas NN NN O
the NN NN O
800 NN NN O
- NN NN O
micrograms NN NN O
dose NN NN O
resulted NN NN O
in NN NN O
significant NN NN O
worsening NN NN O
of NN NN O
renal NN NN O
hemodynamics NN NN O
and NN NN O
sodium NN NN O
retention NN NN O
. NN NN O
   
These NN NN O
changes NN NN O
were NN NN O
maximal NN NN O
in NN NN O
the NN NN O
hour NN NN O
immediately NN NN O
after NN NN O
medications NN NN O
and NN NN O
slowly NN NN O
returned NN NN O
toward NN NN O
base NN NN O
- NN NN O
line NN NN O
levels NN NN O
thereafter NN NN O
. NN NN O
   
These NN NN O
results NN NN O
suggest NN NN O
that NN NN O
the NN NN O
renal NN NN O
protective NN NN O
effects NN NN O
of NN NN O
misoprostol NN NN O
is NN NN O
dose NN NN O
- NN NN O
dependent NN NN O
. NN NN O
   
However NN NN O
, NN NN O
until NN NN O
this NN NN O
apparent NN NN O
ability NN NN O
of NN NN O
200 NN NN O
micrograms NN NN O
of NN NN O
misoprostol NN NN O
to NN NN O
prevent NN NN O
the NN NN O
adverse NN NN O
effects NN NN O
of NN NN O
indomethacin NN NN O
on NN NN O
renal NN NN O
function NN NN O
is NN NN O
confirmed NN NN O
with NN NN O
chronic NN NN O
frequent NN NN O
dosing NN NN O
, NN NN O
it NN NN O
would NN NN O
be NN NN O
prudent NN NN O
to NN NN O
avoid NN NN O
nonsteroidal NN NN O
anti NN NN O
- NN NN O
inflammatory NN NN O
therapy NN NN O
in NN NN O
patients NN NN O
with NN NN O
cirrhosis NN NN B-Disease
. NN NN O
   
Increased NN NN O
frequency NN NN O
and NN NN O
severity NN NN O
of NN NN O
angio NN NN B-Disease
- NN NN I-Disease
oedema NN NN I-Disease
related NN NN O
to NN NN O
long NN NN O
- NN NN O
term NN NN O
therapy NN NN O
with NN NN O
angiotensin NN NN O
- NN NN O
converting NN NN O
enzyme NN NN O
inhibitor NN NN O
in NN NN O
two NN NN O
patients NN NN O
. NN NN O
   
Adverse NN NN O
reactions NN NN O
to NN NN O
drugs NN NN O
are NN NN O
well NN NN O
recognized NN NN O
as NN NN O
a NN NN O
cause NN NN O
of NN NN O
acute NN NN O
or NN NN O
chronic NN NN O
urticaria NN NN B-Disease
, NN NN O
and NN NN O
angio NN NN B-Disease
- NN NN I-Disease
oedema NN NN I-Disease
. NN NN O
   
Angiotensin NN NN O
- NN NN O
converting NN NN O
enzyme NN NN O
( NN NN O
ACE NN NN O
) NN NN O
inhibitors NN NN O
, NN NN O
used NN NN O
to NN NN O
treat NN NN O
hypertension NN NN B-Disease
and NN NN O
congestive NN NN B-Disease
heart NN NN I-Disease
failure NN NN I-Disease
, NN NN O
were NN NN O
introduced NN NN O
in NN NN O
Europe NN NN O
in NN NN O
the NN NN O
middle NN NN O
of NN NN O
the NN NN O
eighties NN NN O
, NN NN O
and NN NN O
the NN NN O
use NN NN O
of NN NN O
these NN NN O
drugs NN NN O
has NN NN O
increased NN NN O
progressively NN NN O
. NN NN O
   
Soon NN NN O
after NN NN O
the NN NN O
introduction NN NN O
of NN NN O
ACE NN NN O
inhibitors NN NN O
, NN NN O
acute NN NN O
bouts NN NN O
of NN NN O
angio NN NN B-Disease
- NN NN I-Disease
oedema NN NN I-Disease
were NN NN O
reported NN NN O
in NN NN O
association NN NN O
with NN NN O
the NN NN O
use NN NN O
of NN NN O
these NN NN O
drugs NN NN O
. NN NN O
   
We NN NN O
wish NN NN O
to NN NN O
draw NN NN O
attention NN NN O
to NN NN O
the NN NN O
possibility NN NN O
of NN NN O
adverse NN NN O
reactions NN NN O
to NN NN O
ACE NN NN O
inhibitors NN NN O
after NN NN O
long NN NN O
- NN NN O
term NN NN O
use NN NN O
and NN NN O
in NN NN O
patients NN NN O
with NN NN O
pre NN NN O
- NN NN O
existing NN NN O
angio NN NN B-Disease
- NN NN I-Disease
oedema NN NN I-Disease
. NN NN O
   
Myoclonus NN NN B-Disease
associated NN NN O
with NN NN O
lorazepam NN NN O
therapy NN NN O
in NN NN O
very NN NN O
- NN NN O
low NN NN O
- NN NN O
birth NN NN O
- NN NN O
weight NN NN O
infants NN NN O
. NN NN O
   
Lorazepam NN NN O
is NN NN O
being NN NN O
used NN NN O
with NN NN O
increasing NN NN O
frequency NN NN O
as NN NN O
a NN NN O
sedative NN NN O
in NN NN O
the NN NN O
newborn NN NN O
and NN NN O
the NN NN O
young NN NN O
infant NN NN O
. NN NN O
   
Concern NN NN O
has NN NN O
been NN NN O
raised NN NN O
with NN NN O
regard NN NN O
to NN NN O
the NN NN O
safety NN NN O
of NN NN O
lorazepam NN NN O
in NN NN O
this NN NN O
age NN NN O
group NN NN O
, NN NN O
especially NN NN O
in NN NN O
very NN NN O
- NN NN O
low NN NN O
- NN NN O
birth NN NN O
- NN NN O
weight NN NN O
( NN NN O
VLBW NN NN O
; NN NN O
< NN NN O
1 NN NN O
, NN NN O
500 NN NN O
g NN NN O
) NN NN O
infants NN NN O
. NN NN O
   
Three NN NN O
young NN NN O
infants NN NN O
, NN NN O
all NN NN O
of NN NN O
birth NN NN O
weight NN NN O
< NN NN O
1 NN NN O
, NN NN O
500 NN NN O
g NN NN O
, NN NN O
experienced NN NN O
myoclonus NN NN B-Disease
following NN NN O
the NN NN O
intravenous NN NN O
administration NN NN O
of NN NN O
lorazepam NN NN O
. NN NN O
   
The NN NN O
potential NN NN O
neurotoxic NN NN B-Disease
effects NN NN O
of NN NN O
the NN NN O
drug NN NN O
( NN NN O
and NN NN O
its NN NN O
vehicle NN NN O
) NN NN O
in NN NN O
this NN NN O
population NN NN O
are NN NN O
discussed NN NN O
. NN NN O
   
Injectable NN NN O
lorazepam NN NN O
should NN NN O
be NN NN O
used NN NN O
with NN NN O
caution NN NN O
in NN NN O
VLBW NN NN O
infants NN NN O
. NN NN O
   
Transvenous NN NN O
right NN NN O
ventricular NN NN O
pacing NN NN O
during NN NN O
cardiopulmonary NN NN O
resuscitation NN NN O
of NN NN O
pediatric NN NN O
patients NN NN O
with NN NN O
acute NN NN O
cardiomyopathy NN NN B-Disease
. NN NN O
   
We NN NN O
describe NN NN O
the NN NN O
cardiopulmonary NN NN O
resuscitation NN NN O
efforts NN NN O
on NN NN O
five NN NN O
patients NN NN O
who NN NN O
presented NN NN O
in NN NN O
acute NN NN O
circulatory NN NN B-Disease
failure NN NN I-Disease
from NN NN O
myocardial NN NN B-Disease
dysfunction NN NN I-Disease
. NN NN O
   
Three NN NN O
patients NN NN O
had NN NN O
acute NN NN O
viral NN NN O
myocarditis NN NN B-Disease
, NN NN O
one NN NN O
had NN NN O
a NN NN O
carbamazepine NN NN O
- NN NN O
induced NN NN O
acute NN NN O
eosinophilic NN NN B-Disease
myocarditis NN NN I-Disease
, NN NN O
and NN NN O
one NN NN O
had NN NN O
cardiac NN NN O
hemosiderosis NN NN O
resulting NN NN O
in NN NN O
acute NN NN O
cardiogenic NN NN B-Disease
shock NN NN I-Disease
. NN NN O
   
All NN NN O
patients NN NN O
were NN NN O
continuously NN NN O
monitored NN NN O
with NN NN O
central NN NN O
venous NN NN O
and NN NN O
arterial NN NN O
catheters NN NN O
in NN NN O
addition NN NN O
to NN NN O
routine NN NN O
noninvasive NN NN O
monitoring NN NN O
. NN NN O
   
An NN NN O
introducer NN NN O
sheath NN NN O
, NN NN O
a NN NN O
pacemaker NN NN O
, NN NN O
and NN NN O
sterile NN NN O
pacing NN NN O
wires NN NN O
were NN NN O
made NN NN O
readily NN NN O
available NN NN O
for NN NN O
the NN NN O
patients NN NN O
, NN NN O
should NN NN O
the NN NN O
need NN NN O
arise NN NN O
to NN NN O
terminate NN NN O
resistant NN NN O
cardiac NN NN O
dysrhythmias NN NN B-Disease
. NN NN O
   
All NN NN O
patients NN NN O
developed NN NN O
cardiocirculatory NN NN O
arrest NN NN O
associated NN NN O
with NN NN O
extreme NN NN O
hypotension NN NN B-Disease
and NN NN O
dysrhythmias NN NN B-Disease
within NN NN O
the NN NN O
first NN NN O
48 NN NN O
hours NN NN O
of NN NN O
their NN NN O
admission NN NN O
to NN NN O
the NN NN O
pediatric NN NN O
intensive NN NN O
care NN NN O
unit NN NN O
( NN NN O
PICU NN NN O
) NN NN O
. NN NN O
   
Right NN NN O
ventricular NN NN O
pacemaker NN NN O
wires NN NN O
were NN NN O
inserted NN NN O
in NN NN O
all NN NN O
of NN NN O
them NN NN O
during NN NN O
cardiopulmonary NN NN O
resuscitation NN NN O
( NN NN O
CPR NN NN O
) NN NN O
. NN NN O
   
In NN NN O
four NN NN O
patients NN NN O
, NN NN O
cardiac NN NN O
pacing NN NN O
was NN NN O
used NN NN O
, NN NN O
resulting NN NN O
in NN NN O
a NN NN O
temporary NN NN O
captured NN NN O
rhythm NN NN O
and NN NN O
restoration NN NN O
of NN NN O
their NN NN O
cardiac NN NN O
output NN NN O
. NN NN O
   
These NN NN O
patients NN NN O
had NN NN O
a NN NN O
second NN NN O
event NN NN O
of NN NN O
cardiac NN NN B-Disease
arrest NN NN I-Disease
, NN NN O
resulting NN NN O
in NN NN O
death NN NN O
, NN NN O
within NN NN O
10 NN NN O
to NN NN O
60 NN NN O
minutes NN NN O
. NN NN O
   
In NN NN O
one NN NN O
patient NN NN O
, NN NN O
cardiac NN NN O
pacing NN NN O
was NN NN O
not NN NN O
used NN NN O
, NN NN O
because NN NN O
he NN NN O
converted NN NN O
to NN NN O
normal NN NN O
sinus NN NN O
rhythm NN NN O
by NN NN O
electrical NN NN O
defibrillation NN NN O
within NN NN O
three NN NN O
minutes NN NN O
of NN NN O
initiating NN NN O
CPR NN NN O
. NN NN O
   
We NN NN O
conclude NN NN O
that NN NN O
cardiac NN NN O
pacing NN NN O
during NN NN O
resuscitative NN NN O
efforts NN NN O
in NN NN O
pediatric NN NN O
patients NN NN O
suffering NN NN O
from NN NN O
acute NN NN O
myocardial NN NN B-Disease
dysfunction NN NN I-Disease
may NN NN O
not NN NN O
have NN NN O
long NN NN O
- NN NN O
term NN NN O
value NN NN O
in NN NN O
and NN NN O
of NN NN O
itself NN NN O
; NN NN O
however NN NN O
, NN NN O
if NN NN O
temporary NN NN O
hemodynamic NN NN O
stability NN NN O
is NN NN O
achieved NN NN O
by NN NN O
this NN NN O
procedure NN NN O
, NN NN O
it NN NN O
may NN NN O
provide NN NN O
additional NN NN O
time NN NN O
needed NN NN O
to NN NN O
institute NN NN O
other NN NN O
therapeutic NN NN O
modalities NN NN O
. NN NN O
   
Efficacy NN NN O
and NN NN O
safety NN NN O
of NN NN O
granisetron NN NN O
, NN NN O
a NN NN O
selective NN NN O
5 NN NN O
- NN NN O
hydroxytryptamine NN NN O
- NN NN O
3 NN NN O
receptor NN NN O
antagonist NN NN O
, NN NN O
in NN NN O
the NN NN O
prevention NN NN O
of NN NN O
nausea NN NN B-Disease
and NN NN O
vomiting NN NN B-Disease
induced NN NN O
by NN NN O
high NN NN O
- NN NN O
dose NN NN O
cisplatin NN NN O
. NN NN O
   
PURPOSE NN NN O
: NN NN O
To NN NN O
assess NN NN O
the NN NN O
antiemetic NN NN O
effects NN NN O
and NN NN O
safety NN NN O
profile NN NN O
of NN NN O
four NN NN O
different NN NN O
doses NN NN O
of NN NN O
granisetron NN NN O
( NN NN O
Kytril NN NN O
; NN NN O
SmithKline NN NN O
Beecham NN NN O
Pharmaceuticals NN NN O
, NN NN O
Philadelphia NN NN O
, NN NN O
PA NN NN O
) NN NN O
when NN NN O
administered NN NN O
as NN NN O
a NN NN O
single NN NN O
intravenous NN NN O
( NN NN O
IV NN NN O
) NN NN O
dose NN NN O
for NN NN O
prophylaxis NN NN O
of NN NN O
cisplatin NN NN O
- NN NN O
induced NN NN O
nausea NN NN B-Disease
and NN NN O
vomiting NN NN B-Disease
. NN NN O
   
PATIENTS NN NN O
AND NN NN O
METHODS NN NN O
: NN NN O
One NN NN O
hundred NN NN O
eighty NN NN O
- NN NN O
four NN NN O
chemotherapy NN NN O
- NN NN O
naive NN NN O
patients NN NN O
receiving NN NN O
high NN NN O
- NN NN O
dose NN NN O
cisplatin NN NN O
( NN NN O
81 NN NN O
to NN NN O
120 NN NN O
mg NN NN O
/ NN NN O
m2 NN NN O
) NN NN O
were NN NN O
randomized NN NN O
to NN NN O
receive NN NN O
one NN NN O
of NN NN O
four NN NN O
granisetron NN NN O
doses NN NN O
( NN NN O
5 NN NN O
, NN NN O
10 NN NN O
, NN NN O
20 NN NN O
, NN NN O
or NN NN O
40 NN NN O
micrograms NN NN O
/ NN NN O
kg NN NN O
) NN NN O
administered NN NN O
before NN NN O
chemotherapy NN NN O
. NN NN O
   
Patients NN NN O
were NN NN O
observed NN NN O
on NN NN O
an NN NN O
inpatient NN NN O
basis NN NN O
for NN NN O
18 NN NN O
to NN NN O
24 NN NN O
hours NN NN O
, NN NN O
and NN NN O
vital NN NN O
signs NN NN O
, NN NN O
nausea NN NN B-Disease
, NN NN O
vomiting NN NN B-Disease
, NN NN O
retching NN NN O
, NN NN O
and NN NN O
appetite NN NN O
were NN NN O
assessed NN NN O
. NN NN O
   
Safety NN NN O
analyses NN NN O
included NN NN O
incidence NN NN O
of NN NN O
adverse NN NN O
experiences NN NN O
and NN NN O
laboratory NN NN O
parameter NN NN O
changes NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
After NN NN O
granisetron NN NN O
doses NN NN O
of NN NN O
5 NN NN O
, NN NN O
10 NN NN O
, NN NN O
20 NN NN O
, NN NN O
and NN NN O
40 NN NN O
micrograms NN NN O
/ NN NN O
kg NN NN O
, NN NN O
a NN NN O
major NN NN O
response NN NN O
( NN NN O
< NN NN O
or NN NN O
= NN NN O
two NN NN O
vomiting NN NN B-Disease
or NN NN O
retching NN NN O
episodes NN NN O
, NN NN O
and NN NN O
no NN NN O
antiemetic NN NN O
rescue NN NN O
) NN NN O
was NN NN O
recorded NN NN O
in NN NN O
23 NN NN O
% NN NN O
, NN NN O
57 NN NN O
% NN NN O
, NN NN O
58 NN NN O
% NN NN O
, NN NN O
and NN NN O
60 NN NN O
% NN NN O
of NN NN O
patients NN NN O
, NN NN O
respectively NN NN O
, NN NN O
and NN NN O
a NN NN O
complete NN NN O
response NN NN O
( NN NN O
no NN NN O
vomiting NN NN B-Disease
or NN NN O
retching NN NN O
, NN NN O
and NN NN O
no NN NN O
antiemetic NN NN O
rescue NN NN O
) NN NN O
in NN NN O
18 NN NN O
% NN NN O
, NN NN O
41 NN NN O
% NN NN O
, NN NN O
40 NN NN O
% NN NN O
, NN NN O
and NN NN O
47 NN NN O
% NN NN O
of NN NN O
patients NN NN O
, NN NN O
respectively NN NN O
. NN NN O
   
There NN NN O
was NN NN O
a NN NN O
statistically NN NN O
longer NN NN O
time NN NN O
to NN NN O
first NN NN O
episode NN NN O
of NN NN O
nausea NN NN B-Disease
( NN NN O
P NN NN O
= NN NN O
. NN NN O
0015 NN NN O
) NN NN O
and NN NN O
vomiting NN NN B-Disease
( NN NN O
P NN NN O
= NN NN O
. NN NN O
0001 NN NN O
) NN NN O
, NN NN O
and NN NN O
fewer NN NN O
patients NN NN O
were NN NN O
administered NN NN O
additional NN NN O
antiemetic NN NN O
medication NN NN O
in NN NN O
the NN NN O
10 NN NN O
- NN NN O
micrograms NN NN O
/ NN NN O
kg NN NN O
dosing NN NN O
groups NN NN O
than NN NN O
in NN NN O
the NN NN O
5 NN NN O
- NN NN O
micrograms NN NN O
/ NN NN O
kg NN NN O
dosing NN NN O
group NN NN O
. NN NN O
   
As NN NN O
granisetron NN NN O
dose NN NN O
increased NN NN O
, NN NN O
appetite NN NN O
return NN NN O
increased NN NN O
( NN NN O
P NN NN O
= NN NN O
. NN NN O
040 NN NN O
) NN NN O
. NN NN O
   
Headache NN NN B-Disease
was NN NN O
the NN NN O
most NN NN O
frequently NN NN O
reported NN NN O
adverse NN NN O
event NN NN O
( NN NN O
20 NN NN O
% NN NN O
) NN NN O
. NN NN O
   
CONCLUSION NN NN O
: NN NN O
A NN NN O
single NN NN O
10 NN NN O
- NN NN O
, NN NN O
20 NN NN O
- NN NN O
, NN NN O
or NN NN O
40 NN NN O
- NN NN O
micrograms NN NN O
/ NN NN O
kg NN NN O
dose NN NN O
of NN NN O
granisetron NN NN O
was NN NN O
effective NN NN O
in NN NN O
controlling NN NN O
vomiting NN NN B-Disease
in NN NN O
57 NN NN O
% NN NN O
to NN NN O
60 NN NN O
% NN NN O
of NN NN O
patients NN NN O
who NN NN O
received NN NN O
cisplatin NN NN O
at NN NN O
doses NN NN O
greater NN NN O
than NN NN O
81 NN NN O
mg NN NN O
/ NN NN O
m2 NN NN O
and NN NN O
totally NN NN O
prevented NN NN O
vomiting NN NN B-Disease
in NN NN O
40 NN NN O
% NN NN O
to NN NN O
47 NN NN O
% NN NN O
of NN NN O
patients NN NN O
. NN NN O
   
There NN NN O
were NN NN O
no NN NN O
statistically NN NN O
significant NN NN O
differences NN NN O
in NN NN O
efficacy NN NN O
between NN NN O
the NN NN O
10 NN NN O
- NN NN O
micrograms NN NN O
/ NN NN O
kg NN NN O
dose NN NN O
and NN NN O
the NN NN O
20 NN NN O
- NN NN O
and NN NN O
40 NN NN O
- NN NN O
micrograms NN NN O
/ NN NN O
kg NN NN O
doses NN NN O
. NN NN O
   
Granisetron NN NN O
was NN NN O
well NN NN O
tolerated NN NN O
at NN NN O
all NN NN O
doses NN NN O
. NN NN O
   
Adverse NN NN O
interaction NN NN O
between NN NN O
clonidine NN NN O
and NN NN O
verapamil NN NN O
. NN NN O
   
OBJECTIVE NN NN O
: NN NN O
To NN NN O
report NN NN O
two NN NN O
cases NN NN O
of NN NN O
a NN NN O
possible NN NN O
adverse NN NN O
interaction NN NN O
between NN NN O
clonidine NN NN O
and NN NN O
verapamil NN NN O
resulting NN NN O
in NN NN O
atrioventricular NN NN B-Disease
( NN NN I-Disease
AV NN NN I-Disease
) NN NN I-Disease
block NN NN I-Disease
in NN NN O
both NN NN O
patients NN NN O
and NN NN O
severe NN NN O
hypotension NN NN B-Disease
in NN NN O
one NN NN O
patient NN NN O
. NN NN O
   
CASE NN NN O
SUMMARIES NN NN O
: NN NN O
A NN NN O
54 NN NN O
- NN NN O
year NN NN O
- NN NN O
old NN NN O
woman NN NN O
with NN NN O
hyperaldosteronism NN NN B-Disease
was NN NN O
treated NN NN O
with NN NN O
verapamil NN NN O
480 NN NN O
mg NN NN O
/ NN NN O
d NN NN O
and NN NN O
spironolactone NN NN O
100 NN NN O
mg NN NN O
/ NN NN O
d NN NN O
. NN NN O
   
After NN NN O
the NN NN O
addition NN NN O
of NN NN O
a NN NN O
minimal NN NN O
dose NN NN O
of NN NN O
clonidine NN NN O
( NN NN O
0 NN NN O
. NN NN O
15 NN NN O
mg NN NN O
bid NN NN O
) NN NN O
, NN NN O
she NN NN O
developed NN NN O
complete NN NN O
AV NN NN B-Disease
block NN NN I-Disease
and NN NN O
severe NN NN O
hypotension NN NN B-Disease
, NN NN O
which NN NN O
resolved NN NN O
upon NN NN O
cessation NN NN O
of NN NN O
all NN NN O
medications NN NN O
. NN NN O
   
A NN NN O
65 NN NN O
- NN NN O
year NN NN O
- NN NN O
old NN NN O
woman NN NN O
was NN NN O
treated NN NN O
with NN NN O
extended NN NN O
- NN NN O
release NN NN O
verapamil NN NN O
240 NN NN O
mg NN NN O
/ NN NN O
d NN NN O
. NN NN O
   
After NN NN O
the NN NN O
addition NN NN O
of NN NN O
clonidine NN NN O
0 NN NN O
. NN NN O
15 NN NN O
mg NN NN O
bid NN NN O
she NN NN O
developed NN NN O
complete NN NN O
AV NN NN B-Disease
block NN NN I-Disease
, NN NN O
which NN NN O
resolved NN NN O
after NN NN O
all NN NN O
therapy NN NN O
was NN NN O
stopped NN NN O
. NN NN O
   
DISCUSSION NN NN O
: NN NN O
An NN NN O
adverse NN NN O
interaction NN NN O
between NN NN O
clonidine NN NN O
and NN NN O
verapamil NN NN O
has NN NN O
not NN NN O
been NN NN O
reported NN NN O
previously NN NN O
. NN NN O
   
We NN NN O
describe NN NN O
two NN NN O
such NN NN O
cases NN NN O
and NN NN O
discuss NN NN O
the NN NN O
various NN NN O
mechanisms NN NN O
that NN NN O
might NN NN O
cause NN NN O
such NN NN O
an NN NN O
interaction NN NN O
. NN NN O
   
Clinicians NN NN O
should NN NN O
be NN NN O
acquainted NN NN O
with NN NN O
this NN NN O
possibly NN NN O
fatal NN NN O
interaction NN NN O
between NN NN O
two NN NN O
commonly NN NN O
used NN NN O
antihypertensive NN NN O
drugs NN NN O
. NN NN O
   
CONCLUSIONS NN NN O
: NN NN O
Caution NN NN O
is NN NN O
recommended NN NN O
in NN NN O
combining NN NN O
clonidine NN NN O
and NN NN O
verapamil NN NN O
therapy NN NN O
, NN NN O
even NN NN O
in NN NN O
patients NN NN O
who NN NN O
do NN NN O
not NN NN O
have NN NN O
sinus NN NN O
or NN NN O
AV NN NN O
node NN NN O
dysfunction NN NN O
. NN NN O
   
The NN NN O
two NN NN O
drugs NN NN O
may NN NN O
act NN NN O
synergistically NN NN O
on NN NN O
both NN NN O
the NN NN O
AV NN NN O
node NN NN O
and NN NN O
the NN NN O
peripheral NN NN O
circulation NN NN O
. NN NN O
   
Pharmacological NN NN O
studies NN NN O
on NN NN O
a NN NN O
new NN NN O
dihydrothienopyridine NN NN O
calcium NN NN O
antagonist NN NN O
, NN NN O
S NN NN O
- NN NN O
312 NN NN O
- NN NN O
d NN NN O
. NN NN O
   
5th NN NN O
communication NN NN O
: NN NN O
anticonvulsant NN NN O
effects NN NN O
in NN NN O
mice NN NN O
. NN NN O
   
S NN NN O
- NN NN O
312 NN NN O
, NN NN O
S NN NN O
- NN NN O
312 NN NN O
- NN NN O
d NN NN O
, NN NN O
but NN NN O
not NN NN O
S NN NN O
- NN NN O
312 NN NN O
- NN NN O
l NN NN O
, NN NN O
L NN NN O
- NN NN O
type NN NN O
calcium NN NN O
channel NN NN O
antagonists NN NN O
, NN NN O
showed NN NN O
anticonvulsant NN NN O
effects NN NN O
on NN NN O
the NN NN O
audiogenic NN NN B-Disease
tonic NN NN I-Disease
convulsions NN NN I-Disease
in NN NN O
DBA NN NN O
/ NN NN O
2 NN NN O
mice NN NN O
; NN NN O
and NN NN O
their NN NN O
ED50 NN NN O
values NN NN O
were NN NN O
18 NN NN O
. NN NN O
4 NN NN O
( NN NN O
12 NN NN O
. NN NN O
8 NN NN O
- NN NN O
27 NN NN O
. NN NN O
1 NN NN O
) NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
, NN NN O
p NN NN O
. NN NN O
o NN NN O
. NN NN O
and NN NN O
15 NN NN O
. NN NN O
0 NN NN O
( NN NN O
10 NN NN O
. NN NN O
2 NN NN O
- NN NN O
23 NN NN O
. NN NN O
7 NN NN O
) NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
, NN NN O
p NN NN O
. NN NN O
o NN NN O
. NN NN O
, NN NN O
respectively NN NN O
, NN NN O
while NN NN O
that NN NN O
of NN NN O
flunarizine NN NN O
was NN NN O
34 NN NN O
. NN NN O
0 NN NN O
( NN NN O
26 NN NN O
. NN NN O
0 NN NN O
- NN NN O
44 NN NN O
. NN NN O
8 NN NN O
) NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
, NN NN O
p NN NN O
. NN NN O
o NN NN O
. NN NN O
   
Although NN NN O
moderate NN NN O
anticonvulsant NN NN O
effects NN NN O
of NN NN O
S NN NN O
- NN NN O
312 NN NN O
- NN NN O
d NN NN O
in NN NN O
higher NN NN O
doses NN NN O
were NN NN O
observed NN NN O
against NN NN O
the NN NN O
clonic NN NN O
convulsions NN NN B-Disease
induced NN NN O
by NN NN O
pentylenetetrazole NN NN O
( NN NN O
85 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
, NN NN O
s NN NN O
. NN NN O
c NN NN O
. NN NN O
) NN NN O
or NN NN O
bemegride NN NN O
( NN NN O
40 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
, NN NN O
s NN NN O
. NN NN O
c NN NN O
. NN NN O
) NN NN O
, NN NN O
no NN NN O
effects NN NN O
were NN NN O
observed NN NN O
in NN NN O
convulsions NN NN B-Disease
induced NN NN O
by NN NN O
N NN NN O
- NN NN O
methyl NN NN O
- NN NN O
D NN NN O
- NN NN O
aspartate NN NN O
, NN NN O
picrotoxin NN NN O
, NN NN O
or NN NN O
electroshock NN NN O
in NN NN O
Slc NN NN O
: NN NN O
ddY NN NN O
mice NN NN O
. NN NN O
   
S NN NN O
- NN NN O
312 NN NN O
- NN NN O
d NN NN O
may NN NN O
be NN NN O
useful NN NN O
in NN NN O
the NN NN O
therapy NN NN O
of NN NN O
certain NN NN O
types NN NN O
of NN NN O
human NN NN O
epilepsy NN NN B-Disease
. NN NN O
   
Transmural NN NN O
myocardial NN NN B-Disease
infarction NN NN I-Disease
with NN NN O
sumatriptan NN NN O
. NN NN O
   
For NN NN O
sumatriptan NN NN O
, NN NN O
tightness NN NN O
in NN NN O
the NN NN O
chest NN NN O
caused NN NN O
by NN NN O
an NN NN O
unknown NN NN O
mechanism NN NN O
has NN NN O
been NN NN O
reported NN NN O
in NN NN O
3 NN NN O
- NN NN O
5 NN NN O
% NN NN O
of NN NN O
users NN NN O
. NN NN O
   
We NN NN O
describe NN NN O
a NN NN O
47 NN NN O
- NN NN O
year NN NN O
- NN NN O
old NN NN O
woman NN NN O
with NN NN O
an NN NN O
acute NN NN O
myocardial NN NN B-Disease
infarction NN NN I-Disease
after NN NN O
administration NN NN O
of NN NN O
sumatriptan NN NN O
6 NN NN O
mg NN NN O
subcutaneously NN NN O
for NN NN O
cluster NN NN B-Disease
headache NN NN I-Disease
. NN NN O
   
The NN NN O
patient NN NN O
had NN NN O
no NN NN O
history NN NN O
of NN NN O
underlying NN NN O
ischaemic NN NN B-Disease
heart NN NN I-Disease
disease NN NN I-Disease
or NN NN O
Prinzmetal NN NN B-Disease
' NN NN I-Disease
s NN NN I-Disease
angina NN NN I-Disease
. NN NN O
   
She NN NN O
recovered NN NN O
without NN NN O
complications NN NN O
. NN NN O
   
Flumazenil NN NN O
induces NN NN O
seizures NN NN B-Disease
and NN NN O
death NN NN O
in NN NN O
mixed NN NN O
cocaine NN NN O
- NN NN O
diazepam NN NN O
intoxications NN NN O
. NN NN O
   
STUDY NN NN O
HYPOTHESIS NN NN O
: NN NN O
Administration NN NN O
of NN NN O
the NN NN O
benzodiazepine NN NN O
antagonist NN NN O
flumazenil NN NN O
may NN NN O
unmask NN NN O
seizures NN NN B-Disease
in NN NN O
mixed NN NN O
cocaine NN NN O
- NN NN O
benzodiazepine NN NN O
intoxication NN NN O
. NN NN O
   
DESIGN NN NN O
: NN NN O
Male NN NN O
Sprague NN NN O
- NN NN O
Dawley NN NN O
rats NN NN O
received NN NN O
100 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
cocaine NN NN O
IP NN NN O
alone NN NN O
, NN NN O
5 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
diazepam NN NN O
alone NN NN O
, NN NN O
or NN NN O
a NN NN O
combination NN NN O
of NN NN O
diazepam NN NN O
and NN NN O
cocaine NN NN O
. NN NN O
   
Three NN NN O
minutes NN NN O
later NN NN O
, NN NN O
groups NN NN O
were NN NN O
challenged NN NN O
with NN NN O
vehicle NN NN O
or NN NN O
flumazenil NN NN O
5 NN NN O
or NN NN O
10 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
IP NN NN O
. NN NN O
   
Animal NN NN O
behavior NN NN O
, NN NN O
seizures NN NN B-Disease
( NN NN O
time NN NN O
to NN NN O
and NN NN O
incidence NN NN O
) NN NN O
, NN NN O
death NN NN O
( NN NN O
time NN NN O
to NN NN O
and NN NN O
incidence NN NN O
) NN NN O
, NN NN O
and NN NN O
cortical NN NN O
EEG NN NN O
tracings NN NN O
were NN NN O
recorded NN NN O
. NN NN O
   
INTERVENTIONS NN NN O
: NN NN O
Administration NN NN O
of NN NN O
flumazenil NN NN O
to NN NN O
animals NN NN O
after NN NN O
they NN NN O
had NN NN O
received NN NN O
a NN NN O
combination NN NN O
dose NN NN O
of NN NN O
cocaine NN NN O
and NN NN O
diazepam NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
In NN NN O
group NN NN O
1 NN NN O
, NN NN O
animals NN NN O
received NN NN O
cocaine NN NN O
followed NN NN O
by NN NN O
vehicle NN NN O
. NN NN O
   
This NN NN O
resulted NN NN O
in NN NN O
100 NN NN O
% NN NN O
developing NN NN O
seizures NN NN B-Disease
and NN NN O
death NN NN O
. NN NN O
   
Group NN NN O
2 NN NN O
received NN NN O
diazepam NN NN O
alone NN NN O
followed NN NN O
by NN NN O
vehicle NN NN O
. NN NN O
   
Animals NN NN O
became NN NN O
somnolent NN NN O
and NN NN O
none NN NN O
died NN NN O
. NN NN O
   
Group NN NN O
3 NN NN O
received NN NN O
diazepam NN NN O
followed NN NN O
by NN NN O
5 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
flumazenil NN NN O
. NN NN O
   
Animals NN NN O
became NN NN O
somnolent NN NN O
after NN NN O
diazepam NN NN O
and NN NN O
then NN NN O
active NN NN O
after NN NN O
flumazenil NN NN O
administration NN NN O
. NN NN O
   
In NN NN O
group NN NN O
4 NN NN O
, NN NN O
a NN NN O
combination NN NN O
of NN NN O
cocaine NN NN O
and NN NN O
diazepam NN NN O
was NN NN O
administered NN NN O
simultaneously NN NN O
. NN NN O
   
This NN NN O
resulted NN NN O
in NN NN O
no NN NN O
overt NN NN O
or NN NN O
EEG NN NN O
- NN NN O
detectable NN NN O
seizures NN NN B-Disease
and NN NN O
a NN NN O
50 NN NN O
% NN NN O
incidence NN NN O
of NN NN O
death NN NN O
. NN NN O
   
Group NN NN O
5 NN NN O
received NN NN O
a NN NN O
similar NN NN O
combination NN NN O
of NN NN O
cocaine NN NN O
and NN NN O
diazepam NN NN O
, NN NN O
followed NN NN O
later NN NN O
by NN NN O
5 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
flumazenil NN NN O
. NN NN O
   
This NN NN O
resulted NN NN O
in NN NN O
an NN NN O
increased NN NN O
incidence NN NN O
of NN NN O
seizures NN NN B-Disease
, NN NN O
90 NN NN O
% NN NN O
( NN NN O
P NN NN O
< NN NN O
. NN NN O
01 NN NN O
) NN NN O
, NN NN O
and NN NN O
death NN NN O
, NN NN O
100 NN NN O
% NN NN O
( NN NN O
P NN NN O
< NN NN O
or NN NN O
= NN NN O
. NN NN O
01 NN NN O
) NN NN O
, NN NN O
compared NN NN O
with NN NN O
group NN NN O
4 NN NN O
. NN NN O
   
Group NN NN O
6 NN NN O
received NN NN O
cocaine NN NN O
and NN NN O
diazepam NN NN O
followed NN NN O
by NN NN O
10 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
flumazenil NN NN O
. NN NN O
   
This NN NN O
also NN NN O
resulted NN NN O
in NN NN O
an NN NN O
increased NN NN O
incidence NN NN O
of NN NN O
seizures NN NN B-Disease
, NN NN O
90 NN NN O
% NN NN O
( NN NN O
P NN NN O
< NN NN O
or NN NN O
= NN NN O
. NN NN O
01 NN NN O
) NN NN O
, NN NN O
and NN NN O
death NN NN O
, NN NN O
90 NN NN O
% NN NN O
( NN NN O
P NN NN O
< NN NN O
or NN NN O
= NN NN O
. NN NN O
05 NN NN O
) NN NN O
, NN NN O
compared NN NN O
with NN NN O
group NN NN O
4 NN NN O
. NN NN O
   
CONCLUSION NN NN O
: NN NN O
Flumazenil NN NN O
can NN NN O
unmask NN NN O
seizures NN NN B-Disease
and NN NN O
increase NN NN O
the NN NN O
incidence NN NN O
of NN NN O
death NN NN O
in NN NN O
a NN NN O
model NN NN O
of NN NN O
combined NN NN O
cocaine NN NN O
- NN NN O
diazepam NN NN O
intoxications NN NN O
. NN NN O
   
Mechanisms NN NN O
for NN NN O
protective NN NN O
effects NN NN O
of NN NN O
free NN NN O
radical NN NN O
scavengers NN NN O
on NN NN O
gentamicin NN NN O
- NN NN O
mediated NN NN O
nephropathy NN NN B-Disease
in NN NN O
rats NN NN O
. NN NN O
   
Studies NN NN O
were NN NN O
performed NN NN O
to NN NN O
examine NN NN O
the NN NN O
mechanisms NN NN O
for NN NN O
the NN NN O
protective NN NN O
effects NN NN O
of NN NN O
free NN NN O
radical NN NN O
scavengers NN NN O
on NN NN O
gentamicin NN NN O
( NN NN O
GM NN NN O
) NN NN O
- NN NN O
mediated NN NN O
nephropathy NN NN B-Disease
. NN NN O
   
Administration NN NN O
of NN NN O
GM NN NN O
at NN NN O
40 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
sc NN NN O
for NN NN O
13 NN NN O
days NN NN O
to NN NN O
rats NN NN O
induced NN NN O
a NN NN O
significant NN NN O
reduction NN NN O
in NN NN O
renal NN NN O
blood NN NN O
flow NN NN O
( NN NN O
RBF NN NN O
) NN NN O
and NN NN O
inulin NN NN O
clearance NN NN O
( NN NN O
CIn NN NN O
) NN NN O
as NN NN O
well NN NN O
as NN NN O
marked NN NN O
tubular NN NN B-Disease
damage NN NN I-Disease
. NN NN O
   
A NN NN O
significant NN NN O
reduction NN NN O
in NN NN O
urinary NN NN O
guanosine NN NN O
3 NN NN O
' NN NN O
, NN NN O
5 NN NN O
' NN NN O
- NN NN O
cyclic NN NN O
monophosphate NN NN O
( NN NN O
cGMP NN NN O
) NN NN O
excretion NN NN O
and NN NN O
a NN NN O
significant NN NN O
increase NN NN O
in NN NN O
renal NN NN O
cortical NN NN O
renin NN NN O
and NN NN O
endothelin NN NN O
- NN NN O
1 NN NN O
contents NN NN O
were NN NN O
also NN NN O
observed NN NN O
in NN NN O
GM NN NN O
- NN NN O
mediated NN NN O
nephropathy NN NN B-Disease
. NN NN O
   
Superoxide NN NN O
dismutase NN NN O
( NN NN O
SOD NN NN O
) NN NN O
or NN NN O
dimethylthiourea NN NN O
( NN NN O
DMTU NN NN O
) NN NN O
significantly NN NN O
lessened NN NN O
the NN NN O
GM NN NN O
- NN NN O
induced NN NN O
decrement NN NN O
in NN NN O
CIn NN NN O
. NN NN O
   
The NN NN O
SOD NN NN O
- NN NN O
induced NN NN O
increase NN NN O
in NN NN O
glomerular NN NN O
filtration NN NN O
rate NN NN O
was NN NN O
associated NN NN O
with NN NN O
a NN NN O
marked NN NN O
improvement NN NN O
in NN NN O
RBF NN NN O
, NN NN O
an NN NN O
increase NN NN O
in NN NN O
urinary NN NN O
cGMP NN NN O
excretion NN NN O
, NN NN O
and NN NN O
a NN NN O
decrease NN NN O
in NN NN O
renal NN NN O
renin NN NN O
and NN NN O
endothelin NN NN O
- NN NN O
1 NN NN O
content NN NN O
. NN NN O
   
SOD NN NN O
did NN NN O
not NN NN O
attenuate NN NN O
the NN NN O
tubular NN NN B-Disease
damage NN NN I-Disease
. NN NN O
   
In NN NN O
contrast NN NN O
, NN NN O
DMTU NN NN O
significantly NN NN O
reduced NN NN O
the NN NN O
tubular NN NN B-Disease
damage NN NN I-Disease
and NN NN O
lipid NN NN O
peroxidation NN NN O
, NN NN O
but NN NN O
it NN NN O
did NN NN O
not NN NN O
affect NN NN O
renal NN NN O
hemodynamics NN NN O
and NN NN O
vasoactive NN NN O
substances NN NN O
. NN NN O
   
Neither NN NN O
SOD NN NN O
nor NN NN O
DMTU NN NN O
affected NN NN O
the NN NN O
renal NN NN O
cortical NN NN O
GM NN NN O
content NN NN O
in NN NN O
GM NN NN O
- NN NN O
treated NN NN O
rats NN NN O
. NN NN O
   
These NN NN O
results NN NN O
suggest NN NN O
that NN NN O
1 NN NN O
) NN NN O
both NN NN O
SOD NN NN O
and NN NN O
DMTU NN NN O
have NN NN O
protective NN NN O
effects NN NN O
on NN NN O
GM NN NN O
- NN NN O
mediated NN NN O
nephropathy NN NN B-Disease
, NN NN O
2 NN NN O
) NN NN O
the NN NN O
mechanisms NN NN O
for NN NN O
the NN NN O
protective NN NN O
effects NN NN O
differ NN NN O
for NN NN O
SOD NN NN O
and NN NN O
DMTU NN NN O
, NN NN O
and NN NN O
3 NN NN O
) NN NN O
superoxide NN NN O
anions NN NN O
play NN NN O
a NN NN O
critical NN NN O
role NN NN O
in NN NN O
GM NN NN O
- NN NN O
induced NN NN O
renal NN NN O
vasoconstriction NN NN O
. NN NN O
   
Cephalothin NN NN O
- NN NN O
induced NN NN O
immune NN NN O
hemolytic NN NN B-Disease
anemia NN NN I-Disease
. NN NN O
   
A NN NN O
patient NN NN O
with NN NN O
renal NN NN B-Disease
disease NN NN I-Disease
developed NN NN O
Coombs NN NN O
- NN NN O
positive NN NN O
hemolytic NN NN B-Disease
anemia NN NN I-Disease
while NN NN O
receiving NN NN O
cephalothin NN NN O
therapy NN NN O
. NN NN O
   
An NN NN O
anti NN NN O
- NN NN O
cephalothin NN NN O
IgG NN NN O
antibody NN NN O
was NN NN O
detected NN NN O
in NN NN O
the NN NN O
patient NN NN O
' NN NN O
s NN NN O
serum NN NN O
and NN NN O
in NN NN O
the NN NN O
eluates NN NN O
from NN NN O
her NN NN O
erythrocytes NN NN O
. NN NN O
   
In NN NN O
addition NN NN O
, NN NN O
nonimmunologic NN NN O
binding NN NN O
of NN NN O
normal NN NN O
and NN NN O
patient NN NN O
' NN NN O
s NN NN O
serum NN NN O
proteins NN NN O
to NN NN O
her NN NN O
own NN NN O
and NN NN O
cephalothin NN NN O
- NN NN O
coated NN NN O
normal NN NN O
red NN NN O
cells NN NN O
was NN NN O
demonstrated NN NN O
. NN NN O
   
Skin NN NN O
tests NN NN O
and NN NN O
in NN NN O
vitro NN NN O
lymphocyte NN NN O
stimulation NN NN O
revealed NN NN O
that NN NN O
the NN NN O
patient NN NN O
was NN NN O
sensitized NN NN O
to NN NN O
cephalothin NN NN O
and NN NN O
also NN NN O
to NN NN O
ampicillin NN NN O
. NN NN O
   
Careful NN NN O
investigation NN NN O
of NN NN O
drug NN NN O
- NN NN O
induced NN NN O
hemolytic NN NN B-Disease
anemias NN NN I-Disease
reveals NN NN O
the NN NN O
complexity NN NN O
of NN NN O
the NN NN O
immune NN NN O
mechanisms NN NN O
involved NN NN O
. NN NN O
   
Assessment NN NN O
of NN NN O
cardiomyocyte NN NN O
DNA NN NN O
synthesis NN NN O
during NN NN O
hypertrophy NN NN B-Disease
in NN NN O
adult NN NN O
mice NN NN O
. NN NN O
   
The NN NN O
ability NN NN O
of NN NN O
cardiomyocytes NN NN O
to NN NN O
synthesize NN NN O
DNA NN NN O
in NN NN O
response NN NN O
to NN NN O
experimentally NN NN O
induced NN NN O
cardiac NN NN B-Disease
hypertrophy NN NN I-Disease
was NN NN O
assessed NN NN O
in NN NN O
adult NN NN O
mice NN NN O
. NN NN O
   
Isoproterenol NN NN O
delivered NN NN O
by NN NN O
osmotic NN NN O
minipump NN NN O
implantation NN NN O
in NN NN O
adult NN NN O
C3Heb NN NN O
/ NN NN O
FeJ NN NN O
mice NN NN O
resulted NN NN O
in NN NN O
a NN NN O
46 NN NN O
% NN NN O
increase NN NN O
in NN NN O
heart NN NN O
weight NN NN O
and NN NN O
a NN NN O
19 NN NN O
. NN NN O
3 NN NN O
% NN NN O
increase NN NN O
in NN NN O
cardiomyocyte NN NN O
area NN NN O
. NN NN O
   
No NN NN O
DNA NN NN O
synthesis NN NN O
, NN NN O
as NN NN O
assessed NN NN O
by NN NN O
autoradiographic NN NN O
analysis NN NN O
of NN NN O
isolated NN NN O
cardiomyocytes NN NN O
, NN NN O
was NN NN O
observed NN NN O
in NN NN O
control NN NN O
or NN NN O
hypertrophic NN NN B-Disease
hearts NN NN I-Disease
. NN NN O
   
A NN NN O
survey NN NN O
of NN NN O
15 NN NN O
independent NN NN O
inbred NN NN O
strains NN NN O
of NN NN O
mice NN NN O
revealed NN NN O
that NN NN O
ventricular NN NN O
cardiomyocyte NN NN O
nuclear NN NN O
number NN NN O
ranged NN NN O
from NN NN O
3 NN NN O
to NN NN O
13 NN NN O
% NN NN O
mononucleate NN NN O
, NN NN O
suggesting NN NN O
that NN NN O
cardiomyocyte NN NN O
terminal NN NN O
differentiation NN NN O
is NN NN O
influenced NN NN O
directly NN NN O
or NN NN O
indirectly NN NN O
by NN NN O
genetic NN NN O
background NN NN O
. NN NN O
   
To NN NN O
determine NN NN O
whether NN NN O
the NN NN O
capacity NN NN O
for NN NN O
reactive NN NN O
DNA NN NN O
synthesis NN NN O
was NN NN O
also NN NN O
subject NN NN O
to NN NN O
genetic NN NN O
regulation NN NN O
, NN NN O
cardiac NN NN B-Disease
hypertrophy NN NN I-Disease
was NN NN O
induced NN NN O
in NN NN O
the NN NN O
strains NN NN O
of NN NN O
mice NN NN O
comprising NN NN O
the NN NN O
extremes NN NN O
of NN NN O
the NN NN O
nuclear NN NN O
number NN NN O
survey NN NN O
. NN NN O
   
These NN NN O
data NN NN O
indicate NN NN O
that NN NN O
adult NN NN O
mouse NN NN O
atrial NN NN O
and NN NN O
ventricular NN NN O
cardiomyocytes NN NN O
do NN NN O
not NN NN O
synthesize NN NN O
DNA NN NN O
in NN NN O
response NN NN O
to NN NN O
isoproterenol NN NN O
- NN NN O
induced NN NN O
cardiac NN NN B-Disease
hypertrophy NN NN I-Disease
. NN NN O
   
Central NN NN O
cardiovascular NN NN O
effects NN NN O
of NN NN O
AVP NN NN O
and NN NN O
ANP NN NN O
in NN NN O
normotensive NN NN O
and NN NN O
spontaneously NN NN O
hypertensive NN NN B-Disease
rats NN NN O
. NN NN O
   
The NN NN O
purpose NN NN O
of NN NN O
the NN NN O
present NN NN O
study NN NN O
was NN NN O
to NN NN O
compare NN NN O
influence NN NN O
of NN NN O
central NN NN O
arginine NN NN O
vasopressin NN NN O
( NN NN O
AVP NN NN O
) NN NN O
and NN NN O
of NN NN O
atrial NN NN O
natriuretic NN NN O
peptide NN NN O
( NN NN O
ANP NN NN O
) NN NN O
on NN NN O
control NN NN O
of NN NN O
arterial NN NN O
blood NN NN O
pressure NN NN O
( NN NN O
MAP NN NN O
) NN NN O
and NN NN O
heart NN NN O
rate NN NN O
( NN NN O
HR NN NN O
) NN NN O
in NN NN O
normotensive NN NN O
( NN NN O
WKY NN NN O
) NN NN O
and NN NN O
spontaneously NN NN O
hypertensive NN NN B-Disease
( NN NN O
SHR NN NN O
) NN NN O
rats NN NN O
. NN NN O
   
Three NN NN O
series NN NN O
of NN NN O
experiments NN NN O
were NN NN O
performed NN NN O
on NN NN O
30 NN NN O
WKY NN NN O
and NN NN O
30 NN NN O
SHR NN NN O
, NN NN O
chronically NN NN O
instrumented NN NN O
with NN NN O
guide NN NN O
tubes NN NN O
in NN NN O
the NN NN O
lateral NN NN O
ventricle NN NN O
( NN NN O
LV NN NN O
) NN NN O
and NN NN O
arterial NN NN O
and NN NN O
venous NN NN O
catheters NN NN O
. NN NN O
   
MAP NN NN O
and NN NN O
HR NN NN O
were NN NN O
monitored NN NN O
before NN NN O
and NN NN O
after NN NN O
i NN NN O
. NN NN O
v NN NN O
. NN NN O
injections NN NN O
of NN NN O
either NN NN O
vehicle NN NN O
or NN NN O
1 NN NN O
, NN NN O
10 NN NN O
and NN NN O
50 NN NN O
ng NN NN O
of NN NN O
AVP NN NN O
and NN NN O
25 NN NN O
, NN NN O
125 NN NN O
and NN NN O
500 NN NN O
ng NN NN O
of NN NN O
ANP NN NN O
. NN NN O
   
Sensitivity NN NN O
of NN NN O
cardiac NN NN O
component NN NN O
of NN NN O
baroreflex NN NN O
( NN NN O
CCB NN NN O
) NN NN O
, NN NN O
expressed NN NN O
as NN NN O
a NN NN O
slope NN NN O
of NN NN O
the NN NN O
regression NN NN O
line NN NN O
was NN NN O
determined NN NN O
from NN NN O
relationships NN NN O
between NN NN O
systolic NN NN O
arterial NN NN O
pressure NN NN O
( NN NN O
SAP NN NN O
) NN NN O
and NN NN O
HR NN NN O
period NN NN O
( NN NN O
HRp NN NN O
) NN NN O
during NN NN O
phenylephrine NN NN O
( NN NN O
Phe NN NN O
) NN NN O
- NN NN O
induced NN NN O
hypertension NN NN B-Disease
and NN NN O
sodium NN NN O
nitroprusside NN NN O
( NN NN O
SN NN NN O
) NN NN O
- NN NN O
induced NN NN O
hypotension NN NN B-Disease
. NN NN O
   
CCB NN NN O
was NN NN O
measured NN NN O
before NN NN O
and NN NN O
after NN NN O
administration NN NN O
of NN NN O
either NN NN O
vehicle NN NN O
, NN NN O
AVP NN NN O
, NN NN O
ANP NN NN O
, NN NN O
or NN NN O
both NN NN O
peptides NN NN O
together NN NN O
. NN NN O
   
Increases NN NN O
of NN NN O
MAP NN NN O
occurred NN NN O
after NN NN O
LV NN NN O
administration NN NN O
of NN NN O
1 NN NN O
, NN NN O
10 NN NN O
and NN NN O
50 NN NN O
ng NN NN O
of NN NN O
AVP NN NN O
in NN NN O
WKY NN NN O
and NN NN O
of NN NN O
10 NN NN O
and NN NN O
50 NN NN O
ng NN NN O
in NN NN O
SHR NN NN O
. NN NN O
   
ANP NN NN O
did NN NN O
not NN NN O
cause NN NN O
significant NN NN O
changes NN NN O
in NN NN O
MAP NN NN O
in NN NN O
both NN NN O
strains NN NN O
as NN NN O
compared NN NN O
to NN NN O
vehicle NN NN O
, NN NN O
but NN NN O
it NN NN O
abolished NN NN O
AVP NN NN O
- NN NN O
induced NN NN O
MAP NN NN O
increase NN NN O
in NN NN O
WKY NN NN O
and NN NN O
SHR NN NN O
. NN NN O
   
CCB NN NN O
was NN NN O
reduced NN NN O
in NN NN O
WKY NN NN O
and NN NN O
SHR NN NN O
after NN NN O
LV NN NN O
administration NN NN O
of NN NN O
AVP NN NN O
during NN NN O
SN NN NN O
- NN NN O
induced NN NN O
hypotension NN NN B-Disease
. NN NN O
   
In NN NN O
SHR NN NN O
but NN NN O
not NN NN O
in NN NN O
WKY NN NN O
administration NN NN O
of NN NN O
ANP NN NN O
, NN NN O
AVP NN NN O
and NN NN O
ANP NN NN O
+ NN NN O
AVP NN NN O
decreased NN NN O
CCB NN NN O
during NN NN O
Phe NN NN O
- NN NN O
induced NN NN O
MAP NN NN O
elevation NN NN O
. NN NN O
   
The NN NN O
results NN NN O
indicate NN NN O
that NN NN O
centrally NN NN O
applied NN NN O
AVP NN NN O
and NN NN O
ANP NN NN O
exert NN NN O
differential NN NN O
effects NN NN O
on NN NN O
blood NN NN O
pressure NN NN O
and NN NN O
baroreflex NN NN O
control NN NN O
of NN NN O
heart NN NN O
rate NN NN O
in NN NN O
WKY NN NN O
and NN NN O
SHR NN NN O
and NN NN O
suggest NN NN O
interaction NN NN O
of NN NN O
these NN NN O
two NN NN O
peptides NN NN O
in NN NN O
blood NN NN O
pressure NN NN O
regulation NN NN O
at NN NN O
the NN NN O
level NN NN O
of NN NN O
central NN NN O
nervous NN NN O
system NN NN O
. NN NN O
   
Cutaneous NN NN O
exposure NN NN O
to NN NN O
warfarin NN NN O
- NN NN O
like NN NN O
anticoagulant NN NN O
causing NN NN O
an NN NN O
intracerebral NN NN B-Disease
hemorrhage NN NN I-Disease
: NN NN O
a NN NN O
case NN NN O
report NN NN O
. NN NN O
   
A NN NN O
case NN NN O
of NN NN O
intercerebral NN NN O
hematoma NN NN B-Disease
due NN NN O
to NN NN O
warfarin NN NN O
- NN NN O
induced NN NN O
coagulopathy NN NN B-Disease
is NN NN O
presented NN NN O
. NN NN O
   
The NN NN O
39 NN NN O
- NN NN O
year NN NN O
- NN NN O
old NN NN O
woman NN NN O
had NN NN O
spread NN NN O
a NN NN O
warfarin NN NN O
- NN NN O
type NN NN O
rat NN NN O
poison NN NN O
around NN NN O
her NN NN O
house NN NN O
weekly NN NN O
using NN NN O
her NN NN O
bare NN NN O
hands NN NN O
, NN NN O
with NN NN O
no NN NN O
washing NN NN O
post NN NN O
application NN NN O
. NN NN O
   
Percutaneous NN NN O
absorption NN NN O
of NN NN O
warfarin NN NN O
causing NN NN O
coagulopathy NN NN B-Disease
, NN NN O
reported NN NN O
three NN NN O
times NN NN O
in NN NN O
the NN NN O
past NN NN O
, NN NN O
is NN NN O
a NN NN O
significant NN NN O
risk NN NN O
if NN NN O
protective NN NN O
measures NN NN O
, NN NN O
such NN NN O
as NN NN O
gloves NN NN O
, NN NN O
are NN NN O
not NN NN O
used NN NN O
. NN NN O
   
An NN NN O
adverse NN NN O
drug NN NN O
interaction NN NN O
with NN NN O
piroxicam NN NN O
, NN NN O
which NN NN O
she NN NN O
took NN NN O
occasionally NN NN O
, NN NN O
may NN NN O
have NN NN O
exacerbated NN NN O
the NN NN O
coagulopathy NN NN B-Disease
. NN NN O
   
Pediatric NN NN O
heart NN NN O
transplantation NN NN O
without NN NN O
chronic NN NN O
maintenance NN NN O
steroids NN NN O
. NN NN O
   
From NN NN O
1986 NN NN O
to NN NN O
February NN NN O
1993 NN NN O
, NN NN O
40 NN NN O
children NN NN O
aged NN NN O
2 NN NN O
months NN NN O
to NN NN O
18 NN NN O
years NN NN O
( NN NN O
average NN NN O
age NN NN O
10 NN NN O
. NN NN O
4 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
5 NN NN O
. NN NN O
8 NN NN O
years NN NN O
) NN NN O
underwent NN NN O
heart NN NN O
transplantation NN NN O
. NN NN O
   
Indications NN NN O
for NN NN O
transplantation NN NN O
were NN NN O
idiopathic NN NN B-Disease
cardiomyopathy NN NN I-Disease
( NN NN O
52 NN NN O
% NN NN O
) NN NN O
, NN NN O
congenital NN NN B-Disease
heart NN NN I-Disease
disease NN NN I-Disease
( NN NN O
35 NN NN O
% NN NN O
) NN NN O
with NN NN O
and NN NN O
without NN NN O
prior NN NN O
repair NN NN O
( NN NN O
71 NN NN O
% NN NN O
and NN NN O
29 NN NN O
% NN NN O
, NN NN O
respectively NN NN O
) NN NN O
, NN NN O
hypertrophic NN NN B-Disease
cardiomyopathy NN NN I-Disease
( NN NN O
5 NN NN O
% NN NN O
) NN NN O
, NN NN O
valvular NN NN B-Disease
heart NN NN I-Disease
disease NN NN I-Disease
( NN NN O
3 NN NN O
% NN NN O
) NN NN O
, NN NN O
and NN NN O
doxorubicin NN NN O
cardiomyopathy NN NN B-Disease
( NN NN O
5 NN NN O
% NN NN O
) NN NN O
. NN NN O
   
Patients NN NN O
were NN NN O
managed NN NN O
with NN NN O
cyclosporine NN NN O
and NN NN O
azathioprine NN NN O
. NN NN O
   
No NN NN O
prophylaxis NN NN O
with NN NN O
antilymphocyte NN NN O
globulin NN NN O
was NN NN O
used NN NN O
. NN NN O
   
Steroids NN NN O
were NN NN O
given NN NN O
to NN NN O
39 NN NN O
% NN NN O
of NN NN O
patients NN NN O
for NN NN O
refractory NN NN O
rejection NN NN O
, NN NN O
but NN NN O
weaning NN NN O
was NN NN O
always NN NN O
attempted NN NN O
and NN NN O
generally NN NN O
successful NN NN O
( NN NN O
64 NN NN O
% NN NN O
) NN NN O
. NN NN O
   
Five NN NN O
patients NN NN O
( NN NN O
14 NN NN O
% NN NN O
) NN NN O
received NN NN O
maintenance NN NN O
steroids NN NN O
. NN NN O
   
Four NN NN O
patients NN NN O
died NN NN O
in NN NN O
the NN NN O
perioperative NN NN O
period NN NN O
and NN NN O
one NN NN O
died NN NN O
4 NN NN O
months NN NN O
later NN NN O
. NN NN O
   
There NN NN O
have NN NN O
been NN NN O
no NN NN O
deaths NN NN O
related NN NN O
to NN NN O
rejection NN NN O
or NN NN O
infection NN NN B-Disease
. NN NN O
   
Average NN NN O
follow NN NN O
- NN NN O
up NN NN O
was NN NN O
36 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
19 NN NN O
months NN NN O
( NN NN O
range NN NN O
1 NN NN O
to NN NN O
65 NN NN O
months NN NN O
) NN NN O
. NN NN O
   
Cumulative NN NN O
survival NN NN O
is NN NN O
88 NN NN O
% NN NN O
at NN NN O
5 NN NN O
years NN NN O
. NN NN O
   
In NN NN O
patients NN NN O
less NN NN O
than NN NN O
7 NN NN O
years NN NN O
of NN NN O
age NN NN O
, NN NN O
rejection NN NN O
was NN NN O
monitored NN NN O
noninvasively NN NN O
. NN NN O
   
In NN NN O
the NN NN O
first NN NN O
postoperative NN NN O
month NN NN O
, NN NN O
89 NN NN O
% NN NN O
of NN NN O
patients NN NN O
were NN NN O
treated NN NN O
for NN NN O
rejection NN NN O
. NN NN O
   
Freedom NN NN O
from NN NN O
serious NN NN O
infections NN NN B-Disease
was NN NN O
83 NN NN O
% NN NN O
at NN NN O
1 NN NN O
month NN NN O
and NN NN O
65 NN NN O
% NN NN O
at NN NN O
1 NN NN O
year NN NN O
. NN NN O
   
Cytomegalovirus NN NN B-Disease
infections NN NN I-Disease
were NN NN O
treated NN NN O
successfully NN NN O
with NN NN O
ganciclovir NN NN O
in NN NN O
11 NN NN O
patients NN NN O
. NN NN O
   
No NN NN O
impairment NN NN O
of NN NN O
growth NN NN O
was NN NN O
observed NN NN O
in NN NN O
children NN NN O
who NN NN O
underwent NN NN O
transplantation NN NN O
compared NN NN O
with NN NN O
a NN NN O
control NN NN O
population NN NN O
. NN NN O
   
Twenty NN NN O
- NN NN O
one NN NN O
patients NN NN O
( NN NN O
60 NN NN O
% NN NN O
) NN NN O
have NN NN O
undergone NN NN O
annual NN NN O
catheterizations NN NN O
and NN NN O
no NN NN O
sign NN NN O
of NN NN O
graft NN NN O
atherosclerosis NN NN B-Disease
has NN NN O
been NN NN O
observed NN NN O
. NN NN O
   
Seizures NN NN B-Disease
occurred NN NN O
in NN NN O
five NN NN O
patients NN NN O
( NN NN O
14 NN NN O
% NN NN O
) NN NN O
and NN NN O
hypertension NN NN B-Disease
was NN NN O
treated NN NN O
in NN NN O
10 NN NN O
patients NN NN O
( NN NN O
28 NN NN O
% NN NN O
) NN NN O
. NN NN O
   
No NN NN O
patient NN NN O
was NN NN O
disabled NN NN O
and NN NN O
no NN NN O
lymphoproliferative NN NN B-Disease
disorder NN NN I-Disease
was NN NN O
observed NN NN O
. NN NN O
( NN NN O
ABSTRACT NN NN O
TRUNCATED NN NN O
AT NN NN O
250 NN NN O
WORDS NN NN O
) NN NN O
   
Delirium NN NN B-Disease
during NN NN O
fluoxetine NN NN O
treatment NN NN O
. NN NN O
   
A NN NN O
case NN NN O
report NN NN O
. NN NN O
   
The NN NN O
correlation NN NN O
between NN NN O
high NN NN O
serum NN NN O
tricyclic NN NN O
antidepressant NN NN O
concentrations NN NN O
and NN NN O
central NN NN O
nervous NN NN O
system NN NN O
side NN NN O
effects NN NN O
has NN NN O
been NN NN O
well NN NN O
established NN NN O
. NN NN O
   
Only NN NN O
a NN NN O
few NN NN O
reports NN NN O
exist NN NN O
, NN NN O
however NN NN O
, NN NN O
on NN NN O
the NN NN O
relationship NN NN O
between NN NN O
the NN NN O
serum NN NN O
concentrations NN NN O
of NN NN O
selective NN NN O
serotonin NN NN O
reuptake NN NN O
inhibitors NN NN O
( NN NN O
SSRIs NN NN O
) NN NN O
and NN NN O
their NN NN O
toxic NN NN O
effects NN NN O
. NN NN O
   
In NN NN O
some NN NN O
cases NN NN O
, NN NN O
a NN NN O
high NN NN O
serum NN NN O
concentration NN NN O
of NN NN O
citalopram NN NN O
( NN NN O
> NN NN O
600 NN NN O
nmol NN NN O
/ NN NN O
L NN NN O
) NN NN O
in NN NN O
elderly NN NN O
patients NN NN O
has NN NN O
been NN NN O
associated NN NN O
with NN NN O
increased NN NN O
somnolence NN NN B-Disease
and NN NN O
movement NN NN B-Disease
difficulties NN NN I-Disease
. NN NN O
   
Widespread NN NN O
cognitive NN NN B-Disease
disorders NN NN I-Disease
, NN NN O
such NN NN O
as NN NN O
delirium NN NN B-Disease
, NN NN O
have NN NN O
not NN NN O
been NN NN O
previously NN NN O
linked NN NN O
with NN NN O
high NN NN O
blood NN NN O
levels NN NN O
of NN NN O
SSRIs NN NN O
. NN NN O
   
In NN NN O
this NN NN O
report NN NN O
, NN NN O
we NN NN O
describe NN NN O
a NN NN O
patient NN NN O
with NN NN O
acute NN NN O
hyperkinetic NN NN B-Disease
delirium NN NN B-Disease
connected NN NN O
with NN NN O
a NN NN O
high NN NN O
serum NN NN O
total NN NN O
fluoxetine NN NN O
( NN NN O
fluoxetine NN NN O
plus NN NN O
desmethylfluoxetine NN NN O
) NN NN O
concentration NN NN O
. NN NN O
   
Pulmonary NN NN B-Disease
edema NN NN I-Disease
and NN NN O
shock NN NN B-Disease
after NN NN O
high NN NN O
- NN NN O
dose NN NN O
aracytine NN NN O
- NN NN O
C NN NN O
for NN NN O
lymphoma NN NN B-Disease
; NN NN O
possible NN NN O
role NN NN O
of NN NN O
TNF NN NN O
- NN NN O
alpha NN NN O
and NN NN O
PAF NN NN O
. NN NN O
   
Four NN NN O
out NN NN O
of NN NN O
23 NN NN O
consecutive NN NN O
patients NN NN O
treated NN NN O
with NN NN O
high NN NN O
- NN NN O
dose NN NN O
Ara NN NN O
- NN NN O
C NN NN O
for NN NN O
lymphomas NN NN B-Disease
in NN NN O
our NN NN O
institution NN NN O
developed NN NN O
a NN NN O
strikingly NN NN O
similar NN NN O
syndrome NN NN O
during NN NN O
the NN NN O
perfusion NN NN O
. NN NN O
   
It NN NN O
was NN NN O
characterized NN NN O
by NN NN O
the NN NN O
onset NN NN O
of NN NN O
fever NN NN B-Disease
, NN NN O
diarrhea NN NN B-Disease
, NN NN O
shock NN NN B-Disease
, NN NN O
pulmonary NN NN B-Disease
edema NN NN I-Disease
, NN NN O
acute NN NN B-Disease
renal NN NN I-Disease
failure NN NN I-Disease
, NN NN O
metabolic NN NN B-Disease
acidosis NN NN I-Disease
, NN NN O
weight NN NN B-Disease
gain NN NN I-Disease
and NN NN O
leukocytosis NN NN B-Disease
. NN NN O
   
Thorough NN NN O
bacteriological NN NN O
screening NN NN O
failed NN NN O
to NN NN O
provide NN NN O
evidence NN NN O
of NN NN O
infection NN NN B-Disease
. NN NN O
   
Sequential NN NN O
biological NN NN O
assays NN NN O
of NN NN O
IL NN NN O
- NN NN O
1 NN NN O
, NN NN O
IL NN NN O
- NN NN O
2 NN NN O
, NN NN O
TNF NN NN O
and NN NN O
PAF NN NN O
were NN NN O
performed NN NN O
during NN NN O
Ara NN NN O
- NN NN O
C NN NN O
infusion NN NN O
to NN NN O
ten NN NN O
patients NN NN O
, NN NN O
including NN NN O
the NN NN O
four NN NN O
who NN NN O
developed NN NN O
the NN NN O
syndrome NN NN O
. NN NN O
   
TNF NN NN O
and NN NN O
PAF NN NN O
activity NN NN O
was NN NN O
found NN NN O
in NN NN O
the NN NN O
serum NN NN O
of NN NN O
respectively NN NN O
two NN NN O
and NN NN O
four NN NN O
of NN NN O
the NN NN O
cases NN NN O
, NN NN O
but NN NN O
not NN NN O
in NN NN O
the NN NN O
six NN NN O
controls NN NN O
. NN NN O
   
As NN NN O
TNF NN NN O
and NN NN O
PAF NN NN O
are NN NN O
thought NN NN O
to NN NN O
be NN NN O
involved NN NN O
in NN NN O
the NN NN O
development NN NN O
of NN NN O
septic NN NN O
shock NN NN B-Disease
and NN NN O
adult NN NN B-Disease
respiratory NN NN I-Disease
distress NN NN I-Disease
syndrome NN NN I-Disease
, NN NN O
we NN NN O
hypothesize NN NN O
that NN NN O
high NN NN O
- NN NN O
dose NN NN O
Ara NN NN O
- NN NN O
C NN NN O
may NN NN O
be NN NN O
associated NN NN O
with NN NN O
cytokine NN NN O
release NN NN O
. NN NN O
   
Protective NN NN O
effect NN NN O
of NN NN O
clentiazem NN NN O
against NN NN O
epinephrine NN NN O
- NN NN O
induced NN NN O
cardiac NN NN B-Disease
injury NN NN I-Disease
in NN NN O
rats NN NN O
. NN NN O
   
We NN NN O
investigated NN NN O
the NN NN O
effects NN NN O
of NN NN O
clentiazem NN NN O
, NN NN O
a NN NN O
1 NN NN O
, NN NN O
5 NN NN O
- NN NN O
benzothiazepine NN NN O
calcium NN NN O
antagonist NN NN O
, NN NN O
on NN NN O
epinephrine NN NN O
- NN NN O
induced NN NN O
cardiomyopathy NN NN B-Disease
in NN NN O
rats NN NN O
. NN NN O
   
With NN NN O
2 NN NN O
- NN NN O
week NN NN O
chronic NN NN O
epinephrine NN NN O
infusion NN NN O
, NN NN O
16 NN NN O
of NN NN O
30 NN NN O
rats NN NN O
died NN NN O
within NN NN O
4 NN NN O
days NN NN O
, NN NN O
and NN NN O
severe NN NN O
ischemic NN NN B-Disease
lesions NN NN I-Disease
and NN NN O
fibrosis NN NN B-Disease
of NN NN O
the NN NN O
left NN NN O
ventricles NN NN O
were NN NN O
observed NN NN O
. NN NN O
   
In NN NN O
epinephrine NN NN O
- NN NN O
treated NN NN O
rats NN NN O
, NN NN O
left NN NN O
atrial NN NN O
and NN NN O
left NN NN O
ventricular NN NN O
papillary NN NN O
muscle NN NN O
contractile NN NN O
responses NN NN O
to NN NN O
isoproterenol NN NN O
were NN NN O
reduced NN NN O
, NN NN O
but NN NN O
responses NN NN O
to NN NN O
calcium NN NN O
were NN NN O
normal NN NN O
or NN NN O
enhanced NN NN O
compared NN NN O
to NN NN O
controls NN NN O
. NN NN O
   
Left NN NN O
ventricular NN NN O
alpha NN NN O
and NN NN O
beta NN NN O
adrenoceptor NN NN O
densities NN NN O
were NN NN O
also NN NN O
reduced NN NN O
compared NN NN O
to NN NN O
controls NN NN O
. NN NN O
   
Treatment NN NN O
with NN NN O
clentiazem NN NN O
prevented NN NN O
epinephrine NN NN O
- NN NN O
induced NN NN O
death NN NN O
( NN NN O
P NN NN O
< NN NN O
. NN NN O
05 NN NN O
) NN NN O
, NN NN O
and NN NN O
attenuated NN NN O
the NN NN O
ventricular NN NN O
ischemic NN NN B-Disease
lesions NN NN I-Disease
and NN NN O
fibrosis NN NN B-Disease
, NN NN O
in NN NN O
a NN NN O
dose NN NN O
- NN NN O
dependent NN NN O
manner NN NN O
. NN NN O
   
Left NN NN O
atrial NN NN O
and NN NN O
left NN NN O
ventricular NN NN O
papillary NN NN O
muscle NN NN O
contractile NN NN O
responses NN NN O
to NN NN O
isoproterenol NN NN O
were NN NN O
reduced NN NN O
compared NN NN O
to NN NN O
controls NN NN O
in NN NN O
groups NN NN O
treated NN NN O
with NN NN O
clentiazem NN NN O
alone NN NN O
, NN NN O
but NN NN O
combined NN NN O
with NN NN O
epinephrine NN NN O
, NN NN O
clentiazem NN NN O
restored NN NN O
left NN NN O
atrial NN NN O
responses NN NN O
and NN NN O
enhanced NN NN O
left NN NN O
ventricular NN NN O
papillary NN NN O
responses NN NN O
to NN NN O
isoproterenol NN NN O
. NN NN O
   
On NN NN O
the NN NN O
other NN NN O
hand NN NN O
clentiazem NN NN O
did NN NN O
not NN NN O
prevent NN NN O
epinephrine NN NN O
- NN NN O
induced NN NN O
down NN NN O
- NN NN O
regulation NN NN O
of NN NN O
alpha NN NN O
and NN NN O
beta NN NN O
adrenoceptors NN NN O
. NN NN O
   
Interestingly NN NN O
, NN NN O
clentiazem NN NN O
, NN NN O
infused NN NN O
alone NN NN O
, NN NN O
resulted NN NN O
in NN NN O
decreased NN NN O
adrenergic NN NN O
receptor NN NN O
densities NN NN O
in NN NN O
the NN NN O
left NN NN O
ventricle NN NN O
. NN NN O
   
Clentiazem NN NN O
also NN NN O
did NN NN O
not NN NN O
prevent NN NN O
the NN NN O
enhanced NN NN O
responses NN NN O
to NN NN O
calcium NN NN O
seen NN NN O
in NN NN O
the NN NN O
epinephrine NN NN O
- NN NN O
treated NN NN O
animals NN NN O
, NN NN O
although NN NN O
the NN NN O
high NN NN O
dose NN NN O
of NN NN O
clentiazem NN NN O
partially NN NN O
attenuated NN NN O
the NN NN O
maximal NN NN O
response NN NN O
to NN NN O
calcium NN NN O
compared NN NN O
to NN NN O
epinephrine NN NN O
- NN NN O
treated NN NN O
animals NN NN O
. NN NN O
   
In NN NN O
conclusion NN NN O
, NN NN O
clentiazem NN NN O
attenuated NN NN O
epinephrine NN NN O
- NN NN O
induced NN NN O
cardiac NN NN B-Disease
injury NN NN I-Disease
, NN NN O
possibly NN NN O
through NN NN O
its NN NN O
effect NN NN O
on NN NN O
the NN NN O
adrenergic NN NN O
pathway NN NN O
. NN NN O
   
Kaliuretic NN NN O
effect NN NN O
of NN NN O
L NN NN O
- NN NN O
dopa NN NN O
treatment NN NN O
in NN NN O
parkinsonian NN NN B-Disease
patients NN NN O
. NN NN O
   
Hypokalemia NN NN B-Disease
, NN NN O
sometimes NN NN O
severe NN NN O
, NN NN O
was NN NN O
observed NN NN O
in NN NN O
some NN NN O
L NN NN O
- NN NN O
dopa NN NN O
- NN NN O
treated NN NN O
parkinsonian NN NN B-Disease
patients NN NN O
. NN NN O
   
The NN NN O
influence NN NN O
of NN NN O
L NN NN O
- NN NN O
dopa NN NN O
on NN NN O
the NN NN O
renal NN NN O
excretion NN NN O
of NN NN O
potassium NN NN O
was NN NN O
studied NN NN O
in NN NN O
3 NN NN O
patients NN NN O
with NN NN O
hypokalemia NN NN B-Disease
and NN NN O
in NN NN O
5 NN NN O
normokalemic NN NN O
patients NN NN O
by NN NN O
determination NN NN O
of NN NN O
renal NN NN O
plasma NN NN O
flow NN NN O
, NN NN O
glomerular NN NN O
filtration NN NN O
rate NN NN O
, NN NN O
plasma NN NN O
concentration NN NN O
of NN NN O
potassium NN NN O
and NN NN O
sodium NN NN O
as NN NN O
well NN NN O
as NN NN O
urinary NN NN O
excretion NN NN O
of NN NN O
potassium NN NN O
, NN NN O
sodium NN NN O
and NN NN O
aldosterone NN NN O
. NN NN O
   
L NN NN O
- NN NN O
Dopa NN NN O
intake NN NN O
was NN NN O
found NN NN O
to NN NN O
cause NN NN O
an NN NN O
increased NN NN O
excretion NN NN O
of NN NN O
potassium NN NN O
, NN NN O
and NN NN O
sometimes NN NN O
also NN NN O
of NN NN O
sodium NN NN O
, NN NN O
in NN NN O
the NN NN O
hypokalemic NN NN O
but NN NN O
not NN NN O
in NN NN O
the NN NN O
normokalemic NN NN O
patients NN NN O
. NN NN O
   
This NN NN O
effect NN NN O
on NN NN O
the NN NN O
renal NN NN O
function NN NN O
could NN NN O
be NN NN O
prohibited NN NN O
by NN NN O
the NN NN O
administration NN NN O
of NN NN O
a NN NN O
peripheral NN NN O
dopa NN NN O
decarbodylase NN NN O
inhibitor NN NN O
. NN NN O
   
It NN NN O
is NN NN O
not NN NN O
known NN NN O
why NN NN O
this NN NN O
effect NN NN O
occurred NN NN O
in NN NN O
some NN NN O
individuals NN NN O
but NN NN O
not NN NN O
in NN NN O
others NN NN O
, NN NN O
but NN NN O
our NN NN O
results NN NN O
indicate NN NN O
a NN NN O
correlation NN NN O
between NN NN O
aldosterone NN NN O
production NN NN O
and NN NN O
this NN NN O
renal NN NN O
effect NN NN O
of NN NN O
L NN NN O
- NN NN O
dopa NN NN O
. NN NN O
   
Cocaine NN NN O
induced NN NN O
myocardial NN NN B-Disease
ischemia NN NN I-Disease
. NN NN O
   
We NN NN O
report NN NN O
a NN NN O
case NN NN O
of NN NN O
myocardial NN NN B-Disease
ischemia NN NN I-Disease
induced NN NN O
by NN NN O
cocaine NN NN O
. NN NN O
   
The NN NN O
ischemia NN NN B-Disease
probably NN NN O
induced NN NN O
by NN NN O
coronary NN NN B-Disease
artery NN NN I-Disease
spasm NN NN I-Disease
was NN NN O
reversed NN NN O
by NN NN O
nitroglycerin NN NN O
and NN NN O
calcium NN NN O
blocking NN NN O
agents NN NN O
. NN NN O
   
Doxorubicin NN NN O
- NN NN O
induced NN NN O
cardiotoxicity NN NN B-Disease
monitored NN NN O
by NN NN O
ECG NN NN O
in NN NN O
freely NN NN O
moving NN NN O
mice NN NN O
. NN NN O
   
A NN NN O
new NN NN O
model NN NN O
to NN NN O
test NN NN O
potential NN NN O
protectors NN NN O
. NN NN O
   
In NN NN O
laboratory NN NN O
animals NN NN O
, NN NN O
histology NN NN O
is NN NN O
most NN NN O
commonly NN NN O
used NN NN O
to NN NN O
study NN NN O
doxorubicin NN NN O
- NN NN O
induced NN NN O
cardiotoxicity NN NN B-Disease
. NN NN O
   
However NN NN O
, NN NN O
for NN NN O
monitoring NN NN O
during NN NN O
treatment NN NN O
, NN NN O
large NN NN O
numbers NN NN O
of NN NN O
animals NN NN O
are NN NN O
needed NN NN O
. NN NN O
   
Recently NN NN O
we NN NN O
developed NN NN O
a NN NN O
new NN NN O
method NN NN O
to NN NN O
measure NN NN O
ECG NN NN O
values NN NN O
in NN NN O
freely NN NN O
moving NN NN O
mice NN NN O
by NN NN O
telemetry NN NN O
. NN NN O
   
With NN NN O
this NN NN O
model NN NN O
we NN NN O
investigated NN NN O
the NN NN O
effect NN NN O
of NN NN O
chronic NN NN O
doxorubicin NN NN O
administration NN NN O
on NN NN O
the NN NN O
ECG NN NN O
of NN NN O
freely NN NN O
moving NN NN O
BALB NN NN O
/ NN NN O
c NN NN O
mice NN NN O
and NN NN O
the NN NN O
efficacy NN NN O
of NN NN O
ICRF NN NN O
- NN NN O
187 NN NN O
as NN NN O
a NN NN O
protective NN NN O
agent NN NN O
. NN NN O
   
The NN NN O
ST NN NN O
interval NN NN O
significantly NN NN O
widened NN NN O
from NN NN O
15 NN NN O
. NN NN O
0 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
1 NN NN O
. NN NN O
5 NN NN O
to NN NN O
56 NN NN O
. NN NN O
8 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
11 NN NN O
. NN NN O
8 NN NN O
ms NN NN O
in NN NN O
week NN NN O
10 NN NN O
( NN NN O
7 NN NN O
weekly NN NN O
doses NN NN O
of NN NN O
4 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
doxorubicin NN NN O
given NN NN O
i NN NN O
. NN NN O
v NN NN O
. NN NN O
plus NN NN O
3 NN NN O
weeks NN NN O
of NN NN O
observation NN NN O
) NN NN O
. NN NN O
   
The NN NN O
ECG NN NN O
of NN NN O
the NN NN O
control NN NN O
animals NN NN O
did NN NN O
not NN NN O
change NN NN O
during NN NN O
the NN NN O
entire NN NN O
study NN NN O
. NN NN O
   
After NN NN O
sacrifice NN NN O
the NN NN O
hearts NN NN O
of NN NN O
doxorubicin NN NN O
- NN NN O
treated NN NN O
animals NN NN O
were NN NN O
enlarged NN NN O
and NN NN O
the NN NN O
atria NN NN O
were NN NN O
hypertrophic NN NN B-Disease
. NN NN O
   
As NN NN O
this NN NN O
schedule NN NN O
exerted NN NN O
more NN NN O
toxicity NN NN B-Disease
than NN NN O
needed NN NN O
to NN NN O
investigate NN NN O
protective NN NN O
agents NN NN O
, NN NN O
the NN NN O
protection NN NN O
of NN NN O
ICRF NN NN O
- NN NN O
187 NN NN O
was NN NN O
determined NN NN O
using NN NN O
a NN NN O
dose NN NN O
schedule NN NN O
with NN NN O
lower NN NN O
general NN NN O
toxicity NN NN B-Disease
( NN NN O
6 NN NN O
weekly NN NN O
doses NN NN O
of NN NN O
4 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
doxorubicin NN NN O
given NN NN O
i NN NN O
. NN NN O
v NN NN O
. NN NN O
plus NN NN O
2 NN NN O
weeks NN NN O
of NN NN O
observation NN NN O
) NN NN O
. NN NN O
   
On NN NN O
this NN NN O
schedule NN NN O
, NN NN O
the NN NN O
animals NN NN O
' NN NN O
hearts NN NN O
appeared NN NN O
normal NN NN O
after NN NN O
sacrifice NN NN O
and NN NN O
ICRF NN NN O
- NN NN O
187 NN NN O
( NN NN O
50 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
given NN NN O
i NN NN O
. NN NN O
p NN NN O
. NN NN O
1 NN NN O
h NN NN O
before NN NN O
doxorubicin NN NN O
) NN NN O
provided NN NN O
almost NN NN O
full NN NN O
protection NN NN O
. NN NN O
   
These NN NN O
data NN NN O
were NN NN O
confirmed NN NN O
by NN NN O
histology NN NN O
. NN NN O
   
The NN NN O
results NN NN O
indicate NN NN O
that NN NN O
this NN NN O
new NN NN O
model NN NN O
is NN NN O
very NN NN O
sensitive NN NN O
and NN NN O
enables NN NN O
monitoring NN NN O
of NN NN O
the NN NN O
development NN NN O
of NN NN O
cardiotoxicity NN NN B-Disease
with NN NN O
time NN NN O
. NN NN O
   
These NN NN O
findings NN NN O
result NN NN O
in NN NN O
a NN NN O
model NN NN O
that NN NN O
allows NN NN O
the NN NN O
testing NN NN O
of NN NN O
protectors NN NN O
against NN NN O
doxorubicin NN NN O
- NN NN O
induced NN NN O
cardiotoxicity NN NN B-Disease
as NN NN O
demonstrated NN NN O
by NN NN O
the NN NN O
protection NN NN O
provided NN NN O
by NN NN O
ICRF NN NN O
- NN NN O
187 NN NN O
. NN NN O
   
Epinephrine NN NN O
dysrhythmogenicity NN NN O
is NN NN O
not NN NN O
enhanced NN NN O
by NN NN O
subtoxic NN NN O
bupivacaine NN NN O
in NN NN O
dogs NN NN O
. NN NN O
   
Since NN NN O
bupivacaine NN NN O
and NN NN O
epinephrine NN NN O
may NN NN O
both NN NN O
precipitate NN NN O
dysrhythmias NN NN B-Disease
, NN NN O
circulating NN NN O
bupivacaine NN NN O
during NN NN O
regional NN NN O
anesthesia NN NN O
could NN NN O
potentiate NN NN O
dysrhythmogenic NN NN O
effects NN NN O
of NN NN O
epinephrine NN NN O
. NN NN O
   
We NN NN O
therefore NN NN O
examined NN NN O
whether NN NN O
bupivacaine NN NN O
alters NN NN O
the NN NN O
dysrhythmogenicity NN NN O
of NN NN O
subsequent NN NN O
administration NN NN O
of NN NN O
epinephrine NN NN O
in NN NN O
conscious NN NN O
, NN NN O
healthy NN NN O
dogs NN NN O
and NN NN O
in NN NN O
anesthetized NN NN O
dogs NN NN O
with NN NN O
myocardial NN NN B-Disease
infarction NN NN I-Disease
. NN NN O
   
Forty NN NN O
- NN NN O
one NN NN O
conscious NN NN O
dogs NN NN O
received NN NN O
10 NN NN O
micrograms NN NN O
. NN NN O
kg NN NN O
- NN NN O
1 NN NN O
. NN NN O
min NN NN O
- NN NN O
1 NN NN O
epinephrine NN NN O
. NN NN O
   
Seventeen NN NN O
animals NN NN O
responded NN NN O
with NN NN O
ventricular NN NN B-Disease
tachycardia NN NN I-Disease
( NN NN O
VT NN NN B-Disease
) NN NN O
within NN NN O
3 NN NN O
min NN NN O
. NN NN O
   
After NN NN O
3 NN NN O
h NN NN O
, NN NN O
these NN NN O
responders NN NN O
randomly NN NN O
received NN NN O
1 NN NN O
or NN NN O
2 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
bupivacaine NN NN O
or NN NN O
saline NN NN O
over NN NN O
5 NN NN O
min NN NN O
, NN NN O
followed NN NN O
by NN NN O
10 NN NN O
micrograms NN NN O
. NN NN O
kg NN NN O
- NN NN O
1 NN NN O
. NN NN O
min NN NN O
- NN NN O
1 NN NN O
epinephrine NN NN O
. NN NN O
   
In NN NN O
the NN NN O
bupivacaine NN NN O
groups NN NN O
, NN NN O
epinephrine NN NN O
caused NN NN O
fewer NN NN O
prodysrhythmic NN NN O
effects NN NN O
than NN NN O
without NN NN O
bupivacaine NN NN O
. NN NN O
   
VT NN NN B-Disease
appeared NN NN O
in NN NN O
fewer NN NN O
dogs NN NN O
and NN NN O
at NN NN O
a NN NN O
later NN NN O
time NN NN O
, NN NN O
and NN NN O
there NN NN O
were NN NN O
more NN NN O
sinoatrial NN NN O
beats NN NN O
and NN NN O
less NN NN O
ectopies NN NN O
. NN NN O
   
Epinephrine NN NN O
shortened NN NN O
QT NN NN O
less NN NN O
after NN NN O
bupivacaine NN NN O
than NN NN O
in NN NN O
control NN NN O
animals NN NN O
. NN NN O
   
One NN NN O
day NN NN O
after NN NN O
experimental NN NN O
myocardial NN NN B-Disease
infarction NN NN I-Disease
, NN NN O
six NN NN O
additional NN NN O
halothane NN NN O
- NN NN O
anesthetized NN NN O
dogs NN NN O
received NN NN O
4 NN NN O
micrograms NN NN O
. NN NN O
kg NN NN O
- NN NN O
1 NN NN O
. NN NN O
min NN NN O
- NN NN O
1 NN NN O
epinephrine NN NN O
until NN NN O
VT NN NN B-Disease
appeared NN NN O
. NN NN O
   
After NN NN O
45 NN NN O
min NN NN O
, NN NN O
1 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
bupivacaine NN NN O
was NN NN O
injected NN NN O
over NN NN O
5 NN NN O
min NN NN O
, NN NN O
again NN NN O
followed NN NN O
by NN NN O
4 NN NN O
micrograms NN NN O
. NN NN O
kg NN NN O
- NN NN O
1 NN NN O
. NN NN O
min NN NN O
- NN NN O
1 NN NN O
epinephrine NN NN O
. NN NN O
   
In NN NN O
these NN NN O
dogs NN NN O
, NN NN O
the NN NN O
prodysrhythmic NN NN O
response NN NN O
to NN NN O
epinephrine NN NN O
was NN NN O
also NN NN O
mitigated NN NN O
by NN NN O
preceding NN NN O
bupivacaine NN NN O
. NN NN O
   
Bupivacaine NN NN O
antagonizes NN NN O
epinephrine NN NN O
dysrhythmogenicity NN NN O
in NN NN O
conscious NN NN O
dogs NN NN O
susceptible NN NN O
to NN NN O
VT NN NN B-Disease
and NN NN O
in NN NN O
anesthetized NN NN O
dogs NN NN O
with NN NN O
spontaneous NN NN O
postinfarct NN NN O
dysrhythmias NN NN B-Disease
. NN NN O
   
There NN NN O
is NN NN O
no NN NN O
evidence NN NN O
that NN NN O
systemic NN NN O
subtoxic NN NN O
bupivacaine NN NN O
administration NN NN O
enhances NN NN O
the NN NN O
dysrhythmogenicity NN NN O
of NN NN O
subsequent NN NN O
epinephrine NN NN O
. NN NN O
   
Milk NN NN B-Disease
- NN NN I-Disease
alkali NN NN I-Disease
syndrome NN NN I-Disease
induced NN NN O
by NN NN O
1 NN NN O
, NN NN O
25 NN NN O
( NN NN O
OH NN NN O
) NN NN O
2D NN NN O
in NN NN O
a NN NN O
patient NN NN O
with NN NN O
hypoparathyroidism NN NN B-Disease
. NN NN O
   
Milk NN NN B-Disease
- NN NN I-Disease
alkali NN NN I-Disease
syndrome NN NN I-Disease
was NN NN O
first NN NN O
described NN NN O
70 NN NN O
years NN NN O
ago NN NN O
in NN NN O
the NN NN O
context NN NN O
of NN NN O
the NN NN O
treatment NN NN O
of NN NN O
peptic NN NN B-Disease
ulcer NN NN I-Disease
disease NN NN I-Disease
with NN NN O
large NN NN O
amounts NN NN O
of NN NN O
calcium NN NN O
and NN NN O
alkali NN NN O
. NN NN O
   
Although NN NN O
with NN NN O
current NN NN O
ulcer NN NN B-Disease
therapy NN NN O
( NN NN O
H NN NN O
- NN NN O
2 NN NN O
blockers NN NN O
, NN NN O
omeprazole NN NN O
, NN NN O
and NN NN O
sucralfate NN NN O
) NN NN O
, NN NN O
the NN NN O
frequency NN NN O
of NN NN O
milk NN NN B-Disease
- NN NN I-Disease
alkali NN NN I-Disease
syndrome NN NN I-Disease
has NN NN O
decreased NN NN O
significantly NN NN O
, NN NN O
the NN NN O
classic NN NN O
triad NN NN O
of NN NN O
hypercalcemia NN NN B-Disease
, NN NN O
alkalosis NN NN B-Disease
, NN NN O
and NN NN O
renal NN NN B-Disease
impairment NN NN I-Disease
remains NN NN O
the NN NN O
hallmark NN NN O
of NN NN O
the NN NN O
syndrome NN NN O
. NN NN O
   
Milk NN NN B-Disease
- NN NN I-Disease
alkali NN NN I-Disease
syndrome NN NN I-Disease
can NN NN O
present NN NN O
serious NN NN O
and NN NN O
occasionally NN NN O
life NN NN O
- NN NN O
threatening NN NN O
illness NN NN O
unless NN NN O
diagnosed NN NN O
and NN NN O
treated NN NN O
appropriately NN NN O
. NN NN O
   
This NN NN O
article NN NN O
presents NN NN O
a NN NN O
patient NN NN O
with NN NN O
hypoparathyroidism NN NN B-Disease
who NN NN O
was NN NN O
treated NN NN O
with NN NN O
calcium NN NN O
carbonate NN NN O
and NN NN O
calcitriol NN NN O
resulting NN NN O
in NN NN O
two NN NN O
admissions NN NN O
to NN NN O
the NN NN O
hospital NN NN O
for NN NN O
milk NN NN B-Disease
- NN NN I-Disease
alkali NN NN I-Disease
syndrome NN NN I-Disease
. NN NN O
   
The NN NN O
patient NN NN O
was NN NN O
successfully NN NN O
treated NN NN O
with NN NN O
intravenous NN NN O
pamidronate NN NN O
on NN NN O
his NN NN O
first NN NN O
admission NN NN O
and NN NN O
with NN NN O
hydrocortisone NN NN O
on NN NN O
the NN NN O
second NN NN O
. NN NN O
   
This NN NN O
illustrates NN NN O
intravenous NN NN O
pamidronate NN NN O
as NN NN O
a NN NN O
valuable NN NN O
therapeutic NN NN O
tool NN NN O
when NN NN O
milk NN NN B-Disease
- NN NN I-Disease
alkali NN NN I-Disease
syndrome NN NN I-Disease
presents NN NN O
as NN NN O
hypercalcemic NN NN B-Disease
emergency NN NN I-Disease
. NN NN O
   
Famotidine NN NN O
- NN NN O
associated NN NN O
delirium NN NN B-Disease
. NN NN O
   
A NN NN O
series NN NN O
of NN NN O
six NN NN O
cases NN NN O
. NN NN O
   
Famotidine NN NN O
is NN NN O
a NN NN O
histamine NN NN O
H2 NN NN O
- NN NN O
receptor NN NN O
antagonist NN NN O
used NN NN O
in NN NN O
inpatient NN NN O
settings NN NN O
for NN NN O
prevention NN NN O
of NN NN O
stress NN NN O
ulcers NN NN B-Disease
and NN NN O
is NN NN O
showing NN NN O
increasing NN NN O
popularity NN NN O
because NN NN O
of NN NN O
its NN NN O
low NN NN O
cost NN NN O
. NN NN O
   
Although NN NN O
all NN NN O
of NN NN O
the NN NN O
currently NN NN O
available NN NN O
H2 NN NN O
- NN NN O
receptor NN NN O
antagonists NN NN O
have NN NN O
shown NN NN O
the NN NN O
propensity NN NN O
to NN NN O
cause NN NN O
delirium NN NN B-Disease
, NN NN O
only NN NN O
two NN NN O
previously NN NN O
reported NN NN O
cases NN NN O
have NN NN O
been NN NN O
associated NN NN O
with NN NN O
famotidine NN NN O
. NN NN O
   
The NN NN O
authors NN NN O
report NN NN O
on NN NN O
six NN NN O
cases NN NN O
of NN NN O
famotidine NN NN O
- NN NN O
associated NN NN O
delirium NN NN B-Disease
in NN NN O
hospitalized NN NN O
patients NN NN O
who NN NN O
cleared NN NN O
completely NN NN O
upon NN NN O
removal NN NN O
of NN NN O
famotidine NN NN O
. NN NN O
   
The NN NN O
pharmacokinetics NN NN O
of NN NN O
famotidine NN NN O
are NN NN O
reviewed NN NN O
, NN NN O
with NN NN O
no NN NN O
change NN NN O
in NN NN O
its NN NN O
metabolism NN NN O
in NN NN O
the NN NN O
elderly NN NN O
population NN NN O
seen NN NN O
. NN NN O
   
The NN NN O
implications NN NN O
of NN NN O
using NN NN O
famotidine NN NN O
in NN NN O
elderly NN NN O
persons NN NN O
are NN NN O
discussed NN NN O
. NN NN O
   
Encephalopathy NN NN B-Disease
during NN NN O
amitriptyline NN NN O
therapy NN NN O
: NN NN O
are NN NN O
neuroleptic NN NN B-Disease
malignant NN NN I-Disease
syndrome NN NN I-Disease
and NN NN O
serotonin NN NN B-Disease
syndrome NN NN I-Disease
spectrum NN NN O
disorders NN NN O
? NN NN O
   
This NN NN O
report NN NN O
describes NN NN O
a NN NN O
case NN NN O
of NN NN O
encephalopathy NN NN B-Disease
developed NN NN O
in NN NN O
the NN NN O
course NN NN O
of NN NN O
amitriptyline NN NN O
therapy NN NN O
, NN NN O
during NN NN O
a NN NN O
remission NN NN O
of NN NN O
unipolar NN NN B-Disease
depression NN NN I-Disease
. NN NN O
   
This NN NN O
patient NN NN O
could NN NN O
have NN NN O
been NN NN O
diagnosed NN NN O
as NN NN O
having NN NN O
either NN NN O
neuroleptic NN NN B-Disease
malignant NN NN I-Disease
syndrome NN NN I-Disease
( NN NN O
NMS NN NN B-Disease
) NN NN O
or NN NN O
serotonin NN NN B-Disease
syndrome NN NN I-Disease
( NN NN O
SS NN NN B-Disease
) NN NN O
. NN NN O
   
The NN NN O
major NN NN O
determinant NN NN O
of NN NN O
the NN NN O
symptoms NN NN O
may NN NN O
have NN NN O
been NN NN O
dopamine NN NN O
/ NN NN O
serotonin NN NN O
imbalance NN NN O
in NN NN O
the NN NN O
central NN NN O
nervous NN NN O
system NN NN O
. NN NN O
   
The NN NN O
NMS NN NN B-Disease
- NN NN O
like NN NN O
encephalopathy NN NN B-Disease
that NN NN O
develops NN NN O
in NN NN O
association NN NN O
with NN NN O
the NN NN O
use NN NN O
of NN NN O
antidepressants NN NN O
indicates NN NN O
that NN NN O
NMS NN NN B-Disease
and NN NN O
SS NN NN B-Disease
are NN NN O
spectrum NN NN O
disorders NN NN O
induced NN NN O
by NN NN O
drugs NN NN O
with NN NN O
both NN NN O
antidopaminergic NN NN O
and NN NN O
serotonergic NN NN O
effects NN NN O
. NN NN O
   
Genetic NN NN O
separation NN NN O
of NN NN O
tumor NN NN B-Disease
growth NN NN O
and NN NN O
hemorrhagic NN NN B-Disease
phenotypes NN NN O
in NN NN O
an NN NN O
estrogen NN NN O
- NN NN O
induced NN NN O
tumor NN NN B-Disease
. NN NN O
   
Chronic NN NN O
administration NN NN O
of NN NN O
estrogen NN NN O
to NN NN O
the NN NN O
Fischer NN NN O
344 NN NN O
( NN NN O
F344 NN NN O
) NN NN O
rat NN NN O
induces NN NN O
growth NN NN O
of NN NN O
large NN NN O
, NN NN O
hemorrhagic NN NN B-Disease
pituitary NN NN B-Disease
tumors NN NN I-Disease
. NN NN O
   
Ten NN NN O
weeks NN NN O
of NN NN O
diethylstilbestrol NN NN O
( NN NN O
DES NN NN O
) NN NN O
treatment NN NN O
caused NN NN O
female NN NN O
F344 NN NN O
rat NN NN O
pituitaries NN NN O
to NN NN O
grow NN NN O
to NN NN O
an NN NN O
average NN NN O
of NN NN O
109 NN NN O
. NN NN O
2 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
6 NN NN O
. NN NN O
3 NN NN O
mg NN NN O
( NN NN O
mean NN NN O
+ NN NN O
/ NN NN O
- NN NN O
SE NN NN O
) NN NN O
versus NN NN O
11 NN NN O
. NN NN O
3 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
1 NN NN O
. NN NN O
4 NN NN O
mg NN NN O
for NN NN O
untreated NN NN O
rats NN NN O
, NN NN O
and NN NN O
to NN NN O
become NN NN O
highly NN NN O
hemorrhagic NN NN B-Disease
. NN NN O
   
The NN NN O
same NN NN O
DES NN NN O
treatment NN NN O
produced NN NN O
no NN NN O
significant NN NN O
growth NN NN O
( NN NN O
8 NN NN O
. NN NN O
9 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
0 NN NN O
. NN NN O
5 NN NN O
mg NN NN O
for NN NN O
treated NN NN O
females NN NN O
versus NN NN O
8 NN NN O
. NN NN O
7 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
1 NN NN O
. NN NN O
1 NN NN O
for NN NN O
untreated NN NN O
females NN NN O
) NN NN O
or NN NN O
morphological NN NN O
changes NN NN O
in NN NN O
Brown NN NN O
Norway NN NN O
( NN NN O
BN NN NN O
) NN NN O
rat NN NN O
pituitaries NN NN O
. NN NN O
   
An NN NN O
F1 NN NN O
hybrid NN NN O
of NN NN O
F344 NN NN O
and NN NN O
BN NN NN O
exhibited NN NN O
significant NN NN O
pituitary NN NN O
growth NN NN O
after NN NN O
10 NN NN O
weeks NN NN O
of NN NN O
DES NN NN O
treatment NN NN O
with NN NN O
an NN NN O
average NN NN O
mass NN NN O
of NN NN O
26 NN NN O
. NN NN O
3 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
0 NN NN O
. NN NN O
7 NN NN O
mg NN NN O
compared NN NN O
with NN NN O
8 NN NN O
. NN NN O
6 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
0 NN NN O
. NN NN O
9 NN NN O
mg NN NN O
for NN NN O
untreated NN NN O
rats NN NN O
. NN NN O
   
Surprisingly NN NN O
, NN NN O
the NN NN O
F1 NN NN O
hybrid NN NN O
tumors NN NN B-Disease
were NN NN O
not NN NN O
hemorrhagic NN NN B-Disease
and NN NN O
had NN NN O
hemoglobin NN NN O
content NN NN O
and NN NN O
outward NN NN O
appearance NN NN O
identical NN NN O
to NN NN O
that NN NN O
of NN NN O
BN NN NN O
. NN NN O
   
Expression NN NN O
of NN NN O
both NN NN O
growth NN NN O
and NN NN O
morphological NN NN O
changes NN NN O
is NN NN O
due NN NN O
to NN NN O
multiple NN NN O
genes NN NN O
. NN NN O
   
However NN NN O
, NN NN O
while NN NN O
DES NN NN O
- NN NN O
induced NN NN O
pituitary NN NN O
growth NN NN O
exhibited NN NN O
quantitative NN NN O
, NN NN O
additive NN NN O
inheritance NN NN O
, NN NN O
the NN NN O
hemorrhagic NN NN B-Disease
phenotype NN NN O
exhibited NN NN O
recessive NN NN O
, NN NN O
epistatic NN NN O
inheritance NN NN O
. NN NN O
   
Only NN NN O
5 NN NN O
of NN NN O
the NN NN O
160 NN NN O
F2 NN NN O
pituitaries NN NN O
exhibited NN NN O
the NN NN O
hemorrhagic NN NN B-Disease
phenotype NN NN O
; NN NN O
36 NN NN O
of NN NN O
the NN NN O
160 NN NN O
F2 NN NN O
pituitaries NN NN O
were NN NN O
in NN NN O
the NN NN O
F344 NN NN O
range NN NN O
of NN NN O
mass NN NN O
, NN NN O
but NN NN O
31 NN NN O
of NN NN O
these NN NN O
were NN NN O
not NN NN O
hemorrhagic NN NN B-Disease
, NN NN O
indicating NN NN O
that NN NN O
the NN NN O
hemorrhagic NN NN B-Disease
phenotype NN NN O
is NN NN O
not NN NN O
merely NN NN O
a NN NN O
consequence NN NN O
of NN NN O
extensive NN NN O
growth NN NN O
. NN NN O
   
The NN NN O
hemorrhagic NN NN B-Disease
F2 NN NN O
pituitaries NN NN O
were NN NN O
all NN NN O
among NN NN O
the NN NN O
most NN NN O
massive NN NN O
, NN NN O
indicating NN NN O
that NN NN O
some NN NN O
of NN NN O
the NN NN O
genes NN NN O
regulate NN NN O
both NN NN O
phenotypes NN NN O
. NN NN O
   
Increased NN NN O
expression NN NN O
of NN NN O
neuronal NN NN O
nitric NN NN O
oxide NN NN O
synthase NN NN O
in NN NN O
bladder NN NN O
afferent NN NN O
pathways NN NN O
following NN NN O
chronic NN NN O
bladder NN NN B-Disease
irritation NN NN I-Disease
. NN NN O
   
Immunocytochemical NN NN O
techniques NN NN O
were NN NN O
used NN NN O
to NN NN O
examine NN NN O
alterations NN NN O
in NN NN O
the NN NN O
expression NN NN O
of NN NN O
neuronal NN NN O
nitric NN NN O
oxide NN NN O
synthase NN NN O
( NN NN O
NOS NN NN O
) NN NN O
in NN NN O
bladder NN NN O
pathways NN NN O
following NN NN O
acute NN NN O
and NN NN O
chronic NN NN O
irritation NN NN B-Disease
of NN NN I-Disease
the NN NN I-Disease
urinary NN NN I-Disease
tract NN NN I-Disease
of NN NN O
the NN NN O
rat NN NN O
. NN NN O
   
Chemical NN NN O
cystitis NN NN B-Disease
was NN NN O
induced NN NN O
by NN NN O
cyclophosphamide NN NN O
( NN NN O
CYP NN NN O
) NN NN O
which NN NN O
is NN NN O
metabolized NN NN O
to NN NN O
acrolein NN NN O
, NN NN O
an NN NN O
irritant NN NN O
eliminated NN NN O
in NN NN O
the NN NN O
urine NN NN O
. NN NN O
   
Injection NN NN O
of NN NN O
CYP NN NN O
( NN NN O
n NN NN O
= NN NN O
10 NN NN O
, NN NN O
75 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
, NN NN O
i NN NN O
. NN NN O
p NN NN O
. NN NN O
) NN NN O
2 NN NN O
hours NN NN O
prior NN NN O
to NN NN O
perfusion NN NN O
( NN NN O
acute NN NN O
treatment NN NN O
) NN NN O
of NN NN O
the NN NN O
animals NN NN O
increased NN NN O
Fos NN NN O
- NN NN O
immunoreactivity NN NN O
( NN NN O
IR NN NN O
) NN NN O
in NN NN O
neurons NN NN O
in NN NN O
the NN NN O
dorsal NN NN O
commissure NN NN O
, NN NN O
dorsal NN NN O
horn NN NN O
, NN NN O
and NN NN O
autonomic NN NN O
regions NN NN O
of NN NN O
spinal NN NN O
segments NN NN O
( NN NN O
L1 NN NN O
- NN NN O
L2 NN NN O
and NN NN O
L6 NN NN O
- NN NN O
S1 NN NN O
) NN NN O
which NN NN O
receive NN NN O
afferent NN NN O
inputs NN NN O
from NN NN O
the NN NN O
bladder NN NN O
, NN NN O
urethra NN NN O
, NN NN O
and NN NN O
ureter NN NN O
. NN NN O
   
Fos NN NN O
- NN NN O
IR NN NN O
in NN NN O
the NN NN O
spinal NN NN O
cord NN NN O
was NN NN O
not NN NN O
changed NN NN O
in NN NN O
rats NN NN O
receiving NN NN O
chronic NN NN O
CYP NN NN O
treatment NN NN O
( NN NN O
n NN NN O
= NN NN O
15 NN NN O
, NN NN O
75 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
, NN NN O
i NN NN O
. NN NN O
p NN NN O
. NN NN O
, NN NN O
every NN NN O
3rd NN NN O
day NN NN O
for NN NN O
2 NN NN O
weeks NN NN O
) NN NN O
. NN NN O
   
In NN NN O
control NN NN O
animals NN NN O
and NN NN O
in NN NN O
animals NN NN O
treated NN NN O
acutely NN NN O
with NN NN O
CYP NN NN O
, NN NN O
only NN NN O
small NN NN O
numbers NN NN O
of NN NN O
NOS NN NN O
- NN NN O
IR NN NN O
cells NN NN O
( NN NN O
0 NN NN O
. NN NN O
5 NN NN O
- NN NN O
0 NN NN O
. NN NN O
7 NN NN O
cell NN NN O
profiles NN NN O
/ NN NN O
sections NN NN O
) NN NN O
were NN NN O
detected NN NN O
in NN NN O
the NN NN O
L6 NN NN O
- NN NN O
S1 NN NN O
dorsal NN NN O
root NN NN O
ganglia NN NN O
( NN NN O
DRG NN NN O
) NN NN O
. NN NN O
   
Chronic NN NN O
CYP NN NN O
administration NN NN O
significantly NN NN O
( NN NN O
P NN NN O
< NN NN O
or NN NN O
= NN NN O
. NN NN O
002 NN NN O
) NN NN O
increased NN NN O
bladder NN NN O
weight NN NN O
by NN NN O
60 NN NN O
% NN NN O
and NN NN O
increased NN NN O
( NN NN O
7 NN NN O
- NN NN O
to NN NN O
11 NN NN O
- NN NN O
fold NN NN O
) NN NN O
the NN NN O
numbers NN NN O
of NN NN O
NOS NN NN O
- NN NN O
immunoreactive NN NN O
( NN NN O
IR NN NN O
) NN NN O
afferent NN NN O
neurons NN NN O
in NN NN O
the NN NN O
L6 NN NN O
- NN NN O
S1 NN NN O
DRG NN NN O
. NN NN O
   
A NN NN O
small NN NN O
increase NN NN O
( NN NN O
1 NN NN O
. NN NN O
5 NN NN O
- NN NN O
fold NN NN O
) NN NN O
also NN NN O
occurred NN NN O
in NN NN O
the NN NN O
L1 NN NN O
DRG NN NN O
, NN NN O
but NN NN O
no NN NN O
change NN NN O
was NN NN O
detected NN NN O
in NN NN O
the NN NN O
L2 NN NN O
and NN NN O
L5 NN NN O
DRG NN NN O
. NN NN O
   
Bladder NN NN O
afferent NN NN O
cells NN NN O
in NN NN O
the NN NN O
L6 NN NN O
- NN NN O
S1 NN NN O
DRG NN NN O
labeled NN NN O
by NN NN O
Fluorogold NN NN O
( NN NN O
40 NN NN O
microliters NN NN O
) NN NN O
injected NN NN O
into NN NN O
the NN NN O
bladder NN NN O
wall NN NN O
did NN NN O
not NN NN O
exhibit NN NN O
NOS NN NN O
- NN NN O
IR NN NN O
in NN NN O
control NN NN O
animals NN NN O
; NN NN O
however NN NN O
, NN NN O
following NN NN O
chronic NN NN O
CYP NN NN O
administration NN NN O
, NN NN O
a NN NN O
significant NN NN O
percentage NN NN O
of NN NN O
bladder NN NN O
afferent NN NN O
neurons NN NN O
were NN NN O
NOS NN NN O
- NN NN O
IR NN NN O
: NN NN O
L6 NN NN O
( NN NN O
19 NN NN O
. NN NN O
8 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
4 NN NN O
. NN NN O
6 NN NN O
% NN NN O
) NN NN O
and NN NN O
S1 NN NN O
( NN NN O
25 NN NN O
. NN NN O
3 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
2 NN NN O
. NN NN O
9 NN NN O
% NN NN O
) NN NN O
. NN NN O
   
These NN NN O
results NN NN O
indicate NN NN O
that NN NN O
neuronal NN NN O
gene NN NN O
expression NN NN O
in NN NN O
visceral NN NN O
sensory NN NN O
pathways NN NN O
can NN NN O
be NN NN O
upregulated NN NN O
by NN NN O
chemical NN NN O
irritation NN NN O
of NN NN O
afferent NN NN O
receptors NN NN O
in NN NN O
the NN NN O
urinary NN NN O
tract NN NN O
and NN NN O
/ NN NN O
or NN NN O
that NN NN O
pathological NN NN O
changes NN NN O
in NN NN O
the NN NN O
urinary NN NN O
tract NN NN O
can NN NN O
initiate NN NN O
chemical NN NN O
signals NN NN O
that NN NN O
alter NN NN O
the NN NN O
chemical NN NN O
properties NN NN O
of NN NN O
visceral NN NN O
afferent NN NN O
neurons NN NN O
. NN NN O
   
Effects NN NN O
of NN NN O
a NN NN O
new NN NN O
calcium NN NN O
antagonist NN NN O
, NN NN O
CD NN NN O
- NN NN O
832 NN NN O
, NN NN O
on NN NN O
isoproterenol NN NN O
- NN NN O
induced NN NN O
myocardial NN NN B-Disease
ischemia NN NN I-Disease
in NN NN O
dogs NN NN O
with NN NN O
partial NN NN O
coronary NN NN B-Disease
stenosis NN NN I-Disease
. NN NN O
   
Effects NN NN O
of NN NN O
CD NN NN O
- NN NN O
832 NN NN O
on NN NN O
isoproterenol NN NN O
( NN NN O
ISO NN NN O
) NN NN O
- NN NN O
induced NN NN O
myocardial NN NN B-Disease
ischemia NN NN I-Disease
were NN NN O
studied NN NN O
in NN NN O
dogs NN NN O
with NN NN O
partial NN NN O
coronary NN NN B-Disease
stenosis NN NN I-Disease
of NN NN O
the NN NN O
left NN NN O
circumflex NN NN O
coronary NN NN O
artery NN NN O
and NN NN O
findings NN NN O
were NN NN O
compared NN NN O
with NN NN O
those NN NN O
for NN NN O
nifedipine NN NN O
or NN NN O
diltiazem NN NN O
. NN NN O
   
In NN NN O
the NN NN O
presence NN NN O
of NN NN O
coronary NN NN B-Disease
artery NN NN I-Disease
stenosis NN NN I-Disease
, NN NN O
3 NN NN O
- NN NN O
min NN NN O
periods NN NN O
of NN NN O
intracoronary NN NN O
ISO NN NN O
infusion NN NN O
( NN NN O
10 NN NN O
ng NN NN O
/ NN NN O
kg NN NN O
/ NN NN O
min NN NN O
) NN NN O
increased NN NN O
heart NN NN O
rate NN NN O
and NN NN O
maximal NN NN O
rate NN NN O
of NN NN O
left NN NN O
ventricular NN NN O
pressure NN NN O
rise NN NN O
, NN NN O
which NN NN O
resulted NN NN O
in NN NN O
a NN NN O
decrease NN NN O
in NN NN O
percentage NN NN O
segmental NN NN O
shortening NN NN O
and NN NN O
ST NN NN O
- NN NN O
segment NN NN O
elevation NN NN O
of NN NN O
the NN NN O
epicardial NN NN O
electrocardiogram NN NN O
. NN NN O
   
After NN NN O
the NN NN O
control NN NN O
ISO NN NN O
infusion NN NN O
with NN NN O
stenosis NN NN B-Disease
was NN NN O
performed NN NN O
, NN NN O
equihypotensive NN NN O
doses NN NN O
of NN NN O
CD NN NN O
- NN NN O
832 NN NN O
( NN NN O
3 NN NN O
and NN NN O
10 NN NN O
micrograms NN NN O
/ NN NN O
kg NN NN O
/ NN NN O
min NN NN O
, NN NN O
n NN NN O
= NN NN O
7 NN NN O
) NN NN O
, NN NN O
nifedipine NN NN O
( NN NN O
1 NN NN O
and NN NN O
3 NN NN O
micrograms NN NN O
/ NN NN O
kg NN NN O
/ NN NN O
min NN NN O
, NN NN O
n NN NN O
= NN NN O
9 NN NN O
) NN NN O
or NN NN O
diltiazem NN NN O
( NN NN O
10 NN NN O
and NN NN O
30 NN NN O
micrograms NN NN O
/ NN NN O
kg NN NN O
/ NN NN O
min NN NN O
, NN NN O
n NN NN O
= NN NN O
7 NN NN O
) NN NN O
were NN NN O
infused NN NN O
5 NN NN O
min NN NN O
before NN NN O
and NN NN O
during NN NN O
the NN NN O
second NN NN O
and NN NN O
third NN NN O
ISO NN NN O
infusion NN NN O
. NN NN O
   
Both NN NN O
CD NN NN O
- NN NN O
832 NN NN O
and NN NN O
diltiazem NN NN O
, NN NN O
but NN NN O
not NN NN O
nifedipine NN NN O
, NN NN O
significantly NN NN O
reduced NN NN O
the NN NN O
increase NN NN O
in NN NN O
heart NN NN O
rate NN NN O
induced NN NN O
by NN NN O
ISO NN NN O
infusion NN NN O
. NN NN O
   
In NN NN O
contrast NN NN O
to NN NN O
nifedipine NN NN O
, NN NN O
CD NN NN O
- NN NN O
832 NN NN O
( NN NN O
10 NN NN O
micrograms NN NN O
/ NN NN O
kg NN NN O
/ NN NN O
min NN NN O
) NN NN O
prevented NN NN O
the NN NN O
decrease NN NN O
in NN NN O
percentage NN NN O
segmental NN NN O
shortening NN NN O
from NN NN O
32 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
12 NN NN O
% NN NN O
to NN NN O
115 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
26 NN NN O
% NN NN O
of NN NN O
the NN NN O
control NN NN O
value NN NN O
( NN NN O
P NN NN O
< NN NN O
. NN NN O
01 NN NN O
) NN NN O
and NN NN O
ST NN NN O
- NN NN O
segment NN NN O
elevation NN NN O
from NN NN O
5 NN NN O
. NN NN O
6 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
1 NN NN O
. NN NN O
0 NN NN O
mV NN NN O
to NN NN O
1 NN NN O
. NN NN O
6 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
1 NN NN O
. NN NN O
3 NN NN O
mV NN NN O
( NN NN O
P NN NN O
< NN NN O
. NN NN O
01 NN NN O
) NN NN O
at NN NN O
3 NN NN O
min NN NN O
after NN NN O
ISO NN NN O
infusion NN NN O
with NN NN O
stenosis NN NN B-Disease
. NN NN O
   
Diltiazem NN NN O
( NN NN O
30 NN NN O
micrograms NN NN O
/ NN NN O
kg NN NN O
/ NN NN O
min NN NN O
) NN NN O
also NN NN O
prevented NN NN O
the NN NN O
decrease NN NN O
in NN NN O
percentage NN NN O
segmental NN NN O
shortening NN NN O
from NN NN O
34 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
14 NN NN O
% NN NN O
to NN NN O
63 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
18 NN NN O
% NN NN O
of NN NN O
the NN NN O
control NN NN O
value NN NN O
( NN NN O
P NN NN O
< NN NN O
. NN NN O
05 NN NN O
) NN NN O
and NN NN O
ST NN NN O
- NN NN O
segment NN NN O
elevation NN NN O
from NN NN O
4 NN NN O
. NN NN O
7 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
0 NN NN O
. NN NN O
7 NN NN O
mV NN NN O
to NN NN O
2 NN NN O
. NN NN O
1 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
0 NN NN O
. NN NN O
7 NN NN O
mV NN NN O
( NN NN O
P NN NN O
< NN NN O
. NN NN O
01 NN NN O
) NN NN O
at NN NN O
3 NN NN O
min NN NN O
after NN NN O
ISO NN NN O
infusion NN NN O
with NN NN O
stenosis NN NN B-Disease
. NN NN O
   
These NN NN O
data NN NN O
show NN NN O
that NN NN O
CD NN NN O
- NN NN O
832 NN NN O
improves NN NN O
myocardial NN NN B-Disease
ischemia NN NN I-Disease
during NN NN O
ISO NN NN O
infusion NN NN O
with NN NN O
stenosis NN NN B-Disease
and NN NN O
suggest NN NN O
that NN NN O
the NN NN O
negative NN NN O
chronotropic NN NN O
property NN NN O
of NN NN O
CD NN NN O
- NN NN O
832 NN NN O
plays NN NN O
a NN NN O
major NN NN O
role NN NN O
in NN NN O
the NN NN O
beneficial NN NN O
effects NN NN O
of NN NN O
CD NN NN O
- NN NN O
832 NN NN O
. NN NN O
   
The NN NN O
effect NN NN O
of NN NN O
recombinant NN NN O
human NN NN O
insulin NN NN O
- NN NN O
like NN NN O
growth NN NN O
factor NN NN O
- NN NN O
I NN NN O
on NN NN O
chronic NN NN O
puromycin NN NN O
aminonucleoside NN NN O
nephropathy NN NN B-Disease
in NN NN O
rats NN NN O
. NN NN O
   
We NN NN O
recently NN NN O
demonstrated NN NN O
that NN NN O
recombinant NN NN O
hGH NN NN O
exacerbates NN NN O
renal NN NN O
functional NN NN O
and NN NN O
structural NN NN O
injury NN NN O
in NN NN O
chronic NN NN O
puromycin NN NN O
aminonucleoside NN NN O
( NN NN O
PAN NN NN O
) NN NN O
nephropathy NN NN B-Disease
, NN NN O
an NN NN O
experimental NN NN O
model NN NN O
of NN NN O
glomerular NN NN B-Disease
disease NN NN I-Disease
. NN NN O
   
Therefore NN NN O
, NN NN O
we NN NN O
examined NN NN O
whether NN NN O
recombinant NN NN O
human NN NN O
( NN NN O
rh NN NN O
) NN NN O
IGF NN NN O
- NN NN O
I NN NN O
is NN NN O
a NN NN O
safer NN NN O
alternative NN NN O
for NN NN O
the NN NN O
treatment NN NN O
of NN NN O
growth NN NN B-Disease
failure NN NN I-Disease
in NN NN O
rats NN NN O
with NN NN O
chronic NN NN O
PAN NN NN O
nephropathy NN NN B-Disease
. NN NN O
   
The NN NN O
glomerulopathy NN NN B-Disease
was NN NN O
induced NN NN O
by NN NN O
seven NN NN O
serial NN NN O
injections NN NN O
of NN NN O
PAN NN NN O
over NN NN O
12 NN NN O
wk NN NN O
. NN NN O
   
Experimental NN NN O
animals NN NN O
( NN NN O
n NN NN O
= NN NN O
6 NN NN O
) NN NN O
received NN NN O
rhIGF NN NN O
- NN NN O
I NN NN O
, NN NN O
400 NN NN O
micrograms NN NN O
/ NN NN O
d NN NN O
, NN NN O
whereas NN NN O
control NN NN O
rats NN NN O
( NN NN O
n NN NN O
= NN NN O
6 NN NN O
) NN NN O
received NN NN O
the NN NN O
vehicle NN NN O
. NN NN O
   
rhIGF NN NN O
- NN NN O
I NN NN O
improved NN NN O
weight NN NN O
gain NN NN O
by NN NN O
14 NN NN O
% NN NN O
( NN NN O
p NN NN O
< NN NN O
0 NN NN O
. NN NN O
05 NN NN O
) NN NN O
, NN NN O
without NN NN O
altering NN NN O
hematocrit NN NN O
or NN NN O
blood NN NN O
pressure NN NN O
in NN NN O
rats NN NN O
with NN NN O
renal NN NN B-Disease
disease NN NN I-Disease
. NN NN O
   
Urinary NN NN O
protein NN NN O
excretion NN NN O
was NN NN O
unaltered NN NN O
by NN NN O
rhIGF NN NN O
- NN NN O
I NN NN O
treatment NN NN O
in NN NN O
rats NN NN O
with NN NN O
chronic NN NN O
PAN NN NN O
nephropathy NN NN B-Disease
. NN NN O
   
After NN NN O
12 NN NN O
wk NN NN O
, NN NN O
the NN NN O
inulin NN NN O
clearance NN NN O
was NN NN O
higher NN NN O
in NN NN O
rhIGF NN NN O
- NN NN O
I NN NN O
- NN NN O
treated NN NN O
rats NN NN O
, NN NN O
0 NN NN O
. NN NN O
48 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
0 NN NN O
. NN NN O
08 NN NN O
versus NN NN O
0 NN NN O
. NN NN O
24 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
0 NN NN O
. NN NN O
06 NN NN O
mL NN NN O
/ NN NN O
min NN NN O
/ NN NN O
100 NN NN O
g NN NN O
of NN NN O
body NN NN O
weight NN NN O
in NN NN O
untreated NN NN O
PAN NN NN O
nephropathy NN NN B-Disease
animals NN NN O
, NN NN O
p NN NN O
< NN NN O
0 NN NN O
. NN NN O
05 NN NN O
. NN NN O
   
The NN NN O
improvement NN NN O
in NN NN O
GFR NN NN O
was NN NN O
not NN NN O
associated NN NN O
with NN NN O
enhanced NN NN O
glomerular NN NN B-Disease
hypertrophy NN NN I-Disease
or NN NN O
increased NN NN O
segmental NN NN O
glomerulosclerosis NN NN B-Disease
, NN NN O
tubulointerstitial NN NN B-Disease
injury NN NN I-Disease
, NN NN O
or NN NN O
renal NN NN O
cortical NN NN O
malondialdehyde NN NN O
content NN NN O
. NN NN O
   
In NN NN O
rats NN NN O
with NN NN O
PAN NN NN O
nephropathy NN NN B-Disease
, NN NN O
administration NN NN O
of NN NN O
rhIGF NN NN O
- NN NN O
I NN NN O
increased NN NN O
IGF NN NN O
- NN NN O
I NN NN O
and NN NN O
GH NN NN O
receptor NN NN O
gene NN NN O
expression NN NN O
, NN NN O
without NN NN O
altering NN NN O
the NN NN O
steady NN NN O
state NN NN O
level NN NN O
of NN NN O
IGF NN NN O
- NN NN O
I NN NN O
receptor NN NN O
mRNA NN NN O
. NN NN O
   
In NN NN O
normal NN NN O
rats NN NN O
with NN NN O
intact NN NN O
kidneys NN NN O
, NN NN O
rhIGF NN NN O
- NN NN O
I NN NN O
administration NN NN O
( NN NN O
n NN NN O
= NN NN O
4 NN NN O
) NN NN O
did NN NN O
not NN NN O
alter NN NN O
weight NN NN O
gain NN NN O
, NN NN O
blood NN NN O
pressure NN NN O
, NN NN O
proteinuria NN NN B-Disease
, NN NN O
GFR NN NN O
, NN NN O
glomerular NN NN O
planar NN NN O
area NN NN O
, NN NN O
renal NN NN O
cortical NN NN O
malondialdehyde NN NN O
content NN NN O
, NN NN O
or NN NN O
glomerular NN NN O
or NN NN O
tubulointerstitial NN NN B-Disease
damage NN NN I-Disease
, NN NN O
compared NN NN O
with NN NN O
untreated NN NN O
animals NN NN O
( NN NN O
n NN NN O
= NN NN O
4 NN NN O
) NN NN O
. NN NN O
   
rhIGF NN NN O
- NN NN O
I NN NN O
treatment NN NN O
reduced NN NN O
the NN NN O
steady NN NN O
state NN NN O
renal NN NN O
IGF NN NN O
- NN NN O
I NN NN O
mRNA NN NN O
level NN NN O
but NN NN O
did NN NN O
not NN NN O
modify NN NN O
gene NN NN O
expression NN NN O
of NN NN O
the NN NN O
IGF NN NN O
- NN NN O
I NN NN O
or NN NN O
GH NN NN O
receptors NN NN O
. NN NN O
   
We NN NN O
conclude NN NN O
that NN NN O
: NN NN O
1 NN NN O
) NN NN O
administration NN NN O
of NN NN O
rhIGF NN NN O
- NN NN O
I NN NN O
improves NN NN O
growth NN NN O
and NN NN O
GFR NN NN O
in NN NN O
rats NN NN O
with NN NN O
chronic NN NN O
PAN NN NN O
nephropathy NN NN B-Disease
and NN NN O
2 NN NN O
) NN NN O
unlike NN NN O
rhGH NN NN O
, NN NN O
long NN NN O
- NN NN O
term NN NN O
use NN NN O
of NN NN O
rhIGF NN NN O
- NN NN O
I NN NN O
does NN NN O
not NN NN O
worsen NN NN O
renal NN NN O
functional NN NN O
and NN NN O
structural NN NN O
injury NN NN O
in NN NN O
this NN NN O
disease NN NN O
model NN NN O
. NN NN O
   
Nefiracetam NN NN O
( NN NN O
DM NN NN O
- NN NN O
9384 NN NN O
) NN NN O
reverses NN NN O
apomorphine NN NN O
- NN NN O
induced NN NN O
amnesia NN NN B-Disease
of NN NN O
a NN NN O
passive NN NN O
avoidance NN NN O
response NN NN O
: NN NN O
delayed NN NN O
emergence NN NN O
of NN NN O
the NN NN O
memory NN NN O
retention NN NN O
effects NN NN O
. NN NN O
   
Nefiracetam NN NN O
is NN NN O
a NN NN O
novel NN NN O
pyrrolidone NN NN O
derivative NN NN O
which NN NN O
attenuates NN NN O
scopolamine NN NN O
- NN NN O
induced NN NN O
learning NN NN B-Disease
and NN NN I-Disease
post NN NN I-Disease
- NN NN I-Disease
training NN NN I-Disease
consolidation NN NN I-Disease
deficits NN NN I-Disease
. NN NN O
   
Given NN NN O
that NN NN O
apomorphine NN NN O
inhibits NN NN O
passive NN NN O
avoidance NN NN O
retention NN NN O
when NN NN O
given NN NN O
during NN NN O
training NN NN O
or NN NN O
in NN NN O
a NN NN O
defined NN NN O
10 NN NN O
- NN NN O
12h NN NN O
post NN NN O
- NN NN O
training NN NN O
period NN NN O
, NN NN O
we NN NN O
evaluated NN NN O
the NN NN O
ability NN NN O
of NN NN O
nefiracetam NN NN O
to NN NN O
attenuate NN NN O
amnesia NN NN B-Disease
induced NN NN O
by NN NN O
dopaminergic NN NN O
agonism NN NN O
. NN NN O
   
A NN NN O
step NN NN O
- NN NN O
down NN NN O
passive NN NN O
avoidance NN NN O
paradigm NN NN O
was NN NN O
employed NN NN O
and NN NN O
nefiracetam NN NN O
( NN NN O
3 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
) NN NN O
and NN NN O
apomorphine NN NN O
( NN NN O
0 NN NN O
. NN NN O
5 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
) NN NN O
were NN NN O
given NN NN O
alone NN NN O
or NN NN O
in NN NN O
combination NN NN O
during NN NN O
training NN NN O
and NN NN O
at NN NN O
the NN NN O
10 NN NN O
- NN NN O
12h NN NN O
post NN NN O
- NN NN O
training NN NN O
period NN NN O
of NN NN O
consolidation NN NN O
. NN NN O
   
Co NN NN O
- NN NN O
administration NN NN O
of NN NN O
nefiracetam NN NN O
and NN NN O
apomorphine NN NN O
during NN NN O
training NN NN O
or NN NN O
10h NN NN O
thereafter NN NN O
produced NN NN O
no NN NN O
significant NN NN O
anti NN NN O
- NN NN O
amnesic NN NN O
effect NN NN O
. NN NN O
   
However NN NN O
, NN NN O
administration NN NN O
of NN NN O
nefiracetam NN NN O
during NN NN O
training NN NN O
completely NN NN O
reversed NN NN O
the NN NN O
amnesia NN NN B-Disease
induced NN NN O
by NN NN O
apomorphine NN NN O
at NN NN O
the NN NN O
10h NN NN O
post NN NN O
- NN NN O
training NN NN O
time NN NN O
and NN NN O
the NN NN O
converse NN NN O
was NN NN O
also NN NN O
true NN NN O
. NN NN O
   
These NN NN O
effects NN NN O
were NN NN O
not NN NN O
mediated NN NN O
by NN NN O
a NN NN O
dopaminergic NN NN O
mechanism NN NN O
as NN NN O
nefiracetam NN NN O
, NN NN O
at NN NN O
millimolar NN NN O
concentrations NN NN O
, NN NN O
failed NN NN O
to NN NN O
displace NN NN O
either NN NN O
[ NN NN O
3H NN NN O
] NN NN O
SCH NN NN O
23390 NN NN O
or NN NN O
[ NN NN O
3H NN NN O
] NN NN O
spiperone NN NN O
binding NN NN O
from NN NN O
D1 NN NN O
or NN NN O
D2 NN NN O
dopamine NN NN O
receptor NN NN O
subtypes NN NN O
, NN NN O
respectively NN NN O
. NN NN O
   
It NN NN O
is NN NN O
suggested NN NN O
that NN NN O
nefiracetam NN NN O
augments NN NN O
molecular NN NN O
processes NN NN O
in NN NN O
the NN NN O
early NN NN O
stages NN NN O
of NN NN O
events NN NN O
which NN NN O
ultimately NN NN O
lead NN NN O
to NN NN O
consolidation NN NN O
of NN NN O
memory NN NN O
. NN NN O
   
Phenytoin NN NN O
encephalopathy NN NN B-Disease
as NN NN O
probable NN NN O
idiosyncratic NN NN O
reaction NN NN O
: NN NN O
case NN NN O
report NN NN O
. NN NN O
   
A NN NN O
case NN NN O
of NN NN O
phenytoin NN NN O
( NN NN O
DPH NN NN O
) NN NN O
encephalopathy NN NN B-Disease
with NN NN O
increasing NN NN O
seizures NN NN B-Disease
and NN NN O
EEG NN NN O
and NN NN O
mental NN NN O
changes NN NN O
is NN NN O
described NN NN O
. NN NN O
   
Despite NN NN O
adequate NN NN O
oral NN NN O
dosage NN NN O
of NN NN O
DPH NN NN O
( NN NN O
5 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
/ NN NN O
daily NN NN O
) NN NN O
the NN NN O
plasma NN NN O
level NN NN O
was NN NN O
very NN NN O
low NN NN O
( NN NN O
2 NN NN O
. NN NN O
8 NN NN O
microgramg NN NN O
/ NN NN O
ml NN NN O
) NN NN O
. NN NN O
   
The NN NN O
encephalopathy NN NN B-Disease
was NN NN O
probably NN NN O
an NN NN O
idiosyncratic NN NN O
and NN NN O
not NN NN O
toxic NN NN O
or NN NN O
allergic NN NN O
reaction NN NN O
. NN NN O
   
In NN NN O
fact NN NN O
the NN NN O
concentration NN NN O
of NN NN O
free NN NN O
DPH NN NN O
was NN NN O
normal NN NN O
, NN NN O
the NN NN O
patient NN NN O
presented NN NN O
a NN NN O
retarded NN NN O
morbilliform NN NN O
rash NN NN B-Disease
during NN NN O
DPH NN NN O
treatment NN NN O
, NN NN O
the NN NN O
protidogram NN NN O
was NN NN O
normal NN NN O
, NN NN O
and NN NN O
an NN NN O
intradermic NN NN O
DPH NN NN O
injection NN NN O
had NN NN O
no NN NN O
local NN NN O
effect NN NN O
. NN NN O
   
The NN NN O
authors NN NN O
conclude NN NN O
that NN NN O
in NN NN O
a NN NN O
patient NN NN O
starting NN NN O
DPH NN NN O
treatment NN NN O
an NN NN O
unexpected NN NN O
increase NN NN O
in NN NN O
seizures NN NN B-Disease
, NN NN O
with NN NN O
EEG NN NN O
and NN NN O
mental NN NN O
changes NN NN O
occurring NN NN O
simultaneously NN NN O
, NN NN O
should NN NN O
alert NN NN O
the NN NN O
physician NN NN O
to NN NN O
the NN NN O
possible NN NN O
need NN NN O
for NN NN O
eliminating NN NN O
DPH NN NN O
from NN NN O
the NN NN O
therapeutic NN NN O
regimen NN NN O
, NN NN O
even NN NN O
if NN NN O
plasma NN NN O
concentrations NN NN O
are NN NN O
low NN NN O
. NN NN O
   
Prevention NN NN O
and NN NN O
treatment NN NN O
of NN NN O
endometrial NN NN B-Disease
disease NN NN I-Disease
in NN NN O
climacteric NN NN O
women NN NN O
receiving NN NN O
oestrogen NN NN O
therapy NN NN O
. NN NN O
   
The NN NN O
treatment NN NN O
regimens NN NN O
are NN NN O
described NN NN O
in NN NN O
74 NN NN O
patients NN NN O
with NN NN O
endometrial NN NN B-Disease
disease NN NN I-Disease
among NN NN O
850 NN NN O
climacteric NN NN O
women NN NN O
receiving NN NN O
oestrogen NN NN O
therapy NN NN O
. NN NN O
   
Cystic NN NN O
hyperplasia NN NN B-Disease
was NN NN O
associated NN NN O
with NN NN O
unopposed NN NN O
oestrogen NN NN O
therapy NN NN O
without NN NN O
progestagen NN NN O
. NN NN O
   
Two NN NN O
courses NN NN O
of NN NN O
21 NN NN O
days NN NN O
of NN NN O
5 NN NN O
mg NN NN O
norethisterone NN NN O
daily NN NN O
caused NN NN O
reversion NN NN O
to NN NN O
normal NN NN O
in NN NN O
all NN NN O
57 NN NN O
cases NN NN O
of NN NN O
cystic NN NN O
hyperplasia NN NN B-Disease
and NN NN O
6 NN NN O
of NN NN O
the NN NN O
8 NN NN O
cases NN NN O
of NN NN O
atypical NN NN O
hyperplasia NN NN B-Disease
. NN NN O
   
4 NN NN O
cases NN NN O
of NN NN O
endometrial NN NN B-Disease
carcinoma NN NN I-Disease
referred NN NN O
from NN NN O
elsewhere NN NN O
demonstrated NN NN O
the NN NN O
problems NN NN O
of NN NN O
inappropriate NN NN O
and NN NN O
unsupervised NN NN O
unopposed NN NN O
oestrogen NN NN O
therapy NN NN O
and NN NN O
the NN NN O
difficulty NN NN O
in NN NN O
distinguishing NN NN O
severe NN NN O
hyperplasia NN NN B-Disease
from NN NN O
malignancy NN NN B-Disease
. NN NN O
   
Cyclical NN NN O
low NN NN O
- NN NN O
dose NN NN O
oestrogen NN NN O
therapy NN NN O
with NN NN O
7 NN NN O
- NN NN O
- NN NN O
13 NN NN O
days NN NN O
of NN NN O
progestagen NN NN O
does NN NN O
not NN NN O
seem NN NN O
to NN NN O
increase NN NN O
the NN NN O
risk NN NN O
of NN NN O
endometrial NN NN B-Disease
hyperplasia NN NN I-Disease
or NN NN O
carcinoma NN NN B-Disease
. NN NN O
   
Effects NN NN O
of NN NN O
exercise NN NN O
on NN NN O
the NN NN O
severity NN NN O
of NN NN O
isoproterenol NN NN O
- NN NN O
induced NN NN O
myocardial NN NN B-Disease
infarction NN NN I-Disease
. NN NN O
   
The NN NN O
effect NN NN O
of NN NN O
exercise NN NN O
on NN NN O
the NN NN O
severity NN NN O
of NN NN O
isoproterenol NN NN O
- NN NN O
induced NN NN O
myocardial NN NN B-Disease
infarction NN NN I-Disease
was NN NN O
studied NN NN O
in NN NN O
male NN NN O
rats NN NN O
. NN NN O
   
Ninety NN NN O
- NN NN O
three NN NN O
rats NN NN O
were NN NN O
randomly NN NN O
divided NN NN O
into NN NN O
three NN NN O
groups NN NN O
. NN NN O
   
The NN NN O
exercise NN NN O
- NN NN O
isoproterenol NN NN O
( NN NN O
E NN NN O
- NN NN O
1 NN NN O
) NN NN O
and NN NN O
exercise NN NN O
control NN NN O
( NN NN O
EC NN NN O
) NN NN O
groups NN NN O
exercised NN NN O
daily NN NN O
for NN NN O
thirty NN NN O
days NN NN O
on NN NN O
a NN NN O
treadmill NN NN O
at NN NN O
1 NN NN O
mph NN NN O
, NN NN O
2 NN NN O
% NN NN O
grade NN NN O
while NN NN O
animals NN NN O
of NN NN O
the NN NN O
sedentary NN NN O
- NN NN O
isoproterenol NN NN O
( NN NN O
S NN NN O
- NN NN O
I NN NN O
) NN NN O
group NN NN O
remained NN NN O
sedentary NN NN O
. NN NN O
   
Eight NN NN O
animals NN NN O
were NN NN O
assigned NN NN O
to NN NN O
the NN NN O
sedentary NN NN O
control NN NN O
( NN NN O
SC NN NN O
) NN NN O
group NN NN O
which NN NN O
remained NN NN O
sedentary NN NN O
throughout NN NN O
the NN NN O
experimental NN NN O
period NN NN O
. NN NN O
   
Forty NN NN O
- NN NN O
eight NN NN O
hours NN NN O
after NN NN O
the NN NN O
final NN NN O
exercise NN NN O
period NN NN O
, NN NN O
S NN NN O
- NN NN O
I NN NN O
and NN NN O
E NN NN O
- NN NN O
I NN NN O
animals NN NN O
received NN NN O
a NN NN O
single NN NN O
subcutaneous NN NN O
injection NN NN O
of NN NN O
isoproterenol NN NN O
( NN NN O
250 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
body NN NN O
weight NN NN O
) NN NN O
. NN NN O
   
Animals NN NN O
of NN NN O
the NN NN O
S NN NN O
- NN NN O
I NN NN O
group NN NN O
exhibited NN NN O
significantly NN NN O
( NN NN O
Pp NN NN O
less NN NN O
than NN NN O
0 NN NN O
. NN NN O
05 NN NN O
) NN NN O
greater NN NN O
mortality NN NN O
from NN NN O
the NN NN O
effects NN NN O
of NN NN O
isoproterenol NN NN O
than NN NN O
animals NN NN O
of NN NN O
the NN NN O
E NN NN O
- NN NN O
I NN NN O
group NN NN O
. NN NN O
   
Serum NN NN O
CPK NN NN O
activity NN NN O
for NN NN O
E NN NN O
- NN NN O
I NN NN O
animals NN NN O
was NN NN O
significantly NN NN O
( NN NN O
p NN NN O
less NN NN O
than NN NN O
0 NN NN O
. NN NN O
05 NN NN O
) NN NN O
greater NN NN O
than NN NN O
for NN NN O
animals NN NN O
in NN NN O
the NN NN O
S NN NN O
- NN NN O
I NN NN O
and NN NN O
EC NN NN O
groups NN NN O
twenty NN NN O
hours NN NN O
following NN NN O
isoproterenol NN NN O
injection NN NN O
. NN NN O
   
No NN NN O
statistically NN NN O
significant NN NN O
differences NN NN O
were NN NN O
observed NN NN O
between NN NN O
the NN NN O
two NN NN O
isoproterenol NN NN O
treated NN NN O
groups NN NN O
for NN NN O
severity NN NN O
of NN NN O
the NN NN O
induced NN NN O
lesions NN NN O
, NN NN O
changes NN NN O
in NN NN O
heart NN NN O
weight NN NN O
, NN NN O
or NN NN O
heart NN NN O
weight NN NN O
to NN NN O
body NN NN O
weight NN NN O
ratios NN NN O
. NN NN O
   
The NN NN O
results NN NN O
indicated NN NN O
that NN NN O
exercise NN NN O
reduced NN NN O
the NN NN O
mortality NN NN O
associated NN NN O
with NN NN O
the NN NN O
effects NN NN O
of NN NN O
large NN NN O
dosages NN NN O
of NN NN O
isoproterenol NN NN O
but NN NN O
had NN NN O
little NN NN O
on NN NN O
the NN NN O
severity NN NN O
of NN NN O
the NN NN O
infarction NN NN B-Disease
. NN NN O
   
Human NN NN O
corticotropin NN NN O
- NN NN O
releasing NN NN O
hormone NN NN O
and NN NN O
thyrotropin NN NN O
- NN NN O
releasing NN NN O
hormone NN NN O
modulate NN NN O
the NN NN O
hypercapnic NN NN B-Disease
ventilatory NN NN O
response NN NN O
in NN NN O
humans NN NN O
. NN NN O
   
Human NN NN O
corticotropin NN NN O
- NN NN O
releasing NN NN O
hormone NN NN O
( NN NN O
hCRH NN NN O
) NN NN O
and NN NN O
thyrotropin NN NN O
- NN NN O
releasing NN NN O
hormone NN NN O
( NN NN O
TRH NN NN O
) NN NN O
are NN NN O
known NN NN O
to NN NN O
stimulate NN NN O
ventilation NN NN O
after NN NN O
i NN NN O
. NN NN O
v NN NN O
. NN NN O
administration NN NN O
in NN NN O
humans NN NN O
. NN NN O
   
In NN NN O
a NN NN O
placebo NN NN O
- NN NN O
controlled NN NN O
, NN NN O
single NN NN O
- NN NN O
blind NN NN O
study NN NN O
we NN NN O
aimed NN NN O
to NN NN O
clarify NN NN O
if NN NN O
both NN NN O
peptides NN NN O
act NN NN O
by NN NN O
altering NN NN O
central NN NN O
chemosensitivity NN NN O
. NN NN O
   
Two NN NN O
subsequent NN NN O
CO2 NN NN O
- NN NN O
rebreathing NN NN O
tests NN NN O
were NN NN O
performed NN NN O
in NN NN O
healthy NN NN O
young NN NN O
volunteers NN NN O
. NN NN O
   
During NN NN O
the NN NN O
first NN NN O
test NN NN O
0 NN NN O
. NN NN O
9 NN NN O
% NN NN O
NaCl NN NN O
was NN NN O
given NN NN O
i NN NN O
. NN NN O
v NN NN O
. NN NN O
; NN NN O
during NN NN O
the NN NN O
second NN NN O
test NN NN O
200 NN NN O
micrograms NN NN O
of NN NN O
hCRH NN NN O
( NN NN O
n NN NN O
= NN NN O
12 NN NN O
) NN NN O
or NN NN O
400 NN NN O
micrograms NN NN O
of NN NN O
TRH NN NN O
( NN NN O
n NN NN O
= NN NN O
6 NN NN O
) NN NN O
was NN NN O
administered NN NN O
i NN NN O
. NN NN O
v NN NN O
. NN NN O
Nine NN NN O
subjects NN NN O
received NN NN O
0 NN NN O
. NN NN O
9 NN NN O
% NN NN O
NaCl NN NN O
i NN NN O
. NN NN O
v NN NN O
. NN NN O
during NN NN O
both NN NN O
rebreathing NN NN O
manoeuvres NN NN O
. NN NN O
   
The NN NN O
CO2 NN NN O
- NN NN O
response NN NN O
curves NN NN O
for NN NN O
the NN NN O
two NN NN O
tests NN NN O
were NN NN O
compared NN NN O
within NN NN O
the NN NN O
same NN NN O
subject NN NN O
. NN NN O
   
In NN NN O
the NN NN O
hCRH NN NN O
group NN NN O
a NN NN O
marked NN NN O
parallel NN NN O
shift NN NN O
of NN NN O
the NN NN O
CO2 NN NN O
- NN NN O
response NN NN O
curve NN NN O
to NN NN O
the NN NN O
left NN NN O
was NN NN O
observed NN NN O
after NN NN O
hCRH NN NN O
( NN NN O
P NN NN O
< NN NN O
0 NN NN O
. NN NN O
01 NN NN O
) NN NN O
. NN NN O
   
The NN NN O
same NN NN O
effect NN NN O
occurred NN NN O
following NN NN O
TRH NN NN O
but NN NN O
was NN NN O
less NN NN O
striking NN NN O
( NN NN O
P NN NN O
= NN NN O
0 NN NN O
. NN NN O
05 NN NN O
) NN NN O
. NN NN O
   
hCRH NN NN O
and NN NN O
TRH NN NN O
caused NN NN O
a NN NN O
reduction NN NN O
in NN NN O
the NN NN O
CO2 NN NN O
threshold NN NN O
. NN NN O
   
The NN NN O
CO2 NN NN O
- NN NN O
response NN NN O
curves NN NN O
in NN NN O
the NN NN O
control NN NN O
group NN NN O
were NN NN O
nearly NN NN O
identical NN NN O
. NN NN O
   
The NN NN O
results NN NN O
indicate NN NN O
an NN NN O
additive NN NN O
effect NN NN O
of NN NN O
both NN NN O
releasing NN NN O
hormones NN NN O
on NN NN O
the NN NN O
hypercapnic NN NN B-Disease
ventilatory NN NN O
response NN NN O
in NN NN O
humans NN NN O
, NN NN O
presumably NN NN O
independent NN NN O
of NN NN O
central NN NN O
chemosensitivity NN NN O
. NN NN O
   
Lamivudine NN NN O
is NN NN O
effective NN NN O
in NN NN O
suppressing NN NN O
hepatitis NN NN B-Disease
B NN NN I-Disease
virus NN NN O
DNA NN NN O
in NN NN O
Chinese NN NN O
hepatitis NN NN O
B NN NN O
surface NN NN O
antigen NN NN O
carriers NN NN O
: NN NN O
a NN NN O
placebo NN NN O
- NN NN O
controlled NN NN O
trial NN NN O
. NN NN O
   
Lamivudine NN NN O
is NN NN O
a NN NN O
novel NN NN O
2 NN NN O
' NN NN O
, NN NN O
3 NN NN O
' NN NN O
- NN NN O
dideoxy NN NN O
cytosine NN NN O
analogue NN NN O
that NN NN O
has NN NN O
potent NN NN O
inhibitory NN NN O
effects NN NN O
on NN NN O
hepatitis NN NN B-Disease
B NN NN I-Disease
virus NN NN O
replication NN NN O
in NN NN O
vitro NN NN O
and NN NN O
in NN NN O
vivo NN NN O
. NN NN O
   
We NN NN O
performed NN NN O
a NN NN O
single NN NN O
- NN NN O
blind NN NN O
, NN NN O
placebo NN NN O
- NN NN O
controlled NN NN O
study NN NN O
to NN NN O
assess NN NN O
its NN NN O
effectiveness NN NN O
and NN NN O
safety NN NN O
in NN NN O
Chinese NN NN O
hepatitis NN NN O
B NN NN O
surface NN NN O
antigen NN NN O
( NN NN O
HBsAg NN NN O
) NN NN O
carriers NN NN O
. NN NN O
   
Forty NN NN O
- NN NN O
two NN NN O
Chinese NN NN O
HBsAg NN NN O
carriers NN NN O
were NN NN O
randomized NN NN O
to NN NN O
receive NN NN O
placebo NN NN O
( NN NN O
6 NN NN O
patients NN NN O
) NN NN O
or NN NN O
lamivudine NN NN O
orally NN NN O
in NN NN O
dosages NN NN O
of NN NN O
25 NN NN O
mg NN NN O
, NN NN O
100 NN NN O
mg NN NN O
, NN NN O
or NN NN O
300 NN NN O
mg NN NN O
daily NN NN O
( NN NN O
12 NN NN O
patients NN NN O
for NN NN O
each NN NN O
dosage NN NN O
) NN NN O
. NN NN O
   
The NN NN O
drug NN NN O
was NN NN O
given NN NN O
for NN NN O
4 NN NN O
weeks NN NN O
. NN NN O
   
The NN NN O
patients NN NN O
were NN NN O
closely NN NN O
monitored NN NN O
clinically NN NN O
, NN NN O
biochemically NN NN O
, NN NN O
and NN NN O
serologically NN NN O
up NN NN O
to NN NN O
4 NN NN O
weeks NN NN O
after NN NN O
drug NN NN O
treatment NN NN O
. NN NN O
   
All NN NN O
36 NN NN O
patients NN NN O
receiving NN NN O
lamivudine NN NN O
had NN NN O
a NN NN O
decrease NN NN O
in NN NN O
hepatitis NN NN B-Disease
B NN NN I-Disease
virus NN NN O
( NN NN O
HBV NN NN O
) NN NN O
DNA NN NN O
values NN NN O
of NN NN O
> NN NN O
90 NN NN O
% NN NN O
( NN NN O
P NN NN O
< NN NN O
. NN NN O
001 NN NN O
compared NN NN O
with NN NN O
placebo NN NN O
) NN NN O
. NN NN O
   
Although NN NN O
25 NN NN O
mg NN NN O
of NN NN O
lamivudine NN NN O
was NN NN O
slightly NN NN O
less NN NN O
effective NN NN O
than NN NN O
100 NN NN O
mg NN NN O
( NN NN O
P NN NN O
= NN NN O
. NN NN O
011 NN NN O
) NN NN O
and NN NN O
300 NN NN O
mg NN NN O
( NN NN O
P NN NN O
= NN NN O
. NN NN O
005 NN NN O
) NN NN O
, NN NN O
it NN NN O
still NN NN O
induced NN NN O
94 NN NN O
% NN NN O
suppression NN NN O
of NN NN O
HBV NN NN O
DNA NN NN O
after NN NN O
the NN NN O
fourth NN NN O
week NN NN O
of NN NN O
therapy NN NN O
. NN NN O
   
HBV NN NN O
DNA NN NN O
values NN NN O
returned NN NN O
to NN NN O
pretreatment NN NN O
levels NN NN O
within NN NN O
4 NN NN O
weeks NN NN O
of NN NN O
cessation NN NN O
of NN NN O
therapy NN NN O
. NN NN O
   
There NN NN O
was NN NN O
no NN NN O
change NN NN O
in NN NN O
the NN NN O
hepatitis NN NN B-Disease
B NN NN I-Disease
e NN NN O
antigen NN NN O
status NN NN O
or NN NN O
in NN NN O
aminotransferase NN NN O
levels NN NN O
. NN NN O
   
No NN NN O
serious NN NN O
adverse NN NN O
events NN NN O
were NN NN O
observed NN NN O
. NN NN O
   
In NN NN O
conclusion NN NN O
, NN NN O
a NN NN O
4 NN NN O
- NN NN O
week NN NN O
course NN NN O
of NN NN O
lamivudine NN NN O
was NN NN O
safe NN NN O
and NN NN O
effective NN NN O
in NN NN O
suppression NN NN O
of NN NN O
HBV NN NN O
DNA NN NN O
in NN NN O
Chinese NN NN O
HBsAg NN NN O
carriers NN NN O
. NN NN O
   
The NN NN O
suppression NN NN O
was NN NN O
> NN NN O
90 NN NN O
% NN NN O
but NN NN O
reversible NN NN O
. NN NN O
   
Studies NN NN O
with NN NN O
long NN NN O
- NN NN O
term NN NN O
lamivudine NN NN O
administration NN NN O
should NN NN O
be NN NN O
performed NN NN O
to NN NN O
determine NN NN O
if NN NN O
prolonged NN NN O
suppression NN NN O
of NN NN O
HBV NN NN O
DNA NN NN O
can NN NN O
be NN NN O
achieved NN NN O
. NN NN O
   
Population NN NN O
- NN NN O
based NN NN O
study NN NN O
of NN NN O
risk NN NN O
of NN NN O
venous NN NN B-Disease
thromboembolism NN NN I-Disease
associated NN NN O
with NN NN O
various NN NN O
oral NN NN O
contraceptives NN NN O
. NN NN O
   
BACKGROUND NN NN O
: NN NN O
Four NN NN O
studies NN NN O
published NN NN O
since NN NN O
December NN NN O
, NN NN O
1995 NN NN O
, NN NN O
reported NN NN O
that NN NN O
the NN NN O
incidence NN NN O
of NN NN O
venous NN NN B-Disease
thromboembolism NN NN I-Disease
( NN NN O
VTE NN NN B-Disease
) NN NN O
was NN NN O
higher NN NN O
in NN NN O
women NN NN O
who NN NN O
used NN NN O
oral NN NN O
contraceptives NN NN O
( NN NN O
OCs NN NN O
) NN NN O
containing NN NN O
the NN NN O
third NN NN O
- NN NN O
generation NN NN O
progestagens NN NN O
gestodene NN NN O
or NN NN O
desogestrel NN NN O
than NN NN O
in NN NN O
users NN NN O
of NN NN O
OCs NN NN O
containing NN NN O
second NN NN O
- NN NN O
generation NN NN O
progestagens NN NN O
. NN NN O
   
However NN NN O
, NN NN O
confounding NN NN O
and NN NN O
bias NN NN O
in NN NN O
the NN NN O
design NN NN O
of NN NN O
these NN NN O
studies NN NN O
may NN NN O
have NN NN O
affected NN NN O
the NN NN O
findings NN NN O
. NN NN O
   
The NN NN O
aim NN NN O
of NN NN O
our NN NN O
study NN NN O
was NN NN O
to NN NN O
re NN NN O
- NN NN O
examine NN NN O
the NN NN O
association NN NN O
between NN NN O
risk NN NN O
of NN NN O
VTE NN NN B-Disease
and NN NN O
OC NN NN O
use NN NN O
with NN NN O
a NN NN O
different NN NN O
study NN NN O
design NN NN O
and NN NN O
analysis NN NN O
to NN NN O
avoid NN NN O
some NN NN O
of NN NN O
the NN NN O
bias NN NN O
and NN NN O
confounding NN NN O
of NN NN O
the NN NN O
earlier NN NN O
studies NN NN O
. NN NN O
   
METHODS NN NN O
: NN NN O
We NN NN O
used NN NN O
computer NN NN O
records NN NN O
of NN NN O
patients NN NN O
from NN NN O
143 NN NN O
general NN NN O
practices NN NN O
in NN NN O
the NN NN O
UK NN NN O
. NN NN O
   
The NN NN O
study NN NN O
was NN NN O
based NN NN O
on NN NN O
the NN NN O
medical NN NN O
records NN NN O
of NN NN O
about NN NN O
540 NN NN O
, NN NN O
000 NN NN O
women NN NN O
born NN NN O
between NN NN O
1941 NN NN O
and NN NN O
1981 NN NN O
. NN NN O
   
All NN NN O
women NN NN O
who NN NN O
had NN NN O
a NN NN O
recorded NN NN O
diagnosis NN NN O
of NN NN O
deep NN NN B-Disease
- NN NN I-Disease
vein NN NN I-Disease
thrombosis NN NN I-Disease
, NN NN O
venous NN NN B-Disease
thrombosis NN NN I-Disease
not NN NN O
otherwise NN NN O
specified NN NN O
, NN NN O
or NN NN O
pulmonary NN NN O
embolus NN NN O
during NN NN O
the NN NN O
study NN NN O
period NN NN O
, NN NN O
and NN NN O
who NN NN O
had NN NN O
been NN NN O
treated NN NN O
with NN NN O
an NN NN O
anticoagulant NN NN O
were NN NN O
identified NN NN O
as NN NN O
potential NN NN O
cases NN NN O
of NN NN O
VTE NN NN B-Disease
. NN NN O
   
We NN NN O
did NN NN O
a NN NN O
cohort NN NN O
analysis NN NN O
to NN NN O
estimate NN NN O
and NN NN O
compare NN NN O
incidence NN NN O
of NN NN O
VTE NN NN B-Disease
in NN NN O
users NN NN O
of NN NN O
the NN NN O
main NN NN O
OC NN NN O
preparations NN NN O
, NN NN O
and NN NN O
a NN NN O
nested NN NN O
case NN NN O
- NN NN O
control NN NN O
study NN NN O
to NN NN O
calculate NN NN O
the NN NN O
odds NN NN O
ratios NN NN O
of NN NN O
VTE NN NN B-Disease
associated NN NN O
with NN NN O
use NN NN O
of NN NN O
different NN NN O
types NN NN O
of NN NN O
OC NN NN O
, NN NN O
after NN NN O
adjustment NN NN O
for NN NN O
potential NN NN O
confounding NN NN O
factors NN NN O
. NN NN O
   
In NN NN O
the NN NN O
case NN NN O
- NN NN O
control NN NN O
study NN NN O
, NN NN O
we NN NN O
matched NN NN O
cases NN NN O
to NN NN O
controls NN NN O
by NN NN O
exact NN NN O
year NN NN O
of NN NN O
birth NN NN O
, NN NN O
practice NN NN O
, NN NN O
and NN NN O
current NN NN O
use NN NN O
of NN NN O
OCs NN NN O
. NN NN O
   
We NN NN O
used NN NN O
a NN NN O
multiple NN NN O
logistic NN NN O
regression NN NN O
model NN NN O
that NN NN O
included NN NN O
body NN NN O
- NN NN O
mass NN NN O
index NN NN O
, NN NN O
number NN NN O
of NN NN O
cycles NN NN O
, NN NN O
change NN NN O
in NN NN O
type NN NN O
of NN NN O
OC NN NN O
prescribed NN NN O
within NN NN O
3 NN NN O
months NN NN O
of NN NN O
the NN NN O
event NN NN O
, NN NN O
previous NN NN O
pregnancy NN NN O
, NN NN O
and NN NN O
concurrent NN NN O
disease NN NN O
. NN NN O
   
FINDINGS NN NN O
: NN NN O
85 NN NN O
women NN NN O
met NN NN O
the NN NN O
inclusion NN NN O
criteria NN NN O
for NN NN O
VTE NN NN B-Disease
, NN NN O
two NN NN O
of NN NN O
whom NN NN O
were NN NN O
users NN NN O
of NN NN O
progestagen NN NN O
- NN NN O
only NN NN O
OCs NN NN O
. NN NN O
   
Of NN NN O
the NN NN O
83 NN NN O
cases NN NN O
of NN NN O
VTE NN NN B-Disease
associated NN NN O
with NN NN O
use NN NN O
of NN NN O
combined NN NN O
OCs NN NN O
, NN NN O
43 NN NN O
were NN NN O
recorded NN NN O
as NN NN O
deep NN NN B-Disease
- NN NN I-Disease
vein NN NN I-Disease
thrombosis NN NN I-Disease
, NN NN O
35 NN NN O
as NN NN O
pulmonary NN NN O
thrombosis NN NN B-Disease
, NN NN O
and NN NN O
five NN NN O
as NN NN O
venous NN NN B-Disease
thrombosis NN NN I-Disease
not NN NN O
otherwise NN NN O
specified NN NN O
. NN NN O
   
The NN NN O
crude NN NN O
rate NN NN O
of NN NN O
VTE NN NN B-Disease
per NN NN O
10 NN NN O
, NN NN O
000 NN NN O
woman NN NN O
- NN NN O
years NN NN O
was NN NN O
4 NN NN O
. NN NN O
10 NN NN O
in NN NN O
current NN NN O
users NN NN O
of NN NN O
any NN NN O
OC NN NN O
, NN NN O
3 NN NN O
. NN NN O
10 NN NN O
in NN NN O
users NN NN O
of NN NN O
second NN NN O
- NN NN O
generation NN NN O
OCs NN NN O
, NN NN O
and NN NN O
4 NN NN O
. NN NN O
96 NN NN O
in NN NN O
users NN NN O
of NN NN O
third NN NN O
- NN NN O
generation NN NN O
preparations NN NN O
. NN NN O
   
After NN NN O
adjustment NN NN O
for NN NN O
age NN NN O
, NN NN O
the NN NN O
rate NN NN O
ratio NN NN O
of NN NN O
VTE NN NN B-Disease
in NN NN O
users NN NN O
of NN NN O
third NN NN O
- NN NN O
generation NN NN O
relative NN NN O
to NN NN O
second NN NN O
- NN NN O
generation NN NN O
OCs NN NN O
was NN NN O
1 NN NN O
. NN NN O
68 NN NN O
( NN NN O
95 NN NN O
% NN NN O
CI NN NN O
1 NN NN O
. NN NN O
04 NN NN O
- NN NN O
2 NN NN O
. NN NN O
75 NN NN O
) NN NN O
. NN NN O
   
Logistic NN NN O
regression NN NN O
showed NN NN O
no NN NN O
significant NN NN O
difference NN NN O
in NN NN O
the NN NN O
risk NN NN O
of NN NN O
VTE NN NN B-Disease
between NN NN O
users NN NN O
of NN NN O
third NN NN O
- NN NN O
generation NN NN O
and NN NN O
second NN NN O
- NN NN O
generation NN NN O
OCs NN NN O
. NN NN O
   
Among NN NN O
users NN NN O
of NN NN O
third NN NN O
- NN NN O
generation NN NN O
progestagens NN NN O
, NN NN O
the NN NN O
risk NN NN O
of NN NN O
VTE NN NN B-Disease
was NN NN O
higher NN NN O
in NN NN O
users NN NN O
of NN NN O
desogestrel NN NN O
with NN NN O
20 NN NN O
g NN NN O
ethinyloestradiol NN NN O
than NN NN O
in NN NN O
users NN NN O
of NN NN O
gestodene NN NN O
or NN NN O
desogestrel NN NN O
with NN NN O
30 NN NN O
g NN NN O
ethinyloestradiol NN NN O
. NN NN O
   
With NN NN O
all NN NN O
second NN NN O
- NN NN O
generation NN NN O
OCs NN NN O
as NN NN O
the NN NN O
reference NN NN O
, NN NN O
the NN NN O
odds NN NN O
ratios NN NN O
for NN NN O
VTE NN NN B-Disease
were NN NN O
3 NN NN O
. NN NN O
49 NN NN O
( NN NN O
1 NN NN O
. NN NN O
21 NN NN O
- NN NN O
10 NN NN O
. NN NN O
12 NN NN O
) NN NN O
for NN NN O
desogestrel NN NN O
plus NN NN O
20 NN NN O
g NN NN O
ethinyloestradiol NN NN O
and NN NN O
1 NN NN O
. NN NN O
18 NN NN O
( NN NN O
0 NN NN O
. NN NN O
66 NN NN O
- NN NN O
2 NN NN O
. NN NN O
17 NN NN O
) NN NN O
for NN NN O
the NN NN O
other NN NN O
third NN NN O
- NN NN O
generation NN NN O
progestagens NN NN O
. NN NN O
   
INTERPRETATION NN NN O
: NN NN O
The NN NN O
previously NN NN O
reported NN NN O
increase NN NN O
in NN NN O
odds NN NN O
ratio NN NN O
associated NN NN O
with NN NN O
third NN NN O
- NN NN O
generation NN NN O
OCs NN NN O
when NN NN O
compared NN NN O
with NN NN O
second NN NN O
- NN NN O
generation NN NN O
products NN NN O
is NN NN O
likely NN NN O
to NN NN O
have NN NN O
been NN NN O
the NN NN O
result NN NN O
of NN NN O
residual NN NN O
confounding NN NN O
by NN NN O
age NN NN O
. NN NN O
   
The NN NN O
increased NN NN O
odds NN NN O
ratio NN NN O
associated NN NN O
with NN NN O
products NN NN O
containing NN NN O
20 NN NN O
micrograms NN NN O
ethinyloestradiol NN NN O
and NN NN O
desogestrel NN NN O
compared NN NN O
with NN NN O
the NN NN O
30 NN NN O
micrograms NN NN O
product NN NN O
is NN NN O
biologically NN NN O
implausible NN NN O
, NN NN O
and NN NN O
is NN NN O
likely NN NN O
to NN NN O
be NN NN O
the NN NN O
result NN NN O
of NN NN O
preferential NN NN O
prescribing NN NN O
and NN NN O
, NN NN O
thus NN NN O
, NN NN O
confounding NN NN O
. NN NN O
   
MK NN NN O
- NN NN O
801 NN NN O
augments NN NN O
pilocarpine NN NN O
- NN NN O
induced NN NN O
electrographic NN NN O
seizure NN NN B-Disease
but NN NN O
protects NN NN O
against NN NN O
brain NN NN B-Disease
damage NN NN I-Disease
in NN NN O
rats NN NN O
. NN NN O
   
1 NN NN O
. NN NN O
   
The NN NN O
authors NN NN O
examined NN NN O
the NN NN O
anticonvulsant NN NN O
effects NN NN O
of NN NN O
MK NN NN O
- NN NN O
801 NN NN O
on NN NN O
the NN NN O
pilocarpine NN NN O
- NN NN O
induced NN NN O
seizure NN NN B-Disease
model NN NN O
. NN NN O
   
Intraperitoneal NN NN O
injection NN NN O
of NN NN O
pilocarpine NN NN O
( NN NN O
400 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
) NN NN O
induced NN NN O
tonic NN NN B-Disease
and NN NN I-Disease
clonic NN NN I-Disease
seizure NN NN I-Disease
. NN NN O
   
Scopolamine NN NN O
( NN NN O
10 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
) NN NN O
and NN NN O
pentobarbital NN NN O
( NN NN O
5 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
) NN NN O
prevented NN NN O
development NN NN O
of NN NN O
pilocarpine NN NN O
- NN NN O
induced NN NN O
behavioral NN NN O
seizure NN NN B-Disease
but NN NN O
MK NN NN O
- NN NN O
801 NN NN O
( NN NN O
0 NN NN O
. NN NN O
5 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
) NN NN O
did NN NN O
not NN NN O
. NN NN O
   
2 NN NN O
. NN NN O
   
An NN NN O
electrical NN NN O
seizure NN NN B-Disease
measured NN NN O
with NN NN O
hippocampal NN NN O
EEG NN NN O
appeared NN NN O
in NN NN O
the NN NN O
pilocarpine NN NN O
- NN NN O
treated NN NN O
group NN NN O
. NN NN O
   
Scopolamine NN NN O
and NN NN O
pentobarbital NN NN O
blocked NN NN O
the NN NN O
pilocarpine NN NN O
- NN NN O
induced NN NN O
electrographic NN NN O
seizure NN NN B-Disease
, NN NN O
MK NN NN O
- NN NN O
801 NN NN O
treatment NN NN O
augmented NN NN O
the NN NN O
electrographic NN NN O
seizure NN NN B-Disease
induced NN NN O
by NN NN O
pilocarpine NN NN O
. NN NN O
   
3 NN NN O
. NN NN O
   
Brain NN NN B-Disease
damage NN NN I-Disease
was NN NN O
assessed NN NN O
by NN NN O
examining NN NN O
the NN NN O
hippocampus NN NN O
microscopically NN NN O
. NN NN O
   
Pilocarpine NN NN O
produced NN NN O
neuronal NN NN B-Disease
death NN NN I-Disease
in NN NN O
the NN NN O
hippocampus NN NN O
, NN NN O
which NN NN O
showed NN NN O
pyknotic NN NN O
changes NN NN O
. NN NN O
   
Pentobarbital NN NN O
, NN NN O
scopolamine NN NN O
and NN NN O
MK NN NN O
- NN NN O
801 NN NN O
protected NN NN O
the NN NN O
brain NN NN B-Disease
damage NN NN I-Disease
by NN NN O
pilocarpine NN NN O
, NN NN O
though NN NN O
in NN NN O
the NN NN O
MK NN NN O
- NN NN O
801 NN NN O
- NN NN O
treated NN NN O
group NN NN O
, NN NN O
the NN NN O
pyramidal NN NN O
cells NN NN O
of NN NN O
hippocampus NN NN O
appeared NN NN O
darker NN NN O
than NN NN O
normal NN NN O
. NN NN O
   
In NN NN O
all NN NN O
treatments NN NN O
, NN NN O
granule NN NN O
cells NN NN O
of NN NN O
the NN NN O
dentate NN NN O
gyrus NN NN O
were NN NN O
not NN NN O
affected NN NN O
. NN NN O
   
4 NN NN O
. NN NN O
   
These NN NN O
results NN NN O
indicate NN NN O
that NN NN O
status NN NN B-Disease
epilepticus NN NN I-Disease
induced NN NN O
by NN NN O
pilocarpine NN NN O
is NN NN O
initiated NN NN O
by NN NN O
cholinergic NN NN O
overstimulation NN NN O
and NN NN O
propagated NN NN O
by NN NN O
glutamatergic NN NN O
transmission NN NN O
, NN NN O
the NN NN O
elevation NN NN O
of NN NN O
which NN NN O
may NN NN O
cause NN NN O
brain NN NN B-Disease
damage NN NN I-Disease
through NN NN O
an NN NN O
excitatory NN NN O
NMDA NN NN O
receptor NN NN O
- NN NN O
mediated NN NN O
mechanism NN NN O
. NN NN O
   
Paclitaxel NN NN O
, NN NN O
5 NN NN O
- NN NN O
fluorouracil NN NN O
, NN NN O
and NN NN O
folinic NN NN O
acid NN NN O
in NN NN O
metastatic NN NN O
breast NN NN B-Disease
cancer NN NN I-Disease
: NN NN O
BRE NN NN O
- NN NN O
26 NN NN O
, NN NN O
a NN NN O
phase NN NN O
II NN NN O
trial NN NN O
. NN NN O
   
5 NN NN O
- NN NN O
Fluorouracil NN NN O
plus NN NN O
folinic NN NN O
acid NN NN O
and NN NN O
paclitaxel NN NN O
( NN NN O
Taxol NN NN O
; NN NN O
Bristol NN NN O
- NN NN O
Myers NN NN O
Squibb NN NN O
Company NN NN O
, NN NN O
Princeton NN NN O
, NN NN O
NJ NN NN O
) NN NN O
are NN NN O
effective NN NN O
salvage NN NN O
therapies NN NN O
for NN NN O
metastatic NN NN O
breast NN NN B-Disease
cancer NN NN I-Disease
patients NN NN O
. NN NN O
   
Paclitaxel NN NN O
and NN NN O
5 NN NN O
- NN NN O
fluorouracil NN NN O
have NN NN O
additive NN NN O
cytotoxicity NN NN B-Disease
in NN NN O
MCF NN NN O
- NN NN O
7 NN NN O
cell NN NN O
lines NN NN O
. NN NN O
   
We NN NN O
performed NN NN O
a NN NN O
phase NN NN O
II NN NN O
trial NN NN O
of NN NN O
paclitaxel NN NN O
175 NN NN O
mg NN NN O
/ NN NN O
m2 NN NN O
over NN NN O
3 NN NN O
hours NN NN O
on NN NN O
day NN NN O
I NN NN O
followed NN NN O
by NN NN O
folinic NN NN O
acid NN NN O
300 NN NN O
mg NN NN O
over NN NN O
1 NN NN O
hour NN NN O
before NN NN O
5 NN NN O
- NN NN O
fluorouracil NN NN O
350 NN NN O
mg NN NN O
/ NN NN O
m2 NN NN O
on NN NN O
days NN NN O
1 NN NN O
to NN NN O
3 NN NN O
every NN NN O
28 NN NN O
days NN NN O
( NN NN O
TFL NN NN O
) NN NN O
in NN NN O
women NN NN O
with NN NN O
metastatic NN NN O
breast NN NN B-Disease
cancer NN NN I-Disease
. NN NN O
   
Analysis NN NN O
is NN NN O
reported NN NN O
on NN NN O
37 NN NN O
patients NN NN O
with NN NN O
a NN NN O
minimum NN NN O
of NN NN O
6 NN NN O
months NN NN O
follow NN NN O
- NN NN O
up NN NN O
who NN NN O
received NN NN O
a NN NN O
total NN NN O
of NN NN O
192 NN NN O
cycles NN NN O
of NN NN O
TFL NN NN O
: NN NN O
nine NN NN O
cycles NN NN O
( NN NN O
5 NN NN O
% NN NN O
) NN NN O
were NN NN O
associated NN NN O
with NN NN O
grade NN NN O
3 NN NN O
/ NN NN O
4 NN NN O
neutropenia NN NN B-Disease
requiring NN NN O
hospitalization NN NN O
; NN NN O
seven NN NN O
( NN NN O
4 NN NN O
% NN NN O
) NN NN O
cycles NN NN O
in NN NN O
two NN NN O
patients NN NN O
required NN NN O
granulocyte NN NN O
colony NN NN O
- NN NN O
stimulating NN NN O
factor NN NN O
due NN NN O
to NN NN O
neutropenia NN NN B-Disease
; NN NN O
no NN NN O
patient NN NN O
required NN NN O
platelet NN NN O
transfusions NN NN O
. NN NN O
   
Grade NN NN O
3 NN NN O
/ NN NN O
4 NN NN O
nonhematologic NN NN O
toxicities NN NN B-Disease
were NN NN O
uncommon NN NN O
. NN NN O
   
Among NN NN O
the NN NN O
34 NN NN O
patients NN NN O
evaluable NN NN O
for NN NN O
response NN NN O
, NN NN O
there NN NN O
were NN NN O
three NN NN O
complete NN NN O
responses NN NN O
( NN NN O
9 NN NN O
% NN NN O
) NN NN O
and NN NN O
18 NN NN O
partial NN NN O
responses NN NN O
( NN NN O
53 NN NN O
% NN NN O
) NN NN O
for NN NN O
an NN NN O
overall NN NN O
response NN NN O
rate NN NN O
of NN NN O
62 NN NN O
% NN NN O
. NN NN O
   
Of NN NN O
the NN NN O
19 NN NN O
evaluable NN NN O
patients NN NN O
with NN NN O
prior NN NN O
doxorubicin NN NN O
exposure NN NN O
, NN NN O
11 NN NN O
( NN NN O
58 NN NN O
% NN NN O
) NN NN O
responded NN NN O
compared NN NN O
with NN NN O
nine NN NN O
of NN NN O
15 NN NN O
( NN NN O
60 NN NN O
% NN NN O
) NN NN O
without NN NN O
prior NN NN O
doxorubicin NN NN O
. NN NN O
   
Plasma NN NN O
paclitaxel NN NN O
concentrations NN NN O
were NN NN O
measured NN NN O
at NN NN O
the NN NN O
completion NN NN O
of NN NN O
paclitaxel NN NN O
infusion NN NN O
and NN NN O
at NN NN O
24 NN NN O
hours NN NN O
in NN NN O
19 NN NN O
patients NN NN O
. NN NN O
   
TFL NN NN O
is NN NN O
an NN NN O
active NN NN O
, NN NN O
well NN NN O
- NN NN O
tolerated NN NN O
regimen NN NN O
in NN NN O
metastatic NN NN O
breast NN NN B-Disease
cancer NN NN I-Disease
. NN NN O
   
Efficacy NN NN O
and NN NN O
proarrhythmia NN NN B-Disease
with NN NN O
the NN NN O
use NN NN O
of NN NN O
d NN NN O
, NN NN O
l NN NN O
- NN NN O
sotalol NN NN O
for NN NN O
sustained NN NN O
ventricular NN NN B-Disease
tachyarrhythmias NN NN I-Disease
. NN NN O
   
This NN NN O
study NN NN O
prospectively NN NN O
evaluated NN NN O
the NN NN O
clinical NN NN O
efficacy NN NN O
, NN NN O
the NN NN O
incidence NN NN O
of NN NN O
torsades NN NN B-Disease
de NN NN I-Disease
pointes NN NN I-Disease
, NN NN O
and NN NN O
the NN NN O
presumable NN NN O
risk NN NN O
factors NN NN O
for NN NN O
torsades NN NN B-Disease
de NN NN I-Disease
pointes NN NN I-Disease
in NN NN O
patients NN NN O
treated NN NN O
with NN NN O
d NN NN O
, NN NN O
l NN NN O
- NN NN O
sotalol NN NN O
for NN NN O
sustained NN NN O
ventricular NN NN B-Disease
tachyarrhythmias NN NN I-Disease
. NN NN O
   
Eighty NN NN O
- NN NN O
one NN NN O
consecutive NN NN O
patients NN NN O
( NN NN O
54 NN NN O
with NN NN O
coronary NN NN B-Disease
artery NN NN I-Disease
disease NN NN I-Disease
, NN NN O
and NN NN O
20 NN NN O
with NN NN O
dilated NN NN B-Disease
cardiomyopathy NN NN I-Disease
) NN NN O
with NN NN O
inducible NN NN O
sustained NN NN O
ventricular NN NN B-Disease
tachycardia NN NN I-Disease
or NN NN O
ventricular NN NN B-Disease
fibrillation NN NN I-Disease
received NN NN O
oral NN NN O
d NN NN O
, NN NN O
l NN NN O
- NN NN O
sotalol NN NN O
to NN NN O
prevent NN NN O
induction NN NN O
of NN NN O
the NN NN O
ventricular NN NN B-Disease
tachyarrhythmia NN NN I-Disease
. NN NN O
   
During NN NN O
oral NN NN O
loading NN NN O
with NN NN O
d NN NN O
, NN NN O
l NN NN O
- NN NN O
sotalol NN NN O
, NN NN O
continuous NN NN O
electrocardiographic NN NN O
( NN NN O
ECG NN NN O
) NN NN O
monitoring NN NN O
was NN NN O
performed NN NN O
. NN NN O
   
Those NN NN O
patients NN NN O
in NN NN O
whom NN NN O
d NN NN O
, NN NN O
l NN NN O
- NN NN O
sotalol NN NN O
prevented NN NN O
induction NN NN O
of NN NN O
ventricular NN NN B-Disease
tachycardia NN NN I-Disease
or NN NN O
ventricular NN NN B-Disease
fibrillation NN NN I-Disease
were NN NN O
discharged NN NN O
with NN NN O
the NN NN O
drug NN NN O
and NN NN O
followed NN NN O
up NN NN O
on NN NN O
an NN NN O
outpatient NN NN O
basis NN NN O
for NN NN O
21 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
18 NN NN O
months NN NN O
. NN NN O
   
Induction NN NN O
of NN NN O
the NN NN O
ventricular NN NN B-Disease
tachyarrhythmia NN NN I-Disease
was NN NN O
prevented NN NN O
by NN NN O
oral NN NN O
d NN NN O
, NN NN O
l NN NN O
- NN NN O
sotalol NN NN O
in NN NN O
35 NN NN O
( NN NN O
43 NN NN O
% NN NN O
) NN NN O
patients NN NN O
; NN NN O
the NN NN O
ventricular NN NN B-Disease
tachyarrhythmia NN NN I-Disease
remained NN NN O
inducible NN NN O
in NN NN O
40 NN NN O
( NN NN O
49 NN NN O
% NN NN O
) NN NN O
patients NN NN O
; NN NN O
and NN NN O
two NN NN O
( NN NN O
2 NN NN O
. NN NN O
5 NN NN O
% NN NN O
) NN NN O
patients NN NN O
did NN NN O
not NN NN O
tolerate NN NN O
even NN NN O
40 NN NN O
mg NN NN O
of NN NN O
d NN NN O
, NN NN O
l NN NN O
- NN NN O
sotalol NN NN O
once NN NN O
daily NN NN O
. NN NN O
   
Four NN NN O
( NN NN O
5 NN NN O
% NN NN O
) NN NN O
patients NN NN O
had NN NN O
from NN NN O
torsades NN NN B-Disease
de NN NN I-Disease
pointes NN NN I-Disease
during NN NN O
the NN NN O
initial NN NN O
oral NN NN O
treatment NN NN O
with NN NN O
d NN NN O
, NN NN O
l NN NN O
- NN NN O
sotalol NN NN O
. NN NN O
   
Neither NN NN O
ECG NN NN O
[ NN NN O
sinus NN NN O
- NN NN O
cycle NN NN O
length NN NN O
( NN NN O
SCL NN NN O
) NN NN O
, NN NN O
QT NN NN O
or NN NN O
QTc NN NN O
interval NN NN O
, NN NN O
or NN NN O
U NN NN O
wave NN NN O
] NN NN O
nor NN NN O
clinical NN NN O
parameters NN NN O
identified NN NN O
patients NN NN O
at NN NN O
risk NN NN O
for NN NN O
torsades NN NN B-Disease
de NN NN I-Disease
pointes NN NN I-Disease
. NN NN O
   
However NN NN O
, NN NN O
the NN NN O
oral NN NN O
dose NN NN O
of NN NN O
d NN NN O
, NN NN O
l NN NN O
- NN NN O
sotalol NN NN O
was NN NN O
significantly NN NN O
lower NN NN O
in NN NN O
patients NN NN O
with NN NN O
torsades NN NN B-Disease
de NN NN I-Disease
pointes NN NN I-Disease
( NN NN O
200 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
46 NN NN O
vs NN NN O
. NN NN O
328 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
53 NN NN O
mg NN NN O
/ NN NN O
day NN NN O
; NN NN O
p NN NN O
= NN NN O
0 NN NN O
. NN NN O
0017 NN NN O
) NN NN O
. NN NN O
   
Risk NN NN O
factors NN NN O
associated NN NN O
with NN NN O
the NN NN O
development NN NN O
of NN NN O
torsades NN NN B-Disease
de NN NN I-Disease
pointes NN NN I-Disease
were NN NN O
the NN NN O
appearance NN NN O
of NN NN O
an NN NN O
U NN NN O
wave NN NN O
( NN NN O
p NN NN O
= NN NN O
0 NN NN O
. NN NN O
049 NN NN O
) NN NN O
, NN NN O
female NN NN O
gender NN NN O
( NN NN O
p NN NN O
= NN NN O
0 NN NN O
. NN NN O
015 NN NN O
) NN NN O
, NN NN O
and NN NN O
significant NN NN O
dose NN NN O
- NN NN O
corrected NN NN O
changes NN NN O
of NN NN O
SCL NN NN O
, NN NN O
QT NN NN O
interval NN NN O
, NN NN O
and NN NN O
QTc NN NN O
interval NN NN O
( NN NN O
p NN NN O
< NN NN O
0 NN NN O
. NN NN O
05 NN NN O
) NN NN O
. NN NN O
   
During NN NN O
follow NN NN O
- NN NN O
up NN NN O
, NN NN O
seven NN NN O
( NN NN O
20 NN NN O
% NN NN O
) NN NN O
patients NN NN O
had NN NN O
a NN NN O
nonfatal NN NN O
ventricular NN NN B-Disease
tachycardia NN NN I-Disease
recurrence NN NN O
, NN NN O
and NN NN O
two NN NN O
( NN NN O
6 NN NN O
% NN NN O
) NN NN O
patients NN NN O
died NN NN O
suddenly NN NN O
. NN NN O
   
One NN NN O
female NN NN O
patient NN NN O
with NN NN O
stable NN NN O
cardiac NN NN B-Disease
disease NN NN I-Disease
had NN NN O
recurrent NN NN O
torsades NN NN B-Disease
de NN NN I-Disease
pointes NN NN I-Disease
after NN NN O
2 NN NN O
years NN NN O
of NN NN O
successful NN NN O
treatment NN NN O
with NN NN O
d NN NN O
, NN NN O
l NN NN O
- NN NN O
sotalol NN NN O
. NN NN O
   
Torsades NN NN B-Disease
de NN NN I-Disease
pointes NN NN I-Disease
occurred NN NN O
early NN NN O
during NN NN O
treatment NN NN O
even NN NN O
with NN NN O
low NN NN O
doses NN NN O
of NN NN O
oral NN NN O
d NN NN O
, NN NN O
l NN NN O
- NN NN O
sotalol NN NN O
. NN NN O
   
Pronounced NN NN O
changes NN NN O
in NN NN O
the NN NN O
surface NN NN O
ECG NN NN O
( NN NN O
cycle NN NN O
length NN NN O
, NN NN O
QT NN NN O
, NN NN O
and NN NN O
QTc NN NN O
) NN NN O
in NN NN O
relation NN NN O
to NN NN O
the NN NN O
dose NN NN O
of NN NN O
oral NN NN O
d NN NN O
, NN NN O
l NN NN O
- NN NN O
sotalol NN NN O
might NN NN O
identify NN NN O
a NN NN O
subgroup NN NN O
of NN NN O
patients NN NN O
with NN NN O
an NN NN O
increased NN NN O
risk NN NN O
for NN NN O
torsades NN NN B-Disease
de NN NN I-Disease
pointes NN NN I-Disease
. NN NN O
   
Other NN NN O
ECG NN NN O
parameters NN NN O
before NN NN O
the NN NN O
application NN NN O
of NN NN O
d NN NN O
, NN NN O
l NN NN O
- NN NN O
sotalol NN NN O
did NN NN O
not NN NN O
identify NN NN O
patients NN NN O
at NN NN O
increased NN NN O
risk NN NN O
for NN NN O
torsades NN NN B-Disease
de NN NN I-Disease
pointes NN NN I-Disease
. NN NN O
   
Recurrence NN NN O
rates NN NN O
of NN NN O
ventricular NN NN B-Disease
tachyarrhythmias NN NN I-Disease
are NN NN O
high NN NN O
despite NN NN O
complete NN NN O
suppression NN NN O
of NN NN O
the NN NN O
arrhythmia NN NN B-Disease
during NN NN O
programmed NN NN O
stimulation NN NN O
. NN NN O
   
Therefore NN NN O
programmed NN NN O
electrical NN NN O
stimulation NN NN O
in NN NN O
the NN NN O
case NN NN O
of NN NN O
d NN NN O
, NN NN O
l NN NN O
- NN NN O
sotalol NN NN O
seems NN NN O
to NN NN O
be NN NN O
of NN NN O
limited NN NN O
prognostic NN NN O
value NN NN O
. NN NN O
   
Chronic NN NN O
hyperprolactinemia NN NN B-Disease
and NN NN O
changes NN NN O
in NN NN O
dopamine NN NN O
neurons NN NN O
. NN NN O
   
The NN NN O
tuberoinfundibular NN NN O
dopaminergic NN NN O
( NN NN O
TIDA NN NN O
) NN NN O
system NN NN O
is NN NN O
known NN NN O
to NN NN O
inhibit NN NN O
prolactin NN NN O
( NN NN O
PRL NN NN O
) NN NN O
secretion NN NN O
. NN NN O
   
In NN NN O
young NN NN O
animals NN NN O
this NN NN O
system NN NN O
responds NN NN O
to NN NN O
acute NN NN O
elevations NN NN O
in NN NN O
serum NN NN O
PRL NN NN O
by NN NN O
increasing NN NN O
its NN NN O
activity NN NN O
. NN NN O
   
However NN NN O
, NN NN O
this NN NN O
responsiveness NN NN O
is NN NN O
lost NN NN O
in NN NN O
aging NN NN O
rats NN NN O
with NN NN O
chronically NN NN O
high NN NN O
serum NN NN O
PRL NN NN O
levels NN NN O
. NN NN O
   
The NN NN O
purpose NN NN O
of NN NN O
this NN NN O
study NN NN O
was NN NN O
to NN NN O
induce NN NN O
hyperprolactinemia NN NN B-Disease
in NN NN O
rats NN NN O
for NN NN O
extended NN NN O
periods NN NN O
of NN NN O
time NN NN O
and NN NN O
examine NN NN O
its NN NN O
effects NN NN O
on NN NN O
dopaminergic NN NN O
systems NN NN O
in NN NN O
the NN NN O
brain NN NN O
. NN NN O
   
Hyperprolactinemia NN NN B-Disease
was NN NN O
induced NN NN O
by NN NN O
treatment NN NN O
with NN NN O
haloperidol NN NN O
, NN NN O
a NN NN O
dopamine NN NN O
receptor NN NN O
antagonist NN NN O
, NN NN O
and NN NN O
Palkovits NN NN O
' NN NN O
microdissection NN NN O
technique NN NN O
in NN NN O
combination NN NN O
with NN NN O
high NN NN O
- NN NN O
performance NN NN O
liquid NN NN O
chromatography NN NN O
was NN NN O
used NN NN O
to NN NN O
measure NN NN O
neurotransmitter NN NN O
concentrations NN NN O
in NN NN O
several NN NN O
areas NN NN O
of NN NN O
the NN NN O
brain NN NN O
. NN NN O
   
After NN NN O
6 NN NN O
months NN NN O
of NN NN O
hyperprolactinemia NN NN B-Disease
, NN NN O
dopamine NN NN O
( NN NN O
DA NN NN O
) NN NN O
concentrations NN NN O
in NN NN O
the NN NN O
median NN NN O
eminence NN NN O
( NN NN O
ME NN NN O
) NN NN O
increased NN NN O
by NN NN O
84 NN NN O
% NN NN O
over NN NN O
the NN NN O
control NN NN O
group NN NN O
. NN NN O
   
Nine NN NN O
months NN NN O
of NN NN O
hyperprolactinemia NN NN B-Disease
produced NN NN O
a NN NN O
50 NN NN O
% NN NN O
increase NN NN O
in NN NN O
DA NN NN O
concentrations NN NN O
in NN NN O
the NN NN O
ME NN NN O
over NN NN O
the NN NN O
control NN NN O
group NN NN O
. NN NN O
   
However NN NN O
, NN NN O
DA NN NN O
response NN NN O
was NN NN O
lost NN NN O
if NN NN O
a NN NN O
9 NN NN O
- NN NN O
month NN NN O
long NN NN O
haloperidol NN NN O
- NN NN O
induced NN NN O
hyperprolactinemia NN NN B-Disease
was NN NN O
followed NN NN O
by NN NN O
a NN NN O
1 NN NN O
1 NN NN O
/ NN NN O
2 NN NN O
month NN NN O
- NN NN O
long NN NN O
extremely NN NN O
high NN NN O
increase NN NN O
in NN NN O
serum NN NN O
PRL NN NN O
levels NN NN O
produced NN NN O
by NN NN O
implantation NN NN O
of NN NN O
MMQ NN NN O
cells NN NN O
under NN NN O
the NN NN O
kidney NN NN O
capsule NN NN O
. NN NN O
   
There NN NN O
was NN NN O
no NN NN O
change NN NN O
in NN NN O
the NN NN O
levels NN NN O
of NN NN O
DA NN NN O
, NN NN O
norepinephrine NN NN O
( NN NN O
NE NN NN O
) NN NN O
, NN NN O
serotonin NN NN O
( NN NN O
5 NN NN O
- NN NN O
HT NN NN O
) NN NN O
, NN NN O
or NN NN O
their NN NN O
metabolites NN NN O
in NN NN O
the NN NN O
arcuate NN NN O
nucleus NN NN O
( NN NN O
AN NN NN O
) NN NN O
, NN NN O
medial NN NN O
preoptic NN NN O
area NN NN O
( NN NN O
MPA NN NN O
) NN NN O
, NN NN O
caudate NN NN O
putamen NN NN O
( NN NN O
CP NN NN O
) NN NN O
, NN NN O
substantia NN NN O
nigra NN NN O
( NN NN O
SN NN NN O
) NN NN O
, NN NN O
and NN NN O
zona NN NN O
incerta NN NN O
( NN NN O
ZI NN NN O
) NN NN O
, NN NN O
except NN NN O
for NN NN O
a NN NN O
decrease NN NN O
in NN NN O
5 NN NN O
- NN NN O
hydroxyindoleacetic NN NN O
acid NN NN O
( NN NN O
5 NN NN O
- NN NN O
HIAA NN NN O
) NN NN O
in NN NN O
the NN NN O
AN NN NN O
after NN NN O
6 NN NN O
- NN NN O
months NN NN O
of NN NN O
hyperprolactinemia NN NN B-Disease
and NN NN O
an NN NN O
increase NN NN O
in NN NN O
DA NN NN O
concentrations NN NN O
in NN NN O
the NN NN O
AN NN NN O
after NN NN O
9 NN NN O
- NN NN O
months NN NN O
of NN NN O
hyperprolactinemia NN NN B-Disease
. NN NN O
   
These NN NN O
results NN NN O
demonstrate NN NN O
that NN NN O
hyperprolactinemia NN NN B-Disease
specifically NN NN O
affects NN NN O
TIDA NN NN O
neurons NN NN O
and NN NN O
these NN NN O
effects NN NN O
vary NN NN O
, NN NN O
depending NN NN O
on NN NN O
the NN NN O
duration NN NN O
and NN NN O
intensity NN NN O
of NN NN O
hyperprolactinemia NN NN B-Disease
. NN NN O
   
The NN NN O
age NN NN O
- NN NN O
related NN NN O
decrease NN NN O
in NN NN O
hypothalamic NN NN O
dopamine NN NN O
function NN NN O
may NN NN O
be NN NN O
associated NN NN O
with NN NN O
increases NN NN O
in NN NN O
PRL NN NN O
secretion NN NN O
. NN NN O
   
Treatment NN NN O
- NN NN O
related NN NN O
disseminated NN NN O
necrotizing NN NN O
leukoencephalopathy NN NN B-Disease
with NN NN O
characteristic NN NN O
contrast NN NN O
enhancement NN NN O
of NN NN O
the NN NN O
white NN NN O
matter NN NN O
. NN NN O
   
This NN NN O
report NN NN O
describes NN NN O
unique NN NN O
contrast NN NN O
enhancement NN NN O
of NN NN O
the NN NN O
white NN NN O
matter NN NN O
on NN NN O
T1 NN NN O
- NN NN O
weighted NN NN O
magnetic NN NN O
resonance NN NN O
images NN NN O
of NN NN O
two NN NN O
patients NN NN O
with NN NN O
disseminated NN NN O
necrotizing NN NN O
leukoencephalopathy NN NN B-Disease
, NN NN O
which NN NN O
developed NN NN O
from NN NN O
acute NN NN B-Disease
lymphoblastic NN NN I-Disease
leukemia NN NN I-Disease
treated NN NN O
with NN NN O
high NN NN O
- NN NN O
dose NN NN O
methotrexate NN NN O
. NN NN O
   
In NN NN O
both NN NN O
patients NN NN O
, NN NN O
the NN NN O
enhancement NN NN O
was NN NN O
more NN NN O
pronounced NN NN O
near NN NN O
the NN NN O
base NN NN O
of NN NN O
the NN NN O
brain NN NN O
than NN NN O
at NN NN O
the NN NN O
vertex NN NN O
. NN NN O
   
Necropsy NN NN O
of NN NN O
the NN NN O
first NN NN O
case NN NN O
revealed NN NN O
loss NN NN B-Disease
of NN NN I-Disease
myelination NN NN I-Disease
and NN NN O
necrosis NN NN B-Disease
of NN NN O
the NN NN O
white NN NN O
matter NN NN O
. NN NN O
   
Possible NN NN O
mechanisms NN NN O
causing NN NN O
such NN NN O
a NN NN O
leukoencephalopathy NN NN B-Disease
are NN NN O
discussed NN NN O
. NN NN O
   
Thrombotic NN NN B-Disease
complications NN NN O
in NN NN O
acute NN NN B-Disease
promyelocytic NN NN I-Disease
leukemia NN NN I-Disease
during NN NN O
all NN NN O
- NN NN O
trans NN NN O
- NN NN O
retinoic NN NN O
acid NN NN O
therapy NN NN O
. NN NN O
   
A NN NN O
case NN NN O
of NN NN O
acute NN NN B-Disease
renal NN NN I-Disease
failure NN NN I-Disease
, NN NN O
due NN NN O
to NN NN O
occlusion NN NN B-Disease
of NN NN I-Disease
renal NN NN I-Disease
vessels NN NN I-Disease
in NN NN O
a NN NN O
patient NN NN O
with NN NN O
acute NN NN B-Disease
promyelocytic NN NN I-Disease
leukemia NN NN I-Disease
( NN NN O
APL NN NN B-Disease
) NN NN O
treated NN NN O
with NN NN O
all NN NN O
- NN NN O
trans NN NN O
- NN NN O
retinoic NN NN O
acid NN NN O
( NN NN O
ATRA NN NN O
) NN NN O
and NN NN O
tranexamic NN NN O
acid NN NN O
has NN NN O
been NN NN O
described NN NN O
recently NN NN O
. NN NN O
   
We NN NN O
report NN NN O
a NN NN O
case NN NN O
of NN NN O
acute NN NN B-Disease
renal NN NN I-Disease
failure NN NN I-Disease
in NN NN O
an NN NN O
APL NN NN B-Disease
patient NN NN O
treated NN NN O
with NN NN O
ATRA NN NN O
alone NN NN O
. NN NN O
   
This NN NN O
case NN NN O
further NN NN O
supports NN NN O
the NN NN O
concern NN NN O
about NN NN O
thromboembolic NN NN B-Disease
complications NN NN O
associated NN NN O
with NN NN O
ATRA NN NN O
therapy NN NN O
in NN NN O
APL NN NN B-Disease
patients NN NN O
. NN NN O
   
The NN NN O
patients NN NN O
, NN NN O
a NN NN O
43 NN NN O
- NN NN O
year NN NN O
- NN NN O
old NN NN O
man NN NN O
, NN NN O
presented NN NN O
all NN NN O
the NN NN O
signs NN NN O
and NN NN O
symptoms NN NN O
of NN NN O
APL NN NN B-Disease
and NN NN O
was NN NN O
included NN NN O
in NN NN O
a NN NN O
treatment NN NN O
protocol NN NN O
with NN NN O
ATRA NN NN O
. NN NN O
   
After NN NN O
10 NN NN O
days NN NN O
of NN NN O
treatment NN NN O
, NN NN O
he NN NN O
developed NN NN O
acute NN NN B-Disease
renal NN NN I-Disease
failure NN NN I-Disease
that NN NN O
was NN NN O
completely NN NN O
reversible NN NN O
after NN NN O
complete NN NN O
remission NN NN O
of NN NN O
APL NN NN B-Disease
was NN NN O
achieved NN NN O
and NN NN O
therapy NN NN O
discontinued NN NN O
. NN NN O
   
We NN NN O
conclude NN NN O
that NN NN O
ATRA NN NN O
is NN NN O
a NN NN O
valid NN NN O
therapeutic NN NN O
choice NN NN O
for NN NN O
patients NN NN O
with NN NN O
APL NN NN B-Disease
, NN NN O
although NN NN O
the NN NN O
procoagulant NN NN O
tendency NN NN O
is NN NN O
not NN NN O
completely NN NN O
corrected NN NN O
. NN NN O
   
Thrombotic NN NN B-Disease
events NN NN O
, NN NN O
however NN NN O
, NN NN O
could NN NN O
be NN NN O
avoided NN NN O
by NN NN O
using NN NN O
low NN NN O
- NN NN O
dose NN NN O
heparin NN NN O
. NN NN O
   
Pupillary NN NN O
changes NN NN O
associated NN NN O
with NN NN O
the NN NN O
development NN NN O
of NN NN O
stimulant NN NN O
- NN NN O
induced NN NN O
mania NN NN B-Disease
: NN NN O
a NN NN O
case NN NN O
report NN NN O
. NN NN O
   
A NN NN O
30 NN NN O
- NN NN O
year NN NN O
- NN NN O
old NN NN O
cocaine NN NN O
- NN NN O
dependent NN NN O
man NN NN O
who NN NN O
was NN NN O
a NN NN O
subject NN NN O
in NN NN O
a NN NN O
study NN NN O
evaluating NN NN O
the NN NN O
anticraving NN NN O
efficacy NN NN O
of NN NN O
the NN NN O
stimulant NN NN O
medication NN NN O
diethylpropion NN NN O
( NN NN O
DEP NN NN O
) NN NN O
became NN NN O
manic NN NN B-Disease
during NN NN O
his NN NN O
second NN NN O
week NN NN O
on NN NN O
the NN NN O
study NN NN O
drug NN NN O
. NN NN O
   
Pupillometric NN NN O
changes NN NN O
while NN NN O
on NN NN O
DEP NN NN O
, NN NN O
especially NN NN O
changes NN NN O
in NN NN O
the NN NN O
total NN NN O
power NN NN O
of NN NN O
pupillary NN NN B-Disease
oscillation NN NN I-Disease
, NN NN O
were NN NN O
dramatically NN NN O
different NN NN O
than NN NN O
those NN NN O
observed NN NN O
in NN NN O
the NN NN O
eight NN NN O
other NN NN O
study NN NN O
subjects NN NN O
who NN NN O
did NN NN O
not NN NN O
become NN NN O
manic NN NN B-Disease
. NN NN O
   
The NN NN O
large NN NN O
changes NN NN O
in NN NN O
total NN NN O
power NN NN O
of NN NN O
pupillary NN NN B-Disease
oscillation NN NN I-Disease
occurred NN NN O
a NN NN O
few NN NN O
days NN NN O
before NN NN O
the NN NN O
patient NN NN O
became NN NN O
fully NN NN O
manic NN NN B-Disease
. NN NN O
   
Such NN NN O
medication NN NN O
- NN NN O
associated NN NN O
changes NN NN O
in NN NN O
the NN NN O
total NN NN O
power NN NN O
of NN NN O
pupillary NN NN B-Disease
oscillation NN NN I-Disease
might NN NN O
be NN NN O
of NN NN O
utility NN NN O
in NN NN O
identifying NN NN O
persons NN NN O
at NN NN O
risk NN NN O
for NN NN O
manic NN NN B-Disease
- NN NN O
like NN NN O
adverse NN NN O
effects NN NN O
during NN NN O
the NN NN O
medical NN NN O
use NN NN O
of NN NN O
psychomotor NN NN O
stimulants NN NN O
or NN NN O
sympathomimetic NN NN O
agents NN NN O
. NN NN O
   
Fetal NN NN O
risks NN NN O
due NN NN O
to NN NN O
warfarin NN NN O
therapy NN NN O
during NN NN O
pregnancy NN NN O
. NN NN O
   
Two NN NN O
mothers NN NN O
with NN NN O
heart NN NN O
valve NN NN O
prosthesis NN NN O
were NN NN O
treated NN NN O
with NN NN O
warfarin NN NN O
during NN NN O
pregnancy NN NN O
. NN NN O
   
In NN NN O
the NN NN O
first NN NN O
case NN NN O
a NN NN O
caesarean NN NN O
section NN NN O
was NN NN O
done NN NN O
one NN NN O
week NN NN O
after NN NN O
replacement NN NN O
of NN NN O
warfarin NN NN O
with NN NN O
heparin NN NN O
. NN NN O
   
The NN NN O
baby NN NN O
died NN NN O
of NN NN O
cerebral NN NN B-Disease
and NN NN I-Disease
pulmonary NN NN I-Disease
hemorrhage NN NN I-Disease
. NN NN O
   
The NN NN O
second NN NN O
mother NN NN O
had NN NN O
a NN NN O
male NN NN O
infant NN NN O
by NN NN O
caesarean NN NN O
section NN NN O
. NN NN O
   
The NN NN O
baby NN NN O
showed NN NN O
warfarin NN NN O
- NN NN O
induced NN NN O
embryopathy NN NN B-Disease
with NN NN O
nasal NN NN B-Disease
hypoplasia NN NN I-Disease
and NN NN O
stippled NN NN B-Disease
epiphyses NN NN I-Disease
( NN NN O
chondrodysplasia NN NN B-Disease
punctata NN NN I-Disease
) NN NN O
. NN NN O
   
Nasal NN NN B-Disease
hypoplasia NN NN I-Disease
with NN NN O
or NN NN O
without NN NN O
stippled NN NN B-Disease
epiphyses NN NN I-Disease
has NN NN O
now NN NN O
been NN NN O
reported NN NN O
in NN NN O
11 NN NN O
infants NN NN O
born NN NN O
to NN NN O
mothers NN NN O
treated NN NN O
with NN NN O
warfarin NN NN O
during NN NN O
the NN NN O
first NN NN O
trimester NN NN O
, NN NN O
and NN NN O
a NN NN O
causal NN NN O
association NN NN O
is NN NN O
probable NN NN O
. NN NN O
   
In NN NN O
view NN NN O
of NN NN O
the NN NN O
risks NN NN O
to NN NN O
both NN NN O
mother NN NN O
and NN NN O
fetus NN NN O
in NN NN O
women NN NN O
with NN NN O
prosthetic NN NN O
cardiac NN NN O
valves NN NN O
it NN NN O
is NN NN O
recommended NN NN O
that NN NN O
therapeutic NN NN O
abortion NN NN O
be NN NN O
advised NN NN O
as NN NN O
the NN NN O
first NN NN O
alternative NN NN O
. NN NN O
   
The NN NN O
negative NN NN O
mucosal NN NN O
potential NN NN O
: NN NN O
separating NN NN O
central NN NN O
and NN NN O
peripheral NN NN O
effects NN NN O
of NN NN O
NSAIDs NN NN O
in NN NN O
man NN NN O
. NN NN O
   
OBJECTIVE NN NN O
: NN NN O
We NN NN O
wanted NN NN O
to NN NN O
test NN NN O
whether NN NN O
assessment NN NN O
of NN NN O
both NN NN O
a NN NN O
central NN NN O
pain NN NN B-Disease
- NN NN O
related NN NN O
signal NN NN O
( NN NN O
chemo NN NN O
- NN NN O
somatosensory NN NN O
evoked NN NN O
potential NN NN O
, NN NN O
CSSEP NN NN O
) NN NN O
and NN NN O
a NN NN O
concomitantly NN NN O
recorded NN NN O
peripheral NN NN O
signal NN NN O
( NN NN O
negative NN NN O
mucosal NN NN O
potential NN NN O
, NN NN O
NMP NN NN O
) NN NN O
allows NN NN O
for NN NN O
separation NN NN O
of NN NN O
central NN NN O
and NN NN O
peripheral NN NN O
effects NN NN O
of NN NN O
NSAIDs NN NN O
. NN NN O
   
For NN NN O
this NN NN O
purpose NN NN O
, NN NN O
experimental NN NN O
conditions NN NN O
were NN NN O
created NN NN O
in NN NN O
which NN NN O
NSAIDs NN NN O
had NN NN O
previously NN NN O
been NN NN O
observed NN NN O
to NN NN O
produce NN NN O
effects NN NN O
on NN NN O
phasic NN NN O
and NN NN O
tonic NN NN O
pain NN NN B-Disease
by NN NN O
either NN NN O
central NN NN O
or NN NN O
peripheral NN NN O
mechanisms NN NN O
. NN NN O
   
METHODS NN NN O
: NN NN O
According NN NN O
to NN NN O
a NN NN O
double NN NN O
- NN NN O
blind NN NN O
, NN NN O
randomised NN NN O
, NN NN O
controlled NN NN O
, NN NN O
threefold NN NN O
cross NN NN O
- NN NN O
over NN NN O
design NN NN O
, NN NN O
18 NN NN O
healthy NN NN O
subjects NN NN O
( NN NN O
11 NN NN O
males NN NN O
, NN NN O
7 NN NN O
females NN NN O
; NN NN O
mean NN NN O
age NN NN O
26 NN NN O
years NN NN O
) NN NN O
received NN NN O
either NN NN O
placebo NN NN O
, NN NN O
400 NN NN O
mg NN NN O
ibuprofen NN NN O
, NN NN O
or NN NN O
800 NN NN O
mg NN NN O
ibuprofen NN NN O
. NN NN O
   
Phasic NN NN O
pain NN NN B-Disease
was NN NN O
applied NN NN O
by NN NN O
means NN NN O
of NN NN O
short NN NN O
pulses NN NN O
of NN NN O
CO2 NN NN O
to NN NN O
the NN NN O
nasal NN NN O
mucosa NN NN O
( NN NN O
stimulus NN NN O
duration NN NN O
500 NN NN O
ms NN NN O
, NN NN O
interval NN NN O
approximately NN NN O
60 NN NN O
s NN NN O
) NN NN O
, NN NN O
and NN NN O
tonic NN NN O
pain NN NN B-Disease
was NN NN O
induced NN NN O
in NN NN O
the NN NN O
nasal NN NN O
cavity NN NN O
by NN NN O
means NN NN O
of NN NN O
dry NN NN O
air NN NN O
of NN NN O
controlled NN NN O
temperature NN NN O
, NN NN O
humidity NN NN O
and NN NN O
flow NN NN O
rate NN NN O
( NN NN O
22 NN NN O
degrees NN NN O
C NN NN O
, NN NN O
0 NN NN O
% NN NN O
relative NN NN O
humidity NN NN O
, NN NN O
145 NN NN O
ml NN NN O
. NN NN O
s NN NN O
- NN NN O
1 NN NN O
) NN NN O
. NN NN O
   
Both NN NN O
CSSEPs NN NN O
as NN NN O
central NN NN O
and NN NN O
NMPs NN NN O
as NN NN O
peripheral NN NN O
correlates NN NN O
of NN NN O
pain NN NN B-Disease
were NN NN O
obtained NN NN O
in NN NN O
response NN NN O
to NN NN O
the NN NN O
CO2 NN NN O
stimuli NN NN O
. NN NN O
   
Additionally NN NN O
, NN NN O
the NN NN O
subjects NN NN O
rated NN NN O
the NN NN O
intensity NN NN O
of NN NN O
both NN NN O
phasic NN NN O
and NN NN O
tonic NN NN O
pain NN NN B-Disease
by NN NN O
means NN NN O
of NN NN O
visual NN NN O
analogue NN NN O
scales NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
As NN NN O
described NN NN O
earlier NN NN O
, NN NN O
administration NN NN O
of NN NN O
ibuprofen NN NN O
was NN NN O
followed NN NN O
by NN NN O
a NN NN O
decrease NN NN O
in NN NN O
tonic NN NN O
pain NN NN B-Disease
but NN NN O
- NN NN O
relative NN NN O
to NN NN O
placebo NN NN O
- NN NN O
an NN NN O
increase NN NN O
in NN NN O
correlates NN NN O
of NN NN O
phasic NN NN O
pain NN NN B-Disease
, NN NN O
indicating NN NN O
a NN NN O
specific NN NN O
effect NN NN O
of NN NN O
ibuprofen NN NN O
on NN NN O
the NN NN O
interaction NN NN O
between NN NN O
the NN NN O
pain NN NN B-Disease
stimuli NN NN O
under NN NN O
these NN NN O
special NN NN O
experimental NN NN O
conditions NN NN O
. NN NN O
   
Based NN NN O
on NN NN O
the NN NN O
similar NN NN O
behaviour NN NN O
of NN NN O
CSSEP NN NN O
and NN NN O
NMP NN NN O
, NN NN O
it NN NN O
was NN NN O
concluded NN NN O
that NN NN O
the NN NN O
pharmacological NN NN O
process NN NN O
underlying NN NN O
this NN NN O
phenomenon NN NN O
was NN NN O
localised NN NN O
in NN NN O
the NN NN O
periphery NN NN O
. NN NN O
   
By NN NN O
means NN NN O
of NN NN O
the NN NN O
simultaneous NN NN O
recording NN NN O
of NN NN O
interrelated NN NN O
peripheral NN NN O
and NN NN O
central NN NN O
electrophysiologic NN NN O
correlates NN NN O
of NN NN O
nociception NN NN O
, NN NN O
it NN NN O
was NN NN O
possible NN NN O
to NN NN O
separate NN NN O
central NN NN O
and NN NN O
peripheral NN NN O
effects NN NN O
of NN NN O
an NN NN O
NSAID NN NN O
. NN NN O
   
The NN NN O
major NN NN O
advantage NN NN O
of NN NN O
this NN NN O
pain NN NN B-Disease
model NN NN O
is NN NN O
the NN NN O
possibility NN NN O
of NN NN O
obtaining NN NN O
peripheral NN NN O
pain NN NN B-Disease
- NN NN O
related NN NN O
activity NN NN O
directly NN NN O
using NN NN O
a NN NN O
non NN NN O
- NN NN O
invasive NN NN O
technique NN NN O
in NN NN O
humans NN NN O
. NN NN O
   
Effect NN NN O
of NN NN O
D NN NN O
- NN NN O
Glucarates NN NN O
on NN NN O
basic NN NN O
antibiotic NN NN O
- NN NN O
induced NN NN O
renal NN NN B-Disease
damage NN NN I-Disease
in NN NN O
rats NN NN O
. NN NN O
   
Dehydrated NN NN B-Disease
rats NN NN O
regularly NN NN O
develop NN NN O
acute NN NN B-Disease
renal NN NN I-Disease
failure NN NN I-Disease
following NN NN O
single NN NN O
injection NN NN O
of NN NN O
aminoglycoside NN NN O
antibiotics NN NN O
combined NN NN O
with NN NN O
dextran NN NN O
or NN NN O
of NN NN O
antibiotics NN NN O
only NN NN O
. NN NN O
   
Oral NN NN O
administration NN NN O
of NN NN O
2 NN NN O
, NN NN O
5 NN NN O
- NN NN O
di NN NN O
- NN NN O
O NN NN O
- NN NN O
acetyl NN NN O
- NN NN O
D NN NN O
- NN NN O
glucaro NN NN O
- NN NN O
1 NN NN O
, NN NN O
4 NN NN O
- NN NN O
6 NN NN O
, NN NN O
3 NN NN O
- NN NN O
dilactone NN NN O
protected NN NN O
rats NN NN O
against NN NN O
renal NN NN B-Disease
failure NN NN I-Disease
induced NN NN O
by NN NN O
kanamycin NN NN O
- NN NN O
dextran NN NN O
. NN NN O
   
The NN NN O
protective NN NN O
effect NN NN O
was NN NN O
prevalent NN NN O
among NN NN O
D NN NN O
- NN NN O
glucarates NN NN O
, NN NN O
and NN NN O
also NN NN O
to NN NN O
other NN NN O
saccharic NN NN O
acid NN NN O
, NN NN O
hexauronic NN NN O
acids NN NN O
and NN NN O
hexaaldonic NN NN O
acids NN NN O
, NN NN O
although NN NN O
to NN NN O
a NN NN O
lesser NN NN O
degree NN NN O
, NN NN O
but NN NN O
not NN NN O
to NN NN O
a NN NN O
hexaaldose NN NN O
, NN NN O
sugar NN NN O
alcohols NN NN O
, NN NN O
substances NN NN O
inthe NN NN O
TCA NN NN O
cycle NN NN O
and NN NN O
other NN NN O
acidic NN NN O
compounds NN NN O
. NN NN O
   
D NN NN O
- NN NN O
Glucarates NN NN O
were NN NN O
effective NN NN O
against NN NN O
renal NN NN B-Disease
damage NN NN I-Disease
induced NN NN O
by NN NN O
peptide NN NN O
antibiotics NN NN O
as NN NN O
well NN NN O
as NN NN O
various NN NN O
aminoglycoside NN NN O
antibitocis NN NN O
. NN NN O
   
Dose NN NN O
- NN NN O
responses NN NN O
were NN NN O
observed NN NN O
in NN NN O
the NN NN O
protective NN NN O
effect NN NN O
of NN NN O
D NN NN O
- NN NN O
Glucarates NN NN O
. NN NN O
   
With NN NN O
a NN NN O
D NN NN O
- NN NN O
glucarate NN NN O
of NN NN O
a NN NN O
fixed NN NN O
size NN NN O
of NN NN O
dose NN NN O
, NN NN O
approximately NN NN O
the NN NN O
same NN NN O
degree NN NN O
of NN NN O
protection NN NN O
was NN NN O
obtained NN NN O
against NN NN O
renal NN NN B-Disease
damages NN NN I-Disease
induced NN NN O
by NN NN O
different NN NN O
basic NN NN O
antibiotics NN NN O
despite NN NN O
large NN NN O
disparities NN NN O
in NN NN O
administration NN NN O
doses NN NN O
of NN NN O
different NN NN O
antibiotics NN NN O
. NN NN O
   
D NN NN O
- NN NN O
Glucarates NN NN O
had NN NN O
the NN NN O
ability NN NN O
to NN NN O
prevent NN NN O
renal NN NN B-Disease
damage NN NN I-Disease
but NN NN O
not NN NN O
to NN NN O
cure NN NN O
it NN NN O
. NN NN O
   
Rats NN NN O
excreted NN NN O
acidic NN NN O
urine NN NN O
when NN NN O
they NN NN O
were NN NN O
spared NN NN O
from NN NN O
renal NN NN B-Disease
lesions NN NN I-Disease
by NN NN O
monosaccharides NN NN O
. NN NN O
   
The NN NN O
reduction NN NN O
effect NN NN O
of NN NN O
D NN NN O
- NN NN O
glucarates NN NN O
against NN NN O
nephrotoxicity NN NN B-Disease
of NN NN O
basic NN NN O
antibiotics NN NN O
was NN NN O
discussed NN NN O
. NN NN O
   
Acute NN NN O
severe NN NN O
depression NN NN B-Disease
following NN NN O
peri NN NN O
- NN NN O
operative NN NN O
ondansetron NN NN O
. NN NN O
   
A NN NN O
41 NN NN O
- NN NN O
year NN NN O
- NN NN O
old NN NN O
woman NN NN O
with NN NN O
a NN NN O
strong NN NN O
history NN NN O
of NN NN O
postoperative NN NN B-Disease
nausea NN NN I-Disease
and NN NN I-Disease
vomiting NN NN I-Disease
presented NN NN O
for NN NN O
abdominal NN NN O
hysterectomy NN NN O
3 NN NN O
months NN NN O
after NN NN O
a NN NN O
previous NN NN O
anaesthetic NN NN O
where NN NN O
ondansetron NN NN O
prophylaxis NN NN O
had NN NN O
been NN NN O
used NN NN O
. NN NN O
   
She NN NN O
had NN NN O
developed NN NN O
a NN NN O
severe NN NN O
acute NN NN O
major NN NN B-Disease
depression NN NN I-Disease
disorder NN NN I-Disease
almost NN NN O
immediately NN NN O
thereafter NN NN O
, NN NN O
possibly NN NN O
related NN NN O
to NN NN O
the NN NN O
use NN NN O
of NN NN O
a NN NN O
serotonin NN NN O
antagonist NN NN O
. NN NN O
   
Nine NN NN O
years NN NN O
before NN NN O
she NN NN O
had NN NN O
experienced NN NN O
a NN NN O
self NN NN O
- NN NN O
limited NN NN O
puerperal NN NN O
depressive NN NN B-Disease
episode NN NN I-Disease
. NN NN O
   
Anaesthesia NN NN O
with NN NN O
a NN NN O
propofol NN NN O
infusion NN NN O
and NN NN O
avoidance NN NN O
of NN NN O
serotonin NN NN O
antagonists NN NN O
provided NN NN O
a NN NN O
nausea NN NN B-Disease
- NN NN O
free NN NN O
postoperative NN NN O
course NN NN O
without NN NN O
exacerbation NN NN O
of NN NN O
the NN NN O
depression NN NN B-Disease
disorder NN NN I-Disease
. NN NN O
   
Hypertensive NN NN B-Disease
response NN NN O
during NN NN O
dobutamine NN NN O
stress NN NN O
echocardiography NN NN O
. NN NN O
   
Among NN NN O
3 NN NN O
, NN NN O
129 NN NN O
dobutamine NN NN O
stress NN NN O
echocardiographic NN NN O
studies NN NN O
, NN NN O
a NN NN O
hypertensive NN NN B-Disease
response NN NN O
, NN NN O
defined NN NN O
as NN NN O
systolic NN NN O
blood NN NN O
pressure NN NN O
( NN NN O
BP NN NN O
) NN NN O
> NN NN O
or NN NN O
= NN NN O
220 NN NN O
mm NN NN O
Hg NN NN O
and NN NN O
/ NN NN O
or NN NN O
diastolic NN NN O
BP NN NN O
> NN NN O
or NN NN O
= NN NN O
110 NN NN O
mm NN NN O
Hg NN NN O
, NN NN O
occurred NN NN O
in NN NN O
30 NN NN O
patients NN NN O
( NN NN O
1 NN NN O
% NN NN O
) NN NN O
. NN NN O
   
Patients NN NN O
with NN NN O
this NN NN O
response NN NN O
more NN NN O
often NN NN O
had NN NN O
a NN NN O
history NN NN O
of NN NN O
hypertension NN NN B-Disease
and NN NN O
had NN NN O
higher NN NN O
resting NN NN O
systolic NN NN O
and NN NN O
diastolic NN NN O
BP NN NN O
before NN NN O
dobutamine NN NN O
infusion NN NN O
. NN NN O
   
Continuously NN NN O
nebulized NN NN O
albuterol NN NN O
in NN NN O
severe NN NN O
exacerbations NN NN O
of NN NN O
asthma NN NN B-Disease
in NN NN O
adults NN NN O
: NN NN O
a NN NN O
case NN NN O
- NN NN O
controlled NN NN O
study NN NN O
. NN NN O
   
A NN NN O
retrospective NN NN O
, NN NN O
case NN NN O
- NN NN O
controlled NN NN O
analysis NN NN O
comparing NN NN O
patients NN NN O
admitted NN NN O
to NN NN O
a NN NN O
medical NN NN O
intensive NN NN O
care NN NN O
unit NN NN O
with NN NN O
severe NN NN O
exacerbations NN NN O
of NN NN O
asthma NN NN B-Disease
who NN NN O
received NN NN O
continuously NN NN O
nebulized NN NN O
albuterol NN NN O
( NN NN O
CNA NN NN O
) NN NN O
versus NN NN O
intermittent NN NN O
albuterol NN NN O
( NN NN O
INA NN NN O
) NN NN O
treatments NN NN O
is NN NN O
reported NN NN O
. NN NN O
   
Forty NN NN O
matched NN NN O
pairs NN NN O
of NN NN O
patients NN NN O
with NN NN O
asthma NN NN B-Disease
are NN NN O
compared NN NN O
. NN NN O
   
CNA NN NN O
was NN NN O
administered NN NN O
for NN NN O
a NN NN O
mean NN NN O
of NN NN O
11 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
10 NN NN O
hr NN NN O
. NN NN O
   
The NN NN O
incidence NN NN O
of NN NN O
cardiac NN NN B-Disease
dysrhythmias NN NN I-Disease
was NN NN O
similar NN NN O
between NN NN O
groups NN NN O
. NN NN O
   
Symptomatic NN NN O
hypokalemia NN NN B-Disease
did NN NN O
not NN NN O
occur NN NN O
. NN NN O
   
CNA NN NN O
patients NN NN O
had NN NN O
higher NN NN O
heart NN NN O
rates NN NN O
during NN NN O
treatment NN NN O
, NN NN O
which NN NN O
may NN NN O
reflect NN NN O
severity NN NN O
of NN NN O
illness NN NN O
. NN NN O
   
The NN NN O
incidence NN NN O
of NN NN O
intubation NN NN O
was NN NN O
similar NN NN O
. NN NN O
   
We NN NN O
conclude NN NN O
that NN NN O
CNA NN NN O
and NN NN O
INA NN NN O
demonstrated NN NN O
similar NN NN O
profiles NN NN O
with NN NN O
regard NN NN O
to NN NN O
safety NN NN O
, NN NN O
morbidity NN NN O
, NN NN O
and NN NN O
mortality NN NN O
. NN NN O
   
Paraplegia NN NN B-Disease
following NN NN O
intrathecal NN NN O
methotrexate NN NN O
: NN NN O
report NN NN O
of NN NN O
a NN NN O
case NN NN O
and NN NN O
review NN NN O
of NN NN O
the NN NN O
literature NN NN O
. NN NN O
   
A NN NN O
patient NN NN O
who NN NN O
developed NN NN O
paraplegia NN NN B-Disease
following NN NN O
the NN NN O
intrathecal NN NN O
instillation NN NN O
of NN NN O
methotrexate NN NN O
is NN NN O
discribed NN NN O
. NN NN O
   
The NN NN O
ten NN NN O
previously NN NN O
reported NN NN O
cases NN NN O
of NN NN O
this NN NN O
unusual NN NN O
complication NN NN O
are NN NN O
reviewed NN NN O
. NN NN O
   
The NN NN O
following NN NN O
factors NN NN O
appear NN NN O
to NN NN O
predispose NN NN O
to NN NN O
the NN NN O
development NN NN O
of NN NN O
this NN NN O
complication NN NN O
: NN NN O
abnormal NN NN O
cerebrospinal NN NN O
dynamics NN NN O
related NN NN O
to NN NN O
the NN NN O
presence NN NN O
of NN NN O
central NN NN B-Disease
nervous NN NN I-Disease
system NN NN I-Disease
leukemia NN NN I-Disease
, NN NN O
and NN NN O
epidural NN NN O
cerebrospinal NN NN O
leakage NN NN O
; NN NN O
elevated NN NN O
cerebrospinal NN NN O
fluid NN NN O
methothexate NN NN O
concentration NN NN O
related NN NN O
to NN NN O
abnormal NN NN O
cerebrospinal NN NN O
fluid NN NN O
dynamics NN NN O
and NN NN O
to NN NN O
inappropriately NN NN O
high NN NN O
methotrexate NN NN O
doses NN NN O
based NN NN O
on NN NN O
body NN NN O
surface NN NN O
area NN NN O
calculations NN NN O
in NN NN O
older NN NN O
children NN NN O
and NN NN O
adults NN NN O
; NN NN O
the NN NN O
presence NN NN O
of NN NN O
neurotoxic NN NN B-Disease
preservatives NN NN O
in NN NN O
commercially NN NN O
available NN NN O
methotrexate NN NN O
preparations NN NN O
and NN NN O
diluents NN NN O
; NN NN O
and NN NN O
the NN NN O
use NN NN O
of NN NN O
methotrexate NN NN O
diluents NN NN O
of NN NN O
unphysiologic NN NN O
pH NN NN O
, NN NN O
ionic NN NN O
content NN NN O
and NN NN O
osmolarity NN NN O
. NN NN O
   
The NN NN O
role NN NN O
of NN NN O
methotrexate NN NN O
contaminants NN NN O
, NN NN O
local NN NN O
folate NN NN B-Disease
deficiency NN NN I-Disease
, NN NN O
and NN NN O
cranial NN NN O
irradiation NN NN O
in NN NN O
the NN NN O
pathogenesis NN NN O
of NN NN O
intrathecal NN NN O
methotrexate NN NN O
toxicity NN NN B-Disease
is NN NN O
unclear NN NN O
. NN NN O
   
The NN NN O
incidence NN NN O
of NN NN O
neurotoxicity NN NN B-Disease
may NN NN O
be NN NN O
reduced NN NN O
by NN NN O
employing NN NN O
lower NN NN O
doses NN NN O
of NN NN O
methotrexate NN NN O
in NN NN O
the NN NN O
presence NN NN O
of NN NN O
central NN NN B-Disease
nervous NN NN I-Disease
system NN NN I-Disease
leukemia NN NN I-Disease
, NN NN O
in NN NN O
older NN NN O
children NN NN O
and NN NN O
adults NN NN O
, NN NN O
and NN NN O
in NN NN O
the NN NN O
presence NN NN O
of NN NN O
epidural NN NN O
leakage NN NN O
. NN NN O
   
Only NN NN O
preservative NN NN O
- NN NN O
free NN NN O
methotrexate NN NN O
in NN NN O
Elliott NN NN O
' NN NN O
s NN NN O
B NN NN O
Solution NN NN O
at NN NN O
a NN NN O
concentration NN NN O
of NN NN O
not NN NN O
more NN NN O
than NN NN O
1 NN NN O
mg NN NN O
/ NN NN O
ml NN NN O
should NN NN O
be NN NN O
used NN NN O
for NN NN O
intrathecal NN NN O
administration NN NN O
. NN NN O
   
Periodic NN NN O
monitoring NN NN O
of NN NN O
cerebruspinal NN NN O
fluid NN NN O
methotrexate NN NN O
levels NN NN O
may NN NN O
be NN NN O
predictive NN NN O
of NN NN O
the NN NN O
development NN NN O
of NN NN O
serious NN NN O
neurotoxicity NN NN B-Disease
. NN NN O
   
Hyperosmolar NN NN B-Disease
nonketotic NN NN I-Disease
coma NN NN I-Disease
precipitated NN NN O
by NN NN O
lithium NN NN O
- NN NN O
induced NN NN O
nephrogenic NN NN B-Disease
diabetes NN NN I-Disease
insipidus NN NN I-Disease
. NN NN O
   
A NN NN O
45 NN NN O
- NN NN O
year NN NN O
- NN NN O
old NN NN O
man NN NN O
, NN NN O
with NN NN O
a NN NN O
10 NN NN O
- NN NN O
year NN NN O
history NN NN O
of NN NN O
manic NN NN B-Disease
depression NN NN I-Disease
treated NN NN O
with NN NN O
lithium NN NN O
, NN NN O
was NN NN O
admitted NN NN O
with NN NN O
hyperosmolar NN NN B-Disease
, NN NN I-Disease
nonketotic NN NN I-Disease
coma NN NN I-Disease
. NN NN O
   
He NN NN O
gave NN NN O
a NN NN O
five NN NN O
- NN NN O
year NN NN O
history NN NN O
of NN NN O
polyuria NN NN B-Disease
and NN NN O
polydipsia NN NN B-Disease
, NN NN O
during NN NN O
which NN NN O
time NN NN O
urinalysis NN NN O
had NN NN O
been NN NN O
negative NN NN O
for NN NN O
glucose NN NN O
. NN NN O
   
After NN NN O
recovery NN NN O
from NN NN O
hyperglycaemia NN NN B-Disease
, NN NN O
he NN NN O
remained NN NN O
polyuric NN NN B-Disease
despite NN NN O
normal NN NN O
blood NN NN O
glucose NN NN O
concentrations NN NN O
; NN NN O
water NN NN O
deprivation NN NN O
testing NN NN O
indicated NN NN O
nephrogenic NN NN B-Disease
diabetes NN NN I-Disease
insipidus NN NN I-Disease
, NN NN O
likely NN NN O
to NN NN O
be NN NN O
lithium NN NN O
- NN NN O
induced NN NN O
. NN NN O
   
We NN NN O
hypothesize NN NN O
that NN NN O
when NN NN O
this NN NN O
man NN NN O
developed NN NN O
type NN NN B-Disease
2 NN NN I-Disease
diabetes NN NN I-Disease
, NN NN O
chronic NN NN O
polyuria NN NN B-Disease
due NN NN O
to NN NN O
nephrogenic NN NN B-Disease
diabetes NN NN I-Disease
insipidus NN NN I-Disease
was NN NN O
sufficient NN NN O
to NN NN O
precipitate NN NN O
hyperosmolar NN NN O
dehydration NN NN B-Disease
. NN NN O
   
Effects NN NN O
of NN NN O
the NN NN O
intracoronary NN NN O
infusion NN NN O
of NN NN O
cocaine NN NN O
on NN NN O
left NN NN O
ventricular NN NN O
systolic NN NN O
and NN NN O
diastolic NN NN O
function NN NN O
in NN NN O
humans NN NN O
. NN NN O
   
BACKGROUND NN NN O
: NN NN O
In NN NN O
dogs NN NN O
, NN NN O
a NN NN O
large NN NN O
amount NN NN O
of NN NN O
intravenous NN NN O
cocaine NN NN O
causes NN NN O
a NN NN O
profound NN NN O
deterioration NN NN B-Disease
of NN NN I-Disease
left NN NN I-Disease
ventricular NN NN I-Disease
( NN NN I-Disease
LV NN NN I-Disease
) NN NN I-Disease
systolic NN NN I-Disease
function NN NN I-Disease
and NN NN O
an NN NN O
increase NN NN O
in NN NN O
LV NN NN O
end NN NN O
- NN NN O
diastolic NN NN O
pressure NN NN O
. NN NN O
   
This NN NN O
study NN NN O
was NN NN O
done NN NN O
to NN NN O
assess NN NN O
the NN NN O
influence NN NN O
of NN NN O
a NN NN O
high NN NN O
intracoronary NN NN O
cocaine NN NN O
concentration NN NN O
on NN NN O
LV NN NN O
systolic NN NN O
and NN NN O
diastolic NN NN O
function NN NN O
in NN NN O
humans NN NN O
. NN NN O
   
METHODS NN NN O
AND NN NN O
RESULTS NN NN O
: NN NN O
In NN NN O
20 NN NN O
patients NN NN O
( NN NN O
14 NN NN O
men NN NN O
and NN NN O
6 NN NN O
women NN NN O
aged NN NN O
39 NN NN O
to NN NN O
72 NN NN O
years NN NN O
) NN NN O
referred NN NN O
for NN NN O
cardiac NN NN O
catheterization NN NN O
for NN NN O
the NN NN O
evaluation NN NN O
of NN NN O
chest NN NN B-Disease
pain NN NN I-Disease
, NN NN O
we NN NN O
measured NN NN O
heart NN NN O
rate NN NN O
, NN NN O
systemic NN NN O
arterial NN NN O
pressure NN NN O
, NN NN O
LV NN NN O
pressure NN NN O
and NN NN O
its NN NN O
first NN NN O
derivative NN NN O
( NN NN O
dP NN NN O
/ NN NN O
dt NN NN O
) NN NN O
, NN NN O
and NN NN O
LV NN NN O
volumes NN NN O
and NN NN O
ejection NN NN O
fraction NN NN O
before NN NN O
and NN NN O
during NN NN O
the NN NN O
final NN NN O
2 NN NN O
to NN NN O
3 NN NN O
minutes NN NN O
of NN NN O
a NN NN O
15 NN NN O
- NN NN O
minute NN NN O
intracoronary NN NN O
infusion NN NN O
of NN NN O
saline NN NN O
( NN NN O
n NN NN O
= NN NN O
10 NN NN O
, NN NN O
control NN NN O
subjects NN NN O
) NN NN O
or NN NN O
cocaine NN NN O
hydrochloride NN NN O
1 NN NN O
mg NN NN O
/ NN NN O
min NN NN O
( NN NN O
n NN NN O
= NN NN O
10 NN NN O
) NN NN O
. NN NN O
   
No NN NN O
variable NN NN O
changed NN NN O
with NN NN O
saline NN NN O
. NN NN O
   
With NN NN O
cocaine NN NN O
, NN NN O
the NN NN O
drug NN NN O
concentration NN NN O
in NN NN O
blood NN NN O
obtained NN NN O
from NN NN O
the NN NN O
coronary NN NN O
sinus NN NN O
was NN NN O
3 NN NN O
. NN NN O
0 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
0 NN NN O
. NN NN O
4 NN NN O
( NN NN O
mean NN NN O
+ NN NN O
/ NN NN O
- NN NN O
SD NN NN O
) NN NN O
mg NN NN O
/ NN NN O
L NN NN O
, NN NN O
similar NN NN O
in NN NN O
magnitude NN NN O
to NN NN O
the NN NN O
blood NN NN O
cocaine NN NN O
concentration NN NN O
reported NN NN O
in NN NN O
abusers NN NN O
dying NN NN O
of NN NN O
cocaine NN NN O
intoxication NN NN O
. NN NN O
   
Cocaine NN NN O
induced NN NN O
no NN NN O
significant NN NN O
change NN NN O
in NN NN O
heart NN NN O
rate NN NN O
, NN NN O
LV NN NN O
dP NN NN O
/ NN NN O
dt NN NN O
( NN NN O
positive NN NN O
or NN NN O
negative NN NN O
) NN NN O
, NN NN O
or NN NN O
LV NN NN O
end NN NN O
- NN NN O
diastolic NN NN O
volume NN NN O
, NN NN O
but NN NN O
it NN NN O
caused NN NN O
an NN NN O
increase NN NN O
in NN NN O
systolic NN NN O
and NN NN O
mean NN NN O
arterial NN NN O
pressures NN NN O
, NN NN O
LV NN NN O
end NN NN O
- NN NN O
diastolic NN NN O
pressure NN NN O
, NN NN O
and NN NN O
LV NN NN O
end NN NN O
- NN NN O
systolic NN NN O
volume NN NN O
, NN NN O
as NN NN O
well NN NN O
as NN NN O
a NN NN O
decrease NN NN O
in NN NN O
LV NN NN O
ejection NN NN O
fraction NN NN O
. NN NN O
   
CONCLUSIONS NN NN O
: NN NN O
In NN NN O
humans NN NN O
, NN NN O
the NN NN O
intracoronary NN NN O
infusion NN NN O
of NN NN O
cocaine NN NN O
sufficient NN NN O
in NN NN O
amount NN NN O
to NN NN O
achieve NN NN O
a NN NN O
high NN NN O
drug NN NN O
concentration NN NN O
in NN NN O
coronary NN NN O
sinus NN NN O
blood NN NN O
causes NN NN O
a NN NN O
deterioration NN NN B-Disease
of NN NN I-Disease
LV NN NN I-Disease
systolic NN NN I-Disease
and NN NN I-Disease
diastolic NN NN I-Disease
performance NN NN I-Disease
. NN NN O
   
Ascending NN NN O
dose NN NN O
tolerance NN NN O
study NN NN O
of NN NN O
intramuscular NN NN O
carbetocin NN NN O
administered NN NN O
after NN NN O
normal NN NN O
vaginal NN NN O
birth NN NN O
. NN NN O
   
OBJECTIVE NN NN O
: NN NN O
To NN NN O
determine NN NN O
the NN NN O
maximum NN NN O
tolerated NN NN O
dose NN NN O
( NN NN O
MTD NN NN O
) NN NN O
of NN NN O
carbetocin NN NN O
( NN NN O
a NN NN O
long NN NN O
- NN NN O
acting NN NN O
synthetic NN NN O
analogue NN NN O
of NN NN O
oxytocin NN NN O
) NN NN O
, NN NN O
when NN NN O
administered NN NN O
immediately NN NN O
after NN NN O
vaginal NN NN O
delivery NN NN O
at NN NN O
term NN NN O
. NN NN O
   
MATERIALS NN NN O
AND NN NN O
METHODS NN NN O
: NN NN O
Carbetocin NN NN O
was NN NN O
given NN NN O
as NN NN O
an NN NN O
intramuscular NN NN O
injection NN NN O
immediately NN NN O
after NN NN O
the NN NN O
birth NN NN O
of NN NN O
the NN NN O
infant NN NN O
in NN NN O
45 NN NN O
healthy NN NN O
women NN NN O
with NN NN O
normal NN NN O
singleton NN NN O
pregnancies NN NN O
who NN NN O
delivered NN NN O
vaginally NN NN O
at NN NN O
term NN NN O
. NN NN O
   
Dosage NN NN O
groups NN NN O
of NN NN O
15 NN NN O
, NN NN O
30 NN NN O
, NN NN O
50 NN NN O
, NN NN O
75 NN NN O
, NN NN O
100 NN NN O
, NN NN O
125 NN NN O
, NN NN O
150 NN NN O
, NN NN O
175 NN NN O
or NN NN O
200 NN NN O
microg NN NN O
carbetocin NN NN O
were NN NN O
assigned NN NN O
to NN NN O
blocks NN NN O
of NN NN O
three NN NN O
women NN NN O
according NN NN O
to NN NN O
the NN NN O
continual NN NN O
reassessment NN NN O
method NN NN O
( NN NN O
CRM NN NN O
) NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
All NN NN O
dosage NN NN O
groups NN NN O
consisted NN NN O
of NN NN O
three NN NN O
women NN NN O
, NN NN O
except NN NN O
those NN NN O
with NN NN O
100 NN NN O
microg NN NN O
( NN NN O
n NN NN O
= NN NN O
6 NN NN O
) NN NN O
and NN NN O
200 NN NN O
microg NN NN O
( NN NN O
n NN NN O
= NN NN O
18 NN NN O
) NN NN O
. NN NN O
   
Recorded NN NN O
were NN NN O
dose NN NN O
- NN NN O
limiting NN NN O
adverse NN NN O
events NN NN O
: NN NN O
hyper NN NN B-Disease
- NN NN I-Disease
or NN NN I-Disease
hypotension NN NN I-Disease
( NN NN O
three NN NN O
) NN NN O
, NN NN O
severe NN NN O
abdominal NN NN B-Disease
pain NN NN I-Disease
( NN NN O
0 NN NN O
) NN NN O
, NN NN O
vomiting NN NN B-Disease
( NN NN O
0 NN NN O
) NN NN O
and NN NN O
retained NN NN B-Disease
placenta NN NN I-Disease
( NN NN O
four NN NN O
) NN NN O
. NN NN O
   
Serious NN NN O
adverse NN NN O
events NN NN O
occurred NN NN O
in NN NN O
seven NN NN O
women NN NN O
: NN NN O
six NN NN O
cases NN NN O
with NN NN O
blood NN NN B-Disease
loss NN NN I-Disease
> NN NN O
or NN NN O
= NN NN O
1000 NN NN O
ml NN NN O
, NN NN O
four NN NN O
cases NN NN O
of NN NN O
manual NN NN O
placenta NN NN O
removal NN NN O
, NN NN O
five NN NN O
cases NN NN O
of NN NN O
additional NN NN O
oxytocics NN NN O
administration NN NN O
and NN NN O
five NN NN O
cases NN NN O
of NN NN O
blood NN NN O
transfusion NN NN O
. NN NN O
   
Maximum NN NN O
blood NN NN B-Disease
loss NN NN I-Disease
was NN NN O
greatest NN NN O
at NN NN O
the NN NN O
upper NN NN O
and NN NN O
lower NN NN O
dose NN NN O
levels NN NN O
, NN NN O
and NN NN O
lowest NN NN O
in NN NN O
the NN NN O
70 NN NN O
- NN NN O
125 NN NN O
microg NN NN O
dose NN NN O
range NN NN O
. NN NN O
   
Four NN NN O
out NN NN O
of NN NN O
six NN NN O
cases NN NN O
with NN NN O
blood NN NN B-Disease
loss NN NN I-Disease
> NN NN O
or NN NN O
= NN NN O
1000 NN NN O
ml NN NN O
occurred NN NN O
in NN NN O
the NN NN O
200 NN NN O
microg NN NN O
group NN NN O
. NN NN O
   
The NN NN O
majority NN NN O
of NN NN O
additional NN NN O
administration NN NN O
of NN NN O
oxytocics NN NN O
( NN NN O
4 NN NN O
/ NN NN O
5 NN NN O
) NN NN O
and NN NN O
blood NN NN O
transfusion NN NN O
( NN NN O
3 NN NN O
/ NN NN O
5 NN NN O
) NN NN O
occurred NN NN O
in NN NN O
the NN NN O
dose NN NN O
groups NN NN O
of NN NN O
200 NN NN O
microg NN NN O
. NN NN O
   
All NN NN O
retained NN NN O
placentae NN NN O
were NN NN O
found NN NN O
in NN NN O
the NN NN O
group NN NN O
of NN NN O
200 NN NN O
microg NN NN O
. NN NN O
   
CONCLUSION NN NN O
: NN NN O
The NN NN O
MTD NN NN O
was NN NN O
calculated NN NN O
to NN NN O
be NN NN O
at NN NN O
200 NN NN O
microg NN NN O
carbetocin NN NN O
. NN NN O
   
Heparin NN NN O
- NN NN O
induced NN NN O
thrombocytopenia NN NN B-Disease
, NN NN O
paradoxical NN NN O
thromboembolism NN NN B-Disease
, NN NN O
and NN NN O
other NN NN O
side NN NN O
effects NN NN O
of NN NN O
heparin NN NN O
therapy NN NN O
. NN NN O
   
Although NN NN O
several NN NN O
new NN NN O
anticoagulant NN NN O
drugs NN NN O
are NN NN O
in NN NN O
development NN NN O
, NN NN O
heparin NN NN O
remains NN NN O
the NN NN O
drug NN NN O
of NN NN O
choice NN NN O
for NN NN O
most NN NN O
anticoagulation NN NN O
needs NN NN O
. NN NN O
   
The NN NN O
clinical NN NN O
effects NN NN O
of NN NN O
heparin NN NN O
are NN NN O
meritorious NN NN O
, NN NN O
but NN NN O
side NN NN O
effects NN NN O
do NN NN O
exist NN NN O
. NN NN O
   
Important NN NN O
untoward NN NN O
effects NN NN O
of NN NN O
heparin NN NN O
therapy NN NN O
including NN NN O
heparin NN NN O
- NN NN O
induced NN NN O
thrombocytopenia NN NN B-Disease
, NN NN O
heparin NN NN O
- NN NN O
associated NN NN O
osteoporosis NN NN B-Disease
, NN NN O
eosinophilia NN NN B-Disease
, NN NN O
skin NN NN B-Disease
reactions NN NN I-Disease
, NN NN O
allergic NN NN B-Disease
reactions NN NN I-Disease
other NN NN O
than NN NN O
thrombocytopenia NN NN B-Disease
and NN NN O
alopecia NN NN B-Disease
will NN NN O
be NN NN O
discussed NN NN O
in NN NN O
this NN NN O
article NN NN O
. NN NN O
   
Nonopaque NN NN O
crystal NN NN O
deposition NN NN O
causing NN NN O
ureteric NN NN B-Disease
obstruction NN NN I-Disease
in NN NN O
patients NN NN O
with NN NN O
HIV NN NN O
undergoing NN NN O
indinavir NN NN O
therapy NN NN O
. NN NN O
   
OBJECTIVE NN NN O
: NN NN O
We NN NN O
describe NN NN O
the NN NN O
unique NN NN O
CT NN NN O
features NN NN O
of NN NN O
ureteric NN NN B-Disease
calculi NN NN I-Disease
in NN NN O
six NN NN O
HIV NN NN B-Disease
- NN NN I-Disease
infected NN NN I-Disease
patients NN NN O
receiving NN NN O
indinavir NN NN O
, NN NN O
the NN NN O
most NN NN O
commonly NN NN O
used NN NN O
HIV NN NN O
protease NN NN O
inhibitor NN NN O
, NN NN O
which NN NN O
is NN NN O
associated NN NN O
with NN NN O
an NN NN O
increased NN NN O
incidence NN NN O
of NN NN O
urolithiasis NN NN B-Disease
. NN NN O
   
CONCLUSION NN NN O
: NN NN O
Ureteric NN NN B-Disease
obstruction NN NN I-Disease
caused NN NN O
by NN NN O
precipitated NN NN O
indinavir NN NN O
crystals NN NN O
may NN NN O
be NN NN O
difficult NN NN O
to NN NN O
diagnose NN NN O
with NN NN O
unenhanced NN NN O
CT NN NN O
. NN NN O
   
The NN NN O
calculi NN NN O
are NN NN O
not NN NN O
opaque NN NN O
, NN NN O
and NN NN O
secondary NN NN O
signs NN NN O
of NN NN O
obstruction NN NN O
may NN NN O
be NN NN O
absent NN NN O
or NN NN O
minimal NN NN O
and NN NN O
should NN NN O
be NN NN O
sought NN NN O
carefully NN NN O
. NN NN O
   
Images NN NN O
may NN NN O
need NN NN O
to NN NN O
be NN NN O
obtained NN NN O
using NN NN O
i NN NN O
. NN NN O
v NN NN O
. NN NN O
contrast NN NN O
material NN NN O
to NN NN O
enable NN NN O
diagnosis NN NN O
of NN NN O
ureteric NN NN B-Disease
stones NN NN I-Disease
or NN NN I-Disease
obstruction NN NN I-Disease
in NN NN O
patients NN NN O
with NN NN O
HIV NN NN B-Disease
infection NN NN I-Disease
who NN NN O
receive NN NN O
indinavir NN NN O
therapy NN NN O
. NN NN O
   
Ischemic NN NN B-Disease
colitis NN NN I-Disease
and NN NN O
sumatriptan NN NN O
use NN NN O
. NN NN O
   
Sumatriptan NN NN O
succinate NN NN O
, NN NN O
a NN NN O
serotonin NN NN O
- NN NN O
1 NN NN O
( NN NN O
5 NN NN O
- NN NN O
hydroxytryptamine NN NN O
- NN NN O
1 NN NN O
) NN NN O
receptor NN NN O
agonist NN NN O
, NN NN O
is NN NN O
an NN NN O
antimigraine NN NN O
drug NN NN O
that NN NN O
is NN NN O
reported NN NN O
to NN NN O
act NN NN O
by NN NN O
selectively NN NN O
constricting NN NN O
intracranial NN NN O
arteries NN NN O
. NN NN O
   
Recently NN NN O
, NN NN O
vasopressor NN NN O
responses NN NN O
that NN NN O
are NN NN O
distinct NN NN O
from NN NN O
the NN NN O
cranial NN NN O
circulation NN NN O
have NN NN O
been NN NN O
demonstrated NN NN O
to NN NN O
occur NN NN O
in NN NN O
the NN NN O
systemic NN NN O
, NN NN O
pulmonary NN NN O
, NN NN O
and NN NN O
coronary NN NN O
circulations NN NN O
. NN NN O
   
Cases NN NN O
have NN NN O
been NN NN O
published NN NN O
of NN NN O
coronary NN NN B-Disease
vasospasm NN NN I-Disease
, NN NN O
myocardial NN NN B-Disease
ischemia NN NN I-Disease
, NN NN O
and NN NN O
myocardial NN NN B-Disease
infarction NN NN I-Disease
occurring NN NN O
after NN NN O
sumatriptan NN NN O
use NN NN O
. NN NN O
   
We NN NN O
report NN NN O
on NN NN O
the NN NN O
development NN NN O
of NN NN O
8 NN NN O
serious NN NN O
cases NN NN O
of NN NN O
ischemic NN NN B-Disease
colitis NN NN I-Disease
in NN NN O
patients NN NN O
with NN NN O
migraine NN NN B-Disease
treated NN NN O
with NN NN O
sumatriptan NN NN O
. NN NN O
   
Pallidotomy NN NN O
with NN NN O
the NN NN O
gamma NN NN O
knife NN NN O
: NN NN O
a NN NN O
positive NN NN O
experience NN NN O
. NN NN O
   
51 NN NN O
patients NN NN O
with NN NN O
medically NN NN O
refractory NN NN O
Parkinson NN NN B-Disease
' NN NN I-Disease
s NN NN I-Disease
disease NN NN I-Disease
underwent NN NN O
stereotactic NN NN O
posteromedial NN NN O
pallidotomy NN NN O
between NN NN O
August NN NN O
1993 NN NN O
and NN NN O
February NN NN O
1997 NN NN O
for NN NN O
treatment NN NN O
of NN NN O
bradykinesia NN NN B-Disease
, NN NN O
rigidity NN NN B-Disease
, NN NN O
and NN NN O
L NN NN O
- NN NN O
DOPA NN NN O
- NN NN O
induced NN NN O
dyskinesias NN NN B-Disease
. NN NN O
   
In NN NN O
29 NN NN O
patients NN NN O
, NN NN O
the NN NN O
pallidotomies NN NN O
were NN NN O
performed NN NN O
with NN NN O
the NN NN O
Leksell NN NN O
Gamma NN NN O
Knife NN NN O
and NN NN O
in NN NN O
22 NN NN O
they NN NN O
were NN NN O
performed NN NN O
with NN NN O
the NN NN O
standard NN NN O
radiofrequency NN NN O
( NN NN O
RF NN NN O
) NN NN O
method NN NN O
. NN NN O
   
Clinical NN NN O
assessment NN NN O
as NN NN O
well NN NN O
as NN NN O
blinded NN NN O
ratings NN NN O
of NN NN O
Unified NN NN O
Parkinson NN NN B-Disease
' NN NN I-Disease
s NN NN I-Disease
Disease NN NN I-Disease
Rating NN NN O
Scale NN NN O
( NN NN O
UPDRS NN NN O
) NN NN O
scores NN NN O
were NN NN O
carried NN NN O
out NN NN O
pre NN NN O
- NN NN O
and NN NN O
postoperatively NN NN O
. NN NN O
   
Mean NN NN O
follow NN NN O
- NN NN O
up NN NN O
time NN NN O
is NN NN O
20 NN NN O
. NN NN O
6 NN NN O
months NN NN O
( NN NN O
range NN NN O
6 NN NN O
- NN NN O
48 NN NN O
) NN NN O
and NN NN O
all NN NN O
except NN NN O
4 NN NN O
patients NN NN O
have NN NN O
been NN NN O
followed NN NN O
more NN NN O
than NN NN O
one NN NN O
year NN NN O
. NN NN O
   
85 NN NN O
percent NN NN O
of NN NN O
patients NN NN O
with NN NN O
dyskinesias NN NN B-Disease
were NN NN O
relieved NN NN O
of NN NN O
symptoms NN NN O
, NN NN O
regardless NN NN O
of NN NN O
whether NN NN O
the NN NN O
pallidotomies NN NN O
were NN NN O
performed NN NN O
with NN NN O
the NN NN O
Gamma NN NN O
Knife NN NN O
or NN NN O
radiofrequency NN NN O
methods NN NN O
. NN NN O
   
About NN NN O
2 NN NN O
/ NN NN O
3 NN NN O
of NN NN O
the NN NN O
patients NN NN O
in NN NN O
both NN NN O
Gamma NN NN O
Knife NN NN O
and NN NN O
radiofrequency NN NN O
groups NN NN O
showed NN NN O
improvements NN NN O
in NN NN O
bradykinesia NN NN B-Disease
and NN NN O
rigidity NN NN B-Disease
, NN NN O
although NN NN O
when NN NN O
considered NN NN O
as NN NN O
a NN NN O
group NN NN O
neither NN NN O
the NN NN O
Gamma NN NN O
Knife NN NN O
nor NN NN O
the NN NN O
radiofrequency NN NN O
group NN NN O
showed NN NN O
statistically NN NN O
significant NN NN O
improvements NN NN O
in NN NN O
UPDRS NN NN O
scores NN NN O
. NN NN O
   
One NN NN O
patient NN NN O
in NN NN O
the NN NN O
Gamma NN NN O
Knife NN NN O
group NN NN O
( NN NN O
3 NN NN O
. NN NN O
4 NN NN O
% NN NN O
) NN NN O
developed NN NN O
a NN NN O
homonymous NN NN B-Disease
hemianopsia NN NN I-Disease
9 NN NN O
months NN NN O
following NN NN O
treatment NN NN O
and NN NN O
5 NN NN O
patients NN NN O
( NN NN O
27 NN NN O
. NN NN O
7 NN NN O
% NN NN O
) NN NN O
in NN NN O
the NN NN O
radiofrequency NN NN O
group NN NN O
became NN NN O
transiently NN NN O
confused NN NN O
postoperatively NN NN O
. NN NN O
   
No NN NN O
other NN NN O
complications NN NN O
were NN NN O
seen NN NN O
. NN NN O
   
Gamma NN NN O
Knife NN NN O
pallidotomy NN NN O
is NN NN O
as NN NN O
effective NN NN O
as NN NN O
radiofrequency NN NN O
pallidotomy NN NN O
in NN NN O
controlling NN NN O
certain NN NN O
of NN NN O
the NN NN O
symptoms NN NN O
of NN NN O
Parkinson NN NN B-Disease
' NN NN I-Disease
s NN NN I-Disease
disease NN NN I-Disease
. NN NN O
   
It NN NN O
may NN NN O
be NN NN O
the NN NN O
only NN NN O
practical NN NN O
technique NN NN O
available NN NN O
in NN NN O
certain NN NN O
patients NN NN O
, NN NN O
such NN NN O
as NN NN O
those NN NN O
who NN NN O
take NN NN O
anticoagulants NN NN O
, NN NN O
have NN NN O
bleeding NN NN B-Disease
diatheses NN NN O
or NN NN O
serious NN NN O
systemic NN NN O
medical NN NN O
illnesses NN NN O
. NN NN O
   
It NN NN O
is NN NN O
a NN NN O
viable NN NN O
option NN NN O
for NN NN O
other NN NN O
patients NN NN O
as NN NN O
well NN NN O
. NN NN O
   
Centrally NN NN O
mediated NN NN O
cardiovascular NN NN O
effects NN NN O
of NN NN O
intracisternal NN NN O
application NN NN O
of NN NN O
carbachol NN NN O
in NN NN O
anesthetized NN NN O
rats NN NN O
. NN NN O
   
The NN NN O
pressor NN NN O
response NN NN O
to NN NN O
the NN NN O
intracisternal NN NN O
( NN NN O
i NN NN O
. NN NN O
c NN NN O
. NN NN O
) NN NN O
injection NN NN O
of NN NN O
carbachol NN NN O
( NN NN O
1 NN NN O
mug NN NN O
) NN NN O
in NN NN O
anesthetized NN NN O
rats NN NN O
was NN NN O
analyzed NN NN O
. NN NN O
   
This NN NN O
response NN NN O
was NN NN O
significantly NN NN O
reduced NN NN O
by NN NN O
the NN NN O
intravenous NN NN O
( NN NN O
i NN NN O
. NN NN O
v NN NN O
. NN NN O
) NN NN O
injection NN NN O
of NN NN O
guanethidine NN NN O
( NN NN O
5 NN NN O
mg NN NN O
) NN NN O
, NN NN O
hexamethonium NN NN O
( NN NN O
10 NN NN O
mg NN NN O
) NN NN O
or NN NN O
phentolamine NN NN O
( NN NN O
5 NN NN O
mg NN NN O
) NN NN O
, NN NN O
and NN NN O
conversely NN NN O
, NN NN O
potentiated NN NN O
by NN NN O
i NN NN O
. NN NN O
v NN NN O
. NN NN O
desmethylimipramine NN NN O
( NN NN O
0 NN NN O
. NN NN O
3 NN NN O
mg NN NN O
) NN NN O
, NN NN O
while NN NN O
propranolol NN NN O
( NN NN O
0 NN NN O
. NN NN O
5 NN NN O
mg NN NN O
) NN NN O
i NN NN O
. NN NN O
v NN NN O
. NN NN O
selectively NN NN O
inhibited NN NN O
the NN NN O
enlargement NN NN B-Disease
of NN NN I-Disease
pulse NN NN I-Disease
pressure NN NN I-Disease
and NN NN O
the NN NN O
tachycardia NN NN B-Disease
following NN NN O
i NN NN O
. NN NN O
c NN NN O
. NN NN O
carbachol NN NN O
( NN NN O
1 NN NN O
mug NN NN O
) NN NN O
. NN NN O
   
On NN NN O
the NN NN O
other NN NN O
hand NN NN O
, NN NN O
the NN NN O
pressor NN NN O
response NN NN O
to NN NN O
i NN NN O
. NN NN O
c NN NN O
. NN NN O
carbachol NN NN O
( NN NN O
1 NN NN O
mug NN NN O
) NN NN O
was NN NN O
almost NN NN O
completely NN NN O
blocked NN NN O
by NN NN O
i NN NN O
. NN NN O
c NN NN O
. NN NN O
atropine NN NN O
( NN NN O
3 NN NN O
mug NN NN O
) NN NN O
or NN NN O
hexamethonium NN NN O
( NN NN O
500 NN NN O
mug NN NN O
) NN NN O
, NN NN O
and NN NN O
significantly NN NN O
reduced NN NN O
by NN NN O
i NN NN O
. NN NN O
c NN NN O
. NN NN O
chlorpromazine NN NN O
( NN NN O
50 NN NN O
mug NN NN O
) NN NN O
but NN NN O
significantly NN NN O
potentiated NN NN O
by NN NN O
i NN NN O
. NN NN O
c NN NN O
. NN NN O
desmethylimipramine NN NN O
( NN NN O
30 NN NN O
mug NN NN O
) NN NN O
. NN NN O
   
The NN NN O
pressor NN NN O
response NN NN O
to NN NN O
i NN NN O
. NN NN O
c NN NN O
. NN NN O
carbachol NN NN O
( NN NN O
1 NN NN O
mug NN NN O
) NN NN O
remained NN NN O
unchanged NN NN O
after NN NN O
sectioning NN NN O
of NN NN O
the NN NN O
bilateral NN NN O
cervical NN NN O
vagal NN NN O
nerves NN NN O
but NN NN O
disappeared NN NN O
after NN NN O
sectioning NN NN O
of NN NN O
the NN NN O
spinal NN NN O
cord NN NN O
( NN NN O
C7 NN NN O
- NN NN O
C8 NN NN O
) NN NN O
. NN NN O
   
From NN NN O
the NN NN O
above NN NN O
result NN NN O
it NN NN O
is NN NN O
suggested NN NN O
that NN NN O
the NN NN O
pressor NN NN O
response NN NN O
to NN NN O
i NN NN O
. NN NN O
c NN NN O
. NN NN O
carbachol NN NN O
ortral NN NN O
and NN NN O
peripheral NN NN O
adrenergic NN NN O
mechanisms NN NN O
, NN NN O
and NN NN O
that NN NN O
the NN NN O
sympathetic NN NN O
trunk NN NN O
is NN NN O
the NN NN O
main NN NN O
pathway NN NN O
. NN NN O
   
Neuroleptic NN NN B-Disease
malignant NN NN I-Disease
syndrome NN NN I-Disease
and NN NN O
methylphenidate NN NN O
. NN NN O
   
A NN NN O
1 NN NN O
- NN NN O
year NN NN O
- NN NN O
old NN NN O
female NN NN O
presented NN NN O
with NN NN O
neuroleptic NN NN B-Disease
malignant NN NN I-Disease
syndrome NN NN I-Disease
probably NN NN O
caused NN NN O
by NN NN O
methylphenidate NN NN O
. NN NN O
   
She NN NN O
had NN NN O
defects NN NN O
in NN NN O
the NN NN O
supratentorial NN NN O
brain NN NN O
including NN NN O
the NN NN O
basal NN NN O
ganglia NN NN O
and NN NN O
the NN NN O
striatum NN NN O
( NN NN O
multicystic NN NN B-Disease
encephalomalacia NN NN I-Disease
) NN NN O
due NN NN O
to NN NN O
severe NN NN O
perinatal NN NN O
hypoxic NN NN B-Disease
- NN NN I-Disease
ischemic NN NN I-Disease
encephalopathy NN NN I-Disease
, NN NN O
which NN NN O
was NN NN O
considered NN NN O
to NN NN O
be NN NN O
a NN NN O
possible NN NN O
predisposing NN NN O
factor NN NN O
causing NN NN O
neuroleptic NN NN B-Disease
malignant NN NN I-Disease
syndrome NN NN I-Disease
. NN NN O
   
A NN NN O
dopaminergic NN NN O
blockade NN NN O
mechanism NN NN O
generally NN NN O
is NN NN O
accepted NN NN O
as NN NN O
the NN NN O
pathogenesis NN NN O
of NN NN O
this NN NN O
syndrome NN NN O
. NN NN O
   
However NN NN O
, NN NN O
methylphenidate NN NN O
is NN NN O
a NN NN O
dopamine NN NN O
agonist NN NN O
via NN NN O
the NN NN O
inhibition NN NN O
of NN NN O
uptake NN NN O
of NN NN O
dopamine NN NN O
, NN NN O
and NN NN O
therefore NN NN O
dopaminergic NN NN O
systems NN NN O
in NN NN O
the NN NN O
brainstem NN NN O
( NN NN O
mainly NN NN O
the NN NN O
midbrain NN NN O
) NN NN O
and NN NN O
the NN NN O
spinal NN NN O
cord NN NN O
were NN NN O
unlikely NN NN O
to NN NN O
participate NN NN O
in NN NN O
the NN NN O
onset NN NN O
of NN NN O
this NN NN O
syndrome NN NN O
. NN NN O
   
A NN NN O
relative NN NN O
gamma NN NN O
- NN NN O
aminobutyric NN NN O
acid NN NN O
- NN NN O
ergic NN NN O
deficiency NN NN O
might NN NN O
occur NN NN O
because NN NN O
diazepam NN NN O
, NN NN O
a NN NN O
gamma NN NN O
- NN NN O
aminobutyric NN NN O
acid NN NN O
- NN NN O
mimetic NN NN O
agent NN NN O
, NN NN O
was NN NN O
strikingly NN NN O
effective NN NN O
. NN NN O
   
This NN NN O
is NN NN O
the NN NN O
first NN NN O
reported NN NN O
patient NN NN O
with NN NN O
neuroleptic NN NN B-Disease
malignant NN NN I-Disease
syndrome NN NN I-Disease
probably NN NN O
caused NN NN O
by NN NN O
methylphenidate NN NN O
. NN NN O
   
Differential NN NN O
effects NN NN O
of NN NN O
17alpha NN NN O
- NN NN O
ethinylestradiol NN NN O
on NN NN O
the NN NN O
neutral NN NN O
and NN NN O
acidic NN NN O
pathways NN NN O
of NN NN O
bile NN NN O
salt NN NN O
synthesis NN NN O
in NN NN O
the NN NN O
rat NN NN O
. NN NN O
   
Effects NN NN O
of NN NN O
17alpha NN NN O
- NN NN O
ethinylestradiol NN NN O
( NN NN O
EE NN NN O
) NN NN O
on NN NN O
the NN NN O
neutral NN NN O
and NN NN O
acidic NN NN O
biosynthetic NN NN O
pathways NN NN O
of NN NN O
bile NN NN O
salt NN NN O
( NN NN O
BS NN NN O
) NN NN O
synthesis NN NN O
were NN NN O
evaluated NN NN O
in NN NN O
rats NN NN O
with NN NN O
an NN NN O
intact NN NN O
enterohepatic NN NN O
circulation NN NN O
and NN NN O
in NN NN O
rats NN NN O
with NN NN O
long NN NN O
- NN NN O
term NN NN O
bile NN NN O
diversion NN NN O
to NN NN O
induce NN NN O
BS NN NN O
synthesis NN NN O
. NN NN O
   
For NN NN O
this NN NN O
purpose NN NN O
, NN NN O
bile NN NN O
salt NN NN O
pool NN NN O
composition NN NN O
, NN NN O
synthesis NN NN O
of NN NN O
individual NN NN O
BS NN NN O
in NN NN O
vivo NN NN O
, NN NN O
hepatic NN NN O
activities NN NN O
, NN NN O
and NN NN O
expression NN NN O
levels NN NN O
of NN NN O
cholesterol NN NN O
7alpha NN NN O
- NN NN O
hydroxylase NN NN O
( NN NN O
CYP7A NN NN O
) NN NN O
, NN NN O
and NN NN O
sterol NN NN O
27 NN NN O
- NN NN O
hydroxylase NN NN O
( NN NN O
CYP27 NN NN O
) NN NN O
, NN NN O
as NN NN O
well NN NN O
as NN NN O
of NN NN O
other NN NN O
enzymes NN NN O
involved NN NN O
in NN NN O
BS NN NN O
synthesis NN NN O
, NN NN O
were NN NN O
analyzed NN NN O
in NN NN O
rats NN NN O
treated NN NN O
with NN NN O
EE NN NN O
( NN NN O
5 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
, NN NN O
3 NN NN O
days NN NN O
) NN NN O
or NN NN O
its NN NN O
vehicle NN NN O
. NN NN O
   
BS NN NN O
pool NN NN O
size NN NN O
was NN NN O
decreased NN NN O
by NN NN O
27 NN NN O
% NN NN O
but NN NN O
total NN NN O
BS NN NN O
synthesis NN NN O
was NN NN O
not NN NN O
affected NN NN O
by NN NN O
EE NN NN O
in NN NN O
intact NN NN O
rats NN NN O
. NN NN O
   
Synthesis NN NN O
of NN NN O
cholate NN NN O
was NN NN O
reduced NN NN O
by NN NN O
68 NN NN O
% NN NN O
in NN NN O
EE NN NN O
- NN NN O
treated NN NN O
rats NN NN O
, NN NN O
while NN NN O
that NN NN O
of NN NN O
chenodeoxycholate NN NN O
was NN NN O
increased NN NN O
by NN NN O
60 NN NN O
% NN NN O
. NN NN O
   
The NN NN O
recently NN NN O
identified NN NN O
Delta22 NN NN O
- NN NN O
isomer NN NN O
of NN NN O
beta NN NN O
- NN NN O
muricholate NN NN O
contributed NN NN O
for NN NN O
5 NN NN O
. NN NN O
4 NN NN O
% NN NN O
and NN NN O
18 NN NN O
. NN NN O
3 NN NN O
% NN NN O
( NN NN O
P NN NN O
< NN NN O
0 NN NN O
. NN NN O
01 NN NN O
) NN NN O
to NN NN O
the NN NN O
pool NN NN O
in NN NN O
control NN NN O
and NN NN O
EE NN NN O
- NN NN O
treated NN NN O
rats NN NN O
, NN NN O
respectively NN NN O
, NN NN O
but NN NN O
could NN NN O
not NN NN O
be NN NN O
detected NN NN O
in NN NN O
bile NN NN O
after NN NN O
exhaustion NN NN O
of NN NN O
the NN NN O
pool NN NN O
. NN NN O
   
A NN NN O
clear NN NN O
reduction NN NN O
of NN NN O
BS NN NN O
synthesis NN NN O
was NN NN O
found NN NN O
in NN NN O
bile NN NN O
- NN NN O
diverted NN NN O
rats NN NN O
treated NN NN O
with NN NN O
EE NN NN O
, NN NN O
yet NN NN O
biliary NN NN O
BS NN NN O
composition NN NN O
was NN NN O
only NN NN O
minimally NN NN O
affected NN NN O
. NN NN O
   
Activity NN NN O
of NN NN O
CYP7A NN NN O
was NN NN O
decreased NN NN O
by NN NN O
EE NN NN O
in NN NN O
both NN NN O
intact NN NN O
and NN NN O
bile NN NN O
- NN NN O
diverted NN NN O
rats NN NN O
, NN NN O
whereas NN NN O
the NN NN O
activity NN NN O
of NN NN O
the NN NN O
CYP27 NN NN O
was NN NN O
not NN NN O
affected NN NN O
. NN NN O
   
Hepatic NN NN O
mRNA NN NN O
levels NN NN O
of NN NN O
CYP7A NN NN O
were NN NN O
significantly NN NN O
reduced NN NN O
by NN NN O
EE NN NN O
in NN NN O
bile NN NN O
- NN NN O
diverted NN NN O
rats NN NN O
only NN NN O
; NN NN O
CYP27 NN NN O
mRNA NN NN O
levels NN NN O
were NN NN O
not NN NN O
affected NN NN O
by NN NN O
EE NN NN O
. NN NN O
   
In NN NN O
addition NN NN O
, NN NN O
mRNA NN NN O
levels NN NN O
of NN NN O
sterol NN NN O
12alpha NN NN O
- NN NN O
hydroxylase NN NN O
and NN NN O
lithocholate NN NN O
6beta NN NN O
- NN NN O
hydroxylase NN NN O
were NN NN O
increased NN NN O
by NN NN O
bile NN NN O
diversion NN NN O
and NN NN O
suppressed NN NN O
by NN NN O
EE NN NN O
. NN NN O
   
This NN NN O
study NN NN O
shows NN NN O
that NN NN O
17alpha NN NN O
- NN NN O
ethinylestradiol NN NN O
( NN NN O
EE NN NN O
) NN NN O
- NN NN O
induced NN NN O
intrahepatic NN NN B-Disease
cholestasis NN NN I-Disease
in NN NN O
rats NN NN O
is NN NN O
associated NN NN O
with NN NN O
selective NN NN O
inhibition NN NN O
of NN NN O
the NN NN O
neutral NN NN O
pathway NN NN O
of NN NN O
bile NN NN O
salt NN NN O
( NN NN O
BS NN NN O
) NN NN O
synthesis NN NN O
. NN NN O
   
Simultaneous NN NN O
impairment NN NN O
of NN NN O
other NN NN O
enzymes NN NN O
in NN NN O
the NN NN O
BS NN NN O
biosynthetic NN NN O
pathways NN NN O
may NN NN O
contribute NN NN O
to NN NN O
overall NN NN O
effects NN NN O
of NN NN O
EE NN NN O
on NN NN O
BS NN NN O
synthesis NN NN O
. NN NN O
   
Glibenclamide NN NN O
- NN NN O
sensitive NN NN O
hypotension NN NN B-Disease
produced NN NN O
by NN NN O
helodermin NN NN O
assessed NN NN O
in NN NN O
the NN NN O
rat NN NN O
. NN NN O
   
The NN NN O
effects NN NN O
of NN NN O
helodermin NN NN O
, NN NN O
a NN NN O
basic NN NN O
35 NN NN O
- NN NN O
amino NN NN O
acid NN NN O
peptide NN NN O
isolated NN NN O
from NN NN O
the NN NN O
venom NN NN O
of NN NN O
a NN NN O
lizard NN NN O
salivary NN NN O
gland NN NN O
, NN NN O
on NN NN O
arterial NN NN O
blood NN NN O
pressure NN NN O
and NN NN O
heart NN NN O
rate NN NN O
were NN NN O
examined NN NN O
in NN NN O
the NN NN O
rat NN NN O
, NN NN O
focusing NN NN O
on NN NN O
the NN NN O
possibility NN NN O
that NN NN O
activation NN NN O
of NN NN O
ATP NN NN O
sensitive NN NN O
K NN NN O
+ NN NN O
( NN NN O
K NN NN O
( NN NN O
ATP NN NN O
) NN NN O
) NN NN O
channels NN NN O
is NN NN O
involved NN NN O
in NN NN O
the NN NN O
responses NN NN O
. NN NN O
   
The NN NN O
results NN NN O
were NN NN O
also NN NN O
compared NN NN O
with NN NN O
those NN NN O
of NN NN O
vasoactive NN NN O
intestinal NN NN O
polypeptide NN NN O
( NN NN O
VIP NN NN O
) NN NN O
. NN NN O
   
Helodermin NN NN O
produced NN NN O
hypotension NN NN B-Disease
in NN NN O
a NN NN O
dose NN NN O
- NN NN O
dependent NN NN O
manner NN NN O
with NN NN O
approximately NN NN O
similar NN NN O
potency NN NN O
and NN NN O
duration NN NN O
to NN NN O
VIP NN NN O
. NN NN O
   
Hypotension NN NN B-Disease
induced NN NN O
by NN NN O
both NN NN O
peptides NN NN O
was NN NN O
significantly NN NN O
attenuated NN NN O
by NN NN O
glibenclamide NN NN O
, NN NN O
which NN NN O
abolished NN NN O
a NN NN O
levcromakalim NN NN O
- NN NN O
produced NN NN O
decrease NN NN O
in NN NN O
arterial NN NN O
blood NN NN O
pressure NN NN O
. NN NN O
   
Oxyhemoglobin NN NN O
did NN NN O
not NN NN O
affect NN NN O
helodermin NN NN O
- NN NN O
induced NN NN O
hypotension NN NN B-Disease
, NN NN O
whereas NN NN O
it NN NN O
shortened NN NN O
the NN NN O
duration NN NN O
of NN NN O
acetylcholine NN NN O
( NN NN O
ACh NN NN O
) NN NN O
- NN NN O
produced NN NN O
hypotension NN NN B-Disease
. NN NN O
   
These NN NN O
findings NN NN O
suggest NN NN O
that NN NN O
helodermin NN NN O
- NN NN O
produced NN NN O
hypotension NN NN B-Disease
is NN NN O
partly NN NN O
attributable NN NN O
to NN NN O
the NN NN O
activation NN NN O
of NN NN O
glibenclamide NN NN O
- NN NN O
sensitive NN NN O
K NN NN O
+ NN NN O
channels NN NN O
( NN NN O
K NN NN O
( NN NN O
ATP NN NN O
) NN NN O
channels NN NN O
) NN NN O
, NN NN O
which NN NN O
presumably NN NN O
exist NN NN O
on NN NN O
arterial NN NN O
smooth NN NN O
muscle NN NN O
cells NN NN O
. NN NN O
   
EDRF NN NN O
( NN NN O
endothelium NN NN O
- NN NN O
derived NN NN O
relaxing NN NN O
factor NN NN O
) NN NN O
/ NN NN O
nitric NN NN O
oxide NN NN O
does NN NN O
not NN NN O
seem NN NN O
to NN NN O
play NN NN O
an NN NN O
important NN NN O
role NN NN O
in NN NN O
the NN NN O
peptide NN NN O
- NN NN O
produced NN NN O
hypotension NN NN B-Disease
. NN NN O
   
Long NN NN O
- NN NN O
term NN NN O
efficacy NN NN O
and NN NN O
adverse NN NN O
event NN NN O
of NN NN O
nifedipine NN NN O
sustained NN NN O
- NN NN O
release NN NN O
tablets NN NN O
for NN NN O
cyclosporin NN NN O
A NN NN O
- NN NN O
induced NN NN O
hypertension NN NN B-Disease
in NN NN O
patients NN NN O
with NN NN O
psoriasis NN NN B-Disease
. NN NN O
   
Thirteen NN NN O
psoriatic NN NN B-Disease
patients NN NN O
with NN NN O
hypertension NN NN B-Disease
during NN NN O
the NN NN O
course NN NN O
of NN NN O
cyclosporin NN NN O
A NN NN O
therapy NN NN O
were NN NN O
treated NN NN O
for NN NN O
25 NN NN O
months NN NN O
with NN NN O
a NN NN O
calcium NN NN O
channel NN NN O
blocker NN NN O
, NN NN O
sustained NN NN O
- NN NN O
release NN NN O
nifedipine NN NN O
, NN NN O
to NN NN O
study NN NN O
the NN NN O
clinical NN NN O
antihypertensive NN NN O
effects NN NN O
and NN NN O
adverse NN NN O
events NN NN O
during NN NN O
treatment NN NN O
with NN NN O
both NN NN O
drugs NN NN O
. NN NN O
   
Seven NN NN O
of NN NN O
the NN NN O
13 NN NN O
patients NN NN O
had NN NN O
exhibited NN NN O
a NN NN O
subclinical NN NN O
hypertensive NN NN B-Disease
state NN NN O
before NN NN O
cyclosporin NN NN O
A NN NN O
therapy NN NN O
. NN NN O
   
Both NN NN O
systolic NN NN O
and NN NN O
diastolic NN NN O
blood NN NN O
pressures NN NN O
of NN NN O
these NN NN O
13 NN NN O
patients NN NN O
were NN NN O
decreased NN NN O
significantly NN NN O
after NN NN O
4 NN NN O
weeks NN NN O
of NN NN O
nifedipine NN NN O
therapy NN NN O
, NN NN O
and NN NN O
blood NN NN O
pressure NN NN O
was NN NN O
maintained NN NN O
within NN NN O
the NN NN O
normal NN NN O
range NN NN O
thereafter NN NN O
for NN NN O
25 NN NN O
months NN NN O
. NN NN O
   
The NN NN O
adverse NN NN O
events NN NN O
during NN NN O
combined NN NN O
therapy NN NN O
with NN NN O
cyclosporin NN NN O
A NN NN O
and NN NN O
nifedipine NN NN O
included NN NN O
an NN NN O
increase NN NN O
in NN NN O
blood NN NN O
urea NN NN O
nitrogen NN NN O
levels NN NN O
in NN NN O
9 NN NN O
of NN NN O
the NN NN O
13 NN NN O
patients NN NN O
and NN NN O
development NN NN O
of NN NN O
gingival NN NN B-Disease
hyperplasia NN NN I-Disease
in NN NN O
2 NN NN O
of NN NN O
the NN NN O
13 NN NN O
patients NN NN O
. NN NN O
   
Our NN NN O
findings NN NN O
indicate NN NN O
that NN NN O
sustained NN NN O
- NN NN O
release NN NN O
nifedipine NN NN O
is NN NN O
useful NN NN O
for NN NN O
hypertensive NN NN B-Disease
psoriatic NN NN B-Disease
patients NN NN O
under NN NN O
long NN NN O
- NN NN O
term NN NN O
treatment NN NN O
with NN NN O
cyclosporin NN NN O
A NN NN O
, NN NN O
but NN NN O
that NN NN O
these NN NN O
patients NN NN O
should NN NN O
be NN NN O
monitored NN NN O
for NN NN O
gingival NN NN B-Disease
hyperplasia NN NN I-Disease
. NN NN O
   
   
